<SEC-DOCUMENT>0001437749-25-005919.txt : 20250303
<SEC-HEADER>0001437749-25-005919.hdr.sgml : 20250303
<ACCEPTANCE-DATETIME>20250303162022
ACCESSION NUMBER:		0001437749-25-005919
CONFORMED SUBMISSION TYPE:	10-K
PUBLIC DOCUMENT COUNT:		90
CONFORMED PERIOD OF REPORT:	20241231
FILED AS OF DATE:		20250303
DATE AS OF CHANGE:		20250303

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			CASSAVA SCIENCES INC
		CENTRAL INDEX KEY:			0001069530
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				911911336
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-41905
		FILM NUMBER:		25698257

	BUSINESS ADDRESS:	
		STREET 1:		6801 N CAPITAL OF TEXAS HIGHWAY
		STREET 2:		BUILDING 1; SUITE 300
		CITY:			AUSTIN
		STATE:			TX
		ZIP:			78731
		BUSINESS PHONE:		512-501-2444

	MAIL ADDRESS:	
		STREET 1:		6801 N CAPITAL OF TEXAS HIGHWAY
		STREET 2:		BUILDING 1; SUITE 300
		CITY:			AUSTIN
		STATE:			TX
		ZIP:			78731

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	PAIN THERAPEUTICS INC
		DATE OF NAME CHANGE:	20000309
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-K
<SEQUENCE>1
<FILENAME>sava20241231c_10k.htm
<DESCRIPTION>FORM 10-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:naics="http://xbrl.sec.gov/naics/2024" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:us-types="http://fasb.org/us-types/2023" xmlns:srt-types="http://fasb.org/srt-types/2023" xmlns:utreg="http://www.xbrl.org/2009/utr" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:us-roles="http://fasb.org/us-roles/2017-01-31" xmlns:stpr="http://xbrl.sec.gov/stpr/2024" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:thunderdome="http://www.RDGFilings.com" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:dei="http://xbrl.sec.gov/dei/2024" xmlns:enum2="http://xbrl.org/2020/extensible-enumerations-2.0" xmlns:sava="http://www.cassavasciences.com/20241231" xmlns:currency="http://xbrl.sec.gov/currency/2024" xmlns:sic="http://xbrl.sec.gov/sic/2024" xmlns:exch="http://xbrl.sec.gov/exch/2024" xmlns:rr="http://xbrl.sec.gov/rr/2023" xmlns:country="http://xbrl.sec.gov/country/2024" xmlns:ecd="http://xbrl.sec.gov/ecd/2024" xmlns:us-gaap="http://fasb.org/us-gaap/2024" xmlns:cyd="http://xbrl.sec.gov/cyd/2024" xmlns:srt="http://fasb.org/srt/2024" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21">
 <head>
  <title>sava20241231c_10k.htm</title>
  <!-- Generated by ThunderDome Portal - 3/3/2025 8:16:24 PM -->
  <meta http-equiv="Content-Type" content="text/html"/></head>
 <body style="font-size: 10pt; font-family: &quot;Times New Roman&quot;; padding: 0in 0.1in; cursor: auto;"><div style="display: none;"><ix:header><ix:hidden>
<ix:nonNumeric contextRef="d_2024-01-01_2024-12-31" name="dei:EntityCentralIndexKey" id="thunderdome-EntityCentralIndexKey">0001069530</ix:nonNumeric>
<ix:nonNumeric contextRef="d_2024-01-01_2024-12-31" name="dei:EntityRegistrantName" id="thunderdome-EntityRegistrantName">CASSAVA SCIENCES INC</ix:nonNumeric>
<ix:nonNumeric contextRef="d_2024-01-01_2024-12-31" name="dei:AmendmentFlag" format="ixt:fixed-false" id="ixv-13141">false</ix:nonNumeric>
<ix:nonNumeric contextRef="d_2024-01-01_2024-12-31" name="dei:CurrentFiscalYearEndDate" id="ixv-13142">--12-31</ix:nonNumeric>
<ix:nonNumeric contextRef="d_2024-01-01_2024-12-31" name="dei:DocumentFiscalPeriodFocus" id="ixv-13143">FY</ix:nonNumeric>
<ix:nonNumeric contextRef="d_2024-01-01_2024-12-31" name="dei:DocumentFiscalYearFocus" id="ixv-13144">2024</ix:nonNumeric>
<ix:nonNumeric contextRef="d_2024-01-01_2024-12-31" name="cyd:CybersecurityRiskManagementProcessesIntegratedFlag" id="c123855784" format="ixt:fixed-true">true</ix:nonNumeric>
<ix:nonNumeric contextRef="d_2024-01-01_2024-12-31" name="cyd:CybersecurityRiskManagementThirdPartyEngagedFlag" id="c123855379" format="ixt:fixed-true">true</ix:nonNumeric>
<ix:nonNumeric contextRef="d_2024-01-01_2024-12-31" name="cyd:CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag" id="c123855380" format="ixt:fixed-false">false</ix:nonNumeric>
<ix:nonNumeric contextRef="d_2024-01-01_2024-12-31" name="cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag" id="c123855788" format="ixt:fixed-true">true</ix:nonNumeric>
<ix:nonNumeric contextRef="d_2024-01-01_2024-12-31" name="cyd:CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" id="c123855789">Our full Board of Directors oversees the risk management process for the Company, which includes identifying, assessing and managing enterprise-level risks. The Board administers this oversight function directly through the Board of Directors as a whole, as well as through its standing committees that address risks inherent in their respective areas of oversight. The risk oversight responsibility of the Board of Directors and its committees is supported by the management reporting processes, which are designed to provide visibility to the Board of Directors and to the personnel who are responsible for risk assessment and information about the identification, assessment and management of critical risks, and management&#8217;s risk mitigation strategies.  Our cybersecurity risk program directly integrates and is intended to align with the Board of Directors&#8217; overall risk management process.</ix:nonNumeric>
<ix:nonFraction id="c123862498" contextRef="i_2024-12-31" unitRef="USD" name="us-gaap:CommitmentsAndContingencies" scale="3" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction id="c123862499" contextRef="i_2023-12-31" unitRef="USD" name="us-gaap:CommitmentsAndContingencies" scale="3" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction id="c123855767" contextRef="i_2024-12-31" unitRef="USDPerShare" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" format="ixt:num-dot-decimal" decimals="INF">0.001</ix:nonFraction>
<ix:nonFraction id="c123855768" contextRef="i_2023-12-31" unitRef="USDPerShare" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" format="ixt:num-dot-decimal" decimals="INF">0.001</ix:nonFraction>
<ix:nonFraction id="c123855769" contextRef="i_2024-12-31" unitRef="Share" name="us-gaap:PreferredStockSharesAuthorized" scale="0" format="ixt:num-dot-decimal" decimals="INF">10,000,000</ix:nonFraction>
<ix:nonFraction id="c123855770" contextRef="i_2023-12-31" unitRef="Share" name="us-gaap:PreferredStockSharesAuthorized" scale="0" format="ixt:num-dot-decimal" decimals="INF">10,000,000</ix:nonFraction>
<ix:nonFraction id="c123855771" contextRef="i_2024-12-31" unitRef="Share" name="us-gaap:PreferredStockSharesIssued" scale="0" format="ixt:num-dot-decimal" decimals="-3">0</ix:nonFraction>
<ix:nonFraction id="c123855773" contextRef="i_2024-12-31" unitRef="Share" name="us-gaap:PreferredStockSharesOutstanding" scale="0" format="ixt:num-dot-decimal" decimals="-3">0</ix:nonFraction>
<ix:nonFraction id="c123855772" contextRef="i_2023-12-31" unitRef="Share" name="us-gaap:PreferredStockSharesIssued" scale="0" format="ixt:num-dot-decimal" decimals="-3">0</ix:nonFraction>
<ix:nonFraction id="c123855774" contextRef="i_2023-12-31" unitRef="Share" name="us-gaap:PreferredStockSharesOutstanding" scale="0" format="ixt:num-dot-decimal" decimals="-3">0</ix:nonFraction>
<ix:nonFraction id="c123855775" contextRef="i_2024-12-31" unitRef="USDPerShare" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" format="ixt:num-dot-decimal" decimals="INF">0.001</ix:nonFraction>
<ix:nonFraction id="c123855776" contextRef="i_2023-12-31" unitRef="USDPerShare" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" format="ixt:num-dot-decimal" decimals="INF">0.001</ix:nonFraction>
<ix:nonFraction id="c123855777" contextRef="i_2024-12-31" unitRef="Share" name="us-gaap:CommonStockSharesAuthorized" scale="0" format="ixt:num-dot-decimal" decimals="INF">120,000,000</ix:nonFraction>
<ix:nonFraction id="c123855778" contextRef="i_2023-12-31" unitRef="Share" name="us-gaap:CommonStockSharesAuthorized" scale="0" format="ixt:num-dot-decimal" decimals="INF">120,000,000</ix:nonFraction>
<ix:nonFraction id="c123855779" contextRef="i_2024-12-31" unitRef="Share" name="us-gaap:CommonStockSharesIssued" scale="0" format="ixt:num-dot-decimal" decimals="INF">48,203,179</ix:nonFraction>
<ix:nonFraction id="c123855781" contextRef="i_2024-12-31" unitRef="Share" name="us-gaap:CommonStockSharesOutstanding" scale="0" format="ixt:num-dot-decimal" decimals="INF">48,203,179</ix:nonFraction>
<ix:nonFraction id="c123855780" contextRef="i_2023-12-31" unitRef="Share" name="us-gaap:CommonStockSharesIssued" scale="0" format="ixt:num-dot-decimal" decimals="INF">42,236,919</ix:nonFraction>
<ix:nonFraction id="c123855782" contextRef="i_2023-12-31" unitRef="Share" name="us-gaap:CommonStockSharesOutstanding" scale="0" format="ixt:num-dot-decimal" decimals="INF">42,236,919</ix:nonFraction>
<ix:nonFraction id="c123855794" contextRef="d_2023-01-01_2023-12-31" unitRef="USD" name="us-gaap:GovernmentAssistanceAmount" scale="6" format="ixt:num-dot-decimal" decimals="-3">0</ix:nonFraction>
<ix:nonNumeric contextRef="d_2024-01-01_2024-12-31" name="us-gaap:GovernmentAssistanceStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration" id="c123855795">http://fasb.org/us-gaap/2024#ResearchAndDevelopmentExpense</ix:nonNumeric>
<ix:nonFraction id="c123854924" contextRef="i_2024-12-31_ClassOfWarrantOrRightAxis-WarrantsToPurchaseCommonStockMember_MeasurementInputTypeAxis-MeasurementInputExpectedDividendRateMember" unitRef="Pure" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="-2" format="ixt:num-dot-decimal" decimals="-3">0</ix:nonFraction>
<ix:nonNumeric contextRef="d_2024-01-01_2024-12-31_AwardTypeAxis-EmployeeStockOptionMember_RangeAxis-MinimumMember" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="c123855418" format="ixt-sec:duryear">1</ix:nonNumeric>
<ix:nonNumeric contextRef="d_2024-01-01_2024-12-31_AwardTypeAxis-EmployeeStockOptionMember_RangeAxis-MaximumMember" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="c123855419" format="ixt-sec:duryear">4</ix:nonNumeric>
<ix:nonFraction id="c123855449" contextRef="d_2024-01-01_2024-09-30_TitleOfIndividualAxis-FormerSeniorOfficerMember" unitRef="Pure" name="sava:NumberOfFormerEmployees" scale="0" format="ixt:num-dot-decimal" decimals="INF">2</ix:nonFraction>
<ix:nonFraction id="c123855525" contextRef="d_2024-01-01_2024-12-31_SubsidiarySaleOfStockAxis-AtthemarketCommonStockOfferingMember" unitRef="Share" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" format="ixt:num-dot-decimal" decimals="-3">0</ix:nonFraction>
<ix:nonNumeric contextRef="d_2022-05-05_2022-05-05_PlanNameAxis-The2018EquityIncentivePlanMember" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" id="c123855537" format="ixt-sec:duryear">10</ix:nonNumeric>
<ix:nonFraction id="c123855198" contextRef="d_2024-01-01_2024-12-31_AwardTypeAxis-EmployeeStockOptionMember" unitRef="Pure" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" format="ixt:num-dot-decimal" decimals="-3">0</ix:nonFraction>
<ix:nonFraction id="c123855199" contextRef="d_2023-01-01_2023-12-31_AwardTypeAxis-EmployeeStockOptionMember" unitRef="Pure" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" format="ixt:num-dot-decimal" decimals="-3">0</ix:nonFraction>
<ix:nonFraction id="c123855200" contextRef="d_2022-01-01_2022-12-31_AwardTypeAxis-EmployeeStockOptionMember" unitRef="Pure" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" format="ixt:num-dot-decimal" decimals="-3">0</ix:nonFraction>
<ix:nonFraction id="c123855201" contextRef="d_2024-01-01_2024-12-31_AwardTypeAxis-EmployeeStockOptionMember" unitRef="Pure" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions" scale="-2" format="ixt:num-dot-decimal" decimals="3">4.3</ix:nonFraction>
<ix:nonFraction id="c123855202" contextRef="d_2023-01-01_2023-12-31_AwardTypeAxis-EmployeeStockOptionMember" unitRef="Pure" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions" scale="-2" format="ixt:num-dot-decimal" decimals="-3">0</ix:nonFraction>
<ix:nonFraction id="c123855203" contextRef="d_2022-01-01_2022-12-31_AwardTypeAxis-EmployeeStockOptionMember" unitRef="Pure" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions" scale="-2" format="ixt:num-dot-decimal" decimals="-3">0</ix:nonFraction>
<ix:nonFraction id="c123855800" contextRef="d_2023-01-01_2023-12-31_SubsidiarySaleOfStockAxis-AtthemarketCommonStockOfferingMember" unitRef="Share" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" format="ixt:num-dot-decimal" decimals="-3">0</ix:nonFraction>
<ix:nonFraction id="c123855801" contextRef="d_2022-01-01_2022-12-31_RestructuringCostAndReserveAxis-EmployeeSeveranceMember" unitRef="USD" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" format="ixt:num-dot-decimal" decimals="-3">0</ix:nonFraction>
<ix:nonFraction id="c123855808" contextRef="d_2023-01-01_2023-12-31" unitRef="Pure" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" format="ixt:num-dot-decimal" decimals="2">21</ix:nonFraction>
<ix:nonFraction id="c123855598" contextRef="d_2024-01-01_2024-12-31" unitRef="USD" name="us-gaap:IncomeTaxExpenseBenefit" scale="0" format="ixt:num-dot-decimal" decimals="-3">0</ix:nonFraction>
<ix:nonNumeric contextRef="d_2024-01-01_2024-12-31" name="us-gaap:OpenTaxYear" id="c123855602">2020 2021 2022 2023 2024</ix:nonNumeric>
<ix:nonFraction id="c123855699" contextRef="d_2021-08-28_2021-10-26_LitigationCaseAxis-ViolationsOfFederalSecuritiesLawsMember" unitRef="Pure" name="us-gaap:LossContingencyNewClaimsFiledNumber" scale="0" format="ixt:num-dot-decimal" decimals="INF">4</ix:nonFraction>
<ix:nonFraction id="c123855700" contextRef="d_2021-08-28_2021-10-26_LitigationCaseAxis-ViolationsOfFederalSecuritiesLawsMember" unitRef="Pure" name="us-gaap:LossContingencyNewClaimsFiledNumber" scale="0" format="ixt:num-dot-decimal" decimals="INF">4</ix:nonFraction>
<ix:nonFraction id="c123855701" contextRef="d_2022-06-30_2022-06-30_LitigationCaseAxis-ViolationsOfFederalSecuritiesLawsMember" unitRef="Pure" name="us-gaap:LossContingencyNewClaimsFiledNumber" scale="0" format="ixt:num-dot-decimal" decimals="INF">1</ix:nonFraction>
<ix:nonFraction id="c123855705" contextRef="d_2021-11-04_2023-06-20_LitigationCaseAxis-ShareholderDerivativeActionsTexasCourtMember" unitRef="Pure" name="us-gaap:LossContingencyNewClaimsFiledNumber" scale="0" format="ixt:num-dot-decimal" decimals="INF">4</ix:nonFraction>
<ix:nonFraction id="c123855706" contextRef="d_2021-11-01_2023-06-20_LitigationCaseAxis-ShareholderDerivativeActionsTexasCourtMember" unitRef="Pure" name="us-gaap:LossContingencyNewClaimsFiledNumber" scale="0" format="ixt:num-dot-decimal" decimals="INF">2</ix:nonFraction>
<ix:nonFraction id="c123855707" contextRef="d_2021-11-01_2023-06-20_LitigationCaseAxis-ShareholderDerivativeActionsTexasStateCourtMember" unitRef="Pure" name="us-gaap:LossContingencyNewClaimsFiledNumber" scale="0" format="ixt:num-dot-decimal" decimals="INF">1</ix:nonFraction>
<ix:nonFraction id="c123855708" contextRef="d_2021-11-01_2023-06-20_LitigationCaseAxis-ShareholderDerivativeActionsDelawareCourtMember" unitRef="Pure" name="us-gaap:LossContingencyNewClaimsFiledNumber" scale="0" format="ixt:num-dot-decimal" decimals="INF">1</ix:nonFraction>
<ix:nonFraction id="c123855709" contextRef="d_2022-07-05_2022-07-05_LitigationCaseAxis-ShareholderDerivativeActionsMember" unitRef="Pure" name="us-gaap:LossContingencyNewClaimsFiledNumber" scale="0" format="ixt:num-dot-decimal" decimals="INF">3</ix:nonFraction>
<ix:nonFraction id="c123855711" contextRef="d_2024-03-18_2024-03-18_LitigationCaseAxis-ShareholderDerivativeActionsMember" unitRef="Pure" name="us-gaap:LossContingencyNewClaimsFiledNumber" scale="0" format="ixt:num-dot-decimal" decimals="INF">2</ix:nonFraction>
<ix:nonFraction id="c123855713" contextRef="d_2024-09-06_2024-09-06_LitigationCaseAxis-ShareholderDerivativeActionsMember" unitRef="Pure" name="us-gaap:LossContingencyNewClaimsFiledNumber" scale="0" format="ixt:num-dot-decimal" decimals="INF">2</ix:nonFraction>
<ix:nonFraction id="c123855719" contextRef="d_2023-12-22_2023-12-22_ClassOfWarrantOrRightAxis-WarrantsToPurchaseCommonStockMember" unitRef="Share" name="sava:ClassOfWarrantOrRightIssuedDuringPeriod" scale="0" format="ixt:num-dot-decimal" decimals="INF">4</ix:nonFraction>
<ix:nonFraction id="c123855721" contextRef="d_2024-01-03_2024-01-03_ClassOfWarrantOrRightAxis-WarrantsToPurchaseCommonStockMember" unitRef="Share" name="sava:ClassOfWarrantOrRightIssuedDuringPeriod" scale="6" format="ixt:num-dot-decimal" decimals="-5">16.9</ix:nonFraction>
<ix:nonFraction id="c123855724" contextRef="i_2024-01-03_ClassOfWarrantOrRightAxis-WarrantsToPurchaseCommonStockMember" unitRef="Share" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" scale="0" format="ixt:num-dot-decimal" decimals="INF">1.5</ix:nonFraction>
<ix:nonFraction id="c123855726" contextRef="i_2024-05-07_ClassOfWarrantOrRightAxis-WarrantsToPurchaseCommonStockMember" unitRef="Pure" name="sava:RedemptionPercentageOfWarrants" scale="-2" format="ixt:num-dot-decimal" decimals="3">0.1</ix:nonFraction>
<ix:nonFraction id="c123855728" contextRef="i_2024-12-31_ClassOfWarrantOrRightAxis-WarrantsToPurchaseCommonStockMember" unitRef="USD" name="us-gaap:WarrantsAndRightsOutstanding" scale="0" format="ixt:num-dot-decimal" decimals="-3">0</ix:nonFraction>
<ix:nonFraction id="c123855372" contextRef="i_2024-06-30_ClassOfWarrantOrRightAxis-WarrantsToPurchaseCommonStockMember" unitRef="Share" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="3" format="ixt:num-dot-decimal" decimals="-3">0</ix:nonFraction>
<ix:nonFraction id="c123855374" contextRef="i_2024-09-30_ClassOfWarrantOrRightAxis-WarrantsToPurchaseCommonStockMember" unitRef="Share" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="3" format="ixt:num-dot-decimal" decimals="-3">0</ix:nonFraction>
<ix:nonFraction id="c123855375" contextRef="i_2024-09-30_ClassOfWarrantOrRightAxis-WarrantsToPurchaseCommonStockMember" unitRef="USD" name="us-gaap:WarrantsAndRightsOutstanding" scale="3" format="ixt:num-dot-decimal" decimals="-3">0</ix:nonFraction>
<ix:nonFraction id="c123855376" contextRef="i_2024-12-31_ClassOfWarrantOrRightAxis-WarrantsToPurchaseCommonStockMember" unitRef="Share" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="3" format="ixt:num-dot-decimal" decimals="-3">0</ix:nonFraction>
<ix:nonFraction id="c123855377" contextRef="i_2024-12-31_ClassOfWarrantOrRightAxis-WarrantsToPurchaseCommonStockMember" unitRef="USD" name="us-gaap:WarrantsAndRightsOutstanding" scale="3" format="ixt:num-dot-decimal" decimals="-3">0</ix:nonFraction>
<ix:nonNumeric contextRef="d_2024-10-01_2024-12-31" name="ecd:Rule10b51ArrAdoptedFlag" id="c123855759" format="ixt:fixed-false">false</ix:nonNumeric>
<ix:nonNumeric contextRef="d_2024-10-01_2024-12-31" name="ecd:NonRule10b51ArrAdoptedFlag" id="c123855822" format="ixt:fixed-false">false</ix:nonNumeric>
<ix:nonNumeric contextRef="d_2024-10-01_2024-12-31" name="ecd:Rule10b51ArrTrmntdFlag" id="c123855823" format="ixt:fixed-false">false</ix:nonNumeric>
<ix:nonNumeric contextRef="d_2024-10-01_2024-12-31" name="ecd:NonRule10b51ArrTrmntdFlag" id="c123855824" format="ixt:fixed-false">false</ix:nonNumeric>
<ix:footnote xml:lang="en-us" id="f6b7c5421-b40f-4704-986f-7fafec64f3cf">Other segment items include interest income, other income, net and gain from change in fair value of warrant liabilities.</ix:footnote></ix:hidden>
<ix:references>
<link:schemaRef xlink:href="sava-20241231.xsd" xlink:type="simple"/></ix:references>
<ix:resources>
<xbrli:context id="d_2024-01-01_2024-12-31"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:unit id="USD"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit>
<xbrli:context id="i_2024-06-28"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2024-06-28</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:unit id="Share"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit>
<xbrli:context id="i_2025-02-27"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2025-02-27</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:unit id="NonApplicable"><xbrli:measure>thunderdome:item</xbrli:measure></xbrli:unit>
<xbrli:context id="i_2024-12-31"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2023-12-31"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:unit id="USDPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit>
<xbrli:context id="d_2023-01-01_2023-12-31"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2022-01-01_2022-12-31"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="i_2021-12-31_StatementEquityComponentsAxis-CommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2021-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2021-12-31_StatementEquityComponentsAxis-RetainedEarningsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2021-12-31"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="d_2022-01-01_2022-12-31_GranteeStatusAxis-ShareBasedPaymentArrangementEmployeeMember_StatementEquityComponentsAxis-CommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2022-01-01_2022-12-31_GranteeStatusAxis-ShareBasedPaymentArrangementEmployeeMember_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2022-01-01_2022-12-31_GranteeStatusAxis-ShareBasedPaymentArrangementEmployeeMember_StatementEquityComponentsAxis-RetainedEarningsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2022-01-01_2022-12-31_GranteeStatusAxis-ShareBasedPaymentArrangementEmployeeMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2022-01-01_2022-12-31_GranteeStatusAxis-ShareBasedPaymentArrangementNonemployeeMember_StatementEquityComponentsAxis-CommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementNonemployeeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2022-01-01_2022-12-31_GranteeStatusAxis-ShareBasedPaymentArrangementNonemployeeMember_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementNonemployeeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2022-01-01_2022-12-31_GranteeStatusAxis-ShareBasedPaymentArrangementNonemployeeMember_StatementEquityComponentsAxis-RetainedEarningsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementNonemployeeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2022-01-01_2022-12-31_GranteeStatusAxis-ShareBasedPaymentArrangementNonemployeeMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementNonemployeeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2022-01-01_2022-12-31_StatementEquityComponentsAxis-CommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2022-01-01_2022-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2022-01-01_2022-12-31_StatementEquityComponentsAxis-RetainedEarningsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="i_2022-12-31_StatementEquityComponentsAxis-CommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2022-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2022-12-31_StatementEquityComponentsAxis-RetainedEarningsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2022-12-31"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="d_2023-01-01_2023-12-31_GranteeStatusAxis-ShareBasedPaymentArrangementEmployeeMember_StatementEquityComponentsAxis-CommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2023-01-01_2023-12-31_GranteeStatusAxis-ShareBasedPaymentArrangementEmployeeMember_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2023-01-01_2023-12-31_GranteeStatusAxis-ShareBasedPaymentArrangementEmployeeMember_StatementEquityComponentsAxis-RetainedEarningsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2023-01-01_2023-12-31_GranteeStatusAxis-ShareBasedPaymentArrangementEmployeeMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2023-01-01_2023-12-31_GranteeStatusAxis-ShareBasedPaymentArrangementNonemployeeMember_StatementEquityComponentsAxis-CommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementNonemployeeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2023-01-01_2023-12-31_GranteeStatusAxis-ShareBasedPaymentArrangementNonemployeeMember_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementNonemployeeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2023-01-01_2023-12-31_GranteeStatusAxis-ShareBasedPaymentArrangementNonemployeeMember_StatementEquityComponentsAxis-RetainedEarningsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementNonemployeeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2023-01-01_2023-12-31_GranteeStatusAxis-ShareBasedPaymentArrangementNonemployeeMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementNonemployeeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2023-01-01_2023-12-31_StatementEquityComponentsAxis-CommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2023-01-01_2023-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2023-01-01_2023-12-31_StatementEquityComponentsAxis-RetainedEarningsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="i_2023-12-31_StatementEquityComponentsAxis-CommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2023-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2023-12-31_StatementEquityComponentsAxis-RetainedEarningsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="d_2024-01-01_2024-12-31_GranteeStatusAxis-ShareBasedPaymentArrangementEmployeeMember_StatementEquityComponentsAxis-CommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2024-01-01_2024-12-31_GranteeStatusAxis-ShareBasedPaymentArrangementEmployeeMember_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2024-01-01_2024-12-31_GranteeStatusAxis-ShareBasedPaymentArrangementEmployeeMember_StatementEquityComponentsAxis-RetainedEarningsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2024-01-01_2024-12-31_GranteeStatusAxis-ShareBasedPaymentArrangementEmployeeMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2024-01-01_2024-12-31_GranteeStatusAxis-ShareBasedPaymentArrangementNonemployeeMember_StatementEquityComponentsAxis-CommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementNonemployeeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2024-01-01_2024-12-31_GranteeStatusAxis-ShareBasedPaymentArrangementNonemployeeMember_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementNonemployeeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2024-01-01_2024-12-31_GranteeStatusAxis-ShareBasedPaymentArrangementNonemployeeMember_StatementEquityComponentsAxis-RetainedEarningsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementNonemployeeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2024-01-01_2024-12-31_GranteeStatusAxis-ShareBasedPaymentArrangementNonemployeeMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementNonemployeeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2024-01-01_2024-12-31_StatementEquityComponentsAxis-CommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2024-01-01_2024-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2024-01-01_2024-12-31_StatementEquityComponentsAxis-RetainedEarningsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="i_2024-12-31_StatementEquityComponentsAxis-CommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2024-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2024-12-31_StatementEquityComponentsAxis-RetainedEarningsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2024-01-03"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2024-01-03</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:unit id="Pure"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit>
<xbrli:context id="i_2024-12-31_ClassOfWarrantOrRightAxis-WarrantsToPurchaseCommonStockMember_MeasurementInputTypeAxis-MeasurementInputExercisePriceMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sava:WarrantsToPurchaseCommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExercisePriceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2024-12-31_ClassOfWarrantOrRightAxis-WarrantsToPurchaseCommonStockMember_MeasurementInputTypeAxis-MeasurementInputConversionPriceMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sava:WarrantsToPurchaseCommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputConversionPriceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2024-12-31_ClassOfWarrantOrRightAxis-WarrantsToPurchaseCommonStockMember_MeasurementInputTypeAxis-MeasurementInputSharePriceMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sava:WarrantsToPurchaseCommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputSharePriceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2024-12-31_ClassOfWarrantOrRightAxis-WarrantsToPurchaseCommonStockMember_MeasurementInputTypeAxis-MeasurementInputPriceVolatilityMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sava:WarrantsToPurchaseCommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2024-12-31_ClassOfWarrantOrRightAxis-WarrantsToPurchaseCommonStockMember_MeasurementInputTypeAxis-MeasurementInputRiskFreeInterestRateMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sava:WarrantsToPurchaseCommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2024-12-31_ClassOfWarrantOrRightAxis-WarrantsToPurchaseCommonStockMember_MeasurementInputTypeAxis-MeasurementInputExpectedTermMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sava:WarrantsToPurchaseCommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2024-12-31_ClassOfWarrantOrRightAxis-WarrantsToPurchaseCommonStockMember_MeasurementInputTypeAxis-MeasurementInputExpectedDividendRateMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sava:WarrantsToPurchaseCommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2024-05-07"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2024-05-07</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="d_2024-01-01_2024-12-31_StatementBusinessSegmentsAxis-CodmMonitoringMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">sava:CodmMonitoringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2023-01-01_2023-12-31_StatementBusinessSegmentsAxis-CodmMonitoringMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">sava:CodmMonitoringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2022-01-01_2022-12-31_StatementBusinessSegmentsAxis-CodmMonitoringMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">sava:CodmMonitoringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="i_2024-12-31_StatementBusinessSegmentsAxis-CodmMonitoringMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">sava:CodmMonitoringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2023-12-31_StatementBusinessSegmentsAxis-CodmMonitoringMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">sava:CodmMonitoringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:unit id="Year"><xbrli:measure>utr:Y</xbrli:measure></xbrli:unit>
<xbrli:context id="d_2024-01-01_2024-12-31_AwardTypeAxis-EmployeeStockOptionMember_RangeAxis-MinimumMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2024-01-01_2024-12-31_AwardTypeAxis-EmployeeStockOptionMember_RangeAxis-MaximumMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2024-01-01_2024-12-31_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-EmployeeStockOptionMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2023-01-01_2023-12-31_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-EmployeeStockOptionMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2022-01-01_2022-12-31_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-EmployeeStockOptionMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2024-01-01_2024-12-31_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-WarrantMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2023-01-01_2023-12-31_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-WarrantMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2022-01-01_2022-12-31_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-WarrantMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="i_2024-12-31_PropertyPlantAndEquipmentByTypeAxis-BuildingMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2024-12-31_PropertyPlantAndEquipmentByTypeAxis-BuildingImprovementsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="d_2024-07-15_2024-07-15_TitleOfIndividualAxis-FormerPresidentAndChiefExecutiveOfficerMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">sava:FormerPresidentAndChiefExecutiveOfficerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-15</xbrli:startDate><xbrli:endDate>2024-07-15</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2024-07-16_2024-07-16_TitleOfIndividualAxis-FormerSeniorVicePresidentMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">sava:FormerSeniorVicePresidentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-16</xbrli:startDate><xbrli:endDate>2024-07-16</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2024-01-01_2024-12-31_TitleOfIndividualAxis-FormerSeniorOfficerMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">sava:FormerSeniorOfficerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2024-01-01_2024-09-30_TitleOfIndividualAxis-FormerSeniorOfficerMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">sava:FormerSeniorOfficerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="i_2024-07-16_RelatedPartyTransactionsByRelatedPartyAxis-FormerSeniorVicePresidentMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">sava:FormerSeniorVicePresidentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-07-16</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="d_2024-01-01_2024-12-31_RelatedPartyTransactionsByRelatedPartyAxis-FormerSeniorVicePresidentMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">sava:FormerSeniorVicePresidentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:unit id="SquareFoot"><xbrli:measure>utr:sqft</xbrli:measure></xbrli:unit>
<xbrli:context id="i_2021-08-04_MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis-OfficeBuildingMember_StatementGeographicalAxis-TX"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis">srt:OfficeBuildingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:TX</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-08-04</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2024-12-31_MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis-OfficeBuildingMember_StatementGeographicalAxis-TX"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis">srt:OfficeBuildingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:TX</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2023-12-31_MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis-OfficeBuildingMember_StatementGeographicalAxis-TX"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis">srt:OfficeBuildingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:TX</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2024-12-31_PropertyPlantAndEquipmentByTypeAxis-LandMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LandMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2023-12-31_PropertyPlantAndEquipmentByTypeAxis-LandMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LandMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2023-12-31_PropertyPlantAndEquipmentByTypeAxis-BuildingMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2023-12-31_PropertyPlantAndEquipmentByTypeAxis-BuildingImprovementsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2024-12-31_PropertyPlantAndEquipmentByTypeAxis-LeaseholdImprovementsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2023-12-31_PropertyPlantAndEquipmentByTypeAxis-LeaseholdImprovementsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2024-12-31_PropertyPlantAndEquipmentByTypeAxis-FurnitureAndFixturesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2023-12-31_PropertyPlantAndEquipmentByTypeAxis-FurnitureAndFixturesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2024-12-31_PropertyPlantAndEquipmentByTypeAxis-ConstructionInProgressMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2023-12-31_PropertyPlantAndEquipmentByTypeAxis-ConstructionInProgressMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2024-12-31_FiniteLivedIntangibleAssetsByMajorClassAxis-LeasesAcquiredInPlaceMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LeasesAcquiredInPlaceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2023-12-31_FiniteLivedIntangibleAssetsByMajorClassAxis-LeasesAcquiredInPlaceMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LeasesAcquiredInPlaceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2024-12-31_FiniteLivedIntangibleAssetsByMajorClassAxis-LeasingCommissionsAndOtherMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">sava:LeasingCommissionsAndOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2023-12-31_FiniteLivedIntangibleAssetsByMajorClassAxis-LeasingCommissionsAndOtherMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">sava:LeasingCommissionsAndOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="d_2022-11-22_2022-11-22_SubsidiarySaleOfStockAxis-The2022RegisteredDirectOfferingMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sava:The2022RegisteredDirectOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-11-22</xbrli:startDate><xbrli:endDate>2022-11-22</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="i_2022-11-22_SubsidiarySaleOfStockAxis-The2022RegisteredDirectOfferingMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sava:The2022RegisteredDirectOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-11-22</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2023-05-01_SubsidiarySaleOfStockAxis-AtthemarketCommonStockOfferingMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sava:AtthemarketCommonStockOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-05-01</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="d_2024-01-01_2024-12-31_SubsidiarySaleOfStockAxis-AtthemarketCommonStockOfferingMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sava:AtthemarketCommonStockOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2022-05-05_2022-05-05_PlanNameAxis-The2018EquityIncentivePlanMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sava:The2018EquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-05-05</xbrli:startDate><xbrli:endDate>2022-05-05</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="i_2022-05-05_PlanNameAxis-The2018EquityIncentivePlanMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sava:The2018EquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-05-05</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="d_2024-01-01_2024-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-RangeOneMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">sava:RangeOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="i_2024-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-RangeOneMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">sava:RangeOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="d_2024-01-01_2024-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-RangeTwoMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">sava:RangeTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="i_2024-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-RangeTwoMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">sava:RangeTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="d_2024-01-01_2024-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-RangeThreeMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">sava:RangeThreeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="i_2024-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-RangeThreeMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">sava:RangeThreeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="d_2024-01-01_2024-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-RangeFourMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">sava:RangeFourMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="i_2024-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-RangeFourMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">sava:RangeFourMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="d_2024-01-01_2024-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-RangeFiveMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">sava:RangeFiveMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="i_2024-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-RangeFiveMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">sava:RangeFiveMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="d_2023-01-01_2023-12-31_AwardTypeAxis-EmployeeStockOptionMember_RangeAxis-MinimumMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2023-01-01_2023-12-31_AwardTypeAxis-EmployeeStockOptionMember_RangeAxis-MaximumMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2022-01-01_2022-12-31_AwardTypeAxis-EmployeeStockOptionMember_RangeAxis-MinimumMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2022-01-01_2022-12-31_AwardTypeAxis-EmployeeStockOptionMember_RangeAxis-MaximumMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2024-01-01_2024-12-31_AwardTypeAxis-EmployeeStockOptionMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2023-01-01_2023-12-31_AwardTypeAxis-EmployeeStockOptionMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2022-01-01_2022-12-31_AwardTypeAxis-EmployeeStockOptionMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="i_2024-12-31_AwardTypeAxis-EmployeeStockOptionMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2023-12-31_AwardTypeAxis-PerformanceSharesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="d_2024-01-01_2024-12-31_AwardTypeAxis-PerformanceSharesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="i_2024-12-31_AwardTypeAxis-PerformanceSharesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="d_2022-01-01_2022-12-31_AwardTypeAxis-PerformanceSharesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="i_2022-12-31_AwardTypeAxis-PerformanceSharesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="d_2024-01-01_2024-12-31_IncomeStatementLocationAxis-ResearchAndDevelopmentExpenseMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2023-01-01_2023-12-31_IncomeStatementLocationAxis-ResearchAndDevelopmentExpenseMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2022-01-01_2022-12-31_IncomeStatementLocationAxis-ResearchAndDevelopmentExpenseMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2024-01-01_2024-12-31_IncomeStatementLocationAxis-GeneralAndAdministrativeExpenseMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2023-01-01_2023-12-31_IncomeStatementLocationAxis-GeneralAndAdministrativeExpenseMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2022-01-01_2022-12-31_IncomeStatementLocationAxis-GeneralAndAdministrativeExpenseMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2024-01-01_2024-12-31_RestructuringCostAndReserveAxis-EmployeeSeveranceMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2023-01-01_2023-12-31_RestructuringCostAndReserveAxis-EmployeeSeveranceMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2023-01-01_2023-12-31_SubsidiarySaleOfStockAxis-AtthemarketCommonStockOfferingMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sava:AtthemarketCommonStockOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2022-01-01_2022-12-31_RestructuringCostAndReserveAxis-EmployeeSeveranceMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="i_2024-12-31_IncomeTaxAuthorityAxis-DomesticCountryMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2024-12-31_IncomeTaxAuthorityAxis-DomesticCountryMember_TaxPeriodAxis-CarryforwardSubjectToExpirationMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">sava:CarryforwardSubjectToExpirationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2024-12-31_IncomeTaxAuthorityAxis-DomesticCountryMember_TaxPeriodAxis-IndefiniteLifeCarryforwardsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">sava:IndefiniteLifeCarryforwardsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2024-12-31_IncomeTaxAuthorityAxis-DomesticCountryMember_TaxCreditCarryforwardAxis-ResearchMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2024-12-31_SupplyCommitmentAxis-SimufilamActiveIngredientMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SupplyCommitmentAxis">sava:SimufilamActiveIngredientMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2025-02-26_CounterpartyNameAxis-YaleUniversityMember_OtherCommitmentsAxis-LicenseAgreementMember_SubsequentEventTypeAxis-SubsequentEventMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sava:YaleUniversityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">sava:LicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-02-26</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2023-03-16_PlanNameAxis-CashIncentiveBonusPlanMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sava:CashIncentiveBonusPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-16</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2023-03-16_PlanNameAxis-CashIncentiveBonusPlanMember_RangeAxis-MinimumMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sava:CashIncentiveBonusPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-16</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2023-03-16_PlanNameAxis-CashIncentiveBonusPlanMember_RangeAxis-MaximumMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sava:CashIncentiveBonusPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-16</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:unit id="Day"><xbrli:measure>utr:D</xbrli:measure></xbrli:unit>
<xbrli:context id="d_2023-03-16_2023-03-16_PlanNameAxis-CashIncentiveBonusPlanMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sava:CashIncentiveBonusPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-03-16</xbrli:startDate><xbrli:endDate>2023-03-16</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2023-01-01_2023-03-16_PlanNameAxis-CashIncentiveBonusPlanMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sava:CashIncentiveBonusPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-16</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="i_2020-10-31_PlanNameAxis-CashIncentiveBonusPlanMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sava:CashIncentiveBonusPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-10-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2021-12-31_PlanNameAxis-CashIncentiveBonusPlanMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sava:CashIncentiveBonusPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2021-12-31_PlanNameAxis-CashIncentiveBonusPlanMember_RangeAxis-MinimumMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sava:CashIncentiveBonusPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="d_2021-01-01_2021-12-31_PlanNameAxis-CashIncentiveBonusPlanMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sava:CashIncentiveBonusPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2024-01-01_2024-12-31_PlanNameAxis-CashIncentiveBonusPlanMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sava:CashIncentiveBonusPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2021-08-28_2021-10-26_LitigationCaseAxis-ViolationsOfFederalSecuritiesLawsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">sava:ViolationsOfFederalSecuritiesLawsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-08-28</xbrli:startDate><xbrli:endDate>2021-10-26</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2022-06-30_2022-06-30_LitigationCaseAxis-ViolationsOfFederalSecuritiesLawsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">sava:ViolationsOfFederalSecuritiesLawsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-06-30</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2021-11-04_2023-06-20_LitigationCaseAxis-ShareholderDerivativeActionsTexasCourtMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">sava:ShareholderDerivativeActionsTexasCourtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-11-04</xbrli:startDate><xbrli:endDate>2023-06-20</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2021-11-01_2023-06-20_LitigationCaseAxis-ShareholderDerivativeActionsTexasCourtMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">sava:ShareholderDerivativeActionsTexasCourtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-11-01</xbrli:startDate><xbrli:endDate>2023-06-20</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2021-11-01_2023-06-20_LitigationCaseAxis-ShareholderDerivativeActionsTexasStateCourtMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">sava:ShareholderDerivativeActionsTexasStateCourtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-11-01</xbrli:startDate><xbrli:endDate>2023-06-20</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2021-11-01_2023-06-20_LitigationCaseAxis-ShareholderDerivativeActionsDelawareCourtMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">sava:ShareholderDerivativeActionsDelawareCourtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-11-01</xbrli:startDate><xbrli:endDate>2023-06-20</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2022-07-05_2022-07-05_LitigationCaseAxis-ShareholderDerivativeActionsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">sava:ShareholderDerivativeActionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-05</xbrli:startDate><xbrli:endDate>2022-07-05</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2024-03-18_2024-03-18_LitigationCaseAxis-ShareholderDerivativeActionsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">sava:ShareholderDerivativeActionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-03-18</xbrli:startDate><xbrli:endDate>2024-03-18</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2024-09-06_2024-09-06_LitigationCaseAxis-ShareholderDerivativeActionsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">sava:ShareholderDerivativeActionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-09-06</xbrli:startDate><xbrli:endDate>2024-09-06</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2025-02-01_2025-02-28_LitigationCaseAxis-ShareholderDerivativeActionsMember_SubsequentEventTypeAxis-SubsequentEventMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">sava:ShareholderDerivativeActionsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-02-01</xbrli:startDate><xbrli:endDate>2025-02-28</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2024-08-06_2024-08-06_LitigationCaseAxis-AntislappLawsuitMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">sava:AntislappLawsuitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-08-06</xbrli:startDate><xbrli:endDate>2024-08-06</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2023-12-22_2023-12-22_ClassOfWarrantOrRightAxis-WarrantsToPurchaseCommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sava:WarrantsToPurchaseCommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-12-22</xbrli:startDate><xbrli:endDate>2023-12-22</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="i_2023-12-22_ClassOfWarrantOrRightAxis-WarrantsToPurchaseCommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sava:WarrantsToPurchaseCommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-22</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="d_2024-01-03_2024-01-03_ClassOfWarrantOrRightAxis-WarrantsToPurchaseCommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sava:WarrantsToPurchaseCommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-03</xbrli:startDate><xbrli:endDate>2024-01-03</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="i_2024-01-03_ClassOfWarrantOrRightAxis-WarrantsToPurchaseCommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sava:WarrantsToPurchaseCommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-01-03</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2024-05-07_ClassOfWarrantOrRightAxis-WarrantsToPurchaseCommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sava:WarrantsToPurchaseCommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-05-07</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2024-12-31_ClassOfWarrantOrRightAxis-WarrantsToPurchaseCommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sava:WarrantsToPurchaseCommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="d_2024-01-04_2024-03-31_ClassOfWarrantOrRightAxis-WarrantsToPurchaseCommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sava:WarrantsToPurchaseCommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-04</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2024-04-01_2024-05-02_ClassOfWarrantOrRightAxis-WarrantsToPurchaseCommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sava:WarrantsToPurchaseCommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-05-02</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2024-01-01_2024-12-31_ClassOfWarrantOrRightAxis-WarrantsToPurchaseCommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sava:WarrantsToPurchaseCommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="i_2024-01-02"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2024-01-02</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="d_2024-01-03_2024-03-31_ClassOfWarrantOrRightAxis-WarrantsToPurchaseCommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sava:WarrantsToPurchaseCommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-03</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="i_2024-03-31_ClassOfWarrantOrRightAxis-WarrantsToPurchaseCommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sava:WarrantsToPurchaseCommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="d_2024-04-01_2024-06-30_ClassOfWarrantOrRightAxis-WarrantsToPurchaseCommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sava:WarrantsToPurchaseCommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="i_2024-06-30_ClassOfWarrantOrRightAxis-WarrantsToPurchaseCommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sava:WarrantsToPurchaseCommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2024-09-30_ClassOfWarrantOrRightAxis-WarrantsToPurchaseCommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sava:WarrantsToPurchaseCommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="d_2025-01-07_2025-01-07_RestructuringCostAndReserveAxis-WorkforceReductionMember_SubsequentEventTypeAxis-SubsequentEventMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">sava:WorkforceReductionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-07</xbrli:startDate><xbrli:endDate>2025-01-07</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="i_2025-03-31_RestructuringCostAndReserveAxis-WorkforceReductionMember_StatementScenarioAxis-ScenarioForecastMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">sava:WorkforceReductionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="d_2024-10-01_2024-12-31"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2024-10-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<ix:relationship linkRole="http://www.xbrl.org/2003/role/link" arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" toRefs="f6b7c5421-b40f-4704-986f-7fafec64f3cf" fromRefs="c123854937 c123854938 c123854939"/></ix:resources>
</ix:header></div>
  <div>
   &#160;
  </div>
  <div><div>
 &#160;
</div>
<p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><a href="#toc" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt">Table of Contents</a></p>
<hr style="height: 3px; color: #000000; background-color: #000000; width: 100%; border: none; margin: 3pt 0"/>
<hr style="height: 1px; color: #000000; background-color: #000000; width: 100%; border: none; margin: 0 0 3pt 0"/>
<p style="font-family:Times New Roman;font-size:12pt;font-variant:normal;text-align:center;margin:0pt;">&#160;</p>
<p style="font-family:Times New Roman;font-size:12pt;font-variant:normal;text-align:center;margin:0pt;"><b>UNITED STATES</b></p>
<p style="font-family:Times New Roman;font-size:12pt;font-variant:normal;text-align:center;margin:0pt;"><b>SECURITIES AND EXCHANGE COMMISSION</b></p>
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Washington, D.C. 20549</b></p>
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">&#160;</p>
<hr style="text-align: center; height: 1px; color: #000000; background-color: #000000; width: 25%; border: none; margin: 3pt auto"/>
<p style="font-family: Times New Roman; font-size: 14pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Form <ix:nonNumeric name="dei:DocumentType" contextRef="d_2024-01-01_2024-12-31" id="ixv-14653">10-K</ix:nonNumeric></b></p>
<hr style="text-align: center; height: 1px; color: #000000; background-color: #000000; width: 25%; border: none; margin: 3pt auto"/>
<p style="margin: 0pt; text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">&#160;<b>(Mark One)</b></p>
<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;"><tbody><tr><td style="vertical-align:top;width:5.2%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"><ix:nonNumeric name="dei:DocumentAnnualReport" format="ixt-sec:boolballotbox" contextRef="d_2024-01-01_2024-12-31" id="ixv-14654">&#9745;</ix:nonNumeric></p> </td><td style="vertical-align:top;width:94.4%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</b></p> </td></tr>
</tbody></table>
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>For the Fiscal Year Ended <ix:nonNumeric name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" contextRef="d_2024-01-01_2024-12-31" id="ixv-14655">December 31, 2024</ix:nonNumeric></b></p>
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>or</b></p>
<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;"><tbody><tr><td style="vertical-align:top;width:5.2%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"><ix:nonNumeric name="dei:DocumentTransitionReport" format="ixt-sec:boolballotbox" contextRef="d_2024-01-01_2024-12-31" id="ixv-14656">&#9744;</ix:nonNumeric></p> </td><td style="vertical-align:top;width:94.4%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</b></p> </td></tr>
</tbody></table>
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>For the transition period from </b><b><span style="text-decoration: underline; ">_____</span></b><b> to </b><b><span style="text-decoration: underline; ">_____</span></b></p>
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Commission File Number: <ix:nonNumeric name="dei:EntityFileNumber" contextRef="d_2024-01-01_2024-12-31" id="ixv-14657">000-29959</ix:nonNumeric></b></p>
<p style="font-family:Times New Roman;font-size:18pt;font-variant:normal;text-align:center;margin:0pt;"><b>Cassava Sciences, Inc.</b></p>
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">(Exact name of registrant as specified in its charter)</p>
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">&#160;</p>
<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;"><tbody><tr><td style="vertical-align: top; width: 50%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><ix:nonNumeric name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen" contextRef="d_2024-01-01_2024-12-31" id="ixv-14658">Delaware</ix:nonNumeric> </b></p> </td><td style="vertical-align: top; width: 50%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><ix:nonNumeric name="dei:EntityTaxIdentificationNumber" contextRef="d_2024-01-01_2024-12-31" id="ixv-14659">91-1911336</ix:nonNumeric> </b></p> </td></tr>
<tr><td style="vertical-align: top; width: 50%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><i>(State or other jurisdiction of</i></p> </td><td style="vertical-align: top; width: 50%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><i>(I.R.S. Employer</i></p> </td></tr>
<tr><td style="vertical-align: top; width: 50%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><i>incorporation or organization)</i></p> </td><td style="vertical-align: top; width: 50%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><i>Identification Number)</i></p> </td></tr>
</tbody></table>
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><ix:nonNumeric name="dei:EntityAddressAddressLine1" contextRef="d_2024-01-01_2024-12-31" id="ixv-14660">6801 N. Capital of Texas Highway, Building 1; Suite 300</ix:nonNumeric>, <ix:nonNumeric name="dei:EntityAddressCityOrTown" contextRef="d_2024-01-01_2024-12-31" id="ixv-14661">Austin</ix:nonNumeric>, <ix:nonNumeric name="dei:EntityAddressStateOrProvince" contextRef="d_2024-01-01_2024-12-31" id="ixv-14662">TX</ix:nonNumeric> <ix:nonNumeric name="dei:EntityAddressPostalZipCode" contextRef="d_2024-01-01_2024-12-31" id="ixv-14663">78731</ix:nonNumeric></p>
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>(<ix:nonNumeric name="dei:CityAreaCode" contextRef="d_2024-01-01_2024-12-31" id="ixv-14664">512</ix:nonNumeric>) <ix:nonNumeric name="dei:LocalPhoneNumber" contextRef="d_2024-01-01_2024-12-31" id="ixv-14665">501-2444</ix:nonNumeric></b></p>
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><i>(Address, including zip code, of registrant's principal executive offices and</i></p>
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><i>telephone number, including area code)</i></p>
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:15pt;">Securities registered pursuant to Section 12(b) of the Act:</p>
<p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">&#160;</p>
<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;"><tbody><tr><td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 40%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Title of each class</b></p> </td><td style="vertical-align: bottom; width: 1%;">&#160;</td><td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 18%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Trading</b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Symbol(s)</b></p> </td><td style="vertical-align: bottom; width: 1%;">&#160;</td><td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 40%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Name of each exchange on which registered</b></p> </td></tr>
<tr><td style="vertical-align: top; width: 40%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><ix:nonNumeric name="dei:Security12bTitle" contextRef="d_2024-01-01_2024-12-31" id="ixv-14666">Common Stock, $0.001 par value</ix:nonNumeric></p> </td><td style="vertical-align: bottom; width: 1%;">&#160;</td><td style="vertical-align: bottom; width: 18%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><ix:nonNumeric name="dei:TradingSymbol" contextRef="d_2024-01-01_2024-12-31" id="ixv-14667">SAVA</ix:nonNumeric></p> </td><td style="vertical-align: bottom; width: 1%;">&#160;</td><td style="vertical-align: bottom; width: 40%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><ix:nonNumeric name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" contextRef="d_2024-01-01_2024-12-31" id="ixv-14668">NASDAQ</ix:nonNumeric> Capital Market</p> </td></tr>
<tr><td style="vertical-align: top; width: 40%;">&#160;</td><td style="vertical-align: bottom; width: 1%;">&#160;</td><td style="vertical-align: bottom; width: 18%;">&#160;</td><td style="vertical-align: bottom; width: 1%;">&#160;</td><td style="vertical-align: bottom; width: 40%;">&#160;</td></tr>
</tbody></table>
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Securities registered pursuant to Section 12(g) of the Act: None</b></p>
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">&#160;</p>
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes&#160;&#9744; <ix:nonNumeric name="dei:EntityWellKnownSeasonedIssuer" contextRef="d_2024-01-01_2024-12-31" id="ixv-14669">No</ix:nonNumeric>&#160;&#9745;</p>
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act. Yes&#160;&#9744; <ix:nonNumeric name="dei:EntityVoluntaryFilers" contextRef="d_2024-01-01_2024-12-31" id="ixv-14670">No</ix:nonNumeric>&#160;&#9745;</p>
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. <ix:nonNumeric name="dei:EntityCurrentReportingStatus" contextRef="d_2024-01-01_2024-12-31" id="ixv-14671">Yes</ix:nonNumeric>&#160;&#9745; No&#160;&#9744;</p>
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (&#167;232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). <ix:nonNumeric name="dei:EntityInteractiveDataCurrent" contextRef="d_2024-01-01_2024-12-31" id="ixv-14672">Yes</ix:nonNumeric>&#160;&#9745; No&#160;&#9744;.</p>
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
 <div class="PGFTR" style="text-align: center; width: 100%">
  <div class="hf-row">
   <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
    1
   </div>
  </div>
 </div>
 <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
 <div class="PGHDR" style="text-align: left; width: 100%">
  <div class="hf-row">
   <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
    <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Table of Contents</a>
   </div>
  </div>
 </div>
</div>
<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company,&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act. (Check one):</p>
<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;"><tbody><tr><td style="vertical-align:top;width:49.9%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Large accelerated filer &#9744;</p> </td><td style="vertical-align:top;width:49.9%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Accelerated filer &#9744;</p> </td></tr>
<tr><td style="vertical-align:top;width:49.9%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><ix:nonNumeric name="dei:EntityFilerCategory" format="ixt-sec:entityfilercategoryen" contextRef="d_2024-01-01_2024-12-31" id="ixv-14673">Non-accelerated filer</ix:nonNumeric> &#9745;</p> </td><td style="vertical-align:top;width:49.9%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Smaller reporting company <ix:nonNumeric name="dei:EntitySmallBusiness" format="ixt-sec:boolballotbox" contextRef="d_2024-01-01_2024-12-31" id="ixv-14674">&#9745;</ix:nonNumeric></p> </td></tr>
<tr><td style="vertical-align:top;width:49.9%;">&#160;</td><td style="vertical-align:top;width:49.9%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Emerging growth company <ix:nonNumeric name="dei:EntityEmergingGrowthCompany" format="ixt-sec:boolballotbox" contextRef="d_2024-01-01_2024-12-31" id="ixv-14675">&#9744;</ix:nonNumeric></p> </td></tr>
</tbody></table>
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.&#160;&#9744;</p>
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">Indicate by check mark whether the registrant has filed a report on and attestation to its management&#8217;s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the&#160;Sarbanes-Oxley Act (15 USC. 7262(b)) by the registered public accounting firm that prepared or issued its audit report. <ix:nonNumeric name="dei:IcfrAuditorAttestationFlag" format="ixt-sec:boolballotbox" contextRef="d_2024-01-01_2024-12-31" id="ixv-14676">&#9744;</ix:nonNumeric></p>
<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 18pt;">If securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant included in the filing reflect the correction of an error to previously issued financial statements.&#160; <ix:nonNumeric name="dei:DocumentFinStmtErrorCorrectionFlag" format="ixt-sec:boolballotbox" contextRef="d_2024-01-01_2024-12-31" id="ixv-14677">&#9744;</ix:nonNumeric></p>
<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 18pt;">Indicate by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensation received by any of the registrant&#8217;s executive officers during the relevant recovery period pursuant to &#167;240.10D-1(b). &#9744;</p>
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act). Yes&#160;<ix:nonNumeric name="dei:EntityShellCompany" format="ixt-sec:boolballotbox" contextRef="d_2024-01-01_2024-12-31" id="ixv-14678">&#9744;</ix:nonNumeric> No&#160;&#9745;</p>
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">The aggregate market value of the voting and non-voting common equity held by non-affiliates was approximately $<ix:nonFraction name="dei:EntityPublicFloat" scale="6" unitRef="USD" decimals="0" format="ixt:num-dot-decimal" contextRef="i_2024-06-28" id="ixv-14679">558</ix:nonFraction>&#160;million computed by reference to the last sales price of $12.35&#160;as reported on the Nasdaq Capital Market, as of the last business day of the Registrant's most recently completed second fiscal quarter, June 28, 2024. The number of shares outstanding of the Registrant's common stock, par value $0.001 per share, on February 27, 2025&#160;was <ix:nonFraction name="dei:EntityCommonStockSharesOutstanding" scale="0" unitRef="Share" decimals="INF" format="ixt:num-dot-decimal" contextRef="i_2025-02-27" id="ixv-14680">48,307,896</ix:nonFraction>.</p>
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">&#160;</p>
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>DOCUMENTS INCORPORATED BY REFERENCE</b></p>
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">&#160;</p>
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">Portions of the Registrant's proxy statement for its 2025&#160;Annual Meeting of Stockholders (the &#8220;Proxy Statement&#8221;), to be filed with the U.S. Securities and Exchange Commission, no later than 120 days after the Registrant&#8217;s fiscal year ended December 31, 2024, are incorporated by reference to Part III of this Annual Report on Form 10-K.&#160;</p>
<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
<hr style="height: 1px; color: #000000; background-color: #000000; width: 100%; border: none; margin: 3pt 0"/>
<hr style="height: 3px; color: #000000; background-color: #000000; width: 100%; border: none; margin: 0 0 3pt 0"/>
<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
 <div class="PGFTR" style="text-align: center; width: 100%">
  <div class="hf-row">
   <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
    2
   </div>
  </div>
 </div>
 <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
 <div class="PGHDR" style="text-align: left; width: 100%">
  <div class="hf-row">
   <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
    <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Table of Contents</a>
   </div>
  </div>
 </div>
</div>
<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p></div>
  <div>
   &#160;
  </div>
  <div>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><a id="toc" title="toc" href="#"></a>CASSAVA SCIENCES, INC.</b></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>FORM 10-K</b></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>INDEX</b></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">&#160;</p>
   <table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">
    <tbody>
     <tr>
      <td style="vertical-align:top;width:10.3%;">&#160;</td>
      <td style="vertical-align:top;width:81.7%;">&#160;</td>
      <td style="vertical-align:top;width:7.4%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><span style="text-decoration: underline; ">Page</span></b></p> </td>
     </tr>

     <tr>
      <td colspan="3" style="vertical-align:top;width:99.8%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>PART I</b></p> </td>
     </tr>

     <tr>
      <td style="vertical-align:top;width:10.3%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Item 1.</p> </td>
      <td style="vertical-align:top;width:81.7%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><a href="#item1" style="-sec-extract:exhibit;">Business</a></p> </td>
      <td style="vertical-align:bottom;width:7.4%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><a class="tocPGNUM" href="#item1">6</a></p> </td>
     </tr>

     <tr>
      <td style="vertical-align:top;width:10.3%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Item 1A.</p> </td>
      <td style="vertical-align:top;width:81.7%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><a href="#item1a" style="-sec-extract:exhibit;">Risk Factors</a></p> </td>
      <td style="vertical-align: bottom; width: 7.4%; text-align: center;"><a class="tocPGNUM" href="#item1a">34</a></td>
     </tr>

     <tr>
      <td style="vertical-align:top;width:10.3%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Item 1B.</p> </td>
      <td style="vertical-align:top;width:81.7%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><a href="#item1b" style="-sec-extract:exhibit;">Unresolved Staff Comments</a></p> </td>
      <td style="vertical-align: bottom; width: 7.4%; text-align: center;"><a class="tocPGNUM" href="#item1b">78</a></td>
     </tr>

     <tr>
      <td style="vertical-align:top;width:10.3%;">Item 1C.</td>
      <td style="vertical-align:top;width:81.7%;"><a href="#item1c" style="-sec-extract:exhibit;">Cybersecurity</a></td>
      <td style="vertical-align: bottom; width: 7.4%; text-align: center;"><a class="tocPGNUM" href="#item1c">78</a></td>
     </tr>

     <tr>
      <td style="vertical-align:top;width:10.3%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Item 2.</p> </td>
      <td style="vertical-align:top;width:81.7%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><a href="#item2" style="-sec-extract:exhibit;">Properties</a></p> </td>
      <td style="vertical-align: bottom; width: 7.4%; text-align: center;"><a class="tocPGNUM" href="#item2">78</a></td>
     </tr>

     <tr>
      <td style="vertical-align:top;width:10.3%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Item 3.</p> </td>
      <td style="vertical-align:top;width:81.7%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><a href="#item3" style="-sec-extract:exhibit;">Legal Proceedings</a></p> </td>
      <td style="vertical-align: bottom; width: 7.4%; text-align: center;"><a class="tocPGNUM" href="#item3">79</a></td>
     </tr>

     <tr>
      <td style="vertical-align:top;width:10.3%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Item 4.</p> </td>
      <td style="vertical-align:top;width:81.7%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><a href="#item4" style="-sec-extract:exhibit;">Mine Safety Disclosures</a></p> </td>
      <td style="vertical-align: bottom; width: 7.4%; text-align: center;"><a class="tocPGNUM" href="#item4">79</a></td>
     </tr>

     <tr>
      <td style="vertical-align:top;width:10.3%;">&#160;</td>
      <td style="vertical-align:top;width:81.7%;">&#160;</td>
      <td style="vertical-align: top; width: 7.4%; text-align: center;">&#160;</td>
     </tr>

     <tr>
      <td colspan="3" style="vertical-align:top;width:99.8%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>PART II</b></p> </td>
     </tr>

     <tr>
      <td style="vertical-align:top;width:10.3%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Item 5.</p> </td>
      <td style="vertical-align:top;width:81.7%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 1pt;"><a href="#item5" style="-sec-extract:exhibit;">Market for Registrant<span style="text-decoration: underline; ">&#8217;</span><span style="text-decoration: underline; ">s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities</span></a></p> </td>
      <td style="vertical-align: bottom; width: 7.4%; text-align: center;"><a class="tocPGNUM" href="#item5">79</a></td>
     </tr>

     <tr>
      <td style="vertical-align:top;width:10.3%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Item 6.</p> </td>
      <td style="vertical-align:top;width:81.7%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><a href="#item6" style="-sec-extract:exhibit;">[Reserved]</a></p> </td>
      <td style="vertical-align: bottom; width: 7.4%; text-align: center;"><a class="tocPGNUM" href="#item6">80</a></td>
     </tr>

     <tr>
      <td style="vertical-align:top;width:10.3%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Item 7.</p> </td>
      <td style="vertical-align:top;width:81.7%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><a href="#item7" style="-sec-extract:exhibit;">Management<span style="text-decoration: underline; ">&#8217;</span><span style="text-decoration: underline; ">s Discussion and Analysis of Financial Condition and Results of Operations</span></a></p> </td>
      <td style="vertical-align: bottom; width: 7.4%; text-align: center;"><a class="tocPGNUM" href="#item7">81</a></td>
     </tr>

     <tr>
      <td style="vertical-align:top;width:10.3%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Item 7A.</p> </td>
      <td style="vertical-align:top;width:81.7%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><a href="#item7a" style="-sec-extract:exhibit;">Quantitative and Qualitative Disclosures About Market Risk</a></p> </td>
      <td style="vertical-align: bottom; width: 7.4%; text-align: center;"><a class="tocPGNUM" href="#item7a">90</a></td>
     </tr>

     <tr>
      <td style="vertical-align:top;width:10.3%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Item 8.</p> </td>
      <td style="vertical-align:top;width:81.7%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><a href="#item8" style="-sec-extract:exhibit;">Consolidated Financial Statements and Supplementary Data</a></p> </td>
      <td style="vertical-align: bottom; width: 7.4%; text-align: center;"><a class="tocPGNUM" href="#item8">90</a></td>
     </tr>

     <tr>
      <td style="vertical-align:top;width:10.3%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Item 9.</p> </td>
      <td style="vertical-align:top;width:81.7%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><a href="#item9" style="-sec-extract:exhibit;">Changes in and Disagreements with Accountants on Accounting and Financial Disclosure</a></p> </td>
      <td style="vertical-align: bottom; width: 7.4%; text-align: center;"><a class="tocPGNUM" href="#item9">115</a></td>
     </tr>

     <tr>
      <td style="vertical-align:top;width:10.3%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Item 9A.</p> </td>
      <td style="vertical-align:top;width:81.7%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><a href="#item9a" style="-sec-extract:exhibit;">Controls and Procedures</a>&#160;</p> </td>
      <td style="vertical-align: bottom; width: 7.4%; text-align: center;"><a class="tocPGNUM" href="#item9a">115</a></td>
     </tr>

     <tr>
      <td style="vertical-align:top;width:10.3%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Item 9B.</p> </td>
      <td style="vertical-align:top;width:81.7%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><a href="#item9b" style="-sec-extract:exhibit;">Other Information</a>&#160;</p> </td>
      <td style="vertical-align: bottom; width: 7.4%; text-align: center;"><a class="tocPGNUM" href="#item9b">116</a></td>
     </tr>

     <tr>
      <td style="vertical-align:top;width:10.3%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Item 9C.</p> </td>
      <td style="vertical-align:top;width:81.7%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><a href="#item9c" style="-sec-extract:exhibit;">Disclosure Regarding Foreign Jurisdiction that Prevent Inspection</a></p> </td>
      <td style="vertical-align: bottom; width: 7.4%; text-align: center;"><a class="tocPGNUM" href="#item9c">116</a></td>
     </tr>

     <tr>
      <td style="vertical-align:top;width:10.3%;">&#160;</td>
      <td style="vertical-align:top;width:81.7%;">&#160;</td>
      <td style="vertical-align: top; width: 7.4%; text-align: center;">&#160;</td>
     </tr>

     <tr>
      <td colspan="3" style="vertical-align:top;width:99.8%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>PART III</b></p> </td>
     </tr>

     <tr>
      <td style="vertical-align:top;width:10.3%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Item 10.</p> </td>
      <td style="vertical-align:top;width:81.7%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><a href="#item10" style="-sec-extract:exhibit;">Directors and Executive Officers and Corporate Governance</a></p> </td>
      <td style="vertical-align: bottom; width: 7.4%; text-align: center;"><a class="tocPGNUM" href="#item10">116</a></td>
     </tr>

     <tr>
      <td style="vertical-align:top;width:10.3%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Item 11.</p> </td>
      <td style="vertical-align:top;width:81.7%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><a href="#item11" style="-sec-extract:exhibit;">Executive Compensation</a></p> </td>
      <td style="vertical-align: bottom; width: 7.4%; text-align: center;"><a class="tocPGNUM" href="#item11">118</a></td>
     </tr>

     <tr>
      <td style="vertical-align:top;width:10.3%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Item 12.</p> </td>
      <td style="vertical-align:top;width:81.7%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><a href="#item12" style="-sec-extract:exhibit;">Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters</a></p> </td>
      <td style="vertical-align: bottom; width: 7.4%; text-align: center;"><a class="tocPGNUM" href="#item12">118</a></td>
     </tr>

     <tr>
      <td style="vertical-align:top;width:10.3%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Item 13.</p> </td>
      <td style="vertical-align:top;width:81.7%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><a href="#item13" style="-sec-extract:exhibit;">Certain Relationships and Related Transactions, and Director Independence</a></p> </td>
      <td style="vertical-align: bottom; width: 7.4%; text-align: center;"><a class="tocPGNUM" href="#item13">119</a></td>
     </tr>

     <tr>
      <td style="vertical-align:top;width:10.3%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Item 14.</p> </td>
      <td style="vertical-align:top;width:81.7%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><a href="#itme14" style="-sec-extract:exhibit;">Principal Accountant Fees and Services</a></p> </td>
      <td style="vertical-align: bottom; width: 7.4%; text-align: center;"><a class="tocPGNUM" href="#itme14">119</a></td>
     </tr>

     <tr>
      <td style="vertical-align:top;width:10.3%;">&#160;</td>
      <td style="vertical-align:top;width:81.7%;">&#160;</td>
      <td style="vertical-align: top; width: 7.4%; text-align: center;">&#160;</td>
     </tr>

     <tr>
      <td colspan="3" style="vertical-align:top;width:99.8%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>PART IV</b></p> </td>
     </tr>

     <tr>
      <td style="vertical-align:top;width:10.3%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Item 15.</p> </td>
      <td style="vertical-align:top;width:81.7%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><a href="#item15" style="-sec-extract:exhibit;">Exhibits and Consolidated Financial Statement Schedules</a></p> </td>
      <td style="vertical-align: top; width: 7.4%; text-align: center;"><a class="tocPGNUM" href="#item15">119</a></td>
     </tr>

     <tr>
      <td style="vertical-align:top;width:10.3%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Item 16.</p> </td>
      <td style="vertical-align:top;width:81.7%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><a href="#item16" style="-sec-extract:exhibit;">Form 10-K Summary</a></p> </td>
      <td style="vertical-align: top; width: 7.4%; text-align: center;"><a class="tocPGNUM" href="#item16">121</a></td>
     </tr>

     <tr>
      <td style="vertical-align:top;width:10.3%;"><a href="#sigs" style="-sec-extract:exhibit;">Signatures</a></td>
      <td style="vertical-align:top;width:81.7%;">&#160;</td>
      <td style="vertical-align: top; width: 7.4%; text-align: center;"><a class="tocPGNUM" href="#sigs">122</a></td>
     </tr>

    </tbody>
   </table>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
    <div class="PGFTR" style="text-align: center; width: 100%">
     <div class="hf-row">
      <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       3
      </div>
     </div>
    </div>
    <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
    <div class="PGHDR" style="text-align: left; width: 100%">
     <div class="hf-row">
      <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
       <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Table of Contents</a>
      </div>
     </div>
    </div>
   </div>
   <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
  </div>
  <div>
   &#160;
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left"><b>PART I</b></p>
  <p style="font-size: 10pt; font-family: &quot;Times New Roman&quot;; margin: 0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>FORWARD-LOOKING STATEMENTS AND NOTICES</b></p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">This Annual Report on Form 10-K, including the portions of our definitive Proxy Statement incorporated by reference herein, contains &#8220;forward-looking statements&#8221;. All statements other than statements of present or historical facts contained in this Annual Report, including statements anticipating or otherwise relating to our future results of operations and financial position, future results of clinical trials, business strategy, plans and objectives for future operations, and anticipated events or trends, are forward-looking statements. In some cases, forward-looking statements are identified by terms such as &#8220;aim,&#8221; &#8220;anticipate,&#8221; &#8220;believe,&#8221; &#8220;could,&#8221; &#8220;drive,&#8221; &#8220;estimate,&#8221; &#8220;expect,&#8221; &#8220;forecast,&#8221; &#8220;future,&#8221; &#8220;goal,&#8221; &#8220;intend,&#8221; &#8220;may,&#8221; &#8220;objective,&#8221; &#8220;plan,&#8221; &#8220;potential,&#8221; &#8220;project,&#8221; &#8220;seek,&#8221; &#8220;should,&#8221; &#8220;strategy,&#8221; &#8220;will&#8221; and &#8220;would&#8221; or the negatives of these terms or other comparable terminology.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 8pt;">Examples of forward-looking statements include, but are not limited to, statements about:</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">&#160;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px; font-size: 10pt;">
   <tbody>
    <tr style="vertical-align: top; font-size: 10pt;">
     <td style="width: 18pt; font-size: 10pt;">&#160;</td>
     <td style="width: 18pt; font-size: 10pt;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p> </td>
     <td style="width: auto; font-size: 10pt;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">the safety profile or treatment benefits, if any, of simufilam;</p> </td>
    </tr>

    <tr style="vertical-align: top; font-size: 10pt;">
     <td style="width: 18pt; font-size: 10pt;">&#160;</td>
     <td style="width: 18pt; font-size: 10pt;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p> </td>
     <td style="width: auto; font-size: 10pt;">our reliance on third-party contractors to conduct all of our clinical and non-clinical trials and to make drug supply, or their ability to do so on-time or on-budget;</td>
    </tr>

    <tr style="vertical-align: top; font-size: 10pt;">
     <td style="width: 18pt; font-size: 10pt;">&#160;</td>
     <td style="width: 18pt; font-size: 10pt;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p> </td>
     <td style="width: auto; font-size: 10pt;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">limitations around the interpretation of data from any studies that are not randomized controlled trials;</p> </td>
    </tr>

    <tr style="vertical-align: top; font-size: 10pt;">
     <td style="width: 18pt; font-size: 10pt;">&#160;</td>
     <td style="width: 18pt; font-size: 10pt;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p> </td>
     <td style="width: auto; font-size: 10pt;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">the ability of clinical scales to assess cognition or health with respect to Alzheimer&#8217;s disease;</p> </td>
    </tr>

    <tr>
     <td style="width: 18pt; font-size: 10pt;">&#160;</td>
     <td style="width: 18pt; font-size: 10pt;">&#9679;</td>
     <td style="width: auto; font-size: 10pt;">our plans or ability to expand therapeutic indications for simufilam outside of Alzheimer&#8217;s disease;</td>
    </tr>

    <tr>
     <td style="width: 18pt; font-size: 10pt;">&#160;</td>
     <td style="width: 18pt; font-size: 10pt;">&#9679;</td>
     <td style="width: auto; font-size: 10pt;">our ability to conduct planned preclinical studies of simufilam relating to epilepsy in Tuberous Sclerosis Complex (TSC)</td>
    </tr>

    <tr>
     <td style="width: 18pt; font-size: 10pt;">&#160;</td>
     <td style="width: 18pt; font-size: 10pt; vertical-align: top;">&#9679;</td>
     <td style="width: auto; font-size: 10pt;">our ability to initiate, conduct or analyze additional clinical and non-clinical studies with our product candidates targeted at Alzheimer&#8217;s disease, TSC-related&#160;epilepsy and other central nervous system disorders;</td>
    </tr>

    <tr style="vertical-align: top; font-size: 10pt;">
     <td style="width: 18pt; font-size: 10pt;">&#160;</td>
     <td style="width: 18pt; font-size: 10pt;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p> </td>
     <td style="width: auto; font-size: 10pt;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">the impact of pre-clinical findings on our ability to develop our product candidates;</p> </td>
    </tr>

    <tr style="vertical-align: top; font-size: 10pt;">
     <td style="width: 18pt; font-size: 10pt;">&#160;</td>
     <td style="width: 18pt; font-size: 10pt;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p> </td>
     <td style="width: auto; font-size: 10pt;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">the interpretation of results from our pre-clinical or early clinical studies, such as Phase 1 and Phase 2 studies;</p> </td>
    </tr>

    <tr style="vertical-align: top; font-size: 10pt;">
     <td style="width: 18pt; font-size: 10pt;">&#160;</td>
     <td style="width: 18pt; font-size: 10pt;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p> </td>
     <td style="width: auto; font-size: 10pt;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">our plans to further develop SavaDx, our investigational blood-based diagnostic product candidate;</p> </td>
    </tr>

    <tr style="vertical-align: top; font-size: 10pt;">
     <td style="width: 18pt; font-size: 10pt;">&#160;</td>
     <td style="width: 18pt; font-size: 10pt;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p> </td>
     <td style="width: auto; font-size: 10pt;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">the safety, efficacy, or potential therapeutic benefits of our product candidates;</p> </td>
    </tr>

    <tr style="font-size: 10pt;">
     <td style="width: 18pt; font-size: 10pt;">&#160;</td>
     <td style="width: 18pt; font-size: 10pt;">&#9679;</td>
     <td style="width: auto; font-size: 10pt;">our use of exploratory &#8216;research use only&#8217; non-safety related biomarkers in our clinical studies;</td>
    </tr>

    <tr style="vertical-align: top; font-size: 10pt;">
     <td style="width: 18pt; font-size: 10pt;">&#160;</td>
     <td style="width: 18pt; font-size: 10pt;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p> </td>
     <td style="width: auto; font-size: 10pt;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">our ability to file for and obtain regulatory approval of our product candidates;</p> </td>
    </tr>

    <tr style="vertical-align: top; font-size: 10pt;">
     <td style="width: 18pt; font-size: 10pt;">&#160;</td>
     <td style="width: 18pt; font-size: 10pt;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p> </td>
     <td style="width: auto; font-size: 10pt;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">our strategy and ability to establish an infrastructure to commercialize any product candidates, if approved;</p> </td>
    </tr>

    <tr style="vertical-align: top; font-size: 10pt;">
     <td style="width: 18pt; font-size: 10pt;">&#160;</td>
     <td style="width: 18pt; font-size: 10pt;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p> </td>
     <td style="width: auto; font-size: 10pt;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">the potential future revenues of our product candidates, if approved and commercialized;</p> </td>
    </tr>

    <tr style="vertical-align: top; font-size: 10pt;">
     <td style="width: 18pt; font-size: 10pt;">&#160;</td>
     <td style="width: 18pt; font-size: 10pt;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p> </td>
     <td style="width: auto; font-size: 10pt;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">the market acceptance of our product candidates, if approved and commercialized;</p> </td>
    </tr>

    <tr style="vertical-align: top; font-size: 10pt;">
     <td style="width: 18pt; font-size: 10pt;">&#160;</td>
     <td style="width: 18pt; font-size: 10pt;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p> </td>
     <td style="width: auto; font-size: 10pt;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">the pricing and reimbursement of our product candidates, if approved and commercialized;</p> </td>
    </tr>

    <tr style="vertical-align: top; font-size: 10pt;">
     <td style="width: 18pt; font-size: 10pt;">&#160;</td>
     <td style="width: 18pt; font-size: 10pt;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p> </td>
     <td style="width: auto; font-size: 10pt;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">the utility of protection, or the sufficiency, of our intellectual property;</p> </td>
    </tr>

    <tr style="vertical-align: top; font-size: 10pt;">
     <td style="width: 18pt; font-size: 10pt;">&#160;</td>
     <td style="width: 18pt; font-size: 10pt;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p> </td>
     <td style="width: auto; font-size: 10pt;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">our potential competitors or competitive products for the treatment of Alzheimer&#8217;s disease and other therapeutic areas we may elect to pursue;</p> </td>
    </tr>

    <tr style="vertical-align: top; font-size: 10pt;">
     <td style="width: 18pt; font-size: 10pt;">&#160;</td>
     <td style="width: 18pt; font-size: 10pt;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p> </td>
     <td style="width: auto; font-size: 10pt;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">our need to raise new capital from time to time to continue our operations or to expand our operations;</p> </td>
    </tr>

    <tr style="vertical-align: top; font-size: 10pt;">
     <td style="width: 18pt; font-size: 10pt;">&#160;</td>
     <td style="width: 18pt; font-size: 10pt;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p> </td>
     <td style="width: auto; font-size: 10pt;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">our use of multiple third-party vendors and collaborators, including a Clinical Research Organization (CRO), to conduct clinical and non-clinical studies of simufilam;</p> </td>
    </tr>

    <tr style="vertical-align: top; font-size: 10pt;">
     <td style="width: 18pt; font-size: 10pt;">&#160;</td>
     <td style="width: 18pt; font-size: 10pt;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p> </td>
     <td style="width: auto; font-size: 10pt;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">expectations regarding trade secrets, technological innovations, licensing agreements and outsourcing of certain business functions;</p> </td>
    </tr>

    <tr>
     <td style="width: 18pt; font-size: 10pt;">&#160;</td>
     <td style="width: 18pt; font-size: 10pt; vertical-align: top;">&#9679;</td>
     <td style="width: auto; font-size: 10pt;">our&#160;ability to successfully carry out our obligations under our License Agreement (as defined below) with Yale University (&#8220;Yale&#8221;), for which we have assumed all responsibility for global development and commercialization for simufilam for the treatment of TSC-related epilepsy;</td>
    </tr>

    <tr style="vertical-align: top; font-size: 10pt;">
     <td style="width: 18pt; font-size: 10pt;">&#160;</td>
     <td style="width: 18pt; font-size: 10pt;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p> </td>
     <td style="width: auto; font-size: 10pt;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">our expenses or incurred costs increasing by material amounts in excess of budgeted amounts due to unexpected cost overruns,&#160;imperfect forecasting, increased scope of activities or other causes;</p> </td>
    </tr>

    <tr style="vertical-align: top; font-size: 10pt;">
     <td style="width: 18pt; font-size: 10pt;">&#160;</td>
     <td style="width: 18pt; font-size: 10pt;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p> </td>
     <td style="width: auto; font-size: 10pt;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">fluctuations in our financial or operating results;</p> </td>
    </tr>

    <tr style="vertical-align: top; font-size: 10pt;">
     <td style="width: 18pt; font-size: 10pt;">&#160;</td>
     <td style="width: 18pt; font-size: 10pt;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p> </td>
     <td style="width: auto; font-size: 10pt;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">our operating losses, anticipated operating and capital expenditures and legal expenses;</p> </td>
    </tr>

    <tr style="vertical-align: top; font-size: 10pt;">
     <td style="width: 18pt; font-size: 10pt;">&#160;</td>
     <td style="width: 18pt; font-size: 10pt;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p> </td>
     <td style="width: auto; font-size: 10pt;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">expectations regarding the issuance of shares of common stock, options or other equity to employees or directors pursuant to equity compensation awards, net of employment taxes;</p> </td>
    </tr>

    <tr style="vertical-align: top; font-size: 10pt;">
     <td style="width: 18pt; font-size: 10pt;">&#160;</td>
     <td style="width: 18pt; font-size: 10pt;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p> </td>
     <td style="width: auto; font-size: 10pt;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">the development and maintenance of our internal information systems and infrastructure;</p> </td>
    </tr>

    <tr style="font-size: 10pt;">
     <td style="width: 18pt; font-size: 10pt;">&#160;</td>
     <td style="width: 18pt; font-size: 10pt;">&#9679;</td>
     <td style="width: auto; font-size: 10pt;">our ability to minimize the likelihood and impact of adverse cybersecurity incidents in our information systems and infrastructure;</td>
    </tr>

   </tbody>
  </table>
  <p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">&#160;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
      4
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px; font-size: 10pt;">
   <tbody>
    <tr style="vertical-align: top; font-size: 10pt;">
     <td style="width: 18pt; font-size: 10pt;">&#160;</td>
     <td style="width: 18pt; font-size: 10pt;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p> </td>
     <td style="width: auto; font-size: 10pt;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">our need to hire additional personnel and our ability to attract and retain such personnel;</p> </td>
    </tr>

    <tr style="vertical-align: top; font-size: 10pt;">
     <td style="width: 18pt; font-size: 10pt;">&#160;</td>
     <td style="width: 18pt; font-size: 10pt;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p> </td>
     <td style="width: auto; font-size: 10pt;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">existing or emerging regulations and regulatory developments in the United States and other jurisdictions in which we operate;</p> </td>
    </tr>

    <tr style="vertical-align: top; font-size: 10pt;">
     <td style="width: 18pt; font-size: 10pt;">&#160;</td>
     <td style="width: 18pt; font-size: 10pt;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p> </td>
     <td style="width: auto; font-size: 10pt;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">our expectations regarding the appropriate size and scope of our operations;</p> </td>
    </tr>

    <tr style="vertical-align: top; font-size: 10pt;">
     <td style="width: 18pt; font-size: 10pt;">&#160;</td>
     <td style="width: 18pt; font-size: 10pt;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p> </td>
     <td style="width: auto; font-size: 10pt;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">the sufficiency of our cash&#160;resources to continue to fund our operations;</p> </td>
    </tr>

    <tr style="vertical-align: top; font-size: 10pt;">
     <td style="width: 18pt; font-size: 10pt;">&#160;</td>
     <td style="width: 18pt; font-size: 10pt;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p> </td>
     <td style="width: auto; font-size: 10pt;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">potential future agreements with third parties in connection with the commercialization of our product candidates;</p> </td>
    </tr>

    <tr style="vertical-align: top; font-size: 10pt;">
     <td style="width: 18pt; font-size: 10pt;">&#160;</td>
     <td style="width: 18pt; font-size: 10pt;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p> </td>
     <td style="width: auto; font-size: 10pt;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">the accuracy of our estimates regarding expenses, loss contingency reserves, capital requirements, and needs for additional financing;</p> </td>
    </tr>

    <tr style="vertical-align: top; font-size: 10pt;">
     <td style="width: 18pt; font-size: 10pt;">&#160;</td>
     <td style="width: 18pt; font-size: 10pt;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p> </td>
     <td style="width: auto; font-size: 10pt;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">assumptions and estimates used for our disclosures regarding stock-based compensation;</p> </td>
    </tr>

    <tr style="vertical-align: top; font-size: 10pt;">
     <td style="width: 18pt; font-size: 10pt;">&#160;</td>
     <td style="width: 18pt; font-size: 10pt;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p> </td>
     <td style="width: auto; font-size: 10pt;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">the expense, timing and outcome of pending or future litigation or other legal proceedings and claims, including U.S. government inquiries; and</p> </td>
    </tr>

    <tr style="vertical-align: top; font-size: 10pt;">
     <td style="width: 18pt; font-size: 10pt;">&#160;</td>
     <td style="width: 18pt; font-size: 10pt;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p> </td>
     <td style="width: auto; font-size: 10pt;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">litigation, claims or other uncertainties that may arise from allegations made against us or our former employees or&#160;collaborators.</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-indent: 18pt; text-align: justify;">The forward-looking statements in this Annual Report are based on our beliefs, assumptions and expectations of our future performance, events and developments, based on currently available information and plans. Forward-looking statements involve risks and uncertainties, and our actual results and the timing of events may differ materially from those discussed in the forward-looking statements. Such forward-looking statements include, but are not limited to, those described in &#8220;Item 1A. Risk Factors&#8221;, and investors should consider such risks before investing in our Company.&#160; Accordingly, you should not place undue reliance upon any forward-looking statements.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -1pt; text-indent: 18pt;">We cannot assure you that we will realize the results or developments we expect or anticipate or, even if substantially realized, that they will affect us or our operations in the way we expect.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -1pt; text-indent: 18pt;">The forward-looking statements included in this Annual Report on Form 10-K are made only as of the date hereof. We undertake no obligation to publicly update or revise any forward-looking statement as a result of new information, future events or otherwise, except as required by law.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -1pt; text-indent: 18pt;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify; text-indent: 18pt;">This Annual&#160;Report on Form 10-K&#160;may also contain statistical data and drug information received from our&#160;independent consultants or based on industry publications or other publicly available information. We have not independently verified the accuracy or completeness of the data contained in these&#160;sources of data and information. Although we believe that such sources are reliable, we make no representations as to the accuracy or completeness of such data and&#160;information. You are cautioned not to give undue weight to such data and information.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 18pt;">In addition, statements that &#8220;we believe&#8221; or similar statements reflecting our beliefs, views, and opinions on the relevant subject are based upon information available to us as of the date of this Annual Report.&#160;While we believe such information forms a reasonable basis for such statements, such information may be limited or incomplete, and our statements should not be read to indicate that we have conducted an exhaustive inquiry into, or review of, all potentially available relevant information. These statements are inherently uncertain and involve a number of assumptions and limitations, and you are cautioned not to unduly rely upon these statements.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">Our research programs in neurodegeneration have historically benefited from scientific and financial support from the National Institutes of Health (NIH). The contents of this Annual Report are solely our responsibility and do not represent any views of NIH, the Department of Health and Human Services, or any other agency of the United States government, or any of our vendors, collaborators or unrelated third-parties<i>.</i></p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 18pt;">All our pharmaceutical assets under development are investigational product candidates. These have not been approved for use in any medical indication by any regulatory authority in any jurisdiction and their safety, efficacy or other desirable attributes, if any, have not been established in any patient population. Consequently, none of our product candidates are approved or available for sale anywhere in the world.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 18pt;">Our clinical results from earlier-stage clinical trials may not be indicative of future results from later-stage or larger scale clinical trials and do not ensure regulatory approval. You are cautioned that subsequent results may differ materially.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">&#160;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
      5
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify; text-indent: 18pt;">Other than our Phase 3 trials, all of our earlier-stage clinical trials have involved a relatively small number of patients and limited data. Information and results generated from our early-stage studies do not constitute, and should not be interpreted as, evidence of safety or efficacy for simufilam in Alzheimer&#8217;s disease. Rigorous evidence for drug safety and efficacy is required for regulatory approval and is derived from one or more large, randomized, placebo-controlled Phase 3 studies. The design and limited size of our early-stage studies may introduce clinical or statistical bias or may generate results that may not fully distinguish between drug effects, if any, placebo effects and random variation. Different methods of statistical analysis on clinical data from the same study may lead to objectively different numerical results. These and other statistical and clinical features of our early-stage clinical studies add complexity or limitations to the scope of data interpretation. In addition, &#8216;top-line results&#8217; is a summary of the clinical data prior to the completion of a full and final audit or quality-control of the clinical database. We generally communicate top-line results so that our stakeholders have timely access to a summary of a study&#8217;s findings prior to us receiving the final dataset. Final data may change from initial top-line data.</p>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 18pt;">Unless otherwise noted, all clinical data in this Annual Report is statistically non-significant at a standard probability level of p&lt;0.05. In addition, from time to time, our scientific research may include the use of exploratory biomarkers, typically labelled &#8216;research use only.&#8217; They are understood to mean non-safety-related, investigational diagnostic products that are in the research phase of development and have not been approved by any regulatory agency to be effective, sensitive, specific, accurate, predictive or linked to a specific diagnosis or indication. At present there is no sufficiently reliable evidence that any observed treatment effect on such biomarkers is reasonably likely to predict clinical benefit.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 18pt;">National Clinical Trial (NCT) is an eight-digit identification number that http://www.ClinicalTrials.gov assigns a clinical study when it is registered with the National Library of Medicine, which is operated by the United&#160;States government.</p>
  <div>
   &#160;
  </div>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><a id="item1" title="item1" href="#"></a>Item 1.</b>&#160;&#160;&#160;&#160;<b><i>Business</i></b></p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>Overview</b></p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">Cassava Sciences, Inc. is a clinical-stage biotechnology company based in Austin, Texas. Our mission is to detect and treat central nervous system disorders, such as Alzheimer&#8217;s disease and Tuberous Sclerosis Complex (TSC)-related epilepsy. Our novel science is based on stabilizing &#8211; but not removing &#8211; a critical protein in the brain for patients with certain central nervous system disorders, such as Alzheimer&#8217;s or TSC. Our lead therapeutic drug candidate, simufilam, was&#160;under clinical evaluation for the proposed treatment of Alzheimer&#8217;s disease&#160;in Phase 3 clinical studies through 2024, when all ongoing clinical trials for simufilam in Alzheimer&#8217;s disease were discontinued.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify; text-indent: 18pt;">We combine innovative&#160;technology with new insights in neurobiology to develop novel solutions targeting&#160;Alzheimer&#8217;s disease, TSC-related epilepsy,&#160;and other central nervous system disorders. Our strategy is to leverage our unique scientific/clinical platform to develop first-in-class programs for treating central nervous system disorders. In addition, we are in the early stages of exploring potential artificial intelligence (&#8220;AI&#8221;) capabilities and related data analytics to target improvements in productivity and efficiency in our business, enhancements to research and development activities, and advancements in statistical analysis capabilities.&#160;</p>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">We currently have two biopharmaceutical assets under development:</p>
  <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt 36pt; text-indent: -18pt;">&#160;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px; font-size: 10pt;">
   <tbody>
    <tr style="vertical-align: top; font-size: 10pt;">
     <td style="width: 18pt; font-size: 10pt;">&#160;</td>
     <td style="width: 18pt; font-size: 10pt;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p> </td>
     <td style="width: auto; font-size: 10pt;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">our lead therapeutic product candidate, called simufilam, is a proprietary small molecule oral treatment drug being studied&#160;for the treatment of Alzheimer&#8217;s disease and TSC-related epilepsy; and</p> </td>
    </tr>

    <tr style="vertical-align: top; font-size: 10pt;">
     <td style="width: 18pt; font-size: 10pt;">&#160;</td>
     <td style="width: 18pt; font-size: 10pt;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p> </td>
     <td style="width: auto; font-size: 10pt;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">our lead investigational diagnostic product candidate, called SavaDx, is a novel biomarker assay being studied for detection of&#160;the presence of Alzheimer&#8217;s disease from a small sample of blood.</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">Simufilam was discovered and designed in-house and was characterized by our academic collaborators during research activities that were conducted from approximately 2008 to date.</p>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 18pt;">Simufilam targets a protein called filamin A (FLNA) in the brain of patients with central nervous system disorders, such as Alzheimer&#8217;s or TSC. Our and our collaborators' published studies have demonstrated that an altered form of FLNA is linked to&#160;neuronal dysfunction, neuronal degeneration and neuroinflammation.&#160; In Alzheimer&#8217;s disease, we&#160;believe&#160;simufilam disrupts amyloid binding to the &#945;7 nicotinic acetylcholine receptor (&#945;7nAChR), which underlies our drug&#8217;s primary mechanism of action in Alzheimer&#8217;s disease. Published pre-clinical studies further show that overexpression of FLNA in patients with TSC may be associated with epileptic seizure activity.&#160;On February 26, 2025, we entered into a License Agreement (the &#8220;License Agreement&#8221;) with Yale to support our development and commercialization efforts for simufilam for the treatment of TSC-related epilepsy.&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">&#160;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
      6
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify; text-indent: 18pt;">We solely own patents covering the composition of matter of our drug simufilam in the United States, Europe, Australia, Israel and Canada. We solely own patents covering certain methods of use of our drug simufilam in the United States, Europe and Japan. We solely own pending patent applications that cover diagnostic assets for simufilam in the United States, Europe, Japan, China, Canada, and Australia. We solely own pending patent applications that cover other diagnostic assets in the United States, Europe, Japan, China and Canada. We have no obligation to pay any royalty to any third party in connection with any of the foregoing described patents and patent applications. In the United States, our patent protection with respect to simufilam, its solid forms, and uses of simufilam for Alzheimer&#8217;s disease and other neurodegenerative diseases includes nine issued United States patents, with terms expiring on dates ranging from 2029 to 2040, subject to any patent extensions that may be available for such patents. Corresponding foreign filings have been made for each of the Unites States filings.</p>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -1pt;"><b>About Alzheimer</b>&#8217;<b>s Disease</b></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 18pt;">Alzheimer&#8217;s disease is a degenerative disease of the brain that affects cognition, function and behavior. Over time, a patient&#8217;s cognition and health functions decline as the disease takes its toll. With disease progression, patients move from mild to moderate to, eventually, severe Alzheimer&#8217;s disease. Cognitive decline becomes more pronounced, and presumably more difficult to treat, in advanced stages of the disease.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -1pt; text-indent: 18pt;">An estimated 6.9&#160;million Americans age 65 and older were&#160;living with Alzheimer's dementia in 2024, according to the Alzheimer&#8217;s Association. According to the same source, in 2011, the largest ever demographic generation of the American population &#8212; the baby-boom generation &#8212; started reaching age 65. By 2030, the segment of the U.S. population age 65 and older will have grown substantially, and the projected 74 million older Americans will make up over 20% of the total population. Because age is a well-known risk factor for Alzheimer&#8217;s dementia, new cases of Alzheimer&#8217;s dementia are expected to climb with the growth in the number of elderly Americans.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -1pt; text-indent: 18pt;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -2pt;"><b>Clinical Trials in Alzheimer</b>&#8217;<b>s Disease&#160;(Discontinued)</b></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-indent: 18pt; text-align: justify;">We have conducted two randomized placebo-controlled Phase 3 clinical trials of oral simufilam in patients with mild-to-moderate Alzheimer&#8217;s disease. Our first Phase 3 study, called RETHINK-ALZ, was designed to evaluate the safety and efficacy of simufilam 100 mg tablets versus placebo over 52 weeks (NCT04994483). Our second Phase 3 study, called REFOCUS-ALZ, was designed to evaluate the safety and efficacy of oral simufilam 100 mg and 50 mg tablets versus placebo over 76 weeks (NCT05026177).</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-indent: 18pt; text-align: justify;">On November 25, 2024, we announced that the top-line results from the Phase 3 RETHINK-ALZ study of simufilam in mild-to-moderate Alzheimer's disease&#160;did not meet each of the pre-specified co-primary, secondary and exploratory biomarker endpoints. The co-primary endpoints were the change in cognition and function from baseline to the end of the double-blind treatment period at week 52, assessed by the ADAS-COG12 and ADCS-ADL scales, comparing simufilam to placebo.&#160;Simufilam continued to demonstrate an overall favorable safety profile.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -2pt; text-indent: 18pt; text-align: justify;">In light of the top-line results from the Phase 3 RETHINK-ALZ study, the Company also outlined its plan to discontinue the Phase 3 REFOCUS-ALZ study and Open Label Extension study and to analyze the complete 52-week dataset from the REFOCUS-ALZ study, along with a large portion of 76-week data. The Company expects to complete these efforts and plans to release top-line REFOCUS-ALZ results late first-quarter/early second-quarter 2025.&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 5pt;text-indent:18pt;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -4pt; text-indent: 18pt;">All statistical analyses for the REFOCUS-ALZ Phase 3 study&#160;data are&#160;being performed by independent biostatisticians at Pentara Corporation. Importantly, the database for each Phase 3 study was or will be unblinded and sent directly from the clinical research organization to the biostatisticians at Pentara. Pentara notifies us when their top-line statistical analyses have been completed. Cassava has no access to the unblinded data until after Pentara has performed its statistical analyses. Similarly, plasma samples have been provided directly to an independent, accredited commercial laboratory to perform analyses of these samples under blinded conditions.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify; text-indent: 18pt;">Following the release of the topline REFOCUS-ALZ results, the Company intends to evaluate the results and determine the next steps for the future advancement, if any, of its Alzheimer&#8217;s program.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;">&#160;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
      7
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -18pt; text-indent: 18pt;"><b>About Tuberous Sclerosis Complex (TSC)</b></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -2pt; text-indent: 18pt;">TSC is a genetic disorder that results from a mutation in the TSC1 or TSC2 genes. According to the Tuberous Sclerosis Alliance (TSCA), TSC is estimated to affect around 1 in 6,000 live births with approximately 50,000 people affected in the United States and more than one million worldwide. Clinical symptoms of TSC are variable and can impact organ systems with non-malignant tumors developing in brain, eyes, heart, kidney, skin and lungs. Interrelated neuropsychiatric manifestations of TSC such as intellectual disability, autism spectrum disorder, anxiety, aggression, attention deficit hyperactivity disorder, and sleep disturbance can significantly impact quality of life. Epilepsy is common in TSC, occurring in 84% of patients registered in the TSC Alliance Natural History Database with onset often occurring in their first year of life. Approximately 60 percent of TSC patients suffer from treatment-resistant seizures despite use of multiple anti-seizure medications. TSC-related epilepsy is associated with poor outcomes and increases the risk of cognitive deficits.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -18pt; text-indent: 18pt;"><b>Exploratory Preclinical Studies with Simufilam in Tuberous Sclerosis Complex (TSC)</b></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 18pt;">Preclinical research&#160;conducted at Yale indicate that simufilam (then PTI-125) may be effective in reducing TSC-related seizure activity. A study conducted by Angelique Bordey, PhD, at Yale&#160;and published in the peer-reviewed journal <i>Neuron</i> found overexpression of FLNA in brain tissue from TSC patients.&#160;The paper, MEK-ERK1/2-Dependent FLNA Overexpression Promotes Abnormal Dendritic Patterning in Tuberous Sclerosis Independent of mTOR (<i>Neuron</i>. 2014 Oct 1. PMID: 25277454), was co-authored by Zhang L, Bartley CM, Gong X, Hsieh LS, Lin TV and Feliciano DM.&#160; A later study conducted by Dr. Bordey and published in the peer-reviewed journal <i>Science Translational Medicine</i> in 2020 likewise found elevated FLNA in brains of a related mouse model. That study further demonstrated that simufilam treatment in the mouse model reduced the number of seizing mice and reduced seizure frequency. This 2020 paper, Filamin A Inhibition Reduces Seizure Activity in a Mouse Model of Focal Cortical Malformations&#160;(<i>Sci Transl Med</i>. 2020 Feb 19. PMID: 32076941), was co-authored by Zhang L, Huang T, Teaw S, Nguyen LH, Hsieh LS, Gong X, and Lindsay Burns, a former employee of the Company.&#160;While these data are promising, understanding their true significance requires additional exploration.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify; text-indent: 18pt;">We intend to conduct exploratory preclinical studies in collaboration with the TSCA to better understand simufilam&#8217;s potential as a treatment for TSC-related seizures. Based on the results of these&#160;studies, considered together with Dr. Bordey&#8217;s work, the Company will assess whether sufficient support exists for an Investigational New Drug (IND) application in respect of a proof-of-concept open-label clinical trial for simufilam in TSC-related epilepsy.</p>
  <p style="text-align: justify; font-size: 10pt; font-family: &quot;Times New Roman&quot;; margin: 0pt;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -20pt; text-indent: 17pt;"><i>License Agreement with Yale</i></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -2pt; text-indent: 17pt;">On February 26, 2025, we entered into the License Agreement with Yale pursuant to which we were granted exclusive worldwide rights, with rights to sublicense, to Yale&#8217;s interest in certain patent and other intellectual property rights that could be useful or necessary to the development and commercialization of simufilam for the treatment of TSC-related epilepsy and other potential indications. Pursuant to the License Agreement, we have agreed to use reasonable commercial efforts to implement a plan that it has designed for such development and commercialization.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -2pt; text-indent: 17pt;">In exchange for the rights acquired pursuant to the License Agreement, we agreed to pay Yale (i) a nominal&#160;upfront license fee, (ii) payments upon the achievement of specified clinical, regulatory and commercial milestones, totaling up to $4.5 million and (iii) upon transfer to a third party of a regulatory priority review voucher, if issued,&#160; a low-to-mid double digit percentage of any consideration received for such transfer. We also agreed to pay Yale tiered royalties, ranging from a low- to mid- single digit percentage, on aggregate net sales of licensed products, subject to tiered minimum annual royalty payments ranging from the low- to mid- hundreds of thousands of dollars.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -2pt; text-indent: 17pt;">Unless earlier terminated, the License Agreement will continue on a country-by-country basis until the later of (i) the date on which the last valid claim of the license patents expires or otherwise lapses, (ii) the end of any government or regulatory exclusivity period, and (iii) 10 years following the date of first sale of licensed product in such country. We may terminate the License Agreement: (i) at our option, upon specified advance notice to Yale and (ii) if Yale commits a material breach of the License Agreement that is not cured within a specified timeframe.&#160; Yale may terminate the License Agreement under specified circumstances, including if we (i) fail to make any payment due under the License Agreement and fail to cure such non-payment within a specified timeframe, (ii) commit a breach of the License Agreement that is not cured within a specified timeframe, (iii) default on a material obligation to any creditor, unless cured within a specified timeframe, (iv) fail to obtain or maintain insurance required by the License Agreement, (v) bring or assist a patent challenge against Yale (or if a sublicensee does so). In addition, the License Agreement will terminate automatically upon the occurrence of certain bankruptcy and insolvency events involving us.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt;">The License Agreement includes customary confidentiality, reporting and inspection, and indemnification provisions.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
      8
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -2pt;"><b>Risk is Fundamental to the Drug Development Process</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -1pt; text-indent: 18pt;">We are in the business of new drug discovery and&#160;development. Our research and development activities are long, complex, costly and involve a high degree of risk. Holders of our common stock should carefully read this Annual Report in its entirety, including &#8220;Item 1A. Risk Factors&#8221;. <i>Because risk is fundamental to the process of drug discovery and</i>&#160;<i>development, you are cautioned to not invest in our securities unless you are prepared to sustain a total loss of the money you have invested.</i></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -1pt;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -1pt;"><b>Our Scientific Approach is Different</b></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -1pt; text-indent: 18pt;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -1pt; text-indent: 18pt;">Our scientific approach is to treat central nervous system diseases by targeting a scaffolding protein called FLNA. Through years of basic research, we and our academic collaborators identified FLNA as a promising target for drug development in Alzheimer&#8217;s disease and, more recently, with respect to TSC-related epilepsy.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify; text-indent: 18pt;">Research that we sponsored has identified a family of high-affinity, small molecules to target FLNA as a means of potentially treating central nervous system disorders, including Alzheimer&#8217;s disease and TSC-related epilepsy. This family of small molecules, including simufilam, our lead small molecule (oral) therapeutic product candidate, was designed in-house and characterized by our academic collaborators.</p>
  <p style="text-align: justify; font-size: 10pt; font-family: &quot;Times New Roman&quot;; margin: 0pt;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -1pt;"><i>Our science is based on targeting a critical protein in the brain</i></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -1pt; text-indent: 18pt;">Proteins are essential for cell function because they participate in virtually every biological process. If protein function is impaired, the health consequences can be devastating. When disease changes the shape and/or function of critical proteins, multiple downstream processes can be impaired. Restoring shape and/or function is a well-accepted therapeutic strategy in clinical medicine.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify; text-indent: 18pt;">FLNA is a scaffolding protein found in the brain. A healthy scaffolding protein brings multiple proteins together, coordinating their interaction. Our product candidate, simufilam, targets&#160;FLNA&#160;and attempts to prevent abnormal functioning of this critical protein in diseases such as Alzheimer&#8217;s disease and TSC.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -2pt; text-indent: 18pt;">We believe simufilam&#160;impedes downstream toxic effects of altered or overexpressed FLNA.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -1pt; text-indent: 18pt;">In Alzheimer&#8217;s disease, this drug effect aims to restore the normal function of key brain receptors, including: the alpha-7 nicotinic acetylcholine receptor (&#945;7nAChR); the N-methyl-D-aspartate (NMDA) receptor; and the insulin receptor. These receptors have pivotal roles in brain cell survival, cognition and memory. By seeking to restore function to multiple receptors, our approach has potential to slow the progression of Alzheimer&#8217;s disease in patients.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -1pt; text-indent: 17pt;">We also believe simufilam may present an opportunity to potentially reduce seizures in patients with TSC.&#160;In TSC, preclinical studies in a mouse model indicate that simufilam reduces seizure activity in a manner similar to normalizing FLNA levels, but without actually lowering the level of FLNA.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;">&#160; &#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -2pt;"><i>Publication Confirming Mechanism of Action of Simufilam in Alzhieimer's disease</i></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-indent: 18pt; text-align: justify;">In September 2023, we&#160;announced the publication of confirmatory research with respect to the proposed mechanism of action of simufilam in Alzheimer&#8217;s disease. Researchers at the Cochin Institute (Paris, France) used a precise cell-based assay based on TR-FRET to show that simufilam interrupts amyloid binding to the &#945;7 nicotinic acetylcholine receptor (&#945;7nAChR). We&#160;believe&#160;disruption of amyloid binding to &#945;7nAChR underlies simufilam&#8217;s primary mechanism of action in Alzheimer&#8217;s disease. The research paper was co-authored by Hoau-Yan Wang and Zhe Pei of the City University of New York, Erika Cecon, Julie Dam and Ralf Jockers of the Institut Cochin, and Lindsay Burns, a former employee of Cassava Sciences, and appeared in a special<i> </i>issue of <i>International Journal of Molecular Sciences, </i>a peer-reviewed journal.</p>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -4pt; text-indent: 18pt;">Experiment conducted by Erika Cecon, Universit&#233; Paris Cit&#233;, Institut Cochin in an assay she developed: Cecon et al 2019; <i>Br J Pharmacol;</i> 176:3475-3488. Data shown are means of pooled data from 4 separate experiments &#177;SEM.&#160;Although Dr. Hoau-Yan Wang is listed as a co-author on the research paper, City University of New York and Dr.&#160;Wang had no involvement in the underlying research activities performed by Institut Cochin and Dr. Cecon. See &#8220;&#8212;2024 Non-Product Development Business Developments&#8212;Indictment of Hoau-Yan Wang.&#8221;</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
      9
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
  <div style="text-align: center;">
   <img alt="cab1ac4300e0img001.jpg" src="cab1ac4300e0img001.jpg"/></div>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -18pt; text-indent: 18pt;"><i>Publication Showing Simufilam Suppresses Overactive mTOR</i></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -18pt;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -10pt; text-indent: 27pt;">Recent data suggest that there also may be a beneficial&#160;impact of simufilam on mTOR signaling.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -4pt; text-indent: 18pt;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -4pt; text-indent: 18pt;">In June 2023, we&#160;announced the publication of research that showed the effects of simufilam on the mechanistic Target of Rapamycin&#160;(mTOR). Scientific literature shows overactive mTOR plays a key role in aging, Alzheimer&#8217;s disease and other conditions. When functioning normally, mTOR monitors cellular needs and is activated by insulin. The research shows mTOR is overactive in lymphocytes isolated from blood collected from Alzheimer's patients versus healthy controls. After oral administration of simufilam 100 mg twice daily to Alzheimer's patients for 28 days, lymphocytes showed normalized mTOR activity and restored&#160;sensitivity to insulin.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -18pt;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -2pt; text-indent: 18pt;">These data suggest a meaningful impact of simufilam on mTOR signaling. The suppression of overactive mTOR signaling and its improved responsiveness to insulin represents a mechanistic benefit of simufilam beyond the disruption of pathogenic signaling pathways of soluble amyloid. These improvements in mTOR signaling may also result from reversing an altered conformation of FLNA, allowing FLNA to dissociate from the insulin receptor when insulin binds and initiates signaling. This mTOR research paper was co-authored by Hoau-Yan Wang, Zhe Pei and Kuo-Chieh Lee of the City University of New York, Boris Nikolov, Tamara Doehner and John Puente, who were&#160;investigators in the clinical trial protocols, and Lindsay Burns, a former employee of Cassava Sciences. This research paper appeared in <i>Frontiers in Aging</i>, a peer-reviewed journal, which has issued an &#8220;Expression of Concern&#8221; noting that concerns have been raised by third parties alleging manipulation of certain images included in the paper.&#160;See &#8220;&#8212;2024 Non-Product Development Business Developments&#8212;Indictment of Hoau-Yan Wang.&#8221;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt 7pt; text-indent: 18pt;">&#160;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
      10
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt;"><b>Simufilam Drug Development</b></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 7pt;">Unless otherwise noted, all clinical data presented is statistically non-significant at a standard probability level of p&lt;0.05.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 7pt;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt;"><i>IND submission to FDA, Drug Safety in Early Clinical Studies</i></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -1pt; text-indent: 18pt;">For over a decade, we conducted basic research, in vitro studies and preclinical studies in support of a successful Investigational New Drug (IND) submission to the Food and Drug Administration (FDA) for simufilam, including requisite studies around safety pharmacology, toxicology, genotoxicity and bioanalytical methods. In 2017 we filed an IND with FDA for simufilam for Alzheimer&#8217;s disease.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -1pt; text-indent: 18pt;">Following FDA acceptance of our IND in 2017, we investigated the safety, dosing and pharmacokinetic profile of simufilam in healthy human volunteers. The design of our first-in-human Phase 1 study was based on regulatory feedback, clinical and scientific rationale and observations from previously conducted preclinical and in vitro studies. In this&#160;Phase 1 study, simufilam was evaluated in 24 healthy human volunteers (18 simufilam, 6 placebo) in a single site in the U.S. for safety, tolerability and pharmacokinetics. Study subjects were administered a single oral dose of 50, 100 or 200 mg of simufilam or placebo. Drug appeared&#160;safe and well-tolerated. Importantly, simufilam showed no treatment-related adverse effects and no dose-limiting safety findings. Pharmacokinetic measurements demonstrated that simufilam, a small molecule, was rapidly absorbed. Dose-proportionality was observed over the full dose range of 50 to 200 mg.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -1pt; text-indent: 18pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>24-Month Clinical Safety</b> <b>Study </b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">In March 2020, we initiated a Phase 2 clinical safety study of&#160;simufilam&#160;in patients with Alzheimer&#8217;s disease (NCT04388254).&#160;This study&#160;was funded in part by a research grant award from NIH. This study was designed to evaluate the long-term clinical safety and tolerability of&#160;simufilam&#160;in patients with Alzheimer&#8217;s disease over 24 months. The study&#160;included a pre-specified exploratory efficacy endpoint of mean change in ADAS-Cog11 scores, a cognitive scale widely used in Alzheimer&#8217;s clinical research. This study enrolled over 200 patients with mild-to-moderate Alzheimer&#8217;s disease (Mini-Mental State Examination (MMSE) 16-26) who were recruited from 16 U.S. clinical sites. Severity of disease was assessed by the MMSE score of enrolled patients, with&#160;mild patients having an MMSE score of 21-26 and moderate patients having an MMSE score of 16-20.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">We conducted the 24-month safety study in three continuous phases:</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 36pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">a 12-month, open-label treatment phase, followed by</p> </td>
    </tr>

    <tr style="vertical-align: top;">
     <td style="width: 36pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">a 6-month randomized, placebo-controlled withdrawal phase (previously referred to as the &#8220;Cognition Maintenance Study&#8221;&#160;or CMS), followed &#160;by</p> </td>
    </tr>

    <tr style="vertical-align: top;">
     <td style="width: 36pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">6 additional months of open-label treatment.</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">Study participants received simufilam oral tablets 100 mg twice-daily in the open-label treatment phases, and simufilam or matching placebo during the randomized withdrawal phase. In an open-label study design, both the health providers and the patients are aware of the drug treatment being given.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">All study participants who completed 12 months of open-label simufilam treatment were eligible to participate in the 6-month randomized, placebo-controlled withdrawal phase. Likewise, all study participants who completed the randomized, placebo-controlled withdrawal phase were eligible for 6 additional months of open-label treatment.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
      11
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>Study Results for the 12-month, Open-label Treatment Phase </b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">In January 2023, we announced top-line results for the 12-month, open-label treatment phase of the safety study.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"><b><i>Safety Data</i></b>&#160;- Simufilam 100 mg tablets twice daily appeared safe and well tolerated in this treatment phase of the open-label study. There were no drug-related serious adverse events. Three treatment-emergent adverse events (TEAEs) occurred in 7% or more of study patients: COVID-19 (12%), urinary tract infection (10%) and headache (9%). Reported TEAEs are based on all study patients who received at least one dose of drug.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"><b><i>Exploratory Efficacy Endpoint Data </i></b>&#8211;<b><i> </i></b>The table below provides a high-level summary of the pre-specified, exploratory efficacy endpoints data.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <table cellpadding="0" cellspacing="0" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 80%; margin-left: 10%; margin-right: 10%;">
   <tbody>
    <tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
     <td style="border-width: 1px; border-style: solid; border-color: rgb(0, 0, 0) black; vertical-align: top; width: 23.7%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td colspan="2" style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 42.7%; border-top: 1px solid rgb(0, 0, 0); border-right: 1px solid black; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Simufilam 100 mg BID</b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>N= 216</b></p> </td>
    </tr>

    <tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 23.7%; border-right: 1px solid black; border-left: 1px solid black; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>Exploratory Endpoint Data*</b></p> </td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 23.7%; border-right: 1px solid black; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">Baseline (Study Entry)</p> </td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 19%; border-right: 1px solid black; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">Month 12</p> </td>
    </tr>

    <tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 23.7%; border-right: 1px solid black; border-left: 1px solid black; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">ADAS-COG11 (&#177;SD)</p> </td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 23.7%; border-right: 1px solid black; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">19.1 (&#177;9.2)</p> </td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 19%; border-right: 1px solid black; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">19.6 (&#177;13.3)</p> </td>
    </tr>

    <tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 23.7%; border-right: 1px solid black; border-left: 1px solid black; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">MMSE (&#177;SD)</p> </td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 23.7%; border-right: 1px solid black; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">21.5 (&#177;3.6 )</p> </td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 19%; border-right: 1px solid black; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">20.2 (&#177;6.4)</p> </td>
    </tr>

    <tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 23.7%; border-right: 1px solid black; border-left: 1px solid black; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">NPI10 (&#177;SD)</p> </td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 23.7%; border-right: 1px solid black; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">3.2 (&#177;4.6 )</p> </td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 19%; border-right: 1px solid black; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">2.9 (&#177;4.6 )</p> </td>
    </tr>

    <tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 23.7%; border-right: 1px solid black; border-left: 1px solid black; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">GDS (&#177;SD)</p> </td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 23.7%; border-right: 1px solid black; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">1.8 (&#177;1.8)</p> </td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 19%; border-right: 1px solid black; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">1.4 (&#177;1.9 )</p> </td>
    </tr>

    <tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
     <td colspan="3" style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 66.4%; border-left: 1px solid black; border-right: 1px solid black; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">*Full Analysis Set Population (N=216)</p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>BID</b>&#160;= twice daily</p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>ADAS-COG11</b>&#160;= The Alzheimer&#8217;s Disease Assessment Scale &#8211;&#160;Cognitive Subscale (a lower number represents less cognitive impairment)</p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>MMSE</b>&#160;= The Mini-Mental State Examination (a higher score indicates better cognitive function)</p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>NPI10</b>&#160;= The Neuropsychiatric Inventory scale, which assesses dementia-related behavior (a lower score indicated higher quality of life)</p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>GDS</b>&#160;= The Geriatric Depression Scale (a lower score signifies lesser severity of depressive symptoms)</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>Study Results for the 6-month,</b>&#160;<b>Randomized Withdrawal Study Phase</b>&#160;<b>("Cognition Maintenance Study")</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">In May 2021, we initiated the randomized, withdrawal phase of the 24-month safety study, which has been previously referred to as the &#8216;Cognition Maintenance Study' or CMS. The CMS utilized&#160;a randomized, withdrawal study design. The International Council for Harmonization of Technical Requirements for Pharmaceuticals for Human Use (ICH) explains that in a randomized withdrawal study,<i> </i>&#8220;<i>subjects receiving a test</i>&#160;<i>treatment for a specified time are randomly assigned to continued treatment with the test treatment or to placebo (i.e., withdrawal of active therapy) </i>&#8230;&#160;<i>Any difference that emerges between the group receiving continued treatment and the group randomized to placebo would demonstrate the effect of the active treatment</i>.&#8221;</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">The design of the randomized, withdrawal phase of the study was intended to provide an exploratory evaluation of simufilam&#8217;s effects on cognition and health outcomes in Alzheimer&#8217;s patients who continue with drug treatment versus patients who discontinue drug treatment. This was a double-blind, randomized, placebo-controlled study of simufilam in patients with mild-to-moderate Alzheimer&#8217;s disease. Study patients were randomized (1:1) to simufilam or placebo for six months. To enroll in the CMS, patients must have previously completed 12 months or more of open-label treatment with simufilam. Final enrollment was 157 patients.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
      12
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"><b>Design</b>&#160;<b>of the Randomized Withdrawal Phase (CMS) </b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <div style="text-align: center;">
   <img alt="cms.jpg" src="cms.jpg"/></div>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Upon randomization into the&#160;withdrawal phase, mean baseline MMSE scores were 20.2&#160;and 19.4&#160;for the simufilam and placebo arms, respectively. Mean baseline ADAS-Cog scores were 19.3 and 21.9 for the simufilam and placebo arms, respectively.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>Safety Data</i></b>&#160;&#8211; Simufilam 100 mg tablets twice daily appeared safe and well tolerated in the 6-month, randomized withdrawal phase of the 24-month safety study.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>Top-line Results</i></b>&#160;&#8211; The table below provides a high-level summary of the exploratory efficacy endpoints data for the 6-month, randomized withdrawal phase of the 24-month safety study.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 100%;">
   <tbody>
    <tr>
     <td style="border-width: 1px; border-style: solid; border-color: black black rgb(0, 0, 0); vertical-align: top; width: auto;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Exploratory Endpoint Data</b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>N=155*</b></p> </td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: auto; border-top: 1px solid black; border-right: 1px solid black;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Simufilam 100 mg BID</b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>N= 78</b></p> </td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: auto; border-top: 1px solid black; border-right: 1px solid black;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Placebo BID</b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>N= 77</b></p> </td>
    </tr>

    <tr>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: auto; border-left: 1px solid black; border-right: 1px solid black;">&#160;</td>
     <td colspan="2" style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: auto; border-right: 1px solid black;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Not statistically significant</b></p> </td>
    </tr>

    <tr>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: auto; border-right: 1px solid black; border-left: 1px solid black;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">6-Month Change in&#160;(&#177;SE)<br/> LS Mean ADAS-COG11 score**</p> </td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: auto; border-right: 1px solid black;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">+0.92 (&#177;0.545)</p> </td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: auto; border-right: 1px solid black;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">+1.49 (&#177;0.561)</p> </td>
    </tr>

    <tr>
     <td colspan="3" style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: auto; border-left: 1px solid black; border-right: 1px solid black;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">*Full Analysis Set Population</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">**Increase represents decline in cognition</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>BID</b>&#160;= twice daily</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>ADAS-COG11</b>&#160;= The Alzheimer&#8217;s Disease Assessment Scale &#8211;&#160;Cognitive Subscale</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>Study Results for the 24-Month Safety Study </b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>Safety Data</i></b>&#160;&#8211; Oral simufilam 100 mg tablets twice daily appeared safe and well tolerated in this study. There were no drug-related serious adverse events. The most common treatment-emergent adverse events (TEAEs) were Covid-19 and urinary tract infection.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
      13
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>Top-line Results</i></b>&#160;&#8211; The table below provides a high-level summary of the exploratory efficacy endpoints data for the 24-month safety study.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <table cellpadding="0" cellspacing="0" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 85%; margin-left: 7.5%; margin-right: 7.5%;">
   <tbody>
    <tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
     <td style="border-width: 1px; border-style: solid; border-color: black black rgb(0, 0, 0); vertical-align: middle; width: 35%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Exploratory Endpoint Data</b></p> </td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 34%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-right: 1px solid black; border-top: 1px solid black;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Simufilam 100 mg BID</b><br/> <b>Continuously for 24-Mos.</b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Mild Patients (N= 47)</b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Moderate Patients (N=32)</b></p> </td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 31%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-right: 1px solid black; border-top: 1px solid black;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Simufilam 100 mg BID</b><br/> <b>Non-continuously* for 24-Mos.</b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Mild Patients (N= 40)</b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Moderate Patients (N=35)</b></p> </td>
    </tr>

    <tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 35%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-left: 1px solid black; border-right: 1px solid black;">&#160;</td>
     <td colspan="2" style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 34%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-right: 1px solid black;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Not statistically significant</b></p> </td>
    </tr>

    <tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 35%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-left: 1px solid black; border-right: 1px solid black;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>Mild Patients -- </b>Average Change in ADAS-COG11 score, Baseline to Month 24 (&#177;SE)**</p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#160;</p> </td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 34%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-right: 1px solid black;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">+0.07 (&#177;1.51)</p> </td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 31%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-right: 1px solid black;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">+1.04 (&#177;1.65)</p> </td>
    </tr>

    <tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 35%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-left: 1px solid black; border-right: 1px solid black;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>Moderate Patients -- </b>Average Change in ADAS-COG11 score, Baseline to Month 24 (&#177;SE)**</p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#160;</p> </td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 34%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-right: 1px solid black;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">+11.05 (&#177;1.91)</p> </td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 31%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-right: 1px solid black;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">+14.26 (&#177;1.79)</p> </td>
    </tr>

    <tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
     <td colspan="3" style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 69%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-left: 1px solid black; border-right: 1px solid black;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>BID</b>&#160;= twice daily</p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>* Non-continuous treatment</b>&#160;= one year on open-label simufilam, six months on placebo, and six months on open-label simufilam</p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">** Increase represents decline in cognition</p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>ADAS-COG11</b>&#160;= The Alzheimer&#8217;s Disease Assessment Scale &#8211;&#160;Cognitive Subscale</p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>Mild Patients = </b>MMSE 21-26 (N=87), with ten exceptions (MMSE&gt;26) due to prior participation or evidence of Alzheimer&#8217;s disease pathology</p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>Moderate = </b>MMSE 16-20 (N=67), with one patient who entered with MMSE 15</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-size: 10pt; font-family: &quot;Times New Roman&quot;; margin: 0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Phase 2b Clinical Study</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">In September 2020, we reported final results of a 28-day, approximately 60-patient, randomized, double-blind, placebo-controlled, multiple dose Phase 2b clinical trial of simufilam for the treatment of Alzheimer&#8217;s disease (the &#8220;Phase 2b Study&#8221;). See &#8220;Item 1A. Risk Factors&#8212;<i>The validity of aspects of</i> <i>the Company</i>&#8217;<i>s Phase 2b Study has been called into question</i>&#8221; in this Annual&#160;Report on Form 10-K.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>Special Protocol Assessments</b></p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">In August 2021, we announced we had reached agreement with FDA under a Special Protocol Assessment (SPA) for our two Phase 3 studies. The first clinical study protocol under the SPA is titled &#8220;A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, 52-Week Study Evaluating the Safety and Efficacy of One Dose of Simufilam in Subjects with Mild-to-Moderate Alzheimer&#8217;s Disease.&#8221; The second clinical study protocol under the SPA is titled &#8220;A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, 76-Week Study Evaluating the Safety and Efficacy of Two Doses of Simufilam in Subjects with Mild-to-Moderate Alzheimer&#8217;s Disease.&#8221;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
      14
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">These SPA agreements document that FDA has reviewed and agreed upon the key design features of our Phase 3 study protocols of simufilam for the treatment of patients with Alzheimer&#8217;s disease. In particular, an SPA agreement indicates concurrence by the FDA with the adequacy and acceptability of specific critical elements of overall protocol design (e.g., entry criteria, dose selection, endpoints, etc.). SPA agreements provide confidence that based on the applicable protocols, the covered&#160;Phase 3 studies of simufilam in Alzheimer&#8217;s disease could&#160;potentially be considered adequate and well-controlled studies in support of a future regulatory submission and marketing application.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-indent: 18pt;">With the failure of RETHINK-ALZ to meet its prespecified co-primary endpoints and our decision to terminate REFOCUS-ALZ early, as announced on November 25, 2024, the SPAs for our Phase 3 clinical trials may no longer apply.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -4pt; text-indent: 18pt;">In Fall 2021, we announced initiation of these two Phase 3 studies of simufilam in mild-to-moderate Alzheimer&#8217;s disease.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 18pt;">Our Phase 3 program consisted&#160;of two large, double-blind, randomized, placebo-controlled studies of simufilam in patients with mild-to-moderate Alzheimer&#8217;s disease. Both studies were&#160;designed to measure changes in cognition and function during their treatment period. Key aspects&#160;of this clinical program are summarized below.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -1pt; text-indent: 18pt;">Premier Research International is the&#160;CRO that supported&#160;the&#160;conduct of our Phase 3 clinical program. Our Phase 3 clinical sites were&#160;located in the United States, Canada, Puerto Rico, Australia, and South Korea.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -1pt; text-indent: 18pt;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt 2pt; text-indent: 18pt;">All statistical analyses for the REFOCUS-ALZ Phase 3 study&#160;will be performed by independent biostatisticians at Pentara Corporation. Importantly, the unblinded database for each Phase 3 study will be sent directly from the clinical research organization to the biostatisticians at Pentara. Pentara will notify us when their top-line statistical analyses have been completed. Cassava will have no access to the unblinded data until after Pentara has performed its statistical analyses. Similarly, plasma samples are being provided directly to an independent, accredited commercial laboratory, which will perform analyses of these samples under blinded conditions.&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 8pt;text-indent:18pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"><b>Summary of Our Phase 3 Clinical Program&#160;(Now Discontinued)</b></p>
  <div style="text-align: center;">
   <img alt="slide03.jpg" src="slide03.jpg"/></div>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
      15
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>RETHINK-ALZ and REFOCUS-ALZ</b></p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -2pt; text-indent: 18pt;">In&#160;November 2023, we announced the completion of patient enrollment in both Phase 3 studies. A total of approximately 1,900 patients were&#160;randomized&#160;into these studies.&#160;Approximately 70% of randomized patients entered our Phase 3 studies with mild Alzheimer&#8217;s disease (MMSE 20 to 27).</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -2pt; text-indent: 18pt;">The first Phase 3 study, called RETHINK-ALZ, was&#160;designed to evaluate the safety and efficacy of oral simufilam 100 mg over 52 weeks (NCT04994483).&#160;Details of the RETHINK-ALZ Phase 3 study include:</p>
  <p style="font-size: 10pt; font-family: &quot;Times New Roman&quot;; margin: 0pt;">&#160;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">
   <tbody>
    <tr style="vertical-align: top; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">
     <td style="width: 18pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">&#160;</td>
     <td style="width: 18pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9658;</p> </td>
     <td style="width: auto; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">Approximately 800&#160;patients were randomized into this study.</td>
    </tr>

    <tr style="vertical-align: top; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">
     <td style="width: 18pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">&#160;</td>
     <td style="width: 18pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9658;</p> </td>
     <td style="width: auto; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Patients were&#160;randomized (1:1) to simufilam 100 mg tablets or matching placebo twice daily.</p> </td>
    </tr>

    <tr style="vertical-align: top; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
     <td style="width: 18pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="width: 18pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9658;</p> </td>
     <td style="width: auto; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Patients were&#160;treated for 52 weeks.</p> </td>
    </tr>

    <tr style="vertical-align: top; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
     <td style="width: 18pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="width: 18pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: justify;">&#9658;</td>
     <td style="width: auto; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="margin: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: justify;">Co-primary efficacy endpoints were&#160;change from baseline in the ADAS-Cog12, a cognitive scale, and the ADCS-ADL, a functional scale, each of which is a standard psychometric assessment tool in trials of Alzheimer&#8217;s disease.</p> </td>
    </tr>

    <tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
     <td style="width: 18pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="width: 18pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: justify;">&#9658;</td>
     <td style="width: auto; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">A secondary efficacy endpoint was change from baseline in the iADRS, which is an integrated tool that combines scores from the ADAS-Cog12 and the ADCS-ADL.</td>
    </tr>

    <tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
     <td style="width: 18pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="width: 18pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: justify; vertical-align: top;">&#9658;</td>
     <td style="width: auto; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; margin: 0pt;">Other secondary endpoints included change from baseline in:</p> <p style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; margin: 0pt;">&#9679; the Neuropsychiatric inventory (NPI), a clinical tool that assesses the frequency and severity of common dementia-related symptoms;&#160;</p> <p style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; margin: 0pt;">&#9679; the Mini-Mental State Exam (MMSE), a screening tool for cognitive impairment that examines orientation, registration, attention and calculation, recall, language, repetition, complex commands, and visuospatial ability;</p> <p style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; margin: 0pt;">&#9679; the Dementia Rating Sum of Boxes (CDR-SB), which characterizes 6 domains of cognitive and functional performance applicable to Alzheimer&#8217;s disease and related dementias; and</p> <p style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; margin: 0pt;">&#9679; the Zarit Burden Interview (ZBI), which is a study partner questionnaire designed to assess the stress or burden experienced by caregivers.</p> </td>
    </tr>

    <tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
     <td style="width: 18pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="width: 18pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; vertical-align: top;">&#9658;</td>
     <td style="width: auto; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Secondary endpoints also included a plasma biomarker sub-study involving a limited number of patients and research sites, which assesses change from baseline in plasma biomarkers of Alzheimer&#8217;s Disease pathology, neurodegeneration and neuroinflammation (p-Tau217,&#160;neurofilament light chain, known as NfL,&#160;glial fibrillary acidic protein, known as GFAP, and Total Tau).</td>
    </tr>

    <tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
     <td style="width: 18pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="width: 18pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; vertical-align: top;">&#9658;</td>
     <td style="width: auto; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">No interim analyses on efficacy were conducted.</td>
    </tr>

   </tbody>
  </table>
  <p style="font-size: 10pt; font-family: &quot;Times New Roman&quot;; margin: 0pt;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 18pt;">Our second Phase 3 study, called REFOCUS-ALZ, was&#160;designed to evaluate the safety and efficacy of oral simufilam 100 mg and 50 mg over 76 weeks (NCT05026177). Details of the REFOCUS-ALZ Phase 3 study include:</p>
  <p style="font-size: 10pt; font-family: &quot;Times New Roman&quot;; margin: 0pt;">&#160;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
   <tbody>
    <tr style="vertical-align: top; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
     <td style="width: 18pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="width: 18pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9658;</p> </td>
     <td style="width: auto; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="margin: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: justify;">Approximately 1,100 patients were&#160;randomized into this study.</p> </td>
    </tr>

    <tr style="vertical-align: top; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
     <td style="width: 18pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="width: 18pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="margin: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: justify;">&#9658;</p> </td>
     <td style="width: auto; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="margin: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: justify;">Patients were&#160;randomized (1:1:1) to simufilam 100 mg tablets, 50 mg tablets, or matching placebo twice daily.</p> </td>
    </tr>

    <tr style="vertical-align: top; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
     <td style="width: 18pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="width: 18pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="margin: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: justify;">&#9658;</p> </td>
     <td style="width: auto; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="margin: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: justify;">Patients that completed the trial prior to its early termination were treated for 76 weeks.</p> </td>
    </tr>

    <tr style="vertical-align: top; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
     <td style="width: 18pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="width: 18pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="margin: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: justify;">&#9658;</p> </td>
     <td style="width: auto; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="margin: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: justify;">Co-primary efficacy endpoints are change from baseline in the ADAS-Cog12, a cognitive scale, and the ADCS-ADL, a functional scale, each of which is a standard psychometric assessment tool in trials of Alzheimer&#8217;s disease.</p> </td>
    </tr>

    <tr style="vertical-align: top; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
     <td style="width: 18pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="width: 18pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="margin: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: justify;">&#9658;</p> </td>
     <td style="width: auto; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">A&#160;secondary efficacy endpoint is change from baseline in the iADRS, which is an integrated tool that combines scores from the ADAS-Cog12 and the ADCS-ADL.</td>
    </tr>

    <tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
     <td style="width: 18pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="width: 18pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9658;</td>
     <td style="width: auto; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">As&#160;in the RETHINK-ALZ trial, other secondary endpoints include change from baseline in NPI, MMSE, CDR-SB and ZBI.</td>
    </tr>

    <tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
     <td style="width: 18pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="width: 18pt; vertical-align: top; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9658;</td>
     <td style="width: auto; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; margin: 0pt;">Additional&#160;secondary endpoints will also include sub-studies involving a limited number of patients and research sites to examine changes in baseline in:&#160;</p> <p style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; margin: 0pt;">&#9679; plasma biomarkers of Alzheimer&#8217;s Disease pathology, neurodegeneration and neuroinflammation (P-tau217, neurofilament light chain, known as NfL,&#160;glial fibrillary acidic protein, known as GFAP, and Total Tau);&#160;</p> <p style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; margin: 0pt;">&#9679; cerebrospinal fluid (CSF) biomarkers of Alzheimer&#8217;s Disease pathology, neurodegeneration and neuroinflammation;&#160;</p> <p style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; margin: 0pt;">&#9679; brain volume&#8212;hippocampus, ventricles and whole brain&#8212;via magnetic resonance imaging (MRI); and&#160;</p> <p style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; margin: 0pt;">&#9679; amyloid and tau deposition in the brain via positron emission topography (PET) imaging</p> </td>
    </tr>

    <tr style="vertical-align: top; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
     <td style="width: 18pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="width: 18pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="margin: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: justify;">&#9658;</p> </td>
     <td style="width: auto; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="margin: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: justify;">No interim analyses on efficacy were conducted.</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-size: 10pt; font-family: &quot;Times New Roman&quot;; margin: 0pt;">&#160;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
      16
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>Phase 3 Entry Criteria </b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -1pt; text-indent: 18pt;">For our Phase 3 clinical studies, eligibility criteria were&#160;the requirements that patients were required to meet to be included in a study. These requirements help make sure that study participants are substantially and closely matched as a group in terms of specific factors such as age, disease or stage of disease, general health, and other key factors. Eligibility criteria can consist of inclusion criteria, which are required for a person to participate in the study, or exclusion criteria, which prevent a person from participating. Certain eligibility criteria are summarized below.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 8pt;text-indent:18pt;">&#160;</p>
  <div style="text-align: center;">
   <div>
    <img alt="slide04.jpg" src="slide04.jpg"/></div>
  </div>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt 8pt; text-indent: -9pt;"><b>Use of Plasma Phosphorylated-tau181 (p</b>&#8208;<b>tau181) </b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -1pt; text-indent: 18pt;">We believe plasma p&#8208;tau181 is a biomarker qualifier of Alzheimer&#8217;s neuropathology. RETHINK-ALZ and REFOCUS-ALZ Phase 3 studies used&#160;a &#8216;research use only&#8217;, non-safety related exploratory p-tau181 plasma assay to qualify mild-to-moderate Alzheimer&#8217;s patients. The plasma assay used did&#160;not rely on age, APOE-gene status or complex algorithms to provide a result. P-Tau181 testing was performed by an independent commercial laboratory.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 8pt; text-indent: -9pt;"><b>Data and Safety Monitoring Board (DSMB)</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -4pt; text-indent: 18pt;">In September&#160;2024, we announced that a third&#160;routine, scheduled meeting of a DSMB&#160;recommended that both of our&#160;Phase 3 studies continue as planned, without modification. This was consistent with DSMB meeting findings in March 2024 and September 2023. The&#160;DSMB reviewed only patient safety. It did&#160;not assess drug efficacy.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 5pt;text-indent:18pt;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -18pt; text-indent: 18pt;"><b>Interim MRI Safety Data</b>&#160;</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -1pt; text-indent: 18pt;">In October&#160;2023, we announced&#160;that interim magnetic resonance imaging (MRI) brain data from Alzheimer&#8217;s patients who were&#160;enrolled in REFOCUS-ALZ suggested that simufilam is not associated with treatment-emergent amyloid-related imaging abnormalities, or ARIA.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -1pt; text-indent: 18pt;">ARIA&#160;describes a spectrum of brain MRI imaging abnormalities, such as brain swelling&#160;and brain bleeds. ARIA is&#160;a known risk factor for Alzheimer&#8217;s patients taking the class of drugs known as monoclonal antibodies directed against&#160;amyloid. In contrast to that&#160;class of drugs, simufilam is a&#160;small-molecule (oral) drug candidate.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -2pt; text-indent: 18pt;">The safety findings were&#160;based on an independent, interim neuroradiological evaluation of brain MRIs taken at week 40 in a blinded sub-study of 180 Alzheimer&#8217;s patients enrolled in&#160;REFOCUS-ALZ. Final MRI data is expected at the conclusion of this Phase 3 study.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -2pt; text-indent: 18pt;">&#160;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
      17
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
  <div style="text-align: center;">
   <div style="margin-left: -9pt;">
    <img alt="slide05.jpg" src="slide05.jpg"/></div>
  </div>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;">&#160;</p>
  <p style="margin: 0pt 0pt 0pt -9pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt;"><b>Statistical Analysis Plan for RETHINK-ALZ</b></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -5pt; text-indent: 18pt;">A statistical analysis plan (SAP) is a formal document defining the detailed analysis to be undertaken by our independent biostatisticians as to efficacy data collected in the trial. An SAP includes in-depth technical details and descriptions on the clinical trial analyses, the statistical methods and models to be used, the populations to be analyzed, the data variables to be analyzed, how to account for missing data, descriptions of covariates to be included in the statistical model, and other statistical factors, all of which have been prospectively defined, documented and finalized prior to unblinding of any efficacy outcomes.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -5pt; text-indent: 18pt;">In July 2024, we submitted to FDA for review an SAP for RETHINK-ALZ. Comments received from the agency were incorporated into the final SAP for RETHINK-ALZ.</p>
  <p style="text-align: justify; margin: 0pt 0pt 0pt -1px; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">&#160;</p>
  <div style="font-size:10pt">
   <div style="font-family:&quot;Times New Roman&quot;">
    <div style="font-variant:normal">
     <b>RETHINK-ALZ Top-line Clinical Results</b>
    </div>
   </div>
  </div>
  <p style="font-size: 10pt; font-family: &quot;Times New Roman&quot;; margin: 0pt; text-indent: 18pt;">&#160;</p>
  <p style="font-size: 10pt; font-family: &quot;Times New Roman&quot;; margin: 0pt; text-indent: 18pt; text-align: justify;">On November 25, 2024, we announced that the top-line results from the Phase 3 RETHINK-ALZ study of simufilam in mild-to-moderate Alzheimer&#8217;s disease did not meet each of the pre-specified co-primary, secondary and exploratory biomarker endpoints. The co-primary endpoints were the change in cognition and function from baseline to the end of the double-blind treatment period at week 52, assessed by the ADAS-COG12 and ADCS-ADL scales, comparing simufilam to placebo.&#160;Simufilam continued to demonstrate an overall favorable safety profile.</p>
  <p style="font-size: 10pt; font-family: &quot;Times New Roman&quot;; margin: 0pt;">&#160;</p>
  <p style="font-size: 10pt; font-family: &quot;Times New Roman&quot;; margin: 0pt;">&#160;</p>
  <div style="font-size:10pt">
   <div style="font-family:&quot;Times New Roman&quot;">
    <div style="font-variant: normal; text-indent: 18pt; text-align: justify;">
     The table below provides a high-level summary of the co-primary endpoints data. Topline analysis of the mild and moderate sub-groups, likewise, did not demonstrate statistical significance at week 52.
     <b> </b>
    </div>
   </div>
  </div>
  <p style="font-size: 10pt; font-family: &quot;Times New Roman&quot;; margin: 0pt;">&#160;</p>
  <div class="PGBK" style="width:100%">
   <div class="PGNUM" style="text-align: center; width: 100%; font-size: 10pt; font-family: Times New Roman;">
    18
   </div>
   <hr style="PAGE-BREAK-AFTER:always; border:none; width:100%; height:2px; color:#000000; background-color:#000000"/>
   <div class="PGHDR" style="text-align:left; width:100%">
    <div class="hf-row">
     <div class="TOCLink hf-cell" style="width: 100%; display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-size: 10pt; font-family: &quot;Times New Roman&quot;; margin: 0pt;">&#160;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">
   <tbody>
    <tr>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 25%; border-left: 1px solid black; border-top: 1px solid black;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Co-Primary Endpoint</b><br/> <b>Data*</b></p> </td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 25%; border-left: 1px solid black; border-top: 1px solid black;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Simufilam 100 mg BID</b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>N= 403</b></p> </td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 20%; border-left: 1px solid black; border-top: 1px solid black;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Placebo BID</b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>N=401</b></p> </td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 15%; border-left: 1px solid black; border-top: 1px solid black;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Delta</b></p> </td>
     <td style="border-width: 1px; border-style: solid; border-color: black black rgb(0, 0, 0); vertical-align: middle; width: 15%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;"><b>P-value</b></p> </td>
    </tr>

    <tr>
     <td colspan="5" style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 85%; border-left: 1px solid black; border-right: 1px solid black;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Co-Primary Endpoints</b><br/> <b>LS means change from baseline to the end of the double-blind treatment period</b></p> </td>
    </tr>

    <tr>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 25%; border-left: 1px solid black;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">ADAS-COG12 (&#177;SE)</p> </td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 25%; border-left: 1px solid black;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">2.8 (&#177; 0.36)</p> </td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 20%; border-left: 1px solid black;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">3.2 (&#177; 0.36)</p> </td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 15%; border-left: 1px solid black;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">-0.39 (&#177; 0.50)</p> </td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 15%; border-left: 1px solid black; border-right: 1px solid black;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">P=0.43</p> </td>
    </tr>

    <tr>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 25%; border-left: 1px solid black;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">ADCS-ADL (&#177;SE)</p> </td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 25%; border-left: 1px solid black;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">-3.3 (&#177; 0.44)</p> </td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 20%; border-left: 1px solid black;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">-3.8 (&#177; 0.44)</p> </td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 15%; border-left: 1px solid black;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">0.51 (&#177; 0.61)</p> </td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 15%; border-left: 1px solid black; border-right: 1px solid black;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">P=0.40</p> </td>
    </tr>

    <tr>
     <td colspan="5" style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 85%; border-left: 1px solid black; border-right: 1px solid black;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">*Based on the intent-to-treat population</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">BID = twice daily</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">ADAS-COG12 = The Alzheimer&#8217;s Disease Assessment Scale &#8211;&#160;Cognitive Subscale (a lower number represents less cognitive impairment)</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">ADCS-ADL = Alzheimer&#8217;s Disease Cooperative Study &#8211;&#160;Activities of Daily Living (a higher number represents less functional impairment)</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <div style="font-size:10pt">
   <div style="font-family:Times New Roman">
    <div style="font-variant: normal; text-align: justify;">
     The table below provides a high-level summary of the patient demographic and safety data. Simufilam continued to demonstrate an overall favorable safety profile.
    </div>
   </div>
  </div>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">
   <tbody>
    <tr>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 35%; border-left: 1px solid black; border-top: 1px solid black;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;"><b>Metrics for Simufilam and Placebo</b></p> </td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 32%; border-left: 1px solid black; border-top: 1px solid black;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Simufilam 100 mg BID</b></p> </td>
     <td style="border-width: 1px; border-style: solid; border-color: black black rgb(0, 0, 0); vertical-align: middle; width: 33%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Placebo BID</b></p> </td>
    </tr>

    <tr>
     <td colspan="3" style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 67%; border-left: 1px solid black; border-right: 1px solid black;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Baseline*</b></p> </td>
    </tr>

    <tr>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 35%; border-left: 1px solid black;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Age, mean (SD), in years</p> </td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 32%; border-left: 1px solid black;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">73.7 &#177;&#160;7.9</p> </td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 33%; border-left: 1px solid black; border-right: 1px solid black;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">74.3&#177;&#160;7.6</p> </td>
    </tr>

    <tr>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 35%; border-left: 1px solid black;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Sex, n (%) female</p> </td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 32%; border-left: 1px solid black;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">225 (55.8%)</p> </td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 33%; border-left: 1px solid black; border-right: 1px solid black;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">222 (55.4%)</p> </td>
    </tr>

    <tr>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 35%; border-left: 1px solid black;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">MMSE Score (No.%,)</p> </td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 32%; border-left: 1px solid black;">&#160;</td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 33%; border-left: 1px solid black; border-right: 1px solid black;">&#160;</td>
    </tr>

    <tr>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 35%; border-left: 1px solid black;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">21-27</p> </td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 32%; border-left: 1px solid black;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">244 (60.5%)</p> </td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 33%; border-left: 1px solid black; border-right: 1px solid black;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">250 (62.3%)</p> </td>
    </tr>

    <tr>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 35%; border-left: 1px solid black;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">16-20</p> </td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 32%; border-left: 1px solid black;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">155 (38.5%)</p> </td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 33%; border-left: 1px solid black; border-right: 1px solid black;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">146 (36.4%)</p> </td>
    </tr>

    <tr>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 35%; border-left: 1px solid black;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Race/Ethnicity</p> </td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 32%; border-left: 1px solid black;">&#160;</td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 33%; border-left: 1px solid black; border-right: 1px solid black;">&#160;</td>
    </tr>

    <tr>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 35%; border-left: 1px solid black;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">White</p> </td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 32%; border-left: 1px solid black;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">366 (90.8%)</p> </td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 33%; border-left: 1px solid black; border-right: 1px solid black;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">376 (93.8%)</p> </td>
    </tr>

    <tr>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 35%; border-left: 1px solid black;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">Black</p> </td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 32%; border-left: 1px solid black;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">20 (5.0%)</p> </td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 33%; border-left: 1px solid black; border-right: 1px solid black;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">18 (4.5%)</p> </td>
    </tr>

    <tr>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 35%; border-left: 1px solid black;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">Asian</p> </td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 32%; border-left: 1px solid black;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">8 (2.0%)</p> </td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 33%; border-left: 1px solid black; border-right: 1px solid black;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">2 (0.5%)</p> </td>
    </tr>

    <tr>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 35%; border-left: 1px solid black;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">Other</p> </td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 32%; border-left: 1px solid black;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">9 (2.2%)</p> </td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 33%; border-left: 1px solid black; border-right: 1px solid black;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">5 (1.0%)</p> </td>
    </tr>

    <tr>
     <td colspan="3" style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 67%; border-left: 1px solid black; border-right: 1px solid black;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Safety**</b></p> </td>
    </tr>

    <tr>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 35%; border-left: 1px solid black;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Any Adverse Event (AE)</p> </td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 32%; border-left: 1px solid black;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">284 (71.2%)</p> </td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 33%; border-left: 1px solid black; border-right: 1px solid black;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">269 (67.6%)</p> </td>
    </tr>

    <tr>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 35%; border-left: 1px solid black;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Serious AEs</p> </td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 32%; border-left: 1px solid black;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">52 (13.0%)</p> </td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 33%; border-left: 1px solid black; border-right: 1px solid black;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">36 (9.0%)</p> </td>
    </tr>

    <tr>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 35%; border-left: 1px solid black;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">Death</p> </td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 32%; border-left: 1px solid black;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">1 (0.3%)</p> </td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 33%; border-left: 1px solid black; border-right: 1px solid black;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">3 (0.8%)</p> </td>
    </tr>

    <tr>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 35%; border-left: 1px solid black;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">AEs leading to discontinuation from the study</p> </td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 32%; border-left: 1px solid black;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">26 (6.5%)</p> </td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 33%; border-left: 1px solid black; border-right: 1px solid black;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">17 (4.3%)</p> </td>
    </tr>

    <tr>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 35%; border-left: 1px solid black;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Most Frequent AEs</p> </td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 32%; border-left: 1px solid black;">&#160;</td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 33%; border-left: 1px solid black; border-right: 1px solid black;">&#160;</td>
    </tr>

    <tr>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 35%; border-left: 1px solid black;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">1: COVID-19</p> </td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 32%; border-left: 1px solid black;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">32 (8.0%)</p> </td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 33%; border-left: 1px solid black; border-right: 1px solid black;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">36 (9.0%)</p> </td>
    </tr>

    <tr>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 35%; border-left: 1px solid black;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">2: Urinary Tract Infection</p> </td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 32%; border-left: 1px solid black;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">31 (7.8%)</p> </td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 33%; border-left: 1px solid black; border-right: 1px solid black;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">29 (7.3%)</p> </td>
    </tr>

    <tr>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 35%; border-left: 1px solid black;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">3: Fall</p> </td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 32%; border-left: 1px solid black;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">30 (7.5%)</p> </td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 33%; border-left: 1px solid black; border-right: 1px solid black;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">30 (7.5%)</p> </td>
    </tr>

    <tr>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 35%; border-left: 1px solid black;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">4: Dizziness</p> </td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 32%; border-left: 1px solid black;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">21 (5.3%)</p> </td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 33%; border-left: 1px solid black; border-right: 1px solid black;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">1 (0.3%)</p> </td>
    </tr>

    <tr>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 35%; border-left: 1px solid black;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">5: Headache</p> </td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 32%; border-left: 1px solid black;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">18 (4.5%)</p> </td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 33%; border-left: 1px solid black; border-right: 1px solid black;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">11 (2.8%)</p> </td>
    </tr>

    <tr>
     <td colspan="3" style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 67%; border-left: 1px solid black; border-right: 1px solid black;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">*Based on the intent-to-treat population<br/> **Based on the safety population</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">BID = twice daily</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">AD = Alzheimer&#8217;s disease</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">MMSE = Mini-Mental State Examination</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <div style="font-size:10pt">
   <div style="font-family:Times New Roman">
    <div style="font-variant: normal; margin: 0pt;">
     We will continue to review all of the data from the study and evaluate next steps. We plan to share the detailed results at a future medical meeting.
    </div>
   </div>
  </div>
  <p style="font-size: 10pt; font-family: &quot;Times New Roman&quot;; margin: 0pt;">&#160;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
      19
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;"><b>REFOCUS-ALZ study status</b></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -5pt;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-indent: 18pt; text-align: justify;">In light of the failure of RETHINNK-ALZ to meet its&#160;prespecified co-primary endpoints, we discontinued the Phase 3 REFOCUS-ALZ study.&#160;We intend&#160;to analyze the complete 52-week dataset from the REFOCUS-ALZ study, along with a large portion of 76-week data. We have finalized&#160;the SAP for REFOCUS-ALZ&#160;and expect&#160;to release top-line REFOCUS-ALZ results late first-quarter/early second-quarter 2025.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-indent: 18pt; text-align: justify;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 4pt; text-indent: 18pt; text-align: justify;">Following the release of the topline REFOCUS-ALZ results, the Company intends to evaluate the results and determine the next steps for the future advancement, if any, of its Alzheimer&#8217;s program.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;"><b>Discontinuation of Open-Label Extension Studies</b></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -5pt; text-indent: 18pt;">In October 2022, we announced the initiation of an open-label extension study for our Phase 3 program. This study was designed to provide no-cost access to oral simufilam for up to one year to Alzheimer&#8217;s patients who had&#160;successfully completed a Phase 3 study of simufilam and who met other entry criteria and to generate additional long-term clinical safety data for oral&#160;simufilam 100 mg twice daily over 52 weeks. In July 2024, we announced our intention to extend the Phase 3 open-label extension trial as well as an ongoing open-label extension trial for patients in the Company&#8217;s Phase 2 clinical programs, in each case by up to an additional 36 months. Following&#160;the announcement of RETHINK-ALZ top-line results in November 2024, the Company&#160;discontinued the Open Label Extension study and all efforts to initiate additional open-label extension trials.&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 8pt;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;"><b>Simufilam Drug Supply</b></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -5pt; text-indent: 18pt;">We have a drug supply agreement with Evonik Industries AG for simufilam. Under the agreement, Evonik supplies and is expected to continue to supply us with clinical-grade quantities of simufilam. Evonik is one of the world&#8217;s largest contract development and manufacturing organizations for pharmaceutical ingredients. Other vendors supply excipients, the finished dosage form (i.e., simufilam tablets), drug packaging, package labeling and other critical components of&#160;the supply chain for drug supply that can be used for clinical studies.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 0pt;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;"><b>SavaDx</b></p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">Our investigational diagnostic product candidate, called SavaDx, is an early-stage program focused on detecting the presence of Alzheimer&#8217;s disease from a small sample of blood. For business, technical and personnel reasons, we continue to prioritize the development of simufilam, our novel drug candidate, over SavaDx, our novel diagnostic candidate. SavaDx is a research-use only, non-safety related exploratory biomarker.&#160;Development activity related to SavaDx accounts for less than 1% of our research budget.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 8pt;text-indent:18pt;">Working with third parties, we continue to evaluate the use of mass spectrometry to detect FLNA or other proteins of interest. The data and information generated from these evaluations continues to be under review for potential intellectual property rights.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 8pt;text-indent:18pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">The regulatory pathway for SavaDx may eventually include formal analytical validation studies and clinical studies that support evidence of sensitivity, specificity and other variables in various healthy and diseased patient populations. We have not conducted such studies and do not expect to conduct such studies in 2025.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">SavaDx is an investigational diagnostic product candidate that has not yet been reviewed by FDA. Early clinical testing consisted&#160;of collecting blood samples on a limited scale to test and validate SavaDx using antibodies or&#160;mass spectrometry. Our ability to test such samples and generate accurate results depends&#160;on multiple factors, many of which are&#160;beyond our control. For example, optimal sample collection depends on risk of sample degradation, storage requirements to preserve samples, cost of sample storage and actual vs. predicted time of assay validation.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">We have conducted four early validation tests using SavaDx. In three blinded studies of test samples, SavaDx detected more than a 10-fold separation between Alzheimer&#8217;s patients and normal healthy control subjects (N=232 test samples). In these three proof-of-concept studies, SavaDx demonstrated nearly 100% accuracy and specificity. The three studies deployed a research grade antibody manufactured by an outside vendor.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">A fourth blinded study of SavaDx failed to generate meaningful diagnostic data. We believe the fourth study may have deployed a faulty research antibody sourced from an outside vendor. Commercially available research antibodies can present certain technical flaws, such as improper validation, significant batch-to-batch variations or inconsistent storage, any of which can jeopardize results of studies and experiments.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
      20
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">We currently have no issued patents in the United States or elsewhere with respect to SavaDx.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Expansion of Our Science to Other Indications</b></p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">We may leverage our scientific insights in neurodegeneration and neuroinflammation and advanced tools in molecular biology, biochemistry, and imaging to expand our science to other diseases, initially focusing on central nervous system disorders. New indications and new drug development approaches may complement or supersede our initial focus on Alzheimer&#8217;s disease.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify; text-indent: 18pt;">We intend to conduct exploratory preclinical studies in collaboration with the TSCA to better understand simufilam&#8217;s potential as a treatment for TSC-related seizures. Based on the results of such additional studies, considered together with pre-clinical academic research, the Company will assess whether there is support for an IND application in respect of a proof-of-concept open-label clinical trial for simufilam in TSC-related epilepsy.</p>
  <p style="text-align: justify; font-size: 10pt; font-family: &quot;Times New Roman&quot;; margin: 0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>We Own Worldwide Rights to Our Neurodegeneration</b> <b> Program</b></p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">We own intellectual property, including patents, patent applications, technology, trade secrets and know-how in the U.S. and other countries. The protection of patents, designs, trademarks and other proprietary rights that we own or license is critical to our success and competitive position. We consider the overall protection of our patents and other intellectual property rights to be of material value and act to protect these rights from infringement.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">We seek to protect our technology by, among other methods, filing and prosecuting U.S. and foreign patents and patent applications with respect to our technology and products and their uses. The focus of our patent strategy is to secure and maintain intellectual property rights to technology for our program in neurodegeneration.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">Simufilam was discovered and designed in-house and was characterized by our academic collaborators during research activities that were conducted from approximately 2008 to date. SavaDx is being developed in-house with outside collaborators. We solely own patents covering the composition of matter of our drug simufilam in the United States, Europe, Australia, Israel and Canada. We solely own patents covering certain methods of use of our drug simufilam in the United States, Europe and Japan. We solely own pending patent applications that cover diagnostic assets for simufilam in the United States, Europe, Japan, China, Canada, and Australia. We solely own pending patent applications that cover other diagnostic assets in the United States, Europe, Japan, China and Canada. We have no obligation to pay any royalty to any third party in connection with any of the foregoing described patents and patent applications. In the United States, our patent protection with respect to simufilam, its solid forms, and uses of simufilam for Alzheimer&#8217;s disease and other neurodegenerative diseases includes nine issued United States patents, with terms expiring on dates ranging from 2029 to 2040, subject to any patent extensions that may be available for such patents. Corresponding foreign filings have been made for each of the United&#160;States filings.&#160;We may also pursue additional intellectual property protections in other jurisdictions or in connection with any potential expansion into other indications, including other central nervous system disorders, such as TSC-related epilepsy, in each case, in light of the Company&#8217;s overall strategic development plans.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -1pt; text-indent: 18pt;">On February 26, 2025, we entered into the License Agreement with Yale pursuant to which we were granted exclusive worldwide rights, with rights to sublicense, to Yale&#8217;s interest in certain patent and other intellectual property rights&#160;that could be useful or necessary to the development and commercialization of simufilam for the treatment of TSC-related epilepsy and other potential indications.</p>
  <p style="margin: 0pt 0pt 0pt -9pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">&#160;</p>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>Our Development Team </b></p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">Our product development team is led by seasoned professionals with a proven track record of innovation in drug discovery and development, as well as substantial business expertise.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
      21
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 18pt; text-align: justify;">Our Chief Medical Officer, James Kupiec, MD, has participated in research programs that led to two FDA drug approvals prior to Cassava Sciences. He previously served at Pfizer, Inc. as VP, Global Clinical Leader for Parkinson&#8217;s Disease and Clinical Head of the Neuroscience Research Unit. Dr. Kupiec also held leadership roles at Sanofi and Ciba-Geigy Pharmaceuticals and before that was a practicing neurologist.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-indent: 18pt; text-align: justify;">Michael Zamloot, SVP of Technology Operations, has participated in research programs that led to four FDA drug approvals prior to Cassava Sciences. He previously worked in drug operations and supply chain management at Boehringer Mannheim (acquired by Roche Diagnostics), Athena Neuroscience (acquired by Elan Pharmaceuticals) and Ciba-Geigy (acquired by Novartis).</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">Michael Marsman, PharmD, SVP of Regulatory Affairs previously held senior positions at Impax Laboratories, Millennium Pharmaceuticals, and Syntex, where he had shared responsibility for the regulatory approval of several high-profile drugs. He also previously led regulatory affairs for our Company for nearly a decade until 2019.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">George (Ben) Thornton, PhD, SVP of Technology, has led research and development teams at Johnson &amp; Johnson as well as translated basic science to the clinical setting at biotechnology start-ups such as GeneMedicine and Apovia.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">Our management team is further supported by scientific advisors who are leading experts in the field and share our commitment to advancing new treatments for central nervous system disorders.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>Our Strategy </i></b></p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">Our goal is to develop product candidates to diagnose and/or treat central nervous system disorders, such as Alzheimer&#8217;s disease and TSC-related epilepsy. Key elements of our business strategy to achieve this mission include:</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 36pt;text-indent:-18pt;">&#160;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">building a lean company that is narrowly focused on developing innovative product candidates for central nervous system disorders&#160;such as Alzheimer&#8217;s disease and TSC-related epilepsy;</p> </td>
    </tr>

    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">publishing scientific data in peer-reviewed journals;</p> </td>
    </tr>

    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">applying development capabilities to advance our product candidates through clinical proof-of-concept studies and beyond;</p> </td>
    </tr>

    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">using our expertise and experience to continue to focus on discovering new indications and product candidates, validated by experimental evidence and leading experts in the field; and</p> </td>
    </tr>

    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">continuing to outsource preclinical studies, clinical studies and formulation development activities in order to allow more efficient deployment of our resources</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">We also conduct basic research and development in collaboration with academic and other partners. Our research and development expenses were $69.6&#160;million, $89.4&#160;million and $68.0&#160;million for the year ended December 31, 2024, 2023&#160;and 2022, respectively. See &#8220;<i>Item 7. Management</i>&#8217;<i>s Discussion and Analysis of Financial Condition and Results of Operations</i>&#8221; for additional details regarding our research and development activities.</p>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>Competition</b></p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">The drug discovery and development industry is characterized by rapidly advancing technologies, intense competition and a strong emphasis on proprietary products. We face potential competition from many different sources, including pharmaceutical and biotechnology companies, academic institutions, governmental agencies, and public and private research institutions. Any product candidates that we successfully develop and commercialize, such as simufilam or SavaDx, may compete with existing therapies and new therapies that may become available in the future.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
      22
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">Many of our competitors have significantly greater financial resources, an established presence in the market, as well as expertise in research and development, manufacturing, preclinical and clinical testing, obtaining regulatory approvals and reimbursement and marketing-approved products. These competitors compete with us in recruiting and retaining qualified scientific and technical personnel, establishing clinical study sites and patient registration for clinical studies, as well as in acquiring or developing technologies complementary to, or necessary for, our programs. Smaller or early-stage companies may also prove to be significant competitors, particularly through collaborative arrangements with large and established companies, significant financial backing from large investors and/or access to intellectual property from large established companies.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">The key competitive factors affecting the success of simufilam, and any other product candidates that we develop, if approved, are likely to be&#160;efficacy, safety, convenience, price, level of generic competition, patient and physician acceptance and&#160;availability of reimbursement from government and other third-party payors. Our commercial opportunity could be reduced or eliminated if our competitors develop and commercialize products that are more effective, have fewer or less severe side effects, are more convenient or are less expensive than products that we may develop.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -19pt; text-indent: 18pt;"><i>Alzheimer's disease</i></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -1pt; text-indent: 18pt;">Our competitors may develop and obtain FDA approval for their products more rapidly than we do. For example,with respect to Alzheimer&#8217;s disease, the FDA approved Eli Lilly's Kisunla (donanemab-azbt) in&#160;July&#160;2024.&#160;The FDA also approved Biogen&#8217;s aducanumab (human monoclonal antibody) for the treatment of Alzheimer&#8217;s disease using an accelerated approval pathway, although its development and commercialization was subsequently discontinued by Biogen in January 2024. In January 2023, lecanemab (humanized version of a mouse monoclonal antibody, marketed as Leqembi&#174;), which is a proprietary drug of Eisai R&amp;D Management Co., Ltd. and Biogen, Inc., received marketing approval from the FDA for the treatment of Alzheimer&#8217;s disease using an accelerated approval pathway and in July&#160;2023, the FDA granted lecanemab full approval for the treatment of Alzheimer&#8217;s disease. Each of the foregoing drugs is&#160;currently delivered by infusion.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -1pt; text-indent: 18pt;">Other currently marketed drugs, called cholinesterase inhibitors, focus solely on treating symptoms mostly in patients with mild-to-moderate Alzheimer's disease. The Alzheimer&#8217;s brain has low levels of a neurotransmitter called acetylcholine. Cholinesterase inhibitors prevent an enzyme in the brain, called&#160;acetylcholinesterase,&#160;from breaking down acetylcholine. Currently marketed cholinesterase inhibitors include donepezil (marketed by Eisai&#160;Co.,&#160;Ltd. and Pfizer,&#160;Inc. as Aricept&#174;), rivastigmine (marketed by Novartis AG as Exelon&#174;) and galantamine (marketed by Janssen Pharmaceuticals, Inc. as Razadyne&#174;). Cholinesterase inhibitors may benefit some patients for several months, after which the targeted brain receptors are desensitized, and drug efficacy is lost. Another approved medication for treating the symptoms of Alzheimer&#8217;s disease is memantine, a non-competitive antagonist of NMDA receptors (marketed by Lundbeck as Namenda&#174;).</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><i>TSC-related seizures</i></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-indent: 18pt; text-align: justify;">With respect to TSC-related epilepsy, two pharmacological treatment categories are approved for this patient population. The first category is Traditional Anti-seizure Medications (ASMs), which include the standard of care (SOC) Vigabatrin, and options such as Levetiracetam, Valproate, and Clobazam. Most ASMs require patients to enroll in the Risk Evaluation and Mitigation Strategy (REMS) program due to a high rate of safety concerns, raising questions about their overall risk-benefit profile.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-indent: 18pt; text-align: justify;">The second category is Disease-Specific ASMs, which are treatments indicated specifically for TSC-related epilepsy. Currently, there are two approved treatments for seizures associated with TSC: Afinitor Disperz (everolimus tablets for oral suspension) and Epidiolex (cannabidiol), both of which offer unique advantages and notable challenges. Everolimus, an mTOR inhibitor, is the only FDA-approved treatment that directly targets the underlying pathophysiology of TSC. While clinical trials have demonstrated its efficacy in reducing seizure frequency in patients with TSC-related epilepsy, it is not effective for all patients, underscoring the need for novel therapeutic approaches. Epidiolex has also been an important addition to the treatment landscape for TSC-related epilepsy, with clinical trials showing a significant reduction in seizure frequency. However, approximately one in four patients with hard-to-treat or refractory epilepsy were found to discontinue Epidiolex shortly after starting treatment, primarily due to side effects or lack of efficacy.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-indent: 18pt; text-align: justify;">According to published research, approximately 60% of TSC patients remain inadequately controlled despite use of multiple ASMs. To date, there is no conclusive evidence that disease-specific ASMs are more effective than traditional ASMs, highlighting the ongoing need for additional therapeutic options to manage refractory TSC patients.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-indent: 18pt;">&#160;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
      23
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>Manufacturing</b></p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -1pt; text-indent: 18pt;">Simufilam and any future product candidates must be manufactured for clinical trial use in compliance with current good manufacturing practices (cGMP) regulations. These regulations are extensive, stringent and complex, and may include requirements regarding the organization of personnel, buildings and facilities, equipment, control of components and drug product containers and closures, production and process controls, packaging and labeling controls, holding and distribution, laboratory controls, records and reports, and returned or salvaged products. Our manufacturing vendors must have facilities to make our product candidates in strict compliance with cGMP requirements and the FDA&#8217;s or comparable foreign regulatory authorities&#8217; satisfaction. Our third-party vendors may also be subject to periodic and unannounced inspections of their respective facilities for general cGMP compliance by the FDA and other foreign authorities. These inspections may include review of procedures and operations used in the testing and manufacture of simufilam to assess compliance with applicable regulations. Failure to comply with statutory and regulatory requirements subjects a manufacturer to possible legal or regulatory action, including warning letters, the seizure or recall of products, injunctions, consent decrees placing significant restrictions on or suspending manufacturing operations and civil and criminal penalties. Contract manufacturers often encounter difficulties involving production yields, quality control and quality assurance, as well as shortages of qualified personnel. Any of these actions or events could have a material impact on the availability of simufilam. Our suppliers may be forced to stop producing, storing, shipping or testing our drug product candidates if they fall out of compliance with government regulations and standards.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -1pt; text-indent: 18pt;">Although we are ultimately responsible for the manufacture of simufilam and any other future product candidates, we have limited or no control over our suppliers&#8217; compliance, or lack thereof, with the multitude of regulations and standards that affect our drug products. We cannot control decisions by our suppliers that affect their ability or willingness to continue to supply us on acceptable terms, or at all.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">We do not own or lease any manufacturing facilities. We outsource formulation, manufacturing and related activities to third parties. For the foreseeable future, we will continue to rely on third parties to conduct certain quality control and assurance testing, shipping or storage of our product candidates.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -1pt; text-indent: 18pt;">We currently rely on one non-affiliated contract development and manufacturing organization (CDMO)&#8212;Evonik Corporation&#8212;to manufacture simufilam and expect to continue to do so.&#160; In 2021, we entered into an agreement with Evonik Corporation to supply clinical-grade quantities of drug substance for simufilam. The goal of our manufacturing strategy is to ensure the integrity of the supply chain for drug substance&#160;in compliance with FDA standards. We believe raw materials for our drug product are readily available from reliable sources.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>Government Regulation </b></p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">Our operations are subject to various levels of governmental controls and regulations in the United States and in other countries where we operate or have operated, including Canada, South Korea and Australia. We attempt to comply with all legal requirements in the conduct of our operations and employ business practices that we consider to be prudent under the circumstances in which we operate.&#160;Government authorities in the U.S. (federal, state and local), Canada, South Korea, Australia and other countries regulate, among other things, the research, development, testing, manufacture, quality control, approval, labeling, packaging, storage, record-keeping, promotion, advertising, distribution, post-approval monitoring and reporting, marketing and export and import of drug and diagnostic products. Generally, before a new drug or diagnostic can be marketed, considerable data demonstrating its quality, safety and efficacy and/or specificity must be obtained, organized into a format specific for each regulatory authority, submitted for review and approved by each regulatory authority.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>U.S. Drug Development </i></b></p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">In the U.S., FDA regulates drugs under the Food, Drug, and Cosmetic Act (FDCA). Both drugs and diagnostics also are subject to other federal, state and local statutes and regulations. The process of obtaining regulatory approvals and the subsequent compliance with appropriate federal, state, local and foreign statutes and regulations requires the expenditure of substantial time and financial resources. Failure to comply with the applicable U.S. requirements at any time during the product development process, approval process or post-market may subject an applicant to administrative or judicial sanctions. These sanctions could include, among other actions, FDA&#8217;s refusal to approve pending applications, withdrawal of an approval, a clinical hold, untitled or warning letters, product recalls or market withdrawals, product seizures, total or partial suspension of production or distribution, injunctions, fines, refusals of government contracts, restitution, disgorgement and civil or criminal penalties. Any agency or judicial enforcement action could have a material adverse effect on us.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
      24
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">Product candidates must be approved by FDA before they may be commercialized in the U.S. The drug approval process generally includes the following sequence of steps:</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Completion of extensive preclinical studies in accordance with applicable regulations, including studies conducted in accordance with good laboratory practice;</p> </td>
    </tr>

    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Submission to FDA of an IND, which must become effective before human clinical studies may begin;</p> </td>
    </tr>

    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Approval by an independent institutional review board (IRB) or ethics committee before each study may be initiated;</p> </td>
    </tr>

    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Performance of adequate and well-controlled human clinical studies in accordance with applicable IND regulations, code of good clinical practice (cGCP), requirements and other clinical trial-related regulations to establish the safety and efficacy of the investigational product for each proposed indication;</p> </td>
    </tr>

    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Submission to FDA of a new drug application&#160;(NDA);</p> </td>
    </tr>

    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">A determination by FDA within 60 days of its receipt of an NDA to accept the filing for review;</p> </td>
    </tr>

    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Satisfactory completion of an FDA pre-approval inspection of the manufacturing facility or facilities where the drug will be produced to assess compliance with cGMP, requirements to assure that the facilities, methods and controls are adequate to preserve the drug&#8217;s identity, strength, quality and purity;</p> </td>
    </tr>

    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Potential FDA audit of the preclinical study and/or clinical study sites that generated the data in support of the NDA;</p> </td>
    </tr>

    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">FDA review and approval of the NDA, including consideration of the views of any FDA advisory committee, prior to any commercial marketing or sale of the drug in the U.S.; and</p> </td>
    </tr>

    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Compliance with any post-approval requirements, including the potential requirement to conduct post-approval studies.</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">The data required to support an NDA are generated in two distinct developmental stages: preclinical and clinical. The preclinical and clinical testing and approval process requires substantial time, effort and financial resources, and we cannot be certain that any approvals for any future product candidates will be granted on a timely basis, or at all.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>Preclinical Studies and IND </i></b></p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">The preclinical developmental stage generally involves laboratory evaluations of drug chemistry, formulation and stability, as well as studies to evaluate toxicity in animals, which support subsequent clinical testing. As sponsor, we must submit the results of the preclinical studies, together with manufacturing information, analytical data, any available clinical data or literature and a proposed clinical protocol, to FDA as part of the IND. An IND is a request for authorization from FDA to administer an investigational product to humans and must become effective before human clinical studies may begin.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">Preclinical studies include laboratory evaluation of product chemistry and formulation, as well as<i> </i>in vitro and animal studies to assess the potential for adverse events and in some cases to establish a rationale for therapeutic use. The conduct of preclinical studies is subject to federal regulations and requirements, including cGCP regulations for safety/toxicology studies. An IND sponsor must submit the results of the preclinical tests, together with manufacturing information, analytical data, any available clinical data or literature and plans for clinical studies, among other things, to FDA as part of an IND. Some long-term preclinical testing, such as long-term toxicity tests, animal tests of reproductive adverse events and carcinogenicity, may continue after the IND is submitted. An IND automatically becomes effective 30 days after receipt by FDA, unless before that time FDA raises concerns or questions about any aspect of the program. In such a case, the IND sponsor and FDA must resolve any outstanding concerns before the clinical study can begin.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>Clinical Studies </i></b></p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">The clinical stage of development involves the administration of the investigational product to healthy volunteers or patients under the supervision of qualified investigators, generally physicians not employed by or under the study sponsor&#8217;s control, in accordance with cGCP requirements, which include the requirement that all research subjects provide their informed consent for&#160;participation in any clinical trial. Clinical studies are conducted under protocols detailing, among other things, the objectives of the clinical trial, dosing procedures, subject selection and exclusion criteria and the parameters to be used to monitor subject safety and assess efficacy. Each protocol, and any subsequent amendments to the protocol, must be submitted to FDA as part of the IND. Furthermore, each clinical study must be reviewed and approved by an IRB for each institution at which the clinical study will be conducted to ensure that the risks to individuals participating in the clinical studies are minimized and are reasonable in relation to anticipated benefits. The IRB also approves the informed consent form that must be provided to each clinical study subject or his or her legal representative and must monitor the clinical study until completed. There also are requirements governing the reporting of ongoing clinical studies and completed clinical study results to public registries.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
      25
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">A sponsor who wishes to conduct a clinical study outside of the U.S. may, but need not, obtain FDA authorization to conduct the clinical study under an IND. If a foreign clinical study is not conducted under an IND, the sponsor may submit data from the clinical study to FDA in support of an NDA. The FDA may accept a well-designed and well-conducted foreign clinical study not conducted under an IND if the study was conducted in accordance with cGCP requirements and FDA is able to validate the data through an onsite inspection if deemed necessary.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">Clinical studies in the U.S. generally are conducted in three sequential phases, known as Phase&#160;1, Phase&#160;2 and Phase&#160;3, and may overlap.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Phase 1 clinical studies generally involve a small number of healthy volunteers or disease-affected patients who are initially exposed to a single dose and then multiple doses of the product candidate. The primary purpose of these clinical studies is to assess the absorption, metabolism, pharmacologic action, tolerability and safety of a drug candidate.</p> </td>
    </tr>

    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Phase 2 clinical studies involve studies in disease-affected patients to determine the proper dose required to produce the desired benefits. At the same time, safety and further pharmacokinetic and pharmacodynamic information is collected, possible adverse effects and safety risks are identified, and a preliminary evaluation of efficacy may be observed.</p> </td>
    </tr>

    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Phase 3 clinical studies generally involve enrolling many patients at multiple sites and are designed to provide the data necessary to demonstrate the effectiveness of the product for its intended use, its safety in use and to establish the overall benefit/risk relationship of the product and provide an adequate basis for product approval. These studies may include comparisons with placebo and/or other comparator treatments. The duration of treatment is often extended to mimic the actual use of a product during marketing.</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">Post-approval studies, sometimes referred to as Phase&#160;4 clinical studies, may be conducted after initial marketing approval. These studies are used to gain additional experience from the treatment of patients in the intended therapeutic indication. In certain instances, FDA may mandate the performance of Phase&#160;4 clinical studies as a condition of approval of an NDA.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">Progress reports detailing the results of the clinical studies, among other information, must be submitted at least annually to FDA. Written safety reports and the investigations&#160;for serious and unexpected adverse events, or any other findings suggesting a significant risk to humans exposed to the drug must be submitted to FDA.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">Phase&#160;1, Phase&#160;2, and Phase&#160;3 clinical studies may not be completed successfully within any specified period, if at all. The FDA or the sponsor may suspend or terminate a clinical study at any time on various grounds, including a finding that the research subjects or patients are being exposed to an unacceptable health risk. Similarly, an IRB can suspend or terminate approval of a clinical study at its institution if the clinical study is not being conducted in accordance with the IRB&#8217;s requirements or if the drug has been associated with unexpected serious harm to patients. Additionally, some clinical studies are overseen by an independent group of qualified experts organized by the clinical study sponsor, known as a Data and Safety Monitoring Board (DSMB). This group provides authorization for whether a study may move forward at designated check-points based on access to certain data from the trial. Concurrent with clinical studies, companies usually complete additional animal studies and must develop additional information about the chemistry and physical characteristics of the drug as well as finalize a process for manufacturing the product in commercial quantities in accordance with cGMP requirements. The manufacturing process must be capable of consistently producing quality batches of the product and, among other things, companies must develop methods for testing the identity, strength, quality and purity of the final product. Additionally, appropriate packaging must be selected and tested, and stability studies must be conducted to demonstrate that our product candidates do not undergo unacceptable deterioration over their shelf life.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>NDA Review Process</i></b></p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">Following completion of the clinical studies, data is analyzed to assess whether the investigational product is safe and effective for the proposed indicated use or uses. The results of preclinical studies and clinical studies are then submitted to FDA as part of an NDA, along with proposed labeling, chemistry and manufacturing information to ensure product quality and other relevant data. In short, the NDA is a request for approval to market a drug for one or more specified indication and must contain proof of safety and efficacy for a drug&#8217;s purity and potency. The application may include both negative and ambiguous results of preclinical studies and clinical studies, as well as positive findings. Data may come from company-sponsored clinical studies intended to test the safety and efficacy of a product&#8217;s use or from several alternative sources, including studies initiated by investigators. To support marketing approval, the data submitted must be sufficient in quality and quantity to establish the safety and efficacy of the investigational product to the satisfaction of FDA. FDA approval of an NDA must be obtained before a drug may be marketed in the U.S.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
      26
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">Under the Prescription Drug User Fee Act (PDUFA), as amended, each NDA must be accompanied by a user fee. FDA adjusts the PDUFA user fees on an annual basis. According to FDA&#8217;s fiscal year 2025&#160;fee schedule, effective through September&#160;30, 2025, the user fee for an application requiring clinical data, such as an NDA, is approximately $4.3&#160;million. Fee waivers or reductions are available in certain circumstances, including a waiver of the application fee for the first application filed by a small business. Additionally, no user fees are assessed on NDAs for products designated as orphan drugs, unless the product also includes a non-orphan indication.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">The FDA reviews all submitted NDAs before it accepts them for filing and may request additional information rather than accept the NDA for filing. The FDA must decide whether to accept an NDA for filing within 60 days of receipt. Once the submission is accepted for filing, FDA begins an in-depth review of the NDA. Under the goals and policies agreed to by FDA under PDUFA, FDA has 10 months, from the filing date, in which to complete its initial review of a new molecular-entity NDA and respond to the applicant, and six months from the filing date of a new molecular-entity NDA designated for priority review. The FDA does not always meet its PDUFA goal dates for standard and priority NDAs, and the review process is often extended by FDA requests for additional information or clarification.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">Before approving an NDA, FDA may conduct a pre-approval inspection of the manufacturing facilities for the new product to determine whether they comply with cGMP requirements. The FDA will not approve the product unless it determines that the manufacturing processes and facilities fully comply with cGMP requirements and are adequate to assure consistent production of the product within required specifications. The FDA also may audit data from clinical studies to ensure compliance with cGCP requirements. Additionally, FDA may refer applications for novel product candidates which present difficult questions of safety or efficacy to an advisory committee, typically a panel that includes clinicians and other experts, for review, evaluation and a recommendation as to whether the application should be approved and under what conditions, if any. The FDA is not bound by recommendations of an advisory committee, but it considers such recommendations when making decisions on approval. The FDA likely will reanalyze the clinical study data, which could result in extensive discussions between FDA and the applicant during the review process. After FDA evaluates an NDA, it will issue either an approval letter or a Complete Response Letter (CRL). An approval letter authorizes commercial marketing of the drug with specific prescribing information for specific indications. A CRL indicates that FDA&#8217;s review of the application is complete and the application cannot be approved in its present form. A CRL usually describes the specific deficiencies in the NDA identified by FDA. The CRL may require additional clinical data, additional pivotal Phase&#160;3 clinical trial(s) and/or other significant and time-consuming requirements related to clinical studies, preclinical studies or manufacturing. If a CRL is issued, the applicant may either resubmit the NDA, addressing all the deficiencies identified in the CRL, or withdraw the application. Even if such data and information are submitted, FDA may decide that the NDA does not satisfy the criteria for approval. Data obtained from clinical studies are not always conclusive and FDA may interpret data differently than we interpret the same data.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>Commercialization Plan</i></b></p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">Our product candidates have not received marketing approval from the FDA, and we do not expect to have any approved product candidates in the near term. We currently have no company experience in marketing drugs and have no personnel, capabilities or infrastructure in sales, marketing, third-party payor programs or commercial product distribution. When and if any of our product candidates are approved for commercialization, we will need to develop a commercialization infrastructure for any such product in the U.S. and potentially in certain other key markets. As a matter of strategy, we may also rely on partnerships or collaborations with larger biopharmaceutical companies to provide commercialization infrastructure, such as sales and marketing and commercial distribution.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>Advertising and Promotion</i></b></p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">The FDA and other federal regulatory agencies closely regulate the marketing and promotion of drugs through, among other things, standards and regulations for direct-to-consumer advertising, communications regarding unapproved uses, industry-sponsored scientific and educational activities, and promotional activities involving the Internet. None of our product candidates can be commercially promoted before receiving FDA approval. After approval, product promotion can include only those claims relating to safety and effectiveness that are consistent with the labeling approved by FDA. Healthcare providers are permitted to prescribe drugs for &#8220;off-label&#8221; uses&#160;&#8212; that is, uses not approved by FDA and therefore not described in the drug&#8217;s labeling&#160;&#8212; because FDA does not regulate the practice of medicine. However, FDA regulations impose stringent restrictions on manufacturers&#8217; communications regarding off-label uses. Failure to comply with applicable FDA requirements and restrictions in this area may subject us to adverse publicity and enforcement action by FDA, the U.S. Department of Justice, or the Office of the Inspector General of Health and Human Services, as well as state authorities. This could subject us to a range of penalties that could have a significant commercial impact, including civil and criminal fines and agreements that materially restrict the manner in which we promote or distribute our product candidates.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
      27
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>Post-Approval Requirements</i></b></p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">After a product candidate receives regulatory approval, it is often subject to pervasive and continuing regulation by FDA, including, among other things, requirements relating to drug listing and registration, recordkeeping, periodic reporting, product sampling and distribution, adverse event reporting and advertising, marketing and promotion restrictions.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">Adverse event reporting and submission of periodic reports is required following FDA approval of an NDA. The FDA also may require post-market testing, known as Phase 4 testing, or FDA may place conditions on an approval that could restrict the distribution or use of the product. In addition, quality control, drug manufacture, packaging, and labeling procedures must continue to conform to cGMP after approval. Drug manufacturers and certain of their subcontractors are required to register their establishments with FDA and certain state agencies. Registration may result in periodic announced or unannounced inspections by FDA or these state agencies, during which the agency inspects manufacturing facilities to assess compliance with cGMP. Accordingly, manufacturers must continue to expend time, money, and effort in the areas of production and quality control to maintain compliance with cGMP. Regulatory authorities may withdraw product approvals or request product recalls if a company fails to comply with regulatory standards, if it encounters problems following initial marketing, or if previously unrecognized problems are subsequently discovered. In addition, other regulatory actions may be taken, including, among other things, warning letters, the seizure of products, injunctions, consent decrees placing significant restrictions on or suspending manufacturing operations, refusal to approve pending applications or supplements to approved applications, civil penalties, and criminal prosecution.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">The FDA may require post-approval clinical studies to help assure continued safety or effectiveness of the approved drug. The FDA may also require a labeling change if it becomes aware of new safety information that it believes should be included in the labeling of a drug.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">In addition to the FDA, manufacturing, sales, promotion and other activities following product approval are also subject to regulation by the Centers for Medicare and Medicaid Services, other divisions of the Department of Health and Human Services, the Department of Justice, the Consumer Product Safety Commission, the Federal Trade Commission, the Occupational Safety &amp; Health Administration, the Environmental Protection Agency, the Affordable Care Act (ACA),&#160;other federal agencies and state and local governments.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">For example, in the United States, sales, marketing and scientific and educational programs must&#160;comply with state and federal fraud and abuse laws. These laws include the federal Anti-Kickback Statute, which makes it illegal for any person, including a prescription drug manufacturer (or a party acting on its behalf), to knowingly and willfully solicit, receive, offer or pay any remuneration that is intended to induce or reward referrals, including the purchase, recommendation, order or prescription of a particular drug, for which payment may be made under a federal healthcare program, such as Medicare or Medicaid. Violations of this law are punishable by prison, criminal fines, administrative civil money penalties and exclusion from participation in federal healthcare programs. Moreover, the ACA provides that the government may assert that a claim including items or services resulting from a violation of the federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the False Claims Act.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">Pricing and rebate programs must comply with the Medicaid rebate requirements of the U.S. Omnibus Budget Reconciliation Act of 1990 and more recent requirements in the ACA. If products are made available to authorized users of the Federal Supply Schedule of the General Services Administration, additional laws and requirements apply. Products must meet applicable child-resistant packaging requirements under the U.S. Poison Prevention Packaging Act. Manufacturing, sales, promotion and other activities also are potentially subject to federal and state consumer protection and unfair competition laws.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">The distribution of pharmaceutical products is subject to additional requirements and regulations, including extensive record-keeping, licensing, storage and security requirements intended to prevent the unauthorized sale of pharmaceutical products.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">The failure to comply with any of these laws or regulatory requirements subjects firms to possible legal or regulatory action. Depending on the circumstances, failure to meet applicable regulatory requirements can result in criminal prosecution, fines or other penalties, injunctions, requests for recall, seizure of products, total or partial suspension of production, denial or withdrawal of product approvals or refusal to allow a firm to enter into supply contracts, including government contracts. Any action against us for violation of these laws, even if we successfully defend against it, could cause us to incur significant legal expenses and divert our management&#8217;s attention from the operation of our business. Prohibitions or restrictions on sales or withdrawal of future products marketed by us could materially affect our business in an adverse way.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">Changes in regulations, statutes or the interpretation of existing regulations could impact our business in the future by requiring, for example: changes to our manufacturing arrangements; additions or modifications to product labeling, if and when approved; the recall or discontinuation of our products; or additional record-keeping requirements. If any such changes were to be imposed, they could adversely affect the operation of our business.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&#160;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
      28
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>The Hatch-Waxman Amendments</i></b></p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">In seeking approval for our product candidates through an NDA, we will be required to list with FDA each patent whose claims cover the drug product. Upon receiving regulatory approval, each of the patents listed in the application for this drug is then published in FDA&#8217;s Approved Drug Products with Therapeutic Equivalence Evaluations, commonly known as the &#8220;Orange Book.&#8221;&#160;Drugs listed in the Orange Book can, in turn, be cited by potential generic competitors in support of approval of an abbreviated NDA, or ANDA. An ANDA provides for marketing of a drug product that has the same active ingredient in the same strengths and dosage form as the listed drug and has been shown through bioequivalence testing to be therapeutically equivalent to the listed drug. Other than the requirement for bioequivalence testing, ANDA applicants are not required to conduct, or submit results of, preclinical or clinical tests to prove the safety or efficacy of their drug product. Drugs approved in this way are commonly referred to as &#8220;generic equivalents&#8221; to the listed drug, and may&#160;be substituted by pharmacists under prescriptions written for the original listed drug.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">The ANDA applicant is required to make certain certifications to FDA concerning any patents listed for the approved product in FDA&#8217;s Orange Book. Specifically, the applicant must certify that: (i)&#160;the required patent information has not been filed; (ii)&#160;the listed patent has expired; (iii)&#160;the listed patent has not expired but will expire on a particular date and approval is sought after patent expiration; or (iv)&#160;the listed patent is invalid or will not be infringed by the new product. The ANDA applicant may also elect to submit a section&#160;viii statement certifying that its proposed ANDA label does not contain (or carves out) any language regarding the patented method-of-use rather than make certifications concerning a listed method-of-use patent. If the applicant does not challenge the listed patents, the ANDA application will not be approved until all the listed patents claiming the referenced product have expired.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">A certification that the new product will not infringe the already approved product&#8217;s listed patents, or that such patents are invalid, is called a Paragraph&#160;IV certification. If the ANDA applicant has provided a Paragraph&#160;IV certification to FDA, the applicant must also send notice of the Paragraph&#160;IV certification to the NDA and patent holders once the ANDA has been accepted for filing by FDA. The NDA and patent holders may then initiate a patent infringement lawsuit in response to the notice of the Paragraph&#160;IV certification. The filing of a patent infringement lawsuit within 45&#160;days of the receipt of a Paragraph&#160;IV certification automatically prevents FDA from approving the ANDA until the earlier of 30&#160;months, expiration of the patent, settlement of the lawsuit, or a decision in the infringement case that is favorable to the ANDA applicant. The ANDA application also will not be approved until any applicable non-patent exclusivity listed in the Orange Book for the referenced product has expired.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>Disclosure of Clinical Study Information</i></b></p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">Sponsors of clinical studies of FDA-regulated products, including drugs, are required to register and disclose certain clinical study information. Information related to the product, patient population, phase of investigation, clinical study sites and investigators, and other aspects of the clinical study is then made public as part of the registration. Sponsors are also obligated to post certain information regarding the results of their clinical studies after completion. Disclosure of the results of these studies can be delayed until the new product or new indication being studied has been approved. Competitors may use this publicly available information to gain knowledge regarding the progress of development programs.</p>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>Other Regulatory Requirements</i></b></p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">We may be subject to federal, state and local environmental laws and regulations, including the Environmental Protection Act and the Clean Air Act. Although we believe that our safety procedures for handling and disposing of controlled materials comply with the standards prescribed by state and federal regulations, accidental contamination or injury from these materials may occur. In the event of such an occurrence, we could be held liable for any damages that result, and any such liability could exceed our resources.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">We may also be subject to regulations under other federal, state, and local laws, including the Occupational Safety and Health Act, national restrictions on technology transfer, and import, export, and customs regulations. It is possible that any portion of the regulatory framework under which we operate may change and that such change could have a negative impact on our current and anticipated operations. Failure to comply with these requirements could result, among other things, in suspension of regulatory approval, recalls, injunctions or civil or criminal sanctions.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&#160;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
      29
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>Third-Party Payor Coverage and Reimbursement</i></b></p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">The commercial success of our product candidates, if approved, will depend, in part, upon the availability of coverage and adequate reimbursement from third-party payors at the federal, state and private levels. Third-party payors include governmental programs such as Medicare or Medicaid, private insurance plans and managed care plans. These third-party payors may deny coverage or reimbursement for our product candidates in whole or in part if they determine that our product candidates are not medically appropriate or necessary. Also, third-party payors attempt to control costs by limiting coverage through the use of formularies and other cost-containment mechanisms and the amount of reimbursement for particular procedures or drug treatments.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">Some third-party payors also require pre-approval of coverage for new or innovative devices or drug therapies before they will reimburse healthcare providers who use such therapies. While we cannot predict whether any proposed cost-containment measures will be adopted or otherwise implemented in the future, these requirements or any announcement or adoption of such proposals could have a material adverse effect on our ability to obtain adequate prices for our approved product candidates to operate profitably.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>Human Capital</b></p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">Our approach to human capital resource management starts with our mission to detect and treat central nervous system disorders , such as Alzheimer&#8217;s disease or&#160;TSC-related epilepsy. Our industry exists in a complex regulatory environment. The unique demands of our industry, together with the challenges of running an enterprise focused on the discovery, development, manufacture and commercialization of innovative medicines, require talent that is highly educated and/or has significant industry experience. Additionally, for certain key functions, we require specific scientific expertise to oversee and conduct research and development activities and the complex manufacturing requirements for biopharmaceutical products.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify; text-indent: 18pt;">Our employees are an essential asset, and we consider our ability to recruit, train, retain and motivate our employees to be critical to our success. We are an equal opportunity employer, and we are fundamentally committed to creating and maintaining a work environment in which employees are treated with respect and dignity. All human resources policies, practices and actions related to hiring, promotion, compensation, benefits and termination are administered in accordance with the principal of equal employment opportunity, meaning that they are made on the basis of individual skills, knowledge, abilities, job performance and other legitimate criteria and without regard to race, color, religion, sex, sexual orientation, gender expression or identity, ethnicity, national origin, ancestry, age, mental or physical disability, genetic information, any veteran status, any military status or application for military service, or membership in any other category protected under applicable law. By focusing on employee retention and engagement, we also improve our ability to support our clinical trials, our pipeline, business and operations, and also protect the long-term interests of our stockholders. Our success also depends on our ability to attract, engage and retain a diverse group of employees.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">Our base pay program aims to compensate management and staff members relative to the value of the contributions of their role, which takes into account the skills, knowledge and abilities required to perform each position, as well as the experience brought to the job. We also may pay cash bonuses to reward our management team and staff members in alignment with achievement of Company-wide goals that are designed to drive aspects of our strategic priorities that support and advance our strategy across our Company. Our management team and staff members are eligible for the grant of equity awards under our long-term incentive program that are designed to align their long-term interests with that of our stockholders.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">Our benefit programs are generally broad-based, promote health and overall well-being and emphasize saving for retirement. All management team and regular staff members are eligible to participate in the same core health and welfare and retirement savings plans. Other employee benefits may include medical plans, dental plans, vacation and sick-pay plans, flexible spending accounts, life and accident insurance and short and long-term disability benefits.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">Our Compensation Committee provides oversight of our executive compensation plans, policies and programs.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">As of December 31, 2024, we had 30&#160;full-time employees. None of our employees is&#160;represented by a labor union or covered under a collective bargaining agreement. We also engage numerous consultants to perform services on retainer, per diem or an hourly basis.&#160;We&#160;consider our relationship with our employees to be good.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-indent: 18pt; text-align: justify;">On January 7, 2025, we announced a reduction&#160;in our&#160;workforce by 10 employees, a reduction of 33% (the &#8220;Workforce Reduction&#8221;). We&#160;communicated the Workforce Reduction to affected employees on January 7, 2025.&#160;The Workforce Reduction was intended to align our human capital resources to meet our strategic goals, in light of the discontinuation of our ongoing clinical trials for Alzheimer&#8217;s disease.&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">&#160;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
      30
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-indent: 18pt; text-align: justify;">We estimate&#160;that we&#160;will incur approximately $0.4 million of one-time costs in connection with the Workforce Reduction, primarily related to severance payments. The Company expects the Workforce Reduction to be completed, and the majority of the associated costs to be incurred, during the first quarter of 2025.&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 8pt;text-indent:18pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>Lawsuit Against Perpetrators of </b>&#8220;<b>Short and Distort</b>&#8221;<b> Campaign</b></p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify; text-indent: 18pt;">In November&#160;2022, we announced that we had filed a lawsuit in federal district court for the Southern District of New York against certain individuals who executed a &#8220;short and distort&#8221; campaign against Cassava Sciences. On March 29, 2024, the court dismissed our complaint, but provided leave for the Company to file an amended complaint against certain defendants whom the Court found had published defamatory statements about the Company.&#160; The Company filed its Second Amended Complaint against these defendants on April 29, 2024.&#160; On August 2, 2024, the Company voluntarily dismissed its claims against the defendants named in the Second Amended Complaint without prejudice.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 4pt;"><b>2024 Non-Product Development </b> <b>Business Developments</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 4pt;"><i>Update on Government Investigations</i></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt 4pt; text-indent: 25pt;">Beginning in August 2021, the Company has received subpoenas, a Civil Investigative Demand (&#8220;CID&#8221;) and other requests for documents and information from the Department of Justice (&#8220;DOJ&#8221;) and document requests from the SEC, each seeking corporate information and documents concerning the research and development of simufilam and/or SavaDx. The Company has been providing documents and information in response to these subpoenas, the CID and requests for information.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt 2pt; text-indent: 25pt;">On September 26, 2024, the Company announced that it had reached a settlement with the SEC&#160;resolving the SEC investigation of the Company&#8217;s disclosures regarding its Phase 2b Study and related matters. The SEC also agreed to a settlement with two former senior employees of the Company. Pursuant to these settlements, the U.S. District Court for the Western District of Texas entered final consent judgment on October 18, 2024, on a complaint filed by the SEC against the Company and its two former senior employees. The Company has neither admitted nor denied the allegations of the complaint. The SEC&#8217;s complaint alleged that certain disclosures by the Company regarding the Phase 2b Study violated certain federal securities laws and SEC rules, including negligence-based disclosure violations of Sections 17(a)(2) and 17(a)(3) of the Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;), as well as recordkeeping and reporting requirements under the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;). The complaint alleges that the Company&#8217;s SEC reports and other public statements regarding the Phase 2b Study negligently contained materially misleading statements and omissions. The SEC&#8217;s allegations with respect to the Company&#8217;s two former employees relate to these employees&#8217; roles in such disclosures. Under its settlement, the Company consented to a permanent injunction against future violations of Section 17(a) of the Securities Act, Section 13(a)(1) of the Exchange Act and Rules 12b-20, 13a-1, 13a-11 and 13a-13 under the Exchange Act. In addition, the Company&#160;paid a civil monetary penalty of $40 million in November 2024.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt 4pt; text-indent: 25pt;">The Company continues to cooperate with the DOJ related to requests for documents and information, including those related to conduct alleged in the indictment of Dr. Hoau-Yan Wang discussed below. The Company cannot predict the outcome or impact of&#160;ongoing matters, including whether a government authority may pursue an enforcement action against the Company or others. The Company does not at this time anticipate, however, that DOJ will bring criminal charges against or seek a criminal resolution with the Company.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt 4pt; text-indent: 25pt;">&#160;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
      31
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 5pt;"><i>Indictment of Dr. Hoau-Yan Wang</i></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 5pt;text-indent:18pt;">On June 28, 2024, the DOJ announced that a federal grand jury in the U.S. District Court for the District of Maryland returned an indictment of Dr. Wang. The indictment alleges that Dr. Wang caused Cassava to submit grant applications to the U.S. National Institutes of Health (&#8220;NIH&#8221;) that contained false and fraudulent representations about his research. Among other things, the indictment alleges that Dr. Wang made materially false, fraudulent, and misleading statements to NIH regarding the mechanism by which the Company&#8217;s therapeutic product candidate, simufilam, was designed to treat Alzheimer&#8217;s disease and the improvement of certain Alzheimer&#8217;s disease indicators in patients treated with simufilam, and that Dr. Wang manipulated or otherwise fabricated research results, including Western Blot images that he prepared.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 5pt;text-indent:18pt;">Dr. Wang, who is employed as a professor at the School of Medicine of the City University of New York (&#8220;CUNY&#8221;), previously served as a scientific collaborator and advisor to Cassava. Dr. Wang&#8217;s research, including foundational research published together with Dr. Lindsay Burns, Cassava&#8217;s former SVP, Neuroscience, led to the discovery of simufilam. Among other work for Cassava, Dr. Wang&#8217;s laboratory at CUNY conducted the final bioanalysis for the&#160;Phase 2b study, which the Company reported as part of the final results of that study.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 5pt;text-indent:18pt;">Dr. Wang received compensation from the Company for his consulting and advisory work for Cassava. For over a decade until Cassava&#8217;s termination of its consulting relationship with him, Dr. Wang was paid a cash stipend of $2,000 per month. He was also&#160;awarded stock options pursuant to the Company&#8217;s equity incentive plans, none of which were&#160;exercised. Dr. Wang held&#160;18,571 stock options, all of which were granted between 2015 and 2019&#160;with a weighted average exercise price of $4.22 per share. Dr. Wang's stock options expired unexercised in August 2024. Dr. Wang was previously a participant in the Company&#8217;s 2020 Cash Incentive Bonus Plan (the CIB Plan). However, Dr. Wang was not in the past allocated and cannot&#160;in the future be allocated any cash bonus award pursuant to the CIB Plan.&#160;Prior to Dr. Wang&#8217;s indictment, the Company terminated its consulting relationship with him, and the Board removed him as a participant in the CIB Plan.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 5pt;text-indent:18pt;">Neither Dr. Wang nor his laboratory at CUNY had any involvement at any time in the Company&#8217;s Phase 3 clinical trials of simufilam.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:27pt;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -27pt; text-indent: 27pt;"><b>Leadership Updates</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:9pt;"><i>Appointment of Executive Chairman of the Board of Directors</i></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 5pt;text-indent:18pt;">On July 15, 2024, Richard J. Barry, an independent director at the time, was named by the Board as its Executive Chairman. On September 6, 2024, Mr. Barry was appointed President and Chief&#160;Executive Officer.&#160;</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 5pt;text-indent:18pt;">Mr. Barry, 66, has served as a director since June 2021. Since June 2015, Mr. Barry has served as a director of Sarepta Therapeutics, Inc. (Nasdaq: SRPT) and from June 2019 through October 2020, he served as a director of MiMedx Group Inc. (Nasdaq: MDXG). Mr. Barry has extensive experience in the investment management business. He was a founding member of Eastbourne Capital Management LLC, and served as a Managing General Partner and Portfolio Manager from 1999 to its close in 2010. Prior to Eastbourne, Mr. Barry was a Portfolio Manager and Managing Director of Robertson Stephens Investment Management. Mr. Barry holds a Bachelor of Arts from Pennsylvania State University. The Board has concluded that Mr. Barry&#8217;s experience as founder and managing director of investment funds and as a director to public companies, including service on Audit, Compensation, and Nominating and Governance Committees, qualifies him to serve as President and Chief&#160;Executive Officer.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -18pt; text-indent: 27pt;"><i>Resignation of Former Executive Officer and Director</i></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 5pt;text-indent:18pt;">On July 15, 2024, Remi Barbier resigned as&#160;President and Chief Executive Officer of the Company, effective as of September 13, 2024 (the &#8220;Effective Date&#8221;). Mr. Barbier was employed by the Company through the Effective Date in a non-executive capacity, without duties or responsibilities. Pursuant to the terms of Mr. Barbier&#8217;s Employment Agreement, Mr. Barbier is receiving&#160;severance compensation equal to $1.23 million over twelve months following the Effective Date.&#160;Mr. Barbier&#160;continues to participate in the Company&#8217;s medical plan at Cassava&#8217;s expense and&#160;received a payment sufficient to provide insurance coverage equivalent to existing third-party plans, in each case for a period of twelve months following separation. In addition, on July 15, 2024, the Company&#8217;s Board accepted Mr. Barbier&#8217;s resignation as Chairman of the Board and from Board membership, effective on that date.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
      32
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 7pt;text-indent:18pt;">On September 13, 2024, the Company&#160;entered into a non-exclusive Consulting Agreement (the &#8220;Consulting Agreement&#8221;) with Mr.&#160;Barbier. Pursuant to the Consulting Agreement, for a period of one year, Mr. Barbier was to&#160;furnish consulting services for $100 per hour as, and to the extent, reasonably requested by the Company&#160;for purposes of providing information and support for scientific research and/or obtaining governmental approval for the Company&#8217;s products. Pursuant to the Consulting Agreement, Mr. Barbier also provided&#160;confidentiality and other customary covenants, terms and conditions&#160;during the Consulting Agreement&#8217;s term. The Consulting Agreement was terminated effective January 23, 2025. Total consulting fees paid to Mr. Barbier were de minimis through the termination of the consulting agreement.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 7pt;text-indent:18pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 5pt;"><i>Other Management Changes</i></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 5pt;text-indent:18pt;">On July 16, 2024, Cassava and Lindsay Burns, Ph.D., SVP, Neuroscience, at the Company, agreed that Dr. Burns would&#160;step down from her employment with the Company, effective on that date.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 5pt;text-indent:18pt;">The terms of Dr. Burns&#8217; separation are set forth in a Consulting Agreement (the &#8220;Burns Agreement&#8221;), which includes a Release Agreement, between Dr. Burns and the Company, dated July 16, 2024.&#160; Pursuant to the Burns Agreement, following her separation from the Company and for a one-year period, Dr. Burns will furnish consulting services as, and to the extent, reasonably requested by Cassava for purposes of providing information and support for scientific research and/or obtaining governmental approval for the Company&#8217;s products. During the period of the Burns Agreement, Dr. Burns will&#160;be&#160;a &#8220;service provider&#8221; as that term is defined in the 2008 Equity Incentive Plan and 2018 Omnibus Incentive Plan. Cassava may, in its sole discretion, extend the term of the Burns Agreement for up to an additional year. The Company may also terminate the Burns Agreement at any time for cause, including, without limitation, for any actions that discredit Cassava&#8217;s business reputation. Dr. Burns will be paid $500 per hour for such consulting services, which will constitute continuous service for purposes of outstanding equity awards held by Dr. Burns.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 5pt;text-indent:18pt;">Pursuant to the Burns Agreement, Dr. Burns is&#160;receiving&#160;severance compensation equal to $0.5 million in quarterly installments over twelve months&#160;from July 16, 2024.&#160;Dr. Burns continues to participate in the Company&#8217;s medical plan at Cassava&#8217;s expense for a period of twelve months following separation, which may be extended to eighteen months in connection with an extension of the term of the Burns Agreement. Dr. Burns remains eligible for applicable indemnification rights under Dr. Burns&#8217; existing indemnification agreement, the Company&#8217;s by-laws and the Company&#8217;s insurance policies, in each case, subject to the terms and conditions and limitations thereof.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 5pt;text-indent:18pt;">The Burns Agreement provides for Dr. Burns&#8217; general release of claims in favor of the Company, subject to certain exceptions. In addition, Dr. Burns is&#160;subject to a one-year non-competition covenant, a two-year non-solicitation covenant, and indefinite non-disparagement and confidentiality covenants. Dr. Burns remains subject to her existing assignment of inventions agreement.</p>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>Corporate Information</b></p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">We were incorporated as a Delaware corporation in May 1998 under the name Pain Therapeutics, Inc. In March 2019, we changed our company name to Cassava Sciences, Inc. Our principal offices are located at 6801 N. Capital of Texas Highway, Building 1; Suite 300, Austin, TX, 78731. Our telephone number is 512-501-2444. Our website address is www.CassavaSciences.com. Information contained on our website is not a part of this Annual Report on Form 10-K and the inclusion of our website address in this Annual Report on Form 10-K is an inactive textual reference only.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">We use Cassava Sciences, the Cassava Sciences logo, artwork and other marks as trademarks in the United States and other countries. Solely for convenience, trademarks and trade names referred to in this Annual Report, including logos, artwork, and other visual displays, may appear without the &#174; or TM&#160;symbols, but such references are not intended to indicate in any way that we will not assert, to the fullest extent under applicable law, our rights, or the rights of the applicable licensor to these trademarks and trade names. We do not intend our use or display of other entities&#8217; trade names, trademarks, or service marks to imply a relationship with, or endorsement or sponsorship of us by, any other entity.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">We file electronically with the Securities and Exchange Commission (SEC)&#160;our annual reports on Form 10-K, quarterly reports on Form 10-Q and current reports on Form 8-K pursuant to Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;). The SEC maintains an Internet site that contains reports, proxy and information statements, and other information regarding issuers that file electronically with the SEC. The address of the site is <span style="text-decoration: underline; ">http://www.sec.gov</span>.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">You may obtain a free copy of our annual reports on Form 10-K, quarterly reports on Form 10-Q and current reports on Form 8-K and amendments to those reports on the day of filing with the SEC on our website at <span style="text-decoration: underline; ">http://www.cassavasciences.com</span>, by contacting our corporate offices by calling 512-501-2450 or by sending an e-mail message to <span style="text-decoration: underline; ">IR@cassavasciences.com</span>.&#160;The contents of our website are not incorporated into this filing.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
      33
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
  <div>
   &#160;
  </div>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><a id="item1a" title="item1a" href="#"></a>Item 1A. </b>&#160;&#160;&#160;&#160;<b><i>Risk Factors</i></b></p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>RISK FACTORS </b></p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"><i>Investing in our securities involves a high degree of risk. This section includes a discussion of what we believe to be the material factors that make an investment in our Company speculative or risky. The risks described in this section are not the only risks we face.</i><i>&#160;Additional risks and uncertainties not presently known to us or that we currently deem immaterial also may impair our business operations and the market price of our securities.</i></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-indent: 18pt;"><i>You should carefully consider the risks described below, as well as other information contained in this Annual Report on Form 10-K, including our consolidated financial statements and the related notes and the section titled </i>&#8220;<i>Management</i>&#8217;<i>s Discussion and Analysis of Financial Condition and Results of Operations,</i>&#8221;<i> before deciding whether to invest in our securities. The occurrence of any of the events or developments described below could harm our business, financial condition, results of operations, and growth prospects. In such an event, the market price of our securities could decline, and you may lose all or </i> <i>part of your investment. </i></p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>Risks Related to the Discovery, Development, and Commercialization of Our Product Candidates </b></p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 36pt;text-indent:-18pt;">&#160;</p>
  <table cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; margin-right: 0pt;">
   <tbody>
    <tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
     <td style="width: 18pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="width: 18pt; vertical-align: top; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><i>&#9679;</i></td>
     <td style="width: auto; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><i>We have no approved products.</i>&#160;<i> Our product candidates are subject to significant development risks, and we may never achieve regulatory approval or commercial success.</i></td>
    </tr>

    <tr style="vertical-align: top; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
     <td style="width: 18pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="width: 18pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><i>&#9679;</i></p> </td>
     <td style="width: auto; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><i>Our product candidates are based on new scientific approaches and novel technology, which makes it difficult to predict the time and cost of product candidate development and likelihood of success.</i></p> </td>
    </tr>

    <tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
     <td style="width: 18pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="width: 18pt; vertical-align: top; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><i>&#9679;</i></td>
     <td style="width: auto; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><i>The drug development process, the clinical trial process and the enrollment and retention of patients in clinical trials could be challenging, expensive and time-consuming for the indications that we are targeting.</i></td>
    </tr>

    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><i>&#9679;</i></p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><i>We are heavily dependent on the success of simufilam, our lead product candidate which is under development. If this product candidate is unsuccessful in clinical development, or does not receive regulatory approval, we will be unable to generate product revenue&#160;and our business will be harmed.</i></p> </td>
    </tr>

    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><i>&#9679;</i></p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><i>We have a limited operating history in our business targeting Alzheimer&#8217;s disease and TSC-</i>related<i> epilepsy and no history of product approvals for commercial sale, which may make it difficult to evaluate our current business and predict our future success and viability.</i></p> </td>
    </tr>

    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><i>&#9679;</i></p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><i>We cannot give any assurance that we will file for regulatory approval for any of our product candidates, or that if we file for approval, our product candidates will receive regulatory approval, which is necessary before they can be commercialized.</i></p> </td>
    </tr>

    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><i>&#9679;</i></p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><i>Results observed in&#160;preclinical studies,</i><b><i>&#160;</i></b><i>early stage&#160;clinical trials for simufilam are not regulatory evidence of drug safety or efficacy.</i></p> </td>
    </tr>

    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><i>&#9679;</i></p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><i>We may encounter substantial delays in&#160;clinical studies that we conduct or may not be able to conduct or complete&#160;clinical studies on the timelines we expect, if at all.</i></p> </td>
    </tr>

    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><i>&#9679;</i></p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><i>If physicians and patients do not accept and use our drugs, we will not achieve sufficient product revenues and our business will suffer.</i></p> </td>
    </tr>

    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><i>&#9679;</i></p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><i>We currently have no in-house capabilities to manufacture or commercialize our product candidates, and we rely on a third-party commercial drug manufacturing organization for supplies of simufilam. If we are unable to develop our own manufacturing, sales, marketing and distribution capabilities, or if we are not successful in contracting with third parties for these services on favorable terms, or at all, our product revenues could be adversely impacted.</i></p> </td>
    </tr>

    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><i>&#9679;</i></p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><i>Clinical studies that we conduct may fail to demonstrate substantial evidence of the safety and efficacy of our product candidates, which would prevent, delay, or limit the scope of regulatory approval and commercialization.</i></p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>Risks Related to Government Regulation and Other Legal Compliance Matters</b></p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 36pt;text-indent:-18pt;">&#160;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><i>&#9679; </i></p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><i>Our financial condition and operating results could be adversely impacted by unfavorable results of legal proceedings, government investigations or allegations and other claims.</i></p> </td>
    </tr>

    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><i>&#9679; </i></p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><i>If we are ultimately unable to file for and obtain regulatory approval for our product candidates, we will be unable to generate product revenue and our business will be substantially harmed.</i></p> </td>
    </tr>

    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><i>&#9679; </i></p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><i>Our ability to market and promote our product candidates will be determined and limited by FDA-approved labeling.</i></p> </td>
    </tr>

    <tr style="vertical-align: top; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
     <td style="width: 18pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="width: 18pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><i>&#9679; </i></p> </td>
     <td style="width: auto; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><i>If we fail to comply or stay in compliance with the complex set of federal, state, local and foreign laws and regulations that apply to our business, we could suffer severe consequences that could materially and adversely affect our operating results and financial condition.</i></p> </td>
    </tr>

    <tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
     <td style="width: 18pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="width: 18pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><i>&#9679;</i></td>
     <td style="width: auto; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><i>Government agencies may establish and promulgate usage guidelines that could limit the use of our product candidates.</i></td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
      34
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>Risks Related to Our Intellectual Property </b></p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 36pt;text-indent:-18pt;">&#160;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><i>&#9679; </i></p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><i>If we are unable to obtain and maintain sufficient patent protection for any product candidates we develop, our competitors could develop and commercialize products similar or identical to ours, and our ability to successfully commercialize any product candidates we may develop may be adversely affected.</i></p> </td>
    </tr>

    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><i>&#9679; </i></p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><i>Issued patents covering our product candidates and other technologies could be found invalid or unenforceable if challenged in court or before administrative bodies in the U.S. or abroad.</i></p> </td>
    </tr>

    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><i>&#9679; </i></p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><i>If we do not obtain patent term extension and data exclusivity for any product candidates we may develop, our business may be materially harmed.</i></p> </td>
    </tr>

    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><i>&#9679; </i></p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><i>If we are unable to protect the confidentiality of our trade secrets, our business and competitive position would be materially harmed.</i></p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>Risks Related to Our Business and Operations </b></p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 36pt;text-indent:-18pt;">&#160;</p>
  <table cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; margin-right: 0pt;">
   <tbody>
    <tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
     <td style="width: 18pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="width: 18pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><i>&#9679;</i></td>
     <td style="width: auto; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><i>The validity of aspects of the Company&#8217;s Phase 2b Study has been called into question.</i></td>
    </tr>

    <tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
     <td style="width: 18pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="width: 18pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><i>&#9679;</i></td>
     <td style="width: auto; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><i>We are subject to lawsuits and governmental investigations and inquiries.</i></td>
    </tr>

    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><i>&#9679; </i></p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><i>Our ability to operate without any significant disruptions will, in part, depend on our ability to source materials and clinical supplies via our product supply chains.</i></p> </td>
    </tr>

    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><i>&#9679; </i></p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><i>Our reliance on third parties for both the supply and manufacture of materials for our product candidates carries the risk that we will not have sufficient quality or quantities of such materials or product candidates, or that such supply will not be available to us at an acceptable cost, which could delay, prevent, or impair our development or commercialization efforts.</i></p> </td>
    </tr>

    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><i>&#9679; </i></p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><i>Our Workforce Reduction may result in operational and strategic challenges.</i></p> </td>
    </tr>

    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><i>&#9679; </i></p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><i>Our internal computer systems, or those used by third parties on whom we rely, may fail or suffer other breakdowns, cyberattacks, or information security breaches that could compromise the confidentiality, integrity, and availability of such systems and data, result in material disruptions of our development programs and business operations, risk disclosure of confidential, financial, or proprietary information, and affect our reputation.</i></p> </td>
    </tr>

    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><i>&#9679; </i></p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><i>Business disruptions and lack of appropriate levels of commercial insurance could seriously harm our future revenue and financial condition and increase our costs and expenses.</i></p> </td>
    </tr>

    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><i>&#9679; </i></p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><i>Social media platforms have significantly altered the dynamics of corporate communications and present risks and challenges, some of which are&#160;and may continue to be unknown to us.</i></p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>Risks Related to Financial Condition and Capital Requirements </b></p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 36pt;text-indent:-18pt;">&#160;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><i>&#9679; </i></p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><i>We have incurred significant net losses in each period since our inception and anticipate that we will continue to incur net losses for the foreseeable future.</i></p> </td>
    </tr>

    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><i>&#9679; </i></p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><i>We have broad discretion in the use of our capital resources, including the net proceeds from</i> <i>any of our financing transactions</i> <i>and may not use them effectively.</i></p> </td>
    </tr>

    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><i>&#9679; </i></p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><i>We have no product revenues and may never achieve revenues or profitability based on product revenues.</i></p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>Risks Related to the Ownership of Our Common Stock </b></p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 36pt;text-indent:-18pt;">&#160;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><i>&#9679;</i></p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><i>The market price of our common stock has historically been highly volatile and we expect it to continue to be volatile, which could result in substantial losses for investors who purchase our shares.</i></p> </td>
    </tr>

    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><i>&#9679;</i></p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><i>Changes in our ownership could limit our ability to utilize net operating loss carryforwards.</i></p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&#160;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
      35
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>Risks Related to the Discovery, Development, and Commercialization of Our Product Candidates </b></p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>We </i></b><b><i>have no approved products. Our product candidates are subject to significant development risk, and we may never achieve regulatory approval or commercial success</i></b></p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">We are developing therapeutic and diagnostic product candidates, but to date have no approved products and have concentrated substantially all of our resources in recent years on research and development efforts on experimental methods for the treatment of Alzheimer&#8217;s disease.&#160; As we explore expansion into other therapeutic indications, we expect that we will continue to expend substantial resources on research and development.&#160; All of the product candidates that we seek to develop are subject to significant development risk, as the development of new pharmaceutical treatments is inherently risky.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -1pt; text-indent: 18pt;">Developing and, if approved, commercializing a novel treatment for a central nervous system disorder, such as Alzheimer&#8217;s disease or TSC-related epilepsy,&#160; subjects us to many challenges, including obtaining regulatory approval from FDA and other regulatory authorities.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt;">Because of the challenges associated with drug development, we may never achieve regulatory approval or commercial success for any of the product candidates that we develop.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -1pt;"><b><i>Our product candidates are based on new scientific approaches and novel technology, which makes it difficult to predict the time and cost of product candidate development and likelihood of success.</i></b></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -1pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">Our lead drug candidate, simufilam,&#160;is based on a new approach of stabilizing&#8212;but not removing&#8212;a critical protein in the brain. We cannot be certain that our novel technologies will yield clinical results that support the approval of a safe and effective therapeutic product or, if approvable, that such a product will be marketable. In addition, because FDA has limited comparators to evaluate our lead drug candidate, we could experience a longer than expected regulatory review process and increased development costs.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -1pt;"><b><i>The drug development process, the clinical trial process and the enrollment and retention of patients in clinical trials could be challenging, expensive and time-consuming&#160;</i></b><b><i>for the indications that we are targeting</i></b><b><i>.</i></b></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-indent: 18pt; text-align: justify;">Identifying and qualifying patients to participate in clinical studies is critical to the success of the relevant product candidate. The timing of clinical studies depends, in part, on the speed of recruitment of patients to participate in testing such product candidates as well as completion of required follow-up periods. We may not be able to identify, recruit and enroll a sufficient number of patients or patients with required or desired characteristics to achieve the objectives of the study. If patients are unable or unwilling to participate in such studies, the timeline for recruiting patients, conducting studies and obtaining regulatory approval of potential products may be delayed. These delays could result in increased costs, delays in advancing our product candidates, delays in testing the effectiveness of our technology, failure to meet study endpoints or objectives or termination of the clinical studies altogether.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -2pt; text-indent: 18pt;">Patient enrollment and retention in clinical trials depends on many factors, including the size of the patient population, the nature of the trial protocol, the existing body of safety and efficacy data, the number and nature of competing treatments and ongoing clinical trials of competing therapies for the same indication, the proximity of patients to clinical sites and the eligibility criteria for the trial. Such enrollment issues could cause delays or prevent development and approval of our drug candidate.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -2pt; text-indent: 18pt;">Furthermore, our efforts to build relationships with patient communities may not succeed, which could result in delays in patient enrollment in our clinical trials. In addition, any negative results we may report in clinical trials of our drug candidate may make it difficult or impossible to recruit and retain patients in other clinical trials of that same drug candidate. For example, our enrollment efforts for future clinical trials, regardless of indication, may face headwinds as a result of the failure of our RETHINK-ALZ clinical trial to achieve its primary endpoints.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -2pt; text-indent: 18pt;">To the extent that we pursue an indication for simufilam for TSC-related epilepsy, we may face particular challenges. Because TSC is a rare neurological disorder, there are limited patient pools from which to draw in order to complete clinical trials in a timely and cost-effective manner. Identifying and qualifying patients to participate in our clinical trials would be critical to our success in pursuing an indication in TSC for simufilam. The number of patients suffering from TSC is small and has not been established with precision. If the actual number of patients with TSC is smaller than we anticipate, we may encounter difficulties in enrolling patients in our clinical trials, thereby delaying or preventing development and approval of a drug candidate. Even once enrolled we may be unable to retain a sufficient number of patients to complete trials for TSC-related epilepsy.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -2pt; text-indent: 18pt;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-indent: 18pt; text-align: justify;">Delays or failures in planned patient enrollment or retention may result in increased costs, program delays or both, which could have a harmful effect on our ability to develop our drug candidates or could render further development impossible.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&#160;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
      36
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>We are heavily </i></b><b><i>dependent on the success of simufilam, our lead product candidate, which is under development. If this product candidate is unsuccessful in clinical development</i></b>&#160;<b><i> or</i></b> <b><i>does not receive regulatory approval, we will be unable to generate product revenue and our business will</i></b>&#160;<b><i>be harmed. </i></b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-indent: 18pt; text-align: justify;">Our business is substantially dependent on our ability to successfully complete clinical development and obtain regulatory approval for simufilam, which may never occur. In recent years, we have invested a significant portion of our efforts and financial resources in the development of simufilam and, to a much lesser extent, SavaDx, for the treatment and detection of Alzheimer&#8217;s disease, respectively. We also intend to conduct exploratory preclinical studies to better understand simufilam&#8217;s potential as a treatment for TSC-related seizures.&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-indent: 18pt; text-align: justify;">The results of clinical studies are subject to a variety of factors, and there can be no assurance for any indication that simufilam will achieve clinical success, advance to regulatory approval, be approved by applicable regulatory agencies, or be successfully commercialized.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify; text-indent: 18pt;">An unfavorable outcome in one or more of the clinical trials that we conduct would be a major setback for our product candidates and for us and may require us to delay, reduce or re-define the scope of, or eliminate one or more product candidate development programs, any of which could have a material adverse effect on our business, financial condition and prospects.&#160; For example, on November 25, 2024, we announced that the topline results from our Phase 3 RETHINK-ALZ study of simufilam in Alzheimer&#8217;s disease did not meet each of the pre-specified co-primary, secondary and exploratory biomarker endpoints.&#160;Following the failure of REITHINK-ALZ, we discontinued our Phase 3 REFOCUS-ALZ study as well as all of our open-label extension studies in Alzheimer&#8217;s disease.&#160; Following the release of the topline REFOCUS-ALZ results, we intend to evaluate the results and determine the next steps for the future advancement, if any, of its Alzheimer&#8217;s program.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>We have a limited operating history in our business targeting Alzheimer</i></b>&#8217;<b><i>s disease and TSC-</i></b>related<b><i> epilepsy and no history of product approvals for commercial sale, which may make it difficult to evaluate our current business and predict our future success and viability. </i></b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -1pt; text-indent: 18pt;">We are a clinical-stage biopharmaceutical company with a limited operating history in our business initially targeting Alzheimer&#8217;s disease and now evaluating TSC-related epilepsy as a target. Since we commenced operations in 1998, we have had no product candidates approved for commercial sale and have not generated any revenue from product sales. Drug development is a highly uncertain undertaking and involves a substantial degree of risk. To date, we have not completed a successful pivotal Phase 3 clinical study in Alzheimer&#8217;s disease or TSC-related epilepsy, obtained marketing approval for any product candidates, or conducted sales and marketing activities necessary for successful product commercialization. Our long operating history as a company without product revenue makes any assessment of our future success and viability subject to significant uncertainty.</p>
  <p style="margin: 0pt 0pt 0pt -9pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">We will continue to encounter risks and difficulties frequently experienced by clinical-stage biopharmaceutical companies in rapidly evolving fields. We have not yet demonstrated an ability to successfully overcome such risks and difficulties. If we do not successfully address these risks and difficulties, our business, results of operations and financial condition will suffer materially.</p>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
      37
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>We cannot give any </i></b><b><i>assurance that we will file for regulatory approval for any of our product candidates or that, if we file for approval, our product candidates will receive regulatory approval, which is necessary before they can be commercialized</i></b><b><i>. </i></b></p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">To date, we have invested substantial effort and financial resources to identify, procure intellectual property for, and develop our programs in neurodegeneration and other central nervous system disorders, including conducting preclinical and clinical studies for our product candidates, simufilam and SavaDx, and providing general and administrative support for these operations. Our future success is dependent on our ability to successfully develop, obtain regulatory approval for, and then successfully commercialize our product candidates, and we may fail to do so for many reasons, including the following: &#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 36pt;text-indent:-18pt;">&#160;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">our product candidates may not successfully complete preclinical studies or clinical studies, as recently occurred with our RETHINK-ALZ Phase 3 clinical study;</p> </td>
    </tr>

    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: justify;">a product candidate may, on further study, be shown to have harmful side effects or other characteristics that indicate it is unlikely to be safe or effective or otherwise does not meet applicable regulatory criteria;</p> </td>
    </tr>

    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: justify;">our competitors may develop products or therapies that render our product candidates obsolete or less attractive;</p> </td>
    </tr>

    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: justify;">the product candidates that we develop may not be sufficiently covered by intellectual property;</p> </td>
    </tr>

    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: justify;">the product candidates that we develop may be challenged by third parties&#8217; patents or other intellectual property or exclusive rights;</p> </td>
    </tr>

    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: justify;">the market for our product candidates may change so that the continued development of a product candidate is no longer reasonable or commercially attractive;</p> </td>
    </tr>

    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: justify;">our product candidates may not be capable of being produced in commercial quantities at an acceptable cost, or at all;</p> </td>
    </tr>

    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: justify;">if a product candidate obtains regulatory approval, we may be unable to establish sales and marketing capabilities, or successfully market such approved product candidate, to gain market acceptance; and</p> </td>
    </tr>

    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: justify;">a product candidate may not be accepted as safe, effective or useful by patients, the medical community or third-party payors, if applicable.</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">If any of these events occur, we may be forced to abandon our development efforts for a program or programs, which would have a material adverse effect on our business and could potentially cause us to cease operations.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">We may not be successful in our efforts to further develop our product candidates. We are not permitted to market or promote any of our product candidates before we receive regulatory approval from FDA or comparable foreign regulatory authorities, and we may never receive such regulatory approval for any of our product candidates. SavaDx is in the early stages of development. Simufilam, our lead&#160;product candidate, will require successful completion of a&#160;Phase 3 program, management of preclinical, clinical, and manufacturing activities, regulatory approval, adequate manufacturing supply, a commercial organization, and significant marketing efforts before we generate any revenue from product sales, if at all.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">We have never completed a product development program in neurodegeneration or other central nervous system disorders. Further, we cannot be certain that any of our product candidates will be successful in clinical studies, and we may terminate existing or future clinical studies&#160;prior to their completion, as occurred with our REFOCUS-ALZ Phase 3 clinical trial and open-label extension trials for Alzheimer&#8217;s disease following the failure of our RETHINK-ALZ Phase 3 clinical trial to achieve its pre-specified endpoints.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">If any of our product candidates successfully complete clinical studies, we may seek regulatory approval to market our product candidates in the U.S., Japan, Canada, the United Kingdom or the European Union, and in additional foreign countries where we believe there is a viable commercial opportunity. We may never receive regulatory approval to market any product candidates anywhere even if such product candidates successfully complete clinical studies, which would adversely affect our viability. To obtain regulatory approval in countries outside the U.S., we would need to comply with numerous and varying regulatory requirements of such other countries regarding safety, efficacy, manufacturing and controls, clinical studies, commercial sales, pricing, and distribution of our product candidates. Even if we are successful in obtaining approval in one jurisdiction, we cannot ensure that we will obtain approval in any other jurisdictions. If we are unable to obtain approval for our product candidates in multiple jurisdictions, our business, financial condition, results of operations, and our growth prospects could be negatively affected.</p>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">Even if we receive regulatory approval to market any of our product candidates, whether for the treatment or diagnosis of neurodegenerative diseases or other diseases, we cannot provide assurance that any such product candidate will be successfully commercialized, widely accepted in the marketplace or more effective than other commercially available alternatives.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
      38
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">Investment in biopharmaceutical product development involves significant risk that any product candidate will fail to demonstrate adequate efficacy or an acceptable safety profile, gain regulatory approval, and become commercially viable. We cannot provide any assurance that we will be able to successfully advance any of our product candidates through the development process or, if approved, successfully commercialize any of our product candidates.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>There can be no assurance that promising results of </i></b><b><i>preclinical studies or</i></b> <b><i>Phase 1 or Phase 2 clinical trials with simufilam will be reproduced in later stage studies, including Phase 3 studies.</i></b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -1pt; text-indent: 18pt;">Results of any of our preclinical studies or Phase 1 or Phase 2 clinical trials with simufilam are not predictive of the future results of any other trial, including any later-stage Phase 3 clinical trials. Notwithstanding promising results in earlier stage trials, our first Phase 3 trial in Alzheimer&#8217;s disease did not meet&#160;each of the pre-specified co-primary, secondary and exploratory biomarker endpoints. Simufilam may fail to show the desired safety and efficacy in additional Phase 3 clinical trials despite having progressed successfully through preclinical studies and initial clinical trials in the applicable indication. Many biopharmaceutical companies have suffered significant setbacks in Phase 3 clinical trials due to lack of efficacy or adverse safety profiles, notwithstanding promising results in earlier trials. We cannot be certain that our product candidates will not continue to face similar setbacks.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -1pt; text-indent: 18pt;">In addition, preliminary conclusions based on data from analyses of Phase 1 and Phase 2 clinical studies and open-label results may not be reproduced when implemented in large, well-controlled, randomized clinical trials. Particular caution should be exercised when interpreting preliminary data, data relating to a small number of patients and data from open-label uncontrolled studies, which are generally not capable of providing interpretable evidence of efficacy. Phase 1 studies are designed to assess the initial safety characteristics of simufilam &#160;and such studies are not designed to, and do not, evaluate safety, tolerability and efficacy of simufilam in patients. Similarly, Phase 2 clinical studies with simufilam that we conduct are designed to assess the safety characteristics of simufilam in patients. Such Phase 2 programs are not designed to, and do not, evaluate large-scale or long-term safety, tolerability and efficacy of simufilam in patients. There can be no assurance that future large, well-controlled, multi-dose studies will demonstrate the safety, tolerability or efficacy of simufilam to treat patients with any indication, including Alzheimer&#8217;s disease or TSC-related epilepsy.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-indent: 18pt;">Even if clinical trials for simufilam are completed, we cannot be certain that their results will support the substantial evidence of safety and efficacy needed to obtain regulatory approval. The failure of simufilam to show safety, tolerability or efficacy in any future clinical studies would significantly harm our business.</p>
  <p style="margin: 0pt 0pt 0pt -9pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">&#160;</p>
  <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;"><b><i>Results observed preclinical studies and early-stage clinical trials for</i></b>&#160;<b><i> simufilam are</i></b>&#160;<b><i>not regulatory evidence of drug safety or efficacy.</i></b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -1pt; text-indent: 18pt;">Data results from any preclinical and non-Phase 3 studies&#160;that we conduct do not constitute, and should not be interpreted as, regulatory evidence of safety or efficacy for simufilam in the applicable indication, including Alzheimer&#8217;s disease or TSC-related epilepsy. Rigorous evidence for drug safety and efficacy is derived only from one or more large, randomized, placebo-controlled studies. The size and open-label design of portions of our non-Phase 3 studies may introduce clinical or statistical bias or may generate results that may not fully distinguish between drug effects and random variation. Different methods of statistical analysis on clinical data from the same study may lead to objectively different numerical results. These and other statistical and clinical features of our non-Phase 3 studies add complexity or limitations to the scope of data interpretation.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 8pt;text-indent:18pt;">&#160;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
      39
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
  <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;"><b><i>We may encounter substantial delays in the clinical studies that we conduct or may not be able to conduct or complete our clinical studies on the timelines we expect, if at all. </i></b></p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">Clinical testing is expensive, time consuming, and subject to uncertainty. We cannot guarantee that any clinical studies will be conducted as planned, enroll patients as planned or be completed on schedule, if at all. Moreover, even after our studies begin, safety or other issues may arise that could suspend or terminate such clinical studies. A failure of one or more clinical studies can occur at any stage of testing, and our ongoing or future clinical studies may not be successful. Events that may prevent successful or timely initiation or completion of clinical studies include:</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 36pt;text-indent:-18pt;">&#160;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: justify;">inability to generate sufficient or necessary preclinical, toxicology, or other in vivo or in vitro data to support the initiation or continuation of clinical studies or to support the filing of a New Drug Application for simufilam;</p> </td>
    </tr>

    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: justify;">delays in confirming target engagement, patient selection, or other relevant biomarkers to be utilized in preclinical and clinical product candidate development;</p> </td>
    </tr>

    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">delays in reaching a consensus with regulatory agencies on study design;</p> </td>
    </tr>

    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: justify;">delays in reaching an agreement on acceptable terms with prospective clinical study sites, the terms of which can be subject to extensive negotiation and may vary significantly among different clinical study sites;</p> </td>
    </tr>

    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: justify;">delays in identifying and recruiting suitable clinical investigators;</p> </td>
    </tr>

    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: justify;">delays in obtaining required IRB approval for each clinical study site or adverse action by one or more IRBs;</p> </td>
    </tr>

    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: justify;">a new safety finding that presents unreasonable risk to clinical study participants;</p> </td>
    </tr>

    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: justify;">a negative finding from an inspection of our clinical research organization (CRO), clinical study operations or study sites;</p> </td>
    </tr>

    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">the finding that the investigational protocol or plan is deficient to meet its stated objectives;</p> </td>
    </tr>

    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: justify;">delays in identifying, recruiting, and enrolling suitable patients to participate in our clinical studies, and delays caused by patients withdrawing from clinical studies, or failing to return for post-treatment follow-up;</p> </td>
    </tr>

    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: justify;">delays caused by disease epidemics, pandemics, or other health crises;</p> </td>
    </tr>

    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: justify;">difficulty collaborating with patient groups and investigators;</p> </td>
    </tr>

    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: justify;">failure by our CRO or other third parties, or us to adhere to clinical study requirements;</p> </td>
    </tr>

    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: justify;">failure to perform in accordance with FDA&#8217;s or any other regulatory authority&#8217;s Code of Good Clinical Practice (GCP) requirements, or other regulatory guidelines in other countries;</p> </td>
    </tr>

    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: justify;">occurrence of adverse events associated with the product candidate that are viewed to outweigh its potential benefits;</p> </td>
    </tr>

    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: justify;">changes in regulatory requirements and guidance that require amending or submitting new clinical protocols;</p> </td>
    </tr>

    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: justify;">changes in the standard of care on which a clinical development plan was based, which may require new or additional studies;</p> </td>
    </tr>

    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: justify;">the cost of clinical studies of our product candidates being greater than we anticipate;</p> </td>
    </tr>

    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: justify;">clinical studies of our product candidates producing negative or inconclusive results, which may result in our deciding, or regulators requiring us, to conduct additional clinical studies or abandon product development programs; and</p> </td>
    </tr>

    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: justify;">delays in manufacturing, testing, releasing, validating, or importing/exporting sufficient stable quantities of our product candidates for use in clinical studies or the inability to do any of the foregoing.</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">Any inability to successfully initiate or complete clinical studies could result in additional costs to us or impair our ability to generate revenue. In addition, if we make manufacturing or formulation changes to our product candidates, we may be required to, or we may elect, to conduct additional studies to bridge our modified product candidates to earlier versions. Clinical study delays could also shorten any periods during which our products have patent protection and may allow our competitors to bring products to market before we do, which could impair our ability to successfully commercialize our product candidates and may harm our business and results of operations.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">Delays in the completion of any clinical study of our product candidates will increase our costs, slow down our product candidate development and approval process and delay, or potentially jeopardize our ability to commence product sales and generate revenue. In addition, many of the factors that cause, or lead to, a delay in the commencement or completion of clinical studies may also ultimately lead to the denial of regulatory approval of our product candidates or the termination of such clinical studies prior to their completion, either of which could adversely affect our business.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
      40
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 7pt;"><b><i>The FDA may not accept data from Phase 3 clinical trials conducted in foreign locations. </i></b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-indent: 18pt; text-align: justify;">We have conducted and may in the future conduct&#160;portions of our Phase 3 clinical trials outside the United States. For example, the clinical trial must be conducted and performed by qualified investigators in accordance with ethical principles. The trial population must also adequately represent the U.S. population, and the data must be applicable to the U.S. population and U.S. medical practice in ways that the FDA deems clinically meaningful. In general, the patient population for any clinical trials we conduct&#160;outside the United States must be representative of the population for which we intend to label the product in the United States. In addition, while Phase 3 clinical trials conducted outside the United States are subject to the applicable local laws, FDA acceptance of the data will be dependent upon its determination that the trials also complied with all applicable U.S. laws and regulations. We cannot assure you that the FDA will accept data from portions of our Phase 3 trials conducted outside the United States. If the FDA does not accept such data from such clinical trials, we would likely need to conduct additional trials, which would be costly and time-consuming and delay or permanently halt our development of simufilam, our lead investigational product.</p>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>The FDA or other regulatory agencies&#160;may put a clinical hold on our clinical studies, which would cause our business to suffer.</i></b></p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">A clinical hold is an order issued by FDA or another regulatory agency to suspend an ongoing clinical trial, typically due to newly identified deficiencies with, or the need for additional information regarding, the subject study or drug candidate. The grounds for imposition of a clinical hold are complex, variable and fact specific. If FDA imposes a clinical hold on any of our future clinical studies, no new patients may be enrolled in the subject study and study patients already in such study may be taken off our drug candidate unless treatment is specifically permitted by FDA in the interest of patient safety.&#160;If we are issued a clinical hold, FDA would expect us to address the cited deficiencies or provide the requested additional information, in each case, through the submission of a detailed, written response. A clinical hold would require us to spend significant resources, potentially over an extended period of time, to address the root causes of FDA&#8217;s concerns, even if we disagreed with the FDA&#8217;s assessment of asserted deficiencies.&#160;If we were unable to find and successfully address such root causes or if our response were deemed inadequate to lift the clinical hold, this could adversely affect our business. If we were subjected to a clinical hold that remained in effect for one&#160;year or longer, the FDA may consider the IND for the affected product candidate to fall into Inactive Status, which may result in termination of the corresponding clinical program.&#160;To the extent we are not successful in lifting any clinical hold that the FDA might impose, our results of operations and business will be materially adversely affected.</p>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>If physicians and patients do not accept and use our drugs, we will not achieve sufficient product revenues and our business will suffer.</i></b></p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">Even if FDA approves our drugs, physicians and patients may not accept and use them. Acceptance and use of our drugs will depend on a number of factors including:</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 36pt;text-indent:-18pt;">&#160;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">when the drug is launched into the market and related competition;</p> </td>
    </tr>

    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">approved label claims;</p> </td>
    </tr>

    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: justify;">perceptions by members of the healthcare community, including physicians, about the safety, side effects and effectiveness of our drugs;</p> </td>
    </tr>

    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">perceptions by physicians regarding the cost-benefit of our product candidates;</p> </td>
    </tr>

    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">published studies demonstrating the cost effectiveness of our drugs relative to competing products;</p> </td>
    </tr>

    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">availability of reimbursement for our products from government or healthcare payers;</p> </td>
    </tr>

    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">effectiveness of marketing and distribution efforts by us and other licensees and distributors.</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="margin: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">Because we expect to rely on sales generated by our current lead product candidates for substantially all of our revenues for the foreseeable future, the failure of any of these drugs to find market acceptance would harm our business and could require us to seek additional financing.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&#160;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
      41
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>We may not be successful in developing our product candidates in neurodegeneration </i></b><b><i>or other forms of central nervous system disorders</i></b> <b><i>. </i></b></p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-indent: 18pt;">All of the product candidates in our pipeline are still in development. Such product candidates will take several&#160;years to develop and must undergo extensive clinical and scientific validations.<b><i> </i></b>Even if we are successful in developing any of our product candidates through clinical and scientific validation, we may not be able to develop a drug or a diagnostic that:</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 36pt;text-indent:-18pt;">&#160;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">meets applicable regulatory standards, in a timely manner or at all;</p> </td>
    </tr>

    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">successfully competes with other technologies and tests;</p> </td>
    </tr>

    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">avoids infringing the proprietary rights of others;</p> </td>
    </tr>

    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">is adequately reimbursed by third-party payors;</p> </td>
    </tr>

    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">can be performed at commercial levels or at reasonable cost; or</p> </td>
    </tr>

    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">can be successfully marketed.</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">To the extent we are not successful in developing product candidates, our results of operations and business will be materially adversely affected.</p>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>Interim, </i></b>&#8220;<b><i>top-line</i></b>&#8221;<b><i> and preliminary data from our clinical trials that we announce or publish from time to time are likely to change as more patient data become available and are subject to audit and verification procedures that could result in material changes in the final dataset.</i></b></p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">From time to time, we may publish &#8220;top-line&#8221; or preliminary data from our clinical trials. We also make assumptions, estimations, calculations and conclusions as part of our analyses of data, and we may not have received or had the opportunity to fully and carefully evaluate all data at the time of its initial release. As a result, the top-line results that we report may differ from future results of the same studies, or different conclusions or considerations may qualify such results, once additional data have been received and fully evaluated. Such data from clinical trials may materially change as more study data become available. Preliminary or &#8220;top-line&#8221; data also remain subject to audit and verification procedures that may result in the final data being materially different from the preliminary data we previously published. As a result, preliminary top-line data should be viewed with caution until the final data is available. Differences between preliminary or top-line data and final data could significantly harm our business prospects and may cause the trading price of our securities&#160;to fluctuate significantly.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">Furthermore, other parties, including regulatory agencies, may not accept or agree with our assumptions, estimates, calculations, conclusions or analyses or may interpret or weigh the importance of data differently than us, which could impact the value of the particular program, the approvability or commercialization of the particular product candidate and our company in general. In addition, the information we choose to publicly disclose regarding a particular study or clinical trial is typically selected from a more extensive amount of available information. You or others may not agree with what we determine is the material or otherwise appropriate information to include in our disclosure, and any information we determine not to disclose may ultimately be deemed significant with respect to future decisions, conclusions, views, activities or otherwise regarding a particular product candidate or our business. If the preliminary or top-line data that we report differ from later, final or actual results, or if others, including regulatory authorities, disagree with the conclusions reached, our ability to obtain approval for, and commercialize our product candidates may be harmed, which could harm our business, financial condition, results of operations and prospects.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>We currently have no in-house capabilities to manufacture or commercialize our product candidates, and we rely on third-party commercial drug manufacturers for supplies of simufilam. If we are unable to develop our own manufacturing, sales, marketing and distribution capabilities, or if we are not successful in contracting with third parties for these services on favorable terms, or at all, our product revenues could be adversely impacted. </i></b></p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">We rely on various third parties to manufacture, fill, label, store, test and ship our product candidates. We plan to continue to outsource formulation, manufacturing and related activities. These suppliers must comply with cGMP regulations enforced by FDA and other government agencies, and are subject to ongoing periodic unannounced inspection, including preapproval inspections by FDA and corresponding state and foreign government agencies to ensure strict compliance with cGMP and other standards. These manufacturers may subsequently be stopped from producing, manufacturing, filling, labeling, storing, testing and shipping our product candidates due to their non-compliance with federal, state or local regulations. We do not have control over our suppliers&#8217; compliance with these regulations and standards and we cannot control decisions by our suppliers that affect their ability or willingness to continue to supply us on acceptable terms, or at all.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
      42
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-indent: 18pt; text-align: justify;">Disputes may arise with third party service providers, which may lead to termination of an agreement. If an agreement is terminated, we would not be able to commercialize our product candidates until another manufacturer is identified and we have entered into a manufacturing agreement with such manufacturer. We may not be able to replace a commercial supplier on commercially reasonable terms, or at all. Replacing any of our commercial suppliers would be expensive and time consuming. Failure by any of our suppliers to perform as expected could delay or prevent the commercialization or potential regulatory approval of our product candidates for an extended period of time, result in shortages, cost overruns or other problems and would materially harm our business.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">We currently have no sales, marketing or distribution capabilities. We have not established commercial strategies regarding any of our product candidates. In order to commercialize our products, if any are approved by FDA, we will either have to develop such capabilities internally or collaborate with third parties who can perform these services for us.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">If we decide to commercialize any of our drugs ourselves, we may not be able to</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 36pt;text-indent:-18pt;">&#160;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">hire and retain the necessary experienced personnel;</p> </td>
    </tr>

    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">build sales, marketing and distribution operations in a cost-effective manner which are capable of successfully launching new drugs;</p> </td>
    </tr>

    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">obtain access to adequate numbers of physicians to prescribe our products; or</p> </td>
    </tr>

    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">generate sufficient product revenues.</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">In addition, establishing such operations on our own will take time and involve significant expense. If our commercial operations lack complementary products, we may not be able to compete in a cost-effective manner with competitors with more products to sell. If we engage third-party collaborators to perform any commercial operations, our future revenues may depend significantly upon the performance of those collaborators. If we decide to enter into new co-promotion or other licensing arrangements with third parties, we may be unable to locate acceptable collaborators because the number of potential collaborators is limited and because of competition from others for similar alliances. Even if we are able to identify one or more acceptable new collaborators, we may not be able to enter into any collaborative arrangements on favorable terms, or at all.</p>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">In addition, due to the nature of the market for our product candidates, it may be necessary for us to license all or substantially all of our product candidates to a single collaborator, thereby eliminating our opportunity to commercialize these other products independently. If we enter into any such new collaborative arrangements, our revenues are likely to be lower than if we marketed and sold our products ourselves.</p>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">In addition, any revenues we receive would depend upon our collaborators&#8217; efforts which may not be adequate due to lack of attention or resource commitments, management turnover, change of strategic focus, business combinations or other factors outside of our control. Depending upon the terms of our collaboration, the remedies we have against an under-performing collaborator may be limited. If we were to terminate the relationship, it may be difficult or impossible to find a replacement collaborator on acceptable terms, or at all.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
      43
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -1pt;"><b><i>We rely on third parties to conduct our studies and some aspects of our research, and such third parties may not perform satisfactorily, which could delay or harm our studies, research, and testing. </i></b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -1pt; text-indent: 18pt;">We substantially rely and expect to continue to rely on third parties, such as contract research organizations (CROs), clinical data management organizations, medical institutions, and clinical investigators, to conduct some aspects of our research and preclinical testing and our clinical studies.&#160;For example, Pentara Corporation, an independent consulting firm that specializes in complex statistical analysis of clinical trials, has conducted statistical analysis relating to cognition endpoints in our clinical studies.&#160;Any of these third parties may terminate their engagements with us or be unable to fulfill their contractual obligations. If we need to enter into alternative arrangements, it will delay our product development activities.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 18pt; text-align: justify;">Our reliance on these third parties for research and development activities reduces our control over these activities but does not relieve us of our responsibilities. For example, we remain responsible for ensuring that all of our clinical studies are conducted in accordance with the general investigational plan and protocols for the trial. Moreover, FDA requires us to comply with the norms of Good Clinical Practice (GCPs) for conducting, recording, and reporting the results of clinical studies to assure that data and reported results are credible, reproducible, and accurate and that the rights, integrity, and confidentiality of study participants are protected. We also are required to register ongoing clinical studies and post the results of completed clinical studies on a government-sponsored database within certain timeframes. Failure to do so can result in fines, adverse publicity, and civil and criminal sanctions.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -1pt; text-indent: 18pt;">If our third-party vendors do not successfully carry out their contractual duties, meet expected deadlines, or conduct studies in accordance with regulatory requirements or our stated protocols, we will not be able to obtain, or may be delayed in obtaining, marketing approvals for any product candidates we may develop and will not be able to, or may be delayed in our efforts to, successfully commercialize our product candidates. For example, one of our vendors failed to fully comply with certain Good Laboratory Practice (GLP) norms in its research facility, which required us to repeat a lab study at a different research site.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -1pt; text-indent: 18pt;">We also rely on other third parties to label, store and distribute drug supplies for our clinical studies. Any performance failure on the part of our distributors, including with the shipment of any drug supplies, could delay clinical development or marketing approval of any product candidates we may develop or commercialization of our product candidates, producing additional losses and depriving us of potential product revenue.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>We may not be successful in our efforts to expand our technology or product candidates in other indications. </i></b></p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">Our drug development strategy has been focused on clinically testing our product candidates in Alzheimer&#8217;s disease, our primary indication. We may expand our research efforts outside of this primary indication and into other areas of clinical medicine based on a variety of factors. For example, we plan&#160;to conduct exploratory preclinical studies in collaboration with the TSCA to better understand simufilam&#8217;s potential as a treatment for seizures in TSC. Conducting clinical studies for additional indications for our product candidates will require substantial technical, financial and human resources and is prone to the inherent risks of failure in drug development. We cannot provide any assurance that we will be successful in our effort to expand our technology or our product candidates in additional indications.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>If we fail to successfully identify and develop additional product candidates, our commercial opportunity will be limited.</i></b></p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">Identifying, developing, obtaining regulatory approval for, and commercializing additional product candidates requires substantial expertise and funding and is prone to the risks of failure inherent in drug development. We cannot provide any assurance that we will be able to successfully identify or acquire additional product candidates, advance any additional product candidates through the development process, or assemble sufficient resources to identify, acquire, or develop additional product candidates. If we are unable to successfully identify, acquire, develop, and commercialize additional product candidates, our commercial opportunity may be limited.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
      44
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>We have never obtained FDA approval for a diagnostic test and we may not be able to secure such approval in a timely manner or at all. </i></b></p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">We are developing an investigational blood-based diagnostic test for Alzheimer&#8217;s disease, called SavaDx, which will require FDA approval prior to commercialization. Our diagnostic product candidate, marketing, sales and development activities and manufacturing processes are subject to extensive and rigorous regulation by FDA pursuant to the FDCA, by comparable agencies in foreign countries, and by other regulatory agencies and governing bodies. Under the FDCA, a diagnostic must receive FDA clearance or approval before it can be commercially marketed in the United States. The process of obtaining marketing approval or clearance from FDA or by comparable agencies in foreign countries for new products could:</p>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">take a significant period of time;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">require the expenditure of substantial resources;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">involve rigorous preclinical testing, as well as increased post-market surveillance;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">require changes to products; and</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">result in limitations on the indicated uses of products.</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>If we do not compete effectively with scientific and commercial competitors, we may not be able to successfully develop our diagnostic test for Alzheimer</i></b>&#8217;<b><i>s disease.</i></b></p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">The field of clinical laboratory testing is highly competitive. Diagnostic tests are characterized by rapid technological change. Our competitors in the United States&#160;and abroad are numerous and include, among others, major diagnostic companies, reference laboratories, molecular diagnostic firms, universities and other research institutions. Most of our potential competitors have considerably greater financial, technical, marketing and other resources than we do, which may allow these competitors to discover important biological markers and determine their function before we do. We could be adversely affected if we do not discover proteins or biomarkers and characterize their function, develop diagnostic and pharmaceutical and clinical services based on these discoveries, obtain required regulatory and other approvals and launch these tests and their related services before our competitors. We also expect to encounter significant competition with respect to any diagnostic tests that we may develop or commercialize. Those companies that bring to market new diagnostic tests before we do may achieve a significant competitive advantage in marketing and commercializing their tests. We may not be able to develop additional diagnostic tests successfully and we may not obtain or enforce patents, if any, covering these tests that provide protection against our competitors. Moreover, our competitors may succeed in developing diagnostic tests that circumvent our technologies or tests. Furthermore, our competitors may succeed in developing technologies or tests that are more effective or less costly than those developed by us or that would render our technologies or tests less competitive or obsolete. We expect competition to intensify in the fields in which we are involved as technical advances in these fields occur and become more widely known and changes in intellectual property laws generate challenges to our intellectual property position.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>We will need to find alternative approaches that do not involve antibodies to advance our SavaDx and our diagnostic program.</i></b></p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">To date, most of our tests with SavaDx have relied on the use of commercially available antibodies, which are complex molecules that can recognize and bind to an intended protein. Commercially available antibodies can present technical challenges, such as improper validation, significant batch-to-batch variations or inconsistent storage, any of which can jeopardize our studies and experiments. Hence, we are&#160;evaluating an alternative approach to detect Alzheimer&#8217;s disease using mass spectrometry to detect FLNA, i.e., without the use of antibodies. The complexity of such an alternative approach also gives rise to many technical issues that are challenging to solve. We cannot be certain that we will be able to successfully complete the development of a detection system for Alzheimer&#8217;s disease that does or does not involve antibodies.</p>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
      45
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>Our Phase 2 clinical studies with simufilam </i></b><b><i>are generally not designed to show a statistically meaningful difference in cognition or other health functions between those patients who receive placebo and those who receive drug.</i></b></p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">Clinical research data is often analyzed with statistical probability (p-value) to address the question of whether a clinical observation is related to a treatment effect, a random effect or something else. This, in turn, requires a clinical study to incorporate a sufficiently large sample patient population to infer the appropriate statistical analysis. By design, our Phase 2 clinical studies with simufilam generally do not include a sufficiently large patient population to generate statistical probability on measures of cognition or other health functions. This feature may make it difficult for investors to properly interpret whether clinical observations in those Phase 2 studies with simufilam are important or meaningful. Conversely, our clinical studies may generate statistically significant data (i.e., p&lt;0.05) on exploratory biomarkers, or other endpoints, that have unknown or no clinical importance. In general, the distinction between statistically significant data and clinically meaningful data is a complex area of research that continues to evolve and may be subject to differences of opinion among scientists, clinicians, biostatisticians and other professionals, as well as among government regulators.</p>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt;"><b><i>To the extent that our open-label study suggested differences in treatment effects by stage of disease, such observations may or may not replicate in any of our subsequent clinical studies.</i></b></p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">Alzheimer&#8217;s dementia is a progressive, degenerate disease. Severity of disease is typically assessed by stage of disease progression, a continuum that ranges from, approximately, mild cognitive impairment (MCI), to early stage, to mild, to moderate and finally to severe disease. Over time, cognition progressively worsens in the mild-to-moderate stages of Alzheimer&#8217;s as the disease takes its toll. However, we do not have a clear understanding of how our drug candidate simufilam may impact&#160;patients by stage of disease, if at all. For example, to the extent that our open-label and small placebo-controlled studies suggested apparent differences in treatment effects by stage of disease, such observations may not replicate in any of our subsequent clinical studies.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -1pt;"><b><i>Our clinical studies may fail to demonstrate substantial evidence of the safety and efficacy of our product candidates and may suffer from improper or inadequate study design or enrollment criteria, which would prevent, delay, or limit the scope of regulatory approval and commercialization. </i></b><b><i> </i></b></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -1pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">Before obtaining regulatory approvals for any of our product candidates, we must demonstrate through lengthy, complex, and expensive preclinical experiments and clinical studies that our product candidates are both safe and effective for use in an intended population. Each product candidate must demonstrate an adequate risk versus benefit profile in its intended patient population and for its intended use, as determined by the FDA in the United States.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -1pt; text-indent: 18pt;">New drug discovery, development and commercialization involves a high degree of risk. The process is expensive and complex and can take many years to complete, and its outcome is inherently uncertain. It can take over 10 to 15 years and cost over $1 to $2 billion for each new drug candidate to achieve regulatory approval. Only a small number of research and development programs achieve regulatory approval and subsequent commercialization of a drug product.&#160;We believe that in recent decades about 90 to 95% of novel drug candidates under development by the biopharmaceutical industry have failed to achieve regulatory approval and subsequent commercialization. Failure can occur at any time during the drug discovery and development process and such failures may be due to lack of clinical efficacy, adverse safety profile, regulatory hurdles, excessive costs, lack of perceived market opportunity, lack of resources, insufficient reimbursement from insurers, inability to compete or for other reasons. Many biopharmaceutical companies have suffered significant setbacks in Phase 3 clinical trials due to lack of efficacy or adverse safety profiles, notwithstanding promising results in earlier trials. Seasoned professionals with a prior track record of innovation in drug discovery and development, as well as substantial business expertise, routinely fail to achieve regulatory approval of new product candidates.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -2pt; text-indent: 18pt;">The results of our preclinical studies with our product candidates may not be predictive of the results of early-stage or later-stage clinical studies, and results of early clinical studies of our product candidates may not be predictive of the results of later-stage clinical studies. The results of clinical studies in one set of patients or disease indications may not be predictive of those obtained in another. In some instances, there can be significant variability in safety or efficacy results between different clinical studies of the same product candidate due to numerous factors, including changes in study procedures set forth in protocols, differences in the size and type of the patient populations, changes in and adherence to the dosing regimen, and other clinical study protocols and the rate of dropout among clinical study participants. Product candidates in later stages of clinical studies may fail to show the desired safety and efficacy profile despite having progressed through preclinical studies and initial clinical studies.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
      46
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -4pt; text-indent: 18pt;">We may suffer significant setbacks in Phase 3 clinical studies due to lack of efficacy or unacceptable safety issues, notwithstanding promising results in earlier studies. For example, our first Phase 3 trial in Alzheimer's disease did not meet each of the pre-specified co-primary, secondary and exploratory biomarker endpoints<i>.</i>&#160;Clinical trials in central nervous system disorders, including Alzheimer&#8217;s disease, have much higher historically failure rates than in many other disease areas. Most new product candidates for central nervous system disorders that begin clinical studies are never approved by regulatory authorities for commercialization.&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 5pt;text-indent:18pt;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-indent: 18pt; text-align: justify;">Our clinical trials may suffer from improper or inadequate study design or enrollment criteria. We have limited experience in designing clinical studies in neurodegeneration and may be unable to design and execute a clinical study to support marketing approval. We cannot be certain that our current clinical studies or any other future clinical studies will be successful. Additionally, any safety concerns observed in any one of our clinical studies in our targeted indications could limit the prospects for regulatory approval of our product candidates in those and other indications, which could have a material adverse effect on our business, financial condition, and results of operations.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">In addition, even if such clinical studies are successfully completed, we cannot guarantee that FDA or foreign regulatory authorities will interpret the results as we do, and more studies could be required before we submit our product candidates for approval. To the extent that the results of the studies are not satisfactory to FDA or foreign regulatory authorities for support of a marketing application, we may be required to expend significant resources, which may not be available to us, to conduct additional studies in support of potential approval of our product candidates. Even if regulatory approval is secured for any of our product candidates, the terms of such approval may limit the scope and use of our product candidates, which may also limit its commercial potential.</p>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>The market opportunities for simufilam, if approved, may be smaller than we anticipate.</i></b></p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">If our clinical development programs succeed with respect to simufilam for a particular indication, we would expect to seek regulatory approval of simufilam for such indication. Projections that we calculate as to the number of patients with the indications that we are studying are based on our beliefs and estimates, derived from a variety of outside sources, including scientific literature, patient foundations and market research. Our projections may prove to be incorrect. The actual number of patients for a particular indication may turn out to be lower than expected. Additionally, the potential patient population for our current programs or future product candidates may be limited. Even if we obtain regulatory approval and capture significant market share for any product candidate, the potential target populations may be smaller than anticipated, and we may never achieve profitability without obtaining marketing approval for additional indications.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>We face significant competition in an environment of rapid technological and scientific change, and there is a possibility that additional competitors may achieve regulatory approval before us or develop therapies that are safer, more advanced, or more effective than ours, any of which may harm our business operations. </i></b></p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">Drug discovery and development is highly competitive. Moreover, the central nervous system disorders field is characterized by intense and increasing competition, and a strong emphasis on intellectual property. We may face competition with respect to any of our product candidates that we seek to develop or commercialize in the future from major pharmaceutical companies, specialty pharmaceutical companies, and biotechnology companies worldwide. Potential competitors also include academic institutions, government agencies, and other public and private research organizations that conduct research, seek patent protection, and establish collaborative arrangements for research, development, manufacturing, and commercialization.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">Several pharmaceutical and biotechnology companies are currently pursuing the development of products for the treatment of central nervous system disorders, including Alzheimer&#8217;s disease and TSC-related epilepsy. Many of these current or potential competitors, either alone or with their strategic partners, have significantly greater financial resources and expertise in research and development, manufacturing, preclinical testing, conducting clinical studies, obtaining regulatory approvals, and marketing approved products than we do.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
      47
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">Our commercial opportunity could be reduced or eliminated if other competitors develop and commercialize products that are safer, are more effective, have fewer or less severe side effects, are more convenient, achieve greater acceptance among physicians and patients, or are less expensive than any products that we may develop. Furthermore, currently approved products could be discovered to have application for treatment of neurodegenerative disease indications, which could give such products significant advantages over any of our product candidates. Competitors may also obtain FDA or other regulatory approval for their products more rapidly than we may obtain approval for ours, which could result in our competitors establishing a strong market position before we are able to enter the market. Additionally, products or technologies developed by our competitors may render our potential product candidates uneconomical or obsolete, and we may not be successful in marketing any product candidates we may develop against competitors.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">In addition, we could face litigation or other proceedings with respect to the scope, ownership, validity, and/or enforceability of our patents relating to our competitors&#8217; products and our competitors may allege that our products infringe, misappropriate, or otherwise violate their intellectual property. The availability of our competitors&#8217; products could limit the demand, and the price we are able to charge, for any products that we may develop and commercialize.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>Risks Related to Government Regulation and Other Legal Compliance Matters</b></p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>Our financial condition and operating results could be adversely impacted by unfavorable results of legal proceedings, government investigations or allegations and other claims</i></b><b><i>.</i></b></p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">We are, and may in the future be, subject to various investigations and legal proceedings.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">In recent years, there has been a trend of increasing government investigations, legal proceedings and law enforcement activities against companies, executives and others operating in our industry, including those arising from whistleblower programs operated by the SEC and DOJ and the <i>qui tam</i> provisions of the False Claims Act.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">We are currently managing inquiries from U.S. government agencies, as well as civil claims under federal and state laws, relating to and/or arising out of research and development of our product candidates, including grant applications, securities disclosures and other aspects of our business. For additional information regarding legal proceedings, see "Notes to Consolidated Financial Statements&#8212;Contingencies".&#160; New claims or inquiries may arise in the future.</p>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">In response to government document requests and other claims asserted against us, we established a comprehensive document retention policy that strictly governs how we handle, store and protect our documents and data. Failure to comply with our document retention policy would expose us to risk of enforcement actions and penalties under applicable laws.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">Legal proceedings are inherently unpredictable, and large judgments or penalties sometimes occur. As a consequence, we may in the future incur judgments or penalties that could involve large cash payments, including the potential repayment of amounts allegedly obtained improperly and other penalties, including enhanced damages. For example, the Company paid&#160;a civil monetary penalty of $40 million in November 2024 as part of a settlement with the SEC&#160;resolving the SEC investigation of the Company&#8217;s disclosures regarding its Phase 2b Study&#160;and related matters.&#160;While we maintain insurance coverage for certain types of claims, such insurance coverage may be insufficient to cover all losses or all types of claims that may arise.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">In addition, such proceedings against us or against third parties with whom we collaborate or otherwise do business may affect our reputation, inhibit our ability to raise fund in the capital markets, create a risk of potential exclusion from government reimbursement or grant programs and may lead to additional civil litigation. Even meritless claims could subject us to adverse publicity, hinder us from securing insurance coverage in the future or require us to incur significant legal costs. As a result, having taken into account all relevant factors, we may in the future enter into settlements of such claims without bringing them to final legal adjudication by courts or other such bodies, despite having potentially significant defenses against them, in order to limit the risks they pose to our business and reputation. Such settlements may require us to pay significant sums of money and to enter into corporate integrity or similar agreements intended to regulate company behavior for a period of years, which can be costly to operate under.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-indent: 18pt; text-align: justify;">As a result, significant claims or legal proceedings to which we are a party, any judgments or settlements against us or involving third parties associated with us relating to such claims or proceedings, and any accruals that we may take with respect to potential judgments or settlements, could have a material adverse impact on our business, financial condition or results of operations, as well as on our reputation.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
      48
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>Additional future litigation involving&#160;us could be costly and time-consuming to defend. </i></b></p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">Innovative drug development is highly litigious, and we may, from time to time, become subject&#160;to or involved in additional legal proceedings, claims and allegations that arise in the ordinary course of business or pursuant to governmental or regulatory enforcement activity. Regardless of merit, any lawsuits against or involving us, individually or in the aggregate, may have a material adverse effect on our business, financial condition, results of operations or cash flows. In addition, any litigation to which we subsequently become a party might result in substantial costs and divert management's attention, time and resources, which might seriously harm our business, financial condition, results of operations and cash flows. Our insurance policies might not cover such claims, might not provide sufficient payments to cover all of the costs to resolve one or more such claims, and might not continue to be available on terms acceptable to us. In particular, any claim could result in potential liability for us if the claim is outside the scope of the indemnification agreement we have with our third-party partners, or our third-party partners do not abide by the indemnification agreement as required, or the liability exceeds the amount of any applicable indemnification limits or available insurance coverage. A claim brought against us that is uninsured or underinsured could result in unanticipated costs and could have a material adverse effect on our financial condition, results of operations, cash flows or reputation.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>If we are ultimately unable to file for and obtain regulatory approval for our product candidates, we will be unable to generate product revenue, and our business will be substantially harmed.</i></b></p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">The time required to obtain approval by FDA and comparable foreign regulatory authorities is unpredictable, typically takes many years following the commencement of clinical studies, and depends upon numerous factors, including the type, complexity, and novelty of the product candidates involved. In addition, approval policies, regulations, or the type and amount of clinical data necessary to gain approval may change during the course of a product candidate&#8217;s clinical development and may vary among jurisdictions, which may cause delays in the approval or the decision not to approve an application. Regulatory authorities have substantial discretion in the approval process and may refuse to accept any application or may decide that our data are insufficient for approval and require additional preclinical, clinical, or other studies. We have not obtained regulatory approval for any product candidate&#160;and it is possible that none of our existing product candidates or any product candidates we may seek to develop in the future will ever obtain regulatory approval.</p>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">Applications for our product candidates could fail to receive regulatory approval in an initial or subsequent indication for many reasons, including but not limited to the following:</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 36pt;text-indent:-18pt;">&#160;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">FDA or comparable foreign regulatory authorities may disagree with the design, implementation, or results of our clinical studies;</p> </td>
    </tr>

    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">FDA or comparable foreign regulatory authorities may determine that our product candidates are not safe and effective, only moderately effective or have undesirable or unintended side effects, toxicities, or other characteristics that preclude our obtaining marketing approval or prevent or limit commercial use;</p> </td>
    </tr>

    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">the population studied in the clinical program may not be sufficiently broad or representative to assure efficacy and safety in the full population for which we seek approval;</p> </td>
    </tr>

    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">we may be unable to demonstrate to FDA or comparable foreign regulatory authorities that a product candidate&#8217;s risk-benefit ratio when compared to the standard of care is acceptable;</p> </td>
    </tr>

    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">FDA or comparable foreign regulatory authorities may disagree with our interpretation of data from preclinical studies or clinical studies;</p> </td>
    </tr>

    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">the data collected from clinical studies of our product candidates may not be sufficient to support the submission of a new drug application (NDA), or other submission or to obtain regulatory approval in the United States or elsewhere;</p> </td>
    </tr>

    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">FDA or comparable foreign regulatory authorities may fail to approve the manufacturing processes, test procedures, and specifications, or facilities of third-party manufacturers with which we contract for clinical and commercial supplies; and</p> </td>
    </tr>

    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">the approval policies or regulations of FDA or comparable foreign regulatory authorities may significantly change in a manner rendering our clinical data insufficient for approval.</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">This lengthy approval process, as well as the unpredictability of the results of clinical studies, may result in our failing to obtain regulatory approval to market any of our product candidates, which would significantly harm our business, results of operations, and growth prospects.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&#160;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
      49
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>Our ability to market and promote our product candidates will be determined and limited by FDA-approved labeling. </i></b></p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">The commercial success of our product candidates will depend upon our ability to obtain FDA-approved labeling&#160;effectively describing their features. If a product receives regulatory approval, the approval may be significantly limited to specific disease stages, patient populations and dosages, or the indications for use may otherwise be limited, which could restrict the availability of the product. Further, the FDA may require that certain contraindications, warnings or precautions be included in the product labeling or may condition the approval of the NDA on other changes to the proposed labeling or a commitment to conduct one or more post-market studies or clinical trials.&#160;For example, the FDA may require Phase 4 testing which involves clinical trials designed to further assess a drug&#8217;s safety and effectiveness.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -1pt; text-indent: 18pt;">Our failure to achieve FDA approval of product labeling containing appropriate information will prevent us from advertising and promoting the key features of our product candidates in order to differentiate them from other similar products. On the other hand, limitations required by the FDA for the product labeling of our product candidates may restrict the patient populations to which our product candidate is available.&#160;Either of these results would make our products less competitive in the market the commercial value of the product.</p>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>Our employees, independent contractors, consultants, commercial partners, and vendors may engage in misconduct or other improper activities, including noncompliance with regulatory standards and requirements. </i></b></p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">We are exposed to the risk of fraud, misconduct, or other illegal activity by our employees, independent contractors, consultants, commercial partners, and vendors. Misconduct by these parties could include intentional, reckless, and negligent conduct that fails to:</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 36pt;text-indent:-18pt;">&#160;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">comply with the laws of FDA and other comparable foreign regulatory authorities;</p> </td>
    </tr>

    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">provide true, complete, and accurate information to FDA and other comparable foreign regulatory authorities;</p> </td>
    </tr>

    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">comply with manufacturing standards we have established;</p> </td>
    </tr>

    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">comply with healthcare fraud and abuse laws in the U.S. and similar foreign fraudulent misconduct laws;</p> </td>
    </tr>

    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">report financial or clinical information or data accurately or to disclose unauthorized activities to us; or</p> </td>
    </tr>

    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">otherwise comply with applicable criminal, civil or regulatory laws governing their conduct.</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -1pt; text-indent: 18pt;">For example, on June 28, 2024, the DOJ announced that a federal grand jury in the U.S. District Court for the District of Maryland returned an indictment of Dr. Hoau-Yan Wang, a former scientific collaborator and advisor to Cassava. The indictment alleges that Dr. Wang caused Cassava to submit grant applications to NIH that contained false and fraudulent representations about his research. See &#8220;&#8212;2024 Non-Product Development Business Developments&#8212;Indictment of Hoau-Yan Wang.&#8221;</p>
  <p style="margin: 0pt 0pt 0pt -9pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">Activities subject to laws also involve the improper use of information obtained in the course of patient recruitment for clinical studies, which could result in regulatory sanctions and cause serious harm to our reputation. Further, it is not always possible to identify and deter misconduct by employees and third parties, and the precautions we take to detect and prevent this activity may not be effective in controlling unknown or unmanaged risks or losses or in protecting us from governmental investigations or other actions or lawsuits stemming from a failure to comply with such laws. If any such actions are instituted against us, and we are not successful in defending ourselves or asserting our rights, those actions could have a significant impact on our business, including the imposition of significant fines or other sanctions.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>If we fail to comply or stay in compliance with the complex set of federal, state, local and foreign laws and regulations that apply to our business, we could suffer severe consequences that could materially and adversely affect our operating results and financial condition. </i></b></p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">We are obligated to comply with the laws of all countries and jurisdictions in which we operate. These laws cover an extremely wide and growing range of activities. Such legal requirements can vary from country to country, and new requirements may be imposed on us from time to time as government and public expectations regarding acceptable corporate behavior change, and enforcement authorities modify interpretations of legal and regulatory provisions and change enforcement priorities. In addition, we rely on numerous associates, independent contractors, consultants, commercial partners and vendors who may put our reputation, business and&#160;operations at risk of material impairment if they engage, or are alleged to engage, in misconduct or other improper activities, including noncompliance with regulatory standards and requirements, in violation of such laws and public expectations.</p>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
      50
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">The laws and regulations that govern our operations include, among others:</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 36pt;text-indent:-18pt;">&#160;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">the Clinical Laboratory Improvement Amendments (CLIA) of 1988, which are United States federal regulatory standards that apply to all clinical laboratory testing performed on humans in the United States, requires that laboratories obtain certification from the federal government, and state licensure laws;</p> </td>
    </tr>

    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">FDA laws and regulations , including those relating to off-label marketing;</p> </td>
    </tr>

    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">the Health Insurance Portability and Accountability Act (HIPAA), which imposes comprehensive federal standards with respect to the privacy and security of protected health information and requirements for the use of certain standardized electronic transactions, including penalties for violators, enforcement authority to state attorneys general and requirements for breach notification;</p> </td>
    </tr>

    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">state laws regulating testing and protecting the privacy of test results, as well as state laws protecting the privacy and security of health information and personal data and mandating reporting of breaches to affected individuals and state regulators;</p> </td>
    </tr>

    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">the federal anti-kickback law, or the Anti-Kickback Statute, which prohibits knowingly and willfully offering, paying, soliciting, receiving, or providing remuneration, directly or indirectly, in exchange for or to induce either the referral of an individual, or the furnishing, arranging for, or recommending of an item or service that is reimbursable, in whole or in part, by a federal health care program;</p> </td>
    </tr>

    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">the federal False Claims Act (FCA), which imposes liability on any person or entity that, among other things, knowingly presents, or causes to be presented, a false or fraudulent claim for payment to the federal government and which, under its <i>qui tam</i> provisions, allows private litigants (relators) to file claims under seal on behalf of the government and to receive a percentage of recoveries obtained as a result;</p> </td>
    </tr>

    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">the federal Civil Monetary Penalties Law, which prohibits, among other things, the offering or transfer of remuneration to a Medicare or state health care program beneficiary if the person knows or should know it is likely to influence the beneficiary&#8217;s selection of a particular provider, practitioner, or supplier of services reimbursable by Medicare or a state health care program, unless an exception applies;</p> </td>
    </tr>

    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">other federal and state fraud and abuse laws, such as anti-kickback laws, prohibitions on self-referral, and false claims acts, which may extend to services reimbursable by any third-party payor, including private insurers;</p> </td>
    </tr>

    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">the Foreign Corrupt Practices Act (FCPA) and other worldwide anti-bribery laws, including those that prohibit companies and their intermediaries from making improper payments to government officials or other third parties for the purpose of obtaining or retaining business, and laws that prohibit commercial bribery;</p> </td>
    </tr>

    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">import, export control and economic sanctions laws and regulations in the U.S. and elsewhere;</p> </td>
    </tr>

    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Federal securities laws, including provisions of the Exchange Act and Dodd-Frank Act under which whistleblowers that report alleged violations of wrongdoing can obtain up to 30% of related recoveries;</p> </td>
    </tr>

    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">the federal Physician Payments Sunshine Act, which requires manufacturers to track and report to the federal government certain payments and other transfers of value made to physicians and teaching hospitals and ownership or investment interests held by physicians and their immediate family members;</p> </td>
    </tr>

    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">section 216 of the federal Protecting Access to Medicare Act of 2014 (PAMA), which requires applicable laboratories to report private payer data in a timely and accurate manner every three years (and in some cases annually);</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">state laws that impose reporting and other compliance-related requirements; and</p> </td>
    </tr>

    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">similar foreign laws and regulations that will apply to us in foreign countries in which we may choose to operate in the future.</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>Government agencies may establish and promulgate usage guidelines that could limit the use of our product candidates. </i></b></p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">Government agencies, professional and medical societies, and other groups may establish usage guidelines that apply to our product candidates. These guidelines could address such matters as usage and dose, among other factors. Application of such guidelines could limit the clinical use or commercial appeal of our product candidates.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&#160;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
      51
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>Our product candidates may cause undesirable side effects or have other properties that could halt their clinical development, prevent their regulatory approval, limit their commercial potential, or result in significant negative consequences. </i></b></p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">During the conduct of clinical trials, study participants report changes in their health to their doctor, including illnesses, injuries and discomforts. Often, it is not possible to determine whether our product candidate caused these conditions. Regulatory authorities may draw different conclusions and may require us to pause our clinical trials or require additional testing to confirm these determinations, if they occur. In addition, we have not yet completed long-term safety studies with simufilam to determine if this product candidate is safe for humans. Adverse events or other undesirable side effects caused by simufilam could cause us or regulatory authorities to interrupt, delay, or halt clinical studies and could result in a more restrictive label or the delay or denial of regulatory approval by FDA or other comparable foreign regulatory authorities. Drug-related side effects could affect patient recruitment, the ability of enrolled patients to complete the study, and/or result in potential claims.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>We may be subject to legal liability associated with clinical trials.</i></b></p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">Our business requires us to engage in the conduct of clinical studies in human volunteers and in patients in the United States and abroad. There are circumstances under which a participant in one of our clinical trials could impose liability on us. For example, a clinical investigator who is a participant in one of our studies may intentionally or unintentionally deviate from a clinical protocol and cause harm to a clinical trial participant, or a clinical trial participant may seek to compel us to continue to supply drug to them after the completion of a study but prior to FDA approval.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">Claims may be brought against us for negligence, breach of contract, harm, injury or death, or other legal theories based on the nature of a study. Clinical trial liability is a complex and somewhat unsettled area of law and may vary by state and by country where we conduct clinical studies. Furthermore, claims may be brought against us by a clinical investigator, a clinical trial participant, or another party associated with a clinical study, long after the completion of a clinical study. Defense of such actions is a fact-intensive process that could be costly and involve significant time and attention of our management and other resources, may result in monetary liabilities or penalties, and may require us to change our business in an adverse manner.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>Our insurance policies may be inadequate and potentially expose us to unrecoverable risks.</i></b></p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">Although we maintain product liability insurance coverage, such insurance may not be adequate to cover all liabilities that we may incur. We anticipate that we may&#160;need to increase our insurance coverage each time we commence a clinical trial and if we successfully commercialize any product candidate. Insurance availability, coverage terms and pricing continue to vary with market conditions. We endeavor to obtain appropriate insurance coverage for insurable risks that we identify; however, we may fail to correctly anticipate or quantify insurable risks, we may not be able to obtain appropriate insurance coverage and insurers may not respond as we intend to cover insurable events that may occur. Conditions in the insurance markets relating to nearly all areas of traditional corporate insurance change rapidly and may result in higher premium costs, higher policy deductibles and lower coverage limits. For some risks, we may not have or maintain insurance coverage because of cost or availability.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">We are and will be required to maintain product liability insurance pursuant to certain of our development and commercialization agreements. We may not be able to maintain insurance coverage at a reasonable cost or in sufficient amounts to protect us against losses due to liability. A successful product liability claim or series of claims brought against us could adversely affect our results of operations, business, and reputation. In addition, regardless of merit or eventual outcome, product liability claims may result in impairment of our business reputation, withdrawal of clinical study participants, costs due to related litigation, distraction of management&#8217;s attention from our primary business, initiation of investigations by regulators, substantial monetary awards to patients or other claimants, the inability to commercialize our product candidates, and decreased demand for our product candidates, if approved for commercial sale.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
      52
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>If our product candidates receive regulatory approval, we and our collaborators will be subject to ongoing FDA obligations and continued regulatory review, such as continued safety reporting requirements, and we and our collaborators may also be subject to additional FDA post-marketing obligations or new regulations, all of which may result in significant expense and limit our and our collaborators</i></b>&#8217;<b><i> ability to commercialize our potential drugs. </i></b></p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">Any regulatory approvals that our product candidates receive may also be subject to limitations on the indicated uses for which the drug may be marketed or contain requirements for potentially costly post-marketing follow-up studies. In addition, if FDA approves any of our product candidates, the labeling, packaging, adverse event reporting, storage, advertising, promotion and record keeping for the drug will be subject to extensive regulatory requirements. The subsequent discovery of previously unknown problems with the drug, including but not limited to adverse events of unanticipated severity or frequency, or the discovery that adverse events previously observed in preclinical research or clinical studies that were believed to be minor actually constitute much more serious problems, may result in restrictions on the marketing of the drug, and could include withdrawal of the drug from the market.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">The FDA&#8217;s policies may change, and additional government regulations may be enacted that could prevent or delay regulatory approval of our product candidates. We cannot predict the likelihood, nature or extent of adverse government regulation that may arise from future legislation or administrative action, either in the U.S. or abroad. If we are not able to maintain regulatory compliance, we may be subject to fines, suspension or withdrawal of regulatory approvals, product recalls, seizure of products, operating restrictions and criminal prosecution. Any of these events could prevent us from marketing our products and our business could suffer.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>Enacted and future legislation may increase the difficulty and cost for us to commercialize our product candidates and may reduce the prices we are able to obtain for our product candidates.</i></b></p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">Legislative and regulatory changes and future changes regarding the healthcare system could prevent or delay marketing approval of our product candidates, restrict or regulate post-approval activities or affect our ability to profitably sell any product candidates for which we obtain marketing approval.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">In the U.S., the Medicare Prescription Drug, Improvement, and Modernization Act of 2003 (the Medicare Modernization Act) established the Medicare Part&#160;D program and provided authority for limiting the number of drugs that will be covered in any therapeutic class thereunder. The Medicare Modernization Act, including its cost reduction initiatives, could limit the coverage and reimbursement rate that we receive for any of our approved products. Private payors may follow Medicare coverage policies and payment limitations in setting their own reimbursement rates resulting in similar limits in payments from private payors.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">The Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act, or collectively, the Affordable Care Act, among other things, imposes a significant annual fee on companies that manufacture or import branded prescription product candidates. It also contains substantial provisions intended to, among other things, broaden access to health insurance, reduce or constrain the growth of health care spending, enhance remedies against healthcare fraud and abuse, add new transparency requirements for the healthcare and health insurance industries, and impose additional health policy reforms, any of which could have a material adverse effect on our business. A significant number of provisions are not yet, or have only recently become, effective, but the Affordable Care Act may result in downward pressure on pharmaceutical pricing, especially under the Medicare program, and may also increase our regulatory burdens and operating costs.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">The Affordable Care Act, as well as other healthcare reform measures that have been and may be adopted in the future, may result in more rigorous coverage criteria and in additional downward pressure on the price that we receive for any approved product, and could seriously harm our future revenues. Any reduction in reimbursement from Medicare or other government programs may result in a similar reduction in payments from private payors. The implementation of cost containment measures or other healthcare reforms may compromise our ability to generate revenue, attain profitability or commercialize our products. The Affordable Care Act is a highly complex piece of legislation that continues to evolve. We do not and cannot understand or anticipate the full impact and potential implications of the Affordable Care Act on our business or on our drugs.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -1pt; text-indent: 18pt;">The purported goal of the Inflation Reduction Act (IRA) of 2022 is to lower healthcare costs for Americans, and includes several provisions aimed at reducing drug spending and increasing access to pharmaceuticals. Specifically, the IRA introduces drug-price negotiations by requiring the federal government to negotiate &#8220;maximum fair prices&#8221; with drug manufacturers for certain brand-name, single-source drugs covered under Medicare Part B and Part D. In addition, the IRA penalizes price increases and expands required discounts on branded, single-source drugs. The IRA is a highly complex piece of legislation that continues to evolve. We do not and cannot understand or anticipate the full impact and potential implications of the IRA on our business or on our drugs, however, we currently believe the IRA may reduce the prices we are able to obtain for our product candidates, if approved in the United States.</p>
  <p style="margin: 0pt 0pt 0pt -9pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">&#160;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
      53
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>Our relationships with customers and payors will be subject to applicable anti-kickback, fraud and abuse, transparency, and other healthcare laws and regulations, which could expose us to criminal sanctions, civil penalties, exclusion from government healthcare programs, contractual damages, reputational harm, administrative burdens, and diminished profits and future earnings. </i></b></p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">Healthcare providers, physicians and payors play a primary role in the recommendation and prescription of any product candidates for which we may obtain marketing approval. Our current or future arrangements with payors and customers may expose us to broadly applicable fraud and abuse and other healthcare laws and regulations that may constrain the business or financial arrangements and relationships through which we market, sell and distribute any product candidates for which we may obtain marketing approval. Even though we do not and will not control referrals of healthcare services or bill directly to Medicare, Medicaid or other third-party payors, federal and state healthcare laws and regulations pertaining to fraud and abuse and patients' rights are and will be applicable to our business. Restrictions under applicable federal, state and foreign healthcare laws and regulations may affect our ability to operate and expose us to areas of risk, including:</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 36pt;text-indent:-18pt;">&#160;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">the federal Anti-Kickback Statute, which prohibits, among other things, knowingly and willfully soliciting, offering, receiving or providing remuneration, directly or indirectly, in cash or in kind, to induce or reward either the referral of an individual for, or the purchase, order or recommendation of, any good or service, for which payment may be made under federal and state healthcare programs such as Medicare and Medicaid. A person or entity does not need to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation;</p> </td>
    </tr>

    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">the FCA, which imposes criminal and civil penalties, including through civil whistleblower or qui tam actions, against individuals or entities for knowingly presenting, or causing to be presented, to the federal government, claims for payment that are false or fraudulent or making a false statement to avoid, decrease or conceal an obligation to pay money to the federal government. In addition, the government may assert that a claim including items and services resulting from a violation of the federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the FCA;</p> </td>
    </tr>

    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">HIPAA, which imposes criminal and civil liability for executing a scheme to defraud any healthcare benefit program or making false statements relating to healthcare matters. Similar to the federal Anti-Kickback Statute, a person or entity does not need to have actual knowledge of the statute to defraud any healthcare benefit program or specific intent to violate it in order to have committed a violation;</p> </td>
    </tr>

    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act of 2009 and its implementing regulations, which also imposes obligations on certain covered entity healthcare providers, health plans, and healthcare clearinghouses as well as their business associates that perform certain services involving the use or disclosure of individually identifiable health information, including mandatory contractual terms, with respect to safeguarding the privacy, security and transmission of individually identifiable health information;</p> </td>
    </tr>

    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">federal laws requiring drug manufacturers to report information related to payments and other transfers of value made to physicians and other healthcare providers, as well as ownership or investment interests held by physicians and their immediate family members, including under the federal Open Payments program, commonly known as the Sunshine Act, as well as other state and foreign laws regulating marketing activities; and</p> </td>
    </tr>

    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">state and foreign equivalents of each of the above laws, including state anti-kickback and false claims laws, which may apply to sales or marketing arrangements and claims involving healthcare items or services reimbursed by non-governmental payors, including private insurers; state laws which require pharmaceutical companies to comply with the pharmaceutical industry's voluntary compliance guidelines and the relevant compliance guidance promulgated by the federal government or otherwise restricting payments that may be made to healthcare providers; and state and foreign laws governing the privacy and security of health information in certain circumstances, many of which differ from each other in significant ways and often are not preempted by HIPAA, thus complicating compliance efforts.</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">Efforts to ensure that our business arrangements with third parties will comply with applicable healthcare laws and regulations will involve substantial costs. Nonetheless, it is possible that governmental authorities will conclude that our business practices may not comply with current or future statutes, regulations or case law involving applicable fraud and abuse or other healthcare laws and regulations. If our operations are found to be in violation of any of these laws or any other governmental regulations that may apply to us, we may be subject to significant civil, criminal and administrative penalties, damages, fines, imprisonment, exclusion from participation in government funded healthcare programs, such as Medicare and Medicaid, and the curtailment or restructuring of our operations.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
      54
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>Risks Related to Our Intellectual Property </b></p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>If we are unable to obtain and maintain sufficient patent protection for any product candidates, our competitors could develop and commercialize products similar or identical to ours, and our ability to successfully commercialize any product candidates we may develop may be adversely affected. </i></b></p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">Our success depends in large part on our ability to obtain and maintain patent protection in the U.S. and other countries with respect to our proprietary product candidates and other technologies we may develop. We seek to protect our proprietary position by filing patent applications in the U.S. and abroad relating to our core programs and product candidates, as well as other technologies that are important to our business. Given that our product candidates are in early or clinical stages of development, our intellectual property portfolio with respect to certain aspects of our product candidates is also at an early stage. We have filed or intend to file patent applications on aspects of our technology and core product candidates; however, there can be no assurance that any such patent applications will issue as granted patents. Furthermore, in some cases, we intend to file&#160;only provisional patent applications on certain aspects of our technology and product candidates and each of these provisional patent applications is not eligible to become an issued patent until, among other things, we file a non-provisional patent application within 12 months of the filing date of the applicable provisional patent application. Any failure to file a non-provisional patent application within this timeline could cause us to lose the ability to obtain patent protection for the inventions disclosed in the associated provisional patent applications.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">Furthermore, in some cases, we may not be able to obtain issued claims covering compositions relating to our core programs and product candidates, as well as other technologies that are important to our business, and instead may need to rely on filing patent applications with claims covering a method of use and/or method of manufacture for protection of such core programs, product candidates, and other technologies. There can be no assurance that any such patent applications will issue as granted patents, and even if they do issue, such patent claims may be insufficient to prevent third parties, such as our competitors, from utilizing our technology. Any failure to obtain or maintain patent protection with respect to our core programs and product candidates could have a material adverse effect on our business, financial condition, results of operations, and growth prospects.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>U.S. intellectual property rights around diagnostic methods is a complex, evolving area of law and effective patent claims may not be available to us for our investigational diagnostic product candidate, SavaDx, in the United States.</i></b></p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">The legal system for intellectual property around diagnostic methods is highly complex, remains uncertain and continues to evolve. In the U.S., patent courts have struggled to define a clear means of patent eligibility for modern age diagnostics. Case law interpretations from the U.S. Supreme Court have left certain important scientific advances in the area of diagnostics without effective patent claims. In 2012, the Supreme Court held that a simple process involving correlations between blood test results and patient health is not eligible for patent claims because such processes incorporate &#8220;laws of nature&#8221;. Since then, different outcomes from different courts, including Federal Circuit, District Court and Patent Trial and Appeal Board decisions, have continued to create a sometimes vague or conflicting legal framework for determining the eligibility of patent claims for diagnostic methods. As a result, we cannot be certain how SavaDx fits into the current U.S. legal framework for obtaining effective patent protection. We currently have no U.S. patents with respect to SavaDx, and we believe it may be protected in the United States only by trade secrets, know-how and other proprietary rights technology. Furthermore, claims for diagnostic methods can be complicated to enforce. For patent infringement to occur with a protected diagnostic, the patented method must generally either be performed by one person in its entirety or performed by multiple parties all under the control or direction of a single party. Accordingly, even if effective patent claims are issued for SavaDx, it may be impractical, impossible or even undesirable to enforce potential infringement claims.</p>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
      55
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>Issued patents covering our product candidates and other technologies could be found invalid or unenforceable if challenged in court or before administrative bodies in the U.S. or abroad. </i></b></p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">If we initiated legal proceedings against a third party to enforce a patent covering our product candidates or other technologies, the defendant could counterclaim that the asserted patent is invalid or unenforceable. In patent litigation in the U.S. and in other jurisdictions, defendant counterclaims alleging invalidity or unenforceability are commonplace. Grounds for a validity challenge could be an alleged failure to meet any of several statutory requirements, including lack of novelty, obviousness, or non-enablement. Grounds for an unenforceability assertion could be an allegation that someone connected with prosecution of the patent withheld relevant information from the USPTO, or made a misleading statement, during prosecution. Third parties may raise claims challenging the validity or enforceability of our patents before administrative bodies in the U.S. or abroad, even outside the context of litigation. Such mechanisms include re-examination, post-grant review, <i>inter partes</i><b><i> </i></b>review, interference proceedings, derivation proceedings, and equivalent proceedings in foreign jurisdictions (e.g., opposition proceedings). Such proceedings could result in the revocation of, cancellation of, or amendment to our patents in such a way that they no longer cover our product candidates or other technologies. The outcome following legal assertions of invalidity and unenforceability is unpredictable. With respect to the validity question, for example, we cannot be certain that there is no invalidating prior art, of which we or our licensing partners and the patent examiner were unaware during prosecution. If a third party were to prevail on a legal assertion of invalidity or unenforceability, we would lose at least part, and perhaps all, of the patent protection on our product candidates or other technologies. Such a loss of patent protection would have a material adverse impact on our business, financial condition, results of operations, and growth prospects.</p>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>If we do not obtain patent term extension and data exclusivity for any product candidates we may develop, our business may be materially harmed. </i></b></p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">Depending upon the timing, duration, and specifics of any FDA marketing approval of any product candidates we may develop, one or more of our U.S. patents may be eligible for limited patent term extension under the Drug Price Competition and Patent Term Restoration Act of 1984 (Hatch-Waxman Act). The Hatch-Waxman Act permits a patent term extension of up to five years as compensation for patent term lost during FDA regulatory review process. A patent term extension cannot extend the remaining term of a patent beyond a total of 14 years from the date of product approval, only one patent may be extended and only those claims covering the approved drug, a method for using it, or a method for manufacturing it may be extended. Similar extensions as compensation for patent term lost during regulatory review processes are also available in certain foreign countries and territories, such as in Europe under a Supplementary Patent Certificate. However, we may not be granted an extension in the U.S. and/or foreign countries and territories because of, for example, failing to exercise due diligence during the testing phase or regulatory review process, failing to apply within applicable deadlines, failing to apply prior to expiration of relevant patents, or otherwise failing to satisfy applicable requirements. Moreover, the applicable time period or the scope of patent protection afforded could be less than we request. If we are unable to obtain a patent term extension or the term of any such extension is shorter than what we request, our competitors may obtain approval of competing products following our patent expiration, and our business, financial condition, results of operations, and growth prospects could be materially harmed.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>If we are unable to protect the confidentiality of our trade secrets, our business and competitive position would be harmed. </i></b></p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">In addition to seeking patents for our product candidates and other technologies, we also rely on trade secrets and confidentiality agreements to protect our unpatented know-how, technology, and other proprietary information and to maintain our competitive position. We consider trade secrets and know-how to be one of our primary sources of intellectual property. Trade secrets and know-how can be difficult to protect. We expect our trade secrets and know-how to over time be disseminated within the industry through independent development, the publication of journal articles describing the methodology, and the movement of personnel from academic to industry scientific positions.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
      56
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">We seek to protect these trade secrets and other proprietary technology, in part, by entering into non-disclosure and confidentiality agreements with parties who have access to them, such as our employees, corporate collaborators, outside scientific collaborators, CROs, CDMOs, consultants, advisors, and other third parties. We also enter into confidentiality and invention or patent assignment agreements with our employees and consultants as well as train our employees not to bring or use proprietary information or technology from former employers to us or in their work, and remind former employees when they leave their employment of their confidentiality obligations. We cannot guarantee that we have entered into such agreements with each party that may have or have had access to our trade secrets or proprietary technology and processes. Despite our efforts, any of these parties may breach the agreements and disclose our proprietary information, including our trade secrets, and we may not be able to obtain adequate remedies for such breaches. Enforcing a claim that a party illegally disclosed or misappropriated a trade secret is difficult, expensive, and time-consuming, and the outcome is unpredictable. In addition, some courts inside and outside the U.S. are less willing or unwilling to protect trade secrets. If any of our trade secrets were to be lawfully obtained or independently developed by a competitor or other third party, we would have no right to prevent them from using that technology or information to compete with us. If any of our trade secrets were to be disclosed to or independently developed by a competitor or other third party, our competitive position would be materially and adversely harmed.</p>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>If any of our patent applications do not issue as patents in any jurisdiction, we may not be able to compete effectively. </i></b></p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">Changes in either the patent laws or their interpretation in the U.S. and other countries may diminish our ability to protect our inventions, obtain, maintain, and enforce our intellectual property rights and, more generally, could affect the value of our intellectual property or narrow the scope of our patents with respect to our product candidates. With respect to our intellectual property related to our product candidates, we cannot predict whether the patent applications we are currently pursuing will issue as patents in any particular jurisdiction or whether the claims of any issued patents will provide sufficient protection from competitors or other third parties.</p>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">The patent prosecution process is expensive, time-consuming, and complex, and we may not be able to file, prosecute, maintain, or enforce all necessary or desirable patent applications at a reasonable cost or in a timely manner. It is also possible that we will fail to identify patentable aspects of our research and development output in time to obtain patent protection. Although we enter into nondisclosure and confidentiality agreements with parties who have access to confidential or patentable aspects of our research and development output, such as our employees, outside scientific collaborators, CROs, CDMOs, consultants, advisors, and other third parties, any of these parties may breach the agreements and disclose such output before a patent application is filed, thereby jeopardizing our ability to seek patent protection. In addition, our ability to obtain and maintain valid and enforceable patents depends on whether the differences between our inventions and the prior art allow our inventions to be patentable. Furthermore, publications of discoveries in the scientific literature often lag behind the actual discoveries, and patent applications in the U.S. and other jurisdictions are typically not published until 18 months after filing, or in some cases not at all. Therefore, we cannot be certain that we were the first to make the inventions claimed in any of our patents or pending patent applications, or that we were the first to file for patent protection of such inventions.</p>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>If the scope of any patent protection we obtain is not sufficiently broad, or if we lose any of our patent protection, our ability to prevent our competitors from commercializing similar or identical technology and product candidates would be adversely affected. </i></b></p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">The patent position of biotechnology and pharmaceutical companies generally is highly uncertain, involves complex legal and factual questions, and has been the subject of much litigation in recent years. As a result, the issuance, scope, validity, enforceability, and commercial value of our patent rights are highly uncertain. Our pending and future patent applications may not result in patents being issued which protect our product candidates or other technologies or which effectively prevent others from commercializing competitive technologies and product candidates.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">Moreover, the coverage claimed in a patent application can be significantly reduced before the patent is issued, and its scope can be reinterpreted after issuance. Even if patent applications we own currently or in the future issue as patents, they may not issue in a form that will provide us with any meaningful protection, prevent competitors or other third parties from competing with us, or otherwise provide us with any competitive advantage. Any patents to which we have rights may be challenged, narrowed, circumvented, or invalidated by third parties. Consequently, we do not know whether product candidates or other technologies will be protectable or remain protected by valid and enforceable patents. Our competitors or other third parties may be able to circumvent our patents by developing similar or alternative technologies or products in a non-infringing manner which could materially adversely affect our business, financial condition, results of operations and growth prospects.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
      57
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">The issuance of a patent is not conclusive as to its inventorship, scope, validity, or enforceability, and our patents may be challenged in the courts or patent offices in the U.S. and abroad. We may be subject to a third-party pre-issuance submission of prior art to the United States Patent and Trademark Office (USPTO) or become involved in opposition, derivation, revocation, reexamination, post-grant and <i>inter partes </i>review, or interference proceedings or other similar proceedings challenging our patent rights. An adverse determination in any such submission, proceeding, or litigation could reduce the scope of, or invalidate or render unenforceable, such patent rights, allow third parties to commercialize our product candidates or other technologies and compete directly with us, without payment to us, or result in our inability to manufacture or commercialize products without infringing third-party patent rights. Moreover, we may have to participate in interference proceedings declared by the USPTO to determine priority of invention or in post-grant challenge proceedings, such as oppositions in a foreign patent office, that challenge our priority of invention or other features of patentability with respect to our patents and patent applications. Such challenges may result in loss of patent rights, loss of exclusivity, or in patent claims being narrowed, invalidated, or held unenforceable, which could limit our ability to stop others from using or commercializing similar or identical technology and products, or limit the duration of the patent protection of our product candidates and other technologies. Such proceedings also may result in substantial cost and require significant time from our scientists and management, even if the eventual outcome is favorable to us. If we are unsuccessful in any such proceeding or other priority or inventorship dispute, we may be required to obtain and maintain licenses from third parties, including parties involved in any such interference proceedings or other priority or inventorship disputes. Such licenses may not be available on commercially reasonable terms or at all or may be non-exclusive. If we are unable to obtain and maintain such licenses, we may need to cease the development, manufacture, and commercialization of one or more of the product candidates we may develop. The loss of exclusivity or the narrowing of our owned and licensed patent claims could limit our ability to stop others from using or commercializing similar or identical technology and products.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">In addition, given the amount of time required for the development, testing, and regulatory review of new product candidates, patents protecting such product candidates might expire before or shortly after such product candidates are commercialized. As a result, our intellectual property may not provide us with sufficient rights to exclude others from commercializing products similar or identical to ours.</p>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>We may not be able to protect our intellectual property and proprietary rights throughout the world. </i></b></p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">Filing, prosecuting, and defending patents on our product candidates and other technologies in all countries throughout the world would be prohibitively expensive, and the laws of foreign countries may not protect our rights to the same extent as the laws of the U.S.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">Consequently, we may not be able to prevent third parties from practicing our inventions in all countries outside the U.S., or from selling or importing products made using our inventions in and into the U.S. or other jurisdictions. Competitors may use our technologies in jurisdictions where we have not obtained patent protection to develop their own products, and, further, may export otherwise infringing products to territories where we have patent protection, but enforcement is not as strong as that in the U.S. These products may compete with our products, and our patents or other intellectual property rights may not be effective or sufficient to prevent them from competing.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">Many companies have encountered significant problems in protecting and defending intellectual property rights in foreign jurisdictions. The legal systems of certain countries, particularly certain developing countries, do not favor the enforcement of patents, trade secrets, and other intellectual property protection, particularly those relating to biotechnology products, which could make it difficult for us to stop the infringement of our patents or marketing of competing products in violation of our intellectual property and proprietary rights generally. Proceedings to enforce our intellectual property and proprietary rights in foreign jurisdictions could result in substantial costs and divert our efforts and attention from other aspects of our business, could put our patents at risk of being invalidated or interpreted narrowly, could put our patent applications at risk of not issuing, and could provoke third parties to assert claims against us. We may not prevail in any lawsuits that we initiate, and the damages or other remedies awarded, if any, may not be commercially meaningful. Accordingly, our efforts to enforce our intellectual property and proprietary rights around the world may be inadequate to obtain a significant commercial advantage from the intellectual property that we develop or license.</p>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
      58
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>Obtaining and maintaining our patent protection depends on compliance with various procedural, document submission, fee payment, and other requirements imposed by government patent agencies, and our patent protection could be reduced or eliminated for non-compliance with these requirements. </i></b></p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">Periodic maintenance fees, renewal fees, annuity fees, and various other government fees on patents and applications will be due to be paid to the USPTO and various government patent agencies outside of the U.S. over the lifetime of our owned or licensed patents and applications. The USPTO and various non-U.S. government agencies require compliance with several procedural, documentary, fee payment, and other similar provisions during the patent application process. In some cases, an inadvertent lapse can be cured by payment of a late fee or by other means in accordance with the applicable rules. There are situations, however, in which non-compliance can result in abandonment or lapse of the patent or patent application, resulting in a partial or complete loss of patent rights in the relevant jurisdiction. In such an event, potential competitors might be able to enter the market with similar or identical products or technology, which could have a material adverse effect on our business, financial condition, results of operations, and growth prospects.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>Changes in U.S. patent law could diminish the value of patents in general, thereby impairing our ability to protect our products. </i></b></p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">Changes in either the patent laws or interpretation of the patent laws in the U.S. could increase the uncertainties and costs surrounding the prosecution of patent applications and the enforcement or defense of issued patents. Assuming that other requirements for patentability are met, prior to March 2013, in the U.S., the first to invent the claimed invention was entitled to the patent, while outside the U.S., the first to file a patent application was entitled to the patent. After March 2013, under the Leahy-Smith America Invents Act (the America Invents Act) enacted in September 2011, the U.S. transitioned to a first inventor to file system in which, assuming that other requirements for patentability are met, the first inventor to file a patent application will be entitled to the patent on an invention regardless of whether a third party was the first to invent the claimed invention. A third party that files a patent application in the USPTO after March 2013, but before us could therefore be awarded a patent covering an invention of ours even if we had made the invention before it was made by such third party. This requires us to be cognizant of the time from invention to filing of a patent application. Since patent applications in the U.S. and most other countries are confidential for a period of time after filing or until issuance, we cannot be certain that we were the first to either (i)&#160;file any patent application related to our product candidates or other technologies or (ii)&#160;invent any of the inventions claimed in our patents or patent applications.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">The America Invents Act also significantly affects the way patent applications are prosecuted and as well as patent litigation. This includes allowing third party submission of prior art to the USPTO during patent prosecution and additional procedures to attack the validity of a patent by USPTO administered post-grant proceedings, including post-grant review, <i>inter partes</i><b><i> </i></b>review, and derivation proceedings. Because of a lower evidentiary standard in USPTO proceedings as compared to the evidentiary standard in U.S. federal courts necessary to invalidate a patent claim, a third party could potentially provide evidence in a USPTO proceeding sufficient for the USPTO to hold a claim invalid even though the same evidence would be insufficient to invalidate the claim if first presented in a district court action. Accordingly, a third party may attempt to use the USPTO procedures to invalidate our patent claims that would not have been invalidated if first challenged by the third party as a defendant in a district court action. Therefore, the America Invents Act and its implementation could increase the uncertainties and costs surrounding the prosecution of our patent applications and the enforcement or defense of our issued patents, all of which could have a material adverse effect on our business, financial condition, results of operations, and growth prospects.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">In addition, the patent positions of companies in the development and commercialization of pharmaceuticals are particularly uncertain. Various U.S. Supreme Court rulings have narrowed the scope of patent protection available in certain circumstances and weakened the rights of patent owners in certain situations. This combination of events has created uncertainty with respect to the validity and enforceability of patents, once obtained. Depending on future actions by the U.S. Congress, the federal courts, and the USPTO, the laws and regulations governing patents could change in unpredictable ways that could have a material adverse effect on our existing patent portfolio and our ability to protect and enforce our intellectual property in the future.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&#160;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
      59
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>We may be subject to claims challenging the inventorship of our patents and other intellectual property. </i></b></p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">We may be subject to claims that former employees, scientific collaborators or other third parties have an interest in our patents, trade secrets, or other intellectual property as an inventor or co-inventor. For example, we may have inventorship disputes arise from conflicting obligations of employees, consultants, or others who are involved in developing our product candidates or other technologies. Litigation may be necessary to defend against these and other claims challenging inventorship or ownership of our patents, trade secrets, or other intellectual property. If the defense of any such claims fails, in addition to paying monetary damages, we may lose valuable intellectual property rights, such as exclusive ownership of, or right to use, intellectual property that is important to our product candidates and other technologies. Even if we are successful in defending against such claims, litigation could result in substantial costs and be a distraction to management and other employees. Any of the foregoing could have a material adverse effect on our business, financial condition, results of operations, and growth prospects.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>We may not be successful in obtaining necessary rights to our product candidates or other technologies. </i></b></p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">Many pharmaceutical companies, biotechnology companies, and academic institutions that compete with us in the field of neurodegeneration therapy may have patents filed and are likely filing patent applications potentially relevant to our business. In order to avoid infringing these third-party patents, we may find it necessary or prudent to obtain licenses to such patents from such third-party intellectual property holders. We may also require licenses from third parties for certain technologies for use with future product candidates. In addition, with respect to any patents we co-own with third parties, we may wish to obtain licenses to such co-owner&#8217;s interest to such patents. However, we may be unable to secure such licenses or otherwise acquire any compositions, methods of use, processes, or other intellectual property rights from third parties that we identify as necessary for our future product candidates. The licensing or acquisition of third-party intellectual property rights is a competitive area, and several more established companies may pursue strategies to license or acquire third-party intellectual property rights that we may consider attractive or necessary. These established companies may have a competitive advantage over us due to their size, capital resources, and greater clinical development and commercialization capabilities. In addition, companies that perceive us to be a competitor may be unwilling to assign or license rights to us. We also may be unable to license or acquire third-party intellectual property rights on terms that would allow us to make an appropriate return on our investment or at all. If we are unable to successfully obtain rights to required third-party intellectual property rights or maintain the existing intellectual property rights we have, we may have to abandon development of the relevant program or product candidate, which could have a material adverse effect on our business, financial condition, results of operations, and growth prospects.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -1pt;"><b><i>Our expansion into additional indications beyond Alzheimer</i></b>&#8217;<b><i>s disease may face challenges if we are unable to obtain additional intellectual property rights that may be necessary or desirable.</i></b></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -1pt; text-indent: 18pt;">We may leverage our scientific insights in neurodegeneration and neuroinflammation and advanced tools in molecular biology, biochemistry, and imaging to expand our science to other diseases, initially focusing on other central nervous system disorders. New indications and new drug development approaches may complement or supersede our initial focus on Alzheimer&#8217;s disease.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -1pt; text-indent: 18pt;">While we expect certain of our existing intellectual property, such as our patents covering the composition of matter of our drug simufilam, to be important for any such expansion, in order to expand our science to other diseases, for some indications, it may be necessary or desirable that we procure additional intellectual property to support new development programs, including for central nervous system disorders beyond Alzheimer&#8217;s disease.&#160;In the absence of such additional intellectual property rights, product candidates that we may develop for such additional indications may not be sufficiently covered by intellectual property or such product candidates may be challenged by third parties possessing other intellectual property or exclusive rights in respect thereof.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -1pt; text-indent: 18pt;">For example, we intend to conduct exploratory preclinical studies in collaboration with the TSCA to better understand simufilam&#8217;s potential as a treatment for TSC-related seizures. Based on the results of such additional studies, considered together with academic research conducted at Yale, we will assess whether there is support for an IND application in respect of a proof-of-concept open-label clinical trial for simufilam in TSC-related epilepsy. On February 26, 2025, we entered into the License Agreement with Yale in connection with our development and commercialization of simufilam for the treatment of TSC-related epilepsy. If we fail to comply with our obligations under the License Agreement, Yale may have the right to terminate the License Agreement, in which event we may not be able to advance our development and commercialization plans for simufilam for the treatment of TSC-related epilepsy. In addition, disagreements with Yale, including over the scope of the License Agreement, contract interpretation, or the implementation of our development plan, may cause delays or termination of development or commercialization of simufilam for the treatment of TSC-related epilepsy, or may result in time-consuming and expensive legal proceedings.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
      60
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-indent: 18pt;">If we are unable to identify and procure intellectual property necessary or desirable for programs in other indications that we may decide to pursue in the future, it may be more challenging or, in some cases, impracticable to expand into such&#160;other indications. There can be no assurance that we will be able to obtain such intellectual property on commercially reasonable terms, or at all, which could have a material adverse effect on our business.</p>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>We may be subject to claims that our employees, consultants, or advisors have wrongfully used or disclosed alleged trade secrets of their current or former employers or claims asserting ownership of what we regard as our own intellectual property which may prevent or delay the development of our product candidates. </i></b></p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">The field of developing innovations for neurodegenerative diseases is highly competitive and dynamic. Due to the focused research and development that is taking place by several companies, including us and our competitors, the intellectual property landscape in this field is in flux, and it may remain uncertain in the future. Additionally, no products utilizing our underlying science and technology have yet reached the market. As such, there may be significant intellectual property related litigation and proceedings relating to our, and other third party, intellectual property and proprietary rights in the future.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">Many of our employees, consultants, and advisors are currently or were previously employed at universities or other biotechnology or pharmaceutical companies, including our competitors and potential competitors. Although we try to ensure that our employees, consultants, and advisors do not use the proprietary information or know-how of others in their work for us, we may be subject to claims that we or these individuals have used or disclosed intellectual property, including trade secrets or other proprietary information, of any such individual&#8217;s current or former employer. Litigation may be necessary to defend against these claims. If we fail in defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights or personnel. Even if we are successful in defending against such claims, litigation could result in substantial costs and be a distraction to management.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">In addition, while it is our policy to require our employees and contractors who may be involved in the conception or development of intellectual property to execute agreements assigning such intellectual property to us, we may be unsuccessful in executing such an agreement with each party who, in fact, conceives or develops intellectual property that we regard as our own. The assignment of intellectual property rights may not be self-executing, or the assignment agreements may be breached, and we may be forced to bring claims against third parties, or defend claims that they may bring against us, to determine the ownership of what we regard as our intellectual property. Such claims could have a material adverse effect on our business, financial condition, results of operations, and growth prospects.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">Our commercial success depends in part on our ability to develop, manufacture, market, and sell any product candidates that we develop and to use our proprietary technologies without infringing, misappropriating, and otherwise violating the patents and other intellectual property rights of third parties. There is a substantial amount of complex litigation involving patents and other intellectual property rights in the biotechnology and pharmaceutical industries, as well as administrative proceedings for challenging patents, including interference, derivation, and reexamination proceedings before the USPTO or oppositions and other comparable proceedings in foreign jurisdictions. We may become party to, or threatened with, such actions in the future, regardless of their merit. As discussed above, recently, due to changes in U.S. law referred to as patent reform, new procedures including <i>inter partes</i> review and post-grant review have been implemented. As stated above, this reform adds uncertainty to the possibility of challenge to our patents in the future.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">Numerous U.S. and foreign issued patents and pending patent applications owned by third parties exist in the fields in which we are developing our product candidates. As the biotechnology and pharmaceutical industries expand and more patents are issued, the risk increases that our product candidates and other technologies may give rise to claims of infringement of the patent rights of others. Although we believe that we do not infringe on any third parties&#8217; patents or other intellectual property, we cannot assure you that our product candidates and other technologies that we have developed, are developing or may develop in the future will not infringe existing or future patents owned by third parties. We may not be aware of patents that have already been issued to a third party, such as a competitor in the fields in which we are developing product candidates, who might assert infringement of patents it may hold by our current or future product candidates or other technologies, including claims to compositions, formulations, methods of manufacture or methods of use or treatment that cover our product candidates or other technologies. It is also possible that patents owned by third parties of which we are aware, but which we do not believe are relevant to our product candidates or other technologies, could be found to be infringed by our product candidates or other technologies. In addition, because patent applications can take many years to issue, there may be currently pending patent applications that may later result in issued patents that our product candidates or other technologies may infringe.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
      61
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">Engaging in litigation to defend against third parties alleging that we have infringed, misappropriated, or otherwise violated their patents or other intellectual property rights is very expensive, particularly for a company of our size, and time-consuming. Some of our competitors may be able to sustain the costs of litigation or administrative proceedings more effectively than we can because of greater financial resources. Patent litigation and other proceedings may also absorb significant management time. Uncertainties resulting from the initiation and continuation of patent litigation or other proceedings against us could impair our ability to compete in the marketplace. The occurrence of any of the foregoing could have a material adverse effect on our business, financial condition, results of operations, and growth prospects.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>We may become involved in lawsuits to protect or enforce our patents and other intellectual property rights, which could be expensive, time consuming, and unsuccessful. </i></b></p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">Competitors may infringe on our patents or the patents of our licensing partners, or we may be required to defend against claims of infringement. In addition, our patents or the patents of our licensing partners also may become involved in inventorship, priority, or validity disputes. To counter or defend against such claims can be expensive and time consuming. In an infringement proceeding, a court may decide that a patent in which we have an interest is invalid or unenforceable, the other party&#8217;s use of our patented technology falls under the safe harbor to patent infringement, or may refuse to stop the other party from using the technology at issue on the grounds that our patents do not cover the technology in question. An adverse result in any litigation proceeding could put one or more of our patents at risk of being invalidated or interpreted narrowly. Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation, there is a risk that some of our confidential information could be compromised by disclosure during this type of litigation.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">Even if resolved in our favor, litigation or other legal proceedings relating to intellectual property claims may cause us to incur significant expenses and could distract our personnel from their normal responsibilities. In addition, there could be public announcements of the results of hearings, motions, or other interim proceedings or developments, and if securities analysts or investors perceive these results to be negative, it could have a substantial adverse effect on the price of our common stock. Such litigation or proceedings could substantially increase our operating losses and reduce the resources available for development activities or any future sales, marketing, or distribution activities. We may not have sufficient financial or other resources to conduct such litigation or proceedings adequately. Some of our competitors may be able to sustain the costs of such litigation or proceedings more effectively than we can because of their greater financial resources and more mature and developed intellectual property portfolios. Uncertainties resulting from the initiation and continuation of patent litigation or other proceedings could have a material adverse effect on our ability to compete in the marketplace.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>Intellectual property rights do not necessarily address all potential threats. </i></b></p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">The degree of future protection afforded by our intellectual property rights is uncertain because intellectual property rights have limitations and may not adequately protect our business or permit us to maintain our competitive advantage. For example:</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 36pt;text-indent:-18pt;">&#160;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">others may be able to make products that are similar to our product candidates or utilize similar technology but that are not covered by the claims of the patents that we may own;</p> </td>
    </tr>

    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">we might not have been the first to make the inventions covered by the issued patent or pending patent application that we own now or in the future;</p> </td>
    </tr>

    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">we might not have been the first to file patent applications covering certain of our inventions;</p> </td>
    </tr>

    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">others may independently develop similar or alternative technologies or duplicate any of our technologies without infringing our owned intellectual property rights;</p> </td>
    </tr>

    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">it is possible that our current or future pending patent applications will not lead to issued patents;</p> </td>
    </tr>

    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">issued patents that we hold rights to may be held invalid or unenforceable, including as a result of legal challenges by our competitors or other third parties;</p> </td>
    </tr>

    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">our competitors or other third parties might conduct research and development activities in countries where we do not have patent rights and then use the information learned from such activities to develop competitive products for sale in our major commercial markets;</p> </td>
    </tr>

    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">we may not develop additional proprietary technologies that are patentable;</p> </td>
    </tr>

    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">the patents of others may harm our business; and</p> </td>
    </tr>

    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">we may choose not to file a patent in order to maintain certain trade secrets or know-how, and a third party may subsequently file a patent covering such intellectual property.</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">Should any of these events occur, they could have a material adverse effect on our business, financial condition, results of operations, and growth prospects.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&#160;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
      62
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>Risks Related to Our Business and Operations </b></p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -20pt; text-indent: 18pt;"><i><b>The validity of aspects of</b> <b>the Company</b>&#8217;<b>s Phase 2b Study has been called into question.</b></i></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 7pt;text-indent:18pt;">The Company&#8217;s Phase 2b Study was designed as a 28-day, approximately 60-patient, randomized, double-blind, placebo-controlled, multiple dose study.&#160; A primary objective of the Phase 2b Study was to measure changes in levels of cerebral spinal fluid (CSF) biomarkers in study participants from baseline value to Day 28. CSF biomarker assays and related bioanalysis for the Phase 2b Study (the CUNY Bioanalysis) were conducted by the laboratory at CUNY of Dr. Hoau-Yan Wang, formerly a paid scientific collaborator, consultant and advisor to Cassava. Based on the CUNY Bioanalysis, Cassava reported statistically significant improvements in CSF biomarkers in treatment groups as compared to the placebo group for the Phase 2b Study.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 7pt;text-indent:18pt;">On June 28, 2024, the DOJ announced that a federal grand jury in the U.S. District Court for the District of Maryland returned an indictment of Dr. Wang alleging that he caused Cassava to submit grant applications to NIH that contained false and fraudulent representations about his research. Among other things, the indictment alleges that Dr. Wang made materially false, fraudulent, and misleading statements to NIH regarding the mechanism by which simufilam was designed to treat Alzheimer&#8217;s disease and the improvement of certain Alzheimer&#8217;s disease indicators in patients treated with simufilam, and that Dr. Wang manipulated or otherwise fabricated research results, including Western Blot images that he prepared.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 8pt; text-indent: 18pt; text-align: justify;">The&#160;Company&#8217;s Board&#160;empowered an&#160;<i>Ad Hoc</i>&#160;Investigation Committee (the Committee), comprising independent directors, to direct an investigation (the Internal Investigation) of supplemental information provided by the SEC. As part of an&#160;Internal Investigation conducted by the&#160;Committee, the Committee&#160;evaluated&#160;information contained in the DOJ indictment of Dr. Wang as well as information from the Company&#8217;s&#160;discussions with the SEC. The Internal Investigation determined that certain statistical information contained in an attachment to an email sent by a former senior employee of Cassava to Dr. Wang before the CUNY Bioanalysis of CSF biomarkers was conducted could have been used to unblind him as to some number of Phase 2b Study participants. Unblinded information, if accessed in connection with bioanalysis, could be improperly utilized to manipulate underlying samples or data to skew reported results.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 7pt;text-indent:18pt;">The Internal Investigation did&#160;not&#160;determine, and may never be able to determine with any reasonable degree of certainty, whether Dr. Wang unblinded himself as to some number of Phase 2b Study participants.&#160;Nevertheless, the fact that Dr. Wang possessed information that could have been used to so unblind himself, together with the allegations in the DOJ indictment, undermine the blinded study design and create substantial uncertainty about the validity of the CUNY Bioanalysis of CSF biomarkers.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 5pt;text-indent:18pt;">In addition, another objective of the Phase 2b Study was to measure changes in cognitive outcome measures using the Cambridge Neuropsychological Test Automated Battery, or CANTAB, over the 28-day study period.&#160;In connection with our settlement with the SEC, the SEC&#8217;s complaint alleged, among other things, that disclosures relating to the Phase 2b Study&#8217;s cognition results (the Cognition Disclosures), which reported results from a <i>post hoc</i> sensitivity analysis, were inadequate and misleading.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 7pt;text-indent:18pt;">Accordingly, in light of the foregoing uncertainties and allegations, you should not rely on the CUNY Bioanalysis of CSF biomarkers reported by the Company in connection with the Phase 2b Study or the Cognition Disclosures from the Phase 2b Study. There can be no assurance that such uncertainties and allegations will not adversely impact any&#160;FDA&#160;review with respect to simufilam following completion of our Phase 3 clinical studies or cause the FDA to request additional information regarding simufilam.&#160;</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -20pt; text-indent: 18pt;"><i><b>We are subject to lawsuits and governmental investigations and inquiries. </b></i></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 7pt;text-indent:18pt;">We are defending ourselves in a number of lawsuits, including securities class action and shareholder derivative actions, and the Company, as well as two former senior employees of the Company, have been and may continue to be subject to governmental investigations and inquiries. Defending litigation and responding to governmental investigations is expensive and time consuming and may divert the time and attention of our management away from the conduct of our primary business.&#160;Moreover, the allegations underlying such litigation and governmental investigations have&#160;damaged our business reputation, which may make it difficult to, among other things: raise capital or engage in a strategic transaction on acceptable terms or at all; hire and retain third-party consultants and collaborators; recruit and retain patients for our studies; and attract and retain qualified executive officers, other employees and directors.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
      63
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 7pt;text-indent:18pt;">As a result of current or future lawsuits, we may have to pay significant damages or amounts in settlement above insurance coverage, including amounts in respect of indemnification obligations of the Company to former officers and senior employees. An unfavorable outcome or prolonged litigation could materially and adversely impact our business, operating results, and financial condition, including our cash runway. In addition, current or future government investigations and inquiries could subject us to various sanctions, including significant penalties, our being prevented from receiving government grants, and other punitive measures. For example, the Company paid&#160;a civil monetary penalty of $40 million in November 2024 as part of a settlement with the SEC&#160;resolving the SEC investigation of the Company&#8217;s disclosures regarding its Phase 2b Study and related matters.&#160;Such payments or settlement arrangements in current or future litigation and government investigations and inquiries could significantly and adversely impact our reputation and divert management&#8217;s attention and resources, which could have a material adverse effect on our business, operating results and financial condition.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 7pt;text-indent:18pt;">While we cannot estimate our potential exposure to future litigation, regulatory claims, investigations or proceedings at this time, we have already incurred significant expense related to litigation, government investigations and the Internal Investigation and expect to continue&#160;to incur significant expense.</p>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
  <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><b><i>Our current dependence on single source suppliers for our drug substance and drug product could materially adversely affect our ability to manufacture our product candidates and materially increase our costs.</i></b></p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">We rely on single source suppliers for materials that are critical to the manufacturing of simufilam, our lead product candidate. This reliance subjects us to risks related to our potential inability to obtain an adequate supply of required materials. If these third parties do not successfully carry out their contractual duties, meet expected deadlines or conduct their activities in accordance with regulatory requirements, or if there are disagreements between us and these third parties, we may not be able to complete, or may be delayed in completing, the clinical studies required to support future regulatory submissions and approval of the product candidates we develop. Our operating results could be materially adversely affected if we were unable to obtain adequate supplies of simufilam in a timely manner or if their cost increased significantly due to inflation or other factors.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">Further, under certain circumstances, service providers that have contracted with us may be entitled to terminate their engagements with us. In such circumstances, product development activities could be delayed while we seek to identify, validate, and negotiate an agreement with a replacement service provider. In some such cases an appropriate replacement may not be readily available or available on acceptable terms, which could cause additional delays to our development process. It would likely result in production and delivery delays if we needed to find alternative suppliers for simufilam, which could lead to delays in our clinical trials and have a material adverse effect on our business, results of operations and financial condition</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -1pt;"><b><i>Inadequate Congressional funding for the FDA, the SEC and other U.S. government agencies or comparable foreign regulatory authorities, including from government shut downs, or other disruptions to these agencies</i></b>&#8217;<b><i> operations, could hinder these agencies</i></b>&#8217;<b><i> ability to hire and retain key leadership and other personnel, prevent new products and services from being developed or commercialized in a timely manner or otherwise prevent government agencies from performing normal business functions on which the operation of our business may rely, which could negatively impact our business. </i></b></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -1pt; text-indent: 23pt;">The ability of the FDA or comparable foreign regulatory authorities to review and approve new products can be affected by a variety of factors, including government budget and funding levels, ability to hire and retain key personnel and accept the payment of user fees, and enact statutory, regulatory and policy changes. Disruptions at the FDA and other agencies may also slow the time necessary for new product candidates to be reviewed and/or approved by necessary government agencies, which would adversely affect our business.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -1pt; text-indent: 32pt;">In addition, government funding of the SEC and other government agencies on which our operations may rely, including those that fund research and development activities, is subject to the political process, which is inherently fluid, unpredictable and entirely beyond our control.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -1pt; text-indent: 32pt;">Disruptions at the FDA and other agencies may also slow the time necessary for us and the FDA to communicate and discuss key aspects of our clinical program, or for new product candidates to be reviewed and/or approved by necessary government agencies, which would adversely affect our business. For example, in prior years the U.S. government has shut down several times and certain regulatory agencies, such as the FDA and the SEC, have had to furlough critical employees and stop critical activities. If a prolonged government shutdown occurs, it could significantly impact the ability of the FDA or SEC to timely review and process our regulatory submissions, which could have a material adverse effect on our business. Further, future government shutdowns could impact our ability to access the public markets and obtain necessary capital in order to properly capitalize and continue our operations.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;">&#160;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
      64
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-indent: 9pt;"><b><i>The FDA may change the statutory requirements for drug approval.</i></b></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -1pt; text-indent: 18pt;">FDA Guidances for Industry are non-binding policy documents that are issued by FDA from time to time to assist sponsors, such as our Company, with the clinical development of drug candidates. Even though such guidance documents do not set legal standards or impose binding requirements they are nonetheless broadly followed by sponsors, including us. In addition, sponsors who adhere in good faith with earlier guidance documents have no assurance or recourse against enforcement actions if the guidance documents are later replaced with conflicting guidance. We have relied heavily on current FDA guidance and meetings with the FDA to advance simufilam through the drug development process. Any future changes to existing FDA Guidance for Industry for indications that we are pursuing may have a material adverse effect on our business, may add significant time, cost or complexity to our drug development program for simufilam, or could cause us to cease or delay development of some or all our product candidates.</p>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -1pt; text-indent: 18pt;">In addition, changes in FDA regulations, statutes or the interpretation of existing regulations and statutes could impact our business by requiring, for example: (i) changes to our manufacturing arrangements for simufilam; (ii) additions or modifications to product labeling, if and when our product candidates are approved for sale; (iii) the recall or discontinuation of our product candidates from investigational clinical sites; or (iv) additional record-keeping requirements. If any such changes were to be imposed, they may have a material adverse effect on our business, may add significant time, cost or complexity to our drug development program for simufilam, or could cause us to cease or delay development of some or all our product candidates.&#160;</p>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>Our reliance on third parties for both the supply and manufacture of materials for our product candidates carries the risk that we will not have sufficient quality or quantities of such materials or product candidates, or that such supply will not be available to us at an acceptable cost, which could delay, prevent, or impair our development or commercialization efforts.</i></b></p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">We do not have any manufacturing facilities. We currently expect to rely on CDMOs for all of the manufacture of our materials for preclinical studies and clinical studies, clinical studies, and for commercial supply of any product candidates that we may develop. We currently have established relationships with several CDMOs for the manufacturing of our product candidates. We may be unable to establish any further agreements with CDMOs or to do so on acceptable terms. Even if we are able to establish agreements with third-party manufacturers, reliance on CDMOs entails additional risks, including:</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 36pt;text-indent:-18pt;">&#160;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">the possible breach of the manufacturing agreement by the third party;</p> </td>
    </tr>

    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">the possible termination or nonrenewal of the agreement by the third party at a time that is costly or inconvenient for us;</p> </td>
    </tr>

    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">reliance on the third party for regulatory compliance, quality assurance, safety, and pharmacovigilance and related reporting; and</p> </td>
    </tr>

    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">the inability to produce required volume in a timely manner and to quality standards.</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">Third-party manufacturers may not be able to comply with cGMP regulations or similar regulatory requirements outside the U.S. Our failure, or the failure of our CDMOs, to comply with applicable regulations could result in clinical holds on our studies, sanctions being imposed on us, including fines, injunctions, civil penalties, delays, suspension or withdrawal of approvals, seizures, or recalls of product candidates or product candidates, operating restrictions, and criminal prosecutions, any of which could significantly and adversely affect supplies of our product candidates and harm our business, financial condition, results of operations, and growth prospects.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">Any product candidates that we may develop may compete with other product candidates and products for access to manufacturing facilities. There are a limited number of manufacturers that operate under cGMP regulations and that might be capable of manufacturing for us.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">Any performance failure on the part of our existing or future third-party manufacturers could delay clinical development or marketing approval. If any one of our current contract manufacturers cannot perform as agreed, we may be required to replace that manufacturer and may incur added costs and delays in identifying and qualifying any such replacement. Furthermore, securing and reserving production capacity with contract manufacturers may result in significant costs.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">We also rely on third-parties for the supply of the raw materials required for the production of our product candidates, and we expect to continue to rely on third party manufacturers for the commercial supply of any of our product candidates for which we obtain marketing approval. Our current and anticipated future dependence upon others for the manufacture of any product candidates we may develop may adversely affect our future profit margins and our ability to commercialize any medicines that receive marketing approval on a timely and competitive basis.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 1pt;">&#160;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
      65
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 1pt;"><b><i>Our employees, principal investigators, consultants and vendors may engage in misconduct or other improper activities, including noncompliance with regulatory standards and requirements and insider trading.</i></b></p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">We are exposed to the risk of fraud or other misconduct by our employees, principal investigators, consultants and vendors. Misconduct by these parties could include intentional failures, reckless and/or negligent conduct or unauthorized activities that violate (i) the laws and regulations of FDA and other regulatory authorities, including those laws requiring the reporting of true, complete and accurate information to such authorities, (ii) manufacturing standards, (iii) federal and state data privacy, security, fraud and abuse and other healthcare laws and regulations in the United States and abroad and (iv) laws that require the true, complete and accurate reporting of financial information or data. In particular, clinical and business arrangements in the biotechnology and healthcare industries are subject to extensive laws and regulations intended to prevent fraud, misconduct, kickbacks, self-dealing and other abusive practices. These laws and regulations restrict or prohibit a wide range of financial arrangements, incentive programs and other business arrangements. Such misconduct also could involve the improper use of individually identifiable information, including, without limitation, information obtained in the conduct of clinical trials, creating fraudulent data in our preclinical studies or clinical trials or illegal misappropriation of drug product, which could result in regulatory sanctions and cause serious harm to our reputation. It is not always possible to identify and deter misconduct by employees and other third parties, and the precautions we take to detect and prevent this activity may not be effective in controlling unknown or unmanaged risks or losses or in protecting us from government investigations or other actions or lawsuits stemming from a failure to comply with these laws or regulations.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">Additionally, we are subject to the risk that a person or government could allege such fraud or other misconduct, even if none occurred. If any such actions are instituted against us and we are not successful in defending ourselves or asserting our rights, those actions could result in significant civil, criminal and administrative penalties, damages, fines, disgorgement, imprisonment, exclusion from participating in government-funded healthcare programs, such as Medicare and Medicaid, additional reporting requirements and oversight if we become subject to a corporate integrity agreement or similar agreement to resolve allegations of noncompliance with these laws, contractual damages, reputational harm and the curtailment or restructuring of our operations, any of which could have a negative impact on our business, financial condition, results of operations and prospects.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -1pt;"><b><i>Our Workforce Reduction may result in operational and strategic challenges.</i></b></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-indent: 18pt;">On January 7, 2025, we announced a reduction&#160;in our&#160;workforce by 10 employees, a reduction of 33%. The Workforce Reduction was intended to align our human capital resources to meet our strategic goals, in light of the discontinuation of our ongoing clinical trials for Alzheimer&#8217;s disease. Headcount reductions, which may result in the loss of institutional knowledge and expertise, may adversely affect operations and yield unintended consequences, such as attrition beyond our intended reductions and reduced employee morale. Our ability to successfully execute on our strategy depends on retaining key remaining personnel, and unanticipated attrition, which may occur on short notice, could potentially harm our business and operations. As a result of the Workforce Reduction, our management may need to divert attention away from day-to-day strategic and operational activities and devote additional time to managing organizational changes.</p>
  <p style="margin: 0pt 0pt 0pt -9pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>Our disclosure controls and procedures may not prevent or detect all errors or acts of fraud.</i></b></p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">We are subject to the periodic reporting requirements of the Exchange Act. We designed our disclosure controls and procedures to reasonably assure that information we must disclose in reports we file or furnish under the Exchange Act is accumulated and communicated to management, and recorded, processed, summarized and reported within the time periods specified in the rules and forms of the SEC. We believe that any disclosure controls and procedures or internal controls and procedures, no matter how well-conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">These inherent limitations include the realities that judgments in decision-making can be faulty, and that breakdowns can occur because of simple mistake or human error. Additionally, controls can be circumvented by the individual acts of some persons, by collusion of two or more people or by an unauthorized override of the controls. Accordingly, because of the inherent limitations in our control system, misstatements due to error or fraud may occur and not be detected.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
      66
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>Failure to comply with laws regarding data privacy could expose us to risk of enforcement actions and penalties under such laws.</i></b></p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">We may be subject to privacy and security laws in the various jurisdictions in which we operate, obtain or store personally identifiable information. The legislative and regulatory landscape for privacy and data protection continues to evolve, and there has been an increasing focus on privacy and data protection issues with the potential to affect our business. Our ongoing efforts to comply with evolving laws and regulations may be costly and require ongoing modifications to our policies, procedures and systems. Failure to comply with laws regarding data protection by us or our partners or service providers would expose us to risk of enforcement actions and penalties under such laws. Even if we are not determined to have violated these laws, government investigations into these issues typically require the expenditure of significant resources and generate negative publicity, which could harm our business, financial condition, results of operations or prospects.</p>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">Within the U.S., there are numerous federal and state laws and regulations related to the privacy and security of personal information. For example, at the federal level, the Health Insurance Portability and Accountability Act of 1996, as amended (&#8220;HIPAA&#8221;), and its implementing regulations establish privacy and security standards that limit the use and disclosure of personally identifiable health information, or protected health information, and require the implementation of administrative, physical and technological safeguards to protect the privacy of protected health information. While we have determined that we are neither a &#8220;covered entity&#8221; nor a &#8220;business associate&#8221; directly subject to HIPAA, many of the U.S. health care providers with which we interact are subject to HIPAA, and we may have assumed obligations related to protecting the privacy of personal information. States are increasingly regulating the privacy and security of personal information. For example, the California Consumer Privacy Act (CCPA), which took effect in 2020, gives California consumers (defined to include all California residents) certain rights, including the right to ask covered companies to disclose the types of personal information collected, the categories of sources from which such information was collected, the business purpose for collecting or selling the consumer&#8217;s personal information, the categories of third parties with whom a covered company shares personal information, and specific pieces of information collected by a covered company. The CCPA imposes several obligations on covered companies to provide notice to California consumers regarding their data processing activities. The CCPA also gives California consumers the right to ask covered companies to delete a consumer&#8217;s personal information and it places limitations on a covered company&#8217;s ability to sell personal information, including providing consumers a right to opt out of sales of their personal information. Additionally, the California Privacy Rights Act (CPRA), which became operational in 2023, significantly modifies the CCPA, including expanding consumers&#8217; rights with respect to certain sensitive personal information, and creates a new state agency vested with authority to implement and enforce the CCPA and CPRA. The Virginia Consumer Data Protection Act (CDPA) went into effect on January 1, 2023. The CDPA provides consumers with new rights to access, correct, delete and obtain a copy of the personal information a covered business holds about them, and to opt out of certain data processing activities.</p>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>Ownership of our corporate headquarters and property leasing are subject to numerous risks and uncertainties.</i></b></p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">In 2021, we made an all-cash purchase of an office complex in Austin, Texas, a portion of which serves as our corporate headquarters. Title to this property is held by Austin Innovation Park, LLC, a Texas limited liability company wholly owned by Cassava Sciences. The purchase required a substantial upfront cash investment and may require further commitments of our resources in the future. We have assumed or entered into lessor commitments with independent third parties for portions of our office complex and expect to&#160;continue to do so in the future. Commercial property ownership and related leasing activity are subject to many factors that pose substantial financial risks and uncertainties, including tenant default or non-payment of lease obligations by tenants. Macro-economic or other factors outside of our control could have an adverse effect on the demand for leased office space in our locale or may cause a decline in the market value of our corporate headquarters.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">At December 31, 2024, we occupied approximately 25% of the property with the remainder&#160;either leased or available for lease to third parties.&#160;Most tenant leases expired&#160;in 2024. We expect to record a net loss on leasing activities&#160;in 2025&#160;as the higher vacancy rates are expected to significantly lower rental income. If we fail to lease unoccupied office space at favorable rates, or if we incur excessive expenses in this effort or incur excessive leasehold improvements or property ownership expenses, our business, operations, future prospects, cash flows, and financial position may be adversely affected. In addition, our property is located in a semi-rural, wooded area of Austin, Texas that is subject to natural disasters such as extreme weather conditions, including but not limited to floods, tornadoes, wildfires, winter storms, lighting, heat waves and drought. Such natural disasters could damage, destroy or impair the value of our property or reduce the number of tenants who are willing or able to continue to lease office space in our property. We may incur substantial expenses as a result of our property&#8217;s exposure to natural disasters, which could have a material adverse effect on our business and prospects.</p>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
      67
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>Our internal computer systems, or those used by third parties on whom we rely, may fail or suffer other breakdowns, cyberattacks, or information security breaches that could compromise the confidentiality, integrity, and availability of such systems and data, result in material disruptions of our development programs and business operations, risk disclosure of confidential, financial, or proprietary information, and affect our reputation. </i></b></p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">In the ordinary course of our business, we collect and store sensitive data, including legally protected patient health information, personally identifiable information about our employees, intellectual property, and proprietary business information. We manage and maintain our applications and data utilizing on-site systems, as well as extensive cloud-based applications and data storage. These applications and data encompass a wide variety of business-critical information including research and development information, commercial information and business and financial information. Despite the implementation of security measures, our internal computer systems and those of our current or future CROs and other contractors and consultants may be vulnerable to damage from computer viruses and unauthorized access. As the cyber-threat landscape evolves, these cyberattacks are growing in frequency, sophistication, and intensity, and are becoming increasingly difficult to detect. Such attacks could include the use of key loggers or other harmful and virulent malware, including ransomware or other denials of service, and can be deployed through malicious websites, the use of social engineering, and/or other means. If a breakdown, cyberattack, or other information security breach were to occur and cause interruptions in our operations, it could result in a misappropriation of confidential information, including our intellectual property or financial information, and a material disruption of our development programs and our business operations. For example, the loss of clinical study data from completed, ongoing, or future clinical studies could result in delays in our regulatory approval efforts and significantly increase our costs to recover or reproduce the data. Likewise, we rely on our third-party research institution collaborators for research and development of our product candidates and other third parties for the manufacture of our product candidates,&#160;to conduct clinical studies, and to analyze our clinical study data and similar events relating to their computer systems could also have a material adverse effect on our business. To the extent that any disruption or security breach were to result in a loss of, or damage to, our data or systems, or inappropriate disclosure of confidential, financial, or proprietary information, including data related to our personnel, we could incur liability or risk disclosure of confidential, financial, or proprietary information, and the further development and commercialization of our product candidates could be delayed. There can be no assurance that we and our business counterparties will be successful in efforts to detect, prevent, or fully recover systems or data from all breakdowns, service interruptions, attacks, or breaches of systems that could adversely affect our business and operations and/or result in the loss of critical or sensitive data, which could result in financial, legal, business, or reputational harm to us.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -1pt; text-indent: 18pt;">We are in the early stages of exploring potential AI capabilities and related data analytics. As an emerging and rapidly evolving technology, our use of AI presents risks that could adversely affect our operations, information security and reputation. AI systems may produce inaccurate or flawed outputs due to flawed algorithms, or insufficient and/or erroneous training data. Reliance on flawed outputs could result in lower quality decision-making or prevent us from effectively utilizing AI in our business. We may also become vulnerable to operational disruptions if the AI technologies we use experience downtimes or are compromised by cyberattacks. If we do not effectively implement guardrails and train our staff on the safe and proper use of AI, or if our staff fail to effectively adhere to our established guardrails and training on the use of AI, we may experience adverse effects on our business, including data breaches, the loss of confidential information (including our intellectual property), unintentional disclosure of personal data, or other misuse of our proprietary information, any of which could result in significant reputational harm and could have a material adverse effect on our business and results of operations.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>Our reliance on third parties requires us to share our proprietary information, which increases the possibility that a competitor will discover this information or that our proprietary information will be misappropriated or inadvertently disclosed.</i></b></p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">Our reliance on third-party vendors requires us to disclose our proprietary information to these parties, which could increase the risk that a competitor will discover this information or that our proprietary information will be misappropriated or disclosed without our intent to do so. If any of these events were to occur, then our ability to obtain patent protection or other intellectual property rights could be irrevocably jeopardized, and costly, distracting litigation could ensue. Furthermore, if these third-party vendors cease to continue operations and we are not able to quickly find a replacement provider or we lose information or items associated with our products or product candidates, our development programs may be delayed. Although we carefully manage our relationships with our third-party collaborators and CROs, there can be no assurance that we will not encounter challenges or delays in the future or that these delays or challenges will not have a material adverse impact on our business, clinical operations, financial condition and prospects.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&#160;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
      68
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>Our business involves environmental risks that may result in liability for us.</i></b></p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">In connection with our research and development activities, we, and our collaborators and vendors, are subject to federal, state and local laws, rules, regulations and policies governing the use, generation, manufacture, storage, air emission, effluent discharge, handling and disposal of certain materials, biological specimens, chemicals and wastes. Although we believe that we comply with such applicable laws, regulations and policies in all material respects and have not been required to correct any material noncompliance, we may incur significant costs to comply with environmental and health and safety regulations in the future. Although we believe that our safety procedures for handling and disposing of controlled materials comply with the standards prescribed by state and federal regulations, accidental contamination or injury from these materials may occur. In the event of such an occurrence, we could be held liable for any damages that result and any such liability could exceed our resources.</p>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>Business disruptions and lack of appropriate levels of commercial insurance could seriously harm our future revenue and financial condition and increase our costs and expenses. </i></b></p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">Our operations, and those of our third-party research institution collaborators, CROs, CDMOs, suppliers, and other contractors and consultants, could be subject to earthquakes, power shortages, telecommunications failures, water shortages, floods, hurricanes, typhoons, fires, extreme weather conditions, disease epidemics or pandemics, and other natural or man-made disasters or business interruptions, for which we are partly or entirely uninsured. In addition, we rely on third parties for conducting certain research and development activities relating to our product candidates, and they may be affected by government shutdowns or withdrawn funding. The occurrence of any such business disruptions could seriously harm our operations and financial condition and increase our costs and expenses. We rely on third party manufacturers to produce and process our product candidates. Our ability to obtain clinical supplies of our product candidates could be disrupted if the operations of these suppliers are affected by a man-made or natural disaster or other business interruption.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">Our day-to-day operations are located in a single office facility in Austin, Texas. Damage or extended periods of interruption to our corporate, development, or research facilities could cause us to cease or delay development of some or all our product candidates. Our insurance might not cover losses under such circumstances and our business may be seriously harmed by such delays and interruption.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>Social media platforms have significantly altered the dynamics of corporate communications and present risks and challenges, some of which are&#160;and may continue to be unknown to us.</i></b></p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">As social media continues to expand, it also presents us with new challenges. The inappropriate or unauthorized use of our confidential information on media platforms could cause brand damage or information leakage, which would cause legal or regulatory issues for us. In addition, negative, inappropriate or inaccurate posts or comments about us or our product candidates on social media internet sites could quickly and irreversibly damage our reputation, image and goodwill. Further, the accidental or intentional disclosure of non-public sensitive information by our workforce or others through media channels could lead to information loss or could lead to legal or regulatory issues for us. In addition, there is a risk of a fraudulent third-party hijacking our information technology systems without our knowledge to access our confidential documents or to use our company name, logo or brand without authorization. If any of these events were to occur or we otherwise fail to comply with applicable regulations, we could incur liability, face restrictive regulatory actions or incur other harm and costs to our business.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>We are a small company with a limited number of employees. We are highly dependent on our key personnel, and if we are not successful in attracting, motivating, and retaining highly qualified personnel, we may not be able to successfully implement our business strategy. </i></b></p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">Our ability to compete in the highly competitive biotechnology and pharmaceutical industries depends upon our ability to attract, motivate, and retain highly qualified managerial, scientific, and medical personnel. We are highly dependent on our management and our scientific and technical personnel. The loss of the services provided by any of our executive officers, other key employees, and other scientific and medical advisors, and our inability to find suitable replacements, could result in delays in the development of our product candidates and harm our business.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
      69
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">To induce valuable employees to remain at our company, in addition to salary and cash incentives, we have provided equity option grants that vest over time and/or a cash bonus plan. The value to employees of these equity grants that vest over time or cash bonus plans may be significantly affected by movements in our stock price that are beyond our control and may at any time be insufficient to counteract more lucrative offers from other companies. Although we have employment agreements with our key employees, these employment agreements provide for at-will employment, which means that any of our employees could leave our employment at any time, with or without notice. If we are unable to attract and incentivize quality personnel on acceptable terms, or at all, it may cause our business and operating results to suffer.</p>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>We may need to cease our operations if we are unable to attract and retain key personnel.</i></b></p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">We are engaged in developing early- and clinical-stage technologies and will continue to do so for the foreseeable future. Unlike larger organizations, we rely on a very small number of highly skilled, and highly sought after, employees to continue the advancement of our development stage technologies. The knowledge and skills contributed by our key employees may be irreplaceable and the loss of a key employee may cause substantial negative financial, operational and scientific consequences for our business. As an example, the intellectual property that is intended to protect our development stage technologies is still evolving and its evolution remains highly dependent on a small number of employees with specific expertise. The loss of a key employee may jeopardize our existing or pending intellectual property or may prevent us from accessing the technical information and knowledge necessary to extend our portfolio of intellectual property. Furthermore, we believe the adverse effects that may result from losing a key employee&#8217;s participation cannot be compensated with any specific insurance policies, such as &#8220;key person&#8221; or &#8220;business life&#8221; insurance. If we are not successful in retaining key employees, our business and financial condition will suffer, and we may need to cease our operations.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>If our current research collaborators or scientific advisors terminate their relationships with us or develop relationships with a competitor, our ability to continue our business operations could be adversely affected.</i></b></p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">We have relationships with unaffiliated research collaborators at academic and other institutions who conduct research at our request. These research collaborators are not our employees. As a result, we have limited control over their activities and, except as otherwise required by our collaboration agreements, can expect only limited amounts of their time to be dedicated to our activities. Our ability to discover drugs and biomarkers involved in human disease and validate and commercialize diagnostic tests may&#160;depend in part on the continuation of these collaborations. If any of these collaborations are terminated, we may not be able to enter into other acceptable collaborations. In addition, our existing collaborations may not be successful. Our research collaborators and scientific advisors may have relationships with other commercial entities, some of which could compete with us. Our research collaborators and scientific advisors sign agreements which provide for the confidentiality of our proprietary information and the results of studies conducted at our request. We may not, however, be able to maintain the confidentiality of our technology and other confidential information related to all collaborations. The dissemination of our confidential information could have a material adverse effect on our business.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>Our business may be impacted by political events, war, terrorism, business interruptions and other geopolitical events and uncertainties beyond our control.</i></b></p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 18pt;">War, terrorism, geopolitical uncertainties and other business interruptions could cause damage to, disrupt or cancel the conduct of our clinical studies on a global or regional basis, which could have a material adverse effect on our business, clinical sites or vendors with which we do business. Such events could also decrease patient demand to enroll in our clinical studies or make it difficult or impossible for us to deliver products and services to our clinical investigational sites. In addition, territorial invasions can lead to cybersecurity attacks on technology companies, such as ours, located far outside of the conflict zone. In the event of prolonged business interruptions due to geopolitical events, we could incur significant losses, require substantial recovery time and experience significant expenditures in order to resume our business or clinical operations. We have no operations in Israel,&#160;Russia or the Ukraine, but we do not and cannot know if the current uncertainties in these geopolitical areas may escalate and result in broad economic and security conditions or rationing of medical supplies, which could limit our ability to conduct clinical trials outside the U.S. or result in material implications for our business. In addition, our insurance policies typically contain a war exclusion of some description and we do not know how our insurers are likely to respond in the event of a loss alleged to have been caused by geopolitical uncertainties.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">&#160;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
      70
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -1pt;"><b><i>Our efforts to minimize the likelihood and impact of a cybersecurity incident may not be successful and our business could be negatively affected by a data breach or other cybersecurity threat or other disruption to our operations, which could result in legal claims against us or could give rise to substantial financial costs to redress any such cybersecurity incident and could harm our relationship with vendors,&#160;clinical study participants or regulators.</i></b></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -1pt; text-indent: 18pt;">Our business operation is data-intensive and relies extensively on the use of information technology. In addition, biopharmaceutical firms have been subject to an increasing number of cyberattacks in recent years, particularly cyberattacks targeting the theft of intellectual property and unauthorized access to proprietary clinical research data or sensitive patient information. Given the nature of our business, we are subject to a variety of evolving cybersecurity threats to our information technology infrastructure, including ransomware, unauthorized attempts to gain access to our operations or to sensitive patient information, denial-of-service attacks or various other methods of attacks. As discussed below, similar security threats may be faced by our vendors, consultants, suppliers, subcontractors, clinical investigational sites and non-clinical research labs.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -2pt; text-indent: 18pt;">Such cybersecurity threats are prevalent and continue to rise, are increasingly difficult to detect, and come from a variety of sources, including traditional computer &#8220;hackers,&#8221; threat actors, nation states and rogue nation-state actors. We could also be impacted by the improper cyber conduct of our employees or others working on behalf of us who have access to our proprietary information or sensitive patient information, which could adversely affect our business and reputation. The occurrence of any material cybersecurity incident could cause substantial disruptions to our business operations. In addition to cyber threats, we may face threats to the security of our facilities or executives, which could materially disrupt our business if carried out.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -2pt; text-indent: 18pt;">We also work cooperatively with numerous vendors, consultants, suppliers, subcontractors, clinical investigational sites and non-clinical research labs, which have access to our proprietary or sensitive information. These third parties, which are typically outside our control, may have varying levels of cybersecurity expertise and safeguards and our ability to monitor their cybersecurity practices is limited. These third parties may not have adequate cybersecurity measures in place, and incidents or other interruptions suffered by them could cause us to experience adverse consequences. In particular, cybersecurity incidents in our drug supply chain could have an adverse impact on our ability to timely deliver product candidates to patients and physicians participating in our clinical studies, which could cause us to delay or cancel the completion of our ongoing clinical and non-clinical studies.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -2pt; text-indent: 18pt;">If cybersecurity threats materialize and we or third-parties that we rely upon are unable to defend against them or to protect sensitive information, including through complying with evolving information security and data protection/privacy regulations, this could cause vendors, clinical study participants, clinical study investigation sites, patients, or governmental authorities to question the adequacy of the threat mitigation and detection processes and procedures that we and our vendors employ. Moreover, depending on the severity of an incident, our proprietary clinical research data, sensitive patient information, intellectual property, including trade secrets and research, development and technical know-how, could be compromised.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-indent: 18pt; text-align: justify;">Nearly all of our operations carry cybersecurity risks, including risks that they could be breached or that we could fail to detect, prevent or combat attacks, which could result in financial losses and claims against us, and could harm our relationships with our vendors or clinical study participants. The costs and expenses to respond to a material cybersecurity incident or other security threat or disruption may be substantial for a company of our size. Further, our&#160;cybersecurity commercial insurance policy covering potential financial losses that may occur in the event we experience a cybersecurity incident may not be sufficient to cover any related damages or losses.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&#160;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
      71
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>Risks Related to Financial Condition and Capital Requirements </b></p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>We have incurred significant net losses in each period since our inception and anticipate that we will continue to incur net losses for the foreseeable future. </i></b></p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">We have incurred net losses in each reporting period since our inception, including a net loss of $24.3&#160;million for the year ended December 31, 2024. As of December 31, 2024, we had an accumulated deficit of $405.1&#160;million.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">We have invested significant financial resources in research and development activities for product candidates. We do not expect to generate revenue from product sales for several years, if at all. The amount of our future net losses will depend, in part, on the level of our future expenditures and revenue. Moreover, our net losses may fluctuate significantly from quarter to quarter and year to year, such that a period-to-period comparison of our results of operations may not be a good indicator of our future performance.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">We expect to continue to incur operating expenses and&#160;losses for the foreseeable future. We anticipate our expenses will remain substantial as we: &#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">continue our research and discovery activities;</p> </td>
    </tr>

    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">advance our current and any future product candidates through preclinical and clinical development;</p> </td>
    </tr>

    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">initiate and conduct additional preclinical, clinical, or other studies for our product candidates;</p> </td>
    </tr>

    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">work with our CDMO&#8217;s for the&#160;manufacture&#160;of&#160;our product candidates;</p> </td>
    </tr>

    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">seek regulatory approvals and marketing authorizations for our product candidates;</p> </td>
    </tr>

    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">obtain, maintain, protect, defend and enforce our intellectual property portfolio;</p> </td>
    </tr>

    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">attract, hire, and retain qualified personnel;</p> </td>
    </tr>

    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">provide additional internal infrastructure to support our continued research and development operations and any planned commercialization efforts in the future;</p> </td>
    </tr>

    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">experience any delays or encounter other issues related to our operations;</p> </td>
    </tr>

    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">meet the requirements and demands of being a public company; and</p> </td>
    </tr>

    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">defend against litigation, claims or other uncertainties that may arise from allegations made against us or our collaborators.</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">Our prior losses and expected future losses have had and will continue to have an adverse effect on our stockholders&#8217; equity and working capital. In any quarter, our operating results could be below the expectations of securities analysts or investors, which could cause our stock price to decline.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>We have broad discretion in the use of </i></b><b><i>our capital resources, including </i></b> <b><i>the net proceeds from any of our financing transactions, and we may not use them effectively. </i></b></p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">We have broad discretion in the application of our capital resources, including the net proceeds from our financing transactions, and investors will not have the opportunity to opine on whether such resources are being used appropriately. We could spend such capital resources in ways that vary substantially from their initially communicated intended use, do not improve our results of operations or enhance the value of our common stock. Our failure to apply these funds effectively could result in financial losses that could have a material adverse effect on our business, cause the price of our common stock to decline and delay the development of our product candidates. Pending their use, we may invest available capital resources, including net proceeds from our financing transactions, in a manner that does not produce income or that loses value.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&#160;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
      72
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>We have no product revenues and may never achieve revenues or profitability based on product revenues. </i></b></p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">We have no products approved for commercial sale. To obtain revenues from the sales of our product candidates that are significant or large enough to achieve profitability, we must succeed, either alone or with third parties, in developing, obtaining regulatory approval for, manufacturing, and marketing product candidates with significant commercial value. This is a significant endeavor that few early-stage biopharmaceutical companies can successfully achieve. Our ability to generate revenue and achieve profitability depends on many factors, including:</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">completing research and preclinical and clinical development of our product candidates;</p> </td>
    </tr>

    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">obtaining regulatory approvals and marketing authorizations for product candidates for which we successfully complete clinical development;</p> </td>
    </tr>

    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">developing a sustainable and scalable manufacturing process for our product candidates, as well as establishing and maintaining commercially viable supply relationships with third parties that can provide adequate products and services to support clinical activities and commercial demand for our product candidates;</p> </td>
    </tr>

    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">identifying, assessing, acquiring, and/or developing new product candidates;</p> </td>
    </tr>

    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">negotiating favorable terms in any collaboration, licensing, or other arrangements into which we may enter;</p> </td>
    </tr>

    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">addressing any competing technological and market developments;</p> </td>
    </tr>

    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">maintaining, protecting, expanding, and enforcing our portfolio of intellectual property rights, including patents, trade secrets, and know-how; and</p> </td>
    </tr>

    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">attracting, hiring, and retaining qualified personnel.</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">Because of the numerous risks and uncertainties associated with drug development, we are unable to predict the timing or amount of our expenses, or when we will be able to generate any meaningful revenue or achieve or maintain profitability, if ever. In addition, our expenses could increase beyond our current expectations if we are required by FDA or foreign regulatory agencies to perform studies in addition to those that we currently anticipate, or if there are any delays in any of our clinical studies or the development of any of our product candidates.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>We may require additional capital to fund our operations and to complete the development of our product candidates. A failure to obtain this necessary capital on acceptable terms, or at all, could force us to delay, limit, reduce, or terminate our commercialization efforts, product development, or other operations. </i></b></p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">Our operations have required substantial amounts of cash since inception, and we expect our expenses to remain substantial for the foreseeable future. To date, we have financed our operations primarily through the sale of equity securities, research grants and payments received from prior third-party collaborations. Developing our product candidates and conducting clinical studies for the treatment of neurodegenerative diseases, including Alzheimer&#8217;s disease, will require substantial amounts of capital. We will also require a significant amount of capital to commercialize any approved products.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">As of December 31, 2024, we had cash and cash equivalents of $128.6&#160;million.&#160;Based on our current operating plan, we believe that our existing cash and cash equivalents will be sufficient to fund our projected operations for at least the next 12&#160;months. Our estimate as to how long we expect our existing cash and cash equivalents to be available to fund our operations is a forward-looking statement, based on assumptions that may prove inaccurate, and we could use our available capital resources sooner than we currently expect. In addition, changing circumstances may cause us to increase our spending significantly faster than we currently anticipate, and we may need to spend more money than currently expected because of currently unanticipated circumstances, which may be beyond our control. We may need to raise additional funds sooner than we anticipate if we choose to expand more rapidly than we presently anticipate.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
      73
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">We may require additional capital for the further development of our product candidates. Additional capital may not be available when we need it, or on terms acceptable to us or at all. We have no committed source of additional capital. If adequate capital is not available to us on a timely basis, we may be required to significantly delay, limit, reduce or terminate our research and development programs or the commercialization of product candidates, if approved, or be unable to continue or expand our operations, or otherwise capitalize on our business opportunities, as desired, which could materially affect our business, financial condition, results of operations, and growth prospects and cause the price of our common stock to decline.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">To the extent that we raise additional capital through the sale of equity or convertible debt securities, the ownership interest of our stockholders will be diluted, and the terms of these securities may include liquidation or other preferences that adversely affect your rights as a common stockholder. Debt financing, if available, may involve agreements that include covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures, or declaring dividends. If we raise additional funds through collaborations, strategic alliances, or licensing arrangements with pharmaceutical partners, we may have to relinquish valuable rights to our technologies, future revenue streams, research programs, or product candidates, or grant licenses on terms that may not be favorable to us.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>Global credit and financial market conditions could negatively impact the value of our portfolio of cash equivalents and our ability to meet our financing objectives.</i></b></p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">Our cash and cash equivalents are generally maintained in highly liquid investments with original maturities of three months&#160;or less at the time of purchase. While, as of the date of this filing, we are not aware of any downgrades, material losses, or other significant deterioration in the fair value of our cash equivalents since December 31, 2024, no assurance can be given that deterioration in conditions of the global credit and financial markets&#160;would not negatively impact our current portfolio of cash equivalents or our ability to meet our financing objectives.</p>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>Risks Related to the Ownership of Our Common Stock</b></p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>We do not know whether a sufficient market will continue to </i></b><b><i>develop for our securities or what the market price of our securities will be, and, as a result, it may be difficult for investors to sell shares of our common stock. </i></b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify; text-indent: 18pt;">If a market for our common stock is not sustained, it may be difficult to sell shares of our common stock at an attractive price or at all. We cannot predict the prices at which our common stock will trade. It is possible that in one or more future periods our results of operations and progression of our product pipeline may not meet the expectations of public market analysts and investors, and, as a result of these and other factors, the price of our common stock may fall.</p>
  <p style="text-align: justify; font-size: 10pt; font-family: &quot;Times New Roman&quot;; margin: 0pt;">&#160;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
      74
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>The market price of our common stock has historically been highly volatile, and we expect it to continue to be volatile, which could result in substantial losses for investors who purchase our shares. </i></b></p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-indent: 18pt; text-align: justify;">The market price of our common stock has historically been highly volatile.&#160;For example, the closing price of our common stock has fluctuated from a low of $2.27&#160;to a high of $35.08&#160;over the 12 months preceding the filing date of this Annual Report on Form 10-K. Some of the factors that may cause the market price of our common stock to fluctuate include:</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 36pt;text-indent:-18pt;">&#160;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">the success of existing or new competitive products or technologies;</p> </td>
    </tr>

    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">the timing and results of clinical studies for our current product candidates and any future product candidates that we may develop;</p> </td>
    </tr>

    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">failure or discontinuation of any of our product development and research programs;</p> </td>
    </tr>

    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">results of preclinical studies, clinical studies, or regulatory approvals of product candidates of our competitors, or announcements about new research programs or product candidates of our competitors;</p> </td>
    </tr>

    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">regulatory or legal developments in the United States and other countries;</p> </td>
    </tr>

    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">developments or disputes concerning patent applications, issued patents, or other proprietary rights;</p> </td>
    </tr>

    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">the recruitment or departure of key personnel;</p> </td>
    </tr>

    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">the level of expenses related to any of our research programs, clinical development programs, or product candidates that we may develop;</p> </td>
    </tr>

    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">the results of our efforts to develop additional product candidates or products;</p> </td>
    </tr>

    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">actual or anticipated changes in estimates as to financial results or development timelines;</p> </td>
    </tr>

    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">announcement or expectation of additional financing efforts;</p> </td>
    </tr>

    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">sales of our common stock by us, our insiders, or other stockholders;</p> </td>
    </tr>

    <tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
     <td style="width: 18pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="width: 18pt; vertical-align: top; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</td>
     <td style="width: auto; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Short&#160;selling of our stock, in which a seller sells shares of our stock that the seller has borrowed from a third party, which often occurs when a short seller expects the price of our common stock to decline;</td>
    </tr>

    <tr style="vertical-align: top; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
     <td style="width: 18pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="width: 18pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p> </td>
     <td style="width: auto; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">variations in our financial results or those of companies that are perceived to be similar to us;</p> </td>
    </tr>

    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">changes in estimates or recommendations by securities analysts, if any, that cover our stock;</p> </td>
    </tr>

    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">market conditions in the pharmaceutical and biotechnology sectors;</p> </td>
    </tr>

    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">general economic, industry, and market conditions; and</p> </td>
    </tr>

    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">securities litigation, regardless of merit.</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">In recent years, the stock market in general, Nasdaq, and the markets for early-stage companies and pharmaceutical and biotechnology companies&#160;have&#160;experienced significant price and volume fluctuations that have often been unrelated or disproportionate to changes in the operating performance of the companies whose stock is experiencing those price and volume fluctuations. Broad market and industry factors may seriously affect the market price of our common stock, regardless of our actual operating performance. Following periods of such volatility in the market price of a company&#8217;s securities, securities class action litigation has often been brought against that company. Because of the potential volatility of our stock price, we are currently and may become the target of securities litigation in the future. Securities litigation could result in substantial costs and divert management&#8217;s attention and resources from our business.</p>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>If securities analysts do not publish research or reports about our business, or we are the subject of negative publicity, the price of our stock could decline. </i></b></p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">The trading market for our securities depends, in part, on the research and reports that securities or industry analysts publish about us or our business. We do not control these analysts. If one or more of the analysts who cover us downgrade our stock or publish inaccurate or unfavorable evaluations of our company or our stock, the price of our securities could decline. If one or more of these analysts cease coverage of our company or fail to publish reports covering our company regularly, our stock may lose visibility in the market, which in turn could cause the price of our securities to decline. In addition, if we are the subject of negative publicity, whether from an analyst, academic, social media, industry group or the general or financial press, the price of our securities may decline.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&#160;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
      75
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>General Risk Factors</i></b></p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>If we are unable to maintain effective internal controls, our business, financial position, and results of operations could be adversely affected. </i></b></p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">As a&#160;smaller reporting company, our independent registered public accounting firm is not required to conduct, and has not conducted, an audit of our internal control over financial reporting. It is possible that, had our independent registered public accounting firm conducted an audit of our internal control over financial reporting, such firm might have identified material weaknesses and deficiencies that we have not identified. If we or our independent auditors discover a material weakness, the disclosure of that fact, even if quickly remedied, could adversely affect the market price and trading liquidity of our common stock, cause investors to lose confidence in our financial reporting and generally materially adversely impact our business and financial condition.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">The rules governing the standards that must be met for management to assess our internal control over financial reporting are complex and require significant documentation, testing and possible remediation to meet the detailed standards under the rules. During testing, our management may identify material weaknesses or deficiencies which may not be remedied in time to meet the deadline imposed by SOX. These reporting and other obligations place significant demands on our management and administrative and operational resources, including accounting resources.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">Our management is responsible for establishing and maintaining adequate internal control over financial reporting. Our internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of consolidated financial statements for external purposes in accordance with accounting principles generally accepted in the U.S. Any failure to maintain effective internal controls, or if our independent registered public accounting firm is unable to attest to the effectiveness of our internal control over financial reporting, could have an adverse effect on our business, financial position, and results of operations.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>Anti-takeover provisions in our charter documents and Delaware law may prevent or delay removal of incumbent management or a change of control. </i></b></p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">Anti-takeover provisions of our amended and restated certificate of incorporation and amended and restated bylaws and Delaware law may have the effect of deterring or delaying attempts by our stockholders to remove or replace management, engage in proxy contests and effect changes in control.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">Key provisions of our current charter documents include:</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 36pt;text-indent:-18pt;">&#160;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">a classified board so that only one of the three classes of directors on our Board of Directors (the &#8220;Board&#8221;) is elected each year;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">elimination of cumulative voting in the election of directors;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">procedures for advance notification of stockholder nominations and proposals;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">the ability of the Board to amend our bylaws without stockholder approval; and</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">the ability of the Board to issue up to 10,000,000 shares of preferred stock without stockholder approval upon the terms and conditions and with the rights, privileges and preferences as the Board may determine.</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">In addition, as a Delaware corporation, we are subject to Delaware law, including Section 203 of the Delaware General Corporation Law. In general, Section 203 prohibits a Delaware corporation from engaging in any business combination with any interested stockholder for a period of three years following the date that the stockholder became an interested stockholder unless certain specific requirements are met as set forth in Section 203.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">These provisions, alone or together, could have the effect of deterring or delaying changes in incumbent management, proxy contests or changes in control.</p>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>Our amended and restated bylaws provide that the federal district courts of the United States of America shall be the exclusive forum for the resolution of any complaint asserting a cause of action arising under the Securities Laws of 1933, which could limit our stockholders</i></b>&#8217;<b><i> ability to obtain a favorable judicial forum for disputes with us or our directors, officers or employees.</i></b></p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:28pt;">&#160;</p>
  <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 18pt;">Our amended and restated bylaws provide that the federal district courts of the United States of America shall be the exclusive forum for the resolution of any complaint asserting a cause of action arising under the Securities Act of 1933.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:28pt;">&#160;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
      76
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
  <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 18pt;">While the Delaware courts have determined that such choice of forum provisions are valid, a stockholder may nevertheless seek to bring a claim in a venue other than those designated in the exclusive forum provisions. In such instance, we would expect to vigorously assert the validity and enforceability of the exclusive forum provisions of our amended and restated bylaws. This may require significant additional costs associated with resolving such action in other jurisdictions and there can be no assurance that the provisions will be enforced by a court in those other jurisdictions.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:28pt;">&#160;</p>
  <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 18pt;">These exclusive-forum provisions may limit a stockholder&#8217;s ability to bring a claim in a judicial forum that it finds favorable for disputes with us or our directors, officers or other employees, which may discourage these types of lawsuits. Furthermore, the enforceability of similar choice of forum provisions in other companies&#8217; certificates of incorporation or bylaws has been challenged in legal proceedings, and it is possible that a court could find these types of provisions to be inapplicable or unenforceable. If a court were to find the exclusive-forum provision contained in our amended and restated bylaws to be inapplicable or unenforceable in an action, we may incur further significant additional costs associated with resolving such action in other jurisdictions, all of which could harm our business.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>Changes in our ownership could limit our ability to utilize net operating loss carryforwards.</i></b></p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">As of December 31, 2024, we had aggregate federal net operating loss carryforwards of approximately $205.5&#160;million, which begin to expire in 2029. Under Section 382 of the Internal Revenue Code of 1986, as amended, changes in our ownership may limit the amount of our net operating loss carryforwards that could be utilized annually to offset our future taxable income, if any. This limitation would generally apply in the event of a cumulative change in ownership of our company of more than 50% within a rolling three-year period. Any such limitation may significantly reduce our ability to utilize our net operating loss carryforwards and tax credit carryforwards. Any such limitation, whether as the result of past offerings, sales of our common stock by our existing stockholders, the issuance of shares of common stock&#160;as a result of the exercise of warrants or additional sales of our common stock by us in the future could have a material adverse effect on our results of operations in future years. We have not completed a study to assess whether an ownership change for purposes of Section 382 has occurred.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>We may sell additional equity or debt securities to fund our operations, and have outstanding securities exercisable for our common stock, which may result in dilution to our stockholders and impose restrictions on our business.</i></b></p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">In order to raise additional capital to support our operations, we may sell additional shares of our common stock or other securities convertible into or exchangeable for our common stock which could result in dilution our stockholders.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">We cannot assure you that we will be able to sell shares or other securities in any other offering at a price per share that is equal to or greater than the price per share paid by investors in prior offerings, and investors purchasing our shares or other securities in the future could have rights superior to existing shareholders. The price per share at which we sell additional shares of our common stock or securities convertible into or exchangeable for our common stock in future transactions may be higher or lower than the price per share in prior offerings. You may also be diluted upon the exercise of outstanding stock options as of December 31, 2024&#160;to purchase approximately 4.5&#160;million&#160;shares of our common stock at a weighted average price of $20.15&#160;per share and&#160;the future issuance of up to approximately 1.0&#160;million&#160;compensatory equity awards authorized under our 2018 Omnibus Incentive Plan. The issuance of such additional shares of common stock or the perception that issuances could occur, could result in significant downward pressure on our stock price.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>The estimates and judgments we make, or the assumptions on which we rely, in preparing our consolidated financial statements could prove inaccurate.</i></b></p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">Our consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the U.S. The preparation of these consolidated financial statements requires us to make estimates and judgments that affect the reported amounts of our assets, liabilities and expenses, the amounts of charges accrued by us and related disclosure of contingent assets and liabilities. Such estimates and judgments include development expenses, valuation of stock-based awards and income tax. We base our estimates on historical experience, facts and circumstances known to us and on various other assumptions that we believe to be reasonable under the circumstances. We cannot provide assurances, however, that our estimates, or the assumptions underlying them, will not change over time or otherwise prove inaccurate. If this is the case, we may be required to restate our consolidated financial statements, which could, in turn, subject us to securities class action litigation. Defending against such potential litigation relating to a restatement of our consolidated financial statements would be expensive and would require significant attention and resources of our management. Moreover, our insurance to cover our obligations with respect to the ultimate resolution of any such litigation may be inadequate. As a result of these factors, any such potential litigation could have a material adverse effect on our financial results and cause our stock price to decline, which could in turn subject us to securities class action litigation.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
      77
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <div>
   &#160;
  </div>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><a id="item1b" title="item1b" href="#"></a>Item 1B. </b>&#160;&#160;&#160;&#160;<b><i>Unresolved Staff Comments</i></b></p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">None.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><a id="item1c" title="item1c" href="#"></a>Item 1C. </b>&#160;&#160;&#160;&#160;<b><i>Cybersecurity</i></b></p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&#160;</p>
  <div>
   &#160;
  </div>
  <ix:nonNumeric contextRef="d_2024-01-01_2024-12-31" name="cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" id="c2851673" escape="true">
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -1pt;"><i>Risk Management and Strategy</i></p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -1pt;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -1pt; text-indent: 18pt;">In the normal course of business, we collect and store sensitive information, including proprietary and confidential business information, intellectual property, information regarding clinical and non-clinical trials, sensitive <em style="font: inherit;">third</em>-party information and employee information.</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -1pt; text-indent: 18pt;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -2pt; text-indent: 18pt;"><ix:nonNumeric contextRef="d_2024-01-01_2024-12-31" name="cyd:CybersecurityRiskManagementProcessesIntegratedTextBlock" id="c123855783">We have processes designed to protect our information systems, data, assets, infrastructure, and computing environments from cybersecurity threats and risks. Our cybersecurity strategy includes the use of managed detection and response services to monitor our network infrastructure and associated endpoints for possible cybersecurity threats. In addition, we use multi-factor authentication, perform periodical penetration testing and other logical, physical and technical controls designed to deter, prevent, mitigate and respond to cybersecurity threats. Further, our information systems include continuous alert plans, and we provide periodical cybersecurity reminders to our employees to emphasizes the importance of adherence to our security policies.</ix:nonNumeric></p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -2pt; text-indent: 18pt;">We conduct organizational risk assessment, which help management in identifying data assets and recognizing and assessing potential threats, and investigating potential vulnerabilities. We are in the process of reviewing and <span style="-sec-ix-hidden:c123855784">implementing</span> incremental information technology strategies to mitigate cybersecurity risks and their possible impacts. Risk assessments enable management to make risk management decisions and assign resources to mitigate risk. We also periodically engage <span style="-sec-ix-hidden:c123855379">third</span> parties to assess the effectiveness of our cybersecurity practices.</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;">&#160;</p>
   <ix:nonNumeric contextRef="d_2024-01-01_2024-12-31" name="cyd:CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock" id="c123855785">As of the date of this Annual Report, we do not believe that any past cybersecurity incidents that have been detected have materially affected, or are reasonably likely to materially affect, our business strategy, results of operations, or financial condition.</ix:nonNumeric><p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -2pt; text-indent: 18pt;"></p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -1pt; text-indent: 18pt;">See &#8220;Risk Factors - Risks Related to Our Business and Operations&#8221; for additional information about the risks to our business associated with cybersecurity or a breach or compromise to our information security systems.</p>
  </ix:nonNumeric>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -1pt; text-indent: 18pt;">&#160;</p>
  <div>
   &#160;
  </div>
  <ix:nonNumeric contextRef="d_2024-01-01_2024-12-31" name="cyd:CybersecurityRiskBoardOfDirectorsOversightTextBlock" id="c2851674" escape="true">
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -20pt; text-indent: 18pt;"><i>Governance</i></p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -2pt; text-indent: 18pt;"><ix:nonNumeric contextRef="d_2024-01-01_2024-12-31" name="cyd:CybersecurityRiskRoleOfManagementTextBlock" id="c123855786">Our Director of Information Technology has responsibilities which include preventing and monitoring cybersecurity threats and utilizes the assistance of external vendors in this effort. Our Director of Information Technology regularly reports to senior management regarding the status of our cybersecurity program, emerging cybersecurity threats, long-term cybersecurity investments and strategies, and oversight of our cybersecurity profile.</ix:nonNumeric></p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -2pt; text-indent: 18pt;"><span style="-sec-ix-hidden:c123855789"><ix:nonNumeric contextRef="d_2024-01-01_2024-12-31" name="cyd:CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" id="c123855790">Our full Board of Directors oversees the risk management process for the Company, which includes identifying, assessing and managing enterprise-level risks. The Board administers this oversight function directly through the Board of Directors as a whole, as well as through its standing committees that address risks inherent in their respective areas of oversight. The risk oversight responsibility of the Board of Directors and its committees is supported by the management reporting processes, which are designed to provide visibility to the Board of Directors and to the personnel who are responsible for risk assessment and information about the identification, assessment and management of critical risks, and management&#8217;s risk mitigation strategies. Our cybersecurity risk program directly integrates and is intended to align with the Board of Directors&#8217; overall risk management process.</ix:nonNumeric></span></p>
  </ix:nonNumeric>
  <p style="margin: 0pt 0pt 0pt -9pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><a id="item2" title="item2" href="#"></a>Item</b>&#160;<b>2. </b>&#160;&#160;&#160;&#160;<b><i>Properties</i></b></p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">We own an office complex in Austin, Texas, a portion of which serves as our corporate headquarters. Maintenance, physical facilities, leasing, property management and other key responsibilities related to property ownership are outsourced to professional real-estate managers. The office complex measures approximately 90,000 rentable square feet.&#160;We occupied approximately 25% of the property as of December 31, 2024.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
      78
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
  <div>
   &#160;
  </div>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><a id="item3" title="item3" href="#"></a>Item</b>&#160;<b>3. </b>&#160;&#160;&#160;&#160;<b><i>Legal Proceedings</i></b></p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify; text-indent: 18pt;">We are, and&#160;from time to time, we may become involved in litigation or other legal proceedings and claims, including U.S. government inquiries, investigations and Citizen Petitions submitted to FDA. In addition, we have received and from time to time&#160;may receive inquiries from government authorities relating to matters arising from the ordinary course of business. The outcome of these proceedings is inherently uncertain. Regardless of outcome, legal proceedings can have an adverse impact on us because of defense and settlement costs, diversion of management resources, and other factors. At this time, no assessment can be made as to their likely outcome or whether the outcome will be material to us. We&#160;believe&#160;that our&#160;total provisions for legal matters are adequate based upon currently available information.&#160;Additional information regarding our legal proceedings is included in this Annual Report on Form 10-K&#160;in Note 12&#160;to our condensed consolidated financial statements entitled, &#8220;Contingencies.&#8221;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <div>
   &#160;
  </div>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><a id="item4" title="item4" href="#"></a>Item 4. </b>&#160;&#160;&#160;&#160;<b><i>Mine Safety Disclosures</i></b></p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">Not applicable.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>PART II</b></p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&#160;</p>
  <div>
   &#160;
  </div>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><a id="item5" title="item5" href="#"></a>Item 5.</b>&#160;&#160;&#160;&#160;<b><i>Market for Registrant's Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities</i></b></p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>Market Information</b></p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">Our common stock is quoted on Nasdaq, under the symbol "SAVA."</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>Holders</b></p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">As of February 20, 2025, there were approximately 26&#160;registered holders of record of our common stock. We believe the actual number of stockholders is greater than this number of record holders and includes stockholders who are beneficial owners but whose shares are held in street name by brokers and other nominees.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>Sales of Non-Registered Securities</b></p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">None.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>Purchases of Equity Securities by the Issuer</b></p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">None.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&#160;</p>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>Dividend Policy</b></p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">We currently expect to retain future earnings, if any, for use in the operation and expansion of our business and, notwithstanding our special non-dividend distributions in December 2012 (of $0.75 per share of common stock totaling $34.0&#160;million) and December 2010 (of $2.00 per share of common stock totaling $85.7&#160;million), we do not anticipate paying any cash dividends in the foreseeable future.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
      79
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Stock Performance Graph</b></p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:28pt;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-indent: 18pt;">We are a smaller reporting company as defined by Rule 12b-2 of the Exchange Act and are not required to provide the information required under this item.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><a id="item6" title="item6" href="#"></a>Item 6.</b>&#160;&#160;&#160;&#160;<b><i>[Reserved]</i></b></p>
  <p style="font-size: 10pt; font-family: &quot;Times New Roman&quot;; margin: 0pt;">&#8206;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
      80
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <div>
   &#160;
  </div>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><a id="item7" title="item7" href="#"></a>Item 7.</b>&#160;&#160;&#160;&#160;<b><i>Management</i></b>&#8217;<b><i>s Discussion and Analysis of Financial Condition and Results of Operations</i></b></p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"><i>This discussion and analysis</i> <i>of our financial condition and results of operations should be read in conjunction with our consolidated financial statements and accompanying notes included elsewhere in this Annual Report on Form 10-K. This discussion contains forward-looking statements that involve risk and uncertainties, such as statements of our plans, objectives, expectations, and intentions, that are based on the beliefs of our management. Operating results are not necessarily indicative of results that may occur in future periods. Factors that could cause or contribute to such differences include, but are not limited to, those discussed in the </i>&#8220;<i>Risk Factors</i>&#8221;<i> section of this Annual Report on Form 10-K.</i></p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>Overview </b></p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">Cassava Sciences, Inc. is a clinical-stage biotechnology company based in Austin, Texas. Our mission is to detect and treat central nervous system disorders, such as Alzheimer&#8217;s disease and TSC-related epilepsy. Our novel science is based on stabilizing &#8211; but not removing &#8211; a critical protein in the brain for patients with certain central nervous system disorders, such as Alzheimer&#8217;s or TSC.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -1pt; text-indent: 18pt;">Our lead therapeutic drug candidate, simufilam, was&#160;under clinical evaluation for the proposed treatment of Alzheimer&#8217;s disease&#160;in Phase 3 clinical studies through 2024, when all ongoing clinical trials for simufilam in Alzheimer&#8217;s disease were discontinued.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-indent: 18pt;">We combine innovative&#160;technology with new insights in neurobiology to develop novel solutions targeting&#160;Alzheimer&#8217;s disease, TSC-related epilepsy,&#160;and other central nervous system disorders. Our strategy is to leverage our unique scientific/clinical platform to develop first-in-class programs for treating central nervous system disorders.&#160;In addition, we are in the early stages of exploring potential artificial intelligence (&#8220;AI&#8221;) capabilities and related data analytics to target improvements in productivity and efficiency in our business, enhancements to research and development activities, and advancements in statistical analysis capabilities.&#160;</p>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">We currently have two biopharmaceutical assets under development:</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 36pt;text-indent:-18pt;">&#160;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">our lead therapeutic product candidate, called simufilam, is a proprietary small molecule oral treatment drug being studied&#160;for the treatment of Alzheimer&#8217;s disease and TSC-related epilepsy; and</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">our lead investigational diagnostic product candidate, called SavaDx, is a novel way to detect the presence of Alzheimer&#8217;s disease from a small sample of blood.</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 18pt;">Simufilam targets a protein called filamin A (FLNA) in the brain of patients with central nervous system disorders, such as Alzheimer&#8217;s or TSC. Our and our collaborators' published studies have demonstrated that the altered form of FLNA is linked to&#160;neuronal dysfunction, neuronal degeneration and neuroinflammation.&#160; In Alzheimer&#8217;s disease, we&#160;believe&#160;simufilam disrupts amyloid binding to the &#945;7 nicotinic acetylcholine receptor (&#945;7nAChR), which underlies our drug&#8217;s primary mechanism of action in Alzheimer&#8217;s disease. Published pre-clinical studies further show that overexpression of FLNA in patients with TSC may be associated with epileptic seizure activity.&#160;On February 26, 2025, we entered into a License Agreement&#160;with Yale to support our development and commercialization efforts for simufilam for the treatment of TSC-related epilepsy.&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify; text-indent: 18pt;">We solely own patents covering the composition of matter of our drug simufilam in the United States, Europe, Australia, Israel and Canada. We solely own patents covering certain methods of use of our drug simufilam in the United States, Europe and Japan. We solely own pending patent applications that cover diagnostic assets for simufilam in the United States, Europe, Japan, China, Canada, and Australia. We solely own pending patent applications that cover other diagnostic assets in the United States, Europe, Japan, China and Canada. We have no obligation to pay any royalty to any third party in connection with any of the foregoing described patents and patent applications. In the United States, our patent protection with respect to simufilam, its solid forms, and uses of simufilam for Alzheimer&#8217;s disease and other neurodegenerative diseases includes nine issued United States patents, with terms expiring on dates ranging from 2029 to 2040, subject to any patent extensions that may be available for such patents. Corresponding foreign filings have been made for each of the Unites States filings.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -2pt;"><b>Clinical Trials in Alzheimer</b>&#8217;<b>s Disease&#160;(Discontinued)</b></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-indent: 18pt; text-align: justify;">We have conducted two randomized placebo-controlled Phase 3 clinical trials of oral simufilam in patients with mild-to-moderate Alzheimer&#8217;s disease. Our first Phase 3 study, called RETHINK-ALZ, was designed to evaluate the safety and efficacy of simufilam 100 mg tablets versus placebo over 52 weeks (NCT04994483). Our second Phase 3 study, called REFOCUS-ALZ, was designed to evaluate the safety and efficacy of oral simufilam 100 mg and 50 mg tablets versus placebo over 76 weeks (NCT05026177).</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;">&#160;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
      81
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-indent: 18pt; text-align: justify;">On November 25, 2024, we announced that the top-line results from the Phase 3 RETHINK-ALZ study of simufilam in mild-to-moderate Alzheimer&#8217;s disease did not meet each of the pre-specified co-primary, secondary and exploratory biomarker endpoints. The co-primary endpoints were the change in cognition and function from baseline to the end of the double-blind treatment period at week 52, assessed by the ADAS-COG12 and ADCS-ADL scales, comparing simufilam to placebo.&#160;Simufilam continued to demonstrate an overall favorable safety profile.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -4pt; text-indent: 18pt;">In light of the top-line results from the Phase 3 RETHINK-ALZ study, the Company also outlined its plan to discontinue the Phase 3 REFOCUS-ALZ study and Open Label Extension study and to analyze the complete 52-week dataset from the REFOCUS-ALZ study, along with a large portion of 76-week data. The Company expects to release top-line REFOCUS-ALZ results late first-quarter/early second-quarter 2025.&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;">Following the release of the topline REFOCUS-ALZ results, the Company intends to evaluate the results and determine the next steps for the future advancement, if any, of its Alzheimer&#8217;s program.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 8pt;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -18pt; text-indent: 18pt;"><b>Exploratory Preclinical Studies with Simufilam in Tuberous Sclerosis Complex (TSC)</b></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -4pt; text-indent: 18pt;">Preclinical research&#160;conducted at Yale indicate that simufilam (then PTI-125) may be effective in reducing TSC-related seizure activity. A study conducted by Angelique Bordey, PhD, at Yale&#160;and published in the peer-reviewed journal <i>Neuron</i> found overexpression of FLNA in brain tissue from TSC patients.&#160;The paper, MEK-ERK1/2-Dependent FLNA Overexpression Promotes Abnormal Dendritic Patterning in Tuberous Sclerosis Independent of mTOR (<i>Neuron</i>. 2014 Oct 1. PMID: 25277454), was co-authored by Zhang L, Bartley CM, Gong X, Hsieh LS, Lin TV and Feliciano DM.&#160; A later study conducted by Dr. Bordey and published in the peer-reviewed journal <i>Science Translational Medicine</i> in 2020 likewise found elevated FLNA in brains of a related mouse model. That study further demonstrated that simufilam treatment in the mouse model reduced the number of seizing mice and reduced seizure frequency. This 2020 paper, Filamin A Inhibition Reduces Seizure Activity in a Mouse Model of Focal Cortical Malformations&#160;(<i>Sci Transl Med</i>. 2020 Feb 19. PMID: 32076941), was co-authored by Zhang L, Huang T, Teaw S, Nguyen LH, Hsieh LS, Gong X, and Lindsay Burns, a former employee of the Company.&#160;While these data are promising, understanding their true significance requires additional exploration.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -4pt; text-indent: 18pt;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -4pt; text-indent: 18pt;">We intend to conduct exploratory preclinical studies in collaboration with the TSCA to better understand simufilam&#8217;s potential as a treatment for TSC-related seizures. Based on the results of these studies, considered together with Dr. Bordey&#8217;s work, the Company will assess whether sufficient support exists for an Investigational New Drug (IND) application in respect of a proof-of-concept open-label clinical trial for simufilam in TSC-related epilepsy.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -4pt; text-indent: 18pt;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -20pt; text-indent: 17pt;"><i>License Agreement with Yale</i></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -2pt; text-indent: 17pt;">On February 26, 2025, we entered into the License Agreement with Yale pursuant to which we were granted exclusive worldwide rights, with rights to sublicense, to Yale&#8217;s interest in certain patent and other intellectual property rights that could be useful or necessary to the development and commercialization of simufilam for the treatment of TSC-related epilepsy and other potential indications. Pursuant to the License Agreement, we have agreed to use reasonable commercial efforts to implement a plan that it has designed for such development and commercialization.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -2pt; text-indent: 17pt;">In exchange for the rights acquired pursuant to the License Agreement, we agreed to pay Yale (i) a nominal&#160;upfront license fee, (ii) payments upon the achievement of specified clinical, regulatory and commercial milestones, totaling up to $4.5 million and (iii) upon transfer to a third party of a regulatory priority review voucher, if issued,&#160; a low-to-mid double digit percentage of any consideration received for such transfer. We also agreed to pay Yale tiered royalties, ranging from a low- to mid- single digit percentage, on aggregate net sales of licensed products, subject to tiered minimum annual royalty payments ranging from the low- to mid- hundreds of thousands of dollars.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -2pt; text-indent: 17pt;">Unless earlier terminated, the License Agreement will continue on a country-by-country basis until the later of (i) the date on which the last valid claim of the license patents expires or otherwise lapses, (ii) the end of any government or regulatory exclusivity period, and (iii) 10 years following the date of first sale of licensed product in such country. We may terminate the License Agreement: (i) at our option, upon specified advance notice to Yale and (ii) if Yale commits a material breach of the License Agreement that is not cured within a specified timeframe.&#160; Yale may terminate the License Agreement under specified circumstances, including if we (i) fail to make any payment due under the License Agreement and fail to cure such non-payment within a specified timeframe, (ii) commit a breach of the License Agreement that is not cured within a specified timeframe, (iii) default on a material obligation to any creditor, unless cured within a specified timeframe, (iv) fail to obtain or maintain insurance required by the License Agreement, (v) bring or assist a patent challenge against Yale (or if a sublicensee does so). In addition, the License Agreement will terminate automatically upon the occurrence of certain bankruptcy and insolvency events involving us.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;">&#160;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
      82
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt;">The License Agreement includes customary confidentiality, reporting and inspection, and indemnification provisions.</p>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>Financial Overview</b></p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">We have yet to generate any revenues from product sales. We have an accumulated deficit of $405.1&#160;million at December 31, 2024. These losses have resulted principally from costs incurred in connection with research and development activities, salaries and other personnel-related costs and general corporate expenses. Research and development activities include costs of preclinical and clinical studies as well as clinical supplies associated with our product candidates. Salaries and other personnel-related costs include stock-based compensation associated with options and other equity awards granted to employees and non-employees. Our operating results may fluctuate substantially from period to period as a result of the timing of preclinical activities, enrollment rates of clinical studies for our product candidates and our need for clinical supplies.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">We believe that our cash and cash equivalents at December 31, 2024, will enable us to fund our operating expenses for at least the next 12 months. In addition, we may seek in the future to fund our operations through additional public or private equity or debt financings or other sources. However, we may be unable to raise additional funds or enter into such other arrangements when needed on favorable terms or at all. If we are unable to obtain financing or reach profitability, the related lack of liquidity will have a material adverse effect on our operations and future prospects, and we may have to significantly delay, scale back or discontinue the development and commercialization of simufilam, our lead drug candidate, or delay our efforts to expand our product pipeline.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">We expect to continue to use significant cash resources in our operations for the next several years. Our cash requirements for operating activities and capital expenditures may increase in the future as we:</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 36pt;text-indent:-18pt;">&#160;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">evaluate, and potentially discontinue, our existing&#160;Phase 3 program with simufilam in Alzheimer's disease;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">conduct other preclinical and clinical studies for our product candidates, including simufilam for TSC-related epilepsy;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">seek regulatory approvals for our product candidates;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">develop, formulate, manufacture and commercialize our product candidates;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">implement additional internal systems and develop new infrastructure;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">acquire or in-license additional products or technologies, or expand the use of our technology;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">maintain, defend and expand the scope of our intellectual property; and</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">expend resources related to legal proceedings and claims, including U.S. government inquiries.</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">Product revenue will depend on our ability to receive regulatory approvals for, and successfully market, our product candidates. If our development efforts result in regulatory approval and successful commercialization of our product candidates, we expect to generate revenue from direct sales of our drugs and/or, if we license our drugs to future collaborators, from the receipt of license fees and royalties from sales of licensed products. We conduct our research and development programs through a combination of internal and collaborative programs. We rely on arrangements with universities, certain collaborators, CDMOs, CROs and clinical research sites for a significant portion of our product development efforts.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
      83
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Components of Operating Results</b></p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>Operating Expenses</i></b></p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>Research and Development Expenses</i></p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify; text-indent: 18pt;">We focus substantially all of our research and development efforts in the development of simufilam. Research and development expenses for our investigational diagnostic product candidate, SavaDx, represented less than 1% of total research and development expenses for the periods presented. The following table summarizes expenses by category for research and development efforts (in thousands):</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;">
   <tbody>
    <tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom">
     <td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td>
     <td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td>
     <td colspan="10" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Years ended December 31,</b></p> </td>
     <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
    </tr>

    <tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom">
     <td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td>
     <td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td>
     <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>2024</b></p> </td>
     <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
     <td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td>
     <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>2023</b></p> </td>
     <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
     <td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td>
     <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>2022</b></p> </td>
     <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
    </tr>

    <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
     <td>&#160;</td>
     <td>&#160;</td>
     <td>&#160;</td>
     <td>&#160;</td>
     <td>&#160;</td>
     <td>&#160;</td>
     <td>&#160;</td>
     <td>&#160;</td>
     <td>&#160;</td>
     <td>&#160;</td>
     <td>&#160;</td>
     <td>&#160;</td>
     <td>&#160;</td>
    </tr>

    <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
     <td style="font-family: Times New Roman; font-size: 10pt; width: 55%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">Phase 2 and Phase 3 clinical trials</p> </td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td>
     <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">42,321</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td>
     <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">71,087</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td>
     <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">54,149</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td>
    </tr>

    <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
     <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">Pre-clinical and Phase 1 studies</p> </td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
     <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">5,109</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
     <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">6,425</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
     <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">2,966</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td>
    </tr>

    <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
     <td style="font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> <p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">Chemical, Manufacturing and Controls costs (&#8220;CMC costs&#8221;)</p> </td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
     <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">6,464</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
     <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">2,910</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
     <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">2,573</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
    </tr>

    <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
     <td style="font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> <p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">Personnel related</p> </td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
     <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">6,640</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
     <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">5,723</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
     <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">5,631</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
    </tr>

    <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
     <td style="font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> <p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">Stock-based compensation</p> </td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
     <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">6,492</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
     <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">2,050</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
     <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">1,631</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
    </tr>

    <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
     <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">Other</p> </td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
     <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">2,611</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
     <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">1,228</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
     <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">1,082</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
    </tr>

    <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
     <td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
     <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">69,637</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
     <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">89,423</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
     <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">68,032</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-indent: 18pt; text-align: justify;">Clinical trial costs include the costs of our CRO. CMC costs include costs related to our contract development and manufacturing organizations. Research and development expenses include compensation, contractor fees and supplies as well as allocated common costs such as facilities.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">During the year&#160;ended December 31, 2024&#160;and 2023, we did not receive reimbursement from NIH research grants. During the year&#160;ended&#160;December 31, 2022, we received $0.9 million&#160;in research grants from the NIH. When applicable, the proceeds from grants are recorded as reductions&#160;to&#160;our research and development expenses.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">Our technology has been applied across certain of our portfolio of product candidates. Data, know-how, personnel, clinical results, research results and other matters related to the research and development of any one of our product candidates also relate to, and further the development of, our other product candidates. As a result, costs allocated to a specific product candidate may not necessarily reflect the actual costs surrounding research and development of such product candidate due to cross application of the foregoing.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">Estimating the dates of completion of clinical development, and the costs to complete development, of our product candidates would be highly speculative and&#160;subjective. Pharmaceutical products take a significant amount of time to research, develop and commercialize. The clinical study portion of the development of a new drug alone usually spans several years. We expect our research and development expenses to decrease significantly in&#160;2025&#160;as a result of decreased spending for our Phase 3 program in Alzheimer's disease, as both Phase 3 studies have either been completed or discontinued. Our open label studies in Alzheimer's disease have also been discontinued. The decrease in clinical program costs is expected to be partially offset by higher stock-based compensation expense. We expect to reassess our future research and development plans based on our review of data we receive from our current research and development activities. In particular, following our release of the topline REFOCUS-ALZ results, we intend to evaluate the results and determine the next steps for the future advancement, if any, of our Alzheimer&#8217;s program. The cost and pace of our future research and development activities are linked and subject to change.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&#160;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
      84
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>Critical Accounting Estimates</b></p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">The preparation of our consolidated financial statements in accordance with U.S. generally accepted accounting principles requires us to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues, expenses and interest income in our consolidated financial statements and accompanying notes. We evaluate our estimates on an ongoing basis, including those estimates related to agreements and research collaborations. We base our estimates on historical experience and various other assumptions that we believe to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">Our significant accounting policies are described in Note&#160;2 to our consolidated financial statements appearing elsewhere in this Annual Report on Form 10-K, and we believe that the accounting policies discussed below involve the greatest degree of complexity and exercise of significant judgments and estimates by our management. The methods, estimates and judgments that we use in applying our accounting policies have a significant impact on our results of operations and, accordingly, we believe the policies described below are the most critical for understanding and evaluating our financial condition and results of operations.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 36pt;text-indent:-18pt;">&#160;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Legal and other contingencies. The Company is currently involved in various claims and legal and regulatory proceedings. The Company regularly reviews the status of each significant matter and assesses its potential financial exposure. If the potential loss from any claim or legal proceeding is considered probable and the amount can be reasonably estimated, the Company accrues a liability for the estimated loss. Significant judgment is required in both the determination of probability and whether an exposure is reasonably estimable. Our judgments are subjective based on the status of the legal or regulatory proceedings, the merits of our defenses and consultation with in-house and outside legal counsel. Because of uncertainties related to these matters, accruals are based only on the best information available at the time. As additional information becomes available, the Company reassesses the potential liability related to its pending claims and legal and regulatory proceedings and may revise its estimates. Due to the inherent uncertainties of the legal and regulatory process, our judgments may be materially different than the actual outcomes. Refer to Note 12 to the Consolidated Financial Statements for further information on contingencies.</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 36pt;text-indent:-18pt;">&#160;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Research Contracts, Prepaids and Accruals. We have entered into various research and development contracts with research institutions and other third-party vendors. These agreements are generally cancelable. Related payments are recorded as research and development expenses as incurred. We record prepaids and accruals for estimated ongoing research costs. When evaluating the adequacy of prepaid expenses and&#160;accrued liabilities, we analyze progress of the studies including the phase or completion of events, invoices received and contracted costs. Significant&#160;judgments and estimates are made in determining the prepaid and accrued balances at the end of any reporting period. Actual results could differ from our estimates. Our historical prepaid and accrual estimates have not been materially different from actual costs.</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">&#160;</p>
  <table cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; margin-right: 0pt;">
   <tbody>
    <tr style="vertical-align: top; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
     <td style="width: 18pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="width: 18pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p> </td>
     <td style="width: auto; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Valuation of Common Stock Warrant Labilities. The fair value of common stock warrant liabilities was&#160;determined on the January 3, 2024 warrant distribution date using a Monte Carlo valuation model. Determining the appropriate fair value model and calculating the fair value of common stock warrants requires considerable judgment. Any change in the estimates used may cause the value to be higher or lower than that reported. Subsequent to&#160;their&#160;distribution, the common stock warrants were&#160;traded on the Nasdaq&#160;Capital Market under the trading symbol "SAVAW". The fair value of common stock warrant liabilities at March 31, 2024 was determined using the closing price for the common stock warrants&#160;on that date. May 2, 2024 was the final day of trading for the common stock warrants on the Nasdaq&#160;Capital Market. Subsequent to that date and through the Warrant Redemption beginning May 7, 2024, the warrants were considered to have no value since there was no active market for trading. All changes in the fair value are recorded in the statements of operations each reporting period.&#160;Fair value changes&#160;may be significantly different from those recorded in the financial statements due to&#160;of the use of judgment and the inherent uncertainty in estimating the fair value of these instruments in the initial valuation as of January 3, 2024, the warrant distribution date.</td>
    </tr>

   </tbody>
  </table>
  <p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>Recent Accounting Pronouncements</b></p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">See Note 2. Summary of Significant Accounting Policies, in Notes to the Consolidated Financial Statements in Item 8 of Part II of this Annual Report on Form 10-K.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&#160;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
      85
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>Results of Operations </b>&#8211;<b> Comparison of years ended December 31, 2024&#160;and 2023</b></p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><i>Research and Development Expense</i></p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">Research and development expenses consist primarily of costs of drug development work associated with our product candidates, including:</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 36pt;text-indent:-18pt;">&#160;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">clinical studies,</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">preclinical testing,</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">clinical supplies and related formulation and design costs, and</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">compensation and other personnel-related expenses.</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">Research and development expenses decreased to $69.6&#160;million in&#160;2024&#160;from $89.4&#160;million in 2023, representing a 22% decrease. This decrease was due primarily to the completion of enrollment for our Phase 3 clinical program in the fall of 2023. Patients continually&#160;completed the Phase 3 program in 2024 and all clinical studies were in the process of being discontinued at year-end 2024. These&#160;decreases were partially offset by a $4.4 million&#160;increase in stock-based compensation expense due to new grant awards in&#160;2024.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">We expect significant costs to continue in the first quarter of 2025&#160;as we wind down our existing clinical studies. Subsequently, we expect research and development expense to decrease significantly in future periods. The decrease in clinical program costs is expected to be partially offset by higher stock-based compensation expense due to new grant awards in 2024.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><i>General and Administrative Expense</i></p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">General and administrative expenses consist of personnel costs, allocated expenses and other expenses for outside professional services, including legal, human resources, audit and accounting services. Personnel costs consist of salaries, bonus, benefits and stock-based compensation. Allocated expenses consist primarily of existing facility costs. We incur insurance, audit, investor relations, SOX compliance and other administrative and professional services expenses associated with operating as a public company, including expenses related to compliance with the rules and regulations of the SEC and Nasdaq. General and administrative expense increased to $71.8&#160;million in 2024&#160;from $16.5&#160;million in 2023. The 334% increase was due primarily to completion of the $40 million settlement with the SEC as well as a $7.3 million increase in stock-based compensation expense due to new grant awards in late 2023 and 2024, increased compensation costs and higher legal related expenses.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><i>Interest Income</i></p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">Interest income&#160;was $8.5&#160;million in 2024&#160;compared to $7.8&#160;million&#160;in 2023. The increase in interest income was due to higher cash balances partially offset by lower&#160;interest rates in 2024&#160;compared to the prior year.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">We expect interest income to decrease in&#160;2025&#160;compared to&#160;2024&#160;as we use&#160;cash balances in operations.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><i>Other income, net </i></p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">We record the activities related to leasing office space to third parties in buildings we own as other income, net, as leasing is not core to the Company&#8217;s operations. Other income, net, was $0.4&#160;million during 2024&#160;compared to $0.9&#160;million&#160;during 2023. We expect to record a net loss on leasing activities&#160;in 2025&#160;as higher vacancy rates are expected to significantly lower rental income.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">Depreciation and amortization for the office complex is included in general and administrative and research and development expense, and thus not reflected in other income, net.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>Comparison of the years ended&#160;December 31, 2023&#160;and 2022</i></b></p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">Refer to &#8220;Item 7. Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8212;Results of Operations&#8221; in our 2023&#160;Annual Report on Form 10-K for a discussion of the results of operations for the year ended December 31, 2023&#160;compared to the year ended December 31, 2022.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&#160;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
      86
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>Liquidity and Capital Resources</b></p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">Since inception, we have financed our operations primarily through public and private stock offerings, payments received under collaborative agreements and interest earned on our cash and cash equivalents balances. We intend to continue to use our capital resources to fund research and development activities, capital expenditures, working capital requirements and other general corporate purposes. As of December 31, 2024, cash and cash equivalents totaled $128.6&#160;million.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -18pt; text-indent: 18pt;"><b><i>2024 Common Stock Warrant Distribution</i></b></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -18pt; text-indent: 18pt;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -2pt; text-indent: 18pt;">On January 3, 2024, we made&#160;a distribution of approximately 16.9 million&#160;warrants&#160;to purchase shares of our common stock to holders of record of our&#160;common stock as of the close of business on December 22, 2023.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -2pt; text-indent: 18pt;">Each warrant entitled&#160;the holder to purchase, at the holder&#8217;s sole expense and exclusive election, at an exercise price of $33.00 per warrant, one and one-half shares of common stock (rounded down&#160;for any fractional shares).</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -2pt; text-indent: 18pt;">On April 15, 2024, the Company announced&#160;that all outstanding warrants were to be redeemed on May 7, 2024&#160;(the Redemption Date). The redemption price&#160;was equal to 1/10 of $0.01 per warrant. The warrants were&#160;exercisable&#160;at any time starting on January 3, 2024&#160;until the business day prior to the Redemption Date.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -4pt; text-indent: 18pt;">From January 3, 2024 to March 31, 2024, a total of approximately 674,000&#160;warrants were exercised resulting in net proceeds to the Company of approximately $22.3&#160;million. The Company issued approximately 1.0 million&#160;shares of common stock&#160;from the exercise of warrants through March 31, 2024.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -4pt; text-indent: 18pt;">Subsequent to March 31, 2024 and through the Redemption Date, a total of approximately 3.15 million&#160;warrants were exercised resulting in gross proceeds to the Company of approximately $104.0&#160;million. The Company issued approximately 4.7 million shares of common stock&#160;from the exercise of warrants from March 31, 2024 through the Redemption Date.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -4pt; text-indent: 18pt;">Gross proceeds in 2024 from the warrant distribution totaled approximately $126.3&#160;million from the issuance of approximately 5.7 million common shares at $22.00 per share. Total net proceeds of the warrant distribution were approximately $123.6&#160;million after deducting exercise&#160;expenses and commissions.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -4pt; text-indent: 18pt;">After the first $20 million of gross proceeds, the Company was&#160;obligated to pay a commission of&#160;2.5% of the gross proceeds from the sale of shares of common stock from warrant exercises&#160;to the Company's financial advisor for the warrant distribution. Total cost&#160;of warrant exercises through the Redemption Date were approximately $2.7&#160;million.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>2022 Registered Direct Offering</i></b></p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">On November 22, 2022, we completed a common stock offering pursuant to which certain investors purchased 1,666,667 shares of common stock at a price of $30.00 per share. Net proceeds of the offering were approximately $47.3&#160;million after deducting offering expenses.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>At the Market (ATM) Common Stock Issuance </i></b></p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-indent: 18pt; text-align: justify;">On May 1, 2023, we entered into an&#160;at-the-market offering program (ATM) to sell, from time to time, shares of our common stock having an aggregate offering price of up to $200 million in common stock pursuant to a shelf registration statement that was filed with the SEC on May 1, 2023 and became effective immediately upon filing. We are obligated to pay a commission of up to 3% of the gross proceeds from the sale of shares of common stock under&#160;the ATM. We are not obligated to sell any shares in the offering.&#160;As of the filing of this Annual Report on Form 10-K, the Company is no longer a Well-Known Seasoned Issuer, as defined by the SEC. Thus, the Company&#160;is not eligible to sell securities under the ATM under its existing &#8220;automatic&#8221; shelf registration statement on Form S-3 unless and until it files a new Form S-3 that is declared effective by the SEC.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 8pt;">&#160;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
      87
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -9pt; text-indent: 27pt;">There were&#160;no&#160;common stock sales under the ATM during the years ended December 31, 2024 and 2023.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>2020 Cash Incentive Bonus Plan Obligations</i></b></p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">In August 2020, the Board approved the <i>2020 Cash Incentive Bonus Plan</i> (the CIB Plan). The CIB Plan was established to promote the long-term success of the Company by creating an &#8220;at-risk&#8221; cash bonus program that rewards&#160;CIB Plan&#160;participants with additional cash compensation in lockstep with significant increases in the Company&#8217;s market capitalization. The CIB Plan is considered &#8220;at-risk&#8221; because CIB Plan participants&#160;will&#160;not receive a cash bonus&#160;unless&#160;the Company&#8217;s market capitalization increases&#160;significantly and&#160;certain&#160;other&#160;conditions specified in the CIB Plan&#160;are met.&#160;Specifically, CIB Plan participants&#160;will&#160;not&#160;be paid&#160;any cash bonuses unless (1) the Company completes a&#160;merger or acquisition transaction that constitutes a sale of ownership of the Company or its assets (a Merger Transaction) or (2) the Compensation Committee&#160;determines the Company has sufficient cash on hand, as defined in the CIB Plan. CIB Plan participants will be paid all earned cash bonuses in the event of a Merger Transaction.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -1pt; text-indent: 18pt;">As of December 31, 2022, the Company&#8217;s independent directors were participants in the CIB Plan. However, effective March 16, 2023, the Board&#160;amended the CIB Plan to remove all independent directors as participants in the CIB Plan and the independent directors consented to such removal. The independent directors&#8217; share of potential benefits under the CIB Plan were completely forfeited to the Company and will not be allocated to any other participant under the CIB Plan. The Company's&#160;independent directors have not received, and as a result of such amendment will never receive, any payments under the CIB Plan.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 8pt;text-indent:18pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">The Company&#8217;s market capitalization, including all outstanding stock options, was $89.4&#160;million at the inception of the CIB Plan in August 2020. If the Company were to exceed a $5&#160;billion market capitalization&#160;for no less than 20 consecutive trading days, and conditions noted above for payment are met, all&#160;CIB Plan milestones would be deemed achieved, in which case total cash bonus awards would&#160;range from&#160;a minimum of&#160;$111.4&#160;million&#160;up to&#160;a hypothetical maximum of&#160;$289.7&#160;million.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">The Company&#8217;s potential financial obligation to CIB Plan participants at&#160;December 31, 2024&#160;totaled $6.5&#160;million (after taking into account the March 2023 CIB Plan amendment), based upon the achievement of one CIB Plan milestone in the Company&#8217;s market capitalization in 2020. No actual cash bonus payments have been made to any CIB Plan participant, as the Company has not yet satisfied all the conditions necessary for amounts to be paid under the CIB Plan.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">During the year ended December 31, 2021, the Company&#8217;s market capitalization increased substantially. These increases triggered the achievement of 11 additional CIB Plan milestones. On February 13, 2025,&#160;the Compensation Committee concluded that no discretionary&#160;cash bonus amounts would be awarded for the 11 milestones achieved in 2021 nor for the 2 remaining CIB Plan milestones, which have not been achieved. Therefore,&#160;no&#160;compensation expense has been recorded&#160;and&#160;no&#160;payments have been made&#160;since no&#160;grant date has occurred and no&#160;Performance Conditions are considered probable of being met.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">The achievement the 11&#160;milestones&#160;in&#160;2021 triggered a&#160;non-discretionary potential Company obligation&#160;to a CIB Plan participant&#160;of $74.9&#160;million&#160;and contingent upon future satisfaction of a Performance Condition. However,&#160;no&#160;compensation expense has been recorded&#160;and&#160;no&#160;payments have been made&#160;since no&#160;grant date has occurred and no&#160;Performance Conditions are considered probable of being met.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 8pt; text-indent: 9pt;">No valuation milestones were achieved during the years ended December 31, 2024, 2023 or 2022.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 18pt; text-align: justify;">On August 19, 2022, a shareholder derivative action was filed, purportedly on behalf of the Company, in the Delaware Court of Chancery, asserting claims under state fiduciary duty laws against certain named officers and members of the Company&#8217;s Board. On May 28, 2024, the parties entered into a Stipulation and Agreement of Settlement, Compromise, and Release (the &#8220;Stipulation&#8221;) to resolve the action. The Stipulation and exhibits thereto, including the proposed Notice of Pendency of Settlement of Class and Derivative Action (the &#8220;Notice&#8221;) and [Proposed] Scheduling Order with Respect to Notice and Settlement Hearing (the &#8220;Scheduling Order&#8221;), were filed in the Delaware Court of Chancery on May 28, 2024.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 18pt; text-align: justify;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 18pt; text-align: justify;">As discussed in Note 12 to the Consolidated Financial Statements, on January 24, 2025, the Delaware Court of Chancery entered a Final Order and Judgment approving the Stipulation and dismissing an action related to the CIB&#160;Plan with prejudice. The Final Order and Judgment requires&#160;the Company to further amend&#160;the CIB Plan, as provided for&#160;in the Stipulation.</p>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">No actual cash payments were authorized or made to participants under the CIB Plan as of December 31, 2024, or through the filing date of this Annual Report on Form 10-K.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&#160;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
      88
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>Use of Cash</i></b></p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">The following table sets forth a summary of the primary sources and uses of cash for each of the periods presented below (in thousands):</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;">
   <tbody>
    <tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom">
     <td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td>
     <td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td>
     <td colspan="10" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Years ended December 31,</b></p> </td>
     <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
    </tr>

    <tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom">
     <td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td>
     <td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td>
     <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>2024</b></p> </td>
     <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
     <td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td>
     <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>2023</b></p> </td>
     <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
     <td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td>
     <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>2022</b></p> </td>
     <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
    </tr>

    <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
     <td>&#160;</td>
     <td>&#160;</td>
     <td>&#160;</td>
     <td>&#160;</td>
     <td>&#160;</td>
     <td>&#160;</td>
     <td>&#160;</td>
     <td>&#160;</td>
     <td>&#160;</td>
     <td>&#160;</td>
     <td>&#160;</td>
     <td>&#160;</td>
     <td>&#160;</td>
    </tr>

    <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
     <td style="font-family: Times New Roman; font-size: 10pt; width: 55%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">Net cash used in operating activities</p> </td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td>
     <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(116,929</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td>
     <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(82,025</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td>
     <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(77,514</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td>
    </tr>

    <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
     <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">Net cash used in investing activities</p> </td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
     <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(103</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
     <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(414</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td>
     <td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">(2,712</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">)</td>
    </tr>

    <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
     <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">Net cash provided by financing activities</p> </td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
     <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">124,470</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
     <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">2,560</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
     <td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;">47,804</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
    </tr>

    <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
     <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">Net increase (decrease) in cash and cash equivalents</p> </td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
     <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">7,438</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">&#160;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
     <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(79,879</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">)</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
     <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(32,422</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">)</td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">Net cash used in operating activities was $116.9 million for the year ended December 31, 2024, resulting primarily from the net loss reported of $24.3&#160;million, change in fair value of warrants of $108.2 million and a&#160;decrease in accounts payable and other accrued expenses of $2.9 million. This change was partially offset by stock compensation expense of $16.3 million, depreciation and amortization of $1.1&#160;million and an increase in accrued compensation and benefits of $1.2 million.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">Net cash used in operating activities was $82.0&#160;million for the year ended&#160;December 31, 2023, resulting primarily from the net loss reported of $97.2&#160;million partially offset by&#160;an increase in accounts payable and other accrued expenses&#160;of $6.9&#160;million and accrued development expense of $0.8 million,&#160;a decrease in prepaid and other assets of $1.7&#160;million, stock-based compensation expense of $4.6&#160;million and depreciation and amortization of $1.0 million.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">Net cash used in investing activities during the year ended&#160;December 31, 2024&#160;was $0.1&#160;million for computers and equipment and other assets.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">Net cash used in investing activities during the year ended&#160;December 31, 2023&#160;was $0.4 million as final payment was made on renovations and fixtures for our corporate headquarters.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">Net cash provided by financing activities during the year ended December 31, 2024 was $124.5 million including&#160;$123.6&#160;million of net proceeds from the exercise of warrants and $0.9 million from the exercise of stock options.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">Net cash provided by financing activities during the year ended&#160;December 31, 2023&#160;was $2.6&#160;million from the exercise of stock options.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>Use of Cash </i></b>&#8211;<b> </b><b><i>Comparison of the years ended December 31, 2023&#160;and 2022</i></b></p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 18pt;">Refer to &#8220;Item 7. Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8212;Results of Operations&#8221; in our 2023&#160;Annual Report on Form 10-K for a discussion of use of cash for the year ended December 31, 2023&#160;compared to the year ended December 31, 2022.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>Property and Leases</i></b></p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -2pt; text-indent: 18pt;">We own an office complex in Austin, Texas, a portion of which serves as our corporate headquarters. Maintenance, physical facilities, leasing, property management and other key responsibilities related to property ownership are outsourced to professional real-estate managers. The office complex measures approximately 90,000 rentable square feet. At December&#160;31, 2024, we occupied approximately 25% of the property with the remainder either leased or available for lease to third parties. Most tenant leases expired&#160;in 2024. We expect to record a net loss on leasing activities&#160;in 2025&#160;as the higher vacancy rates are expected to significantly lower rental income.</p>
  <p style="margin: 0pt 0pt 0pt -9pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
      89
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -18pt; text-indent: 18pt;"><i><b>Future Funding Requirements</b></i></p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">We have an accumulated deficit of $405.1&#160;million at December 31, 2024. We expect our cash requirements to be significant in the future. The amount and timing of our future cash requirements will depend on regulatory and market acceptance of our product candidates and the resources we devote to researching and developing, formulating, manufacturing, commercializing and supporting our products. We believe that our current resources should be sufficient to fund our operations for at least the next 12 months. We may seek additional future funding through public or private financing in the future, if such funding is available and on terms acceptable to us.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">If we raise additional funds by issuing equity or equity-linked securities, our stockholders will experience dilution, which may be substantial. If we raise additional funds through the issuance of preferred equity securities or through debt financing, the terms of such future preferred equity or debt into which we enter may impose upon us additional covenants that restrict our operations, including limitations on our ability to incur liens or additional debt, pay dividends, repurchase our common stock, make certain investments and engage in certain merger, consolidation or asset sale transactions. Any debt financing or additional equity that we raise may contain terms that are not favorable to us or our stockholders. If we are unable to raise additional funds when needed, we may be required to delay, reduce, or terminate some or all of our development programs and clinical trials. We may also be required to sell or license to others rights to our drug candidates in certain territories or indications that we would prefer to develop and commercialize ourselves.</p>
  <div>
   &#160;
  </div>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><a id="item7a" title="item7a" href="#"></a>Item 7A.</b>&#160;&#160;&#160;&#160;<b><i>Quantitative and Qualitative Disclosures about Market Risk</i></b></p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">We are exposed to market risks in the ordinary course of our business, primarily related to interest rate sensitivities and, to a lesser extent, currency fluctuations related to our clinical operations outside the U.S.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>Interest Rate Sensitivity</b></p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">We are exposed to market risk related to changes in interest rates. We had cash and cash equivalents of $128.6&#160;million as of December 31, 2024, which consisted primarily of U.S. Treasury securities and money market accounts.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">The primary objective of our investment activities is to preserve capital to fund our operations. We also seek to maximize income from our investments without assuming significant risk. To achieve our objectives, we maintain investment vehicles with high credit quality and short-term duration, in accordance with our board-approved investment policy. Such interest-earning instruments carry a degree of interest rate risk. However, due to the generally short-term maturities and low risk profile of our cash equivalents, an immediate 100 basis point increase or decrease in interest rates during any of the periods presented would increase or decrease our annual net loss by less than $1.3&#160;million in our condensed consolidated financial statements.&#160; &#160;</p>
  <div>
   &#160;
  </div>
  <div><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><a id="item8" title="item8" href="#"></a>Item 8.</b>&#160;&#160;&#160;&#160;<b><i>Consolidated Financial Statements and Supplementary Data</i></b></p>
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>INDEX TO CONSOLIDATED FINANCIAL STATEMENTS</b></p>
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;"><tbody><tr><td style="vertical-align:top;width:92.9%;">&#160;</td><td style="vertical-align:top;width:6.7%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><span style="text-decoration: underline; ">Page</span></b></p> </td></tr>
<tr><td style="vertical-align:top;width:92.9%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a style="-sec-extract:exhibit;" href="#report">Report of Independent Registered Public Accounting Firm</a>&#160;(PCAOB ID: <ix:nonNumeric name="dei:AuditorFirmId" contextRef="d_2024-01-01_2024-12-31" id="ixv-14685">42</ix:nonNumeric>)</p> </td><td style="vertical-align: top; width: 6.7%; text-align: center;"><a class="tocPGNUM" href="#report">91</a></td></tr>
<tr><td style="vertical-align:top;width:92.9%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><a style="-sec-extract:exhibit;" href="#balance_sheet">Consolidated Balance Sheets</a></p> </td><td style="vertical-align: top; width: 6.7%; text-align: center;"><a class="tocPGNUM" href="#balance_sheet">93</a></td></tr>
<tr><td style="vertical-align:top;width:92.9%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><a style="-sec-extract:exhibit;" href="#state_of_op">Consolidated Statements of Operations</a></p> </td><td style="vertical-align: top; width: 6.7%; text-align: center;"><a class="tocPGNUM" href="#state_of_op">94</a></td></tr>
<tr><td style="vertical-align:top;width:92.9%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><a style="-sec-extract:exhibit;" href="#equity">Consolidated Statements of Stockholders<span style="text-decoration: underline; ">&#8217;</span><span style="text-decoration: underline; ">&#160;Equity</span></a></p> </td><td style="vertical-align: top; width: 6.7%; text-align: center;"><a class="tocPGNUM" href="#equity">95</a></td></tr>
<tr><td style="vertical-align:top;width:92.9%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><a style="-sec-extract:exhibit;" href="#cash_flows">Consolidated Statements of Cash Flows</a></p> </td><td style="vertical-align: top; width: 6.7%; text-align: center;"><a class="tocPGNUM" href="#cash_flows">96</a></td></tr>
<tr><td style="vertical-align:top;width:92.9%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><a style="-sec-extract:exhibit;" href="#notes">Notes to Consolidated Financial Statements</a></p> </td><td style="vertical-align: top; width: 6.7%; text-align: center;"><a class="tocPGNUM" href="#notes">97</a></td></tr>
</tbody></table>
<p style="font-size: 10pt; font-family: &quot;Times New Roman&quot;; margin: 0pt;">&#160;</p>
<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
 <div class="PGFTR" style="text-align: center; width: 100%">
  <div class="hf-row">
   <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
    90
   </div>
  </div>
 </div>
 <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
 <div class="PGHDR" style="text-align: left; width: 100%">
  <div class="hf-row">
   <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
    <a style="font-weight: initial; font-style: initial; font-variant: initial; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;" href="#toc">Table of Contents</a>
   </div>
  </div>
 </div>
</div>
<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><a id="report" title="report" href="#"></a>Report of Independent Registered Public Accounting Firm</b></p>
<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">To the Stockholders and the Board of Directors of Cassava Sciences, Inc.</p>
<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>Opinion on the Financial Statements</b></p>
<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">We have audited the accompanying consolidated balance sheets of Cassava Sciences, Inc. (the Company) as of December 31, 2024 and 2023, the related consolidated statements of operations, stockholders' equity and cash flows for each of the three years in the period ended December 31, 2024, and the related notes (collectively referred to as the &#8220;consolidated financial statements&#8221;). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company at December 31, 2024 and 2023, and the results of its operations and its cash flows for each of the three years in the period ended December 31, 2024, in conformity with U.S. generally accepted accounting principles.</p>
<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>Basis for Opinion</b></p>
<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">These financial statements are the responsibility of the Company's management. Our responsibility is to express an opinion on the Company&#8217;s financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (PCAOB) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</p>
<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Company's internal control over financial reporting. Accordingly, we express no such opinion.</p>
<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion.</p>
<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>Critical Audit Matter </b></p>
<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">The critical audit matter communicated below is a matter arising from the current period audit of the financial statements that was communicated or required to be communicated to the audit committee and that: (1) relates to accounts or disclosures that are material to the financial statements and (2) involved our especially challenging, subjective or complex judgments. The communication of the critical audit matter does not alter in any way our opinion on the consolidated financial statements, taken as a whole, and we are not, by communicating the critical audit matter below, providing a separate opinion on the critical audit matter or on the account or disclosure to which it relates.</p>
<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
 <div class="PGFTR" style="text-align: center; width: 100%">
  <div class="hf-row">
   <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
    91
   </div>
  </div>
 </div>
 <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
 <div class="PGHDR" style="text-align: left; width: 100%">
  <div class="hf-row">
   <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
    <a style="font-weight: initial; font-style: initial; font-variant: initial; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;" href="#toc">Table of Contents</a>
   </div>
  </div>
 </div>
</div>
<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;"><tbody><tr><td style="vertical-align:top;width:12%;">&#160;</td><td style="vertical-align:top;width:39.9%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>Loss Contingencies</i></b></p> </td></tr>
<tr><td style="vertical-align:top;width:12%;">&#160;</td><td style="vertical-align:top;width:39.9%;">&#160;</td></tr>
<tr><td style="vertical-align:top;width:12%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>Description of the Matter</i></p> </td><td style="vertical-align:top;width:39.9%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">The Company is subject to lawsuits, claims, allegations, and investigations regarding simufilam and SavaDx. As described in Note 12 to the consolidated financial statements, such lawsuits, claims, allegations and investigations can have an adverse impact on the Company. During the year ended December 31, 2024, the Company incurred and paid a civil monetary penalty of $40 million to settle an investigation. With respect to the remaining ongoing lawsuits, claims, allegations and investigations regarding simufilam&#160;and SavaDx, the Company believes that the likelihood of an unfavorable outcome is not probable, however, it is reasonably possible that the Company may incur a loss. The Company is unable to reasonably estimate the amount or range of potential loss at December 31, 2024.</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Auditing management&#8217;s accounting for, and disclosure of, loss contingencies related to the lawsuits, claims, allegations and investigations was challenging because management&#8217;s evaluation of the likelihood of loss required judgment.</p> </td></tr>
<tr><td style="vertical-align:top;width:12%;">&#160;</td><td style="vertical-align:top;width:39.9%;">&#160;</td></tr>
<tr><td style="vertical-align:top;width:12%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>How We Addressed the Matter in Our Audit</i></p> </td><td style="vertical-align:top;width:39.9%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Our audit procedures included gaining an understanding of the status of ongoing lawsuits and investigations, reading the meeting minutes of the board of directors and of the committees of the board of directors, reading summaries of the proceedings and related correspondence, requesting letters from internal and external legal counsel, meeting with internal and external legal counsel to discuss developments related to the lawsuits, claims, allegations and investigations together with our forensic professionals, vouching accruals and subsequent payments to third party evidence, and obtaining written representations from the Company on these matters. We also evaluated the Company&#8217;s disclosures in relation to these matters.</p> </td></tr>
</tbody></table>
<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">/s/ <ix:nonNumeric name="dei:AuditorName" contextRef="d_2024-01-01_2024-12-31" id="ixv-14686">Ernst &amp; Young LLP</ix:nonNumeric></p>
<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">We have served as the Company&#8217;s auditor since 2002.</p>
<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><ix:nonNumeric name="dei:AuditorLocation" contextRef="d_2024-01-01_2024-12-31" id="ixv-14687">Austin, Texas</ix:nonNumeric></p>
<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">March 3, 2025</p>
<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
 <div class="PGFTR" style="text-align: center; width: 100%">
  <div class="hf-row">
   <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
    92
   </div>
  </div>
 </div>
 <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
 <div class="PGHDR" style="text-align: left; width: 100%">
  <div class="hf-row">
   <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
    <a style="font-weight: initial; font-style: initial; font-variant: initial; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;" href="#toc">Table of Contents</a>
   </div>
  </div>
 </div>
</div>
<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;&#160;</p></div>
  <div>
   &#160;
  </div>
  <p style="font-family: Times New Roman; font-size: 10pt; margin: 0pt; text-align: center;"><b><a id="balance_sheet" title="balance sheet" href="#"></a>CASSAVA SCIENCES, INC.</b></p>
  <p style="font-family: Times New Roman; font-size: 10pt; margin: 0pt; text-align: center;">&#160;</p>
  <p style="font-family: Times New Roman; font-size: 10pt; margin: 0pt; text-align: center;"><b>CONSOLIDATED BALANCE SHEETS</b></p>
  <p style="font-family: Times New Roman; font-size: 10pt; margin: 0pt; text-align: center;"><b>(In thousands, except share and par value data)</b></p>
  <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">&#160;</p>
  <div>
   <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="6" rowspan="1" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;"><em style="font: inherit;">December 31,</em></em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"><b><em style="font: inherit;">2024</em></b></td><td style="font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"><b><em style="font: inherit;">2023</em></b></td><td style="font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td colspan="8" style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt; text-align: center;"><b><em style="font: inherit;"><em style="font: inherit;">ASSETS</em></em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 70%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">Current assets:</p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt; text-indent: -9pt;">Cash and cash equivalents</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c123854612" contextRef="i_2024-12-31" unitRef="USD" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" format="ixt:num-dot-decimal" decimals="-3">128,574</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c123854613" contextRef="i_2023-12-31" unitRef="USD" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" format="ixt:num-dot-decimal" decimals="-3">121,136</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt; text-indent: -9pt;">Prepaid expenses and other current assets</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c123854614" contextRef="i_2024-12-31" unitRef="USD" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="3" format="ixt:num-dot-decimal" decimals="-3">7,958</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c123854615" contextRef="i_2023-12-31" unitRef="USD" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="3" format="ixt:num-dot-decimal" decimals="-3">8,497</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 27pt; text-indent: -9pt;">Total current assets</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c123854616" contextRef="i_2024-12-31" unitRef="USD" name="us-gaap:AssetsCurrent" scale="3" format="ixt:num-dot-decimal" decimals="-3">136,532</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c123854617" contextRef="i_2023-12-31" unitRef="USD" name="us-gaap:AssetsCurrent" scale="3" format="ixt:num-dot-decimal" decimals="-3">129,633</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">Property and equipment, net</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c123854618" contextRef="i_2024-12-31" unitRef="USD" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" format="ixt:num-dot-decimal" decimals="-3">20,964</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c123854619" contextRef="i_2023-12-31" unitRef="USD" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" format="ixt:num-dot-decimal" decimals="-3">21,854</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">Intangible assets, net</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c123854620" contextRef="i_2024-12-31" unitRef="USD" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" scale="3" format="ixt:num-dot-decimal" decimals="-3">37</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c123854621" contextRef="i_2023-12-31" unitRef="USD" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" scale="3" format="ixt:num-dot-decimal" decimals="-3">176</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">Total assets</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c123854622" contextRef="i_2024-12-31" unitRef="USD" name="us-gaap:Assets" scale="3" format="ixt:num-dot-decimal" decimals="-3">157,533</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c123854623" contextRef="i_2023-12-31" unitRef="USD" name="us-gaap:Assets" scale="3" format="ixt:num-dot-decimal" decimals="-3">151,663</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td colspan="8" style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt; text-align: center;"><b><em style="font: inherit;"><em style="font: inherit;">LIABILITIES AND STOCKHOLDERS' EQUITY</em></em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">Current liabilities:</p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt; text-indent: -9pt;">Accounts payable and other accrued expenses</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c123854626" contextRef="i_2024-12-31" unitRef="USD" name="us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent" scale="3" format="ixt:num-dot-decimal" decimals="-3">7,654</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c123854627" contextRef="i_2023-12-31" unitRef="USD" name="us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent" scale="3" format="ixt:num-dot-decimal" decimals="-3">10,573</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt; text-indent: -9pt;">Accrued development expense</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c123854628" contextRef="i_2024-12-31" unitRef="USD" name="sava:AccruedDevelopmentExpenseCurrent" scale="3" format="ixt:num-dot-decimal" decimals="-4">2,440</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c123854629" contextRef="i_2023-12-31" unitRef="USD" name="sava:AccruedDevelopmentExpenseCurrent" scale="3" format="ixt:num-dot-decimal" decimals="-3">3,037</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt; text-indent: -9pt;">Accrued compensation and benefits</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c123854630" contextRef="i_2024-12-31" unitRef="USD" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" scale="3" format="ixt:num-dot-decimal" decimals="-3">1,357</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c123854631" contextRef="i_2023-12-31" unitRef="USD" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" scale="3" format="ixt:num-dot-decimal" decimals="-5">200</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt; text-indent: -9pt;">Other current liabilities</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c123854632" contextRef="i_2024-12-31" unitRef="USD" name="us-gaap:OtherLiabilitiesCurrent" scale="3" format="ixt:num-dot-decimal" decimals="-3">299</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c123854633" contextRef="i_2023-12-31" unitRef="USD" name="us-gaap:OtherLiabilitiesCurrent" scale="3" format="ixt:num-dot-decimal" decimals="-3">385</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 27pt; text-indent: -9pt;">Total current liabilities</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c123854634" contextRef="i_2024-12-31" unitRef="USD" name="us-gaap:LiabilitiesCurrent" scale="3" format="ixt:num-dot-decimal" decimals="-4">11,750</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c123854635" contextRef="i_2023-12-31" unitRef="USD" name="us-gaap:LiabilitiesCurrent" scale="3" format="ixt:num-dot-decimal" decimals="-3">14,195</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">Other non-current liabilities</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"><ix:nonFraction id="c123854636" contextRef="i_2024-12-31" unitRef="USD" name="us-gaap:OtherLiabilitiesNoncurrent" scale="3" format="ixt:num-dot-decimal" decimals="-3">79</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c123854637" contextRef="i_2023-12-31" unitRef="USD" name="us-gaap:OtherLiabilitiesNoncurrent" scale="3" format="ixt:fixed-zero" decimals="-3">&#8212;</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 27pt; text-indent: -9pt;">Total liabilities</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c123854638" contextRef="i_2024-12-31" unitRef="USD" name="us-gaap:Liabilities" scale="3" format="ixt:num-dot-decimal" decimals="-3">11,829</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c123854639" contextRef="i_2023-12-31" unitRef="USD" name="us-gaap:Liabilities" scale="3" format="ixt:num-dot-decimal" decimals="-3">14,195</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">Commitments and contingencies (Notes 10, 11 and 12)</p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;<span style="-sec-ix-hidden:c123862498">&#160;</span></td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;<span style="-sec-ix-hidden:c123862499">&#160;</span></td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">Stockholders' equity:</p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">Preferred stock, $<span style="-sec-ix-hidden:c123855767"><span style="-sec-ix-hidden:c123855768">0.001</span></span> par value; <span style="-sec-ix-hidden:c123855769"><span style="-sec-ix-hidden:c123855770">10,000,000</span></span> shares authorized, <span style="-sec-ix-hidden:c123855771"><span style="-sec-ix-hidden:c123855773"><span style="-sec-ix-hidden:c123855772"><span style="-sec-ix-hidden:c123855774">none</span></span></span></span> issued and outstanding</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c123854640" contextRef="i_2024-12-31" unitRef="USD" name="us-gaap:PreferredStockValue" scale="3" format="ixt:fixed-zero" decimals="-3">&#8212;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c123854641" contextRef="i_2023-12-31" unitRef="USD" name="us-gaap:PreferredStockValue" scale="3" format="ixt:fixed-zero" decimals="-3">&#8212;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">Common stock, $<span style="-sec-ix-hidden:c123855775"><span style="-sec-ix-hidden:c123855776">0.001</span></span> par value; <span style="-sec-ix-hidden:c123855777"><span style="-sec-ix-hidden:c123855778">120,000,000</span></span> shares authorized; <span style="-sec-ix-hidden:c123855779"><span style="-sec-ix-hidden:c123855781">48,203,179</span></span> and <span style="-sec-ix-hidden:c123855780"><span style="-sec-ix-hidden:c123855782">42,236,919</span></span> shares issued and outstanding at December 31, 2024 and 2023, respectively</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c123854642" contextRef="i_2024-12-31" unitRef="USD" name="us-gaap:CommonStockValue" scale="3" format="ixt:num-dot-decimal" decimals="-3">48</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c123854643" contextRef="i_2023-12-31" unitRef="USD" name="us-gaap:CommonStockValue" scale="3" format="ixt:num-dot-decimal" decimals="-3">42</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt; text-indent: -9pt;">Additional paid-in capital</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c123854644" contextRef="i_2024-12-31" unitRef="USD" name="us-gaap:AdditionalPaidInCapital" scale="3" format="ixt:num-dot-decimal" decimals="-3">550,767</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c123854645" contextRef="i_2023-12-31" unitRef="USD" name="us-gaap:AdditionalPaidInCapital" scale="3" format="ixt:num-dot-decimal" decimals="-3">518,195</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt; text-indent: -9pt;">Accumulated deficit</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(<ix:nonFraction id="c123854646" contextRef="i_2024-12-31" unitRef="USD" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="3" format="ixt:num-dot-decimal" decimals="-3" sign="-">405,111</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(<ix:nonFraction id="c123854647" contextRef="i_2023-12-31" unitRef="USD" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="3" format="ixt:num-dot-decimal" decimals="-3" sign="-">380,769</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 27pt; text-indent: -9pt;">Total stockholders' equity</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c123854648" contextRef="i_2024-12-31" unitRef="USD" name="us-gaap:StockholdersEquity" scale="3" format="ixt:num-dot-decimal" decimals="-3">145,704</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c123854649" contextRef="i_2023-12-31" unitRef="USD" name="us-gaap:StockholdersEquity" scale="3" format="ixt:num-dot-decimal" decimals="-3">137,468</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 27pt; text-indent: -9pt;">Total liabilities and stockholders' equity</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c123854650" contextRef="i_2024-12-31" unitRef="USD" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="3" format="ixt:num-dot-decimal" decimals="-3">157,533</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c123854651" contextRef="i_2023-12-31" unitRef="USD" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="3" format="ixt:num-dot-decimal" decimals="-3">151,663</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td></tr>
</tbody></table>
  </div>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">See accompanying notes to consolidated financial statements.</p>
  <p style="font-size: 10pt; font-family: &quot;Times New Roman&quot;; margin: 0pt;">&#160;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
      93
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <div>
   &#160;
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
  <p style="font-family: Times New Roman; font-size: 10pt; margin: 0pt; text-align: center;"><b><a id="state_of_op" title="state of op" href="#"></a>CASSAVA SCIENCES, INC.</b></p>
  <p style="font-family: Times New Roman; font-size: 10pt; margin: 0pt; text-align: center;">&#160;</p>
  <p style="font-family: Times New Roman; font-size: 10pt; margin: 0pt; text-align: center;"><b>CONSOLIDATED STATEMENTS OF OPERATIONS</b></p>
  <p style="font-family: Times New Roman; font-size: 10pt; margin: 0pt; text-align: center;"><b>(In thousands, except per share data)</b></p>
  <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center;">&#160;</p>
  <div>
   <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="10" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;"><em style="font: inherit;"><em style="font: inherit;">Years ended December 31,</em></em></em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">2024</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">2023</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">2022</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 55%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">Operating expenses:</p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt; text-indent: -9pt;">Research and development, net of grant reimbursement</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c123854662" contextRef="d_2024-01-01_2024-12-31" unitRef="USD" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" format="ixt:num-dot-decimal" decimals="-3">69,637</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c123854663" contextRef="d_2023-01-01_2023-12-31" unitRef="USD" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" format="ixt:num-dot-decimal" decimals="-3">89,423</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c123854664" contextRef="d_2022-01-01_2022-12-31" unitRef="USD" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" format="ixt:num-dot-decimal" decimals="-3">68,032</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt; text-indent: -9pt;">General and administrative</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c123854665" contextRef="d_2024-01-01_2024-12-31" unitRef="USD" name="us-gaap:GeneralAndAdministrativeExpense" scale="3" format="ixt:num-dot-decimal" decimals="-3">71,809</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c123854666" contextRef="d_2023-01-01_2023-12-31" unitRef="USD" name="us-gaap:GeneralAndAdministrativeExpense" scale="3" format="ixt:num-dot-decimal" decimals="-3">16,534</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c123854667" contextRef="d_2022-01-01_2022-12-31" unitRef="USD" name="us-gaap:GeneralAndAdministrativeExpense" scale="3" format="ixt:num-dot-decimal" decimals="-3">11,988</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 27pt; text-indent: -9pt;">Total operating expenses</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c123854668" contextRef="d_2024-01-01_2024-12-31" unitRef="USD" name="us-gaap:OperatingExpenses" scale="3" format="ixt:num-dot-decimal" decimals="-3">141,446</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c123854669" contextRef="d_2023-01-01_2023-12-31" unitRef="USD" name="us-gaap:OperatingExpenses" scale="3" format="ixt:num-dot-decimal" decimals="-3">105,957</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c123854670" contextRef="d_2022-01-01_2022-12-31" unitRef="USD" name="us-gaap:OperatingExpenses" scale="3" format="ixt:num-dot-decimal" decimals="-4">80,020</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Operating loss</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c123854671" contextRef="d_2024-01-01_2024-12-31" unitRef="USD" name="us-gaap:OperatingIncomeLoss" scale="3" format="ixt:num-dot-decimal" decimals="-3" sign="-">141,446</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c123854672" contextRef="d_2023-01-01_2023-12-31" unitRef="USD" name="us-gaap:OperatingIncomeLoss" scale="3" format="ixt:num-dot-decimal" decimals="-3" sign="-">105,957</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c123854673" contextRef="d_2022-01-01_2022-12-31" unitRef="USD" name="us-gaap:OperatingIncomeLoss" scale="3" format="ixt:num-dot-decimal" decimals="-4" sign="-">80,020</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">Interest income</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c123854674" contextRef="d_2024-01-01_2024-12-31" unitRef="USD" name="us-gaap:InterestIncomeExpenseNonoperatingNet" scale="3" format="ixt:num-dot-decimal" decimals="-4">8,510</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c123854675" contextRef="d_2023-01-01_2023-12-31" unitRef="USD" name="us-gaap:InterestIncomeExpenseNonoperatingNet" scale="3" format="ixt:num-dot-decimal" decimals="-3">7,833</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c123854676" contextRef="d_2022-01-01_2022-12-31" unitRef="USD" name="us-gaap:InterestIncomeExpenseNonoperatingNet" scale="3" format="ixt:num-dot-decimal" decimals="-3">2,777</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">Other income, net</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c123854677" contextRef="d_2024-01-01_2024-12-31" unitRef="USD" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" format="ixt:num-dot-decimal" decimals="-3">411</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c123854678" contextRef="d_2023-01-01_2023-12-31" unitRef="USD" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" format="ixt:num-dot-decimal" decimals="-3">907</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c123854679" contextRef="d_2022-01-01_2022-12-31" unitRef="USD" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" format="ixt:num-dot-decimal" decimals="-3">997</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px;"> <p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">Gain from change in fair value of warrant liabilities</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c123854680" contextRef="d_2024-01-01_2024-12-31" unitRef="USD" name="us-gaap:FairValueAdjustmentOfWarrants" scale="3" format="ixt:num-dot-decimal" decimals="-3" sign="-">108,183</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c123854681" contextRef="d_2023-01-01_2023-12-31" unitRef="USD" name="us-gaap:FairValueAdjustmentOfWarrants" scale="3" format="ixt:fixed-zero" decimals="-3" sign="-">&#8212;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c123854682" contextRef="d_2022-01-01_2022-12-31" unitRef="USD" name="us-gaap:FairValueAdjustmentOfWarrants" scale="3" format="ixt:fixed-zero" decimals="-3" sign="-">&#8212;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">Net loss</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(<ix:nonFraction id="c123854683" contextRef="d_2024-01-01_2024-12-31" unitRef="USD" name="us-gaap:NetIncomeLoss" scale="3" format="ixt:num-dot-decimal" decimals="-3" sign="-">24,342</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(<ix:nonFraction id="c123854684" contextRef="d_2023-01-01_2023-12-31" unitRef="USD" name="us-gaap:NetIncomeLoss" scale="3" format="ixt:num-dot-decimal" decimals="-3" sign="-">97,217</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(<ix:nonFraction id="c123854685" contextRef="d_2022-01-01_2022-12-31" unitRef="USD" name="us-gaap:NetIncomeLoss" scale="3" format="ixt:num-dot-decimal" decimals="-3" sign="-">76,246</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">)</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> <p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">Shares used in computing net loss per share, basic</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"><ix:nonFraction id="c123854686" contextRef="d_2024-01-01_2024-12-31" unitRef="Share" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="3" format="ixt:num-dot-decimal" decimals="-3">46,329</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"><ix:nonFraction id="c123854687" contextRef="d_2023-01-01_2023-12-31" unitRef="Share" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="3" format="ixt:num-dot-decimal" decimals="-3">41,932</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"><ix:nonFraction id="c123854688" contextRef="d_2022-01-01_2022-12-31" unitRef="Share" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="3" format="ixt:num-dot-decimal" decimals="-3">40,202</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> <p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">Net loss per share, basic</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">(<ix:nonFraction id="c123854689" contextRef="d_2024-01-01_2024-12-31" unitRef="USDPerShare" name="us-gaap:EarningsPerShareBasic" scale="0" format="ixt:num-dot-decimal" decimals="INF" sign="-">0.53</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">(<ix:nonFraction id="c123854690" contextRef="d_2023-01-01_2023-12-31" unitRef="USDPerShare" name="us-gaap:EarningsPerShareBasic" scale="0" format="ixt:num-dot-decimal" decimals="INF" sign="-">2.32</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">(<ix:nonFraction id="c123854691" contextRef="d_2022-01-01_2022-12-31" unitRef="USDPerShare" name="us-gaap:EarningsPerShareBasic" scale="0" format="ixt:num-dot-decimal" decimals="INF" sign="-">1.90</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">)</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 55%; padding: 0; margin: 0"> <p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">Numerator, diluted:</p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> <p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">Net loss</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">(<ix:nonFraction id="c123854692" contextRef="d_2024-01-01_2024-12-31" unitRef="USD" name="us-gaap:NetIncomeLoss" scale="3" format="ixt:num-dot-decimal" decimals="-3" sign="-">24,342</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">(<ix:nonFraction id="c123854693" contextRef="d_2023-01-01_2023-12-31" unitRef="USD" name="us-gaap:NetIncomeLoss" scale="3" format="ixt:num-dot-decimal" decimals="-3" sign="-">97,217</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">(<ix:nonFraction id="c123854694" contextRef="d_2022-01-01_2022-12-31" unitRef="USD" name="us-gaap:NetIncomeLoss" scale="3" format="ixt:num-dot-decimal" decimals="-3" sign="-">76,246</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">)</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px;"> <p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">Adjustment for change in fair value of warrant liabilities</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);">(<ix:nonFraction id="c123854695" contextRef="d_2024-01-01_2024-12-31" unitRef="USD" name="us-gaap:PreferredStockDividendsAndOtherAdjustments" scale="3" format="ixt:num-dot-decimal" decimals="-3">43,793</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c123854696" contextRef="d_2023-01-01_2023-12-31" unitRef="USD" name="us-gaap:PreferredStockDividendsAndOtherAdjustments" scale="3" format="ixt:fixed-zero" decimals="-3" sign="-">&#8212;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c123854697" contextRef="d_2022-01-01_2022-12-31" unitRef="USD" name="us-gaap:PreferredStockDividendsAndOtherAdjustments" scale="3" format="ixt:fixed-zero" decimals="-3" sign="-">&#8212;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> <p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">Adjusted numerator, diluted</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">(<ix:nonFraction id="c123854698" contextRef="d_2024-01-01_2024-12-31" unitRef="USD" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted" scale="3" format="ixt:num-dot-decimal" decimals="-3" sign="-">68,135</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">(<ix:nonFraction id="c123854699" contextRef="d_2023-01-01_2023-12-31" unitRef="USD" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted" scale="3" format="ixt:num-dot-decimal" decimals="-3" sign="-">97,217</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">(<ix:nonFraction id="c123854700" contextRef="d_2022-01-01_2022-12-31" unitRef="USD" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted" scale="3" format="ixt:num-dot-decimal" decimals="-3" sign="-">76,246</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">)</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">Shares used in computing net loss per share, diluted</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c123854701" contextRef="d_2024-01-01_2024-12-31" unitRef="Share" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="3" format="ixt:num-dot-decimal" decimals="-3">46,604</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c123854702" contextRef="d_2023-01-01_2023-12-31" unitRef="Share" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="3" format="ixt:num-dot-decimal" decimals="-3">41,932</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c123854703" contextRef="d_2022-01-01_2022-12-31" unitRef="Share" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="3" format="ixt:num-dot-decimal" decimals="-3">40,202</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">Net loss per share, diluted</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(<ix:nonFraction id="c123854704" contextRef="d_2024-01-01_2024-12-31" unitRef="USDPerShare" name="us-gaap:EarningsPerShareDiluted" scale="0" format="ixt:num-dot-decimal" decimals="INF" sign="-">1.46</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(<ix:nonFraction id="c123854705" contextRef="d_2023-01-01_2023-12-31" unitRef="USDPerShare" name="us-gaap:EarningsPerShareDiluted" scale="0" format="ixt:num-dot-decimal" decimals="INF" sign="-">2.32</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(<ix:nonFraction id="c123854706" contextRef="d_2022-01-01_2022-12-31" unitRef="USDPerShare" name="us-gaap:EarningsPerShareDiluted" scale="0" format="ixt:num-dot-decimal" decimals="INF" sign="-">1.90</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">)</td></tr>
</tbody></table>
  </div>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">See accompanying notes to consolidated financial statements.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
      94
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <div>
   &#160;
  </div>
  <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center;">&#160;</p>
  <p style="font-family: Times New Roman; font-size: 10pt; margin: 0pt; text-align: center;"><b><a id="equity" title="equity" href="#"></a>CASSAVA SCIENCES, INC.</b></p>
  <p style="font-family: Times New Roman; font-size: 10pt; margin: 0pt; text-align: center;">&#160;</p>
  <p style="font-family: Times New Roman; font-size: 10pt; margin: 0pt; text-align: center;"><b>CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY</b></p>
  <p style="font-family: Times New Roman; font-size: 10pt; margin: 0pt; text-align: center;"><b>(In thousands, except share data)</b></p>
  <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">&#160;</p>
  <div>
   <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"><tbody><tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td></tr>
<tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><em style="font: inherit;">&#160;</em></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><em style="font: inherit;">&#160;</em></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><em style="font: inherit;">&#160;</em></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><em style="font: inherit;">&#160;</em></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">Total</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;"><em style="font: inherit;">Common stock</em></em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">Additional</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">Accumulated</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">stockholders'</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr class="finHeading" style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">Shares</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">Par value</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">paid-in capital</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">deficit</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">equity</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 40%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>Balance at December 31, 2021</b></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c123854724" contextRef="i_2021-12-31_StatementEquityComponentsAxis-CommonStockMember" unitRef="Share" name="us-gaap:SharesOutstanding" scale="0" format="ixt:num-dot-decimal" decimals="INF">40,016,792</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c123854725" contextRef="i_2021-12-31_StatementEquityComponentsAxis-CommonStockMember" unitRef="USD" name="us-gaap:StockholdersEquity" scale="3" format="ixt:num-dot-decimal" decimals="-4">40</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c123854726" contextRef="i_2021-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember" unitRef="USD" name="us-gaap:StockholdersEquity" scale="3" format="ixt:num-dot-decimal" decimals="-3">461,181</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c123854727" contextRef="i_2021-12-31_StatementEquityComponentsAxis-RetainedEarningsMember" unitRef="USD" name="us-gaap:StockholdersEquity" scale="3" format="ixt:num-dot-decimal" decimals="-3" sign="-">207,306</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c123854728" contextRef="i_2021-12-31" unitRef="USD" name="us-gaap:StockholdersEquity" scale="3" format="ixt:num-dot-decimal" decimals="-3">253,915</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Stock-based compensation for:</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">Stock options for employees</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><em style="font: inherit;">&#8212;</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c123854730" contextRef="d_2022-01-01_2022-12-31_GranteeStatusAxis-ShareBasedPaymentArrangementEmployeeMember_StatementEquityComponentsAxis-CommonStockMember" unitRef="USD" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" scale="3" format="ixt:fixed-zero" decimals="-3">&#8212;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c123854731" contextRef="d_2022-01-01_2022-12-31_GranteeStatusAxis-ShareBasedPaymentArrangementEmployeeMember_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember" unitRef="USD" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" scale="3" format="ixt:num-dot-decimal" decimals="-3">1,972</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c123854732" contextRef="d_2022-01-01_2022-12-31_GranteeStatusAxis-ShareBasedPaymentArrangementEmployeeMember_StatementEquityComponentsAxis-RetainedEarningsMember" unitRef="USD" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" scale="3" format="ixt:fixed-zero" decimals="-3">&#8212;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c123854733" contextRef="d_2022-01-01_2022-12-31_GranteeStatusAxis-ShareBasedPaymentArrangementEmployeeMember" unitRef="USD" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" scale="3" format="ixt:num-dot-decimal" decimals="-3">1,972</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">Stock options for non-employees</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><em style="font: inherit;">&#8212;</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c123854735" contextRef="d_2022-01-01_2022-12-31_GranteeStatusAxis-ShareBasedPaymentArrangementNonemployeeMember_StatementEquityComponentsAxis-CommonStockMember" unitRef="USD" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" scale="3" format="ixt:fixed-zero" decimals="-3">&#8212;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c123854736" contextRef="d_2022-01-01_2022-12-31_GranteeStatusAxis-ShareBasedPaymentArrangementNonemployeeMember_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember" unitRef="USD" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" scale="3" format="ixt:num-dot-decimal" decimals="-3">94</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c123854737" contextRef="d_2022-01-01_2022-12-31_GranteeStatusAxis-ShareBasedPaymentArrangementNonemployeeMember_StatementEquityComponentsAxis-RetainedEarningsMember" unitRef="USD" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" scale="3" format="ixt:fixed-zero" decimals="-3">&#8212;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c123854738" contextRef="d_2022-01-01_2022-12-31_GranteeStatusAxis-ShareBasedPaymentArrangementNonemployeeMember" unitRef="USD" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" scale="3" format="ixt:num-dot-decimal" decimals="-3">94</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Expiration of restricted stock Performance Awards</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c123854739" contextRef="d_2022-01-01_2022-12-31_StatementEquityComponentsAxis-CommonStockMember" unitRef="Share" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensationForfeited" scale="0" format="ixt:num-dot-decimal" decimals="INF">57,143</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c123854740" contextRef="d_2022-01-01_2022-12-31_StatementEquityComponentsAxis-CommonStockMember" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationForfeited" scale="3" format="ixt:fixed-zero" decimals="-3" sign="-">&#8212;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c123854741" contextRef="d_2022-01-01_2022-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationForfeited" scale="3" format="ixt:fixed-zero" decimals="-3" sign="-">&#8212;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c123854742" contextRef="d_2022-01-01_2022-12-31_StatementEquityComponentsAxis-RetainedEarningsMember" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationForfeited" scale="3" format="ixt:fixed-zero" decimals="-3" sign="-">&#8212;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c123854743" contextRef="d_2022-01-01_2022-12-31" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationForfeited" scale="3" format="ixt:fixed-zero" decimals="-3" sign="-">&#8212;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Issuance of common stock pursuant to exercise of stock options</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c123854744" contextRef="d_2022-01-01_2022-12-31_StatementEquityComponentsAxis-CommonStockMember" unitRef="Share" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" format="ixt:num-dot-decimal" decimals="INF">109,241</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c123854745" contextRef="d_2022-01-01_2022-12-31_StatementEquityComponentsAxis-CommonStockMember" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" format="ixt:fixed-zero" decimals="-3">&#8212;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c123854746" contextRef="d_2022-01-01_2022-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" format="ixt:num-dot-decimal" decimals="-3">475</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c123854747" contextRef="d_2022-01-01_2022-12-31_StatementEquityComponentsAxis-RetainedEarningsMember" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" format="ixt:fixed-zero" decimals="-3">&#8212;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c123854748" contextRef="d_2022-01-01_2022-12-31" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" format="ixt:num-dot-decimal" decimals="-3">475</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Issuance of common stock pursuant to stock offering, net of issuance costs</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c123854749" contextRef="d_2022-01-01_2022-12-31_StatementEquityComponentsAxis-CommonStockMember" unitRef="Share" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" format="ixt:num-dot-decimal" decimals="INF">1,666,667</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c123854750" contextRef="d_2022-01-01_2022-12-31_StatementEquityComponentsAxis-CommonStockMember" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" format="ixt:num-dot-decimal" decimals="-3">2</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c123854751" contextRef="d_2022-01-01_2022-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" format="ixt:num-dot-decimal" decimals="-3">47,327</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c123854752" contextRef="d_2022-01-01_2022-12-31_StatementEquityComponentsAxis-RetainedEarningsMember" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" format="ixt:fixed-zero" decimals="-3">&#8212;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c123854753" contextRef="d_2022-01-01_2022-12-31" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" format="ixt:num-dot-decimal" decimals="-3">47,329</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Net loss</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"><em style="font: inherit;">&#8212;</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"><ix:nonFraction id="c123854755" contextRef="d_2022-01-01_2022-12-31_StatementEquityComponentsAxis-CommonStockMember" unitRef="USD" name="us-gaap:NetIncomeLoss" scale="3" format="ixt:fixed-zero" decimals="-3">&#8212;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"><ix:nonFraction id="c123854756" contextRef="d_2022-01-01_2022-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember" unitRef="USD" name="us-gaap:NetIncomeLoss" scale="3" format="ixt:fixed-zero" decimals="-3">&#8212;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(<ix:nonFraction id="c123854757" contextRef="d_2022-01-01_2022-12-31_StatementEquityComponentsAxis-RetainedEarningsMember" unitRef="USD" name="us-gaap:NetIncomeLoss" scale="3" format="ixt:num-dot-decimal" decimals="-3" sign="-">76,246</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(<ix:nonFraction id="c123854758" contextRef="d_2022-01-01_2022-12-31" unitRef="USD" name="us-gaap:NetIncomeLoss" scale="3" format="ixt:num-dot-decimal" decimals="-3" sign="-">76,246</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>Balance at December 31, 2022</b></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c123854759" contextRef="i_2022-12-31_StatementEquityComponentsAxis-CommonStockMember" unitRef="Share" name="us-gaap:SharesOutstanding" scale="0" format="ixt:num-dot-decimal" decimals="INF">41,735,557</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c123854760" contextRef="i_2022-12-31_StatementEquityComponentsAxis-CommonStockMember" unitRef="USD" name="us-gaap:StockholdersEquity" scale="3" format="ixt:num-dot-decimal" decimals="-3">42</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c123854761" contextRef="i_2022-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember" unitRef="USD" name="us-gaap:StockholdersEquity" scale="3" format="ixt:num-dot-decimal" decimals="-3">511,049</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c123854762" contextRef="i_2022-12-31_StatementEquityComponentsAxis-RetainedEarningsMember" unitRef="USD" name="us-gaap:StockholdersEquity" scale="3" format="ixt:num-dot-decimal" decimals="-3" sign="-">283,552</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c123854763" contextRef="i_2022-12-31" unitRef="USD" name="us-gaap:StockholdersEquity" scale="3" format="ixt:num-dot-decimal" decimals="-3">227,539</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Stock-based compensation for:</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">Stock options for employees</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><em style="font: inherit;">&#8212;</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c123854765" contextRef="d_2023-01-01_2023-12-31_GranteeStatusAxis-ShareBasedPaymentArrangementEmployeeMember_StatementEquityComponentsAxis-CommonStockMember" unitRef="USD" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" scale="3" format="ixt:fixed-zero" decimals="-3">&#8212;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c123854766" contextRef="d_2023-01-01_2023-12-31_GranteeStatusAxis-ShareBasedPaymentArrangementEmployeeMember_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember" unitRef="USD" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" scale="3" format="ixt:num-dot-decimal" decimals="-3">4,493</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c123854767" contextRef="d_2023-01-01_2023-12-31_GranteeStatusAxis-ShareBasedPaymentArrangementEmployeeMember_StatementEquityComponentsAxis-RetainedEarningsMember" unitRef="USD" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" scale="3" format="ixt:fixed-zero" decimals="-3">&#8212;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c123854768" contextRef="d_2023-01-01_2023-12-31_GranteeStatusAxis-ShareBasedPaymentArrangementEmployeeMember" unitRef="USD" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" scale="3" format="ixt:num-dot-decimal" decimals="-3">4,493</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">Stock options for non-employees</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><em style="font: inherit;">&#8212;</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c123854770" contextRef="d_2023-01-01_2023-12-31_GranteeStatusAxis-ShareBasedPaymentArrangementNonemployeeMember_StatementEquityComponentsAxis-CommonStockMember" unitRef="USD" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" scale="3" format="ixt:fixed-zero" decimals="-3">&#8212;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c123854771" contextRef="d_2023-01-01_2023-12-31_GranteeStatusAxis-ShareBasedPaymentArrangementNonemployeeMember_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember" unitRef="USD" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" scale="3" format="ixt:num-dot-decimal" decimals="-3">93</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c123854772" contextRef="d_2023-01-01_2023-12-31_GranteeStatusAxis-ShareBasedPaymentArrangementNonemployeeMember_StatementEquityComponentsAxis-RetainedEarningsMember" unitRef="USD" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" scale="3" format="ixt:fixed-zero" decimals="-3">&#8212;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c123854773" contextRef="d_2023-01-01_2023-12-31_GranteeStatusAxis-ShareBasedPaymentArrangementNonemployeeMember" unitRef="USD" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" scale="3" format="ixt:num-dot-decimal" decimals="-3">93</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Issuance of common stock pursuant to exercise of stock options</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c123854774" contextRef="d_2023-01-01_2023-12-31_StatementEquityComponentsAxis-CommonStockMember" unitRef="Share" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" format="ixt:num-dot-decimal" decimals="INF">501,362</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c123854775" contextRef="d_2023-01-01_2023-12-31_StatementEquityComponentsAxis-CommonStockMember" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" format="ixt:fixed-zero" decimals="-3">&#8212;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c123854776" contextRef="d_2023-01-01_2023-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" format="ixt:num-dot-decimal" decimals="-4">2,560</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c123854777" contextRef="d_2023-01-01_2023-12-31_StatementEquityComponentsAxis-RetainedEarningsMember" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" format="ixt:fixed-zero" decimals="-3">&#8212;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c123854778" contextRef="d_2023-01-01_2023-12-31" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" format="ixt:num-dot-decimal" decimals="-4">2,560</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Net loss</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"><em style="font: inherit;">&#8212;</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"><ix:nonFraction id="c123854780" contextRef="d_2023-01-01_2023-12-31_StatementEquityComponentsAxis-CommonStockMember" unitRef="USD" name="us-gaap:NetIncomeLoss" scale="3" format="ixt:fixed-zero" decimals="-3">&#8212;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"><ix:nonFraction id="c123854781" contextRef="d_2023-01-01_2023-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember" unitRef="USD" name="us-gaap:NetIncomeLoss" scale="3" format="ixt:fixed-zero" decimals="-3">&#8212;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(<ix:nonFraction id="c123854782" contextRef="d_2023-01-01_2023-12-31_StatementEquityComponentsAxis-RetainedEarningsMember" unitRef="USD" name="us-gaap:NetIncomeLoss" scale="3" format="ixt:num-dot-decimal" decimals="-3" sign="-">97,217</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(<ix:nonFraction id="c123854783" contextRef="d_2023-01-01_2023-12-31" unitRef="USD" name="us-gaap:NetIncomeLoss" scale="3" format="ixt:num-dot-decimal" decimals="-3" sign="-">97,217</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>Balance at December 31, 2023</b></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c123854784" contextRef="i_2023-12-31_StatementEquityComponentsAxis-CommonStockMember" unitRef="Share" name="us-gaap:SharesOutstanding" scale="0" format="ixt:num-dot-decimal" decimals="INF">42,236,919</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c123854785" contextRef="i_2023-12-31_StatementEquityComponentsAxis-CommonStockMember" unitRef="USD" name="us-gaap:StockholdersEquity" scale="3" format="ixt:num-dot-decimal" decimals="-3">42</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c123854786" contextRef="i_2023-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember" unitRef="USD" name="us-gaap:StockholdersEquity" scale="3" format="ixt:num-dot-decimal" decimals="-3">518,195</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(<ix:nonFraction id="c123854787" contextRef="i_2023-12-31_StatementEquityComponentsAxis-RetainedEarningsMember" unitRef="USD" name="us-gaap:StockholdersEquity" scale="3" format="ixt:num-dot-decimal" decimals="-3" sign="-">380,769</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c123854788" contextRef="i_2023-12-31" unitRef="USD" name="us-gaap:StockholdersEquity" scale="3" format="ixt:num-dot-decimal" decimals="-3">137,468</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Stock-based compensation for:</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">Stock options for employees</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><em style="font: inherit;">&#8212;</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c123854790" contextRef="d_2024-01-01_2024-12-31_GranteeStatusAxis-ShareBasedPaymentArrangementEmployeeMember_StatementEquityComponentsAxis-CommonStockMember" unitRef="USD" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" scale="3" format="ixt:fixed-zero" decimals="-3">&#8212;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c123854791" contextRef="d_2024-01-01_2024-12-31_GranteeStatusAxis-ShareBasedPaymentArrangementEmployeeMember_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember" unitRef="USD" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" scale="3" format="ixt:num-dot-decimal" decimals="-3">15,054</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c123854792" contextRef="d_2024-01-01_2024-12-31_GranteeStatusAxis-ShareBasedPaymentArrangementEmployeeMember_StatementEquityComponentsAxis-RetainedEarningsMember" unitRef="USD" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" scale="3" format="ixt:fixed-zero" decimals="-3">&#8212;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c123854793" contextRef="d_2024-01-01_2024-12-31_GranteeStatusAxis-ShareBasedPaymentArrangementEmployeeMember" unitRef="USD" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" scale="3" format="ixt:num-dot-decimal" decimals="-3">15,054</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">Stock options for non-employees</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><em style="font: inherit;">&#8212;</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c123854795" contextRef="d_2024-01-01_2024-12-31_GranteeStatusAxis-ShareBasedPaymentArrangementNonemployeeMember_StatementEquityComponentsAxis-CommonStockMember" unitRef="USD" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" scale="3" format="ixt:fixed-zero" decimals="-3">&#8212;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c123854796" contextRef="d_2024-01-01_2024-12-31_GranteeStatusAxis-ShareBasedPaymentArrangementNonemployeeMember_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember" unitRef="USD" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" scale="3" format="ixt:num-dot-decimal" decimals="-3">1,237</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c123854797" contextRef="d_2024-01-01_2024-12-31_GranteeStatusAxis-ShareBasedPaymentArrangementNonemployeeMember_StatementEquityComponentsAxis-RetainedEarningsMember" unitRef="USD" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" scale="3" format="ixt:fixed-zero" decimals="-3">&#8212;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c123854798" contextRef="d_2024-01-01_2024-12-31_GranteeStatusAxis-ShareBasedPaymentArrangementNonemployeeMember" unitRef="USD" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" scale="3" format="ixt:num-dot-decimal" decimals="-3">1,237</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Issuance of warrants</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><em style="font: inherit;">&#8212;</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c123854800" contextRef="d_2024-01-01_2024-12-31_StatementEquityComponentsAxis-CommonStockMember" unitRef="USD" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" scale="3" format="ixt:fixed-zero" decimals="-3" sign="-">&#8212;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c123854801" contextRef="d_2024-01-01_2024-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember" unitRef="USD" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" scale="3" format="ixt:num-dot-decimal" decimals="-3">113,363</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c123854802" contextRef="d_2024-01-01_2024-12-31_StatementEquityComponentsAxis-RetainedEarningsMember" unitRef="USD" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" scale="3" format="ixt:fixed-zero" decimals="-3" sign="-">&#8212;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c123854803" contextRef="d_2024-01-01_2024-12-31" unitRef="USD" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" scale="3" format="ixt:num-dot-decimal" decimals="-3">113,363</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Common stock issued pursuant to warrant exercises, net of exercise costs</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c123854804" contextRef="d_2024-01-01_2024-12-31_StatementEquityComponentsAxis-CommonStockMember" unitRef="Share" name="sava:StockIssuedDuringPeriodSharesWarrantExercises" scale="0" format="ixt:num-dot-decimal" decimals="INF">5,739,247</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c123854805" contextRef="d_2024-01-01_2024-12-31_StatementEquityComponentsAxis-CommonStockMember" unitRef="USD" name="sava:StockIssuedDuringPeriodValueWarrantExercises" scale="3" format="ixt:num-dot-decimal" decimals="-3">6</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c123854806" contextRef="d_2024-01-01_2024-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember" unitRef="USD" name="sava:StockIssuedDuringPeriodValueWarrantExercises" scale="3" format="ixt:num-dot-decimal" decimals="-3">123,546</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c123854807" contextRef="d_2024-01-01_2024-12-31_StatementEquityComponentsAxis-RetainedEarningsMember" unitRef="USD" name="sava:StockIssuedDuringPeriodValueWarrantExercises" scale="3" format="ixt:fixed-zero" decimals="-3">&#8212;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c123854808" contextRef="d_2024-01-01_2024-12-31" unitRef="USD" name="sava:StockIssuedDuringPeriodValueWarrantExercises" scale="3" format="ixt:num-dot-decimal" decimals="-3">123,552</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Derecognition of warrant liabilities upon exercise of warrants</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><em style="font: inherit;">&#8212;</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c123854810" contextRef="d_2024-01-01_2024-12-31_StatementEquityComponentsAxis-CommonStockMember" unitRef="USD" name="sava:AdjustmentsToAdditionalPaidInCapitalDerecognitionOfWarrantLiabilitiesUponExerciseOfWarrants" scale="3" format="ixt:fixed-zero" decimals="-3">&#8212;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c123854811" contextRef="d_2024-01-01_2024-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember" unitRef="USD" name="sava:AdjustmentsToAdditionalPaidInCapitalDerecognitionOfWarrantLiabilitiesUponExerciseOfWarrants" scale="3" format="ixt:num-dot-decimal" decimals="-4">5,180</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c123854812" contextRef="d_2024-01-01_2024-12-31_StatementEquityComponentsAxis-RetainedEarningsMember" unitRef="USD" name="sava:AdjustmentsToAdditionalPaidInCapitalDerecognitionOfWarrantLiabilitiesUponExerciseOfWarrants" scale="3" format="ixt:fixed-zero" decimals="-3">&#8212;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c123854813" contextRef="d_2024-01-01_2024-12-31" unitRef="USD" name="sava:AdjustmentsToAdditionalPaidInCapitalDerecognitionOfWarrantLiabilitiesUponExerciseOfWarrants" scale="3" format="ixt:num-dot-decimal" decimals="-4">5,180</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Issuance of common stock pursuant to exercise of stock options</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c123854814" contextRef="d_2024-01-01_2024-12-31_StatementEquityComponentsAxis-CommonStockMember" unitRef="Share" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" format="ixt:num-dot-decimal" decimals="INF">227,013</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c123854815" contextRef="d_2024-01-01_2024-12-31_StatementEquityComponentsAxis-CommonStockMember" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" format="ixt:fixed-zero" decimals="-3">&#8212;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c123854816" contextRef="d_2024-01-01_2024-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" format="ixt:num-dot-decimal" decimals="-3">918</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c123854817" contextRef="d_2024-01-01_2024-12-31_StatementEquityComponentsAxis-RetainedEarningsMember" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" format="ixt:fixed-zero" decimals="-3">&#8212;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c123854818" contextRef="d_2024-01-01_2024-12-31" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" format="ixt:num-dot-decimal" decimals="-3">918</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Net loss</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"><em style="font: inherit;">&#8212;</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"><ix:nonFraction id="c123854820" contextRef="d_2024-01-01_2024-12-31_StatementEquityComponentsAxis-CommonStockMember" unitRef="USD" name="us-gaap:NetIncomeLoss" scale="3" format="ixt:fixed-zero" decimals="-3">&#8212;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"><ix:nonFraction id="c123854821" contextRef="d_2024-01-01_2024-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember" unitRef="USD" name="us-gaap:NetIncomeLoss" scale="3" format="ixt:fixed-zero" decimals="-3">&#8212;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(<ix:nonFraction id="c123854822" contextRef="d_2024-01-01_2024-12-31_StatementEquityComponentsAxis-RetainedEarningsMember" unitRef="USD" name="us-gaap:NetIncomeLoss" scale="3" format="ixt:num-dot-decimal" decimals="-3" sign="-">24,342</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(<ix:nonFraction id="c123854823" contextRef="d_2024-01-01_2024-12-31" unitRef="USD" name="us-gaap:NetIncomeLoss" scale="3" format="ixt:num-dot-decimal" decimals="-3" sign="-">24,342</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>Balance at December 31, 2024</b></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c123854824" contextRef="i_2024-12-31_StatementEquityComponentsAxis-CommonStockMember" unitRef="Share" name="us-gaap:SharesOutstanding" scale="0" format="ixt:num-dot-decimal" decimals="INF">48,203,179</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c123854825" contextRef="i_2024-12-31_StatementEquityComponentsAxis-CommonStockMember" unitRef="USD" name="us-gaap:StockholdersEquity" scale="3" format="ixt:num-dot-decimal" decimals="-3">48</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c123854826" contextRef="i_2024-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember" unitRef="USD" name="us-gaap:StockholdersEquity" scale="3" format="ixt:num-dot-decimal" decimals="-3">550,767</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(<ix:nonFraction id="c123854827" contextRef="i_2024-12-31_StatementEquityComponentsAxis-RetainedEarningsMember" unitRef="USD" name="us-gaap:StockholdersEquity" scale="3" format="ixt:num-dot-decimal" decimals="-3" sign="-">405,111</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c123854828" contextRef="i_2024-12-31" unitRef="USD" name="us-gaap:StockholdersEquity" scale="3" format="ixt:num-dot-decimal" decimals="-3">145,704</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td></tr>
</tbody></table>
  </div>
  <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">See accompanying notes to consolidated financial statements.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">&#160;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
      95
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <div>
   &#160;
  </div>
  <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center;">&#160;</p>
  <p style="font-family: Times New Roman; font-size: 10pt; margin: 0pt; text-align: center;"><b><a id="cash_flows" title="cash flows" href="#"></a>CASSAVA SCIENCES, INC.</b></p>
  <p style="font-family: Times New Roman; font-size: 10pt; margin: 0pt; text-align: center;">&#160;</p>
  <p style="font-family: Times New Roman; font-size: 10pt; margin: 0pt; text-align: center;"><b>CONSOLIDATED STATEMENTS OF CASH FLOWS</b></p>
  <p style="font-family: Times New Roman; font-size: 10pt; margin: 0pt; text-align: center;"><b>(In thousands)</b></p>
  <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">&#160;</p>
  <div>
   <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="10" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;"><em style="font: inherit;"><em style="font: inherit;">Years ended December 31,</em></em></em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">2024</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">2023</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">2022</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 55%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;"><b>Cash flows from operating activities:</b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt; text-indent: -9pt;">Net loss</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c123854838" contextRef="d_2024-01-01_2024-12-31" unitRef="USD" name="us-gaap:NetIncomeLoss" scale="3" format="ixt:num-dot-decimal" decimals="-3" sign="-">24,342</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c123854839" contextRef="d_2023-01-01_2023-12-31" unitRef="USD" name="us-gaap:NetIncomeLoss" scale="3" format="ixt:num-dot-decimal" decimals="-3" sign="-">97,217</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c123854840" contextRef="d_2022-01-01_2022-12-31" unitRef="USD" name="us-gaap:NetIncomeLoss" scale="3" format="ixt:num-dot-decimal" decimals="-3" sign="-">76,246</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt; text-indent: -9pt;">Adjustments to reconcile net loss to net cash used in operating activities:</p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 27pt; text-indent: -9pt;">Stock-based compensation</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c123854841" contextRef="d_2024-01-01_2024-12-31" unitRef="USD" name="us-gaap:ShareBasedCompensation" scale="3" format="ixt:num-dot-decimal" decimals="-3">16,291</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c123854842" contextRef="d_2023-01-01_2023-12-31" unitRef="USD" name="us-gaap:ShareBasedCompensation" scale="3" format="ixt:num-dot-decimal" decimals="-3">4,586</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c123854843" contextRef="d_2022-01-01_2022-12-31" unitRef="USD" name="us-gaap:ShareBasedCompensation" scale="3" format="ixt:num-dot-decimal" decimals="-3">2,066</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> <p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">Gain from change in fair value of warrant liabilities</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">(<ix:nonFraction id="c123854844" contextRef="d_2024-01-01_2024-12-31" unitRef="USD" name="us-gaap:FairValueAdjustmentOfWarrants" scale="3" format="ixt:num-dot-decimal" decimals="-3" sign="-">108,183</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"><ix:nonFraction id="c123854845" contextRef="d_2023-01-01_2023-12-31" unitRef="USD" name="us-gaap:FairValueAdjustmentOfWarrants" scale="3" format="ixt:fixed-zero" decimals="-3">&#8212;</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"><ix:nonFraction id="c123854846" contextRef="d_2022-01-01_2022-12-31" unitRef="USD" name="us-gaap:FairValueAdjustmentOfWarrants" scale="3" format="ixt:fixed-zero" decimals="-3">&#8212;</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 27pt; text-indent: -9pt;">Depreciation</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c123854847" contextRef="d_2024-01-01_2024-12-31" unitRef="USD" name="us-gaap:Depreciation" scale="3" format="ixt:num-dot-decimal" decimals="-3">952</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c123854848" contextRef="d_2023-01-01_2023-12-31" unitRef="USD" name="us-gaap:Depreciation" scale="3" format="ixt:num-dot-decimal" decimals="-3">1,084</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c123854849" contextRef="d_2022-01-01_2022-12-31" unitRef="USD" name="us-gaap:Depreciation" scale="3" format="ixt:num-dot-decimal" decimals="-3">804</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 27pt; text-indent: -9pt;">Amortization of intangible assets</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c123854850" contextRef="d_2024-01-01_2024-12-31" unitRef="USD" name="us-gaap:AmortizationOfIntangibleAssets" scale="3" format="ixt:num-dot-decimal" decimals="-4">180</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c123854851" contextRef="d_2023-01-01_2023-12-31" unitRef="USD" name="us-gaap:AmortizationOfIntangibleAssets" scale="3" format="ixt:num-dot-decimal" decimals="-3">446</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c123854852" contextRef="d_2022-01-01_2022-12-31" unitRef="USD" name="us-gaap:AmortizationOfIntangibleAssets" scale="3" format="ixt:num-dot-decimal" decimals="-3">497</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 27pt; text-indent: -9pt;">Changes in operating assets and liabilities:</p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: -9pt;">Prepaid expenses and other current assets</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c123854853" contextRef="d_2024-01-01_2024-12-31" unitRef="USD" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="3" format="ixt:num-dot-decimal" decimals="-3" sign="-">539</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c123854854" contextRef="d_2023-01-01_2023-12-31" unitRef="USD" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="3" format="ixt:num-dot-decimal" decimals="-3" sign="-">1,714</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c123854855" contextRef="d_2022-01-01_2022-12-31" unitRef="USD" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="3" format="ixt:num-dot-decimal" decimals="-3" sign="-">1,189</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: -9pt;">Operating lease right-of-use assets and liabilities</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c123854856" contextRef="d_2024-01-01_2024-12-31" unitRef="USD" name="sava:IncreaseDecreaseInOperatingLeaseRightOfUseAssetsAndLiabilitiesNet" scale="3" format="ixt:fixed-zero" decimals="-3" sign="-">&#8212;</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c123854857" contextRef="d_2023-01-01_2023-12-31" unitRef="USD" name="sava:IncreaseDecreaseInOperatingLeaseRightOfUseAssetsAndLiabilitiesNet" scale="3" format="ixt:num-dot-decimal" decimals="-3">17</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">(<ix:nonFraction id="c123854858" contextRef="d_2022-01-01_2022-12-31" unitRef="USD" name="sava:IncreaseDecreaseInOperatingLeaseRightOfUseAssetsAndLiabilitiesNet" scale="3" format="ixt:num-dot-decimal" decimals="-3">9</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">)</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: -9pt;">Accounts payable and other accrued expenses</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c123854859" contextRef="d_2024-01-01_2024-12-31" unitRef="USD" name="us-gaap:IncreaseDecreaseInAccountsPayable" scale="3" format="ixt:num-dot-decimal" decimals="-3" sign="-">2,919</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c123854860" contextRef="d_2023-01-01_2023-12-31" unitRef="USD" name="us-gaap:IncreaseDecreaseInAccountsPayable" scale="3" format="ixt:num-dot-decimal" decimals="-3">6,896</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">(<ix:nonFraction id="c123854861" contextRef="d_2022-01-01_2022-12-31" unitRef="USD" name="us-gaap:IncreaseDecreaseInAccountsPayable" scale="3" format="ixt:num-dot-decimal" decimals="-3" sign="-">3,449</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">)</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: -9pt;">Accrued development expense</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c123854862" contextRef="d_2024-01-01_2024-12-31" unitRef="USD" name="sava:IncreaseDecreaseInDevelopmentExpense" scale="3" format="ixt:num-dot-decimal" decimals="-3" sign="-">597</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c123854863" contextRef="d_2023-01-01_2023-12-31" unitRef="USD" name="sava:IncreaseDecreaseInDevelopmentExpense" scale="3" format="ixt:num-dot-decimal" decimals="-3">757</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">(<ix:nonFraction id="c123854864" contextRef="d_2022-01-01_2022-12-31" unitRef="USD" name="sava:IncreaseDecreaseInDevelopmentExpense" scale="3" format="ixt:num-dot-decimal" decimals="-3" sign="-">523</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">)</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: -9pt;">Accrued compensation and benefits</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c123854865" contextRef="d_2024-01-01_2024-12-31" unitRef="USD" name="us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities" scale="3" format="ixt:num-dot-decimal" decimals="-3">1,157</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c123854866" contextRef="d_2023-01-01_2023-12-31" unitRef="USD" name="us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities" scale="3" format="ixt:num-dot-decimal" decimals="-4">30</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">(<ix:nonFraction id="c123854867" contextRef="d_2022-01-01_2022-12-31" unitRef="USD" name="us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities" scale="3" format="ixt:num-dot-decimal" decimals="-3" sign="-">1,707</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">)</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: -9pt;">Other liabilities</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(<ix:nonFraction id="c123854868" contextRef="d_2024-01-01_2024-12-31" unitRef="USD" name="us-gaap:IncreaseDecreaseInOtherOperatingLiabilities" scale="3" format="ixt:num-dot-decimal" decimals="-3" sign="-">7</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(<ix:nonFraction id="c123854869" contextRef="d_2023-01-01_2023-12-31" unitRef="USD" name="us-gaap:IncreaseDecreaseInOtherOperatingLiabilities" scale="3" format="ixt:num-dot-decimal" decimals="-3" sign="-">304</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;">(<ix:nonFraction id="c123854870" contextRef="d_2022-01-01_2022-12-31" unitRef="USD" name="us-gaap:IncreaseDecreaseInOtherOperatingLiabilities" scale="3" format="ixt:num-dot-decimal" decimals="-3" sign="-">136</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">)</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 45pt; text-indent: -9pt;">Net cash used in operating activities</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(<ix:nonFraction id="c123854871" contextRef="d_2024-01-01_2024-12-31" unitRef="USD" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="3" format="ixt:num-dot-decimal" decimals="-3" sign="-">116,929</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(<ix:nonFraction id="c123854872" contextRef="d_2023-01-01_2023-12-31" unitRef="USD" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="3" format="ixt:num-dot-decimal" decimals="-3" sign="-">82,025</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(<ix:nonFraction id="c123854873" contextRef="d_2022-01-01_2022-12-31" unitRef="USD" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="3" format="ixt:num-dot-decimal" decimals="-3" sign="-">77,514</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">)</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;"><b>Cash flows from investing activities:</b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt; text-indent: -9pt;">Purchases of property and equipment</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(<ix:nonFraction id="c123854874" contextRef="d_2024-01-01_2024-12-31" unitRef="USD" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" format="ixt:num-dot-decimal" decimals="-3">103</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(<ix:nonFraction id="c123854875" contextRef="d_2023-01-01_2023-12-31" unitRef="USD" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" format="ixt:num-dot-decimal" decimals="-3">414</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;">(<ix:nonFraction id="c123854876" contextRef="d_2022-01-01_2022-12-31" unitRef="USD" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" format="ixt:num-dot-decimal" decimals="-3">2,712</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">)</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 45pt; text-indent: -9pt;">Net cash used in investing activities</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(<ix:nonFraction id="c123854877" contextRef="d_2024-01-01_2024-12-31" unitRef="USD" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="3" format="ixt:num-dot-decimal" decimals="-3" sign="-">103</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(<ix:nonFraction id="c123854878" contextRef="d_2023-01-01_2023-12-31" unitRef="USD" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="3" format="ixt:num-dot-decimal" decimals="-3" sign="-">414</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;">(<ix:nonFraction id="c123854879" contextRef="d_2022-01-01_2022-12-31" unitRef="USD" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="3" format="ixt:num-dot-decimal" decimals="-3" sign="-">2,712</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">)</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;"><b>Cash flows from financing activities:</b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt; text-indent: -9pt;">Proceeds from issuance of common stock upon exercise of stock options</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c123854880" contextRef="d_2024-01-01_2024-12-31" unitRef="USD" name="us-gaap:ProceedsFromStockOptionsExercised" scale="3" format="ixt:num-dot-decimal" decimals="-3">918</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c123854881" contextRef="d_2023-01-01_2023-12-31" unitRef="USD" name="us-gaap:ProceedsFromStockOptionsExercised" scale="3" format="ixt:num-dot-decimal" decimals="-4">2,560</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c123854882" contextRef="d_2022-01-01_2022-12-31" unitRef="USD" name="us-gaap:ProceedsFromStockOptionsExercised" scale="3" format="ixt:num-dot-decimal" decimals="-3">475</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> <p style="margin: 0pt 0pt 0pt 9pt; font-size: 10pt; font-family: Times New Roman;">Proceeds from exercise of common stock warrants, net of exercise costs</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"><ix:nonFraction id="c123854883" contextRef="d_2024-01-01_2024-12-31" unitRef="USD" name="us-gaap:ProceedsFromWarrantExercises" scale="3" format="ixt:num-dot-decimal" decimals="-3">123,552</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"><ix:nonFraction id="c123854884" contextRef="d_2023-01-01_2023-12-31" unitRef="USD" name="us-gaap:ProceedsFromWarrantExercises" scale="3" format="ixt:fixed-zero" decimals="-3">&#8212;</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"><ix:nonFraction id="c123854885" contextRef="d_2022-01-01_2022-12-31" unitRef="USD" name="us-gaap:ProceedsFromWarrantExercises" scale="3" format="ixt:fixed-zero" decimals="-3">&#8212;</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px;"> <p style="margin: 0pt 0pt 0pt 9pt; font-size: 10pt; font-family: Times New Roman;">Proceeds from common stock offering, net of issuance costs</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c123854886" contextRef="d_2024-01-01_2024-12-31" unitRef="USD" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="3" format="ixt:fixed-zero" decimals="-3">&#8212;</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c123854887" contextRef="d_2023-01-01_2023-12-31" unitRef="USD" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="3" format="ixt:fixed-zero" decimals="-3">&#8212;</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c123854888" contextRef="d_2022-01-01_2022-12-31" unitRef="USD" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="3" format="ixt:num-dot-decimal" decimals="-3">47,329</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 45pt; text-indent: -9pt;">Net cash provided by financing activities</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c123854889" contextRef="d_2024-01-01_2024-12-31" unitRef="USD" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="3" format="ixt:num-dot-decimal" decimals="-4">124,470</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c123854890" contextRef="d_2023-01-01_2023-12-31" unitRef="USD" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="3" format="ixt:num-dot-decimal" decimals="-4">2,560</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"><ix:nonFraction id="c123854891" contextRef="d_2022-01-01_2022-12-31" unitRef="USD" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="3" format="ixt:num-dot-decimal" decimals="-3">47,804</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">Net increase (decrease) in cash and cash equivalents</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c123854892" contextRef="d_2024-01-01_2024-12-31" unitRef="USD" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" scale="3" format="ixt:num-dot-decimal" decimals="-3">7,438</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c123854893" contextRef="d_2023-01-01_2023-12-31" unitRef="USD" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" scale="3" format="ixt:num-dot-decimal" decimals="-3" sign="-">79,879</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c123854894" contextRef="d_2022-01-01_2022-12-31" unitRef="USD" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" scale="3" format="ixt:num-dot-decimal" decimals="-3" sign="-">32,422</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">Cash and cash equivalents at beginning of period</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c123854895" contextRef="i_2023-12-31" unitRef="USD" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" scale="3" format="ixt:num-dot-decimal" decimals="-3">121,136</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c123854896" contextRef="i_2022-12-31" unitRef="USD" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" scale="3" format="ixt:num-dot-decimal" decimals="-3">201,015</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"><ix:nonFraction id="c123854897" contextRef="i_2021-12-31" unitRef="USD" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" scale="3" format="ixt:num-dot-decimal" decimals="-3">233,437</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">Cash and cash equivalents at end of period</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c123854898" contextRef="i_2024-12-31" unitRef="USD" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" scale="3" format="ixt:num-dot-decimal" decimals="-3">128,574</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c123854899" contextRef="i_2023-12-31" unitRef="USD" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" scale="3" format="ixt:num-dot-decimal" decimals="-3">121,136</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c123854900" contextRef="i_2022-12-31" unitRef="USD" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" scale="3" format="ixt:num-dot-decimal" decimals="-3">201,015</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> <p style="margin: 0pt; font-size: 10pt; font-family: Times New Roman;">Supplemental cash flow information:</p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> <p style="margin: 0pt; font-size: 10pt; font-family: Times New Roman;">Non-cash investing activities</p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px;"> <p style="margin: 0pt 0pt 0pt 9pt; font-size: 10pt; font-family: Times New Roman;">Purchases of property and equipment included in accounts payable</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0px 0px 3px; margin: 0px;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c123854901" contextRef="d_2024-01-01_2024-12-31" unitRef="USD" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" scale="3" format="ixt:fixed-zero" decimals="-3">&#8212;</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0px 0px 3px; margin: 0px;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0px 0px 3px; margin: 0px;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c123854902" contextRef="d_2023-01-01_2023-12-31" unitRef="USD" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" scale="3" format="ixt:fixed-zero" decimals="-3">&#8212;</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0px 0px 3px; margin: 0px;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0px 0px 3px; margin: 0px;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c123854903" contextRef="d_2022-01-01_2022-12-31" unitRef="USD" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" scale="3" format="ixt:num-dot-decimal" decimals="-4">340</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0px 0px 3px; margin: 0px;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> <p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">Non-cash financing activities</p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> <p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">Issuance of warrants resulting in recognition of warrant liabilities</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"><ix:nonFraction id="c123854904" contextRef="d_2024-01-01_2024-12-31" unitRef="USD" name="sava:IssuanceOfWarrantsResultingInRecognitionOfWarrantLiabilities" scale="3" format="ixt:num-dot-decimal" decimals="-3">113,363</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"><ix:nonFraction id="c123854905" contextRef="d_2023-01-01_2023-12-31" unitRef="USD" name="sava:IssuanceOfWarrantsResultingInRecognitionOfWarrantLiabilities" scale="3" format="ixt:fixed-zero" decimals="-3">&#8212;</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"><ix:nonFraction id="c123854906" contextRef="d_2022-01-01_2022-12-31" unitRef="USD" name="sava:IssuanceOfWarrantsResultingInRecognitionOfWarrantLiabilities" scale="3" format="ixt:fixed-zero" decimals="-3">&#8212;</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> <p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">Derecognition of warrant liabilities upon exercise of warrants</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">(<ix:nonFraction id="c123854907" contextRef="d_2024-01-01_2024-12-31" unitRef="USD" name="sava:DerecognitionOfWarrantLiabilitiesThroughExercises" scale="3" format="ixt:num-dot-decimal" decimals="-4" sign="-">5,180</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"><ix:nonFraction id="c123854908" contextRef="d_2023-01-01_2023-12-31" unitRef="USD" name="sava:DerecognitionOfWarrantLiabilitiesThroughExercises" scale="3" format="ixt:fixed-zero" decimals="-3">&#8212;</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"><ix:nonFraction id="c123854909" contextRef="d_2022-01-01_2022-12-31" unitRef="USD" name="sava:DerecognitionOfWarrantLiabilitiesThroughExercises" scale="3" format="ixt:fixed-zero" decimals="-3">&#8212;</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td></tr>
</tbody></table>
  </div>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">See accompanying notes to consolidated financial statements.<br/> &#8206;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
      96
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><a id="notes" title="notes" href="#"></a>CASSAVA SCIENCES, INC.</b></p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <div>
   &#160;
  </div>
  <ix:nonNumeric contextRef="d_2024-01-01_2024-12-31" name="us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" id="c2851675" escape="true">
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><em style="font: inherit;">1.</em></b> <b>General, Liquidity and Basis of Presentation</b></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">Cassava Sciences, Inc. and its wholly-owned subsidiary (collectively referred to as the &#8220;Company&#8221;) discovers and develops proprietary pharmaceutical product candidates that <em style="font: inherit;"> may </em>offer significant improvements to patients and healthcare professionals. The Company generally focuses its product discovery and development efforts on disorders of the nervous system.</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>Basis of Consolidation</i></b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;&#65279;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">The consolidated financial statements include the accounts of the Company and its wholly-owned subsidiary. All intercompany transactions have been eliminated in consolidation.</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>Liquidity </i></b></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">The Company has incurred significant net losses and negative cash flows since inception, and as a result has an accumulated deficit of $<ix:nonFraction id="c123855382" contextRef="i_2024-12-31" unitRef="USD" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="6" format="ixt:num-dot-decimal" decimals="-5" sign="-">405.1</ix:nonFraction>&#160;million at <em style="font: inherit;"> December 31, 2024. </em>The Company expects its cash requirements to be significant in the future. The amount and timing of the Company&#8217;s future cash requirements will depend on regulatory and market acceptance of its product candidates and the resources it devotes to researching and developing, formulating, manufacturing, commercializing and supporting its products. The Company <em style="font: inherit;"> may </em>seek additional funding through public or private financing in the future, if such funding is available and on terms acceptable to the Company. There are <em style="font: inherit;">no</em> assurances that additional financing will be available on favorable terms, or at all. However, management believes that the current working capital position will be sufficient to meet the Company&#8217;s working capital needs for at least the next <em style="font: inherit;">12</em> months.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;&#160;</p>
  </ix:nonNumeric>
  <div>
   &#160;
  </div>
  <ix:nonNumeric contextRef="d_2024-01-01_2024-12-31" name="us-gaap:SignificantAccountingPoliciesTextBlock" id="c2851676" escape="true">
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><em style="font: inherit;">2.</em> Summary of Significant Accounting Policies</b></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i></i></b></p><ix:nonNumeric contextRef="d_2024-01-01_2024-12-31" name="us-gaap:UseOfEstimates" id="c123862978" escape="true"><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>Use of Estimates</i></b></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">The Company makes estimates and assumptions in preparing its consolidated financial statements in conformity with accounting principles generally accepted in the United States. These estimates and assumptions affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amount of revenue earned and expenses incurred during the reporting period. The Company evaluates&#160;its estimates on an ongoing basis, including those estimates related to legal liabilities, common stock warrant liabilities, stock based compensation, clinical trials and manufacturing agreements. Actual results could differ from these estimates and assumptions.</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&#160;</p></ix:nonNumeric><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i></i></b></p><ix:nonNumeric contextRef="d_2024-01-01_2024-12-31" name="us-gaap:GovernmentAssistancePolicyTextBlock" id="c123862979" escape="true"><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>Proceeds from Grants</i></b></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">During <em style="font: inherit;">2024</em> and <em style="font: inherit;">2023,</em> there were <ix:nonFraction id="c123855388" contextRef="d_2024-01-01_2024-12-31" unitRef="USD" name="us-gaap:GovernmentAssistanceAmount" scale="6" format="ixt-sec:numwordsen" decimals="-3">no</ix:nonFraction> reimbursements received pursuant to National Institutes of Health (&#8220;NIH&#8221;) research grants. In <em style="font: inherit;">2022,</em> the Company received $<ix:nonFraction id="c123855390" contextRef="d_2022-01-01_2022-12-31" unitRef="USD" name="us-gaap:GovernmentAssistanceAmount" scale="6" format="ixt:num-dot-decimal" decimals="-5">0.9</ix:nonFraction> million of reimbursement&#160;from the NIH&#160;and National Institute on Drug Abuse. The Company records the proceeds from these grants as reductions to its <span style="-sec-ix-hidden:c123855795">research and development expenses</span>.</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"></p></ix:nonNumeric><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">&#160;</p>
   <ix:exclude>
    <div class="PGFTR" style="text-align: center; width: 100%">
     <div class="hf-row">
      <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       <em style="font: inherit;">97</em>
      </div>
     </div>
    </div>
    <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
    <div class="PGHDR" style="text-align: left; width: 100%">
     <div class="hf-row">
      <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
       <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Table of Contents</a>
      </div>
     </div>
    </div>
   </ix:exclude>
   <ix:exclude>&#160;</ix:exclude>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i></i></b></p><ix:nonNumeric contextRef="d_2024-01-01_2024-12-31" name="us-gaap:CashAndCashEquivalentsPolicyTextBlock" id="c123862980" escape="true"><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>Cash and Cash Equivalents and Concentration of Credit Risk</i></b></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">The Company invests in cash and cash equivalents. The Company considers highly-liquid financial instruments with original maturities of <em style="font: inherit;">three</em> months or less to be cash equivalents. Highly liquid investments that are considered cash equivalents include money market accounts and funds, certificates of deposit and U.S. Treasury securities. The Company maintains&#160;its cash and cash equivalents at <em style="font: inherit;">one</em> financial institution.</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&#160;</p></ix:nonNumeric><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i></i></b></p><ix:nonNumeric contextRef="d_2024-01-01_2024-12-31" name="us-gaap:FairValueMeasurementPolicyPolicyTextBlock" id="c123862981" escape="true"><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>Fair Value Measurements </i></b></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&#160;</p>
   <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 18pt;">The Company recognizes financial instruments in accordance with the authoritative guidance on fair value measurements and disclosures for financial assets and liabilities. This guidance defines fair value, establishes a framework for measuring fair value in accordance with GAAP, and expands disclosures about fair value measurements. The guidance also establishes a <em style="font: inherit;">three</em>-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value. These tiers include:</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 36pt;text-indent:-18pt;">&#160;</p>
   <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;"><tbody><tr style="vertical-align: top;"><td style="width: 18pt;">&#160;</td><td style="width: 18pt;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p> </td><td style="width: auto;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Level <em style="font: inherit;">1</em> includes quoted prices in active markets.</p> </td></tr>
</tbody></table>
   <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;"><tbody><tr style="vertical-align: top;"><td style="width: 18pt;">&#160;</td><td style="width: 18pt;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p> </td><td style="width: auto;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Level <em style="font: inherit;">2</em> includes significant observable inputs, such as quoted prices for identical or similar securities, or other inputs that are observable and can be corroborated by observable market data for similar securities. The Company uses market pricing and other observable market inputs obtained from <em style="font: inherit;">third</em>-party providers. It uses the bid price to establish fair value where a bid price is available. The Company does <em style="font: inherit;">not</em> have any financial instruments where the fair value is based on Level <em style="font: inherit;">2</em> inputs.</p> </td></tr>
</tbody></table>
   <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;"><tbody><tr style="vertical-align: top;"><td style="width: 18pt;">&#160;</td><td style="width: 18pt;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p> </td><td style="width: auto;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Level <em style="font: inherit;">3</em> includes unobservable inputs that are supported by little or <em style="font: inherit;">no</em> market activity. The Company does <em style="font: inherit;">not</em> have any financial instruments where the fair value is based on Level <em style="font: inherit;">3</em> inputs.</p> </td></tr>
</tbody></table>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">If a financial instrument uses inputs that fall in different levels of the hierarchy, the instrument will be categorized based upon the lowest level of input that is significant to the fair value calculation. The fair value of cash and cash equivalents was based on Level <em style="font: inherit;">1</em> inputs at <em style="font: inherit;"> December 31, 2024&#160;</em>and <em style="font: inherit;">2023.</em></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify; text-indent: 18pt;">The fair value of common stock warrants of $<ix:nonFraction id="c123855406" contextRef="i_2024-01-03" unitRef="USDPerShare" name="sava:ClassOfWarrantOrRightFairValueOfCommonStockWarrantsPerWarrant" scale="0" format="ixt:num-dot-decimal" decimals="INF">6.71</ix:nonFraction> per warrant was determined at distribution on <em style="font: inherit;"> January 3, 2024 </em>using a Monte Carlo valuation model since the warrants were&#160;<em style="font: inherit;">not</em> traded on the open market on <em style="font: inherit;"> January 3, 2024. </em>Warrant trading on Nasdaq began on <em style="font: inherit;"> January 4, 2024. </em>Quantitative information regarding Level <em style="font: inherit;">3</em> fair value measurements for common stock warrants is&#160;as follows:</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&#160;</p>
   <ix:nonNumeric contextRef="d_2024-01-01_2024-12-31" name="us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" id="c2851677" escape="true">
    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"><tbody><tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 85%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Exercise price per warrant</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c123854918" contextRef="i_2024-12-31_ClassOfWarrantOrRightAxis-WarrantsToPurchaseCommonStockMember_MeasurementInputTypeAxis-MeasurementInputExercisePriceMember" unitRef="Pure" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="0" format="ixt:num-dot-decimal" decimals="INF">33.00</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Conversion rate - common shares per warrant</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c123854919" contextRef="i_2024-12-31_ClassOfWarrantOrRightAxis-WarrantsToPurchaseCommonStockMember_MeasurementInputTypeAxis-MeasurementInputConversionPriceMember" unitRef="Pure" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="0" format="ixt:num-dot-decimal" decimals="INF">1.50</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Closing price of common stock</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c123854920" contextRef="i_2024-12-31_ClassOfWarrantOrRightAxis-WarrantsToPurchaseCommonStockMember_MeasurementInputTypeAxis-MeasurementInputSharePriceMember" unitRef="Pure" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="0" format="ixt:num-dot-decimal" decimals="INF">23.72</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Volatility</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c123854921" contextRef="i_2024-12-31_ClassOfWarrantOrRightAxis-WarrantsToPurchaseCommonStockMember_MeasurementInputTypeAxis-MeasurementInputPriceVolatilityMember" unitRef="Pure" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="-2" format="ixt:num-dot-decimal" decimals="2">75</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">%</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Risk-free interest rate</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c123854922" contextRef="i_2024-12-31_ClassOfWarrantOrRightAxis-WarrantsToPurchaseCommonStockMember_MeasurementInputTypeAxis-MeasurementInputRiskFreeInterestRateMember" unitRef="Pure" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="-2" format="ixt:num-dot-decimal" decimals="3">5.40</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">%</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Expected life of option (in years)</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c123854923" contextRef="i_2024-12-31_ClassOfWarrantOrRightAxis-WarrantsToPurchaseCommonStockMember_MeasurementInputTypeAxis-MeasurementInputExpectedTermMember" unitRef="Pure" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="0" format="ixt:num-dot-decimal" decimals="INF">0.3</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Dividend yield</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: right; margin: 0pt;"><span style="-sec-ix-hidden:c123854924">zero</span></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
</tbody></table>
   </ix:nonNumeric>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -1pt; text-indent: 18pt;">The common stock warrants stopped&#160;trading on Nasdaq after <em style="font: inherit;"> May 2, 2024 </em>and subsequently had little or <em style="font: inherit;">no</em> market activity. As of <em style="font: inherit;"> May 7, 2024,&#160;</em>the warrants were presumed to have <em style="font: inherit;">no</em> value since they&#160;were redeemed for a nominal payment of $<ix:nonFraction id="c123855411" contextRef="i_2024-05-07" unitRef="USDPerShare" name="sava:ClassOfWarrantOrRightRedemptionPricePerShare" scale="0" format="ixt:num-dot-decimal" decimals="INF">0.001</ix:nonFraction> per warrant.</p>
   <p style="margin: 0pt 0pt 0pt -9pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">&#160;</p></ix:nonNumeric><p style="margin: 0pt 0pt 0pt -9pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i></i></b></p><ix:nonNumeric contextRef="d_2024-01-01_2024-12-31" name="us-gaap:SegmentReportingPolicyPolicyTextBlock" id="c123862982" escape="true"><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>Segment Information</i></b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">The Company reports segment information based on how it internally evaluates the operating performance of its business units, or segments. The Company&#8217;s operations are confined to <ix:nonFraction id="c123855412" contextRef="d_2024-01-01_2024-12-31" unitRef="Pure" name="us-gaap:NumberOfOperatingSegments" scale="0" format="ixt-sec:numwordsen" decimals="INF">one</ix:nonFraction> business segment: the development of novel drugs and diagnostics.</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-indent: 18pt; text-align: justify;">The Company&#8217;s reportable segment&#160;reflects the manner in which its chief operating decision maker ("CODM") allocates resources and assesses performance. The Company's CODM is the President and Chief Executive Officer. The primary measure used by the Company's CODM for purposes of allocating resources is based on net loss that also is reported on the income statement as consolidated net loss. The measure of segment assets is reported on the balance sheet as cash and cash equivalents.</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-indent: 18pt;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify; text-indent: 18pt;">The Company has <em style="font: inherit;">not</em> generated any product revenue in the current period and expects to continue to incur significant expenses and operating losses for the foreseeable future as we advance our product candidates through stages of development and clinical trials.</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify; text-indent: 18pt;">As such, the CODM uses cash forecast models in deciding how to invest in&#160;the development of novel drugs and diagnostics. Such cash forecast models are reviewed to assess the entity-wide operating results and performance. Net loss is used to monitor budget versus actual results. Monitoring budgeted versus actual results, net cash used in operating activities for the period and cash on hand are used in assessing performance of the segment.</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-indent: 18pt;">&#160;</p>
   <ix:exclude>
    <div class="PGFTR" style="text-align: center; width: 100%">
     <div class="hf-row">
      <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       <em style="font: inherit;">98</em>
      </div>
     </div>
    </div>
    <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
    <div class="PGHDR" style="text-align: left; width: 100%">
     <div class="hf-row">
      <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
       <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Table of Contents</a>
      </div>
     </div>
    </div>
   </ix:exclude>
   <ix:exclude>&#160;</ix:exclude>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-indent: 18pt;">The following table summarizes expenses by category regularly reviewed by the CODM&#160;(in thousands):</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <ix:nonNumeric contextRef="d_2024-01-01_2024-12-31" name="us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock" id="A9262710-C620-44C9-9C88-087499052833" escape="true" continuedAt="DA6EA017-8369-46DF-9B6E-ABF4B9F5FA18">
    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"><tbody><tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td colspan="10" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;"><em style="font: inherit;"><em style="font: inherit;">Years Ended December 31,</em></em></em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">2024</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">2023</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">2022</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 55%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Operating expenses</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Research and development</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c123854931" contextRef="d_2024-01-01_2024-12-31_StatementBusinessSegmentsAxis-CodmMonitoringMember" unitRef="USD" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" format="ixt:num-dot-decimal" decimals="-3">69,637</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c123854932" contextRef="d_2023-01-01_2023-12-31_StatementBusinessSegmentsAxis-CodmMonitoringMember" unitRef="USD" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" format="ixt:num-dot-decimal" decimals="-3">89,423</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c123854933" contextRef="d_2022-01-01_2022-12-31_StatementBusinessSegmentsAxis-CodmMonitoringMember" unitRef="USD" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" format="ixt:num-dot-decimal" decimals="-3">68,032</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">General and administrative</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c123854934" contextRef="d_2024-01-01_2024-12-31_StatementBusinessSegmentsAxis-CodmMonitoringMember" unitRef="USD" name="us-gaap:GeneralAndAdministrativeExpense" scale="3" format="ixt:num-dot-decimal" decimals="-3">71,809</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c123854935" contextRef="d_2023-01-01_2023-12-31_StatementBusinessSegmentsAxis-CodmMonitoringMember" unitRef="USD" name="us-gaap:GeneralAndAdministrativeExpense" scale="3" format="ixt:num-dot-decimal" decimals="-3">16,534</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c123854936" contextRef="d_2022-01-01_2022-12-31_StatementBusinessSegmentsAxis-CodmMonitoringMember" unitRef="USD" name="us-gaap:GeneralAndAdministrativeExpense" scale="3" format="ixt:num-dot-decimal" decimals="-3">11,988</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Other segment items(a)</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(<ix:nonFraction id="c123854937" contextRef="d_2024-01-01_2024-12-31_StatementBusinessSegmentsAxis-CodmMonitoringMember" unitRef="USD" name="us-gaap:SegmentReportingOtherItemAmount" scale="3" format="ixt:num-dot-decimal" decimals="-3" sign="-">117,104</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(<ix:nonFraction id="c123854938" contextRef="d_2023-01-01_2023-12-31_StatementBusinessSegmentsAxis-CodmMonitoringMember" unitRef="USD" name="us-gaap:SegmentReportingOtherItemAmount" scale="3" format="ixt:num-dot-decimal" decimals="-4" sign="-">8,740</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(<ix:nonFraction id="c123854939" contextRef="d_2022-01-01_2022-12-31_StatementBusinessSegmentsAxis-CodmMonitoringMember" unitRef="USD" name="us-gaap:SegmentReportingOtherItemAmount" scale="3" format="ixt:num-dot-decimal" decimals="-3" sign="-">3,774</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Net loss</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c123854940" contextRef="d_2024-01-01_2024-12-31_StatementBusinessSegmentsAxis-CodmMonitoringMember" unitRef="USD" name="us-gaap:NetIncomeLoss" scale="3" format="ixt:num-dot-decimal" decimals="-3">24,342</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c123854941" contextRef="d_2023-01-01_2023-12-31_StatementBusinessSegmentsAxis-CodmMonitoringMember" unitRef="USD" name="us-gaap:NetIncomeLoss" scale="3" format="ixt:num-dot-decimal" decimals="-3">97,217</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c123854942" contextRef="d_2022-01-01_2022-12-31_StatementBusinessSegmentsAxis-CodmMonitoringMember" unitRef="USD" name="us-gaap:NetIncomeLoss" scale="3" format="ixt:num-dot-decimal" decimals="-3">76,246</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td></tr>
</tbody></table>
   </ix:nonNumeric>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">(a) Other segment items include interest income, other income, net and gain from change in fair value of warrant liabilities.</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 18pt;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 18pt;">The following table summarizes assets regularly reviewed by the CODM&#160;(in thousands):</p>
   <ix:continuation id="DA6EA017-8369-46DF-9B6E-ABF4B9F5FA18">
    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"><tbody><tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>December 31,</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>2024</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>2023</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 70%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Cash and cash equivalents</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c123854944" contextRef="i_2024-12-31_StatementBusinessSegmentsAxis-CodmMonitoringMember" unitRef="USD" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" format="ixt:num-dot-decimal" decimals="-3">128,574</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c123854945" contextRef="i_2023-12-31_StatementBusinessSegmentsAxis-CodmMonitoringMember" unitRef="USD" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" format="ixt:num-dot-decimal" decimals="-3">121,136</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td></tr>
</tbody></table>
   </ix:continuation>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-indent: 18pt;">For the year ended <em style="font: inherit;"> December 31, 2024, </em>and <em style="font: inherit;">2023,</em> the net cash used in operating activities was $<ix:nonFraction id="c123855416" contextRef="d_2024-01-01_2024-12-31" unitRef="USD" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="6" format="ixt:num-dot-decimal" decimals="-5" sign="-">116.9</ix:nonFraction>&#160;million and $<ix:nonFraction id="c123855417" contextRef="d_2023-01-01_2023-12-31" unitRef="USD" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="6" format="ixt:num-dot-decimal" decimals="-6" sign="-">82.0</ix:nonFraction>&#160;million, respectively.&#160;</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p></ix:nonNumeric><p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i></i></b></p><ix:nonNumeric contextRef="d_2024-01-01_2024-12-31" name="us-gaap:CompensationRelatedCostsPolicyTextBlock" id="c123862983" escape="true"><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>Stock-based Compensation</i></b><b> </b></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">The Company recognizes non-cash expense for the fair value of all stock options and other share-based awards. The Company uses the Black-Scholes option valuation model (&#8220;Black-Scholes&#8221;) to calculate the fair value of stock options, using the single-option award approach and straight-line attribution method. This model requires the input of subjective assumptions including expected stock price volatility, expected life and estimated forfeitures of each award. These assumptions consist of estimates of future market conditions, which are inherently uncertain, and therefore, are subject to management&#8217;s judgment. For all options granted, it recognizes the resulting fair value as expense on a straight-line basis over the vesting period of each respective stock option, generally <span style="-sec-ix-hidden:c123855418">one</span>&#160;to&#160;<span style="-sec-ix-hidden:c123855419">four</span> years.</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">The Company has granted share-based awards that vest upon achievement of certain performance criteria (&#8220;Performance Awards&#8221;). The Company multiplies the number of Performance Awards by the fair value of its common stock on the date of grant to calculate the fair value of each award. It estimates an implicit service period for achieving performance criteria for each award. The Company recognizes the resulting fair value as expense over the implicit service period when it concludes that achieving the performance criteria is probable. It periodically reviews and updates as appropriate its estimates of implicit service periods and conclusions on achieving the performance criteria. Performance Awards vest and common stock is issued upon achievement of the performance criteria.</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">&#160;</p>
   <ix:exclude>
    <div class="PGFTR" style="text-align: center; width: 100%">
     <div class="hf-row">
      <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       <em style="font: inherit;"></em></div></div></div></ix:exclude></ix:nonNumeric><ix:exclude><div class="PGFTR" style="text-align: center; width: 100%"><div class="hf-row"><div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;"><em style="font: inherit;">99</em>
      </div>
     </div>
    </div>
    <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
    <div class="PGHDR" style="text-align: left; width: 100%">
     <div class="hf-row">
      <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
       <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Table of Contents</a>
      </div>
     </div>
    </div>
   </ix:exclude>
   <ix:exclude>&#160;</ix:exclude>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i></i></b></p><ix:nonNumeric contextRef="d_2024-01-01_2024-12-31" name="us-gaap:EarningsPerSharePolicyTextBlock" id="c123862984" escape="true"><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>Net Loss per Share</i></b></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-indent: 18pt; text-align: justify;">Basic net loss&#160;per common share is computed by dividing the net loss&#160;available to common stockholders by the weighted-average number of common shares outstanding during the period. Diluted net loss&#160;per common share is computed by dividing the net loss&#160;available to common stockholders by the weighted-average number of common shares outstanding and potentially dilutive securities outstanding during the period using the treasury stock method. Potentially dilutive securities are excluded from the computations of diluted earnings per share if their effect would be anti-dilutive. A net loss&#160;causes all potentially dilutive securities to be anti-dilutive. Potentially dilutive securities consist of outstanding common stock options&#160;and Performance Awards.&#160;There is <em style="font: inherit;">no</em> difference between the Company&#8217;s net loss and comprehensive loss. The numerators and denominators in the calculation of basic and diluted net loss per share were as follows (in thousands, except net loss per share data):</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
   <ix:nonNumeric contextRef="d_2024-01-01_2024-12-31" name="us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" id="c2851680" escape="true">
    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"><tbody><tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="10" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;"><em style="font: inherit;"><em style="font: inherit;">Years ended December 31,</em></em></em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">2024</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">2023</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">2022</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 55%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Numerator, basic:</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Net loss</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c123854952" contextRef="d_2024-01-01_2024-12-31" unitRef="USD" name="us-gaap:NetIncomeLoss" scale="3" format="ixt:num-dot-decimal" decimals="-3" sign="-">24,342</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c123854953" contextRef="d_2023-01-01_2023-12-31" unitRef="USD" name="us-gaap:NetIncomeLoss" scale="3" format="ixt:num-dot-decimal" decimals="-3" sign="-">97,217</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c123854954" contextRef="d_2022-01-01_2022-12-31" unitRef="USD" name="us-gaap:NetIncomeLoss" scale="3" format="ixt:num-dot-decimal" decimals="-3" sign="-">76,246</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Denominator, basic:</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Weighted average common shares outstanding</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c123854955" contextRef="d_2024-01-01_2024-12-31" unitRef="Share" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="3" format="ixt:num-dot-decimal" decimals="-3">46,329</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c123854956" contextRef="d_2023-01-01_2023-12-31" unitRef="Share" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="3" format="ixt:num-dot-decimal" decimals="-3">41,932</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c123854957" contextRef="d_2022-01-01_2022-12-31" unitRef="Share" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="3" format="ixt:num-dot-decimal" decimals="-3">40,202</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Net loss per share, basic</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(<ix:nonFraction id="c123854958" contextRef="d_2024-01-01_2024-12-31" unitRef="USDPerShare" name="us-gaap:EarningsPerShareBasic" scale="0" format="ixt:num-dot-decimal" decimals="INF" sign="-">0.53</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(<ix:nonFraction id="c123854959" contextRef="d_2023-01-01_2023-12-31" unitRef="USDPerShare" name="us-gaap:EarningsPerShareBasic" scale="0" format="ixt:num-dot-decimal" decimals="INF" sign="-">2.32</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(<ix:nonFraction id="c123854960" contextRef="d_2022-01-01_2022-12-31" unitRef="USDPerShare" name="us-gaap:EarningsPerShareBasic" scale="0" format="ixt:num-dot-decimal" decimals="INF" sign="-">1.90</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">)</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Numerator, diluted:</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Net loss</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c123854961" contextRef="d_2024-01-01_2024-12-31" unitRef="USD" name="us-gaap:NetIncomeLoss" scale="3" format="ixt:num-dot-decimal" decimals="-3" sign="-">24,342</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c123854962" contextRef="d_2023-01-01_2023-12-31" unitRef="USD" name="us-gaap:NetIncomeLoss" scale="3" format="ixt:num-dot-decimal" decimals="-3" sign="-">97,217</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c123854963" contextRef="d_2022-01-01_2022-12-31" unitRef="USD" name="us-gaap:NetIncomeLoss" scale="3" format="ixt:num-dot-decimal" decimals="-3" sign="-">76,246</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Adjustment for change in fair value of warrant liabilities</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(<ix:nonFraction id="c123854964" contextRef="d_2024-01-01_2024-12-31" unitRef="USD" name="us-gaap:DilutiveSecurities" scale="3" format="ixt:num-dot-decimal" decimals="-3" sign="-">43,793</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"><ix:nonFraction id="c123854965" contextRef="d_2023-01-01_2023-12-31" unitRef="USD" name="us-gaap:DilutiveSecurities" scale="3" format="ixt:fixed-zero" decimals="-3">&#8212;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"><ix:nonFraction id="c123854966" contextRef="d_2022-01-01_2022-12-31" unitRef="USD" name="us-gaap:DilutiveSecurities" scale="3" format="ixt:fixed-zero" decimals="-3">&#8212;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Adjusted numerator, diluted</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c123854967" contextRef="d_2024-01-01_2024-12-31" unitRef="USD" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted" scale="3" format="ixt:num-dot-decimal" decimals="-3" sign="-">68,135</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c123854968" contextRef="d_2023-01-01_2023-12-31" unitRef="USD" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted" scale="3" format="ixt:num-dot-decimal" decimals="-3" sign="-">97,217</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c123854969" contextRef="d_2022-01-01_2022-12-31" unitRef="USD" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted" scale="3" format="ixt:num-dot-decimal" decimals="-3" sign="-">76,246</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Denominator, diluted:</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Weighted average common shares outstanding</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c123854970" contextRef="d_2024-01-01_2024-12-31" unitRef="Share" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="3" format="ixt:num-dot-decimal" decimals="-3">46,329</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c123854971" contextRef="d_2023-01-01_2023-12-31" unitRef="Share" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="3" format="ixt:num-dot-decimal" decimals="-3">41,932</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c123854972" contextRef="d_2022-01-01_2022-12-31" unitRef="Share" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="3" format="ixt:num-dot-decimal" decimals="-3">40,202</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Dilutive effect of common stock warrants</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c123854973" contextRef="d_2024-01-01_2024-12-31" unitRef="Share" name="us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment" scale="3" format="ixt:num-dot-decimal" decimals="-3">275</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c123854974" contextRef="d_2023-01-01_2023-12-31" unitRef="Share" name="us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment" scale="3" format="ixt:fixed-zero" decimals="-3">&#8212;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c123854975" contextRef="d_2022-01-01_2022-12-31" unitRef="Share" name="us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment" scale="3" format="ixt:fixed-zero" decimals="-3">&#8212;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Weighted average dilutive common shares</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c123854976" contextRef="d_2024-01-01_2024-12-31" unitRef="Share" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="3" format="ixt:num-dot-decimal" decimals="-3">46,604</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c123854977" contextRef="d_2023-01-01_2023-12-31" unitRef="Share" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="3" format="ixt:num-dot-decimal" decimals="-3">41,932</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c123854978" contextRef="d_2022-01-01_2022-12-31" unitRef="Share" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="3" format="ixt:num-dot-decimal" decimals="-3">40,202</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Net loss per share, diluted</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(<ix:nonFraction id="c123854979" contextRef="d_2024-01-01_2024-12-31" unitRef="USDPerShare" name="us-gaap:EarningsPerShareDiluted" scale="0" format="ixt:num-dot-decimal" decimals="INF" sign="-">1.46</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(<ix:nonFraction id="c123854980" contextRef="d_2023-01-01_2023-12-31" unitRef="USDPerShare" name="us-gaap:EarningsPerShareDiluted" scale="0" format="ixt:num-dot-decimal" decimals="INF" sign="-">2.32</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(<ix:nonFraction id="c123854981" contextRef="d_2022-01-01_2022-12-31" unitRef="USDPerShare" name="us-gaap:EarningsPerShareDiluted" scale="0" format="ixt:num-dot-decimal" decimals="INF" sign="-">1.90</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">)</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Dilutive common stock options excluded from net loss per share, diluted</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c123854982" contextRef="d_2024-01-01_2024-12-31_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-EmployeeStockOptionMember" unitRef="Share" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="3" format="ixt:num-dot-decimal" decimals="-3">3,154</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c123854983" contextRef="d_2023-01-01_2023-12-31_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-EmployeeStockOptionMember" unitRef="Share" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="3" format="ixt:num-dot-decimal" decimals="-3">2,123</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c123854984" contextRef="d_2022-01-01_2022-12-31_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-EmployeeStockOptionMember" unitRef="Share" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="3" format="ixt:num-dot-decimal" decimals="-3">2,055</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Dilutive Performance Awards excluded from loss per share, diluted</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c123854985" contextRef="d_2024-01-01_2024-12-31_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-WarrantMember" unitRef="Share" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="3" format="ixt:num-dot-decimal" decimals="-3">7</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c123854986" contextRef="d_2023-01-01_2023-12-31_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-WarrantMember" unitRef="Share" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="3" format="ixt:num-dot-decimal" decimals="-3">7</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c123854987" contextRef="d_2022-01-01_2022-12-31_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-WarrantMember" unitRef="Share" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="3" format="ixt:num-dot-decimal" decimals="-3">7</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
</tbody></table>
   </ix:nonNumeric>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p></ix:nonNumeric><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"></p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"><b><i></i></b></p><ix:nonNumeric contextRef="d_2024-01-01_2024-12-31" name="us-gaap:DerivativesPolicyTextBlock" id="c123863015" escape="true"><p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"><b><i>Warrant Liabilities</i></b></p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 18pt;">The Company accounts for warrants as either equity-classified or liability-classified instruments based on an assessment of the warrant&#8217;s specific terms and in accordance with the Financial Accounting Standards Board (&#8220;FASB&#8221;) Accounting Standards Codification (&#8220;ASC&#8220;) <em style="font: inherit;">480,</em> &#8220;Distinguishing Liabilities from Equity&#8221;, and ASC <em style="font: inherit;">815,</em> &#8220;Derivatives and Hedging&#8221;. The assessment considers whether the warrants are freestanding financial instruments pursuant to ASC <em style="font: inherit;">480,</em> meet the definition of a liability pursuant to ASC <em style="font: inherit;">480,</em> and whether the warrants meet all of the requirements for equity classification under ASC <em style="font: inherit;">815,</em> including whether the warrants are indexed to the Company&#8217;s own shares, among other conditions for equity classification. This assessment, which requires the use of professional judgment, is conducted at the time of warrant issuance and as of each subsequent quarterly period end date while the warrants are outstanding.</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 18pt;">For issued or modified warrants that meet all of the criteria for equity classification, the warrants are required to be recorded as a component of additional paid-in capital at the time of issuance. For issued or modified warrants that do <em style="font: inherit;">not</em> meet all the criteria for equity classification, the warrants are required to be recorded at their initial fair value of the date of issuance, and each balance sheet date thereafter. Changes in the estimated fair value of liability classified warrants are recognized as a non-cash gain or loss on the statements of operations. Costs associated with issuing the warrants classified as derivative liabilities are charged to operations when the warrants are issued.</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&#160;</p></ix:nonNumeric><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"></p>
   <ix:exclude>
    <div class="PGFTR" style="text-align: center; width: 100%">
     <div class="hf-row">
      <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       <em style="font: inherit;">100</em>
      </div>
     </div>
    </div>
    <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
    <div class="PGHDR" style="text-align: left; width: 100%">
     <div class="hf-row">
      <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
       <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Table of Contents</a>
      </div>
     </div>
    </div>
   </ix:exclude>
   <ix:exclude>&#160;</ix:exclude>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i></i></b></p><ix:nonNumeric contextRef="d_2024-01-01_2024-12-31" name="us-gaap:FairValueOfFinancialInstrumentsPolicy" id="c123863016" escape="true"><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>Fair Value of Financial Instruments</i></b></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">Financial instruments include accounts payable, accrued expenses, accrued development expense and other liabilities. The estimated fair value of certain financial instruments <em style="font: inherit;"> may </em>be determined using available market information or other appropriate valuation methodologies. However, considerable judgment is required in interpreting market data to develop estimates of fair value; therefore, the estimates are <em style="font: inherit;">not</em> necessarily indicative of the amounts that could be realized or would be paid in a current market exchange. The effect of using different market assumptions and/or estimation methodologies <em style="font: inherit;"> may </em>be material to the estimated fair value amounts. The carrying amounts of accounts payable,&#160;accrued expenses, accrued development expense&#160;and other liabilities&#160;are at cost, which approximates fair value due to the short maturity of those instruments.</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&#160;</p></ix:nonNumeric><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i></i></b></p><ix:nonNumeric contextRef="d_2024-01-01_2024-12-31" name="us-gaap:ResearchAndDevelopmentExpensePolicy" id="c123863017" escape="true"><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>Research Contracts, Prepaids and Accruals</i></b></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">The Company has entered into various research and development contracts with research institutions and other <em style="font: inherit;">third</em>-party vendors. These agreements are generally cancelable. Related payments are recorded as research and development expenses as incurred. The Company records prepaids and accruals for estimated ongoing research costs. When evaluating the adequacy of&#160;prepaid expenses and accrued liabilities, the Company analyzes progress of the studies including the phase or completion of events, invoices received and contracted costs. Significant judgments and estimates are made in determining the prepaid and accrued balances at the end of any reporting period. Actual results could differ from the Company&#8217;s estimates. The Company&#8217;s historical prepaid and accrual estimates have <em style="font: inherit;">not</em> been materially different from actual costs.</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&#160;</p></ix:nonNumeric><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i></i></b></p><ix:nonNumeric contextRef="d_2024-01-01_2024-12-31" name="us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy" id="c123863018" escape="true"><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>Incentive Bonus Plan</i></b></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">In <em style="font: inherit;">2020,</em> the Company established the <em style="font: inherit;">2020</em> Cash Incentive Bonus Plan (the &#8220;CIB Plan&#8221;) to incentivize CIB Plan participants. Awards under the CIB Plan are accounted for as liability awards under ASC&#160;<em style="font: inherit;">718</em> &#8220;<i>Stock-based Compensation</i>&#8221;.&#160;The fair value of each&#160;potential CIB Plan&#160;award&#160;will be&#160;determined&#160;once&#160;a&#160;grant date occurs and&#160;will be&#160;remeasured each reporting period.&#160;Compensation expense associated with the CIB Plan&#160;will be&#160;recognized over the expected achievement period for each&#160;CIB Plan award, when&#160;a Performance Condition&#160;(as defined below) is considered probable of being met. See Note <em style="font: inherit;">11</em> for further discussion of the CIB Plan.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p></ix:nonNumeric><p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"></p>
   <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left"><b><i></i></b></p><ix:nonNumeric contextRef="d_2024-01-01_2024-12-31" name="us-gaap:PropertyPlantAndEquipmentPolicyTextBlock" id="c123863019" escape="true"><p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left"><b><i>Property and Equipment</i></b></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">Property and equipment are&#160;recorded at cost, net of accumulated depreciation. Depreciation is recorded using the straight-line method over the estimated useful lives of the assets. Owned buildings and related improvements have estimated useful lives of <ix:nonNumeric contextRef="i_2024-12-31_PropertyPlantAndEquipmentByTypeAxis-BuildingMember" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="c123855436" format="ixt-sec:duryear">39</ix:nonNumeric> years and approximately <ix:nonNumeric contextRef="i_2024-12-31_PropertyPlantAndEquipmentByTypeAxis-BuildingImprovementsMember" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="c123855437" format="ixt-sec:duryear">10</ix:nonNumeric> years, respectively. Tenant improvements&#160;related to leased space are amortized using the straight-line method over the useful lives of the improvements or the remaining term of the corresponding leases, whichever is shorter.</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">Property and equipment are reviewed for impairment when events or changes in circumstances indicate the carrying amount of an asset <em style="font: inherit;"> may </em><em style="font: inherit;">not</em> be recoverable. If property and equipment are considered to be impaired, an impairment loss is recognized.</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&#160;</p></ix:nonNumeric><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i></i></b></p><ix:nonNumeric contextRef="d_2024-01-01_2024-12-31" name="us-gaap:IntangibleAssetsFiniteLivedPolicy" id="c123863020" escape="true"><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>Intangible Assets</i></b></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">Acquired intangible assets are recorded at fair value at the date of acquisition and primarily consist of lease-in-place agreements and leasing commissions. Intangible assets are amortized over the estimated life of the lease-in-place agreements.&#160;Intangible assets also include&#160;leasing commissions, which are amortized over the life of the lease agreement.</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">Intangible assets are reviewed for impairment on an annual basis, and when there is reason to believe that their values have been diminished or impaired. If intangible assets are considered to be impaired, an impairment loss is recognized.</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p></ix:nonNumeric><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"></p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;"><b><i></i></b></p><ix:nonNumeric contextRef="d_2024-01-01_2024-12-31" name="us-gaap:CommitmentsAndContingenciesPolicyTextBlock" id="c123863021" escape="true"><p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;"><b><i>Insurance Recoveries</i></b></p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 18pt;">We record proceeds from our&#160;insurance policies&#160;when the loss event has&#160;occurred, and proceeds are estimable and probable of being recovered. Insurance recoveries&#160;and proceeds received are recorded as a reduction to general and administrative expense.&#160;There was approximately $<ix:nonFraction id="c123855439" contextRef="d_2024-01-01_2024-12-31" unitRef="USD" name="us-gaap:ProceedsFromInsuranceSettlementOperatingActivities" scale="6" format="ixt:num-dot-decimal" decimals="-5">9.9</ix:nonFraction>&#160;million&#160;and $<ix:nonFraction id="c123855440" contextRef="d_2023-01-01_2023-12-31" unitRef="USD" name="us-gaap:ProceedsFromInsuranceSettlementOperatingActivities" scale="6" format="ixt:num-dot-decimal" decimals="-5">0.1</ix:nonFraction> million of insurance recoveries recorded during the year ended <em style="font: inherit;"> December 31, 2024 </em>and <em style="font: inherit;">2023,</em> respectively. The applicable policy year had&#160;a $<ix:nonFraction id="c123855442" contextRef="d_2024-01-01_2024-12-31" unitRef="USD" name="sava:InsuranceSettlementsMaximumRecoveryLimit" scale="6" format="ixt:num-dot-decimal" decimals="-7">10.0</ix:nonFraction> million recovery limit which has been reached at <em style="font: inherit;"> December 31, 2024.</em></p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;">&#160;</p></ix:nonNumeric><p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;"></p>
   <ix:exclude>
    <div class="PGFTR" style="text-align: center; width: 100%">
     <div class="hf-row">
      <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       <em style="font: inherit;">101</em>
      </div>
     </div>
    </div>
    <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
    <div class="PGHDR" style="text-align: left; width: 100%">
     <div class="hf-row">
      <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
       <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Table of Contents</a>
      </div>
     </div>
    </div>
   </ix:exclude>
   <ix:exclude>&#160;</ix:exclude>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;"><b><i></i></b></p><ix:nonNumeric contextRef="d_2024-01-01_2024-12-31" name="sava:RelatedPartyTransactionPolicyTextBlock" id="c123863022" escape="true"><p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;"><b><i>Related Party Transactions</i></b></p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-indent: 18pt; text-align: justify;">On <em style="font: inherit;"> July 15, 2024, </em>our former&#160;President and Chief Executive Officer&#160;resigned from the Company, effective as of <em style="font: inherit;"> September 13, 2024 (</em>the &#8220;Effective Date&#8221;). Pursuant to the terms of his employment agreement, our former&#160;President and Chief Executive Officer is&#160;receiving&#160;severance compensation equal to $<ix:nonFraction id="c123855444" contextRef="d_2024-07-15_2024-07-15_TitleOfIndividualAxis-FormerPresidentAndChiefExecutiveOfficerMember" unitRef="USD" name="us-gaap:SeveranceCosts1" scale="6" format="ixt:num-dot-decimal" decimals="-4">1.23</ix:nonFraction> million over <em style="font: inherit;">twelve</em> months following the Effective Date. Severance compensation was included in general and administrative expense.</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-indent: 18pt;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-indent: 18pt; text-align: justify;">On <em style="font: inherit;"> July 16, 2024, </em>our former Senior Vice President (SVP), Neuroscience agreed to step down from her employment with the Company, effective immediately. Our former SVP, Neuroscience is the spouse of our former&#160;President and Chief Executive Officer. Pursuant to a separation agreement, our former SVP, Neuroscience is&#160;receiving&#160;severance compensation equal to $<ix:nonFraction id="c123855446" contextRef="d_2024-07-16_2024-07-16_TitleOfIndividualAxis-FormerSeniorVicePresidentMember" unitRef="USD" name="us-gaap:SeveranceCosts1" scale="6" format="ixt:num-dot-decimal" decimals="-5">0.5</ix:nonFraction> million in quarterly installments over <em style="font: inherit;">twelve</em> months.&#160;Severance compensation was included in research and development&#160;expense.</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-indent: 18pt;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -2pt; text-indent: 18pt; text-align: justify;">Included in accrued compensation and benefits at <em style="font: inherit;"> December 31, 2024 </em>is approximately $<ix:nonFraction id="c123855448" contextRef="d_2024-01-01_2024-12-31_TitleOfIndividualAxis-FormerSeniorOfficerMember" unitRef="USD" name="us-gaap:SeveranceCosts1" scale="6" format="ixt:num-dot-decimal" decimals="-5">1.2</ix:nonFraction>&#160;million of accrued severance costs for the <span style="-sec-ix-hidden:c123855449">two</span> former senior officers.</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -2pt; text-indent: 18pt; text-align: justify;">On <em style="font: inherit;"> July 16, 2024, </em>the Company entered into a <ix:nonFraction id="c123855450" contextRef="i_2024-07-16_RelatedPartyTransactionsByRelatedPartyAxis-FormerSeniorVicePresidentMember" unitRef="Pure" name="sava:ConsultingAgreementTerm" scale="0" format="ixt-sec:numwordsen" decimals="INF">one</ix:nonFraction>-year consulting agreement&#160;with the Company&#8217;s former SVP, Neuroscience.&#160;Pursuant to the terms of the consulting agreement, the&#160;consultant is providing services&#160;for purposes of providing information and support for scientific research and/or obtaining governmental approval for the Company&#8217;s products.&#160;The Company will pay&#160;$<ix:nonFraction id="c123855451" contextRef="i_2024-07-16_RelatedPartyTransactionsByRelatedPartyAxis-FormerSeniorVicePresidentMember" unitRef="USD" name="sava:ConsultingServicePricePerHour" scale="0" format="ixt:num-dot-decimal" decimals="INF">500</ix:nonFraction>&#160;per hour&#160;for such&#160;consulting services. The Company incurred fees totaling $<ix:nonFraction id="c123855452" contextRef="d_2024-01-01_2024-12-31_RelatedPartyTransactionsByRelatedPartyAxis-FormerSeniorVicePresidentMember" unitRef="USD" name="us-gaap:RelatedPartyTransactionAmountsOfTransaction" scale="0" format="ixt:num-dot-decimal" decimals="INF">43,000</ix:nonFraction> under the consulting agreement during the year ended <em style="font: inherit;"> December 31, 2024.</em></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p></ix:nonNumeric><p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i></i></b></p><ix:nonNumeric contextRef="d_2024-01-01_2024-12-31" name="us-gaap:IncomeTaxPolicyTextBlock" id="c123863023" escape="true"><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>Income Taxes</i></b></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">The Company accounts for income taxes under the asset and liability method.&#160;Deferred tax assets and liabilities are recognized for the estimated future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. &#160;Deferred tax balances are adjusted to reflect tax rates based on currently enacted tax laws, which will be in effect in the years in which the temporary differences are expected to reverse.&#160;The Company has accumulated significant deferred tax assets that reflect the tax effects of net operating loss and tax credit carryovers and temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. Realization of certain deferred tax assets is dependent upon future earnings. The Company is uncertain about the timing and amount of any future earnings. Accordingly, the Company offsets these deferred tax assets with a valuation allowance.</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">The Company accounts for uncertain tax positions in accordance with ASC <em style="font: inherit;">740,</em> &#8220;Income Taxes&#8221;, which clarifies the accounting for uncertainty in tax positions. These provisions require recognition of the impact of a tax position in the Company&#8217;s financial statements only if that position is more likely than <em style="font: inherit;">not</em> of being sustained upon examination by taxing authorities, based on the technical merits of the position. Any interest and penalties related to uncertain tax positions will be reflected as a component of income tax expense.</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p></ix:nonNumeric><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"></p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;"><b><i></i></b></p><ix:nonNumeric contextRef="d_2024-01-01_2024-12-31" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="c123863024" escape="true"><p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;"><b><i>Recent Accounting Pronouncements</i></b></p>
   <p style="text-align: justify; margin: 0pt 0pt 0pt -9pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify; text-indent: 18pt;">In <em style="font: inherit;"> November 2023, </em>the FASB&#160;issued Accounting Standards Update ("ASU") <em style="font: inherit;">2023</em>-<em style="font: inherit;">07,</em> Segment Reporting (Topic <em style="font: inherit;">280</em>): Improvements to Reportable Segment Disclosures. This ASU includes amendments that expand the existing reportable segment disclosure requirements and requires disclosure of (i) significant expense categories and amounts by reportable segment as well as the segment&#8217;s profit or loss measure(s) that are regularly provided to the chief operating decision maker (the &#8220;CODM&#8221;) to allocate resources and assess performance; (ii) how the CODM uses each reported segment profit or loss measure to allocate resources and assess performance; (iii) the nature of other segment balances contributing to reported segment profit or loss that are <em style="font: inherit;">not</em> captured within segment revenues or expenses; and (iv) the title and position of the individual or name of the group or committee identified as the CODM. This guidance requires retrospective application to all prior periods presented in the financial statements and is effective for fiscal years beginning after <em style="font: inherit;"> December 15, 2023 </em>and interim periods within fiscal years beginning after <em style="font: inherit;"> December 15, 2024.&#160;</em>The Company adopted this guidance and has included enhanced disclosures relating to its reportable segments. See <i>Business Segments</i>, included in this Note <em style="font: inherit;">2</em> to the Consolidated Financial Statements, for the Company's updated disclosure.</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify; text-indent: 18pt;">&#160;</p>
   <ix:exclude>
    <div class="PGFTR" style="text-align: center; width: 100%">
     <div class="hf-row">
      <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       <em style="font: inherit;">102</em>
      </div>
     </div>
    </div>
    <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
    <div class="PGHDR" style="text-align: left; width: 100%">
     <div class="hf-row">
      <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
       <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Table of Contents</a>
      </div>
     </div>
    </div>
   </ix:exclude>
   <ix:exclude>&#160;</ix:exclude>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt;"><i><b>Accounting Guidance Issued But <em style="font: inherit;">Not</em> Adopted as of <em style="font: inherit;"> December 31, 2024</em></b></i></p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-indent: 18pt; text-align: justify;">In <em style="font: inherit;"> November 2024, </em>the FASB issued ASU <em style="font: inherit;">2024</em>-<em style="font: inherit;">03,</em> Income Statement&#8212;Reporting Comprehensive Income&#8212;Expense Disaggregation Disclosures (Subtopic <em style="font: inherit;">220</em>-<em style="font: inherit;">40</em>): Disaggregation of Income Statement Expenses. This ASU includes amendments that require entities to bifurcate specified expense line items on the income statement into underlying components, including employee compensation, depreciation, and intangible asset amortization, as applicable. Qualitative descriptions of the remaining components are required. These enhanced disclosures are required for both interim and annual periods. In <em style="font: inherit;"> January 2025, </em>the FASB subsequently issued ASU <em style="font: inherit;">2025</em>-<em style="font: inherit;">01,</em> Income Statement&#8212;Reporting Comprehensive Income&#8212;Expense Disaggregation Disclosures (Subtopic <em style="font: inherit;">220</em>-<em style="font: inherit;">40</em>): Clarifying the Effective Date, to provide clarification on the ASU's effective date. The new standard is effective for fiscal years beginning after <em style="font: inherit;"> December 15, 2026 </em>on a prospective basis with the option to apply it retrospectively, and for interim periods&#160;within fiscal years beginning after <em style="font: inherit;"> December 15, 2027. </em>Early adoption is permitted. The adoption of this guidance will result in the Company being required to include enhanced disclosures around income statement expenses.</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-indent: 18pt; text-align: justify;">In <em style="font: inherit;"> December 2023, </em>the FASB issued ASU <em style="font: inherit;">2023</em>-<em style="font: inherit;">09,</em> Income Taxes (Topic <em style="font: inherit;">740</em>): Improvements to Income Tax Disclosures. The ASU requires that an entity disclose specific categories in the effective tax rate reconciliation as well as reconciling items that meet a quantitative threshold. Further, the ASU requires additional disclosures on income tax expense and taxes paid, net of refunds received, by jurisdiction. The new standard is effective for annual periods beginning after <em style="font: inherit;"> December 15, 2024 </em>on a prospective basis with the option to apply it retrospectively. Early adoption is permitted. The adoption of this guidance will result in the company being required to include enhanced income tax related disclosures.</p>
   <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p></ix:nonNumeric><p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left"></p>
  </ix:nonNumeric>
  <div>
   &#160;
  </div>
  <ix:nonNumeric contextRef="d_2024-01-01_2024-12-31" name="sava:PrepaidExpensesAndOtherCurrentAssetsTextBock" id="c2851681" escape="true">
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><em style="font: inherit;">3.</em> Prepaid Expenses and Other Current Assets</b></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">Prepaid and other current assets at&#160;<em style="font: inherit;"> December 31, 2024&#160;</em>and <em style="font: inherit;">2023</em>&#160;consisted of the following (in thousands):</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
   <ix:nonNumeric contextRef="d_2024-01-01_2024-12-31" name="us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" id="c2851682" escape="true">
    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;">&#160;</td><td colspan="6" rowspan="1" style="text-align: center; font-family: Times New Roman; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"><b><em style="font: inherit;"><em style="font: inherit;">December 31,</em></em></b></td><td style="font-family: Times New Roman; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;">&#160;</td></tr>
<tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">2024</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">2023</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 70%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">Prepaid insurance</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c123854996" contextRef="i_2024-12-31" unitRef="USD" name="us-gaap:PrepaidInsurance" scale="3" format="ixt:num-dot-decimal" decimals="-5">800</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c123854997" contextRef="i_2023-12-31" unitRef="USD" name="us-gaap:PrepaidInsurance" scale="3" format="ixt:num-dot-decimal" decimals="-3">759</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">Contract research organization and other deposits</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c123854998" contextRef="i_2024-12-31" unitRef="USD" name="us-gaap:DepositContractsAssets" scale="3" format="ixt:num-dot-decimal" decimals="-3">6,173</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c123854999" contextRef="i_2023-12-31" unitRef="USD" name="us-gaap:DepositContractsAssets" scale="3" format="ixt:num-dot-decimal" decimals="-3">6,489</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">Interest receivable</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c123855000" contextRef="i_2024-12-31" unitRef="USD" name="us-gaap:InterestReceivableCurrent" scale="3" format="ixt:num-dot-decimal" decimals="-3">947</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c123855001" contextRef="i_2023-12-31" unitRef="USD" name="us-gaap:InterestReceivableCurrent" scale="3" format="ixt:num-dot-decimal" decimals="-3">962</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">Other</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c123855002" contextRef="i_2024-12-31" unitRef="USD" name="us-gaap:OtherAssetsCurrent" scale="3" format="ixt:num-dot-decimal" decimals="-3">38</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c123855003" contextRef="i_2023-12-31" unitRef="USD" name="us-gaap:OtherAssetsCurrent" scale="3" format="ixt:num-dot-decimal" decimals="-3">287</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt; text-indent: -9pt;">Total prepaid expenses and other current assets</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c123855004" contextRef="i_2024-12-31" unitRef="USD" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="3" format="ixt:num-dot-decimal" decimals="-3">7,958</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c123855005" contextRef="i_2023-12-31" unitRef="USD" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="3" format="ixt:num-dot-decimal" decimals="-3">8,497</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td></tr>
</tbody></table>
   </ix:nonNumeric>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">Contract research organization and other deposits represent cash payments made to vendors in excess of expenses incurred.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;&#160;</p>
  </ix:nonNumeric>
  <div>
   &#160;
  </div>
  <ix:nonNumeric contextRef="d_2024-01-01_2024-12-31" name="us-gaap:RealEstateOwnedTextBlock" id="c2851683" escape="true">
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><em style="font: inherit;">4.</em> Real Property and Other Income, Expense</b></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">The Company owns a <em style="font: inherit;">two</em>-building office complex in Austin, Texas, a portion of which serves as its corporate headquarters. Maintenance, physical facilities, leasing, property management and other key responsibilities related to property ownership are&#160;outsourced to professional real-estate managers. The office complex measures approximately <ix:nonFraction id="c123855477" contextRef="i_2021-08-04_MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis-OfficeBuildingMember_StatementGeographicalAxis-TX" unitRef="SquareFoot" name="us-gaap:NetRentableArea" scale="0" format="ixt:num-dot-decimal" decimals="INF">90,000</ix:nonFraction> rentable square feet.&#160;At <em style="font: inherit;"> December 31, 2024, </em>the Company&#160;occupied approximately <ix:nonFraction id="c123855478" contextRef="i_2024-12-31_MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis-OfficeBuildingMember_StatementGeographicalAxis-TX" unitRef="Pure" name="sava:PercentageOfOccupancy" scale="-2" format="ixt:num-dot-decimal" decimals="2">25</ix:nonFraction>% of the property with the remainder&#160;either leased or available for lease to <em style="font: inherit;">third</em> parties. Gross rental income under existing <em style="font: inherit;">third</em>-party leases at <em style="font: inherit;"> December 31, 2024 </em>is expected to total&#160;$<ix:nonFraction id="c123855481" contextRef="i_2024-12-31" unitRef="USD" name="us-gaap:LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths" scale="6" format="ixt:num-dot-decimal" decimals="-5">0.3</ix:nonFraction> million in <em style="font: inherit;">2025,</em> $<ix:nonFraction id="c123855483" contextRef="i_2024-12-31" unitRef="USD" name="us-gaap:LessorOperatingLeasePaymentsToBeReceivedTwoYears" scale="6" format="ixt:num-dot-decimal" decimals="-5">0.4</ix:nonFraction>&#160;million in <em style="font: inherit;">2026</em> and $<ix:nonFraction id="c123855485" contextRef="i_2024-12-31" unitRef="USD" name="us-gaap:LessorOperatingLeasePaymentsToBeReceivedThreeYears" scale="6" format="ixt:num-dot-decimal" decimals="-5">0.2</ix:nonFraction>&#160;million in <em style="font: inherit;">2027.</em></p>
   <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
   <ix:exclude>
    <div class="PGFTR" style="text-align: center; width: 100%">
     <div class="hf-row">
      <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       <em style="font: inherit;">103</em>
      </div>
     </div>
    </div>
    <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
    <div class="PGHDR" style="text-align: left; width: 100%">
     <div class="hf-row">
      <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
       <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Table of Contents</a>
      </div>
     </div>
    </div>
   </ix:exclude>
   <ix:exclude>&#160;</ix:exclude>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">The Company records the net income from building operations and leases as other income, net, as leasing is <em style="font: inherit;">not</em> core to the Company&#8217;s operations. Building depreciation and amortization for space <em style="font: inherit;">not</em> occupied by the Company is included in general and administrative expense. Building depreciation and amortization for space occupied by the Company is allocated between general and administrative expense and research and development expense. Components of other income, net, for the periods presented were as follows (in thousands):</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">&#160;</p>
   <ix:nonNumeric contextRef="d_2024-01-01_2024-12-31" name="us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock" id="c2851684" escape="true">
    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="10" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;"><em style="font: inherit;"><em style="font: inherit;">Years ended December 31,</em></em></em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">2024</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">2023</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">2022</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 55%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">Lease revenue</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c123855012" contextRef="d_2024-01-01_2024-12-31" unitRef="USD" name="us-gaap:OtherNonoperatingIncome" scale="3" format="ixt:num-dot-decimal" decimals="-3">1,244</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c123855013" contextRef="d_2023-01-01_2023-12-31" unitRef="USD" name="us-gaap:OtherNonoperatingIncome" scale="3" format="ixt:num-dot-decimal" decimals="-3">2,283</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c123855014" contextRef="d_2022-01-01_2022-12-31" unitRef="USD" name="us-gaap:OtherNonoperatingIncome" scale="3" format="ixt:num-dot-decimal" decimals="-3">2,459</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">Property operating expenses</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(<ix:nonFraction id="c123855015" contextRef="d_2024-01-01_2024-12-31" unitRef="USD" name="us-gaap:OtherNonoperatingExpense" scale="3" format="ixt:num-dot-decimal" decimals="-3">832</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(<ix:nonFraction id="c123855016" contextRef="d_2023-01-01_2023-12-31" unitRef="USD" name="us-gaap:OtherNonoperatingExpense" scale="3" format="ixt:num-dot-decimal" decimals="-3">1,376</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;">(<ix:nonFraction id="c123855017" contextRef="d_2022-01-01_2022-12-31" unitRef="USD" name="us-gaap:OtherNonoperatingExpense" scale="3" format="ixt:num-dot-decimal" decimals="-3">1,462</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">)</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt; text-indent: -9pt;">Other income, net</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c123855018" contextRef="d_2024-01-01_2024-12-31" unitRef="USD" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" format="ixt:num-dot-decimal" decimals="-3">411</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c123855019" contextRef="d_2023-01-01_2023-12-31" unitRef="USD" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" format="ixt:num-dot-decimal" decimals="-3">907</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c123855020" contextRef="d_2022-01-01_2022-12-31" unitRef="USD" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" format="ixt:num-dot-decimal" decimals="-3">997</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td></tr>
</tbody></table>
   </ix:nonNumeric>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&#160;</p>
   <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 18pt;">The Company had accrued property taxes related to the building totaling $<ix:nonFraction id="c123855490" contextRef="i_2024-12-31_MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis-OfficeBuildingMember_StatementGeographicalAxis-TX" unitRef="USD" name="us-gaap:AccrualForTaxesOtherThanIncomeTaxesCurrent" scale="0" format="ixt:num-dot-decimal" decimals="INF">254,000</ix:nonFraction> and $<ix:nonFraction id="c123855491" contextRef="i_2023-12-31_MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis-OfficeBuildingMember_StatementGeographicalAxis-TX" unitRef="USD" name="us-gaap:AccrualForTaxesOtherThanIncomeTaxesCurrent" scale="0" format="ixt:num-dot-decimal" decimals="INF">338,000</ix:nonFraction> at&#160;<em style="font: inherit;"> December 31, 2024&#160;</em>and&#160;<em style="font: inherit;">2023,</em> respectively, included in other current liabilities.</p>
   <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
  </ix:nonNumeric>
  <div>
   &#160;
  </div>
  <ix:nonNumeric contextRef="d_2024-01-01_2024-12-31" name="us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock" id="c2851685" escape="true">
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><em style="font: inherit;">5.</em> Property and Equipment</b></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">The components of property and equipment, net, as of&#160;<em style="font: inherit;"> December 31, 2024&#160;</em>and <em style="font: inherit;">2023</em>&#160;were as follows (in thousands):</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
   <ix:nonNumeric contextRef="d_2024-01-01_2024-12-31" name="us-gaap:PropertyPlantAndEquipmentTextBlock" id="c2851686" escape="true">
    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td colspan="6" rowspan="1" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: center;"><b><em style="font: inherit;"><em style="font: inherit;">December 31,</em></em></b></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td></tr>
<tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">2024</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">2023</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 70%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">Land</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c123855025" contextRef="i_2024-12-31_PropertyPlantAndEquipmentByTypeAxis-LandMember" unitRef="USD" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" format="ixt:num-dot-decimal" decimals="-3">3,734</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c123855026" contextRef="i_2023-12-31_PropertyPlantAndEquipmentByTypeAxis-LandMember" unitRef="USD" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" format="ixt:num-dot-decimal" decimals="-3">3,734</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">Buildings</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c123855027" contextRef="i_2024-12-31_PropertyPlantAndEquipmentByTypeAxis-BuildingMember" unitRef="USD" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" format="ixt:num-dot-decimal" decimals="-4">15,980</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c123855028" contextRef="i_2023-12-31_PropertyPlantAndEquipmentByTypeAxis-BuildingMember" unitRef="USD" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" format="ixt:num-dot-decimal" decimals="-4">15,980</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">Site improvements</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c123855029" contextRef="i_2024-12-31_PropertyPlantAndEquipmentByTypeAxis-BuildingImprovementsMember" unitRef="USD" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" format="ixt:num-dot-decimal" decimals="-3">494</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c123855030" contextRef="i_2023-12-31_PropertyPlantAndEquipmentByTypeAxis-BuildingImprovementsMember" unitRef="USD" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" format="ixt:num-dot-decimal" decimals="-3">494</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">Tenant improvements</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c123855031" contextRef="i_2024-12-31_PropertyPlantAndEquipmentByTypeAxis-LeaseholdImprovementsMember" unitRef="USD" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" format="ixt:num-dot-decimal" decimals="-3">3,062</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c123855032" contextRef="i_2023-12-31_PropertyPlantAndEquipmentByTypeAxis-LeaseholdImprovementsMember" unitRef="USD" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" format="ixt:num-dot-decimal" decimals="-3">3,062</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">Furniture and equipment</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c123855033" contextRef="i_2024-12-31_PropertyPlantAndEquipmentByTypeAxis-FurnitureAndFixturesMember" unitRef="USD" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" format="ixt:num-dot-decimal" decimals="-3">875</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c123855034" contextRef="i_2023-12-31_PropertyPlantAndEquipmentByTypeAxis-FurnitureAndFixturesMember" unitRef="USD" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" format="ixt:num-dot-decimal" decimals="-3">868</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px;"> <p style="margin: 0pt; font-size: 10pt; font-family: Times New Roman;">Construction in progress</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c123855035" contextRef="i_2024-12-31_PropertyPlantAndEquipmentByTypeAxis-ConstructionInProgressMember" unitRef="USD" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" format="ixt:num-dot-decimal" decimals="-3">55</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c123855036" contextRef="i_2023-12-31_PropertyPlantAndEquipmentByTypeAxis-ConstructionInProgressMember" unitRef="USD" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" format="ixt:fixed-zero" decimals="-3">&#8212;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt; text-indent: -9pt;">Gross property and equipment</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c123855037" contextRef="i_2024-12-31" unitRef="USD" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" format="ixt:num-dot-decimal" decimals="-5">24,200</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c123855038" contextRef="i_2023-12-31" unitRef="USD" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" format="ixt:num-dot-decimal" decimals="-3">24,138</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">Accumulated depreciation</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(<ix:nonFraction id="c123855039" contextRef="i_2024-12-31" unitRef="USD" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="3" format="ixt:num-dot-decimal" decimals="-3">3,236</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(<ix:nonFraction id="c123855040" contextRef="i_2023-12-31" unitRef="USD" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="3" format="ixt:num-dot-decimal" decimals="-3">2,284</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt; text-indent: -9pt;">Property and equipment, net</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c123855041" contextRef="i_2024-12-31" unitRef="USD" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" format="ixt:num-dot-decimal" decimals="-3">20,964</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c123855042" contextRef="i_2023-12-31" unitRef="USD" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" format="ixt:num-dot-decimal" decimals="-3">21,854</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td></tr>
</tbody></table>
   </ix:nonNumeric>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">Depreciation expense for property and equipment was&#160;$<ix:nonFraction id="c123855495" contextRef="d_2024-01-01_2024-12-31" unitRef="USD" name="us-gaap:Depreciation" scale="0" format="ixt:num-dot-decimal" decimals="INF">952,000</ix:nonFraction>, $<ix:nonFraction id="c123855496" contextRef="d_2023-01-01_2023-12-31" unitRef="USD" name="us-gaap:Depreciation" scale="0" format="ixt:num-dot-decimal" decimals="INF">1,084,000</ix:nonFraction>&#160;and&#160;$<ix:nonFraction id="c123855497" contextRef="d_2022-01-01_2022-12-31" unitRef="USD" name="us-gaap:Depreciation" scale="0" format="ixt:num-dot-decimal" decimals="INF">804,000</ix:nonFraction>&#160;for the years ended <em style="font: inherit;"> December 31, 2024, </em><em style="font: inherit;">2023</em>&#160;and <em style="font: inherit;">2022,</em> respectively.&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">&#160;</p>
  </ix:nonNumeric>
  <div>
   &#160;
  </div>
  <ix:nonNumeric contextRef="d_2024-01-01_2024-12-31" name="us-gaap:IntangibleAssetsDisclosureTextBlock" id="c2851687" escape="true">
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><em style="font: inherit;">6.</em> Intangible Assets</b></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">The components of intangible assets, net, as of&#160;<em style="font: inherit;"> December 31, 2024&#160;</em>and <em style="font: inherit;">2023</em>&#160;were as follows (in thousands):</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
   <ix:nonNumeric contextRef="d_2024-01-01_2024-12-31" name="us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" id="c2851688" escape="true">
    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;">&#160;</td><td colspan="6" rowspan="1" style="font-family: Times New Roman; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; text-align: center; border-bottom: 1px solid rgb(0, 0, 0);"><b><em style="font: inherit;"><em style="font: inherit;">December 31,</em></em></b></td><td style="font-family: Times New Roman; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;">&#160;</td></tr>
<tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">2024</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">2023</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 70%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">Lease-in-place agreements</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c123855047" contextRef="i_2024-12-31_FiniteLivedIntangibleAssetsByMajorClassAxis-LeasesAcquiredInPlaceMember" unitRef="USD" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="3" format="ixt:num-dot-decimal" decimals="-3">1,053</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c123855048" contextRef="i_2023-12-31_FiniteLivedIntangibleAssetsByMajorClassAxis-LeasesAcquiredInPlaceMember" unitRef="USD" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="3" format="ixt:num-dot-decimal" decimals="-3">1,053</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">Leasing commissions and other</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c123855049" contextRef="i_2024-12-31_FiniteLivedIntangibleAssetsByMajorClassAxis-LeasingCommissionsAndOtherMember" unitRef="USD" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="3" format="ixt:num-dot-decimal" decimals="-3">334</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c123855050" contextRef="i_2023-12-31_FiniteLivedIntangibleAssetsByMajorClassAxis-LeasingCommissionsAndOtherMember" unitRef="USD" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="3" format="ixt:num-dot-decimal" decimals="-3">293</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt; text-indent: -9pt;">Gross intangible assets</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c123855051" contextRef="i_2024-12-31" unitRef="USD" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="3" format="ixt:num-dot-decimal" decimals="-3">1,387</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c123855052" contextRef="i_2023-12-31" unitRef="USD" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="3" format="ixt:num-dot-decimal" decimals="-3">1,346</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">Accumulated amortization</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(<ix:nonFraction id="c123855053" contextRef="i_2024-12-31" unitRef="USD" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="3" format="ixt:num-dot-decimal" decimals="-4">1,350</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(<ix:nonFraction id="c123855054" contextRef="i_2023-12-31" unitRef="USD" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="3" format="ixt:num-dot-decimal" decimals="-4">1,170</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt; text-indent: -9pt;">Intangible assets, net</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c123855055" contextRef="i_2024-12-31" unitRef="USD" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="3" format="ixt:num-dot-decimal" decimals="-3">37</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c123855056" contextRef="i_2023-12-31" unitRef="USD" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="3" format="ixt:num-dot-decimal" decimals="-3">176</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td></tr>
</tbody></table>
   </ix:nonNumeric>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">Amortization expense for intangible assets was $<ix:nonFraction id="c123855502" contextRef="d_2024-01-01_2024-12-31" unitRef="USD" name="us-gaap:AmortizationOfIntangibleAssets" scale="0" format="ixt:num-dot-decimal" decimals="INF">180,000</ix:nonFraction>, $<ix:nonFraction id="c123855503" contextRef="d_2023-01-01_2023-12-31" unitRef="USD" name="us-gaap:AmortizationOfIntangibleAssets" scale="0" format="ixt:num-dot-decimal" decimals="INF">446,000</ix:nonFraction> and $<ix:nonFraction id="c123855504" contextRef="d_2022-01-01_2022-12-31" unitRef="USD" name="us-gaap:AmortizationOfIntangibleAssets" scale="0" format="ixt:num-dot-decimal" decimals="INF">497,000</ix:nonFraction> for the years ended <em style="font: inherit;"> December 31, 2024, </em><em style="font: inherit;">2023</em>&#160;and <em style="font: inherit;">2022,</em> respectively.&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
   <ix:exclude>
    <div class="PGFTR" style="text-align: center; width: 100%">
     <div class="hf-row">
      <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       <em style="font: inherit;">104</em>
      </div>
     </div>
    </div>
    <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
    <div class="PGHDR" style="text-align: left; width: 100%">
     <div class="hf-row">
      <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
       <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Table of Contents</a>
      </div>
     </div>
    </div>
   </ix:exclude>
   <ix:exclude>&#160;</ix:exclude>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">Amortization expense for finite-lived intangible assets is expected to be as follows (in thousands):</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
   <ix:nonNumeric contextRef="d_2024-01-01_2024-12-31" name="us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" id="c2851689" escape="true">
    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 85%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;"><b><span style="text-decoration: underline; ">For the year ending December 31,</span></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">2025</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c123855057" contextRef="i_2024-12-31" unitRef="USD" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" scale="3" format="ixt:num-dot-decimal" decimals="-3">17</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">2026</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c123855058" contextRef="i_2024-12-31" unitRef="USD" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" scale="3" format="ixt:num-dot-decimal" decimals="-3">14</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px;"> <p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">2027</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c123855059" contextRef="i_2024-12-31" unitRef="USD" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" scale="3" format="ixt:num-dot-decimal" decimals="-3">6</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">Total amortization</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c123855060" contextRef="i_2024-12-31" unitRef="USD" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="3" format="ixt:num-dot-decimal" decimals="-3">37</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td></tr>
</tbody></table>
   </ix:nonNumeric>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  </ix:nonNumeric>
  <div>
   &#160;
  </div>
  <ix:nonNumeric contextRef="d_2024-01-01_2024-12-31" name="us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock" id="c2851690" escape="true">
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><em style="font: inherit;">7.</em> Stockholders' Equity and Stock-Based Compensation</b></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>Preferred Stock</i></b></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">The Company&#8217;s Board of Directors (the &#8220;Board&#8221;) has the authority to issue preferred stock in <em style="font: inherit;">one</em> or more series and to fix the rights, preferences, privileges, restrictions and the number of shares constituting any series or the designation of the series.</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i><em style="font: inherit;">2022</em> Registered Direct Offering</i></b></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">On <em style="font: inherit;"> November&#160;</em><em style="font: inherit;">22,</em> <em style="font: inherit;">2022,</em> the Company completed a common stock offering pursuant to which certain investors purchased <ix:nonFraction id="c123855513" contextRef="d_2022-11-22_2022-11-22_SubsidiarySaleOfStockAxis-The2022RegisteredDirectOfferingMember" unitRef="Share" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" format="ixt:num-dot-decimal" decimals="INF">1,666,667</ix:nonFraction> shares of common stock at a price of $<ix:nonFraction id="c123855514" contextRef="i_2022-11-22_SubsidiarySaleOfStockAxis-The2022RegisteredDirectOfferingMember" unitRef="USDPerShare" name="us-gaap:SharesIssuedPricePerShare" scale="0" format="ixt:num-dot-decimal" decimals="INF">30.00</ix:nonFraction> per share. Net proceeds of the offering were approximately $<ix:nonFraction id="c123855515" contextRef="d_2022-11-22_2022-11-22_SubsidiarySaleOfStockAxis-The2022RegisteredDirectOfferingMember" unitRef="USD" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="6" format="ixt:num-dot-decimal" decimals="-5">47.3</ix:nonFraction>&#160;million after deducting offering expenses.</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -1pt;"><b><i>Common Stock Warrant Distribution</i></b></p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -1pt; text-indent: 18pt;">See Notes <em style="font: inherit;">2</em> and <em style="font: inherit;">13</em>&#160;regarding the distribution of common stock warrants on <em style="font: inherit;"> January 3, 2024.</em></p>
   <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>At the Market (ATM) Common Stock Issuance </i></b></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">On <em style="font: inherit;"> May 1, 2023, </em>the Company entered into an&#160;at-the-market offering program (&#8220;ATM&#8221;) to sell, from time to time, shares of Company common stock having an aggregate offering price of up to $<ix:nonFraction id="c123855518" contextRef="i_2023-05-01_SubsidiarySaleOfStockAxis-AtthemarketCommonStockOfferingMember" unitRef="USD" name="sava:EquityOfferingMaximumAmount" scale="6" format="ixt:num-dot-decimal" decimals="-8">200</ix:nonFraction> million in common stock pursuant to a shelf registration statement that was filed with the U.S. Securities and Exchange Commission (the &#8220;SEC&#8221;) on <em style="font: inherit;"> May 1, 2023 </em>and became effective immediately upon filing. The Company is obligated to pay a commission of up to <ix:nonFraction id="c123855519" contextRef="i_2023-05-01_SubsidiarySaleOfStockAxis-AtthemarketCommonStockOfferingMember" unitRef="Pure" name="sava:EquityOfferingPercentageOfCommission" scale="-2" format="ixt:num-dot-decimal" decimals="2">3</ix:nonFraction>% of the gross proceeds from the sale of shares of common stock under&#160;the ATM. As of the filing of this Annual Report on Form <em style="font: inherit;">10</em>-K, the Company is <em style="font: inherit;">no</em> longer a Well-Known Seasoned Issuer, as defined by the SEC. Thus, the Company&#160;is <em style="font: inherit;">not</em> eligible to sell securities under the ATM under its existing &#8220;automatic&#8221; shelf registration statement on Form S-<em style="font: inherit;">3</em> unless and until it files a new Form S-<em style="font: inherit;">3</em> that is declared effective by the SEC.</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">There were&#160;<span style="-sec-ix-hidden:c123855525">no</span>&#160;common stock sales under the ATM during the year&#160;ended <em style="font: inherit;"> December 31, 2024 </em>and <em style="font: inherit;">2023.</em></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i><em style="font: inherit;">2008</em> Equity Incentive Plan </i></b></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">Under the Company&#8217;s <em style="font: inherit;">2008</em> Equity Incentive Plan, or <em style="font: inherit;">2008</em> Equity Plan, its employees, directors and consultants received share-based awards, including grants of stock options and performance awards. The <em style="font: inherit;">2008</em> Equity Plan expired in <em style="font: inherit;"> December 2017. </em>Share-based awards generally expire <em style="font: inherit;">ten</em> years from the date of grant.</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i><em style="font: inherit;">2018</em> Equity Incentive Plan </i></b></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">The Company&#8217;s Board or a designated Committee of the Board is responsible for administration of the Company&#8217;s <em style="font: inherit;">2018</em> Omnibus Incentive Plan (the <em style="font: inherit;">2018</em> Plan) and determines the terms and conditions of each option granted, consistent with the terms of the <em style="font: inherit;">2018</em> Plan. The Company&#8217;s employees, directors, and consultants are eligible to receive awards under the <em style="font: inherit;">2018</em> Plan, including grants of stock options and performance awards. Share-based awards generally expire <span style="-sec-ix-hidden:c123855537">ten</span> years from the date of grant. The <em style="font: inherit;">2018</em> Plan, as amended in <em style="font: inherit;"> May&#160;</em><em style="font: inherit;">2022,</em> provides for issuance of up to <ix:nonFraction id="c123855540" contextRef="i_2022-05-05_PlanNameAxis-The2018EquityIncentivePlanMember" unitRef="Share" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" scale="0" format="ixt:num-dot-decimal" decimals="INF">5,000,000</ix:nonFraction> shares of common stock, par value $<ix:nonFraction id="c123855541" contextRef="i_2022-05-05_PlanNameAxis-The2018EquityIncentivePlanMember" unitRef="USDPerShare" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" format="ixt:num-dot-decimal" decimals="INF">0.001</ix:nonFraction> per share, subject to adjustment as provided in the <em style="font: inherit;">2018</em> Plan.</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">When stock options or performance awards are exercised net of the exercise price and taxes, the number of shares of stock issued is reduced by the number of shares equal to the amount of taxes owed by the award recipient and that number of shares are cancelled. The Company <em style="font: inherit;"> may </em>then use its cash to pay tax authorities the amount of statutory taxes owed by and on behalf of the award recipient.</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">&#160;</p>
   <ix:exclude>
    <div class="PGFTR" style="text-align: center; width: 100%">
     <div class="hf-row">
      <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       <em style="font: inherit;">105</em>
      </div>
     </div>
    </div>
    <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
    <div class="PGHDR" style="text-align: left; width: 100%">
     <div class="hf-row">
      <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
       <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Table of Contents</a>
      </div>
     </div>
    </div>
   </ix:exclude>
   <ix:exclude>&#160;</ix:exclude>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>Stock Options</i></b></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">The following summarizes information about stock option activity during <em style="font: inherit;">2024:</em></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
   <ix:nonNumeric contextRef="d_2024-01-01_2024-12-31" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" id="c2851691" escape="true">
    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="text-align: center; font-family: Times New Roman; font-size: 10pt;"><em style="font: inherit;">&#160;</em></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Weighted Average</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Weighted Average</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="text-align: center; font-family: Times New Roman; font-size: 10pt;"><em style="font: inherit;">&#160;</em></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td></tr>
<tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Number of</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Weighted Average</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Remaining Contractual</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Aggregate Intrinsic Value</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td></tr>
<tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Options</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Exercise Price</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Term in Years</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">in Millions</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 40%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">Outstanding as of December 31, 2023</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c123855074" contextRef="i_2023-12-31" unitRef="Share" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" format="ixt:num-dot-decimal" decimals="INF">3,039,029</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c123855075" contextRef="i_2023-12-31" unitRef="USDPerShare" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" format="ixt:num-dot-decimal" decimals="INF">15.13</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonNumeric contextRef="d_2023-01-01_2023-12-31" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" id="c123855076" format="ixt-sec:duryear">6.21</ix:nonNumeric></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c123855077" contextRef="i_2023-12-31" unitRef="USD" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" scale="6" format="ixt:num-dot-decimal" decimals="-4">30.28</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> <p style="margin: 0pt 0pt 0pt 9pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">Options granted</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; text-align: right; padding: 0; margin: 0"><ix:nonFraction id="c123855078" contextRef="d_2024-01-01_2024-12-31" unitRef="Share" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" format="ixt:num-dot-decimal" decimals="INF">2,083,000</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"><ix:nonFraction id="c123855079" contextRef="d_2024-01-01_2024-12-31" unitRef="USDPerShare" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" format="ixt:num-dot-decimal" decimals="INF">26.65</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"><em style="font: inherit;">&#160;</em></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"><em style="font: inherit;">&#160;</em></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> <p style="margin: 0pt 0pt 0pt 9pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">Options exercised</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; text-align: right; padding: 0; margin: 0">(<ix:nonFraction id="c123855082" contextRef="d_2024-01-01_2024-12-31" unitRef="Share" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" format="ixt:num-dot-decimal" decimals="INF">240,147</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0; margin: 0">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"><ix:nonFraction id="c123855083" contextRef="d_2024-01-01_2024-12-31" unitRef="USDPerShare" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" scale="0" format="ixt:num-dot-decimal" decimals="INF">5.25</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"><em style="font: inherit;">&#160;</em></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"><em style="font: inherit;">&#160;</em></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> <p style="margin: 0pt 0pt 0pt 9pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">Options forfeited/canceled</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; text-align: right; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);">(<ix:nonFraction id="c123855086" contextRef="d_2024-01-01_2024-12-31" unitRef="Share" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" scale="0" format="ixt:num-dot-decimal" decimals="INF">418,854</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"><ix:nonFraction id="c123855087" contextRef="d_2024-01-01_2024-12-31" unitRef="USDPerShare" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" scale="0" format="ixt:num-dot-decimal" decimals="INF">24.64</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"><em style="font: inherit;">&#160;</em></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"><em style="font: inherit;">&#160;</em></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">Outstanding as of December 31, 2024</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c123855090" contextRef="i_2024-12-31" unitRef="Share" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" format="ixt:num-dot-decimal" decimals="INF">4,463,028</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c123855091" contextRef="i_2024-12-31" unitRef="USDPerShare" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" format="ixt:num-dot-decimal" decimals="INF">20.15</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonNumeric contextRef="d_2024-01-01_2024-12-31" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" id="c123855092" format="ixt-sec:duryear">7.61</ix:nonNumeric></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c123855093" contextRef="i_2024-12-31" unitRef="USD" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" scale="6" format="ixt:num-dot-decimal" decimals="-5">0.30</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">Vested and expected to vest at December 31, 2024</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c123855094" contextRef="i_2024-12-31" unitRef="Share" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" scale="0" format="ixt:num-dot-decimal" decimals="INF">3,965,665</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c123855095" contextRef="i_2024-12-31" unitRef="USDPerShare" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" scale="0" format="ixt:num-dot-decimal" decimals="INF">19.93</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonNumeric contextRef="d_2024-01-01_2024-12-31" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" id="c123855096" format="ixt-sec:duryear">7.44</ix:nonNumeric></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c123855097" contextRef="i_2024-12-31" unitRef="USD" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" scale="6" format="ixt:num-dot-decimal" decimals="-5">0.30</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">Exercisable at December 31, 2024</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c123855098" contextRef="i_2024-12-31" unitRef="Share" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" scale="0" format="ixt:num-dot-decimal" decimals="INF">1,794,501</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c123855099" contextRef="i_2024-12-31" unitRef="USDPerShare" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" scale="0" format="ixt:num-dot-decimal" decimals="INF">12.86</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonNumeric contextRef="d_2024-01-01_2024-12-31" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" id="c123855100" format="ixt-sec:duryear">4.95</ix:nonNumeric></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c123855101" contextRef="i_2024-12-31" unitRef="USD" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" scale="6" format="ixt:num-dot-decimal" decimals="-5">0.30</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
</tbody></table>
   </ix:nonNumeric>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">Of the stock options exercised during the year ended <em style="font: inherit;"> December 31, 2024, </em><ix:nonFraction id="c123855545" contextRef="d_2024-01-01_2024-12-31" unitRef="Share" name="sava:StockOptionsExercisedNetSettledSatisfactionOfExercisePrice" scale="0" format="ixt:num-dot-decimal" decimals="INF">6,634</ix:nonFraction>&#160;stock options were net settled in satisfaction of the exercise price, with <em style="font: inherit;">no</em> cash proceeds received. In addition, an employee surrendered <ix:nonFraction id="c123855547" contextRef="d_2024-01-01_2024-12-31_GranteeStatusAxis-ShareBasedPaymentArrangementEmployeeMember" unitRef="Share" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" scale="0" format="ixt:num-dot-decimal" decimals="INF">6,500</ix:nonFraction> shares of common stock in conjunction with&#160;a net exercise of a stock option. The common shares&#160;surrendered were&#160;retired by the Company.</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">The following summarizes information about stock options at <em style="font: inherit;"> December 31, 2024&#160;</em>by a range of exercise prices:</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
   <ix:nonNumeric contextRef="d_2024-01-01_2024-12-31" name="us-gaap:ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" id="c2851692" escape="true">
    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="text-align: center; font-family: Times New Roman; font-size: 10pt;"><b><em style="font: inherit;">&#160;</em></b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="text-align: center; font-family: Times New Roman; font-size: 10pt;"><b><em style="font: inherit;">&#160;</em></b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="10" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;"><em style="font: inherit;"><em style="font: inherit;">Options outstanding</em></em></em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;"><em style="font: inherit;">Options exercisable</em></em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td></tr>
<tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="text-align: center; font-family: Times New Roman; font-size: 10pt;"><b><em style="font: inherit;">&#160;</em></b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="text-align: center; font-family: Times New Roman; font-size: 10pt;"><b><em style="font: inherit;">&#160;</em></b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="text-align: center; font-family: Times New Roman; font-size: 10pt;"><b><em style="font: inherit;">&#160;</em></b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Weighted</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="text-align: center; font-family: Times New Roman; font-size: 10pt;"><b><em style="font: inherit;">&#160;</em></b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="text-align: center; font-family: Times New Roman; font-size: 10pt;"><b><em style="font: inherit;">&#160;</em></b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="text-align: center; font-family: Times New Roman; font-size: 10pt;"><b><em style="font: inherit;">&#160;</em></b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td></tr>
<tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="text-align: center; font-family: Times New Roman; font-size: 10pt;"><b><em style="font: inherit;">&#160;</em></b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="text-align: center; font-family: Times New Roman; font-size: 10pt;"><b><em style="font: inherit;">&#160;</em></b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="text-align: center; font-family: Times New Roman; font-size: 10pt;"><b><em style="font: inherit;">&#160;</em></b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">average</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Weighted</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="text-align: center; font-family: Times New Roman; font-size: 10pt;"><b><em style="font: inherit;">&#160;</em></b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Weighted</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td></tr>
<tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="text-align: center; font-family: Times New Roman; font-size: 10pt;"><b><em style="font: inherit;">&#160;</em></b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="text-align: center; font-family: Times New Roman; font-size: 10pt;"><b><em style="font: inherit;">&#160;</em></b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Number of</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">remaining</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">average</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Number of</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">average</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td></tr>
<tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td colspan="6" style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;"><em style="font: inherit;">Range of exercise prices</em></em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">outstanding</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">contractual</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">exercise</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">vested</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">exercise</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td></tr>
<tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td colspan="2" style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">From</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">To</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">options</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">life (in years)</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">price</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">options</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">price</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">$</td><td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c123855144" contextRef="d_2024-01-01_2024-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-RangeOneMember" unitRef="USDPerShare" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" scale="0" format="ixt:num-dot-decimal" decimals="INF">0.95</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c123855145" contextRef="d_2024-01-01_2024-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-RangeOneMember" unitRef="USDPerShare" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" scale="0" format="ixt:num-dot-decimal" decimals="INF">4.10</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c123855146" contextRef="i_2024-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-RangeOneMember" unitRef="Share" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" scale="0" format="ixt:num-dot-decimal" decimals="INF">900,303</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonNumeric contextRef="d_2024-01-01_2024-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-RangeOneMember" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" id="c123855147" format="ixt-sec:duryear">3.5</ix:nonNumeric></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c123855148" contextRef="i_2024-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-RangeOneMember" unitRef="USDPerShare" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" scale="0" format="ixt:num-dot-decimal" decimals="INF">2.80</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c123855149" contextRef="i_2024-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-RangeOneMember" unitRef="Share" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" scale="0" format="ixt:num-dot-decimal" decimals="INF">900,303</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c123855150" contextRef="i_2024-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-RangeOneMember" unitRef="USDPerShare" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" scale="0" format="ixt:num-dot-decimal" decimals="INF">2.80</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">$</td><td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c123855151" contextRef="d_2024-01-01_2024-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-RangeTwoMember" unitRef="USDPerShare" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" scale="0" format="ixt:num-dot-decimal" decimals="INF">5.46</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c123855152" contextRef="d_2024-01-01_2024-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-RangeTwoMember" unitRef="USDPerShare" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" scale="0" format="ixt:num-dot-decimal" decimals="INF">17.54</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c123855153" contextRef="i_2024-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-RangeTwoMember" unitRef="Share" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" scale="0" format="ixt:num-dot-decimal" decimals="INF">1,049,656</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonNumeric contextRef="d_2024-01-01_2024-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-RangeTwoMember" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" id="c123855154" format="ixt-sec:duryear">7.1</ix:nonNumeric></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c123855155" contextRef="i_2024-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-RangeTwoMember" unitRef="USDPerShare" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" scale="0" format="ixt:num-dot-decimal" decimals="INF">16.21</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c123855156" contextRef="i_2024-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-RangeTwoMember" unitRef="Share" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" scale="0" format="ixt:num-dot-decimal" decimals="INF">560,765</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c123855157" contextRef="i_2024-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-RangeTwoMember" unitRef="USDPerShare" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" scale="0" format="ixt:num-dot-decimal" decimals="INF">15.06</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">$</td><td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"><ix:nonFraction id="c123855158" contextRef="d_2024-01-01_2024-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-RangeThreeMember" unitRef="USDPerShare" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" scale="0" format="ixt:num-dot-decimal" decimals="INF">18.78</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">$</td><td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"><ix:nonFraction id="c123855159" contextRef="d_2024-01-01_2024-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-RangeThreeMember" unitRef="USDPerShare" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" scale="0" format="ixt:num-dot-decimal" decimals="INF">26.57</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"><ix:nonFraction id="c123855160" contextRef="i_2024-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-RangeThreeMember" unitRef="Share" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" scale="0" format="ixt:num-dot-decimal" decimals="INF">539,277</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"><ix:nonNumeric contextRef="d_2024-01-01_2024-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-RangeThreeMember" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" id="c123855161" format="ixt-sec:duryear">8.7</ix:nonNumeric></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">$</td><td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"><ix:nonFraction id="c123855162" contextRef="i_2024-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-RangeThreeMember" unitRef="USDPerShare" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" scale="0" format="ixt:num-dot-decimal" decimals="INF">21.90</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"><ix:nonFraction id="c123855163" contextRef="i_2024-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-RangeThreeMember" unitRef="Share" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" scale="0" format="ixt:num-dot-decimal" decimals="INF">197,198</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">$</td><td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"><ix:nonFraction id="c123855164" contextRef="i_2024-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-RangeThreeMember" unitRef="USDPerShare" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" scale="0" format="ixt:num-dot-decimal" decimals="INF">21.81</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px;">$</td><td style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px;"><ix:nonFraction id="c123855165" contextRef="d_2024-01-01_2024-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-RangeFourMember" unitRef="USDPerShare" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" scale="0" format="ixt:num-dot-decimal" decimals="INF">26.91</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px;">$</td><td style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px;"><ix:nonFraction id="c123855166" contextRef="d_2024-01-01_2024-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-RangeFourMember" unitRef="USDPerShare" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" scale="0" format="ixt:num-dot-decimal" decimals="INF">26.91</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px;">&#160;</td><td style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px;"><ix:nonFraction id="c123855167" contextRef="i_2024-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-RangeFourMember" unitRef="Share" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" scale="0" format="ixt:num-dot-decimal" decimals="INF">1,080,000</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px;">&#160;</td><td style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px;"><ix:nonNumeric contextRef="d_2024-01-01_2024-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-RangeFourMember" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" id="c123855168" format="ixt-sec:duryear">9.7</ix:nonNumeric></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px;">$</td><td style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px;"><ix:nonFraction id="c123855169" contextRef="i_2024-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-RangeFourMember" unitRef="USDPerShare" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" scale="0" format="ixt:num-dot-decimal" decimals="INF">26.91</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px;">&#160;</td><td style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px;"><ix:nonFraction id="c123855170" contextRef="i_2024-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-RangeFourMember" unitRef="Share" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" scale="0" format="ixt:num-dot-decimal" decimals="INF">364</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px;">$</td><td style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px;"><ix:nonFraction id="c123855171" contextRef="i_2024-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-RangeFourMember" unitRef="USDPerShare" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" scale="0" format="ixt:num-dot-decimal" decimals="INF">26.91</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">$</td><td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c123855172" contextRef="d_2024-01-01_2024-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-RangeFiveMember" unitRef="USDPerShare" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" scale="0" format="ixt:num-dot-decimal" decimals="INF">27.42</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c123855173" contextRef="d_2024-01-01_2024-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-RangeFiveMember" unitRef="USDPerShare" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" scale="0" format="ixt:num-dot-decimal" decimals="INF">77.00</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid black;">&#160;</td><td style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid black;"><ix:nonFraction id="c123855174" contextRef="i_2024-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-RangeFiveMember" unitRef="Share" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" scale="0" format="ixt:num-dot-decimal" decimals="INF">893,792</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonNumeric contextRef="d_2024-01-01_2024-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-RangeFiveMember" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" id="c123855175" format="ixt-sec:duryear">9.2</ix:nonNumeric></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c123855176" contextRef="i_2024-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-RangeFiveMember" unitRef="USDPerShare" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" scale="0" format="ixt:num-dot-decimal" decimals="INF">33.02</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid black;">&#160;</td><td style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid black;"><ix:nonFraction id="c123855177" contextRef="i_2024-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-RangeFiveMember" unitRef="Share" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" scale="0" format="ixt:num-dot-decimal" decimals="INF">135,871</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c123855178" contextRef="i_2024-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-RangeFiveMember" unitRef="USDPerShare" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" scale="0" format="ixt:num-dot-decimal" decimals="INF">57.40</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="text-align: right; font-family: Times New Roman; font-size: 10pt;"><em style="font: inherit;">&#160;</em></td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="text-align: right; font-family: Times New Roman; font-size: 10pt;"><em style="font: inherit;">&#160;</em></td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c123855181" contextRef="i_2024-12-31" unitRef="Share" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" scale="0" format="ixt:num-dot-decimal" decimals="INF">4,463,028</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonNumeric contextRef="d_2024-01-01_2024-12-31" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" id="c123855182" format="ixt-sec:duryear">7.6</ix:nonNumeric></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c123855183" contextRef="i_2024-12-31" unitRef="USDPerShare" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" scale="0" format="ixt:num-dot-decimal" decimals="INF">20.15</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c123855184" contextRef="i_2024-12-31" unitRef="Share" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" scale="0" format="ixt:num-dot-decimal" decimals="INF">1,794,501</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c123855185" contextRef="i_2024-12-31" unitRef="USDPerShare" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" scale="0" format="ixt:num-dot-decimal" decimals="INF">12.86</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
</tbody></table>
   </ix:nonNumeric>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">The Company uses Black-Scholes to estimate the fair value of options granted. Black-Scholes considers a number of factors, including the market price of the Company&#8217;s common stock. Factors utilized in Black-Scholes to value each stock option granted, and the weighted average fair value of options granted during the years ended&#160;<em style="font: inherit;"> December 31, 2024, </em><em style="font: inherit;">2023</em>&#160;and <em style="font: inherit;">2022</em>&#160;were as follows:</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
   <ix:nonNumeric contextRef="d_2024-01-01_2024-12-31" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" id="c2851693" escape="true">
    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">2024</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">2023</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">2022</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 55%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">Volatility</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c123855209" contextRef="d_2024-01-01_2024-12-31_AwardTypeAxis-EmployeeStockOptionMember_RangeAxis-MinimumMember" unitRef="Pure" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" format="ixt:num-dot-decimal" decimals="2">151</ix:nonFraction>% to <ix:nonFraction id="c123855210" contextRef="d_2024-01-01_2024-12-31_AwardTypeAxis-EmployeeStockOptionMember_RangeAxis-MaximumMember" unitRef="Pure" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" format="ixt:num-dot-decimal" decimals="1">170</ix:nonFraction>%</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c123855223" contextRef="d_2023-01-01_2023-12-31_AwardTypeAxis-EmployeeStockOptionMember_RangeAxis-MinimumMember" unitRef="Pure" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" format="ixt:num-dot-decimal" decimals="2">152</ix:nonFraction>% to <ix:nonFraction id="c123855224" contextRef="d_2023-01-01_2023-12-31_AwardTypeAxis-EmployeeStockOptionMember_RangeAxis-MaximumMember" unitRef="Pure" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" format="ixt:num-dot-decimal" decimals="2">155</ix:nonFraction>%</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c123855237" contextRef="d_2022-01-01_2022-12-31_AwardTypeAxis-EmployeeStockOptionMember_RangeAxis-MinimumMember" unitRef="Pure" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" format="ixt:num-dot-decimal" decimals="2">151</ix:nonFraction>% to <ix:nonFraction id="c123855238" contextRef="d_2022-01-01_2022-12-31_AwardTypeAxis-EmployeeStockOptionMember_RangeAxis-MaximumMember" unitRef="Pure" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" format="ixt:num-dot-decimal" decimals="2">154</ix:nonFraction>%</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">Risk-free interest rates</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c123855211" contextRef="d_2024-01-01_2024-12-31_AwardTypeAxis-EmployeeStockOptionMember_RangeAxis-MinimumMember" unitRef="Pure" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" format="ixt:num-dot-decimal" decimals="4">3.53</ix:nonFraction>% to <ix:nonFraction id="c123855212" contextRef="d_2024-01-01_2024-12-31_AwardTypeAxis-EmployeeStockOptionMember_RangeAxis-MaximumMember" unitRef="Pure" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" format="ixt:num-dot-decimal" decimals="4">4.47</ix:nonFraction>%</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c123855225" contextRef="d_2023-01-01_2023-12-31_AwardTypeAxis-EmployeeStockOptionMember_RangeAxis-MinimumMember" unitRef="Pure" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" format="ixt:num-dot-decimal" decimals="4">3.82</ix:nonFraction>% to <ix:nonFraction id="c123855226" contextRef="d_2023-01-01_2023-12-31_AwardTypeAxis-EmployeeStockOptionMember_RangeAxis-MaximumMember" unitRef="Pure" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" format="ixt:num-dot-decimal" decimals="4">4.37</ix:nonFraction>%</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c123855239" contextRef="d_2022-01-01_2022-12-31_AwardTypeAxis-EmployeeStockOptionMember_RangeAxis-MinimumMember" unitRef="Pure" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" format="ixt:num-dot-decimal" decimals="4">1.98</ix:nonFraction>% to <ix:nonFraction id="c123855240" contextRef="d_2022-01-01_2022-12-31_AwardTypeAxis-EmployeeStockOptionMember_RangeAxis-MaximumMember" unitRef="Pure" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" format="ixt:num-dot-decimal" decimals="4">3.69</ix:nonFraction>%</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">Expected life of option (in years)</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonNumeric contextRef="d_2024-01-01_2024-12-31_AwardTypeAxis-EmployeeStockOptionMember" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="c123855195" format="ixt-sec:duryear">7</ix:nonNumeric></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonNumeric contextRef="d_2023-01-01_2023-12-31_AwardTypeAxis-EmployeeStockOptionMember" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="c123855196" format="ixt-sec:duryear">7</ix:nonNumeric></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonNumeric contextRef="d_2022-01-01_2022-12-31_AwardTypeAxis-EmployeeStockOptionMember" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="c123855197" format="ixt-sec:duryear">7</ix:nonNumeric></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">Dividend yield</p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: right;"><span style="-sec-ix-hidden:c123855198">zero</span></p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: right;"><span style="-sec-ix-hidden:c123855199">zero</span></p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: right;"><span style="-sec-ix-hidden:c123855200">zero</span></p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">Forfeiture rate</p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: right;"><span style="-sec-ix-hidden:c123855201">4.3</span></p> </td><td style="font-family: Times New Roman; font-size: 10pt;">%</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: right;"><span style="-sec-ix-hidden:c123855202">zero</span></p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: right;"><span style="-sec-ix-hidden:c123855203">zero</span></p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">Weighted average fair value of stock options granted</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c123855204" contextRef="d_2024-01-01_2024-12-31_AwardTypeAxis-EmployeeStockOptionMember" unitRef="USDPerShare" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" format="ixt:num-dot-decimal" decimals="INF">25.85</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c123855205" contextRef="d_2023-01-01_2023-12-31_AwardTypeAxis-EmployeeStockOptionMember" unitRef="USDPerShare" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" format="ixt:num-dot-decimal" decimals="INF">18.21</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c123855206" contextRef="d_2022-01-01_2022-12-31_AwardTypeAxis-EmployeeStockOptionMember" unitRef="USDPerShare" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" format="ixt:num-dot-decimal" decimals="INF">35.16</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
</tbody></table>
   </ix:nonNumeric>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">Volatility is based on reviews of the historical volatility of the Company&#8217;s common stock. Risk-free interest rates are based on yields of U.S. treasury notes in effect at the date of grant. Expected life of option is based on actual historical option exercises. Dividend yield is <ix:nonFraction id="c123855550" contextRef="d_2024-01-01_2024-12-31_AwardTypeAxis-EmployeeStockOptionMember" unitRef="Pure" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" format="ixt-sec:numwordsen" decimals="-3">zero</ix:nonFraction> because the Company does <em style="font: inherit;">not</em> anticipate paying cash dividends in the foreseeable future.</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">As of <em style="font: inherit;"> December 31, 2024, </em>the Company expects to recognize compensation expense of $<ix:nonFraction id="c123855552" contextRef="i_2024-12-31_AwardTypeAxis-EmployeeStockOptionMember" unitRef="USD" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" scale="6" format="ixt:num-dot-decimal" decimals="-5">50.6</ix:nonFraction>&#160;million related to non-vested options held by equity plan participants over the weighted average remaining recognition period of <ix:nonNumeric contextRef="d_2024-01-01_2024-12-31_AwardTypeAxis-EmployeeStockOptionMember" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" id="c123855553" format="ixt-sec:duryear">2.3</ix:nonNumeric>&#160;years.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <ix:exclude>
    <div class="PGFTR" style="text-align: center; width: 100%">
     <div class="hf-row">
      <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       <em style="font: inherit;">106</em>
      </div>
     </div>
    </div>
    <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
    <div class="PGHDR" style="text-align: left; width: 100%">
     <div class="hf-row">
      <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
       <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Table of Contents</a>
      </div>
     </div>
    </div>
   </ix:exclude>
   <ix:exclude>&#160;</ix:exclude>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><i>Performance Awards</i></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">The following summarizes information about performance award activity during <em style="font: inherit;">2024:</em></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
   <ix:nonNumeric contextRef="d_2024-01-01_2024-12-31" name="us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock" id="c2851694" escape="true">
    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Number of Performance Awards</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 85%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">Outstanding as of December 31, 2023</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c123855250" contextRef="i_2023-12-31_AwardTypeAxis-PerformanceSharesMember" unitRef="Share" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="0" format="ixt:num-dot-decimal" decimals="INF">7,142</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt; text-indent: -9pt;">Granted</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c123855251" contextRef="d_2024-01-01_2024-12-31_AwardTypeAxis-PerformanceSharesMember" unitRef="Share" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" scale="0" format="ixt:fixed-zero" decimals="INF">&#8212;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt; text-indent: -9pt;">Vested</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c123855252" contextRef="d_2024-01-01_2024-12-31_AwardTypeAxis-PerformanceSharesMember" unitRef="Share" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" scale="0" format="ixt:fixed-zero" decimals="INF">&#8212;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt; text-indent: -9pt;">Forfeited/canceled</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"><ix:nonFraction id="c123855253" contextRef="d_2024-01-01_2024-12-31_AwardTypeAxis-PerformanceSharesMember" unitRef="Share" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" scale="0" format="ixt:fixed-zero" decimals="INF" sign="-">&#8212;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">Outstanding as of December 31, 2024</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c123855254" contextRef="i_2024-12-31_AwardTypeAxis-PerformanceSharesMember" unitRef="Share" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="0" format="ixt:num-dot-decimal" decimals="INF">7,142</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td></tr>
</tbody></table>
   </ix:nonNumeric>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">During the year ended <em style="font: inherit;"> December 31, 2022, </em>a total of <ix:nonFraction id="c123855556" contextRef="d_2022-01-01_2022-12-31_AwardTypeAxis-PerformanceSharesMember" unitRef="Share" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations" scale="0" format="ixt:num-dot-decimal" decimals="INF">57,143</ix:nonFraction> shares of restricted stock awards expired as performance criteria related to these Performance Awards were <em style="font: inherit;">not</em> attained. These shares of restricted stock were returned to the <em style="font: inherit;">2008</em> Equity Incentive Plan, which expired in <em style="font: inherit;"> December 2017, </em>and thus were retired.</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">If and when outstanding Performance Awards vest, the Company would recognize $<ix:nonFraction id="c123855559" contextRef="i_2022-12-31_AwardTypeAxis-PerformanceSharesMember" unitRef="USD" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" scale="0" format="ixt:num-dot-decimal" decimals="INF">101,000</ix:nonFraction> in stock-based compensation expense. These performance awards expire in <em style="font: inherit;">2026.</em></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>Stock-Based Compensation Expense</i></b></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">The following summarizes information about stock-based compensation expense, in thousands:</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
   <ix:nonNumeric contextRef="d_2024-01-01_2024-12-31" name="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" id="c2851695" escape="true">
    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="10" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;"><em style="font: inherit;"><em style="font: inherit;">Years ended December 31,</em></em></em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">2024</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">2023</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">2022</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 55%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">Research and development</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c123855261" contextRef="d_2024-01-01_2024-12-31_IncomeStatementLocationAxis-ResearchAndDevelopmentExpenseMember" unitRef="USD" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" format="ixt:num-dot-decimal" decimals="-3">6,492</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c123855262" contextRef="d_2023-01-01_2023-12-31_IncomeStatementLocationAxis-ResearchAndDevelopmentExpenseMember" unitRef="USD" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" format="ixt:num-dot-decimal" decimals="-4">2,050</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c123855263" contextRef="d_2022-01-01_2022-12-31_IncomeStatementLocationAxis-ResearchAndDevelopmentExpenseMember" unitRef="USD" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" format="ixt:num-dot-decimal" decimals="-3">1,631</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">General and administrative</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c123855264" contextRef="d_2024-01-01_2024-12-31_IncomeStatementLocationAxis-GeneralAndAdministrativeExpenseMember" unitRef="USD" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" format="ixt:num-dot-decimal" decimals="-3">9,799</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c123855265" contextRef="d_2023-01-01_2023-12-31_IncomeStatementLocationAxis-GeneralAndAdministrativeExpenseMember" unitRef="USD" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" format="ixt:num-dot-decimal" decimals="-3">2,536</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c123855266" contextRef="d_2022-01-01_2022-12-31_IncomeStatementLocationAxis-GeneralAndAdministrativeExpenseMember" unitRef="USD" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" format="ixt:num-dot-decimal" decimals="-3">435</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td>&#160;</td><td style="padding-bottom: 1px;">&#160;</td><td style="border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="padding-bottom: 1px;">&#160;</td><td style="padding-bottom: 1px;">&#160;</td><td style="border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="padding-bottom: 1px;">&#160;</td><td style="padding-bottom: 1px;">&#160;</td><td style="border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="padding-bottom: 1px;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">Total stock-based compensation expense</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c123855267" contextRef="d_2024-01-01_2024-12-31" unitRef="USD" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" format="ixt:num-dot-decimal" decimals="-3">16,291</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c123855268" contextRef="d_2023-01-01_2023-12-31" unitRef="USD" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" format="ixt:num-dot-decimal" decimals="-3">4,586</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c123855269" contextRef="d_2022-01-01_2022-12-31" unitRef="USD" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" format="ixt:num-dot-decimal" decimals="-3">2,066</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td></tr>
</tbody></table>
   </ix:nonNumeric>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-indent: 18pt; text-align: justify;">On <em style="font: inherit;"> September 13, 2024, </em>the Company&#160;entered into a Consulting Agreement&#160;with our former President and Chief Executive Officer for a period of <em style="font: inherit;">one</em> year, which was&#160;subsequently terminated on <em style="font: inherit;"> January 23, 2025. </em>The services to be provided under the Consulting Agreement were <em style="font: inherit;">not</em> deemed substantive for continuous service requirements of stock option vesting, resulting in&#160;a stock option modification under ASC <em style="font: inherit;">718.</em> The Company's stock-based compensation expense for the year ended <em style="font: inherit;"> December 31, 2024 </em>included approximately $<ix:nonFraction id="c123855564" contextRef="d_2024-01-01_2024-12-31_RestructuringCostAndReserveAxis-EmployeeSeveranceMember" unitRef="USD" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" format="ixt:num-dot-decimal" decimals="-5">0.6</ix:nonFraction>&#160;million from the stock option modification accounting. See further discussion in Note <em style="font: inherit;">2</em> under "Related Party Transactions". There were <ix:nonFraction id="c123855566" contextRef="d_2023-01-01_2023-12-31_RestructuringCostAndReserveAxis-EmployeeSeveranceMember" unitRef="USD" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" format="ixt-sec:numwordsen" decimals="-3">no</ix:nonFraction> such costs during the years ended <em style="font: inherit;"> December 31, 2023 </em>and <em style="font: inherit;">2022.</em></p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
  </ix:nonNumeric>
  <div>
   &#160;
  </div>
  <ix:nonNumeric contextRef="d_2024-01-01_2024-12-31" name="us-gaap:CompensationAndEmployeeBenefitPlansTextBlock" id="c2851696" escape="true">
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><b><em style="font: inherit;">8.</em> Employee <em style="font: inherit;">401</em>(k) Benefit Plan</b></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">The Company has a defined-contribution savings plan under Section <em style="font: inherit;">401</em>(k) of the Internal Revenue Code. The plan covers substantially all employees. Employees are eligible to participate in the plan the <em style="font: inherit;">first</em> day of the month after hire and <em style="font: inherit;"> may </em>contribute up to the current statutory limits under Internal Revenue Service regulations. The <em style="font: inherit;">401</em>(k) plan permits the Company to make additional matching contributions on behalf of all employees. Through <em style="font: inherit;"> December 31, 2024, </em>the Company has <em style="font: inherit;">not</em> made any matching contributions to the <em style="font: inherit;">401</em>(k) plan.</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
   <ix:exclude>
    <div class="PGFTR" style="text-align: center; width: 100%">
     <div class="hf-row">
      <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       <em style="font: inherit;">107</em>
      </div>
     </div>
    </div>
    <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
    <div class="PGHDR" style="text-align: left; width: 100%">
     <div class="hf-row">
      <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
       <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Table of Contents</a>
      </div>
     </div>
    </div>
   </ix:exclude>
   <ix:exclude>&#160;</ix:exclude>
  </ix:nonNumeric>
  <div>
   &#160;
  </div>
  <ix:nonNumeric contextRef="d_2024-01-01_2024-12-31" name="us-gaap:IncomeTaxDisclosureTextBlock" id="c2851697" escape="true">
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><em style="font: inherit;">9.</em> Income Taxes</b></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">The Company did <em style="font: inherit;">not</em> provide for income taxes during the periods presented because it had book and federal taxable losses in those years and the tax benefit that would have resulted from the pre-tax losses was fully offset by a change in the valuation allowance.</p>
   <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">The reconciliation of the statutory federal income tax rate to the Company&#8217;s effective tax rate for periods presented was as follows:</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
   <ix:nonNumeric contextRef="d_2024-01-01_2024-12-31" name="us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" id="c2851698" escape="true">
    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="10" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;"><em style="font: inherit;"><em style="font: inherit;">Year ended December 31,</em></em></em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">2024</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">2023</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">2022</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 55%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">Tax at federal statutory rate</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c123855276" contextRef="d_2024-01-01_2024-12-31" unitRef="Pure" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" format="ixt:num-dot-decimal" decimals="2">21</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">%</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c123855277" contextRef="d_2023-01-01_2023-12-31" unitRef="Pure" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" format="ixt:num-dot-decimal" decimals="2">21</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">%</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c123855278" contextRef="d_2022-01-01_2022-12-31" unitRef="Pure" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" format="ixt:num-dot-decimal" decimals="2">21</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">%</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">State tax, net of federal benefit</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c123855279" contextRef="d_2024-01-01_2024-12-31" unitRef="Pure" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" scale="-2" format="ixt:fixed-zero" decimals="0">&#8212;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c123855280" contextRef="d_2023-01-01_2023-12-31" unitRef="Pure" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" scale="-2" format="ixt:fixed-zero" decimals="0">&#8212;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c123855281" contextRef="d_2022-01-01_2022-12-31" unitRef="Pure" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" scale="-2" format="ixt:fixed-zero" decimals="0">&#8212;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">Share-based compensation</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c123855282" contextRef="d_2024-01-01_2024-12-31" unitRef="Pure" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" scale="-2" format="ixt:num-dot-decimal" decimals="3" sign="-">5.7</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c123855283" contextRef="d_2023-01-01_2023-12-31" unitRef="Pure" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" scale="-2" format="ixt:num-dot-decimal" decimals="3">0.2</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c123855284" contextRef="d_2022-01-01_2022-12-31" unitRef="Pure" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" scale="-2" format="ixt:num-dot-decimal" decimals="3" sign="-">0.5</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">Research and development credits</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c123855285" contextRef="d_2024-01-01_2024-12-31" unitRef="Pure" name="sava:EffectiveIncomeTaxRateReconciliationTaxCreditResearchAndDevelopmentPercent" scale="-2" format="ixt:num-dot-decimal" decimals="3">15.4</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c123855286" contextRef="d_2023-01-01_2023-12-31" unitRef="Pure" name="sava:EffectiveIncomeTaxRateReconciliationTaxCreditResearchAndDevelopmentPercent" scale="-2" format="ixt:num-dot-decimal" decimals="3">5.1</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c123855287" contextRef="d_2022-01-01_2022-12-31" unitRef="Pure" name="sava:EffectiveIncomeTaxRateReconciliationTaxCreditResearchAndDevelopmentPercent" scale="-2" format="ixt:num-dot-decimal" decimals="3">4.9</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">Section 162(m) limitation</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c123855288" contextRef="d_2024-01-01_2024-12-31" unitRef="Pure" name="sava:EffectiveIncomeTaxRateReconciliationSection162mLimitationPercent" scale="-2" format="ixt:num-dot-decimal" decimals="3" sign="-">0.2</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c123855289" contextRef="d_2023-01-01_2023-12-31" unitRef="Pure" name="sava:EffectiveIncomeTaxRateReconciliationSection162mLimitationPercent" scale="-2" format="ixt:fixed-zero" decimals="0">&#8212;</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">(<ix:nonFraction id="c123855290" contextRef="d_2022-01-01_2022-12-31" unitRef="Pure" name="sava:EffectiveIncomeTaxRateReconciliationSection162mLimitationPercent" scale="-2" format="ixt:num-dot-decimal" decimals="3" sign="-">0.2</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">)</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> <p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">Uncertain tax positions</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">(<ix:nonFraction id="c123855291" contextRef="d_2024-01-01_2024-12-31" unitRef="Pure" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxContingencies" scale="-2" format="ixt:num-dot-decimal" decimals="3" sign="-">6.1</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">(<ix:nonFraction id="c123855292" contextRef="d_2023-01-01_2023-12-31" unitRef="Pure" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxContingencies" scale="-2" format="ixt:num-dot-decimal" decimals="2" sign="-">2.0</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">(<ix:nonFraction id="c123855293" contextRef="d_2022-01-01_2022-12-31" unitRef="Pure" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxContingencies" scale="-2" format="ixt:num-dot-decimal" decimals="2" sign="-">2.0</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">)</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> <p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">Tax attribute expiration</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">(<ix:nonFraction id="c123855294" contextRef="d_2024-01-01_2024-12-31" unitRef="Pure" name="sava:EffectiveIncomeTaxRateReconciliationTaxAttributeExpirationPercent" scale="-2" format="ixt:num-dot-decimal" decimals="3" sign="-">4.1</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"><ix:nonFraction id="c123855295" contextRef="d_2023-01-01_2023-12-31" unitRef="Pure" name="sava:EffectiveIncomeTaxRateReconciliationTaxAttributeExpirationPercent" scale="-2" format="ixt:fixed-zero" decimals="0">&#8212;</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"><ix:nonFraction id="c123855296" contextRef="d_2022-01-01_2022-12-31" unitRef="Pure" name="sava:EffectiveIncomeTaxRateReconciliationTaxAttributeExpirationPercent" scale="-2" format="ixt:fixed-zero" decimals="0">&#8212;</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> <p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">Change in fair value of warrant liabilities</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"><ix:nonFraction id="c123855297" contextRef="d_2024-01-01_2024-12-31" unitRef="Pure" name="sava:EffectiveIncomeTaxRateReconciliationChangeInFairValueOfWarrantLiabilities" scale="-2" format="ixt:num-dot-decimal" decimals="3">93.3</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"><ix:nonFraction id="c123855298" contextRef="d_2023-01-01_2023-12-31" unitRef="Pure" name="sava:EffectiveIncomeTaxRateReconciliationChangeInFairValueOfWarrantLiabilities" scale="-2" format="ixt:fixed-zero" decimals="0">&#8212;</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"><ix:nonFraction id="c123855299" contextRef="d_2022-01-01_2022-12-31" unitRef="Pure" name="sava:EffectiveIncomeTaxRateReconciliationChangeInFairValueOfWarrantLiabilities" scale="-2" format="ixt:fixed-zero" decimals="0">&#8212;</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> <p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">SEC settlement payment</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">(<ix:nonFraction id="c123855300" contextRef="d_2024-01-01_2024-12-31" unitRef="Pure" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxSettlements" scale="-2" format="ixt:num-dot-decimal" decimals="3">34.5</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"><ix:nonFraction id="c123855301" contextRef="d_2023-01-01_2023-12-31" unitRef="Pure" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxSettlements" scale="-2" format="ixt:fixed-zero" decimals="0" sign="-">&#8212;</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"><ix:nonFraction id="c123855302" contextRef="d_2022-01-01_2022-12-31" unitRef="Pure" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxSettlements" scale="-2" format="ixt:fixed-zero" decimals="0" sign="-">&#8212;</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">Other</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c123855303" contextRef="d_2024-01-01_2024-12-31" unitRef="Pure" name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" scale="-2" format="ixt:num-dot-decimal" decimals="3">0.3</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c123855304" contextRef="d_2023-01-01_2023-12-31" unitRef="Pure" name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" scale="-2" format="ixt:num-dot-decimal" decimals="3" sign="-">0.3</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c123855305" contextRef="d_2022-01-01_2022-12-31" unitRef="Pure" name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" scale="-2" format="ixt:num-dot-decimal" decimals="3">0.2</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">Change in valuation allowance</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(<ix:nonFraction id="c123855306" contextRef="d_2024-01-01_2024-12-31" unitRef="Pure" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" scale="-2" format="ixt:num-dot-decimal" decimals="3" sign="-">79.4</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(<ix:nonFraction id="c123855307" contextRef="d_2023-01-01_2023-12-31" unitRef="Pure" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" scale="-2" format="ixt:num-dot-decimal" decimals="2" sign="-">24.0</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(<ix:nonFraction id="c123855308" contextRef="d_2022-01-01_2022-12-31" unitRef="Pure" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" scale="-2" format="ixt:num-dot-decimal" decimals="3" sign="-">23.4</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">)</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">Effective income tax rate</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c123855309" contextRef="d_2024-01-01_2024-12-31" unitRef="Pure" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" format="ixt:fixed-zero" decimals="0">&#8212;</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">%</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c123855310" contextRef="d_2023-01-01_2023-12-31" unitRef="Pure" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" format="ixt:fixed-zero" decimals="0">&#8212;</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">%</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c123855311" contextRef="d_2022-01-01_2022-12-31" unitRef="Pure" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" format="ixt:fixed-zero" decimals="0">&#8212;</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">%</td></tr>
</tbody></table>
   </ix:nonNumeric>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><i>Deferred tax assets and valuation allowance</i></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">Deferred tax assets reflect the tax effects of net operating loss and tax credit carryforwards and temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. The Company&#8217;s deferred taxes assets at&#160;<em style="font: inherit;"> December 31, 2024&#160;</em>and <em style="font: inherit;">2023</em>&#160;were valued at the corporate tax rate of <ix:nonFraction id="c123855579" contextRef="d_2024-01-01_2024-12-31" unitRef="Pure" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" format="ixt:num-dot-decimal" decimals="2">21</ix:nonFraction>%. The Company offsets its deferred tax assets by a valuation allowance because it is uncertain about the timing and amount of any future profits. Significant components of its deferred tax assets are as follows (in thousands):</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
   <ix:nonNumeric contextRef="d_2024-01-01_2024-12-31" name="us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" id="c2851699" escape="true">
    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;"><em style="font: inherit;">December 31,</em></em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">2024</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">2023</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 70%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Deferred tax assets:</p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Net operating loss carryforwards</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c123855316" contextRef="i_2024-12-31" unitRef="USD" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" scale="3" format="ixt:num-dot-decimal" decimals="-3">43,148</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c123855317" contextRef="i_2023-12-31" unitRef="USD" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" scale="3" format="ixt:num-dot-decimal" decimals="-3">33,322</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Share-based compensation</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c123855318" contextRef="i_2024-12-31" unitRef="USD" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" scale="3" format="ixt:num-dot-decimal" decimals="-3">4,814</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c123855319" contextRef="i_2023-12-31" unitRef="USD" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" scale="3" format="ixt:num-dot-decimal" decimals="-3">2,561</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Research and development credit carryforwards</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c123855320" contextRef="i_2024-12-31" unitRef="USD" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch" scale="3" format="ixt:num-dot-decimal" decimals="-3">13,789</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c123855321" contextRef="i_2023-12-31" unitRef="USD" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch" scale="3" format="ixt:num-dot-decimal" decimals="-3">12,557</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Capitalized research and development expenses</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c123855322" contextRef="i_2024-12-31" unitRef="USD" name="sava:DeferredTaxAssetsCapitalizedResearchAndDevelopmentExpenses" scale="3" format="ixt:num-dot-decimal" decimals="-3">33,598</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c123855323" contextRef="i_2023-12-31" unitRef="USD" name="sava:DeferredTaxAssetsCapitalizedResearchAndDevelopmentExpenses" scale="3" format="ixt:num-dot-decimal" decimals="-3">27,538</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Other</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c123855324" contextRef="i_2024-12-31" unitRef="USD" name="us-gaap:DeferredTaxAssetsOther" scale="3" format="ixt:num-dot-decimal" decimals="-4">1,340</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c123855325" contextRef="i_2023-12-31" unitRef="USD" name="us-gaap:DeferredTaxAssetsOther" scale="3" format="ixt:num-dot-decimal" decimals="-3">1,371</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Total deferred tax assets</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c123855326" contextRef="i_2024-12-31" unitRef="USD" name="us-gaap:DeferredTaxAssetsGross" scale="3" format="ixt:num-dot-decimal" decimals="-3">96,689</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c123855327" contextRef="i_2023-12-31" unitRef="USD" name="us-gaap:DeferredTaxAssetsGross" scale="3" format="ixt:num-dot-decimal" decimals="-3">77,349</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Valuation allowance</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(<ix:nonFraction id="c123855328" contextRef="i_2024-12-31" unitRef="USD" name="us-gaap:DeferredTaxAssetsValuationAllowance" scale="3" format="ixt:num-dot-decimal" decimals="-3">96,689</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(<ix:nonFraction id="c123855329" contextRef="i_2023-12-31" unitRef="USD" name="us-gaap:DeferredTaxAssetsValuationAllowance" scale="3" format="ixt:num-dot-decimal" decimals="-3">77,349</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Net deferred tax assets</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c123855330" contextRef="i_2024-12-31" unitRef="USD" name="us-gaap:DeferredTaxAssetsNet" scale="3" format="ixt:fixed-zero" decimals="-3">&#8212;</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c123855331" contextRef="i_2023-12-31" unitRef="USD" name="us-gaap:DeferredTaxAssetsNet" scale="3" format="ixt:fixed-zero" decimals="-3">&#8212;</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Deferred tax liabilities:</p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Operating lease right-of-use assets</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c123855332" contextRef="i_2024-12-31" unitRef="USD" name="us-gaap:DeferredTaxLiabilitiesLeasingArrangements" scale="3" format="ixt:fixed-zero" decimals="-3" sign="-">&#8212;</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c123855333" contextRef="i_2023-12-31" unitRef="USD" name="us-gaap:DeferredTaxLiabilitiesLeasingArrangements" scale="3" format="ixt:fixed-zero" decimals="-3" sign="-">&#8212;</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Total deferred tax liabilities</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c123855334" contextRef="i_2024-12-31" unitRef="USD" name="us-gaap:DeferredIncomeTaxLiabilities" scale="3" format="ixt:fixed-zero" decimals="-3" sign="-">&#8212;</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c123855335" contextRef="i_2023-12-31" unitRef="USD" name="us-gaap:DeferredIncomeTaxLiabilities" scale="3" format="ixt:fixed-zero" decimals="-3" sign="-">&#8212;</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Net deferred tax asset (liability)</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c123855336" contextRef="i_2024-12-31" unitRef="USD" name="us-gaap:DeferredTaxAssetsLiabilitiesNet" scale="3" format="ixt:fixed-zero" decimals="-3">&#8212;</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c123855337" contextRef="i_2023-12-31" unitRef="USD" name="us-gaap:DeferredTaxAssetsLiabilitiesNet" scale="3" format="ixt:fixed-zero" decimals="-3">&#8212;</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td></tr>
</tbody></table>
   </ix:nonNumeric>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">The valuation allowance increased by $<ix:nonFraction id="c123855580" contextRef="d_2024-01-01_2024-12-31" unitRef="USD" name="us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount" scale="6" format="ixt:num-dot-decimal" decimals="-5">19.4</ix:nonFraction>&#160;million and $<ix:nonFraction id="c123855581" contextRef="d_2023-01-01_2023-12-31" unitRef="USD" name="us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount" scale="6" format="ixt:num-dot-decimal" decimals="-5">23.3</ix:nonFraction>&#160;million in&#160;<em style="font: inherit;">2024</em>&#160;and <em style="font: inherit;">2023,</em> respectively, due primarily to continuing operations.</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">The Company&#8217;s net operating loss carryforwards of $<ix:nonFraction id="c123855584" contextRef="i_2024-12-31_IncomeTaxAuthorityAxis-DomesticCountryMember" unitRef="USD" name="us-gaap:OperatingLossCarryforwards" scale="6" format="ixt:num-dot-decimal" decimals="-5">205.5</ix:nonFraction>&#160;million are federal, of which $<ix:nonFraction id="c123855585" contextRef="i_2024-12-31_IncomeTaxAuthorityAxis-DomesticCountryMember_TaxPeriodAxis-CarryforwardSubjectToExpirationMember" unitRef="USD" name="us-gaap:OperatingLossCarryforwards" scale="6" format="ixt:num-dot-decimal" decimals="-5">74.1</ix:nonFraction>&#160;million expires between <em style="font: inherit;">2029</em> and <em style="font: inherit;">2037</em> and $<ix:nonFraction id="c123855588" contextRef="i_2024-12-31_IncomeTaxAuthorityAxis-DomesticCountryMember_TaxPeriodAxis-IndefiniteLifeCarryforwardsMember" unitRef="USD" name="us-gaap:OperatingLossCarryforwards" scale="6" format="ixt:num-dot-decimal" decimals="-5">131.4</ix:nonFraction>&#160;million carries forward indefinitely. As of <em style="font: inherit;"> December 31, 2024, </em>the Company had federal research and development tax credits of approximately $<ix:nonFraction id="c123855589" contextRef="i_2024-12-31_IncomeTaxAuthorityAxis-DomesticCountryMember_TaxCreditCarryforwardAxis-ResearchMember" unitRef="USD" name="us-gaap:TaxCreditCarryforwardAmount" scale="6" format="ixt:num-dot-decimal" decimals="-6">23.0</ix:nonFraction>&#160;million, which expire in the years <em style="font: inherit;">2025</em>&#160;through <em style="font: inherit;">2044.</em></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">&#160;</p>
   <ix:exclude>
    <div class="PGFTR" style="text-align: center; width: 100%">
     <div class="hf-row">
      <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       <em style="font: inherit;">108</em>
      </div>
     </div>
    </div>
    <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
    <div class="PGHDR" style="text-align: left; width: 100%">
     <div class="hf-row">
      <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
       <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Table of Contents</a>
      </div>
     </div>
    </div>
   </ix:exclude>
   <ix:exclude>&#160;</ix:exclude>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><i>Unrecognized tax benefits</i></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">As of <em style="font: inherit;"> December 31, 2024, </em><em style="font: inherit;">2023</em>&#160;and <em style="font: inherit;">2022,</em> the Company has unrecognized tax benefits related to tax credits of $<ix:nonFraction id="c123855595" contextRef="i_2024-12-31" unitRef="USD" name="us-gaap:UnrecognizedTaxBenefits" scale="6" format="ixt:num-dot-decimal" decimals="-5">9.2</ix:nonFraction>&#160;million, $<ix:nonFraction id="c123855596" contextRef="i_2023-12-31" unitRef="USD" name="us-gaap:UnrecognizedTaxBenefits" scale="6" format="ixt:num-dot-decimal" decimals="-5">8.4</ix:nonFraction>&#160;million and $<ix:nonFraction id="c123855597" contextRef="i_2022-12-31" unitRef="USD" name="us-gaap:UnrecognizedTaxBenefits" scale="6" format="ixt:num-dot-decimal" decimals="-5">6.5</ix:nonFraction>&#160;million, respectively. <span style="-sec-ix-hidden:c123855598">None</span> of the unrecognized tax benefits as of <em style="font: inherit;"> December 31, 2024, </em>if recognized, would impact the effective tax rate due to the valuation allowance and <ix:nonFraction id="c123855599" contextRef="i_2024-12-31" unitRef="USD" name="us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" scale="0" format="ixt-sec:numwordsen" decimals="-3">no</ix:nonFraction> interest or penalties have been recognized. A reconciliation of the beginning and ending balance of unrecognized tax benefits is as follows (in thousands):</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
   <ix:nonNumeric contextRef="d_2024-01-01_2024-12-31" name="us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" id="c2851700" escape="true">
    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="10" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;"><em style="font: inherit;"><em style="font: inherit;">Year ended December 31,</em></em></em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">2024</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">2023</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">2022</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 55%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Beginning balance</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c123855346" contextRef="i_2023-12-31" unitRef="USD" name="us-gaap:UnrecognizedTaxBenefits" scale="3" format="ixt:num-dot-decimal" decimals="-3">8,413</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c123855347" contextRef="i_2022-12-31" unitRef="USD" name="us-gaap:UnrecognizedTaxBenefits" scale="3" format="ixt:num-dot-decimal" decimals="-3">6,496</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c123855348" contextRef="i_2021-12-31" unitRef="USD" name="us-gaap:UnrecognizedTaxBenefits" scale="3" format="ixt:num-dot-decimal" decimals="-3">5,001</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> <p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">Expired research and development tax credits</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">(<ix:nonFraction id="c123855349" contextRef="d_2024-01-01_2024-12-31" unitRef="USD" name="us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations" scale="3" format="ixt:num-dot-decimal" decimals="-3">665</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">(<ix:nonFraction id="c123855350" contextRef="d_2023-01-01_2023-12-31" unitRef="USD" name="us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations" scale="3" format="ixt:num-dot-decimal" decimals="-4">50</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"><ix:nonFraction id="c123855351" contextRef="d_2022-01-01_2022-12-31" unitRef="USD" name="us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations" scale="3" format="ixt:fixed-zero" decimals="-3" sign="-">&#8212;</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Additions based on tax positions related to the current year</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c123855352" contextRef="d_2024-01-01_2024-12-31" unitRef="USD" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" scale="3" format="ixt:num-dot-decimal" decimals="-3">1,494</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c123855353" contextRef="d_2023-01-01_2023-12-31" unitRef="USD" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" scale="3" format="ixt:num-dot-decimal" decimals="-3">1,967</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c123855354" contextRef="d_2022-01-01_2022-12-31" unitRef="USD" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" scale="3" format="ixt:num-dot-decimal" decimals="-3">1,495</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Ending balance</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c123855355" contextRef="i_2024-12-31" unitRef="USD" name="us-gaap:UnrecognizedTaxBenefits" scale="3" format="ixt:num-dot-decimal" decimals="-3">9,242</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c123855356" contextRef="i_2023-12-31" unitRef="USD" name="us-gaap:UnrecognizedTaxBenefits" scale="3" format="ixt:num-dot-decimal" decimals="-3">8,413</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c123855357" contextRef="i_2022-12-31" unitRef="USD" name="us-gaap:UnrecognizedTaxBenefits" scale="3" format="ixt:num-dot-decimal" decimals="-3">6,496</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td></tr>
</tbody></table>
   </ix:nonNumeric>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">&#160;</p>
   <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 18pt;">As of <em style="font: inherit;"> December 31, 2024, </em>there were <em style="font: inherit;">no</em> unrecognized tax benefits that we expect would change significantly over the next <em style="font: inherit;">12</em> months.</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">&#160;</p>
   <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 18pt;">The Company files U.S. and Texas income tax returns. In the United States, the statute of limitations with respect to the federal income tax returns for tax years after <span style="-sec-ix-hidden:c123855602">2020</span>&#160;are open to audit; however, since the Company has net operating losses, the taxing authority has the ability to review tax returns prior to the <em style="font: inherit;">2021</em>&#160;tax year and make adjustments to these net operating loss carryforwards.&#160;We are <em style="font: inherit;">not</em> under audit in any taxing jurisdiction at this time.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;&#160;</p>
  </ix:nonNumeric>
  <div>
   &#160;
  </div>
  <ix:nonNumeric contextRef="d_2024-01-01_2024-12-31" name="sava:LeasesAndCommitmentsDisclosureTextBlock" id="c2851701" escape="true">
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><em style="font: inherit;">10.</em> Commitments</b></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><i>Other Commitments</i></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">The Company conducts its product research and development programs through a combination of internal and collaborative programs that include, among others, arrangements with universities, contract research organizations and clinical research sites. It has contractual arrangements with these organizations that are generally cancelable. The Company&#8217;s obligations under these contracts are largely based on services performed.&#160;The Company also had non-cancellable commitments for the manufacture of simufilam's active pharmaceutical ingredient totaling approximately $<ix:nonFraction id="c123855606" contextRef="i_2024-12-31_SupplyCommitmentAxis-SimufilamActiveIngredientMember" unitRef="USD" name="us-gaap:SignificantSupplyCommitmentRemainingMinimumAmountCommitted" scale="6" format="ixt:num-dot-decimal" decimals="-5">1.2</ix:nonFraction>&#160;million recorded in prepaid expenses and other current assets&#160;at <em style="font: inherit;"> December 31, 2024. </em>The Company is dependent on contract development and manufacturing organizations for the manufacture of all our materials for clinical studies.</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify; text-indent: 18pt;">On <em style="font: inherit;"> February 26, 2025, </em>the Company&#160;entered into a License Agreement (the &#8220;License Agreement&#8221;) with Yale University (&#8220;Yale&#8221;) pursuant to which the Company was granted exclusive worldwide rights, with rights to sublicense, to Yale&#8217;s interest in certain patent and other intellectual property rights that could be useful or necessary to the development and commercialization of simufilam for the treatment of Tuberous Sclerosis Complex (TSC)-related epilepsy and other potential indications. Pursuant to the License Agreement, the Company has agreed to use reasonable commercial efforts to implement a plan that it has designed for such development and commercialization. In exchange for the rights acquired pursuant to the License Agreement, the Company agreed to pay Yale (i) a nominal upfront license fee, (ii) payments upon the achievement of specified clinical, regulatory and commercial milestones, totaling up to $<ix:nonFraction id="c123855607" contextRef="i_2025-02-26_CounterpartyNameAxis-YaleUniversityMember_OtherCommitmentsAxis-LicenseAgreementMember_SubsequentEventTypeAxis-SubsequentEventMember" unitRef="USD" name="us-gaap:OtherCommitment" scale="6" format="ixt:num-dot-decimal" decimals="-5">4.5</ix:nonFraction> million and (iii) upon transfer to a <em style="font: inherit;">third</em> party in connection with a regulatory priority review voucher, if issued, a low-to-mid double digit percentage of any consideration received for such transfer. The Company also agreed to pay Yale tiered royalties, ranging from a low- to mid- single digit percentage, on aggregate net sales of licensed products, subject to tiered minimum annual royalty payments ranging from the low- to mid- hundreds of thousands of dollars.</p>
   <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify; text-indent: 9pt;">Unless earlier terminated, the License Agreement will continue on a country-by-country basis until the later of (i) the date on which the last valid claim of the license patents expires or otherwise lapses, (ii) the end of any government or regulatory exclusivity period, and (iii) <em style="font: inherit;">10</em> years following the date of <em style="font: inherit;">first</em> sale of licensed product in such country.</p>
   <p style="text-align: justify; font-size: 10pt; font-family: &quot;Times New Roman&quot;; margin: 0pt;">&#160;</p>
   <ix:exclude>
    <div class="PGFTR" style="text-align: center; width: 100%">
     <div class="hf-row">
      <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       <em style="font: inherit;">109</em>
      </div>
     </div>
    </div>
    <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
    <div class="PGHDR" style="text-align: left; width: 100%">
     <div class="hf-row">
      <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
       <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Table of Contents</a>
      </div>
     </div>
    </div>
   </ix:exclude>
   <ix:exclude>&#160;&#160;</ix:exclude>
  </ix:nonNumeric>
  <div>
   &#160;
  </div>
  <ix:nonNumeric contextRef="d_2024-01-01_2024-12-31" name="sava:CashIncentiveBonusPlanTextBlock" id="c2851702" escape="true">
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>Note <em style="font: inherit;">11.</em></b>&#160;<b> <em style="font: inherit;">2020</em> Cash Incentive Bonus Plan</b></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">In <em style="font: inherit;"> August 2020, </em>the Board approved the CIB Plan. The CIB Plan was established to promote the long-term success of the Company by creating an &#8220;at-risk&#8221; cash bonus program that rewards&#160;CIB Plan&#160;participants with additional cash compensation in lockstep with significant increases in the Company&#8217;s market capitalization. The CIB Plan is considered &#8220;at-risk&#8221; because CIB Plan participants&#160;will&#160;<em style="font: inherit;">not</em> receive a cash bonus&#160;unless&#160;the Company&#8217;s market capitalization increases&#160;significantly and&#160;certain&#160;other&#160;conditions specified in the CIB Plan&#160;are met.&#160;Specifically, CIB Plan participants&#160;will&#160;<em style="font: inherit;">not</em>&#160;be paid&#160;any cash bonuses unless (<em style="font: inherit;">1</em>) the Company completes a&#160;merger or acquisition transaction that constitutes a sale of ownership of the Company or its assets (a Merger Transaction) or (<em style="font: inherit;">2</em>) the Compensation Committee of the Board&#160;(the Compensation Committee) determines the Company has sufficient cash on hand, as defined in the CIB Plan. Because&#160;of the inherent discretion and uncertainty regarding&#160;these&#160;requirements, the Company has concluded that&#160;a&#160;CIB Plan&#160;grant date has <em style="font: inherit;">not</em> occurred&#160;as of <em style="font: inherit;"> December 31, 2024.&#160;</em></p>
   <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">CIB Plan participants will be paid all earned cash bonuses allocated under the CIB&#160;Plan in the event of a Merger Transaction.</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-indent: 18pt; text-align: justify;">As of <em style="font: inherit;"> December 31, 2022, </em>the Company&#8217;s independent directors were participants in the CIB Plan. However, effective <em style="font: inherit;"> March 16, 2023, </em>the Board&#160;amended the CIB Plan to remove all independent directors as participants in the CIB Plan and the independent directors consented to such removal. The independent directors&#8217; share of potential benefits under the CIB Plan were completely forfeited to the Company and will <em style="font: inherit;">not</em> be allocated to any other participant under the CIB Plan. The Company&#8217;s independent directors have <em style="font: inherit;">not</em> received, and as a result of such amendment will never receive, any payments under the CIB Plan.</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">The Company&#8217;s market capitalization for purposes of the CIB Plan&#160;is&#160;determined based on either (<em style="font: inherit;">1</em>) the closing price&#160;of <em style="font: inherit;">one</em> share of the Company's common stock on the Nasdaq Capital&#160;Market&#160;multiplied by the total issued and outstanding shares and options to purchase shares of the Company, or (<em style="font: inherit;">2</em>) the aggregate consideration payable to security holders of the Company in a&#160;Merger Transaction. This constitutes a market condition under applicable accounting guidance.&#160; &#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">The CIB Plan&#160;triggers a potential cash bonus each time&#160;the&#160;Company&#8217;s market capitalization increases significantly, up to a maximum&#160;<em style="font: inherit;">$5</em>&#160;billion in market capitalization. The CIB Plan specifies <ix:nonFraction id="c123855625" contextRef="i_2023-03-16_PlanNameAxis-CashIncentiveBonusPlanMember" unitRef="Pure" name="sava:CashBonusIncentiveIncrementalAmounts" scale="0" format="ixt:num-dot-decimal" decimals="INF">14</ix:nonFraction>&#160;incremental&#160;amounts&#160;between&#160;$<ix:nonFraction id="c123855626" contextRef="i_2023-03-16_PlanNameAxis-CashIncentiveBonusPlanMember_RangeAxis-MinimumMember" unitRef="USD" name="sava:PerformancePlanValuationMilestoneAmount" scale="6" format="ixt:num-dot-decimal" decimals="-8">200</ix:nonFraction>&#160;million and&#160;$<ix:nonFraction id="c123855627" contextRef="i_2023-03-16_PlanNameAxis-CashIncentiveBonusPlanMember_RangeAxis-MaximumMember" unitRef="USD" name="sava:PerformancePlanValuationMilestoneAmount" scale="9" format="ixt:num-dot-decimal" decimals="-9">5</ix:nonFraction>&#160;billion&#160;(each increment,&#160;a &#8220;Valuation Milestone&#8221;). Each&#160;Valuation Milestone&#160;triggers&#160;a potential cash bonus award in a pre-set amount defined in the CIB Plan. Each&#160;Valuation&#160;Milestone&#160;must be achieved and maintained for <em style="font: inherit;">no</em> less than <ix:nonNumeric contextRef="d_2023-03-16_2023-03-16_PlanNameAxis-CashIncentiveBonusPlanMember" name="sava:PerformancePlanMinimumNumberOfDaysValuationMilestoneMustBeAchievedAndMaintained" id="c123855629" format="ixt-sec:durday">20</ix:nonNumeric> consecutive trading days for&#160;CIB Plan&#160;participants to be eligible for a potential cash bonus award.&#160;Approximately <ix:nonFraction id="c123855630" contextRef="i_2023-03-16_PlanNameAxis-CashIncentiveBonusPlanMember" unitRef="Pure" name="sava:PercentageValuationMilestoneCashBonusAwardSubjectToApprovalAndAdjustment" scale="-2" format="ixt:num-dot-decimal" decimals="2">67</ix:nonFraction>% of each&#160;cash bonus award&#160;associated with a Valuation Milestone&#160;is subject to&#160;adjustment and&#160;approval&#160;by the Compensation Committee.&#160;Any amounts&#160;<em style="font: inherit;">not</em> awarded by the Compensation Committee&#160;are&#160;<em style="font: inherit;">no</em> longer available for distribution.</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">If the Company were to exceed a $<ix:nonFraction id="c123855633" contextRef="i_2023-03-16_PlanNameAxis-CashIncentiveBonusPlanMember_RangeAxis-MaximumMember" unitRef="USD" name="sava:PerformancePlanValuationMilestoneAmount" scale="9" format="ixt:num-dot-decimal" decimals="-9">5</ix:nonFraction>&#160;billion market capitalization&#160;for <em style="font: inherit;">no</em> less than <ix:nonNumeric contextRef="d_2023-01-01_2023-03-16_PlanNameAxis-CashIncentiveBonusPlanMember" name="sava:PerformancePlanMinimumNumberOfDaysValuationMilestoneMustBeAchievedAndMaintained" id="c123855635" format="ixt-sec:durday">20</ix:nonNumeric> consecutive trading days, all&#160;Valuation&#160;Milestones would be deemed achieved, in which case cash bonus awards would&#160;range from&#160;a minimum of&#160;$<ix:nonFraction id="c123855636" contextRef="i_2023-03-16_PlanNameAxis-CashIncentiveBonusPlanMember_RangeAxis-MinimumMember" unitRef="USD" name="sava:CashIncentiveBonusAwardExceedsMaximum" scale="6" format="ixt:num-dot-decimal" decimals="-5">111.4</ix:nonFraction>&#160;million&#160;up to&#160;a hypothetical maximum of&#160;$<ix:nonFraction id="c123855637" contextRef="i_2023-03-16_PlanNameAxis-CashIncentiveBonusPlanMember_RangeAxis-MaximumMember" unitRef="USD" name="sava:CashIncentiveBonusAwardExceedsMaximum" scale="6" format="ixt:num-dot-decimal" decimals="-5">289.7</ix:nonFraction>&#160;million.&#160;Payment of cash bonuses is deferred until such time as&#160;(<em style="font: inherit;">1</em>)&#160;the Company completes a Merger Transaction, or&#160;(<em style="font: inherit;">2</em>)&#160;the&#160;Compensation Committee determines the&#160;Company has sufficient cash&#160;on hand&#160;to render payment&#160;(each, a &#8220;Performance Condition&#8221;),&#160;neither&#160;of which <em style="font: inherit;"> may </em>ever occur. Accordingly, there can be <em style="font: inherit;">no</em> assurance that&#160;CIB Plan&#160;participants will&#160;ever&#160;be&#160;paid a cash bonus that is awarded under the CIB Plan, even if the Company&#8217;s market capitalization increases&#160;significantly.</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">The CIB Plan is accounted for as a liability award.&#160;The fair value of each&#160;Valuation&#160;Milestone&#160;award&#160;will be&#160;determined&#160;once&#160;a&#160;grant date occurs and&#160;will be&#160;remeasured each reporting period.&#160;Compensation expense associated with the CIB Plan&#160;will be&#160;recognized over the expected achievement period for each&#160;of the <ix:nonFraction id="c123855641" contextRef="i_2023-03-16_PlanNameAxis-CashIncentiveBonusPlanMember" unitRef="Pure" name="sava:CashBonusIncentiveIncrementalAmounts" scale="0" format="ixt:num-dot-decimal" decimals="INF">14</ix:nonFraction>&#160;Valuation&#160;Milestones, when&#160;a Performance Condition&#160;is considered probable of being met. &#160;&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
   <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 18pt;">In <em style="font: inherit;"> October 2020, </em>the Company&#160;achieved&#160;the <em style="font: inherit;">first</em>&#160;Valuation&#160;Milestone.&#160;Subsequently in <em style="font: inherit;">2020,</em> the Compensation Committee&#160;approved&#160;a potential cash bonus&#160;award&#160;of&#160;$<ix:nonFraction id="c123855644" contextRef="i_2020-10-31_PlanNameAxis-CashIncentiveBonusPlanMember" unitRef="USD" name="sava:CashIncentiveBonusAward" scale="6" format="ixt:num-dot-decimal" decimals="-5">6.5</ix:nonFraction>&#160;million&#160;in total&#160;for&#160;all CIB Plan participants (after taking into account the <em style="font: inherit;"> March 2023 </em>CIB Plan amendment), subject to future satisfaction of a Performance Condition.&#160;There is <em style="font: inherit;">no</em> continuing service requirement for CIB Plan participants once&#160;the Compensation Committee approves a cash&#160;bonus award.</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">During the year ended <em style="font: inherit;"> December 31, 2021, </em>the Company achieved <ix:nonFraction id="c123855646" contextRef="i_2021-12-31_PlanNameAxis-CashIncentiveBonusPlanMember" unitRef="Pure" name="sava:CashBonusIncentiveIncrementalAmounts" scale="0" format="ixt:num-dot-decimal" decimals="INF">11</ix:nonFraction> additional Valuation Milestones.&#160;On <em style="font: inherit;"> February 13, 2025,&#160;</em>the Compensation Committee concluded that <em style="font: inherit;">no</em> discretionary&#160;cash bonus amounts would be awarded for the <ix:nonFraction id="c123855648" contextRef="i_2021-12-31_PlanNameAxis-CashIncentiveBonusPlanMember" unitRef="Pure" name="sava:CashBonusIncentiveIncrementalAmounts" scale="0" format="ixt:num-dot-decimal" decimals="INF">11</ix:nonFraction> milestones achieved in <em style="font: inherit;">2021</em> nor for the <em style="font: inherit;">2</em> remaining CIB Plan milestones, which have <em style="font: inherit;">not</em> been achieved. Therefore,&#160;<em style="font: inherit;">no</em>&#160;compensation expense has been recorded&#160;and&#160;<em style="font: inherit;">no</em>&#160;payments have been made&#160;since <em style="font: inherit;">no</em>&#160;grant date has occurred and <em style="font: inherit;">no</em>&#160;Performance Conditions are considered probable of being met.</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
   <ix:exclude>
    <div class="PGFTR" style="text-align: center; width: 100%">
     <div class="hf-row">
      <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       <em style="font: inherit;">110</em>
      </div>
     </div>
    </div>
    <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
    <div class="PGHDR" style="text-align: left; width: 100%">
     <div class="hf-row">
      <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
       <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Table of Contents</a>
      </div>
     </div>
    </div>
   </ix:exclude>
   <ix:exclude>&#160;</ix:exclude>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">The achievement the <ix:nonFraction id="c123855657" contextRef="i_2021-12-31_PlanNameAxis-CashIncentiveBonusPlanMember" unitRef="Pure" name="sava:CashBonusIncentiveIncrementalAmounts" scale="0" format="ixt:num-dot-decimal" decimals="INF">11</ix:nonFraction>&#160;milestones&#160;in&#160;<em style="font: inherit;">2021</em> triggered a&#160;non-discretionary potential Company obligation&#160;to a CIB Plan participant&#160;of $<ix:nonFraction id="c123855659" contextRef="i_2021-12-31_PlanNameAxis-CashIncentiveBonusPlanMember_RangeAxis-MinimumMember" unitRef="USD" name="sava:PerformancePlanValuationMilestoneAmount" scale="6" format="ixt:num-dot-decimal" decimals="-5">74.9</ix:nonFraction>&#160;million&#160;(after taking into account the <em style="font: inherit;"> March 2023 </em>CIB Plan amendment) and contingent upon future satisfaction of a Performance Condition. However,&#160;<ix:nonFraction id="c123855660" contextRef="d_2021-01-01_2021-12-31_PlanNameAxis-CashIncentiveBonusPlanMember" unitRef="USD" name="us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax" scale="6" format="ixt-sec:numwordsen" decimals="-3">no</ix:nonFraction>&#160;compensation expense has been recorded&#160;and&#160;<em style="font: inherit;">no</em>&#160;payments have been made&#160;since <em style="font: inherit;">no</em>&#160;grant date has occurred and <em style="font: inherit;">no</em>&#160;Performance Conditions are considered probable of being met.</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"><em style="font: inherit;">No</em> Valuation Milestones were achieved during the years&#160;ended <em style="font: inherit;"> December 31, 2024, </em><em style="font: inherit;">2023</em>&#160;and <em style="font: inherit;">2022.</em></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">As discussed in Note <em style="font: inherit;">12,</em> on <em style="font: inherit;"> January 24, 2025, </em>the Delaware Court of Chancery entered a Final Order and Judgment approving the Stipulation and dismissing an action related to the CIB&#160;Plan with prejudice. The Final Order and Judgment requires&#160;the Company to further amend&#160;the CIB Plan, as provided in the Stipulation.</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"><ix:nonFraction id="c123855668" contextRef="d_2024-01-01_2024-12-31_PlanNameAxis-CashIncentiveBonusPlanMember" unitRef="USD" name="sava:PaymentsForCashIncentiveBonus" scale="6" format="ixt-sec:numwordsen" decimals="-3">No</ix:nonFraction> actual cash payments were authorized or made to participants under the CIB Plan through <em style="font: inherit;"> December 31, 2024&#160;</em>and the date of filing of this Annual Report on Form <em style="font: inherit;">10</em>-K.</p>
   <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
  </ix:nonNumeric>
  <div>
   &#160;
  </div>
  <ix:nonNumeric contextRef="d_2024-01-01_2024-12-31" name="us-gaap:LossContingencyDisclosures" id="c2851703" escape="true">
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><em style="font: inherit;">12.</em> Contingencies</b></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&#160;</p>
   <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 18pt;">The Company is, and from time to time, the Company <em style="font: inherit;"> may </em>become, involved in litigation or other legal proceedings and claims, including U.S. government inquiries, investigations and Citizen Petitions submitted to FDA. In addition, the Company has received, and from time to time <em style="font: inherit;"> may </em>receive, inquiries from government authorities relating to matters arising from the ordinary course of business.&#160;The outcome of these proceedings is inherently uncertain. Regardless of outcome, legal proceedings can have an adverse impact on the Company because of defense and settlement costs, diversion of management resources, and other factors. At this time, <em style="font: inherit;">no</em> assessment can be made as to their likely outcome or whether the outcome will be material to the Company other than as disclosed below. The Company believes that its total provisions for legal matters are adequate based upon currently available information.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 5pt;"><i>Update on Government Investigations</i></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 5pt;text-indent:25pt;">Beginning in <em style="font: inherit;"> August 2021, </em>the Company has received subpoenas, a Civil Investigative Demand (&#8220;CID&#8221;) and other requests for documents and information from the Department of Justice (&#8220;DOJ&#8221;) and document requests from the SEC, each seeking corporate information and documents concerning the research and development of simufilam and/or SavaDx. The Company has been providing documents and information in response to these subpoenas, the CID and requests for information.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 4pt;text-indent:25pt;">On <em style="font: inherit;"> September 26, 2024, </em>the Company announced that it had reached a settlement with the SEC&#160;resolving the SEC investigation of the Company&#8217;s disclosures regarding its Phase <em style="font: inherit;">2b</em> clinical trial of simufilam for the treatment of Alzheimer&#8217;s disease (the &#8220;Phase <em style="font: inherit;">2b</em> Study&#8221;) and related matters. The SEC also agreed to a settlement with <em style="font: inherit;">two</em> former senior employees of the Company. Pursuant to these settlements, the U.S. District Court for the Western District of Texas entered final consent judgment on <em style="font: inherit;"> October 18, 2024, </em>on a complaint filed by the SEC against the Company and its <em style="font: inherit;">two</em> former senior employees. The Company has neither admitted nor denied the allegations of the complaint. The SEC&#8217;s complaint alleged that certain disclosures by the Company regarding the Phase <em style="font: inherit;">2b</em> Study violated certain federal securities laws and SEC rules, including negligence-based disclosure violations of Sections <em style="font: inherit;">17</em>(a)(<em style="font: inherit;">2</em>) and <em style="font: inherit;">17</em>(a)(<em style="font: inherit;">3</em>) of the Securities Act of <em style="font: inherit;">1933,</em> as amended (the &#8220;Securities Act&#8221;), as well as recordkeeping and reporting requirements under the Securities Exchange Act of <em style="font: inherit;">1934,</em> as amended (the &#8220;Exchange Act&#8221;). The complaint alleges that the Company&#8217;s SEC reports and other public statements regarding the Phase <em style="font: inherit;">2b</em> Study negligently contained materially misleading statements and omissions. The SEC&#8217;s allegations with respect to the Company&#8217;s <em style="font: inherit;">two</em> former employees relate to these employees&#8217; roles in such disclosures. Under its settlement, the Company consented to a permanent injunction against future violations of Section <em style="font: inherit;">17</em>(a) of the Securities Act, Section <em style="font: inherit;">13</em>(a)(<em style="font: inherit;">1</em>) of the Exchange Act and Rules <em style="font: inherit;">12b</em>-<em style="font: inherit;">20,</em> <em style="font: inherit;">13a</em>-<em style="font: inherit;">1,</em> <em style="font: inherit;">13a</em>-<em style="font: inherit;">11</em> and <em style="font: inherit;">13a</em>-<em style="font: inherit;">13</em> under the Exchange Act. In addition, the Company&#160;paid a civil monetary penalty of <em style="font: inherit;">$40</em> million in <em style="font: inherit;"> November 2024.</em></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 5pt;text-indent:25pt;">The Company continues to cooperate with the DOJ related to requests for documents and information, including those related to conduct alleged in the indictment of Dr. Hoau-Yan Wang announced by DOJ on <em style="font: inherit;"> June 28, 2024. </em>The Company cannot predict the outcome or impact of&#160;ongoing matters, including whether a government authority <em style="font: inherit;"> may </em>pursue an enforcement action against the Company or others. The Company does <em style="font: inherit;">not</em> at this time anticipate, however, that DOJ will bring criminal charges against or seek a criminal resolution with the Company.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <ix:exclude>
    <div class="PGFTR" style="text-align: center; width: 100%">
     <div class="hf-row">
      <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       <em style="font: inherit;">111</em>
      </div>
     </div>
    </div>
    <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
    <div class="PGHDR" style="text-align: left; width: 100%">
     <div class="hf-row">
      <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
       <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Table of Contents</a>
      </div>
     </div>
    </div>
   </ix:exclude>
   <ix:exclude>&#160;</ix:exclude>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 5pt;"><i>Securities Class Actions and Shareholder Derivative Actions</i></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 5pt;text-indent:18pt;">Between <em style="font: inherit;"> August 27, 2021 </em>and <em style="font: inherit;"> October 26, 2021, </em><span style="-sec-ix-hidden:c123855699">four</span> putative class action lawsuits were filed alleging violations of the federal securities laws by the Company and certain named officers. The complaints rely on allegations contained in Citizen Petitions submitted to FDA and allege that various statements made by the defendants regarding simufilam were rendered materially false and misleading. The Citizen Petitions were all subsequently denied by FDA. These actions were filed in the U.S. District Court for the Western District of Texas. The complaints seek unspecified compensatory damages and other relief on behalf of a purported class of purchasers.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 8pt; text-align: justify; text-indent: 18pt;">On <em style="font: inherit;"> June 30, 2022, </em>a federal judge consolidated the <span style="-sec-ix-hidden:c123855700">four</span> class action lawsuits into <span style="-sec-ix-hidden:c123855701">one</span> case and appointed a lead plaintiff and a lead counsel. Lead plaintiff filed a consolidated amended complaint on <em style="font: inherit;"> August 18, 2022 </em>on behalf of a putative class of purchasers of the Company&#8217;s securities between <em style="font: inherit;"> September 14, 2020 </em>and <em style="font: inherit;"> July 26, 2022. </em>On <em style="font: inherit;"> May 11, 2023, </em>the court dismissed with prejudice plaintiffs&#8217; claims against&#160;defendant Nadav Friedmann, PhD, MD,&#160;our former Chief Medical Officer and a Company director, who&#160;is now deceased, but otherwise denied defendants&#8217; motion to&#160;dismiss. Defendants filed an answer to the consolidated amended complaint on <em style="font: inherit;"> July 3, 2023. </em>On <em style="font: inherit;"> February 22, 2024, </em>plaintiffs filed a motion to supplement their complaint to extend the putative class period through <em style="font: inherit;"> October 12, 2023.&#160; </em>The court granted that Motion on <em style="font: inherit;"> June 12, 2024, </em>and plaintiffs filed a supplemental complaint on <em style="font: inherit;"> June 13, 2024.&#160;</em>On <em style="font: inherit;"> November 13, 2024, </em>Plaintiffs filed a <em style="font: inherit;">second</em> motion to supplement their complaint. On <em style="font: inherit;"> March 13, 2024, </em>plaintiffs filed a Motion for Class Certification. On <em style="font: inherit;"> February 25, 2025, </em>the Court denied Plaintiff&#8217;s Motion for Class Certification without prejudice, explaining that rulings on pending motions, including specifically Plaintiffs&#8217; <em style="font: inherit;">second</em> motion to supplement their complaint, could affect disposition of class certification.&#160;</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 5pt;text-indent:18pt;">On <em style="font: inherit;"> November 4, 2021, </em>a related shareholder derivative action was filed, purportedly on behalf of the Company, in the U.S. District Court for the Western District of Texas, asserting claims under the U.S. securities laws and state fiduciary duty laws against certain named officers and the members of the Company&#8217;s Board. This complaint relies on the allegations made in Citizen Petitions that were submitted to (and subsequently denied by) FDA. The complaint alleges, among other things, that the individual defendants exposed the Company to unspecified damages and securities law liability by causing it to make materially false and misleading statements, in violation of the U.S. securities laws and in breach of their fiduciary duties to the Company. The derivative case seeks, among other things, to recover unspecified compensatory damages on behalf of the Company arising out of the individual defendants&#8217; alleged wrongful conduct. Although the plaintiff in this derivative case does <em style="font: inherit;">not</em> seek relief against the Company, the Company has certain indemnification obligations to the individual defendants. Between <em style="font: inherit;"> November 4, 2021 </em>and <em style="font: inherit;"> June 20, 2023, </em><span style="-sec-ix-hidden:c123855705">four</span> additional shareholder derivative actions were filed alleging substantially similar claims, <span style="-sec-ix-hidden:c123855706">two</span> in the U.S. District Court for the Western District of Texas, <span style="-sec-ix-hidden:c123855707">one</span> in Texas state court (Travis County District Court) and <span style="-sec-ix-hidden:c123855708">one</span> in the Delaware Court of Chancery. On <em style="font: inherit;"> July 5, 2022, </em>the <span style="-sec-ix-hidden:c123855709">three</span> actions in the Western District of Texas were consolidated into a single action. All of the foregoing actions are currently stayed pending further developments in the consolidated securities action described above.&#160;On <em style="font: inherit;"> November 9, 2023, </em>another shareholder derivative action alleging substantially similar claims was filed in the U.S. District Court for the Western District of Texas.&#160;The parties to that case expect that it will be consolidated into the existing consolidated federal court shareholder derivative action.</p>
   <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 5pt;text-indent:18pt;">On <em style="font: inherit;"> February 2, 2024, </em>a putative class action lawsuit was filed, purportedly on behalf of the Company,&#160;alleging violations of the federal securities law by the Company and certain named officers. The complaint relies on an <em style="font: inherit;"> October 12, 2023 </em>article that describes a purported leaked report of alleged scientific misconduct by a&#160;scientific collaborator of the Company at City University of New York. The complaint alleges that various statements made by the defendants regarding simufilam were rendered materially false and misleading by this article. The action was filed in the U.S. District Court for the Northern District of Illinois. The complaint seeks unspecified compensatory damages and other relief on behalf of a purported class of purchasers of the Company&#8217;s securities between <em style="font: inherit;"> August 18, 2022 </em>and <em style="font: inherit;"> October 12, 2023. </em>On <em style="font: inherit;"> May 28, 2024, </em>the Northern District of Illinois transferred this action to the Western District of Texas.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <ix:exclude>
    <div class="PGFTR" style="text-align: center; width: 100%">
     <div class="hf-row">
      <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       <em style="font: inherit;">112</em>
      </div>
     </div>
    </div>
    <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
    <div class="PGHDR" style="text-align: left; width: 100%">
     <div class="hf-row">
      <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
       <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Table of Contents</a>
      </div>
     </div>
    </div>
   </ix:exclude>
   <ix:exclude>&#160;</ix:exclude>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 5pt;text-indent:18pt;">Beginning on <em style="font: inherit;"> March 18, 2024, </em><span style="-sec-ix-hidden:c123855711">two</span> related shareholder derivative actions were filed, purportedly on behalf of the Company, in the U.S. District Court for the Northern District of Illinois, asserting claims under the U.S. securities laws and state fiduciary duty laws against certain named officers and the members of the Company&#8217;s Board. The complaints rely on an <em style="font: inherit;"> October 12, 2023 </em>article that describes a purported leaked report of alleged scientific misconduct by a&#160;scientific collaborator of the Company at City University of New York. The complaints allege, among other things, that the individual defendants exposed the Company to unspecified damages and securities law liability by causing it to make materially false and misleading statements, in violation of the U.S. securities laws and in breach of their fiduciary duties to the Company. The derivative cases seek, among other things, to recover unspecified compensatory damages on behalf of the Company arising out of the individual defendant&#8217;s alleged wrongful conduct. Although the plaintiffs in these derivative cases do <em style="font: inherit;">not</em> seek relief against the Company, the Company has certain indemnification obligations to the individual defendants.&#160;On <em style="font: inherit;"> September 6, 2024, </em>these <span style="-sec-ix-hidden:c123855713">two</span> cases were consolidated and stayed pending further developments in the shareholder class action initially filed in the Northern District of Illinois on <em style="font: inherit;"> February 2, 2024.</em></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 5pt;text-indent:18pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 5pt;text-indent:18pt;">The Company disputes the allegations and intends to defend against these lawsuits vigorously. The Company is unable to estimate the possible loss or range of loss, if any, associated with these lawsuits.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 5pt;text-indent:18pt;">On <em style="font: inherit;"> December 13, 2024, </em>a putative class action lawsuit was filed, purportedly on behalf of the Company,&#160;alleging violations of the federal securities law by the Company and certain named officers. The complaint alleges that various statements made by the defendants regarding simufilam were revealed to be materially false and misleading by the release of top-line results for the Company&#8217;s RETHINK-ALZ Phase <em style="font: inherit;">3</em> clinical trial on <em style="font: inherit;"> November 25, 2024. </em>The action was filed in the U.S. District Court for the Western District of Texas. The complaint seeks unspecified compensatory damages and other relief on behalf of a purported class of purchasers of the Company&#8217;s securities between <em style="font: inherit;"> February 7, 2024, </em>and <em style="font: inherit;"> November 24, 2024.&#160;</em>The Company believes that the likelihood of an unfavorable outcome is <em style="font: inherit;">not</em> probable, however, it is reasonably possible that the Company <em style="font: inherit;"> may </em>incur a loss. The Company is unable to reasonably estimate the amount or range of potential loss at this time.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 5pt;text-indent:18pt;">On <em style="font: inherit;"> August 19, 2022, </em>a shareholder derivative action was filed, purportedly on behalf of the Company, in the Delaware Court of Chancery, asserting claims under state fiduciary duty laws against certain named officers and members of the Company&#8217;s Board. The complaint alleges, among other things, that the individual defendants breached their fiduciary duties by approving the CIB Plan in <em style="font: inherit;"> August 2020. </em>The complaints sought unspecified compensatory damages and other relief. On <em style="font: inherit;"> January 6, 2023, </em>the plaintiffs filed an amended complaint. Defendants filed a partial answer to the amended complaint on <em style="font: inherit;"> March 10, 2023, </em>and moved to partially dismiss the amended complaint on <em style="font: inherit;"> March 14, 2023.</em></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 5pt;text-indent:18pt;">On <em style="font: inherit;"> May 28, 2024, </em>the parties entered into a Stipulation and Agreement of Settlement, Compromise, and Release (the &#8220;Stipulation&#8221;) to resolve the action. The Stipulation and exhibits thereto, including the proposed Notice of Pendency of Settlement of Class and Derivative Action (the &#8220;Notice&#8221;) and [Proposed] Scheduling Order with Respect to Notice and Settlement Hearing (the &#8220;Scheduling Order&#8221;), were filed in the Delaware Court of Chancery on <em style="font: inherit;"> May 28, 2024.&#160;</em></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 5pt;text-indent:18pt;">On <em style="font: inherit;"> June 26, 2024, </em>the Delaware Court of Chancery entered the Scheduling Order, which included approval of the Notice.&#160; The Delaware Court of Chancery held a settlement hearing on <em style="font: inherit;"> September 9, 2024. </em>On <em style="font: inherit;"> January 24, 2025, </em>the Delaware Court of Chancery entered a Final Order and Judgment approving the Stipulation and dismissing the action with prejudice. Pursuant to the Final Order, the Company paid $<ix:nonFraction id="c123855716" contextRef="d_2025-02-01_2025-02-28_LitigationCaseAxis-ShareholderDerivativeActionsMember_SubsequentEventTypeAxis-SubsequentEventMember" unitRef="USD" name="us-gaap:LegalFees" scale="6" format="ixt:num-dot-decimal" decimals="-6">1</ix:nonFraction> million in attorneys&#8217; fees and expenses in <em style="font: inherit;"> February 2025, </em>which was recorded in accounts payable and other accrued expenses at <em style="font: inherit;"> December 31, 2024.</em></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 7pt;"><i>Anti-SLAPP Lawsuit</i></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 7pt; text-indent: 18pt; text-align: justify;">On <em style="font: inherit;"> August 6, 2024, </em>a lawsuit was filed in the District Court for the Southern District of New York which, as amended and as joined by intervenor plaintiffs, asserts claims, including a claim under the New York Anti-SLAPP Law, against the Company and against <ix:nonFraction id="c123855717" contextRef="d_2024-08-06_2024-08-06_LitigationCaseAxis-AntislappLawsuitMember" unitRef="Pure" name="sava:NumberOfFormerEmployees" scale="0" format="ixt-sec:numwordsen" decimals="INF">two</ix:nonFraction> former officers to whom the Company has certain indemnification obligations.&#160;The amended complaint and the complaint in intervention seeks costs and damages relating to a defamation action filed by the Company against the plaintiffs and subsequently dismissed voluntarily and without prejudice by the Company.&#160;The Company intends to&#160;defend the lawsuit vigorously.&#160;The Company is unable to estimate the possible loss or range of loss, if any, associated with this lawsuit.</p>
   <p style="text-align: justify; font-size: 10pt; font-family: &quot;Times New Roman&quot;; margin: 0pt;">&#160;</p>
  </ix:nonNumeric>
  <div>
   &#160;
  </div>
  <ix:nonNumeric contextRef="d_2024-01-01_2024-12-31" name="sava:WarrantDividendDistributionTextBlock" id="c2851704" escape="true">
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><em style="font: inherit;">13.</em> Warrant Dividend Distribution</b></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -2pt; text-indent: 18pt;">On <em style="font: inherit;"> January 3, 2024, </em>the Company&#160;made a distribution&#160;to the holders of record of the Company&#8217;s&#160;common stock&#160;in the form of warrants to purchase shares of common stock. Each holder of record of the Company's common stock as of the close of business on <em style="font: inherit;"> December 22, 2023 </em>received <span style="-sec-ix-hidden:c123855719">four</span> warrants for every <ix:nonFraction id="c123855720" contextRef="i_2023-12-22_ClassOfWarrantOrRightAxis-WarrantsToPurchaseCommonStockMember" unitRef="Share" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="0" format="ixt:num-dot-decimal" decimals="INF">10</ix:nonFraction>&#160;shares of common stock (rounded down&#160;for any fractional warrant) resulting in the issuance of approximately <span style="-sec-ix-hidden:c123855721">16.9</span> million&#160;warrants.</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;">&#160;</p>
   <ix:exclude>
    <div class="PGFTR" style="text-align: center; width: 100%">
     <div class="hf-row">
      <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       <em style="font: inherit;">113</em>
      </div>
     </div>
    </div>
    <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
    <div class="PGHDR" style="text-align: left; width: 100%">
     <div class="hf-row">
      <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
       <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Table of Contents</a>
      </div>
     </div>
    </div>
   </ix:exclude>
   <ix:exclude>&#160;</ix:exclude>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-indent: 18pt;">Each warrant entitled&#160;the holder to purchase, at the holder&#8217;s sole expense and exclusive election, at an exercise price of $<ix:nonFraction id="c123855723" contextRef="i_2024-01-03_ClassOfWarrantOrRightAxis-WarrantsToPurchaseCommonStockMember" unitRef="USDPerShare" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" format="ixt:num-dot-decimal" decimals="INF">33.00</ix:nonFraction> per warrant, <span style="-sec-ix-hidden:c123855724">one</span> and <em style="font: inherit;">one</em>-half shares of common stock (rounded down&#160;for any fractional shares). Payment for shares of common stock upon exercise of warrants was required to&#160;be in cash.</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -2pt; text-indent: 18pt;">On <em style="font: inherit;"> April 15, 2024, </em>the Company announced&#160;that all outstanding warrants would&#160;be redeemed on <em style="font: inherit;"> May 7, 2024&#160;(</em>the &#8220;Redemption Date&#8221;). The redemption price was equal to <span style="-sec-ix-hidden:c123855726">1/10</span> of $<ix:nonFraction id="c123855727" contextRef="i_2024-05-07_ClassOfWarrantOrRightAxis-WarrantsToPurchaseCommonStockMember" unitRef="USDPerShare" name="sava:WarrantRedemptionPrice" scale="0" format="ixt:num-dot-decimal" decimals="INF">0.01</ix:nonFraction> per warrant. The warrants were exercisable at any time starting on <em style="font: inherit;"> January 3, 2024&#160;</em>until the business day prior to the Redemption Date. There are <span style="-sec-ix-hidden:c123855728">no</span> remaining warrants currently outstanding.</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -2pt; text-indent: 18pt;">The warrants were subject to the terms and conditions of the Warrant Agreement (including Form of Warrant), dated <em style="font: inherit;"> January 3, 2024, </em>between Cassava Sciences, Inc., Computershare Inc., and Computershare Trust Company, N.A. as filed in a Current Report on&#160;Form <em style="font: inherit;">8</em>-K with the SEC on <em style="font: inherit;"> January 3, 2024. </em>The warrants were&#160;listed and traded separately from the Company's common stock on the Nasdaq Capital Market under the ticker &#8220;SAVAW&#8221;.</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -4pt; text-indent: 9pt;">From <em style="font: inherit;"> January 3, 2024 </em>to <em style="font: inherit;"> March 31, 2024, </em>a total of approximately <ix:nonFraction id="c123855730" contextRef="d_2024-01-04_2024-03-31_ClassOfWarrantOrRightAxis-WarrantsToPurchaseCommonStockMember" unitRef="Share" name="sava:ClassOfWarrantOrRightExercisedDuringPeriod" scale="0" format="ixt:num-dot-decimal" decimals="INF">674,000</ix:nonFraction>&#160;warrants were exercised resulting in net proceeds to the Company of approximately $<ix:nonFraction id="c123855731" contextRef="d_2024-01-04_2024-03-31_ClassOfWarrantOrRightAxis-WarrantsToPurchaseCommonStockMember" unitRef="USD" name="us-gaap:ProceedsFromWarrantExercises" scale="6" format="ixt:num-dot-decimal" decimals="-5">22.3</ix:nonFraction>&#160;million. The Company issued approximately <ix:nonFraction id="c123855732" contextRef="d_2024-01-04_2024-03-31_ClassOfWarrantOrRightAxis-WarrantsToPurchaseCommonStockMember" unitRef="Share" name="sava:StockIssuedDuringPeriodSharesWarrantExercises" scale="0" format="ixt:num-dot-decimal" decimals="INF">1.0</ix:nonFraction> million&#160;shares of common stock&#160;from the exercise of warrants through <em style="font: inherit;"> March 31, 2024.</em></p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -4pt; text-indent: 9pt;">Subsequent to <em style="font: inherit;"> March 31, 2024 </em>and through the Redemption Date, a total of approximately <em style="font: inherit;">3.15</em> million&#160;warrants were exercised resulting in gross proceeds to the Company of approximately <em style="font: inherit;">$104.0</em>&#160;million. The Company issued approximately <ix:nonFraction id="c123855735" contextRef="d_2024-04-01_2024-05-02_ClassOfWarrantOrRightAxis-WarrantsToPurchaseCommonStockMember" unitRef="Share" name="sava:StockIssuedDuringPeriodSharesWarrantExercises" scale="0" format="ixt:num-dot-decimal" decimals="INF">4.7</ix:nonFraction> million shares of common stock&#160;from the exercise of warrants from <em style="font: inherit;"> March 31, 2024 </em>through the Redemption Date.</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;">Gross proceeds for the year ended <em style="font: inherit;"> December 31,&#160;</em><em style="font: inherit;">2024</em> from the warrant distribution totaled approximately $<ix:nonFraction id="c123855737" contextRef="d_2024-01-01_2024-12-31_ClassOfWarrantOrRightAxis-WarrantsToPurchaseCommonStockMember" unitRef="USD" name="sava:GrossProceedsFromIssuanceOfWarrants" scale="6" format="ixt:num-dot-decimal" decimals="-5">126.3</ix:nonFraction>&#160;million from the issuance of approximately <ix:nonFraction id="c123855738" contextRef="i_2024-12-31_ClassOfWarrantOrRightAxis-WarrantsToPurchaseCommonStockMember" unitRef="Share" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="6" format="ixt:num-dot-decimal" decimals="-5">5.7</ix:nonFraction> million common shares at $<ix:nonFraction id="c123855739" contextRef="i_2024-12-31_ClassOfWarrantOrRightAxis-WarrantsToPurchaseCommonStockMember" unitRef="USDPerShare" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" format="ixt:num-dot-decimal" decimals="INF">22.00</ix:nonFraction> per share. Total net proceeds of the warrant distribution were approximately $<ix:nonFraction id="c123855740" contextRef="d_2024-01-01_2024-12-31_ClassOfWarrantOrRightAxis-WarrantsToPurchaseCommonStockMember" unitRef="USD" name="us-gaap:ProceedsFromIssuanceOfWarrants" scale="6" format="ixt:num-dot-decimal" decimals="-5">123.6</ix:nonFraction>&#160;million&#160;after deducting&#160;exercise&#160;expenses and commissions.</p>
   <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -4pt; text-indent: 9pt;">After the <em style="font: inherit;">first</em> $<ix:nonFraction id="c123855742" contextRef="d_2024-01-04_2024-03-31_ClassOfWarrantOrRightAxis-WarrantsToPurchaseCommonStockMember" unitRef="USD" name="sava:ProceedsFromWarrantsExercisedThatObligatedToPayCommission" scale="6" format="ixt:num-dot-decimal" decimals="-7">20</ix:nonFraction> million of gross proceeds, the Company was&#160;obligated to pay a commission of&#160;<ix:nonFraction id="c123855743" contextRef="d_2024-01-04_2024-03-31_ClassOfWarrantOrRightAxis-WarrantsToPurchaseCommonStockMember" unitRef="Pure" name="sava:CommissionPercentageOfGrossProceeds" scale="-2" format="ixt:num-dot-decimal" decimals="3">2.5</ix:nonFraction>% of the gross proceeds from the sale of shares of common stock from&#160;warrant exercises&#160;to the Company's financial advisor for the warrant distribution. Total cost&#160;of warrant exercises through the Redemption Date were approximately $<ix:nonFraction id="c123855744" contextRef="d_2024-01-01_2024-12-31_ClassOfWarrantOrRightAxis-WarrantsToPurchaseCommonStockMember" unitRef="USD" name="sava:PaymentsOfWarrantExerciseCosts" scale="6" format="ixt:num-dot-decimal" decimals="-5">2.7</ix:nonFraction>&#160;million.</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -4pt; text-indent: 9pt;">Costs of the warrant distribution totaling&#160;approximately $<ix:nonFraction id="c123855745" contextRef="d_2024-01-03_2024-01-03_ClassOfWarrantOrRightAxis-WarrantsToPurchaseCommonStockMember" unitRef="USD" name="us-gaap:PaymentsOfStockIssuanceCosts" scale="0" format="ixt:num-dot-decimal" decimals="INF">537,000</ix:nonFraction> were recorded&#160;as general and administrative expenses in the statements of operations upon distribution of the warrants on <em style="font: inherit;"> January 3, 2024.</em></p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -4pt; text-indent: 9pt; text-align: justify;">The outstanding warrants were&#160;classified as liabilities in accordance with ASC <em style="font: inherit;">480</em> and ASC <em style="font: inherit;">815,</em> which requires&#160;the warrants to be measured at initial fair value&#160;on <em style="font: inherit;"> January 3, 2024&#160;</em>and at each reporting period thereafter, with the changes in fair value recognized as a non-cash gain or loss&#160;in our consolidated statements of operations. As of <em style="font: inherit;"> December 31, 2024, </em>there were <ix:nonFraction id="c123855748" contextRef="i_2024-12-31_ClassOfWarrantOrRightAxis-WarrantsToPurchaseCommonStockMember" unitRef="USD" name="us-gaap:WarrantsAndRightsOutstanding" scale="0" format="ixt-sec:numwordsen" decimals="-3">no</ix:nonFraction> warrants outstanding.</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-indent: 18pt; text-align: justify;">During the period from common stock warrant distribution on <em style="font: inherit;"> January 3, 2024 </em>to the Redemption Date, changes in the Company's common stock warrants liability and&#160;warrants outstanding were as follows (in thousands):</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt;">&#160;</p>
   <ix:nonNumeric contextRef="d_2024-01-01_2024-12-31" name="us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" id="c2851705" escape="true">
    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"><tbody><tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Number of Common Stock Warrants</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Common Stock Warrant Liability</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 70%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Distribution of common stock warrants on January 3, 2024</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c123855358" contextRef="i_2024-01-02" unitRef="Share" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="3" format="ixt:num-dot-decimal" decimals="-3">16,895</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c123855359" contextRef="i_2024-01-02" unitRef="USD" name="us-gaap:WarrantsAndRightsOutstanding" scale="3" format="ixt:num-dot-decimal" decimals="-3">113,363</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Warrants exercised</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c123855360" contextRef="d_2024-01-03_2024-03-31_ClassOfWarrantOrRightAxis-WarrantsToPurchaseCommonStockMember" unitRef="Share" name="sava:ClassOfWarrantOrRightExercisedDuringPeriod" scale="3" format="ixt:num-dot-decimal" decimals="-3">674</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c123855361" contextRef="d_2024-01-03_2024-03-31_ClassOfWarrantOrRightAxis-WarrantsToPurchaseCommonStockMember" unitRef="USD" name="sava:ExerciseOfWarrantsResultingInDecreaseInWarrantLiability" scale="3" format="ixt:num-dot-decimal" decimals="-3">4,954</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Gain from change in fair value of warrant liabilities</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"><em style="font: inherit;">&#8212;</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(<ix:nonFraction id="c123855363" contextRef="d_2024-01-03_2024-03-31_ClassOfWarrantOrRightAxis-WarrantsToPurchaseCommonStockMember" unitRef="USD" name="us-gaap:FairValueAdjustmentOfWarrants" scale="3" format="ixt:num-dot-decimal" decimals="-3">43,041</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Balance at March 31, 2024</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c123855364" contextRef="i_2024-03-31_ClassOfWarrantOrRightAxis-WarrantsToPurchaseCommonStockMember" unitRef="Share" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="3" format="ixt:num-dot-decimal" decimals="-3">16,221</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c123855365" contextRef="i_2024-03-31_ClassOfWarrantOrRightAxis-WarrantsToPurchaseCommonStockMember" unitRef="USD" name="us-gaap:WarrantsAndRightsOutstanding" scale="3" format="ixt:num-dot-decimal" decimals="-3">65,368</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Warrants exercised</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c123855366" contextRef="d_2024-04-01_2024-06-30_ClassOfWarrantOrRightAxis-WarrantsToPurchaseCommonStockMember" unitRef="Share" name="sava:ClassOfWarrantOrRightExercisedDuringPeriod" scale="3" format="ixt:num-dot-decimal" decimals="-3">3,152</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c123855367" contextRef="d_2024-04-01_2024-06-30_ClassOfWarrantOrRightAxis-WarrantsToPurchaseCommonStockMember" unitRef="USD" name="sava:ExerciseOfWarrantsResultingInDecreaseInWarrantLiability" scale="3" format="ixt:num-dot-decimal" decimals="-3">226</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Gain from change in fair value of warrant liabilities</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><em style="font: inherit;">&#8212;</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c123855369" contextRef="d_2024-04-01_2024-06-30_ClassOfWarrantOrRightAxis-WarrantsToPurchaseCommonStockMember" unitRef="USD" name="us-gaap:FairValueAdjustmentOfWarrants" scale="3" format="ixt:num-dot-decimal" decimals="-3">65,142</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Redemption of common stock warrants</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(<ix:nonFraction id="c123855370" contextRef="d_2024-04-01_2024-06-30_ClassOfWarrantOrRightAxis-WarrantsToPurchaseCommonStockMember" unitRef="Share" name="sava:ClassOfWarrantsOrRightsCommonStockWarrantsRedeemed" scale="3" format="ixt:num-dot-decimal" decimals="-3">13,069</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"><em style="font: inherit;">&#8212;</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Balance as of June 30, 2024</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;"><span style="-sec-ix-hidden:c123855372">&#8212;</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">&#8212;<ix:nonFraction id="c123855373" contextRef="i_2024-06-30_ClassOfWarrantOrRightAxis-WarrantsToPurchaseCommonStockMember" unitRef="USD" name="us-gaap:WarrantsAndRightsOutstanding" scale="3" format="ixt:fixed-zero" decimals="-3"></ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Balance as of September 30, 2024</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;"><span style="-sec-ix-hidden:c123855374">&#8212;</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><span style="-sec-ix-hidden:c123855375">&#8212;</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Balance as of December 31, 2024</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;"><span style="-sec-ix-hidden:c123855376">&#8212;</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><span style="-sec-ix-hidden:c123855377">&#8212;</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td></tr>
</tbody></table>
   </ix:nonNumeric>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -10pt; text-indent: 18pt;">See Note <em style="font: inherit;">2</em> for additional information regarding common stock warrants and associated warrant liability.</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -10pt; text-indent: 18pt;">&#160;</p>
   <ix:exclude>
    <div class="PGFTR" style="text-align: center; width: 100%">
     <div class="hf-row">
      <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       <em style="font: inherit;">114</em>
      </div>
     </div>
    </div>
    <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
    <div class="PGHDR" style="text-align: left; width: 100%">
     <div class="hf-row">
      <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
       <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Table of Contents</a>
      </div>
     </div>
    </div>
   </ix:exclude>
   <ix:exclude>&#160;&#160;</ix:exclude>
  </ix:nonNumeric>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -10pt; text-indent: 18pt;">&#160;</p>
  <div>
   &#160;
  </div>
  <ix:nonNumeric contextRef="d_2024-01-01_2024-12-31" name="us-gaap:SubsequentEventsTextBlock" id="c2851706" escape="true">
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -19pt; text-indent: 18pt;"><b><em style="font: inherit;">14.</em> Subsequent Event</b></p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -19pt; text-indent: 18pt;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-indent: 18pt;">On <em style="font: inherit;"> January 7, 2025, </em>the Company announced a reduction&#160;its workforce by <ix:nonFraction id="c123855752" contextRef="d_2025-01-07_2025-01-07_RestructuringCostAndReserveAxis-WorkforceReductionMember_SubsequentEventTypeAxis-SubsequentEventMember" unitRef="Pure" name="us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminated" scale="0" format="ixt:num-dot-decimal" decimals="INF">10</ix:nonFraction> employees, a reduction of <ix:nonFraction id="c123855753" contextRef="d_2025-01-07_2025-01-07_RestructuringCostAndReserveAxis-WorkforceReductionMember_SubsequentEventTypeAxis-SubsequentEventMember" unitRef="Pure" name="us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent" scale="-2" format="ixt:num-dot-decimal" decimals="2">33</ix:nonFraction>% (the &#8220;Workforce Reduction&#8221;). The Company communicated the Workforce Reduction to affected employees on <em style="font: inherit;"> January 7, 2025.</em></p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-indent: 18pt;">The Company estimates that it will incur approximately $<ix:nonFraction id="c123855754" contextRef="i_2025-03-31_RestructuringCostAndReserveAxis-WorkforceReductionMember_StatementScenarioAxis-ScenarioForecastMember" unitRef="USD" name="us-gaap:RestructuringAndRelatedCostExpectedCost1" scale="6" format="ixt:num-dot-decimal" decimals="-5">0.4</ix:nonFraction> million of <em style="font: inherit;">one</em>-time costs in connection with the Workforce Reduction, primarily related to severance payments. The Company expects the Workforce Reduction to be completed, and the majority of the associated costs and cash payments to be incurred, during the <em style="font: inherit;">first</em> quarter of <em style="font: inherit;">2025.</em>&#160;</p>
  </ix:nonNumeric>
  <div>
   &#160;
  </div>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><a id="item9" title="item9" href="#"></a>Item 9.</b>&#160;&#160;&#160;&#160;<b><i>Changes in and Disagreements with Accountants on Accounting and Financial Disclosure</i></b></p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">None.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&#160;</p>
  <div>
   &#160;
  </div>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><a id="item9a" title="item9a" href="#"></a>Item 9A.</b>&#160;&#160;&#160;&#160;<b><i>Controls and Procedures</i></b></p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><i>Evaluation of disclosure controls and procedures.</i></p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">Our management, with the participation of our Chief Executive Officer and our Chief Financial Officer, evaluated the effectiveness of our disclosure controls and procedures as of the end of the period covered by this Annual Report on Form 10-K. Based on this evaluation, our Chief Executive Officer and our Chief Financial Officer have concluded that our disclosure controls and procedures were effective to ensure that information we are required to disclose in reports that we file or submit under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the Securities and Exchange Commission, or SEC, rules and forms and that such information is accumulated and communicated to management as appropriate to allow timely decisions regarding required disclosures.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"><i>Management</i>&#8217;<i>s annual report on internal control over financial reporting.</i> Our management is responsible for establishing and maintaining adequate internal control over our financial reporting. Our management has assessed the effectiveness of internal control over financial reporting as of December 31, 2024. Our assessment was based on criteria set forth by the Committee of Sponsoring Organizations of the Treadway Commission, or COSO, in Internal Control-Integrated Framework (2013 Framework).</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">Our internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of consolidated financial statements for external purposes in accordance with generally accepted accounting principles. Our internal control over financial reporting includes those policies and procedures that:</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 36pt;text-indent:-18pt;">&#160;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">(1)</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect our transactions and dispositions of our assets;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">(2)</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">provide reasonable assurance that transactions are recorded as necessary to permit preparation of consolidated financial statements in accordance with generally accepted accounting principles, and that our receipts and expenditures are being made only in accordance with authorizations of our management and board of directors; and</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">(3)</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of our assets that could have a material effect on the consolidated financial statements.</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">Based on it&#8217;s assessment under the COSO framework, management concluded that our internal control over financial reporting as of&#160;December 31, 2024&#160;was effective.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><i>Changes in internal control over financial reporting.</i></p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">There was no change in our internal control over financial reporting that occurred during the quarter ended December 31, 2024&#160;that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
      115
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-indent: 18pt;">This report does not include an attestation report of our registered public accounting firm regarding internal control over financial reporting. As a &#8220;smaller reporting company,&#8221; management&#8217;s report is not subject to attestation by our registered public accounting firm.</p>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
  <div>
   &#160;
  </div>
  <div>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><a id="item9b" title="item9b" href="#"></a>Item <em style="font: inherit;">9B.</em></b>&#160;&#160;&#160;&#160;<b><i>Other Information</i></b></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 8pt;text-indent:18pt;">During the quarter ended <em style="font: inherit;"> December 31, 2024, </em><span style="-sec-ix-hidden:c123855759"><span style="-sec-ix-hidden:c123855822"><span style="-sec-ix-hidden:c123855823"><span style="-sec-ix-hidden:c123855824">none</span></span></span></span> of our directors or officers (as defined in Rule <em style="font: inherit;">16a</em>-<em style="font: inherit;">1</em>(f) of the Exchange Act) informed us of the adoption or termination of a &#8220;Rule <em style="font: inherit;">10b5</em>-<em style="font: inherit;">1</em> trading arrangement&#8221; or &#8220;non-Rule <em style="font: inherit;">10b5</em>-<em style="font: inherit;">1</em> trading arrangement,&#8221; as those terms are defined in Regulation S-K, Item <em style="font: inherit;">408.</em></p>
  </div>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&#160;</p>
  <div>
   &#160;
  </div>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><a id="item9c" title="item9c" href="#"></a>Item 9C. </b><b><i>Disclosure Regarding Foreign Jurisdictions that Prevent Inspection</i></b></p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">None<b>.</b></p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>PART III</b></p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&#160;</p>
  <div>
   &#160;
  </div>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><a id="item10" title="item10" href="#"></a>Item 10.</b>&#160;&#160;&#160;&#160;<b><i>Directors, Executive Officers and Corporate Governance </i></b></p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">The information regarding our directors (other than the biographies below), executive officers, director nomination process and the audit committee of the Board is incorporated by reference from "Directors and Executive Officers" in our Proxy Statement for our 2025&#160;Annual Meeting of Stockholders.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>Biographies of Directors and Executive Officers</b></p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:14pt;">&#160;</p>
  <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 18pt;"><i>Richard J. Barry</i> has served as a director since June 2021 and was appointed Chief Executive Officer in September 2024. Mr. Barry served as Executive Chairman of the Board beginning July 2024 until his appointment as Chief Executive Officer.&#160;Since June 2015, Mr. Barry has also served as a director of Sarepta Therapeutics, Inc., (Nasdaq: SRPT). Mr. Barry has extensive experience in the investment management business. He was a founding member of Eastbourne Capital Management LLC, and served as a Managing General Partner and Portfolio Manager from 1999 to its close in 2010. Prior to Eastbourne, Mr. Barry was a Portfolio Manager and Managing Director of Robertson Stephens Investment Management. Mr. Barry holds a Bachelor of Arts from Pennsylvania State<b> </b>University.&#65279;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:14pt;">&#160;</p>
  <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 18pt;"><i>R. Christopher Cook</i> has served as Senior Vice President and General Counsel since October 2022. He previously served, since 2017, as the Global Head of Litigation and Government Investigations for Alcon, a publicly traded medical device and pharmaceutical company, as well as the Vice President and division General Counsel for Walmart Central America in San Jose, Costa Rica. Mr. Cook&#160;also spent seventeen years at Jones Day, where he was a litigation partner in the firm's Washington, DC and Chicago offices. He&#160;served as an Assistant United States Attorney in Chicago and graduated from Harvard Law School.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:14pt;">&#160;</p>
  <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 18pt;"><i>James W. Kupiec, M.D.</i> joined the Company in January 2021 as Chief Clinical Development Officer and has served as our Chief Medical Officer since December 2022. Dr. Kupiec joined the Company after three decades of drug development experience at Pfizer, Sanofi and Ciba-Geigy. Dr. Kupiec previously served as Vice President, Global Clinical Leader for Parkinson&#8217;s Disease and Clinical Head of the Neuroscience Research Unit for Pfizer, Inc., in Cambridge, MA. He joined Pfizer in 2000 after seven years with Sanofi, and two years with Ciba-Geigy Pharmaceuticals. During his 17-year career at Pfizer, Dr. Kupiec had extensive governance, business development, alliance and leadership responsibilities. Dr. Kupiec earned his BS with Honors in Biochemistry at Stony Brook University and his MD from the Albert Einstein College of Medicine. He completed his residency training at the Strong Memorial Hospital, University of Rochester School of Medicine, and is certified by the American Board of Internal Medicine. He served as an investigator on many clinical trials before transitioning to the pharmaceutical industry.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:14pt;">&#160;</p>
  <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 18pt;"><i>Eric Schoen</i> has served as Chief Financial Officer since 2018. Prior to joining the Company, Mr. Schoen served in numerous financial leadership roles. Most recently, he served as Vice President, Senior Vice President, Finance and Chief Accounting Officer of Aspira Women&#8217;s Health Inc. (formerly Vermillion, Inc.), a publicly-held women&#8217;s health company, from 2011 to 2017. Mr. Schoen also began his career and spent nine years with PricewaterhouseCoopers in the audit and assurance, transaction services and global capital markets practices. Mr. Schoen received his B.S. in Finance from Santa Clara University.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:14pt;">&#160;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
      116
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
  <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 18pt;"><i>Robert Anderson, Jr.</i>&#160;has served as a director since December 2023.&#160;Mr. Anderson has decades of operational experience in cybersecurity, counterintelligence, economic espionage and critical incident response and management. Mr. Anderson previously led more than 20,000 FBI employees as the bureau&#8217;s Executive Assistant Director of the Criminal, Cyber, Response and Services Branch&#8212; the No. 3 position in the organization. Mr. Anderson is currently Chairman of the Board and Chief Executive Officer of Cyber Defense Labs, an advisory firm focused on cybersecurity, where he has served as CEO since March 2019 and Chairman since January 2022. Mr. Anderson holds a Bachelor of Science and a Master in Public Administration from Wilmington University.</p>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
  <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 18pt;"><i>Pierre Gravier</i>&#160;has served as a director since December 2023. Since&#160;July 2023, Mr. Gravier has been the&#160;Chief Financial Officer of PTC Therapeutics, Inc., a publicly traded biotechnology company. From 2013 to July 2023, Mr. Gravier was previously Managing Director in the healthcare group of Perella Weinberg Partners, a leading global independent advisory firm that provides strategic, financial, and tactical advice in connection with executing mergers, acquisitions and other corporate&#160;strategies.&#160;Mr. Gravier holds a Master&#8217;s Degree in Finance from ESCP Business School and a Master of Science in Bioengineering from the University of Technology of Compi&#232;gne.</p>
  <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 18pt;">&#160;</p>
  <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 18pt;"><i>Robert Z. Gussin, Ph.D</i>. has served as a director since 2003. Dr. Gussin worked at Johnson &amp; Johnson for 26 years, most recently as Chief Scientific Officer and Corporate Vice President, Science and Technology from 1986 through his retirement in 2000. Dr. Gussin served on the board of directors of Duquesne University and the advisory boards of the Duquesne University Pharmacy School and the University of Michigan Medical School Department of Pharmacology. Dr. Gussin received his B.S. and M.S. degrees and D.Sc. with honors from Duquesne University and his Ph.D. in Pharmacology from the University of Michigan, Ann Arbor.</p>
  <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 18pt;">&#160;</p>
  <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 18pt;"><i>Claude Nicaise, M.D.</i>&#160;has served as a director since December 2023.&#160;Since June 2015, Dr. Nicaise has also served as a director of Sarepta Therapeutics, Inc., (Nasdaq: SRPT). Since January 2021, Dr. Nicaise has served as a member of the board of directors of Gain Therapeutics. Since March 2021, Dr. Nicaise has served as a member of the board of directors of Chemomab Therapeutics Ltd. Dr. Nicaise has held clinical/regulatory leadership roles that have resulted in 14 new drug approvals in various diseases areas, including neuroscience. Dr. Nicaise is the founder of Clinical Regulatory Services, a company providing advice on clinical and regulatory matters to biotechnology companies.&#160;Dr. Nicaise served&#160;as Executive Vice President, Regulatory and Head of Research and Development at Ovid Therapeutics Inc., a company that develops medicines for orphan diseases of the brain, from 2015 to&#160;2023.&#160;Dr. Nicaise was a Senior Vice President of Strategic Development and Global Regulatory Affairs at Alexion Pharmaceuticals from 2008 to 2014. From 1983 to 2008, Dr. Nicaise served in various positions of increasing responsibility at Bristol-Myers Squibb, including senior positions such as Vice President of Global Development and Vice-President of Worldwide Regulatory Science and Strategy.&#160;Dr. Nicaise received his M.D. from the Universit&#233; Libre de Bruxelles in Belgium.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:14pt;">&#160;</p>
  <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 18pt;"><i>Michael J. O</i>&#8217;<i>Donnell, Esq</i>. has served as a director since 1998. Mr. O&#8217;Donnell is employed at the law firm of Orrick Herrington Sutcliffe LLP since June 2021 with the title Senior Partner. Orrick, Herrington &amp; Sutcliffe LLP&#160;provides legal services to the Company. Previously, Mr. O&#8217;Donnell was a member of Morrison &amp; Foerster LLP from 2011 to 2021. Mr. O&#8217;Donnell serves as corporate counsel to numerous public and private biopharmaceutical and life sciences companies. Previously, Mr. O&#8217;Donnell was a member of Wilson Sonsini Goodrich &amp; Rosati. Mr. O&#8217;Donnell received his J.D., cum laude, from Harvard University and his B.A. from Bucknell University, summa cum laude.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:14pt;">&#160;</p>
  <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 18pt;"><i>Patrick J. Scannon, M.D., Ph.D.</i> has served as a director since 2007. Dr. Scannon is one of the founders of XOMA. From 2006 to 2016, Dr. Scannon was Executive Vice President, Chief Biotechnology Officer of XOMA. From 1993 to 2006, Dr. Scannon served as Chief Scientific and Medical Officer of XOMA.&#160;Dr. Scannon retired from XOMA and resigned from XOMA&#8217;s board of directors in 2016.&#160;Dr. Scannon received his Ph.D. in organic chemistry from the University of California, Berkeley and his M.D. from the Medical College of Georgia.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&#160;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
      117
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>Section 16(a) Beneficial Ownership Reporting Compliance</b></p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">Section 16(a) of the Exchange Act requires our executive officers and directors and persons who own more than ten percent (10%) of a registered class of our equity securities to file reports of ownership and changes in ownership with the SEC. Executive officers, directors and greater than ten percent (10%) stockholders are required to furnish us with copies of all Section 16(a) forms they file. We believe all of our executive officers and directors complied with all applicable filing requirements during 2024.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>Code of Ethics </b></p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">We have adopted a Code of Ethics that applies to all of our directors, officers and employees, including our principal executive officer and principal financial officer. We publicize the Code of Ethics through posting the policy on our website, <span style="text-decoration: underline; ">http://www.cassavasciences.com</span>. We will disclose on our website any waivers of, or amendments to, our Code of Ethics.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&#160;</p>
  <div>
   &#160;
  </div>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><a id="item11" title="item11" href="#"></a>Item 11.</b>&#160;&#160;&#160;&#160;<b><i>Executive Compensation</i></b></p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">The information required by this Item is incorporated by reference from our definitive Proxy Statement referred to in Item 10 above where it appears under the heading "Executive Compensation and Other Matters."</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&#160;</p>
  <div>
   &#160;
  </div>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><a id="item12" title="item12" href="#"></a>Item 12.</b><b><i> Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters</i></b></p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">The information required by this Item regarding security ownership of certain beneficial owners and management is incorporated by reference from our definitive Proxy Statement referred to in Item 10 above where it appears under the heading "Security Ownership of Certain Beneficial Owners and Management."</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">&#160;</p>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">The following table summarizes the securities authorized for issuance under our equity compensation plans as of&#160;December 31, 2024:</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;">
   <tbody>
    <tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom">
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 40%;">&#160;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td>
     <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 1%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Number of</b></p> </td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td>
     <td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td>
     <td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 16%;">&#160;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;"><b>&#160;</b></td>
     <td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td>
     <td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 16%;">&#160;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;"><b>&#160;</b></td>
     <td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td>
    </tr>

    <tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom">
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 40%;">&#160;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td>
     <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 1%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>&#8206;Securities to be</b></p> </td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td>
     <td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td>
     <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 1%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Weighted Average</b></p> </td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td>
     <td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td>
     <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 1%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Number of Securities</b></p> </td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td>
     <td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td>
    </tr>

    <tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom">
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 40%;">&#160;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td>
     <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 1%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>&#8206;Issued Upon</b></p> </td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td>
     <td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td>
     <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 1%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>&#8206;Exercise Price of</b></p> </td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td>
     <td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td>
     <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 1%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>&#8206;Remaining Available</b></p> </td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td>
     <td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td>
    </tr>

    <tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom">
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 40%;">&#160;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td>
     <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 1%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>&#8206;Exercise of</b></p> </td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td>
     <td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td>
     <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 1%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>&#8206;Outstanding</b></p> </td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td>
     <td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td>
     <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 1%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>&#8206;for Future Issuance</b></p> </td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td>
     <td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td>
    </tr>

    <tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom">
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 40%;">&#160;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td>
     <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 1%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>&#8206;Outstanding</b></p> </td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td>
     <td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td>
     <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 1%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>&#8206;Options,</b></p> </td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td>
     <td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td>
     <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 1%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>&#8206;Under Equity</b></p> </td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td>
     <td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td>
    </tr>

    <tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom">
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 40%;">&#160;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td>
     <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 1%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>&#8206;Options, Warrants</b></p> </td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td>
     <td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td>
     <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 1%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>&#8206;Warrants</b></p> </td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td>
     <td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td>
     <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 1%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>&#8206;Compensation</b></p> </td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td>
     <td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td>
    </tr>

    <tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom">
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 40%;">&#160;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td>
     <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>&#8206;and Rights</b></p> </td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; width: 1%;">&#160;</td>
     <td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td>
     <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>&#8206;and Rights</b></p> </td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; width: 1%;">&#160;</td>
     <td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td>
     <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>&#8206;Plans</b></p> </td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; width: 1%;">&#160;</td>
     <td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td>
    </tr>

    <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 40%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Equity compensation plans approved by stockholders</p> </td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">4,470,170</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;"> <p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">(1)</p> </td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
     <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">20.12</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;"> <p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">(2)</p> </td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">1,023,595</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;"> <p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">(3)</p> </td>
    </tr>

    <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 40%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Equity compensation plans not approved by stockholders</p> </td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
     <td style="width: 16%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;">&#8212;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
     <td style="width: 16%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;">&#8212;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
     <td style="width: 16%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;">&#8212;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td>
    </tr>

    <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 40%;">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td>
     <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">4,470,170</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td>
     <td style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
     <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">20.12</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td>
     <td style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td>
     <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">1,023,595</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td>
     <td style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">(1)</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: justify;">Includes outstanding stock options and awards for 753,725&#160;shares of our common stock under the 2008 Plan and 3,716,445</p> <p style="margin: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: justify;">&#160;shares of our common stock under the 2018 Plan.</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">(2)</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: justify;">Includes the weighted average stock price for outstanding stock options of $6.17&#160;under the 2008 Plan and $22.96&#160;for the 2018 Plan.</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">(3)</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: justify;">Represents 965,578&#160;shares of our common stock for the 2018 Plan and 58,017 for the Employee Stock Purchase Plan. No future awards shall occur under the 2008 Plan.</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&#160;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
      118
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><a id="item13" title="item13" href="#"></a>Item 13.</b>&#160;&#160;&#160;&#160;<b><i>Certain Relationships and Related Transactions and Director Independence</i></b></p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">The information required by this Item is incorporated by reference from our definitive Proxy Statement referred to in Item 10 above where it appears under the heading "Certain Relationships and Related Transactions."</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><a id="itme14" title="itme14" href="#"></a>Item 14.</b>&#160;&#160;&#160;&#160;<b><i>Principal Accountant Fees and Services</i></b></p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">The information required by this Item is incorporated by reference from our definitive Proxy Statement referred to in Item 10 above where it appears under the heading &#8220;Principal Accountant Fees and Services.&#8221;</p>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>PART IV</b></p>
  <div>
   &#160;
  </div>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><a id="item15" title="item15" href="#"></a>Item 15.</b>&#160;&#160;&#160;&#160;<b><i>Exhibits and Financial Statement Schedules</i></b></p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 16pt;text-indent:-16pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 16pt;text-indent:-16pt;">(a) The following documents are filed as part of this Form 10-K:</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(1)<i> </i></p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><i>Consolidated Financial Statements (included in Part II of this report):</i></p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Report of Independent Registered Public Accounting Firm</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Consolidated Balance Sheets</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Consolidated Statements of Operations</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Consolidated Statements of Stockholders' Equity</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Consolidated Statements of Cash Flows</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Notes to Consolidated Financial Statements</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(2)<i> </i></p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><i>Consolidated Financial Statement Schedules:</i></p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">All consolidated financial statement schedules are omitted because the information is inapplicable or presented in the notes to the consolidated financial statements.</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(3)</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><i>Management Contracts, Compensatory Plans and Arrangements</i>.</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Management contracts, compensatory plans and arrangements are indicated by the symbol &#8220;*&#8221; in the applicable exhibits listed in Item 15(b), below.</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 16pt;text-indent:-16pt;">&#160;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
      119
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 16pt;text-indent:-16pt;">(b) <i>Exhibits </i></p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">The exhibits listed below are filed as part of this Form 10-K other than Exhibit 32.1, which shall be deemed furnished.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="font-family: Times New Roman; font-size: 10pt; width: 100%;">
   <tbody>
    <tr>
     <td style="vertical-align: bottom; width: 8%;">&#160;</td>
     <td style="vertical-align: top; width: 1%;">&#160;</td>
     <td style="vertical-align: bottom; width: 52%;">&#160;</td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td colspan="5" style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 22%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Incorporated by Reference</b></p> </td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: bottom; width: 8%;">&#160;</td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 8%; text-align: center; border-bottom: 1px solid black;"><b>Exhibit</b><br/> &#8206;<b>No.</b></td>
     <td style="vertical-align: top; width: 1%;">&#160;</td>
     <td style="vertical-align: bottom; width: 52%; border-bottom: 1px solid black;"><b>Description</b></td>
     <td style="vertical-align: bottom; width: 1%; border-bottom: 1px solid black;">&#160;</td>
     <td style="vertical-align: bottom; width: 5%; text-align: center; border-bottom: 1px solid black;"><b>Form</b></td>
     <td style="vertical-align: top; width: 1%; border-bottom: 1px solid black;">&#160;</td>
     <td style="vertical-align: bottom; width: 15%; text-align: center; border-bottom: 1px solid black;"><b>Filing</b><br/> &#8206;<b>Date</b></td>
     <td style="vertical-align: top; width: 1%; border-bottom: 1px solid black;">&#160;</td>
     <td style="vertical-align: bottom; width: 7%; text-align: center; border-bottom: 1px solid black;"><b>Exhibit</b><br/> &#8206;<b>No.</b></td>
     <td style="vertical-align: top; width: 1%; border-bottom: 1px solid black;">&#160;</td>
     <td style="vertical-align: bottom; width: 8%; text-align: center; border-bottom: 1px solid black;"><b>Filed</b><br/> &#8206;<b>Herewith</b></td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 8%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1069530/000119312505152582/dex31.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">3.1</span></a></p> </td>
     <td style="vertical-align: top; width: 1%;">&#160;</td>
     <td style="vertical-align: top; width: 52%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1069530/000119312505152582/dex31.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">Amended and Restated Certificate of Incorporation.</span></a></p> </td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: top; width: 5%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">10-Q</p> </td>
     <td style="vertical-align: top; width: 1%;">&#160;</td>
     <td style="vertical-align: top; width: 15%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">7/29/2005</p> </td>
     <td style="vertical-align: top; width: 1%;">&#160;</td>
     <td style="vertical-align: top; width: 7%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">3.1</p> </td>
     <td style="vertical-align: top; width: 1%;">&#160;</td>
     <td style="vertical-align: top; width: 8%;">&#160;</td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 8%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1069530/000106953017000028/ptie-20170508xex3_1.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">3.2</span></a></p> </td>
     <td style="vertical-align: top; width: 1%;">&#160;</td>
     <td style="vertical-align: top; width: 52%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1069530/000106953017000028/ptie-20170508xex3_1.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">Certificate of Amendment of Restated Certificate of Incorporation.</span></a></p> </td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: top; width: 5%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">8-K</p> </td>
     <td style="vertical-align: top; width: 1%;">&#160;</td>
     <td style="vertical-align: top; width: 15%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">5/8/2017</p> </td>
     <td style="vertical-align: top; width: 1%;">&#160;</td>
     <td style="vertical-align: top; width: 7%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">3.1</p> </td>
     <td style="vertical-align: top; width: 1%;">&#160;</td>
     <td style="vertical-align: top; width: 8%;">&#160;</td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 8%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1069530/000106953019000019/sava-20181231xex3_3.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">3.3</span></a></p> </td>
     <td style="vertical-align: top; width: 1%;">&#160;</td>
     <td style="vertical-align: top; width: 52%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1069530/000106953019000019/sava-20181231xex3_3.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">Certificate of Amendment of Restated Certificate of Incorporation.</span></a></p> </td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: top; width: 5%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">10-K</p> </td>
     <td style="vertical-align: top; width: 1%;">&#160;</td>
     <td style="vertical-align: top; width: 15%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">3/29/2019</p> </td>
     <td style="vertical-align: top; width: 1%;">&#160;</td>
     <td style="vertical-align: top; width: 7%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">3.3</p> </td>
     <td style="vertical-align: top; width: 1%;">&#160;</td>
     <td style="vertical-align: top; width: 8%;">&#160;</td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 8%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1069530/000106953023000047/sava-20230908xex3_4.htm" style="-sec-extract:exhibit;">3.4</a></p> </td>
     <td style="vertical-align: top; width: 1%;">&#160;</td>
     <td style="vertical-align: top; width: 52%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1069530/000106953023000047/sava-20230908xex3_4.htm" style="-sec-extract:exhibit;">Amended and Restated Bylaws of Cassava Sciences, Inc.</a></p> </td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: top; width: 5%; text-align: center;">8-K</td>
     <td style="vertical-align: top; width: 1%;">&#160;</td>
     <td style="vertical-align: top; width: 15%; text-align: center;">9/13/23</td>
     <td style="vertical-align: top; width: 1%;">&#160;</td>
     <td style="vertical-align: top; width: 7%; text-align: center;">3.4</td>
     <td style="vertical-align: top; width: 1%;">&#160;</td>
     <td style="vertical-align: top; width: 8%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">&#160;</p> </td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 8%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1069530/000106953019000032/sava-20190630xex4_1.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">4.1</span></a></p> </td>
     <td style="vertical-align: top; width: 1%;">&#160;</td>
     <td style="vertical-align: top; width: 52%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1069530/000106953019000032/sava-20190630xex4_1.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">Specimen Common Stock Certificate.</span></a></p> </td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: top; width: 5%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">10-Q</p> </td>
     <td style="vertical-align: top; width: 1%;">&#160;</td>
     <td style="vertical-align: top; width: 15%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">8/12/2019</p> </td>
     <td style="vertical-align: top; width: 1%;">&#160;</td>
     <td style="vertical-align: top; width: 7%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">4.1</p> </td>
     <td style="vertical-align: top; width: 1%;">&#160;</td>
     <td style="vertical-align: top; width: 8%;">&#160;</td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 8%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><a href="ex_756945.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">4.2</span></a></p> </td>
     <td style="vertical-align: top; width: 1%;">&#160;</td>
     <td style="vertical-align: top; width: 52%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><a href="ex_756945.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">Description of Registrant&#8217;s Securities.</span></a></p> </td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: top; width: 5%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">&#160;</p> </td>
     <td style="vertical-align: top; width: 1%;">&#160;</td>
     <td style="vertical-align: top; width: 15%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">&#160;</p> </td>
     <td style="vertical-align: top; width: 1%;">&#160;</td>
     <td style="vertical-align: top; width: 7%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">&#160;</p> </td>
     <td style="vertical-align: top; width: 1%;">&#160;</td>
     <td style="vertical-align: top; width: 8%; text-align: center;">X</td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 8%; text-align: center;"><a href="http://www.sec.gov/Archives/edgar/data/1069530/000149315224000209/ex4-1.htm" style="-sec-extract:exhibit;">4.3</a></td>
     <td style="vertical-align: top; width: 1%;">&#160;</td>
     <td style="vertical-align: top; width: 52%;"><a href="http://www.sec.gov/Archives/edgar/data/1069530/000149315224000209/ex4-1.htm" style="-sec-extract:exhibit;">Warrant Agreement (including Form of Warrant), dated January 3, 2024, between the Company, Computershare Inc., a Delaware corporation, and Computershare Trust Company, N.A., as Warrant Agent.</a></td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: top; width: 5%; text-align: center;">8-K</td>
     <td style="vertical-align: top; width: 1%; text-align: center;">&#160;</td>
     <td style="vertical-align: top; width: 15%; text-align: center;">1/3/24</td>
     <td style="vertical-align: top; width: 1%; text-align: center;">&#160;</td>
     <td style="vertical-align: top; width: 7%; text-align: center;">4.1</td>
     <td style="vertical-align: top; width: 1%;">&#160;</td>
     <td style="vertical-align: top; width: 8%;">&#160;</td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 8%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1069530/000106953022000011/sava-20211231xex10_1.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">10.1</span></a></p> </td>
     <td style="vertical-align: top; width: 1%;">&#160;</td>
     <td style="vertical-align: top; width: 52%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1069530/000106953022000011/sava-20211231xex10_1.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">Form of Indemnification Agreement between Registrant and each of its directors and officers.</span></a></p> </td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: top; width: 5%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">10-K</p> </td>
     <td style="vertical-align: top; width: 1%;">&#160;</td>
     <td style="vertical-align: top; width: 15%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">3/1/2022</p> </td>
     <td style="vertical-align: top; width: 1%;">&#160;</td>
     <td style="vertical-align: top; width: 7%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">10.1</p> </td>
     <td style="vertical-align: top; width: 1%;">&#160;</td>
     <td style="vertical-align: top; width: 8%;">&#160;</td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 8%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1069530/000119312509027574/dex1012.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">10.5</span></a>*</p> </td>
     <td style="vertical-align: top; width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&#160;</p> </td>
     <td style="vertical-align: top; width: 52%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1069530/000119312509027574/dex1012.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">Employment Agreement, dated July&#160;</span><span style="text-decoration: underline; ">1, 1998 and amended December</span><span style="text-decoration: underline; ">&#160;</span><span style="text-decoration: underline; ">17, 2008, between Registrant and Remi Barbier.</span></a></p> </td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: top; width: 5%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">10-K</p> </td>
     <td style="vertical-align: top; width: 1%;">&#160;</td>
     <td style="vertical-align: top; width: 15%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">2/13/2009</p> </td>
     <td style="vertical-align: top; width: 1%;">&#160;</td>
     <td style="vertical-align: top; width: 7%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">10.12</p> </td>
     <td style="vertical-align: top; width: 1%;">&#160;</td>
     <td style="vertical-align: top; width: 8%;">&#160;</td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 8%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1069530/000119312510170701/dex101.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">10.6</span></a>*</p> </td>
     <td style="vertical-align: top; width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&#160;</p> </td>
     <td style="vertical-align: top; width: 52%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1069530/000119312510170701/dex101.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">2000 Employee Stock Purchase Plan, as amended and restated.</span></a></p> </td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: top; width: 5%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">10-Q</p> </td>
     <td style="vertical-align: top; width: 1%;">&#160;</td>
     <td style="vertical-align: top; width: 15%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">7/29/2010</p> </td>
     <td style="vertical-align: top; width: 1%;">&#160;</td>
     <td style="vertical-align: top; width: 7%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">10.1</p> </td>
     <td style="vertical-align: top; width: 1%;">&#160;</td>
     <td style="vertical-align: top; width: 8%;">&#160;</td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 8%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1069530/000119312508124661/dex101.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">10.7</span></a>*</p> </td>
     <td style="vertical-align: top; width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&#160;</p> </td>
     <td style="vertical-align: top; width: 52%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1069530/000119312508124661/dex101.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">2008 Equity Incentive Plan.</span></a></p> </td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: top; width: 5%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">8-K</p> </td>
     <td style="vertical-align: top; width: 1%;">&#160;</td>
     <td style="vertical-align: top; width: 15%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">5/29/2008</p> </td>
     <td style="vertical-align: top; width: 1%;">&#160;</td>
     <td style="vertical-align: top; width: 7%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">10.1</p> </td>
     <td style="vertical-align: top; width: 1%;">&#160;</td>
     <td style="vertical-align: top; width: 8%;">&#160;</td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 8%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1069530/000119312513315094/d547249dex101.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">10.8</span></a>*</p> </td>
     <td style="vertical-align: top; width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&#160;</p> </td>
     <td style="vertical-align: top; width: 52%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1069530/000119312513315094/d547249dex101.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">Amendment Number 1 to the 2008 Equity Incentive Plan.</span></a></p> </td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: top; width: 5%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">10-Q</p> </td>
     <td style="vertical-align: top; width: 1%;">&#160;</td>
     <td style="vertical-align: top; width: 15%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">8/1/2013</p> </td>
     <td style="vertical-align: top; width: 1%;">&#160;</td>
     <td style="vertical-align: top; width: 7%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">10.1</p> </td>
     <td style="vertical-align: top; width: 1%;">&#160;</td>
     <td style="vertical-align: top; width: 8%;">&#160;</td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 8%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1069530/000119312513315094/d547249dex102.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">10.9</span></a>*</p> </td>
     <td style="vertical-align: top; width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&#160;</p> </td>
     <td style="vertical-align: top; width: 52%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1069530/000119312513315094/d547249dex102.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">Amendment No. 2 to Employment Agreement between Registrant and Remi Barbier.</span></a></p> </td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: top; width: 5%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">10-Q</p> </td>
     <td style="vertical-align: top; width: 1%;">&#160;</td>
     <td style="vertical-align: top; width: 15%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">8/1/2013</p> </td>
     <td style="vertical-align: top; width: 1%;">&#160;</td>
     <td style="vertical-align: top; width: 7%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">10.2</p> </td>
     <td style="vertical-align: top; width: 1%;">&#160;</td>
     <td style="vertical-align: top; width: 8%;">&#160;</td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 8%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1069530/000106953018000025/ptie-20180511xex10_1.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">10.10</span></a>*</p> </td>
     <td style="vertical-align: top; width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&#160;</p> </td>
     <td style="vertical-align: top; width: 52%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1069530/000106953018000025/ptie-20180511xex10_1.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">2018 Omnibus Incentive Plan.</span></a></p> </td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: top; width: 5%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">8-K</p> </td>
     <td style="vertical-align: top; width: 1%;">&#160;</td>
     <td style="vertical-align: top; width: 15%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">5/11/2018</p> </td>
     <td style="vertical-align: top; width: 1%;">&#160;</td>
     <td style="vertical-align: top; width: 7%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">10.1</p> </td>
     <td style="vertical-align: top; width: 1%;">&#160;</td>
     <td style="vertical-align: middle; width: 8%;">&#160;</td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 8%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1069530/000149315223015041/ex1-1.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">10.11</span></a></p> </td>
     <td style="vertical-align: top; width: 1%;">&#160;</td>
     <td style="vertical-align: top; width: 52%;"><a href="http://www.sec.gov/Archives/edgar/data/1069530/000149315223015041/ex1-1.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">Capital On Demand<sup style="vertical-align:top;line-height:120%;">TM</sup>&#160;Sales Agreement, dated as of May 1, 2023, between Cassava Sciences, Inc. and JonesTrading Institutional Services LLC</span></a></td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: top; width: 5%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">8-K</p> </td>
     <td style="vertical-align: top; width: 1%;">&#160;</td>
     <td style="vertical-align: top; width: 15%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">5/1/2023</p> </td>
     <td style="vertical-align: top; width: 1%;">&#160;</td>
     <td style="vertical-align: top; width: 7%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">1.1</p> </td>
     <td style="vertical-align: top; width: 1%;">&#160;</td>
     <td style="vertical-align: middle; width: 8%;">&#160;</td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 8%; text-indent: 0pt; text-align: center;"><a href="http://www.sec.gov/Archives/edgar/data/0001069530/000106953023000039/sava-20230630xex10_2.htm" style="-sec-extract:exhibit;">10.12</a>*</td>
     <td style="vertical-align: top; width: 1%;">&#160;</td>
     <td style="vertical-align: top; width: 52%;"><a href="http://www.sec.gov/Archives/edgar/data/0001069530/000106953023000039/sava-20230630xex10_2.htm" style="-sec-extract:exhibit;">Cassava Sciences, Inc. 2020 Cash Incentive Bonus Plan (As Amended March 16, 2023)</a></td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: top; width: 5%; text-align: center;">10-Q</td>
     <td style="vertical-align: top; width: 1%;">&#160;</td>
     <td style="vertical-align: top; width: 15%; text-align: center;">8/3/2023</td>
     <td style="vertical-align: top; width: 1%;">&#160;</td>
     <td style="vertical-align: top; width: 7%; text-align: center;">10.2</td>
     <td style="vertical-align: top; width: 1%;">&#160;</td>
     <td style="vertical-align: middle; width: 8%;">&#160;</td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 8%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1069530/000106953018000058/ptie-20181011xex10_1.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">10.13</span></a>*</p> </td>
     <td style="vertical-align: top; width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&#160;</p> </td>
     <td style="vertical-align: top; width: 52%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1069530/000106953018000058/ptie-20181011xex10_1.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">Employment Agreement, executed on October&#160;</span><span style="text-decoration: underline; ">9, 2018, by and between Registrant and Eric Schoen.</span></a></p> </td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: top; width: 5%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">8-K</p> </td>
     <td style="vertical-align: top; width: 1%;">&#160;</td>
     <td style="vertical-align: top; width: 15%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">10/11/2018</p> </td>
     <td style="vertical-align: top; width: 1%;">&#160;</td>
     <td style="vertical-align: top; width: 7%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">10.1</p> </td>
     <td style="vertical-align: top; width: 1%;">&#160;</td>
     <td style="vertical-align: middle; width: 8%;">&#160;</td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 8%; text-align: center;"><a href="http://www.sec.gov/Archives/edgar/data/0001069530/000143774924018029/ex_678411.htm" style="-sec-extract:exhibit;">10.14</a>*</td>
     <td style="vertical-align: top; width: 1%;">&#160;</td>
     <td style="vertical-align: top; width: 52%;"><a href="http://www.sec.gov/Archives/edgar/data/0001069530/000143774924018029/ex_678411.htm" style="-sec-extract:exhibit;">Employment agreement amendment, dated May 20, 2024, by and between Cassava Sciences, Inc. and Eric J. Schoen</a></td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: top; width: 5%; text-align: center;">8-K</td>
     <td style="vertical-align: top; width: 1%;">&#160;</td>
     <td style="vertical-align: top; width: 15%; text-align: center;">5/22/2024</td>
     <td style="vertical-align: top; width: 1%;">&#160;</td>
     <td style="vertical-align: top; width: 7%; text-align: center;">10.1</td>
     <td style="vertical-align: top; width: 1%;">&#160;</td>
     <td style="vertical-align: middle; width: 8%;">&#160;</td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 8%; text-align: center;"><a href="http://www.sec.gov/Archives/edgar/data/0001069530/000143774924029380/ex_724740.htm" style="-sec-extract:exhibit;">10.15</a>*</td>
     <td style="vertical-align: top; width: 1%;">&#160;</td>
     <td style="vertical-align: top; width: 52%;"><a href="http://www.sec.gov/Archives/edgar/data/0001069530/000143774924029380/ex_724740.htm" style="-sec-extract:exhibit;">Remi Barbier Consulting Agreement, dated September 13, 2024</a></td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: top; width: 5%; text-align: center;">8-K</td>
     <td style="vertical-align: top; width: 1%;">&#160;</td>
     <td style="vertical-align: top; width: 15%; text-align: center;">9/17/2024</td>
     <td style="vertical-align: top; width: 1%;">&#160;</td>
     <td style="vertical-align: top; width: 7%; text-align: center;">10.1</td>
     <td style="vertical-align: top; width: 1%;">&#160;</td>
     <td style="vertical-align: middle; width: 8%;">&#160;</td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 8%; text-align: center;"><a href="http://www.sec.gov/Archives/edgar/data/0001069530/000143774924030345/ex_728679.htm" style="-sec-extract:exhibit;">10.16</a>*</td>
     <td style="vertical-align: top; width: 1%;">&#160;</td>
     <td style="vertical-align: top; width: 52%;"><a href="http://www.sec.gov/Archives/edgar/data/0001069530/000143774924030345/ex_728679.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">Employment agreement, dated October 1, 2024, by and between Cassava Sciences, Inc. and Richard J. Barry</span></a></td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: top; width: 5%; text-align: center;">8-K</td>
     <td style="vertical-align: top; width: 1%;">&#160;</td>
     <td style="vertical-align: top; width: 15%; text-align: center;">10/1/2024</td>
     <td style="vertical-align: top; width: 1%;">&#160;</td>
     <td style="vertical-align: top; width: 7%; text-align: center;">10.1</td>
     <td style="vertical-align: top; width: 1%;">&#160;</td>
     <td style="vertical-align: middle; width: 8%;">&#160;</td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 8%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1069530/000106953021000002/sava-20210106xex10_1.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">10.17*</span></a></p> </td>
     <td style="vertical-align: top; width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&#160;</p> </td>
     <td style="vertical-align: top; width: 52%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1069530/000106953021000002/sava-20210106xex10_1.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">Employment Agreement, executed on January&#160;</span><span style="text-decoration: underline; ">1, 2021, by and between Registrant and Dr. James Kupiec.</span></a></p> </td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: top; width: 5%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">8-K</p> </td>
     <td style="vertical-align: top; width: 1%;">&#160;</td>
     <td style="vertical-align: top; width: 15%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">1/6/2021</p> </td>
     <td style="vertical-align: top; width: 1%;">&#160;</td>
     <td style="vertical-align: top; width: 7%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">10.1</p> </td>
     <td style="vertical-align: top; width: 1%;">&#160;</td>
     <td style="vertical-align: middle; width: 8%;">&#160;</td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 8%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1069530/000106953021000011/sava-20210311xex10_1.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">10.18</span></a>+</p> </td>
     <td style="vertical-align: top; width: 1%;">&#160;</td>
     <td style="vertical-align: top; width: 52%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1069530/000106953021000011/sava-20210311xex10_1.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">Master Services Agreement between Cassava Sciences, Inc. and Evonik Corporation, dated February 22, 2021.</span></a></p> </td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: top; width: 5%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">8-K</p> </td>
     <td style="vertical-align: top; width: 1%;">&#160;</td>
     <td style="vertical-align: top; width: 15%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">3/11/2021</p> </td>
     <td style="vertical-align: top; width: 1%;">&#160;</td>
     <td style="vertical-align: top; width: 7%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">10.1</p> </td>
     <td style="vertical-align: top; width: 1%;">&#160;</td>
     <td style="vertical-align: middle; width: 8%;">&#160;</td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 8%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1069530/000106953021000045/sava-20210630xex10_3.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">10.19</span></a>+</p> </td>
     <td style="vertical-align: top; width: 1%;">&#160;</td>
     <td style="vertical-align: top; width: 52%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1069530/000106953021000045/sava-20210630xex10_3.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">Master Services Agreement between Cassava Sciences, Inc. and Premier Research International LLC, dated June 11, 2021</span></a></p> </td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: top; width: 5%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">10-Q</p> </td>
     <td style="vertical-align: top; width: 1%;">&#160;</td>
     <td style="vertical-align: top; width: 15%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">8/4/2021</p> </td>
     <td style="vertical-align: top; width: 1%;">&#160;</td>
     <td style="vertical-align: top; width: 7%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">10.3</p> </td>
     <td style="vertical-align: top; width: 1%;">&#160;</td>
     <td style="vertical-align: middle; width: 8%;">&#160;</td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">&#160;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
      120
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">
   <tbody>
    <tr>
     <td style="vertical-align: top; width: 8%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1069530/000106953021000050/sava-20210930xex10_4.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">10.20</span></a>+</p> </td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: top; width: 52%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1069530/000106953021000050/sava-20210930xex10_4.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">Agreement of Sale and Purchase Between DWF IV Lakewood, LP and Cassava Sciences, Inc. dated July 2, 2021</span></a></p> </td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: top; width: 5%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">10-Q</p> </td>
     <td style="vertical-align: top; width: 1%;">&#160;</td>
     <td style="vertical-align: top; width: 15%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">11/15/2021</p> </td>
     <td style="vertical-align: top; width: 1%;">&#160;</td>
     <td style="vertical-align: top; width: 7%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">10.4</p> </td>
     <td style="vertical-align: top; width: 1%;">&#160;</td>
     <td style="vertical-align: middle; width: 8%;">&#160;</td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 8%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1069530/000106953022000033/sava-20220630xex10_1.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">10.21</span></a>*</p> </td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: top; width: 52%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1069530/000106953022000033/sava-20220630xex10_1.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">Amendment 1 to 2018 Omnibus Incentive Plan</span></a></p> </td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: top; width: 5%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">10-Q</p> </td>
     <td style="vertical-align: top; width: 1%;">&#160;</td>
     <td style="vertical-align: top; width: 15%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">8/4/2022</p> </td>
     <td style="vertical-align: top; width: 1%;">&#160;</td>
     <td style="vertical-align: top; width: 7%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">10.1</p> </td>
     <td style="vertical-align: top; width: 1%;">&#160;</td>
     <td style="vertical-align: top; width: 8%;">&#160;</td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 8%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1069530/000106953022000051/sava-20221013xex10_1.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">10.22</span></a>*</p> </td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: top; width: 52%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1069530/000106953022000051/sava-20221013xex10_1.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">Employment Agreement, executed on October 13, 2022, by and between Registrant and R. Christopher Cook</span></a></p> </td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: top; width: 5%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">8-K</p> </td>
     <td style="vertical-align: top; width: 1%;">&#160;</td>
     <td style="vertical-align: top; width: 15%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">10/27/2022</p> </td>
     <td style="vertical-align: top; width: 1%;">&#160;</td>
     <td style="vertical-align: top; width: 7%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">10.1</p> </td>
     <td style="vertical-align: top; width: 1%;">&#160;</td>
     <td style="vertical-align: top; width: 8%;">&#160;</td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 8%; text-align: center;"><a href="http://www.sec.gov/Archives/edgar/data/1069530/000106953023000039/sava-20230630xex10_3.htm" style="-sec-extract:exhibit;">10.23</a>*</td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: top; width: 52%;"><a href="http://www.sec.gov/Archives/edgar/data/1069530/000106953023000039/sava-20230630xex10_3.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">Cassava Sciences Non-Employee Director Compensation Plan</span></a></td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: top; width: 5%; text-align: center;">10-Q</td>
     <td style="vertical-align: top; width: 1%;">&#160;</td>
     <td style="vertical-align: top; width: 15%; text-align: center;">8/3/2023</td>
     <td style="vertical-align: top; width: 1%;">&#160;</td>
     <td style="vertical-align: top; width: 7%; text-align: center;">10.3</td>
     <td style="vertical-align: top; width: 1%;">&#160;</td>
     <td style="vertical-align: top; width: 8%;">&#160;</td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 8%; text-align: center;"><a href="ex_771827.htm" style="-sec-extract:exhibit;">10.24</a>*</td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: top; width: 52%;"><a href="ex_771827.htm" style="-sec-extract:exhibit;">Employment Agreement, executed on November 18, 2024, by and between Registrant and Freda Nassif</a></td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: top; width: 5%;">&#160;</td>
     <td style="vertical-align: top; width: 1%;">&#160;</td>
     <td style="vertical-align: top; width: 15%;">&#160;</td>
     <td style="vertical-align: top; width: 1%;">&#160;</td>
     <td style="vertical-align: top; width: 7%;">&#160;</td>
     <td style="vertical-align: top; width: 1%;">&#160;</td>
     <td style="vertical-align: middle; width: 8%; text-align: center;">X</td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 8%; text-align: center;"><a href="http://www.sec.gov/Archives/edgar/data/1069530/000143774925005338/ex_781585.htm" style="-sec-extract:exhibit;">10.25</a>+</td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: top; width: 52%;"><a href="http://www.sec.gov/Archives/edgar/data/1069530/000143774925005338/ex_781585.htm" style="-sec-extract:exhibit;">License Agreement, dated February 26, 2025, by and between Cassava Sciences, Inc. and Yale University</a></td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: top; width: 5%; text-align: center;">8-K</td>
     <td style="vertical-align: top; width: 1%;">&#160;</td>
     <td style="vertical-align: top; width: 15%; text-align: center;">2/27/2025</td>
     <td style="vertical-align: top; width: 1%;">&#160;</td>
     <td style="vertical-align: top; width: 7%; text-align: center;">10.1</td>
     <td style="vertical-align: top; width: 1%;">&#160;</td>
     <td style="vertical-align: middle; width: 8%; text-align: center;">&#160;</td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 8%; text-align: center;"><a href="ex_771826.htm" style="-sec-extract:exhibit;">19.1</a></td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: top; width: 52%;"><a href="ex_771826.htm" style="-sec-extract:exhibit;">Insider Trading Policy</a></td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: top; width: 5%;">&#160;</td>
     <td style="vertical-align: top; width: 1%;">&#160;</td>
     <td style="vertical-align: top; width: 15%;">&#160;</td>
     <td style="vertical-align: top; width: 1%;">&#160;</td>
     <td style="vertical-align: top; width: 7%;">&#160;</td>
     <td style="vertical-align: top; width: 1%;">&#160;</td>
     <td style="vertical-align: middle; width: 8%; text-align: center;">X</td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 8%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><a href="ex_756946.htm" style="-sec-extract:exhibit;">21.1</a></p> </td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: top; width: 52%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><a href="ex_756946.htm" style="-sec-extract:exhibit;">Subsidiaries of the Registrant.</a></p> </td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: top; width: 5%;">&#160;</td>
     <td style="vertical-align: top; width: 1%;">&#160;</td>
     <td style="vertical-align: top; width: 15%;">&#160;</td>
     <td style="vertical-align: top; width: 1%;">&#160;</td>
     <td style="vertical-align: top; width: 7%;">&#160;</td>
     <td style="vertical-align: top; width: 1%;">&#160;</td>
     <td style="vertical-align: middle; width: 8%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">X</p> </td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 8%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><a href="ex_756947.htm" style="-sec-extract:exhibit;">23.1</a></p> </td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: top; width: 52%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><a href="ex_756947.htm" style="-sec-extract:exhibit;">Consent of Independent Registered Public Accounting Firm.</a></p> </td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: top; width: 5%;">&#160;</td>
     <td style="vertical-align: top; width: 1%;">&#160;</td>
     <td style="vertical-align: top; width: 15%;">&#160;</td>
     <td style="vertical-align: top; width: 1%;">&#160;</td>
     <td style="vertical-align: top; width: 7%;">&#160;</td>
     <td style="vertical-align: top; width: 1%;">&#160;</td>
     <td style="vertical-align: middle; width: 8%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">X</p> </td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 8%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><a href="ex_756948.htm" style="-sec-extract:exhibit;">31.1</a></p> </td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: top; width: 52%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><a href="ex_756948.htm" style="-sec-extract:exhibit;">Certification of Principal Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.&#160;</a></p> </td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: top; width: 5%;">&#160;</td>
     <td style="vertical-align: top; width: 1%;">&#160;</td>
     <td style="vertical-align: top; width: 15%;">&#160;</td>
     <td style="vertical-align: top; width: 1%;">&#160;</td>
     <td style="vertical-align: top; width: 7%;">&#160;</td>
     <td style="vertical-align: top; width: 1%;">&#160;</td>
     <td style="vertical-align: middle; width: 8%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">X</p> </td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 8%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><a href="ex_756949.htm" style="-sec-extract:exhibit;">31.2</a></p> </td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: top; width: 52%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><a href="ex_756949.htm" style="-sec-extract:exhibit;">Certification of Principal Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.&#160;</a></p> </td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: top; width: 5%;">&#160;</td>
     <td style="vertical-align: top; width: 1%;">&#160;</td>
     <td style="vertical-align: top; width: 15%;">&#160;</td>
     <td style="vertical-align: top; width: 1%;">&#160;</td>
     <td style="vertical-align: top; width: 7%;">&#160;</td>
     <td style="vertical-align: top; width: 1%;">&#160;</td>
     <td style="vertical-align: middle; width: 8%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">X</p> </td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 8%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><a href="ex_756950.htm" style="-sec-extract:exhibit;">32.1</a></p> </td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: top; width: 52%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><a href="ex_756950.htm" style="-sec-extract:exhibit;">Certifications of the Chief Executive Officer and the Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</a></p> </td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: top; width: 5%;">&#160;</td>
     <td style="vertical-align: top; width: 1%;">&#160;</td>
     <td style="vertical-align: top; width: 15%;">&#160;</td>
     <td style="vertical-align: top; width: 1%;">&#160;</td>
     <td style="vertical-align: top; width: 7%;">&#160;</td>
     <td style="vertical-align: top; width: 1%;">&#160;</td>
     <td style="vertical-align: middle; width: 8%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">X</p> </td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 8%; text-align: center;"><a href="ex_756951.htm" style="-sec-extract:exhibit;">97</a></td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: top; width: 52%;"><a href="ex_756951.htm" style="-sec-extract:exhibit;">Policy Regarding Recovery of Erroneously Awarded Compensation</a></td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: top; width: 5%;">&#160;</td>
     <td style="vertical-align: top; width: 1%;">&#160;</td>
     <td style="vertical-align: top; width: 15%;">&#160;</td>
     <td style="vertical-align: top; width: 1%;">&#160;</td>
     <td style="vertical-align: top; width: 7%;">&#160;</td>
     <td style="vertical-align: top; width: 1%;">&#160;</td>
     <td style="vertical-align: middle; width: 8%; text-align: center;">X</td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 8%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">101.INS</p> </td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: top; width: 52%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Inline XBRL Instance Document.</p> </td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: top; width: 5%;">&#160;</td>
     <td style="vertical-align: top; width: 1%;">&#160;</td>
     <td style="vertical-align: top; width: 15%;">&#160;</td>
     <td style="vertical-align: top; width: 1%;">&#160;</td>
     <td style="vertical-align: top; width: 7%;">&#160;</td>
     <td style="vertical-align: top; width: 1%;">&#160;</td>
     <td style="vertical-align: middle; width: 8%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">X</p> </td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 8%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">101.SCH</p> </td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: top; width: 52%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Inline XBRL Taxonomy Extension Schema Document.</p> </td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: top; width: 5%;">&#160;</td>
     <td style="vertical-align: top; width: 1%;">&#160;</td>
     <td style="vertical-align: top; width: 15%;">&#160;</td>
     <td style="vertical-align: top; width: 1%;">&#160;</td>
     <td style="vertical-align: top; width: 7%;">&#160;</td>
     <td style="vertical-align: top; width: 1%;">&#160;</td>
     <td style="vertical-align: middle; width: 8%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">X</p> </td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 8%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">101.CAL</p> </td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: top; width: 52%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Inline XBRL Taxonomy Extension Calculation Linkbase Document.</p> </td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: top; width: 5%;">&#160;</td>
     <td style="vertical-align: top; width: 1%;">&#160;</td>
     <td style="vertical-align: top; width: 15%;">&#160;</td>
     <td style="vertical-align: top; width: 1%;">&#160;</td>
     <td style="vertical-align: top; width: 7%;">&#160;</td>
     <td style="vertical-align: top; width: 1%;">&#160;</td>
     <td style="vertical-align: middle; width: 8%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">X</p> </td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 8%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">101.DEF</p> </td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: top; width: 52%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Inline XBRL Taxonomy Extension Definition Linkbase Document.</p> </td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: top; width: 5%;">&#160;</td>
     <td style="vertical-align: top; width: 1%;">&#160;</td>
     <td style="vertical-align: top; width: 15%;">&#160;</td>
     <td style="vertical-align: top; width: 1%;">&#160;</td>
     <td style="vertical-align: top; width: 7%;">&#160;</td>
     <td style="vertical-align: top; width: 1%;">&#160;</td>
     <td style="vertical-align: middle; width: 8%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">X</p> </td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 8%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">101.LAB</p> </td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: top; width: 52%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Inline XBRL Taxonomy Extension Labels Linkbase Document.</p> </td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: top; width: 5%;">&#160;</td>
     <td style="vertical-align: top; width: 1%;">&#160;</td>
     <td style="vertical-align: top; width: 15%;">&#160;</td>
     <td style="vertical-align: top; width: 1%;">&#160;</td>
     <td style="vertical-align: top; width: 7%;">&#160;</td>
     <td style="vertical-align: top; width: 1%;">&#160;</td>
     <td style="vertical-align: middle; width: 8%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">X</p> </td>
    </tr>

    <tr>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 8%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">101.PRE</p> </td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: top; width: 52%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Inline XBRL Taxonomy Extension Presentation Linkbase Document.</p> </td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: top; width: 5%;">&#160;</td>
     <td style="vertical-align: top; width: 1%;">&#160;</td>
     <td style="vertical-align: top; width: 15%;">&#160;</td>
     <td style="vertical-align: top; width: 1%;">&#160;</td>
     <td style="vertical-align: top; width: 7%;">&#160;</td>
     <td style="vertical-align: top; width: 1%;">&#160;</td>
     <td style="vertical-align: middle; width: 8%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">X</p> </td>
    </tr>

    <tr>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 8%; text-align: center;">104</td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: top; width: 52%; text-align: justify;">The cover page from the Company&#8217;s Annual Report on Form 10-K for the fiscal year ended December 31, 2024, formatted in Inline XBRL (included in Exhibit 101).</td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: top; width: 5%;">&#160;</td>
     <td style="vertical-align: top; width: 1%;">&#160;</td>
     <td style="vertical-align: top; width: 15%;">&#160;</td>
     <td style="vertical-align: top; width: 1%;">&#160;</td>
     <td style="vertical-align: top; width: 7%;">&#160;</td>
     <td style="vertical-align: top; width: 1%;">&#160;</td>
     <td style="vertical-align: top; width: 8%; text-align: center;">X</td>
    </tr>

   </tbody>
  </table>
  <p style="font-family: Times New Roman; font-size: 10pt; margin: 0pt;">* Management contract, compensatory plan or arrangement.</p>
  <p style="font-family: Times New Roman; font-size: 10pt; margin: 0pt;">+ Confidential portions of this document have been redacted as permitted by applicable regulations.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 16pt;text-indent:-16pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 16pt;text-indent:-16pt;">(c)<i> Consolidated Financial Statement Schedules </i></p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">All consolidated financial statement schedules are omitted because the information is inapplicable or presented in the notes to the consolidated financial statements.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&#160;</p>
  <div>
   &#160;
  </div>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><a id="item16" title="item16" href="#"></a>Item 16.</b>&#160;&#160;&#160;&#160;<b><i>Form 10-K Summary</i></b></p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&#160;</p>
  <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 18pt;">The Company has elected not to include summary information.</p>
  <p style="font-size: 10pt; font-family: &quot;Times New Roman&quot;; margin: 0pt;">&#8206;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
      121
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <div>
   &#160;
  </div>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><a id="sigs" title="sigs" href="#"></a>SIGNATURES</b></p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">
   <tbody>
    <tr>
     <td style="vertical-align: top; width: 45%;">&#160;</td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 35%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Cassava Sciences, Inc.</p> </td>
     <td style="vertical-align: top; width: 20%;">&#160;</td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 45%;">&#160;</td>
     <td colspan="2" style="vertical-align: top; width: 35%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">(Registrant)</p> </td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 45%;">&#160;</td>
     <td colspan="2" style="vertical-align: top; width: 35%;">&#160;</td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 45%;">&#160;</td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 35%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">/s/ RICHARD J. BARRY</p> </td>
     <td style="vertical-align: top; width: 20%;">&#160;</td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 45%;">&#160;</td>
     <td colspan="2" style="vertical-align: top; width: 35%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Richard J. Barry,</p> </td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 45%;">&#160;</td>
     <td colspan="2" style="vertical-align: top; width: 35%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">President, Chief Executive Officer and&#160;Director</p> </td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 45%;">&#160;</td>
     <td colspan="2" style="vertical-align: top; width: 35%;">(Principal Executive Officer)</td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Dated: March 3, 2025</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">
   <tbody>
    <tr>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 40%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Signature</b>&#160;</p> </td>
     <td style="vertical-align: middle; width: 2%;">&#160;</td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 40%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Title </b></p> </td>
     <td style="vertical-align: middle; width: 2%;">&#160;</td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 16%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Date</b></p> </td>
    </tr>

    <tr>
     <td style="vertical-align: middle; width: 40%;">&#160;</td>
     <td style="vertical-align: middle; width: 2%;">&#160;</td>
     <td style="vertical-align: middle; width: 40%;">&#160;</td>
     <td style="vertical-align: middle; width: 2%;">&#160;</td>
     <td style="vertical-align: middle; width: 16%;">&#160;</td>
    </tr>

    <tr>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 40%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">/s/ RICHARD J. BARRY</p> </td>
     <td style="vertical-align: middle; width: 2%;">&#160;</td>
     <td style="vertical-align: top; width: 40%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">President, Chief Executive Officer and</p> </td>
     <td style="vertical-align: middle; width: 2%;">&#160;</td>
     <td style="vertical-align: top; width: 16%; text-align: center;">March 3, 2025</td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 40%; text-indent: 99pt;">Richard J. Barry</td>
     <td style="vertical-align: middle; width: 2%;">&#160;</td>
     <td style="vertical-align: top; width: 40%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Director</p> </td>
     <td style="vertical-align: middle; width: 2%;">&#160;</td>
     <td style="vertical-align: top; width: 16%;">&#160;</td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 40%;">&#160;</td>
     <td style="vertical-align: middle; width: 2%;">&#160;</td>
     <td style="vertical-align: top; width: 40%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">(Principal Executive Officer)</p> </td>
     <td style="vertical-align: middle; width: 2%;">&#160;</td>
     <td style="vertical-align: top; width: 16%;">&#160;</td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 40%;">&#160;</td>
     <td style="vertical-align: middle; width: 2%;">&#160;</td>
     <td style="vertical-align: top; width: 40%;">&#160;</td>
     <td style="vertical-align: middle; width: 2%;">&#160;</td>
     <td style="vertical-align: top; width: 16%;">&#160;</td>
    </tr>

    <tr>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 40%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">/s/ ERIC J. SCHOEN</p> </td>
     <td style="vertical-align: middle; width: 2%;">&#160;</td>
     <td style="vertical-align: top; width: 40%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Chief Financial Officer</p> </td>
     <td style="vertical-align: middle; width: 2%;">&#160;</td>
     <td style="vertical-align: top; width: 16%; text-align: center;">March 3, 2025</td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 40%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Eric J. Schoen</p> </td>
     <td style="vertical-align: middle; width: 2%;">&#160;</td>
     <td style="vertical-align: top; width: 40%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">(Principal Financial Officer and Principal Accounting Officer)</p> </td>
     <td style="vertical-align: middle; width: 2%;">&#160;</td>
     <td style="vertical-align: top; width: 16%;">&#160;</td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 40%;">&#160;</td>
     <td style="vertical-align: middle; width: 2%;">&#160;</td>
     <td style="vertical-align: top; width: 40%;">&#160;</td>
     <td style="vertical-align: middle; width: 2%;">&#160;</td>
     <td style="vertical-align: top; width: 16%;">&#160;</td>
    </tr>

    <tr>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 40%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">/s/ ROBERT ANDERSON, JR.</p> </td>
     <td style="vertical-align: middle; width: 2%;">&#160;</td>
     <td style="vertical-align: top; width: 40%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Director</p> </td>
     <td style="vertical-align: middle; width: 2%;">&#160;</td>
     <td style="vertical-align: top; width: 16%; text-align: center;">March 3, 2025</td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 40%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Robert Anderson, Jr.</p> </td>
     <td style="vertical-align: middle; width: 2%;">&#160;</td>
     <td style="vertical-align: top; width: 40%;">&#160;</td>
     <td style="vertical-align: middle; width: 2%;">&#160;</td>
     <td style="vertical-align: top; width: 16%;">&#160;</td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 40%;">&#160;</td>
     <td style="vertical-align: middle; width: 2%;">&#160;</td>
     <td style="vertical-align: top; width: 40%;">&#160;</td>
     <td style="vertical-align: middle; width: 2%;">&#160;</td>
     <td style="vertical-align: top; width: 16%;">&#160;</td>
    </tr>

    <tr>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 40%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">/s/ RICHARD J. BARRY</p> </td>
     <td style="vertical-align: middle; width: 2%;">&#160;</td>
     <td style="vertical-align: top; width: 40%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Director</p> </td>
     <td style="vertical-align: middle; width: 2%;">&#160;</td>
     <td style="vertical-align: top; width: 16%; text-align: center;">March 3, 2025</td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 40%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Richard J. Barry</p> </td>
     <td style="vertical-align: middle; width: 2%;">&#160;</td>
     <td style="vertical-align: top; width: 40%;">&#160;</td>
     <td style="vertical-align: middle; width: 2%;">&#160;</td>
     <td style="vertical-align: top; width: 16%;">&#160;</td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 40%;">&#160;</td>
     <td style="vertical-align: middle; width: 2%;">&#160;</td>
     <td style="vertical-align: top; width: 40%;">&#160;</td>
     <td style="vertical-align: middle; width: 2%;">&#160;</td>
     <td style="vertical-align: top; width: 16%;">&#160;</td>
    </tr>

    <tr>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 40%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">/s/ PIERRE GRAVIER</p> </td>
     <td style="vertical-align: middle; width: 2%;">&#160;</td>
     <td style="vertical-align: top; width: 40%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Director</p> </td>
     <td style="vertical-align: middle; width: 2%;">&#160;</td>
     <td style="vertical-align: top; width: 16%; text-align: center;">March 3, 2025</td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 40%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Pierre Gravier</p> </td>
     <td style="vertical-align: middle; width: 2%;">&#160;</td>
     <td style="vertical-align: top; width: 40%;">&#160;</td>
     <td style="vertical-align: middle; width: 2%;">&#160;</td>
     <td style="vertical-align: top; width: 16%;">&#160;</td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 40%;">&#160;</td>
     <td style="vertical-align: middle; width: 2%;">&#160;</td>
     <td style="vertical-align: top; width: 40%;">&#160;</td>
     <td style="vertical-align: middle; width: 2%;">&#160;</td>
     <td style="vertical-align: top; width: 16%;">&#160;</td>
    </tr>

    <tr>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 40%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">/s/ ROBERT Z. GUSSIN, PH.D.</p> </td>
     <td style="vertical-align: middle; width: 2%;">&#160;</td>
     <td style="vertical-align: top; width: 40%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Director</p> </td>
     <td style="vertical-align: middle; width: 2%;">&#160;</td>
     <td style="vertical-align: top; width: 16%; text-align: center;">March 3, 2025</td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 40%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Robert Z. Gussin, Ph.D.</p> </td>
     <td style="vertical-align: middle; width: 2%;">&#160;</td>
     <td style="vertical-align: top; width: 40%;">&#160;</td>
     <td style="vertical-align: middle; width: 2%;">&#160;</td>
     <td style="vertical-align: top; width: 16%;">&#160;</td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 40%;">&#160;</td>
     <td style="vertical-align: middle; width: 2%;">&#160;</td>
     <td style="vertical-align: top; width: 40%;">&#160;</td>
     <td style="vertical-align: middle; width: 2%;">&#160;</td>
     <td style="vertical-align: top; width: 16%;">&#160;</td>
    </tr>

    <tr>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 40%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">/s/ CLAUDE NICAISE, M.D.</p> </td>
     <td style="vertical-align: middle; width: 2%;">&#160;</td>
     <td style="vertical-align: top; width: 40%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Director</p> </td>
     <td style="vertical-align: middle; width: 2%;">&#160;</td>
     <td style="vertical-align: top; width: 16%; text-align: center;">March 3, 2025</td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 40%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Claude Nicaise, M.D.</p> </td>
     <td style="vertical-align: middle; width: 2%;">&#160;</td>
     <td style="vertical-align: top; width: 40%;">&#160;</td>
     <td style="vertical-align: middle; width: 2%;">&#160;</td>
     <td style="vertical-align: top; width: 16%;">&#160;</td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 40%;">&#160;</td>
     <td style="vertical-align: middle; width: 2%;">&#160;</td>
     <td style="vertical-align: top; width: 40%;">&#160;</td>
     <td style="vertical-align: middle; width: 2%;">&#160;</td>
     <td style="vertical-align: top; width: 16%;">&#160;</td>
    </tr>

    <tr>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 40%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">/s/ MICHAEL J. O'DONNELL, ESQ.</p> </td>
     <td style="vertical-align: middle; width: 2%;">&#160;</td>
     <td style="vertical-align: top; width: 40%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Director</p> </td>
     <td style="vertical-align: middle; width: 2%;">&#160;</td>
     <td style="vertical-align: top; width: 16%; text-align: center;">March 3, 2025</td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 40%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Michael J. O'Donnell, Esq.</p> </td>
     <td style="vertical-align: middle; width: 2%;">&#160;</td>
     <td style="vertical-align: top; width: 40%;">&#160;</td>
     <td style="vertical-align: middle; width: 2%;">&#160;</td>
     <td style="vertical-align: top; width: 16%;">&#160;</td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 40%;">&#160;</td>
     <td style="vertical-align: middle; width: 2%;">&#160;</td>
     <td style="vertical-align: top; width: 40%;">&#160;</td>
     <td style="vertical-align: middle; width: 2%;">&#160;</td>
     <td style="vertical-align: top; width: 16%;">&#160;</td>
    </tr>

    <tr>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 40%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">/s/ PATRICK SCANNON, M.D., PH.D.</p> </td>
     <td style="vertical-align: middle; width: 2%;">&#160;</td>
     <td style="vertical-align: top; width: 40%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Director</p> </td>
     <td style="vertical-align: middle; width: 2%;">&#160;</td>
     <td style="vertical-align: top; width: 16%; text-align: center;">March 3, 2025</td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 40%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Patrick Scannon, M.D., Ph.D.</p> </td>
     <td style="vertical-align: middle; width: 2%;">&#160;</td>
     <td style="vertical-align: top; width: 40%;">&#160;</td>
     <td style="vertical-align: middle; width: 2%;">&#160;</td>
     <td style="vertical-align: top; width: 16%;">&#160;</td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <div class="LAST-PAGE-BREAK">
   <div class="PGFTR">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
      122
     </div>
    </div>
   </div>
  </div>
 </body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.2
<SEQUENCE>2
<FILENAME>ex_756945.htm
<DESCRIPTION>EXHIBIT 4.2
<TEXT>
<html><head>
	<title>ex_756945.htm</title>

	<!-- Generated by ThunderDome Portal - 1/30/2025 10:09:11 PM --><meta charset="utf-8"><meta name="format-detection" content="telephone=no">
</head>
<body style="font-size: 10pt; font-family: &quot;Times New Roman&quot;; padding: 0in 0.1in; cursor: auto;">
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt 0pt 0pt 72pt;text-indent:36pt;"><b>Exhibit 4.2</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>DESCRIPTION OF THE REGISTRANT</b>&#8217;<b>S SECURITIES</b></p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">The following is a brief description of (i) the common stock, $0.001 par value per share ( &#8220;Common Stock&#8221;), of Cassava Sciences, Inc. (the &#8220;Company&#8221;) and (ii) the warrants, each whole warrant exercisable for shares of Common Stock (&#8220;Warrants&#8221;), of the Company, each of which is registered pursuant to Section 12 of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;).</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Description of Common Stock</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 36pt;"><b>General</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;&#65279;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">The following summary of the material features of our Common Stock and certain provisions of Delaware law do not purport to be complete and is subject to, and qualified in its entirety by, the provisions of our amended and restated certificate of incorporation, our bylaws, the Delaware General Corporation Law (&#8220;DGCL&#8221;) and other applicable law. For additional detail about our capital stock, please refer to our amended and restated certificate of incorporation and bylaws, each as amended, copies of which are included as exhibits to our Annual Report on Form 10-K for the year ended December 31, 2023.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;&#65279;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">As of the date of this Exhibit to the Form 10-K, our authorized capital stock consists of 130,000,000 shares. The Company is authorized to issue two classes of shares to be designated, respectively, Common Stock and Preferred Stock. The total number of shares of Common Stock which this Company is authorized to issue is 120,000,000, with a par value of $0.001, and the total number of shares of Preferred Stock which we is authorized to issue is 10,000,000, with a par value of $0.001. As of December 31, 2023, there were 42,236,919 shares of Common Stock issued and outstanding. Our Common Stock is listed on the Nasdaq Capital Market under the symbol &#8220;SAVA.&#8221;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;&#65279;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>Liquidation Rights </i></b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;&#65279;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">In the event of our liquidation, dissolution or winding up, the holders of Common Stock are entitled to share ratably in all assets remaining after payment of liabilities, subject to prior distribution rights of preferred stock then outstanding. The Common Stock has no preemptive or conversion rights or other subscription rights. There are no redemption or sinking fund provisions applicable to the Common Stock.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;&#65279;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>Voting Right</i></b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;&#65279;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">The holders of Common Stock are entitled to one vote per share on all matters to be voted upon by the stockholders.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;&#65279;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM">&nbsp;</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>Dividends </i></b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;&#65279;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">Subject to preferences that may be applicable to any outstanding preferred stock, the holders of Common Stock are entitled to receive ratably any dividends that may be declared from time to time by the board of directors out of funds legally available for that purpose. However, the Company is not currently paying any dividends.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;&#65279;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>No Preemptive or Similar Rights </i></b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;&#65279;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">The Common Stock has no preemptive or conversion rights or other subscription rights. There are no redemption or sinking fund provisions applicable to the Common Stock.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;&#65279;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Limitation on Rights of Holders of Common Stock </b>&#8211;<b> Preferred Stock</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;&#65279;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt;">We currently have no shares of preferred stock outstanding. Our board of directors has the authority, without further action by the stockholders, to issue up to 10,000,000 shares of preferred stock in one or more series and to fix the rights, preferences, privileges and restrictions granted to or imposed upon the preferred stock. Any or all of these rights may be greater than the rights of the Common Stock.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt;">The board of directors, without stockholder approval, can issue preferred stock with voting, conversion or other rights that could negatively affect the voting power and other rights of the holders of Common Stock. Preferred stock could thus be issued quickly with terms calculated to delay or prevent a change in control of us or make it more difficult to remove our management. Additionally, the issuance of preferred stock may have the effect of decreasing the market price of the Common Stock.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">&nbsp;&#65279;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>Certain Anti-Takeover Matters</b></p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">&nbsp;&#65279;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 25pt;">Our amended and restated certificate of incorporation requires that certain amendments of the amended and restated certificate of incorporation and certain amendments by the stockholders of our bylaws require the approval of at least 66 2/3% of the voting power of all outstanding stock. These provisions could discourage a potential acquirer from making a tender offer or otherwise attempting to obtain control of our company and could delay changes in our management.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">&nbsp;&#65279;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 25pt;">Our bylaws establish an advance notice procedure for stockholder proposals to be brought before an annual meeting of our stockholders, including proposed nominations of persons for election to the board of directors. At an annual meeting, stockholders may only consider proposals or nominations specified in the notice of meeting or brought before the meeting by or at the direction of the board of directors. Stockholders may also consider a proposal or nomination by a person who was a stockholder of record on the record date for the meeting, who is entitled to vote at the meeting and who has given to our Secretary timely written notice, in proper form, of his or her intention to bring that business before the meeting. The bylaws do not give the board of directors the power to approve or disapprove stockholder nominations of candidates or proposals regarding other business to be conducted at a special or annual meeting of the stockholders. However, our bylaws may have the effect of precluding the conduct of business at a meeting if the proper procedures are not followed. These provisions may also discourage or deter a potential acquirer from conducting a solicitation of proxies to elect the acquirer&#8217;s own slate of directors or otherwise attempting to obtain control of our company.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;&#65279;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM">&nbsp;</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 25pt;">Our bylaws provide that only our board of directors, the chairman of the board, the president or the chief executive officer may call a special meeting of stockholders. Because our stockholders do not have the right to call a special meeting, a stockholder could not force stockholder consideration of a proposal over the opposition of the board of directors by calling a special meeting of stockholders prior to such time as a majority of the board of directors believed or the chief executive officer believed the matter should be considered or until the next annual meeting provided that the requestor met the notice requirements. The restriction on the ability of stockholders to call a special meeting means that a proposal to replace the board also could be delayed until the next annual meeting.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;&#65279;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>Director Classification</i></b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;&#65279;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 25pt;">Our amended and restated certificate of incorporation provides for our board of directors to be divided into three classes serving staggered terms. Approximately one-third of the board of directors will be elected each year. The provision for a classified board could prevent a party who acquires control of a majority of the outstanding voting stock from obtaining control of the board of directors until the second annual stockholders meeting following the date the acquirer obtains the controlling stock interest. The classified board provision could discourage a potential acquirer from making a tender offer or otherwise attempting to obtain control of our company and could increase the likelihood that incumbent directors will retain their positions. Our amended and restated certificate of incorporation provides that directors may be removed with cause by the affirmative vote of the holders of the outstanding shares of Common Stock.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;&#65279;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>Limitation of Liability and Indemnification Matters</i></b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;&#65279;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 25pt;">Our amended and restated certificate of incorporation provides that to the fullest extent permitted by the DGCL as the same exists or as may hereafter be amended, a director of the Company or any subsidiary of the Company will not be held personally liable to the Company or its stockholders and will otherwise be indemnified by the Company for monetary damages for breach of fiduciary duty as a director of the Company, any predecessor of the Company or any subsidiary of the Company.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 25pt;">The Company, under the amended and restated certificate of incorporation, also indemnifies to the fullest extent permitted by law any person made or threatened to be made a party to an action or proceeding, whether criminal, civil, administrative or investigative, by reason of the fact that he, his testator or intestate is or was a director or officer of the Company, any predecessor of the Company or any subsidiary of the Company or serves or served at any other enterprise as a director or officer at the request of the Company, any predecessor to the Company or any subsidiary of the Company.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;&#65279;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM">&nbsp;</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>Section 203 of the Delaware General Corporation Law</i></b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;&#65279;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 27pt;">We are subject to the provisions of Section 203 of the DGCL. Under Section 203, we would generally be prohibited from engaging in any business combination with any interested stockholder for a period of three years following the time that this stockholder became an interested stockholder unless:</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;&#65279;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 27pt;">&nbsp;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#183;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">prior to this time, the board of directors of the Company approved either the business combination or the transaction that resulted in the stockholder becoming an interested stockholder;</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;&#65279;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 27pt;">&nbsp;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#183;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">upon consummation of the transaction that resulted in the stockholder&#8217;s becoming an interested stockholder, the interested stockholder owned at least 85% of the voting stock of the Company outstanding at the time the transaction commenced, excluding shares owned by persons who are directors and also officers, and by employee stock plans in which employee participants do not have the right to determine confidentially whether shares held subject to the plan will be tendered in a tender or exchange offer; or</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;&#65279;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 27pt;">&nbsp;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#183;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">at or subsequent to such time, the business combination is approved by the board of directors and authorized at an annual or special meeting of stockholders, and not by written consent, by the affirmative vote of at least 66 2&#8260;3% of the outstanding voting stock that is not owned by the interested stockholder.</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;&#65279;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">Under Section 203, a &#8220;business combination&#8221; includes:</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 45pt;">&nbsp;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">any merger or consolidation involving the Company and the interested stockholder;</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 45pt;">&nbsp;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">any merger or consolidation involving the Company and the interested stockholder;</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 45pt;">&nbsp;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">any sale, transfer, pledge or other disposition of 10% or more of the assets of the Company involving the interested stockholder;</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 45pt;">&nbsp;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">any transaction that results in the issuance or transfer by the Company of any stock of the Company to the interested stockholder, subject to limited exceptions;</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 45pt;">&nbsp;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">any transaction involving the Company that has the effect of increasing the proportionate share of the stock of any class or series of the Company beneficially owned by the interested stockholder; or</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 45pt;">&nbsp;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">the receipt by the interested stockholder of the benefit of any loans, advances, guarantees, pledges or other financial benefits provided by or through the Company</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM">&nbsp;</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt;">In general, Section 203 defines an interested stockholder as an entity or person beneficially owning 15% or more of the outstanding voting stock of the Company and any entity or person affiliated with or controlling or controlled by such entity or person.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Description of the Warrants</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>&#65279;General</i></b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt;">The following summary of the material features of our Warrants and certain provisions of Delaware law do not purport to be complete and is subject to, and qualified in its entirety by, the provisions of our amended and restated certificate of incorporation, our bylaws, the warrant agreement, dated as of January 3, 2024 (the &#8220;Warrant Agreement&#8221;), between the Company and Computershare Inc. and Computershare Trust Company, N.A., as warrant agents, the DGCL and other applicable law. For additional detail about our Warrants, please refer to our amended and restated certificate of incorporation and bylaws, each as amended from time to time, copies of which are included as exhibits to our Annual Report on Form 10-K for the year ended December 31, 2023.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;&#65279;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">As of the date of distribution of the Warrants, January 3, 2024 , there were 16,894,704 Warrants issued and outstanding. Our Warrants are listed on the Nasdaq Capital Market under the symbol &#8220;SAVAW.&#8221;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>Warrant Exercise Rate</i></b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">Each Warrant represents the right to purchase from the Company one share of Common Stock (the &#8220;Basic Warrant Exercise Rate&#8221;) plus the Bonus Share Fraction (as defined below), if any as described below, for the applicable exercise date for cash at an initial exercise price of $33.00 (the &#8220;Exercise Price&#8221;) per Warrant, payable in U.S. dollars.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">Until the Bonus Share Fraction Expiration Date (as defined below), a holder exercising its Warrants will receive, in addition to the Basic Warrant Exercise Rate, initially, an additional 0.5 of a Common Share for each Warrant exercised (subject to adjustment as described herein, the &#8220;Bonus Share Fraction&#8221;) without payment of any additional Exercise Price.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">The right to receive the Bonus Share Fraction will expire at 5:00 p.m. New York City time (the &#8220;Bonus Share Expiration Date&#8221;) upon the earlier of (i) the first business day following the last day of the first 30 consecutive trading day period commencing on or after the distribution date in which the daily VWAPs (as defined in the Warrant Agreement) of the shares of Common Stock has been at least equal to the then applicable Bonus Share Expiration Trigger Price (as defined in the Warrant Agreement) for at least 20 trading days (whether or not consecutive) (the &#8220;Bonus Price Condition&#8221;) and (ii) the date specified by the Company upon not less than 20 business days&#8217; notice. Any Warrant exercised with an exercise date after the Bonus Share Expiration Date will not be entitled to any Bonus Share Fraction.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">The &#8220;Bonus Share Expiration Trigger Price&#8221; is initially $26.40, subject to certain adjustments described in the Warrant Agreement.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM">&nbsp;</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">The Basic Warrant Exercise Rate plus any Bonus Share Fraction is referred to as the Warrant Exercise Rate. The Basic Warrant Exercise Rate, the Bonus Share Fraction and the Bonus Share Expiration Trigger Price are each subject to certain adjustments described in the &#8220;Anti-Dilution Adjustments&#8221; section below.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">The Company will make a public announcement of the Bonus Share Expiration Date (i) prior to market open on the Bonus Share Expiration Date in the case of a Bonus Price Condition and (ii) at least 20 Business Days prior to such date, in the case of the Company setting a Bonus Share Expiration Date.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>Expiration</i></b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">Except as described below, the Warrants will expire and cease to be exercisable at 5:00 p.m. New York City time on November 15, 2024 (the &#8220;Expiration Date&#8221;).</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>Redemption</i></b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">The Warrants are redeemable at the Company&#8217;s sole option at any time with a redemption date on or after April 15, 2024.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">By public announcement only, the Company will provide at least 20 calendar days&#8217; notice (the &#8220;Redemption Notice&#8221;) of the date selected for redemption (the &#8220;Redemption Date&#8221;). The redemption price upon any redemption shall equal to 1/10 of $0.01 per Warrant.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">In the event of a redemption of the Warrants, Warrants will be exercisable until 5:00 p.m. New York City time on the business day immediately preceding the Redemption Date. The Warrants will not be exercisable after 5:00 p.m. New York City time on the business day immediately preceding the Redemption Date and will cease to be outstanding after the Redemption Date.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>Exercise</i></b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">All or any part of the Warrants may be exercised prior to the earlier of (x) 5:00 p.m. New York City time on the Expiration Date and (y) 5:00 p.m. New York City time on the Business Day prior to the Redemption Date by delivering a completed form of election to purchase shares of Common Stock, which contains certain representations by the holder of the Warrants, and payment of the Exercise Price in cash. Any such delivery that occurs on a day that is not a Business Day or is received after 5:00 p.m., New York City time, on any given Business Day will be deemed received and exercised on the next succeeding Business Day. Record owners of Warrants may exercise Warrants through the process established by the Warrant Agent. Indirect, &#8220;street name&#8221; holders of Warrants should contact their broker, bank or other intermediary for information on how to exercise Warrants.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM">&nbsp;</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">If a registration statement is not effective at any time or from time to time, the right to exercise Warrants shall be automatically suspended until such registration statement becomes effective as described under &#8220;Registration and Suspension&#8221; below.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">Upon delivery of Warrant Shares upon exercise of Warrants, the Company will issue such whole number of Warrant Shares as the exercising Warrant holder is entitled to receive.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">Without the prior written consent of the Company (which consent may be withheld in the Company&#8217;s sole discretion), a holder will not be permitted to exercise Warrants for any shares of Common Stock, and the Company shall not be obligated to effect such exercise if, following such exercise, the holder (together with such holder&#8217;s affiliates, and any other persons acting as a group with such holder and its affiliates) would beneficially own 9.9% or more of the shares of Common Stock outstanding, including without limitation, through synthetic or derivative financial instruments that give effect to a direct or indirect ownership in the common stock of the Company (the &#8220;Ownership Limitation&#8221;). No consideration or repayment will be made to any holder as a result of an inability to exercise a Warrant in whole or in part because of such ownership limitations. The terms &#8220;beneficial ownership&#8221; and &#8220;group&#8221; shall be determined in accordance with Section 13(d) of the Exchange Act and the rules and regulations promulgated thereunder. For purposes of determining whether the Ownership Limitation has been reached, a holder may rely on the number of outstanding shares of Common Stock reflected in (x) the Company&#8217;s most recent periodic or annual report filed with the SEC or (y) any more recent notice published on the Company&#8217;s website.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>Registration and Suspension</i></b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">The Company has agreed in the Warrant Agreement to use commercially reasonable efforts to cause a shelf registration statement (including, at the Company&#8217;s election, an existing registration statement), to be filed pursuant to Rule 415 (or any successor provision) of the Securities Act, covering the issuance of shares of Common Stock to the Warrant holders upon exercise of the Warrants to remain effective until the earlier of (i) such time as all Warrants have been exercised and (ii) the earlier of the Expiration Date and the Redemption Date.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>Anti-Dilution Adjustments</i></b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">The Basic Warrant Exercise Rate shall be subject to adjustment, without duplication, upon the occurrence&nbsp;of certain events, including, among others, stock dividends payable in shares of Common Stock, stock splits, reclassifications and combinations, certain rights offerings to holders of shares of Common Stock, other distributions and spin-offs of securities to holders of shares of Common Stock, and cash dividends on shares of Common Stock, each as more fully described in the Warrant Agreement, except that the Company shall not make any such adjustments if each holder has the opportunity to participate, at the same time and upon the same terms as holders of the shares of Common Stock and solely as a result of holding the Warrants in any of the transactions described below, without having to exercise such holder&#8217;s Warrants, as if such holder held a number of shares of Common Stock equal to the product (rounded down to the nearest whole multiple of a share of Common Stock) of (i) the Warrant Exercise Rate in effect on the record date for such transaction and (ii) the number of Warrants held by it on such record date. The Bonus Share Fraction and the Bonus Share Expiration Trigger Price will be proportionately adjusted for any adjustment to the Basic Warrant Exercise Rate.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM">&nbsp;</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">All adjustments to the Basic Warrant Exercise Rate shall be made by the Calculation Agent to the nearest whole multiple of 0.00001 (with 0.000005 being rounded upwards) share of Common Stock. Any adjustments described above shall be made successively whenever an event referred to therein shall occur.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>Business Combinations and Reorganizations</i></b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">In the event of a merger, consolidation, amalgamation, statutory share exchange or similar transaction that requires the approval of the Company&#8217;s shareholders (a &#8220;Business Combination&#8221;) or reclassification of Common Stock, other than a reclassification of Common Stock referred to in &#8220;Anti-Dilution Adjustments&#8221; above, the right of a Warrant holder to receive Common Stock upon exercise of a Warrant will be converted into the right to exercise a Warrant to acquire, per each Warrant, the number of shares or other securities or property (including cash) that a number of shares of Common Stock equal to the Warrant Exercise Rate (in effect at the time of such Business Combination or reclassification) immediately prior to such Business Combination or reclassification would have been entitled to receive upon consummation of such Business Combination or reclassification (the amount of such shares, other securities or property in respect of a share of Common Stock being herein referred to as a &#8220;Unit of Reference Property&#8221;). If the Business Combination causes the Common Stock to be converted into, or exchanged for, the right to receive more than a single type of consideration (determined based in part upon any form of shareholder election), then the composition of the Unit of Reference Property into which the Warrants will be exercisable will be deemed to be the weighted average of the types and amounts of consideration actually received by the holders of Common Stock.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="LAST-PAGE-BREAK">
<div class="PGFTR">
<div class="hf-row">
<div class="hf-cell PGNUM">&nbsp;</div>
</div>
</div>
</div>


</body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.24
<SEQUENCE>3
<FILENAME>ex_771827.htm
<DESCRIPTION>EXHIBIT 10.24
<TEXT>
<html><head>
	<title>ex_771827.htm</title>

	<!-- Generated by ThunderDome Portal - 2/26/2025 10:53:32 PM --><meta charset="utf-8"><meta name="format-detection" content="telephone=no">
</head>
<body style="font-size: 10pt; font-family: &quot;Times New Roman&quot;; padding: 0in 0.1in; cursor: auto;">
<p style="margin: 0px 0pt; text-align: right; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt"><b>Exhibit 10.24</b></font></p>

<div contenteditable="false" data-applyto="p" data-auto-pgnum="start" data-displaynum="1" data-fontname="Times New Roman" data-fontsize="10pt" data-numstyle="a" data-prefix="" data-startnum="1" data-suffix="" data-textalign="center">&nbsp;</div>

<p style="margin: 0px 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><b><u>EXECUTIVE EMPLOYMENT AGREEMENT</u></b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">This EXECUTIVE EMPLOYMENT AGREEMENT (the &#8220;Agreement&#8221;) is made this 15<sup style="vertical-align:top;line-height:120%;">th</sup> day of November 2024, by and between CASSAVA SCIENCES, INC., 6801 N. Capital of Texas Highway, Building 1, Suite 300, Austin, TX 78731 (&#8220;Cassava&#8221; or &#8220;Company&#8221;), and FREDA NASSIF, an individual (&#8220;Nassif&#8221; or &#8220;Executive&#8221;). Executive&#8217;s first day of employment will be November 18, 2024 (the &#8220;Effective Date&#8221;).</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin: 0pt 0pt 0pt 0pt;text-indent:36pt;"><b>1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Position and Duties</u>.</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 27pt;">a.<b>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</b><u>Position</u>. Executive has been appointed to serve as Chief Commercial Officer of Cassava reporting to the President and Chief Executive Officer and shall perform the usual and customary duties of Chief Commercial Officer under the direction of the President and Chief Executive Officer.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: -9pt;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 27pt;">b.<b>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</b><u>Duties</u>. As Chief Commercial Officer, Executive will be primarily responsible for leading the Company&#8217;s commercial function. Examples of such duties include: (i) conducting a category needs assessment; (ii) developing Key Opinion Leader relationships; (iii) assessing market analytics; (iv) developing a strategic plan for market development; (v) defining the brand vision for simufilam; (vi) determining physician targeting strategies; (vii) developing a commercial strategy; (viii) building and leading a commercial team; (ix) executing on the agreed commercial strategy; and (x) such other duties as the President and Chief Executive Officer shall assign Executive from time to time. Executive agrees to devote Executive&#8217;s full business time and best efforts, business judgment, skill, and knowledge exclusively to the advancement of the business and interests of the Company and to the discharge of Executive&#8217;s duties and responsibilities; <i>provided, however</i>, that Executive may serve on outside boards (with prior written notice to and written approval by the Chief Executive Officer), participate in charitable and civic organizations, and manage personal investments to the extent such activities do not interfere with the performance of Executive&#8217;s duties and responsibilities to the Company.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin: 0pt 0pt 0pt 0pt;text-indent:36pt;"><b>2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Compensation and Benefits</u>.</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 27pt;">a.<b>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</b><u>Base Salary</u>. The Company will pay Executive as compensation for Executive&#8217;s services a base salary at the annualized rate of Four Hundred Seventy-Five Thousand Dollars and No Cents ($475,000.00) (&#8220;Base Salary&#8221;), paid semi-monthly. Base Salary is subject to customary payroll deductions and withholdings authorized or required by applicable law. Executive&#8217;s Base Salary will be subject to review and adjustment from time to time.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: -9pt;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 27pt;">b.<b>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</b><u>Bonuses</u>. Executive will be eligible to receive an annual bonus (target bonus amount will be forty percent (40%) of Base Salary, prorated for partial years of service) based upon performance-related criteria to be established by the Company, and subject to establishment of a Bonus Plan by the Company&#8217;s Board of Directors (the &#8220;Board&#8221;).</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: -9pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="1" data-prefix="" data-suffix="" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">1</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 27pt;">c.<b>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</b><u>Stock Options</u>. On the Effective Date, Executive will be granted (such date, the &#8220;Grant Date&#8221;) options to purchase one hundred thousand (100,000) shares of Common Stock (&#8220;Options&#8221;). Options vest in four equal annual installments (25% each year) commencing on the Grant Date. The exercise price of such Options will be priced at the closing price of the Company&#8217;s Common Stock on the Nasdaq Capital Market on the Grant Date. Options will be issued pursuant to the Company&#8217;s 2018 Omnibus Equity Incentive Plan and will be subject to all terms and conditions set forth in the agreement covering Executive&#8217;s stock option. From time to time, the Company may grant, in its sole discretion, additional stock options or other types of equity-based compensation.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: -9pt;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 27pt;">d.<b>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</b><u>Benefits</u>. Executive will be eligible to participate in the employee benefit plans maintained by the Company applicable to other key executives of the Company, including (without limitation) retirement plans, savings or profit-sharing plans, deferred compensation plans, supplemental retirement or excess benefit plans, disability, health, accident and other insurance programs, and similar plans or programs, subject in each case to the generally applicable terms and conditions of the plan or program in question and to the determination of any committee administering such plan or program.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: -9pt;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 27pt;">e.<b>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</b><u>Paid Time Off</u>. As an Officer of Cassava Sciences, Executive will not accrue, and the Company will not record, any specific amount of vacation or paid time off. The ability to take paid time off is not intended to be a form of additional wages for services performed. Instead, Executive may utilize paid time off as Executive&#8217;s work responsibilities allow.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: -9pt;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 27pt;">f.<b>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</b><u>Expenses</u>. The Company will reimburse Executive for all reasonable business, entertainment, and travel expenses actually incurred or paid by the Executive in the performance of Executive&#8217;s services on behalf of the Company, in accordance with the Company&#8217;s expense reimbursement policy in effect from time to time.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: -9pt;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 27pt;">g.<b>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</b><u>Relocation</u>. Executive will report to and, as necessary to perform Executive&#8217;s duties, travel to the Company&#8217;s headquarters in Austin, Texas. Should Executive relocate to the Austin, Texas area at the request of the Company, the Company will provide relocation assistance to Executive. Should Executive voluntarily terminate employment with Company within six (6) months after relocation, Executive agrees to reimburse the Company for the entire amount of relocation assistance provided to Executive on Executive&#8217;s last day of full-time employment with Company.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin: 0pt 0pt 0pt 0pt;text-indent:36pt;"><b>3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Term of Employment</u>.</b> Executive&#8217;s employment pursuant to this Agreement will commence on the Effective Date and continue indefinitely unless and until terminated in accordance with paragraph 4 of this Agreement. During the Term, the Company reserves the right to make personnel decisions regarding Executive&#8217;s employment, including but not limited to, promotions, salary adjustment, changes to scope of responsibilities, transfer and termination consistent with the Company&#8217;s needs, subject to the provisions of paragraph 4(c)(ii) of this Agreement.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="2" data-prefix="" data-suffix="" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">2</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin: 0pt 0pt 0pt 0pt;text-indent:36pt;"><b>4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Termination of Employment</u>.</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 27pt;">a.<b>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</b><u>Death</u>. Executive&#8217;s employment with the Company will terminate automatically upon the death of the Executive. In such event, the Company shall pay to Executive&#8217;s beneficiaries or Executive&#8217;s estate, as the case may be, any accrued Base Salary and any unreimbursed business expenses incurred by Executive in connection with Executive&#8217;s duties through the date of Executive&#8217;s death. Nothing in this paragraph shall affect any entitlement of the Executive&#8217;s heirs to the benefits of any life insurance provided by the Company.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: -9pt;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 27pt;">b.<b>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</b><u>Disability</u>. If Executive is unable to perform Executive&#8217;s duties for a period of sixty (60) consecutive days as a result of any physical or mental impairment, then, to the extent permitted by law, the Company may terminate this Agreement on or after the sixtieth (60th) day of Executive&#8217;s inability to perform Executive&#8217;s job duties. In such event, the Company will pay Base Salary to Executive until such time as Executive shall become entitled to receive disability benefit under the long-term disability insurance policy maintained by the Company (but not more than ninety (90) days following termination of employment), but no other compensation or reimbursement of any kind, including without limitation, severance compensation. Nothing in this paragraph shall affect Executive&#8217;s rights to benefits under any disability plan in which she is a participant.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: -9pt;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 27pt;">c.<b>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</b><u>Voluntary Resignation without Good Reason or Termination By Company for Cause</u>. If Executive&#8217;s employment with the Company terminates due to Executive&#8217;s voluntary resignation without Good Reason (as defined below), or if the Company involuntarily terminates Executive&#8217;s employment for Cause (as defined below), the Company will pay Executive all accrued Base Salary though the termination date but no other compensation or reimbursement of any kind, including without limitation, severance compensation. If Executive resigns from employment with the Company without Good Reason, Executive agrees to provide a minimum of thirty (30) days&#8217; advance notice of such resignation.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 63pt; text-indent: 27pt;">i.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; For purposes of this Agreement, Termination for &#8220;Cause&#8221; means: (a) any intentional action or intentional failure to act that was performed in bad faith and to the detriment of the Company; (b) any intentional refusal or intentional failure to act in accordance with any lawful and proper directive or order of the Board; (c) willful and habitual neglect of the duties assigned by the Board; (d) any action or omission that materially and negatively affects the business and/or reputation of the Company; (e) violation of any federal, state or local laws in connection with the performance of Executive&#8217;s job duties (including without limitation laws prohibiting employment discrimination and workplace harassment), or (f) any conviction for, or plea of guilty or <i>nolo contendere</i> to, a felony or misdemeanor involving moral turpitude under any applicable federal, state or local law; <i>provided, however,</i> that, in the event that any of the foregoing Cause events is capable of being cured, the Company will provide written notice to Executive describing the nature of such Cause event, and Executive will have five (5) business days to cure such event.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-indent: -9pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="3" data-prefix="" data-suffix="" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">3</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 63pt; text-indent: 27pt;">ii.&nbsp;&nbsp; &nbsp; &nbsp; For purposes of this Agreement, &#8220;Good Reason&#8221; means the occurrence of any of the following events without the Executive's prior consent: (a) material reduction in Executive's Base Salary; (b) following Executive&#8217;s relocation to Austin, Texas pursuant to Section 2(g) of this Agreement, any relocation of Executive's reporting location by more than 100 miles of Austin, Texas; (c) material breach by the Company of any provision of this Agreement; (d) material, adverse change in Executive's duties or responsibilities (other than temporarily while Executive is physically or mentally disabled or as required by applicable law); or (e) material adverse change in the management reporting structure applicable to Executive.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 27pt;">d.<b>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</b><u>Termination By Company Without Cause or Resignation by Executive for Good Reason</u>. After Executive completes one hundred eighty (180) days of employment with the Company, if Executive&#8217;s employment with the Company is involuntarily terminated for any reason other than Cause or if Executive resigns from Executive&#8217;s position for Good Reason, Executive will be entitled to receive: (i) Base Salary through the effective date of Executive&#8217;s termination from employment (the &#8220;Termination Date&#8221;); (ii) severance compensation equal to Executive&#8217;s Base Salary, immediately prior to the Termination Date, for three (3) months after the date of termination; (iii) continued participation in the Company medical plan, at the Company&#8217;s expense, until the earlier of (a) the date Executive becomes covered under another employer-sponsored medical plan, or (b) three (3) months after the Termination Date. Payment of the separation benefits outlined in this paragraph 4(d) is expressly conditioned on Executive&#8217;s entering into and not revoking an employment separation and release agreement in a form acceptable to the Company.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: -9pt;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 27pt;">e.<b>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</b><u>No Duty to Mitigate</u>. The Executive shall not be required to mitigate the amount of any payment contemplated by paragraph 4(d) (whether by seeking new employment or in any other manner).</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: -9pt;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 27pt;">f.<b>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</b><u>Change in Control</u>. In the event Executive&#8217;s employment with Company is terminated without Cause after a Change in Control (as defined herein), Executive will be paid Executive&#8217;s regular base salary, and will continue to receive employment benefits, for a period of twelve (12) months following Executive&#8217;s last date of employment with the Company; <i>provided, however,</i> that Executive signs and does not revoke an employment separation and release agreement acceptable to the Company. For purposes of this Agreement, a &#8220;Change in Control&#8221; means the occurrence of one or more of the following four events:</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 63pt; text-indent: 27pt;">i.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Any one person or more than one person acting as a &#8220;group&#8221; (within the meaning of Rule 13d-5 promulgated under the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;)), becomes the beneficial owner (as such term is defined in Rule 13d-3 promulgated under the Exchange Act) of equity securities of the Company that, together with equity securities previously held by such person or group, constitutes more than 50% of the total fair market value or total voting power of the outstanding equity securities of the Company; <i>provided, however</i>, if any one person or more than one person acting as a &#8220;group&#8221;, is considered to own more than 50% of the total fair market value or total voting power of the equity securities of the Company, the acquisition of additional equity securities by the same person or group will not be considered a Change-in-Control. Acquisitions of equity securities of the Company through the issuance of equity securities by the Company in capital raising transactions by the Company shall not constitute a Change-in-Control.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-indent: -9pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="4" data-prefix="" data-suffix="" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">4</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 63pt; text-indent: 27pt;">ii.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; A sale of all or substantially all the assets of the Company to a non-affiliate third party, <i>provided, however</i>, that any sale of all or substantially all assets of the Company to an entity shall not constitute a Change in Control if the holders of the voting securities of the Company outstanding immediately prior to such transaction hold securities which represent, immediately after such transaction, more than 50% of the combined voting power of the voting securities of such entity (or the parent of such entity).</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-indent: -9pt;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 63pt; text-indent: 27pt;">iii.&nbsp; &nbsp; &nbsp; Within six (6) months after a merger, consolidation or liquidation involving the Company or a contested election of a Company director, the individuals who were directors of the Company immediately prior thereto shall cease to constitute a majority of the board of directors of the surviving entity (or the parent of such entity).</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-indent: -9pt;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 63pt; text-indent: 27pt;">iv.&nbsp; &nbsp; &nbsp; Within six (6) months after the consummation of a tender offer or exchange offer for voting securities of the Company, the individuals who were directors of the Company immediately prior to the commencement thereof shall cease to constitute a majority of the board of directors of the surviving entity (or the parent of such entity).</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 27pt;">g.<b>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</b><u>409A Compliance</u>.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 63pt; text-indent: 27pt;">i.&nbsp;&nbsp; &nbsp; &nbsp;&nbsp; Notwithstanding anything to the contrary in this Agreement, no severance or other benefits payable upon termination from employment pursuant to this Agreement, when considered together with any other payments or benefits that are considered deferred compensation (together, the &#8220;Deferred Payments&#8221;) under Section 409A, will be payable until the Executive has a &#8220;separation from service&#8221; within the meaning of Section 409A.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-indent: -9pt;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 63pt; text-indent: 27pt;">ii.&nbsp; &nbsp; &nbsp;&nbsp; Notwithstanding anything to the contrary in this Agreement, if the Executive is a &#8220;specified employee&#8221; within the meaning of Section 409A at the time of Executive&#8217;s termination from employment, then, if required, the Deferred Payments, which are otherwise due to Executive on or within the six (6) month period following Executive&#8217;s termination from employment will accrue, to the extent required, during such six (6) month period and will become payable in a lump sum payment on the date six (6) months and one day following the date of Executive&#8217;s termination of employment or the date of the Executive&#8217;s death, if earlier. All subsequent Deferred Payments, if any, will be payable in accordance with the payment schedule applicable to each payment or benefit. Each payment and benefit payable under this Agreement is intended to constitute a separate payment for purposes of Section 1.409A-2(b)(2) of the Treasury Regulations.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-indent: -9pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="5" data-prefix="" data-suffix="" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">5</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 63pt; text-indent: 27pt;">iii.&nbsp;&nbsp; &nbsp;&nbsp; The foregoing provision is intended to comply with the requirements of Section 409A so that none of the payments and benefits to be provided under this Agreement will be subject to the additional tax imposed under Section 409A, and any ambiguities herein will be interpreted to so comply. Executive and the Company agree to work together in good faith to consider amendments to this Agreement and to take such reasonable actions which are necessary, appropriate or desirable to avoid imposition of any additional tax or income recognition prior to actual payment to Executive under Section 409A.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin: 0pt 0pt 0pt 0pt;text-indent:36pt;"><b>5.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Indemnification</u></b>. Subject to and in accordance with the terms of the attached Indemnification Agreement, in the event that Executive is made a party or threatened to be made a party to any action, suit, or proceeding, whether civil, criminal, administrative, or investigative (a &#8220;Proceeding&#8221;), other than any Proceeding initiated by the Executive or the Company related to any contest or dispute between the Executive and the Company or any of its affiliates with respect to this Agreement or the Executive's employment, by reason of the fact that the Executive is or was a director or officer of the Company, or any affiliate of the Company, Executive shall be indemnified and held harmless by the Company to the fullest extent applicable to any other officer or director of the Company/to the maximum extent permitted under applicable law and the Company's bylaws from and against any liabilities, costs, claims, and expenses, including all costs and expenses incurred in defense of any Proceeding (including attorneys' fees).</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin: 0pt 0pt 0pt 0pt;text-indent:36pt;"><b>6.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Confidential Information</u>.</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 27pt;">a.<b>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</b><u>Confidentiality Agreement</u>. At all times during the term of Executive&#8217;s employment and thereafter, Executive shall hold in strictest confidence and not to use, except for the benefit of the Company, or to disclose to any person, firm or corporation without written authorization of the Company, any Confidential Information or trade secrets belonging to the Company. As a condition of employment, Executive will enter into the attached Confidential Information and Invention Assignment Agreement.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 63pt; text-indent: 27pt;">i.&nbsp;&nbsp; &nbsp; &nbsp;&nbsp; Pursuant to the Defend Trade Secrets Act, 28 U.S.C. &#167; 1833, Executive will not be held criminally or civilly liable under any Federal or State trade secret law for the disclosure of a trade secret that is: (i) made in confidence to a Federal, State, or local government official, either directly or indirectly, or to an attorney, and solely for the purpose of reporting or investigating a suspected violation of law, or (ii) made in a complaint or other document filed in a lawsuit or other proceeding if such a filing is made under seal. Executive further understands that any individual who files a lawsuit for retaliation by an employer for reporting a suspected violation of law may disclose a trade secret to Executive&#8217;s attorney and use the trade secret information in the court proceeding so long as the individual: (i) files any document containing the trade secret under seal, and (ii) does not disclose the trade secret, except pursuant to court order.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-indent: -9pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="6" data-prefix="" data-suffix="" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">6</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 63pt; text-indent: 27pt;">ii.&nbsp;&nbsp; &nbsp; &nbsp; Nothing in this Agreement prevents Executive from providing, without prior notice to the Company, information to governmental authorities regarding possible legal violations or otherwise testifying or participating in any investigation or proceeding by any governmental authorities regarding possible legal violations.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 27pt;">b.<b>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</b><u>Former Employer Information</u>. During Executive&#8217;s employment with the Company, Executive will not improperly use or disclose any proprietary information or trade secrets of any former or concurrent employer or other person or entity and that Executive will not bring onto the premises of the Company any unpublished document or proprietary information belonging to any such employer, person or entity unless consented to in writing by such employer, person or entity.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: -9pt;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 27pt;">c.<b>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</b><u>Third Party Information</u>. Executive recognizes that the Company has received and, in the future, will receive from third parties their confidential or proprietary information subject to a duty on the Company&#8217;s part to maintain the confidentiality of such information and to use it only for certain limited purposes. Executive agrees to hold all such confidential or proprietary information in the strictest confidence and not to disclose it to any person, firm or corporation or to use it except as necessary in carrying out Executive&#8217;s work for the Company consistent with the Company&#8217;s agreement with such third party.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin: 0pt 0pt 0pt 0pt;text-indent:36pt;"><b>7.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Dispute Resolution</u></b>. Executive will attempt in good faith to resolve any dispute with the Company through discussion, evaluation, negotiation and conciliation. If any dispute arising out or relating to this Agreement, or the interpretation, application or enforcement of its terms, or any other dispute arising out of relating to Executive&#8217;s employment with the Company (including, without limitation, statutory or common law employment claims but excluding claims not subject to arbitration under Section 402 of the Ending Forced Arbitration of Sexual Assault and Sexual Harassment Act of 2021, 9 U.S.C. &#167; 402), such dispute(s) will be resolved by final and binding arbitration in accordance with the then existing Employment Arbitration Rules of the American Arbitration Association (&#8220;AAA&#8221;). This arbitration provision constitutes a waiver by the Parties of any right to a jury trial and relates to the resolution of all claims arising out of, relating to, or in connection with this Agreement, the interpretation, validity, construction, performance, breach or termination of this Agreement.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 27pt;">a.<b>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</b>The Parties will agree upon one arbitrator, who shall be an individual skilled in the legal and business aspects of the subject matter of this Agreement and of the dispute. If the Parties cannot agree upon one arbitrator, an arbitrator shall be selected by the Parties through the arbitrator selection procedures established by the AAA. The arbitration proceedings shall take place in Austin, Texas or such other location as the Parties may agree upon. The arbitration proceedings (including any pre-hearing depositions and written discovery responses) will be completely confidential and only the Parties and their authorized representatives, legal counsel and witnesses will be permitted to attend the arbitration hearing.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: -9pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="7" data-prefix="" data-suffix="" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">7</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 27pt;">b.<b>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</b>In rendering an award, the arbitrator shall determine the rights and obligations of the Parties according to the substantive law of the State of Texas (or federal law, where applicable) without regard to any principles governing conflicts of laws and the arbitrator&#8217;s decision shall be governed by state and federal substantive law, as though the matter were before a court of law. Such decision shall be final, conclusive and binding on the Parties to the arbitration. The decision of the arbitrator shall be made within thirty (30) days following the close of the hearing. The Parties agree that the award shall be enforceable exclusively by any state or federal court of competent jurisdiction.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: -9pt;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 27pt;">c.<b>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</b>If any part of this arbitration procedure is in conflict with any mandatory requirement or applicable law, the law shall govern, and that part of this arbitration procedure shall be reformed and construed to the maximum extent possible in conformance with the applicable law. The arbitration procedure shall remain otherwise unaffected and enforceable. The Parties agree that any Party shall be entitled to commence legal action in any court of competent jurisdiction to compel any other Party to this Agreement to submit any claim or controversy covered by this paragraph 7 to mandatory and binding arbitration in accordance with the terms and provisions outlined herein and/or for preliminary injunctive relief to preserve the <i>status quo</i> or to prevent any potential or on-going violation of this Agreement pending the outcome of arbitration proceedings under this paragraph.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin: 0pt 0pt 0pt 0pt;text-indent:36pt;"><b>8.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Governing Law and Consent to Jurisdiction</u>.</b> This Agreement shall be deemed to have been made and delivered in the State of Texas, where Executive&#8217;s services will be performed, in whole or in part, and shall be governed as to validity, interpretation, construction, effect and in all other respects by the internal laws of the State of Texas and controlling federal law without giving effect to any conflicts of laws provisions. Further, to the extent that any Party is required to initiate legal action to enforce any right or obligation under this Agreement (including arbitration under paragraph 7), the Parties agree that any such litigation shall be filed in the United States District Court for the Western District of Texas or the District Court of Travis County, Texas, and both Parties consent to the exclusive personal jurisdiction of such courts.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin: 0pt 0pt 0pt 0pt;text-indent:36pt;"><b>9.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Assignment</u>.</b> This Agreement, and the rights and obligations of Executive under this Agreement, may not be assigned by Executive without the express written consent of the Company. The rights and obligations of the Company under this Agreement shall be binding upon, and inure to the benefit of, the Company, its successors and assigns. However, this Agreement will be enforceable by and as to the Company and its successors and assigns. Further, in the event of a change in ownership of Cassava, the Company will have the right to assign all rights and obligations under this Agreement to any successor owner without Executive&#8217;s consent.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="8" data-prefix="" data-suffix="" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">8</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin: 0pt 0pt 0pt 0pt;text-indent:36pt;"><b>10.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <u>Notices</u>.</b> All notices, requests, demands, claims and other communications that are required to be, or which may be, given under this Agreement shall be in writing and (a) delivered in person or by courier; (b) sent by e-mail, telecopy or facsimile transmission; or (c) mailed, certified first class mail, postage prepaid, return receipt requested, to the Parties at the following addresses:</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 63pt;">&nbsp;</td>
			<td style="width: 27pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">a.</p>
			</td>
			<td style="width: auto;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">If to COMPANY:</p>
			</td>
		</tr>

</table>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 90pt;">CASSAVA SCIENCES, INC.</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 90pt;">Attn: Christopher Cook</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 90pt;">SVP and General Counsel</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 90pt;">6801 N. Capital of Texas Highway</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 90pt;">Building 1, Suite 300</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 90pt;">Austin, TX 78731</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 90pt;">ccook@cassavasciences.com</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 63pt;">&nbsp;</td>
			<td style="width: 27pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">b.</p>
			</td>
			<td style="width: auto;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">If to EXECUTIVE:</p>
			</td>
		</tr>

</table>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 90pt;">Freda Nassif<br>
XXX<br>
XXX<br>
XXX</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 36pt;">or to such other address as the Party to whom notice is being given shall have furnished to the other Party. Such notices shall be effective (i) if delivered in person or by courier, upon actual receipt by the intended recipient, (ii) if sent by e-mail, telecopy or facsimile transmission, when the sender receives confirmation that such notice was received at the e-mail address or telecopier number of the addressee, or (iii) if mailed, upon the earlier of five (5) business days after deposit in the mail or the date of delivery as shown by the return receipt. Any notice delivered in person, by courier, or by mail shall also be sent via email to the address listed above.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin: 0pt 0pt 0pt 0pt;text-indent:36pt;"><b>11.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <u>Attorneys</u></b><u>&#8217;</u><b><u> Fees</u></b><b>. </b>In the event that either Party initiates legal action in any court or adjudicative body to enforce any provision of this Agreement, or initiates legal action based upon the breach of any provision of this Agreement by any other Party, or submits any dispute to arbitration under paragraph 7 of this Agreement, each party shall bear its own fees and expenses.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin: 0pt 0pt 0pt 0pt;text-indent:36pt;"><b>12.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <u>Waivers</u>.</b> No claim arising out of a breach of this Agreement can be discharged, in whole or in part, by a waiver of that claim, unless such waiver is in writing and executed by the Party against whom the waiver is asserted. Any waiver by either Party of a breach of any provision of this Agreement by the other Party shall not be construed as a continuing waiver, or as a waiver of any breach of another provision of this Agreement.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin: 0pt 0pt 0pt 0pt;text-indent:36pt;"><b>13.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <u>Severability</u>.</b> In the event that any provision of this Agreement shall be deemed to be invalid, illegal or unenforceable, the validity, legality and enforceability of the remaining provisions shall not in any way be affected or impaired.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin: 0pt 0pt 0pt 0pt;text-indent:36pt;"><b>14.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <u>Captions</u>. </b>The captions of the paragraphs and provisions of this Agreement are for convenience only and shall not affect in any way the meaning or interpretation of this Agreement or any of its provisions.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="9" data-prefix="" data-suffix="" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">9</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin: 0pt 0pt 0pt 0pt;text-indent:36pt;"><b>15.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <u>Entire Agreement</u>.</b> The Parties acknowledge and agree that this Agreement, together with the Release, constitute the entire agreement between the Parties; that the Parties have executed this Agreement based upon the terms set forth herein; that the Parties have not relied on any prior agreement or representation, whether oral or written, which is not set forth in this Agreement; that no prior agreement, whether oral or written, shall have any effect on the terms and provisions of this Agreement; and that, except as otherwise provided in this Agreement, all prior agreements pertaining to the subject matter of this Agreement, whether oral or written, are expressly superseded and/or revoked by this Agreement.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin: 0pt 0pt 0pt 0pt;text-indent:36pt;"><b>16.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <u>Amendment</u>.</b> The Parties further agree that the provisions of this Agreement may not be modified by any subsequent agreement unless the modifying agreement is: (i) in writing; (ii) specifically references this Agreement; (iii) signed by Executive; and (iv) signed and approved by an authorized representative of Cassava.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt;"><i>IN WITNESS WHEREOF</i>, the Parties hereto have executed this Agreement as of the date first above written.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="text-indent: 0; width: 100%;font-family: 'Times New Roman', Times, serif; font-size: 10pt">

		<tr>
			<td valign="top" width="50%">
			<p style="margin: 0px 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>
			</td>
			<td colspan="2" valign="top" width="38%">
			<p style="margin: 0px 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">CASSAVA SCIENCES, INC.</p>
			</td>
			<td valign="top" width="12%">
			<p style="margin: 0px 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>
			</td>
		</tr>
		<tr>
			<td valign="top" width="50%">&nbsp;</td>
			<td valign="top" width="3%">&nbsp;</td>
			<td valign="top" width="35%">&nbsp;</td>
			<td valign="top" width="12%">&nbsp;</td>
		</tr>
		<tr>
			<td valign="top" width="50%">
			<p style="margin: 0px 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>
			</td>
			<td valign="top" width="3%">
			<p style="margin: 0px 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>
			</td>
			<td valign="top" width="35%">
			<p style="margin: 0px 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>
			</td>
			<td valign="top" width="12%">
			<p style="margin: 0px 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>
			</td>
		</tr>
		<tr>
			<td valign="top" width="50%">
			<p style="margin: 0px 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>
			</td>
			<td valign="top" width="3%">
			<p style="margin: 0px 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>
			</td>
			<td align="left" nowrap="nowrap" valign="bottom" width="35%">
			<p style="margin: 0px 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>
			</td>
			<td valign="top" width="12%">
			<p style="margin: 0px 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>
			</td>
		</tr>
		<tr>
			<td align="left" style="text-align: left;" valign="top" width="50%">
			<p style="margin: 0px 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>
			</td>
			<td style="text-align: left" valign="top" width="3%">
			<p style="margin: 0px 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">By: </font></p>
			</td>
			<td align="left" nowrap="nowrap" style="border-bottom: 1px solid rgb(0, 0, 0); padding-left: 9pt;" valign="top" width="35%">/s/ RICHARD BARRY</td>
			<td valign="top" width="12%">
			<p style="margin: 0px 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>
			</td>
		</tr>
		<tr>
			<td valign="top" width="50%">
			<p style="margin: 0px 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>
			</td>
			<td valign="top" width="3%">
			<p style="margin: 0px 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>
			</td>
			<td valign="top" width="35%">
			<p style="margin: 0px 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">Richard J. Barry</p>
			</td>
			<td valign="top" width="12%">
			<p style="margin: 0px 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>
			</td>
		</tr>
		<tr>
			<td valign="top" width="50%">
			<p style="margin: 0px 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>
			</td>
			<td valign="top" width="3%">
			<p style="margin: 0px 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>
			</td>
			<td valign="top" width="35%">
			<p style="margin: 0px 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">President and Chief Executive Officer</p>
			</td>
			<td valign="top" width="12%">
			<p style="margin: 0px 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>
			</td>
		</tr>
		<tr>
			<td valign="top" width="50%">&nbsp;</td>
			<td valign="top" width="3%">&nbsp;</td>
			<td valign="top" width="35%">&nbsp;</td>
			<td valign="top" width="12%">&nbsp;</td>
		</tr>
		<tr>
			<td valign="top" width="50%">&nbsp;</td>
			<td valign="top" width="3%">&nbsp;</td>
			<td valign="top" width="35%">&nbsp;</td>
			<td valign="top" width="12%">&nbsp;</td>
		</tr>
		<tr>
			<td valign="top" width="50%">&nbsp;</td>
			<td valign="top" width="3%">&nbsp;</td>
			<td valign="top" width="35%">&nbsp;</td>
			<td valign="top" width="12%">&nbsp;</td>
		</tr>
		<tr>
			<td valign="top" width="50%">&nbsp;</td>
			<td colspan="2" rowspan="1" valign="top" width="3%">FREDA NASSIF</td>
			<td valign="top" width="12%">&nbsp;</td>
		</tr>
		<tr>
			<td valign="top" width="50%">&nbsp;</td>
			<td valign="top" width="3%">&nbsp;</td>
			<td valign="top" width="35%">&nbsp;</td>
			<td valign="top" width="12%">&nbsp;</td>
		</tr>
		<tr>
			<td valign="top" width="50%">&nbsp;</td>
			<td valign="top" width="3%">&nbsp;</td>
			<td valign="top" width="35%">&nbsp;</td>
			<td valign="top" width="12%">&nbsp;</td>
		</tr>
		<tr>
			<td valign="top" width="50%">&nbsp;</td>
			<td valign="top" width="3%">&nbsp;</td>
			<td valign="top" width="35%">&nbsp;</td>
			<td valign="top" width="12%">&nbsp;</td>
		</tr>
		<tr>
			<td valign="top" width="50%">&nbsp;</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0);" valign="top" width="3%">&nbsp;</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0);" valign="top" width="35%">/s/ FREDA NASSIF</td>
			<td valign="top" width="12%">&nbsp;</td>
		</tr>

</table>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:216pt;">&nbsp;</p>

<div class="LAST-PAGE-BREAK">
<div class="PGFTR">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="10" data-prefix="" data-suffix="" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">10</div>
</div>
</div>
</div>


</body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-19.1
<SEQUENCE>4
<FILENAME>ex_771826.htm
<DESCRIPTION>EXHIBIT 19.1
<TEXT>
<html><head>
	<title>ex_771826.htm</title>

	<!-- Generated by ThunderDome Portal - 1/29/2025 12:38:12 AM --><meta charset="utf-8"><meta name="format-detection" content="telephone=no">
</head>
<body style="font-size: 10pt; font-family: &quot;Times New Roman&quot;; padding: 0in 0.1in; cursor: auto;">
<p style="margin: 0px 0pt; text-align: right; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt"><b>Exhibit 19.1</b></font></p>

<p style="margin: 0px 0pt; text-align: left; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>

<div style="text-align: center;"><img alt="largelogo.jpg" src="largelogo.jpg"></div>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:12pt;font-variant:normal;text-align:center;margin:0pt;"><b>INSIDER TRADING POLICY</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 36pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>1. </b></p>
			</td>
			<td style="width: auto;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>General Purpose</b></p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">Federal securities laws prohibit the purchase or sale of securities by persons who are aware of material nonpublic information about a company, as well as the disclosure of material, nonpublic information about a company to others who then trade in the company&#8217;s securities. These transactions are commonly known as &#8220;insider trading.&#8221;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">Insider trading violations are heavily pursued by the Securities and Exchange Commission and the U.S. Attorney Offices and are punished. &nbsp;While the regulatory authorities concentrate their efforts on individuals who trade, or who provide inside information to others who trade, the Federal securities laws also impose potential liability on companies and other &#8220;controlling persons&#8221; if they fail to take reasonable steps to prevent insider trading by company personnel.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">Cassava Sciences, Inc. (&#8220;Cassava&#8221; or &#8220;we&#8221;) has adopted this Insider Trading Policy (the &#8220;Policy&#8221;) both to satisfy Cassava&#8217;s obligation to prevent insider trading and to help Cassava personnel avoid the consequences associated with violations of the insider trading laws. &nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">This Policy is also intended to prevent even the appearance of improper conduct on the part of anyone employed by or associated with Cassava, not just so-called &#8220;insiders.&#8221; &nbsp;Everyone within Cassava works very hard to establish Cassava as a company known for integrity and ethical conduct, and Cassava cannot afford to have that reputation damaged.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 36pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>2.</b></p>
			</td>
			<td style="width: auto;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>Persons Covered</b></p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">This Policy refers to an &#8220;insider&#8221; and we wish to define it herein. &nbsp;Insiders of Cassava are defined as (a) members of our Board of Directors, corporate officers and employees; (b) consultants to Cassava or other persons associated with Cassava who may, in the course of their work with Cassava, receive access to confidential, material non-public information; and (c) household and immediate family members of those listed in (a) and (b) above.</p>

<div contenteditable="false" data-hf-endpoint="start" data-hf-html="%3Cdiv%20style%3D%22width%3A%20100%25%3B%22%3E%3Cdiv%20class%3D%22hf-row%22%3E%3Cdiv%20class%3D%22hf-cell%20TOCLink%22%20style%3D%22text-align%3A%20left%3B%20margin%3A%200pt%3B%20width%3A%2099.9%25%3B%20display%3A%20inline-block%3B%22%3E%3C%2Fdiv%3E%3C%2Fdiv%3E%3Cdiv%20class%3D%22hf-row%22%3E%3Cdiv%20class%3D%22hf-cell%22%20style%3D%22font-family%3A%20%26quot%3BTimes%20New%20Roman%26quot%3B%2C%20Times%2C%20serif%3B%20font-size%3A%2011pt%3B%20text-align%3A%20center%3B%20font-weight%3A%20bold%3B%20margin%3A%200pt%3B%20width%3A%2099.9%25%3B%20display%3A%20inline-block%3B%22%3EINSIDER%20TRADING%20POLICY%3C%2Fdiv%3E%3C%2Fdiv%3E%3C%2Fdiv%3E" data-hf-type="header">&nbsp;</div>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 36pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>3.</b></p>
			</td>
			<td style="width: auto;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>Definitions</b></p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">A) <u>Material non-public information</u>: &nbsp;Material non-public information is defined to be information that is not known to persons outside Cassava that could be relied upon or considered significant if a reasonable investor would likely consider it important in making a decision to buy, sell or hold Cassava securities. &nbsp;It is currently very difficult to define each and every category under this heading. &nbsp;However, information that should always be considered material, sensitive and non-public includes but is not limited to the following:</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 18pt;">&nbsp;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">Clinical data, even if blinded</p>
			</td>
		</tr>

</table>

<p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM">&nbsp;</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="width: 100%;">
<div class="hf-row">
<div class="hf-cell TOCLink" style="text-align: left; margin: 0pt; width: 99.9%; display: inline-block;">&nbsp;</div>
</div>

<div class="hf-row">
<div class="hf-cell" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 11pt; text-align: center; font-weight: bold; margin: 0pt; width: 99.9%; display: inline-block;">INSIDER TRADING POLICY</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 18pt;">&nbsp;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">Regulatory updates</p>
			</td>
		</tr>

</table>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 18pt;">&nbsp;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">Financial results</p>
			</td>
		</tr>

</table>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 18pt;">&nbsp;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">News of a pending or proposed sale, merger or acquisition</p>
			</td>
		</tr>

</table>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 18pt;">&nbsp;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">Developments relating to intellectual property</p>
			</td>
		</tr>

</table>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 18pt;">&nbsp;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">Scientific achievements or other developments from research efforts</p>
			</td>
		</tr>

</table>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 18pt;">&nbsp;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">Changes in senior management or Board members</p>
			</td>
		</tr>

</table>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 18pt;">&nbsp;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">Contracts or research grant applications in a pending status or in discussion</p>
			</td>
		</tr>

</table>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 18pt;">&nbsp;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">Developments in litigation or government investigations or other inquiries</p>
			</td>
		</tr>

</table>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 18pt;">&nbsp;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">Proposed debt or equity offerings by the Company</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;"><b><i>Remember</i></b><b>, anyone who is reviewing your securities transactions will be doing so after the fact, with the benefit of hindsight. </b>&nbsp;<b>As such, before engaging in any transaction, you should carefully consider how the others might view the transaction.</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">B) <u>Securities</u>: &nbsp;Securities of Cassava are defined as common stock, preferred stock, options to purchase stock, warrants, convertible debt and/or derivative securities.</p>

<div contenteditable="false" data-applyto="p" data-auto-pgnum="start" data-displaynum="2" data-fontname="Times New Roman" data-fontsize="10pt" data-numstyle="a" data-prefix="Page " data-startnum="2" data-suffix=" of 5" data-textalign="center">&nbsp;</div>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 36pt;">
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>4.</b></p>
			</td>
			<td style="width: auto;">
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>Policy</b></p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">No insider may buy or sell Cassava securities at any time when they are aware of any material non-public information relating to Cassava, regardless of the source of information.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">No insider may buy or sell securities of another company at any time when they are aware of material non-public information about that company, including, without limitation, any company that we conduct ordinary business with, such as vendors or suppliers, when that information is obtained during the course of his/her employment with Cassava.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">No insider may disclose material non-public information to third parties or to any other person (&#8220;tipping&#8221;), including family members, or make investment recommendations or express investment opinions based on material non-public information, regardless of whether you profit or intend to profit by the practice of tipping. Tipping violates securities laws and can result in the same civil or criminal penalties that apply to insider trading, even though you did not trade, profit or gain any benefit from another person&#8217;s trading.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">No insider who receives or has access to material non-public information may comment on the stock price movement or rumors of other corporate developments that are of possible significance to the investing public, unless it is part of his/her job description (e.g., Investor Relations) or you have been specifically pre-authorized to do so by the CEO, CFO or General Counsel (GC) of Cassava in each instance.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">Any written or verbal statement that would be prohibited under the law or under this Insider Trading Policy is equally prohibited if made on electronic bulletin boards, chat rooms, blogs, websites or any other form of social media, including the disclosure of material non-public information about the Company or material non-public information with respect to other companies that you come into possession of as an employee or associate of the Company.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">If you comment on stock price movement or rumors and/or disclose material non-public information, you must immediately contact the CEO, CFO or GC of Cassava.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="2" data-prefix="Page " data-suffix=" of 5" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">Page 2 of 5</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="width: 100%;">
<div class="hf-row">
<div class="hf-cell TOCLink" style="text-align: left; margin: 0pt; width: 99.9%; display: inline-block;">&nbsp;</div>
</div>

<div class="hf-row">
<div class="hf-cell" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 11pt; text-align: center; font-weight: bold; margin: 0pt; width: 99.9%; display: inline-block;">INSIDER TRADING POLICY</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">This Policy continues in effect after termination of employment or other relationship with Cassava until such time as the insider is no longer in possession of material non-public information.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 36pt;">
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>5.</b></p>
			</td>
			<td style="width: auto;">
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">S<b>pecial Rules </b></p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">If a concern or question relating to your status within Cassava (insider or not, etc.) should arise, please contact the CEO, CFO or GC of Cassava.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;"><b>In addition to the restrictions related to the trading of Cassava securities as defined in Section 4 above, insiders shall not purchase or sell any Cassava securities, or cause others to do so, except after first consulting with and obtaining </b><b><u>written pre-clearance for each such transaction</u></b><b> with Cassava</b>&#8217;<b>s CFO.</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">In addition to the restrictions related to the trading of Cassava securities as defined in Section 4 above, insiders shall not engage in short sales of Cassava securities or hedging transactions, nor buy or sell put options, call options or other derivatives of Cassava&#8217;s securities.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">The restriction related to the trading of Cassava securities as defined in Section 4 above does not apply to the exercise of stock options for cash under any equity or stock option plan (but <b><i>not</i></b> the sale of such shares), since the market price does not affect the exercise price stated in the agreement.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 36pt;">
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>6.</b></p>
			</td>
			<td style="width: auto;">
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>Rule 10b5-1 Trading Plans</b></p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 72pt;">In 2023, the SEC significantly expanded compliance rules and Company disclosure requirements for Rule 10b5-1 trading plans. Please see the Compliance Officer for more information on Rule 10b5-1 trading plans. Such plans may only be entered into during an open trading window and require the <b><u>written pre-clearance</u></b><b> from Cassava</b>&#8217;<b>s CFO prior to entering into such a plan.</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 36pt;">
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>7.</b></p>
			</td>
			<td style="width: auto;">
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>Potential Criminal and/or Civil Liability and/or Disciplinary Action</b></p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">This Policy does not and cannot comprehensively describe all potential circumstances relating to insider trading and the laws that apply to the purchase or sale of securities by individual investors, including Cassava employees. &nbsp;Each individual is responsible for his or her own decisions and must exercise appropriate judgment when buying and selling securities.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">Insiders found liable for insider trading may be subject to criminal penalties of up to $5,000,000 and up to twenty (20) years in prison for trading of securities based on material non-public information.&nbsp;In addition, insiders may also be liable for transactions conducted improperly by any person to whom they have disclosed the material non-public information. &nbsp;The Securities and Exchange Commission has imposed large penalties even when the disclosing person did not profit, directly or indirectly, from the trade(s). &nbsp;There are also civil penalties of up to three times the profit gained, or loss avoided, that may be imposed.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">Personnel who are implicated in insider trading by Federal authorities will need to engage their own attorneys and other professionals to defend or assist them, at their own expense. Legal fees and expenses associated with the investigation, preparation, defense and settlement of insider trading cases can be substantial.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="3" data-prefix="Page " data-suffix=" of 5" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">Page 3 of 5</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="width: 100%;">
<div class="hf-row">
<div class="hf-cell TOCLink" style="text-align: left; margin: 0pt; width: 99.9%; display: inline-block;">&nbsp;</div>
</div>

<div class="hf-row">
<div class="hf-cell" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 11pt; text-align: center; font-weight: bold; margin: 0pt; width: 99.9%; display: inline-block;">INSIDER TRADING POLICY</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">Furthermore, any personnel who violate this Policy will be subject to disciplinary action as outlined in the Employee Handbook, up to and including immediate termination of employment.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">For purposes of this Policy, Eric Schoen shall be designated as the &#8220;Chief Compliance Officer.&#8221; &nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">All communications of every kind hereunder shall be in writing or shall be of no effect.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>[SIGNATURE PAGE FOLLOWS]</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGNUM" data-number="4" data-prefix="Page " data-suffix=" of 5" style="text-align: center; width: 100%; font-size: 10pt; font-family: Times New Roman;">Page 4 of 5</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="width: 100%;">
<div class="hf-row">
<div class="hf-cell TOCLink" style="text-align: left; margin: 0pt; width: 99.9%; display: inline-block;">&nbsp;</div>
</div>

<div class="hf-row">
<div class="hf-cell" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 11pt; text-align: center; font-weight: bold; margin: 0pt; width: 99.9%; display: inline-block;">INSIDER TRADING POLICY</div>
</div>
</div>
</div>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>ACKNOWLEDGMENT CONCERNING INSIDER TRADING POLICY</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;"><b>I, ____________________ (print name) acknowledge that I have read and understand the Insider Trading Policy of Cassava Sciences, Inc. and that I agree to abide by the provisions stated therein. </b>&nbsp;<b>I further certify that I understand that failure to adhere to these rules may result in serious consequences with Federal authorities and in immediate termination of my employment with Cassava Sciences, Inc.</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Dated this ____ day of _________2024</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Signature: _______________________</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Name: __________________________</b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="LAST-PAGE-BREAK">
<div class="PGFTR">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="5" data-prefix="Page " data-suffix=" of 5" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">Page 5 of 5</div>
</div>
</div>
</div>


</body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-21.1
<SEQUENCE>5
<FILENAME>ex_756946.htm
<DESCRIPTION>EXHIBIT 21.1
<TEXT>
<html><head>
	<title>ex_756946.htm</title>

	<meta charset="utf-8"><meta name="format-detection" content="telephone=no">
</head>
<body style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0in 0.1in; cursor: auto;">
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt 0pt 0pt 80pt;"><b>Exhibit 21.1</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Cassava Sciences, Inc. Subsidiaries</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table cellpadding="0pt" cellspacing="0pt" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 80%; margin-left: 0pt; margin-right: auto;">

		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 54%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-top: 1px solid rgb(0, 0, 0); border-left: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><u>Subsidiary</u></p>
			</td>
			<td style="border-width: 1px; border-style: solid; border-color: rgb(0, 0, 0); vertical-align: top; width: 46%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><u>State/Country of Incorporation/Formation</u></p>
			</td>
		</tr>
		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 54%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-left: 1px solid rgb(0, 0, 0);">&nbsp;</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 46%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-right: 1px solid rgb(0, 0, 0); border-left: 1px solid rgb(0, 0, 0);">&nbsp;</td>
		</tr>
		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 54%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-left: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Austin Innovation Park, LLC</p>
			</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 46%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-left: 1px solid rgb(0, 0, 0); border-right: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Texas</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="LAST-PAGE-BREAK">
<div class="PGFTR">
<div class="hf-row">
<div class="hf-cell PGNUM">&nbsp;</div>
</div>
</div>
</div>


</body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>6
<FILENAME>ex_756947.htm
<DESCRIPTION>EXHIBIT 23.1
<TEXT>
<html><head>
	<title>ex_756947.htm</title>
	<!-- Generated by ThunderDome Portal - 2/27/2025 10:56:03 PM --><meta charset="utf-8"><meta name="format-detection" content="telephone=no">
</head>
<body style="font-size:10pt;font-family:'Times New Roman';padding:0in .1in;">
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt 0pt 0pt 54pt;text-indent:-18pt;"><b>EXHIBIT 23.1</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt 0pt 0pt 36pt;"><b>Consent of Independent Registered Public Accounting Firm</b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt 0pt 0pt 36pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">We consent to the incorporation by reference in the following Registration Statements: &nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width:18pt;">&nbsp;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">1)</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Registration Statement (Form S-8 No. 333-265540) pertaining to the 2018 Omnibus Incentive Plan of Registrant,</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width:18pt;">&nbsp;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">2)</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Registration Statement (Form S-3 No. 333-271542) and related Prospectus of Cassava Sciences, Inc.,</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width:18pt;">&nbsp;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">3)</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Registration Statement (Form S-8 No. 333-168390) pertaining to the 2000 Employee Stock Purchase Plan of Registrant,</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width:18pt;">&nbsp;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">4)</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Registration Statement (Form S-8 No. 333-225708) pertaining to the 2018 Omnibus Incentive Plan of Registrant,</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width:18pt;">&nbsp;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">5)</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Registration Statement (Form S-8 No. 333-147336) pertaining to the 2000 Employee Stock Purchase Plan of Registrant, and</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width:18pt;">&nbsp;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">6)</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Registration Statement (Form S-8&nbsp;No. 333-152676) pertaining to the 2008 Equity Incentive Plan of Registrant;</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">of our report&nbsp;dated March 3, 2025, with respect to the consolidated financial statements of Cassava Sciences, Inc. included in this Annual Report (Form 10-K) of Cassava Sciences, Inc. for the year ended December 31, 2024.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">/s/ Ernst &amp;Young LLP</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Austin, Texas</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">March 3, 2025</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="LAST-PAGE-BREAK">
<div class="PGFTR">
<div class="hf-row">
<div class="hf-cell PGNUM">&nbsp;</div>
</div>
</div>
</div>


</body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>7
<FILENAME>ex_756948.htm
<DESCRIPTION>EXHIBIT 31.1
<TEXT>
<html><head>
	<title>ex_756948.htm</title>
	<meta charset="utf-8"><meta name="format-detection" content="telephone=no">
</head>
<body style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0in 0.1in; cursor: auto;">
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt 0pt 0pt 80pt;">EXHIBIT 31.1</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">PRINCIPAL EXECUTIVE OFFICER CERTIFICATION PURSUANT TO</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">I, Richard Barry, certify that:</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 18pt;">&nbsp;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">1.</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">I have reviewed this Annual Report on Form 10-K of Cassava Sciences, Inc.;</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 18pt;">&nbsp;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">2.</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 18pt;">&nbsp;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">3.</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 18pt;">&nbsp;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">4.</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">The registrant&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 36pt;">&nbsp;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">a.</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 36pt;">&nbsp;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">b.</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 36pt;">&nbsp;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">c.</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 36pt;">&nbsp;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">d.</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 18pt;">&nbsp;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">5.</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions):</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 36pt;">&nbsp;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">a.</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information; and</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 36pt;">&nbsp;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">b.</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; width: 100%;">

		<tr>
			<td style="width: 45%;">&nbsp;</td>
			<td style="width: 55%;"><u>/s/ RICHARD J. BARRY</u></td>
		</tr>
		<tr>
			<td style="width: 45%;">&nbsp;</td>
			<td style="width: 55%;">Richard J. Barry,</td>
		</tr>
		<tr>
			<td style="width: 45%;">&nbsp;</td>
			<td style="width: 55%;">President and Chief Executive Officer</td>
		</tr>
		<tr>
			<td style="width: 45%;">&nbsp;</td>
			<td style="width: 55%;">(Principal Executive Officer)</td>
		</tr>

</table>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 350pt;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">Date: March 3, 2025</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="LAST-PAGE-BREAK">
<div class="PGFTR">
<div class="hf-row">
<div class="hf-cell PGNUM">&nbsp;</div>
</div>
</div>
</div>


</body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>8
<FILENAME>ex_756949.htm
<DESCRIPTION>EXHIBIT 31.2
<TEXT>
<html><head>
	<title>ex_756949.htm</title>
	<meta charset="utf-8"><meta name="format-detection" content="telephone=no">
</head>
<body style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0in 0.1in; cursor: auto;">
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt 0pt 0pt 80pt;">EXHIBIT 31.2</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">PRINCIPAL FINANCIAL OFFICER CERTIFICATION PURSUANT TO</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">I, Eric J. Schoen, certify that:</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 18pt;">&nbsp;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">1.</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">I have reviewed this Annual Report on Form 10-K of Cassava Sciences, Inc.;</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 18pt;">&nbsp;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">2.</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 18pt;">&nbsp;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">3.</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 18pt;">&nbsp;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">4.</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">The registrant&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 36pt;">&nbsp;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">a.</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 36pt;">&nbsp;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">b.</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 36pt;">&nbsp;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">c.</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 36pt;">&nbsp;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">d.</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting; and</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 18pt;">&nbsp;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">5.</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions):</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 36pt;">&nbsp;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">a.</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information; and</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 36pt;">&nbsp;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">b.</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; width: 100%;">

		<tr>
			<td style="width: 45%;">&nbsp;</td>
			<td style="width: 55%;"><u>/s/ ERIC J. SCHOEN</u></td>
		</tr>
		<tr>
			<td style="width: 45%;">&nbsp;</td>
			<td style="width: 55%;">Eric J. Schoen,</td>
		</tr>
		<tr>
			<td style="width: 45%;">&nbsp;</td>
			<td style="width: 55%;">Chief Financial Officer</td>
		</tr>
		<tr>
			<td style="width: 45%;">&nbsp;</td>
			<td style="width: 55%;">(Principal Financial Officer)</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">Date: March 3, 2025</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">&nbsp;</p>

<div class="LAST-PAGE-BREAK">
<div class="PGFTR">
<div class="hf-row">
<div class="hf-cell PGNUM">&nbsp;</div>
</div>
</div>
</div>


</body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>9
<FILENAME>ex_756950.htm
<DESCRIPTION>EXHIBIT 32.1
<TEXT>
<html><head>
	<title>ex_756950.htm</title>
	<meta charset="utf-8"><meta name="format-detection" content="telephone=no">
</head>
<body style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0in 0.1in; cursor: auto;">
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt 0pt 0pt 476pt;">EXHIBIT 32.1</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">CERTIFICATIONS OF THE CHIEF EXECUTIVE OFFICER AND THE</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">CHIEF FINANCIAL OFFICER PURSUANT TO 18 U.S.C. SECTION 1350,</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">Pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, each of the undersigned officers of Cassava Sciences, Inc. (the &#8220;Company&#8221;), hereby certifies that to the best of such officer&#8217;s knowledge:</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 18pt;">&nbsp;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">1.</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">The Company&#8217;s Annual Report on Form 10-K for the fiscal year ended December 31, 2024, and to which this certification is attached as Exhibit 32.1 (the &#8220;Periodic Report&#8221;), fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, and</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 18pt;">&nbsp;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">2.</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">The information contained in this Periodic Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; width: 100%;">

		<tr>
			<td style="width: 45%;">&nbsp;</td>
			<td style="width: 55%;">Date: March 3, 2025</td>
		</tr>
		<tr>
			<td style="width: 45%;">&nbsp;</td>
			<td style="width: 55%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="width: 45%;">&nbsp;</td>
			<td style="width: 55%;"><u>/s/ RICHARD J. BARRY</u>&nbsp;</td>
		</tr>
		<tr>
			<td style="width: 45%;">&nbsp;</td>
			<td style="width: 55%;">Richard J. Barry,</td>
		</tr>
		<tr>
			<td style="width: 45%;">&nbsp;</td>
			<td style="width: 55%;">President and Chief Executive Officer</td>
		</tr>
		<tr>
			<td style="width: 45%;">&nbsp;</td>
			<td style="width: 55%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="width: 45%;">&nbsp;</td>
			<td style="width: 55%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="width: 45%;">&nbsp;</td>
			<td style="width: 55%;"><u>/s/ ERIC J. SCHOEN</u>&nbsp;</td>
		</tr>
		<tr>
			<td style="width: 45%;">&nbsp;</td>
			<td style="width: 55%;">Eric J. Schoen,</td>
		</tr>
		<tr>
			<td style="width: 45%;">&nbsp;</td>
			<td style="width: 55%;">Chief Financial Officer</td>
		</tr>

</table>

<p style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; margin: 0pt;">&nbsp;</p>

<p style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; margin: 0pt;">&nbsp;</p>

<div class="LAST-PAGE-BREAK">
<div class="PGFTR">
<div class="hf-row">
<div class="hf-cell PGNUM">&nbsp;</div>
</div>
</div>
</div>


</body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-97
<SEQUENCE>10
<FILENAME>ex_756951.htm
<DESCRIPTION>EXHIBIT 97
<TEXT>
<html><head>
	<title>ex_756951.htm</title>

	<!-- Generated by ThunderDome Portal - 12/12/2024 8:41:41 PM --><meta charset="utf-8"><meta name="format-detection" content="telephone=no">
</head>
<body style="font-size:10pt;font-family:'Times New Roman';padding:0in .1in;">
<p style="margin: 0px 0pt; text-align: right; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt"><b>Exhibit 97</b></font></p>

<p style="margin: 0px 0pt; text-align: left; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;"><img alt="ex_611641img001.jpg" src="ex_611641img001.jpg" style="width:470;height:123;"></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:small-caps;text-align:center;margin:0pt;">Policy Regarding Recovery of Erroneously Awarded Compensation<br>
<b>Effective October 2, 2023</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">This Policy Regarding Recovery of Erroneously Awarded Compensation (the &#8220;<b><i>Policy</i></b>&#8221;) is established by Cassava Sciences, Inc. (the &#8220;<b><i>Company</i></b>&#8221;), a Delaware corporation, effective as of October 2, 2023 (the &#8220;<b><i>Effective Date</i></b>&#8221;).</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>1. </b>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<b>Purpose</b>.<b> </b>The Company is committed to promoting high standards of honest and ethical business conduct and compliance with applicable laws, rules, and regulations. In accordance with the applicable rules of The Nasdaq Stock Market (the &#8220;<b><i>Nasdaq Rules</i></b>&#8221;) and Section 10D and Rule 10D-1 of the Securities Exchange Act of 1934, as amended (the &#8220;<b><i>Exchange Act</i></b>&#8221;) (&#8220;<b><i>Rule 10D-1</i></b>&#8221;), this Policy explains when the Company will be required to seek recovery of Incentive Compensation erroneously awarded to a Covered Person.&nbsp; All capitalized terms used and not otherwise defined herein shall have the meanings set forth in Section 11, below.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>2. </b>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<b>Miscalculation of Financial Reporting Measure Results</b>. In the event of a Restatement, the Company will seek to recover, reasonably promptly, all Recoverable Incentive Compensation from a Covered Person in accordance with this Policy, the Nasdaq Rules, and Rule 10D-1. Such recovery, in the case of a Restatement, will be made without regard to any individual knowledge or responsibility related to the Restatement.&nbsp; Notwithstanding the foregoing, if the Company is required to undertake a Restatement, the Company will not be required to recover the Recoverable Incentive Compensation if the Compensation Committee determines it Impracticable to do so, in the reasonable exercise of its business judgment after reviewing all the relevant facts and circumstances.&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">If such Recoverable Incentive Compensation was not awarded or paid on a formulaic basis, the Company will seek to recover the amount of Recoverable Incentive Compensation that the Compensation Committee determines in good faith should be recouped pursuant to this Policy.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>3. </b>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<b>Other Actions</b>. The Compensation Committee may, subject to applicable law, seek recovery in the manner it chooses, including by seeking reimbursement from the Covered Person of all or part of the compensation awarded or paid, by electing to withhold unpaid compensation, by set-off, or by rescinding or canceling unvested stock.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">In the reasonable exercise of its business judgment under this Policy, the Compensation Committee may in its sole discretion determine whether and to what extent additional action is appropriate to address the circumstances surrounding a Restatement to minimize the likelihood of any recurrence and to impose such other discipline as it deems appropriate.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>4. </b>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<b>No Indemnification or Reimbursement. </b>Notwithstanding the terms of any other policy, program, agreement, or arrangement, in no event will the Company or any of its affiliates indemnify or reimburse a Covered Person for any loss under this Policy and in no event will the Company or any of its affiliates pay premiums on any insurance policy that would cover a Covered Person&#8217;s potential obligations with respect to Recoverable Incentive Compensation under this Policy.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>5. </b>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<b>Administration and Interpretation of Policy. </b>The Compensation Committee shall have the sole and exclusive authority to administer this Policy in accordance with and subject to the Nasdaq Rules and Rule 10D-1. The Compensation Committee is authorized to make such determinations and interpretations and to take such actions as it deems necessary, appropriate, or advisable for the administration of this Policy and for the Company&#8217;s continued compliance with Nasdaq Rules, Section 10D, Rule 10D-1, and any other applicable law, regulation, rule, or interpretation of the U.S. Securities and Exchange Commission (&#8220;<b><i>SEC</i></b>&#8221;) or Nasdaq promulgated or issued therewith.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>6. </b>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<b>Other Claims and Rights. </b>The remedies under this Policy are in addition to, and not in lieu of, any legal and equitable claims the Company or any of its affiliates may have or any actions that may be imposed by law enforcement agencies, regulators, administrative bodies, or other authorities. Further, the exercise by the Compensation Committee of any rights pursuant to this Policy will not impact any other rights that the Company or any of its affiliates may have with respect to any Covered Person subject to this Policy.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">This Policy has been established for the exclusive benefit of the Company. This Policy does not confer any rights, remedies, or authority upon, nor shall this Policy be enforced by, any person or entity other than the Company, the Board, and the Compensation Committee as set forth in this Policy.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>7. </b>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<b>Acknowledgement by Covered Persons; Condition to Eligibility for Incentive Compensation. </b>The Company will provide notice to and seek acknowledgement of this Policy from each Covered Person, provided that the failure to provide such notice or obtain such acknowledgement will have no impact on the applicability or enforceability of this Policy. After the Effective Date, the Company must be in receipt of a Covered Person&#8217;s acknowledgement as a condition to such Covered Person&#8217;s eligibility to receive Incentive Compensation.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>8. </b>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<b>Amendment; Termination</b>. The Board or the Compensation Committee may in its discretion amend or terminate this Policy at any time as it deems necessary. Notwithstanding anything in this Section 8 to the contrary, no amendment or termination of this Policy shall be effective if such amendment or termination would (after taking into account any actions taken by the Company contemporaneously with such amendment or termination) cause the Company to violate any federal securities laws, SEC rule, or Nasdaq Rule.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>9. </b>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<b>Effectiveness. </b>Except as otherwise determined in writing by the Compensation Committee, this Policy will apply to any Incentive Compensation that is Received by a Covered Person on or after the Effective Date.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>10. </b>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<b>Disclosure Requirements.</b> The Company shall file all disclosures with respect to this Policy required by applicable SEC filings and rulings.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>11.</b>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<b>Definitions. </b> For purposes of this Policy, the following capitalized terms shall have the meanings set forth below.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>11.1</b>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#8220;<b><i>Applicable Period</i></b>&#8221; means the three completed fiscal years of the Company immediately preceding the earlier of (i) the date the Board, a committee of the Board, or the officer or officers of the Company authorized to take such action if Board action is not required, concludes (or reasonably should have concluded) that a Restatement is required or (ii) the date a court, regulator, or other legally authorized body directs the Company to prepare a Restatement. The &#8220;Applicable Period&#8221; also includes any transition period (that results from a change in the Company&#8217;s fiscal year) within or immediately following the three completed fiscal years identified in the preceding sentence.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>11.2</b>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#8220;<b><i>Board</i></b>&#8221; means the Board of Directors of the Company.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>11.3</b>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#8220;<b><i>Company</i></b>&#8221; shall refer solely and exclusively to Cassava Sciences, Inc. and shall not include any other person or entity, including any successor company or acquiror.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>11.4</b>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#8220;<b><i>Compensation Committee</i></b>&#8221; means the Company&#8217;s committee of independent directors responsible for executive compensation decisions, or in the absence of such a committee, a majority of the independent directors serving on the Board of the Company.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>11.5</b>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#8220;<b><i>Covered Person</i></b>&#8221; means any person who is, or was at any time, during the Applicable Period, an Executive Officer of the Company.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>11.6</b>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#8220;<b><i>Executive Officer</i></b>&#8221; means each individual who is currently or was previously designated as an &#8220;officer&#8221; of the Company as defined in Rule 16a-1(f) under the Exchange Act. For the avoidance of doubt, the identification of an executive officer for purposes of this Policy shall include each executive officer who is or was identified pursuant to Item 401(b) of Regulation S-K or Item 6.A of Form 20-F, as applicable, as well as the principal financial officer and principal accounting officer (or, if there is no principal accounting officer, the controller).</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>11.7</b>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#8220;<b><i>Financial Reporting Measure</i></b>&#8221; means a measure that is determined and presented in accordance with the accounting principles used in preparing the Company&#8217;s financial statements (including but not limited to &#8220;non-GAAP&#8221; financial measures, such as those appearing in the Company&#8217;s earnings releases or Management Discussion and Analysis), and any measure that is derived wholly or in part from such measure. Stock price and total shareholder return (and any measures derived wholly or in part therefrom) shall be considered Financial Reporting Measures.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>11.8</b>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#8220;<b><i>Impracticable.</i></b>&#8221; The Compensation Committee may determine in good faith that recovery of Recoverable Incentive Compensation is &#8220;Impracticable&#8221; if: (i) pursuing such recovery would violate home country law of the jurisdiction of incorporation of the Company where that law was adopted prior to November 28, 2022 and the Company provides an opinion of home country counsel to that effect acceptable to the Company&#8217;s applicable listing exchange; (ii) the direct expense paid to a third party to assist in enforcing this Policy would exceed the Recoverable Incentive Compensation and the Company has (A) made a reasonable attempt to recover such amounts and (B) provided documentation of such attempts to recover to the Company&#8217;s applicable listing exchange; or (iii) recovery would likely cause an otherwise tax-qualified retirement plan, under which benefits are broadly available to employees of the Company, to fail to meet the requirements of Section 401(a)(13) or Section 411(a) of the Internal Revenue Code of 1986, as amended.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>11.9</b>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#8220;<b><i>Incentive Compensation</i></b>&#8221; means any compensation that is granted, earned, or vested based wholly or in part upon the attainment of a Financial Reporting Measure. Incentive Compensation does not include any base salaries (except with respect to any salary increases earned wholly or in part based on the attainment of a Financial Reporting Measure performance goal); bonuses paid solely at the discretion of the Compensation Committee or Board that are not paid from a &#8220;bonus pool&#8221; that is determined by satisfying a Financial Reporting Measure performance goal; bonuses paid solely upon satisfying one or more subjective standards and/or completion of a specified employment period; non-equity incentive plan awards earned solely upon satisfying one or more strategic measures or operational measures; and equity awards that vest solely based on the passage of time and/or attaining one or more non-Financial Reporting Measures.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>11.10</b>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#8220;<b><i>Received.</i></b>&#8221; Incentive Compensation is deemed &#8220;Received&#8221; in the Company&#8217;s fiscal period during which the Financial Reporting Measure specified in the Incentive Compensation award is attained, even if the payment or grant of the Incentive Compensation occurs after the end of that period.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>11.11</b>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#8220;<b><i>Recoverable Incentive Compensation</i></b>&#8221; means the amount of any erroneously awarded Incentive Compensation (calculated on a pre-tax basis) Received by a Covered Person during the Applicable Period that is in excess of the amount that otherwise would have been Received if the calculation were based on the Restatement. For the avoidance of doubt Recoverable Incentive Compensation does not include any Incentive Compensation Received by a person (i) before such person began service in a position or capacity meeting the definition of an Executive Officer, (ii) who did not serve as an Executive Officer at any time during the performance period for that Incentive Compensation, or (iii) during any period the Company did not have a class of its securities listed on a national securities exchange or a national securities association. For Incentive Compensation based on (or derived from) stock price or total shareholder return where the amount of Recoverable Incentive Compensation is not subject to mathematical recalculation directly from the information in the applicable Restatement, the amount will be determined by the Compensation Committee based on a reasonable estimate of the effect of the Restatement on the stock price or total shareholder return upon which the Incentive Compensation was Received (in which case, the Company will maintain documentation of such determination of that reasonable estimate and provide such documentation to the Company&#8217;s applicable listing exchange).</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>11.12</b>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#8220;<b><i>Restatement</i></b>&#8221; means an accounting restatement of any of the Company&#8217;s financial statements filed with the Securities and Exchange Commission under the Exchange Act, or the Securities Act of 1933, as amended, due to the Company&#8217;s material noncompliance with any financial reporting requirement under U.S. securities laws, including any required accounting restatement to correct an error in previously issued financial statements that is material to the previously issued financial statements (commonly referred to as &#8220;Big R&#8221; restatements), or that would result in a material misstatement if the error were corrected in the current period or left uncorrected in the current period (commonly referred to as &#8220;little r&#8221; restatements).</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="LAST-PAGE-BREAK">
<div class="PGFTR">
<div class="hf-row">
<div class="hf-cell PGNUM">&nbsp;</div>
</div>
</div>
</div>


</body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>11
<FILENAME>sava-20241231.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
<!--Generated by ThunderDome XBRL - 08:53PM UTC 2025-03-03--><xsd:schema xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:country="http://xbrl.sec.gov/country/2024" xmlns:currency="http://xbrl.sec.gov/currency/2024" xmlns:cyd="http://xbrl.sec.gov/cyd/2024" xmlns:dei="http://xbrl.sec.gov/dei/2024" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:ecd="http://xbrl.sec.gov/ecd/2024" xmlns:enum2="http://xbrl.org/2020/extensible-enumerations-2.0" xmlns:exch="http://xbrl.sec.gov/exch/2024" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:naics="http://xbrl.sec.gov/naics/2024" xmlns:sava="http://www.cassavasciences.com/20241231" xmlns:sic="http://xbrl.sec.gov/sic/2024" xmlns:srt="http://fasb.org/srt/2024" xmlns:srt-types="http://fasb.org/srt-types/2024" xmlns:stpr="http://xbrl.sec.gov/stpr/2024" xmlns:us-gaap="http://fasb.org/us-gaap/2024" xmlns:us-types="http://fasb.org/us-types/2024" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.cassavasciences.com/20241231">
  <xsd:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xsd:import namespace="http://xbrl.sec.gov/country/2024" schemaLocation="https://xbrl.sec.gov/country/2024/country-2024.xsd"/>
  <xsd:import namespace="http://xbrl.sec.gov/naics/2024" schemaLocation="https://xbrl.sec.gov/naics/2024/naics-2024.xsd"/>
  <xsd:import namespace="http://xbrl.sec.gov/exch/2024" schemaLocation="https://xbrl.sec.gov/exch/2024/exch-2024.xsd"/>
  <xsd:import namespace="http://xbrl.sec.gov/dei/2024" schemaLocation="https://xbrl.sec.gov/dei/2024/dei-2024.xsd"/>
  <xsd:import namespace="http://fasb.org/srt/2024" schemaLocation="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd"/>
  <xsd:import namespace="http://xbrl.sec.gov/currency/2024" schemaLocation="https://xbrl.sec.gov/currency/2024/currency-2024.xsd"/>
  <xsd:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
  <xsd:import namespace="http://xbrl.sec.gov/stpr/2024" schemaLocation="https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd"/>
  <xsd:import namespace="http://fasb.org/srt-types/2024" schemaLocation="https://xbrl.fasb.org/srt/2024/elts/srt-types-2024.xsd"/>
  <xsd:import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd"/>
  <xsd:import namespace="http://xbrl.org/2020/extensible-enumerations-2.0" schemaLocation="https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd"/>
  <xsd:import namespace="http://xbrl.sec.gov/cyd-af-sub/2024" schemaLocation="https://xbrl.sec.gov/cyd/2024/cyd-af-sub-2024.xsd"/>
  <xsd:import namespace="http://xbrl.sec.gov/sic/2024" schemaLocation="https://xbrl.sec.gov/sic/2024/sic-2024.xsd"/>
  <xsd:import namespace="http://xbrl.sec.gov/ecd/2024" schemaLocation="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd"/>
  <xsd:import namespace="http://fasb.org/us-types/2024" schemaLocation="https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd"/>
  <xsd:import namespace="http://fasb.org/us-gaap/2024" schemaLocation="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd"/>
  <xsd:import namespace="http://www.xbrl.org/2009/role/negated" schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd"/>
  <xsd:annotation>
    <xsd:appinfo>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="sava-20241231_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="sava-20241231_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="sava-20241231_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="sava-20241231_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="statement-document-and-entity-information" roleURI="http://www.cassavasciences.com/20241231/role/statement-document-and-entity-information">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">000 - Document - Document And Entity Information</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-consolidated-balance-sheets" roleURI="http://www.cassavasciences.com/20241231/role/statement-consolidated-balance-sheets">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">001 - Statement - Consolidated Balance Sheets</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-consolidated-balance-sheets-parentheticals" roleURI="http://www.cassavasciences.com/20241231/role/statement-consolidated-balance-sheets-parentheticals">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">002 - Statement - Consolidated Balance Sheets (Parentheticals)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-consolidated-statements-of-operations-" roleURI="http://www.cassavasciences.com/20241231/role/statement-consolidated-statements-of-operations-">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">003 - Statement - Consolidated Statements of Operations</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-consolidated-statements-of-stockholders-equity" roleURI="http://www.cassavasciences.com/20241231/role/statement-consolidated-statements-of-stockholders-equity">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">004 - Statement - Consolidated Statements of Stockholders' Equity</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-consolidated-statements-of-cash-flows" roleURI="http://www.cassavasciences.com/20241231/role/statement-consolidated-statements-of-cash-flows">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">005 - Statement - Consolidated Statements of Cash Flows</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-1-general-liquidity-and-basis-of-presentation" roleURI="http://www.cassavasciences.com/20241231/role/statement-note-1-general-liquidity-and-basis-of-presentation">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">995552 - Disclosure - Note 1 - General, Liquidity and Basis of Presentation</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-2-summary-of-significant-accounting-policies" roleURI="http://www.cassavasciences.com/20241231/role/statement-note-2-summary-of-significant-accounting-policies">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">995553 - Disclosure - Note 2 - Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-3-prepaid-expenses-and-other-current-assets" roleURI="http://www.cassavasciences.com/20241231/role/statement-note-3-prepaid-expenses-and-other-current-assets">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">995554 - Disclosure - Note 3 - Prepaid Expenses and Other Current Assets</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-4-real-property-and-other-income-expense" roleURI="http://www.cassavasciences.com/20241231/role/statement-note-4-real-property-and-other-income-expense">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">995555 - Disclosure - Note 4 - Real Property and Other Income, Expense</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-5-property-and-equipment" roleURI="http://www.cassavasciences.com/20241231/role/statement-note-5-property-and-equipment">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">995556 - Disclosure - Note 5 - Property and Equipment</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-6-intangible-assets" roleURI="http://www.cassavasciences.com/20241231/role/statement-note-6-intangible-assets">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">995557 - Disclosure - Note 6 - Intangible Assets</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-7-stockholders-equity-and-stockbased-compensation" roleURI="http://www.cassavasciences.com/20241231/role/statement-note-7-stockholders-equity-and-stockbased-compensation">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">995558 - Disclosure - Note 7 - Stockholders' Equity and Stock-based Compensation</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-8-employee-401k-benefit-plan" roleURI="http://www.cassavasciences.com/20241231/role/statement-note-8-employee-401k-benefit-plan">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">995559 - Disclosure - Note 8 - Employee 401(k) Benefit Plan</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-9-income-taxes" roleURI="http://www.cassavasciences.com/20241231/role/statement-note-9-income-taxes">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">995560 - Disclosure - Note 9 - Income Taxes</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-10-commitments" roleURI="http://www.cassavasciences.com/20241231/role/statement-note-10-commitments">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">995561 - Disclosure - Note 10 - Commitments</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-11-2020-cash-incentive-bonus-plan" roleURI="http://www.cassavasciences.com/20241231/role/statement-note-11-2020-cash-incentive-bonus-plan">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">995562 - Disclosure - Note 11 - 2020 Cash Incentive Bonus Plan</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-12-contingencies" roleURI="http://www.cassavasciences.com/20241231/role/statement-note-12-contingencies">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">995563 - Disclosure - Note 12 - Contingencies</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-13-warrant-dividend-distribution" roleURI="http://www.cassavasciences.com/20241231/role/statement-note-13-warrant-dividend-distribution">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">995564 - Disclosure - Note 13 - Warrant Dividend Distribution</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-14-subsequent-event" roleURI="http://www.cassavasciences.com/20241231/role/statement-note-14-subsequent-event">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">995565 - Disclosure - Note 14 - Subsequent Event</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-significant-accounting-policies-policies" roleURI="http://www.cassavasciences.com/20241231/role/statement-significant-accounting-policies-policies">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">995567 - Disclosure - Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-2-summary-of-significant-accounting-policies-tables" roleURI="http://www.cassavasciences.com/20241231/role/statement-note-2-summary-of-significant-accounting-policies-tables">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">995568 - Disclosure - Note 2 - Summary of Significant Accounting Policies (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-3-prepaid-expenses-and-other-current-assets-tables" roleURI="http://www.cassavasciences.com/20241231/role/statement-note-3-prepaid-expenses-and-other-current-assets-tables">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">995569 - Disclosure - Note 3 - Prepaid Expenses and Other Current Assets (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-4-real-property-and-other-income-expense-tables" roleURI="http://www.cassavasciences.com/20241231/role/statement-note-4-real-property-and-other-income-expense-tables">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">995570 - Disclosure - Note 4 - Real Property and Other Income, Expense (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-5-property-and-equipment-tables" roleURI="http://www.cassavasciences.com/20241231/role/statement-note-5-property-and-equipment-tables">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">995571 - Disclosure - Note 5 - Property and Equipment (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-6-intangible-assets-tables" roleURI="http://www.cassavasciences.com/20241231/role/statement-note-6-intangible-assets-tables">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">995572 - Disclosure - Note 6 - Intangible Assets (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-7-stockholders-equity-and-stockbased-compensation-tables" roleURI="http://www.cassavasciences.com/20241231/role/statement-note-7-stockholders-equity-and-stockbased-compensation-tables">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">995573 - Disclosure - Note 7 - Stockholders' Equity and Stock-based Compensation (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-9-income-taxes-tables" roleURI="http://www.cassavasciences.com/20241231/role/statement-note-9-income-taxes-tables">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">995574 - Disclosure - Note 9 - Income Taxes (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-13-warrant-dividend-distribution-tables" roleURI="http://www.cassavasciences.com/20241231/role/statement-note-13-warrant-dividend-distribution-tables">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">995575 - Disclosure - Note 13 - Warrant Dividend Distribution (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-1-general-liquidity-and-basis-of-presentation-details-textual" roleURI="http://www.cassavasciences.com/20241231/role/statement-note-1-general-liquidity-and-basis-of-presentation-details-textual">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">995576 - Disclosure - Note 1 - General, Liquidity and Basis of Presentation (Details Textual)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-2-summary-of-significant-accounting-policies-details-textual" roleURI="http://www.cassavasciences.com/20241231/role/statement-note-2-summary-of-significant-accounting-policies-details-textual">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">995577 - Disclosure - Note 2 - Summary of Significant Accounting Policies (Details Textual)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-2-summary-of-significant-accounting-policies-quantitative-information-of-warrants-details" roleURI="http://www.cassavasciences.com/20241231/role/statement-note-2-summary-of-significant-accounting-policies-quantitative-information-of-warrants-details">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">995578 - Disclosure - Note 2 - Summary of Significant Accounting Policies - Quantitative Information of Warrants (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-2-summary-of-significant-accounting-policies-summary-of-codm-segments-details" roleURI="http://www.cassavasciences.com/20241231/role/statement-note-2-summary-of-significant-accounting-policies-summary-of-codm-segments-details">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">995579 - Disclosure - Note 2 - Summary of Significant Accounting Policies - Summary Of CODM Segments (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-2-significant-accounting-policies-calculation-of-net-loss-per-share-details" roleURI="http://www.cassavasciences.com/20241231/role/statement-note-2-significant-accounting-policies-calculation-of-net-loss-per-share-details">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">995580 - Disclosure - Note 2 - Significant Accounting Policies - Calculation of Net Loss Per Share (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-3-prepaid-expenses-and-other-current-assets-prepaid-expenses-and-other-current-assets-details" roleURI="http://www.cassavasciences.com/20241231/role/statement-note-3-prepaid-expenses-and-other-current-assets-prepaid-expenses-and-other-current-assets-details">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">995581 - Disclosure - Note 3 - Prepaid Expenses and Other Current Assets - Prepaid Expenses and Other Current Assets (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-4-real-property-and-other-income-expense-details-textual" roleURI="http://www.cassavasciences.com/20241231/role/statement-note-4-real-property-and-other-income-expense-details-textual">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">995582 - Disclosure - Note 4 - Real Property and Other Income, Expense (Details Textual)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-4-real-property-and-other-income-expense-components-of-other-income-net-details" roleURI="http://www.cassavasciences.com/20241231/role/statement-note-4-real-property-and-other-income-expense-components-of-other-income-net-details">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">995583 - Disclosure - Note 4 - Real Property and Other Income, Expense - Components of Other Income, Net (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-5-property-and-equipment-details-textual" roleURI="http://www.cassavasciences.com/20241231/role/statement-note-5-property-and-equipment-details-textual">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">995584 - Disclosure - Note 5 - Property and Equipment (Details Textual)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-5-property-and-equipment-components-of-property-and-equipment-details" roleURI="http://www.cassavasciences.com/20241231/role/statement-note-5-property-and-equipment-components-of-property-and-equipment-details">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">995585 - Disclosure - Note 5 - Property and Equipment - Components of Property and Equipment (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-6-intangible-assets-details-textual" roleURI="http://www.cassavasciences.com/20241231/role/statement-note-6-intangible-assets-details-textual">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">995586 - Disclosure - Note 6 - Intangible Assets (Details Textual)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-6-intangible-assets-components-of-intangible-assets-details" roleURI="http://www.cassavasciences.com/20241231/role/statement-note-6-intangible-assets-components-of-intangible-assets-details">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">995587 - Disclosure - Note 6 - Intangible Assets - Components of Intangible Assets (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-6-intangible-assets-amortization-expense-for-finitelived-intangible-assets-details" roleURI="http://www.cassavasciences.com/20241231/role/statement-note-6-intangible-assets-amortization-expense-for-finitelived-intangible-assets-details">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">995588 - Disclosure - Note 6 - Intangible Assets - Amortization Expense for Finite-lived Intangible Assets (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-7-stockholders-equity-and-stockbased-compensation-details-textual" roleURI="http://www.cassavasciences.com/20241231/role/statement-note-7-stockholders-equity-and-stockbased-compensation-details-textual">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">995589 - Disclosure - Note 7 - Stockholders' Equity and Stock-based Compensation (Details Textual)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-7-stockholders-equity-and-stockbased-compensation-stock-option-activity-details" roleURI="http://www.cassavasciences.com/20241231/role/statement-note-7-stockholders-equity-and-stockbased-compensation-stock-option-activity-details">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">995590 - Disclosure - Note 7 - Stockholders' Equity and Stock-based Compensation - Stock Option Activity (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-7-stockholders-equity-and-stockbased-compensation-schedule-of-stock-options-by-exercise-price-details" roleURI="http://www.cassavasciences.com/20241231/role/statement-note-7-stockholders-equity-and-stockbased-compensation-schedule-of-stock-options-by-exercise-price-details">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">995591 - Disclosure - Note 7 - Stockholders' Equity and Stock-based Compensation - Schedule of Stock Options by Exercise Price (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-7-stockholders-equity-and-stockbased-compensation-stock-option-valuation-assumptions-details" roleURI="http://www.cassavasciences.com/20241231/role/statement-note-7-stockholders-equity-and-stockbased-compensation-stock-option-valuation-assumptions-details">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">995592 - Disclosure - Note 7 - Stockholders' Equity and Stock-based Compensation - Stock Option Valuation Assumptions (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-7-stockholders-equity-and-stockbased-compensation-stock-option-and-performance-award-activity-details" roleURI="http://www.cassavasciences.com/20241231/role/statement-note-7-stockholders-equity-and-stockbased-compensation-stock-option-and-performance-award-activity-details">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">995593 - Disclosure - Note 7 - Stockholders' Equity and Stock-based Compensation - Stock Option and Performance Award Activity (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-7-stockholders-equity-and-stockbased-compensation-stockbased-compensation-expense-details" roleURI="http://www.cassavasciences.com/20241231/role/statement-note-7-stockholders-equity-and-stockbased-compensation-stockbased-compensation-expense-details">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">995594 - Disclosure - Note 7 - Stockholders' Equity and Stock-based Compensation - Stock-based Compensation Expense (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-9-income-taxes-details-textual" roleURI="http://www.cassavasciences.com/20241231/role/statement-note-9-income-taxes-details-textual">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">995595 - Disclosure - Note 9 - Income Taxes (Details Textual)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-9-income-taxes-schedule-of-effective-income-tax-reconciliation-details" roleURI="http://www.cassavasciences.com/20241231/role/statement-note-9-income-taxes-schedule-of-effective-income-tax-reconciliation-details">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">995596 - Disclosure - Note 9 - Income Taxes - Schedule of Effective Income Tax Reconciliation (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-9-income-taxes-schedule-of-deferred-tax-assets-and-liabilities-details" roleURI="http://www.cassavasciences.com/20241231/role/statement-note-9-income-taxes-schedule-of-deferred-tax-assets-and-liabilities-details">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">995597 - Disclosure - Note 9 - Income Taxes - Schedule of Deferred Tax Assets and Liabilities (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-9-income-taxes-schedule-of-unrecognized-tax-benefits-details" roleURI="http://www.cassavasciences.com/20241231/role/statement-note-9-income-taxes-schedule-of-unrecognized-tax-benefits-details">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">995598 - Disclosure - Note 9 - Income Taxes - Schedule of Unrecognized Tax Benefits (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-10-commitments-details-textual" roleURI="http://www.cassavasciences.com/20241231/role/statement-note-10-commitments-details-textual">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">995599 - Disclosure - Note 10 - Commitments (Details Textual)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-11-2020-cash-incentive-bonus-plan-details-textual" roleURI="http://www.cassavasciences.com/20241231/role/statement-note-11-2020-cash-incentive-bonus-plan-details-textual">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">995600 - Disclosure - Note 11 - 2020 Cash Incentive Bonus Plan (Details Textual)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-12-contingencies-details-textual" roleURI="http://www.cassavasciences.com/20241231/role/statement-note-12-contingencies-details-textual">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">995601 - Disclosure - Note 12 - Contingencies (Details Textual)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-13-warrant-dividend-distribution-details-textual" roleURI="http://www.cassavasciences.com/20241231/role/statement-note-13-warrant-dividend-distribution-details-textual">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">995602 - Disclosure - Note 13 - Warrant Dividend Distribution (Details Textual)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-13-warrant-dividend-distribution-changes-in-warrants-outstanding-and-warrant-liability-details" roleURI="http://www.cassavasciences.com/20241231/role/statement-note-13-warrant-dividend-distribution-changes-in-warrants-outstanding-and-warrant-liability-details">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">995603 - Disclosure - Note 13 - Warrant Dividend Distribution - Changes in Warrants Outstanding and Warrant Liability (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-14-subsequent-event-details-textual" roleURI="http://www.cassavasciences.com/20241231/role/statement-note-14-subsequent-event-details-textual">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">995604 - Disclosure - Note 14 - Subsequent Event (Details Textual)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
    </xsd:appinfo>
  </xsd:annotation>
  <xsd:element id="sava_AccruedDevelopmentExpenseCurrent" name="AccruedDevelopmentExpenseCurrent" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant"/>
  <xsd:element id="sava_AdjustmentsToAdditionalPaidInCapitalDerecognitionOfWarrantLiabilitiesUponExerciseOfWarrants" name="AdjustmentsToAdditionalPaidInCapitalDerecognitionOfWarrantLiabilitiesUponExerciseOfWarrants" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="sava_AntislappLawsuitMember" name="AntislappLawsuitMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="sava_AtthemarketCommonStockOfferingMember" name="AtthemarketCommonStockOfferingMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="sava_CarryforwardSubjectToExpirationMember" name="CarryforwardSubjectToExpirationMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element id="sava_CashBonusIncentiveIncrementalAmounts" name="CashBonusIncentiveIncrementalAmounts" nillable="true" substitutionGroup="xbrli:item" type="xbrli:integerItemType" xbrli:periodType="instant"/>
  <xsd:element id="sava_CashIncentiveBonusAward" name="CashIncentiveBonusAward" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant"/>
  <xsd:element id="sava_CashIncentiveBonusAwardExceedsMaximum" name="CashIncentiveBonusAwardExceedsMaximum" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant"/>
  <xsd:element abstract="true" id="sava_CashIncentiveBonusPlanMember" name="CashIncentiveBonusPlanMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element id="sava_CashIncentiveBonusPlanTextBlock" name="CashIncentiveBonusPlanTextBlock" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType" xbrli:periodType="duration"/>
  <xsd:element id="sava_ClassOfWarrantOrRightExercisedDuringPeriod" name="ClassOfWarrantOrRightExercisedDuringPeriod" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="duration"/>
  <xsd:element id="sava_ClassOfWarrantOrRightFairValueOfCommonStockWarrantsPerWarrant" name="ClassOfWarrantOrRightFairValueOfCommonStockWarrantsPerWarrant" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:perShareItemType" xbrli:periodType="instant"/>
  <xsd:element id="sava_ClassOfWarrantOrRightIssuedDuringPeriod" name="ClassOfWarrantOrRightIssuedDuringPeriod" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="duration"/>
  <xsd:element id="sava_ClassOfWarrantOrRightRedemptionPricePerShare" name="ClassOfWarrantOrRightRedemptionPricePerShare" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:perShareItemType" xbrli:periodType="instant"/>
  <xsd:element id="sava_ClassOfWarrantsOrRightsCommonStockWarrantsRedeemed" name="ClassOfWarrantsOrRightsCommonStockWarrantsRedeemed" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="sava_CodmMonitoringMember" name="CodmMonitoringMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element id="sava_CommissionPercentageOfGrossProceeds" name="CommissionPercentageOfGrossProceeds" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:percentItemType" xbrli:periodType="duration"/>
  <xsd:element id="sava_ConsultingAgreementTerm" name="ConsultingAgreementTerm" nillable="true" substitutionGroup="xbrli:item" type="xbrli:integerItemType" xbrli:periodType="instant"/>
  <xsd:element id="sava_ConsultingServicePricePerHour" name="ConsultingServicePricePerHour" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant"/>
  <xsd:element id="sava_DeferredTaxAssetsCapitalizedResearchAndDevelopmentExpenses" name="DeferredTaxAssetsCapitalizedResearchAndDevelopmentExpenses" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant"/>
  <xsd:element id="sava_DerecognitionOfWarrantLiabilitiesThroughExercises" name="DerecognitionOfWarrantLiabilitiesThroughExercises" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="sava_DocumentAndEntityInformation" name="DocumentAndEntityInformation" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element id="sava_EffectiveIncomeTaxRateReconciliationChangeInFairValueOfWarrantLiabilities" name="EffectiveIncomeTaxRateReconciliationChangeInFairValueOfWarrantLiabilities" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:percentItemType" xbrli:periodType="duration"/>
  <xsd:element id="sava_EffectiveIncomeTaxRateReconciliationSection162mLimitationPercent" name="EffectiveIncomeTaxRateReconciliationSection162mLimitationPercent" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:percentItemType" xbrli:periodType="duration"/>
  <xsd:element id="sava_EffectiveIncomeTaxRateReconciliationTaxAttributeExpirationPercent" name="EffectiveIncomeTaxRateReconciliationTaxAttributeExpirationPercent" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:percentItemType" xbrli:periodType="duration"/>
  <xsd:element id="sava_EffectiveIncomeTaxRateReconciliationTaxCreditResearchAndDevelopmentPercent" name="EffectiveIncomeTaxRateReconciliationTaxCreditResearchAndDevelopmentPercent" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:percentItemType" xbrli:periodType="duration"/>
  <xsd:element id="sava_EquityOfferingMaximumAmount" name="EquityOfferingMaximumAmount" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant"/>
  <xsd:element id="sava_EquityOfferingPercentageOfCommission" name="EquityOfferingPercentageOfCommission" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:percentItemType" xbrli:periodType="instant"/>
  <xsd:element id="sava_ExerciseOfWarrantsResultingInDecreaseInWarrantLiability" name="ExerciseOfWarrantsResultingInDecreaseInWarrantLiability" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="sava_FormerPresidentAndChiefExecutiveOfficerMember" name="FormerPresidentAndChiefExecutiveOfficerMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="sava_FormerSeniorOfficerMember" name="FormerSeniorOfficerMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="sava_FormerSeniorVicePresidentMember" name="FormerSeniorVicePresidentMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element id="sava_GrossProceedsFromIssuanceOfWarrants" name="GrossProceedsFromIssuanceOfWarrants" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
  <xsd:element id="sava_IncreaseDecreaseInDevelopmentExpense" name="IncreaseDecreaseInDevelopmentExpense" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
  <xsd:element id="sava_IncreaseDecreaseInOperatingLeaseRightOfUseAssetsAndLiabilitiesNet" name="IncreaseDecreaseInOperatingLeaseRightOfUseAssetsAndLiabilitiesNet" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="sava_IndefiniteLifeCarryforwardsMember" name="IndefiniteLifeCarryforwardsMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element id="sava_InsuranceSettlementsMaximumRecoveryLimit" name="InsuranceSettlementsMaximumRecoveryLimit" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
  <xsd:element id="sava_IssuanceOfWarrantsResultingInRecognitionOfWarrantLiabilities" name="IssuanceOfWarrantsResultingInRecognitionOfWarrantLiabilities" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
  <xsd:element id="sava_LeasesAndCommitmentsDisclosureTextBlock" name="LeasesAndCommitmentsDisclosureTextBlock" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="sava_LeasingCommissionsAndOtherMember" name="LeasingCommissionsAndOtherMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="sava_LicenseAgreementMember" name="LicenseAgreementMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="sava_NoteToFinancialStatementDetailsTextual" name="NoteToFinancialStatementDetailsTextual" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="sava_NotesToFinancialStatements" name="NotesToFinancialStatements" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="sava_NotesToFinancialStatementsAbstract" name="NotesToFinancialStatementsAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element id="sava_NumberOfFormerEmployees" name="NumberOfFormerEmployees" nillable="true" substitutionGroup="xbrli:item" type="xbrli:integerItemType" xbrli:periodType="duration"/>
  <xsd:element id="sava_PaymentsForCashIncentiveBonus" name="PaymentsForCashIncentiveBonus" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
  <xsd:element id="sava_PaymentsOfWarrantExerciseCosts" name="PaymentsOfWarrantExerciseCosts" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
  <xsd:element id="sava_PercentageOfOccupancy" name="PercentageOfOccupancy" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:percentItemType" xbrli:periodType="instant"/>
  <xsd:element id="sava_PercentageValuationMilestoneCashBonusAwardSubjectToApprovalAndAdjustment" name="PercentageValuationMilestoneCashBonusAwardSubjectToApprovalAndAdjustment" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:percentItemType" xbrli:periodType="instant"/>
  <xsd:element id="sava_PerformancePlanMinimumNumberOfDaysValuationMilestoneMustBeAchievedAndMaintained" name="PerformancePlanMinimumNumberOfDaysValuationMilestoneMustBeAchievedAndMaintained" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="duration"/>
  <xsd:element id="sava_PerformancePlanValuationMilestoneAmount" name="PerformancePlanValuationMilestoneAmount" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant"/>
  <xsd:element id="sava_PrepaidExpensesAndOtherCurrentAssetsTextBock" name="PrepaidExpensesAndOtherCurrentAssetsTextBock" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType" xbrli:periodType="duration"/>
  <xsd:element id="sava_ProceedsFromWarrantsExercisedThatObligatedToPayCommission" name="ProceedsFromWarrantsExercisedThatObligatedToPayCommission" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="sava_RangeFiveMember" name="RangeFiveMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="sava_RangeFourMember" name="RangeFourMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="sava_RangeOneMember" name="RangeOneMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="sava_RangeThreeMember" name="RangeThreeMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="sava_RangeTwoMember" name="RangeTwoMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element id="sava_RedemptionPercentageOfWarrants" name="RedemptionPercentageOfWarrants" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:percentItemType" xbrli:periodType="instant"/>
  <xsd:element id="sava_RelatedPartyTransactionPolicyTextBlock" name="RelatedPartyTransactionPolicyTextBlock" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="sava_ShareholderDerivativeActionsDelawareCourtMember" name="ShareholderDerivativeActionsDelawareCourtMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="sava_ShareholderDerivativeActionsMember" name="ShareholderDerivativeActionsMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="sava_ShareholderDerivativeActionsTexasCourtMember" name="ShareholderDerivativeActionsTexasCourtMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="sava_ShareholderDerivativeActionsTexasStateCourtMember" name="ShareholderDerivativeActionsTexasStateCourtMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="sava_SimufilamActiveIngredientMember" name="SimufilamActiveIngredientMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element id="sava_StockIssuedDuringPeriodSharesWarrantExercises" name="StockIssuedDuringPeriodSharesWarrantExercises" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="duration"/>
  <xsd:element id="sava_StockIssuedDuringPeriodValueWarrantExercises" name="StockIssuedDuringPeriodValueWarrantExercises" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
  <xsd:element id="sava_StockOptionsExercisedNetSettledSatisfactionOfExercisePrice" name="StockOptionsExercisedNetSettledSatisfactionOfExercisePrice" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="sava_The2018EquityIncentivePlanMember" name="The2018EquityIncentivePlanMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="sava_The2022RegisteredDirectOfferingMember" name="The2022RegisteredDirectOfferingMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="sava_ViolationsOfFederalSecuritiesLawsMember" name="ViolationsOfFederalSecuritiesLawsMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element id="sava_WarrantDividendDistributionTextBlock" name="WarrantDividendDistributionTextBlock" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType" xbrli:periodType="duration"/>
  <xsd:element id="sava_WarrantRedemptionPrice" name="WarrantRedemptionPrice" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:perShareItemType" xbrli:periodType="instant"/>
  <xsd:element abstract="true" id="sava_WarrantsToPurchaseCommonStockMember" name="WarrantsToPurchaseCommonStockMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="sava_WorkforceReductionMember" name="WorkforceReductionMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="sava_YaleUniversityMember" name="YaleUniversityMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="sava_statement-statement-note-13-warrant-dividend-distribution-changes-in-warrants-outstanding-and-warrant-liability-details" name="statement-statement-note-13-warrant-dividend-distribution-changes-in-warrants-outstanding-and-warrant-liability-details" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="sava_statement-statement-note-13-warrant-dividend-distribution-tables" name="statement-statement-note-13-warrant-dividend-distribution-tables" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="sava_statement-statement-note-2-significant-accounting-policies-calculation-of-net-loss-per-share-details" name="statement-statement-note-2-significant-accounting-policies-calculation-of-net-loss-per-share-details" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="sava_statement-statement-note-2-summary-of-significant-accounting-policies-quantitative-information-of-warrants-details" name="statement-statement-note-2-summary-of-significant-accounting-policies-quantitative-information-of-warrants-details" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="sava_statement-statement-note-2-summary-of-significant-accounting-policies-summary-of-codm-segments-details" name="statement-statement-note-2-summary-of-significant-accounting-policies-summary-of-codm-segments-details" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="sava_statement-statement-note-2-summary-of-significant-accounting-policies-tables" name="statement-statement-note-2-summary-of-significant-accounting-policies-tables" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="sava_statement-statement-note-3-prepaid-expenses-and-other-current-assets-prepaid-expenses-and-other-current-assets-details" name="statement-statement-note-3-prepaid-expenses-and-other-current-assets-prepaid-expenses-and-other-current-assets-details" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="sava_statement-statement-note-3-prepaid-expenses-and-other-current-assets-tables" name="statement-statement-note-3-prepaid-expenses-and-other-current-assets-tables" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="sava_statement-statement-note-4-real-property-and-other-income-expense-components-of-other-income-net-details" name="statement-statement-note-4-real-property-and-other-income-expense-components-of-other-income-net-details" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="sava_statement-statement-note-4-real-property-and-other-income-expense-tables" name="statement-statement-note-4-real-property-and-other-income-expense-tables" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="sava_statement-statement-note-5-property-and-equipment-components-of-property-and-equipment-details" name="statement-statement-note-5-property-and-equipment-components-of-property-and-equipment-details" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="sava_statement-statement-note-5-property-and-equipment-tables" name="statement-statement-note-5-property-and-equipment-tables" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="sava_statement-statement-note-6-intangible-assets-amortization-expense-for-finitelived-intangible-assets-details" name="statement-statement-note-6-intangible-assets-amortization-expense-for-finitelived-intangible-assets-details" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="sava_statement-statement-note-6-intangible-assets-components-of-intangible-assets-details" name="statement-statement-note-6-intangible-assets-components-of-intangible-assets-details" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="sava_statement-statement-note-6-intangible-assets-tables" name="statement-statement-note-6-intangible-assets-tables" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="sava_statement-statement-note-7-stockholders-equity-and-stockbased-compensation-schedule-of-stock-options-by-exercise-price-details" name="statement-statement-note-7-stockholders-equity-and-stockbased-compensation-schedule-of-stock-options-by-exercise-price-details" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="sava_statement-statement-note-7-stockholders-equity-and-stockbased-compensation-stock-option-activity-details" name="statement-statement-note-7-stockholders-equity-and-stockbased-compensation-stock-option-activity-details" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="sava_statement-statement-note-7-stockholders-equity-and-stockbased-compensation-stock-option-and-performance-award-activity-details" name="statement-statement-note-7-stockholders-equity-and-stockbased-compensation-stock-option-and-performance-award-activity-details" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="sava_statement-statement-note-7-stockholders-equity-and-stockbased-compensation-stock-option-valuation-assumptions-details" name="statement-statement-note-7-stockholders-equity-and-stockbased-compensation-stock-option-valuation-assumptions-details" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="sava_statement-statement-note-7-stockholders-equity-and-stockbased-compensation-stockbased-compensation-expense-details" name="statement-statement-note-7-stockholders-equity-and-stockbased-compensation-stockbased-compensation-expense-details" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="sava_statement-statement-note-7-stockholders-equity-and-stockbased-compensation-tables" name="statement-statement-note-7-stockholders-equity-and-stockbased-compensation-tables" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="sava_statement-statement-note-9-income-taxes-schedule-of-deferred-tax-assets-and-liabilities-details" name="statement-statement-note-9-income-taxes-schedule-of-deferred-tax-assets-and-liabilities-details" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="sava_statement-statement-note-9-income-taxes-schedule-of-effective-income-tax-reconciliation-details" name="statement-statement-note-9-income-taxes-schedule-of-effective-income-tax-reconciliation-details" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="sava_statement-statement-note-9-income-taxes-schedule-of-unrecognized-tax-benefits-details" name="statement-statement-note-9-income-taxes-schedule-of-unrecognized-tax-benefits-details" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="sava_statement-statement-note-9-income-taxes-tables" name="statement-statement-note-9-income-taxes-tables" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="sava_statement-statement-significant-accounting-policies-policies" name="statement-statement-significant-accounting-policies-policies" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>12
<FILENAME>sava-20241231_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
<!--Generated by ThunderDome XBRL - 08:53PM UTC 2025-03-03--><link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.cassavasciences.com/20241231/role/statement-note-6-intangible-assets-amortization-expense-for-finitelived-intangible-assets-details" xlink:href="sava-20241231.xsd#statement-note-6-intangible-assets-amortization-expense-for-finitelived-intangible-assets-details" xlink:type="simple"/>
  <link:calculationLink xlink:role="http://www.cassavasciences.com/20241231/role/statement-note-6-intangible-assets-amortization-expense-for-finitelived-intangible-assets-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:type="locator"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:type="arc"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.cassavasciences.com/20241231/role/statement-consolidated-statements-of-operations-" xlink:href="sava-20241231.xsd#statement-consolidated-statements-of-operations-" xlink:type="simple"/>
  <link:calculationLink xlink:role="http://www.cassavasciences.com/20241231/role/statement-consolidated-statements-of-operations-" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="us-gaap_FairValueAdjustmentOfWarrants" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:label="us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockDividendsAndOtherAdjustments" xlink:label="us-gaap_PreferredStockDividendsAndOtherAdjustments" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xlink:type="locator"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_ResearchAndDevelopmentExpense" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_GeneralAndAdministrativeExpense" xlink:type="arc"/>
    <link:calculationArc order="0" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingExpenses" xlink:type="arc"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_OtherNonoperatingIncomeExpense" xlink:type="arc"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_FairValueAdjustmentOfWarrants" xlink:type="arc"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss" xlink:type="arc"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:to="us-gaap_NetIncomeLoss" xlink:type="arc"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:to="us-gaap_PreferredStockDividendsAndOtherAdjustments" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.cassavasciences.com/20241231/role/statement-consolidated-statements-of-cash-flows" xlink:href="sava-20241231.xsd#statement-consolidated-statements-of-cash-flows" xlink:type="simple"/>
  <link:calculationLink xlink:role="http://www.cassavasciences.com/20241231/role/statement-consolidated-statements-of-cash-flows" xlink:type="extended">
    <link:loc xlink:href="sava-20241231.xsd#sava_IncreaseDecreaseInDevelopmentExpense" xlink:label="sava_IncreaseDecreaseInDevelopmentExpense" xlink:type="locator"/>
    <link:loc xlink:href="sava-20241231.xsd#sava_IncreaseDecreaseInOperatingLeaseRightOfUseAssetsAndLiabilitiesNet" xlink:label="sava_IncreaseDecreaseInOperatingLeaseRightOfUseAssetsAndLiabilitiesNet" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="us-gaap_AmortizationOfIntangibleAssets" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="us-gaap_FairValueAdjustmentOfWarrants" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="us-gaap_ProceedsFromWarrantExercises" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation" xlink:type="locator"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_AmortizationOfIntangibleAssets" xlink:type="arc"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="arc"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:type="arc"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetIncomeLoss" xlink:type="arc"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_ShareBasedCompensation" xlink:type="arc"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="sava_IncreaseDecreaseInOperatingLeaseRightOfUseAssetsAndLiabilitiesNet" xlink:type="arc"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:type="arc"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_FairValueAdjustmentOfWarrants" xlink:type="arc"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_Depreciation" xlink:type="arc"/>
    <link:calculationArc order="10" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="sava_IncreaseDecreaseInDevelopmentExpense" xlink:type="arc"/>
    <link:calculationArc order="0" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromStockOptionsExercised" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromWarrantExercises" xlink:type="arc"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="arc"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="arc"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.cassavasciences.com/20241231/role/statement-note-3-prepaid-expenses-and-other-current-assets-prepaid-expenses-and-other-current-assets-details" xlink:href="sava-20241231.xsd#statement-note-3-prepaid-expenses-and-other-current-assets-prepaid-expenses-and-other-current-assets-details" xlink:type="simple"/>
  <link:calculationLink xlink:role="http://www.cassavasciences.com/20241231/role/statement-note-3-prepaid-expenses-and-other-current-assets-prepaid-expenses-and-other-current-assets-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DepositContractsAssets" xlink:label="us-gaap_DepositContractsAssets" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestReceivableCurrent" xlink:label="us-gaap_InterestReceivableCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAssetsCurrent" xlink:label="us-gaap_OtherAssetsCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidInsurance" xlink:label="us-gaap_PrepaidInsurance" xlink:type="locator"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidInsurance" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_DepositContractsAssets" xlink:type="arc"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_InterestReceivableCurrent" xlink:type="arc"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_OtherAssetsCurrent" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.cassavasciences.com/20241231/role/statement-note-5-property-and-equipment-components-of-property-and-equipment-details" xlink:href="sava-20241231.xsd#statement-note-5-property-and-equipment-components-of-property-and-equipment-details" xlink:type="simple"/>
  <link:calculationLink xlink:role="http://www.cassavasciences.com/20241231/role/statement-note-5-property-and-equipment-components-of-property-and-equipment-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:type="locator"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" xlink:type="arc"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.cassavasciences.com/20241231/role/statement-note-6-intangible-assets-components-of-intangible-assets-details" xlink:href="sava-20241231.xsd#statement-note-6-intangible-assets-components-of-intangible-assets-details" xlink:type="simple"/>
  <link:calculationLink xlink:role="http://www.cassavasciences.com/20241231/role/statement-note-6-intangible-assets-components-of-intangible-assets-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsGross" xlink:label="us-gaap_FiniteLivedIntangibleAssetsGross" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:type="locator"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="us-gaap_FiniteLivedIntangibleAssetsGross" xlink:type="arc"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.cassavasciences.com/20241231/role/statement-note-9-income-taxes-schedule-of-effective-income-tax-reconciliation-details" xlink:href="sava-20241231.xsd#statement-note-9-income-taxes-schedule-of-effective-income-tax-reconciliation-details" xlink:type="simple"/>
  <link:calculationLink xlink:role="http://www.cassavasciences.com/20241231/role/statement-note-9-income-taxes-schedule-of-effective-income-tax-reconciliation-details" xlink:type="extended">
    <link:loc xlink:href="sava-20241231.xsd#sava_EffectiveIncomeTaxRateReconciliationChangeInFairValueOfWarrantLiabilities" xlink:label="sava_EffectiveIncomeTaxRateReconciliationChangeInFairValueOfWarrantLiabilities" xlink:type="locator"/>
    <link:loc xlink:href="sava-20241231.xsd#sava_EffectiveIncomeTaxRateReconciliationSection162mLimitationPercent" xlink:label="sava_EffectiveIncomeTaxRateReconciliationSection162mLimitationPercent" xlink:type="locator"/>
    <link:loc xlink:href="sava-20241231.xsd#sava_EffectiveIncomeTaxRateReconciliationTaxAttributeExpirationPercent" xlink:label="sava_EffectiveIncomeTaxRateReconciliationTaxAttributeExpirationPercent" xlink:type="locator"/>
    <link:loc xlink:href="sava-20241231.xsd#sava_EffectiveIncomeTaxRateReconciliationTaxCreditResearchAndDevelopmentPercent" xlink:label="sava_EffectiveIncomeTaxRateReconciliationTaxCreditResearchAndDevelopmentPercent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxContingencies" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxContingencies" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlements" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlements" xlink:type="locator"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="sava_EffectiveIncomeTaxRateReconciliationChangeInFairValueOfWarrantLiabilities" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:type="arc"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="sava_EffectiveIncomeTaxRateReconciliationTaxCreditResearchAndDevelopmentPercent" xlink:type="arc"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlements" xlink:type="arc"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" xlink:type="arc"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="sava_EffectiveIncomeTaxRateReconciliationSection162mLimitationPercent" xlink:type="arc"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxContingencies" xlink:type="arc"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="arc"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:type="arc"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:type="arc"/>
    <link:calculationArc order="10" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="sava_EffectiveIncomeTaxRateReconciliationTaxAttributeExpirationPercent" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.cassavasciences.com/20241231/role/statement-note-2-significant-accounting-policies-calculation-of-net-loss-per-share-details" xlink:href="sava-20241231.xsd#statement-note-2-significant-accounting-policies-calculation-of-net-loss-per-share-details" xlink:type="simple"/>
  <link:calculationLink xlink:role="http://www.cassavasciences.com/20241231/role/statement-note-2-significant-accounting-policies-calculation-of-net-loss-per-share-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DilutiveSecurities" xlink:label="us-gaap_DilutiveSecurities" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:label="us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="locator"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:to="us-gaap_NetIncomeLoss" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:to="us-gaap_DilutiveSecurities" xlink:type="arc"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.cassavasciences.com/20241231/role/statement-note-4-real-property-and-other-income-expense-components-of-other-income-net-details" xlink:href="sava-20241231.xsd#statement-note-4-real-property-and-other-income-expense-components-of-other-income-net-details" xlink:type="simple"/>
  <link:calculationLink xlink:role="http://www.cassavasciences.com/20241231/role/statement-note-4-real-property-and-other-income-expense-components-of-other-income-net-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNonoperatingExpense" xlink:label="us-gaap_OtherNonoperatingExpense" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNonoperatingIncome" xlink:label="us-gaap_OtherNonoperatingIncome" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense" xlink:type="locator"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OtherNonoperatingIncomeExpense" xlink:to="us-gaap_OtherNonoperatingIncome" xlink:type="arc"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OtherNonoperatingIncomeExpense" xlink:to="us-gaap_OtherNonoperatingExpense" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.cassavasciences.com/20241231/role/statement-note-9-income-taxes-schedule-of-deferred-tax-assets-and-liabilities-details" xlink:href="sava-20241231.xsd#statement-note-9-income-taxes-schedule-of-deferred-tax-assets-and-liabilities-details" xlink:type="simple"/>
  <link:calculationLink xlink:role="http://www.cassavasciences.com/20241231/role/statement-note-9-income-taxes-schedule-of-deferred-tax-assets-and-liabilities-details" xlink:type="extended">
    <link:loc xlink:href="sava-20241231.xsd#sava_DeferredTaxAssetsCapitalizedResearchAndDevelopmentExpenses" xlink:label="sava_DeferredTaxAssetsCapitalizedResearchAndDevelopmentExpenses" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredIncomeTaxLiabilities" xlink:label="us-gaap_DeferredIncomeTaxLiabilities" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="us-gaap_DeferredTaxAssetsNet" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="us-gaap_DeferredTaxAssetsOther" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxLiabilitiesLeasingArrangements" xlink:label="us-gaap_DeferredTaxLiabilitiesLeasingArrangements" xlink:type="locator"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:type="arc"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:type="arc"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="sava_DeferredTaxAssetsCapitalizedResearchAndDevelopmentExpenses" xlink:type="arc"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsOther" xlink:type="arc"/>
    <link:calculationArc order="0" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsGross" xlink:type="arc"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredIncomeTaxLiabilities" xlink:to="us-gaap_DeferredTaxLiabilitiesLeasingArrangements" xlink:type="arc"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredTaxAssetsNet" xlink:type="arc"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredIncomeTaxLiabilities" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.cassavasciences.com/20241231/role/statement-consolidated-balance-sheets" xlink:href="sava-20241231.xsd#statement-consolidated-balance-sheets" xlink:type="simple"/>
  <link:calculationLink xlink:role="http://www.cassavasciences.com/20241231/role/statement-consolidated-balance-sheets" xlink:type="extended">
    <link:loc xlink:href="sava-20241231.xsd#sava_AccruedDevelopmentExpenseCurrent" xlink:label="sava_AccruedDevelopmentExpenseCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="us-gaap_OtherLiabilitiesCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="us-gaap_OtherLiabilitiesNoncurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" xlink:type="locator"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_AssetsCurrent" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" xlink:type="arc"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:type="arc"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="sava_AccruedDevelopmentExpenseCurrent" xlink:type="arc"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:type="arc"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_OtherLiabilitiesCurrent" xlink:type="arc"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_LiabilitiesCurrent" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_OtherLiabilitiesNoncurrent" xlink:type="arc"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_PreferredStockValue" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_CommonStockValue" xlink:type="arc"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_AdditionalPaidInCapital" xlink:type="arc"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_StockholdersEquity" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_Liabilities" xlink:type="arc"/>
  </link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>13
<FILENAME>sava-20241231_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
<!--Generated by ThunderDome XBRL - 08:53PM UTC 2025-03-03--><link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" xlink:type="simple"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" xlink:type="simple"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" xlink:type="simple"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" xlink:type="simple"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.cassavasciences.com/20241231/role/statement-note-8-employee-401k-benefit-plan" xlink:href="sava-20241231.xsd#statement-note-8-employee-401k-benefit-plan" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.cassavasciences.com/20241231/role/statement-note-8-employee-401k-benefit-plan" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CompensationAndEmployeeBenefitPlansTextBlock" xlink:label="us-gaap_CompensationAndEmployeeBenefitPlansTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_CompensationAndEmployeeBenefitPlansTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cassavasciences.com/20241231/role/statement-note-3-prepaid-expenses-and-other-current-assets" xlink:href="sava-20241231.xsd#statement-note-3-prepaid-expenses-and-other-current-assets" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.cassavasciences.com/20241231/role/statement-note-3-prepaid-expenses-and-other-current-assets" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="sava-20241231.xsd#sava_PrepaidExpensesAndOtherCurrentAssetsTextBock" xlink:label="sava_PrepaidExpensesAndOtherCurrentAssetsTextBock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="sava_PrepaidExpensesAndOtherCurrentAssetsTextBock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cassavasciences.com/20241231/role/statement-document-and-entity-information" xlink:href="sava-20241231.xsd#statement-document-and-entity-information" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.cassavasciences.com/20241231/role/statement-document-and-entity-information" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorFirmId" xlink:label="dei_AuditorFirmId" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorLocation" xlink:label="dei_AuditorLocation" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorName" xlink:label="dei_AuditorName" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFinStmtErrorCorrectionFlag" xlink:label="dei_DocumentFinStmtErrorCorrectionFlag" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentInformationLineItems" xlink:label="dei_DocumentInformationLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentInformationTable" xlink:label="dei_DocumentInformationTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType" xlink:label="dei_DocumentType" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_IcfrAuditorAttestationFlag" xlink:label="dei_IcfrAuditorAttestationFlag" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="dei_DocumentInformationTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentInformationTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCentralIndexKey" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityRegistrantName" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AmendmentFlag" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_CurrentFiscalYearEndDate" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentFiscalPeriodFocus" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentFiscalYearFocus" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentType" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentAnnualReport" xlink:type="arc"/>
    <link:definitionArc order="9" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentPeriodEndDate" xlink:type="arc"/>
    <link:definitionArc order="10" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentTransitionReport" xlink:type="arc"/>
    <link:definitionArc order="11" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityFileNumber" xlink:type="arc"/>
    <link:definitionArc order="12" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityIncorporationStateCountryCode" xlink:type="arc"/>
    <link:definitionArc order="13" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityTaxIdentificationNumber" xlink:type="arc"/>
    <link:definitionArc order="14" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressAddressLine1" xlink:type="arc"/>
    <link:definitionArc order="15" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressCityOrTown" xlink:type="arc"/>
    <link:definitionArc order="16" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressStateOrProvince" xlink:type="arc"/>
    <link:definitionArc order="17" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressPostalZipCode" xlink:type="arc"/>
    <link:definitionArc order="18" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_CityAreaCode" xlink:type="arc"/>
    <link:definitionArc order="19" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_LocalPhoneNumber" xlink:type="arc"/>
    <link:definitionArc order="20" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_Security12bTitle" xlink:type="arc"/>
    <link:definitionArc order="21" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_TradingSymbol" xlink:type="arc"/>
    <link:definitionArc order="22" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_SecurityExchangeName" xlink:type="arc"/>
    <link:definitionArc order="23" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityWellKnownSeasonedIssuer" xlink:type="arc"/>
    <link:definitionArc order="24" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityVoluntaryFilers" xlink:type="arc"/>
    <link:definitionArc order="25" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCurrentReportingStatus" xlink:type="arc"/>
    <link:definitionArc order="26" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityInteractiveDataCurrent" xlink:type="arc"/>
    <link:definitionArc order="27" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityFilerCategory" xlink:type="arc"/>
    <link:definitionArc order="28" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntitySmallBusiness" xlink:type="arc"/>
    <link:definitionArc order="29" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityEmergingGrowthCompany" xlink:type="arc"/>
    <link:definitionArc order="30" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_IcfrAuditorAttestationFlag" xlink:type="arc"/>
    <link:definitionArc order="31" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentFinStmtErrorCorrectionFlag" xlink:type="arc"/>
    <link:definitionArc order="32" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityShellCompany" xlink:type="arc"/>
    <link:definitionArc order="33" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityPublicFloat" xlink:type="arc"/>
    <link:definitionArc order="34" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCommonStockSharesOutstanding" xlink:type="arc"/>
    <link:definitionArc order="35" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AuditorFirmId" xlink:type="arc"/>
    <link:definitionArc order="36" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AuditorName" xlink:type="arc"/>
    <link:definitionArc order="37" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AuditorLocation" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cassavasciences.com/20241231/role/statement-consolidated-balance-sheets-parentheticals" xlink:href="sava-20241231.xsd#statement-consolidated-balance-sheets-parentheticals" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.cassavasciences.com/20241231/role/statement-consolidated-balance-sheets-parentheticals" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesAuthorized" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesIssued" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesOutstanding" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesIssued" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cassavasciences.com/20241231/role/statement-note-1-general-liquidity-and-basis-of-presentation" xlink:href="sava-20241231.xsd#statement-note-1-general-liquidity-and-basis-of-presentation" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.cassavasciences.com/20241231/role/statement-note-1-general-liquidity-and-basis-of-presentation" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cassavasciences.com/20241231/role/statement-note-2-summary-of-significant-accounting-policies" xlink:href="sava-20241231.xsd#statement-note-2-summary-of-significant-accounting-policies" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.cassavasciences.com/20241231/role/statement-note-2-summary-of-significant-accounting-policies" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="sava-20241231.xsd#sava_FormerPresidentAndChiefExecutiveOfficerMember" xlink:label="sava_FormerPresidentAndChiefExecutiveOfficerMember" xlink:type="locator"/>
    <link:loc xlink:href="sava-20241231.xsd#sava_FormerSeniorOfficerMember" xlink:label="sava_FormerSeniorOfficerMember" xlink:type="locator"/>
    <link:loc xlink:href="sava-20241231.xsd#sava_FormerSeniorVicePresidentMember" xlink:label="sava_FormerSeniorVicePresidentMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BuildingImprovementsMember" xlink:label="us-gaap_BuildingImprovementsMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BuildingMember" xlink:label="us-gaap_BuildingMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AwardTypeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_RangeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_BuildingMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_BuildingImprovementsMember" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_TitleOfIndividualAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="sava_FormerPresidentAndChiefExecutiveOfficerMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="sava_FormerSeniorVicePresidentMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="sava_FormerSeniorOfficerMember" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="sava_FormerSeniorVicePresidentMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain-default" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cassavasciences.com/20241231/role/statement-note-4-real-property-and-other-income-expense" xlink:href="sava-20241231.xsd#statement-note-4-real-property-and-other-income-expense" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.cassavasciences.com/20241231/role/statement-note-4-real-property-and-other-income-expense" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis" xlink:label="srt_MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MortgageLoansOnRealEstateNamePropertyTypeDomain" xlink:label="srt_MortgageLoansOnRealEstateNamePropertyTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MortgageLoansOnRealEstateNamePropertyTypeDomain" xlink:label="srt_MortgageLoansOnRealEstateNamePropertyTypeDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_OfficeBuildingMember" xlink:label="srt_OfficeBuildingMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd#stpr_TX" xlink:label="stpr_TX" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RealEstateOwnedTextBlock" xlink:label="us-gaap_RealEstateOwnedTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis" xlink:to="srt_MortgageLoansOnRealEstateNamePropertyTypeDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_MortgageLoansOnRealEstateNamePropertyTypeDomain" xlink:to="srt_OfficeBuildingMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis" xlink:to="srt_MortgageLoansOnRealEstateNamePropertyTypeDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_StatementGeographicalAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_SegmentGeographicalDomain" xlink:to="stpr_TX" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain-default" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_RealEstateOwnedTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cassavasciences.com/20241231/role/statement-note-5-property-and-equipment" xlink:href="sava-20241231.xsd#statement-note-5-property-and-equipment" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.cassavasciences.com/20241231/role/statement-note-5-property-and-equipment" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cassavasciences.com/20241231/role/statement-note-6-intangible-assets" xlink:href="sava-20241231.xsd#statement-note-6-intangible-assets" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.cassavasciences.com/20241231/role/statement-note-6-intangible-assets" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:label="us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cassavasciences.com/20241231/role/statement-note-7-stockholders-equity-and-stockbased-compensation" xlink:href="sava-20241231.xsd#statement-note-7-stockholders-equity-and-stockbased-compensation" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.cassavasciences.com/20241231/role/statement-note-7-stockholders-equity-and-stockbased-compensation" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="sava-20241231.xsd#sava_AtthemarketCommonStockOfferingMember" xlink:label="sava_AtthemarketCommonStockOfferingMember" xlink:type="locator"/>
    <link:loc xlink:href="sava-20241231.xsd#sava_The2018EquityIncentivePlanMember" xlink:label="sava_The2018EquityIncentivePlanMember" xlink:type="locator"/>
    <link:loc xlink:href="sava-20241231.xsd#sava_The2022RegisteredDirectOfferingMember" xlink:label="sava_The2022RegisteredDirectOfferingMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeSeveranceMember" xlink:label="us-gaap_EmployeeSeveranceMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GranteeStatusAxis" xlink:label="us-gaap_GranteeStatusAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GranteeStatusDomain" xlink:label="us-gaap_GranteeStatusDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GranteeStatusDomain" xlink:label="us-gaap_GranteeStatusDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PerformanceSharesMember" xlink:label="us-gaap_PerformanceSharesMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringCostAndReserveAxis" xlink:label="us-gaap_RestructuringCostAndReserveAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedPaymentArrangementEmployeeMember" xlink:label="us-gaap_ShareBasedPaymentArrangementEmployeeMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock" xlink:label="us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfRestructuringDomain" xlink:label="us-gaap_TypeOfRestructuringDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfRestructuringDomain" xlink:label="us-gaap_TypeOfRestructuringDomain-default" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RestructuringCostAndReserveAxis" xlink:to="us-gaap_TypeOfRestructuringDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_GranteeStatusAxis" xlink:to="us-gaap_GranteeStatusDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="sava_The2022RegisteredDirectOfferingMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="sava_AtthemarketCommonStockOfferingMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_PlanNameAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="sava_The2018EquityIncentivePlanMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_GranteeStatusAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_GranteeStatusDomain" xlink:to="us-gaap_ShareBasedPaymentArrangementEmployeeMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_GranteeStatusAxis" xlink:to="us-gaap_GranteeStatusDomain-default" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AwardTypeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_PerformanceSharesMember" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_RestructuringCostAndReserveAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TypeOfRestructuringDomain" xlink:to="us-gaap_EmployeeSeveranceMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RestructuringCostAndReserveAxis" xlink:to="us-gaap_TypeOfRestructuringDomain-default" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cassavasciences.com/20241231/role/statement-note-9-income-taxes" xlink:href="sava-20241231.xsd#statement-note-9-income-taxes" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.cassavasciences.com/20241231/role/statement-note-9-income-taxes" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="sava-20241231.xsd#sava_CarryforwardSubjectToExpirationMember" xlink:label="sava_CarryforwardSubjectToExpirationMember" xlink:type="locator"/>
    <link:loc xlink:href="sava-20241231.xsd#sava_IndefiniteLifeCarryforwardsMember" xlink:label="sava_IndefiniteLifeCarryforwardsMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DomesticCountryMember" xlink:label="us-gaap_DomesticCountryMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchMember" xlink:label="us-gaap_ResearchMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxCreditCarryforwardAxis" xlink:label="us-gaap_TaxCreditCarryforwardAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxPeriodAxis" xlink:label="us-gaap_TaxPeriodAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxPeriodDomain" xlink:label="us-gaap_TaxPeriodDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxPeriodDomain" xlink:label="us-gaap_TaxPeriodDomain-default" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TaxPeriodAxis" xlink:to="us-gaap_TaxPeriodDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TaxCreditCarryforwardAxis" xlink:to="us-gaap_TaxCreditCarryforwardNameDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_IncomeTaxAuthorityAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_DomesticCountryMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_TaxPeriodAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TaxPeriodDomain" xlink:to="sava_CarryforwardSubjectToExpirationMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_TaxPeriodAxis" xlink:to="us-gaap_TaxPeriodDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TaxPeriodDomain" xlink:to="sava_IndefiniteLifeCarryforwardsMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_TaxCreditCarryforwardAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TaxCreditCarryforwardNameDomain" xlink:to="us-gaap_ResearchMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_TaxCreditCarryforwardAxis" xlink:to="us-gaap_TaxCreditCarryforwardNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cassavasciences.com/20241231/role/statement-note-10-commitments" xlink:href="sava-20241231.xsd#statement-note-10-commitments" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.cassavasciences.com/20241231/role/statement-note-10-commitments" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="sava-20241231.xsd#sava_LeasesAndCommitmentsDisclosureTextBlock" xlink:label="sava_LeasesAndCommitmentsDisclosureTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="sava-20241231.xsd#sava_LicenseAgreementMember" xlink:label="sava_LicenseAgreementMember" xlink:type="locator"/>
    <link:loc xlink:href="sava-20241231.xsd#sava_SimufilamActiveIngredientMember" xlink:label="sava_SimufilamActiveIngredientMember" xlink:type="locator"/>
    <link:loc xlink:href="sava-20241231.xsd#sava_YaleUniversityMember" xlink:label="sava_YaleUniversityMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherCommitmentsAxis" xlink:label="us-gaap_OtherCommitmentsAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherCommitmentsDomain" xlink:label="us-gaap_OtherCommitmentsDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherCommitmentsDomain" xlink:label="us-gaap_OtherCommitmentsDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SupplyCommitmentArrangementMember" xlink:label="us-gaap_SupplyCommitmentArrangementMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SupplyCommitmentArrangementMember" xlink:label="us-gaap_SupplyCommitmentArrangementMember-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SupplyCommitmentAxis" xlink:label="us-gaap_SupplyCommitmentAxis" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_OtherCommitmentsAxis" xlink:to="us-gaap_OtherCommitmentsDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SupplyCommitmentAxis" xlink:to="us-gaap_SupplyCommitmentArrangementMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SupplyCommitmentAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SupplyCommitmentArrangementMember" xlink:to="sava_SimufilamActiveIngredientMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SupplyCommitmentAxis" xlink:to="us-gaap_SupplyCommitmentArrangementMember-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_CounterpartyNameAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="sava_YaleUniversityMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_OtherCommitmentsAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherCommitmentsDomain" xlink:to="sava_LicenseAgreementMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_OtherCommitmentsAxis" xlink:to="us-gaap_OtherCommitmentsDomain-default" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsequentEventTypeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain-default" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="sava_LeasesAndCommitmentsDisclosureTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cassavasciences.com/20241231/role/statement-note-11-2020-cash-incentive-bonus-plan" xlink:href="sava-20241231.xsd#statement-note-11-2020-cash-incentive-bonus-plan" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.cassavasciences.com/20241231/role/statement-note-11-2020-cash-incentive-bonus-plan" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="sava-20241231.xsd#sava_CashIncentiveBonusPlanMember" xlink:label="sava_CashIncentiveBonusPlanMember" xlink:type="locator"/>
    <link:loc xlink:href="sava-20241231.xsd#sava_CashIncentiveBonusPlanTextBlock" xlink:label="sava_CashIncentiveBonusPlanTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_PlanNameAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="sava_CashIncentiveBonusPlanMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_RangeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="sava_CashIncentiveBonusPlanTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cassavasciences.com/20241231/role/statement-note-12-contingencies" xlink:href="sava-20241231.xsd#statement-note-12-contingencies" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.cassavasciences.com/20241231/role/statement-note-12-contingencies" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="sava-20241231.xsd#sava_AntislappLawsuitMember" xlink:label="sava_AntislappLawsuitMember" xlink:type="locator"/>
    <link:loc xlink:href="sava-20241231.xsd#sava_ShareholderDerivativeActionsDelawareCourtMember" xlink:label="sava_ShareholderDerivativeActionsDelawareCourtMember" xlink:type="locator"/>
    <link:loc xlink:href="sava-20241231.xsd#sava_ShareholderDerivativeActionsMember" xlink:label="sava_ShareholderDerivativeActionsMember" xlink:type="locator"/>
    <link:loc xlink:href="sava-20241231.xsd#sava_ShareholderDerivativeActionsTexasCourtMember" xlink:label="sava_ShareholderDerivativeActionsTexasCourtMember" xlink:type="locator"/>
    <link:loc xlink:href="sava-20241231.xsd#sava_ShareholderDerivativeActionsTexasStateCourtMember" xlink:label="sava_ShareholderDerivativeActionsTexasStateCourtMember" xlink:type="locator"/>
    <link:loc xlink:href="sava-20241231.xsd#sava_ViolationsOfFederalSecuritiesLawsMember" xlink:label="sava_ViolationsOfFederalSecuritiesLawsMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_LitigationCaseAxis" xlink:label="srt_LitigationCaseAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_LitigationCaseTypeDomain" xlink:label="srt_LitigationCaseTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_LitigationCaseTypeDomain" xlink:label="srt_LitigationCaseTypeDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LossContingencyDisclosures" xlink:label="us-gaap_LossContingencyDisclosures" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain-default" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_LitigationCaseAxis" xlink:to="srt_LitigationCaseTypeDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_LitigationCaseAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_LitigationCaseTypeDomain" xlink:to="sava_ViolationsOfFederalSecuritiesLawsMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_LitigationCaseAxis" xlink:to="srt_LitigationCaseTypeDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_LitigationCaseTypeDomain" xlink:to="sava_ShareholderDerivativeActionsTexasCourtMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_LitigationCaseTypeDomain" xlink:to="sava_ShareholderDerivativeActionsTexasStateCourtMember" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_LitigationCaseTypeDomain" xlink:to="sava_ShareholderDerivativeActionsDelawareCourtMember" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_LitigationCaseTypeDomain" xlink:to="sava_ShareholderDerivativeActionsMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsequentEventTypeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain-default" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_LitigationCaseTypeDomain" xlink:to="sava_AntislappLawsuitMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_LossContingencyDisclosures" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cassavasciences.com/20241231/role/statement-note-13-warrant-dividend-distribution" xlink:href="sava-20241231.xsd#statement-note-13-warrant-dividend-distribution" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.cassavasciences.com/20241231/role/statement-note-13-warrant-dividend-distribution" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="sava-20241231.xsd#sava_WarrantDividendDistributionTextBlock" xlink:label="sava_WarrantDividendDistributionTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="sava-20241231.xsd#sava_WarrantsToPurchaseCommonStockMember" xlink:label="sava_WarrantsToPurchaseCommonStockMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="sava_WarrantsToPurchaseCommonStockMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="sava_WarrantDividendDistributionTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cassavasciences.com/20241231/role/statement-note-14-subsequent-event" xlink:href="sava-20241231.xsd#statement-note-14-subsequent-event" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.cassavasciences.com/20241231/role/statement-note-14-subsequent-event" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="sava-20241231.xsd#sava_WorkforceReductionMember" xlink:label="sava_WorkforceReductionMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScenarioForecastMember" xlink:label="srt_ScenarioForecastMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringCostAndReserveAxis" xlink:label="us-gaap_RestructuringCostAndReserveAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="us-gaap_SubsequentEventsTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfRestructuringDomain" xlink:label="us-gaap_TypeOfRestructuringDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfRestructuringDomain" xlink:label="us-gaap_TypeOfRestructuringDomain-default" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RestructuringCostAndReserveAxis" xlink:to="us-gaap_TypeOfRestructuringDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_RestructuringCostAndReserveAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TypeOfRestructuringDomain" xlink:to="sava_WorkforceReductionMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RestructuringCostAndReserveAxis" xlink:to="us-gaap_TypeOfRestructuringDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsequentEventTypeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain-default" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_StatementScenarioAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="srt_ScenarioForecastMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain-default" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_SubsequentEventsTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cassavasciences.com/20241231/role/statement-significant-accounting-policies-policies" xlink:href="sava-20241231.xsd#statement-significant-accounting-policies-policies" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.cassavasciences.com/20241231/role/statement-significant-accounting-policies-policies" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="sava-20241231.xsd#sava_RelatedPartyTransactionPolicyTextBlock" xlink:label="sava_RelatedPartyTransactionPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesPolicyTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:label="us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativesPolicyTextBlock" xlink:label="us-gaap_DerivativesPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GovernmentAssistancePolicyTextBlock" xlink:label="us-gaap_GovernmentAssistancePolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="us-gaap_IncomeTaxPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:label="us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PolicyTextBlockAbstract" xlink:label="us-gaap_PolicyTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PolicyTextBlockAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PolicyTextBlockAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_UseOfEstimates" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_GovernmentAssistancePolicyTextBlock" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_DerivativesPolicyTextBlock" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:type="arc"/>
    <link:definitionArc order="9" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:type="arc"/>
    <link:definitionArc order="10" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:type="arc"/>
    <link:definitionArc order="11" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:type="arc"/>
    <link:definitionArc order="12" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:type="arc"/>
    <link:definitionArc order="13" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesPolicyTextBlock" xlink:type="arc"/>
    <link:definitionArc order="14" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="sava_RelatedPartyTransactionPolicyTextBlock" xlink:type="arc"/>
    <link:definitionArc order="15" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_IncomeTaxPolicyTextBlock" xlink:type="arc"/>
    <link:definitionArc order="16" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cassavasciences.com/20241231/role/statement-note-2-summary-of-significant-accounting-policies-tables" xlink:href="sava-20241231.xsd#statement-note-2-summary-of-significant-accounting-policies-tables" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.cassavasciences.com/20241231/role/statement-note-2-summary-of-significant-accounting-policies-tables" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TableTextBlock" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cassavasciences.com/20241231/role/statement-note-3-prepaid-expenses-and-other-current-assets-tables" xlink:href="sava-20241231.xsd#statement-note-3-prepaid-expenses-and-other-current-assets-tables" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.cassavasciences.com/20241231/role/statement-note-3-prepaid-expenses-and-other-current-assets-tables" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:label="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TableTextBlock" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cassavasciences.com/20241231/role/statement-note-4-real-property-and-other-income-expense-tables" xlink:href="sava-20241231.xsd#statement-note-4-real-property-and-other-income-expense-tables" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.cassavasciences.com/20241231/role/statement-note-4-real-property-and-other-income-expense-tables" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock" xlink:label="us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TableTextBlock" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cassavasciences.com/20241231/role/statement-note-5-property-and-equipment-tables" xlink:href="sava-20241231.xsd#statement-note-5-property-and-equipment-tables" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.cassavasciences.com/20241231/role/statement-note-5-property-and-equipment-tables" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TableTextBlock" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cassavasciences.com/20241231/role/statement-note-6-intangible-assets-tables" xlink:href="sava-20241231.xsd#statement-note-6-intangible-assets-tables" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.cassavasciences.com/20241231/role/statement-note-6-intangible-assets-tables" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:label="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TableTextBlock" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cassavasciences.com/20241231/role/statement-note-7-stockholders-equity-and-stockbased-compensation-tables" xlink:href="sava-20241231.xsd#statement-note-7-stockholders-equity-and-stockbased-compensation-tables" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.cassavasciences.com/20241231/role/statement-note-7-stockholders-equity-and-stockbased-compensation-tables" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TableTextBlock" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cassavasciences.com/20241231/role/statement-note-9-income-taxes-tables" xlink:href="sava-20241231.xsd#statement-note-9-income-taxes-tables" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.cassavasciences.com/20241231/role/statement-note-9-income-taxes-tables" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:label="us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TableTextBlock" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cassavasciences.com/20241231/role/statement-note-13-warrant-dividend-distribution-tables" xlink:href="sava-20241231.xsd#statement-note-13-warrant-dividend-distribution-tables" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.cassavasciences.com/20241231/role/statement-note-13-warrant-dividend-distribution-tables" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:label="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TableTextBlock" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cassavasciences.com/20241231/role/statement-note-1-general-liquidity-and-basis-of-presentation-details-textual" xlink:href="sava-20241231.xsd#statement-note-1-general-liquidity-and-basis-of-presentation-details-textual" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.cassavasciences.com/20241231/role/statement-note-1-general-liquidity-and-basis-of-presentation-details-textual" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cassavasciences.com/20241231/role/statement-note-2-summary-of-significant-accounting-policies-details-textual" xlink:href="sava-20241231.xsd#statement-note-2-summary-of-significant-accounting-policies-details-textual" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.cassavasciences.com/20241231/role/statement-note-2-summary-of-significant-accounting-policies-details-textual" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="sava-20241231.xsd#sava_ClassOfWarrantOrRightFairValueOfCommonStockWarrantsPerWarrant" xlink:label="sava_ClassOfWarrantOrRightFairValueOfCommonStockWarrantsPerWarrant" xlink:type="locator"/>
    <link:loc xlink:href="sava-20241231.xsd#sava_ClassOfWarrantOrRightRedemptionPricePerShare" xlink:label="sava_ClassOfWarrantOrRightRedemptionPricePerShare" xlink:type="locator"/>
    <link:loc xlink:href="sava-20241231.xsd#sava_ConsultingAgreementTerm" xlink:label="sava_ConsultingAgreementTerm" xlink:type="locator"/>
    <link:loc xlink:href="sava-20241231.xsd#sava_ConsultingServicePricePerHour" xlink:label="sava_ConsultingServicePricePerHour" xlink:type="locator"/>
    <link:loc xlink:href="sava-20241231.xsd#sava_FormerPresidentAndChiefExecutiveOfficerMember" xlink:label="sava_FormerPresidentAndChiefExecutiveOfficerMember" xlink:type="locator"/>
    <link:loc xlink:href="sava-20241231.xsd#sava_FormerSeniorOfficerMember" xlink:label="sava_FormerSeniorOfficerMember" xlink:type="locator"/>
    <link:loc xlink:href="sava-20241231.xsd#sava_FormerSeniorVicePresidentMember" xlink:label="sava_FormerSeniorVicePresidentMember" xlink:type="locator"/>
    <link:loc xlink:href="sava-20241231.xsd#sava_InsuranceSettlementsMaximumRecoveryLimit" xlink:label="sava_InsuranceSettlementsMaximumRecoveryLimit" xlink:type="locator"/>
    <link:loc xlink:href="sava-20241231.xsd#sava_NumberOfFormerEmployees" xlink:label="sava_NumberOfFormerEmployees" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BuildingImprovementsMember" xlink:label="us-gaap_BuildingImprovementsMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BuildingMember" xlink:label="us-gaap_BuildingMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GovernmentAssistanceAmount" xlink:label="us-gaap_GovernmentAssistanceAmount" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="us-gaap_NumberOfOperatingSegments" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromInsuranceSettlementOperatingActivities" xlink:label="us-gaap_ProceedsFromInsuranceSettlementOperatingActivities" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionAmountsOfTransaction" xlink:label="us-gaap_RelatedPartyTransactionAmountsOfTransaction" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeveranceCosts1" xlink:label="us-gaap_SeveranceCosts1" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AwardTypeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_RangeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_BuildingMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_BuildingImprovementsMember" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_TitleOfIndividualAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="sava_FormerPresidentAndChiefExecutiveOfficerMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="sava_FormerSeniorVicePresidentMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="sava_FormerSeniorOfficerMember" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="sava_FormerSeniorVicePresidentMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain-default" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_GovernmentAssistanceAmount" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="sava_ClassOfWarrantOrRightFairValueOfCommonStockWarrantsPerWarrant" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="sava_ClassOfWarrantOrRightRedemptionPricePerShare" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NumberOfOperatingSegments" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ProceedsFromInsuranceSettlementOperatingActivities" xlink:type="arc"/>
    <link:definitionArc order="9" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="sava_InsuranceSettlementsMaximumRecoveryLimit" xlink:type="arc"/>
    <link:definitionArc order="10" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SeveranceCosts1" xlink:type="arc"/>
    <link:definitionArc order="11" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="sava_NumberOfFormerEmployees" xlink:type="arc"/>
    <link:definitionArc order="12" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="sava_ConsultingAgreementTerm" xlink:type="arc"/>
    <link:definitionArc order="13" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="sava_ConsultingServicePricePerHour" xlink:type="arc"/>
    <link:definitionArc order="14" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_RelatedPartyTransactionAmountsOfTransaction" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cassavasciences.com/20241231/role/statement-note-4-real-property-and-other-income-expense-details-textual" xlink:href="sava-20241231.xsd#statement-note-4-real-property-and-other-income-expense-details-textual" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.cassavasciences.com/20241231/role/statement-note-4-real-property-and-other-income-expense-details-textual" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="sava-20241231.xsd#sava_PercentageOfOccupancy" xlink:label="sava_PercentageOfOccupancy" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis" xlink:label="srt_MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MortgageLoansOnRealEstateNamePropertyTypeDomain" xlink:label="srt_MortgageLoansOnRealEstateNamePropertyTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MortgageLoansOnRealEstateNamePropertyTypeDomain" xlink:label="srt_MortgageLoansOnRealEstateNamePropertyTypeDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_OfficeBuildingMember" xlink:label="srt_OfficeBuildingMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd#stpr_TX" xlink:label="stpr_TX" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccrualForTaxesOtherThanIncomeTaxesCurrent" xlink:label="us-gaap_AccrualForTaxesOtherThanIncomeTaxesCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths" xlink:label="us-gaap_LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LessorOperatingLeasePaymentsToBeReceivedThreeYears" xlink:label="us-gaap_LessorOperatingLeasePaymentsToBeReceivedThreeYears" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LessorOperatingLeasePaymentsToBeReceivedTwoYears" xlink:label="us-gaap_LessorOperatingLeasePaymentsToBeReceivedTwoYears" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetRentableArea" xlink:label="us-gaap_NetRentableArea" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis" xlink:to="srt_MortgageLoansOnRealEstateNamePropertyTypeDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_MortgageLoansOnRealEstateNamePropertyTypeDomain" xlink:to="srt_OfficeBuildingMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis" xlink:to="srt_MortgageLoansOnRealEstateNamePropertyTypeDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_StatementGeographicalAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_SegmentGeographicalDomain" xlink:to="stpr_TX" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain-default" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetRentableArea" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="sava_PercentageOfOccupancy" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LessorOperatingLeasePaymentsToBeReceivedTwoYears" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LessorOperatingLeasePaymentsToBeReceivedThreeYears" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AccrualForTaxesOtherThanIncomeTaxesCurrent" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cassavasciences.com/20241231/role/statement-note-5-property-and-equipment-details-textual" xlink:href="sava-20241231.xsd#statement-note-5-property-and-equipment-details-textual" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.cassavasciences.com/20241231/role/statement-note-5-property-and-equipment-details-textual" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_Depreciation" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cassavasciences.com/20241231/role/statement-note-6-intangible-assets-details-textual" xlink:href="sava-20241231.xsd#statement-note-6-intangible-assets-details-textual" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.cassavasciences.com/20241231/role/statement-note-6-intangible-assets-details-textual" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="us-gaap_AmortizationOfIntangibleAssets" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AmortizationOfIntangibleAssets" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cassavasciences.com/20241231/role/statement-note-7-stockholders-equity-and-stockbased-compensation-details-textual" xlink:href="sava-20241231.xsd#statement-note-7-stockholders-equity-and-stockbased-compensation-details-textual" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.cassavasciences.com/20241231/role/statement-note-7-stockholders-equity-and-stockbased-compensation-details-textual" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="sava-20241231.xsd#sava_AtthemarketCommonStockOfferingMember" xlink:label="sava_AtthemarketCommonStockOfferingMember" xlink:type="locator"/>
    <link:loc xlink:href="sava-20241231.xsd#sava_EquityOfferingMaximumAmount" xlink:label="sava_EquityOfferingMaximumAmount" xlink:type="locator"/>
    <link:loc xlink:href="sava-20241231.xsd#sava_EquityOfferingPercentageOfCommission" xlink:label="sava_EquityOfferingPercentageOfCommission" xlink:type="locator"/>
    <link:loc xlink:href="sava-20241231.xsd#sava_StockOptionsExercisedNetSettledSatisfactionOfExercisePrice" xlink:label="sava_StockOptionsExercisedNetSettledSatisfactionOfExercisePrice" xlink:type="locator"/>
    <link:loc xlink:href="sava-20241231.xsd#sava_The2018EquityIncentivePlanMember" xlink:label="sava_The2018EquityIncentivePlanMember" xlink:type="locator"/>
    <link:loc xlink:href="sava-20241231.xsd#sava_The2022RegisteredDirectOfferingMember" xlink:label="sava_The2022RegisteredDirectOfferingMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeSeveranceMember" xlink:label="us-gaap_EmployeeSeveranceMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GranteeStatusAxis" xlink:label="us-gaap_GranteeStatusAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GranteeStatusDomain" xlink:label="us-gaap_GranteeStatusDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GranteeStatusDomain" xlink:label="us-gaap_GranteeStatusDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PerformanceSharesMember" xlink:label="us-gaap_PerformanceSharesMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringCostAndReserveAxis" xlink:label="us-gaap_RestructuringCostAndReserveAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedPaymentArrangementEmployeeMember" xlink:label="us-gaap_ShareBasedPaymentArrangementEmployeeMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfRestructuringDomain" xlink:label="us-gaap_TypeOfRestructuringDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfRestructuringDomain" xlink:label="us-gaap_TypeOfRestructuringDomain-default" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RestructuringCostAndReserveAxis" xlink:to="us-gaap_TypeOfRestructuringDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_GranteeStatusAxis" xlink:to="us-gaap_GranteeStatusDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="sava_The2022RegisteredDirectOfferingMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="sava_AtthemarketCommonStockOfferingMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_PlanNameAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="sava_The2018EquityIncentivePlanMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_GranteeStatusAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_GranteeStatusDomain" xlink:to="us-gaap_ShareBasedPaymentArrangementEmployeeMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_GranteeStatusAxis" xlink:to="us-gaap_GranteeStatusDomain-default" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AwardTypeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_PerformanceSharesMember" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_RestructuringCostAndReserveAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TypeOfRestructuringDomain" xlink:to="us-gaap_EmployeeSeveranceMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RestructuringCostAndReserveAxis" xlink:to="us-gaap_TypeOfRestructuringDomain-default" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesIssuedPricePerShare" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="sava_EquityOfferingMaximumAmount" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="sava_EquityOfferingPercentageOfCommission" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="arc"/>
    <link:definitionArc order="9" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="sava_StockOptionsExercisedNetSettledSatisfactionOfExercisePrice" xlink:type="arc"/>
    <link:definitionArc order="10" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:type="arc"/>
    <link:definitionArc order="11" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="arc"/>
    <link:definitionArc order="12" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:type="arc"/>
    <link:definitionArc order="13" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="arc"/>
    <link:definitionArc order="14" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations" xlink:type="arc"/>
    <link:definitionArc order="15" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cassavasciences.com/20241231/role/statement-note-7-stockholders-equity-and-stockbased-compensation-stock-option-valuation-assumptions-details" xlink:href="sava-20241231.xsd#statement-note-7-stockholders-equity-and-stockbased-compensation-stock-option-valuation-assumptions-details" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.cassavasciences.com/20241231/role/statement-note-7-stockholders-equity-and-stockbased-compensation-stock-option-valuation-assumptions-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AwardTypeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_RangeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cassavasciences.com/20241231/role/statement-note-9-income-taxes-details-textual" xlink:href="sava-20241231.xsd#statement-note-9-income-taxes-details-textual" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.cassavasciences.com/20241231/role/statement-note-9-income-taxes-details-textual" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="sava-20241231.xsd#sava_CarryforwardSubjectToExpirationMember" xlink:label="sava_CarryforwardSubjectToExpirationMember" xlink:type="locator"/>
    <link:loc xlink:href="sava-20241231.xsd#sava_IndefiniteLifeCarryforwardsMember" xlink:label="sava_IndefiniteLifeCarryforwardsMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DomesticCountryMember" xlink:label="us-gaap_DomesticCountryMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OpenTaxYear" xlink:label="us-gaap_OpenTaxYear" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="us-gaap_OperatingLossCarryforwards" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchMember" xlink:label="us-gaap_ResearchMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxCreditCarryforwardAmount" xlink:label="us-gaap_TaxCreditCarryforwardAmount" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxCreditCarryforwardAxis" xlink:label="us-gaap_TaxCreditCarryforwardAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxPeriodAxis" xlink:label="us-gaap_TaxPeriodAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxPeriodDomain" xlink:label="us-gaap_TaxPeriodDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxPeriodDomain" xlink:label="us-gaap_TaxPeriodDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="us-gaap_UnrecognizedTaxBenefits" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TaxPeriodAxis" xlink:to="us-gaap_TaxPeriodDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TaxCreditCarryforwardAxis" xlink:to="us-gaap_TaxCreditCarryforwardNameDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_IncomeTaxAuthorityAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_DomesticCountryMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_TaxPeriodAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TaxPeriodDomain" xlink:to="sava_CarryforwardSubjectToExpirationMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_TaxPeriodAxis" xlink:to="us-gaap_TaxPeriodDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TaxPeriodDomain" xlink:to="sava_IndefiniteLifeCarryforwardsMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_TaxCreditCarryforwardAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TaxCreditCarryforwardNameDomain" xlink:to="us-gaap_ResearchMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_TaxCreditCarryforwardAxis" xlink:to="us-gaap_TaxCreditCarryforwardNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingLossCarryforwards" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TaxCreditCarryforwardAmount" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_UnrecognizedTaxBenefits" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncomeTaxExpenseBenefit" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OpenTaxYear" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cassavasciences.com/20241231/role/statement-note-10-commitments-details-textual" xlink:href="sava-20241231.xsd#statement-note-10-commitments-details-textual" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.cassavasciences.com/20241231/role/statement-note-10-commitments-details-textual" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="sava-20241231.xsd#sava_LicenseAgreementMember" xlink:label="sava_LicenseAgreementMember" xlink:type="locator"/>
    <link:loc xlink:href="sava-20241231.xsd#sava_SimufilamActiveIngredientMember" xlink:label="sava_SimufilamActiveIngredientMember" xlink:type="locator"/>
    <link:loc xlink:href="sava-20241231.xsd#sava_YaleUniversityMember" xlink:label="sava_YaleUniversityMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherCommitment" xlink:label="us-gaap_OtherCommitment" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherCommitmentsAxis" xlink:label="us-gaap_OtherCommitmentsAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherCommitmentsDomain" xlink:label="us-gaap_OtherCommitmentsDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherCommitmentsDomain" xlink:label="us-gaap_OtherCommitmentsDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SignificantSupplyCommitmentRemainingMinimumAmountCommitted" xlink:label="us-gaap_SignificantSupplyCommitmentRemainingMinimumAmountCommitted" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SupplyCommitmentArrangementMember" xlink:label="us-gaap_SupplyCommitmentArrangementMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SupplyCommitmentArrangementMember" xlink:label="us-gaap_SupplyCommitmentArrangementMember-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SupplyCommitmentAxis" xlink:label="us-gaap_SupplyCommitmentAxis" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_OtherCommitmentsAxis" xlink:to="us-gaap_OtherCommitmentsDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SupplyCommitmentAxis" xlink:to="us-gaap_SupplyCommitmentArrangementMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SupplyCommitmentAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SupplyCommitmentArrangementMember" xlink:to="sava_SimufilamActiveIngredientMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SupplyCommitmentAxis" xlink:to="us-gaap_SupplyCommitmentArrangementMember-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_CounterpartyNameAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="sava_YaleUniversityMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_OtherCommitmentsAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherCommitmentsDomain" xlink:to="sava_LicenseAgreementMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_OtherCommitmentsAxis" xlink:to="us-gaap_OtherCommitmentsDomain-default" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsequentEventTypeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain-default" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SignificantSupplyCommitmentRemainingMinimumAmountCommitted" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherCommitment" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cassavasciences.com/20241231/role/statement-note-11-2020-cash-incentive-bonus-plan-details-textual" xlink:href="sava-20241231.xsd#statement-note-11-2020-cash-incentive-bonus-plan-details-textual" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.cassavasciences.com/20241231/role/statement-note-11-2020-cash-incentive-bonus-plan-details-textual" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="sava-20241231.xsd#sava_CashBonusIncentiveIncrementalAmounts" xlink:label="sava_CashBonusIncentiveIncrementalAmounts" xlink:type="locator"/>
    <link:loc xlink:href="sava-20241231.xsd#sava_CashIncentiveBonusAward" xlink:label="sava_CashIncentiveBonusAward" xlink:type="locator"/>
    <link:loc xlink:href="sava-20241231.xsd#sava_CashIncentiveBonusAwardExceedsMaximum" xlink:label="sava_CashIncentiveBonusAwardExceedsMaximum" xlink:type="locator"/>
    <link:loc xlink:href="sava-20241231.xsd#sava_CashIncentiveBonusPlanMember" xlink:label="sava_CashIncentiveBonusPlanMember" xlink:type="locator"/>
    <link:loc xlink:href="sava-20241231.xsd#sava_PaymentsForCashIncentiveBonus" xlink:label="sava_PaymentsForCashIncentiveBonus" xlink:type="locator"/>
    <link:loc xlink:href="sava-20241231.xsd#sava_PercentageValuationMilestoneCashBonusAwardSubjectToApprovalAndAdjustment" xlink:label="sava_PercentageValuationMilestoneCashBonusAwardSubjectToApprovalAndAdjustment" xlink:type="locator"/>
    <link:loc xlink:href="sava-20241231.xsd#sava_PerformancePlanMinimumNumberOfDaysValuationMilestoneMustBeAchievedAndMaintained" xlink:label="sava_PerformancePlanMinimumNumberOfDaysValuationMilestoneMustBeAchievedAndMaintained" xlink:type="locator"/>
    <link:loc xlink:href="sava-20241231.xsd#sava_PerformancePlanValuationMilestoneAmount" xlink:label="sava_PerformancePlanValuationMilestoneAmount" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax" xlink:label="us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_PlanNameAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="sava_CashIncentiveBonusPlanMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_RangeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="sava_CashBonusIncentiveIncrementalAmounts" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="sava_PerformancePlanValuationMilestoneAmount" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="sava_PerformancePlanMinimumNumberOfDaysValuationMilestoneMustBeAchievedAndMaintained" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="sava_PercentageValuationMilestoneCashBonusAwardSubjectToApprovalAndAdjustment" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="sava_CashIncentiveBonusAwardExceedsMaximum" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="sava_CashIncentiveBonusAward" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="sava_PaymentsForCashIncentiveBonus" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cassavasciences.com/20241231/role/statement-note-12-contingencies-details-textual" xlink:href="sava-20241231.xsd#statement-note-12-contingencies-details-textual" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.cassavasciences.com/20241231/role/statement-note-12-contingencies-details-textual" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="sava-20241231.xsd#sava_AntislappLawsuitMember" xlink:label="sava_AntislappLawsuitMember" xlink:type="locator"/>
    <link:loc xlink:href="sava-20241231.xsd#sava_NumberOfFormerEmployees" xlink:label="sava_NumberOfFormerEmployees" xlink:type="locator"/>
    <link:loc xlink:href="sava-20241231.xsd#sava_ShareholderDerivativeActionsDelawareCourtMember" xlink:label="sava_ShareholderDerivativeActionsDelawareCourtMember" xlink:type="locator"/>
    <link:loc xlink:href="sava-20241231.xsd#sava_ShareholderDerivativeActionsMember" xlink:label="sava_ShareholderDerivativeActionsMember" xlink:type="locator"/>
    <link:loc xlink:href="sava-20241231.xsd#sava_ShareholderDerivativeActionsTexasCourtMember" xlink:label="sava_ShareholderDerivativeActionsTexasCourtMember" xlink:type="locator"/>
    <link:loc xlink:href="sava-20241231.xsd#sava_ShareholderDerivativeActionsTexasStateCourtMember" xlink:label="sava_ShareholderDerivativeActionsTexasStateCourtMember" xlink:type="locator"/>
    <link:loc xlink:href="sava-20241231.xsd#sava_ViolationsOfFederalSecuritiesLawsMember" xlink:label="sava_ViolationsOfFederalSecuritiesLawsMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_LitigationCaseAxis" xlink:label="srt_LitigationCaseAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_LitigationCaseTypeDomain" xlink:label="srt_LitigationCaseTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_LitigationCaseTypeDomain" xlink:label="srt_LitigationCaseTypeDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LegalFees" xlink:label="us-gaap_LegalFees" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LossContingencyNewClaimsFiledNumber" xlink:label="us-gaap_LossContingencyNewClaimsFiledNumber" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain-default" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_LitigationCaseAxis" xlink:to="srt_LitigationCaseTypeDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_LitigationCaseAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_LitigationCaseTypeDomain" xlink:to="sava_ViolationsOfFederalSecuritiesLawsMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_LitigationCaseAxis" xlink:to="srt_LitigationCaseTypeDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_LitigationCaseTypeDomain" xlink:to="sava_ShareholderDerivativeActionsTexasCourtMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_LitigationCaseTypeDomain" xlink:to="sava_ShareholderDerivativeActionsTexasStateCourtMember" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_LitigationCaseTypeDomain" xlink:to="sava_ShareholderDerivativeActionsDelawareCourtMember" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_LitigationCaseTypeDomain" xlink:to="sava_ShareholderDerivativeActionsMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsequentEventTypeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain-default" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_LitigationCaseTypeDomain" xlink:to="sava_AntislappLawsuitMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LossContingencyNewClaimsFiledNumber" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LegalFees" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="sava_NumberOfFormerEmployees" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cassavasciences.com/20241231/role/statement-note-13-warrant-dividend-distribution-details-textual" xlink:href="sava-20241231.xsd#statement-note-13-warrant-dividend-distribution-details-textual" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.cassavasciences.com/20241231/role/statement-note-13-warrant-dividend-distribution-details-textual" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="sava-20241231.xsd#sava_ClassOfWarrantOrRightExercisedDuringPeriod" xlink:label="sava_ClassOfWarrantOrRightExercisedDuringPeriod" xlink:type="locator"/>
    <link:loc xlink:href="sava-20241231.xsd#sava_ClassOfWarrantOrRightIssuedDuringPeriod" xlink:label="sava_ClassOfWarrantOrRightIssuedDuringPeriod" xlink:type="locator"/>
    <link:loc xlink:href="sava-20241231.xsd#sava_CommissionPercentageOfGrossProceeds" xlink:label="sava_CommissionPercentageOfGrossProceeds" xlink:type="locator"/>
    <link:loc xlink:href="sava-20241231.xsd#sava_GrossProceedsFromIssuanceOfWarrants" xlink:label="sava_GrossProceedsFromIssuanceOfWarrants" xlink:type="locator"/>
    <link:loc xlink:href="sava-20241231.xsd#sava_PaymentsOfWarrantExerciseCosts" xlink:label="sava_PaymentsOfWarrantExerciseCosts" xlink:type="locator"/>
    <link:loc xlink:href="sava-20241231.xsd#sava_ProceedsFromWarrantsExercisedThatObligatedToPayCommission" xlink:label="sava_ProceedsFromWarrantsExercisedThatObligatedToPayCommission" xlink:type="locator"/>
    <link:loc xlink:href="sava-20241231.xsd#sava_RedemptionPercentageOfWarrants" xlink:label="sava_RedemptionPercentageOfWarrants" xlink:type="locator"/>
    <link:loc xlink:href="sava-20241231.xsd#sava_StockIssuedDuringPeriodSharesWarrantExercises" xlink:label="sava_StockIssuedDuringPeriodSharesWarrantExercises" xlink:type="locator"/>
    <link:loc xlink:href="sava-20241231.xsd#sava_WarrantRedemptionPrice" xlink:label="sava_WarrantRedemptionPrice" xlink:type="locator"/>
    <link:loc xlink:href="sava-20241231.xsd#sava_WarrantsToPurchaseCommonStockMember" xlink:label="sava_WarrantsToPurchaseCommonStockMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfWarrants" xlink:label="us-gaap_ProceedsFromIssuanceOfWarrants" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="us-gaap_ProceedsFromWarrantExercises" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantsAndRightsOutstanding" xlink:label="us-gaap_WarrantsAndRightsOutstanding" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="sava_WarrantsToPurchaseCommonStockMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="sava_ClassOfWarrantOrRightIssuedDuringPeriod" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="sava_RedemptionPercentageOfWarrants" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="sava_WarrantRedemptionPrice" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_WarrantsAndRightsOutstanding" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="sava_ClassOfWarrantOrRightExercisedDuringPeriod" xlink:type="arc"/>
    <link:definitionArc order="9" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ProceedsFromWarrantExercises" xlink:type="arc"/>
    <link:definitionArc order="10" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="sava_StockIssuedDuringPeriodSharesWarrantExercises" xlink:type="arc"/>
    <link:definitionArc order="11" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="sava_GrossProceedsFromIssuanceOfWarrants" xlink:type="arc"/>
    <link:definitionArc order="12" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfWarrants" xlink:type="arc"/>
    <link:definitionArc order="13" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="sava_ProceedsFromWarrantsExercisedThatObligatedToPayCommission" xlink:type="arc"/>
    <link:definitionArc order="14" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="sava_CommissionPercentageOfGrossProceeds" xlink:type="arc"/>
    <link:definitionArc order="15" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="sava_PaymentsOfWarrantExerciseCosts" xlink:type="arc"/>
    <link:definitionArc order="16" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cassavasciences.com/20241231/role/statement-note-14-subsequent-event-details-textual" xlink:href="sava-20241231.xsd#statement-note-14-subsequent-event-details-textual" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.cassavasciences.com/20241231/role/statement-note-14-subsequent-event-details-textual" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="sava-20241231.xsd#sava_WorkforceReductionMember" xlink:label="sava_WorkforceReductionMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScenarioForecastMember" xlink:label="srt_ScenarioForecastMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringAndRelatedCostExpectedCost1" xlink:label="us-gaap_RestructuringAndRelatedCostExpectedCost1" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated" xlink:label="us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent" xlink:label="us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringCostAndReserveAxis" xlink:label="us-gaap_RestructuringCostAndReserveAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfRestructuringDomain" xlink:label="us-gaap_TypeOfRestructuringDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfRestructuringDomain" xlink:label="us-gaap_TypeOfRestructuringDomain-default" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RestructuringCostAndReserveAxis" xlink:to="us-gaap_TypeOfRestructuringDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_RestructuringCostAndReserveAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TypeOfRestructuringDomain" xlink:to="sava_WorkforceReductionMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RestructuringCostAndReserveAxis" xlink:to="us-gaap_TypeOfRestructuringDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsequentEventTypeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain-default" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_StatementScenarioAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="srt_ScenarioForecastMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain-default" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_RestructuringAndRelatedCostExpectedCost1" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cassavasciences.com/20241231/role/statement-note-2-summary-of-significant-accounting-policies-quantitative-information-of-warrants-details" xlink:href="sava-20241231.xsd#statement-note-2-summary-of-significant-accounting-policies-quantitative-information-of-warrants-details" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.cassavasciences.com/20241231/role/statement-note-2-summary-of-significant-accounting-policies-quantitative-information-of-warrants-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="sava-20241231.xsd#sava_WarrantsToPurchaseCommonStockMember" xlink:label="sava_WarrantsToPurchaseCommonStockMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputConversionPriceMember" xlink:label="us-gaap_MeasurementInputConversionPriceMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputExercisePriceMember" xlink:label="us-gaap_MeasurementInputExercisePriceMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputExpectedDividendRateMember" xlink:label="us-gaap_MeasurementInputExpectedDividendRateMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputExpectedTermMember" xlink:label="us-gaap_MeasurementInputExpectedTermMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputPriceVolatilityMember" xlink:label="us-gaap_MeasurementInputPriceVolatilityMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:label="us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputSharePriceMember" xlink:label="us-gaap_MeasurementInputSharePriceMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="us-gaap_MeasurementInputTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="us-gaap_MeasurementInputTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="us-gaap_MeasurementInputTypeDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:label="us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputTypeDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="sava_WarrantsToPurchaseCommonStockMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_MeasurementInputTypeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputExercisePriceMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputTypeDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputConversionPriceMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputSharePriceMember" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputPriceVolatilityMember" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputExpectedTermMember" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputExpectedDividendRateMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cassavasciences.com/20241231/role/statement-note-6-intangible-assets-amortization-expense-for-finitelived-intangible-assets-details" xlink:href="sava-20241231.xsd#statement-note-6-intangible-assets-amortization-expense-for-finitelived-intangible-assets-details" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.cassavasciences.com/20241231/role/statement-note-6-intangible-assets-amortization-expense-for-finitelived-intangible-assets-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cassavasciences.com/20241231/role/statement-note-7-stockholders-equity-and-stockbased-compensation-stock-option-and-performance-award-activity-details" xlink:href="sava-20241231.xsd#statement-note-7-stockholders-equity-and-stockbased-compensation-stock-option-and-performance-award-activity-details" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.cassavasciences.com/20241231/role/statement-note-7-stockholders-equity-and-stockbased-compensation-stock-option-and-performance-award-activity-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PerformanceSharesMember" xlink:label="us-gaap_PerformanceSharesMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AwardTypeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_PerformanceSharesMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cassavasciences.com/20241231/role/statement-note-13-warrant-dividend-distribution-changes-in-warrants-outstanding-and-warrant-liability-details" xlink:href="sava-20241231.xsd#statement-note-13-warrant-dividend-distribution-changes-in-warrants-outstanding-and-warrant-liability-details" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.cassavasciences.com/20241231/role/statement-note-13-warrant-dividend-distribution-changes-in-warrants-outstanding-and-warrant-liability-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="sava-20241231.xsd#sava_ClassOfWarrantOrRightExercisedDuringPeriod" xlink:label="sava_ClassOfWarrantOrRightExercisedDuringPeriod" xlink:type="locator"/>
    <link:loc xlink:href="sava-20241231.xsd#sava_ClassOfWarrantsOrRightsCommonStockWarrantsRedeemed" xlink:label="sava_ClassOfWarrantsOrRightsCommonStockWarrantsRedeemed" xlink:type="locator"/>
    <link:loc xlink:href="sava-20241231.xsd#sava_ExerciseOfWarrantsResultingInDecreaseInWarrantLiability" xlink:label="sava_ExerciseOfWarrantsResultingInDecreaseInWarrantLiability" xlink:type="locator"/>
    <link:loc xlink:href="sava-20241231.xsd#sava_WarrantsToPurchaseCommonStockMember" xlink:label="sava_WarrantsToPurchaseCommonStockMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="us-gaap_FairValueAdjustmentOfWarrants" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantsAndRightsOutstanding" xlink:label="us-gaap_WarrantsAndRightsOutstanding" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="sava_WarrantsToPurchaseCommonStockMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_WarrantsAndRightsOutstanding" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="sava_ClassOfWarrantOrRightExercisedDuringPeriod" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="sava_ExerciseOfWarrantsResultingInDecreaseInWarrantLiability" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_FairValueAdjustmentOfWarrants" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="sava_ClassOfWarrantsOrRightsCommonStockWarrantsRedeemed" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cassavasciences.com/20241231/role/statement-consolidated-statements-of-operations-" xlink:href="sava-20241231.xsd#statement-consolidated-statements-of-operations-" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.cassavasciences.com/20241231/role/statement-consolidated-statements-of-operations-" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="us-gaap_FairValueAdjustmentOfWarrants" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:label="us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockDividendsAndOtherAdjustments" xlink:label="us-gaap_PreferredStockDividendsAndOtherAdjustments" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingExpensesAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpense" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_GeneralAndAdministrativeExpense" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpenses" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingIncomeLoss" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OtherNonoperatingIncomeExpense" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_FairValueAdjustmentOfWarrants" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_NetIncomeLoss" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc"/>
    <link:definitionArc order="9" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_EarningsPerShareBasic" xlink:type="arc"/>
    <link:definitionArc order="10" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_PreferredStockDividendsAndOtherAdjustments" xlink:type="arc"/>
    <link:definitionArc order="11" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:type="arc"/>
    <link:definitionArc order="12" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="arc"/>
    <link:definitionArc order="13" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_EarningsPerShareDiluted" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cassavasciences.com/20241231/role/statement-consolidated-statements-of-cash-flows" xlink:href="sava-20241231.xsd#statement-consolidated-statements-of-cash-flows" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.cassavasciences.com/20241231/role/statement-consolidated-statements-of-cash-flows" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="sava-20241231.xsd#sava_DerecognitionOfWarrantLiabilitiesThroughExercises" xlink:label="sava_DerecognitionOfWarrantLiabilitiesThroughExercises" xlink:type="locator"/>
    <link:loc xlink:href="sava-20241231.xsd#sava_IncreaseDecreaseInDevelopmentExpense" xlink:label="sava_IncreaseDecreaseInDevelopmentExpense" xlink:type="locator"/>
    <link:loc xlink:href="sava-20241231.xsd#sava_IncreaseDecreaseInOperatingLeaseRightOfUseAssetsAndLiabilitiesNet" xlink:label="sava_IncreaseDecreaseInOperatingLeaseRightOfUseAssetsAndLiabilitiesNet" xlink:type="locator"/>
    <link:loc xlink:href="sava-20241231.xsd#sava_IssuanceOfWarrantsResultingInRecognitionOfWarrantLiabilities" xlink:label="sava_IssuanceOfWarrantsResultingInRecognitionOfWarrantLiabilities" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="us-gaap_AmortizationOfIntangibleAssets" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:label="us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="us-gaap_FairValueAdjustmentOfWarrants" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="us-gaap_ProceedsFromWarrantExercises" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetIncomeLoss" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensation" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_FairValueAdjustmentOfWarrants" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_Depreciation" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AmortizationOfIntangibleAssets" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="sava_IncreaseDecreaseInOperatingLeaseRightOfUseAssetsAndLiabilitiesNet" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="sava_IncreaseDecreaseInDevelopmentExpense" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromStockOptionsExercised" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromWarrantExercises" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="sava_IssuanceOfWarrantsResultingInRecognitionOfWarrantLiabilities" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="sava_DerecognitionOfWarrantLiabilitiesThroughExercises" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cassavasciences.com/20241231/role/statement-note-3-prepaid-expenses-and-other-current-assets-prepaid-expenses-and-other-current-assets-details" xlink:href="sava-20241231.xsd#statement-note-3-prepaid-expenses-and-other-current-assets-prepaid-expenses-and-other-current-assets-details" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.cassavasciences.com/20241231/role/statement-note-3-prepaid-expenses-and-other-current-assets-prepaid-expenses-and-other-current-assets-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DepositContractsAssets" xlink:label="us-gaap_DepositContractsAssets" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestReceivableCurrent" xlink:label="us-gaap_InterestReceivableCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAssetsCurrent" xlink:label="us-gaap_OtherAssetsCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidInsurance" xlink:label="us-gaap_PrepaidInsurance" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PrepaidInsurance" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DepositContractsAssets" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_InterestReceivableCurrent" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherAssetsCurrent" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cassavasciences.com/20241231/role/statement-note-5-property-and-equipment-components-of-property-and-equipment-details" xlink:href="sava-20241231.xsd#statement-note-5-property-and-equipment-components-of-property-and-equipment-details" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.cassavasciences.com/20241231/role/statement-note-5-property-and-equipment-components-of-property-and-equipment-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BuildingImprovementsMember" xlink:label="us-gaap_BuildingImprovementsMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BuildingMember" xlink:label="us-gaap_BuildingMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConstructionInProgressMember" xlink:label="us-gaap_ConstructionInProgressMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="us-gaap_FurnitureAndFixturesMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LandMember" xlink:label="us-gaap_LandMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_LandMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_BuildingMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_BuildingImprovementsMember" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_LeaseholdImprovementsMember" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_FurnitureAndFixturesMember" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_ConstructionInProgressMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cassavasciences.com/20241231/role/statement-note-6-intangible-assets-components-of-intangible-assets-details" xlink:href="sava-20241231.xsd#statement-note-6-intangible-assets-components-of-intangible-assets-details" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.cassavasciences.com/20241231/role/statement-note-6-intangible-assets-components-of-intangible-assets-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="sava-20241231.xsd#sava_LeasingCommissionsAndOtherMember" xlink:label="sava_LeasingCommissionsAndOtherMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsGross" xlink:label="us-gaap_FiniteLivedIntangibleAssetsGross" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeasesAcquiredInPlaceMember" xlink:label="us-gaap_LeasesAcquiredInPlaceMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="us-gaap_LeasesAcquiredInPlaceMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="sava_LeasingCommissionsAndOtherMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsGross" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cassavasciences.com/20241231/role/statement-note-9-income-taxes-schedule-of-effective-income-tax-reconciliation-details" xlink:href="sava-20241231.xsd#statement-note-9-income-taxes-schedule-of-effective-income-tax-reconciliation-details" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.cassavasciences.com/20241231/role/statement-note-9-income-taxes-schedule-of-effective-income-tax-reconciliation-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="sava-20241231.xsd#sava_EffectiveIncomeTaxRateReconciliationChangeInFairValueOfWarrantLiabilities" xlink:label="sava_EffectiveIncomeTaxRateReconciliationChangeInFairValueOfWarrantLiabilities" xlink:type="locator"/>
    <link:loc xlink:href="sava-20241231.xsd#sava_EffectiveIncomeTaxRateReconciliationSection162mLimitationPercent" xlink:label="sava_EffectiveIncomeTaxRateReconciliationSection162mLimitationPercent" xlink:type="locator"/>
    <link:loc xlink:href="sava-20241231.xsd#sava_EffectiveIncomeTaxRateReconciliationTaxAttributeExpirationPercent" xlink:label="sava_EffectiveIncomeTaxRateReconciliationTaxAttributeExpirationPercent" xlink:type="locator"/>
    <link:loc xlink:href="sava-20241231.xsd#sava_EffectiveIncomeTaxRateReconciliationTaxCreditResearchAndDevelopmentPercent" xlink:label="sava_EffectiveIncomeTaxRateReconciliationTaxCreditResearchAndDevelopmentPercent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxContingencies" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxContingencies" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlements" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlements" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="sava_EffectiveIncomeTaxRateReconciliationTaxCreditResearchAndDevelopmentPercent" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="sava_EffectiveIncomeTaxRateReconciliationSection162mLimitationPercent" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxContingencies" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="sava_EffectiveIncomeTaxRateReconciliationTaxAttributeExpirationPercent" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="sava_EffectiveIncomeTaxRateReconciliationChangeInFairValueOfWarrantLiabilities" xlink:type="arc"/>
    <link:definitionArc order="9" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlements" xlink:type="arc"/>
    <link:definitionArc order="10" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" xlink:type="arc"/>
    <link:definitionArc order="11" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="arc"/>
    <link:definitionArc order="12" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cassavasciences.com/20241231/role/statement-note-9-income-taxes-schedule-of-unrecognized-tax-benefits-details" xlink:href="sava-20241231.xsd#statement-note-9-income-taxes-schedule-of-unrecognized-tax-benefits-details" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.cassavasciences.com/20241231/role/statement-note-9-income-taxes-schedule-of-unrecognized-tax-benefits-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="us-gaap_UnrecognizedTaxBenefits" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations" xlink:label="us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_UnrecognizedTaxBenefits" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cassavasciences.com/20241231/role/statement-note-2-summary-of-significant-accounting-policies-summary-of-codm-segments-details" xlink:href="sava-20241231.xsd#statement-note-2-summary-of-significant-accounting-policies-summary-of-codm-segments-details" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.cassavasciences.com/20241231/role/statement-note-2-summary-of-significant-accounting-policies-summary-of-codm-segments-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="sava-20241231.xsd#sava_CodmMonitoringMember" xlink:label="sava_CodmMonitoringMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentDomain" xlink:label="us-gaap_SegmentDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentDomain" xlink:label="us-gaap_SegmentDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingOtherItemAmount" xlink:label="us-gaap_SegmentReportingOtherItemAmount" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementBusinessSegmentsAxis" xlink:label="us-gaap_StatementBusinessSegmentsAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementBusinessSegmentsAxis" xlink:to="us-gaap_SegmentDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementBusinessSegmentsAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SegmentDomain" xlink:to="sava_CodmMonitoringMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementBusinessSegmentsAxis" xlink:to="us-gaap_SegmentDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ResearchAndDevelopmentExpense" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_GeneralAndAdministrativeExpense" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SegmentReportingOtherItemAmount" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cassavasciences.com/20241231/role/statement-note-2-significant-accounting-policies-calculation-of-net-loss-per-share-details" xlink:href="sava-20241231.xsd#statement-note-2-significant-accounting-policies-calculation-of-net-loss-per-share-details" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.cassavasciences.com/20241231/role/statement-note-2-significant-accounting-policies-calculation-of-net-loss-per-share-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DilutiveSecurities" xlink:label="us-gaap_DilutiveSecurities" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:label="us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_WarrantMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EarningsPerShareBasic" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DilutiveSecurities" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EarningsPerShareDiluted" xlink:type="arc"/>
    <link:definitionArc order="9" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cassavasciences.com/20241231/role/statement-note-4-real-property-and-other-income-expense-components-of-other-income-net-details" xlink:href="sava-20241231.xsd#statement-note-4-real-property-and-other-income-expense-components-of-other-income-net-details" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.cassavasciences.com/20241231/role/statement-note-4-real-property-and-other-income-expense-components-of-other-income-net-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNonoperatingExpense" xlink:label="us-gaap_OtherNonoperatingExpense" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNonoperatingIncome" xlink:label="us-gaap_OtherNonoperatingIncome" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherNonoperatingIncome" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherNonoperatingExpense" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherNonoperatingIncomeExpense" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cassavasciences.com/20241231/role/statement-note-7-stockholders-equity-and-stockbased-compensation-stockbased-compensation-expense-details" xlink:href="sava-20241231.xsd#statement-note-7-stockholders-equity-and-stockbased-compensation-stockbased-compensation-expense-details" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.cassavasciences.com/20241231/role/statement-note-7-stockholders-equity-and-stockbased-compensation-stockbased-compensation-expense-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_IncomeStatementLocationAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cassavasciences.com/20241231/role/statement-note-9-income-taxes-schedule-of-deferred-tax-assets-and-liabilities-details" xlink:href="sava-20241231.xsd#statement-note-9-income-taxes-schedule-of-deferred-tax-assets-and-liabilities-details" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.cassavasciences.com/20241231/role/statement-note-9-income-taxes-schedule-of-deferred-tax-assets-and-liabilities-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="sava-20241231.xsd#sava_DeferredTaxAssetsCapitalizedResearchAndDevelopmentExpenses" xlink:label="sava_DeferredTaxAssetsCapitalizedResearchAndDevelopmentExpenses" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredIncomeTaxLiabilities" xlink:label="us-gaap_DeferredIncomeTaxLiabilities" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="us-gaap_DeferredTaxAssetsNet" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="us-gaap_DeferredTaxAssetsOther" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxLiabilitiesLeasingArrangements" xlink:label="us-gaap_DeferredTaxLiabilitiesLeasingArrangements" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="sava_DeferredTaxAssetsCapitalizedResearchAndDevelopmentExpenses" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DeferredTaxAssetsOther" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DeferredTaxAssetsGross" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DeferredTaxAssetsNet" xlink:type="arc"/>
    <link:definitionArc order="9" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DeferredTaxLiabilitiesLeasingArrangements" xlink:type="arc"/>
    <link:definitionArc order="10" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DeferredIncomeTaxLiabilities" xlink:type="arc"/>
    <link:definitionArc order="11" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cassavasciences.com/20241231/role/statement-consolidated-balance-sheets" xlink:href="sava-20241231.xsd#statement-consolidated-balance-sheets" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.cassavasciences.com/20241231/role/statement-consolidated-balance-sheets" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="sava-20241231.xsd#sava_AccruedDevelopmentExpenseCurrent" xlink:label="sava_AccruedDevelopmentExpenseCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="us-gaap_OtherLiabilitiesCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="us-gaap_OtherLiabilitiesNoncurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AssetsCurrentAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrent" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_Assets" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LiabilitiesCurrentAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="sava_AccruedDevelopmentExpenseCurrent" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_OtherLiabilitiesCurrent" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrent" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_OtherLiabilitiesNoncurrent" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_Liabilities" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_CommitmentsAndContingencies" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquityAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_PreferredStockValue" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_CommonStockValue" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AdditionalPaidInCapital" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquity" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cassavasciences.com/20241231/role/statement-consolidated-statements-of-stockholders-equity" xlink:href="sava-20241231.xsd#statement-consolidated-statements-of-stockholders-equity" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.cassavasciences.com/20241231/role/statement-consolidated-statements-of-stockholders-equity" xlink:type="extended">
    <link:loc xlink:href="sava-20241231.xsd#sava_AdjustmentsToAdditionalPaidInCapitalDerecognitionOfWarrantLiabilitiesUponExerciseOfWarrants" xlink:label="sava_AdjustmentsToAdditionalPaidInCapitalDerecognitionOfWarrantLiabilitiesUponExerciseOfWarrants" xlink:type="locator"/>
    <link:loc xlink:href="sava-20241231.xsd#sava_StockIssuedDuringPeriodSharesWarrantExercises" xlink:label="sava_StockIssuedDuringPeriodSharesWarrantExercises" xlink:type="locator"/>
    <link:loc xlink:href="sava-20241231.xsd#sava_StockIssuedDuringPeriodValueWarrantExercises" xlink:label="sava_StockIssuedDuringPeriodValueWarrantExercises" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GranteeStatusAxis" xlink:label="us-gaap_GranteeStatusAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GranteeStatusDomain" xlink:label="us-gaap_GranteeStatusDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GranteeStatusDomain" xlink:label="us-gaap_GranteeStatusDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedPaymentArrangementEmployeeMember" xlink:label="us-gaap_ShareBasedPaymentArrangementEmployeeMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedPaymentArrangementNonemployeeMember" xlink:label="us-gaap_ShareBasedPaymentArrangementNonemployeeMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationForfeited" xlink:label="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationForfeited" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationForfeited" xlink:label="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationForfeited" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_GranteeStatusAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_GranteeStatusDomain" xlink:to="us-gaap_ShareBasedPaymentArrangementEmployeeMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_GranteeStatusAxis" xlink:to="us-gaap_GranteeStatusDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_GranteeStatusDomain" xlink:to="us-gaap_ShareBasedPaymentArrangementNonemployeeMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AdditionalPaidInCapitalMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_RetainedEarningsMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_GranteeStatusAxis" xlink:to="us-gaap_GranteeStatusDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationForfeited" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationForfeited" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="arc"/>
    <link:definitionArc order="9" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:type="arc"/>
    <link:definitionArc order="10" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" xlink:type="arc"/>
    <link:definitionArc order="11" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:type="arc"/>
    <link:definitionArc order="12" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="sava_StockIssuedDuringPeriodSharesWarrantExercises" xlink:type="arc"/>
    <link:definitionArc order="13" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="sava_StockIssuedDuringPeriodValueWarrantExercises" xlink:type="arc"/>
    <link:definitionArc order="14" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="sava_AdjustmentsToAdditionalPaidInCapitalDerecognitionOfWarrantLiabilitiesUponExerciseOfWarrants" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cassavasciences.com/20241231/role/statement-note-7-stockholders-equity-and-stockbased-compensation-stock-option-activity-details" xlink:href="sava-20241231.xsd#statement-note-7-stockholders-equity-and-stockbased-compensation-stock-option-activity-details" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.cassavasciences.com/20241231/role/statement-note-7-stockholders-equity-and-stockbased-compensation-stock-option-activity-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="arc"/>
    <link:definitionArc order="9" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:type="arc"/>
    <link:definitionArc order="10" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:type="arc"/>
    <link:definitionArc order="11" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:type="arc"/>
    <link:definitionArc order="12" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:type="arc"/>
    <link:definitionArc order="13" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:type="arc"/>
    <link:definitionArc order="14" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:type="arc"/>
    <link:definitionArc order="15" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="arc"/>
    <link:definitionArc order="16" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="arc"/>
    <link:definitionArc order="17" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:type="arc"/>
    <link:definitionArc order="18" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cassavasciences.com/20241231/role/statement-note-7-stockholders-equity-and-stockbased-compensation-schedule-of-stock-options-by-exercise-price-details" xlink:href="sava-20241231.xsd#statement-note-7-stockholders-equity-and-stockbased-compensation-schedule-of-stock-options-by-exercise-price-details" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.cassavasciences.com/20241231/role/statement-note-7-stockholders-equity-and-stockbased-compensation-schedule-of-stock-options-by-exercise-price-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="sava-20241231.xsd#sava_RangeFiveMember" xlink:label="sava_RangeFiveMember" xlink:type="locator"/>
    <link:loc xlink:href="sava-20241231.xsd#sava_RangeFourMember" xlink:label="sava_RangeFourMember" xlink:type="locator"/>
    <link:loc xlink:href="sava-20241231.xsd#sava_RangeOneMember" xlink:label="sava_RangeOneMember" xlink:type="locator"/>
    <link:loc xlink:href="sava-20241231.xsd#sava_RangeThreeMember" xlink:label="sava_RangeThreeMember" xlink:type="locator"/>
    <link:loc xlink:href="sava-20241231.xsd#sava_RangeTwoMember" xlink:label="sava_RangeTwoMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="sava_RangeOneMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="sava_RangeTwoMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="sava_RangeThreeMember" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="sava_RangeFourMember" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="sava_RangeFiveMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-roles-2024.xsd#eedm" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpense" xlink:type="arc"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>14
<FILENAME>sava-20241231_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
<!--Generated by ThunderDome XBRL - 08:53PM UTC 2025-03-03--><link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" xlink:type="simple"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:loc xlink:href="sava-20241231.xsd#sava_DocumentAndEntityInformation" xlink:label="sava_DocumentAndEntityInformation" xlink:type="locator"/>
    <link:label xlink:label="sava_DocumentAndEntityInformation-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document And Entity Information</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sava_DocumentAndEntityInformation" xlink:to="sava_DocumentAndEntityInformation-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Dividend yield</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate-label" xlink:type="arc"/>
    <link:loc xlink:href="sava-20241231.xsd#sava_NoteToFinancialStatementDetailsTextual" xlink:label="sava_NoteToFinancialStatementDetailsTextual" xlink:type="locator"/>
    <link:label xlink:label="sava_NoteToFinancialStatementDetailsTextual-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note To Financial Statement Details Textual</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sava_NoteToFinancialStatementDetailsTextual" xlink:to="sava_NoteToFinancialStatementDetailsTextual-label" xlink:type="arc"/>
    <link:loc xlink:href="sava-20241231.xsd#sava_statement-statement-significant-accounting-policies-policies" xlink:label="sava_statement-statement-significant-accounting-policies-policies" xlink:type="locator"/>
    <link:label xlink:label="sava_statement-statement-significant-accounting-policies-policies-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Significant Accounting Policies</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sava_statement-statement-significant-accounting-policies-policies" xlink:to="sava_statement-statement-significant-accounting-policies-policies-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Option, Exercise Price Range [Table Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="sava-20241231.xsd#sava_statement-statement-note-2-summary-of-significant-accounting-policies-tables" xlink:label="sava_statement-statement-note-2-summary-of-significant-accounting-policies-tables" xlink:type="locator"/>
    <link:label xlink:label="sava_statement-statement-note-2-summary-of-significant-accounting-policies-tables-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 2 - Summary of Significant Accounting Policies</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sava_statement-statement-note-2-summary-of-significant-accounting-policies-tables" xlink:to="sava_statement-statement-note-2-summary-of-significant-accounting-policies-tables-label" xlink:type="arc"/>
    <link:loc xlink:href="sava-20241231.xsd#sava_statement-statement-note-3-prepaid-expenses-and-other-current-assets-tables" xlink:label="sava_statement-statement-note-3-prepaid-expenses-and-other-current-assets-tables" xlink:type="locator"/>
    <link:label xlink:label="sava_statement-statement-note-3-prepaid-expenses-and-other-current-assets-tables-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 3 - Prepaid Expenses and Other Current Assets</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sava_statement-statement-note-3-prepaid-expenses-and-other-current-assets-tables" xlink:to="sava_statement-statement-note-3-prepaid-expenses-and-other-current-assets-tables-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Risk-free interest rates</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate-label" xlink:type="arc"/>
    <link:loc xlink:href="sava-20241231.xsd#sava_statement-statement-note-4-real-property-and-other-income-expense-tables" xlink:label="sava_statement-statement-note-4-real-property-and-other-income-expense-tables" xlink:type="locator"/>
    <link:label xlink:label="sava_statement-statement-note-4-real-property-and-other-income-expense-tables-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 4 - Real Property and Other Income, Expense</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sava_statement-statement-note-4-real-property-and-other-income-expense-tables" xlink:to="sava_statement-statement-note-4-real-property-and-other-income-expense-tables-label" xlink:type="arc"/>
    <link:loc xlink:href="sava-20241231.xsd#sava_statement-statement-note-5-property-and-equipment-tables" xlink:label="sava_statement-statement-note-5-property-and-equipment-tables" xlink:type="locator"/>
    <link:label xlink:label="sava_statement-statement-note-5-property-and-equipment-tables-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 5 - Property and Equipment</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sava_statement-statement-note-5-property-and-equipment-tables" xlink:to="sava_statement-statement-note-5-property-and-equipment-tables-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Forfeiture rate</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions-label" xlink:type="arc"/>
    <link:loc xlink:href="sava-20241231.xsd#sava_statement-statement-note-6-intangible-assets-tables" xlink:label="sava_statement-statement-note-6-intangible-assets-tables" xlink:type="locator"/>
    <link:label xlink:label="sava_statement-statement-note-6-intangible-assets-tables-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 6 - Intangible Assets</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sava_statement-statement-note-6-intangible-assets-tables" xlink:to="sava_statement-statement-note-6-intangible-assets-tables-label" xlink:type="arc"/>
    <link:loc xlink:href="sava-20241231.xsd#sava_statement-statement-note-7-stockholders-equity-and-stockbased-compensation-tables" xlink:label="sava_statement-statement-note-7-stockholders-equity-and-stockbased-compensation-tables" xlink:type="locator"/>
    <link:label xlink:label="sava_statement-statement-note-7-stockholders-equity-and-stockbased-compensation-tables-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 7 - Stockholders' Equity and Stock-based Compensation</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sava_statement-statement-note-7-stockholders-equity-and-stockbased-compensation-tables" xlink:to="sava_statement-statement-note-7-stockholders-equity-and-stockbased-compensation-tables-label" xlink:type="arc"/>
    <link:loc xlink:href="sava-20241231.xsd#sava_statement-statement-note-9-income-taxes-tables" xlink:label="sava_statement-statement-note-9-income-taxes-tables" xlink:type="locator"/>
    <link:label xlink:label="sava_statement-statement-note-9-income-taxes-tables-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 9 - Income Taxes</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sava_statement-statement-note-9-income-taxes-tables" xlink:to="sava_statement-statement-note-9-income-taxes-tables-label" xlink:type="arc"/>
    <link:loc xlink:href="sava-20241231.xsd#sava_statement-statement-note-13-warrant-dividend-distribution-tables" xlink:label="sava_statement-statement-note-13-warrant-dividend-distribution-tables" xlink:type="locator"/>
    <link:label xlink:label="sava_statement-statement-note-13-warrant-dividend-distribution-tables-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 13 - Warrant Dividend Distribution</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sava_statement-statement-note-13-warrant-dividend-distribution-tables" xlink:to="sava_statement-statement-note-13-warrant-dividend-distribution-tables-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncomeTaxDisclosureTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Disclosure [Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="sava-20241231.xsd#sava_statement-statement-note-2-summary-of-significant-accounting-policies-quantitative-information-of-warrants-details" xlink:label="sava_statement-statement-note-2-summary-of-significant-accounting-policies-quantitative-information-of-warrants-details" xlink:type="locator"/>
    <link:label xlink:label="sava_statement-statement-note-2-summary-of-significant-accounting-policies-quantitative-information-of-warrants-details-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 2 - Summary of Significant Accounting Policies - Quantitative Information of Warrants (Details)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sava_statement-statement-note-2-summary-of-significant-accounting-policies-quantitative-information-of-warrants-details" xlink:to="sava_statement-statement-note-2-summary-of-significant-accounting-policies-quantitative-information-of-warrants-details-label" xlink:type="arc"/>
    <link:loc xlink:href="sava-20241231.xsd#sava_statement-statement-note-2-summary-of-significant-accounting-policies-summary-of-codm-segments-details" xlink:label="sava_statement-statement-note-2-summary-of-significant-accounting-policies-summary-of-codm-segments-details" xlink:type="locator"/>
    <link:label xlink:label="sava_statement-statement-note-2-summary-of-significant-accounting-policies-summary-of-codm-segments-details-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 2 - Summary of Significant Accounting Policies - Summary Of CODM Segments (Details)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sava_statement-statement-note-2-summary-of-significant-accounting-policies-summary-of-codm-segments-details" xlink:to="sava_statement-statement-note-2-summary-of-significant-accounting-policies-summary-of-codm-segments-details-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SignificantSupplyCommitmentRemainingMinimumAmountCommitted" xlink:label="us-gaap_SignificantSupplyCommitmentRemainingMinimumAmountCommitted" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SignificantSupplyCommitmentRemainingMinimumAmountCommitted-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_SignificantSupplyCommitmentRemainingMinimumAmountCommitted</link:label>
    <link:label xlink:label="us-gaap_SignificantSupplyCommitmentRemainingMinimumAmountCommitted-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Supply Commitment, Remaining Minimum Amount Committed</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SignificantSupplyCommitmentRemainingMinimumAmountCommitted" xlink:to="us-gaap_SignificantSupplyCommitmentRemainingMinimumAmountCommitted-label" xlink:type="arc"/>
    <link:loc xlink:href="sava-20241231.xsd#sava_statement-statement-note-2-significant-accounting-policies-calculation-of-net-loss-per-share-details" xlink:label="sava_statement-statement-note-2-significant-accounting-policies-calculation-of-net-loss-per-share-details" xlink:type="locator"/>
    <link:label xlink:label="sava_statement-statement-note-2-significant-accounting-policies-calculation-of-net-loss-per-share-details-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 2 - Significant Accounting Policies - Calculation of Net Loss Per Share (Details)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sava_statement-statement-note-2-significant-accounting-policies-calculation-of-net-loss-per-share-details" xlink:to="sava_statement-statement-note-2-significant-accounting-policies-calculation-of-net-loss-per-share-details-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Volatility</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate-label" xlink:type="arc"/>
    <link:loc xlink:href="sava-20241231.xsd#sava_statement-statement-note-3-prepaid-expenses-and-other-current-assets-prepaid-expenses-and-other-current-assets-details" xlink:label="sava_statement-statement-note-3-prepaid-expenses-and-other-current-assets-prepaid-expenses-and-other-current-assets-details" xlink:type="locator"/>
    <link:label xlink:label="sava_statement-statement-note-3-prepaid-expenses-and-other-current-assets-prepaid-expenses-and-other-current-assets-details-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 3 - Prepaid Expenses and Other Current Assets - Prepaid Expenses and Other Current Assets (Details)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sava_statement-statement-note-3-prepaid-expenses-and-other-current-assets-prepaid-expenses-and-other-current-assets-details" xlink:to="sava_statement-statement-note-3-prepaid-expenses-and-other-current-assets-prepaid-expenses-and-other-current-assets-details-label" xlink:type="arc"/>
    <link:loc xlink:href="sava-20241231.xsd#sava_statement-statement-note-4-real-property-and-other-income-expense-components-of-other-income-net-details" xlink:label="sava_statement-statement-note-4-real-property-and-other-income-expense-components-of-other-income-net-details" xlink:type="locator"/>
    <link:label xlink:label="sava_statement-statement-note-4-real-property-and-other-income-expense-components-of-other-income-net-details-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 4 - Real Property and Other Income, Expense - Components of Other Income, Net (Details)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sava_statement-statement-note-4-real-property-and-other-income-expense-components-of-other-income-net-details" xlink:to="sava_statement-statement-note-4-real-property-and-other-income-expense-components-of-other-income-net-details-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_LiabilitiesCurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_LiabilitiesCurrent</link:label>
    <link:label xlink:label="us-gaap_LiabilitiesCurrent-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total current liabilities</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="sava-20241231.xsd#sava_statement-statement-note-5-property-and-equipment-components-of-property-and-equipment-details" xlink:label="sava_statement-statement-note-5-property-and-equipment-components-of-property-and-equipment-details" xlink:type="locator"/>
    <link:label xlink:label="sava_statement-statement-note-5-property-and-equipment-components-of-property-and-equipment-details-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 5 - Property and Equipment - Components of Property and Equipment (Details)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sava_statement-statement-note-5-property-and-equipment-components-of-property-and-equipment-details" xlink:to="sava_statement-statement-note-5-property-and-equipment-components-of-property-and-equipment-details-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SupplyCommitmentAxis" xlink:label="us-gaap_SupplyCommitmentAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SupplyCommitmentAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Supply Commitment [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplyCommitmentAxis" xlink:to="us-gaap_SupplyCommitmentAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="sava-20241231.xsd#sava_statement-statement-note-6-intangible-assets-components-of-intangible-assets-details" xlink:label="sava_statement-statement-note-6-intangible-assets-components-of-intangible-assets-details" xlink:type="locator"/>
    <link:label xlink:label="sava_statement-statement-note-6-intangible-assets-components-of-intangible-assets-details-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 6 - Intangible Assets - Components of Intangible Assets (Details)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sava_statement-statement-note-6-intangible-assets-components-of-intangible-assets-details" xlink:to="sava_statement-statement-note-6-intangible-assets-components-of-intangible-assets-details-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SupplyCommitmentArrangementMember" xlink:label="us-gaap_SupplyCommitmentArrangementMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SupplyCommitmentArrangementMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Supply Commitment Arrangement [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplyCommitmentArrangementMember" xlink:to="us-gaap_SupplyCommitmentArrangementMember-label" xlink:type="arc"/>
    <link:loc xlink:href="sava-20241231.xsd#sava_statement-statement-note-6-intangible-assets-amortization-expense-for-finitelived-intangible-assets-details" xlink:label="sava_statement-statement-note-6-intangible-assets-amortization-expense-for-finitelived-intangible-assets-details" xlink:type="locator"/>
    <link:label xlink:label="sava_statement-statement-note-6-intangible-assets-amortization-expense-for-finitelived-intangible-assets-details-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 6 - Intangible Assets - Amortization Expense for Finite-lived Intangible Assets (Details)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sava_statement-statement-note-6-intangible-assets-amortization-expense-for-finitelived-intangible-assets-details" xlink:to="sava_statement-statement-note-6-intangible-assets-amortization-expense-for-finitelived-intangible-assets-details-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Expected life of option (in years) (Year)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="us-gaap_OtherLiabilitiesCurrent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_OtherLiabilitiesCurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other current liabilities</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherLiabilitiesCurrent" xlink:to="us-gaap_OtherLiabilitiesCurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="sava-20241231.xsd#sava_statement-statement-note-7-stockholders-equity-and-stockbased-compensation-stock-option-activity-details" xlink:label="sava_statement-statement-note-7-stockholders-equity-and-stockbased-compensation-stock-option-activity-details" xlink:type="locator"/>
    <link:label xlink:label="sava_statement-statement-note-7-stockholders-equity-and-stockbased-compensation-stock-option-activity-details-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 7 - Stockholders' Equity and Stock-based Compensation - Stock Option Activity (Details)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sava_statement-statement-note-7-stockholders-equity-and-stockbased-compensation-stock-option-activity-details" xlink:to="sava_statement-statement-note-7-stockholders-equity-and-stockbased-compensation-stock-option-activity-details-label" xlink:type="arc"/>
    <link:loc xlink:href="sava-20241231.xsd#sava_statement-statement-note-7-stockholders-equity-and-stockbased-compensation-schedule-of-stock-options-by-exercise-price-details" xlink:label="sava_statement-statement-note-7-stockholders-equity-and-stockbased-compensation-schedule-of-stock-options-by-exercise-price-details" xlink:type="locator"/>
    <link:label xlink:label="sava_statement-statement-note-7-stockholders-equity-and-stockbased-compensation-schedule-of-stock-options-by-exercise-price-details-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 7 - Stockholders' Equity and Stock-based Compensation - Schedule of Stock Options by Exercise Price (Details)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sava_statement-statement-note-7-stockholders-equity-and-stockbased-compensation-schedule-of-stock-options-by-exercise-price-details" xlink:to="sava_statement-statement-note-7-stockholders-equity-and-stockbased-compensation-schedule-of-stock-options-by-exercise-price-details-label" xlink:type="arc"/>
    <link:loc xlink:href="sava-20241231.xsd#sava_statement-statement-note-7-stockholders-equity-and-stockbased-compensation-stock-option-valuation-assumptions-details" xlink:label="sava_statement-statement-note-7-stockholders-equity-and-stockbased-compensation-stock-option-valuation-assumptions-details" xlink:type="locator"/>
    <link:label xlink:label="sava_statement-statement-note-7-stockholders-equity-and-stockbased-compensation-stock-option-valuation-assumptions-details-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 7 - Stockholders' Equity and Stock-based Compensation - Stock Option Valuation Assumptions (Details)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sava_statement-statement-note-7-stockholders-equity-and-stockbased-compensation-stock-option-valuation-assumptions-details" xlink:to="sava_statement-statement-note-7-stockholders-equity-and-stockbased-compensation-stock-option-valuation-assumptions-details-label" xlink:type="arc"/>
    <link:loc xlink:href="sava-20241231.xsd#sava_statement-statement-note-7-stockholders-equity-and-stockbased-compensation-stock-option-and-performance-award-activity-details" xlink:label="sava_statement-statement-note-7-stockholders-equity-and-stockbased-compensation-stock-option-and-performance-award-activity-details" xlink:type="locator"/>
    <link:label xlink:label="sava_statement-statement-note-7-stockholders-equity-and-stockbased-compensation-stock-option-and-performance-award-activity-details-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 7 - Stockholders' Equity and Stock-based Compensation - Stock Option and Performance Award Activity (Details)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sava_statement-statement-note-7-stockholders-equity-and-stockbased-compensation-stock-option-and-performance-award-activity-details" xlink:to="sava_statement-statement-note-7-stockholders-equity-and-stockbased-compensation-stock-option-and-performance-award-activity-details-label" xlink:type="arc"/>
    <link:loc xlink:href="sava-20241231.xsd#sava_statement-statement-note-7-stockholders-equity-and-stockbased-compensation-stockbased-compensation-expense-details" xlink:label="sava_statement-statement-note-7-stockholders-equity-and-stockbased-compensation-stockbased-compensation-expense-details" xlink:type="locator"/>
    <link:label xlink:label="sava_statement-statement-note-7-stockholders-equity-and-stockbased-compensation-stockbased-compensation-expense-details-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 7 - Stockholders' Equity and Stock-based Compensation - Stock-based Compensation Expense (Details)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sava_statement-statement-note-7-stockholders-equity-and-stockbased-compensation-stockbased-compensation-expense-details" xlink:to="sava_statement-statement-note-7-stockholders-equity-and-stockbased-compensation-stockbased-compensation-expense-details-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestReceivableCurrent" xlink:label="us-gaap_InterestReceivableCurrent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_InterestReceivableCurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest receivable</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestReceivableCurrent" xlink:to="us-gaap_InterestReceivableCurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="sava-20241231.xsd#sava_statement-statement-note-9-income-taxes-schedule-of-effective-income-tax-reconciliation-details" xlink:label="sava_statement-statement-note-9-income-taxes-schedule-of-effective-income-tax-reconciliation-details" xlink:type="locator"/>
    <link:label xlink:label="sava_statement-statement-note-9-income-taxes-schedule-of-effective-income-tax-reconciliation-details-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 9 - Income Taxes - Schedule of Effective Income Tax Reconciliation (Details)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sava_statement-statement-note-9-income-taxes-schedule-of-effective-income-tax-reconciliation-details" xlink:to="sava_statement-statement-note-9-income-taxes-schedule-of-effective-income-tax-reconciliation-details-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="sava-20241231.xsd#sava_statement-statement-note-9-income-taxes-schedule-of-deferred-tax-assets-and-liabilities-details" xlink:label="sava_statement-statement-note-9-income-taxes-schedule-of-deferred-tax-assets-and-liabilities-details" xlink:type="locator"/>
    <link:label xlink:label="sava_statement-statement-note-9-income-taxes-schedule-of-deferred-tax-assets-and-liabilities-details-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 9 - Income Taxes - Schedule of Deferred Tax Assets and Liabilities (Details)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sava_statement-statement-note-9-income-taxes-schedule-of-deferred-tax-assets-and-liabilities-details" xlink:to="sava_statement-statement-note-9-income-taxes-schedule-of-deferred-tax-assets-and-liabilities-details-label" xlink:type="arc"/>
    <link:loc xlink:href="sava-20241231.xsd#sava_statement-statement-note-9-income-taxes-schedule-of-unrecognized-tax-benefits-details" xlink:label="sava_statement-statement-note-9-income-taxes-schedule-of-unrecognized-tax-benefits-details" xlink:type="locator"/>
    <link:label xlink:label="sava_statement-statement-note-9-income-taxes-schedule-of-unrecognized-tax-benefits-details-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 9 - Income Taxes - Schedule of Unrecognized Tax Benefits (Details)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sava_statement-statement-note-9-income-taxes-schedule-of-unrecognized-tax-benefits-details" xlink:to="sava_statement-statement-note-9-income-taxes-schedule-of-unrecognized-tax-benefits-details-label" xlink:type="arc"/>
    <link:loc xlink:href="sava-20241231.xsd#sava_statement-statement-note-13-warrant-dividend-distribution-changes-in-warrants-outstanding-and-warrant-liability-details" xlink:label="sava_statement-statement-note-13-warrant-dividend-distribution-changes-in-warrants-outstanding-and-warrant-liability-details" xlink:type="locator"/>
    <link:label xlink:label="sava_statement-statement-note-13-warrant-dividend-distribution-changes-in-warrants-outstanding-and-warrant-liability-details-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 13 - Warrant Dividend Distribution - Changes in Warrants Outstanding and Warrant Liability (Details)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sava_statement-statement-note-13-warrant-dividend-distribution-changes-in-warrants-outstanding-and-warrant-liability-details" xlink:to="sava_statement-statement-note-13-warrant-dividend-distribution-changes-in-warrants-outstanding-and-warrant-liability-details-label" xlink:type="arc"/>
    <link:loc xlink:href="sava-20241231.xsd#sava_NotesToFinancialStatements" xlink:label="sava_NotesToFinancialStatements" xlink:type="locator"/>
    <link:label xlink:label="sava_NotesToFinancialStatements-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Notes To Financial Statements</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sava_NotesToFinancialStatements" xlink:to="sava_NotesToFinancialStatements-label" xlink:type="arc"/>
    <link:loc xlink:href="sava-20241231.xsd#sava_NotesToFinancialStatementsAbstract" xlink:label="sava_NotesToFinancialStatementsAbstract" xlink:type="locator"/>
    <link:label xlink:label="sava_NotesToFinancialStatementsAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Notes To Financial Statements [Abstract]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sava_NotesToFinancialStatementsAbstract" xlink:to="sava_NotesToFinancialStatementsAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Option, Activity [Table Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Activity [Table Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod-label" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Forfeited/canceled, awards (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber-label" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Outstanding, awards (in shares)</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber-label" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Outstanding, awards (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Granted, awards (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Vested, awards (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Vested and expected to vest at December 31, 2022, weighted average contractual term (Year)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Vested and expected to vest at December 31, 2024 (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Vested and expected to vest at December 31, 2022, weighted average exercise price (in dollars per share)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Vested and expected to vest at December 31, 2022, aggregate intrinsic value</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Exercisable at December 31, 2022, weighted average exercise price (in dollars per share)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Exercisable at December 31, 2022, weighted average contractual term (Year)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Exercisable at December 31, 2022, aggregate intrinsic value</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Exercisable at December 31, 2024 (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Outstanding as of December 31, 2022, weighted average contractual term (Year)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Outstanding as of December 31, 2022, aggregate intrinsic value</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted average fair value of stock options granted (in dollars per share)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice-label" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Outstanding, options, weighted average exercise price (in dollars per share)</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice-label" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Outstanding, options, weighted average exercise price (in dollars per share)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts payable and other accrued expenses</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" xlink:to="us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Options forfeited/canceled, weighted average exercise price (in dollars per share)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccrualForTaxesOtherThanIncomeTaxesCurrent" xlink:label="us-gaap_AccrualForTaxesOtherThanIncomeTaxesCurrent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AccrualForTaxesOtherThanIncomeTaxesCurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_AccrualForTaxesOtherThanIncomeTaxesCurrent</link:label>
    <link:label xlink:label="us-gaap_AccrualForTaxesOtherThanIncomeTaxesCurrent-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrual for Taxes Other than Income Taxes, Current</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccrualForTaxesOtherThanIncomeTaxesCurrent" xlink:to="us-gaap_AccrualForTaxesOtherThanIncomeTaxesCurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Options granted, weighted average exercise price (in dollars per share)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Options exercised, weighted average exercise price (in dollars per share)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued compensation and benefits</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Expirations (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber-label" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Outstanding, options (in shares)</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber-label" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Outstanding, options (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:label="us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CapitalExpendituresIncurredButNotYetPaid-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Purchases of property and equipment included in accounts payable</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:to="us-gaap_CapitalExpendituresIncurredButNotYetPaid-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PolicyTextBlockAbstract" xlink:label="us-gaap_PolicyTextBlockAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PolicyTextBlockAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_PolicyTextBlockAbstract</link:label>
    <link:label xlink:label="us-gaap_PolicyTextBlockAbstract-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounting Policies</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PolicyTextBlockAbstract" xlink:to="us-gaap_PolicyTextBlockAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LossContingencyNewClaimsFiledNumber" xlink:label="us-gaap_LossContingencyNewClaimsFiledNumber" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_LossContingencyNewClaimsFiledNumber-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_LossContingencyNewClaimsFiledNumber</link:label>
    <link:label xlink:label="us-gaap_LossContingencyNewClaimsFiledNumber-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Loss Contingency, New Claims Filed, Number</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LossContingencyNewClaimsFiledNumber" xlink:to="us-gaap_LossContingencyNewClaimsFiledNumber-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</link:label>
    <link:label xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment-label" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Purchases of property and equipment</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-cash investing activities</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="us-gaap_NoncashInvestingAndFinancingItemsAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod</link:label>
    <link:label xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period (Year)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period (Year)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GranteeStatusDomain" xlink:label="us-gaap_GranteeStatusDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_GranteeStatusDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Grantee Status [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GranteeStatusDomain" xlink:to="us-gaap_GranteeStatusDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GranteeStatusAxis" xlink:label="us-gaap_GranteeStatusAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_GranteeStatusAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Grantee Status [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GranteeStatusAxis" xlink:to="us-gaap_GranteeStatusAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeasesAcquiredInPlaceMember" xlink:label="us-gaap_LeasesAcquiredInPlaceMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_LeasesAcquiredInPlaceMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Leases, Acquired-in-Place [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeasesAcquiredInPlaceMember" xlink:to="us-gaap_LeasesAcquiredInPlaceMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_LiabilitiesCurrentAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current liabilities:</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_Assets-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_Assets</link:label>
    <link:label xlink:label="us-gaap_Assets-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total assets</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PlanNameAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock" xlink:label="us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Shareholders' Equity and Share-Based Payments [Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock" xlink:to="us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PlanNameDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameDomain" xlink:to="us-gaap_PlanNameDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CompensationAndEmployeeBenefitPlansTextBlock" xlink:label="us-gaap_CompensationAndEmployeeBenefitPlansTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CompensationAndEmployeeBenefitPlansTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Compensation and Employee Benefit Plans [Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CompensationAndEmployeeBenefitPlansTextBlock" xlink:to="us-gaap_CompensationAndEmployeeBenefitPlansTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized</link:label>
    <link:label xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</link:label>
    <link:label xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition (Year)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted</link:label>
    <link:label xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Adjusted numerator, diluted</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DilutiveSecurities" xlink:label="us-gaap_DilutiveSecurities" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DilutiveSecurities-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_DilutiveSecurities</link:label>
    <link:label xlink:label="us-gaap_DilutiveSecurities-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adjustment for change in fair value of warrant liabilities</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DilutiveSecurities" xlink:to="us-gaap_DilutiveSecurities-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockDividendsAndOtherAdjustments" xlink:label="us-gaap_PreferredStockDividendsAndOtherAdjustments" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PreferredStockDividendsAndOtherAdjustments-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_PreferredStockDividendsAndOtherAdjustments</link:label>
    <link:label xlink:label="us-gaap_PreferredStockDividendsAndOtherAdjustments-label" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Adjustment for change in fair value of warrant liabilities</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockDividendsAndOtherAdjustments" xlink:to="us-gaap_PreferredStockDividendsAndOtherAdjustments-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="sava-20241231.xsd#sava_AdjustmentsToAdditionalPaidInCapitalDerecognitionOfWarrantLiabilitiesUponExerciseOfWarrants" xlink:label="sava_AdjustmentsToAdditionalPaidInCapitalDerecognitionOfWarrantLiabilitiesUponExerciseOfWarrants" xlink:type="locator"/>
    <link:label xlink:label="sava_AdjustmentsToAdditionalPaidInCapitalDerecognitionOfWarrantLiabilitiesUponExerciseOfWarrants-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derecognition of warrant liabilities upon exercise of warrants</link:label>
    <link:label xlink:label="sava_AdjustmentsToAdditionalPaidInCapitalDerecognitionOfWarrantLiabilitiesUponExerciseOfWarrants-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Amount of increase in additional paid in capital (APIC) resulting from derecognition of warrant liabilities upon exercise of warrants.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sava_AdjustmentsToAdditionalPaidInCapitalDerecognitionOfWarrantLiabilitiesUponExerciseOfWarrants" xlink:to="sava_AdjustmentsToAdditionalPaidInCapitalDerecognitionOfWarrantLiabilitiesUponExerciseOfWarrants-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AwardTypeAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_AwardTypeAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_NetIncomeLoss-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net loss</link:label>
    <link:label xlink:label="us-gaap_NetIncomeLoss-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net loss</link:label>
    <link:label xlink:label="us-gaap_NetIncomeLoss-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net loss</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization</link:label>
    <link:label xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization-label" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Accumulated amortization</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_FiniteLivedIntangibleAssetsNet</link:label>
    <link:label xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total amortization</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNet-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Intangible assets, net</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:to="us-gaap_IntangibleAssetsNetExcludingGoodwill-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsGross" xlink:label="us-gaap_FiniteLivedIntangibleAssetsGross" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_FiniteLivedIntangibleAssetsGross-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Gross intangible assets</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsGross" xlink:to="us-gaap_FiniteLivedIntangibleAssetsGross-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PerformanceSharesMember" xlink:label="us-gaap_PerformanceSharesMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PerformanceSharesMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Performance Shares [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PerformanceSharesMember" xlink:to="us-gaap_PerformanceSharesMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_EmployeeStockOptionMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Option [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeStockOptionMember" xlink:to="us-gaap_EmployeeStockOptionMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_WarrantMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Warrant [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantMember" xlink:to="us-gaap_WarrantMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</link:label>
    <link:label xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment-label" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Accumulated depreciation</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PropertyPlantAndEquipmentNet-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property and equipment, net</link:label>
    <link:label xlink:label="us-gaap_PropertyPlantAndEquipmentNet-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Property and equipment, net</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LossContingencyDisclosures" xlink:label="us-gaap_LossContingencyDisclosures" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_LossContingencyDisclosures-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contingencies Disclosure [Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LossContingencyDisclosures" xlink:to="us-gaap_LossContingencyDisclosures-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PropertyPlantAndEquipmentGross-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Gross property and equipment</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentGross" xlink:to="us-gaap_PropertyPlantAndEquipmentGross-label" xlink:type="arc"/>
    <link:loc xlink:href="sava-20241231.xsd#sava_ExerciseOfWarrantsResultingInDecreaseInWarrantLiability" xlink:label="sava_ExerciseOfWarrantsResultingInDecreaseInWarrantLiability" xlink:type="locator"/>
    <link:label xlink:label="sava_ExerciseOfWarrantsResultingInDecreaseInWarrantLiability-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">sava_ExerciseOfWarrantsResultingInDecreaseInWarrantLiability</link:label>
    <link:label xlink:label="sava_ExerciseOfWarrantsResultingInDecreaseInWarrantLiability-label" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Warrants exercised, liability</link:label>
    <link:label xlink:label="sava_ExerciseOfWarrantsResultingInDecreaseInWarrantLiability-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Amount of decrease in warrant liability from exercise of warrants.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sava_ExerciseOfWarrantsResultingInDecreaseInWarrantLiability" xlink:to="sava_ExerciseOfWarrantsResultingInDecreaseInWarrantLiability-label" xlink:type="arc"/>
    <link:loc xlink:href="sava-20241231.xsd#sava_WarrantDividendDistributionTextBlock" xlink:label="sava_WarrantDividendDistributionTextBlock" xlink:type="locator"/>
    <link:label xlink:label="sava_WarrantDividendDistributionTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Warrant Dividend Distribution [Text Block]</link:label>
    <link:label xlink:label="sava_WarrantDividendDistributionTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The entire disclosure of warrant dividend distribution.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sava_WarrantDividendDistributionTextBlock" xlink:to="sava_WarrantDividendDistributionTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="sava-20241231.xsd#sava_IssuanceOfWarrantsResultingInRecognitionOfWarrantLiabilities" xlink:label="sava_IssuanceOfWarrantsResultingInRecognitionOfWarrantLiabilities" xlink:type="locator"/>
    <link:label xlink:label="sava_IssuanceOfWarrantsResultingInRecognitionOfWarrantLiabilities-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Issuance of warrants resulting in recognition of warrant liabilities</link:label>
    <link:label xlink:label="sava_IssuanceOfWarrantsResultingInRecognitionOfWarrantLiabilities-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Amount of issuance of warrants resulting in recognition of warrant liabilities.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sava_IssuanceOfWarrantsResultingInRecognitionOfWarrantLiabilities" xlink:to="sava_IssuanceOfWarrantsResultingInRecognitionOfWarrantLiabilities-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash flows from investing activities:</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingLiabilities-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_IncreaseDecreaseInOtherOperatingLiabilities</link:label>
    <link:label xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingLiabilities-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other liabilities</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:to="us-gaap_IncreaseDecreaseInOtherOperatingLiabilities-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" xlink:to="us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionAmountsOfTransaction" xlink:label="us-gaap_RelatedPartyTransactionAmountsOfTransaction" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_RelatedPartyTransactionAmountsOfTransaction-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_RelatedPartyTransactionAmountsOfTransaction</link:label>
    <link:label xlink:label="us-gaap_RelatedPartyTransactionAmountsOfTransaction-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Related Party Transaction, Amounts of Transaction</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionAmountsOfTransaction" xlink:to="us-gaap_RelatedPartyTransactionAmountsOfTransaction-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities</link:label>
    <link:label xlink:label="us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued compensation and benefits</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncomeTaxExpenseBenefit-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_IncomeTaxExpenseBenefit</link:label>
    <link:label xlink:label="us-gaap_IncomeTaxExpenseBenefit-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Tax Expense (Benefit)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxExpenseBenefit-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_IncreaseDecreaseInAccountsPayable</link:label>
    <link:label xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts payable and other accrued expenses</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_OperatingExpenses-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_OperatingExpenses</link:label>
    <link:label xlink:label="us-gaap_OperatingExpenses-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total operating expenses</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_GeneralAndAdministrativeExpense-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">General and administrative</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_GeneralAndAdministrativeExpense-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax" xlink:label="us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax</link:label>
    <link:label xlink:label="us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Expense, after Tax</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax" xlink:to="us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AllocatedShareBasedCompensationExpense-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Total stock-based compensation expense</link:label>
    <link:label xlink:label="us-gaap_AllocatedShareBasedCompensationExpense-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Expense</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense-label" xlink:type="arc"/>
    <link:loc xlink:href="sava-20241231.xsd#sava_StockIssuedDuringPeriodSharesWarrantExercises" xlink:label="sava_StockIssuedDuringPeriodSharesWarrantExercises" xlink:type="locator"/>
    <link:label xlink:label="sava_StockIssuedDuringPeriodSharesWarrantExercises-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common stock issued pursuant to warrant exercises, net of exercise costs (in shares)</link:label>
    <link:label xlink:label="sava_StockIssuedDuringPeriodSharesWarrantExercises-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Shares, Warrant Exercises (in shares)</link:label>
    <link:label xlink:label="sava_StockIssuedDuringPeriodSharesWarrantExercises-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Number of shares of stock issued attributable to warrant exercises.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sava_StockIssuedDuringPeriodSharesWarrantExercises" xlink:to="sava_StockIssuedDuringPeriodSharesWarrantExercises-label" xlink:type="arc"/>
    <link:loc xlink:href="sava-20241231.xsd#sava_StockIssuedDuringPeriodValueWarrantExercises" xlink:label="sava_StockIssuedDuringPeriodValueWarrantExercises" xlink:type="locator"/>
    <link:label xlink:label="sava_StockIssuedDuringPeriodValueWarrantExercises-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common stock issued pursuant to warrant exercises, net of exercise costs</link:label>
    <link:label xlink:label="sava_StockIssuedDuringPeriodValueWarrantExercises-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Value of shares of stock issued attributable to exercises of warrants.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sava_StockIssuedDuringPeriodValueWarrantExercises" xlink:to="sava_StockIssuedDuringPeriodValueWarrantExercises-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LegalFees" xlink:label="us-gaap_LegalFees" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_LegalFees-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_LegalFees</link:label>
    <link:label xlink:label="us-gaap_LegalFees-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Legal Fees</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LegalFees" xlink:to="us-gaap_LegalFees-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RealEstateOwnedTextBlock" xlink:label="us-gaap_RealEstateOwnedTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_RealEstateOwnedTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Real Estate Owned [Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RealEstateOwnedTextBlock" xlink:to="us-gaap_RealEstateOwnedTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" xlink:type="locator"/>
    <link:label xlink:label="dei_AmendmentFlag-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" xlink:type="locator"/>
    <link:label xlink:label="dei_CityAreaCode-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">City Area Code</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_UseOfEstimates-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseOfEstimates" xlink:to="us-gaap_UseOfEstimates-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SharesOutstanding-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_SharesOutstanding</link:label>
    <link:label xlink:label="us-gaap_SharesOutstanding-label" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Balance (in shares)</link:label>
    <link:label xlink:label="us-gaap_SharesOutstanding-label" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Balance (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CommonStockSharesOutstanding-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common stock, shares outstanding (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PreferredStockSharesOutstanding-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred stock, shares outstanding (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesOutstanding" xlink:to="us-gaap_PreferredStockSharesOutstanding-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetRentableArea" xlink:label="us-gaap_NetRentableArea" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_NetRentableArea-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_NetRentableArea</link:label>
    <link:label xlink:label="us-gaap_NetRentableArea-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net Rentable Area (Square Foot)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetRentableArea" xlink:to="us-gaap_NetRentableArea-label" xlink:type="arc"/>
    <link:loc xlink:href="sava-20241231.xsd#sava_EffectiveIncomeTaxRateReconciliationTaxAttributeExpirationPercent" xlink:label="sava_EffectiveIncomeTaxRateReconciliationTaxAttributeExpirationPercent" xlink:type="locator"/>
    <link:label xlink:label="sava_EffectiveIncomeTaxRateReconciliationTaxAttributeExpirationPercent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tax attribute expiration</link:label>
    <link:label xlink:label="sava_EffectiveIncomeTaxRateReconciliationTaxAttributeExpirationPercent-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to tax attribute expiration.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sava_EffectiveIncomeTaxRateReconciliationTaxAttributeExpirationPercent" xlink:to="sava_EffectiveIncomeTaxRateReconciliationTaxAttributeExpirationPercent-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" xlink:type="locator"/>
    <link:label xlink:label="dei_CurrentFiscalYearEndDate-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate-label" xlink:type="arc"/>
    <link:loc xlink:href="sava-20241231.xsd#sava_CodmMonitoringMember" xlink:label="sava_CodmMonitoringMember" xlink:type="locator"/>
    <link:label xlink:label="sava_CodmMonitoringMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">CODM Monitoring [Member]</link:label>
    <link:label xlink:label="sava_CodmMonitoringMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Relating to CODM monitoring.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sava_CodmMonitoringMember" xlink:to="sava_CodmMonitoringMember-label" xlink:type="arc"/>
    <link:loc xlink:href="sava-20241231.xsd#sava_LicenseAgreementMember" xlink:label="sava_LicenseAgreementMember" xlink:type="locator"/>
    <link:label xlink:label="sava_LicenseAgreementMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">License Agreement [Member]</link:label>
    <link:label xlink:label="sava_LicenseAgreementMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Relating to a license agreement.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sava_LicenseAgreementMember" xlink:to="sava_LicenseAgreementMember-label" xlink:type="arc"/>
    <link:loc xlink:href="sava-20241231.xsd#sava_YaleUniversityMember" xlink:label="sava_YaleUniversityMember" xlink:type="locator"/>
    <link:label xlink:label="sava_YaleUniversityMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Yale University [Member]</link:label>
    <link:label xlink:label="sava_YaleUniversityMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Relating to Yale University.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sava_YaleUniversityMember" xlink:to="sava_YaleUniversityMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</link:label>
    <link:label xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets-label" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" xlink:type="locator"/>
    <link:label xlink:label="dei_DocumentFiscalPeriodFocus-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" xlink:type="locator"/>
    <link:label xlink:label="dei_DocumentFiscalYearFocus-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" xlink:type="locator"/>
    <link:label xlink:label="dei_DocumentPeriodEndDate-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" xlink:type="locator"/>
    <link:label xlink:label="dei_EntityFileNumber-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity File Number</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" xlink:type="locator"/>
    <link:label xlink:label="dei_EntityEmergingGrowthCompany-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType" xlink:label="dei_DocumentType" xlink:type="locator"/>
    <link:label xlink:label="dei_DocumentType-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" xlink:type="locator"/>
    <link:label xlink:label="dei_EntitySmallBusiness-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Small Business</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" xlink:type="locator"/>
    <link:label xlink:label="dei_EntityShellCompany-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Shell Company</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentInformationLineItems" xlink:label="dei_DocumentInformationLineItems" xlink:type="locator"/>
    <link:label xlink:label="dei_DocumentInformationLineItems-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Information [Line Items]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentInformationLineItems-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentInformationTable" xlink:label="dei_DocumentInformationTable" xlink:type="locator"/>
    <link:label xlink:label="dei_DocumentInformationTable-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Information [Table]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentInformationTable" xlink:to="dei_DocumentInformationTable-label" xlink:type="arc"/>
    <link:loc xlink:href="sava-20241231.xsd#sava_RangeOneMember" xlink:label="sava_RangeOneMember" xlink:type="locator"/>
    <link:label xlink:label="sava_RangeOneMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Range One [Member]</link:label>
    <link:label xlink:label="sava_RangeOneMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Relating to range one.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sava_RangeOneMember" xlink:to="sava_RangeOneMember-label" xlink:type="arc"/>
    <link:loc xlink:href="sava-20241231.xsd#sava_StockOptionsExercisedNetSettledSatisfactionOfExercisePrice" xlink:label="sava_StockOptionsExercisedNetSettledSatisfactionOfExercisePrice" xlink:type="locator"/>
    <link:label xlink:label="sava_StockOptionsExercisedNetSettledSatisfactionOfExercisePrice-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">sava_StockOptionsExercisedNetSettledSatisfactionOfExercisePrice</link:label>
    <link:label xlink:label="sava_StockOptionsExercisedNetSettledSatisfactionOfExercisePrice-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock Options Exercised Net Settled Satisfaction Of Exercise Price (in shares)</link:label>
    <link:label xlink:label="sava_StockOptionsExercisedNetSettledSatisfactionOfExercisePrice-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the number of stock options exercised net settled in satisfaction of the exercise price.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sava_StockOptionsExercisedNetSettledSatisfactionOfExercisePrice" xlink:to="sava_StockOptionsExercisedNetSettledSatisfactionOfExercisePrice-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat" xlink:type="locator"/>
    <link:label xlink:label="dei_EntityPublicFloat-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Public Float</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeveranceCosts1" xlink:label="us-gaap_SeveranceCosts1" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SeveranceCosts1-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_SeveranceCosts1</link:label>
    <link:label xlink:label="us-gaap_SeveranceCosts1-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Severance Costs</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SeveranceCosts1" xlink:to="us-gaap_SeveranceCosts1-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" xlink:type="locator"/>
    <link:label xlink:label="dei_EntityFilerCategory-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Filer Category</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" xlink:type="locator"/>
    <link:label xlink:label="dei_EntityCurrentReportingStatus-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers" xlink:type="locator"/>
    <link:label xlink:label="dei_EntityVoluntaryFilers-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Voluntary Filers</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer" xlink:type="locator"/>
    <link:label xlink:label="dei_EntityWellKnownSeasonedIssuer-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer-label" xlink:type="arc"/>
    <link:loc xlink:href="sava-20241231.xsd#sava_IndefiniteLifeCarryforwardsMember" xlink:label="sava_IndefiniteLifeCarryforwardsMember" xlink:type="locator"/>
    <link:label xlink:label="sava_IndefiniteLifeCarryforwardsMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Indefinite Life Carryforwards [Member]</link:label>
    <link:label xlink:label="sava_IndefiniteLifeCarryforwardsMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Relating to indefinite life tax carryforwards.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sava_IndefiniteLifeCarryforwardsMember" xlink:to="sava_IndefiniteLifeCarryforwardsMember-label" xlink:type="arc"/>
    <link:loc xlink:href="sava-20241231.xsd#sava_CarryforwardSubjectToExpirationMember" xlink:label="sava_CarryforwardSubjectToExpirationMember" xlink:type="locator"/>
    <link:label xlink:label="sava_CarryforwardSubjectToExpirationMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Carryforward Subject to Expiration [Member]</link:label>
    <link:label xlink:label="sava_CarryforwardSubjectToExpirationMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Relating to tax carryforwards subject to expiration.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sava_CarryforwardSubjectToExpirationMember" xlink:to="sava_CarryforwardSubjectToExpirationMember-label" xlink:type="arc"/>
    <link:loc xlink:href="sava-20241231.xsd#sava_RangeThreeMember" xlink:label="sava_RangeThreeMember" xlink:type="locator"/>
    <link:label xlink:label="sava_RangeThreeMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Range Three [Member]</link:label>
    <link:label xlink:label="sava_RangeThreeMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Relating to range three.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sava_RangeThreeMember" xlink:to="sava_RangeThreeMember-label" xlink:type="arc"/>
    <link:loc xlink:href="sava-20241231.xsd#sava_RangeTwoMember" xlink:label="sava_RangeTwoMember" xlink:type="locator"/>
    <link:label xlink:label="sava_RangeTwoMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Range Two [Member]</link:label>
    <link:label xlink:label="sava_RangeTwoMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Relating to range two.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sava_RangeTwoMember" xlink:to="sava_RangeTwoMember-label" xlink:type="arc"/>
    <link:loc xlink:href="sava-20241231.xsd#sava_RangeFiveMember" xlink:label="sava_RangeFiveMember" xlink:type="locator"/>
    <link:label xlink:label="sava_RangeFiveMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Range Five [Member]</link:label>
    <link:label xlink:label="sava_RangeFiveMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Relating to range five.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sava_RangeFiveMember" xlink:to="sava_RangeFiveMember-label" xlink:type="arc"/>
    <link:loc xlink:href="sava-20241231.xsd#sava_RangeFourMember" xlink:label="sava_RangeFourMember" xlink:type="locator"/>
    <link:label xlink:label="sava_RangeFourMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Range Four [Member]</link:label>
    <link:label xlink:label="sava_RangeFourMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Relating to range four.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sava_RangeFourMember" xlink:to="sava_RangeFourMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued</link:label>
    <link:label xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued-label" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Issuance of warrants</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued-label" xlink:type="arc"/>
    <link:loc xlink:href="sava-20241231.xsd#sava_LeasesAndCommitmentsDisclosureTextBlock" xlink:label="sava_LeasesAndCommitmentsDisclosureTextBlock" xlink:type="locator"/>
    <link:label xlink:label="sava_LeasesAndCommitmentsDisclosureTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Leases And Commitments Disclosure [Text Block]</link:label>
    <link:label xlink:label="sava_LeasesAndCommitmentsDisclosureTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The entire disclosure regarding leases and commitments.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sava_LeasesAndCommitmentsDisclosureTextBlock" xlink:to="sava_LeasesAndCommitmentsDisclosureTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="sava-20241231.xsd#sava_DeferredTaxAssetsCapitalizedResearchAndDevelopmentExpenses" xlink:label="sava_DeferredTaxAssetsCapitalizedResearchAndDevelopmentExpenses" xlink:type="locator"/>
    <link:label xlink:label="sava_DeferredTaxAssetsCapitalizedResearchAndDevelopmentExpenses-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Capitalized research and development expenses</link:label>
    <link:label xlink:label="sava_DeferredTaxAssetsCapitalizedResearchAndDevelopmentExpenses-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Amount before allocation of valuation allowances of deferred tax asset attributable to capitalized research and development expenses.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sava_DeferredTaxAssetsCapitalizedResearchAndDevelopmentExpenses" xlink:to="sava_DeferredTaxAssetsCapitalizedResearchAndDevelopmentExpenses-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" xlink:type="locator"/>
    <link:label xlink:label="dei_EntityTaxIdentificationNumber-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" xlink:type="locator"/>
    <link:label xlink:label="dei_EntityCentralIndexKey-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths" xlink:label="us-gaap_LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths</link:label>
    <link:label xlink:label="us-gaap_LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lessor, Operating Lease, Payment to be Received, Year One</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths" xlink:to="us-gaap_LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" xlink:type="locator"/>
    <link:label xlink:label="dei_EntityRegistrantName-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LessorOperatingLeasePaymentsToBeReceivedTwoYears" xlink:label="us-gaap_LessorOperatingLeasePaymentsToBeReceivedTwoYears" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_LessorOperatingLeasePaymentsToBeReceivedTwoYears-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_LessorOperatingLeasePaymentsToBeReceivedTwoYears</link:label>
    <link:label xlink:label="us-gaap_LessorOperatingLeasePaymentsToBeReceivedTwoYears-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lessor, Operating Lease, Payment to be Received, Year Two</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LessorOperatingLeasePaymentsToBeReceivedTwoYears" xlink:to="us-gaap_LessorOperatingLeasePaymentsToBeReceivedTwoYears-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock-based compensation for stock options</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LessorOperatingLeasePaymentsToBeReceivedThreeYears" xlink:label="us-gaap_LessorOperatingLeasePaymentsToBeReceivedThreeYears" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_LessorOperatingLeasePaymentsToBeReceivedThreeYears-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_LessorOperatingLeasePaymentsToBeReceivedThreeYears</link:label>
    <link:label xlink:label="us-gaap_LessorOperatingLeasePaymentsToBeReceivedThreeYears-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lessor, Operating Lease, Payment to be Received, Year Three</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LessorOperatingLeasePaymentsToBeReceivedThreeYears" xlink:to="us-gaap_LessorOperatingLeasePaymentsToBeReceivedThreeYears-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:label xlink:label="dei_EntityDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityDomain" xlink:to="dei_EntityDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:label xlink:label="dei_LegalEntityAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Legal Entity [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LegalEntityAxis" xlink:to="dei_LegalEntityAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" xlink:type="locator"/>
    <link:label xlink:label="dei_EntityAddressAddressLine1-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="us-gaap_AmortizationOfIntangibleAssets" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AmortizationOfIntangibleAssets-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amortization of intangible assets</link:label>
    <link:label xlink:label="us-gaap_AmortizationOfIntangibleAssets-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amortization of Intangible Assets</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AmortizationOfIntangibleAssets" xlink:to="us-gaap_AmortizationOfIntangibleAssets-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonRule10b51ArrTrmntdFlag" xlink:label="ecd_NonRule10b51ArrTrmntdFlag" xlink:type="locator"/>
    <link:label xlink:label="ecd_NonRule10b51ArrTrmntdFlag-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">ecd_NonRule10b51ArrTrmntdFlag</link:label>
    <link:label xlink:label="ecd_NonRule10b51ArrTrmntdFlag-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-Rule 10b5-1 Arrangement Terminated [Flag]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_NonRule10b51ArrTrmntdFlag" xlink:to="ecd_NonRule10b51ArrTrmntdFlag-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" xlink:type="locator"/>
    <link:label xlink:label="dei_EntityAddressCityOrTown-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_Rule10b51ArrTrmntdFlag" xlink:label="ecd_Rule10b51ArrTrmntdFlag" xlink:type="locator"/>
    <link:label xlink:label="ecd_Rule10b51ArrTrmntdFlag-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">ecd_Rule10b51ArrTrmntdFlag</link:label>
    <link:label xlink:label="ecd_Rule10b51ArrTrmntdFlag-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Rule 10b5-1 Arrangement Terminated [Flag]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_Rule10b51ArrTrmntdFlag" xlink:to="ecd_Rule10b51ArrTrmntdFlag-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_Rule10b51ArrAdoptedFlag" xlink:label="ecd_Rule10b51ArrAdoptedFlag" xlink:type="locator"/>
    <link:label xlink:label="ecd_Rule10b51ArrAdoptedFlag-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">ecd_Rule10b51ArrAdoptedFlag</link:label>
    <link:label xlink:label="ecd_Rule10b51ArrAdoptedFlag-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Rule 10b5-1 Arrangement Adopted [Flag]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_Rule10b51ArrAdoptedFlag" xlink:to="ecd_Rule10b51ArrAdoptedFlag-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" xlink:type="locator"/>
    <link:label xlink:label="dei_EntityAddressPostalZipCode-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" xlink:type="locator"/>
    <link:label xlink:label="dei_EntityAddressStateOrProvince-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonRule10b51ArrAdoptedFlag" xlink:label="ecd_NonRule10b51ArrAdoptedFlag" xlink:type="locator"/>
    <link:label xlink:label="ecd_NonRule10b51ArrAdoptedFlag-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">ecd_NonRule10b51ArrAdoptedFlag</link:label>
    <link:label xlink:label="ecd_NonRule10b51ArrAdoptedFlag-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-Rule 10b5-1 Arrangement Adopted [Flag]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_NonRule10b51ArrAdoptedFlag" xlink:to="ecd_NonRule10b51ArrAdoptedFlag-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_MtrlTermsOfTrdArrTextBlock" xlink:label="ecd_MtrlTermsOfTrdArrTextBlock" xlink:type="locator"/>
    <link:label xlink:label="ecd_MtrlTermsOfTrdArrTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Material Terms of Trading Arrangement [Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_MtrlTermsOfTrdArrTextBlock" xlink:to="ecd_MtrlTermsOfTrdArrTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" xlink:type="locator"/>
    <link:label xlink:label="dei_EntityCommonStockSharesOutstanding-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" xlink:type="locator"/>
    <link:label xlink:label="dei_TradingSymbol-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Symbol</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" xlink:type="locator"/>
    <link:label xlink:label="dei_LocalPhoneNumber-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Local Phone Number</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Issuance of common stock pursuant to exercise of stock options (in shares)</link:label>
    <link:label xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised-label" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Options exercised (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_TableTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_TableTextBlock</link:label>
    <link:label xlink:label="us-gaap_TableTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Notes Tables</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_TableTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Issuance of common stock pursuant to exercise of stock options</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Related and Nonrelated Parties [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_RelatedPartyDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Related and Nonrelated Parties [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="us-gaap_RelatedPartyDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationForfeited" xlink:label="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationForfeited" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationForfeited-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationForfeited</link:label>
    <link:label xlink:label="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationForfeited-label" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Expiration of restricted stock Performance Awards (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationForfeited" xlink:to="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationForfeited-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationForfeited" xlink:label="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationForfeited" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationForfeited-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationForfeited</link:label>
    <link:label xlink:label="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationForfeited-label" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Expiration of restricted stock Performance Awards</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationForfeited" xlink:to="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationForfeited-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Options granted (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period (in shares)</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod-label" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Options forfeited/canceled (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:label="us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_WarrantsAndRightsOutstandingMeasurementInput-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Warrant measurement</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:to="us-gaap_WarrantsAndRightsOutstandingMeasurementInput-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Issuance of common stock pursuant to stock offering, net of issuance costs (in shares)</link:label>
    <link:label xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Shares, New Issues (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingOtherItemAmount" xlink:label="us-gaap_SegmentReportingOtherItemAmount" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SegmentReportingOtherItemAmount-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other segment items(a)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingOtherItemAmount" xlink:to="us-gaap_SegmentReportingOtherItemAmount-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_LiabilitiesAndStockholdersEquity-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_LiabilitiesAndStockholdersEquity</link:label>
    <link:label xlink:label="us-gaap_LiabilitiesAndStockholdersEquity-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total liabilities and stockholders' equity</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Issuance of common stock pursuant to stock offering, net of issuance costs</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_RetainedEarningsAccumulatedDeficit</link:label>
    <link:label xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ResearchAndDevelopmentExpense-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Expense</link:label>
    <link:label xlink:label="us-gaap_ResearchAndDevelopmentExpense-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and development</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputSharePriceMember" xlink:label="us-gaap_MeasurementInputSharePriceMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_MeasurementInputSharePriceMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measurement Input, Share Price [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputSharePriceMember" xlink:to="us-gaap_MeasurementInputSharePriceMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputPriceVolatilityMember" xlink:label="us-gaap_MeasurementInputPriceVolatilityMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_MeasurementInputPriceVolatilityMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measurement Input, Price Volatility [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputPriceVolatilityMember" xlink:to="us-gaap_MeasurementInputPriceVolatilityMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Changes in operating assets and liabilities:</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:label="us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_MeasurementInputRiskFreeInterestRateMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measurement Input, Risk Free Interest Rate [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:to="us-gaap_MeasurementInputRiskFreeInterestRateMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DisclosureTextBlockAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_DisclosureTextBlockAbstract</link:label>
    <link:label xlink:label="us-gaap_DisclosureTextBlockAbstract-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Notes to Financial Statements</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_DisclosureTextBlockAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SubsequentEventMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Event [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventMember" xlink:to="us-gaap_SubsequentEventMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputExpectedDividendRateMember" xlink:label="us-gaap_MeasurementInputExpectedDividendRateMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_MeasurementInputExpectedDividendRateMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measurement Input, Expected Dividend Rate [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputExpectedDividendRateMember" xlink:to="us-gaap_MeasurementInputExpectedDividendRateMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputExpectedTermMember" xlink:label="us-gaap_MeasurementInputExpectedTermMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_MeasurementInputExpectedTermMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measurement Input, Expected Term [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputExpectedTermMember" xlink:to="us-gaap_MeasurementInputExpectedTermMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SubsequentEventTypeAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputExercisePriceMember" xlink:label="us-gaap_MeasurementInputExercisePriceMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_MeasurementInputExercisePriceMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measurement Input, Exercise Price [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputExercisePriceMember" xlink:to="us-gaap_MeasurementInputExercisePriceMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SubsequentEventTypeDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventTypeDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputConversionPriceMember" xlink:label="us-gaap_MeasurementInputConversionPriceMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_MeasurementInputConversionPriceMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measurement Input, Conversion Price [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputConversionPriceMember" xlink:to="us-gaap_MeasurementInputConversionPriceMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="us-gaap_SubsequentEventsTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SubsequentEventsTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Events [Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsTextBlock" xlink:to="us-gaap_SubsequentEventsTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="sava-20241231.xsd#sava_WarrantRedemptionPrice" xlink:label="sava_WarrantRedemptionPrice" xlink:type="locator"/>
    <link:label xlink:label="sava_WarrantRedemptionPrice-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">sava_WarrantRedemptionPrice</link:label>
    <link:label xlink:label="sava_WarrantRedemptionPrice-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Warrant Redemption Price (in dollars per share)</link:label>
    <link:label xlink:label="sava_WarrantRedemptionPrice-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Price of warrants if they are redeemed.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sava_WarrantRedemptionPrice" xlink:to="sava_WarrantRedemptionPrice-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="us-gaap_MeasurementInputTypeAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_MeasurementInputTypeAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measurement Input Type [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputTypeAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="us-gaap_MeasurementInputTypeDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_MeasurementInputTypeDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measurement Input Type [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputTypeDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Measurement, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:to="us-gaap_FairValueMeasurementPolicyPolicyTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo</link:label>
    <link:label xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2026</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value of Financial Instruments, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:to="us-gaap_FairValueOfFinancialInstrumentsPolicy-label" xlink:type="arc"/>
    <link:loc xlink:href="sava-20241231.xsd#sava_NumberOfFormerEmployees" xlink:label="sava_NumberOfFormerEmployees" xlink:type="locator"/>
    <link:label xlink:label="sava_NumberOfFormerEmployees-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">sava_NumberOfFormerEmployees</link:label>
    <link:label xlink:label="sava_NumberOfFormerEmployees-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of Former Employees</link:label>
    <link:label xlink:label="sava_NumberOfFormerEmployees-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the number of former employees.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sava_NumberOfFormerEmployees" xlink:to="sava_NumberOfFormerEmployees-label" xlink:type="arc"/>
    <link:loc xlink:href="sava-20241231.xsd#sava_RedemptionPercentageOfWarrants" xlink:label="sava_RedemptionPercentageOfWarrants" xlink:type="locator"/>
    <link:label xlink:label="sava_RedemptionPercentageOfWarrants-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">sava_RedemptionPercentageOfWarrants</link:label>
    <link:label xlink:label="sava_RedemptionPercentageOfWarrants-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Redemption Percentage of Warrants</link:label>
    <link:label xlink:label="sava_RedemptionPercentageOfWarrants-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The Percent of the cost for redemption of warrants.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sava_RedemptionPercentageOfWarrants" xlink:to="sava_RedemptionPercentageOfWarrants-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree</link:label>
    <link:label xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2027</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree-label" xlink:type="arc"/>
    <link:loc xlink:href="sava-20241231.xsd#sava_FormerSeniorOfficerMember" xlink:label="sava_FormerSeniorOfficerMember" xlink:type="locator"/>
    <link:label xlink:label="sava_FormerSeniorOfficerMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Former Senior Officer [Member]</link:label>
    <link:label xlink:label="sava_FormerSeniorOfficerMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the former senior officers.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sava_FormerSeniorOfficerMember" xlink:to="sava_FormerSeniorOfficerMember-label" xlink:type="arc"/>
    <link:loc xlink:href="sava-20241231.xsd#sava_CommissionPercentageOfGrossProceeds" xlink:label="sava_CommissionPercentageOfGrossProceeds" xlink:type="locator"/>
    <link:label xlink:label="sava_CommissionPercentageOfGrossProceeds-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">sava_CommissionPercentageOfGrossProceeds</link:label>
    <link:label xlink:label="sava_CommissionPercentageOfGrossProceeds-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Commission Percentage of Gross Proceeds</link:label>
    <link:label xlink:label="sava_CommissionPercentageOfGrossProceeds-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the percentage of commission required to be paid from gross proceeds.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sava_CommissionPercentageOfGrossProceeds" xlink:to="sava_CommissionPercentageOfGrossProceeds-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:label="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:to="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Segment Reporting, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="sava-20241231.xsd#sava_GrossProceedsFromIssuanceOfWarrants" xlink:label="sava_GrossProceedsFromIssuanceOfWarrants" xlink:type="locator"/>
    <link:label xlink:label="sava_GrossProceedsFromIssuanceOfWarrants-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">sava_GrossProceedsFromIssuanceOfWarrants</link:label>
    <link:label xlink:label="sava_GrossProceedsFromIssuanceOfWarrants-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Gross Proceeds From Issuance of Warrants</link:label>
    <link:label xlink:label="sava_GrossProceedsFromIssuanceOfWarrants-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Gross proceeds received from the issuance and sale of warrants.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sava_GrossProceedsFromIssuanceOfWarrants" xlink:to="sava_GrossProceedsFromIssuanceOfWarrants-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths</link:label>
    <link:label xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2025</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths-label" xlink:type="arc"/>
    <link:loc xlink:href="sava-20241231.xsd#sava_FormerSeniorVicePresidentMember" xlink:label="sava_FormerSeniorVicePresidentMember" xlink:type="locator"/>
    <link:label xlink:label="sava_FormerSeniorVicePresidentMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Former Senior Vice President [Member]</link:label>
    <link:label xlink:label="sava_FormerSeniorVicePresidentMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the former vice president.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sava_FormerSeniorVicePresidentMember" xlink:to="sava_FormerSeniorVicePresidentMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedPaymentArrangementEmployeeMember" xlink:label="us-gaap_ShareBasedPaymentArrangementEmployeeMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedPaymentArrangementEmployeeMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Employee [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedPaymentArrangementEmployeeMember" xlink:to="us-gaap_ShareBasedPaymentArrangementEmployeeMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="us-gaap_FairValueAdjustmentOfWarrants" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_FairValueAdjustmentOfWarrants-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Gain from change in fair value of warrant liabilities</link:label>
    <link:label xlink:label="us-gaap_FairValueAdjustmentOfWarrants-label" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">gain from change in fair value of warrant liabilities, liability</link:label>
    <link:label xlink:label="us-gaap_FairValueAdjustmentOfWarrants-label" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">gain from change in fair value of warrant liabilities, liability</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAdjustmentOfWarrants" xlink:to="us-gaap_FairValueAdjustmentOfWarrants-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensation-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ShareBasedCompensation</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensation-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock-based compensation</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation-label" xlink:type="arc"/>
    <link:loc xlink:href="sava-20241231.xsd#sava_ConsultingServicePricePerHour" xlink:label="sava_ConsultingServicePricePerHour" xlink:type="locator"/>
    <link:label xlink:label="sava_ConsultingServicePricePerHour-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">sava_ConsultingServicePricePerHour</link:label>
    <link:label xlink:label="sava_ConsultingServicePricePerHour-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Consulting Service, Price Per Hour</link:label>
    <link:label xlink:label="sava_ConsultingServicePricePerHour-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The cost per hour for the consulting services.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sava_ConsultingServicePricePerHour" xlink:to="sava_ConsultingServicePricePerHour-label" xlink:type="arc"/>
    <link:loc xlink:href="sava-20241231.xsd#sava_ClassOfWarrantsOrRightsCommonStockWarrantsRedeemed" xlink:label="sava_ClassOfWarrantsOrRightsCommonStockWarrantsRedeemed" xlink:type="locator"/>
    <link:label xlink:label="sava_ClassOfWarrantsOrRightsCommonStockWarrantsRedeemed-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">sava_ClassOfWarrantsOrRightsCommonStockWarrantsRedeemed</link:label>
    <link:label xlink:label="sava_ClassOfWarrantsOrRightsCommonStockWarrantsRedeemed-label" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Redemption of common stock warrants (in shares)</link:label>
    <link:label xlink:label="sava_ClassOfWarrantsOrRightsCommonStockWarrantsRedeemed-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the warrants redeemed common stock warrants.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sava_ClassOfWarrantsOrRightsCommonStockWarrantsRedeemed" xlink:to="sava_ClassOfWarrantsOrRightsCommonStockWarrantsRedeemed-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedPaymentArrangementNonemployeeMember" xlink:label="us-gaap_ShareBasedPaymentArrangementNonemployeeMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedPaymentArrangementNonemployeeMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Nonemployee [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedPaymentArrangementNonemployeeMember" xlink:to="us-gaap_ShareBasedPaymentArrangementNonemployeeMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_EarningsPerSharePolicyTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="sava-20241231.xsd#sava_RelatedPartyTransactionPolicyTextBlock" xlink:label="sava_RelatedPartyTransactionPolicyTextBlock" xlink:type="locator"/>
    <link:label xlink:label="sava_RelatedPartyTransactionPolicyTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Related Party Transaction [Policy Text Block]</link:label>
    <link:label xlink:label="sava_RelatedPartyTransactionPolicyTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Policy describing the related party transactions.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sava_RelatedPartyTransactionPolicyTextBlock" xlink:to="sava_RelatedPartyTransactionPolicyTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="sava-20241231.xsd#sava_InsuranceSettlementsMaximumRecoveryLimit" xlink:label="sava_InsuranceSettlementsMaximumRecoveryLimit" xlink:type="locator"/>
    <link:label xlink:label="sava_InsuranceSettlementsMaximumRecoveryLimit-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">sava_InsuranceSettlementsMaximumRecoveryLimit</link:label>
    <link:label xlink:label="sava_InsuranceSettlementsMaximumRecoveryLimit-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Insurance Settlements, Maximum Recovery Limit</link:label>
    <link:label xlink:label="sava_InsuranceSettlementsMaximumRecoveryLimit-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the maximum amount of monetary recovery for insurance policies.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sava_InsuranceSettlementsMaximumRecoveryLimit" xlink:to="sava_InsuranceSettlementsMaximumRecoveryLimit-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_OperatingExpensesAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating expenses:</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpensesAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="us-gaap_IncomeTaxPolicyTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncomeTaxPolicyTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxPolicyTextBlock" xlink:to="us-gaap_IncomeTaxPolicyTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="sava-20241231.xsd#sava_ClassOfWarrantOrRightFairValueOfCommonStockWarrantsPerWarrant" xlink:label="sava_ClassOfWarrantOrRightFairValueOfCommonStockWarrantsPerWarrant" xlink:type="locator"/>
    <link:label xlink:label="sava_ClassOfWarrantOrRightFairValueOfCommonStockWarrantsPerWarrant-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">sava_ClassOfWarrantOrRightFairValueOfCommonStockWarrantsPerWarrant</link:label>
    <link:label xlink:label="sava_ClassOfWarrantOrRightFairValueOfCommonStockWarrantsPerWarrant-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right, Fair Value of Common Stock Warrants per Warrant (in dollars per share)</link:label>
    <link:label xlink:label="sava_ClassOfWarrantOrRightFairValueOfCommonStockWarrantsPerWarrant-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the fair value of common stock warrants per warrant.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sava_ClassOfWarrantOrRightFairValueOfCommonStockWarrantsPerWarrant" xlink:to="sava_ClassOfWarrantOrRightFairValueOfCommonStockWarrantsPerWarrant-label" xlink:type="arc"/>
    <link:loc xlink:href="sava-20241231.xsd#sava_ClassOfWarrantOrRightRedemptionPricePerShare" xlink:label="sava_ClassOfWarrantOrRightRedemptionPricePerShare" xlink:type="locator"/>
    <link:label xlink:label="sava_ClassOfWarrantOrRightRedemptionPricePerShare-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">sava_ClassOfWarrantOrRightRedemptionPricePerShare</link:label>
    <link:label xlink:label="sava_ClassOfWarrantOrRightRedemptionPricePerShare-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right, Redemption Price per Share (in dollars per share)</link:label>
    <link:label xlink:label="sava_ClassOfWarrantOrRightRedemptionPricePerShare-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the redemption price per share of warrants or rights.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sava_ClassOfWarrantOrRightRedemptionPricePerShare" xlink:to="sava_ClassOfWarrantOrRightRedemptionPricePerShare-label" xlink:type="arc"/>
    <link:loc xlink:href="sava-20241231.xsd#sava_AntislappLawsuitMember" xlink:label="sava_AntislappLawsuitMember" xlink:type="locator"/>
    <link:label xlink:label="sava_AntislappLawsuitMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Anti-SLAPP Lawsuit [Member]</link:label>
    <link:label xlink:label="sava_AntislappLawsuitMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the anti-SLAAP lawsuit</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sava_AntislappLawsuitMember" xlink:to="sava_AntislappLawsuitMember-label" xlink:type="arc"/>
    <link:loc xlink:href="sava-20241231.xsd#sava_AccruedDevelopmentExpenseCurrent" xlink:label="sava_AccruedDevelopmentExpenseCurrent" xlink:type="locator"/>
    <link:label xlink:label="sava_AccruedDevelopmentExpenseCurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued development expense</link:label>
    <link:label xlink:label="sava_AccruedDevelopmentExpenseCurrent-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Amount of accrued development expense, classified as current.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sava_AccruedDevelopmentExpenseCurrent" xlink:to="sava_AccruedDevelopmentExpenseCurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets [Table Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:to="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Expense, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_Depreciation-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Depreciation</link:label>
    <link:label xlink:label="us-gaap_Depreciation-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Depreciation</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Depreciation" xlink:to="us-gaap_Depreciation-label" xlink:type="arc"/>
    <link:loc xlink:href="sava-20241231.xsd#sava_ConsultingAgreementTerm" xlink:label="sava_ConsultingAgreementTerm" xlink:type="locator"/>
    <link:label xlink:label="sava_ConsultingAgreementTerm-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">sava_ConsultingAgreementTerm</link:label>
    <link:label xlink:label="sava_ConsultingAgreementTerm-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Consulting Agreement, Term</link:label>
    <link:label xlink:label="sava_ConsultingAgreementTerm-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The consulting agreement term.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sava_ConsultingAgreementTerm" xlink:to="sava_ConsultingAgreementTerm-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:label="us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IntangibleAssetsDisclosureTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Intangible Assets Disclosure [Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:to="us-gaap_IntangibleAssetsDisclosureTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SharesIssuedPricePerShare-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_SharesIssuedPricePerShare</link:label>
    <link:label xlink:label="us-gaap_SharesIssuedPricePerShare-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Shares Issued, Price Per Share (in dollars per share)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesIssuedPricePerShare" xlink:to="us-gaap_SharesIssuedPricePerShare-label" xlink:type="arc"/>
    <link:loc xlink:href="sava-20241231.xsd#sava_SimufilamActiveIngredientMember" xlink:label="sava_SimufilamActiveIngredientMember" xlink:type="locator"/>
    <link:label xlink:label="sava_SimufilamActiveIngredientMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Simufilam Active Ingredient [Member]</link:label>
    <link:label xlink:label="sava_SimufilamActiveIngredientMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the simufilam active ingredient.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sava_SimufilamActiveIngredientMember" xlink:to="sava_SimufilamActiveIngredientMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AssetsCurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_AssetsCurrent</link:label>
    <link:label xlink:label="us-gaap_AssetsCurrent-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total current assets</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement [Policy Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:label="us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CompensationRelatedCostsPolicyTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Compensation Related Costs, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:to="us-gaap_CompensationRelatedCostsPolicyTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:label="us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_InterestIncomeExpenseNonoperatingNet-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest income</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:to="us-gaap_InterestIncomeExpenseNonoperatingNet-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Measurement Inputs and Valuation Techniques [Table Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CommonStockValue-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common stock, $0.001 par value; 120,000,000 shares authorized; 48,203,179 and 42,236,919 shares issued and outstanding at December 31, 2024 and 2023, respectively</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments to reconcile net loss to net cash used in operating activities:</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CommonStockSharesAuthorized-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common stock, shares authorized (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CommonStockSharesIssued-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common stock, shares issued (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CommonStockParOrStatedValuePerShare-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common stock, par value (in dollars per share)</link:label>
    <link:label xlink:label="us-gaap_CommonStockParOrStatedValuePerShare-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common Stock, Par or Stated Value Per Share (in dollars per share)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount</link:label>
    <link:label xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:to="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_DeferredTaxAssetsValuationAllowance</link:label>
    <link:label xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance-label" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Valuation allowance</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember" xlink:type="locator"/>
    <link:label xlink:label="srt_RangeMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeMember" xlink:to="srt_RangeMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" xlink:type="locator"/>
    <link:label xlink:label="srt_MaximumMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Maximum [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MaximumMember" xlink:to="srt_MaximumMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesPolicyTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesPolicyTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CommitmentsAndContingenciesPolicyTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesPolicyTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesPolicyTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" xlink:type="locator"/>
    <link:label xlink:label="srt_MinimumMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Minimum [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MinimumMember" xlink:to="srt_MinimumMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAssetsCurrent" xlink:label="us-gaap_OtherAssetsCurrent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_OtherAssetsCurrent-label" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Other</link:label>
    <link:label xlink:label="us-gaap_OtherAssetsCurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_OtherAssetsCurrent</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsCurrent" xlink:to="us-gaap_OtherAssetsCurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="us-gaap_DeferredTaxAssetsNet" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DeferredTaxAssetsNet-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_DeferredTaxAssetsNet</link:label>
    <link:label xlink:label="us-gaap_DeferredTaxAssetsNet-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net deferred tax assets</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsNet-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" xlink:type="locator"/>
    <link:label xlink:label="srt_RangeAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeAxis" xlink:to="srt_RangeAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_LitigationCaseAxis" xlink:label="srt_LitigationCaseAxis" xlink:type="locator"/>
    <link:label xlink:label="srt_LitigationCaseAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Litigation Case [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_LitigationCaseAxis" xlink:to="srt_LitigationCaseAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_LitigationCaseTypeDomain" xlink:label="srt_LitigationCaseTypeDomain" xlink:type="locator"/>
    <link:label xlink:label="srt_LitigationCaseTypeDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Litigation Case [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_LitigationCaseTypeDomain" xlink:to="srt_LitigationCaseTypeDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PreferredStockValue-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred stock, $0.001 par value; 10,000,000 shares authorized, none issued and outstanding</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockValue" xlink:to="us-gaap_PreferredStockValue-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_DeferredTaxAssetsLiabilitiesNet</link:label>
    <link:label xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net deferred tax asset (liability)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredTaxAssetsLiabilitiesNet-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PreferredStockSharesIssued-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred stock, shares issued (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesIssued" xlink:to="us-gaap_PreferredStockSharesIssued-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:label="us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IntangibleAssetsFiniteLivedPolicy-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Intangible Assets, Finite-Lived, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:to="us-gaap_IntangibleAssetsFiniteLivedPolicy-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="us-gaap_DeferredTaxAssetsOther" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DeferredTaxAssetsOther-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_DeferredTaxAssetsOther</link:label>
    <link:label xlink:label="us-gaap_DeferredTaxAssetsOther-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOther" xlink:to="us-gaap_DeferredTaxAssetsOther-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis" xlink:type="locator"/>
    <link:label xlink:label="srt_StatementGeographicalAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_StatementGeographicalAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment Disclosure [Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain" xlink:type="locator"/>
    <link:label xlink:label="srt_SegmentGeographicalDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_SegmentGeographicalDomain" xlink:to="srt_SegmentGeographicalDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Table Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DeferredTaxAssetsGross-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_DeferredTaxAssetsGross</link:label>
    <link:label xlink:label="us-gaap_DeferredTaxAssetsGross-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total deferred tax assets</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsGross-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PreferredStockSharesAuthorized-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred stock, shares authorized (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesAuthorized" xlink:to="us-gaap_PreferredStockSharesAuthorized-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredIncomeTaxLiabilities" xlink:label="us-gaap_DeferredIncomeTaxLiabilities" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DeferredIncomeTaxLiabilities-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_DeferredIncomeTaxLiabilities</link:label>
    <link:label xlink:label="us-gaap_DeferredIncomeTaxLiabilities-label" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xml:lang="en-US">Total deferred tax liabilities</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredIncomeTaxLiabilities" xlink:to="us-gaap_DeferredIncomeTaxLiabilities-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred stock, par value (in dollars per share)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidInsurance" xlink:label="us-gaap_PrepaidInsurance" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PrepaidInsurance-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Prepaid insurance</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidInsurance" xlink:to="us-gaap_PrepaidInsurance-label" xlink:type="arc"/>
    <link:loc xlink:href="sava-20241231.xsd#sava_IncreaseDecreaseInDevelopmentExpense" xlink:label="sava_IncreaseDecreaseInDevelopmentExpense" xlink:type="locator"/>
    <link:label xlink:label="sava_IncreaseDecreaseInDevelopmentExpense-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">sava_IncreaseDecreaseInDevelopmentExpense</link:label>
    <link:label xlink:label="sava_IncreaseDecreaseInDevelopmentExpense-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued development expense</link:label>
    <link:label xlink:label="sava_IncreaseDecreaseInDevelopmentExpense-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Amount of increase (decrease) in development expense.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sava_IncreaseDecreaseInDevelopmentExpense" xlink:to="sava_IncreaseDecreaseInDevelopmentExpense-label" xlink:type="arc"/>
    <link:loc xlink:href="sava-20241231.xsd#sava_IncreaseDecreaseInOperatingLeaseRightOfUseAssetsAndLiabilitiesNet" xlink:label="sava_IncreaseDecreaseInOperatingLeaseRightOfUseAssetsAndLiabilitiesNet" xlink:type="locator"/>
    <link:label xlink:label="sava_IncreaseDecreaseInOperatingLeaseRightOfUseAssetsAndLiabilitiesNet-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">sava_IncreaseDecreaseInOperatingLeaseRightOfUseAssetsAndLiabilitiesNet</link:label>
    <link:label xlink:label="sava_IncreaseDecreaseInOperatingLeaseRightOfUseAssetsAndLiabilitiesNet-label" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Operating lease right-of-use assets and liabilities</link:label>
    <link:label xlink:label="sava_IncreaseDecreaseInOperatingLeaseRightOfUseAssetsAndLiabilitiesNet-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Amount of increase (decrease) in operating lease right of use assets and liabilities, net.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sava_IncreaseDecreaseInOperatingLeaseRightOfUseAssetsAndLiabilitiesNet" xlink:to="sava_IncreaseDecreaseInOperatingLeaseRightOfUseAssetsAndLiabilitiesNet-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromInsuranceSettlementOperatingActivities" xlink:label="us-gaap_ProceedsFromInsuranceSettlementOperatingActivities" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ProceedsFromInsuranceSettlementOperatingActivities-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ProceedsFromInsuranceSettlementOperatingActivities</link:label>
    <link:label xlink:label="us-gaap_ProceedsFromInsuranceSettlementOperatingActivities-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from Insurance Settlement, Operating Activities</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromInsuranceSettlementOperatingActivities" xlink:to="us-gaap_ProceedsFromInsuranceSettlementOperatingActivities-label" xlink:type="arc"/>
    <link:loc xlink:href="sava-20241231.xsd#sava_PrepaidExpensesAndOtherCurrentAssetsTextBock" xlink:label="sava_PrepaidExpensesAndOtherCurrentAssetsTextBock" xlink:type="locator"/>
    <link:label xlink:label="sava_PrepaidExpensesAndOtherCurrentAssetsTextBock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Prepaid Expenses and Other Current Assets [Text Bock]</link:label>
    <link:label xlink:label="sava_PrepaidExpensesAndOtherCurrentAssetsTextBock-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The entire disclosure of prepaid expenses and other current assets.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sava_PrepaidExpensesAndOtherCurrentAssetsTextBock" xlink:to="sava_PrepaidExpensesAndOtherCurrentAssetsTextBock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_PropertyPlantAndEquipmentUsefulLife</link:label>
    <link:label xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Useful Life (Year)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife-label" xlink:type="arc"/>
    <link:loc xlink:href="sava-20241231.xsd#sava_WarrantsToPurchaseCommonStockMember" xlink:label="sava_WarrantsToPurchaseCommonStockMember" xlink:type="locator"/>
    <link:label xlink:label="sava_WarrantsToPurchaseCommonStockMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Warrants to Purchase Common Stock [Member]</link:label>
    <link:label xlink:label="sava_WarrantsToPurchaseCommonStockMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the warrants used to purchase common stock.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sava_WarrantsToPurchaseCommonStockMember" xlink:to="sava_WarrantsToPurchaseCommonStockMember-label" xlink:type="arc"/>
    <link:loc xlink:href="sava-20241231.xsd#sava_ClassOfWarrantOrRightIssuedDuringPeriod" xlink:label="sava_ClassOfWarrantOrRightIssuedDuringPeriod" xlink:type="locator"/>
    <link:label xlink:label="sava_ClassOfWarrantOrRightIssuedDuringPeriod-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">sava_ClassOfWarrantOrRightIssuedDuringPeriod</link:label>
    <link:label xlink:label="sava_ClassOfWarrantOrRightIssuedDuringPeriod-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class Of Warrant Or Right Issued During Period (in shares)</link:label>
    <link:label xlink:label="sava_ClassOfWarrantOrRightIssuedDuringPeriod-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The number of warrants or rights issued during period.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sava_ClassOfWarrantOrRightIssuedDuringPeriod" xlink:to="sava_ClassOfWarrantOrRightIssuedDuringPeriod-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConstructionInProgressMember" xlink:label="us-gaap_ConstructionInProgressMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ConstructionInProgressMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Construction in Progress [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConstructionInProgressMember" xlink:to="us-gaap_ConstructionInProgressMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash flows from operating activities:</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Segment Reporting Information, by Segment [Table Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:to="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantsAndRightsOutstanding" xlink:label="us-gaap_WarrantsAndRightsOutstanding" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_WarrantsAndRightsOutstanding-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Balance, liability</link:label>
    <link:label xlink:label="us-gaap_WarrantsAndRightsOutstanding-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Warrants and Rights Outstanding</link:label>
    <link:label xlink:label="us-gaap_WarrantsAndRightsOutstanding-label" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Balance, liability</link:label>
    <link:label xlink:label="us-gaap_WarrantsAndRightsOutstanding-label" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Balance, liability</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantsAndRightsOutstanding" xlink:to="us-gaap_WarrantsAndRightsOutstanding-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StatementLineItems-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems-label" xlink:type="arc"/>
    <link:loc xlink:href="sava-20241231.xsd#sava_ClassOfWarrantOrRightExercisedDuringPeriod" xlink:label="sava_ClassOfWarrantOrRightExercisedDuringPeriod" xlink:type="locator"/>
    <link:label xlink:label="sava_ClassOfWarrantOrRightExercisedDuringPeriod-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">sava_ClassOfWarrantOrRightExercisedDuringPeriod</link:label>
    <link:label xlink:label="sava_ClassOfWarrantOrRightExercisedDuringPeriod-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right, Exercised During Period (in shares)</link:label>
    <link:label xlink:label="sava_ClassOfWarrantOrRightExercisedDuringPeriod-label" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Warrants exercised, shares (in shares)</link:label>
    <link:label xlink:label="sava_ClassOfWarrantOrRightExercisedDuringPeriod-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the warrants or rights exercised during the period.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sava_ClassOfWarrantOrRightExercisedDuringPeriod" xlink:to="sava_ClassOfWarrantOrRightExercisedDuringPeriod-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd#stpr_TX" xlink:label="stpr_TX" xlink:type="locator"/>
    <link:label xlink:label="stpr_TX-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">TEXAS</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="stpr_TX" xlink:to="stpr_TX-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="us-gaap_NumberOfOperatingSegments" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_NumberOfOperatingSegments-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_NumberOfOperatingSegments</link:label>
    <link:label xlink:label="us-gaap_NumberOfOperatingSegments-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of Operating Segments</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NumberOfOperatingSegments" xlink:to="us-gaap_NumberOfOperatingSegments-label" xlink:type="arc"/>
    <link:loc xlink:href="sava-20241231.xsd#sava_PercentageOfOccupancy" xlink:label="sava_PercentageOfOccupancy" xlink:type="locator"/>
    <link:label xlink:label="sava_PercentageOfOccupancy-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">sava_PercentageOfOccupancy</link:label>
    <link:label xlink:label="sava_PercentageOfOccupancy-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Percentage of Occupancy</link:label>
    <link:label xlink:label="sava_PercentageOfOccupancy-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Percentage of occupancy.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sava_PercentageOfOccupancy" xlink:to="sava_PercentageOfOccupancy-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="us-gaap_FurnitureAndFixturesMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_FurnitureAndFixturesMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Furniture and Fixtures [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FurnitureAndFixturesMember" xlink:to="us-gaap_FurnitureAndFixturesMember-label" xlink:type="arc"/>
    <link:loc xlink:href="sava-20241231.xsd#sava_ProceedsFromWarrantsExercisedThatObligatedToPayCommission" xlink:label="sava_ProceedsFromWarrantsExercisedThatObligatedToPayCommission" xlink:type="locator"/>
    <link:label xlink:label="sava_ProceedsFromWarrantsExercisedThatObligatedToPayCommission-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">sava_ProceedsFromWarrantsExercisedThatObligatedToPayCommission</link:label>
    <link:label xlink:label="sava_ProceedsFromWarrantsExercisedThatObligatedToPayCommission-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds From Warrants Exercised That Obligated to Pay Commission</link:label>
    <link:label xlink:label="sava_ProceedsFromWarrantsExercisedThatObligatedToPayCommission-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Dollar amount required to be paid for commission from warrants exercised during the period.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sava_ProceedsFromWarrantsExercisedThatObligatedToPayCommission" xlink:to="sava_ProceedsFromWarrantsExercisedThatObligatedToPayCommission-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost</link:label>
    <link:label xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based compensation</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AdditionalPaidInCapital-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapital" xlink:to="us-gaap_AdditionalPaidInCapital-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BuildingMember" xlink:label="us-gaap_BuildingMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_BuildingMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Building [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BuildingMember" xlink:to="us-gaap_BuildingMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BuildingImprovementsMember" xlink:label="us-gaap_BuildingImprovementsMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_BuildingImprovementsMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Building Improvements [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BuildingImprovementsMember" xlink:to="us-gaap_BuildingImprovementsMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StockholdersEquityAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stockholders' equity:</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LandMember" xlink:label="us-gaap_LandMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_LandMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Land [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LandMember" xlink:to="us-gaap_LandMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_LeaseholdImprovementsMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Leasehold Improvements [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseholdImprovementsMember" xlink:to="us-gaap_LeaseholdImprovementsMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNonoperatingExpense" xlink:label="us-gaap_OtherNonoperatingExpense" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_OtherNonoperatingExpense-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_OtherNonoperatingExpense</link:label>
    <link:label xlink:label="us-gaap_OtherNonoperatingExpense-label" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Property operating expenses</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNonoperatingExpense" xlink:to="us-gaap_OtherNonoperatingExpense-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_OtherNonoperatingIncomeExpense-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other income, net</link:label>
    <link:label xlink:label="us-gaap_OtherNonoperatingIncomeExpense-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Other income, net</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNonoperatingIncomeExpense" xlink:to="us-gaap_OtherNonoperatingIncomeExpense-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-Lived Tangible Asset [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-Lived Tangible Asset [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net operating loss carryforwards</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and development credit carryforwards</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNonoperatingIncome" xlink:label="us-gaap_OtherNonoperatingIncome" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_OtherNonoperatingIncome-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lease revenue</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNonoperatingIncome" xlink:to="us-gaap_OtherNonoperatingIncome-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AssetsCurrentAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current assets:</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations</link:label>
    <link:label xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations-label" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents at beginning of period</link:label>
    <link:label xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations-label" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents at end of period</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DepositContractsAssets" xlink:label="us-gaap_DepositContractsAssets" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DepositContractsAssets-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contract research organization and other deposits</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepositContractsAssets" xlink:to="us-gaap_DepositContractsAssets-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_NetCashProvidedByUsedInFinancingActivities</link:label>
    <link:label xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash provided by financing activities</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_Liabilities-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_Liabilities</link:label>
    <link:label xlink:label="us-gaap_Liabilities-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total liabilities</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect</link:label>
    <link:label xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net increase (decrease) in cash and cash equivalents</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CommitmentsAndContingencies-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commitments and contingencies (Notes 10, 11 and 12)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingencies" xlink:to="us-gaap_CommitmentsAndContingencies-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SubsidiarySaleOfStockAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale of Stock [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SubsidiarySaleOfStockAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale of Stock [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:label="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Table Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:to="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_OperatingIncomeLoss-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_OperatingIncomeLoss</link:label>
    <link:label xlink:label="us-gaap_OperatingIncomeLoss-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Operating loss</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_NetCashProvidedByUsedInOperatingActivities</link:label>
    <link:label xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:label xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash used in operating activities</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_NetCashProvidedByUsedInInvestingActivities</link:label>
    <link:label xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash used in investing activities</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total prepaid expenses and other current assets</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis" xlink:type="locator"/>
    <link:label xlink:label="srt_CounterpartyNameAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_CounterpartyNameAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="locator"/>
    <link:label xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:label="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:to="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativesPolicyTextBlock" xlink:label="us-gaap_DerivativesPolicyTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DerivativesPolicyTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivatives, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativesPolicyTextBlock" xlink:to="us-gaap_DerivativesPolicyTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxLiabilitiesLeasingArrangements" xlink:label="us-gaap_DeferredTaxLiabilitiesLeasingArrangements" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DeferredTaxLiabilitiesLeasingArrangements-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_DeferredTaxLiabilitiesLeasingArrangements</link:label>
    <link:label xlink:label="us-gaap_DeferredTaxLiabilitiesLeasingArrangements-label" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Operating lease right-of-use assets</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxLiabilitiesLeasingArrangements" xlink:to="us-gaap_DeferredTaxLiabilitiesLeasingArrangements-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock" xlink:label="us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Other Nonoperating Income (Expense) [Table Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock" xlink:to="us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="sava-20241231.xsd#sava_CashIncentiveBonusPlanTextBlock" xlink:label="sava_CashIncentiveBonusPlanTextBlock" xlink:type="locator"/>
    <link:label xlink:label="sava_CashIncentiveBonusPlanTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash Incentive Bonus Plan [Text Block]</link:label>
    <link:label xlink:label="sava_CashIncentiveBonusPlanTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The entire disclosure for the cash incentive bonus plan.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sava_CashIncentiveBonusPlanTextBlock" xlink:to="sava_CashIncentiveBonusPlanTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued</link:label>
    <link:label xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued-label" xlink:type="arc"/>
    <link:loc xlink:href="sava-20241231.xsd#sava_ViolationsOfFederalSecuritiesLawsMember" xlink:label="sava_ViolationsOfFederalSecuritiesLawsMember" xlink:type="locator"/>
    <link:label xlink:label="sava_ViolationsOfFederalSecuritiesLawsMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Violations of Federal Securities Laws [Member]</link:label>
    <link:label xlink:label="sava_ViolationsOfFederalSecuritiesLawsMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the violations of federal securities laws.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sava_ViolationsOfFederalSecuritiesLawsMember" xlink:to="sava_ViolationsOfFederalSecuritiesLawsMember-label" xlink:type="arc"/>
    <link:loc xlink:href="sava-20241231.xsd#sava_PerformancePlanValuationMilestoneAmount" xlink:label="sava_PerformancePlanValuationMilestoneAmount" xlink:type="locator"/>
    <link:label xlink:label="sava_PerformancePlanValuationMilestoneAmount-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">sava_PerformancePlanValuationMilestoneAmount</link:label>
    <link:label xlink:label="sava_PerformancePlanValuationMilestoneAmount-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Performance Plan, Valuation Milestone Amount</link:label>
    <link:label xlink:label="sava_PerformancePlanValuationMilestoneAmount-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Amount of valuation milestone for performance plan.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sava_PerformancePlanValuationMilestoneAmount" xlink:to="sava_PerformancePlanValuationMilestoneAmount-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PaymentsOfStockIssuanceCosts-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_PaymentsOfStockIssuanceCosts</link:label>
    <link:label xlink:label="us-gaap_PaymentsOfStockIssuanceCosts-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Payments of Stock Issuance Costs</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsOfStockIssuanceCosts" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts-label" xlink:type="arc"/>
    <link:loc xlink:href="sava-20241231.xsd#sava_CashBonusIncentiveIncrementalAmounts" xlink:label="sava_CashBonusIncentiveIncrementalAmounts" xlink:type="locator"/>
    <link:label xlink:label="sava_CashBonusIncentiveIncrementalAmounts-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">sava_CashBonusIncentiveIncrementalAmounts</link:label>
    <link:label xlink:label="sava_CashBonusIncentiveIncrementalAmounts-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash Bonus Incentive, Incremental Amounts</link:label>
    <link:label xlink:label="sava_CashBonusIncentiveIncrementalAmounts-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The number of incremental amounts for cash bonus incentive.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sava_CashBonusIncentiveIncrementalAmounts" xlink:to="sava_CashBonusIncentiveIncrementalAmounts-label" xlink:type="arc"/>
    <link:loc xlink:href="sava-20241231.xsd#sava_PerformancePlanMinimumNumberOfDaysValuationMilestoneMustBeAchievedAndMaintained" xlink:label="sava_PerformancePlanMinimumNumberOfDaysValuationMilestoneMustBeAchievedAndMaintained" xlink:type="locator"/>
    <link:label xlink:label="sava_PerformancePlanMinimumNumberOfDaysValuationMilestoneMustBeAchievedAndMaintained-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">sava_PerformancePlanMinimumNumberOfDaysValuationMilestoneMustBeAchievedAndMaintained</link:label>
    <link:label xlink:label="sava_PerformancePlanMinimumNumberOfDaysValuationMilestoneMustBeAchievedAndMaintained-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Performance Plan, Minimum Number of Days Valuation Milestone Must be Achieved and Maintained (Day)</link:label>
    <link:label xlink:label="sava_PerformancePlanMinimumNumberOfDaysValuationMilestoneMustBeAchievedAndMaintained-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The minimum number of days valuation milestone must be achieved and maintained in performance plan.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sava_PerformancePlanMinimumNumberOfDaysValuationMilestoneMustBeAchievedAndMaintained" xlink:to="sava_PerformancePlanMinimumNumberOfDaysValuationMilestoneMustBeAchievedAndMaintained-label" xlink:type="arc"/>
    <link:loc xlink:href="sava-20241231.xsd#sava_CashIncentiveBonusPlanMember" xlink:label="sava_CashIncentiveBonusPlanMember" xlink:type="locator"/>
    <link:label xlink:label="sava_CashIncentiveBonusPlanMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash Incentive Bonus Plan [Member]</link:label>
    <link:label xlink:label="sava_CashIncentiveBonusPlanMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the cash incentive bonus plan.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sava_CashIncentiveBonusPlanMember" xlink:to="sava_CashIncentiveBonusPlanMember-label" xlink:type="arc"/>
    <link:loc xlink:href="sava-20241231.xsd#sava_ShareholderDerivativeActionsTexasCourtMember" xlink:label="sava_ShareholderDerivativeActionsTexasCourtMember" xlink:type="locator"/>
    <link:label xlink:label="sava_ShareholderDerivativeActionsTexasCourtMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Shareholder Derivative Actions, Texas Court [Member]</link:label>
    <link:label xlink:label="sava_ShareholderDerivativeActionsTexasCourtMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents shareholder derivative actions in Texas Court</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sava_ShareholderDerivativeActionsTexasCourtMember" xlink:to="sava_ShareholderDerivativeActionsTexasCourtMember-label" xlink:type="arc"/>
    <link:loc xlink:href="sava-20241231.xsd#sava_ShareholderDerivativeActionsMember" xlink:label="sava_ShareholderDerivativeActionsMember" xlink:type="locator"/>
    <link:label xlink:label="sava_ShareholderDerivativeActionsMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Shareholder Derivative Actions [Member]</link:label>
    <link:label xlink:label="sava_ShareholderDerivativeActionsMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents shareholder derivative actions.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sava_ShareholderDerivativeActionsMember" xlink:to="sava_ShareholderDerivativeActionsMember-label" xlink:type="arc"/>
    <link:loc xlink:href="sava-20241231.xsd#sava_ShareholderDerivativeActionsDelawareCourtMember" xlink:label="sava_ShareholderDerivativeActionsDelawareCourtMember" xlink:type="locator"/>
    <link:label xlink:label="sava_ShareholderDerivativeActionsDelawareCourtMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Shareholder Derivative Actions, Delaware Court [Member]</link:label>
    <link:label xlink:label="sava_ShareholderDerivativeActionsDelawareCourtMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents shareholder derivative actions in Delaware court.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sava_ShareholderDerivativeActionsDelawareCourtMember" xlink:to="sava_ShareholderDerivativeActionsDelawareCourtMember-label" xlink:type="arc"/>
    <link:loc xlink:href="sava-20241231.xsd#sava_ShareholderDerivativeActionsTexasStateCourtMember" xlink:label="sava_ShareholderDerivativeActionsTexasStateCourtMember" xlink:type="locator"/>
    <link:label xlink:label="sava_ShareholderDerivativeActionsTexasStateCourtMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Shareholder Derivative Actions, Texas State Court Member</link:label>
    <link:label xlink:label="sava_ShareholderDerivativeActionsTexasStateCourtMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents shareholder derivative actions in Texas State Court.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sava_ShareholderDerivativeActionsTexasStateCourtMember" xlink:to="sava_ShareholderDerivativeActionsTexasStateCourtMember-label" xlink:type="arc"/>
    <link:loc xlink:href="sava-20241231.xsd#sava_AtthemarketCommonStockOfferingMember" xlink:label="sava_AtthemarketCommonStockOfferingMember" xlink:type="locator"/>
    <link:label xlink:label="sava_AtthemarketCommonStockOfferingMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">At-the-market Common Stock Offering [Member]</link:label>
    <link:label xlink:label="sava_AtthemarketCommonStockOfferingMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the At-the-Market Common Stock Offering.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sava_AtthemarketCommonStockOfferingMember" xlink:to="sava_AtthemarketCommonStockOfferingMember-label" xlink:type="arc"/>
    <link:loc xlink:href="sava-20241231.xsd#sava_The2022RegisteredDirectOfferingMember" xlink:label="sava_The2022RegisteredDirectOfferingMember" xlink:type="locator"/>
    <link:label xlink:label="sava_The2022RegisteredDirectOfferingMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">The 2022 Registered Direct Offering [Member]</link:label>
    <link:label xlink:label="sava_The2022RegisteredDirectOfferingMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the 2022 Registered Direct Offering.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sava_The2022RegisteredDirectOfferingMember" xlink:to="sava_The2022RegisteredDirectOfferingMember-label" xlink:type="arc"/>
    <link:loc xlink:href="sava-20241231.xsd#sava_EquityOfferingPercentageOfCommission" xlink:label="sava_EquityOfferingPercentageOfCommission" xlink:type="locator"/>
    <link:label xlink:label="sava_EquityOfferingPercentageOfCommission-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">sava_EquityOfferingPercentageOfCommission</link:label>
    <link:label xlink:label="sava_EquityOfferingPercentageOfCommission-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Offering, Percentage of Commission</link:label>
    <link:label xlink:label="sava_EquityOfferingPercentageOfCommission-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Percentage of commission in equity offering.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sava_EquityOfferingPercentageOfCommission" xlink:to="sava_EquityOfferingPercentageOfCommission-label" xlink:type="arc"/>
    <link:loc xlink:href="sava-20241231.xsd#sava_EquityOfferingMaximumAmount" xlink:label="sava_EquityOfferingMaximumAmount" xlink:type="locator"/>
    <link:label xlink:label="sava_EquityOfferingMaximumAmount-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">sava_EquityOfferingMaximumAmount</link:label>
    <link:label xlink:label="sava_EquityOfferingMaximumAmount-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Offering, Maximum Amount</link:label>
    <link:label xlink:label="sava_EquityOfferingMaximumAmount-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The maximum amount to be issued in the equity offering.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sava_EquityOfferingMaximumAmount" xlink:to="sava_EquityOfferingMaximumAmount-label" xlink:type="arc"/>
    <link:loc xlink:href="sava-20241231.xsd#sava_CashIncentiveBonusAwardExceedsMaximum" xlink:label="sava_CashIncentiveBonusAwardExceedsMaximum" xlink:type="locator"/>
    <link:label xlink:label="sava_CashIncentiveBonusAwardExceedsMaximum-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">sava_CashIncentiveBonusAwardExceedsMaximum</link:label>
    <link:label xlink:label="sava_CashIncentiveBonusAwardExceedsMaximum-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash Incentive Bonus Award, Exceeds Maximum</link:label>
    <link:label xlink:label="sava_CashIncentiveBonusAwardExceedsMaximum-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Amount of cash incentive bonus award if the maximum milestone is exceeded.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sava_CashIncentiveBonusAwardExceedsMaximum" xlink:to="sava_CashIncentiveBonusAwardExceedsMaximum-label" xlink:type="arc"/>
    <link:loc xlink:href="sava-20241231.xsd#sava_PercentageValuationMilestoneCashBonusAwardSubjectToApprovalAndAdjustment" xlink:label="sava_PercentageValuationMilestoneCashBonusAwardSubjectToApprovalAndAdjustment" xlink:type="locator"/>
    <link:label xlink:label="sava_PercentageValuationMilestoneCashBonusAwardSubjectToApprovalAndAdjustment-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">sava_PercentageValuationMilestoneCashBonusAwardSubjectToApprovalAndAdjustment</link:label>
    <link:label xlink:label="sava_PercentageValuationMilestoneCashBonusAwardSubjectToApprovalAndAdjustment-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Percentage Valuation Milestone Cash Bonus Award Subject to Approval and Adjustment</link:label>
    <link:label xlink:label="sava_PercentageValuationMilestoneCashBonusAwardSubjectToApprovalAndAdjustment-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">the percentage of valuation milestone cash bonus award subject to approval and adjustment.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sava_PercentageValuationMilestoneCashBonusAwardSubjectToApprovalAndAdjustment" xlink:to="sava_PercentageValuationMilestoneCashBonusAwardSubjectToApprovalAndAdjustment-label" xlink:type="arc"/>
    <link:loc xlink:href="sava-20241231.xsd#sava_PaymentsForCashIncentiveBonus" xlink:label="sava_PaymentsForCashIncentiveBonus" xlink:type="locator"/>
    <link:label xlink:label="sava_PaymentsForCashIncentiveBonus-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">sava_PaymentsForCashIncentiveBonus</link:label>
    <link:label xlink:label="sava_PaymentsForCashIncentiveBonus-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Payments for Cash Incentive Bonus</link:label>
    <link:label xlink:label="sava_PaymentsForCashIncentiveBonus-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Amount of payments for cash incentive bonus.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sava_PaymentsForCashIncentiveBonus" xlink:to="sava_PaymentsForCashIncentiveBonus-label" xlink:type="arc"/>
    <link:loc xlink:href="sava-20241231.xsd#sava_CashIncentiveBonusAward" xlink:label="sava_CashIncentiveBonusAward" xlink:type="locator"/>
    <link:label xlink:label="sava_CashIncentiveBonusAward-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">sava_CashIncentiveBonusAward</link:label>
    <link:label xlink:label="sava_CashIncentiveBonusAward-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash Incentive Bonus Award</link:label>
    <link:label xlink:label="sava_CashIncentiveBonusAward-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Amount of cash incentive bonus award.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sava_CashIncentiveBonusAward" xlink:to="sava_CashIncentiveBonusAward-label" xlink:type="arc"/>
    <link:loc xlink:href="sava-20241231.xsd#sava_LeasingCommissionsAndOtherMember" xlink:label="sava_LeasingCommissionsAndOtherMember" xlink:type="locator"/>
    <link:label xlink:label="sava_LeasingCommissionsAndOtherMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Leasing Commissions and Other [Member]</link:label>
    <link:label xlink:label="sava_LeasingCommissionsAndOtherMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents leasing commissions and other.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sava_LeasingCommissionsAndOtherMember" xlink:to="sava_LeasingCommissionsAndOtherMember-label" xlink:type="arc"/>
    <link:loc xlink:href="sava-20241231.xsd#sava_The2018EquityIncentivePlanMember" xlink:label="sava_The2018EquityIncentivePlanMember" xlink:type="locator"/>
    <link:label xlink:label="sava_The2018EquityIncentivePlanMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">The 2018 Equity Incentive Plan [Member]</link:label>
    <link:label xlink:label="sava_The2018EquityIncentivePlanMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the 2018 Equity Incentive Plan.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sava_The2018EquityIncentivePlanMember" xlink:to="sava_The2018EquityIncentivePlanMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfWarrants" xlink:label="us-gaap_ProceedsFromIssuanceOfWarrants" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ProceedsFromIssuanceOfWarrants-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ProceedsFromIssuanceOfWarrants</link:label>
    <link:label xlink:label="us-gaap_ProceedsFromIssuanceOfWarrants-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from Issuance of Warrants</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfWarrants" xlink:to="us-gaap_ProceedsFromIssuanceOfWarrants-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:label xlink:label="srt_ScenarioUnspecifiedDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Scenario [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="srt_ScenarioUnspecifiedDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="us-gaap_ProceedsFromWarrantExercises" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ProceedsFromWarrantExercises-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from exercise of common stock warrants, net of exercise costs</link:label>
    <link:label xlink:label="us-gaap_ProceedsFromWarrantExercises-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from Warrant Exercises</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromWarrantExercises" xlink:to="us-gaap_ProceedsFromWarrantExercises-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScenarioForecastMember" xlink:label="srt_ScenarioForecastMember" xlink:type="locator"/>
    <link:label xlink:label="srt_ScenarioForecastMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Forecast [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ScenarioForecastMember" xlink:to="srt_ScenarioForecastMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_RetainedEarningsMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ProceedsFromStockOptionsExercised-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from issuance of common stock upon exercise of stock options</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromStockOptionsExercised" xlink:to="us-gaap_ProceedsFromStockOptionsExercised-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="locator"/>
    <link:label xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Title and Position [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from common stock offering, net of issuance costs</link:label>
    <link:label xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from Issuance of Common Stock</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis" xlink:type="locator"/>
    <link:label xlink:label="srt_TitleOfIndividualAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Title and Position [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis" xlink:type="locator"/>
    <link:label xlink:label="srt_StatementScenarioAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Scenario [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_StatementScenarioAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="sava-20241231.xsd#sava_PaymentsOfWarrantExerciseCosts" xlink:label="sava_PaymentsOfWarrantExerciseCosts" xlink:type="locator"/>
    <link:label xlink:label="sava_PaymentsOfWarrantExerciseCosts-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">sava_PaymentsOfWarrantExerciseCosts</link:label>
    <link:label xlink:label="sava_PaymentsOfWarrantExerciseCosts-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Payments of Warrant Exercise Costs</link:label>
    <link:label xlink:label="sava_PaymentsOfWarrantExerciseCosts-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the amount of warrant exercise costs during the period.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sava_PaymentsOfWarrantExerciseCosts" xlink:to="sava_PaymentsOfWarrantExerciseCosts-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AdditionalPaidInCapitalMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CommonStockMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember-label" xlink:type="arc"/>
    <link:loc xlink:href="sava-20241231.xsd#sava_DerecognitionOfWarrantLiabilitiesThroughExercises" xlink:label="sava_DerecognitionOfWarrantLiabilitiesThroughExercises" xlink:type="locator"/>
    <link:label xlink:label="sava_DerecognitionOfWarrantLiabilitiesThroughExercises-label" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Derecognition of warrant liabilities upon exercise of warrants</link:label>
    <link:label xlink:label="sava_DerecognitionOfWarrantLiabilitiesThroughExercises-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">sava_DerecognitionOfWarrantLiabilitiesThroughExercises</link:label>
    <link:label xlink:label="sava_DerecognitionOfWarrantLiabilitiesThroughExercises-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the cash flow effect of derecognition of warrant liabilities through exercises.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sava_DerecognitionOfWarrantLiabilitiesThroughExercises" xlink:to="sava_DerecognitionOfWarrantLiabilitiesThroughExercises-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StatementEquityComponentsAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_EquityComponentDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_EquityComponentDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</link:label>
    <link:label xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ClassOfWarrantOrRightAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ClassOfWarrantOrRightDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="us-gaap_ClassOfWarrantOrRightDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight</link:label>
    <link:label xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right, Number of Securities Called by Each Warrant or Right (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Balance, shares (in shares)</link:label>
    <link:label xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding-label" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Balance, shares (in shares)</link:label>
    <link:label xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding-label" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Balance, shares (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightOutstanding" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</link:label>
    <link:label xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_IcfrAuditorAttestationFlag" xlink:label="dei_IcfrAuditorAttestationFlag" xlink:type="locator"/>
    <link:label xlink:label="dei_IcfrAuditorAttestationFlag-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">ICFR Auditor Attestation Flag</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_IcfrAuditorAttestationFlag" xlink:to="dei_IcfrAuditorAttestationFlag-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncomeTaxAuthorityAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Jurisdiction [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncomeTaxAuthorityDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Jurisdiction [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_IncomeTaxAuthorityDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DomesticCountryMember" xlink:label="us-gaap_DomesticCountryMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DomesticCountryMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Domestic Tax Jurisdiction [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DomesticCountryMember" xlink:to="us-gaap_DomesticCountryMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport" xlink:type="locator"/>
    <link:label xlink:label="dei_DocumentAnnualReport-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Annual Report</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" xlink:type="locator"/>
    <link:label xlink:label="dei_EntityIncorporationStateCountryCode-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="us-gaap_UnrecognizedTaxBenefits" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_UnrecognizedTaxBenefits-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_UnrecognizedTaxBenefits</link:label>
    <link:label xlink:label="us-gaap_UnrecognizedTaxBenefits-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unrecognized Tax Benefits</link:label>
    <link:label xlink:label="us-gaap_UnrecognizedTaxBenefits-label" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning balance</link:label>
    <link:label xlink:label="us-gaap_UnrecognizedTaxBenefits-label" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Ending balance</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefits" xlink:to="us-gaap_UnrecognizedTaxBenefits-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">General and Administrative Expense [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AccountingPoliciesAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Significant Accounting Policies [Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OpenTaxYear" xlink:label="us-gaap_OpenTaxYear" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_OpenTaxYear-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_OpenTaxYear</link:label>
    <link:label xlink:label="us-gaap_OpenTaxYear-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Open Tax Year</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OpenTaxYear" xlink:to="us-gaap_OpenTaxYear-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport" xlink:type="locator"/>
    <link:label xlink:label="dei_DocumentTransitionReport-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Transition Report</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFinStmtErrorCorrectionFlag" xlink:label="dei_DocumentFinStmtErrorCorrectionFlag" xlink:type="locator"/>
    <link:label xlink:label="dei_DocumentFinStmtErrorCorrectionFlag-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Financial Statement Error Correction [Flag]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFinStmtErrorCorrectionFlag" xlink:to="dei_DocumentFinStmtErrorCorrectionFlag-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations" xlink:label="us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations</link:label>
    <link:label xlink:label="us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations-label" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Expired research and development tax credits</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations" xlink:to="us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent" xlink:type="locator"/>
    <link:label xlink:label="dei_EntityInteractiveDataCurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GovernmentAssistanceAmount" xlink:label="us-gaap_GovernmentAssistanceAmount" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_GovernmentAssistanceAmount-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_GovernmentAssistanceAmount</link:label>
    <link:label xlink:label="us-gaap_GovernmentAssistanceAmount-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Government Assistance, Income, Increase (Decrease)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GovernmentAssistanceAmount" xlink:to="us-gaap_GovernmentAssistanceAmount-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" xlink:type="locator"/>
    <link:label xlink:label="dei_SecurityExchangeName-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Security Exchange Name</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additions based on tax positions related to the current year</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" xlink:type="locator"/>
    <link:label xlink:label="dei_Security12bTitle-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Expense [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GovernmentAssistancePolicyTextBlock" xlink:label="us-gaap_GovernmentAssistancePolicyTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_GovernmentAssistancePolicyTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Government Assistance [Policy Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GovernmentAssistancePolicyTextBlock" xlink:to="us-gaap_GovernmentAssistancePolicyTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GovernmentAssistanceStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration" xlink:label="us-gaap_GovernmentAssistanceStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_GovernmentAssistanceStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_GovernmentAssistanceStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration</link:label>
    <link:label xlink:label="us-gaap_GovernmentAssistanceStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Government Assistance, Income, Increase (Decrease), Statement of Income or Comprehensive Income [Extensible Enumeration]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GovernmentAssistanceStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration" xlink:to="us-gaap_GovernmentAssistanceStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncomeStatementLocationAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Income Location, Balance [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncomeStatementLocationDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Income Location, Balance [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_IncomeStatementLocationDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_OfficeBuildingMember" xlink:label="srt_OfficeBuildingMember" xlink:type="locator"/>
    <link:label xlink:label="srt_OfficeBuildingMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Office Building [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_OfficeBuildingMember" xlink:to="srt_OfficeBuildingMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis" xlink:label="srt_MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis" xlink:type="locator"/>
    <link:label xlink:label="srt_MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Real Estate, Type of Property [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis" xlink:to="srt_MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxPeriodDomain" xlink:label="us-gaap_TaxPeriodDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_TaxPeriodDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tax Period [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxPeriodDomain" xlink:to="us-gaap_TaxPeriodDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MortgageLoansOnRealEstateNamePropertyTypeDomain" xlink:label="srt_MortgageLoansOnRealEstateNamePropertyTypeDomain" xlink:type="locator"/>
    <link:label xlink:label="srt_MortgageLoansOnRealEstateNamePropertyTypeDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Real Estate [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MortgageLoansOnRealEstateNamePropertyTypeDomain" xlink:to="srt_MortgageLoansOnRealEstateNamePropertyTypeDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorName" xlink:label="dei_AuditorName" xlink:type="locator"/>
    <link:label xlink:label="dei_AuditorName-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Auditor Name</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorName" xlink:to="dei_AuditorName-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxPeriodAxis" xlink:label="us-gaap_TaxPeriodAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_TaxPeriodAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tax Period [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxPeriodAxis" xlink:to="us-gaap_TaxPeriodAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorFirmId" xlink:label="dei_AuditorFirmId" xlink:type="locator"/>
    <link:label xlink:label="dei_AuditorFirmId-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Auditor Firm ID</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorFirmId" xlink:to="dei_AuditorFirmId-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorLocation" xlink:label="dei_AuditorLocation" xlink:type="locator"/>
    <link:label xlink:label="dei_AuditorLocation-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Auditor Location</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorLocation" xlink:to="dei_AuditorLocation-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementBusinessSegmentsAxis" xlink:label="us-gaap_StatementBusinessSegmentsAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StatementBusinessSegmentsAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Segments [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementBusinessSegmentsAxis" xlink:to="us-gaap_StatementBusinessSegmentsAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentDomain" xlink:label="us-gaap_SegmentDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SegmentDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Segments [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentDomain" xlink:to="us-gaap_SegmentDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:label="us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment</link:label>
    <link:label xlink:label="us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Dilutive effect of common stock warrants (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:to="us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxCreditCarryforwardAmount" xlink:label="us-gaap_TaxCreditCarryforwardAmount" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_TaxCreditCarryforwardAmount-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_TaxCreditCarryforwardAmount</link:label>
    <link:label xlink:label="us-gaap_TaxCreditCarryforwardAmount-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Tax Credit Carryforward, Amount</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxCreditCarryforwardAmount" xlink:to="us-gaap_TaxCreditCarryforwardAmount-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchMember" xlink:label="us-gaap_ResearchMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ResearchMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research Tax Credit Carryforward [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchMember" xlink:to="us-gaap_ResearchMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</link:label>
    <link:label xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Dilutive common stock options excluded from net loss per share, diluted (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Shares used in computing net loss per share, diluted (in shares)</link:label>
    <link:label xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Weighted average dilutive common shares (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxCreditCarryforwardAxis" xlink:label="us-gaap_TaxCreditCarryforwardAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_TaxCreditCarryforwardAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tax Credit Carryforward [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxCreditCarryforwardAxis" xlink:to="us-gaap_TaxCreditCarryforwardAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_TaxCreditCarryforwardNameDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tax Credit Carryforward, Name [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxCreditCarryforwardNameDomain" xlink:to="us-gaap_TaxCreditCarryforwardNameDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="us-gaap_OperatingLossCarryforwards" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_OperatingLossCarryforwards-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_OperatingLossCarryforwards</link:label>
    <link:label xlink:label="us-gaap_OperatingLossCarryforwards-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating Loss Carryforwards</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwards" xlink:to="us-gaap_OperatingLossCarryforwards-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StatementTable-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement [Table]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StatementOfFinancialPositionAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementOfFinancialPositionAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_EarningsPerShareDiluted-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net loss per share, diluted (in dollars per share)</link:label>
    <link:label xlink:label="us-gaap_EarningsPerShareDiluted-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net loss per share, diluted (in dollars per share)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareDiluted" xlink:to="us-gaap_EarningsPerShareDiluted-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Shares used in computing net loss per share, basic (in shares)</link:label>
    <link:label xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted average common shares outstanding (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_EffectiveIncomeTaxRateContinuingOperations</link:label>
    <link:label xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Effective income tax rate</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_EarningsPerShareBasic-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net loss per share, basic (in dollars per share)</link:label>
    <link:label xlink:label="us-gaap_EarningsPerShareBasic-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net loss per share, basic (in dollars per share)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasic" xlink:to="us-gaap_EarningsPerShareBasic-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Change in valuation allowance</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StatementOfCashFlowsAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StatementOfStockholdersEquityAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementOfStockholdersEquityAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncomeStatementAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeStatementAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="sava-20241231.xsd#sava_EffectiveIncomeTaxRateReconciliationChangeInFairValueOfWarrantLiabilities" xlink:label="sava_EffectiveIncomeTaxRateReconciliationChangeInFairValueOfWarrantLiabilities" xlink:type="locator"/>
    <link:label xlink:label="sava_EffectiveIncomeTaxRateReconciliationChangeInFairValueOfWarrantLiabilities-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Change in fair value of warrant liabilities</link:label>
    <link:label xlink:label="sava_EffectiveIncomeTaxRateReconciliationChangeInFairValueOfWarrantLiabilities-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Percentage of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operations, attributable to the change in fair value of warrant liabilities.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sava_EffectiveIncomeTaxRateReconciliationChangeInFairValueOfWarrantLiabilities" xlink:to="sava_EffectiveIncomeTaxRateReconciliationChangeInFairValueOfWarrantLiabilities-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxContingencies" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxContingencies" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxContingencies-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Uncertain tax positions</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationTaxContingencies" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxContingencies-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlements" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlements" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlements-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlements</link:label>
    <link:label xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlements-label" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">SEC settlement payment</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlements" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlements-label" xlink:type="arc"/>
    <link:loc xlink:href="sava-20241231.xsd#sava_FormerPresidentAndChiefExecutiveOfficerMember" xlink:label="sava_FormerPresidentAndChiefExecutiveOfficerMember" xlink:type="locator"/>
    <link:label xlink:label="sava_FormerPresidentAndChiefExecutiveOfficerMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Former President and Chief Executive Officer [Member]</link:label>
    <link:label xlink:label="sava_FormerPresidentAndChiefExecutiveOfficerMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The former President and Chief Executive Officer.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sava_FormerPresidentAndChiefExecutiveOfficerMember" xlink:to="sava_FormerPresidentAndChiefExecutiveOfficerMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated" xlink:label="us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated</link:label>
    <link:label xlink:label="us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restructuring and Related Cost, Number of Positions Eliminated</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated" xlink:to="us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated-label" xlink:type="arc"/>
    <link:loc xlink:href="sava-20241231.xsd#sava_WorkforceReductionMember" xlink:label="sava_WorkforceReductionMember" xlink:type="locator"/>
    <link:label xlink:label="sava_WorkforceReductionMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Workforce Reduction [Member]</link:label>
    <link:label xlink:label="sava_WorkforceReductionMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The workforce reduction.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sava_WorkforceReductionMember" xlink:to="sava_WorkforceReductionMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent" xlink:label="us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent</link:label>
    <link:label xlink:label="us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restructuring and Related Cost, Number of Positions Eliminated, Period Percent</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent" xlink:to="us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:label="us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Unrecognized Tax Benefits Roll Forward [Table Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:to="us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringAndRelatedCostExpectedCost1" xlink:label="us-gaap_RestructuringAndRelatedCostExpectedCost1" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_RestructuringAndRelatedCostExpectedCost1-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_RestructuringAndRelatedCostExpectedCost1</link:label>
    <link:label xlink:label="us-gaap_RestructuringAndRelatedCostExpectedCost1-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restructuring and Related Cost, Expected Cost</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestructuringAndRelatedCostExpectedCost1" xlink:to="us-gaap_RestructuringAndRelatedCostExpectedCost1-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Deferred Tax Assets and Liabilities [Table Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherCommitment" xlink:label="us-gaap_OtherCommitment" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_OtherCommitment-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_OtherCommitment</link:label>
    <link:label xlink:label="us-gaap_OtherCommitment-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other Commitment</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherCommitment" xlink:to="us-gaap_OtherCommitment-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost</link:label>
    <link:label xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based compensation</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfRestructuringDomain" xlink:label="us-gaap_TypeOfRestructuringDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_TypeOfRestructuringDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Type of Restructuring [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TypeOfRestructuringDomain" xlink:to="us-gaap_TypeOfRestructuringDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="sava-20241231.xsd#sava_EffectiveIncomeTaxRateReconciliationSection162mLimitationPercent" xlink:label="sava_EffectiveIncomeTaxRateReconciliationSection162mLimitationPercent" xlink:type="locator"/>
    <link:label xlink:label="sava_EffectiveIncomeTaxRateReconciliationSection162mLimitationPercent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Section 162(m) limitation</link:label>
    <link:label xlink:label="sava_EffectiveIncomeTaxRateReconciliationSection162mLimitationPercent-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to section 162(m) limitation.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sava_EffectiveIncomeTaxRateReconciliationSection162mLimitationPercent" xlink:to="sava_EffectiveIncomeTaxRateReconciliationSection162mLimitationPercent-label" xlink:type="arc"/>
    <link:loc xlink:href="sava-20241231.xsd#sava_EffectiveIncomeTaxRateReconciliationTaxCreditResearchAndDevelopmentPercent" xlink:label="sava_EffectiveIncomeTaxRateReconciliationTaxCreditResearchAndDevelopmentPercent" xlink:type="locator"/>
    <link:label xlink:label="sava_EffectiveIncomeTaxRateReconciliationTaxCreditResearchAndDevelopmentPercent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and development credits</link:label>
    <link:label xlink:label="sava_EffectiveIncomeTaxRateReconciliationTaxCreditResearchAndDevelopmentPercent-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research and development tax credit.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sava_EffectiveIncomeTaxRateReconciliationTaxCreditResearchAndDevelopmentPercent" xlink:to="sava_EffectiveIncomeTaxRateReconciliationTaxCreditResearchAndDevelopmentPercent-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeSeveranceMember" xlink:label="us-gaap_EmployeeSeveranceMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_EmployeeSeveranceMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Employee Severance [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeSeveranceMember" xlink:to="us-gaap_EmployeeSeveranceMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">State tax, net of federal benefit</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherCommitmentsAxis" xlink:label="us-gaap_OtherCommitmentsAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_OtherCommitmentsAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Commitments [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherCommitmentsAxis" xlink:to="us-gaap_OtherCommitmentsAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringCostAndReserveAxis" xlink:label="us-gaap_RestructuringCostAndReserveAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_RestructuringCostAndReserveAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restructuring Type [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestructuringCostAndReserveAxis" xlink:to="us-gaap_RestructuringCostAndReserveAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherCommitmentsDomain" xlink:label="us-gaap_OtherCommitmentsDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_OtherCommitmentsDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Commitments [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherCommitmentsDomain" xlink:to="us-gaap_OtherCommitmentsDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash flows from financing activities:</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tax at federal statutory rate</link:label>
    <link:label xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="us-gaap_OtherLiabilitiesNoncurrent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_OtherLiabilitiesNoncurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other non-current liabilities</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherLiabilitiesNoncurrent" xlink:to="us-gaap_OtherLiabilitiesNoncurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StockholdersEquity-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_StockholdersEquity</link:label>
    <link:label xlink:label="us-gaap_StockholdersEquity-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total stockholders' equity</link:label>
    <link:label xlink:label="us-gaap_StockholdersEquity-label" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Balance</link:label>
    <link:label xlink:label="us-gaap_StockholdersEquity-label" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Balance</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StatementClassOfStockAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_StatementClassOfStockAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1-label" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Options outstanding, weighted average exercise price (in dollars per share)</link:label>
    <link:label xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" xlink:to="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2-label" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Options outstanding, weighted average contractual life (Year)</link:label>
    <link:label xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions-label" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Options exercisable (in shares)</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1-label" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Options exercisable, weighted average exercise price (in dollars per share)</link:label>
    <link:label xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" xlink:to="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Options, exercise price, upper limit (in dollars per share)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions-label" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Options outstanding (in shares)</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Exercise Price Range [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Exercise Price Range [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Options, exercise price, lower limit (in dollars per share)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit-label" xlink:type="arc"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>15
<FILENAME>sava-20241231_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
<!--Generated by ThunderDome XBRL - 08:53PM UTC 2025-03-03--><link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.cassavasciences.com/20241231/role/statement-note-8-employee-401k-benefit-plan" xlink:href="sava-20241231.xsd#statement-note-8-employee-401k-benefit-plan" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.cassavasciences.com/20241231/role/statement-note-8-employee-401k-benefit-plan" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="sava-20241231.xsd#sava_NotesToFinancialStatementsAbstract" xlink:label="sava_NotesToFinancialStatementsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CompensationAndEmployeeBenefitPlansTextBlock" xlink:label="us-gaap_CompensationAndEmployeeBenefitPlansTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sava_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_CompensationAndEmployeeBenefitPlansTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cassavasciences.com/20241231/role/statement-note-3-prepaid-expenses-and-other-current-assets" xlink:href="sava-20241231.xsd#statement-note-3-prepaid-expenses-and-other-current-assets" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.cassavasciences.com/20241231/role/statement-note-3-prepaid-expenses-and-other-current-assets" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="sava-20241231.xsd#sava_NotesToFinancialStatementsAbstract" xlink:label="sava_NotesToFinancialStatementsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="sava-20241231.xsd#sava_PrepaidExpensesAndOtherCurrentAssetsTextBock" xlink:label="sava_PrepaidExpensesAndOtherCurrentAssetsTextBock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sava_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="sava_PrepaidExpensesAndOtherCurrentAssetsTextBock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cassavasciences.com/20241231/role/statement-document-and-entity-information" xlink:href="sava-20241231.xsd#statement-document-and-entity-information" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.cassavasciences.com/20241231/role/statement-document-and-entity-information" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorFirmId" xlink:label="dei_AuditorFirmId" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorLocation" xlink:label="dei_AuditorLocation" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorName" xlink:label="dei_AuditorName" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFinStmtErrorCorrectionFlag" xlink:label="dei_DocumentFinStmtErrorCorrectionFlag" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentInformationLineItems" xlink:label="dei_DocumentInformationLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentInformationTable" xlink:label="dei_DocumentInformationTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType" xlink:label="dei_DocumentType" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_IcfrAuditorAttestationFlag" xlink:label="dei_IcfrAuditorAttestationFlag" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationTable" xlink:to="dei_DocumentInformationLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCentralIndexKey" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityRegistrantName" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AmendmentFlag" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_CurrentFiscalYearEndDate" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentFiscalPeriodFocus" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentFiscalYearFocus" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentType" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentAnnualReport" xlink:type="arc"/>
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentPeriodEndDate" xlink:type="arc"/>
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentTransitionReport" xlink:type="arc"/>
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityFileNumber" xlink:type="arc"/>
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityIncorporationStateCountryCode" xlink:type="arc"/>
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityTaxIdentificationNumber" xlink:type="arc"/>
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressAddressLine1" xlink:type="arc"/>
    <link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressCityOrTown" xlink:type="arc"/>
    <link:presentationArc order="15" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressStateOrProvince" xlink:type="arc"/>
    <link:presentationArc order="16" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressPostalZipCode" xlink:type="arc"/>
    <link:presentationArc order="17" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_CityAreaCode" xlink:type="arc"/>
    <link:presentationArc order="18" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_LocalPhoneNumber" xlink:type="arc"/>
    <link:presentationArc order="19" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_Security12bTitle" xlink:type="arc"/>
    <link:presentationArc order="20" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_TradingSymbol" xlink:type="arc"/>
    <link:presentationArc order="21" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_SecurityExchangeName" xlink:type="arc"/>
    <link:presentationArc order="22" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityWellKnownSeasonedIssuer" xlink:type="arc"/>
    <link:presentationArc order="23" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityVoluntaryFilers" xlink:type="arc"/>
    <link:presentationArc order="24" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCurrentReportingStatus" xlink:type="arc"/>
    <link:presentationArc order="25" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityInteractiveDataCurrent" xlink:type="arc"/>
    <link:presentationArc order="26" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityFilerCategory" xlink:type="arc"/>
    <link:presentationArc order="27" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntitySmallBusiness" xlink:type="arc"/>
    <link:presentationArc order="28" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityEmergingGrowthCompany" xlink:type="arc"/>
    <link:presentationArc order="29" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_IcfrAuditorAttestationFlag" xlink:type="arc"/>
    <link:presentationArc order="30" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentFinStmtErrorCorrectionFlag" xlink:type="arc"/>
    <link:presentationArc order="31" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityShellCompany" xlink:type="arc"/>
    <link:presentationArc order="32" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityPublicFloat" xlink:type="arc"/>
    <link:presentationArc order="33" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCommonStockSharesOutstanding" xlink:type="arc"/>
    <link:presentationArc order="34" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AuditorFirmId" xlink:type="arc"/>
    <link:presentationArc order="35" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AuditorName" xlink:type="arc"/>
    <link:presentationArc order="36" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AuditorLocation" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cassavasciences.com/20241231/role/statement-consolidated-balance-sheets-parentheticals" xlink:href="sava-20241231.xsd#statement-consolidated-balance-sheets-parentheticals" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.cassavasciences.com/20241231/role/statement-consolidated-balance-sheets-parentheticals" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesAuthorized" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesIssued" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesOutstanding" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesIssued" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cassavasciences.com/20241231/role/statement-note-1-general-liquidity-and-basis-of-presentation" xlink:href="sava-20241231.xsd#statement-note-1-general-liquidity-and-basis-of-presentation" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.cassavasciences.com/20241231/role/statement-note-1-general-liquidity-and-basis-of-presentation" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="sava-20241231.xsd#sava_NotesToFinancialStatementsAbstract" xlink:label="sava_NotesToFinancialStatementsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sava_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cassavasciences.com/20241231/role/statement-note-2-summary-of-significant-accounting-policies" xlink:href="sava-20241231.xsd#statement-note-2-summary-of-significant-accounting-policies" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.cassavasciences.com/20241231/role/statement-note-2-summary-of-significant-accounting-policies" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="sava-20241231.xsd#sava_FormerPresidentAndChiefExecutiveOfficerMember" xlink:label="sava_FormerPresidentAndChiefExecutiveOfficerMember" xlink:type="locator"/>
    <link:loc xlink:href="sava-20241231.xsd#sava_FormerSeniorOfficerMember" xlink:label="sava_FormerSeniorOfficerMember" xlink:type="locator"/>
    <link:loc xlink:href="sava-20241231.xsd#sava_FormerSeniorVicePresidentMember" xlink:label="sava_FormerSeniorVicePresidentMember" xlink:type="locator"/>
    <link:loc xlink:href="sava-20241231.xsd#sava_NotesToFinancialStatementsAbstract" xlink:label="sava_NotesToFinancialStatementsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BuildingImprovementsMember" xlink:label="us-gaap_BuildingImprovementsMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BuildingMember" xlink:label="us-gaap_BuildingMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sava_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AwardTypeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_EmployeeStockOptionMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_RangeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MinimumMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MaximumMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_BuildingMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_BuildingImprovementsMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_TitleOfIndividualAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis" xlink:to="sava_FormerPresidentAndChiefExecutiveOfficerMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis" xlink:to="sava_FormerSeniorVicePresidentMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis" xlink:to="sava_FormerSeniorOfficerMember" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="sava_FormerSeniorVicePresidentMember" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cassavasciences.com/20241231/role/statement-note-4-real-property-and-other-income-expense" xlink:href="sava-20241231.xsd#statement-note-4-real-property-and-other-income-expense" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.cassavasciences.com/20241231/role/statement-note-4-real-property-and-other-income-expense" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="sava-20241231.xsd#sava_NotesToFinancialStatementsAbstract" xlink:label="sava_NotesToFinancialStatementsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis" xlink:label="srt_MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MortgageLoansOnRealEstateNamePropertyTypeDomain" xlink:label="srt_MortgageLoansOnRealEstateNamePropertyTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_OfficeBuildingMember" xlink:label="srt_OfficeBuildingMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd#stpr_TX" xlink:label="stpr_TX" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RealEstateOwnedTextBlock" xlink:label="us-gaap_RealEstateOwnedTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sava_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis" xlink:to="srt_MortgageLoansOnRealEstateNamePropertyTypeDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis" xlink:to="srt_OfficeBuildingMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_StatementGeographicalAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementGeographicalAxis" xlink:to="stpr_TX" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_RealEstateOwnedTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cassavasciences.com/20241231/role/statement-note-5-property-and-equipment" xlink:href="sava-20241231.xsd#statement-note-5-property-and-equipment" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.cassavasciences.com/20241231/role/statement-note-5-property-and-equipment" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="sava-20241231.xsd#sava_NotesToFinancialStatementsAbstract" xlink:label="sava_NotesToFinancialStatementsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sava_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cassavasciences.com/20241231/role/statement-note-6-intangible-assets" xlink:href="sava-20241231.xsd#statement-note-6-intangible-assets" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.cassavasciences.com/20241231/role/statement-note-6-intangible-assets" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="sava-20241231.xsd#sava_NotesToFinancialStatementsAbstract" xlink:label="sava_NotesToFinancialStatementsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:label="us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sava_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cassavasciences.com/20241231/role/statement-note-7-stockholders-equity-and-stockbased-compensation" xlink:href="sava-20241231.xsd#statement-note-7-stockholders-equity-and-stockbased-compensation" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.cassavasciences.com/20241231/role/statement-note-7-stockholders-equity-and-stockbased-compensation" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="sava-20241231.xsd#sava_AtthemarketCommonStockOfferingMember" xlink:label="sava_AtthemarketCommonStockOfferingMember" xlink:type="locator"/>
    <link:loc xlink:href="sava-20241231.xsd#sava_NotesToFinancialStatementsAbstract" xlink:label="sava_NotesToFinancialStatementsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="sava-20241231.xsd#sava_The2018EquityIncentivePlanMember" xlink:label="sava_The2018EquityIncentivePlanMember" xlink:type="locator"/>
    <link:loc xlink:href="sava-20241231.xsd#sava_The2022RegisteredDirectOfferingMember" xlink:label="sava_The2022RegisteredDirectOfferingMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeSeveranceMember" xlink:label="us-gaap_EmployeeSeveranceMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GranteeStatusAxis" xlink:label="us-gaap_GranteeStatusAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GranteeStatusDomain" xlink:label="us-gaap_GranteeStatusDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PerformanceSharesMember" xlink:label="us-gaap_PerformanceSharesMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringCostAndReserveAxis" xlink:label="us-gaap_RestructuringCostAndReserveAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedPaymentArrangementEmployeeMember" xlink:label="us-gaap_ShareBasedPaymentArrangementEmployeeMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock" xlink:label="us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfRestructuringDomain" xlink:label="us-gaap_TypeOfRestructuringDomain" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sava_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestructuringCostAndReserveAxis" xlink:to="us-gaap_TypeOfRestructuringDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GranteeStatusAxis" xlink:to="us-gaap_GranteeStatusDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="sava_The2022RegisteredDirectOfferingMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="sava_AtthemarketCommonStockOfferingMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_PlanNameAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="sava_The2018EquityIncentivePlanMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_GranteeStatusAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GranteeStatusAxis" xlink:to="us-gaap_ShareBasedPaymentArrangementEmployeeMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AwardTypeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_EmployeeStockOptionMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_PerformanceSharesMember" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_RestructuringCostAndReserveAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestructuringCostAndReserveAxis" xlink:to="us-gaap_EmployeeSeveranceMember" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cassavasciences.com/20241231/role/statement-note-9-income-taxes" xlink:href="sava-20241231.xsd#statement-note-9-income-taxes" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.cassavasciences.com/20241231/role/statement-note-9-income-taxes" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="sava-20241231.xsd#sava_CarryforwardSubjectToExpirationMember" xlink:label="sava_CarryforwardSubjectToExpirationMember" xlink:type="locator"/>
    <link:loc xlink:href="sava-20241231.xsd#sava_IndefiniteLifeCarryforwardsMember" xlink:label="sava_IndefiniteLifeCarryforwardsMember" xlink:type="locator"/>
    <link:loc xlink:href="sava-20241231.xsd#sava_NotesToFinancialStatementsAbstract" xlink:label="sava_NotesToFinancialStatementsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DomesticCountryMember" xlink:label="us-gaap_DomesticCountryMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchMember" xlink:label="us-gaap_ResearchMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxCreditCarryforwardAxis" xlink:label="us-gaap_TaxCreditCarryforwardAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxPeriodAxis" xlink:label="us-gaap_TaxPeriodAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxPeriodDomain" xlink:label="us-gaap_TaxPeriodDomain" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sava_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxPeriodAxis" xlink:to="us-gaap_TaxPeriodDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxCreditCarryforwardAxis" xlink:to="us-gaap_TaxCreditCarryforwardNameDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_IncomeTaxAuthorityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_DomesticCountryMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_TaxPeriodAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxPeriodAxis" xlink:to="sava_CarryforwardSubjectToExpirationMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxPeriodAxis" xlink:to="sava_IndefiniteLifeCarryforwardsMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_TaxCreditCarryforwardAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxCreditCarryforwardAxis" xlink:to="us-gaap_ResearchMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cassavasciences.com/20241231/role/statement-note-10-commitments" xlink:href="sava-20241231.xsd#statement-note-10-commitments" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.cassavasciences.com/20241231/role/statement-note-10-commitments" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="sava-20241231.xsd#sava_LeasesAndCommitmentsDisclosureTextBlock" xlink:label="sava_LeasesAndCommitmentsDisclosureTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="sava-20241231.xsd#sava_LicenseAgreementMember" xlink:label="sava_LicenseAgreementMember" xlink:type="locator"/>
    <link:loc xlink:href="sava-20241231.xsd#sava_NotesToFinancialStatementsAbstract" xlink:label="sava_NotesToFinancialStatementsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="sava-20241231.xsd#sava_SimufilamActiveIngredientMember" xlink:label="sava_SimufilamActiveIngredientMember" xlink:type="locator"/>
    <link:loc xlink:href="sava-20241231.xsd#sava_YaleUniversityMember" xlink:label="sava_YaleUniversityMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherCommitmentsAxis" xlink:label="us-gaap_OtherCommitmentsAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherCommitmentsDomain" xlink:label="us-gaap_OtherCommitmentsDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SupplyCommitmentArrangementMember" xlink:label="us-gaap_SupplyCommitmentArrangementMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SupplyCommitmentAxis" xlink:label="us-gaap_SupplyCommitmentAxis" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sava_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsAxis" xlink:to="us-gaap_OtherCommitmentsDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplyCommitmentAxis" xlink:to="us-gaap_SupplyCommitmentArrangementMember" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SupplyCommitmentAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplyCommitmentAxis" xlink:to="sava_SimufilamActiveIngredientMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_CounterpartyNameAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis" xlink:to="sava_YaleUniversityMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_OtherCommitmentsAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsAxis" xlink:to="sava_LicenseAgreementMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsequentEventTypeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventMember" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="sava_LeasesAndCommitmentsDisclosureTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cassavasciences.com/20241231/role/statement-note-11-2020-cash-incentive-bonus-plan" xlink:href="sava-20241231.xsd#statement-note-11-2020-cash-incentive-bonus-plan" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.cassavasciences.com/20241231/role/statement-note-11-2020-cash-incentive-bonus-plan" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="sava-20241231.xsd#sava_CashIncentiveBonusPlanMember" xlink:label="sava_CashIncentiveBonusPlanMember" xlink:type="locator"/>
    <link:loc xlink:href="sava-20241231.xsd#sava_CashIncentiveBonusPlanTextBlock" xlink:label="sava_CashIncentiveBonusPlanTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="sava-20241231.xsd#sava_NotesToFinancialStatementsAbstract" xlink:label="sava_NotesToFinancialStatementsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sava_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_PlanNameAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="sava_CashIncentiveBonusPlanMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_RangeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MinimumMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MaximumMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="sava_CashIncentiveBonusPlanTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cassavasciences.com/20241231/role/statement-note-12-contingencies" xlink:href="sava-20241231.xsd#statement-note-12-contingencies" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.cassavasciences.com/20241231/role/statement-note-12-contingencies" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="sava-20241231.xsd#sava_AntislappLawsuitMember" xlink:label="sava_AntislappLawsuitMember" xlink:type="locator"/>
    <link:loc xlink:href="sava-20241231.xsd#sava_NotesToFinancialStatementsAbstract" xlink:label="sava_NotesToFinancialStatementsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="sava-20241231.xsd#sava_ShareholderDerivativeActionsDelawareCourtMember" xlink:label="sava_ShareholderDerivativeActionsDelawareCourtMember" xlink:type="locator"/>
    <link:loc xlink:href="sava-20241231.xsd#sava_ShareholderDerivativeActionsMember" xlink:label="sava_ShareholderDerivativeActionsMember" xlink:type="locator"/>
    <link:loc xlink:href="sava-20241231.xsd#sava_ShareholderDerivativeActionsTexasCourtMember" xlink:label="sava_ShareholderDerivativeActionsTexasCourtMember" xlink:type="locator"/>
    <link:loc xlink:href="sava-20241231.xsd#sava_ShareholderDerivativeActionsTexasStateCourtMember" xlink:label="sava_ShareholderDerivativeActionsTexasStateCourtMember" xlink:type="locator"/>
    <link:loc xlink:href="sava-20241231.xsd#sava_ViolationsOfFederalSecuritiesLawsMember" xlink:label="sava_ViolationsOfFederalSecuritiesLawsMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_LitigationCaseAxis" xlink:label="srt_LitigationCaseAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_LitigationCaseTypeDomain" xlink:label="srt_LitigationCaseTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LossContingencyDisclosures" xlink:label="us-gaap_LossContingencyDisclosures" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sava_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_LitigationCaseAxis" xlink:to="srt_LitigationCaseTypeDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_LitigationCaseAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_LitigationCaseAxis" xlink:to="sava_ViolationsOfFederalSecuritiesLawsMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_LitigationCaseAxis" xlink:to="sava_ShareholderDerivativeActionsTexasCourtMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_LitigationCaseAxis" xlink:to="sava_ShareholderDerivativeActionsTexasStateCourtMember" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_LitigationCaseAxis" xlink:to="sava_ShareholderDerivativeActionsDelawareCourtMember" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_LitigationCaseAxis" xlink:to="sava_ShareholderDerivativeActionsMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsequentEventTypeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventMember" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_LitigationCaseAxis" xlink:to="sava_AntislappLawsuitMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_LossContingencyDisclosures" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cassavasciences.com/20241231/role/statement-note-13-warrant-dividend-distribution" xlink:href="sava-20241231.xsd#statement-note-13-warrant-dividend-distribution" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.cassavasciences.com/20241231/role/statement-note-13-warrant-dividend-distribution" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="sava-20241231.xsd#sava_NotesToFinancialStatementsAbstract" xlink:label="sava_NotesToFinancialStatementsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="sava-20241231.xsd#sava_WarrantDividendDistributionTextBlock" xlink:label="sava_WarrantDividendDistributionTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="sava-20241231.xsd#sava_WarrantsToPurchaseCommonStockMember" xlink:label="sava_WarrantsToPurchaseCommonStockMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sava_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="sava_WarrantsToPurchaseCommonStockMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="sava_WarrantDividendDistributionTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cassavasciences.com/20241231/role/statement-note-14-subsequent-event" xlink:href="sava-20241231.xsd#statement-note-14-subsequent-event" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.cassavasciences.com/20241231/role/statement-note-14-subsequent-event" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="sava-20241231.xsd#sava_NotesToFinancialStatementsAbstract" xlink:label="sava_NotesToFinancialStatementsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="sava-20241231.xsd#sava_WorkforceReductionMember" xlink:label="sava_WorkforceReductionMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScenarioForecastMember" xlink:label="srt_ScenarioForecastMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringCostAndReserveAxis" xlink:label="us-gaap_RestructuringCostAndReserveAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="us-gaap_SubsequentEventsTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfRestructuringDomain" xlink:label="us-gaap_TypeOfRestructuringDomain" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sava_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestructuringCostAndReserveAxis" xlink:to="us-gaap_TypeOfRestructuringDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_RestructuringCostAndReserveAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestructuringCostAndReserveAxis" xlink:to="sava_WorkforceReductionMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsequentEventTypeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_StatementScenarioAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioForecastMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_SubsequentEventsTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#InsiderTradingArrangements" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_InsiderTradingArrLineItems" xlink:label="ecd_InsiderTradingArrLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_MtrlTermsOfTrdArrTextBlock" xlink:label="ecd_MtrlTermsOfTrdArrTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonRule10b51ArrAdoptedFlag" xlink:label="ecd_NonRule10b51ArrAdoptedFlag-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonRule10b51ArrTrmntdFlag" xlink:label="ecd_NonRule10b51ArrTrmntdFlag-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_Rule10b51ArrAdoptedFlag" xlink:label="ecd_Rule10b51ArrAdoptedFlag-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_Rule10b51ArrTrmntdFlag" xlink:label="ecd_Rule10b51ArrTrmntdFlag-2" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ecd_InsiderTradingArrLineItems" xlink:to="ecd_MtrlTermsOfTrdArrTextBlock" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ecd_InsiderTradingArrLineItems" xlink:to="ecd_Rule10b51ArrAdoptedFlag-2" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ecd_InsiderTradingArrLineItems" xlink:to="ecd_NonRule10b51ArrAdoptedFlag-2" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ecd_InsiderTradingArrLineItems" xlink:to="ecd_Rule10b51ArrTrmntdFlag-2" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ecd_InsiderTradingArrLineItems" xlink:to="ecd_NonRule10b51ArrTrmntdFlag-2" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cassavasciences.com/20241231/role/statement-significant-accounting-policies-policies" xlink:href="sava-20241231.xsd#statement-significant-accounting-policies-policies" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.cassavasciences.com/20241231/role/statement-significant-accounting-policies-policies" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="sava-20241231.xsd#sava_RelatedPartyTransactionPolicyTextBlock" xlink:label="sava_RelatedPartyTransactionPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="sava-20241231.xsd#sava_statement-statement-significant-accounting-policies-policies" xlink:label="sava_statement-statement-significant-accounting-policies-policies" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesPolicyTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:label="us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativesPolicyTextBlock" xlink:label="us-gaap_DerivativesPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GovernmentAssistancePolicyTextBlock" xlink:label="us-gaap_GovernmentAssistancePolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="us-gaap_IncomeTaxPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:label="us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PolicyTextBlockAbstract" xlink:label="us-gaap_PolicyTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PolicyTextBlockAbstract" xlink:label="us-gaap_PolicyTextBlockAbstract-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sava_statement-statement-significant-accounting-policies-policies" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PolicyTextBlockAbstract-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PolicyTextBlockAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_UseOfEstimates" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_GovernmentAssistancePolicyTextBlock" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_DerivativesPolicyTextBlock" xlink:type="arc"/>
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:type="arc"/>
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:type="arc"/>
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:type="arc"/>
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:type="arc"/>
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:type="arc"/>
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesPolicyTextBlock" xlink:type="arc"/>
    <link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="sava_RelatedPartyTransactionPolicyTextBlock" xlink:type="arc"/>
    <link:presentationArc order="15" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_IncomeTaxPolicyTextBlock" xlink:type="arc"/>
    <link:presentationArc order="16" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cassavasciences.com/20241231/role/statement-note-2-summary-of-significant-accounting-policies-tables" xlink:href="sava-20241231.xsd#statement-note-2-summary-of-significant-accounting-policies-tables" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.cassavasciences.com/20241231/role/statement-note-2-summary-of-significant-accounting-policies-tables" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="sava-20241231.xsd#sava_statement-statement-note-2-summary-of-significant-accounting-policies-tables" xlink:label="sava_statement-statement-note-2-summary-of-significant-accounting-policies-tables" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock-2" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sava_statement-statement-note-2-summary-of-significant-accounting-policies-tables" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TableTextBlock-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cassavasciences.com/20241231/role/statement-note-3-prepaid-expenses-and-other-current-assets-tables" xlink:href="sava-20241231.xsd#statement-note-3-prepaid-expenses-and-other-current-assets-tables" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.cassavasciences.com/20241231/role/statement-note-3-prepaid-expenses-and-other-current-assets-tables" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="sava-20241231.xsd#sava_statement-statement-note-3-prepaid-expenses-and-other-current-assets-tables" xlink:label="sava_statement-statement-note-3-prepaid-expenses-and-other-current-assets-tables" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:label="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock-2" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sava_statement-statement-note-3-prepaid-expenses-and-other-current-assets-tables" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TableTextBlock-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cassavasciences.com/20241231/role/statement-note-4-real-property-and-other-income-expense-tables" xlink:href="sava-20241231.xsd#statement-note-4-real-property-and-other-income-expense-tables" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.cassavasciences.com/20241231/role/statement-note-4-real-property-and-other-income-expense-tables" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="sava-20241231.xsd#sava_statement-statement-note-4-real-property-and-other-income-expense-tables" xlink:label="sava_statement-statement-note-4-real-property-and-other-income-expense-tables" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock" xlink:label="us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock-2" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sava_statement-statement-note-4-real-property-and-other-income-expense-tables" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TableTextBlock-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cassavasciences.com/20241231/role/statement-note-5-property-and-equipment-tables" xlink:href="sava-20241231.xsd#statement-note-5-property-and-equipment-tables" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.cassavasciences.com/20241231/role/statement-note-5-property-and-equipment-tables" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="sava-20241231.xsd#sava_statement-statement-note-5-property-and-equipment-tables" xlink:label="sava_statement-statement-note-5-property-and-equipment-tables" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock-2" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sava_statement-statement-note-5-property-and-equipment-tables" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TableTextBlock-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cassavasciences.com/20241231/role/statement-note-6-intangible-assets-tables" xlink:href="sava-20241231.xsd#statement-note-6-intangible-assets-tables" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.cassavasciences.com/20241231/role/statement-note-6-intangible-assets-tables" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="sava-20241231.xsd#sava_statement-statement-note-6-intangible-assets-tables" xlink:label="sava_statement-statement-note-6-intangible-assets-tables" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:label="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock-2" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sava_statement-statement-note-6-intangible-assets-tables" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TableTextBlock-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cassavasciences.com/20241231/role/statement-note-7-stockholders-equity-and-stockbased-compensation-tables" xlink:href="sava-20241231.xsd#statement-note-7-stockholders-equity-and-stockbased-compensation-tables" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.cassavasciences.com/20241231/role/statement-note-7-stockholders-equity-and-stockbased-compensation-tables" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="sava-20241231.xsd#sava_statement-statement-note-7-stockholders-equity-and-stockbased-compensation-tables" xlink:label="sava_statement-statement-note-7-stockholders-equity-and-stockbased-compensation-tables" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock-2" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sava_statement-statement-note-7-stockholders-equity-and-stockbased-compensation-tables" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TableTextBlock-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cassavasciences.com/20241231/role/statement-note-9-income-taxes-tables" xlink:href="sava-20241231.xsd#statement-note-9-income-taxes-tables" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.cassavasciences.com/20241231/role/statement-note-9-income-taxes-tables" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="sava-20241231.xsd#sava_statement-statement-note-9-income-taxes-tables" xlink:label="sava_statement-statement-note-9-income-taxes-tables" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:label="us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock-2" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sava_statement-statement-note-9-income-taxes-tables" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TableTextBlock-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cassavasciences.com/20241231/role/statement-note-13-warrant-dividend-distribution-tables" xlink:href="sava-20241231.xsd#statement-note-13-warrant-dividend-distribution-tables" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.cassavasciences.com/20241231/role/statement-note-13-warrant-dividend-distribution-tables" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="sava-20241231.xsd#sava_statement-statement-note-13-warrant-dividend-distribution-tables" xlink:label="sava_statement-statement-note-13-warrant-dividend-distribution-tables" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:label="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock-2" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sava_statement-statement-note-13-warrant-dividend-distribution-tables" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TableTextBlock-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cassavasciences.com/20241231/role/statement-note-1-general-liquidity-and-basis-of-presentation-details-textual" xlink:href="sava-20241231.xsd#statement-note-1-general-liquidity-and-basis-of-presentation-details-textual" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.cassavasciences.com/20241231/role/statement-note-1-general-liquidity-and-basis-of-presentation-details-textual" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="sava-20241231.xsd#sava_NoteToFinancialStatementDetailsTextual" xlink:label="sava_NoteToFinancialStatementDetailsTextual" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit-n2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sava_NoteToFinancialStatementDetailsTextual" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit-n2" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cassavasciences.com/20241231/role/statement-note-2-summary-of-significant-accounting-policies-details-textual" xlink:href="sava-20241231.xsd#statement-note-2-summary-of-significant-accounting-policies-details-textual" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.cassavasciences.com/20241231/role/statement-note-2-summary-of-significant-accounting-policies-details-textual" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="sava-20241231.xsd#sava_ClassOfWarrantOrRightFairValueOfCommonStockWarrantsPerWarrant" xlink:label="sava_ClassOfWarrantOrRightFairValueOfCommonStockWarrantsPerWarrant-2" xlink:type="locator"/>
    <link:loc xlink:href="sava-20241231.xsd#sava_ClassOfWarrantOrRightRedemptionPricePerShare" xlink:label="sava_ClassOfWarrantOrRightRedemptionPricePerShare-2" xlink:type="locator"/>
    <link:loc xlink:href="sava-20241231.xsd#sava_ConsultingAgreementTerm" xlink:label="sava_ConsultingAgreementTerm-2" xlink:type="locator"/>
    <link:loc xlink:href="sava-20241231.xsd#sava_ConsultingServicePricePerHour" xlink:label="sava_ConsultingServicePricePerHour-2" xlink:type="locator"/>
    <link:loc xlink:href="sava-20241231.xsd#sava_FormerPresidentAndChiefExecutiveOfficerMember" xlink:label="sava_FormerPresidentAndChiefExecutiveOfficerMember" xlink:type="locator"/>
    <link:loc xlink:href="sava-20241231.xsd#sava_FormerSeniorOfficerMember" xlink:label="sava_FormerSeniorOfficerMember" xlink:type="locator"/>
    <link:loc xlink:href="sava-20241231.xsd#sava_FormerSeniorVicePresidentMember" xlink:label="sava_FormerSeniorVicePresidentMember" xlink:type="locator"/>
    <link:loc xlink:href="sava-20241231.xsd#sava_InsuranceSettlementsMaximumRecoveryLimit" xlink:label="sava_InsuranceSettlementsMaximumRecoveryLimit-2" xlink:type="locator"/>
    <link:loc xlink:href="sava-20241231.xsd#sava_NoteToFinancialStatementDetailsTextual" xlink:label="sava_NoteToFinancialStatementDetailsTextual" xlink:type="locator"/>
    <link:loc xlink:href="sava-20241231.xsd#sava_NumberOfFormerEmployees" xlink:label="sava_NumberOfFormerEmployees-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BuildingImprovementsMember" xlink:label="us-gaap_BuildingImprovementsMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BuildingMember" xlink:label="us-gaap_BuildingMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GovernmentAssistanceAmount" xlink:label="us-gaap_GovernmentAssistanceAmount-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GovernmentAssistanceStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration" xlink:label="us-gaap_GovernmentAssistanceStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities-n2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="us-gaap_NumberOfOperatingSegments-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromInsuranceSettlementOperatingActivities" xlink:label="us-gaap_ProceedsFromInsuranceSettlementOperatingActivities-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionAmountsOfTransaction" xlink:label="us-gaap_RelatedPartyTransactionAmountsOfTransaction-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeveranceCosts1" xlink:label="us-gaap_SeveranceCosts1-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sava_NoteToFinancialStatementDetailsTextual" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AwardTypeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_EmployeeStockOptionMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_RangeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MinimumMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MaximumMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_BuildingMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_BuildingImprovementsMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_TitleOfIndividualAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis" xlink:to="sava_FormerPresidentAndChiefExecutiveOfficerMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis" xlink:to="sava_FormerSeniorVicePresidentMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis" xlink:to="sava_FormerSeniorOfficerMember" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="sava_FormerSeniorVicePresidentMember" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_GovernmentAssistanceAmount-2" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="sava_ClassOfWarrantOrRightFairValueOfCommonStockWarrantsPerWarrant-2" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="sava_ClassOfWarrantOrRightRedemptionPricePerShare-2" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NumberOfOperatingSegments-2" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities-n2" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1-2" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife-2" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ProceedsFromInsuranceSettlementOperatingActivities-2" xlink:type="arc"/>
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="sava_InsuranceSettlementsMaximumRecoveryLimit-2" xlink:type="arc"/>
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SeveranceCosts1-2" xlink:type="arc"/>
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="sava_NumberOfFormerEmployees-2" xlink:type="arc"/>
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="sava_ConsultingAgreementTerm-2" xlink:type="arc"/>
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="sava_ConsultingServicePricePerHour-2" xlink:type="arc"/>
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_RelatedPartyTransactionAmountsOfTransaction-2" xlink:type="arc"/>
    <link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_GovernmentAssistanceStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration-2" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cassavasciences.com/20241231/role/statement-note-4-real-property-and-other-income-expense-details-textual" xlink:href="sava-20241231.xsd#statement-note-4-real-property-and-other-income-expense-details-textual" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.cassavasciences.com/20241231/role/statement-note-4-real-property-and-other-income-expense-details-textual" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="sava-20241231.xsd#sava_NoteToFinancialStatementDetailsTextual" xlink:label="sava_NoteToFinancialStatementDetailsTextual" xlink:type="locator"/>
    <link:loc xlink:href="sava-20241231.xsd#sava_PercentageOfOccupancy" xlink:label="sava_PercentageOfOccupancy-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis" xlink:label="srt_MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MortgageLoansOnRealEstateNamePropertyTypeDomain" xlink:label="srt_MortgageLoansOnRealEstateNamePropertyTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_OfficeBuildingMember" xlink:label="srt_OfficeBuildingMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd#stpr_TX" xlink:label="stpr_TX" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccrualForTaxesOtherThanIncomeTaxesCurrent" xlink:label="us-gaap_AccrualForTaxesOtherThanIncomeTaxesCurrent-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths" xlink:label="us-gaap_LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LessorOperatingLeasePaymentsToBeReceivedThreeYears" xlink:label="us-gaap_LessorOperatingLeasePaymentsToBeReceivedThreeYears-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LessorOperatingLeasePaymentsToBeReceivedTwoYears" xlink:label="us-gaap_LessorOperatingLeasePaymentsToBeReceivedTwoYears-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetRentableArea" xlink:label="us-gaap_NetRentableArea-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sava_NoteToFinancialStatementDetailsTextual" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis" xlink:to="srt_MortgageLoansOnRealEstateNamePropertyTypeDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis" xlink:to="srt_OfficeBuildingMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_StatementGeographicalAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementGeographicalAxis" xlink:to="stpr_TX" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetRentableArea-2" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="sava_PercentageOfOccupancy-2" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths-2" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LessorOperatingLeasePaymentsToBeReceivedTwoYears-2" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LessorOperatingLeasePaymentsToBeReceivedThreeYears-2" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AccrualForTaxesOtherThanIncomeTaxesCurrent-2" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cassavasciences.com/20241231/role/statement-note-5-property-and-equipment-details-textual" xlink:href="sava-20241231.xsd#statement-note-5-property-and-equipment-details-textual" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.cassavasciences.com/20241231/role/statement-note-5-property-and-equipment-details-textual" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="sava-20241231.xsd#sava_NoteToFinancialStatementDetailsTextual" xlink:label="sava_NoteToFinancialStatementDetailsTextual" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sava_NoteToFinancialStatementDetailsTextual" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_Depreciation-2" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cassavasciences.com/20241231/role/statement-note-6-intangible-assets-details-textual" xlink:href="sava-20241231.xsd#statement-note-6-intangible-assets-details-textual" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.cassavasciences.com/20241231/role/statement-note-6-intangible-assets-details-textual" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="sava-20241231.xsd#sava_NoteToFinancialStatementDetailsTextual" xlink:label="sava_NoteToFinancialStatementDetailsTextual" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="us-gaap_AmortizationOfIntangibleAssets-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sava_NoteToFinancialStatementDetailsTextual" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AmortizationOfIntangibleAssets-2" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cassavasciences.com/20241231/role/statement-note-7-stockholders-equity-and-stockbased-compensation-details-textual" xlink:href="sava-20241231.xsd#statement-note-7-stockholders-equity-and-stockbased-compensation-details-textual" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.cassavasciences.com/20241231/role/statement-note-7-stockholders-equity-and-stockbased-compensation-details-textual" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="sava-20241231.xsd#sava_AtthemarketCommonStockOfferingMember" xlink:label="sava_AtthemarketCommonStockOfferingMember" xlink:type="locator"/>
    <link:loc xlink:href="sava-20241231.xsd#sava_EquityOfferingMaximumAmount" xlink:label="sava_EquityOfferingMaximumAmount-2" xlink:type="locator"/>
    <link:loc xlink:href="sava-20241231.xsd#sava_EquityOfferingPercentageOfCommission" xlink:label="sava_EquityOfferingPercentageOfCommission-2" xlink:type="locator"/>
    <link:loc xlink:href="sava-20241231.xsd#sava_NoteToFinancialStatementDetailsTextual" xlink:label="sava_NoteToFinancialStatementDetailsTextual" xlink:type="locator"/>
    <link:loc xlink:href="sava-20241231.xsd#sava_StockOptionsExercisedNetSettledSatisfactionOfExercisePrice" xlink:label="sava_StockOptionsExercisedNetSettledSatisfactionOfExercisePrice-2" xlink:type="locator"/>
    <link:loc xlink:href="sava-20241231.xsd#sava_The2018EquityIncentivePlanMember" xlink:label="sava_The2018EquityIncentivePlanMember" xlink:type="locator"/>
    <link:loc xlink:href="sava-20241231.xsd#sava_The2022RegisteredDirectOfferingMember" xlink:label="sava_The2022RegisteredDirectOfferingMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeSeveranceMember" xlink:label="us-gaap_EmployeeSeveranceMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GranteeStatusAxis" xlink:label="us-gaap_GranteeStatusAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GranteeStatusDomain" xlink:label="us-gaap_GranteeStatusDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PerformanceSharesMember" xlink:label="us-gaap_PerformanceSharesMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringCostAndReserveAxis" xlink:label="us-gaap_RestructuringCostAndReserveAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedPaymentArrangementEmployeeMember" xlink:label="us-gaap_ShareBasedPaymentArrangementEmployeeMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfRestructuringDomain" xlink:label="us-gaap_TypeOfRestructuringDomain" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sava_NoteToFinancialStatementDetailsTextual" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestructuringCostAndReserveAxis" xlink:to="us-gaap_TypeOfRestructuringDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GranteeStatusAxis" xlink:to="us-gaap_GranteeStatusDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="sava_The2022RegisteredDirectOfferingMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="sava_AtthemarketCommonStockOfferingMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_PlanNameAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="sava_The2018EquityIncentivePlanMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_GranteeStatusAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GranteeStatusAxis" xlink:to="us-gaap_ShareBasedPaymentArrangementEmployeeMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AwardTypeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_EmployeeStockOptionMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_PerformanceSharesMember" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_RestructuringCostAndReserveAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestructuringCostAndReserveAxis" xlink:to="us-gaap_EmployeeSeveranceMember" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues-2" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesIssuedPricePerShare-2" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock-2" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="sava_EquityOfferingMaximumAmount-2" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="sava_EquityOfferingPercentageOfCommission-2" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod-2" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized-2" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare-2" xlink:type="arc"/>
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="sava_StockOptionsExercisedNetSettledSatisfactionOfExercisePrice-2" xlink:type="arc"/>
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod-2" xlink:type="arc"/>
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate-2" xlink:type="arc"/>
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized-2" xlink:type="arc"/>
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1-2" xlink:type="arc"/>
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations-2" xlink:type="arc"/>
    <link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense-2" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cassavasciences.com/20241231/role/statement-note-7-stockholders-equity-and-stockbased-compensation-stock-option-valuation-assumptions-details" xlink:href="sava-20241231.xsd#statement-note-7-stockholders-equity-and-stockbased-compensation-stock-option-valuation-assumptions-details" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.cassavasciences.com/20241231/role/statement-note-7-stockholders-equity-and-stockbased-compensation-stock-option-valuation-assumptions-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="sava-20241231.xsd#sava_statement-statement-note-7-stockholders-equity-and-stockbased-compensation-stock-option-valuation-assumptions-details" xlink:label="sava_statement-statement-note-7-stockholders-equity-and-stockbased-compensation-stock-option-valuation-assumptions-details" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sava_statement-statement-note-7-stockholders-equity-and-stockbased-compensation-stock-option-valuation-assumptions-details" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AwardTypeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_EmployeeStockOptionMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_RangeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MinimumMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MaximumMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cassavasciences.com/20241231/role/statement-note-9-income-taxes-details-textual" xlink:href="sava-20241231.xsd#statement-note-9-income-taxes-details-textual" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.cassavasciences.com/20241231/role/statement-note-9-income-taxes-details-textual" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="sava-20241231.xsd#sava_CarryforwardSubjectToExpirationMember" xlink:label="sava_CarryforwardSubjectToExpirationMember" xlink:type="locator"/>
    <link:loc xlink:href="sava-20241231.xsd#sava_IndefiniteLifeCarryforwardsMember" xlink:label="sava_IndefiniteLifeCarryforwardsMember" xlink:type="locator"/>
    <link:loc xlink:href="sava-20241231.xsd#sava_NoteToFinancialStatementDetailsTextual" xlink:label="sava_NoteToFinancialStatementDetailsTextual" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DomesticCountryMember" xlink:label="us-gaap_DomesticCountryMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OpenTaxYear" xlink:label="us-gaap_OpenTaxYear-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="us-gaap_OperatingLossCarryforwards-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchMember" xlink:label="us-gaap_ResearchMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxCreditCarryforwardAmount" xlink:label="us-gaap_TaxCreditCarryforwardAmount-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxCreditCarryforwardAxis" xlink:label="us-gaap_TaxCreditCarryforwardAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxPeriodAxis" xlink:label="us-gaap_TaxPeriodAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxPeriodDomain" xlink:label="us-gaap_TaxPeriodDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="us-gaap_UnrecognizedTaxBenefits-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount-2" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sava_NoteToFinancialStatementDetailsTextual" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxPeriodAxis" xlink:to="us-gaap_TaxPeriodDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxCreditCarryforwardAxis" xlink:to="us-gaap_TaxCreditCarryforwardNameDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_IncomeTaxAuthorityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_DomesticCountryMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_TaxPeriodAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxPeriodAxis" xlink:to="sava_CarryforwardSubjectToExpirationMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxPeriodAxis" xlink:to="sava_IndefiniteLifeCarryforwardsMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_TaxCreditCarryforwardAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxCreditCarryforwardAxis" xlink:to="us-gaap_ResearchMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate-2" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount-2" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingLossCarryforwards-2" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TaxCreditCarryforwardAmount-2" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_UnrecognizedTaxBenefits-2" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncomeTaxExpenseBenefit-2" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued-2" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OpenTaxYear-2" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cassavasciences.com/20241231/role/statement-note-10-commitments-details-textual" xlink:href="sava-20241231.xsd#statement-note-10-commitments-details-textual" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.cassavasciences.com/20241231/role/statement-note-10-commitments-details-textual" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="sava-20241231.xsd#sava_LicenseAgreementMember" xlink:label="sava_LicenseAgreementMember" xlink:type="locator"/>
    <link:loc xlink:href="sava-20241231.xsd#sava_NoteToFinancialStatementDetailsTextual" xlink:label="sava_NoteToFinancialStatementDetailsTextual" xlink:type="locator"/>
    <link:loc xlink:href="sava-20241231.xsd#sava_SimufilamActiveIngredientMember" xlink:label="sava_SimufilamActiveIngredientMember" xlink:type="locator"/>
    <link:loc xlink:href="sava-20241231.xsd#sava_YaleUniversityMember" xlink:label="sava_YaleUniversityMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherCommitment" xlink:label="us-gaap_OtherCommitment-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherCommitmentsAxis" xlink:label="us-gaap_OtherCommitmentsAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherCommitmentsDomain" xlink:label="us-gaap_OtherCommitmentsDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SignificantSupplyCommitmentRemainingMinimumAmountCommitted" xlink:label="us-gaap_SignificantSupplyCommitmentRemainingMinimumAmountCommitted-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SupplyCommitmentArrangementMember" xlink:label="us-gaap_SupplyCommitmentArrangementMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SupplyCommitmentAxis" xlink:label="us-gaap_SupplyCommitmentAxis" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sava_NoteToFinancialStatementDetailsTextual" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsAxis" xlink:to="us-gaap_OtherCommitmentsDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplyCommitmentAxis" xlink:to="us-gaap_SupplyCommitmentArrangementMember" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SupplyCommitmentAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplyCommitmentAxis" xlink:to="sava_SimufilamActiveIngredientMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_CounterpartyNameAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis" xlink:to="sava_YaleUniversityMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_OtherCommitmentsAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsAxis" xlink:to="sava_LicenseAgreementMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsequentEventTypeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventMember" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SignificantSupplyCommitmentRemainingMinimumAmountCommitted-2" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherCommitment-2" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cassavasciences.com/20241231/role/statement-note-11-2020-cash-incentive-bonus-plan-details-textual" xlink:href="sava-20241231.xsd#statement-note-11-2020-cash-incentive-bonus-plan-details-textual" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.cassavasciences.com/20241231/role/statement-note-11-2020-cash-incentive-bonus-plan-details-textual" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="sava-20241231.xsd#sava_CashBonusIncentiveIncrementalAmounts" xlink:label="sava_CashBonusIncentiveIncrementalAmounts-2" xlink:type="locator"/>
    <link:loc xlink:href="sava-20241231.xsd#sava_CashIncentiveBonusAward" xlink:label="sava_CashIncentiveBonusAward-2" xlink:type="locator"/>
    <link:loc xlink:href="sava-20241231.xsd#sava_CashIncentiveBonusAwardExceedsMaximum" xlink:label="sava_CashIncentiveBonusAwardExceedsMaximum-2" xlink:type="locator"/>
    <link:loc xlink:href="sava-20241231.xsd#sava_CashIncentiveBonusPlanMember" xlink:label="sava_CashIncentiveBonusPlanMember" xlink:type="locator"/>
    <link:loc xlink:href="sava-20241231.xsd#sava_NoteToFinancialStatementDetailsTextual" xlink:label="sava_NoteToFinancialStatementDetailsTextual" xlink:type="locator"/>
    <link:loc xlink:href="sava-20241231.xsd#sava_PaymentsForCashIncentiveBonus" xlink:label="sava_PaymentsForCashIncentiveBonus-2" xlink:type="locator"/>
    <link:loc xlink:href="sava-20241231.xsd#sava_PercentageValuationMilestoneCashBonusAwardSubjectToApprovalAndAdjustment" xlink:label="sava_PercentageValuationMilestoneCashBonusAwardSubjectToApprovalAndAdjustment-2" xlink:type="locator"/>
    <link:loc xlink:href="sava-20241231.xsd#sava_PerformancePlanMinimumNumberOfDaysValuationMilestoneMustBeAchievedAndMaintained" xlink:label="sava_PerformancePlanMinimumNumberOfDaysValuationMilestoneMustBeAchievedAndMaintained-2" xlink:type="locator"/>
    <link:loc xlink:href="sava-20241231.xsd#sava_PerformancePlanValuationMilestoneAmount" xlink:label="sava_PerformancePlanValuationMilestoneAmount-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax" xlink:label="us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sava_NoteToFinancialStatementDetailsTextual" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_PlanNameAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="sava_CashIncentiveBonusPlanMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_RangeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MinimumMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MaximumMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="sava_CashBonusIncentiveIncrementalAmounts-2" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="sava_PerformancePlanValuationMilestoneAmount-2" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="sava_PerformancePlanMinimumNumberOfDaysValuationMilestoneMustBeAchievedAndMaintained-2" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="sava_PercentageValuationMilestoneCashBonusAwardSubjectToApprovalAndAdjustment-2" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="sava_CashIncentiveBonusAwardExceedsMaximum-2" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="sava_CashIncentiveBonusAward-2" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax-2" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="sava_PaymentsForCashIncentiveBonus-2" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cassavasciences.com/20241231/role/statement-note-12-contingencies-details-textual" xlink:href="sava-20241231.xsd#statement-note-12-contingencies-details-textual" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.cassavasciences.com/20241231/role/statement-note-12-contingencies-details-textual" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="sava-20241231.xsd#sava_AntislappLawsuitMember" xlink:label="sava_AntislappLawsuitMember" xlink:type="locator"/>
    <link:loc xlink:href="sava-20241231.xsd#sava_NoteToFinancialStatementDetailsTextual" xlink:label="sava_NoteToFinancialStatementDetailsTextual" xlink:type="locator"/>
    <link:loc xlink:href="sava-20241231.xsd#sava_NumberOfFormerEmployees" xlink:label="sava_NumberOfFormerEmployees-2" xlink:type="locator"/>
    <link:loc xlink:href="sava-20241231.xsd#sava_ShareholderDerivativeActionsDelawareCourtMember" xlink:label="sava_ShareholderDerivativeActionsDelawareCourtMember" xlink:type="locator"/>
    <link:loc xlink:href="sava-20241231.xsd#sava_ShareholderDerivativeActionsMember" xlink:label="sava_ShareholderDerivativeActionsMember" xlink:type="locator"/>
    <link:loc xlink:href="sava-20241231.xsd#sava_ShareholderDerivativeActionsTexasCourtMember" xlink:label="sava_ShareholderDerivativeActionsTexasCourtMember" xlink:type="locator"/>
    <link:loc xlink:href="sava-20241231.xsd#sava_ShareholderDerivativeActionsTexasStateCourtMember" xlink:label="sava_ShareholderDerivativeActionsTexasStateCourtMember" xlink:type="locator"/>
    <link:loc xlink:href="sava-20241231.xsd#sava_ViolationsOfFederalSecuritiesLawsMember" xlink:label="sava_ViolationsOfFederalSecuritiesLawsMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_LitigationCaseAxis" xlink:label="srt_LitigationCaseAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_LitigationCaseTypeDomain" xlink:label="srt_LitigationCaseTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LegalFees" xlink:label="us-gaap_LegalFees-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LossContingencyNewClaimsFiledNumber" xlink:label="us-gaap_LossContingencyNewClaimsFiledNumber-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sava_NoteToFinancialStatementDetailsTextual" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_LitigationCaseAxis" xlink:to="srt_LitigationCaseTypeDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_LitigationCaseAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_LitigationCaseAxis" xlink:to="sava_ViolationsOfFederalSecuritiesLawsMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_LitigationCaseAxis" xlink:to="sava_ShareholderDerivativeActionsTexasCourtMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_LitigationCaseAxis" xlink:to="sava_ShareholderDerivativeActionsTexasStateCourtMember" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_LitigationCaseAxis" xlink:to="sava_ShareholderDerivativeActionsDelawareCourtMember" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_LitigationCaseAxis" xlink:to="sava_ShareholderDerivativeActionsMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsequentEventTypeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventMember" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_LitigationCaseAxis" xlink:to="sava_AntislappLawsuitMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LossContingencyNewClaimsFiledNumber-2" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LegalFees-2" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="sava_NumberOfFormerEmployees-2" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cassavasciences.com/20241231/role/statement-note-13-warrant-dividend-distribution-details-textual" xlink:href="sava-20241231.xsd#statement-note-13-warrant-dividend-distribution-details-textual" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.cassavasciences.com/20241231/role/statement-note-13-warrant-dividend-distribution-details-textual" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="sava-20241231.xsd#sava_ClassOfWarrantOrRightExercisedDuringPeriod" xlink:label="sava_ClassOfWarrantOrRightExercisedDuringPeriod-2" xlink:type="locator"/>
    <link:loc xlink:href="sava-20241231.xsd#sava_ClassOfWarrantOrRightIssuedDuringPeriod" xlink:label="sava_ClassOfWarrantOrRightIssuedDuringPeriod-2" xlink:type="locator"/>
    <link:loc xlink:href="sava-20241231.xsd#sava_CommissionPercentageOfGrossProceeds" xlink:label="sava_CommissionPercentageOfGrossProceeds-2" xlink:type="locator"/>
    <link:loc xlink:href="sava-20241231.xsd#sava_GrossProceedsFromIssuanceOfWarrants" xlink:label="sava_GrossProceedsFromIssuanceOfWarrants-2" xlink:type="locator"/>
    <link:loc xlink:href="sava-20241231.xsd#sava_NoteToFinancialStatementDetailsTextual" xlink:label="sava_NoteToFinancialStatementDetailsTextual" xlink:type="locator"/>
    <link:loc xlink:href="sava-20241231.xsd#sava_PaymentsOfWarrantExerciseCosts" xlink:label="sava_PaymentsOfWarrantExerciseCosts-2" xlink:type="locator"/>
    <link:loc xlink:href="sava-20241231.xsd#sava_ProceedsFromWarrantsExercisedThatObligatedToPayCommission" xlink:label="sava_ProceedsFromWarrantsExercisedThatObligatedToPayCommission-2" xlink:type="locator"/>
    <link:loc xlink:href="sava-20241231.xsd#sava_RedemptionPercentageOfWarrants" xlink:label="sava_RedemptionPercentageOfWarrants-2" xlink:type="locator"/>
    <link:loc xlink:href="sava-20241231.xsd#sava_StockIssuedDuringPeriodSharesWarrantExercises" xlink:label="sava_StockIssuedDuringPeriodSharesWarrantExercises-2" xlink:type="locator"/>
    <link:loc xlink:href="sava-20241231.xsd#sava_WarrantRedemptionPrice" xlink:label="sava_WarrantRedemptionPrice-2" xlink:type="locator"/>
    <link:loc xlink:href="sava-20241231.xsd#sava_WarrantsToPurchaseCommonStockMember" xlink:label="sava_WarrantsToPurchaseCommonStockMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfWarrants" xlink:label="us-gaap_ProceedsFromIssuanceOfWarrants-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="us-gaap_ProceedsFromWarrantExercises-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantsAndRightsOutstanding" xlink:label="us-gaap_WarrantsAndRightsOutstanding-2" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sava_NoteToFinancialStatementDetailsTextual" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="sava_WarrantsToPurchaseCommonStockMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="sava_ClassOfWarrantOrRightIssuedDuringPeriod-2" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights-2" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1-2" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight-2" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="sava_RedemptionPercentageOfWarrants-2" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="sava_WarrantRedemptionPrice-2" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_WarrantsAndRightsOutstanding-2" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="sava_ClassOfWarrantOrRightExercisedDuringPeriod-2" xlink:type="arc"/>
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ProceedsFromWarrantExercises-2" xlink:type="arc"/>
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="sava_StockIssuedDuringPeriodSharesWarrantExercises-2" xlink:type="arc"/>
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="sava_GrossProceedsFromIssuanceOfWarrants-2" xlink:type="arc"/>
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfWarrants-2" xlink:type="arc"/>
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="sava_ProceedsFromWarrantsExercisedThatObligatedToPayCommission-2" xlink:type="arc"/>
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="sava_CommissionPercentageOfGrossProceeds-2" xlink:type="arc"/>
    <link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="sava_PaymentsOfWarrantExerciseCosts-2" xlink:type="arc"/>
    <link:presentationArc order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts-2" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cassavasciences.com/20241231/role/statement-note-14-subsequent-event-details-textual" xlink:href="sava-20241231.xsd#statement-note-14-subsequent-event-details-textual" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.cassavasciences.com/20241231/role/statement-note-14-subsequent-event-details-textual" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="sava-20241231.xsd#sava_NoteToFinancialStatementDetailsTextual" xlink:label="sava_NoteToFinancialStatementDetailsTextual" xlink:type="locator"/>
    <link:loc xlink:href="sava-20241231.xsd#sava_WorkforceReductionMember" xlink:label="sava_WorkforceReductionMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScenarioForecastMember" xlink:label="srt_ScenarioForecastMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringAndRelatedCostExpectedCost1" xlink:label="us-gaap_RestructuringAndRelatedCostExpectedCost1-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated" xlink:label="us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent" xlink:label="us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringCostAndReserveAxis" xlink:label="us-gaap_RestructuringCostAndReserveAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfRestructuringDomain" xlink:label="us-gaap_TypeOfRestructuringDomain" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sava_NoteToFinancialStatementDetailsTextual" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestructuringCostAndReserveAxis" xlink:to="us-gaap_TypeOfRestructuringDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_RestructuringCostAndReserveAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestructuringCostAndReserveAxis" xlink:to="sava_WorkforceReductionMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsequentEventTypeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_StatementScenarioAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioForecastMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated-2" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent-2" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_RestructuringAndRelatedCostExpectedCost1-2" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cassavasciences.com/20241231/role/statement-note-2-summary-of-significant-accounting-policies-quantitative-information-of-warrants-details" xlink:href="sava-20241231.xsd#statement-note-2-summary-of-significant-accounting-policies-quantitative-information-of-warrants-details" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.cassavasciences.com/20241231/role/statement-note-2-summary-of-significant-accounting-policies-quantitative-information-of-warrants-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="sava-20241231.xsd#sava_WarrantsToPurchaseCommonStockMember" xlink:label="sava_WarrantsToPurchaseCommonStockMember" xlink:type="locator"/>
    <link:loc xlink:href="sava-20241231.xsd#sava_statement-statement-note-2-summary-of-significant-accounting-policies-quantitative-information-of-warrants-details" xlink:label="sava_statement-statement-note-2-summary-of-significant-accounting-policies-quantitative-information-of-warrants-details" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputConversionPriceMember" xlink:label="us-gaap_MeasurementInputConversionPriceMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputExercisePriceMember" xlink:label="us-gaap_MeasurementInputExercisePriceMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputExpectedDividendRateMember" xlink:label="us-gaap_MeasurementInputExpectedDividendRateMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputExpectedTermMember" xlink:label="us-gaap_MeasurementInputExpectedTermMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputPriceVolatilityMember" xlink:label="us-gaap_MeasurementInputPriceVolatilityMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:label="us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputSharePriceMember" xlink:label="us-gaap_MeasurementInputSharePriceMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="us-gaap_MeasurementInputTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="us-gaap_MeasurementInputTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:label="us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sava_statement-statement-note-2-summary-of-significant-accounting-policies-quantitative-information-of-warrants-details" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputTypeDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="sava_WarrantsToPurchaseCommonStockMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_MeasurementInputTypeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputExercisePriceMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputConversionPriceMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputSharePriceMember" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputPriceVolatilityMember" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputExpectedTermMember" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputExpectedDividendRateMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cassavasciences.com/20241231/role/statement-note-6-intangible-assets-amortization-expense-for-finitelived-intangible-assets-details" xlink:href="sava-20241231.xsd#statement-note-6-intangible-assets-amortization-expense-for-finitelived-intangible-assets-details" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.cassavasciences.com/20241231/role/statement-note-6-intangible-assets-amortization-expense-for-finitelived-intangible-assets-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="sava-20241231.xsd#sava_statement-statement-note-6-intangible-assets-amortization-expense-for-finitelived-intangible-assets-details" xlink:label="sava_statement-statement-note-6-intangible-assets-amortization-expense-for-finitelived-intangible-assets-details" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet-3" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sava_statement-statement-note-6-intangible-assets-amortization-expense-for-finitelived-intangible-assets-details" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths-2" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo-2" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree-2" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNet-3" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cassavasciences.com/20241231/role/statement-note-7-stockholders-equity-and-stockbased-compensation-stock-option-and-performance-award-activity-details" xlink:href="sava-20241231.xsd#statement-note-7-stockholders-equity-and-stockbased-compensation-stock-option-and-performance-award-activity-details" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.cassavasciences.com/20241231/role/statement-note-7-stockholders-equity-and-stockbased-compensation-stock-option-and-performance-award-activity-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="sava-20241231.xsd#sava_statement-statement-note-7-stockholders-equity-and-stockbased-compensation-stock-option-and-performance-award-activity-details" xlink:label="sava_statement-statement-note-7-stockholders-equity-and-stockbased-compensation-stock-option-and-performance-award-activity-details" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PerformanceSharesMember" xlink:label="us-gaap_PerformanceSharesMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod-n8" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber-4" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber-5" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sava_statement-statement-note-7-stockholders-equity-and-stockbased-compensation-stock-option-and-performance-award-activity-details" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AwardTypeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_PerformanceSharesMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber-4" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod-n8" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber-5" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cassavasciences.com/20241231/role/statement-note-13-warrant-dividend-distribution-changes-in-warrants-outstanding-and-warrant-liability-details" xlink:href="sava-20241231.xsd#statement-note-13-warrant-dividend-distribution-changes-in-warrants-outstanding-and-warrant-liability-details" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.cassavasciences.com/20241231/role/statement-note-13-warrant-dividend-distribution-changes-in-warrants-outstanding-and-warrant-liability-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="sava-20241231.xsd#sava_ClassOfWarrantOrRightExercisedDuringPeriod" xlink:label="sava_ClassOfWarrantOrRightExercisedDuringPeriod-n9" xlink:type="locator"/>
    <link:loc xlink:href="sava-20241231.xsd#sava_ClassOfWarrantsOrRightsCommonStockWarrantsRedeemed" xlink:label="sava_ClassOfWarrantsOrRightsCommonStockWarrantsRedeemed-n9" xlink:type="locator"/>
    <link:loc xlink:href="sava-20241231.xsd#sava_ExerciseOfWarrantsResultingInDecreaseInWarrantLiability" xlink:label="sava_ExerciseOfWarrantsResultingInDecreaseInWarrantLiability-n9" xlink:type="locator"/>
    <link:loc xlink:href="sava-20241231.xsd#sava_WarrantsToPurchaseCommonStockMember" xlink:label="sava_WarrantsToPurchaseCommonStockMember" xlink:type="locator"/>
    <link:loc xlink:href="sava-20241231.xsd#sava_statement-statement-note-13-warrant-dividend-distribution-changes-in-warrants-outstanding-and-warrant-liability-details" xlink:label="sava_statement-statement-note-13-warrant-dividend-distribution-changes-in-warrants-outstanding-and-warrant-liability-details" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding-4" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding-5" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="us-gaap_FairValueAdjustmentOfWarrants-n8" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="us-gaap_FairValueAdjustmentOfWarrants-n9" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantsAndRightsOutstanding" xlink:label="us-gaap_WarrantsAndRightsOutstanding" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantsAndRightsOutstanding" xlink:label="us-gaap_WarrantsAndRightsOutstanding-4" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantsAndRightsOutstanding" xlink:label="us-gaap_WarrantsAndRightsOutstanding-5" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sava_statement-statement-note-13-warrant-dividend-distribution-changes-in-warrants-outstanding-and-warrant-liability-details" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="sava_WarrantsToPurchaseCommonStockMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding-4" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_WarrantsAndRightsOutstanding-4" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="sava_ClassOfWarrantOrRightExercisedDuringPeriod-n9" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="sava_ExerciseOfWarrantsResultingInDecreaseInWarrantLiability-n9" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_FairValueAdjustmentOfWarrants-n9" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_FairValueAdjustmentOfWarrants-n8" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="sava_ClassOfWarrantsOrRightsCommonStockWarrantsRedeemed-n9" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding-5" xlink:type="arc"/>
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_WarrantsAndRightsOutstanding-5" xlink:type="arc"/>
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding" xlink:type="arc"/>
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_WarrantsAndRightsOutstanding" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cassavasciences.com/20241231/role/statement-consolidated-statements-of-operations-" xlink:href="sava-20241231.xsd#statement-consolidated-statements-of-operations-" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.cassavasciences.com/20241231/role/statement-consolidated-statements-of-operations-" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="us-gaap_FairValueAdjustmentOfWarrants-n8" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:label="us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss-3" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted-3" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses-3" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss-3" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockDividendsAndOtherAdjustments" xlink:label="us-gaap_PreferredStockDividendsAndOtherAdjustments-n8" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingExpensesAbstract" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpense" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_GeneralAndAdministrativeExpense" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpenses-3" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingIncomeLoss-3" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OtherNonoperatingIncomeExpense" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_FairValueAdjustmentOfWarrants-n8" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_NetIncomeLoss-3" xlink:type="arc"/>
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc"/>
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_EarningsPerShareBasic" xlink:type="arc"/>
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_NetIncomeLoss" xlink:type="arc"/>
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_PreferredStockDividendsAndOtherAdjustments-n8" xlink:type="arc"/>
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted-3" xlink:type="arc"/>
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="arc"/>
    <link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_EarningsPerShareDiluted" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cassavasciences.com/20241231/role/statement-consolidated-statements-of-cash-flows" xlink:href="sava-20241231.xsd#statement-consolidated-statements-of-cash-flows" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.cassavasciences.com/20241231/role/statement-consolidated-statements-of-cash-flows" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="sava-20241231.xsd#sava_DerecognitionOfWarrantLiabilitiesThroughExercises" xlink:label="sava_DerecognitionOfWarrantLiabilitiesThroughExercises-1" xlink:type="locator"/>
    <link:loc xlink:href="sava-20241231.xsd#sava_IncreaseDecreaseInDevelopmentExpense" xlink:label="sava_IncreaseDecreaseInDevelopmentExpense-2" xlink:type="locator"/>
    <link:loc xlink:href="sava-20241231.xsd#sava_IncreaseDecreaseInOperatingLeaseRightOfUseAssetsAndLiabilitiesNet" xlink:label="sava_IncreaseDecreaseInOperatingLeaseRightOfUseAssetsAndLiabilitiesNet-n8" xlink:type="locator"/>
    <link:loc xlink:href="sava-20241231.xsd#sava_IssuanceOfWarrantsResultingInRecognitionOfWarrantLiabilities" xlink:label="sava_IssuanceOfWarrantsResultingInRecognitionOfWarrantLiabilities" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="us-gaap_AmortizationOfIntangibleAssets" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:label="us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations-4" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations-5" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect-3" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="us-gaap_FairValueAdjustmentOfWarrants" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingLiabilities-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets-n8" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities-3" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities-3" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities-3" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment-n8" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="us-gaap_ProceedsFromWarrantExercises" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetIncomeLoss" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensation-2" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_FairValueAdjustmentOfWarrants" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_Depreciation" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AmortizationOfIntangibleAssets" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets-n8" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="sava_IncreaseDecreaseInOperatingLeaseRightOfUseAssetsAndLiabilitiesNet-n8" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable-2" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="sava_IncreaseDecreaseInDevelopmentExpense-2" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities-2" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOtherOperatingLiabilities-2" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities-3" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment-n8" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities-3" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromStockOptionsExercised" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromWarrantExercises" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities-3" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect-3" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations-4" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations-5" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="sava_IssuanceOfWarrantsResultingInRecognitionOfWarrantLiabilities" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="sava_DerecognitionOfWarrantLiabilitiesThroughExercises-1" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cassavasciences.com/20241231/role/statement-note-3-prepaid-expenses-and-other-current-assets-prepaid-expenses-and-other-current-assets-details" xlink:href="sava-20241231.xsd#statement-note-3-prepaid-expenses-and-other-current-assets-prepaid-expenses-and-other-current-assets-details" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.cassavasciences.com/20241231/role/statement-note-3-prepaid-expenses-and-other-current-assets-prepaid-expenses-and-other-current-assets-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="sava-20241231.xsd#sava_statement-statement-note-3-prepaid-expenses-and-other-current-assets-prepaid-expenses-and-other-current-assets-details" xlink:label="sava_statement-statement-note-3-prepaid-expenses-and-other-current-assets-prepaid-expenses-and-other-current-assets-details" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DepositContractsAssets" xlink:label="us-gaap_DepositContractsAssets" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestReceivableCurrent" xlink:label="us-gaap_InterestReceivableCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAssetsCurrent" xlink:label="us-gaap_OtherAssetsCurrent-1" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent-3" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidInsurance" xlink:label="us-gaap_PrepaidInsurance" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sava_statement-statement-note-3-prepaid-expenses-and-other-current-assets-prepaid-expenses-and-other-current-assets-details" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PrepaidInsurance" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DepositContractsAssets" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_InterestReceivableCurrent" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherAssetsCurrent-1" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent-3" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cassavasciences.com/20241231/role/statement-note-5-property-and-equipment-components-of-property-and-equipment-details" xlink:href="sava-20241231.xsd#statement-note-5-property-and-equipment-components-of-property-and-equipment-details" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.cassavasciences.com/20241231/role/statement-note-5-property-and-equipment-components-of-property-and-equipment-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="sava-20241231.xsd#sava_statement-statement-note-5-property-and-equipment-components-of-property-and-equipment-details" xlink:label="sava_statement-statement-note-5-property-and-equipment-components-of-property-and-equipment-details" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment-n8" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BuildingImprovementsMember" xlink:label="us-gaap_BuildingImprovementsMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BuildingMember" xlink:label="us-gaap_BuildingMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConstructionInProgressMember" xlink:label="us-gaap_ConstructionInProgressMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="us-gaap_FurnitureAndFixturesMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LandMember" xlink:label="us-gaap_LandMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet-3" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sava_statement-statement-note-5-property-and-equipment-components-of-property-and-equipment-details" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_LandMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_BuildingMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_BuildingImprovementsMember" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_LeaseholdImprovementsMember" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_FurnitureAndFixturesMember" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_ConstructionInProgressMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment-n8" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentNet-3" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cassavasciences.com/20241231/role/statement-note-6-intangible-assets-components-of-intangible-assets-details" xlink:href="sava-20241231.xsd#statement-note-6-intangible-assets-components-of-intangible-assets-details" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.cassavasciences.com/20241231/role/statement-note-6-intangible-assets-components-of-intangible-assets-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="sava-20241231.xsd#sava_LeasingCommissionsAndOtherMember" xlink:label="sava_LeasingCommissionsAndOtherMember" xlink:type="locator"/>
    <link:loc xlink:href="sava-20241231.xsd#sava_statement-statement-note-6-intangible-assets-components-of-intangible-assets-details" xlink:label="sava_statement-statement-note-6-intangible-assets-components-of-intangible-assets-details" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization-n8" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsGross" xlink:label="us-gaap_FiniteLivedIntangibleAssetsGross" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet-3" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeasesAcquiredInPlaceMember" xlink:label="us-gaap_LeasesAcquiredInPlaceMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sava_statement-statement-note-6-intangible-assets-components-of-intangible-assets-details" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_LeasesAcquiredInPlaceMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="sava_LeasingCommissionsAndOtherMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsGross" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization-n8" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNet-3" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cassavasciences.com/20241231/role/statement-note-9-income-taxes-schedule-of-effective-income-tax-reconciliation-details" xlink:href="sava-20241231.xsd#statement-note-9-income-taxes-schedule-of-effective-income-tax-reconciliation-details" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.cassavasciences.com/20241231/role/statement-note-9-income-taxes-schedule-of-effective-income-tax-reconciliation-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="sava-20241231.xsd#sava_EffectiveIncomeTaxRateReconciliationChangeInFairValueOfWarrantLiabilities" xlink:label="sava_EffectiveIncomeTaxRateReconciliationChangeInFairValueOfWarrantLiabilities" xlink:type="locator"/>
    <link:loc xlink:href="sava-20241231.xsd#sava_EffectiveIncomeTaxRateReconciliationSection162mLimitationPercent" xlink:label="sava_EffectiveIncomeTaxRateReconciliationSection162mLimitationPercent" xlink:type="locator"/>
    <link:loc xlink:href="sava-20241231.xsd#sava_EffectiveIncomeTaxRateReconciliationTaxAttributeExpirationPercent" xlink:label="sava_EffectiveIncomeTaxRateReconciliationTaxAttributeExpirationPercent" xlink:type="locator"/>
    <link:loc xlink:href="sava-20241231.xsd#sava_EffectiveIncomeTaxRateReconciliationTaxCreditResearchAndDevelopmentPercent" xlink:label="sava_EffectiveIncomeTaxRateReconciliationTaxCreditResearchAndDevelopmentPercent" xlink:type="locator"/>
    <link:loc xlink:href="sava-20241231.xsd#sava_statement-statement-note-9-income-taxes-schedule-of-effective-income-tax-reconciliation-details" xlink:label="sava_statement-statement-note-9-income-taxes-schedule-of-effective-income-tax-reconciliation-details" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations-3" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxContingencies" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxContingencies" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlements" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlements-n8" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sava_statement-statement-note-9-income-taxes-schedule-of-effective-income-tax-reconciliation-details" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost-2" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="sava_EffectiveIncomeTaxRateReconciliationTaxCreditResearchAndDevelopmentPercent" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="sava_EffectiveIncomeTaxRateReconciliationSection162mLimitationPercent" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxContingencies" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="sava_EffectiveIncomeTaxRateReconciliationTaxAttributeExpirationPercent" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="sava_EffectiveIncomeTaxRateReconciliationChangeInFairValueOfWarrantLiabilities" xlink:type="arc"/>
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlements-n8" xlink:type="arc"/>
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" xlink:type="arc"/>
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="arc"/>
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations-3" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cassavasciences.com/20241231/role/statement-note-9-income-taxes-schedule-of-unrecognized-tax-benefits-details" xlink:href="sava-20241231.xsd#statement-note-9-income-taxes-schedule-of-unrecognized-tax-benefits-details" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.cassavasciences.com/20241231/role/statement-note-9-income-taxes-schedule-of-unrecognized-tax-benefits-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="sava-20241231.xsd#sava_statement-statement-note-9-income-taxes-schedule-of-unrecognized-tax-benefits-details" xlink:label="sava_statement-statement-note-9-income-taxes-schedule-of-unrecognized-tax-benefits-details" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="us-gaap_UnrecognizedTaxBenefits-4" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="us-gaap_UnrecognizedTaxBenefits-5" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations" xlink:label="us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations-n8" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sava_statement-statement-note-9-income-taxes-schedule-of-unrecognized-tax-benefits-details" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_UnrecognizedTaxBenefits-4" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations-n8" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_UnrecognizedTaxBenefits-5" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cassavasciences.com/20241231/role/statement-note-2-summary-of-significant-accounting-policies-summary-of-codm-segments-details" xlink:href="sava-20241231.xsd#statement-note-2-summary-of-significant-accounting-policies-summary-of-codm-segments-details" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.cassavasciences.com/20241231/role/statement-note-2-summary-of-significant-accounting-policies-summary-of-codm-segments-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="sava-20241231.xsd#sava_CodmMonitoringMember" xlink:label="sava_CodmMonitoringMember" xlink:type="locator"/>
    <link:loc xlink:href="sava-20241231.xsd#sava_statement-statement-note-2-summary-of-significant-accounting-policies-summary-of-codm-segments-details" xlink:label="sava_statement-statement-note-2-summary-of-significant-accounting-policies-summary-of-codm-segments-details" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentDomain" xlink:label="us-gaap_SegmentDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingOtherItemAmount" xlink:label="us-gaap_SegmentReportingOtherItemAmount" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementBusinessSegmentsAxis" xlink:label="us-gaap_StatementBusinessSegmentsAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sava_statement-statement-note-2-summary-of-significant-accounting-policies-summary-of-codm-segments-details" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementBusinessSegmentsAxis" xlink:to="us-gaap_SegmentDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementBusinessSegmentsAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementBusinessSegmentsAxis" xlink:to="sava_CodmMonitoringMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ResearchAndDevelopmentExpense-2" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_GeneralAndAdministrativeExpense" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SegmentReportingOtherItemAmount" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cassavasciences.com/20241231/role/statement-note-2-significant-accounting-policies-calculation-of-net-loss-per-share-details" xlink:href="sava-20241231.xsd#statement-note-2-significant-accounting-policies-calculation-of-net-loss-per-share-details" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.cassavasciences.com/20241231/role/statement-note-2-significant-accounting-policies-calculation-of-net-loss-per-share-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="sava-20241231.xsd#sava_statement-statement-note-2-significant-accounting-policies-calculation-of-net-loss-per-share-details" xlink:label="sava_statement-statement-note-2-significant-accounting-policies-calculation-of-net-loss-per-share-details" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DilutiveSecurities" xlink:label="us-gaap_DilutiveSecurities-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted-3" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:label="us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding-3" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic-2" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sava_statement-statement-note-2-significant-accounting-policies-calculation-of-net-loss-per-share-details" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_EmployeeStockOptionMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_WarrantMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss-2" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic-2" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EarningsPerShareBasic-2" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DilutiveSecurities-2" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted-3" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment-2" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding-3" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EarningsPerShareDiluted-2" xlink:type="arc"/>
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount-2" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cassavasciences.com/20241231/role/statement-note-4-real-property-and-other-income-expense-components-of-other-income-net-details" xlink:href="sava-20241231.xsd#statement-note-4-real-property-and-other-income-expense-components-of-other-income-net-details" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.cassavasciences.com/20241231/role/statement-note-4-real-property-and-other-income-expense-components-of-other-income-net-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="sava-20241231.xsd#sava_statement-statement-note-4-real-property-and-other-income-expense-components-of-other-income-net-details" xlink:label="sava_statement-statement-note-4-real-property-and-other-income-expense-components-of-other-income-net-details" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNonoperatingExpense" xlink:label="us-gaap_OtherNonoperatingExpense-n8" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNonoperatingIncome" xlink:label="us-gaap_OtherNonoperatingIncome" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense-3" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sava_statement-statement-note-4-real-property-and-other-income-expense-components-of-other-income-net-details" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherNonoperatingIncome" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherNonoperatingExpense-n8" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherNonoperatingIncomeExpense-3" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cassavasciences.com/20241231/role/statement-note-7-stockholders-equity-and-stockbased-compensation-stockbased-compensation-expense-details" xlink:href="sava-20241231.xsd#statement-note-7-stockholders-equity-and-stockbased-compensation-stockbased-compensation-expense-details" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.cassavasciences.com/20241231/role/statement-note-7-stockholders-equity-and-stockbased-compensation-stockbased-compensation-expense-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="sava-20241231.xsd#sava_statement-statement-note-7-stockholders-equity-and-stockbased-compensation-stockbased-compensation-expense-details" xlink:label="sava_statement-statement-note-7-stockholders-equity-and-stockbased-compensation-stockbased-compensation-expense-details" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sava_statement-statement-note-7-stockholders-equity-and-stockbased-compensation-stockbased-compensation-expense-details" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_IncomeStatementLocationAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cassavasciences.com/20241231/role/statement-note-9-income-taxes-schedule-of-deferred-tax-assets-and-liabilities-details" xlink:href="sava-20241231.xsd#statement-note-9-income-taxes-schedule-of-deferred-tax-assets-and-liabilities-details" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.cassavasciences.com/20241231/role/statement-note-9-income-taxes-schedule-of-deferred-tax-assets-and-liabilities-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="sava-20241231.xsd#sava_DeferredTaxAssetsCapitalizedResearchAndDevelopmentExpenses" xlink:label="sava_DeferredTaxAssetsCapitalizedResearchAndDevelopmentExpenses" xlink:type="locator"/>
    <link:loc xlink:href="sava-20241231.xsd#sava_statement-statement-note-9-income-taxes-schedule-of-deferred-tax-assets-and-liabilities-details" xlink:label="sava_statement-statement-note-9-income-taxes-schedule-of-deferred-tax-assets-and-liabilities-details" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredIncomeTaxLiabilities" xlink:label="us-gaap_DeferredIncomeTaxLiabilities-n10" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross-3" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet-3" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="us-gaap_DeferredTaxAssetsNet-3" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="us-gaap_DeferredTaxAssetsOther-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance-n8" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxLiabilitiesLeasingArrangements" xlink:label="us-gaap_DeferredTaxLiabilitiesLeasingArrangements-n8" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sava_statement-statement-note-9-income-taxes-schedule-of-deferred-tax-assets-and-liabilities-details" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost-2" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="sava_DeferredTaxAssetsCapitalizedResearchAndDevelopmentExpenses" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DeferredTaxAssetsOther-2" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DeferredTaxAssetsGross-3" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance-n8" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DeferredTaxAssetsNet-3" xlink:type="arc"/>
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DeferredTaxLiabilitiesLeasingArrangements-n8" xlink:type="arc"/>
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DeferredIncomeTaxLiabilities-n10" xlink:type="arc"/>
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DeferredTaxAssetsLiabilitiesNet-3" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cassavasciences.com/20241231/role/statement-consolidated-balance-sheets" xlink:href="sava-20241231.xsd#statement-consolidated-balance-sheets" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.cassavasciences.com/20241231/role/statement-consolidated-balance-sheets" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="sava-20241231.xsd#sava_AccruedDevelopmentExpenseCurrent" xlink:label="sava_AccruedDevelopmentExpenseCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets-3" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent-3" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities-3" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity-3" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent-3" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="us-gaap_OtherLiabilitiesCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="us-gaap_OtherLiabilitiesNoncurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity-3" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AssetsCurrentAbstract" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrent-3" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_Assets-3" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LiabilitiesCurrentAbstract" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="sava_AccruedDevelopmentExpenseCurrent" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_OtherLiabilitiesCurrent" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrent-3" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_OtherLiabilitiesNoncurrent" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_Liabilities-3" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_CommitmentsAndContingencies" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquityAbstract" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_PreferredStockValue" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_CommonStockValue" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AdditionalPaidInCapital" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit-2" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquity-3" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity-3" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cassavasciences.com/20241231/role/statement-consolidated-statements-of-stockholders-equity" xlink:href="sava-20241231.xsd#statement-consolidated-statements-of-stockholders-equity" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.cassavasciences.com/20241231/role/statement-consolidated-statements-of-stockholders-equity" xlink:type="extended">
    <link:loc xlink:href="sava-20241231.xsd#sava_AdjustmentsToAdditionalPaidInCapitalDerecognitionOfWarrantLiabilitiesUponExerciseOfWarrants" xlink:label="sava_AdjustmentsToAdditionalPaidInCapitalDerecognitionOfWarrantLiabilitiesUponExerciseOfWarrants" xlink:type="locator"/>
    <link:loc xlink:href="sava-20241231.xsd#sava_StockIssuedDuringPeriodSharesWarrantExercises" xlink:label="sava_StockIssuedDuringPeriodSharesWarrantExercises" xlink:type="locator"/>
    <link:loc xlink:href="sava-20241231.xsd#sava_StockIssuedDuringPeriodValueWarrantExercises" xlink:label="sava_StockIssuedDuringPeriodValueWarrantExercises" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued-n8" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GranteeStatusAxis" xlink:label="us-gaap_GranteeStatusAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GranteeStatusDomain" xlink:label="us-gaap_GranteeStatusDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedPaymentArrangementEmployeeMember" xlink:label="us-gaap_ShareBasedPaymentArrangementEmployeeMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedPaymentArrangementNonemployeeMember" xlink:label="us-gaap_ShareBasedPaymentArrangementNonemployeeMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding-4" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding-5" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationForfeited" xlink:label="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationForfeited-n8" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationForfeited" xlink:label="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationForfeited-n8" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity-4" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity-5" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_GranteeStatusAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GranteeStatusAxis" xlink:to="us-gaap_ShareBasedPaymentArrangementEmployeeMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GranteeStatusAxis" xlink:to="us-gaap_ShareBasedPaymentArrangementNonemployeeMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_CommonStockMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_AdditionalPaidInCapitalMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_RetainedEarningsMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GranteeStatusAxis" xlink:to="us-gaap_GranteeStatusDomain" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding-4" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity-4" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationForfeited-n8" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationForfeited-n8" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="arc"/>
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:type="arc"/>
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" xlink:type="arc"/>
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued-n8" xlink:type="arc"/>
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="sava_StockIssuedDuringPeriodSharesWarrantExercises" xlink:type="arc"/>
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="sava_StockIssuedDuringPeriodValueWarrantExercises" xlink:type="arc"/>
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="sava_AdjustmentsToAdditionalPaidInCapitalDerecognitionOfWarrantLiabilitiesUponExerciseOfWarrants" xlink:type="arc"/>
    <link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding-5" xlink:type="arc"/>
    <link:presentationArc order="15" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity-5" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cassavasciences.com/20241231/role/statement-note-7-stockholders-equity-and-stockbased-compensation-stock-option-activity-details" xlink:href="sava-20241231.xsd#statement-note-7-stockholders-equity-and-stockbased-compensation-stock-option-activity-details" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.cassavasciences.com/20241231/role/statement-note-7-stockholders-equity-and-stockbased-compensation-stock-option-activity-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="sava-20241231.xsd#sava_statement-statement-note-7-stockholders-equity-and-stockbased-compensation-stock-option-activity-details" xlink:label="sava_statement-statement-note-7-stockholders-equity-and-stockbased-compensation-stock-option-activity-details" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod-n8" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber-4" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber-5" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice-4" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice-5" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised-n8" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sava_statement-statement-note-7-stockholders-equity-and-stockbased-compensation-stock-option-activity-details" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber-4" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice-4" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised-n8" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="arc"/>
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod-n8" xlink:type="arc"/>
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:type="arc"/>
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber-5" xlink:type="arc"/>
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice-5" xlink:type="arc"/>
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:type="arc"/>
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:type="arc"/>
    <link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:type="arc"/>
    <link:presentationArc order="15" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:type="arc"/>
    <link:presentationArc order="16" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="arc"/>
    <link:presentationArc order="17" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="arc"/>
    <link:presentationArc order="18" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:type="arc"/>
    <link:presentationArc order="19" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cassavasciences.com/20241231/role/statement-note-7-stockholders-equity-and-stockbased-compensation-schedule-of-stock-options-by-exercise-price-details" xlink:href="sava-20241231.xsd#statement-note-7-stockholders-equity-and-stockbased-compensation-schedule-of-stock-options-by-exercise-price-details" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.cassavasciences.com/20241231/role/statement-note-7-stockholders-equity-and-stockbased-compensation-schedule-of-stock-options-by-exercise-price-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="sava-20241231.xsd#sava_RangeFiveMember" xlink:label="sava_RangeFiveMember" xlink:type="locator"/>
    <link:loc xlink:href="sava-20241231.xsd#sava_RangeFourMember" xlink:label="sava_RangeFourMember" xlink:type="locator"/>
    <link:loc xlink:href="sava-20241231.xsd#sava_RangeOneMember" xlink:label="sava_RangeOneMember" xlink:type="locator"/>
    <link:loc xlink:href="sava-20241231.xsd#sava_RangeThreeMember" xlink:label="sava_RangeThreeMember" xlink:type="locator"/>
    <link:loc xlink:href="sava-20241231.xsd#sava_RangeTwoMember" xlink:label="sava_RangeTwoMember" xlink:type="locator"/>
    <link:loc xlink:href="sava-20241231.xsd#sava_statement-statement-note-7-stockholders-equity-and-stockbased-compensation-schedule-of-stock-options-by-exercise-price-details" xlink:label="sava_statement-statement-note-7-stockholders-equity-and-stockbased-compensation-schedule-of-stock-options-by-exercise-price-details" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions-1" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions-1" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1-1" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1-1" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2-1" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sava_statement-statement-note-7-stockholders-equity-and-stockbased-compensation-schedule-of-stock-options-by-exercise-price-details" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="sava_RangeOneMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="sava_RangeTwoMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="sava_RangeThreeMember" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="sava_RangeFourMember" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="sava_RangeFiveMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions-1" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2-1" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1-1" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions-1" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1-1" xlink:type="arc"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>cab1ac4300e0img001.jpg
<TEXT>
begin 644 cab1ac4300e0img001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" %4 FX# 2(  A$! Q$!_\0
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MT(.10%QU%)D>M&1ZT +13!+&S,JNI9>H!Z4[(]: %HHI,CUH 6BDR/6C(]:
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MM_$&CO')+>OY$TT)215.<,A/O6S\-)=<\/:C>>$-9LKAK>V8FROEA_=NOH6
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MJS.BI<5SG_"52_\ 0"U+_OV*/^$JE_Z 6I?]^Q3Y&.QT16C'O7._\)5+_P!
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MC%8'_"3R?] 74/\ O@4?\)/)_P! 74/^^!2YT5]6J]CH,8H-<_\ \)/)_P!
M74/^^!1_PD\O_0%U#_O@4<\0^K5>QOX]Z,<U@?\ "3R_] 74/^^!4UKK\ES<
M+$=*O8L_QNHP*7M(H3P]1:M&SSZT8]ZK_:SC_42?E2_:C_SPD_*I^L4^YFX,
ML 4M5OM1_P">$GY4?:V_YX2?E1]8I]PY66:*K?:V_P">$GY4?:S_ ,\)/RH]
MO3[ARLLTAI$;<H.",]C2FM4[ZHD,4E.HH ;12XHQ3 2C-+BC% "9-*.E+BB@
M!**6B@!**6B@!*.M+10 VC\#3J* &_@:/P-.HH 3 HI:* "BBB@ HHHH *3%
M*:\];Q]=V&L:Q;7%G)>[-6CT^R@@"JQ+1;^2>.N>: /03Q29->777Q&U"?4]
M#O-/TRZE@EBO%NM.#('$D) ;+'C YZ=:A\0_$"[DLKF^T>XN55K*RNHH#$G
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M[Z"Q&I:>(0"JPOD*K8[J<9^M;GP^US5;O5=6TW5;Z>?[/'!-#]KA$<I#K\S
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MY$6#P0#7?T %%%% !112;A0 'I7%>*-$MYO$NCN;B^C^VW#1SI%=.BL!&2.
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M%22$08&2<G]:GS0 M%)FEH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M57#12#*-D?D1VK$N?AE+J&MW,]_J4#V+?:#$L-HL<V9EP0[C[RC.1^M7="\
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M\1>'TAU_Q!-#)-,)9C/DP#R^"#CC)XYK>_X0.3_H;/$?_@6/_B: .RHKC?\
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MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ I#2TAH
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M:NNFBU6$^8VZ(.&W9[$XKG+;6KOQ3J%[-J-Y;71D\/73-:P(5^S,'^XW/+#
MYX- 'N)D0+N+ +ZD\4N:\VOI6?PO\/[5W/V>YO+19FS]\",LJGZD"N2M-7UV
MWNM3TZ*[NY3XCOKBVM)"Q/V62.4J^/0>7R,>E 'NVY=VW<-V,XSS2UY)X-GN
M$U7P3)Y\TLESI][!<-*Q+.D;Y4G/<$=?>O6Z "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ I#2TAH 6BBB@ I,T'D5QDGC0Z9>:V=0C:2VL[R*VA6"/+_.._//--)L+G
M:45C:+XC@UFXO+86UQ:W-HP$L-PN& (R#QV-4Y/&EC#KD>F36MU'YLWD1SNH
M"._H!G./?&*+,5T=)2UC:UXB@T9[> VUQ=7=QN\JVMUW.P49)] !6=-XZT];
M>UE@M+VX>>$W!A2+#Q1@X+,#CH>U"3"Z.IS1FN"U?QI=1W.H/ISP/:QZ2E[
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MK/SX;F]N;R:=(1;P!2?+8C&,_K5P>.K"2SLY;>TO)KFZE>)+1(QYH9/O9&<
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M\2Z=H3*EWYY+*9"(86?:HZLV.@HN[A96,63P??V=PTFCW]M L]D+2X66$D<
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M;+^UOLBVM['/DQR[3\K @9!KN^*.*?,PLCBU\-Z[.VA3:CJ$-W<6=ZUS.Q&
M%(X1..<>]4YO UW=ZANNEM9K1]7>\DC9B=T13&",=<UZ!Q11S,+(X:+1]6\(
MVNKC14M7LGQ+9QR*=\;D_,IP.1Z<UM^(=+N=8T1;=+>TFE!5WBN<A2>^"O*G
MT-;U'X4KL+(X*#PGK9M]/6YN8G^S:B+A8C*S^5$!C8'898YYYIVG^#]1M8-
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JHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H-%% '__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>17
<FILENAME>cms.jpg
<TEXT>
begin 644 cms.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_X0 L17AI9@  34T *@    @  0$Q  (
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MS:NKI/9M;J_3N245%Y\6W=OP.^0P8<9PRD!E/LP!!XQF@3Q'.&Z=20P'?G)
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ME-M>XU>-VK7=V]+_ (M=TUU-_:0LKS@I6]Y<RT?5=/QU)J*B\Z(C(?/T!/\
M(>U'G1_WL8]0P_I3Y9?RO[F'M(?SP_\  E_F2T5%Y\7]_CUPV/SQBE$J$ @D
M@]"%8C\P*+/L_N'SQ>THOYHDHIF]>N?S!'\Q1O7&<\?0_P L4M>P<\?YH_>A
M]%1F6,=7 ^O'Z'%)YT/_ #U3_OH?XT[2>R;^3#GC_-'[U_F2T5%YT7_/1/\
MOH4OFQ_\]%_,'^5'++^5_<PYX_S1^]?YDE%1>?#T\U,CK\PI1+&W1P><<&BT
MNS^Y_P!=0YHO:4?O1)14?FQC^,?J?Y4>;'W8#_>RN?INQGZ]#VHL^S^X?,NZ
M^\DHIN]/[R_]]#_&C>O]ZBS[/[OZ[H+KNAU%,\Q/[PH\R/\ OI_WT/\ &BS[
M/[OZ[K[PNNZ_K_AT/HI-P]1^8I-Z_P!Y?S%%GV?W?UW0[_U_7JOO'44W>O\
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MPHUM<^1:+?>)/"&M^"-4&IVRAUU& Z%XAU);9':$VUX8IP9%3;7I(1BB9RI
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MXF?$'Q5:6UGH]M>%;M;_ .(/C/Q$F@6EO:7-[-<7&FSZ3'+%&9KV0M81O#]
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MQ=\.KNVUK5+Z7P'X[^-4?Q27XK>*+"5_"V7N-9CL_@O!ITL%J+C3)+WQC?P
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M^OW4T/ANUTOPZ]E-9WUOI&E7M_?Z;:_8HC)10<JP.>N_G !YSD@D9!.#C&X
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M[>_U_2C^U,9_-1_\(L/_ /*O)?</^R\/_-6_\'5O_EGK_2U^.O\ AFCXI?\
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M+4O#&G>()59M2M/#VL7]EJFJ:3%*"%6RO+_3[*XFMBC"22VB8RKMVUWX'/\
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M]FO?#GA-Y;7P_%JEQ<6QURPMH=+'ASPV-.T/2OC7X8_\$]_VX/AQ/\2/$_\
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M %%%% !1110 4444 !Y&*;M&!VQW''^?6G44 -V+Z?J:-J^E.HH ;M'^0/\
M"C:OI_3^6*=10 @&.@Q_7WXI:** "BBB@ HHHH **** "BBB@ HHHH ****
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M_LZLKX7:W[<]LZJ!ACOW_!=@P=@ 610\8"% 6!-9]_\ '/\ X*C:LEI'JO\
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MW^OY>_M]/SK\ES^T;_P5<)X_X)^?L[G/<_MSP)R>N%'P98*,YP-QP,9.:/\
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M'WPT^#_P;^(DNIZ+XLT[P-=^'=,\0Z_>Z)XYU?P<]]X#U#Q!\0/$,):UN_\
MA&=>U#PEHL%M:R0VNMIJ,Z6;<[X=_P""C'Q@T?Q_KU[XHU2]\8^%M(^*G[7Y
MT7PW::;X&\)6NH_#_P"#GPKT'QYX-\.Z[?GP=K/B&&Z#:DWDZMHNI:=>&YD>
M/6AK=O$MO7GOQ"_:B_X)F?&#X@7/Q-\??LV_&'7/&.HVGA32]8NK?7-6\/Z%
MX@T7P3>MJ7AK0?$O@[PM\8=&\&^)=!T[4<7W]B:_X=U/2KV[C@GO[*YEMX9$
MU+C]I#_@FQJNJ:GJUW^S?\5Y;_7=8^)WB#5)3J5Y:I/JWQBT&W\,?$.=;:V^
M+<5O;CQ!X?M8-.6UMH4M]'2-9]"&FW&)*B'C5X40253B3 .3A=1J2J:**C=Z
M-:W;=THI+E5M.9O_ (@OXKM^YPEFZ:GJXT+7WT^%]%MS-MZWM=+Z%MO^"KGC
M>/3K/2?$_P"R]INC_$KQUX3_ &>_%OP9\)Z;\<+36_#WBNU_:$U$:7H5GXW\
M77'PVTS_ (0*70KH-<ZS_9N@>-(UL#$UA+<7YDM$^H/V$/CI\8_C4/VG5^-U
MOIFD^(?AI^TCXR^&^E>&-&GTG5-.\'Z%H^C:1<0:';^)M)T;P]+XLM5N+F:>
MS\0:UH^FZM>0W$:W%I!+%Y8_.W6/CW_P3:\7:?+I>N?LV_$R^MI_AUX%^%,7
MF:G?6]YI_@SX8:A%JOP^M=$U:U^*BZKH&N>%K^&.\TKQGHUY8>,HYUW3>()6
M+$I\._C9^PI\*_'OP_\ ''PK^%WQC\%OX%\1?$CQ?)I\NIWOB6?Q1XK^)^B6
MN@^(];\1:SXK^*VOWE[/+;6D=RYN([JZGOP;MM0B=Y4ERK>,_A6\/6C#B;+8
M3?L^5^TJ)Q5X2MS3E;6&MEKK?J=$/!?Q7=6E?@[.IW;?O89-.*W<5&.KYE:[
MWMI:S:^Q_'O_  4/\:>#/%?[4]I%\%? O_"N_P!F#Q5X:\ W_CKQ;\>CX1O/
M&?C7QMINFWOA;2-+\--\,]?DM+5Y]0%KJ+6>JZYX@ED6"#PUX9U^_G^PQ^3>
M&_\ @JO\2?'>E_#K3_"7[*^GS_$CQ;JW[1FAZWX3\8?&/6? NC^&K[]G32HM
M<U>]74O$/P8'BN\TWQ'ITBRZ?%K/P^\+^(M-F:**\T@)+]H3E?$_[0/["'C[
M3?BSI/B3X#?$?4++XX>+?#_C[XE/'J=_IM[JGC3PK!:V_AOQ3I&K:7\3;;5_
M!^N:*EE:_P!G:CX)OO#D]G/"EW$#<$SU0\"?$+_@GMX#OM'U7PC^S[\1]+U#
M0[OXD:AI=W<>(M=U:6"]^+VEIHGQ)U":?6/BEJ$VH:AXKL$SJEWJ4MW=B[>;
M4K2XAU2:6Z>\/XR^%E2$HOB3+ZM244Z?+7:27LK7>KNG-N6FZ79&>(\&O%:F
MY-\)YK2CS-2_V2[T=VK<NEH\M_/K9Q*GQ;_X*G_&#Q_\$O%OB[]FOX3V?A3_
M (1'P%\!O%OC_P"(7BKQOX>O]4\ :W\8O%FG:?!X>\-_#V_\%ZOI/Q#L--TY
M;^/5_$%YK/A)D2XMYM'L=1O$:%/9KW_@J?J.A6DGC>]^ LDWP0U7Q=\3?A7X
M!^)B?$JUC\6^*_BA\*_#%[K6J+XB^&">#99/"'@3Q)J.E:CI>CZ]:^*?$6N6
M<L(NM5\&:;9RQ2OX+JNG?\$S?$UAX;TW4/V9_B&FG^%?#/ASPAIEGIWC'QEH
M=KJ'A[P=K)\0>$;/Q3%H?Q:L(?&T_AC5V:Z\/:IXT@U_5]%\QX;+4(K=VC/>
M_P!J?\$]KOQKXD^(+?L[>+U\3^+K+Q5:ZN5U;6X_#L-WXYT;_A'_ !;XAT+P
M9#\1X_!_ACQEXDT8?8-=\<>&=!TCQ??0@F35Y)6+GL7BUX8U.54LZP3?M)?\
MOIMN+4%&*=X^\I1E9ZV3<>6_O')+PE\4*>M3AO,XIQYD_J:5DN65W>#3CRJV
MG5JSWNVR_P""MOQ+-HFL>(_V1='TG0]/\)?L^_%#Q/=V/[0UIK$VD?#+]H+Q
M#:>&?#E_9V8^%.F/J_C?3-8NO.O_  R;BST,:2HF'C*2^=M/C6/_ (*0?''P
M?X3@U+0?A1H7[0'B#QG^UM\3/V>/!?@_7?BKI_@/XEZMJ7A_Q/%::98^!O"_
M@;X#:KH6O>%?#/AUI?$/BWQ)XDU72+WPU80L-6U'7)"EV^M->?L#W^E:EHMQ
M\ O&\NFZOX'^%WPYU"V?Q%XB(N?!GP:U:+7?ASHRSM\2C<QGP]JMO#=?;HY(
M=1U,+Y.M7>HQ$I7-ZOX'_P""=NO^(].\6S? WXNZ3XITG5_%^O:3XB\(_%OX
ML>!]:TO5O'VHQ:KXON]/U/P;\:- O+'^W+Z&*2\M;6YBM6C18%MQ 3"=8>*?
MAQ:\LYP;NGRVJ5'M9:^]MS;NZZ)V=V8R\*_$A?\ ,@S+1KFOA8JVBW]QI;OI
M?JM#J_\ A\AX1L/&GQ-TO7/@[K0\#?#ZU^*FGMXC\-Z[K_B+Q*WB[X1V%O-K
M%AXETF;X:Z9X'\,^%?%.LSS:#X)\2Q_$O7-0N[BVDN/$GAWPU$\49]E_91_:
M>_:$^,'[4_Q+\#?%_P &Z!\+O">G_LV_!OXM>%_A[X=\5Z5\0[?3[KQ_JVKR
MW&M2^/(?"'@[6[C49](CM+75-!N=.?2M*OK>0Z)?ZK%(=0F\QTR[_89TKQ7X
MG\8VGP*\:3ZCXTTCQ)HOB+2=5\1>)-9\$7T'C+38=)\::@OPZU?XDW_@+3O$
M/C33X(8O%OBO2O#=MXG\1NBS:SJ=[<%[AM7X&>(?V+OV;?$.M^+?@[\'?B+X
M9\0^(O#GA_P;K&J:EXO\4^-[V[\)^%IY[KP_H"-\0/B7XICLM)T1[F6#1[;3
MS9C3;3986JQ6,,,:%7Q/\/'3FZ6<X6GS0:YW*I*-[QUYK24>NKONMM6YAX9>
M("G"-7(LQ;N[16'CJ[+I97O>^C77=;>*>._VT?VRM0_9&A_:5^&\_P /]*\/
M>(?VB=9M+_Q'XCM]-FU/X?\ P?C^,FC_  X\*>"/!GA:+2IK3Q1XI\26DE[<
MZQXR\7:FEOHL+2+:VE]>R6T=K]_?M,?%']J[PG\,OC_J_P '_A/X @U'P1X,
MTW6_AS\3/'/C^";1=8M/^$'U/Q!X_P#%.J^!=,T6XUBROO %]8Q6&@>'[NXD
MA\97EQ;W$ESINE0W"/\ &GPVU']GKPS\$_&O[.OQ"\->*OB'\)-6^+OB3XD^
M$M#@LY?#=WH6CZGXUB\?Z#X;U74--\96MQ>7OAOQ(@FAO]*FLK&]M8HH9[8(
MTT,WMT_QW_9B;5_BQX@G^&GQ!EU3XY>&]-\(_$^8ZG=M%XE\/:1X>E\)V-BF
MGOXTETWP^L?A^XFL3>>&K?2=0N<_:;N>2]"W(RJ^)W D5!//L'%WJ3N_:6E"
M7)97MT2E?>S;OO<TI^&''U3GC#AW,ZTN:.GU=*TM.ZT;>EGV=D[669\"/VI/
MB_K'C3]@G3O'_B"S\1>'OVJ?V8/$?B#Q!"GAS1M+OK;XM^"+31/$-WXDM9-(
MMK4V6F^(-'UTV%WH<0;3;.:RMVL;99;BX+?2'[4G[3'C/X'>)/V?? GP[^$V
ME_%3QM^T#X[\0> _#]AK?Q%?X;Z)H-[H7AFX\2OJ^KZU%X.\;W)L3#;2V]Q'
M9Z1)>1Y1HH+ICY%?FY\07_9_\9:UX,TRQT[QEX7^$GPU_9L^(?[/W@+P+::4
M^IZGH4OQ+%II>L^*'UN\^(,-[=1Z7X7TS3M/T:%]0753J*7-U>Z@]I+]DE7X
M_>(O@5\;E_9,T#5+;XBP> OV:M?N=4U32'%YI?B?Q98KX$;P;H[>'?&GA#Q]
MH.O^#_$NEW,<6LQZ_9ZC#<PYDAM;M2[[E+Q0\/>>$WQ'@:<$VI0;G>5W)Q?*
MFFU:5/2\=%92N;1\+_$*"]G_ *LYC[2W,Y>P4ND6U9WLVU*U]4VKI;%FS_X*
ME^-]1\>3^-KS0=#\*^ ]$_9IU76?$/P;\7>+="TS3K7X_P"B_'J^^$5W9V_Q
MCB\,W^LZAH[2PQKHR:'X>N=3U^W"#3_ \VNSK:5Z;X)_X*D_$/XF:+X;\/?#
MG]E5M6^/-[JOQYCUWX6^)_BM>_#?0;#0/@!<:?:^(=1T_P 6>,?ACI.NMK/B
MBYU2VM?#/A[Q7\/O![I*LDOBJ]\.V2)=MYGJ$G_!."YT"P\-R?LT^,K?2=*^
M']G\,M-BTS6M:TF\T_PQI_BV3QW:W%IJ^F?$VRU:W\6Q>,I9?$B^/8[Q?',N
MHRS3S>("9#&_.:FW_!-:\\'_ /""W?[.GQ1/AU?$_BWQ<[6/CWQY8:_)K/Q
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MD\9AVDWHOM[K5-JUV[[M!"K9?Q:BUVAAJD7K9;N+W\NKU[+Q3PO\8_BYX/\
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MF2]EM]3.JV]W-<2+:MI_D+%=231_L3>_LK?\%"_@W\(OVZ?&/[0W[7=CX_\
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MNTTZPENH]-3^R=YB$UQI\)M;>^O%:[O5EN""<3X=^!-#?1?@X?"O@#PIXO\
M"GB;4_%L/QF\4:SHEAJFH^&FMM1U"(V+ZO>3K-X0M--LHH)-.,+VZ,XC2&%V
M.T>VO";"TIT:6 SJ=3W?;3G6A'G;K8? SA&EAJ4>;V4*N+ES5.>2A1A*37NG
MB?\ $<,6_K57,,FHPE"K4PU/#TIRC3I>RQF;TJKKXZMR1]K5P^61AA<.\-"4
M\16C&-5JK:E\*V5KE48#.2 -N]P2>=ORC=N'.Y>67!)4<UVVD:5/?W=G96<+
M7-Y>W-O96D$6XRSW5RXC@@B7O+(S8"Y'RY<D*I(^X/#^C^ -'A^!.D:3X/\
M!6L:3XT\?^*]!OM7UO0--UG4]1\/6=S=&TQ?WT,C"X;:C+J)W7Z+&GD,BG?7
MG?PLT32-._:7BTZ.*.UL-,\9^(%TFWPHA:YLH[K^RT)EM@TRPN66UD4(X*[6
MPH!;NAX=PR_%93AZN:4*ZQN-HX*M[&Z5*>(I1Q,ZD9WM.,E)N,DVKVMIMSQ\
M6)9Q@\YKT<HQ&&66Y3CLPPJQ$HJ=6EA<55PGLJ]/5T*BJ4U>#]HY0;=X2CKX
MC?>'[_0-5OM&U>!+34M,N'M+V#[3#.L%Q$H:2,W%M+/;/Y2D"1XIG1&RKMD$
M#J$\(:O#X?L_%$EF%T+4+Z;3;2Z-U;,T]]" TD(M5G-ZI"\JSVRQ2#&QV'3[
M&^#7AC0?$&D7LVO>&H;K5M3\?^)8M0UZY\,Z9XOM9";BY\NP\01(YU[P=9Q\
MM_:<#:?;9";+E=Q4['@+P#X12V\)6MQH_AO5O,^)7C;2KF^BL;348-1TVTMI
M#;P?;)XS=S6-NP M3<7$K1!=L3*<D_=X#PV7NUZ>,=+#8JE6>&4W&-7#U*57
MV=%3A.G-N/(E[2,?9R]I?WFK7_.\R\7Y1E.A4P/M<1@ZN$AB^12E1Q-%X:4\
M0J<Z=:,8OGB_8>TE7<:%HRBIQ:C\/163-R"C+G 8%2N>NW>"1G&!@\YR#DY
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MT'"4>=X/%5*,*T.;F?+.$$IQYY-3B[.RN<+J*JP((Z'D[CW_ )^@_I7]&_\
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MA[.YAD)]2:V3?R?ZIA];?_/R/W^GGYH^D/M[_P!YO^^3_P#'J7[>^0-S9.,
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M2VVCVLUR1;PSW[P0R2?)&Y(.'_9Z_E:_[=?7Y?(/K;_Y^1U\^_S\SZ1^WO\
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M'ZBOT5K\ZO\ @K3_ ,HVOVVL<G_AG'XF''TT*3_/\J]3(_\ D=90N^9X%/\
M\*:9Q9D[8#&OMA<0_2U&9<^&=^1\-OALH=>/AS\/ACH?^1*T-3P?]H$?AGH<
MUW'V\_WUZ <'C(&#^M>)_#:_ ^'/PZ&3Q\._A^.,8R/!VB>OOZ_RKM/[0'JW
MX8QSSVXK]"K8.U6::>LI62C=_%*[M_P#\^HXE^S731:-VZRZ_=_6W<?;S_?'
MY_\ UJ/MY_OC\_\ ZU</_:(]7H_M$>KUG]4?2,O_  '_ (#-?K3[K_P([?\
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M"1SU-3]2Z\LO_ ?TZ?<6L6]EHO6W_!.X^WG^^/S_ /K4?;S_ 'Q^?_UJX?\
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M4DU!7Q'3EBEV45=;'X]7C78D+&YO!E]X9[FZ;;(JA%DVJT9\Q5(5'293Y *
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MVSO)_P#L:8'\<33_ %M;S//S6_\ 9F86Z8/$O_RC,\@^'5^5^'OP_7=T\ >
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MH#X+O@I\4O ;#'&WQ=H1!^A^WX/IP<#VJ=?CQ\('Y7XF>!B/4>*]!QV]+_\
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M9-7TWUJGW7_@2/F_J]3^;\?^"<EYC?WA_P"/4>8W]X?^/5UO]A_],FH_L/\
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M+_AE;_@J\>3^T;^PSGO_ ,8V_%$_S^)S']37[:JK<9SCOSC\\?X?XT_:/?\
M,_Y]/RKZ9\;9Y)MR>&3NW:.$PEK2?-_SYM=-[=]M-O CPKE*WA6NKK2M4BMT
M]XS5_F]=GY?B/_PRK_P5=_Z.-_89_P#$;/BC_P#/,H_X95_X*N_]'&_L,_\
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M *A?_"7!^7_4/Z_UL?ZK93_)7_\ "BOY?]/?Z^;/Q&_X94_X*N_]'&_L-?\
MB-OQ1_\ GF_Y_ 4?\,J?\%7?^CC?V&O_ !&WXH__ #S?\_@*_;G'N?S;_P"*
M^O\ D<F/<_FW_P 5]?\ (Y/]=L]_ZA?_  EP?E_U#^O];'^JV4_R5_\ PHK^
M7_3W^OFS\1O^&5/^"KO_ $<;^PU_XC;\4?\ YYO^?P%'_#*G_!5W_HXW]AK_
M ,1M^*/_ ,\W_/X"OVYQ[G\V_P#BOK_D<F/<_FW_ ,5]?\CD_P!=L]_ZA?\
MPEP?E_U#^O\ 6Q_JME/\E?\ \**_E_T]_KYL_$;_ (94_P""KO\ T<;^PU_X
MC;\4?_GF_P"?P%'_  RI_P %7?\ HXW]AK_Q&WXH_P#SS?\ /X"OVYQ[G\V_
M^*^O^1R8]S^;?_%?7_(Y/]=L]_ZA?_"7!^7_ %#^O];'^JV4_P E?_PHK^7_
M $]_KYL_$;_AE3_@J[_T<;^PU_XC;\4?_GF_Y_ 4?\,J?\%7?^CC?V&O_$;?
MBC_\\W_/X"OVYQ[G\V_^*^O^1R8]S^;?_%?7_(Y/]=L]_P"H7_PEP?E_U#^O
M];'^JV4_R5__  HK^7_3W^OFS\1O^&5/^"KO_1QO[#7_ (C;\4?_ )YO^?P%
M-/[*O_!6 Y'_  T=^PT!V*_LW?%,$?\ F45'Z#UK]N\>Y_-O_BOK_D<QLC=5
M)!/^3U/?_/2FN-L\ZK"N^FN#P4NW>@ET>OGMV/\ 5?*M+0K;J]\16\N\Y?EY
M]S^6#]I?_@B3^VW^UEX^TCXB?%K]I3]FF/Q%H?A6V\'62^"_A1\1_#FEMH]M
MJ5YJD,EQ87?BK7B^H"[O)0]TDT0-OY<8CW FOG[_ (AKOVBSU_:6^"K#W\">
M/^O\153JN1\V<9?T.%^Z/[']G<KEO7<1^@/]:7:_Y>_\OR'X_G6=?C#.<2XR
MJ5*?N+EC&%*E326G2%.,>^SU_*J/#F6T8RC&-1)RNOWE2IIITGITW^7I_&[_
M ,0U?[10Z?M+?!7K]X^ _'RD?EJ[_P NE+_Q#6?M%G.?VE_@J/8>!?'Y''_<
M2!Y]Q7]D.UO\G_/H/T_!P#@8X_6N9\39H].96](>6WNZOU?GOH;+(L DTHSU
M5GS7VT\E_6O<_!?_ ()5?\$G/BI^P!\9?B/\2_'/Q7^'_P 0].\;?#-? UGI
MGA/P_P"*=#OK&^'BG1M?;4+N;7KZ]MIK-K;3'MC#;Q0.)I(GV$*[']5_VL?!
M<WQ#_9T^,_@=-6BT27Q=\//$GAV#6;NWFU&UTV?5[![&&[FTZWF26>*!YP\P
M@>.1U 1%)W$?2)4GKUST_A_Q_K^E>4_&G(^&?C#G;_Q*IA_Y%@/'&<<=^W>O
MF>(,34S/#8RIB8>U<\-4IU4WR\U/D2=FI1UM&WNOOH>]DM%9?BL%]7G.,Z6)
MI5*<K)VG&<6F[QELU?7MO8_EGT[_ (-WOC[;6]M%_P -#?"63R;>W@W#P9XY
M(?R88XMX+ZQNPP0'DY'('  KH[;_ (-\_CQ",GX__"ES[>"_%^#C_?U,M[<D
M^N:_K&C' )P5"IAN?F!4'(&.O<CI[>DF&]"/HWO[_P">]?D#\"?#VM>I5RNN
MJD^24I0QV*<6[7=J?M.5;[QV:2/V2G](#Q+HQA3I9U3C"G=13R_!N22<8J\G
MA^9JU-;Z/1]#^5*W_P""!GQT@^]\=_A<V,8V>$?&2>AZ+JNT>^!US^._;?\
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MIK'Z27BNM%GM)6MO@,);1*W_ "X\K^1^!%O_ ,$F?BO" #\4_!+$'.!X<\2
MD^O_ "$^N,8YXQTK>M/^"6'Q-MF'F?$OP2<<$CPWKNXGGN^H%N0><Y/;@5^[
M6T_WCG\A_6HCP>>3WY_Q'I_CD]*S?T<O#"ZD\JKW5O\ F*Q#[?\ 3U]+J_Y-
MZ7_Q,KXM/W?[>I6[++\'Y7_Y<:-[=[?A^)5K_P $R?B/ W/Q'\&N%QD?V#K@
M]^]_\O\ 7N:Z"U_X)O?$.$#?\0O!^!@G&B:QQQ\H):_&WMMW$9]A7[(-GS$P
M^W.[:N6#9/RL0#( 0,Y'[F15ZD8R1^,5M_P5G\0Q:[?:WKG['GQ,T_X :1^T
M/-^S=K/Q^L_B=\*-3TRQ\9GQ*OA*TF'P\2\L/B!=6MWK$MOYZV^G!+>VE^TB
M]E";#Z.%^CQX>2UP^5UG[.SDGC,0D[Z62=5*]^B][RT1Y^)^D?XGI+VV>T[3
M=M,OPG:[>E#32UV^R733K[?_ ()Z^/;=-K^/_"> <Y_LO6$/Y&^QG/!V\ XQ
MVST5O^P;XX@QGQSX;)X'_(*U? 7LN#? \8'/6O=/&7[=7[/NF&[TCX??%CX(
M_$3QKI'C7P[X-\3>%9OC3X1\&R^'Y=:\3)X5NO[0U34(KZ%-=M-3?[!I_A.6
M"#5M>OR-.L<7#;VZN^_;F_8[TK7]9\)ZA^U%\!]/\1>'&\1Q:WH>H?$GPO9:
MKI$WA&00^([34;*7489+2]T>4B*ZLI$2[#X5(7:O2AX'<%4M:>45DDMOK&)]
MU+E=[*IHG=;Z6\SSJOCQX@UTE//*$M>:WU+"1UNE_P ^D]U;U3]3Y^MOV(_&
M<&W/C#PZW '_ ""]2!8#N,W)_4G\,5NV_P"QIXLB /\ PEV@YQR!INI8_+[:
MOZ!?RZ^Z^(_VT/V4/"'@CP5\2/$_[1_P4T/P'\1XYI_ 7BO4OB)X;MM%\906
MY NYO#=XVH;-3ALB=M]+;>8MBV5NS P(J/QY^VO^R9\+]4CT/X@_M'?!CP?K
M%QHFD>)[?2]>\>:'9ZA/X;U^U-]HVOPVKW9FGT74;,&ZMM4A5K&2W_>^>$YK
MMI>#W"D+<F5U^J5L3BM6N6]K5&FUHFEWUZ'GU?&7C:I?VF;T.G_,)A;=M?W5
MM5;_ (9'DL'[(WBB+ ;Q5H+,,+DZ9?G@@C'-R3R/5CVJ\/V4?$(&#XFT+CC/
M]FW^ 0,D$BXVY]L@D] >E?4^G_&'X9ZOXLT?P%I7CWPEJ?C36_!UM\1M)\,6
M&M6-UK.H> [J5+:T\7VFGQ3/<3>'KN=TCL]5"?9KIV"V\CD5^>&K_P#!0?X]
M:O\ &GXV_"OX'?L'_$3XYZ3\"OB+:_#;Q7X\T3XW_!/P7ICZO<6-CJI:+0_'
M.J:-KS)#I]\+EXK;[4I$9A%R;AUBKLH^%7#;YHT\OG'DBIS=3&5X^Y>,=Y5=
M[M;:LXJOBSQ9:,YYG!J<K1Y,)AW=VUU5%Z63??\ 7V"?]DOQ,_(\2Z&!U&=,
MO^1ZX\_(Z=\\5F7'['OBN4$+XMT!.0!G3KX!2W0']\>OU[XR1FO;F_;'_9EL
M?'-E\*=>^/?P@\._%FZUZT\)7?PRU'X@^&U\96'C2YL8;T^%)]*-\L_]K(LO
MEQ1+$%O"H-KYFX"O)?CM_P % _@E\&OB1X#^$&E>(?"WQ.^*WBWXO^"?A)XA
M^'/A;QWX:7QG\/#XTBNY;;Q'XCT%I;C44LK-;53=Z8D:7C"XB/\ H@< DO"G
MABI9?V96<VN9MXC%).-EJOWFJU6O6Z5VVD:Q\6^+Z:7)FE'1_P#0+A;IZ+7]
MS?2W?6VUT<;<_L5^,KC[OC'P^I]],U7)^H%ZHZ9^ZBCVK#N?V%_'$P(3QMX=
M0$D9_LG5CT['_3N3D' QDGCFOK3P9^U]^S%\0_'D?PN\"_M"?"#Q?\19O[7$
M'@GP]XZ\/W_B>=] N'M=:@BTBWOI+R2ZTN:-TOK-(WN;8(SR1B,%ZJP_M;?
M#Q%/\4]!^'?QG^$7COQ_\(_#7B?Q#XN\%:7\2O"\=YH:>&+6[EOU\27@O)H]
M TZWN[22QUG6[J&>P\.ONGU0%+?RCP5/!W@^K[M;*JS5D_=Q.)35TDKKGNEV
MO9';2\:N.:/\/-Z*Z*^%PK[;?NEK\O+3<^-[K_@G_P"/YCE?'GAGH1\^C:N?
M7&1]LS]<CK[USEQ_P3G^(<V[/Q!\)KN!;#:)JO0$<C.H*2.>>. >G4U];V7[
M>7[,&D^&?!&H?$_X^? ;X:^)_%WA#P;XO/AF_P#C)X-UFWAL/' "^'[O1_$<
M$VF6'B?0M3GS#I?B73;.'2]14++%L1U)N> _VT_@G\1_VH?B?^REX7\06EW\
M2OA9X8T+Q'K$CZEIJ6.LSZG&;C4]+\.6T%S+J&I7/A*RFTY_$5\;=+>PEU.V
ML22&+KYU?P%X$K)\^68E12<F_K.*MI[KU]JEHTU>^Z>NC/0H>/WB-2<73SRA
M&3LDOJ>$;>J:]WV/2VO](^'+K_@FA\29V?;\1O"*@]_["UHGCITOCCMT_E7/
M7'_!+KXGS$E?B7X.4GN?#NN$]\#)ONW3..X]*_<>-B4!7!&,_+C'0],%ACZ$
M],9J7+8SG ^@_P 2?TKR)_1\\,JC=\LKMO1_[9B=].OM/U_X'KTOI(>*]%KD
MSVEVUR_!N^S6]'^E8_!2;_@E%\4YR2WQ/\%#)/\ S+OB(=O]C4@/;A1^%85U
M_P $BOBS.SF/XK^!E!S@/X?\2G ],_VG_4GOWK^@GGKNXZ_='2C![-^@K*/T
M=/#%:1RRO_X68CR[5?ZU[LUE]);Q:D[O/J-W;_F7X.W3_IS<_G9N/^".?Q?E
MRR_%WX?@L,$-X:\2D9/7IJGZXZ=>HKGKG_@BY\99Q@?&7X>)_P!RIXG/0],_
MVF>OX_X?TCX;^]^@HVG^\?\ /^1_GIJOH\>&FW]F8C2S3^MXGRV?M4MNS_S6
M<OI(>*[WSZB_3+\&NW_3C^ODC^9BY_X(A_&N?=M^-?PW&<XW^%/%G.>>G]H\
M'WSCZ5AW'_!"WXW39V_'#X:*2#_S*7BO&3D\9U'/7\,<9S7]06T_WB/\_7_/
MI2_-TR/K^?M]._:M(_1^\-U:V6XC2V^*Q2VM_P!/>_Z,Q?TBO%1[Y]3_ /"#
M!^7_ $X\OR['\KMU_P $%OCK<9V_'?X8+GIGPGXQS^.W5POY+CGZUSMQ_P &
M_OQZF#!?C]\+023][P9XR8#/O_;/..F<#N>]?UA8;W_[Z^O_ -;_ #T4@Y^[
MZ<Y],>OT_G6T? 3PZ@TXY9B'Y/%8KRVO57_#&4OI!^)]3X\ZI2L[K_8<&NR_
MY\^77IY7/Y'KC_@WH^/\P./V@OA,H]?^$*\:_K_Q./\ ]5?H]_P2_P#^">7C
M_P#8/^)7Q2M/&_Q"\(>.I_B3X7\.W>FMX7TC6]*73H_#.HZO;R'4$UJ:[\YK
MU]55E%M,!&(900@>,G]P2I*G Z9ZMZ<'M[?YXKRR8 ?%W2278A_ VJ[QZ"+6
M+1ATYZNX ZD ^O/?E_A7P?PSF>79KE67U:6+I8RE"$I8BM/^)>.BG4FMM[:V
M//S+Q=XWXIRW,,ISG,:=? U<'6G4I1PU"GS>S49)-TJ4'O9J[<=/*YP?[1/P
MQ\9_$G0?!,?@63PK'K7@WXC6/C4VOB^YUBST74[&#PIXQ\-75BUUX?M+_4;.
M]8^*8[NVN4M+F,I9[)B&<5X$/@I^TD !_8_P%. !G_A,?BASCO\ \B1_GT%?
MH2<@J%'4]NV?R_/UJ0!B!R?^^L?I@_SK]NP>=8[ X>.%HU%R*3J648_$U&,M
M6M6N51:O=/U/PS%9-@\75CB*U-NHX<O-=OW(SO&-E9+=O:]K;:'YY_\ "E?V
MDO\ H#_ 7_PLOBA_\Q%'_"E?VDO^@/\  7_PLOBA_P#,17Z&[3ZG_OK_ .QH
MVGU/_?7_ -C73_K)F?\ /_Y+3\O+U^_R.?\ U>R_^27W/R_X']+3\\O^%*_M
M)?\ 0'^ O_A9?%#_ .8BC_A2O[27_0'^ O\ X67Q0_\ F(K]#=I]3_WU_P#8
MT;3ZG_OK_P"QH_UDS/\ G_\ ):?EY>OW^0?ZO9?_ "2^Y^7_  /Z6GYY?\*5
M_:2_Z _P%_\ "R^*'_S$4?\ "E?VDO\ H#_ 7_PLOBA_\Q%?H;M/J?\ OK_[
M&C:?4_\ ?7_V-'^LF9_S_P#DM/R\O7[_ "#_ %>R_P#DE]S\O^!_2T_/+_A2
MO[27_0'^ O\ X67Q0_\ F(H_X4K^TE_T!_@+_P"%E\4/_F(K]#=I]3_WU_\
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M7WY!!_$@G^52TG9N$9V=US=/-:/7[@=VK*4H*32ERNW-"_O1?J11J@ 4C&"
M.2>@X&>IQZGK^=3CH,?Y_*DV#.><YS^-.I];[72]U;+;9$Q32L]7U?>VBOWL
MK+Y!1113*"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
5HHH **** "BBB@ HHHH **** /_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>18
<FILENAME>ex_611641img001.jpg
<TEXT>
begin 644 ex_611641img001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" ![ =8# 2(  A$! Q$!_\0
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MN>')684445V$A1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MV:/[3O\ _G\G_P"^S7D_5GW/1_LR?\R/0**\_P#[3O\ _G\G_P"^S1_:=_\
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MYLY#8)S#*4S\[]0.#3JI5)J*%#W(W9[W17S':_%OQI:H$_M1)P/^>]NC'\P
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MG;W,?]V:,./UKE[KX6^"[LL6T.&-F[PN\>/P!Q78T4*36S!I/<X+_A3O@O\
MZ!T__@5)_C6QIGP_\*:1*LMGH=JLJ]))%,C#Z%LXKI:*;G)[L.5+H%4[_2M.
MU2+R]0L;:Z3&,3Q*^/SJY14C.-NOA5X+NLDZ)'$Q[PRNGZ XJK_PIWP7_P!
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MG'<_+0E"4G"P-R24KGLWC3QG8>"])6[ND::>5MEO;H<&1N_/8#N:\P@^*/Q
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M,N&GMEM[ZT<+,D9)1@V=K+GD=#Q[5-2+Y;V7R'%Z[G:4445SFH4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%?('_"[?B'_T,/\
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MXH?#F;Q;'!J.EF,:E;IY1BD.U9H\Y SV().,\<UX1_PNWXA_]##_ .25O_\
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M9:%\2_AY<SV^C6YO;*5]W[I!+&Y_O;20RG &?ZUY[_PNWXA_]##_ .25O_\
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##__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>19
<FILENAME>largelogo.jpg
<TEXT>
begin 644 largelogo.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_X0 L17AI9@  34T *@    @  0$Q  (
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MU-76U]C9VN+CY.7FY^CIZO+S]/7V]_CY^O_:  P# 0 "$0,1 #\ _OXHHHH
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MVG_'W?6=KSC_ $BYAAY]/WCKS[4 7**K6][9W8W6MW;7*_WK>>*8?G&["K-
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MA+^V1^T7)/,XN]:T;4OB5K^@I*6)>,ZI%=V_AJU"L2/(BGB2/[HC4# ^OO\
M@@S_ ,$X_"G_  4%_:TU,_%NPEU/X"? +0=-\>?$70D>6WA\;:SJM_/8>"/
M=Y<PE98M)U6[L-4U;7DA>.:[T?0[C38YH/MYF3_2K\(^#O"7@#P[I/A#P-X9
MT'P?X5T*S@T_1O#GAG2;'1-$TNRMHUA@M;'3-.@M[2VABC1$5(HE&%&<GFOU
MK.<\R/@>=/*,GR?#8G'0I4YXFO7M>'/%2A[:MR2K5ZU2-JKA&5.E3C*')OR0
M^)P&79CQ%&6.QV.JTL/*<HTJ=.]I<KM+V=/F5.G3B[P4G&4I2C+FO;F?^7'<
M?\$]O^"QGP]A&OQ?L]?MFZ+Y $XO?#VH>++R^A"#=O$/A[Q+>7X* 9.("W'
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M)1>7VCVEPCK+JEK:M&CSQPBO]/1%1%5$541%541 %544 *JJ  JJ  H
M&*_8^(<_P?!-;#93E&1X.[PL*\L37BTIJ4YP2<H156O4O3<JE6=;1M+E[?!Y
M7EE?B&G5QN.S&O95I4E2IN[BU&$VTI-PIQ]]*,(T];-W6Q_E::A^R5_P6)^
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MORAU;2[[0]3O]'U*%H+_ $VZFL[J)@05EA<J2,@$HXP\;=&1E8<&OV0KXO\
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M$?MV6WQB\0Z3]K^'?[*VBQ>.Y7GAWV-U\1-8%SI7@#3\LIB>:PD34O$/DG)
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M7QQ+X<T^;5-;\)>+=-MC'IX\2)HMK=ZQI6J:=!;1ZI#8:A;7%JMTL#R_M_\
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M-_HVL7OB?7KAM3\:^(+W2+;PSJ4%LTLD>EZ-8L;N25[/2S*WEK<"-?Q%U/\
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M$E\6^$EU&SV*-]Q?Z+ID0RTE?Z E?Y"OQ)^'?Q\_X)Y?M9R^$_$PB\(?'O\
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MJ<O]"%=?\/(JHFMZ*B*H5574K%555&%55$P 4      # XI?^$AT#_H.:/\
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M&=24(_T??:K3_G[M/_ JW_\ CE'VJT_Y^[3_ ,"K?_XY7\X/]H:A_P!!"_\
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M.UK9ZEXOUB#3WU.[1!(]II%@/-U+5KI$*L\&FVEU+&K*TBJK*3_'!^VX,?\
M!T]^S2!T'Q$_99 ^@\#(!^GKS7RK_P %E_CA\.OB7_P6YO/"?[8+_$CQ#^RQ
M^S]=^!/"6H>!/AO;OJ'B.X\,R>#-,\::]:^'=/;4M+2*]\6Z_K$5OK.IP7MK
M>)I< $,ZM;PA?<7#+SBMP]0K8[&5,/'A6EF=6$*6'G7IT:<HP6"P,84J*E*<
MZD53EB)59J[<IRLD>8\X6 AFM2GAZ$:KSN>#@Y3JQI3G)<TL1B&Y3<5&$9.2
MI*$7I:*5VO[*O@G_ ,%9_P#@G5^T/XTT_P"'7PF_:M^&?B+QMK%RMEHOAR]N
MM4\,7^MWKDK%9Z./%.F:-#J=Y,PVP6=G--<SL52&)V90?=OVGOVR?V;/V-/#
M_A3Q3^TK\4-*^%V@>-_$+>%/#&I:M8:U?0ZIKZVC7S:?&NBZ;J4D+K:(\QEN
M$A@"*<R9XK_//_X*4_%G_@D5\6/AIX%O/^"=W[-GQV_9]^.7A'Q9ISWU]?>"
M=1\->%M>\'K9W)N9[VY7QWXJN(_%FDZI#I=]HNJVEG;7C$WBW%XP,6S](?\
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MQ:W*V=_J'A#6(;Z72KQXQ*EIK&G.(=3TBYDCR\<&I6=K)*JLT:NJL1_G._\
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MIS_2S_P3V_9V/P>^%:^,O$5B(/'GQ)BMM4O1-'MN=(\.;1+HNCG< T;R1O\
MVA>( ,S3QHV3",;NB_\ !.+]DG0=7TW6['X=WC7NE7MM?VJWGBGQ'>6K3VLR
M3Q"XM+C47@N83(B^9!,CQ2*"KJ5)%?<JJJ*J(JHB*%1% 5551A550 %50
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M>^%?#OB+4[+Q/#JFN^)?%5Q<Z3=Q0'Q+%8&4Z%:&#688H+"/=+"@>Y (%?T
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=110 4444 %%%% !1110 4444 %%%% !1110!_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>20
<FILENAME>slide03.jpg
<TEXT>
begin 644 slide03.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" $1 ?L# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#W^BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HKPWXN/I(^)FD)
MKUU>V^EG3296LV(?.]]N.O?':H/AW-_Q5>L1^&KK5;CPP-/<R/?9XDQQCWZ^
MAQFNGZO[G-<S]IK8]YHKP3P5XVUSPM\-K?4%T+[9H\%TRW-U)=8<[GQ\B\\#
M(&3WKTCQ)XMUJQEM%T71(KB":W^T/>7URL$" ]%W?WJB5"496&IIJYV=%>9#
MXMJ?AZGB/^RP+EKW[#Y!F C$G]XOCA<5M^&_%6M7R7EQK6F6$%A;PF87MC?I
M<1G R1@<YQFDZ,TKL:FF=E17E4?Q<O?L\.M7&AP1^'9IA&LHO%-RJEMH=H_3
M/:O4)@\UI(+>4)(Z'RY,;@I(X..]3.G*'Q I)[$M%>#_ -C3>%?B1H%E:^(-
M1N-:GN-VI7-VVRWEC/.U<GEB.-N3SCI7MNIB[;2;Q=/*K>&%Q 6Z!\';^N*J
M=-1M9[A&5RW17S%;QZ?;@#Q%K/B;0O%0ERU[<*SP!L^WS8_']*[GQGK/B:+Q
M=X,M]/F@O8Y$$D+)<&.*^E"C)<#HO<=>M:/#6=DR54TV/9**Y'2?%UUJ'C[5
MO#<UG%&EA:QS>:KDEF8+D8] 2?RKGK?XLR?\(3<:W<:6K7?]HMI]K:PR']Z_
M&"21QWK)49O;^KE<Z/3Z*\6U'4_$%Y\5O!\>M:6FFW:K*52*X\R*0$''([@C
M!%=%%\3W7X?ZKKMY8Q1:GIURUI)9"0X,NX!1G&<'.?P-4Z$E:VMQ*:/1Z*J:
M7-=7.DVD]]"D-U+$KRQ(20C$9(R?2O#O OP]T_QG9ZS?7VH:G!<Q:C-#&8)\
M* .0<$'/)]:4*::;D[6&Y-6L>^45XYX3\>7/A?PGXBAUR:749-#OA:6[%OGF
MW$A5)/NIY/05T>A_$&_E\16NC>(-+M;.:]B:2UDM+M9U)49*-CHV*<J$U<2F
MF>@45Y=HWQ-UWQ%="72=!T^>S,YB\EM31+H*#C<4/2K^HZG96_QFL()K "<:
M6\IO#<.-BC=E?+'RGH>>M)T9)V8^=/8]"HKRE_BKKLGA^^\2VGA='T&)F2"=
MKG$A(.-S)C[N>..E7[[XD:G!<^%[:ST2*\N-<LO/6)9]FU\ @9(QM'4D]A3]
MA,7.CT>BN-\&>,K[7]5U?1M7TQ+#4],91(L4OF(P;."#^'ZUV59RBXNS*3N%
M%%%2,**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH XC5?"^H7OQ:T?Q (87T
MRUL)()B[C.\[\?+W^\*ZZYMPVGW$$"*I>-E4 8&2,59HJG-NWD))(\DA\ Z^
MGP0N?"S00?VK)-O5/.&W'FJWWOH#4NJ^"_$W_"2Z;J5M9:7JD$>FQ6@M]1D)
MCM9  "X7!#<\\<UZM16GMY7_ *ZD\B/+/#_A#Q/HG@34-';3M&O;J34'F$=X
M2T,\38Y 'W3D<9Z5!X6^'&I1>(KW4+NPLM"L9[*2U>QL+AI1*7&"QSP,9_05
MZU11[>6OF'(CQ#2_A=J^GF'3I_"WAF^BCDPVIW$LF^2//= ?O8_SWKV6ZL_/
MTN:RBE>VWPF))(CAH\C *^XJU14SJRF[L:BD>-_\(+X^UG^S=#U_4+*71]/N
MQ<"^#EKB8*3CKSG!/7]<5ZQJMB=2TF[LEN);9IXFC6:%BKQDCA@1W%7**)U7
M*WD"BD>.77AKXI7.B2>&;F;1[VQ=3%]ON&+2[#WYYSCOC/O6EK7@+6["/P=-
MH'V>^GT!2C1W,GEB3('.?3.>/I7J-%5[>79"Y$>:77ASQ?IOCZ\\0Z+;Z;.-
M4M(X9Q<3,HMW &2,#Y@"/QK%LOA?KQ^'TFFSR6T.L6VK'4;5M^Z.3@#!QTS@
M_I7LM%"KR6W]6#D1Y:?#WC;6O'OAWQ!K-GIUM!8;U>&VG+% 0?FYZY)Z#IBL
M#4]"AU7XWKI=C=1S:7<O%JM_#&VY5DC!'S8[DD?]]5[C63I'AG1-!FN)M+TR
MWM9;@YE>->7YSU],]JJ-=K[K"<#6KQC0M ^)_A:/4+32+'1S;W5W)<"2>7<R
MECUX('0#M7L]%9PJ.":M>Y3C<\H'PFNY?A_J.FW6H12:Y?W8OI9R#Y9D!X7U
MQR><=34OA'P1?V6O07EYX1\.:8ENI*SVTLCRF3! *\X ]C7J5%4Z\VFGU%R(
M\6\0?#WQ)XANY$?PYX=L;IY@PU>SG=&5<YSL[GWKI[WP?J,OQ'L=7E(ETN#2
M'LYYV?\ >,Q5@3M]\UZ%10Z\GH'(CYUN9M4TOX5ZKHEIJNA76@Q%C'=QW&9Y
M%+@^6(^S9/?H,UW-CX4U6ZUCX>ZO%%&;/3=."W)9]K*6CX 7OUKK9/A_X2EU
M+^T)/#]@UT7WES%U;UQT_2ND  & , 5<ZZ:]WS_$2AW.(\.^&=3T[XE>)M;N
M8XQ8Z@D8MV60%CM SD=J[>BBL)2<G=EI6"BBBI&%%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110!G?V?=_]!2;_OA:3^SKS_H*3_\ ?"UI45S_ %6G
MY_>_\S;V\_+[E_D9O]G7G_04G_[X6C^SKS_H*3_]\+6E11]5I^?WO_,/;S\O
MN7^11ALKF-R7U"608Q@J*G\B7_GX?\A4]%'U:GY_>_\ ,AS;=V0>1+_S\/\
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M?\CF_P#A'=8_Z&J]_P"_,?\ A1_PCNL?]#5>_P#?F/\ PKI**+L/K=7R_P#
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M*Y_\&$5']M:__P!"N?\ P814>S?]-!S(Z*BN=_MK7_\ H5S_ .#"*C^VM?\
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M_#=P[:?<O)&8G:_N6:,G.PF4Y'X5R$2FPU^7[%#KTEO)/=3:Q;7<1,$L97^
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M_ .9&_\ V/J/_0UZI_WZ@_\ B*/['U'_ *&O5/\ OU!_\16==^.- LEMVEU
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M!XZ5V5C%'8:?;641)CMXEB4MU(48JC_;=A_SSU#_ ,%\W_Q-']MV'_//4/\
MP7S?_$TG=[AJ:WG>]'G>]9/]MV'_ #SU#_P7S?\ Q-']MV'_ #SU#_P7S?\
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M@TBHW549RRC\%(%;=%%9MW=RDK*P4444AA1110 4444 %%%% !1110 4444
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M+M R2".O2O*QX1FFU".YN-(B=G\0O=3.X0EK8KQGGE<_P_I6[H.E7-GX)O\
M2KJQSOFN?+M?-\L/&S$JH9<[00?PJ72BNH<[-R/QSISZ4=2>UU."W)C$7G6C
M*UP7^Z(QGYB:T],U^RU;3?M]M*RP!F5_.7RVB93AE<'[I'>O,H_#NHQNU[I^
MCR6%G;W5I<0Z4]PK-(T>1(P.2H)!XR><<XK:M=+U >"O$,,MOLO=4DNITMMX
M)3S,[4)Z9]>U-TH] YV=S_:UB1D7UK@,$SYZ_>/0=>I]*=)J5K%+Y4MW!'(
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M0>9\K;662-D93Z$$ U:KFY-^LZU'8ZE');PK:^?]D\W_ %K%B#N*GD* ./\
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M$M;-<""./>?E;;LW?=W=_ID]JI^T>C(C"G%W21OW5U':0^8^22=JHHRSL>@
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MBB4N%)9O7)X'>CDG>P^9&Q_8,W_0R:W_ -_H_P#XBC^P9O\ H9-;_P"_T?\
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M7_[3C_Z!FL_^"Z7_  KN;U=CDLRMX?TJXTJYOKZ^O([F^O6C,C0Q&- $7:H
M))SCJ<UA)X!CCLO$, O1OU20/;OL/^B@.7 Z\X8YXQ73?VG'_P! S6?_  72
M_P"%']IQ_P#0,UG_ ,%TO^%',PLSD[GX=12I9+'=6Q,5FEI/]H@9PVTY+H P
MPQR?O9'-65\!V\?B%K]);<VK3BX\N2$M*K!<;5;=M"Y /W<^]='_ &G'_P!
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MX!P,\=J33/"KV&KVT[WZRV%C-//9VXBPZ-+][<V>0,G& *V/[3C_ .@9K/\
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M:=%16SM):PNQRS("3[XJ6I&%%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 56O+07*JRL8YXSF*4#E3_4'N*LT4TVG= U<JVE
MV9BT,RB.ZC^^F>"/[R^H-6JK7=H+D*Z/Y=Q'S'*!ROL?4'N*;:7GGEX9E\JZ
MB_UD>>W]X>JFFU=70D[:,J-XI\/JQ5M<TT,#@@W2<?K2?\)7X=_Z#NF_^!2?
MXUB^$(;8^$]/+V\#,5;):,$GYV]JV_)M/^?6W_[]+_A6DH13L0I-JXG_  E?
MAW_H.Z;_ .!2?XT?\)7X=_Z#NF_^!2?XTODVG_/K;_\ ?I?\*/)M/^?6W_[]
M+_A2Y8AS,3_A*_#O_0=TW_P*3_&C_A*_#O\ T'=-_P# I/\ &G>1:?\ /I;_
M /?I?\*3R+3_ )]+?_OTO^%'+$.9B?\ "5^'?^@[IO\ X%)_C1_PE?AW_H.Z
M;_X%)_C2^1:?\^EO_P!^E_PH\BT_Y]+?_OTO^%'+$.9B?\)7X=_Z#NF_^!2?
MXT?\)7X=_P"@[IO_ (%)_C2^3:?\^MO_ -^E_P */(M/^?2W_P"_2_X4<L0Y
MF)_PE?AW_H.Z;_X%)_C1_P )7X=_Z#NF_P#@4G^-+Y-I_P ^MO\ ]^E_PH\B
MT_Y]+?\ []+_ (4<L0YF)_PE?AW_ *#NF_\ @4G^-'_"5^'?^@[IO_@4G^-+
MY%I_SZ6__?I?\*/)M/\ GUM_^_2_X4<L0YF)_P )7X=_Z#NF_P#@4G^-'_"5
M^'?^@[IO_@4G^-+Y-I_SZV__ 'Z7_"CR+3_GTM_^_2_X4<L0YF)_PE?AW_H.
MZ;_X%)_C1_PE?AW_ *#NF_\ @4G^-+Y-I_SZV_\ WZ7_  H\FT_Y];?_ +]+
M_A1RQ#F8G_"5^'?^@[IO_@4G^-'_  E?AW_H.Z;_ .!2?XTODVG_ #ZV_P#W
MZ7_"CR;3_GUM_P#OTO\ A1RQ#F8G_"5^'?\ H.Z;_P"!2?XUI6UU;WMNEQ:S
MQSPO]V2-@RMVX(K/6"S+J/LMOU_YY+_A5/P1@>%8   //N, ?]=GI2BN6Z&I
M-NQT-%%%9EA1110!!]BMQ?F^\H?:C%Y/F=]F<X_.J2>'-(C$X2QC N'5Y1D_
M,RN9 >O9B3^-4?%JSQVMK<6]]=VSM=P0$0N "KRJK<$'G!/-8\WC.?2Y9K<6
MQN8(DN5CF9V)+PJ6PS[=I)VGA<XXS6D8R:NB6TGJ=#<>'+2>_M)PJ)%!=->F
M,)DO.5*ARV>, G@#TJ23PUH\S*7L8R0S,<$C=N;>P;GY@6YP<CVJ.VUB2[O-
M4M?*$?V2&)U<-DDNA;I[8KCH]2UO_A%H]2M;C5-W]ER3W4UV%V;O)RK1\==^
M".V,YIJ,GU$VD=G=>%]%O$=)[!&5S(7 9AOWG+@X/()YP>*OM8VKSVTS0J9+
M4$0M_<!&#C\*PK.SNIK&8S2:S;'R@P>6ZC;)Z\;2<?C5GPD)I/#5A=W%W<7,
MUU;QRR-,X.&*@G& ,"DT[;C5K[%R\T6PO[M;N>)_M"1^6)(YGC.W.<?*1D9J
M4:;:![60Q;I+0,('=RS)D8/).3D>M6Z*B['9!4%[_P >%Q_UR;^1J>H;M6>R
MG502S1L !W.*%N#V"S_X\K?_ *YK_*IJRK+6M--O#%]LB61552C':0<8Q@U+
MJ6J?V?-:PI:S7,UT[)&D14=%+$DL0.@JI1E?5"35C0HKG/\ A+[9I(XH[.=I
M61V9'DB385<QLI+. 2&4],U.OB:W:\N8#;R)':LRSRM+& FU0Q.W=N( /4"E
MR2'S(W**PCXHMH4\R]M;JSC>)IH6F4?O5&,@!22&Y'RG!_6I1KZH\<=UI]Y:
MR231Q()%4@[\X.Y6(['(SD<<<T<C"Z-BBL.Z\46MM=M:+!-+<"9H0@*+N*JK
M'!9@.CKQG)YXXJ[+K%G;6$-Y<M)!',!L22)O,R1G;LQNR!G(QQ@T<K"Z+]%8
M\GBG1T:1$O%E=(_,VQ@G<-F\ 'IDJ,@9YJU8ZQ9:C'"UO,&,H8JI'(VXW _0
MD4N5KH%T7J***0PHHHH **** "BBB@ HHHH **** "BBB@ HHHH *R==TZ[U
M"TQ83PP7*@A974D@$8(R#W_']*UJ*J,G%W0FKJS.%\).(_"FG1@_=C*_DS5L
M^=[US?AIF'ARSQZ/_P"AM6KN:NV4;R;.12LB_P"=[T>=[U0W-1N:IY YCG/&
M\+W-SIMM9:AJ-MJ6HS"WB,%X\<<:+\SN4!P2%_F*Q/[:U*+QC+-/<WO]GV>J
M0Z:FR[QP4XW1$8?<>68D'GBNVEL[>>^M[V6$-<VP80R$G*!AAL?456DT/3)=
M775I+")KY<$3'.<@8!QT) [XS6D6DK,5V8/C?7+_ $+70UO<3^7J6G/:6\:N
M=JW.\!6 ['#=?:N?7Q9J^C^5:W%S<7=SX?2X%V&D;%P[2+'"9.Y'S9_"O0[W
M3;/4I;66\M4F>TD\V!FS\C^HJ)]$TR2>_GDL(GDU!!'=%@3YJCH"/\*<7%*S
M079SC_$/5XK=+:2P OI+P6\<YL9PC)LWEA#]\D8QC/O6;=?$#58-6L;UK:6%
MY]/:-X)=XMX9//V^>Z]0N/QYQFNN'A?11IQL/[-C^SF3S2-S;M_][?G=G''7
MI4B>'])C0(FG0A!;&TV@''DDY*X]SSGK1[G8+LHW'BS6;/Q0MC=16<.G>;%"
MMP\<FV?<.2LBDJC9X",.?6L[X@7.IR>)M'LK!]899+:9W@TNY$,CE2,')XP*
MVQX7T07D5W_9L?GQ;=C%F/*C"DC.&('<@FK\EG;RZC#J#PAKN!&CCE).55OO
M#TYI+E3N@YF<1;:UKWA^;2VUJ\D$D6E7<S17,Q(.''E^:5!W, 0,@$U=M?'V
MMR":QFL[5-1:]M[6"22)XHP)5+;G0L6X X&03D=*Z2^TC3]2F\V]LXYW\EH,
MOG_5MRRX]\54C\*:%%:SVJ:7$(;C;YJEF)8K]TY)SD>O6G[CW079E:GXXUW3
MS:V'V:QDU%HYY97MXY+B-A&VT *G*D]\D[>]41XNUY+[Q!J]L(5M;:SM;J6R
MO6<E 4RR)CA3UY/7CBNC?PGH,EE#9MI4/D0EF106!!;[V6!R<]\DYHN?"F@W
M=U]IGTJ%Y<(,Y8 A  HP#C P.,8H7)V"[,^?QWJ06\U2"UM/[)LKN*TE@D+?
M:9"^W+*<X&-PP"#G!KNC-@D9Z5SDWA_2;C55U.73H6O%(82$'DCH2.A([$C-
M:>]JB48O8:DR_P"=[T>=[U0W-1N:IY YC12?YUY[TSP/SX4MS_TVN/\ T<]4
ME9MZ_6KG@7_D4;;_ *ZS_P#HYZBJK0^?^9I2=Y'1T445RG0%%%% $%U9V][&
ML=S$)$2195![,I!4_@0#6>WA?16N#.]BC.3(V&=BH,@(?"YP-V3G YJMJ^IR
MZ+KMI=7,Y&DSP212*0,12J"ZMGW4./J!61I7B758K1YK^!9(X[B);HN^'C:<
MJ55%QC""1 <G)P:T496NF2VKZG3V&B:=IGG_ &2WV&X"B5F=G+A1@9+$G@<5
M*=+LCI']E?9U^P^3Y'DY./+QC;Z]*Y+1?%UV="WW,0N)X?LBM(S8,AF?:20!
MQC]:$\:ZH]J;G^S+01_8I+_'VAL^7&^UE^[]X]1V]:;ISN+FB=5::3:66[R1
M/AEV$27$D@Q]&8@58M;6&RM(;6VC$<$*!(T'15 P!7%WOC>ZEM+]["V555+A
M()2CDH\:L=S?+MVDJ0,$]L]3B5O%5] @-W!%Y-M<V]O+)%*0SLT:R,<;?NX;
MIW]J/9S>X<T3M:*R=(O]0O[);NYMH(8)X5F@\N4LP##.UL@<@8Y''6N&M_%F
MKMX.BB>\W:L'CF>;8N3;L48-C&.=VS./7O25-L;DD>GU!>_\>%Q_UR;^1KA+
M;6+U[^%%O-2^V3:M+!&LJ 6KQ)*VY<XQD1@XYR2._-='HUW/?>$Y9[F4R2$W
M*[B .%D=1T]@!0Z;CJ'-<UK"-([&W"(JCRUX48[54U;0[769K-KQ1)%;.[^4
MRY#[D*_AC.:O6?\ QY6__7-?Y5-4MM.X[:'*P^#WM7@,-Y;2);P&WC6ZLA+B
M/>67^(<C.">_4\UI0^';,1Z@+A(YGOG<R2",*P#(%*@]<<?K6Q10YR8<J.=F
M\+R7T:1:EJ+W"01-';E(A&R$C&]CDAF  [ =>*EFT.^NTW7>K^9/')') 4MP
ML<;(<Y*Y)8G)!Y''3%;M%'.PY4<Y+X8EF@E66]@G>XE:6X2XLUDAD)4*/D)R
M,!0 =WKG.>+#>'V2QTR*UO72XT[_ %,TR>9G*E3N&1G@^O&!6W11SR#E1RJ>
M"8(K$VD=[*$,JR9* G(A,7ZYW?I5O0]$?3M3OKER^UUCBB#$=%0!G '3<0./
M:M^BFYR:LPY4%%%%0,**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M#CK3P=JEC;);6WB%%ACSL5K!6(!)/7=SUJ;_ (1C6_\ H8X__!<G_P 575T5
MK[:?])&?LHG*?\(QK?\ T,<?_@N3_P"*H_X1C6_^ACC_ /!<G_Q5=711[:?]
M)#]G$Y3_ (1C6_\ H8X__!<G_P 51_PC&M_]#''_ ."Y/_BJZNBCVT_Z2#V<
M3E/^$8UO_H8X_P#P7)_\51_PC&M_]#''_P""Y/\ XJNKHH]M/^D@]G$Y3_A&
M-;_Z&./_ ,%R?_%4?\(QK?\ T,<?_@N3_P"*KJZ*/;3_ *2#V<3E/^$8UO\
MZ&./_P %R?\ Q5'_  C&M_\ 0QQ_^"Y/_BJZNBCVT_Z2#V<3E/\ A&-;_P"A
MCC_\%R?_ !5'_",:W_T,<?\ X+D_^*KJZ*/;3_I(/9Q.4_X1C6_^ACC_ /!<
MG_Q5'_",:W_T,<?_ (+D_P#BJZNBCVT_Z2#V<3E/^$8UO_H8X_\ P7)_\51_
MPC&M_P#0QQ_^"Y/_ (JNKHH]M/\ I(/9Q.4_X1C6_P#H8X__  7)_P#%4?\
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; %%%% !1110 4444 %%%% !1110 4444 ?_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>21
<FILENAME>slide04.jpg
<TEXT>
begin 644 slide04.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" #\ A<# 2(  A$! Q$!_\0
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M67.[&2?S%;FH>*M TF_CL=0UBRMKI\;8I9@K<],^GXUY?HYV_M):TP7)%JQ
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MXR:9H7PRFMO$MOX@\0^(;K6[^U7%OYB;%CZX.,GID\<<\UTW]I:]_P! )?\
MP+6C^TM>_P"@$O\ X%K1S5+6NOO06C>]CF-<^&$MQXDN->\.^(;K0[V[&+D1
M)O60]SC(QGKWYYK;\$^";;P983Q)>7%[=7+[Y[B8\L>>@SP.3]<U<_M+7O\
MH!+_ .!:T?VEKW_0"7_P+6DW4<>5M6]4-**=RWKNB67B+1;K2=0C+VUPNUMI
MP5/4$'L00#7F=M\#5,]O!J?B:^O=(MGW16)4J![9W$#/? 'X5Z =2U\=- 4_
M]O:TG]I^(?\ H7T_\#%_PHA*I!6B_P 4-P4M6;<4:0Q)%$H2-%"JH'  Z"O.
MO&/PPO/$WBV/7[+Q"^F3QPK$GEPDNI&>0P88R&KJO[3\0_\ 0OI_X&+_ (4?
MVGXA_P"A?3_P,7_"E#G@[Q:_ ;@I*S.%7X5^+ RD_$C4R 0<8DY_\B5T>L>
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MXF!$.S9@'CJ<]:;:^ FMOB=<^,?[1#+/$8_LODX(^55SNS_L^E;7]HZY_P!
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M ,"B<X6]WMV!)]39HHHKG- HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MZ<W<=MI=[<(#;P%@\K&$LWF'IM!X"_B:P[[6]93XA33+JNH"PBUN*S\]9/\
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MVK6-M=28V0S3JK'/3@FH]2\4Z!HUT+74]9L;.<J'$<\ZHQ!Z'!/3@UYG#?\
MAS1F\86?BZQ%QJEUJ$LB6\D):6\A8#REB/?T&#Q5V;5?#VD?$B5M=^SV-H^@
M6R1P7JABOSM\F.<D#CO6_L5YF?.>A7_B31-+MK>YO]6LK:"XYAEEF4+)W^4Y
MP>M6--U;3M9MOM.F7UO>0 [3)!(' /ID=Z\3T_3M1EL?!-M;.MDT^H:A)8?:
MK?S1' 5)0&,XX(Z>F0:Z/P)-J%A;>(S!8)=^*Q?*-0L6E6VB  PCQX4C:5YS
MC)-$J*4='K_P; IML]$U3Q!H^B>7_:NJ6=D9/N"XF5"WTR:E.K:<#9@WUO\
MZ:<6V) ?..,_+_>XYXKRR\OH=(\7^([KQ)'866HWUK;G39M2B,]LJ!,21!AC
M.&SD#!/6JFDSRRV?@-X].@L]NIWGV>&&-XXV C?:P#DL QY_&CV*M?\ K:X<
MY[55:QO[34[1+NQN8KFW?.V6)@RG!P<$>X->0^$M9O;C7/#QAUK4[S6;J24:
M[8W#,8[= #SL(Q'@[0N.M9/@'4!;#PM%I.KZA-J,EW,M_II9C"EM\Y+!.@[$
M-W)-/ZN[/7^M?\@]IJ>^.ZQHSNP55&23T J"UOK2^L8[VUN8IK61=Z3(P*,O
MJ#Z5XWX?\13WWB>Q\F_N3;7]C>M/;W%\T\A9<E?,7 2-ASA5' ZUU7A9()?@
M79QW,-U-;OI3+)':#,K*00=@]<=*F5'EW_K<:G<Z_3?$6BZQ/+#INJV5Y+%]
M]()U<K]0#6G7B/A;4OL^M6-IHUQIWB!TT^<6UPECY-U8A8\JDI'RD$X7!YS5
MGPYK+G1KBXTKQ#K&H>)VTB66XL)]TD<=P!W!&(V!R HQGWIRH6V$IGLM%>(V
M.LS?9[S^Q-?U34H6\/W%QJ;W,SM]FN0GRE2?N/G<-H]*-2FO],\/^$VN-9U!
M=.U.W-U?W<^HR19F,2E$\U58HO4A0,$CFCZN[VN'M#VZD) !). .I-<AH]WK
M8^%OVM;J/4=66RE:">,,1,P#>6?F4$GIU')KAM!U"2]NK>VTS7]6U&.ZTB>3
M6Q/*Q^RS;!MQD?NVW;AM'85*I-WUV&YGKNGZKI^K0//IU[!=1(Y1GA<,H8=1
MD4S3M:TO5VF73=1M;MH&V2B"97V'T.#Q7%>$K.X/P,BBLI)I+FXTJ0Q MDAR
MA 5?09Z"L+P1J&E)X@L-0L7B@T_3O#*1:I*$V+%*&!VOQ]X88GO3]DO>MT#F
M>AZ9JGB;0M$G2#5-7LK*:1=Z)/,J%AG&0#VS6H"&4,#D$9!%>.>.[[3XO$%]
MJECK%_#K;65N=.M_LZ/!>J22JID$N"3STQFO5M.U.WO6EMA-$;VU5!=P(V3"
MS+N /X5,Z?+%-#4KNQ,]]:17T-B]S$MW,K/'"7&]U7J0.N!D58KSJ?2H-/\
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M_A./#J:RMZ^F&SNC/':^9DXV8)$?S$9_I7J%4)]'L;G6;35I8B;VTC>.%]Y
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MKV#DTL>7PZ3K&J?$C4I(=1N]#D_LJT,GV:%'4M\V4RZD?*?2O3D4K&JLQ8@
M%CU/O3J*SG/F*2L%%%%0,**** "BBB@ HK-U_1XO$&A7FE33SP1W,>QI8&VN
MO?@U-I6GII.DVFG1RS3);1+$LDS;G8 8R3ZT]+!U.7N_B586D^I*=&UJ:VTV
M9H;J[AME:*,K@L<[LX (/2ND.N:2HM3)J5I$;M%>W6294:13T*@G)KQ_5_"^
MH37GBJ-_#>OW%S?7TLEE/:W:QVQ! VEU+@$9&3E3Q5OQ=H'BO4;.\M)-(\V=
M].M%6:Q@AQ/(A!D$CL=RA3G:JXS72Z4':SL9<TD>M3:II]O>Q6<]]:Q74O\
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M;6"8PR22RJ@!!P#R> <<9ZTE_P"+]'T[4-+M9[E/+U))7AN@Z^2JQKN)9\X
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MIHM]K>I:7;7/F/IL'G7,RX,2#)R-P/)&.:@^'VB_V%X(TJTDL4M+P6Z?:4"
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M;FWO+>*XA)!,<J!E)!R#@^A&:GK$TOQ;HNM7BVMA=M)*\9FCW0NBRH#@LC,
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M19VYUV)4;9BWP\66Q@[B<?05KZUX&U;4-7UW4+>6T226]L;VQ64DH[0*05D
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
00 4444 %%%% !1110!__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>22
<FILENAME>slide05.jpg
<TEXT>
begin 644 slide05.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" %F K<# 2(  A$! Q$!_\0
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M>-;GQAXKN+<Z@Z%(H+<Y"Y 7)/3 7@#GUKB_AGX0TCQ5XA\4'68&N8+>Z8)
M794W,[_,<$9( X^IK1QIM2?DMN_D2G+0]\M[FWO(%GM9XIX6^[)$X93]"*J-
MKVCK=?96U:P%QG;Y1N4WY],9S7CGPNNK32=-\=6-[>3P:59R'+HY#1K\ZDKC
MHQ '3OBN5U[2-%;P)+J.A>$M0CLQ(&76K^Y =P7Q@(#R">.E2L.N=Q;'[32Y
M],7%S;VD#37,\<$2_>>5PJC\34%EJVFZD6%AJ%I=%>6\B97Q^1KQSQ+H'B#Q
M-X"\%:A:VS:M!:VJ/=V)D*F8E5P>N3P"..>:C\$ZCX1LO&UE!<^$+[PYK4G[
MJ#=+(8V8Y&,'!YZ<@CI4^P7*VG=CY];'M%[JFGZ:%-]?6UJ'^Z9YE3/TR:L1
M2QSQ++#(DD;C*NC9!'L:^=T63Q3\2/$MQJ?AF[\1BUF:WBMX[D1+;J&91U([
M+V[YKN_A'I/B#0IM8L=0TRZL=)>036,=Q*KF/).5R#Z8S]*4Z"C&]]0C-MG;
M>*]8O-"\.W-_I^FS:C=H (K>)2Q8GN<<X'4UYVGCWQKX<UG15\76%A]AUAPD
M:VP(EA)('(SU&X9'ZUZK>ZA9:;!Y]_=P6L.<>9/($7/IDUXS\1K"?PKXGTWQ
MS->IK-K)=XCLKD$I I&5\OG'0$Y]<&G049>ZUN$VUJF>WUYCKGCCQ-J7CBZ\
M*>#[2R\ZSCWW%S>DX'3.!Z#<!WKTN*02Q)(N<.H89]Z\D\3>"=+\7>,+R^\+
M>)DLO$%N!]KBB8D CY<DKRIXP>M114;OF'.]M#5\,^-O$<7C3_A$_%VGVZ7<
MD>^"[M ?+?@G!^H!YXY&,5WM[J^FZ:RK?ZC:6I;E1/,J9^F37DFA^)/&W@[Q
MQIGAKQ7<1ZA:ZBP2&8,&89. P; )YQD,.]0ZQ9^&/$'CG6/[/\-ZIXHU)#Y=
MSYET([:W;I@,<$8P1CV.*UE23EY6Z?UH2IV1ZWJ.N6&GZ%/JS75NUM'&SH_F
MJ%<@'"ANF21BO/?AOXU\4^,=4^TWDVBQZ:?,W6D;8N5P."%SG;D@9-<E\.;"
MWU/X;^,K#4(?-M[5VFBA9R1'(J,01CT*C\JC\)06^B_!76/%%C (];/F6HO%
M)W+&S(/H,9ZU7L8Q4H[NZ7WBYVVF>\#6=+:]^Q+J5F;O./($Z[\_[N<UR7Q(
M^(/_  A5E:QVD=O<7]U)L"22?ZI?[[*.2/3I7D-EX1GU/P-;-IW@C49-5E43
M1ZREZF';.<[=W3'XUJ?%+3ICX4\):EK%GY>O2E;:\=FRS!0>#@X]_P :(T(*
M:3=P<Y<I[C:^(-&O)(88-7L)IY1\D<=RC,_K@ Y/0U9NM2L+&2&.[O;:WDF.
MV)9I50R'T4$\GD=/6O'OB3X9L_!D'AOQ+H%DMM%IET!+'&2>&;=WYZ[A_P "
MJV)(O'?QPMI8B)M+T*U68,.5,C#</QRP_P"^*R]C%KF3TU*YW>Q[!7BWASQ9
M\3/%S:B^D2Z((K.X,+"XB92>N,8SV%>TUY%\"O\ 4>)O^PA_C2I64)2M>UAR
MO=(T_"GQ UG_ (2]_"7B^Q@M=39=UO- ?DEXSCJ>HS@CT(ZUWM[K&F::ZI?:
MC:6K,,J)YU0G\S7DOCDB;X]>$H[?YIHUB,@7J!O8\_AFJNIV7AGQ#XPUM]+\
M-:IXGOPQ2YDFNA';0/R/E;@]B,>W%:.E&5I;71*DU='KFL:_8Z1X>N=9>>&2
M"*)I(\2J!*0"0JMT).,"L/X>>-!XRT,W=R]I%>F60_9(I 6CC!PI(SG\<5Y;
MX!LH-4^$7BZTOX_/ALVDG@C9CB*18B01]",UI?#O3_#FG_"6_P#$&J"2U>9)
MK:YN[=V$K1[QA%]R<#I1*C&,6NM["4VVF>PIKVCR77V5-6L&N"=OE+<H7SZ8
MSFM"OEWQ3I.F0>"+?4=&\)7UA:B9/+U>]N1YLP.<?(#T/KQT%?2/A^62?PWI
M<TKEY'M(F9CU)*#)K.K24$FF7&;;L6[FZM[* SW5Q%!$.LDKA5'XFFV=_9ZA
M$9;*[@N8P<%X) X_,5X]K]JOC7XYIX=UEY&TFQM_,CM0Y42-L#$GZD_7 J/4
M-+MOA]\8O#T/AS?;VNJ@1W-F'++@MMS@_F/0@TU15K7UM<7._D>OG6=*#7"G
M4K,-;?Z\&=<Q?[W/R_C4]I>VE_!YUE=0W,6<>9#('7/U%>%^'O#&F^*/C/XM
MMM6B::T@FDE,&\JLC;P!NQUQDUJ?"VUCT3XJ>+=#LBZV$2DQQ%L@;7&/QPV,
MTY4(I.SU2N"F[GL]>%:]\7?$=KXAU&?38K5_#]C?):NYB)9NN?FSWVOC\*]4
M\<Z\/#?@S4]3# 2QPE8?>1OE7]3G\*\'TK7_  A#\(K_ ,/W=Y+_ &Q>,UPQ
M^SL0)0?D&[IT4<_[1JL/337,U?H*I+6R9]":KJ9B\*WFJV+*Q2R>X@9AD'Y"
MRG'ITKS#PSX@^*GBS1(]5TZ;0!;NS(!-&RME3@\#-6O >O?VS\$M3MI'W7&G
M6<]LX[[=A*'\CC\*X[PC=_$+2?AK_:GAZ:Q?2H'D9H/*WSC!^9L$<COUZ54*
M7*I+2]^HG*[3/1? /CS5]8\1ZEX9\1V<$&J6(+;[?.UP" 1U/J"".U/^&'C'
M5O%D^OIJA@(L;E8H?*CV\$OUY.?NBLGX-Z;8Z@;_ ,6R:JVH:S=DQW*M'L\@
MDY(QWS@<],#BJ'P6NHK%/&EW.VV&"Y$CMZ*/,)I5(1M.RVL$6]+EOXA_$;Q#
MI/BBXTGPVELZV%E]IO&EBW[>_J.@*_G7H/@_7E\3>$].U?Y1)/$/-"]%D'##
M\P:\-\&>-?#,5_XHU/Q/<2K=:T6B") S[86SD9'U Q_LBNE^ FN1F+5O#WG>
M8D,GVFV)&-R$[6X_!3^-.K1M3T6UOF$9WEON>TT445Q&P4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !112;E'4C\Z %HI-R_P!X?G1N7^\/SI70
M6%HI-R_WA^=&Y?[P_.BZ"PM%)N7^\/SHW+_>'YT706%HI-P/0BC(]:+H!:*3
M(]:,CUHN@%HI,CUHR/6BZ 6BDR/6C<!W%.X"T4FY?[P_.C<O]X?G0!QMIX$>
MV^)UWXP.H*R3P^7]E\K!7Y5&=V?]GTH\"^!7\&W>L3OJ"W?]HS"4 1;/+Y8X
MZG/WJ[+<O]X?G1N7^\/SK1U)M6?]6)Y8WN<1X0^'O_",W'B%Y]0%W'K#Y*+%
ML,8R^1G)S]_]*S_"_P +)O#PO;"XU^6]T&YCD1M/:':"7 &XG/W@!V%>C[E_
MO#\Z-R_WA^=/VT]==Q<D3R=/@[J=O;G2[7QKJ$.AF3S/LBQ_,.<\,&]?;WQ7
M0>+/AV/$6G:%96VI/;QZ5*'#3J9GE QU)(.>.M=QN'J/SHR/44.M4;O<.2-K
M&%XS\.MXK\*WFC)="V:XV_O2F_;A@W3(]/6N6UKX7RZMHOA?3QJR1'0\;G,&
M?.QM[;OE^[[]:]&R/449'J*4:DHJR&XI[G&>+? DGB;Q1H6L+J"VXTN0.8C%
MN\SY@W7(QT]Z-<\"/K'Q!T;Q0-06)=.4*;<Q9,F"Q^]GC[WI79Y'J*,CU%"J
MS0<J%KCO!'@=_"%[K5P]^MU_:5QYP41;/+Y8XZG/WJ[#(]1064#)8#\:E2:3
M2ZCLF[BUQ?@;P))X.OM:N7U!;O\ M*?S0HBV>7RQQU.?O?I79>8G]]?SH\Q/
M[Z_G0I22:74+)NYY[HWPLBL8?$]O?:C]IM]=.2L<6QHOF9ASDY(+#\JQQ\&+
M^31)-'N_&%Y-I\8)M+80[8XW[%AN^8#)XXZUZUYB?WU_.CS$_OK^=:>WJ7O<
MGDB<!>?#2XO/#.BV">(;NTU#28Q'%=6V51P#\NZ/=U''.:CTCX8W:^)+/7?$
MOB2YUJYLN;96B$:H>H/4]#S]:]#\Q/[Z_G1YB?WU_.E[:=K#Y(GGNN?#&>X\
M2W&O^'/$%QHE[=#%P(X]ZN>YQD8SP>_/-;W@OP>/"-A-"^J7>HW$[[Y9KAR1
MGT5<G'4_6ND\Q/[Z_G2>;'_?7\Z3JS<>5@HI.Z,CQ3X8L/%V@S:3J 81.0R2
M)]Z-QT8?Y[FN(LOA!/)>6 \0>)[O5M.TX@VMF\>U1CH"<G(X'X<5Z=YL?]]?
MSH\V/^^OYT1JSBK)@XIN['UYYK_PN^V^))/$/A_7+G1-2F_US1)N5R>IQD=>
MXZ&O0/-C_OK^='FQ_P!]?SI0G*#O$;BGN<#X?^&367B2+Q#X@UVYUO4H1B%I
M4VI'[@9/3)QVJG<?":ZB\1ZAJ&B>*;S2[747+75O#'EFR22 V>.2<<9&:]*\
MV/\ OK^='FQ_WU_.J]M4O>XN2)P7A?X:MX8T[Q%IT.J":TU5&2+?#\\.5902
M<_-PWMTJ[X6\ 0:'X&N/"^H7"W]O<-(9'$?EY#8Z#)Y&.M=?Y\/_ #U3_OH4
M>?#_ ,]4_P"^A2=:;W8U32Z'E<?P>U.&W72XO&VH1Z&LGF+:I'AASGA@W],=
M\5TGC+X>V_BKPU8Z3'?36KV#*T$[YE/ Q\V3DY]<UV'GP_\ /5/^^A1Y\/\
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M?F@NIK&QC:2"W&,N(P &;_:(/O79?#[Q"==MK[/B&/5O*D&P-:_9YX5/:1>
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MQ\;]:FGFM)OLFG+,@EM Y5/X54D_*P)^]W]*UI/@[HCHT*ZGJZ6@N1=0VHN
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MV=C+<YA@8_W1C/X$TY_AGI36DL27M]',VJ-JL5PCJ'AF/]WY<8]B#3YZ=_\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **9YL8C\SS%\O^]GC\Z<74%06 += 3UH 6BB@D 9)P!0 44@(
M90RD$'D$=Z6@ HIAEC$7FF11'C.XGC\Z<"& (((/((H 6BFK(C[MCJVTX.#G
M!]*:UQ"JLS2Q@*<,2PX/H: )**CBN(9B1%-')CKL8'%/5E<95@P]0: %HHHH
M **** "BBB@ HHHH **** "BD5E;.U@<'!P>AI: "BBD#JS,H8$KU /2@!:*
M;YB>9Y>]?,QG;GG'TIU !1129&[&1D<XH 6BF++&[,JNK,OW@#DCZTJR1L[(
MKJ77[R@\CZT .HHIKR)$A>1U11U+' H =12,ZJA=F 4#)8GBD$D9C\P.ICQG
M<#QCZT .HIJR(\?F*ZLA&=P.1^=$<B2IOC=74]U.10 ZBD+JK*I8!F^Z">33
M)+B&$@2S1H3TW,!F@"2BD5E=0RL&4]"#D&EH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** .5\0^*[[1O%6AZ1;Z)<7EOJ+E9
M;I,XAYQZ8XZG)'%=5115-II60CRN33UOK:7P'(2L3ZQ/O4'D6NW[0OX;G44R
M/Q%(]O::U/%YTWA[19'EC/3[4S>5@^G^K;\&KT%/#MA'XHE\0J)/MTEL+9LM
M\FT'.0/7@#/H!45IX3TFT&LJ(#)'K$C27:2'*MD8*CT'4_4FMO:QZ_UW(Y&<
ME;^+]=TU)[J^BO+^T6QFN99)=+>T6"1%W!0Q^\K<CGD8IEIK_B"ZC,-VMW=6
MU[8SF=WTI[:.T81%EVN>&4\KSST-=39>#=/M9-UQ=7^H((&MHX[VX,B1QL,,
MH&!G( &3DX'6F6?@JPM&7=?:E<I' ]O;QW%R66!&&TA1CKCC+9.*.>GV#ED<
M]X%\3O<Z0)KF8V6EZ3801M;/ 3-(2@/G'C.P\A0!S@DU8\1>-=)U&T@TRSU>
M.TCOE?S[N7,)BA7A@N\ [V)VC\3VKI+/PQ86-[I]Y;O.DUE9_8@=X_>Q#& _
M'.",@\8R?6M:6"*92)$5LC&2 :ESAS<R0U&5K'EOAW[#K>F^!=*D:&ZTX6MP
M\T!.Y&EB5 JN.A(WDX/I76>!Q]GCUO3H@5M+'5)8;9,Y"(0K;1[ L<#M5D^#
MM.&C:=IT,MU;_P!G?\>MS#(%FC.,'YL8.0<$$8-:6D:1:Z)8?9+7S&4NTDDD
MK[GD=CEF8]R31.HFG;^M11BTSSGPS?IX:UGQ%>S-_HM_<:A/@G_EM;S-D#W9
M&'_?-8*Z?-::'JMK=6ZW=U)XBLI)X9& $LCJC,I)X RQ%>H7'@C1[JVCMYA.
MR1ZB^HC]YR9&8LRGC[A)/'I3Y_!^FW$US*[W&ZYOHK]\./\ 61@!<<?=^49%
M:*M&]Q<CL<II5FLOQ#LX(]"L_#=Q81-/(D#@M?1,"N%V*%*AN3GD$#CG-0V&
MI:OIOA#3/[/$\5F]W>?:[JVM/M,D.)GV_N_[I.<G!QBN^U'0[34M1T[4)&EC
MNM/D+PR1-M)###(W'*D=1["L\^#+%+.U@MKW4+1[625XIX)PKCS&+.IX((R>
MXXP*GVD7O_6X^5]"32-0O=7\&BZM[ZTGOGAD6.XMT(C,@R =K<@Y RIZ'(KD
MT^(=VMW874OE?V8=+WW7R\B[,;2!<]N(V&/4BN]TG2K;1=.2RM _EJS.S2-N
M=W8EF9CW)))/UK!E^'>@RZ;=6#)<>1<ZA_:#CS.1)GH..%ZC'H34QE3N[H;4
MM+'/-XJ\12SIIWGSPW=K8P37+VVE-<^9/*I;:0O"* ,>IY]*TK37M?U+6+99
M7&EPQ:5%?W=JUMNDW[W#)\W*@A?KTK>U3PK::GJ#7R7=]8W4D0AFDLIO+,J#
MH&X/3)P1@C/6K%CX=L-.O5NK99%*V:62HS[E$:$D=>2?F.233<X6T0N65SB]
M!\7>(-1N=+O3#=W%MJ$H$MJNEND5M$V<.L_1MO&<\')QBM[QEX@O-*GTO3[$
MRQS7\DFZ:*U:Y>-$7)VQCJ3D#G@<FI[+P5IUA=6\D5SJ!M;60RVUB]P3!"QS
MRJ]>,G )(&>*T=9T*UUM+?SGG@GMI/,M[FW?9)$V,'!]P2"""#2<H<Z:6@TI
M6./?Q3X@LO#5SJ]U'((]*NQYWVBT-NU_;$#E5;[K@MQC@E<=ZFDU_51X>TN\
MN=:L[.34Y'F7RK<W$B1D92.)%!WD#&YCTY]JW(O!NG(ML)9[RY\F[^V.;B;?
MY\V,*S\<[>, 8 ('%0'P+IJ^2;6[U"T>":66W>WF ,(E(+QKD$;"1G!S@]*?
M-3%:1SMAXJ\0:G#IMG!=Q17$NJW%A+<2VA5F2.,L',9/ROTXZ9IT/B#Q-#:R
MWUQJ-K-#I^L#398A:[3<IYBH7)S\K?-T'''O73:?X+TO39K>6"2[9H+R2]4R
M3;R9)$V,22,D$<]>M2MX3TYK*[M"UQY=U?\ ]H2?.,^;O5^./NY4<4W.%]$'
M+(Y>/5]7-]#I^FRV=FUWKE[;R2"V!PB*6W8&,OQU/7O3+GQ?K5G;C2I)O-U
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MW=/:K';S.TL!"EE+G&WM@@<C/>B\>P6EW.O\K_II-_W^?_&CRA_STF_[_/\
MXUP-IK6MS>#YKW6/L\H&IK!&;69XW_X^=F"<#Y1V]0.:FNOB'LU:[C@2T>VM
M+\63P%G^TRG<%9T &T $]#U /2B\>P>_W.X\H?\ /2;_ +_/_C1Y0_YZ3?\
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M,VDS)97YL60,,LPD6/</;+9K*N/"FL:G<W&IW\EE'?SSV>(H68QQ0P2%R-Q
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M %%%% !1110 4444 (0""",@]0:%544*H"J!@ #@4M% !1110 4444 %%%%
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M$'KFN@_X1>X_=_\ %2ZK^Z_U?[NW^3_=_=<?A4UIX?N+6Z@F;7]2G6$\12)
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MK45%:)I2=YFC1116!TA1110 4444 <WKGC;2] \1Z3H=XEP;K4VVQ-&F57G
MW'/<^F:Z2H9;2VGGBGEMXI)H23%(Z LA/7:>WX5-5.UE86IYIXG\32VWBN:_
MAU00V6@M"EQ:"8#[3YA_>_+GYMB%"/?-6/$]VC>/(8+AM;GLO[)\Y8M*DE^]
MYI&\B,CMQFMW3_!.EPZ7/;ZE;VVH75U)+)<74ENNYVD))QG)  ( Y[4F@>%)
M]'O[.[N-2-V]MI@T[)BVEU5]RL3D\XP/PS6W/!;=".61R<6H7Y\"^(M3L;W4
M!I+M&VF274Y:X7! D^;)8#=P QR.:T/'>L77]IQ6.G:H+.;3;5M3D'G!//8'
M$<)YY#8?(^E:MSX(\R'7[2VO_(L=799O(\K(@FR"[+ST; R/7FKUIX3L1J.I
M7^I16VH7%[.) TUNI\J,*%5!G/  Z]R31SPO?^N@N66Q=M=?TRZTZRO?MMO%
M'>1++")954L& /<^]<EH/BY[.;6[>ZL=<OVCU:Y5)+>SDG14#<*&'3'IVK<T
MCP9INGV7V2[M[2_BAN))+/S[96:WC9MPC!.> 2>1CMZ5>T+1CHJ7ZFX\[[7?
M2W>=NW;O.=O7G'K47@DUN5[SL9WP]NY[SP#I-U=3RS321,SR2L68_,W4GFLB
MU\2ZG'I&GZG! +RXU[46C@BFF*)!'A]G8X 5 3QR2:ZCPUHG_"/>&[/2#/\
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MUVOB.#[>P_MFWC@#-'N,6V/9D\_,3U[4NI^#8-6GS<W3B$Z6VGE47# ET82
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M'B'69-&LH&M[87-W=7"6MM$S[5,C9QN/90 2>.U<Q+\.;AX9[5-7A6UDO1>
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M-J/Q&C1117.=04444 %%%% !1110!335M-DGD@34+5IHE+R1K,I9%!P21G@
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M 59TG[EU_P!=S_Z"M5JLZ3]RZ_Z[G_T%:RJ_";4?B-&BBBN<Z@HHHH ****
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M<+*A8X^@)-8?C30-2U75=9%C:R,)=)ME5UPHE:.X9VC#'C=M]?45$(1:U?\
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MI56E8AT4W<P?-'_/.;_OR_\ A2^;_P!,Y_\ OR_^%;M%'MF'L(F%YW.=D_\
MWY?_  H\W_IG-_WY?_"MVBCVK#V$3"\[_IG/_P!^7_PH\[C&R?'_ %Q?_"MV
MBCVS#V$3"\[_ &)_^_+_ .%'G?\ 3.?_ +\O_A6[11[9A[")A>:/^><W_?E_
M\*/.XQLG_P"_+_X5NT4>V8>PB8/FC_GG-_WY?_"CS1_SSF_[\O\ X5O44>V8
M>PB8/FC_ )YS?]^7_P *O:2&\JX8HZAIB1N4C(P/6M"BIE4<E9E0IJ+N@HHH
MJ#0**** "BBB@ HHHH **** "BBB@ HHHH JOIUJ^J1ZDT6;N*)H4DW'A&()
M&.G4"K5%%%P"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *JV>G6
MNGO=/;1;&NIS<3'<3ND( )YZ<*.GI5JBBX!1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
%110!_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46586286455744">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Document And Entity Information - USD ($)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Feb. 27, 2025</div></th>
<th class="th"><div>Jun. 28, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001069530<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">CASSAVA SCIENCES INC<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-K<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentAnnualReport', window );">Document Annual Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec. 31,  2024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">000-29959<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">91-1911336<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">6801 N. Capital of Texas Highway, Building 1; Suite 300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Austin<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">TX<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">78731<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">512<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">501-2444<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, $0.001 par value<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">SAVA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_IcfrAuditorAttestationFlag', window );">ICFR Auditor Attestation Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFinStmtErrorCorrectionFlag', window );">Document Financial Statement Error Correction [Flag]</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityPublicFloat', window );">Entity Public Float</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 558,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">48,307,896<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorFirmId', window );">Auditor Firm ID</a></td>
<td class="text">42<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorName', window );">Auditor Name</a></td>
<td class="text">Ernst & Young LLP<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorLocation', window );">Auditor Location</a></td>
<td class="text">Austin, Texas<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorFirmId">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>PCAOB issued Audit Firm Identifier</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorFirmId</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:nonemptySequenceNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorLocation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorLocation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentAnnualReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an annual report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentAnnualReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFinStmtErrorCorrectionFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates whether any of the financial statement period in the filing include a restatement due to error correction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection w<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFinStmtErrorCorrectionFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPublicFloat">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityPublicFloat</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_IcfrAuditorAttestationFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_IcfrAuditorAttestationFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46586285401792">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 128,574<span></span>
</td>
<td class="nump">$ 121,136<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">7,958<span></span>
</td>
<td class="nump">8,497<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">136,532<span></span>
</td>
<td class="nump">129,633<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">20,964<span></span>
</td>
<td class="nump">21,854<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Intangible assets, net</a></td>
<td class="nump">37<span></span>
</td>
<td class="nump">176<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">157,533<span></span>
</td>
<td class="nump">151,663<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent', window );">Accounts payable and other accrued expenses</a></td>
<td class="nump">7,654<span></span>
</td>
<td class="nump">10,573<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sava_AccruedDevelopmentExpenseCurrent', window );">Accrued development expense</a></td>
<td class="nump">2,440<span></span>
</td>
<td class="nump">3,037<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Accrued compensation and benefits</a></td>
<td class="nump">1,357<span></span>
</td>
<td class="nump">200<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrent', window );">Other current liabilities</a></td>
<td class="nump">299<span></span>
</td>
<td class="nump">385<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">11,750<span></span>
</td>
<td class="nump">14,195<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other non-current liabilities</a></td>
<td class="nump">79<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">11,829<span></span>
</td>
<td class="nump">14,195<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies (Notes 10, 11 and 12)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders' equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock, $0.001 par value; 10,000,000 shares authorized, none issued and outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.001 par value; 120,000,000 shares authorized; 48,203,179 and 42,236,919 shares issued and outstanding at December 31, 2024 and 2023, respectively</a></td>
<td class="nump">48<span></span>
</td>
<td class="nump">42<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">550,767<span></span>
</td>
<td class="nump">518,195<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Retained Earnings (Accumulated Deficit)</a></td>
<td class="num">(405,111)<span></span>
</td>
<td class="num">(380,769)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders' equity</a></td>
<td class="nump">145,704<span></span>
</td>
<td class="nump">137,468<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders' equity</a></td>
<td class="nump">$ 157,533<span></span>
</td>
<td class="nump">$ 151,663<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sava_AccruedDevelopmentExpenseCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accrued development expense, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sava_AccruedDevelopmentExpenseCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sava_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities incurred to vendors for goods and services received, and accrued liabilities classified as other, payable within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset recognized for present right to economic benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 12: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 30: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset recognized for present right to economic benefit, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482686/350-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 15: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 28: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 29: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-5<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 21: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478451/942-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46586283947728">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets (Parentheticals) - $ / shares<br></strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized (in shares)</a></td>
<td class="nump">10,000,000<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized (in shares)</a></td>
<td class="nump">120,000,000<span></span>
</td>
<td class="nump">120,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued (in shares)</a></td>
<td class="nump">48,203,179<span></span>
</td>
<td class="nump">42,236,919<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding (in shares)</a></td>
<td class="nump">48,203,179<span></span>
</td>
<td class="nump">42,236,919<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46586283330304">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Operations - USD ($)<br> shares in Thousands, $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and Development Expense</a></td>
<td class="nump">$ 69,637<span></span>
</td>
<td class="nump">$ 89,423<span></span>
</td>
<td class="nump">$ 68,032<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">71,809<span></span>
</td>
<td class="nump">16,534<span></span>
</td>
<td class="nump">11,988<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">141,446<span></span>
</td>
<td class="nump">105,957<span></span>
</td>
<td class="nump">80,020<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Operating loss</a></td>
<td class="num">(141,446)<span></span>
</td>
<td class="num">(105,957)<span></span>
</td>
<td class="num">(80,020)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestIncomeExpenseNonoperatingNet', window );">Interest income</a></td>
<td class="nump">8,510<span></span>
</td>
<td class="nump">7,833<span></span>
</td>
<td class="nump">2,777<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other income, net</a></td>
<td class="nump">411<span></span>
</td>
<td class="nump">907<span></span>
</td>
<td class="nump">997<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">gain from change in fair value of warrant liabilities, liability</a></td>
<td class="nump">108,183<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (24,342)<span></span>
</td>
<td class="num">$ (97,217)<span></span>
</td>
<td class="num">$ (76,246)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Shares used in computing net loss per share, basic (in shares)</a></td>
<td class="nump">46,329<span></span>
</td>
<td class="nump">41,932<span></span>
</td>
<td class="nump">40,202<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net loss per share, basic (in dollars per share)</a></td>
<td class="num">$ (0.53)<span></span>
</td>
<td class="num">$ (2.32)<span></span>
</td>
<td class="num">$ (1.9)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (24,342)<span></span>
</td>
<td class="num">$ (97,217)<span></span>
</td>
<td class="num">$ (76,246)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockDividendsAndOtherAdjustments', window );">Adjustment for change in fair value of warrant liabilities</a></td>
<td class="num">(43,793)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted', window );">Adjusted numerator, diluted</a></td>
<td class="num">$ (68,135)<span></span>
</td>
<td class="num">$ (97,217)<span></span>
</td>
<td class="num">$ (76,246)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Shares used in computing net loss per share, diluted (in shares)</a></td>
<td class="nump">46,604<span></span>
</td>
<td class="nump">41,932<span></span>
</td>
<td class="nump">40,202<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net loss per share, diluted (in dollars per share)</a></td>
<td class="num">$ (1.46)<span></span>
</td>
<td class="num">$ (2.32)<span></span>
</td>
<td class="num">$ (1.9)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAdjustmentOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (income) related to adjustment to fair value of warrant liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 13<br> -SubTopic 10<br> -Topic 480<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481766/480-10-25-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAdjustmentOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestIncomeExpenseNonoperatingNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of interest income (expense) classified as nonoperating.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestIncomeExpenseNonoperatingNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities, and addition from assumption of issuance of common shares for dilutive potential common shares; of income (loss) available to common shareholders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5<br> -Subparagraph (SAB Topic 6.B)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-5<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-16<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 40<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-40<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 40<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-40<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 40<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-40<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 40<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-40<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockDividendsAndOtherAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate value of preferred stock dividends and other adjustments necessary to derive net income apportioned to common stockholders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5<br> -Subparagraph (SAB Topic 6.B)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-5<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-11<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockDividendsAndOtherAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 912<br> -SubTopic 730<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479532/912-730-25-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46586285531520">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Statements of Stockholders' Equity - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Share-Based Payment Arrangement, Employee [Member] </div>
<div>Common Stock [Member]</div>
</th>
<th class="th">
<div>Share-Based Payment Arrangement, Employee [Member] </div>
<div>Additional Paid-in Capital [Member]</div>
</th>
<th class="th">
<div>Share-Based Payment Arrangement, Employee [Member] </div>
<div>Retained Earnings [Member]</div>
</th>
<th class="th"><div>Share-Based Payment Arrangement, Employee [Member]</div></th>
<th class="th">
<div>Share-Based Payment Arrangement, Nonemployee [Member] </div>
<div>Common Stock [Member]</div>
</th>
<th class="th">
<div>Share-Based Payment Arrangement, Nonemployee [Member] </div>
<div>Additional Paid-in Capital [Member]</div>
</th>
<th class="th">
<div>Share-Based Payment Arrangement, Nonemployee [Member] </div>
<div>Retained Earnings [Member]</div>
</th>
<th class="th"><div>Share-Based Payment Arrangement, Nonemployee [Member]</div></th>
<th class="th"><div>Common Stock [Member]</div></th>
<th class="th"><div>Additional Paid-in Capital [Member]</div></th>
<th class="th"><div>Retained Earnings [Member]</div></th>
<th class="th"><div>Total</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in shares) at Dec. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40,016,792<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 40<span></span>
</td>
<td class="nump">$ 461,181<span></span>
</td>
<td class="num">$ (207,306)<span></span>
</td>
<td class="nump">$ 253,915<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition', window );">Stock-based compensation for stock options</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 1,972<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 1,972<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 94<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 94<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationForfeited', window );">Expiration of restricted stock Performance Awards (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(57,143)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationForfeited', window );">Expiration of restricted stock Performance Awards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Issuance of common stock pursuant to exercise of stock options (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">109,241<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Issuance of common stock pursuant to exercise of stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">475<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">475<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock pursuant to stock offering, net of issuance costs (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,666,667<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock pursuant to stock offering, net of issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2<span></span>
</td>
<td class="nump">47,327<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">47,329<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(76,246)<span></span>
</td>
<td class="num">(76,246)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in shares) at Dec. 31, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">41,735,557<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 42<span></span>
</td>
<td class="nump">511,049<span></span>
</td>
<td class="num">(283,552)<span></span>
</td>
<td class="nump">227,539<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition', window );">Stock-based compensation for stock options</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">4,493<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">4,493<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">93<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">93<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Issuance of common stock pursuant to exercise of stock options (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">501,362<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Issuance of common stock pursuant to exercise of stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">2,560<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">2,560<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(97,217)<span></span>
</td>
<td class="num">(97,217)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in shares) at Dec. 31, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">42,236,919<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 42<span></span>
</td>
<td class="nump">518,195<span></span>
</td>
<td class="num">(380,769)<span></span>
</td>
<td class="nump">$ 137,468<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition', window );">Stock-based compensation for stock options</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 15,054<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 15,054<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 1,237<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 1,237<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Issuance of common stock pursuant to exercise of stock options (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">227,013<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">240,147<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Issuance of common stock pursuant to exercise of stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">918<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 918<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(24,342)<span></span>
</td>
<td class="num">(24,342)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued', window );">Issuance of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="num">(113,363)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(113,363)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sava_StockIssuedDuringPeriodSharesWarrantExercises', window );">Common stock issued pursuant to warrant exercises, net of exercise costs (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,739,247<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sava_StockIssuedDuringPeriodValueWarrantExercises', window );">Common stock issued pursuant to warrant exercises, net of exercise costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6<span></span>
</td>
<td class="nump">123,546<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">123,552<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sava_AdjustmentsToAdditionalPaidInCapitalDerecognitionOfWarrantLiabilitiesUponExerciseOfWarrants', window );">Derecognition of warrant liabilities upon exercise of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">5,180<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">5,180<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in shares) at Dec. 31, 2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">48,203,179<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 48<span></span>
</td>
<td class="nump">$ 550,767<span></span>
</td>
<td class="num">$ (405,111)<span></span>
</td>
<td class="nump">$ 145,704<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sava_AdjustmentsToAdditionalPaidInCapitalDerecognitionOfWarrantLiabilitiesUponExerciseOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in additional paid in capital (APIC) resulting from derecognition of warrant liabilities upon exercise of warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sava_AdjustmentsToAdditionalPaidInCapitalDerecognitionOfWarrantLiabilitiesUponExerciseOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sava_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sava_StockIssuedDuringPeriodSharesWarrantExercises">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued attributable to warrant exercises.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sava_StockIssuedDuringPeriodSharesWarrantExercises</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sava_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sava_StockIssuedDuringPeriodValueWarrantExercises">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of shares of stock issued attributable to exercises of warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sava_StockIssuedDuringPeriodValueWarrantExercises</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sava_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in additional paid in capital (APIC) resulting from the issuance of warrants. Includes allocation of proceeds of debt securities issued with detachable stock purchase warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 25<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481284/470-20-25-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationForfeited">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares (or other type of equity) forfeited during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationForfeited</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478009/946-205-45-4<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationForfeited">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of forfeited shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationForfeited</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46586286113936">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Cash Flows - USD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows from operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (24,342,000)<span></span>
</td>
<td class="num">$ (97,217,000)<span></span>
</td>
<td class="num">$ (76,246,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="nump">16,291,000<span></span>
</td>
<td class="nump">4,586,000<span></span>
</td>
<td class="nump">2,066,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Gain from change in fair value of warrant liabilities</a></td>
<td class="num">(108,183,000)<span></span>
</td>
<td class="nump">(0)<span></span>
</td>
<td class="nump">(0)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation</a></td>
<td class="nump">952,000<span></span>
</td>
<td class="nump">1,084,000<span></span>
</td>
<td class="nump">804,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization of intangible assets</a></td>
<td class="nump">180,000<span></span>
</td>
<td class="nump">446,000<span></span>
</td>
<td class="nump">497,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">539,000<span></span>
</td>
<td class="nump">1,714,000<span></span>
</td>
<td class="nump">1,189,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sava_IncreaseDecreaseInOperatingLeaseRightOfUseAssetsAndLiabilitiesNet', window );">Operating lease right-of-use assets and liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(17,000)<span></span>
</td>
<td class="num">(9,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable and other accrued expenses</a></td>
<td class="num">(2,919,000)<span></span>
</td>
<td class="nump">6,896,000<span></span>
</td>
<td class="num">(3,449,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sava_IncreaseDecreaseInDevelopmentExpense', window );">Accrued development expense</a></td>
<td class="num">(597,000)<span></span>
</td>
<td class="nump">757,000<span></span>
</td>
<td class="num">(523,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities', window );">Accrued compensation and benefits</a></td>
<td class="nump">1,157,000<span></span>
</td>
<td class="nump">30,000<span></span>
</td>
<td class="num">(1,707,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities', window );">Other liabilities</a></td>
<td class="num">(7,000)<span></span>
</td>
<td class="num">(304,000)<span></span>
</td>
<td class="num">(136,000)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(116,929,000)<span></span>
</td>
<td class="num">(82,025,000)<span></span>
</td>
<td class="num">(77,514,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows from investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of property and equipment</a></td>
<td class="num">(103,000)<span></span>
</td>
<td class="num">(414,000)<span></span>
</td>
<td class="num">(2,712,000)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash used in investing activities</a></td>
<td class="num">(103,000)<span></span>
</td>
<td class="num">(414,000)<span></span>
</td>
<td class="num">(2,712,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds from issuance of common stock upon exercise of stock options</a></td>
<td class="nump">918,000<span></span>
</td>
<td class="nump">2,560,000<span></span>
</td>
<td class="nump">475,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromWarrantExercises', window );">Proceeds from exercise of common stock warrants, net of exercise costs</a></td>
<td class="nump">123,552,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from common stock offering, net of issuance costs</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">47,329,000<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">124,470,000<span></span>
</td>
<td class="nump">2,560,000<span></span>
</td>
<td class="nump">47,804,000<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect', window );">Net increase (decrease) in cash and cash equivalents</a></td>
<td class="nump">7,438,000<span></span>
</td>
<td class="num">(79,879,000)<span></span>
</td>
<td class="num">(32,422,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations', window );">Cash and cash equivalents at beginning of period</a></td>
<td class="nump">121,136,000<span></span>
</td>
<td class="nump">201,015,000<span></span>
</td>
<td class="nump">233,437,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations', window );">Cash and cash equivalents at end of period</a></td>
<td class="nump">128,574,000<span></span>
</td>
<td class="nump">121,136,000<span></span>
</td>
<td class="nump">201,015,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract', window );"><strong>Non-cash investing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid', window );">Purchases of property and equipment included in accounts payable</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">340,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sava_IssuanceOfWarrantsResultingInRecognitionOfWarrantLiabilities', window );">Issuance of warrants resulting in recognition of warrant liabilities</a></td>
<td class="nump">113,363,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sava_DerecognitionOfWarrantLiabilitiesThroughExercises', window );">Derecognition of warrant liabilities upon exercise of warrants</a></td>
<td class="num">$ (5,180,000)<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sava_DerecognitionOfWarrantLiabilitiesThroughExercises">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the cash flow effect of derecognition of warrant liabilities through exercises.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sava_DerecognitionOfWarrantLiabilitiesThroughExercises</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sava_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sava_IncreaseDecreaseInDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in development expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sava_IncreaseDecreaseInDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sava_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sava_IncreaseDecreaseInOperatingLeaseRightOfUseAssetsAndLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in operating lease right of use assets and liabilities, net.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sava_IncreaseDecreaseInOperatingLeaseRightOfUseAssetsAndLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sava_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sava_IssuanceOfWarrantsResultingInRecognitionOfWarrantLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of issuance of warrants resulting in recognition of warrant liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sava_IssuanceOfWarrantsResultingInRecognitionOfWarrantLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sava_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482686/350-30-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Future cash outflow to pay for purchases of fixed assets that have occurred.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-3<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalExpendituresIncurredButNotYetPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; excluding effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -SubTopic 230<br> -Topic 830<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477401/830-230-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAdjustmentOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (income) related to adjustment to fair value of warrant liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 13<br> -SubTopic 10<br> -Topic 480<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481766/480-10-25-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAdjustmentOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in operating liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherOperatingLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncashInvestingAndFinancingItemsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromWarrantExercises">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from holders exercising their stock warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromWarrantExercises</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46586286368432">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Insider Trading Arrangements<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_InsiderTradingArrLineItems', window );"><strong>Insider Trading Arr Line Items</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_Rule10b51ArrAdoptedFlag', window );">Rule 10b5-1 Arrangement Adopted [Flag]</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_NonRule10b51ArrAdoptedFlag', window );">Non-Rule 10b5-1 Arrangement Adopted [Flag]</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_Rule10b51ArrTrmntdFlag', window );">Rule 10b5-1 Arrangement Terminated [Flag]</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_NonRule10b51ArrTrmntdFlag', window );">Non-Rule 10b5-1 Arrangement Terminated [Flag]</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_InsiderTradingArrLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_InsiderTradingArrLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_NonRule10b51ArrAdoptedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_NonRule10b51ArrAdoptedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_NonRule10b51ArrTrmntdFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_NonRule10b51ArrTrmntdFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_Rule10b51ArrAdoptedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_Rule10b51ArrAdoptedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_Rule10b51ArrTrmntdFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_Rule10b51ArrTrmntdFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46586284642048">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cybersecurity Risk Management and Strategy Disclosure<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems', window );"><strong>Cybersecurity Risk Management, Strategy, and Governance [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock', window );">Cybersecurity Risk Management Processes for Assessing, Identifying, and Managing Threats [Text Block]</a></td>
<td class="text">
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -1pt;"><i>Risk Management and Strategy</i></p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -1pt;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -1pt; text-indent: 18pt;">In the normal course of business, we collect and store sensitive information, including proprietary and confidential business information, intellectual property, information regarding clinical and non-clinical trials, sensitive <em style="font: inherit;">third</em>-party information and employee information.</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -1pt; text-indent: 18pt;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -2pt; text-indent: 18pt;">We have processes designed to protect our information systems, data, assets, infrastructure, and computing environments from cybersecurity threats and risks. Our cybersecurity strategy includes the use of managed detection and response services to monitor our network infrastructure and associated endpoints for possible cybersecurity threats. In addition, we use multi-factor authentication, perform periodical penetration testing and other logical, physical and technical controls designed to deter, prevent, mitigate and respond to cybersecurity threats. Further, our information systems include continuous alert plans, and we provide periodical cybersecurity reminders to our employees to emphasizes the importance of adherence to our security policies.</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -2pt; text-indent: 18pt;">We conduct organizational risk assessment, which help management in identifying data assets and recognizing and assessing potential threats, and investigating potential vulnerabilities. We are in the process of reviewing and <span style="-sec-ix-hidden:c123855784">implementing</span> incremental information technology strategies to mitigate cybersecurity risks and their possible impacts. Risk assessments enable management to make risk management decisions and assign resources to mitigate risk. We also periodically engage <span style="-sec-ix-hidden:c123855379">third</span> parties to assess the effectiveness of our cybersecurity practices.</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;">&#160;</p>
   As of the date of this Annual Report, we do not believe that any past cybersecurity incidents that have been detected have materially affected, or are reasonably likely to materially affect, our business strategy, results of operations, or financial condition.<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -2pt; text-indent: 18pt;"></p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -1pt; text-indent: 18pt;">See &#8220;Risk Factors - Risks Related to Our Business and Operations&#8221; for additional information about the risks to our business associated with cybersecurity or a breach or compromise to our information security systems.</p>
  <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementProcessesIntegratedFlag', window );">Cybersecurity Risk Management Processes Integrated [Flag]</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock', window );">Cybersecurity Risk Management Processes Integrated [Text Block]</a></td>
<td class="text">We have processes designed to protect our information systems, data, assets, infrastructure, and computing environments from cybersecurity threats and risks. Our cybersecurity strategy includes the use of managed detection and response services to monitor our network infrastructure and associated endpoints for possible cybersecurity threats. In addition, we use multi-factor authentication, perform periodical penetration testing and other logical, physical and technical controls designed to deter, prevent, mitigate and respond to cybersecurity threats. Further, our information systems include continuous alert plans, and we provide periodical cybersecurity reminders to our employees to emphasizes the importance of adherence to our security policies.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementThirdPartyEngagedFlag', window );">Cybersecurity Risk Management Third Party Engaged [Flag]</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag', window );">Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Flag]</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock', window );">Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Text Block]</a></td>
<td class="text">As of the date of this Annual Report, we do not believe that any past cybersecurity incidents that have been detected have materially affected, or are reasonably likely to materially affect, our business strategy, results of operations, or financial condition.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock', window );">Cybersecurity Risk Board of Directors Oversight [Text Block]</a></td>
<td class="text">
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -20pt; text-indent: 18pt;"><i>Governance</i></p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -2pt; text-indent: 18pt;">Our Director of Information Technology has responsibilities which include preventing and monitoring cybersecurity threats and utilizes the assistance of external vendors in this effort. Our Director of Information Technology regularly reports to senior management regarding the status of our cybersecurity program, emerging cybersecurity threats, long-term cybersecurity investments and strategies, and oversight of our cybersecurity profile.</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -2pt; text-indent: 18pt;"><span style="-sec-ix-hidden:c123855789">Our full Board of Directors oversees the risk management process for the Company, which includes identifying, assessing and managing enterprise-level risks. The Board administers this oversight function directly through the Board of Directors as a whole, as well as through its standing committees that address risks inherent in their respective areas of oversight. The risk oversight responsibility of the Board of Directors and its committees is supported by the management reporting processes, which are designed to provide visibility to the Board of Directors and to the personnel who are responsible for risk assessment and information about the identification, assessment and management of critical risks, and management&#8217;s risk mitigation strategies. Our cybersecurity risk program directly integrates and is intended to align with the Board of Directors&#8217; overall risk management process.</span></p>
  <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock', window );">Cybersecurity Risk Board Committee or Subcommittee Responsible for Oversight [Text Block]</a></td>
<td class="text">Our full Board of Directors oversees the risk management process for the Company, which includes identifying, assessing and managing enterprise-level risks. The Board administers this oversight function directly through the Board of Directors as a whole, as well as through its standing committees that address risks inherent in their respective areas of oversight. The risk oversight responsibility of the Board of Directors and its committees is supported by the management reporting processes, which are designed to provide visibility to the Board of Directors and to the personnel who are responsible for risk assessment and information about the identification, assessment and management of critical risks, and management&#8217;s risk mitigation strategies.  Our cybersecurity risk program directly integrates and is intended to align with the Board of Directors&#8217; overall risk management process.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock', window );">Cybersecurity Risk Process for Informing Board Committee or Subcommittee Responsible for Oversight [Text Block]</a></td>
<td class="text">Our full Board of Directors oversees the risk management process for the Company, which includes identifying, assessing and managing enterprise-level risks. The Board administers this oversight function directly through the Board of Directors as a whole, as well as through its standing committees that address risks inherent in their respective areas of oversight. The risk oversight responsibility of the Board of Directors and its committees is supported by the management reporting processes, which are designed to provide visibility to the Board of Directors and to the personnel who are responsible for risk assessment and information about the identification, assessment and management of critical risks, and management&#8217;s risk mitigation strategies. Our cybersecurity risk program directly integrates and is intended to align with the Board of Directors&#8217; overall risk management process.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskRoleOfManagementTextBlock', window );">Cybersecurity Risk Role of Management [Text Block]</a></td>
<td class="text">Our Director of Information Technology has responsibilities which include preventing and monitoring cybersecurity threats and utilizes the assistance of external vendors in this effort. Our Director of Information Technology regularly reports to senior management regarding the status of our cybersecurity program, emerging cybersecurity threats, long-term cybersecurity investments and strategies, and oversight of our cybersecurity profile.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag', window );">Cybersecurity Risk Management Positions or Committees Responsible Report to Board [Flag]</a></td>
<td class="text">true<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 1<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 1<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph iii<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph iii<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 1<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementProcessesIntegratedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph i<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph i<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementProcessesIntegratedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph i<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph i<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementThirdPartyEngagedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph ii<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph ii<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementThirdPartyEngagedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 2<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 2<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 1<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskRoleOfManagementTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 2<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskRoleOfManagementTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46586285958064">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 1 - General, Liquidity and Basis of Presentation<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes to Financial Statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock', window );">Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]</a></td>
<td class="text">
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><em style="font: inherit;">1.</em></b> <b>General, Liquidity and Basis of Presentation</b></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">Cassava Sciences, Inc. and its wholly-owned subsidiary (collectively referred to as the &#8220;Company&#8221;) discovers and develops proprietary pharmaceutical product candidates that <em style="font: inherit;"> may </em>offer significant improvements to patients and healthcare professionals. The Company generally focuses its product discovery and development efforts on disorders of the nervous system.</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>Basis of Consolidation</i></b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;&#65279;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">The consolidated financial statements include the accounts of the Company and its wholly-owned subsidiary. All intercompany transactions have been eliminated in consolidation.</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>Liquidity </i></b></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">The Company has incurred significant net losses and negative cash flows since inception, and as a result has an accumulated deficit of $405.1&#160;million at <em style="font: inherit;"> December 31, 2024. </em>The Company expects its cash requirements to be significant in the future. The amount and timing of the Company&#8217;s future cash requirements will depend on regulatory and market acceptance of its product candidates and the resources it devotes to researching and developing, formulating, manufacturing, commercializing and supporting its products. The Company <em style="font: inherit;"> may </em>seek additional funding through public or private financing in the future, if such funding is available and on terms acceptable to the Company. There are <em style="font: inherit;">no</em> assurances that additional financing will be available on favorable terms, or at all. However, management believes that the current working capital position will be sufficient to meet the Company&#8217;s working capital needs for at least the next <em style="font: inherit;">12</em> months.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;&#160;</p>
  <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480424/946-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480424/946-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/810/tableOfContent<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/205/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46586285903472">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 2 - Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes to Financial Statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Significant Accounting Policies [Text Block]</a></td>
<td class="text">
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><em style="font: inherit;">2.</em> Summary of Significant Accounting Policies</b></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i></i></b></p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>Use of Estimates</i></b></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">The Company makes estimates and assumptions in preparing its consolidated financial statements in conformity with accounting principles generally accepted in the United States. These estimates and assumptions affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amount of revenue earned and expenses incurred during the reporting period. The Company evaluates&#160;its estimates on an ongoing basis, including those estimates related to legal liabilities, common stock warrant liabilities, stock based compensation, clinical trials and manufacturing agreements. Actual results could differ from these estimates and assumptions.</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&#160;</p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i></i></b></p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>Proceeds from Grants</i></b></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">During <em style="font: inherit;">2024</em> and <em style="font: inherit;">2023,</em> there were no reimbursements received pursuant to National Institutes of Health (&#8220;NIH&#8221;) research grants. In <em style="font: inherit;">2022,</em> the Company received $0.9 million of reimbursement&#160;from the NIH&#160;and National Institute on Drug Abuse. The Company records the proceeds from these grants as reductions to its <span style="-sec-ix-hidden:c123855795">research and development expenses</span>.</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"></p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">&#160;</p>


   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i></i></b></p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>Cash and Cash Equivalents and Concentration of Credit Risk</i></b></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">The Company invests in cash and cash equivalents. The Company considers highly-liquid financial instruments with original maturities of <em style="font: inherit;">three</em> months or less to be cash equivalents. Highly liquid investments that are considered cash equivalents include money market accounts and funds, certificates of deposit and U.S. Treasury securities. The Company maintains&#160;its cash and cash equivalents at <em style="font: inherit;">one</em> financial institution.</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&#160;</p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i></i></b></p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>Fair Value Measurements </i></b></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&#160;</p>
   <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 18pt;">The Company recognizes financial instruments in accordance with the authoritative guidance on fair value measurements and disclosures for financial assets and liabilities. This guidance defines fair value, establishes a framework for measuring fair value in accordance with GAAP, and expands disclosures about fair value measurements. The guidance also establishes a <em style="font: inherit;">three</em>-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value. These tiers include:</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 36pt;text-indent:-18pt;">&#160;</p>
   <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;"><tbody><tr style="vertical-align: top;"><td style="width: 18pt;">&#160;</td><td style="width: 18pt;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p> </td><td style="width: auto;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Level <em style="font: inherit;">1</em> includes quoted prices in active markets.</p> </td></tr>
</tbody></table>
   <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;"><tbody><tr style="vertical-align: top;"><td style="width: 18pt;">&#160;</td><td style="width: 18pt;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p> </td><td style="width: auto;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Level <em style="font: inherit;">2</em> includes significant observable inputs, such as quoted prices for identical or similar securities, or other inputs that are observable and can be corroborated by observable market data for similar securities. The Company uses market pricing and other observable market inputs obtained from <em style="font: inherit;">third</em>-party providers. It uses the bid price to establish fair value where a bid price is available. The Company does <em style="font: inherit;">not</em> have any financial instruments where the fair value is based on Level <em style="font: inherit;">2</em> inputs.</p> </td></tr>
</tbody></table>
   <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;"><tbody><tr style="vertical-align: top;"><td style="width: 18pt;">&#160;</td><td style="width: 18pt;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p> </td><td style="width: auto;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Level <em style="font: inherit;">3</em> includes unobservable inputs that are supported by little or <em style="font: inherit;">no</em> market activity. The Company does <em style="font: inherit;">not</em> have any financial instruments where the fair value is based on Level <em style="font: inherit;">3</em> inputs.</p> </td></tr>
</tbody></table>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">If a financial instrument uses inputs that fall in different levels of the hierarchy, the instrument will be categorized based upon the lowest level of input that is significant to the fair value calculation. The fair value of cash and cash equivalents was based on Level <em style="font: inherit;">1</em> inputs at <em style="font: inherit;"> December 31, 2024&#160;</em>and <em style="font: inherit;">2023.</em></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify; text-indent: 18pt;">The fair value of common stock warrants of $6.71 per warrant was determined at distribution on <em style="font: inherit;"> January 3, 2024 </em>using a Monte Carlo valuation model since the warrants were&#160;<em style="font: inherit;">not</em> traded on the open market on <em style="font: inherit;"> January 3, 2024. </em>Warrant trading on Nasdaq began on <em style="font: inherit;"> January 4, 2024. </em>Quantitative information regarding Level <em style="font: inherit;">3</em> fair value measurements for common stock warrants is&#160;as follows:</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&#160;</p>

    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"><tbody><tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 85%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Exercise price per warrant</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">33.00</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Conversion rate - common shares per warrant</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">1.50</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Closing price of common stock</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">23.72</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Volatility</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">75</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">%</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Risk-free interest rate</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">5.40</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">%</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Expected life of option (in years)</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">0.3</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Dividend yield</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: right; margin: 0pt;"><span style="-sec-ix-hidden:c123854924">zero</span></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
</tbody></table>

   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -1pt; text-indent: 18pt;">The common stock warrants stopped&#160;trading on Nasdaq after <em style="font: inherit;"> May 2, 2024 </em>and subsequently had little or <em style="font: inherit;">no</em> market activity. As of <em style="font: inherit;"> May 7, 2024,&#160;</em>the warrants were presumed to have <em style="font: inherit;">no</em> value since they&#160;were redeemed for a nominal payment of $0.001 per warrant.</p>
   <p style="margin: 0pt 0pt 0pt -9pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">&#160;</p><p style="margin: 0pt 0pt 0pt -9pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i></i></b></p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>Segment Information</i></b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">The Company reports segment information based on how it internally evaluates the operating performance of its business units, or segments. The Company&#8217;s operations are confined to one business segment: the development of novel drugs and diagnostics.</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-indent: 18pt; text-align: justify;">The Company&#8217;s reportable segment&#160;reflects the manner in which its chief operating decision maker ("CODM") allocates resources and assesses performance. The Company's CODM is the President and Chief Executive Officer. The primary measure used by the Company's CODM for purposes of allocating resources is based on net loss that also is reported on the income statement as consolidated net loss. The measure of segment assets is reported on the balance sheet as cash and cash equivalents.</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-indent: 18pt;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify; text-indent: 18pt;">The Company has <em style="font: inherit;">not</em> generated any product revenue in the current period and expects to continue to incur significant expenses and operating losses for the foreseeable future as we advance our product candidates through stages of development and clinical trials.</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify; text-indent: 18pt;">As such, the CODM uses cash forecast models in deciding how to invest in&#160;the development of novel drugs and diagnostics. Such cash forecast models are reviewed to assess the entity-wide operating results and performance. Net loss is used to monitor budget versus actual results. Monitoring budgeted versus actual results, net cash used in operating activities for the period and cash on hand are used in assessing performance of the segment.</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-indent: 18pt;">&#160;</p>


   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-indent: 18pt;">The following table summarizes expenses by category regularly reviewed by the CODM&#160;(in thousands):</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"><tbody><tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td colspan="10" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;"><em style="font: inherit;"><em style="font: inherit;">Years Ended December 31,</em></em></em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">2024</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">2023</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">2022</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 55%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Operating expenses</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Research and development</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">69,637</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">89,423</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">68,032</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">General and administrative</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">71,809</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">16,534</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">11,988</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Other segment items(a)</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(117,104</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(8,740</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(3,774</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Net loss</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">24,342</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">97,217</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">76,246</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td></tr>
</tbody></table>

   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">(a) Other segment items include interest income, other income, net and gain from change in fair value of warrant liabilities.</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 18pt;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 18pt;">The following table summarizes assets regularly reviewed by the CODM&#160;(in thousands):</p>

    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"><tbody><tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>December 31,</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>2024</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>2023</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 70%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Cash and cash equivalents</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">128,574</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">121,136</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td></tr>
</tbody></table>

   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-indent: 18pt;">For the year ended <em style="font: inherit;"> December 31, 2024, </em>and <em style="font: inherit;">2023,</em> the net cash used in operating activities was $116.9&#160;million and $82.0&#160;million, respectively.&#160;</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p><p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i></i></b></p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>Stock-based Compensation</i></b><b> </b></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">The Company recognizes non-cash expense for the fair value of all stock options and other share-based awards. The Company uses the Black-Scholes option valuation model (&#8220;Black-Scholes&#8221;) to calculate the fair value of stock options, using the single-option award approach and straight-line attribution method. This model requires the input of subjective assumptions including expected stock price volatility, expected life and estimated forfeitures of each award. These assumptions consist of estimates of future market conditions, which are inherently uncertain, and therefore, are subject to management&#8217;s judgment. For all options granted, it recognizes the resulting fair value as expense on a straight-line basis over the vesting period of each respective stock option, generally <span style="-sec-ix-hidden:c123855418">one</span>&#160;to&#160;<span style="-sec-ix-hidden:c123855419">four</span> years.</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">The Company has granted share-based awards that vest upon achievement of certain performance criteria (&#8220;Performance Awards&#8221;). The Company multiplies the number of Performance Awards by the fair value of its common stock on the date of grant to calculate the fair value of each award. It estimates an implicit service period for achieving performance criteria for each award. The Company recognizes the resulting fair value as expense over the implicit service period when it concludes that achieving the performance criteria is probable. It periodically reviews and updates as appropriate its estimates of implicit service periods and conclusions on achieving the performance criteria. Performance Awards vest and common stock is issued upon achievement of the performance criteria.</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">&#160;</p>


   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i></i></b></p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>Net Loss per Share</i></b></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-indent: 18pt; text-align: justify;">Basic net loss&#160;per common share is computed by dividing the net loss&#160;available to common stockholders by the weighted-average number of common shares outstanding during the period. Diluted net loss&#160;per common share is computed by dividing the net loss&#160;available to common stockholders by the weighted-average number of common shares outstanding and potentially dilutive securities outstanding during the period using the treasury stock method. Potentially dilutive securities are excluded from the computations of diluted earnings per share if their effect would be anti-dilutive. A net loss&#160;causes all potentially dilutive securities to be anti-dilutive. Potentially dilutive securities consist of outstanding common stock options&#160;and Performance Awards.&#160;There is <em style="font: inherit;">no</em> difference between the Company&#8217;s net loss and comprehensive loss. The numerators and denominators in the calculation of basic and diluted net loss per share were as follows (in thousands, except net loss per share data):</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>

    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"><tbody><tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="10" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;"><em style="font: inherit;"><em style="font: inherit;">Years ended December 31,</em></em></em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">2024</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">2023</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">2022</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 55%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Numerator, basic:</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Net loss</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(24,342</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(97,217</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(76,246</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Denominator, basic:</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Weighted average common shares outstanding</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">46,329</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">41,932</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">40,202</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Net loss per share, basic</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(0.53</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(2.32</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(1.90</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">)</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Numerator, diluted:</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Net loss</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(24,342</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(97,217</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(76,246</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Adjustment for change in fair value of warrant liabilities</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(43,793</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;">&#8212;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;">&#8212;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Adjusted numerator, diluted</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(68,135</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(97,217</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(76,246</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Denominator, diluted:</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Weighted average common shares outstanding</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">46,329</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">41,932</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">40,202</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Dilutive effect of common stock warrants</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">275</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">&#8212;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">&#8212;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Weighted average dilutive common shares</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">46,604</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">41,932</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">40,202</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Net loss per share, diluted</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(1.46</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(2.32</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(1.90</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">)</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Dilutive common stock options excluded from net loss per share, diluted</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">3,154</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">2,123</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">2,055</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Dilutive Performance Awards excluded from loss per share, diluted</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">7</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">7</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">7</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
</tbody></table>

   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"></p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"><b><i></i></b></p><p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"><b><i>Warrant Liabilities</i></b></p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 18pt;">The Company accounts for warrants as either equity-classified or liability-classified instruments based on an assessment of the warrant&#8217;s specific terms and in accordance with the Financial Accounting Standards Board (&#8220;FASB&#8221;) Accounting Standards Codification (&#8220;ASC&#8220;) <em style="font: inherit;">480,</em> &#8220;Distinguishing Liabilities from Equity&#8221;, and ASC <em style="font: inherit;">815,</em> &#8220;Derivatives and Hedging&#8221;. The assessment considers whether the warrants are freestanding financial instruments pursuant to ASC <em style="font: inherit;">480,</em> meet the definition of a liability pursuant to ASC <em style="font: inherit;">480,</em> and whether the warrants meet all of the requirements for equity classification under ASC <em style="font: inherit;">815,</em> including whether the warrants are indexed to the Company&#8217;s own shares, among other conditions for equity classification. This assessment, which requires the use of professional judgment, is conducted at the time of warrant issuance and as of each subsequent quarterly period end date while the warrants are outstanding.</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 18pt;">For issued or modified warrants that meet all of the criteria for equity classification, the warrants are required to be recorded as a component of additional paid-in capital at the time of issuance. For issued or modified warrants that do <em style="font: inherit;">not</em> meet all the criteria for equity classification, the warrants are required to be recorded at their initial fair value of the date of issuance, and each balance sheet date thereafter. Changes in the estimated fair value of liability classified warrants are recognized as a non-cash gain or loss on the statements of operations. Costs associated with issuing the warrants classified as derivative liabilities are charged to operations when the warrants are issued.</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&#160;</p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"></p>


   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i></i></b></p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>Fair Value of Financial Instruments</i></b></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">Financial instruments include accounts payable, accrued expenses, accrued development expense and other liabilities. The estimated fair value of certain financial instruments <em style="font: inherit;"> may </em>be determined using available market information or other appropriate valuation methodologies. However, considerable judgment is required in interpreting market data to develop estimates of fair value; therefore, the estimates are <em style="font: inherit;">not</em> necessarily indicative of the amounts that could be realized or would be paid in a current market exchange. The effect of using different market assumptions and/or estimation methodologies <em style="font: inherit;"> may </em>be material to the estimated fair value amounts. The carrying amounts of accounts payable,&#160;accrued expenses, accrued development expense&#160;and other liabilities&#160;are at cost, which approximates fair value due to the short maturity of those instruments.</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&#160;</p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i></i></b></p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>Research Contracts, Prepaids and Accruals</i></b></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">The Company has entered into various research and development contracts with research institutions and other <em style="font: inherit;">third</em>-party vendors. These agreements are generally cancelable. Related payments are recorded as research and development expenses as incurred. The Company records prepaids and accruals for estimated ongoing research costs. When evaluating the adequacy of&#160;prepaid expenses and accrued liabilities, the Company analyzes progress of the studies including the phase or completion of events, invoices received and contracted costs. Significant judgments and estimates are made in determining the prepaid and accrued balances at the end of any reporting period. Actual results could differ from the Company&#8217;s estimates. The Company&#8217;s historical prepaid and accrual estimates have <em style="font: inherit;">not</em> been materially different from actual costs.</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&#160;</p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i></i></b></p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>Incentive Bonus Plan</i></b></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">In <em style="font: inherit;">2020,</em> the Company established the <em style="font: inherit;">2020</em> Cash Incentive Bonus Plan (the &#8220;CIB Plan&#8221;) to incentivize CIB Plan participants. Awards under the CIB Plan are accounted for as liability awards under ASC&#160;<em style="font: inherit;">718</em> &#8220;<i>Stock-based Compensation</i>&#8221;.&#160;The fair value of each&#160;potential CIB Plan&#160;award&#160;will be&#160;determined&#160;once&#160;a&#160;grant date occurs and&#160;will be&#160;remeasured each reporting period.&#160;Compensation expense associated with the CIB Plan&#160;will be&#160;recognized over the expected achievement period for each&#160;CIB Plan award, when&#160;a Performance Condition&#160;(as defined below) is considered probable of being met. See Note <em style="font: inherit;">11</em> for further discussion of the CIB Plan.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p><p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"></p>
   <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left"><b><i></i></b></p><p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left"><b><i>Property and Equipment</i></b></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">Property and equipment are&#160;recorded at cost, net of accumulated depreciation. Depreciation is recorded using the straight-line method over the estimated useful lives of the assets. Owned buildings and related improvements have estimated useful lives of 39 years and approximately 10 years, respectively. Tenant improvements&#160;related to leased space are amortized using the straight-line method over the useful lives of the improvements or the remaining term of the corresponding leases, whichever is shorter.</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">Property and equipment are reviewed for impairment when events or changes in circumstances indicate the carrying amount of an asset <em style="font: inherit;"> may </em><em style="font: inherit;">not</em> be recoverable. If property and equipment are considered to be impaired, an impairment loss is recognized.</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&#160;</p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i></i></b></p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>Intangible Assets</i></b></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">Acquired intangible assets are recorded at fair value at the date of acquisition and primarily consist of lease-in-place agreements and leasing commissions. Intangible assets are amortized over the estimated life of the lease-in-place agreements.&#160;Intangible assets also include&#160;leasing commissions, which are amortized over the life of the lease agreement.</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">Intangible assets are reviewed for impairment on an annual basis, and when there is reason to believe that their values have been diminished or impaired. If intangible assets are considered to be impaired, an impairment loss is recognized.</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"></p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;"><b><i></i></b></p><p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;"><b><i>Insurance Recoveries</i></b></p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 18pt;">We record proceeds from our&#160;insurance policies&#160;when the loss event has&#160;occurred, and proceeds are estimable and probable of being recovered. Insurance recoveries&#160;and proceeds received are recorded as a reduction to general and administrative expense.&#160;There was approximately $9.9&#160;million&#160;and $0.1 million of insurance recoveries recorded during the year ended <em style="font: inherit;"> December 31, 2024 </em>and <em style="font: inherit;">2023,</em> respectively. The applicable policy year had&#160;a $10.0 million recovery limit which has been reached at <em style="font: inherit;"> December 31, 2024.</em></p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;">&#160;</p><p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;"></p>


   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;"><b><i></i></b></p><p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;"><b><i>Related Party Transactions</i></b></p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-indent: 18pt; text-align: justify;">On <em style="font: inherit;"> July 15, 2024, </em>our former&#160;President and Chief Executive Officer&#160;resigned from the Company, effective as of <em style="font: inherit;"> September 13, 2024 (</em>the &#8220;Effective Date&#8221;). Pursuant to the terms of his employment agreement, our former&#160;President and Chief Executive Officer is&#160;receiving&#160;severance compensation equal to $1.23 million over <em style="font: inherit;">twelve</em> months following the Effective Date. Severance compensation was included in general and administrative expense.</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-indent: 18pt;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-indent: 18pt; text-align: justify;">On <em style="font: inherit;"> July 16, 2024, </em>our former Senior Vice President (SVP), Neuroscience agreed to step down from her employment with the Company, effective immediately. Our former SVP, Neuroscience is the spouse of our former&#160;President and Chief Executive Officer. Pursuant to a separation agreement, our former SVP, Neuroscience is&#160;receiving&#160;severance compensation equal to $0.5 million in quarterly installments over <em style="font: inherit;">twelve</em> months.&#160;Severance compensation was included in research and development&#160;expense.</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-indent: 18pt;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -2pt; text-indent: 18pt; text-align: justify;">Included in accrued compensation and benefits at <em style="font: inherit;"> December 31, 2024 </em>is approximately $1.2&#160;million of accrued severance costs for the <span style="-sec-ix-hidden:c123855449">two</span> former senior officers.</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -2pt; text-indent: 18pt; text-align: justify;">On <em style="font: inherit;"> July 16, 2024, </em>the Company entered into a one-year consulting agreement&#160;with the Company&#8217;s former SVP, Neuroscience.&#160;Pursuant to the terms of the consulting agreement, the&#160;consultant is providing services&#160;for purposes of providing information and support for scientific research and/or obtaining governmental approval for the Company&#8217;s products.&#160;The Company will pay&#160;$500&#160;per hour&#160;for such&#160;consulting services. The Company incurred fees totaling $43,000 under the consulting agreement during the year ended <em style="font: inherit;"> December 31, 2024.</em></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p><p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i></i></b></p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>Income Taxes</i></b></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">The Company accounts for income taxes under the asset and liability method.&#160;Deferred tax assets and liabilities are recognized for the estimated future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. &#160;Deferred tax balances are adjusted to reflect tax rates based on currently enacted tax laws, which will be in effect in the years in which the temporary differences are expected to reverse.&#160;The Company has accumulated significant deferred tax assets that reflect the tax effects of net operating loss and tax credit carryovers and temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. Realization of certain deferred tax assets is dependent upon future earnings. The Company is uncertain about the timing and amount of any future earnings. Accordingly, the Company offsets these deferred tax assets with a valuation allowance.</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">The Company accounts for uncertain tax positions in accordance with ASC <em style="font: inherit;">740,</em> &#8220;Income Taxes&#8221;, which clarifies the accounting for uncertainty in tax positions. These provisions require recognition of the impact of a tax position in the Company&#8217;s financial statements only if that position is more likely than <em style="font: inherit;">not</em> of being sustained upon examination by taxing authorities, based on the technical merits of the position. Any interest and penalties related to uncertain tax positions will be reflected as a component of income tax expense.</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"></p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;"><b><i></i></b></p><p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;"><b><i>Recent Accounting Pronouncements</i></b></p>
   <p style="text-align: justify; margin: 0pt 0pt 0pt -9pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify; text-indent: 18pt;">In <em style="font: inherit;"> November 2023, </em>the FASB&#160;issued Accounting Standards Update ("ASU") <em style="font: inherit;">2023</em>-<em style="font: inherit;">07,</em> Segment Reporting (Topic <em style="font: inherit;">280</em>): Improvements to Reportable Segment Disclosures. This ASU includes amendments that expand the existing reportable segment disclosure requirements and requires disclosure of (i) significant expense categories and amounts by reportable segment as well as the segment&#8217;s profit or loss measure(s) that are regularly provided to the chief operating decision maker (the &#8220;CODM&#8221;) to allocate resources and assess performance; (ii) how the CODM uses each reported segment profit or loss measure to allocate resources and assess performance; (iii) the nature of other segment balances contributing to reported segment profit or loss that are <em style="font: inherit;">not</em> captured within segment revenues or expenses; and (iv) the title and position of the individual or name of the group or committee identified as the CODM. This guidance requires retrospective application to all prior periods presented in the financial statements and is effective for fiscal years beginning after <em style="font: inherit;"> December 15, 2023 </em>and interim periods within fiscal years beginning after <em style="font: inherit;"> December 15, 2024.&#160;</em>The Company adopted this guidance and has included enhanced disclosures relating to its reportable segments. See <i>Business Segments</i>, included in this Note <em style="font: inherit;">2</em> to the Consolidated Financial Statements, for the Company's updated disclosure.</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify; text-indent: 18pt;">&#160;</p>


   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt;"><i><b>Accounting Guidance Issued But <em style="font: inherit;">Not</em> Adopted as of <em style="font: inherit;"> December 31, 2024</em></b></i></p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-indent: 18pt; text-align: justify;">In <em style="font: inherit;"> November 2024, </em>the FASB issued ASU <em style="font: inherit;">2024</em>-<em style="font: inherit;">03,</em> Income Statement&#8212;Reporting Comprehensive Income&#8212;Expense Disaggregation Disclosures (Subtopic <em style="font: inherit;">220</em>-<em style="font: inherit;">40</em>): Disaggregation of Income Statement Expenses. This ASU includes amendments that require entities to bifurcate specified expense line items on the income statement into underlying components, including employee compensation, depreciation, and intangible asset amortization, as applicable. Qualitative descriptions of the remaining components are required. These enhanced disclosures are required for both interim and annual periods. In <em style="font: inherit;"> January 2025, </em>the FASB subsequently issued ASU <em style="font: inherit;">2025</em>-<em style="font: inherit;">01,</em> Income Statement&#8212;Reporting Comprehensive Income&#8212;Expense Disaggregation Disclosures (Subtopic <em style="font: inherit;">220</em>-<em style="font: inherit;">40</em>): Clarifying the Effective Date, to provide clarification on the ASU's effective date. The new standard is effective for fiscal years beginning after <em style="font: inherit;"> December 15, 2026 </em>on a prospective basis with the option to apply it retrospectively, and for interim periods&#160;within fiscal years beginning after <em style="font: inherit;"> December 15, 2027. </em>Early adoption is permitted. The adoption of this guidance will result in the Company being required to include enhanced disclosures around income statement expenses.</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-indent: 18pt; text-align: justify;">In <em style="font: inherit;"> December 2023, </em>the FASB issued ASU <em style="font: inherit;">2023</em>-<em style="font: inherit;">09,</em> Income Taxes (Topic <em style="font: inherit;">740</em>): Improvements to Income Tax Disclosures. The ASU requires that an entity disclose specific categories in the effective tax rate reconciliation as well as reconciling items that meet a quantitative threshold. Further, the ASU requires additional disclosures on income tax expense and taxes paid, net of refunds received, by jurisdiction. The new standard is effective for annual periods beginning after <em style="font: inherit;"> December 15, 2024 </em>on a prospective basis with the option to apply it retrospectively. Early adoption is permitted. The adoption of this guidance will result in the company being required to include enhanced income tax related disclosures.</p>
   <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p><p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left"></p>
  <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483426/235-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 235<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/235/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46586285152416">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 3 - Prepaid Expenses and Other Current Assets<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes to Financial Statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sava_PrepaidExpensesAndOtherCurrentAssetsTextBock', window );">Prepaid Expenses and Other Current Assets [Text Bock]</a></td>
<td class="text">
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><em style="font: inherit;">3.</em> Prepaid Expenses and Other Current Assets</b></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">Prepaid and other current assets at&#160;<em style="font: inherit;"> December 31, 2024&#160;</em>and <em style="font: inherit;">2023</em>&#160;consisted of the following (in thousands):</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>

    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;">&#160;</td><td colspan="6" rowspan="1" style="text-align: center; font-family: Times New Roman; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"><b><em style="font: inherit;"><em style="font: inherit;">December 31,</em></em></b></td><td style="font-family: Times New Roman; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;">&#160;</td></tr>
<tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">2024</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">2023</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 70%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">Prepaid insurance</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">800</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">759</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">Contract research organization and other deposits</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">6,173</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">6,489</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">Interest receivable</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">947</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">962</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">Other</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">38</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">287</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt; text-indent: -9pt;">Total prepaid expenses and other current assets</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">7,958</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">8,497</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td></tr>
</tbody></table>

   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">Contract research organization and other deposits represent cash payments made to vendors in excess of expenses incurred.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;&#160;</p>
  <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sava_PrepaidExpensesAndOtherCurrentAssetsTextBock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of prepaid expenses and other current assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sava_PrepaidExpensesAndOtherCurrentAssetsTextBock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sava_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46586284231216">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 4 - Real Property and Other Income, Expense<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes to Financial Statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RealEstateOwnedTextBlock', window );">Real Estate Owned [Text Block]</a></td>
<td class="text">
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><em style="font: inherit;">4.</em> Real Property and Other Income, Expense</b></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">The Company owns a <em style="font: inherit;">two</em>-building office complex in Austin, Texas, a portion of which serves as its corporate headquarters. Maintenance, physical facilities, leasing, property management and other key responsibilities related to property ownership are&#160;outsourced to professional real-estate managers. The office complex measures approximately 90,000 rentable square feet.&#160;At <em style="font: inherit;"> December 31, 2024, </em>the Company&#160;occupied approximately 25% of the property with the remainder&#160;either leased or available for lease to <em style="font: inherit;">third</em> parties. Gross rental income under existing <em style="font: inherit;">third</em>-party leases at <em style="font: inherit;"> December 31, 2024 </em>is expected to total&#160;$0.3 million in <em style="font: inherit;">2025,</em> $0.4&#160;million in <em style="font: inherit;">2026</em> and $0.2&#160;million in <em style="font: inherit;">2027.</em></p>
   <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>


   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">The Company records the net income from building operations and leases as other income, net, as leasing is <em style="font: inherit;">not</em> core to the Company&#8217;s operations. Building depreciation and amortization for space <em style="font: inherit;">not</em> occupied by the Company is included in general and administrative expense. Building depreciation and amortization for space occupied by the Company is allocated between general and administrative expense and research and development expense. Components of other income, net, for the periods presented were as follows (in thousands):</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">&#160;</p>

    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="10" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;"><em style="font: inherit;"><em style="font: inherit;">Years ended December 31,</em></em></em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">2024</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">2023</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">2022</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 55%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">Lease revenue</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">1,244</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">2,283</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">2,459</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">Property operating expenses</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(832</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(1,376</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;">(1,462</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">)</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt; text-indent: -9pt;">Other income, net</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">411</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">907</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">997</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td></tr>
</tbody></table>

   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&#160;</p>
   <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 18pt;">The Company had accrued property taxes related to the building totaling $254,000 and $338,000 at&#160;<em style="font: inherit;"> December 31, 2024&#160;</em>and&#160;<em style="font: inherit;">2023,</em> respectively, included in other current liabilities.</p>
   <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
  <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RealEstateOwnedTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for real estate owned (as defined). Generally, the largest component of real estate owned by lenders is assets taken in settlement of troubled loans through surrender or foreclosure. Real estate investments, real estate loans that qualify as investments in real estate, and premises that are no longer used in operations may also be included in real estate owned.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481990/310-10-45-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RealEstateOwnedTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46586284520880">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 5 - Property and Equipment<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes to Financial Statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock', window );">Property, Plant and Equipment Disclosure [Text Block]</a></td>
<td class="text">
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><em style="font: inherit;">5.</em> Property and Equipment</b></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">The components of property and equipment, net, as of&#160;<em style="font: inherit;"> December 31, 2024&#160;</em>and <em style="font: inherit;">2023</em>&#160;were as follows (in thousands):</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>

    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td colspan="6" rowspan="1" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: center;"><b><em style="font: inherit;"><em style="font: inherit;">December 31,</em></em></b></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td></tr>
<tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">2024</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">2023</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 70%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">Land</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">3,734</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">3,734</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">Buildings</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">15,980</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">15,980</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">Site improvements</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">494</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">494</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">Tenant improvements</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">3,062</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">3,062</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">Furniture and equipment</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">875</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">868</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px;"> <p style="margin: 0pt; font-size: 10pt; font-family: Times New Roman;">Construction in progress</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);">55</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);">&#8212;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt; text-indent: -9pt;">Gross property and equipment</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">24,200</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">24,138</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">Accumulated depreciation</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(3,236</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(2,284</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt; text-indent: -9pt;">Property and equipment, net</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">20,964</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">21,854</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td></tr>
</tbody></table>

   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">Depreciation expense for property and equipment was&#160;$952,000, $1,084,000&#160;and&#160;$804,000&#160;for the years ended <em style="font: inherit;"> December 31, 2024, </em><em style="font: inherit;">2023</em>&#160;and <em style="font: inherit;">2022,</em> respectively.&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">&#160;</p>
  <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/360/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-6<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46586284164304">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 6 - Intangible Assets<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes to Financial Statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsDisclosureTextBlock', window );">Intangible Assets Disclosure [Text Block]</a></td>
<td class="text">
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><em style="font: inherit;">6.</em> Intangible Assets</b></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">The components of intangible assets, net, as of&#160;<em style="font: inherit;"> December 31, 2024&#160;</em>and <em style="font: inherit;">2023</em>&#160;were as follows (in thousands):</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>

    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;">&#160;</td><td colspan="6" rowspan="1" style="font-family: Times New Roman; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; text-align: center; border-bottom: 1px solid rgb(0, 0, 0);"><b><em style="font: inherit;"><em style="font: inherit;">December 31,</em></em></b></td><td style="font-family: Times New Roman; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;">&#160;</td></tr>
<tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">2024</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">2023</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 70%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">Lease-in-place agreements</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">1,053</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">1,053</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">Leasing commissions and other</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">334</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">293</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt; text-indent: -9pt;">Gross intangible assets</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">1,387</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">1,346</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">Accumulated amortization</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(1,350</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(1,170</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt; text-indent: -9pt;">Intangible assets, net</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">37</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">176</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td></tr>
</tbody></table>

   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">Amortization expense for intangible assets was $180,000, $446,000 and $497,000 for the years ended <em style="font: inherit;"> December 31, 2024, </em><em style="font: inherit;">2023</em>&#160;and <em style="font: inherit;">2022,</em> respectively.&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>


   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">Amortization expense for finite-lived intangible assets is expected to be as follows (in thousands):</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>

    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 85%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;"><b><span style="text-decoration: underline; ">For the year ending December 31,</span></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">2025</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">17</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">2026</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">14</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px;"> <p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">2027</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);">6</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">Total amortization</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">37</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td></tr>
</tbody></table>

   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all or part of the information related to intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/350-30/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/985-20/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46586285144496">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 7 - Stockholders' Equity and Stock-based Compensation<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes to Financial Statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock', window );">Shareholders' Equity and Share-Based Payments [Text Block]</a></td>
<td class="text">
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><em style="font: inherit;">7.</em> Stockholders' Equity and Stock-Based Compensation</b></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>Preferred Stock</i></b></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">The Company&#8217;s Board of Directors (the &#8220;Board&#8221;) has the authority to issue preferred stock in <em style="font: inherit;">one</em> or more series and to fix the rights, preferences, privileges, restrictions and the number of shares constituting any series or the designation of the series.</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i><em style="font: inherit;">2022</em> Registered Direct Offering</i></b></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">On <em style="font: inherit;"> November&#160;</em><em style="font: inherit;">22,</em> <em style="font: inherit;">2022,</em> the Company completed a common stock offering pursuant to which certain investors purchased 1,666,667 shares of common stock at a price of $30.00 per share. Net proceeds of the offering were approximately $47.3&#160;million after deducting offering expenses.</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -1pt;"><b><i>Common Stock Warrant Distribution</i></b></p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -1pt; text-indent: 18pt;">See Notes <em style="font: inherit;">2</em> and <em style="font: inherit;">13</em>&#160;regarding the distribution of common stock warrants on <em style="font: inherit;"> January 3, 2024.</em></p>
   <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>At the Market (ATM) Common Stock Issuance </i></b></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">On <em style="font: inherit;"> May 1, 2023, </em>the Company entered into an&#160;at-the-market offering program (&#8220;ATM&#8221;) to sell, from time to time, shares of Company common stock having an aggregate offering price of up to $200 million in common stock pursuant to a shelf registration statement that was filed with the U.S. Securities and Exchange Commission (the &#8220;SEC&#8221;) on <em style="font: inherit;"> May 1, 2023 </em>and became effective immediately upon filing. The Company is obligated to pay a commission of up to 3% of the gross proceeds from the sale of shares of common stock under&#160;the ATM. As of the filing of this Annual Report on Form <em style="font: inherit;">10</em>-K, the Company is <em style="font: inherit;">no</em> longer a Well-Known Seasoned Issuer, as defined by the SEC. Thus, the Company&#160;is <em style="font: inherit;">not</em> eligible to sell securities under the ATM under its existing &#8220;automatic&#8221; shelf registration statement on Form S-<em style="font: inherit;">3</em> unless and until it files a new Form S-<em style="font: inherit;">3</em> that is declared effective by the SEC.</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">There were&#160;<span style="-sec-ix-hidden:c123855525">no</span>&#160;common stock sales under the ATM during the year&#160;ended <em style="font: inherit;"> December 31, 2024 </em>and <em style="font: inherit;">2023.</em></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i><em style="font: inherit;">2008</em> Equity Incentive Plan </i></b></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">Under the Company&#8217;s <em style="font: inherit;">2008</em> Equity Incentive Plan, or <em style="font: inherit;">2008</em> Equity Plan, its employees, directors and consultants received share-based awards, including grants of stock options and performance awards. The <em style="font: inherit;">2008</em> Equity Plan expired in <em style="font: inherit;"> December 2017. </em>Share-based awards generally expire <em style="font: inherit;">ten</em> years from the date of grant.</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i><em style="font: inherit;">2018</em> Equity Incentive Plan </i></b></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">The Company&#8217;s Board or a designated Committee of the Board is responsible for administration of the Company&#8217;s <em style="font: inherit;">2018</em> Omnibus Incentive Plan (the <em style="font: inherit;">2018</em> Plan) and determines the terms and conditions of each option granted, consistent with the terms of the <em style="font: inherit;">2018</em> Plan. The Company&#8217;s employees, directors, and consultants are eligible to receive awards under the <em style="font: inherit;">2018</em> Plan, including grants of stock options and performance awards. Share-based awards generally expire <span style="-sec-ix-hidden:c123855537">ten</span> years from the date of grant. The <em style="font: inherit;">2018</em> Plan, as amended in <em style="font: inherit;"> May&#160;</em><em style="font: inherit;">2022,</em> provides for issuance of up to 5,000,000 shares of common stock, par value $0.001 per share, subject to adjustment as provided in the <em style="font: inherit;">2018</em> Plan.</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">When stock options or performance awards are exercised net of the exercise price and taxes, the number of shares of stock issued is reduced by the number of shares equal to the amount of taxes owed by the award recipient and that number of shares are cancelled. The Company <em style="font: inherit;"> may </em>then use its cash to pay tax authorities the amount of statutory taxes owed by and on behalf of the award recipient.</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">&#160;</p>


   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>Stock Options</i></b></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">The following summarizes information about stock option activity during <em style="font: inherit;">2024:</em></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>

    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="text-align: center; font-family: Times New Roman; font-size: 10pt;"><em style="font: inherit;">&#160;</em></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Weighted Average</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Weighted Average</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="text-align: center; font-family: Times New Roman; font-size: 10pt;"><em style="font: inherit;">&#160;</em></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td></tr>
<tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Number of</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Weighted Average</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Remaining Contractual</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Aggregate Intrinsic Value</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td></tr>
<tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Options</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Exercise Price</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Term in Years</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">in Millions</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 40%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">Outstanding as of December 31, 2023</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">3,039,029</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">15.13</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">6.21</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">30.28</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> <p style="margin: 0pt 0pt 0pt 9pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">Options granted</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; text-align: right; padding: 0; margin: 0">2,083,000</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">26.65</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"><em style="font: inherit;">&#160;</em></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"><em style="font: inherit;">&#160;</em></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> <p style="margin: 0pt 0pt 0pt 9pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">Options exercised</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; text-align: right; padding: 0; margin: 0">(240,147</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0; margin: 0">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">5.25</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"><em style="font: inherit;">&#160;</em></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"><em style="font: inherit;">&#160;</em></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> <p style="margin: 0pt 0pt 0pt 9pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">Options forfeited/canceled</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; text-align: right; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);">(418,854</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">24.64</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"><em style="font: inherit;">&#160;</em></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"><em style="font: inherit;">&#160;</em></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">Outstanding as of December 31, 2024</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">4,463,028</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">20.15</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">7.61</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">0.30</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">Vested and expected to vest at December 31, 2024</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 3px double rgb(0, 0, 0);">3,965,665</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">19.93</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">7.44</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">0.30</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">Exercisable at December 31, 2024</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 3px double rgb(0, 0, 0);">1,794,501</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">12.86</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">4.95</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">0.30</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
</tbody></table>

   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">Of the stock options exercised during the year ended <em style="font: inherit;"> December 31, 2024, </em>6,634&#160;stock options were net settled in satisfaction of the exercise price, with <em style="font: inherit;">no</em> cash proceeds received. In addition, an employee surrendered 6,500 shares of common stock in conjunction with&#160;a net exercise of a stock option. The common shares&#160;surrendered were&#160;retired by the Company.</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">The following summarizes information about stock options at <em style="font: inherit;"> December 31, 2024&#160;</em>by a range of exercise prices:</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>

    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="text-align: center; font-family: Times New Roman; font-size: 10pt;"><b><em style="font: inherit;">&#160;</em></b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="text-align: center; font-family: Times New Roman; font-size: 10pt;"><b><em style="font: inherit;">&#160;</em></b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="10" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;"><em style="font: inherit;"><em style="font: inherit;">Options outstanding</em></em></em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;"><em style="font: inherit;">Options exercisable</em></em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td></tr>
<tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="text-align: center; font-family: Times New Roman; font-size: 10pt;"><b><em style="font: inherit;">&#160;</em></b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="text-align: center; font-family: Times New Roman; font-size: 10pt;"><b><em style="font: inherit;">&#160;</em></b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="text-align: center; font-family: Times New Roman; font-size: 10pt;"><b><em style="font: inherit;">&#160;</em></b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Weighted</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="text-align: center; font-family: Times New Roman; font-size: 10pt;"><b><em style="font: inherit;">&#160;</em></b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="text-align: center; font-family: Times New Roman; font-size: 10pt;"><b><em style="font: inherit;">&#160;</em></b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="text-align: center; font-family: Times New Roman; font-size: 10pt;"><b><em style="font: inherit;">&#160;</em></b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td></tr>
<tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="text-align: center; font-family: Times New Roman; font-size: 10pt;"><b><em style="font: inherit;">&#160;</em></b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="text-align: center; font-family: Times New Roman; font-size: 10pt;"><b><em style="font: inherit;">&#160;</em></b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="text-align: center; font-family: Times New Roman; font-size: 10pt;"><b><em style="font: inherit;">&#160;</em></b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">average</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Weighted</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="text-align: center; font-family: Times New Roman; font-size: 10pt;"><b><em style="font: inherit;">&#160;</em></b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Weighted</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td></tr>
<tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="text-align: center; font-family: Times New Roman; font-size: 10pt;"><b><em style="font: inherit;">&#160;</em></b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="text-align: center; font-family: Times New Roman; font-size: 10pt;"><b><em style="font: inherit;">&#160;</em></b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Number of</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">remaining</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">average</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Number of</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">average</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td></tr>
<tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td colspan="6" style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;"><em style="font: inherit;">Range of exercise prices</em></em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">outstanding</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">contractual</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">exercise</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">vested</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">exercise</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td></tr>
<tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td colspan="2" style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">From</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">To</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">options</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">life (in years)</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">price</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">options</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">price</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">$</td><td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">0.95</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">4.10</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">900,303</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">3.5</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">2.80</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">900,303</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">2.80</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">$</td><td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">5.46</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">17.54</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">1,049,656</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">7.1</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">16.21</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">560,765</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">15.06</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">$</td><td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">18.78</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">$</td><td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">26.57</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">539,277</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">8.7</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">$</td><td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">21.90</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">197,198</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">$</td><td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">21.81</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px;">$</td><td style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px;">26.91</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px;">$</td><td style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px;">26.91</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px;">&#160;</td><td style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px;">1,080,000</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px;">&#160;</td><td style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px;">9.7</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px;">$</td><td style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px;">26.91</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px;">&#160;</td><td style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px;">364</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px;">$</td><td style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px;">26.91</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">$</td><td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">27.42</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">77.00</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid black;">&#160;</td><td style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid black;">893,792</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">9.2</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">33.02</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid black;">&#160;</td><td style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid black;">135,871</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">57.40</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="text-align: right; font-family: Times New Roman; font-size: 10pt;"><em style="font: inherit;">&#160;</em></td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="text-align: right; font-family: Times New Roman; font-size: 10pt;"><em style="font: inherit;">&#160;</em></td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">4,463,028</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">7.6</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">20.15</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">1,794,501</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">12.86</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
</tbody></table>

   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">The Company uses Black-Scholes to estimate the fair value of options granted. Black-Scholes considers a number of factors, including the market price of the Company&#8217;s common stock. Factors utilized in Black-Scholes to value each stock option granted, and the weighted average fair value of options granted during the years ended&#160;<em style="font: inherit;"> December 31, 2024, </em><em style="font: inherit;">2023</em>&#160;and <em style="font: inherit;">2022</em>&#160;were as follows:</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>

    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">2024</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">2023</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">2022</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 55%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">Volatility</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">151% to 170%</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">152% to 155%</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">151% to 154%</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">Risk-free interest rates</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">3.53% to 4.47%</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">3.82% to 4.37%</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">1.98% to 3.69%</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">Expected life of option (in years)</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">7</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">7</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">7</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">Dividend yield</p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: right;"><span style="-sec-ix-hidden:c123855198">zero</span></p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: right;"><span style="-sec-ix-hidden:c123855199">zero</span></p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: right;"><span style="-sec-ix-hidden:c123855200">zero</span></p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">Forfeiture rate</p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: right;"><span style="-sec-ix-hidden:c123855201">4.3</span></p> </td><td style="font-family: Times New Roman; font-size: 10pt;">%</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: right;"><span style="-sec-ix-hidden:c123855202">zero</span></p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: right;"><span style="-sec-ix-hidden:c123855203">zero</span></p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">Weighted average fair value of stock options granted</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">25.85</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">18.21</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">35.16</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
</tbody></table>

   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">Volatility is based on reviews of the historical volatility of the Company&#8217;s common stock. Risk-free interest rates are based on yields of U.S. treasury notes in effect at the date of grant. Expected life of option is based on actual historical option exercises. Dividend yield is zero because the Company does <em style="font: inherit;">not</em> anticipate paying cash dividends in the foreseeable future.</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">As of <em style="font: inherit;"> December 31, 2024, </em>the Company expects to recognize compensation expense of $50.6&#160;million related to non-vested options held by equity plan participants over the weighted average remaining recognition period of 2.3&#160;years.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>


   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><i>Performance Awards</i></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">The following summarizes information about performance award activity during <em style="font: inherit;">2024:</em></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>

    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Number of Performance Awards</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 85%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">Outstanding as of December 31, 2023</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">7,142</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt; text-indent: -9pt;">Granted</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">&#8212;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt; text-indent: -9pt;">Vested</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">&#8212;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt; text-indent: -9pt;">Forfeited/canceled</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;">&#8212;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">Outstanding as of December 31, 2024</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">7,142</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td></tr>
</tbody></table>

   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">During the year ended <em style="font: inherit;"> December 31, 2022, </em>a total of 57,143 shares of restricted stock awards expired as performance criteria related to these Performance Awards were <em style="font: inherit;">not</em> attained. These shares of restricted stock were returned to the <em style="font: inherit;">2008</em> Equity Incentive Plan, which expired in <em style="font: inherit;"> December 2017, </em>and thus were retired.</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">If and when outstanding Performance Awards vest, the Company would recognize $101,000 in stock-based compensation expense. These performance awards expire in <em style="font: inherit;">2026.</em></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>Stock-Based Compensation Expense</i></b></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">The following summarizes information about stock-based compensation expense, in thousands:</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>

    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="10" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;"><em style="font: inherit;"><em style="font: inherit;">Years ended December 31,</em></em></em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">2024</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">2023</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">2022</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 55%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">Research and development</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">6,492</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">2,050</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">1,631</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">General and administrative</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">9,799</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">2,536</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">435</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td>&#160;</td><td style="padding-bottom: 1px;">&#160;</td><td style="border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="padding-bottom: 1px;">&#160;</td><td style="padding-bottom: 1px;">&#160;</td><td style="border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="padding-bottom: 1px;">&#160;</td><td style="padding-bottom: 1px;">&#160;</td><td style="border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="padding-bottom: 1px;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">Total stock-based compensation expense</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">16,291</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">4,586</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">2,066</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td></tr>
</tbody></table>

   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-indent: 18pt; text-align: justify;">On <em style="font: inherit;"> September 13, 2024, </em>the Company&#160;entered into a Consulting Agreement&#160;with our former President and Chief Executive Officer for a period of <em style="font: inherit;">one</em> year, which was&#160;subsequently terminated on <em style="font: inherit;"> January 23, 2025. </em>The services to be provided under the Consulting Agreement were <em style="font: inherit;">not</em> deemed substantive for continuous service requirements of stock option vesting, resulting in&#160;a stock option modification under ASC <em style="font: inherit;">718.</em> The Company's stock-based compensation expense for the year ended <em style="font: inherit;"> December 31, 2024 </em>included approximately $0.6&#160;million from the stock option modification accounting. See further discussion in Note <em style="font: inherit;">2</em> under "Related Party Transactions". There were no such costs during the years ended <em style="font: inherit;"> December 31, 2023 </em>and <em style="font: inherit;">2022.</em></p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
  <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity and share-based payment arrangement. Includes, but is not limited to, disclosure of policy and terms of share-based payment arrangement, deferred compensation arrangement, and employee stock purchase plan (ESPP).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/505/tableOfContent<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/718/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46586284037808">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 8 - Employee 401(k) Benefit Plan<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes to Financial Statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CompensationAndEmployeeBenefitPlansTextBlock', window );">Compensation and Employee Benefit Plans [Text Block]</a></td>
<td class="text">
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><b><em style="font: inherit;">8.</em> Employee <em style="font: inherit;">401</em>(k) Benefit Plan</b></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">The Company has a defined-contribution savings plan under Section <em style="font: inherit;">401</em>(k) of the Internal Revenue Code. The plan covers substantially all employees. Employees are eligible to participate in the plan the <em style="font: inherit;">first</em> day of the month after hire and <em style="font: inherit;"> may </em>contribute up to the current statutory limits under Internal Revenue Service regulations. The <em style="font: inherit;">401</em>(k) plan permits the Company to make additional matching contributions on behalf of all employees. Through <em style="font: inherit;"> December 31, 2024, </em>the Company has <em style="font: inherit;">not</em> made any matching contributions to the <em style="font: inherit;">401</em>(k) plan.</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>


  <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndEmployeeBenefitPlansTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for an entity's employee compensation and benefit plans, including, but not limited to, postemployment and postretirement benefit plans, defined benefit pension plans, defined contribution plans, non-qualified and supplemental benefit plans, deferred compensation, share-based compensation, life insurance, severance, health care, unemployment and other benefit plans.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 710<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/710/tableOfContent<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 712<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/712/tableOfContent<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 715<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/715/tableOfContent<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/718/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndEmployeeBenefitPlansTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46586283108048">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 9 - Income Taxes<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes to Financial Statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Tax Disclosure [Text Block]</a></td>
<td class="text">
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><em style="font: inherit;">9.</em> Income Taxes</b></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">The Company did <em style="font: inherit;">not</em> provide for income taxes during the periods presented because it had book and federal taxable losses in those years and the tax benefit that would have resulted from the pre-tax losses was fully offset by a change in the valuation allowance.</p>
   <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">The reconciliation of the statutory federal income tax rate to the Company&#8217;s effective tax rate for periods presented was as follows:</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>

    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="10" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;"><em style="font: inherit;"><em style="font: inherit;">Year ended December 31,</em></em></em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">2024</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">2023</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">2022</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 55%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">Tax at federal statutory rate</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">21</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">%</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">21</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">%</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">21</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">%</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">State tax, net of federal benefit</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">&#8212;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">&#8212;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">&#8212;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">Share-based compensation</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(5.7</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">0.2</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(0.5</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">Research and development credits</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">15.4</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">5.1</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">4.9</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">Section 162(m) limitation</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(0.2</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#8212;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">(0.2</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">)</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> <p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">Uncertain tax positions</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">(6.1</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">(2.0</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">(2.0</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">)</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> <p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">Tax attribute expiration</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">(4.1</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#8212;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#8212;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> <p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">Change in fair value of warrant liabilities</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">93.3</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#8212;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#8212;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> <p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">SEC settlement payment</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">(34.5</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#8212;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#8212;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">Other</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">0.3</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(0.3</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">0.2</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">Change in valuation allowance</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(79.4</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(24.0</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(23.4</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">)</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">Effective income tax rate</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">&#8212;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">%</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">&#8212;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">%</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">&#8212;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">%</td></tr>
</tbody></table>

   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><i>Deferred tax assets and valuation allowance</i></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">Deferred tax assets reflect the tax effects of net operating loss and tax credit carryforwards and temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. The Company&#8217;s deferred taxes assets at&#160;<em style="font: inherit;"> December 31, 2024&#160;</em>and <em style="font: inherit;">2023</em>&#160;were valued at the corporate tax rate of 21%. The Company offsets its deferred tax assets by a valuation allowance because it is uncertain about the timing and amount of any future profits. Significant components of its deferred tax assets are as follows (in thousands):</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>

    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;"><em style="font: inherit;">December 31,</em></em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">2024</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">2023</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 70%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Deferred tax assets:</p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Net operating loss carryforwards</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">43,148</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">33,322</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Share-based compensation</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">4,814</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">2,561</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Research and development credit carryforwards</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">13,789</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">12,557</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Capitalized research and development expenses</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">33,598</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">27,538</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Other</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">1,340</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">1,371</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Total deferred tax assets</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">96,689</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">77,349</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Valuation allowance</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(96,689</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(77,349</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Net deferred tax assets</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#8212;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#8212;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Deferred tax liabilities:</p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Operating lease right-of-use assets</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">&#8212;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">&#8212;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Total deferred tax liabilities</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">&#8212;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">&#8212;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Net deferred tax asset (liability)</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">&#8212;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">&#8212;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td></tr>
</tbody></table>

   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">The valuation allowance increased by $19.4&#160;million and $23.3&#160;million in&#160;<em style="font: inherit;">2024</em>&#160;and <em style="font: inherit;">2023,</em> respectively, due primarily to continuing operations.</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">The Company&#8217;s net operating loss carryforwards of $205.5&#160;million are federal, of which $74.1&#160;million expires between <em style="font: inherit;">2029</em> and <em style="font: inherit;">2037</em> and $131.4&#160;million carries forward indefinitely. As of <em style="font: inherit;"> December 31, 2024, </em>the Company had federal research and development tax credits of approximately $23.0&#160;million, which expire in the years <em style="font: inherit;">2025</em>&#160;through <em style="font: inherit;">2044.</em></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">&#160;</p>


   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><i>Unrecognized tax benefits</i></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">As of <em style="font: inherit;"> December 31, 2024, </em><em style="font: inherit;">2023</em>&#160;and <em style="font: inherit;">2022,</em> the Company has unrecognized tax benefits related to tax credits of $9.2&#160;million, $8.4&#160;million and $6.5&#160;million, respectively. <span style="-sec-ix-hidden:c123855598">None</span> of the unrecognized tax benefits as of <em style="font: inherit;"> December 31, 2024, </em>if recognized, would impact the effective tax rate due to the valuation allowance and no interest or penalties have been recognized. A reconciliation of the beginning and ending balance of unrecognized tax benefits is as follows (in thousands):</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>

    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="10" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;"><em style="font: inherit;"><em style="font: inherit;">Year ended December 31,</em></em></em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">2024</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">2023</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">2022</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 55%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Beginning balance</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">8,413</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">6,496</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">5,001</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> <p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">Expired research and development tax credits</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">(665</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">(50</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#8212;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Additions based on tax positions related to the current year</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">1,494</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">1,967</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">1,495</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Ending balance</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">9,242</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">8,413</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">6,496</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td></tr>
</tbody></table>

   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">&#160;</p>
   <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 18pt;">As of <em style="font: inherit;"> December 31, 2024, </em>there were <em style="font: inherit;">no</em> unrecognized tax benefits that we expect would change significantly over the next <em style="font: inherit;">12</em> months.</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">&#160;</p>
   <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 18pt;">The Company files U.S. and Texas income tax returns. In the United States, the statute of limitations with respect to the federal income tax returns for tax years after <span style="-sec-ix-hidden:c123855602">2020</span>&#160;are open to audit; however, since the Company has net operating losses, the taxing authority has the ability to review tax returns prior to the <em style="font: inherit;">2021</em>&#160;tax year and make adjustments to these net operating loss carryforwards.&#160;We are <em style="font: inherit;">not</em> under audit in any taxing jurisdiction at this time.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;&#160;</p>
  <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income tax.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12C<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12B<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 270<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477891/740-270-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.5.Q1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-13<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/740/tableOfContent<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-14<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-21<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-17<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482603/740-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46586371150016">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 10 - Commitments<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes to Financial Statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sava_LeasesAndCommitmentsDisclosureTextBlock', window );">Leases And Commitments Disclosure [Text Block]</a></td>
<td class="text">
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><em style="font: inherit;">10.</em> Commitments</b></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><i>Other Commitments</i></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">The Company conducts its product research and development programs through a combination of internal and collaborative programs that include, among others, arrangements with universities, contract research organizations and clinical research sites. It has contractual arrangements with these organizations that are generally cancelable. The Company&#8217;s obligations under these contracts are largely based on services performed.&#160;The Company also had non-cancellable commitments for the manufacture of simufilam's active pharmaceutical ingredient totaling approximately $1.2&#160;million recorded in prepaid expenses and other current assets&#160;at <em style="font: inherit;"> December 31, 2024. </em>The Company is dependent on contract development and manufacturing organizations for the manufacture of all our materials for clinical studies.</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify; text-indent: 18pt;">On <em style="font: inherit;"> February 26, 2025, </em>the Company&#160;entered into a License Agreement (the &#8220;License Agreement&#8221;) with Yale University (&#8220;Yale&#8221;) pursuant to which the Company was granted exclusive worldwide rights, with rights to sublicense, to Yale&#8217;s interest in certain patent and other intellectual property rights that could be useful or necessary to the development and commercialization of simufilam for the treatment of Tuberous Sclerosis Complex (TSC)-related epilepsy and other potential indications. Pursuant to the License Agreement, the Company has agreed to use reasonable commercial efforts to implement a plan that it has designed for such development and commercialization. In exchange for the rights acquired pursuant to the License Agreement, the Company agreed to pay Yale (i) a nominal upfront license fee, (ii) payments upon the achievement of specified clinical, regulatory and commercial milestones, totaling up to $4.5 million and (iii) upon transfer to a <em style="font: inherit;">third</em> party in connection with a regulatory priority review voucher, if issued, a low-to-mid double digit percentage of any consideration received for such transfer. The Company also agreed to pay Yale tiered royalties, ranging from a low- to mid- single digit percentage, on aggregate net sales of licensed products, subject to tiered minimum annual royalty payments ranging from the low- to mid- hundreds of thousands of dollars.</p>
   <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify; text-indent: 9pt;">Unless earlier terminated, the License Agreement will continue on a country-by-country basis until the later of (i) the date on which the last valid claim of the license patents expires or otherwise lapses, (ii) the end of any government or regulatory exclusivity period, and (iii) <em style="font: inherit;">10</em> years following the date of <em style="font: inherit;">first</em> sale of licensed product in such country.</p>
   <p style="text-align: justify; font-size: 10pt; font-family: &quot;Times New Roman&quot;; margin: 0pt;">&#160;</p>


  <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sava_LeasesAndCommitmentsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure regarding leases and commitments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sava_LeasesAndCommitmentsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sava_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46586371073792">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 11 - 2020 Cash Incentive Bonus Plan<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes to Financial Statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sava_CashIncentiveBonusPlanTextBlock', window );">Cash Incentive Bonus Plan [Text Block]</a></td>
<td class="text">
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>Note <em style="font: inherit;">11.</em></b>&#160;<b> <em style="font: inherit;">2020</em> Cash Incentive Bonus Plan</b></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">In <em style="font: inherit;"> August 2020, </em>the Board approved the CIB Plan. The CIB Plan was established to promote the long-term success of the Company by creating an &#8220;at-risk&#8221; cash bonus program that rewards&#160;CIB Plan&#160;participants with additional cash compensation in lockstep with significant increases in the Company&#8217;s market capitalization. The CIB Plan is considered &#8220;at-risk&#8221; because CIB Plan participants&#160;will&#160;<em style="font: inherit;">not</em> receive a cash bonus&#160;unless&#160;the Company&#8217;s market capitalization increases&#160;significantly and&#160;certain&#160;other&#160;conditions specified in the CIB Plan&#160;are met.&#160;Specifically, CIB Plan participants&#160;will&#160;<em style="font: inherit;">not</em>&#160;be paid&#160;any cash bonuses unless (<em style="font: inherit;">1</em>) the Company completes a&#160;merger or acquisition transaction that constitutes a sale of ownership of the Company or its assets (a Merger Transaction) or (<em style="font: inherit;">2</em>) the Compensation Committee of the Board&#160;(the Compensation Committee) determines the Company has sufficient cash on hand, as defined in the CIB Plan. Because&#160;of the inherent discretion and uncertainty regarding&#160;these&#160;requirements, the Company has concluded that&#160;a&#160;CIB Plan&#160;grant date has <em style="font: inherit;">not</em> occurred&#160;as of <em style="font: inherit;"> December 31, 2024.&#160;</em></p>
   <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">CIB Plan participants will be paid all earned cash bonuses allocated under the CIB&#160;Plan in the event of a Merger Transaction.</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-indent: 18pt; text-align: justify;">As of <em style="font: inherit;"> December 31, 2022, </em>the Company&#8217;s independent directors were participants in the CIB Plan. However, effective <em style="font: inherit;"> March 16, 2023, </em>the Board&#160;amended the CIB Plan to remove all independent directors as participants in the CIB Plan and the independent directors consented to such removal. The independent directors&#8217; share of potential benefits under the CIB Plan were completely forfeited to the Company and will <em style="font: inherit;">not</em> be allocated to any other participant under the CIB Plan. The Company&#8217;s independent directors have <em style="font: inherit;">not</em> received, and as a result of such amendment will never receive, any payments under the CIB Plan.</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">The Company&#8217;s market capitalization for purposes of the CIB Plan&#160;is&#160;determined based on either (<em style="font: inherit;">1</em>) the closing price&#160;of <em style="font: inherit;">one</em> share of the Company's common stock on the Nasdaq Capital&#160;Market&#160;multiplied by the total issued and outstanding shares and options to purchase shares of the Company, or (<em style="font: inherit;">2</em>) the aggregate consideration payable to security holders of the Company in a&#160;Merger Transaction. This constitutes a market condition under applicable accounting guidance.&#160; &#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">The CIB Plan&#160;triggers a potential cash bonus each time&#160;the&#160;Company&#8217;s market capitalization increases significantly, up to a maximum&#160;<em style="font: inherit;">$5</em>&#160;billion in market capitalization. The CIB Plan specifies 14&#160;incremental&#160;amounts&#160;between&#160;$200&#160;million and&#160;$5&#160;billion&#160;(each increment,&#160;a &#8220;Valuation Milestone&#8221;). Each&#160;Valuation Milestone&#160;triggers&#160;a potential cash bonus award in a pre-set amount defined in the CIB Plan. Each&#160;Valuation&#160;Milestone&#160;must be achieved and maintained for <em style="font: inherit;">no</em> less than 20 consecutive trading days for&#160;CIB Plan&#160;participants to be eligible for a potential cash bonus award.&#160;Approximately 67% of each&#160;cash bonus award&#160;associated with a Valuation Milestone&#160;is subject to&#160;adjustment and&#160;approval&#160;by the Compensation Committee.&#160;Any amounts&#160;<em style="font: inherit;">not</em> awarded by the Compensation Committee&#160;are&#160;<em style="font: inherit;">no</em> longer available for distribution.</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">If the Company were to exceed a $5&#160;billion market capitalization&#160;for <em style="font: inherit;">no</em> less than 20 consecutive trading days, all&#160;Valuation&#160;Milestones would be deemed achieved, in which case cash bonus awards would&#160;range from&#160;a minimum of&#160;$111.4&#160;million&#160;up to&#160;a hypothetical maximum of&#160;$289.7&#160;million.&#160;Payment of cash bonuses is deferred until such time as&#160;(<em style="font: inherit;">1</em>)&#160;the Company completes a Merger Transaction, or&#160;(<em style="font: inherit;">2</em>)&#160;the&#160;Compensation Committee determines the&#160;Company has sufficient cash&#160;on hand&#160;to render payment&#160;(each, a &#8220;Performance Condition&#8221;),&#160;neither&#160;of which <em style="font: inherit;"> may </em>ever occur. Accordingly, there can be <em style="font: inherit;">no</em> assurance that&#160;CIB Plan&#160;participants will&#160;ever&#160;be&#160;paid a cash bonus that is awarded under the CIB Plan, even if the Company&#8217;s market capitalization increases&#160;significantly.</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">The CIB Plan is accounted for as a liability award.&#160;The fair value of each&#160;Valuation&#160;Milestone&#160;award&#160;will be&#160;determined&#160;once&#160;a&#160;grant date occurs and&#160;will be&#160;remeasured each reporting period.&#160;Compensation expense associated with the CIB Plan&#160;will be&#160;recognized over the expected achievement period for each&#160;of the 14&#160;Valuation&#160;Milestones, when&#160;a Performance Condition&#160;is considered probable of being met. &#160;&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
   <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 18pt;">In <em style="font: inherit;"> October 2020, </em>the Company&#160;achieved&#160;the <em style="font: inherit;">first</em>&#160;Valuation&#160;Milestone.&#160;Subsequently in <em style="font: inherit;">2020,</em> the Compensation Committee&#160;approved&#160;a potential cash bonus&#160;award&#160;of&#160;$6.5&#160;million&#160;in total&#160;for&#160;all CIB Plan participants (after taking into account the <em style="font: inherit;"> March 2023 </em>CIB Plan amendment), subject to future satisfaction of a Performance Condition.&#160;There is <em style="font: inherit;">no</em> continuing service requirement for CIB Plan participants once&#160;the Compensation Committee approves a cash&#160;bonus award.</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">During the year ended <em style="font: inherit;"> December 31, 2021, </em>the Company achieved 11 additional Valuation Milestones.&#160;On <em style="font: inherit;"> February 13, 2025,&#160;</em>the Compensation Committee concluded that <em style="font: inherit;">no</em> discretionary&#160;cash bonus amounts would be awarded for the 11 milestones achieved in <em style="font: inherit;">2021</em> nor for the <em style="font: inherit;">2</em> remaining CIB Plan milestones, which have <em style="font: inherit;">not</em> been achieved. Therefore,&#160;<em style="font: inherit;">no</em>&#160;compensation expense has been recorded&#160;and&#160;<em style="font: inherit;">no</em>&#160;payments have been made&#160;since <em style="font: inherit;">no</em>&#160;grant date has occurred and <em style="font: inherit;">no</em>&#160;Performance Conditions are considered probable of being met.</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>


   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">The achievement the 11&#160;milestones&#160;in&#160;<em style="font: inherit;">2021</em> triggered a&#160;non-discretionary potential Company obligation&#160;to a CIB Plan participant&#160;of $74.9&#160;million&#160;(after taking into account the <em style="font: inherit;"> March 2023 </em>CIB Plan amendment) and contingent upon future satisfaction of a Performance Condition. However,&#160;no&#160;compensation expense has been recorded&#160;and&#160;<em style="font: inherit;">no</em>&#160;payments have been made&#160;since <em style="font: inherit;">no</em>&#160;grant date has occurred and <em style="font: inherit;">no</em>&#160;Performance Conditions are considered probable of being met.</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"><em style="font: inherit;">No</em> Valuation Milestones were achieved during the years&#160;ended <em style="font: inherit;"> December 31, 2024, </em><em style="font: inherit;">2023</em>&#160;and <em style="font: inherit;">2022.</em></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">As discussed in Note <em style="font: inherit;">12,</em> on <em style="font: inherit;"> January 24, 2025, </em>the Delaware Court of Chancery entered a Final Order and Judgment approving the Stipulation and dismissing an action related to the CIB&#160;Plan with prejudice. The Final Order and Judgment requires&#160;the Company to further amend&#160;the CIB Plan, as provided in the Stipulation.</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">No actual cash payments were authorized or made to participants under the CIB Plan through <em style="font: inherit;"> December 31, 2024&#160;</em>and the date of filing of this Annual Report on Form <em style="font: inherit;">10</em>-K.</p>
   <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
  <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sava_CashIncentiveBonusPlanTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the cash incentive bonus plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sava_CashIncentiveBonusPlanTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sava_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46586285097872">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 12 - Contingencies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes to Financial Statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyDisclosures', window );">Contingencies Disclosure [Text Block]</a></td>
<td class="text">
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><em style="font: inherit;">12.</em> Contingencies</b></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&#160;</p>
   <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 18pt;">The Company is, and from time to time, the Company <em style="font: inherit;"> may </em>become, involved in litigation or other legal proceedings and claims, including U.S. government inquiries, investigations and Citizen Petitions submitted to FDA. In addition, the Company has received, and from time to time <em style="font: inherit;"> may </em>receive, inquiries from government authorities relating to matters arising from the ordinary course of business.&#160;The outcome of these proceedings is inherently uncertain. Regardless of outcome, legal proceedings can have an adverse impact on the Company because of defense and settlement costs, diversion of management resources, and other factors. At this time, <em style="font: inherit;">no</em> assessment can be made as to their likely outcome or whether the outcome will be material to the Company other than as disclosed below. The Company believes that its total provisions for legal matters are adequate based upon currently available information.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 5pt;"><i>Update on Government Investigations</i></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 5pt;text-indent:25pt;">Beginning in <em style="font: inherit;"> August 2021, </em>the Company has received subpoenas, a Civil Investigative Demand (&#8220;CID&#8221;) and other requests for documents and information from the Department of Justice (&#8220;DOJ&#8221;) and document requests from the SEC, each seeking corporate information and documents concerning the research and development of simufilam and/or SavaDx. The Company has been providing documents and information in response to these subpoenas, the CID and requests for information.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 4pt;text-indent:25pt;">On <em style="font: inherit;"> September 26, 2024, </em>the Company announced that it had reached a settlement with the SEC&#160;resolving the SEC investigation of the Company&#8217;s disclosures regarding its Phase <em style="font: inherit;">2b</em> clinical trial of simufilam for the treatment of Alzheimer&#8217;s disease (the &#8220;Phase <em style="font: inherit;">2b</em> Study&#8221;) and related matters. The SEC also agreed to a settlement with <em style="font: inherit;">two</em> former senior employees of the Company. Pursuant to these settlements, the U.S. District Court for the Western District of Texas entered final consent judgment on <em style="font: inherit;"> October 18, 2024, </em>on a complaint filed by the SEC against the Company and its <em style="font: inherit;">two</em> former senior employees. The Company has neither admitted nor denied the allegations of the complaint. The SEC&#8217;s complaint alleged that certain disclosures by the Company regarding the Phase <em style="font: inherit;">2b</em> Study violated certain federal securities laws and SEC rules, including negligence-based disclosure violations of Sections <em style="font: inherit;">17</em>(a)(<em style="font: inherit;">2</em>) and <em style="font: inherit;">17</em>(a)(<em style="font: inherit;">3</em>) of the Securities Act of <em style="font: inherit;">1933,</em> as amended (the &#8220;Securities Act&#8221;), as well as recordkeeping and reporting requirements under the Securities Exchange Act of <em style="font: inherit;">1934,</em> as amended (the &#8220;Exchange Act&#8221;). The complaint alleges that the Company&#8217;s SEC reports and other public statements regarding the Phase <em style="font: inherit;">2b</em> Study negligently contained materially misleading statements and omissions. The SEC&#8217;s allegations with respect to the Company&#8217;s <em style="font: inherit;">two</em> former employees relate to these employees&#8217; roles in such disclosures. Under its settlement, the Company consented to a permanent injunction against future violations of Section <em style="font: inherit;">17</em>(a) of the Securities Act, Section <em style="font: inherit;">13</em>(a)(<em style="font: inherit;">1</em>) of the Exchange Act and Rules <em style="font: inherit;">12b</em>-<em style="font: inherit;">20,</em> <em style="font: inherit;">13a</em>-<em style="font: inherit;">1,</em> <em style="font: inherit;">13a</em>-<em style="font: inherit;">11</em> and <em style="font: inherit;">13a</em>-<em style="font: inherit;">13</em> under the Exchange Act. In addition, the Company&#160;paid a civil monetary penalty of <em style="font: inherit;">$40</em> million in <em style="font: inherit;"> November 2024.</em></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 5pt;text-indent:25pt;">The Company continues to cooperate with the DOJ related to requests for documents and information, including those related to conduct alleged in the indictment of Dr. Hoau-Yan Wang announced by DOJ on <em style="font: inherit;"> June 28, 2024. </em>The Company cannot predict the outcome or impact of&#160;ongoing matters, including whether a government authority <em style="font: inherit;"> may </em>pursue an enforcement action against the Company or others. The Company does <em style="font: inherit;">not</em> at this time anticipate, however, that DOJ will bring criminal charges against or seek a criminal resolution with the Company.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>


   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 5pt;"><i>Securities Class Actions and Shareholder Derivative Actions</i></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 5pt;text-indent:18pt;">Between <em style="font: inherit;"> August 27, 2021 </em>and <em style="font: inherit;"> October 26, 2021, </em><span style="-sec-ix-hidden:c123855699">four</span> putative class action lawsuits were filed alleging violations of the federal securities laws by the Company and certain named officers. The complaints rely on allegations contained in Citizen Petitions submitted to FDA and allege that various statements made by the defendants regarding simufilam were rendered materially false and misleading. The Citizen Petitions were all subsequently denied by FDA. These actions were filed in the U.S. District Court for the Western District of Texas. The complaints seek unspecified compensatory damages and other relief on behalf of a purported class of purchasers.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 8pt; text-align: justify; text-indent: 18pt;">On <em style="font: inherit;"> June 30, 2022, </em>a federal judge consolidated the <span style="-sec-ix-hidden:c123855700">four</span> class action lawsuits into <span style="-sec-ix-hidden:c123855701">one</span> case and appointed a lead plaintiff and a lead counsel. Lead plaintiff filed a consolidated amended complaint on <em style="font: inherit;"> August 18, 2022 </em>on behalf of a putative class of purchasers of the Company&#8217;s securities between <em style="font: inherit;"> September 14, 2020 </em>and <em style="font: inherit;"> July 26, 2022. </em>On <em style="font: inherit;"> May 11, 2023, </em>the court dismissed with prejudice plaintiffs&#8217; claims against&#160;defendant Nadav Friedmann, PhD, MD,&#160;our former Chief Medical Officer and a Company director, who&#160;is now deceased, but otherwise denied defendants&#8217; motion to&#160;dismiss. Defendants filed an answer to the consolidated amended complaint on <em style="font: inherit;"> July 3, 2023. </em>On <em style="font: inherit;"> February 22, 2024, </em>plaintiffs filed a motion to supplement their complaint to extend the putative class period through <em style="font: inherit;"> October 12, 2023.&#160; </em>The court granted that Motion on <em style="font: inherit;"> June 12, 2024, </em>and plaintiffs filed a supplemental complaint on <em style="font: inherit;"> June 13, 2024.&#160;</em>On <em style="font: inherit;"> November 13, 2024, </em>Plaintiffs filed a <em style="font: inherit;">second</em> motion to supplement their complaint. On <em style="font: inherit;"> March 13, 2024, </em>plaintiffs filed a Motion for Class Certification. On <em style="font: inherit;"> February 25, 2025, </em>the Court denied Plaintiff&#8217;s Motion for Class Certification without prejudice, explaining that rulings on pending motions, including specifically Plaintiffs&#8217; <em style="font: inherit;">second</em> motion to supplement their complaint, could affect disposition of class certification.&#160;</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 5pt;text-indent:18pt;">On <em style="font: inherit;"> November 4, 2021, </em>a related shareholder derivative action was filed, purportedly on behalf of the Company, in the U.S. District Court for the Western District of Texas, asserting claims under the U.S. securities laws and state fiduciary duty laws against certain named officers and the members of the Company&#8217;s Board. This complaint relies on the allegations made in Citizen Petitions that were submitted to (and subsequently denied by) FDA. The complaint alleges, among other things, that the individual defendants exposed the Company to unspecified damages and securities law liability by causing it to make materially false and misleading statements, in violation of the U.S. securities laws and in breach of their fiduciary duties to the Company. The derivative case seeks, among other things, to recover unspecified compensatory damages on behalf of the Company arising out of the individual defendants&#8217; alleged wrongful conduct. Although the plaintiff in this derivative case does <em style="font: inherit;">not</em> seek relief against the Company, the Company has certain indemnification obligations to the individual defendants. Between <em style="font: inherit;"> November 4, 2021 </em>and <em style="font: inherit;"> June 20, 2023, </em><span style="-sec-ix-hidden:c123855705">four</span> additional shareholder derivative actions were filed alleging substantially similar claims, <span style="-sec-ix-hidden:c123855706">two</span> in the U.S. District Court for the Western District of Texas, <span style="-sec-ix-hidden:c123855707">one</span> in Texas state court (Travis County District Court) and <span style="-sec-ix-hidden:c123855708">one</span> in the Delaware Court of Chancery. On <em style="font: inherit;"> July 5, 2022, </em>the <span style="-sec-ix-hidden:c123855709">three</span> actions in the Western District of Texas were consolidated into a single action. All of the foregoing actions are currently stayed pending further developments in the consolidated securities action described above.&#160;On <em style="font: inherit;"> November 9, 2023, </em>another shareholder derivative action alleging substantially similar claims was filed in the U.S. District Court for the Western District of Texas.&#160;The parties to that case expect that it will be consolidated into the existing consolidated federal court shareholder derivative action.</p>
   <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 5pt;text-indent:18pt;">On <em style="font: inherit;"> February 2, 2024, </em>a putative class action lawsuit was filed, purportedly on behalf of the Company,&#160;alleging violations of the federal securities law by the Company and certain named officers. The complaint relies on an <em style="font: inherit;"> October 12, 2023 </em>article that describes a purported leaked report of alleged scientific misconduct by a&#160;scientific collaborator of the Company at City University of New York. The complaint alleges that various statements made by the defendants regarding simufilam were rendered materially false and misleading by this article. The action was filed in the U.S. District Court for the Northern District of Illinois. The complaint seeks unspecified compensatory damages and other relief on behalf of a purported class of purchasers of the Company&#8217;s securities between <em style="font: inherit;"> August 18, 2022 </em>and <em style="font: inherit;"> October 12, 2023. </em>On <em style="font: inherit;"> May 28, 2024, </em>the Northern District of Illinois transferred this action to the Western District of Texas.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>


   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 5pt;text-indent:18pt;">Beginning on <em style="font: inherit;"> March 18, 2024, </em><span style="-sec-ix-hidden:c123855711">two</span> related shareholder derivative actions were filed, purportedly on behalf of the Company, in the U.S. District Court for the Northern District of Illinois, asserting claims under the U.S. securities laws and state fiduciary duty laws against certain named officers and the members of the Company&#8217;s Board. The complaints rely on an <em style="font: inherit;"> October 12, 2023 </em>article that describes a purported leaked report of alleged scientific misconduct by a&#160;scientific collaborator of the Company at City University of New York. The complaints allege, among other things, that the individual defendants exposed the Company to unspecified damages and securities law liability by causing it to make materially false and misleading statements, in violation of the U.S. securities laws and in breach of their fiduciary duties to the Company. The derivative cases seek, among other things, to recover unspecified compensatory damages on behalf of the Company arising out of the individual defendant&#8217;s alleged wrongful conduct. Although the plaintiffs in these derivative cases do <em style="font: inherit;">not</em> seek relief against the Company, the Company has certain indemnification obligations to the individual defendants.&#160;On <em style="font: inherit;"> September 6, 2024, </em>these <span style="-sec-ix-hidden:c123855713">two</span> cases were consolidated and stayed pending further developments in the shareholder class action initially filed in the Northern District of Illinois on <em style="font: inherit;"> February 2, 2024.</em></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 5pt;text-indent:18pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 5pt;text-indent:18pt;">The Company disputes the allegations and intends to defend against these lawsuits vigorously. The Company is unable to estimate the possible loss or range of loss, if any, associated with these lawsuits.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 5pt;text-indent:18pt;">On <em style="font: inherit;"> December 13, 2024, </em>a putative class action lawsuit was filed, purportedly on behalf of the Company,&#160;alleging violations of the federal securities law by the Company and certain named officers. The complaint alleges that various statements made by the defendants regarding simufilam were revealed to be materially false and misleading by the release of top-line results for the Company&#8217;s RETHINK-ALZ Phase <em style="font: inherit;">3</em> clinical trial on <em style="font: inherit;"> November 25, 2024. </em>The action was filed in the U.S. District Court for the Western District of Texas. The complaint seeks unspecified compensatory damages and other relief on behalf of a purported class of purchasers of the Company&#8217;s securities between <em style="font: inherit;"> February 7, 2024, </em>and <em style="font: inherit;"> November 24, 2024.&#160;</em>The Company believes that the likelihood of an unfavorable outcome is <em style="font: inherit;">not</em> probable, however, it is reasonably possible that the Company <em style="font: inherit;"> may </em>incur a loss. The Company is unable to reasonably estimate the amount or range of potential loss at this time.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 5pt;text-indent:18pt;">On <em style="font: inherit;"> August 19, 2022, </em>a shareholder derivative action was filed, purportedly on behalf of the Company, in the Delaware Court of Chancery, asserting claims under state fiduciary duty laws against certain named officers and members of the Company&#8217;s Board. The complaint alleges, among other things, that the individual defendants breached their fiduciary duties by approving the CIB Plan in <em style="font: inherit;"> August 2020. </em>The complaints sought unspecified compensatory damages and other relief. On <em style="font: inherit;"> January 6, 2023, </em>the plaintiffs filed an amended complaint. Defendants filed a partial answer to the amended complaint on <em style="font: inherit;"> March 10, 2023, </em>and moved to partially dismiss the amended complaint on <em style="font: inherit;"> March 14, 2023.</em></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 5pt;text-indent:18pt;">On <em style="font: inherit;"> May 28, 2024, </em>the parties entered into a Stipulation and Agreement of Settlement, Compromise, and Release (the &#8220;Stipulation&#8221;) to resolve the action. The Stipulation and exhibits thereto, including the proposed Notice of Pendency of Settlement of Class and Derivative Action (the &#8220;Notice&#8221;) and [Proposed] Scheduling Order with Respect to Notice and Settlement Hearing (the &#8220;Scheduling Order&#8221;), were filed in the Delaware Court of Chancery on <em style="font: inherit;"> May 28, 2024.&#160;</em></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 5pt;text-indent:18pt;">On <em style="font: inherit;"> June 26, 2024, </em>the Delaware Court of Chancery entered the Scheduling Order, which included approval of the Notice.&#160; The Delaware Court of Chancery held a settlement hearing on <em style="font: inherit;"> September 9, 2024. </em>On <em style="font: inherit;"> January 24, 2025, </em>the Delaware Court of Chancery entered a Final Order and Judgment approving the Stipulation and dismissing the action with prejudice. Pursuant to the Final Order, the Company paid $1 million in attorneys&#8217; fees and expenses in <em style="font: inherit;"> February 2025, </em>which was recorded in accounts payable and other accrued expenses at <em style="font: inherit;"> December 31, 2024.</em></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 7pt;"><i>Anti-SLAPP Lawsuit</i></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 7pt; text-indent: 18pt; text-align: justify;">On <em style="font: inherit;"> August 6, 2024, </em>a lawsuit was filed in the District Court for the Southern District of New York which, as amended and as joined by intervenor plaintiffs, asserts claims, including a claim under the New York Anti-SLAPP Law, against the Company and against two former officers to whom the Company has certain indemnification obligations.&#160;The amended complaint and the complaint in intervention seeks costs and damages relating to a defamation action filed by the Company against the plaintiffs and subsequently dismissed voluntarily and without prejudice by the Company.&#160;The Company intends to&#160;defend the lawsuit vigorously.&#160;The Company is unable to estimate the possible loss or range of loss, if any, associated with this lawsuit.</p>
   <p style="text-align: justify; font-size: 10pt; font-family: &quot;Times New Roman&quot;; margin: 0pt;">&#160;</p>
  <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyDisclosures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for loss and gain contingencies. Describes any existing condition, situation, or set of circumstances involving uncertainty as of the balance sheet date (or prior to issuance of the financial statements) as to a probable or reasonably possible loss incurred by an entity that will ultimately be resolved when one or more future events occur or fail to occur, and typically discloses the amount of loss recorded or a range of possible loss, or an assertion that no reasonable estimate can be made.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 720<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483359/720-20-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.Y.Q4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480102/450-20-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.Y.Q2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480102/450-20-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483076/450-20-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/450-20/tableOfContent<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483076/450-20-50-4<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483076/450-20-50-9<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 450<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/450-30/tableOfContent<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 450<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483049/450-30-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyDisclosures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46586430209040">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 13 - Warrant Dividend Distribution<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes to Financial Statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sava_WarrantDividendDistributionTextBlock', window );">Warrant Dividend Distribution [Text Block]</a></td>
<td class="text">
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><em style="font: inherit;">13.</em> Warrant Dividend Distribution</b></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -2pt; text-indent: 18pt;">On <em style="font: inherit;"> January 3, 2024, </em>the Company&#160;made a distribution&#160;to the holders of record of the Company&#8217;s&#160;common stock&#160;in the form of warrants to purchase shares of common stock. Each holder of record of the Company's common stock as of the close of business on <em style="font: inherit;"> December 22, 2023 </em>received <span style="-sec-ix-hidden:c123855719">four</span> warrants for every 10&#160;shares of common stock (rounded down&#160;for any fractional warrant) resulting in the issuance of approximately <span style="-sec-ix-hidden:c123855721">16.9</span> million&#160;warrants.</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;">&#160;</p>


   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-indent: 18pt;">Each warrant entitled&#160;the holder to purchase, at the holder&#8217;s sole expense and exclusive election, at an exercise price of $33.00 per warrant, <span style="-sec-ix-hidden:c123855724">one</span> and <em style="font: inherit;">one</em>-half shares of common stock (rounded down&#160;for any fractional shares). Payment for shares of common stock upon exercise of warrants was required to&#160;be in cash.</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -2pt; text-indent: 18pt;">On <em style="font: inherit;"> April 15, 2024, </em>the Company announced&#160;that all outstanding warrants would&#160;be redeemed on <em style="font: inherit;"> May 7, 2024&#160;(</em>the &#8220;Redemption Date&#8221;). The redemption price was equal to <span style="-sec-ix-hidden:c123855726">1/10</span> of $0.01 per warrant. The warrants were exercisable at any time starting on <em style="font: inherit;"> January 3, 2024&#160;</em>until the business day prior to the Redemption Date. There are <span style="-sec-ix-hidden:c123855728">no</span> remaining warrants currently outstanding.</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -2pt; text-indent: 18pt;">The warrants were subject to the terms and conditions of the Warrant Agreement (including Form of Warrant), dated <em style="font: inherit;"> January 3, 2024, </em>between Cassava Sciences, Inc., Computershare Inc., and Computershare Trust Company, N.A. as filed in a Current Report on&#160;Form <em style="font: inherit;">8</em>-K with the SEC on <em style="font: inherit;"> January 3, 2024. </em>The warrants were&#160;listed and traded separately from the Company's common stock on the Nasdaq Capital Market under the ticker &#8220;SAVAW&#8221;.</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -4pt; text-indent: 9pt;">From <em style="font: inherit;"> January 3, 2024 </em>to <em style="font: inherit;"> March 31, 2024, </em>a total of approximately 674,000&#160;warrants were exercised resulting in net proceeds to the Company of approximately $22.3&#160;million. The Company issued approximately 1.0 million&#160;shares of common stock&#160;from the exercise of warrants through <em style="font: inherit;"> March 31, 2024.</em></p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -4pt; text-indent: 9pt;">Subsequent to <em style="font: inherit;"> March 31, 2024 </em>and through the Redemption Date, a total of approximately <em style="font: inherit;">3.15</em> million&#160;warrants were exercised resulting in gross proceeds to the Company of approximately <em style="font: inherit;">$104.0</em>&#160;million. The Company issued approximately 4.7 million shares of common stock&#160;from the exercise of warrants from <em style="font: inherit;"> March 31, 2024 </em>through the Redemption Date.</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;">Gross proceeds for the year ended <em style="font: inherit;"> December 31,&#160;</em><em style="font: inherit;">2024</em> from the warrant distribution totaled approximately $126.3&#160;million from the issuance of approximately 5.7 million common shares at $22.00 per share. Total net proceeds of the warrant distribution were approximately $123.6&#160;million&#160;after deducting&#160;exercise&#160;expenses and commissions.</p>
   <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -4pt; text-indent: 9pt;">After the <em style="font: inherit;">first</em> $20 million of gross proceeds, the Company was&#160;obligated to pay a commission of&#160;2.5% of the gross proceeds from the sale of shares of common stock from&#160;warrant exercises&#160;to the Company's financial advisor for the warrant distribution. Total cost&#160;of warrant exercises through the Redemption Date were approximately $2.7&#160;million.</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -4pt; text-indent: 9pt;">Costs of the warrant distribution totaling&#160;approximately $537,000 were recorded&#160;as general and administrative expenses in the statements of operations upon distribution of the warrants on <em style="font: inherit;"> January 3, 2024.</em></p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -4pt; text-indent: 9pt; text-align: justify;">The outstanding warrants were&#160;classified as liabilities in accordance with ASC <em style="font: inherit;">480</em> and ASC <em style="font: inherit;">815,</em> which requires&#160;the warrants to be measured at initial fair value&#160;on <em style="font: inherit;"> January 3, 2024&#160;</em>and at each reporting period thereafter, with the changes in fair value recognized as a non-cash gain or loss&#160;in our consolidated statements of operations. As of <em style="font: inherit;"> December 31, 2024, </em>there were no warrants outstanding.</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-indent: 18pt; text-align: justify;">During the period from common stock warrant distribution on <em style="font: inherit;"> January 3, 2024 </em>to the Redemption Date, changes in the Company's common stock warrants liability and&#160;warrants outstanding were as follows (in thousands):</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt;">&#160;</p>

    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"><tbody><tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Number of Common Stock Warrants</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Common Stock Warrant Liability</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 70%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Distribution of common stock warrants on January 3, 2024</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">16,895</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">113,363</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Warrants exercised</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(674</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(4,954</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Gain from change in fair value of warrant liabilities</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"><em style="font: inherit;">&#8212;</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(43,041</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Balance at March 31, 2024</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">16,221</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">65,368</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Warrants exercised</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(3,152</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(226</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Gain from change in fair value of warrant liabilities</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><em style="font: inherit;">&#8212;</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(65,142</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Redemption of common stock warrants</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(13,069</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"><em style="font: inherit;">&#8212;</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Balance as of June 30, 2024</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;"><span style="-sec-ix-hidden:c123855372">&#8212;</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">&#8212;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Balance as of September 30, 2024</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;"><span style="-sec-ix-hidden:c123855374">&#8212;</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><span style="-sec-ix-hidden:c123855375">&#8212;</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Balance as of December 31, 2024</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;"><span style="-sec-ix-hidden:c123855376">&#8212;</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><span style="-sec-ix-hidden:c123855377">&#8212;</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td></tr>
</tbody></table>

   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -10pt; text-indent: 18pt;">See Note <em style="font: inherit;">2</em> for additional information regarding common stock warrants and associated warrant liability.</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -10pt; text-indent: 18pt;">&#160;</p>


  <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sava_WarrantDividendDistributionTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of warrant dividend distribution.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sava_WarrantDividendDistributionTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sava_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46586284989760">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 14 - Subsequent Event<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes to Financial Statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">Subsequent Events [Text Block]</a></td>
<td class="text">
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -19pt; text-indent: 18pt;"><b><em style="font: inherit;">14.</em> Subsequent Event</b></p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -19pt; text-indent: 18pt;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-indent: 18pt;">On <em style="font: inherit;"> January 7, 2025, </em>the Company announced a reduction&#160;its workforce by 10 employees, a reduction of 33% (the &#8220;Workforce Reduction&#8221;). The Company communicated the Workforce Reduction to affected employees on <em style="font: inherit;"> January 7, 2025.</em></p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-indent: 18pt;">The Company estimates that it will incur approximately $0.4 million of <em style="font: inherit;">one</em>-time costs in connection with the Workforce Reduction, primarily related to severance payments. The Company expects the Workforce Reduction to be completed, and the majority of the associated costs and cash payments to be incurred, during the <em style="font: inherit;">first</em> quarter of <em style="font: inherit;">2025.</em>&#160;</p>
  <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/855/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483399/855-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46586283330768">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates, Policy [Policy Text Block]</a></td>
<td class="text"><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>Use of Estimates</i></b></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">The Company makes estimates and assumptions in preparing its consolidated financial statements in conformity with accounting principles generally accepted in the United States. These estimates and assumptions affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amount of revenue earned and expenses incurred during the reporting period. The Company evaluates&#160;its estimates on an ongoing basis, including those estimates related to legal liabilities, common stock warrant liabilities, stock based compensation, clinical trials and manufacturing agreements. Actual results could differ from these estimates and assumptions.</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&#160;</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GovernmentAssistancePolicyTextBlock', window );">Government Assistance [Policy Text Block]</a></td>
<td class="text"><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>Proceeds from Grants</i></b></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">During <em style="font: inherit;">2024</em> and <em style="font: inherit;">2023,</em> there were no reimbursements received pursuant to National Institutes of Health (&#8220;NIH&#8221;) research grants. In <em style="font: inherit;">2022,</em> the Company received $0.9 million of reimbursement&#160;from the NIH&#160;and National Institute on Drug Abuse. The Company records the proceeds from these grants as reductions to its <span style="-sec-ix-hidden:c123855795">research and development expenses</span>.</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash and Cash Equivalents, Policy [Policy Text Block]</a></td>
<td class="text"><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>Cash and Cash Equivalents and Concentration of Credit Risk</i></b></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">The Company invests in cash and cash equivalents. The Company considers highly-liquid financial instruments with original maturities of <em style="font: inherit;">three</em> months or less to be cash equivalents. Highly liquid investments that are considered cash equivalents include money market accounts and funds, certificates of deposit and U.S. Treasury securities. The Company maintains&#160;its cash and cash equivalents at <em style="font: inherit;">one</em> financial institution.</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&#160;</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock', window );">Fair Value Measurement, Policy [Policy Text Block]</a></td>
<td class="text"><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>Fair Value Measurements </i></b></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&#160;</p>
   <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 18pt;">The Company recognizes financial instruments in accordance with the authoritative guidance on fair value measurements and disclosures for financial assets and liabilities. This guidance defines fair value, establishes a framework for measuring fair value in accordance with GAAP, and expands disclosures about fair value measurements. The guidance also establishes a <em style="font: inherit;">three</em>-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value. These tiers include:</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 36pt;text-indent:-18pt;">&#160;</p>
   <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;"><tbody><tr style="vertical-align: top;"><td style="width: 18pt;">&#160;</td><td style="width: 18pt;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p> </td><td style="width: auto;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Level <em style="font: inherit;">1</em> includes quoted prices in active markets.</p> </td></tr>
</tbody></table>
   <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;"><tbody><tr style="vertical-align: top;"><td style="width: 18pt;">&#160;</td><td style="width: 18pt;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p> </td><td style="width: auto;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Level <em style="font: inherit;">2</em> includes significant observable inputs, such as quoted prices for identical or similar securities, or other inputs that are observable and can be corroborated by observable market data for similar securities. The Company uses market pricing and other observable market inputs obtained from <em style="font: inherit;">third</em>-party providers. It uses the bid price to establish fair value where a bid price is available. The Company does <em style="font: inherit;">not</em> have any financial instruments where the fair value is based on Level <em style="font: inherit;">2</em> inputs.</p> </td></tr>
</tbody></table>
   <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;"><tbody><tr style="vertical-align: top;"><td style="width: 18pt;">&#160;</td><td style="width: 18pt;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p> </td><td style="width: auto;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Level <em style="font: inherit;">3</em> includes unobservable inputs that are supported by little or <em style="font: inherit;">no</em> market activity. The Company does <em style="font: inherit;">not</em> have any financial instruments where the fair value is based on Level <em style="font: inherit;">3</em> inputs.</p> </td></tr>
</tbody></table>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">If a financial instrument uses inputs that fall in different levels of the hierarchy, the instrument will be categorized based upon the lowest level of input that is significant to the fair value calculation. The fair value of cash and cash equivalents was based on Level <em style="font: inherit;">1</em> inputs at <em style="font: inherit;"> December 31, 2024&#160;</em>and <em style="font: inherit;">2023.</em></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify; text-indent: 18pt;">The fair value of common stock warrants of $6.71 per warrant was determined at distribution on <em style="font: inherit;"> January 3, 2024 </em>using a Monte Carlo valuation model since the warrants were&#160;<em style="font: inherit;">not</em> traded on the open market on <em style="font: inherit;"> January 3, 2024. </em>Warrant trading on Nasdaq began on <em style="font: inherit;"> January 4, 2024. </em>Quantitative information regarding Level <em style="font: inherit;">3</em> fair value measurements for common stock warrants is&#160;as follows:</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&#160;</p>

    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"><tbody><tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 85%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Exercise price per warrant</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">33.00</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Conversion rate - common shares per warrant</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">1.50</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Closing price of common stock</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">23.72</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Volatility</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">75</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">%</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Risk-free interest rate</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">5.40</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">%</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Expected life of option (in years)</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">0.3</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Dividend yield</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: right; margin: 0pt;"><span style="-sec-ix-hidden:c123854924">zero</span></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
</tbody></table>

   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -1pt; text-indent: 18pt;">The common stock warrants stopped&#160;trading on Nasdaq after <em style="font: inherit;"> May 2, 2024 </em>and subsequently had little or <em style="font: inherit;">no</em> market activity. As of <em style="font: inherit;"> May 7, 2024,&#160;</em>the warrants were presumed to have <em style="font: inherit;">no</em> value since they&#160;were redeemed for a nominal payment of $0.001 per warrant.</p>
   <p style="margin: 0pt 0pt 0pt -9pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">&#160;</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingPolicyPolicyTextBlock', window );">Segment Reporting, Policy [Policy Text Block]</a></td>
<td class="text"><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>Segment Information</i></b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">The Company reports segment information based on how it internally evaluates the operating performance of its business units, or segments. The Company&#8217;s operations are confined to one business segment: the development of novel drugs and diagnostics.</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-indent: 18pt; text-align: justify;">The Company&#8217;s reportable segment&#160;reflects the manner in which its chief operating decision maker ("CODM") allocates resources and assesses performance. The Company's CODM is the President and Chief Executive Officer. The primary measure used by the Company's CODM for purposes of allocating resources is based on net loss that also is reported on the income statement as consolidated net loss. The measure of segment assets is reported on the balance sheet as cash and cash equivalents.</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-indent: 18pt;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify; text-indent: 18pt;">The Company has <em style="font: inherit;">not</em> generated any product revenue in the current period and expects to continue to incur significant expenses and operating losses for the foreseeable future as we advance our product candidates through stages of development and clinical trials.</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify; text-indent: 18pt;">As such, the CODM uses cash forecast models in deciding how to invest in&#160;the development of novel drugs and diagnostics. Such cash forecast models are reviewed to assess the entity-wide operating results and performance. Net loss is used to monitor budget versus actual results. Monitoring budgeted versus actual results, net cash used in operating activities for the period and cash on hand are used in assessing performance of the segment.</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-indent: 18pt;">&#160;</p>


   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-indent: 18pt;">The following table summarizes expenses by category regularly reviewed by the CODM&#160;(in thousands):</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"><tbody><tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td colspan="10" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;"><em style="font: inherit;"><em style="font: inherit;">Years Ended December 31,</em></em></em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">2024</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">2023</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">2022</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 55%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Operating expenses</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Research and development</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">69,637</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">89,423</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">68,032</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">General and administrative</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">71,809</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">16,534</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">11,988</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Other segment items(a)</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(117,104</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(8,740</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(3,774</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Net loss</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">24,342</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">97,217</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">76,246</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td></tr>
</tbody></table>

   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">(a) Other segment items include interest income, other income, net and gain from change in fair value of warrant liabilities.</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 18pt;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 18pt;">The following table summarizes assets regularly reviewed by the CODM&#160;(in thousands):</p>

    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"><tbody><tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>December 31,</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>2024</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>2023</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 70%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Cash and cash equivalents</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">128,574</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">121,136</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td></tr>
</tbody></table>

   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-indent: 18pt;">For the year ended <em style="font: inherit;"> December 31, 2024, </em>and <em style="font: inherit;">2023,</em> the net cash used in operating activities was $116.9&#160;million and $82.0&#160;million, respectively.&#160;</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CompensationRelatedCostsPolicyTextBlock', window );">Compensation Related Costs, Policy [Policy Text Block]</a></td>
<td class="text"><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>Stock-based Compensation</i></b><b> </b></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">The Company recognizes non-cash expense for the fair value of all stock options and other share-based awards. The Company uses the Black-Scholes option valuation model (&#8220;Black-Scholes&#8221;) to calculate the fair value of stock options, using the single-option award approach and straight-line attribution method. This model requires the input of subjective assumptions including expected stock price volatility, expected life and estimated forfeitures of each award. These assumptions consist of estimates of future market conditions, which are inherently uncertain, and therefore, are subject to management&#8217;s judgment. For all options granted, it recognizes the resulting fair value as expense on a straight-line basis over the vesting period of each respective stock option, generally <span style="-sec-ix-hidden:c123855418">one</span>&#160;to&#160;<span style="-sec-ix-hidden:c123855419">four</span> years.</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">The Company has granted share-based awards that vest upon achievement of certain performance criteria (&#8220;Performance Awards&#8221;). The Company multiplies the number of Performance Awards by the fair value of its common stock on the date of grant to calculate the fair value of each award. It estimates an implicit service period for achieving performance criteria for each award. The Company recognizes the resulting fair value as expense over the implicit service period when it concludes that achieving the performance criteria is probable. It periodically reviews and updates as appropriate its estimates of implicit service periods and conclusions on achieving the performance criteria. Performance Awards vest and common stock is issued upon achievement of the performance criteria.</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">&#160;</p>
   <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Earnings Per Share, Policy [Policy Text Block]</a></td>
<td class="text"><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>Net Loss per Share</i></b></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-indent: 18pt; text-align: justify;">Basic net loss&#160;per common share is computed by dividing the net loss&#160;available to common stockholders by the weighted-average number of common shares outstanding during the period. Diluted net loss&#160;per common share is computed by dividing the net loss&#160;available to common stockholders by the weighted-average number of common shares outstanding and potentially dilutive securities outstanding during the period using the treasury stock method. Potentially dilutive securities are excluded from the computations of diluted earnings per share if their effect would be anti-dilutive. A net loss&#160;causes all potentially dilutive securities to be anti-dilutive. Potentially dilutive securities consist of outstanding common stock options&#160;and Performance Awards.&#160;There is <em style="font: inherit;">no</em> difference between the Company&#8217;s net loss and comprehensive loss. The numerators and denominators in the calculation of basic and diluted net loss per share were as follows (in thousands, except net loss per share data):</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>

    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"><tbody><tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="10" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;"><em style="font: inherit;"><em style="font: inherit;">Years ended December 31,</em></em></em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">2024</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">2023</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">2022</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 55%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Numerator, basic:</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Net loss</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(24,342</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(97,217</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(76,246</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Denominator, basic:</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Weighted average common shares outstanding</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">46,329</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">41,932</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">40,202</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Net loss per share, basic</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(0.53</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(2.32</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(1.90</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">)</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Numerator, diluted:</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Net loss</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(24,342</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(97,217</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(76,246</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Adjustment for change in fair value of warrant liabilities</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(43,793</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;">&#8212;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;">&#8212;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Adjusted numerator, diluted</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(68,135</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(97,217</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(76,246</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Denominator, diluted:</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Weighted average common shares outstanding</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">46,329</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">41,932</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">40,202</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Dilutive effect of common stock warrants</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">275</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">&#8212;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">&#8212;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Weighted average dilutive common shares</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">46,604</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">41,932</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">40,202</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Net loss per share, diluted</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(1.46</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(2.32</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(1.90</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">)</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Dilutive common stock options excluded from net loss per share, diluted</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">3,154</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">2,123</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">2,055</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Dilutive Performance Awards excluded from loss per share, diluted</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">7</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">7</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">7</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
</tbody></table>

   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativesPolicyTextBlock', window );">Derivatives, Policy [Policy Text Block]</a></td>
<td class="text"><p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"><b><i>Warrant Liabilities</i></b></p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 18pt;">The Company accounts for warrants as either equity-classified or liability-classified instruments based on an assessment of the warrant&#8217;s specific terms and in accordance with the Financial Accounting Standards Board (&#8220;FASB&#8221;) Accounting Standards Codification (&#8220;ASC&#8220;) <em style="font: inherit;">480,</em> &#8220;Distinguishing Liabilities from Equity&#8221;, and ASC <em style="font: inherit;">815,</em> &#8220;Derivatives and Hedging&#8221;. The assessment considers whether the warrants are freestanding financial instruments pursuant to ASC <em style="font: inherit;">480,</em> meet the definition of a liability pursuant to ASC <em style="font: inherit;">480,</em> and whether the warrants meet all of the requirements for equity classification under ASC <em style="font: inherit;">815,</em> including whether the warrants are indexed to the Company&#8217;s own shares, among other conditions for equity classification. This assessment, which requires the use of professional judgment, is conducted at the time of warrant issuance and as of each subsequent quarterly period end date while the warrants are outstanding.</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 18pt;">For issued or modified warrants that meet all of the criteria for equity classification, the warrants are required to be recorded as a component of additional paid-in capital at the time of issuance. For issued or modified warrants that do <em style="font: inherit;">not</em> meet all the criteria for equity classification, the warrants are required to be recorded at their initial fair value of the date of issuance, and each balance sheet date thereafter. Changes in the estimated fair value of liability classified warrants are recognized as a non-cash gain or loss on the statements of operations. Costs associated with issuing the warrants classified as derivative liabilities are charged to operations when the warrants are issued.</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&#160;</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueOfFinancialInstrumentsPolicy', window );">Fair Value of Financial Instruments, Policy [Policy Text Block]</a></td>
<td class="text"><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>Fair Value of Financial Instruments</i></b></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">Financial instruments include accounts payable, accrued expenses, accrued development expense and other liabilities. The estimated fair value of certain financial instruments <em style="font: inherit;"> may </em>be determined using available market information or other appropriate valuation methodologies. However, considerable judgment is required in interpreting market data to develop estimates of fair value; therefore, the estimates are <em style="font: inherit;">not</em> necessarily indicative of the amounts that could be realized or would be paid in a current market exchange. The effect of using different market assumptions and/or estimation methodologies <em style="font: inherit;"> may </em>be material to the estimated fair value amounts. The carrying amounts of accounts payable,&#160;accrued expenses, accrued development expense&#160;and other liabilities&#160;are at cost, which approximates fair value due to the short maturity of those instruments.</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&#160;</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development Expense, Policy [Policy Text Block]</a></td>
<td class="text"><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>Research Contracts, Prepaids and Accruals</i></b></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">The Company has entered into various research and development contracts with research institutions and other <em style="font: inherit;">third</em>-party vendors. These agreements are generally cancelable. Related payments are recorded as research and development expenses as incurred. The Company records prepaids and accruals for estimated ongoing research costs. When evaluating the adequacy of&#160;prepaid expenses and accrued liabilities, the Company analyzes progress of the studies including the phase or completion of events, invoices received and contracted costs. Significant judgments and estimates are made in determining the prepaid and accrued balances at the end of any reporting period. Actual results could differ from the Company&#8217;s estimates. The Company&#8217;s historical prepaid and accrual estimates have <em style="font: inherit;">not</em> been materially different from actual costs.</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&#160;</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Share-Based Payment Arrangement [Policy Text Block]</a></td>
<td class="text"><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>Incentive Bonus Plan</i></b></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">In <em style="font: inherit;">2020,</em> the Company established the <em style="font: inherit;">2020</em> Cash Incentive Bonus Plan (the &#8220;CIB Plan&#8221;) to incentivize CIB Plan participants. Awards under the CIB Plan are accounted for as liability awards under ASC&#160;<em style="font: inherit;">718</em> &#8220;<i>Stock-based Compensation</i>&#8221;.&#160;The fair value of each&#160;potential CIB Plan&#160;award&#160;will be&#160;determined&#160;once&#160;a&#160;grant date occurs and&#160;will be&#160;remeasured each reporting period.&#160;Compensation expense associated with the CIB Plan&#160;will be&#160;recognized over the expected achievement period for each&#160;CIB Plan award, when&#160;a Performance Condition&#160;(as defined below) is considered probable of being met. See Note <em style="font: inherit;">11</em> for further discussion of the CIB Plan.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property, Plant and Equipment, Policy [Policy Text Block]</a></td>
<td class="text"><p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left"><b><i>Property and Equipment</i></b></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">Property and equipment are&#160;recorded at cost, net of accumulated depreciation. Depreciation is recorded using the straight-line method over the estimated useful lives of the assets. Owned buildings and related improvements have estimated useful lives of 39 years and approximately 10 years, respectively. Tenant improvements&#160;related to leased space are amortized using the straight-line method over the useful lives of the improvements or the remaining term of the corresponding leases, whichever is shorter.</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">Property and equipment are reviewed for impairment when events or changes in circumstances indicate the carrying amount of an asset <em style="font: inherit;"> may </em><em style="font: inherit;">not</em> be recoverable. If property and equipment are considered to be impaired, an impairment loss is recognized.</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&#160;</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsFiniteLivedPolicy', window );">Intangible Assets, Finite-Lived, Policy [Policy Text Block]</a></td>
<td class="text"><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>Intangible Assets</i></b></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">Acquired intangible assets are recorded at fair value at the date of acquisition and primarily consist of lease-in-place agreements and leasing commissions. Intangible assets are amortized over the estimated life of the lease-in-place agreements.&#160;Intangible assets also include&#160;leasing commissions, which are amortized over the life of the lease agreement.</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">Intangible assets are reviewed for impairment on an annual basis, and when there is reason to believe that their values have been diminished or impaired. If intangible assets are considered to be impaired, an impairment loss is recognized.</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesPolicyTextBlock', window );">Commitments and Contingencies, Policy [Policy Text Block]</a></td>
<td class="text"><p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;"><b><i>Insurance Recoveries</i></b></p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 18pt;">We record proceeds from our&#160;insurance policies&#160;when the loss event has&#160;occurred, and proceeds are estimable and probable of being recovered. Insurance recoveries&#160;and proceeds received are recorded as a reduction to general and administrative expense.&#160;There was approximately $9.9&#160;million&#160;and $0.1 million of insurance recoveries recorded during the year ended <em style="font: inherit;"> December 31, 2024 </em>and <em style="font: inherit;">2023,</em> respectively. The applicable policy year had&#160;a $10.0 million recovery limit which has been reached at <em style="font: inherit;"> December 31, 2024.</em></p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;">&#160;</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sava_RelatedPartyTransactionPolicyTextBlock', window );">Related Party Transaction [Policy Text Block]</a></td>
<td class="text"><p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;"><b><i>Related Party Transactions</i></b></p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-indent: 18pt; text-align: justify;">On <em style="font: inherit;"> July 15, 2024, </em>our former&#160;President and Chief Executive Officer&#160;resigned from the Company, effective as of <em style="font: inherit;"> September 13, 2024 (</em>the &#8220;Effective Date&#8221;). Pursuant to the terms of his employment agreement, our former&#160;President and Chief Executive Officer is&#160;receiving&#160;severance compensation equal to $1.23 million over <em style="font: inherit;">twelve</em> months following the Effective Date. Severance compensation was included in general and administrative expense.</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-indent: 18pt;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-indent: 18pt; text-align: justify;">On <em style="font: inherit;"> July 16, 2024, </em>our former Senior Vice President (SVP), Neuroscience agreed to step down from her employment with the Company, effective immediately. Our former SVP, Neuroscience is the spouse of our former&#160;President and Chief Executive Officer. Pursuant to a separation agreement, our former SVP, Neuroscience is&#160;receiving&#160;severance compensation equal to $0.5 million in quarterly installments over <em style="font: inherit;">twelve</em> months.&#160;Severance compensation was included in research and development&#160;expense.</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-indent: 18pt;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -2pt; text-indent: 18pt; text-align: justify;">Included in accrued compensation and benefits at <em style="font: inherit;"> December 31, 2024 </em>is approximately $1.2&#160;million of accrued severance costs for the <span style="-sec-ix-hidden:c123855449">two</span> former senior officers.</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -2pt; text-indent: 18pt; text-align: justify;">On <em style="font: inherit;"> July 16, 2024, </em>the Company entered into a one-year consulting agreement&#160;with the Company&#8217;s former SVP, Neuroscience.&#160;Pursuant to the terms of the consulting agreement, the&#160;consultant is providing services&#160;for purposes of providing information and support for scientific research and/or obtaining governmental approval for the Company&#8217;s products.&#160;The Company will pay&#160;$500&#160;per hour&#160;for such&#160;consulting services. The Company incurred fees totaling $43,000 under the consulting agreement during the year ended <em style="font: inherit;"> December 31, 2024.</em></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Tax, Policy [Policy Text Block]</a></td>
<td class="text"><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>Income Taxes</i></b></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">The Company accounts for income taxes under the asset and liability method.&#160;Deferred tax assets and liabilities are recognized for the estimated future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. &#160;Deferred tax balances are adjusted to reflect tax rates based on currently enacted tax laws, which will be in effect in the years in which the temporary differences are expected to reverse.&#160;The Company has accumulated significant deferred tax assets that reflect the tax effects of net operating loss and tax credit carryovers and temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. Realization of certain deferred tax assets is dependent upon future earnings. The Company is uncertain about the timing and amount of any future earnings. Accordingly, the Company offsets these deferred tax assets with a valuation allowance.</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">The Company accounts for uncertain tax positions in accordance with ASC <em style="font: inherit;">740,</em> &#8220;Income Taxes&#8221;, which clarifies the accounting for uncertainty in tax positions. These provisions require recognition of the impact of a tax position in the Company&#8217;s financial statements only if that position is more likely than <em style="font: inherit;">not</em> of being sustained upon examination by taxing authorities, based on the technical merits of the position. Any interest and penalties related to uncertain tax positions will be reflected as a component of income tax expense.</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">New Accounting Pronouncements, Policy [Policy Text Block]</a></td>
<td class="text"><p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;"><b><i>Recent Accounting Pronouncements</i></b></p>
   <p style="text-align: justify; margin: 0pt 0pt 0pt -9pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify; text-indent: 18pt;">In <em style="font: inherit;"> November 2023, </em>the FASB&#160;issued Accounting Standards Update ("ASU") <em style="font: inherit;">2023</em>-<em style="font: inherit;">07,</em> Segment Reporting (Topic <em style="font: inherit;">280</em>): Improvements to Reportable Segment Disclosures. This ASU includes amendments that expand the existing reportable segment disclosure requirements and requires disclosure of (i) significant expense categories and amounts by reportable segment as well as the segment&#8217;s profit or loss measure(s) that are regularly provided to the chief operating decision maker (the &#8220;CODM&#8221;) to allocate resources and assess performance; (ii) how the CODM uses each reported segment profit or loss measure to allocate resources and assess performance; (iii) the nature of other segment balances contributing to reported segment profit or loss that are <em style="font: inherit;">not</em> captured within segment revenues or expenses; and (iv) the title and position of the individual or name of the group or committee identified as the CODM. This guidance requires retrospective application to all prior periods presented in the financial statements and is effective for fiscal years beginning after <em style="font: inherit;"> December 15, 2023 </em>and interim periods within fiscal years beginning after <em style="font: inherit;"> December 15, 2024.&#160;</em>The Company adopted this guidance and has included enhanced disclosures relating to its reportable segments. See <i>Business Segments</i>, included in this Note <em style="font: inherit;">2</em> to the Consolidated Financial Statements, for the Company's updated disclosure.</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify; text-indent: 18pt;">&#160;</p>


   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt;"><i><b>Accounting Guidance Issued But <em style="font: inherit;">Not</em> Adopted as of <em style="font: inherit;"> December 31, 2024</em></b></i></p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-indent: 18pt; text-align: justify;">In <em style="font: inherit;"> November 2024, </em>the FASB issued ASU <em style="font: inherit;">2024</em>-<em style="font: inherit;">03,</em> Income Statement&#8212;Reporting Comprehensive Income&#8212;Expense Disaggregation Disclosures (Subtopic <em style="font: inherit;">220</em>-<em style="font: inherit;">40</em>): Disaggregation of Income Statement Expenses. This ASU includes amendments that require entities to bifurcate specified expense line items on the income statement into underlying components, including employee compensation, depreciation, and intangible asset amortization, as applicable. Qualitative descriptions of the remaining components are required. These enhanced disclosures are required for both interim and annual periods. In <em style="font: inherit;"> January 2025, </em>the FASB subsequently issued ASU <em style="font: inherit;">2025</em>-<em style="font: inherit;">01,</em> Income Statement&#8212;Reporting Comprehensive Income&#8212;Expense Disaggregation Disclosures (Subtopic <em style="font: inherit;">220</em>-<em style="font: inherit;">40</em>): Clarifying the Effective Date, to provide clarification on the ASU's effective date. The new standard is effective for fiscal years beginning after <em style="font: inherit;"> December 15, 2026 </em>on a prospective basis with the option to apply it retrospectively, and for interim periods&#160;within fiscal years beginning after <em style="font: inherit;"> December 15, 2027. </em>Early adoption is permitted. The adoption of this guidance will result in the Company being required to include enhanced disclosures around income statement expenses.</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-indent: 18pt; text-align: justify;">In <em style="font: inherit;"> December 2023, </em>the FASB issued ASU <em style="font: inherit;">2023</em>-<em style="font: inherit;">09,</em> Income Taxes (Topic <em style="font: inherit;">740</em>): Improvements to Income Tax Disclosures. The ASU requires that an entity disclose specific categories in the effective tax rate reconciliation as well as reconciling items that meet a quantitative threshold. Further, the ASU requires additional disclosures on income tax expense and taxes paid, net of refunds received, by jurisdiction. The new standard is effective for annual periods beginning after <em style="font: inherit;"> December 15, 2024 </em>on a prospective basis with the option to apply it retrospectively. Early adoption is permitted. The adoption of this guidance will result in the company being required to include enhanced income tax related disclosures.</p>
   <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sava_RelatedPartyTransactionPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Policy describing the related party transactions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sava_RelatedPartyTransactionPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sava_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for commitments and contingencies, which may include policies for recognizing and measuring loss and gain contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 954<br> -SubTopic 450<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477850/954-450-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 460<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482425/460-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationRelatedCostsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for salaries, bonuses, incentive awards, postretirement and postemployment benefits granted to employees, including equity-based arrangements; discloses methodologies for measurement, and the bases for recognizing related assets and liabilities and recognizing and reporting compensation expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationRelatedCostsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for its derivative instruments and hedging activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 815<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(n))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-1A<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueOfFinancialInstrumentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for determining the fair value of financial instruments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 825<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueOfFinancialInstrumentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GovernmentAssistancePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for government assistance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 832<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483507/832-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 832<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483507/832-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GovernmentAssistancePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-20<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-19<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482525/740-10-45-25<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(h)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-17<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482525/740-10-45-28<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsFiniteLivedPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for finite-lived intangible assets. This accounting policy also might address: (1) the amortization method used; (2) the useful lives of such assets; and (3) how the entity assesses and measures impairment of such assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483426/235-10-50-4<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/350-30/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 926<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483154/926-20-50-5<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 920<br> -SubTopic 350<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478609/920-350-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 920<br> -SubTopic 350<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478609/920-350-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 920<br> -SubTopic 350<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478609/920-350-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsFiniteLivedPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-6<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483044/730-10-05-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for segment reporting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 36<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-36<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.C.Q3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.1.Q5)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.3.Q2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2.Q6)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/718/tableOfContent<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-9<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-12<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46586285145312">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 2 - Summary of Significant Accounting Policies (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TableTextBlock', window );"><strong>Notes Tables</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock', window );">Fair Value Measurement Inputs and Valuation Techniques [Table Text Block]</a></td>
<td class="text">
    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"><tbody><tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 85%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Exercise price per warrant</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">33.00</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Conversion rate - common shares per warrant</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">1.50</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Closing price of common stock</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">23.72</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Volatility</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">75</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">%</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Risk-free interest rate</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">5.40</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">%</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Expected life of option (in years)</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">0.3</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Dividend yield</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: right; margin: 0pt;"><span style="-sec-ix-hidden:c123854924">zero</span></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
</tbody></table>
   <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock', window );">Schedule of Segment Reporting Information, by Segment [Table Text Block]</a></td>
<td class="text">
    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"><tbody><tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td colspan="10" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;"><em style="font: inherit;"><em style="font: inherit;">Years Ended December 31,</em></em></em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">2024</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">2023</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">2022</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 55%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Operating expenses</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Research and development</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">69,637</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">89,423</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">68,032</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">General and administrative</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">71,809</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">16,534</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">11,988</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Other segment items(a)</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(117,104</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(8,740</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(3,774</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Net loss</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">24,342</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">97,217</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">76,246</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td></tr>
</tbody></table>

    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"><tbody><tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>December 31,</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>2024</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>2023</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 70%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Cash and cash equivalents</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">128,574</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">121,136</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td></tr>
</tbody></table>
   <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]</a></td>
<td class="text">
    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"><tbody><tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="10" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;"><em style="font: inherit;"><em style="font: inherit;">Years ended December 31,</em></em></em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">2024</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">2023</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">2022</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 55%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Numerator, basic:</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Net loss</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(24,342</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(97,217</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(76,246</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Denominator, basic:</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Weighted average common shares outstanding</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">46,329</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">41,932</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">40,202</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Net loss per share, basic</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(0.53</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(2.32</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(1.90</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">)</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Numerator, diluted:</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Net loss</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(24,342</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(97,217</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(76,246</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Adjustment for change in fair value of warrant liabilities</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(43,793</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;">&#8212;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;">&#8212;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Adjusted numerator, diluted</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(68,135</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(97,217</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(76,246</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Denominator, diluted:</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Weighted average common shares outstanding</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">46,329</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">41,932</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">40,202</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Dilutive effect of common stock warrants</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">275</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">&#8212;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">&#8212;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Weighted average dilutive common shares</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">46,604</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">41,932</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">40,202</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Net loss per share, diluted</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(1.46</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(2.32</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(1.90</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">)</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Dilutive common stock options excluded from net loss per share, diluted</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">3,154</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">2,123</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">2,055</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Dilutive Performance Awards excluded from loss per share, diluted</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">7</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">7</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">7</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
</tbody></table>
   <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 103<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-103<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-25<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46586284229376">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 3 - Prepaid Expenses and Other Current Assets (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TableTextBlock', window );"><strong>Notes Tables</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock', window );">Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Table Text Block]</a></td>
<td class="text">
    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;">&#160;</td><td colspan="6" rowspan="1" style="text-align: center; font-family: Times New Roman; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"><b><em style="font: inherit;"><em style="font: inherit;">December 31,</em></em></b></td><td style="font-family: Times New Roman; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;">&#160;</td></tr>
<tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">2024</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">2023</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 70%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">Prepaid insurance</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">800</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">759</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">Contract research organization and other deposits</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">6,173</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">6,489</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">Interest receivable</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">947</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">962</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">Other</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">38</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">287</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt; text-indent: -9pt;">Total prepaid expenses and other current assets</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">7,958</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">8,497</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td></tr>
</tbody></table>
   <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the amounts paid in advance for capitalized costs that will be expensed with the passage of time or the occurrence of a triggering event, and will be charged against earnings within one year or the normal operating cycle, if longer; the aggregate carrying amount of current assets, not separately presented elsewhere in the balance sheet; and other deferred costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46586283108048">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 4 - Real Property and Other Income, Expense (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TableTextBlock', window );"><strong>Notes Tables</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock', window );">Schedule of Other Nonoperating Income (Expense) [Table Text Block]</a></td>
<td class="text">
    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="10" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;"><em style="font: inherit;"><em style="font: inherit;">Years ended December 31,</em></em></em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">2024</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">2023</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">2022</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 55%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">Lease revenue</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">1,244</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">2,283</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">2,459</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">Property operating expenses</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(832</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(1,376</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;">(1,462</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">)</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt; text-indent: -9pt;">Other income, net</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">411</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">907</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">997</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td></tr>
</tbody></table>
   <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of non-operating income or non-operating expense that may include amounts earned from dividends, interest on securities, gains (losses) on securities sold, equity earnings of unconsolidated affiliates, net gain (loss) on sales of business, interest expense and other miscellaneous income or expense items.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46586284167152">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 5 - Property and Equipment (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TableTextBlock', window );"><strong>Notes Tables</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Property, Plant and Equipment [Table Text Block]</a></td>
<td class="text">
    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td colspan="6" rowspan="1" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: center;"><b><em style="font: inherit;"><em style="font: inherit;">December 31,</em></em></b></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td></tr>
<tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">2024</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">2023</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 70%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">Land</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">3,734</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">3,734</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">Buildings</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">15,980</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">15,980</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">Site improvements</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">494</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">494</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">Tenant improvements</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">3,062</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">3,062</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">Furniture and equipment</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">875</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">868</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px;"> <p style="margin: 0pt; font-size: 10pt; font-family: Times New Roman;">Construction in progress</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);">55</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);">&#8212;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt; text-indent: -9pt;">Gross property and equipment</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">24,200</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">24,138</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">Accumulated depreciation</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(3,236</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(2,284</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt; text-indent: -9pt;">Property and equipment, net</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">20,964</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">21,854</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td></tr>
</tbody></table>
   <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46586285903472">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 6 - Intangible Assets (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TableTextBlock', window );"><strong>Notes Tables</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock', window );">Schedule of Finite-Lived Intangible Assets [Table Text Block]</a></td>
<td class="text">
    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;">&#160;</td><td colspan="6" rowspan="1" style="font-family: Times New Roman; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; text-align: center; border-bottom: 1px solid rgb(0, 0, 0);"><b><em style="font: inherit;"><em style="font: inherit;">December 31,</em></em></b></td><td style="font-family: Times New Roman; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;">&#160;</td></tr>
<tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">2024</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">2023</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 70%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">Lease-in-place agreements</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">1,053</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">1,053</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">Leasing commissions and other</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">334</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">293</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt; text-indent: -9pt;">Gross intangible assets</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">1,387</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">1,346</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">Accumulated amortization</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(1,350</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(1,170</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt; text-indent: -9pt;">Intangible assets, net</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">37</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">176</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td></tr>
</tbody></table>
   <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock', window );">Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]</a></td>
<td class="text">
    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 85%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;"><b><span style="text-decoration: underline; ">For the year ending December 31,</span></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">2025</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">17</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">2026</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">14</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px;"> <p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">2027</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);">6</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">Total amortization</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">37</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td></tr>
</tbody></table>
   <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46586285279568">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 7 - Stockholders' Equity and Stock-based Compensation (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TableTextBlock', window );"><strong>Notes Tables</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Share-Based Payment Arrangement, Option, Activity [Table Text Block]</a></td>
<td class="text">
    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="text-align: center; font-family: Times New Roman; font-size: 10pt;"><em style="font: inherit;">&#160;</em></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Weighted Average</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Weighted Average</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="text-align: center; font-family: Times New Roman; font-size: 10pt;"><em style="font: inherit;">&#160;</em></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td></tr>
<tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Number of</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Weighted Average</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Remaining Contractual</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Aggregate Intrinsic Value</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td></tr>
<tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Options</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Exercise Price</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Term in Years</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">in Millions</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 40%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">Outstanding as of December 31, 2023</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">3,039,029</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">15.13</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">6.21</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">30.28</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> <p style="margin: 0pt 0pt 0pt 9pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">Options granted</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; text-align: right; padding: 0; margin: 0">2,083,000</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">26.65</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"><em style="font: inherit;">&#160;</em></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"><em style="font: inherit;">&#160;</em></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> <p style="margin: 0pt 0pt 0pt 9pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">Options exercised</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; text-align: right; padding: 0; margin: 0">(240,147</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0; margin: 0">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">5.25</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"><em style="font: inherit;">&#160;</em></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"><em style="font: inherit;">&#160;</em></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> <p style="margin: 0pt 0pt 0pt 9pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">Options forfeited/canceled</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; text-align: right; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);">(418,854</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">24.64</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"><em style="font: inherit;">&#160;</em></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"><em style="font: inherit;">&#160;</em></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">Outstanding as of December 31, 2024</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">4,463,028</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">20.15</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">7.61</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">0.30</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">Vested and expected to vest at December 31, 2024</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 3px double rgb(0, 0, 0);">3,965,665</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">19.93</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">7.44</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">0.30</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">Exercisable at December 31, 2024</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 3px double rgb(0, 0, 0);">1,794,501</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">12.86</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">4.95</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">0.30</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
</tbody></table>
   <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock', window );">Share-Based Payment Arrangement, Option, Exercise Price Range [Table Text Block]</a></td>
<td class="text">
    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="text-align: center; font-family: Times New Roman; font-size: 10pt;"><b><em style="font: inherit;">&#160;</em></b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="text-align: center; font-family: Times New Roman; font-size: 10pt;"><b><em style="font: inherit;">&#160;</em></b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="10" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;"><em style="font: inherit;"><em style="font: inherit;">Options outstanding</em></em></em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;"><em style="font: inherit;">Options exercisable</em></em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td></tr>
<tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="text-align: center; font-family: Times New Roman; font-size: 10pt;"><b><em style="font: inherit;">&#160;</em></b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="text-align: center; font-family: Times New Roman; font-size: 10pt;"><b><em style="font: inherit;">&#160;</em></b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="text-align: center; font-family: Times New Roman; font-size: 10pt;"><b><em style="font: inherit;">&#160;</em></b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Weighted</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="text-align: center; font-family: Times New Roman; font-size: 10pt;"><b><em style="font: inherit;">&#160;</em></b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="text-align: center; font-family: Times New Roman; font-size: 10pt;"><b><em style="font: inherit;">&#160;</em></b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="text-align: center; font-family: Times New Roman; font-size: 10pt;"><b><em style="font: inherit;">&#160;</em></b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td></tr>
<tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="text-align: center; font-family: Times New Roman; font-size: 10pt;"><b><em style="font: inherit;">&#160;</em></b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="text-align: center; font-family: Times New Roman; font-size: 10pt;"><b><em style="font: inherit;">&#160;</em></b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="text-align: center; font-family: Times New Roman; font-size: 10pt;"><b><em style="font: inherit;">&#160;</em></b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">average</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Weighted</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="text-align: center; font-family: Times New Roman; font-size: 10pt;"><b><em style="font: inherit;">&#160;</em></b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Weighted</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td></tr>
<tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="text-align: center; font-family: Times New Roman; font-size: 10pt;"><b><em style="font: inherit;">&#160;</em></b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="text-align: center; font-family: Times New Roman; font-size: 10pt;"><b><em style="font: inherit;">&#160;</em></b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Number of</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">remaining</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">average</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Number of</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">average</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td></tr>
<tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td colspan="6" style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;"><em style="font: inherit;">Range of exercise prices</em></em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">outstanding</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">contractual</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">exercise</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">vested</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">exercise</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td></tr>
<tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td colspan="2" style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">From</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">To</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">options</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">life (in years)</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">price</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">options</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">price</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">$</td><td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">0.95</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">4.10</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">900,303</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">3.5</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">2.80</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">900,303</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">2.80</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">$</td><td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">5.46</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">17.54</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">1,049,656</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">7.1</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">16.21</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">560,765</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">15.06</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">$</td><td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">18.78</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">$</td><td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">26.57</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">539,277</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">8.7</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">$</td><td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">21.90</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">197,198</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">$</td><td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">21.81</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px;">$</td><td style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px;">26.91</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px;">$</td><td style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px;">26.91</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px;">&#160;</td><td style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px;">1,080,000</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px;">&#160;</td><td style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px;">9.7</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px;">$</td><td style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px;">26.91</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px;">&#160;</td><td style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px;">364</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px;">$</td><td style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px;">26.91</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">$</td><td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">27.42</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">77.00</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid black;">&#160;</td><td style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid black;">893,792</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">9.2</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">33.02</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid black;">&#160;</td><td style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid black;">135,871</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">57.40</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="text-align: right; font-family: Times New Roman; font-size: 10pt;"><em style="font: inherit;">&#160;</em></td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="text-align: right; font-family: Times New Roman; font-size: 10pt;"><em style="font: inherit;">&#160;</em></td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">4,463,028</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">7.6</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">20.15</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">1,794,501</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">12.86</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
</tbody></table>
   <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</a></td>
<td class="text">
    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">2024</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">2023</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">2022</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 55%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">Volatility</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">151% to 170%</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">152% to 155%</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">151% to 154%</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">Risk-free interest rates</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">3.53% to 4.47%</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">3.82% to 4.37%</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">1.98% to 3.69%</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">Expected life of option (in years)</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">7</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">7</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">7</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">Dividend yield</p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: right;"><span style="-sec-ix-hidden:c123855198">zero</span></p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: right;"><span style="-sec-ix-hidden:c123855199">zero</span></p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: right;"><span style="-sec-ix-hidden:c123855200">zero</span></p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">Forfeiture rate</p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: right;"><span style="-sec-ix-hidden:c123855201">4.3</span></p> </td><td style="font-family: Times New Roman; font-size: 10pt;">%</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: right;"><span style="-sec-ix-hidden:c123855202">zero</span></p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: right;"><span style="-sec-ix-hidden:c123855203">zero</span></p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">Weighted average fair value of stock options granted</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">25.85</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">18.21</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">35.16</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
</tbody></table>
   <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock', window );">Share-Based Payment Arrangement, Activity [Table Text Block]</a></td>
<td class="text">
    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Number of Performance Awards</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 85%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">Outstanding as of December 31, 2023</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">7,142</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt; text-indent: -9pt;">Granted</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">&#8212;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt; text-indent: -9pt;">Vested</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">&#8212;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt; text-indent: -9pt;">Forfeited/canceled</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;">&#8212;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">Outstanding as of December 31, 2024</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">7,142</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td></tr>
</tbody></table>
   <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]</a></td>
<td class="text">
    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="10" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;"><em style="font: inherit;"><em style="font: inherit;">Years ended December 31,</em></em></em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">2024</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">2023</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">2022</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 55%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">Research and development</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">6,492</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">2,050</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">1,631</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">General and administrative</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">9,799</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">2,536</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">435</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td>&#160;</td><td style="padding-bottom: 1px;">&#160;</td><td style="border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="padding-bottom: 1px;">&#160;</td><td style="padding-bottom: 1px;">&#160;</td><td style="border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="padding-bottom: 1px;">&#160;</td><td style="padding-bottom: 1px;">&#160;</td><td style="border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="padding-bottom: 1px;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">Total stock-based compensation expense</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">16,291</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">4,586</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">2,066</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td></tr>
</tbody></table>
   <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of activity for award under share-based payment arrangement. Includes, but is not limited to, outstanding award at beginning and end of year, granted, exercised, forfeited, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of option exercise prices, by grouped ranges, including the upper and lower limits of the price range, the number of shares under option, weighted average exercise price and remaining contractual option terms.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (f)(2)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46586284163280">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 9 - Income Taxes (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TableTextBlock', window );"><strong>Notes Tables</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]</a></td>
<td class="text">
    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="10" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;"><em style="font: inherit;"><em style="font: inherit;">Year ended December 31,</em></em></em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">2024</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">2023</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">2022</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 55%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">Tax at federal statutory rate</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">21</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">%</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">21</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">%</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">21</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">%</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">State tax, net of federal benefit</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">&#8212;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">&#8212;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">&#8212;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">Share-based compensation</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(5.7</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">0.2</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(0.5</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">Research and development credits</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">15.4</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">5.1</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">4.9</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">Section 162(m) limitation</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(0.2</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#8212;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">(0.2</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">)</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> <p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">Uncertain tax positions</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">(6.1</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">(2.0</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">(2.0</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">)</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> <p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">Tax attribute expiration</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">(4.1</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#8212;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#8212;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> <p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">Change in fair value of warrant liabilities</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">93.3</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#8212;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#8212;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> <p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">SEC settlement payment</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">(34.5</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#8212;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#8212;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">Other</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">0.3</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(0.3</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">0.2</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">Change in valuation allowance</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(79.4</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(24.0</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(23.4</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">)</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">Effective income tax rate</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">&#8212;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">%</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">&#8212;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">%</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">&#8212;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">%</td></tr>
</tbody></table>
   <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Schedule of Deferred Tax Assets and Liabilities [Table Text Block]</a></td>
<td class="text">
    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;"><em style="font: inherit;">December 31,</em></em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">2024</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">2023</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 70%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Deferred tax assets:</p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Net operating loss carryforwards</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">43,148</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">33,322</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Share-based compensation</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">4,814</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">2,561</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Research and development credit carryforwards</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">13,789</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">12,557</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Capitalized research and development expenses</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">33,598</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">27,538</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Other</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">1,340</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">1,371</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Total deferred tax assets</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">96,689</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">77,349</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Valuation allowance</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(96,689</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(77,349</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Net deferred tax assets</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#8212;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#8212;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Deferred tax liabilities:</p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Operating lease right-of-use assets</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">&#8212;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">&#8212;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Total deferred tax liabilities</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">&#8212;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">&#8212;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Net deferred tax asset (liability)</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">&#8212;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">&#8212;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td></tr>
</tbody></table>
   <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock', window );">Schedule of Unrecognized Tax Benefits Roll Forward [Table Text Block]</a></td>
<td class="text">
    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="10" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;"><em style="font: inherit;"><em style="font: inherit;">Year ended December 31,</em></em></em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">2024</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">2023</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">2022</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 55%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Beginning balance</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">8,413</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">6,496</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">5,001</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> <p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">Expired research and development tax credits</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">(665</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">(50</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#8212;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Additions based on tax positions related to the current year</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">1,494</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">1,967</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">1,495</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Ending balance</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">9,242</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">8,413</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">6,496</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td></tr>
</tbody></table>
   <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the change in unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 217<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-217<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-15A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46586284260000">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 13 - Warrant Dividend Distribution (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TableTextBlock', window );"><strong>Notes Tables</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock', window );">Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]</a></td>
<td class="text">
    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"><tbody><tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Number of Common Stock Warrants</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Common Stock Warrant Liability</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 70%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Distribution of common stock warrants on January 3, 2024</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">16,895</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">113,363</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Warrants exercised</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(674</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(4,954</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Gain from change in fair value of warrant liabilities</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"><em style="font: inherit;">&#8212;</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(43,041</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Balance at March 31, 2024</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">16,221</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">65,368</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Warrants exercised</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(3,152</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(226</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Gain from change in fair value of warrant liabilities</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><em style="font: inherit;">&#8212;</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(65,142</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Redemption of common stock warrants</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(13,069</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"><em style="font: inherit;">&#8212;</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Balance as of June 30, 2024</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;"><span style="-sec-ix-hidden:c123855372">&#8212;</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">&#8212;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Balance as of September 30, 2024</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;"><span style="-sec-ix-hidden:c123855374">&#8212;</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><span style="-sec-ix-hidden:c123855375">&#8212;</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Balance as of December 31, 2024</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;"><span style="-sec-ix-hidden:c123855376">&#8212;</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><span style="-sec-ix-hidden:c123855377">&#8212;</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td></tr>
</tbody></table>
   <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46586371013584">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Note 1 - General, Liquidity and Basis of Presentation (Details Textual) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Retained Earnings (Accumulated Deficit)</a></td>
<td class="num">$ (405,111)<span></span>
</td>
<td class="num">$ (380,769)<span></span>
</td>
</tr>
</table>
<div style="display: none;"><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table></div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46586288999232">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 2 - Summary of Significant Accounting Policies (Details Textual)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Jul. 16, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jul. 15, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>May 07, 2024 </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Jan. 03, 2024 </div>
<div>$ / shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GovernmentAssistanceAmount', window );">Government Assistance, Income, Increase (Decrease)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sava_ClassOfWarrantOrRightFairValueOfCommonStockWarrantsPerWarrant', window );">Class of Warrant or Right, Fair Value of Common Stock Warrants per Warrant (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6.71<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sava_ClassOfWarrantOrRightRedemptionPricePerShare', window );">Class of Warrant or Right, Redemption Price per Share (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfOperatingSegments', window );">Number of Operating Segments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net Cash Provided by (Used in) Operating Activities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (116,929,000)<span></span>
</td>
<td class="num">(82,025,000)<span></span>
</td>
<td class="num">$ (77,514,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromInsuranceSettlementOperatingActivities', window );">Proceeds from Insurance Settlement, Operating Activities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,900,000<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sava_InsuranceSettlementsMaximumRecoveryLimit', window );">Insurance Settlements, Maximum Recovery Limit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GovernmentAssistanceStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration', window );">Government Assistance, Income, Increase (Decrease), Statement of Income or Comprehensive Income [Extensible Enumeration]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Research and development<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=sava_FormerSeniorVicePresidentMember', window );">Former Senior Vice President [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sava_ConsultingAgreementTerm', window );">Consulting Agreement, Term</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sava_ConsultingServicePricePerHour', window );">Consulting Service, Price Per Hour</a></td>
<td class="nump">$ 500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAmountsOfTransaction', window );">Related Party Transaction, Amounts of Transaction</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 43,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=sava_FormerPresidentAndChiefExecutiveOfficerMember', window );">Former President and Chief Executive Officer [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SeveranceCosts1', window );">Severance Costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,230,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=sava_FormerSeniorVicePresidentMember', window );">Former Senior Vice President [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SeveranceCosts1', window );">Severance Costs</a></td>
<td class="nump">$ 500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=sava_FormerSeniorOfficerMember', window );">Former Senior Officer [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SeveranceCosts1', window );">Severance Costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sava_NumberOfFormerEmployees', window );">Number of Former Employees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingMember', window );">Building [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property, Plant and Equipment, Useful Life (Year)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">39 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingImprovementsMember', window );">Building Improvements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property, Plant and Equipment, Useful Life (Year)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Share-Based Payment Arrangement, Option [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period (Year)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Share-Based Payment Arrangement, Option [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period (Year)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sava_ClassOfWarrantOrRightFairValueOfCommonStockWarrantsPerWarrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the fair value of common stock warrants per warrant.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sava_ClassOfWarrantOrRightFairValueOfCommonStockWarrantsPerWarrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sava_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sava_ClassOfWarrantOrRightRedemptionPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the redemption price per share of warrants or rights.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sava_ClassOfWarrantOrRightRedemptionPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sava_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sava_ConsultingAgreementTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The consulting agreement term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sava_ConsultingAgreementTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sava_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sava_ConsultingServicePricePerHour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cost per hour for the consulting services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sava_ConsultingServicePricePerHour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sava_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sava_InsuranceSettlementsMaximumRecoveryLimit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the maximum amount of monetary recovery for insurance policies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sava_InsuranceSettlementsMaximumRecoveryLimit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sava_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sava_NumberOfFormerEmployees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the number of former employees.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sava_NumberOfFormerEmployees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sava_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GovernmentAssistanceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in income from government assistance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 832<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483507/832-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GovernmentAssistanceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GovernmentAssistanceStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of income or comprehensive income that includes increase (decrease) in income from government assistance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 832<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483507/832-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GovernmentAssistanceStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfOperatingSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfOperatingSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromInsuranceSettlementOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow for proceeds from settlement of insurance claim, classified as operating activities. Excludes insurance settlement classified as investing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Subparagraph (c)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-16<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 21B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-21B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromInsuranceSettlementOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAmountsOfTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of transactions with related party during the financial reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAmountsOfTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SeveranceCosts1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses for special or contractual termination benefits provided to current employees involuntarily terminated under a benefit arrangement associated exit or disposal activities pursuant to an authorized plan. Excludes expenses related to one-time termination benefits, a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SeveranceCosts1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=sava_FormerSeniorVicePresidentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=sava_FormerSeniorVicePresidentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=sava_FormerPresidentAndChiefExecutiveOfficerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=sava_FormerPresidentAndChiefExecutiveOfficerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=sava_FormerSeniorVicePresidentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=sava_FormerSeniorVicePresidentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=sava_FormerSeniorOfficerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=sava_FormerSeniorOfficerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46586286229328">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Note 2 - Summary of Significant Accounting Policies - Quantitative Information of Warrants (Details) - Warrants to Purchase Common Stock [Member]<br></strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=sava_WarrantsToPurchaseCommonStockMember', window );">Measurement Input, Exercise Price [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrant measurement</a></td>
<td class="nump">33<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=sava_WarrantsToPurchaseCommonStockMember', window );">Measurement Input, Conversion Price [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrant measurement</a></td>
<td class="nump">1.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=sava_WarrantsToPurchaseCommonStockMember', window );">Measurement Input, Share Price [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrant measurement</a></td>
<td class="nump">23.72<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=sava_WarrantsToPurchaseCommonStockMember', window );">Measurement Input, Price Volatility [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrant measurement</a></td>
<td class="nump">0.75<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=sava_WarrantsToPurchaseCommonStockMember', window );">Measurement Input, Risk Free Interest Rate [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrant measurement</a></td>
<td class="nump">0.054<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=sava_WarrantsToPurchaseCommonStockMember', window );">Measurement Input, Expected Term [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrant measurement</a></td>
<td class="nump">0.3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=sava_WarrantsToPurchaseCommonStockMember', window );">Measurement Input, Expected Dividend Rate [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrant measurement</a></td>
<td class="nump">0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of input used to measure outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstandingMeasurementInput</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=sava_WarrantsToPurchaseCommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=sava_WarrantsToPurchaseCommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExercisePriceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExercisePriceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputConversionPriceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputConversionPriceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputSharePriceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputSharePriceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedDividendRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedDividendRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46586288266672">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>Note 2 - Summary of Significant Accounting Policies - Summary Of CODM Segments (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 69,637<span></span>
</td>
<td class="nump">$ 89,423<span></span>
</td>
<td class="nump">$ 68,032<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">71,809<span></span>
</td>
<td class="nump">16,534<span></span>
</td>
<td class="nump">11,988<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(24,342)<span></span>
</td>
<td class="num">(97,217)<span></span>
</td>
<td class="num">(76,246)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">128,574<span></span>
</td>
<td class="nump">121,136<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=sava_CodmMonitoringMember', window );">CODM Monitoring [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">69,637<span></span>
</td>
<td class="nump">89,423<span></span>
</td>
<td class="nump">68,032<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">71,809<span></span>
</td>
<td class="nump">16,534<span></span>
</td>
<td class="nump">11,988<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingOtherItemAmount', window );">Other segment items(a)</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="num">(117,104)<span></span>
</td>
<td class="num">(8,740)<span></span>
</td>
<td class="num">(3,774)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">24,342<span></span>
</td>
<td class="nump">97,217<span></span>
</td>
<td class="nump">$ 76,246<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 128,574<span></span>
</td>
<td class="nump">$ 121,136<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr><td colspan="4"></td></tr>
<tr><td colspan="4"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">Other segment items include interest income, other income, net and gain from change in fair value of warrant liabilities.</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 912<br> -SubTopic 730<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479532/912-730-25-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingOtherItemAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of other expense (income) and loss (gain) calculated as difference between segment revenue and separately disclosed expense category to arrive at segment profit (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26C<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingOtherItemAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=sava_CodmMonitoringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=sava_CodmMonitoringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46586283727472">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 2 - Significant Accounting Policies - Calculation of Net Loss Per Share (Details) - USD ($)<br> $ / shares in Units, shares in Thousands, $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (24,342)<span></span>
</td>
<td class="num">$ (97,217)<span></span>
</td>
<td class="num">$ (76,246)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average common shares outstanding (in shares)</a></td>
<td class="nump">46,329<span></span>
</td>
<td class="nump">41,932<span></span>
</td>
<td class="nump">40,202<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net loss per share, basic (in dollars per share)</a></td>
<td class="num">$ (0.53)<span></span>
</td>
<td class="num">$ (2.32)<span></span>
</td>
<td class="num">$ (1.9)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DilutiveSecurities', window );">Adjustment for change in fair value of warrant liabilities</a></td>
<td class="num">$ (43,793)<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted', window );">Adjusted numerator, diluted</a></td>
<td class="num">$ (68,135)<span></span>
</td>
<td class="num">$ (97,217)<span></span>
</td>
<td class="num">$ (76,246)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment', window );">Dilutive effect of common stock warrants (in shares)</a></td>
<td class="nump">275<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted average dilutive common shares (in shares)</a></td>
<td class="nump">46,604<span></span>
</td>
<td class="nump">41,932<span></span>
</td>
<td class="nump">40,202<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net loss per share, diluted (in dollars per share)</a></td>
<td class="num">$ (1.46)<span></span>
</td>
<td class="num">$ (2.32)<span></span>
</td>
<td class="num">$ (1.9)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember', window );">Share-Based Payment Arrangement, Option [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Dilutive common stock options excluded from net loss per share, diluted (in shares)</a></td>
<td class="nump">3,154<span></span>
</td>
<td class="nump">2,123<span></span>
</td>
<td class="nump">2,055<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember', window );">Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Dilutive common stock options excluded from net loss per share, diluted (in shares)</a></td>
<td class="nump">7<span></span>
</td>
<td class="nump">7<span></span>
</td>
<td class="nump">7<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DilutiveSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) to net income used for calculating diluted earnings per share (EPS), resulting from the assumed exercise stock options, restrictive stock units (RSUs), convertible preferred stock of an employee stock ownership plan (ESOP), and other dilutive convertible securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DilutiveSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities, and addition from assumption of issuance of common shares for dilutive potential common shares; of income (loss) available to common shareholders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5<br> -Subparagraph (SAB Topic 6.B)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-5<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-16<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 40<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-40<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 40<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-40<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 40<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-40<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 40<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-40<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The sum of dilutive potential common shares or units used in the calculation of the diluted per-share or per-unit computation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46586283842320">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Note 3 - Prepaid Expenses and Other Current Assets - Prepaid Expenses and Other Current Assets (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidInsurance', window );">Prepaid insurance</a></td>
<td class="nump">$ 800<span></span>
</td>
<td class="nump">$ 759<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepositContractsAssets', window );">Contract research organization and other deposits</a></td>
<td class="nump">6,173<span></span>
</td>
<td class="nump">6,489<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestReceivableCurrent', window );">Interest receivable</a></td>
<td class="nump">947<span></span>
</td>
<td class="nump">962<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsCurrent', window );">Other</a></td>
<td class="nump">38<span></span>
</td>
<td class="nump">287<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Total prepaid expenses and other current assets</a></td>
<td class="nump">$ 7,958<span></span>
</td>
<td class="nump">$ 8,497<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepositContractsAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount of assets as of the balance sheet date pertaining to amounts paid by the insured (including a ceding company) under insurance or reinsurance contracts for which insurance risk is not transferred.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 340<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483081/340-30-45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 340<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483054/340-30-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepositContractsAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestReceivableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of current interest earned but not received. Also called accrued interest or accrued interest receivable. For classified balance sheets, represents the current amount receivable, that is amounts expected to be collected within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestReceivableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidInsurance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for insurance that provides economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 340<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483032/340-10-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 340<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 5<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482955/340-10-05-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidInsurance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46586284069728">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Note 4 - Real Property and Other Income, Expense (Details Textual)<br></strong></div></th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Aug. 04, 2021 </div>
<div>ft&#178;</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths', window );">Lessor, Operating Lease, Payment to be Received, Year One</a></td>
<td class="nump">$ 300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LessorOperatingLeasePaymentsToBeReceivedTwoYears', window );">Lessor, Operating Lease, Payment to be Received, Year Two</a></td>
<td class="nump">400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LessorOperatingLeasePaymentsToBeReceivedThreeYears', window );">Lessor, Operating Lease, Payment to be Received, Year Three</a></td>
<td class="nump">$ 200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis=srt_OfficeBuildingMember', window );">Office Building [Member] | TEXAS</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetRentableArea', window );">Net Rentable Area (Square Foot) | ft&#178;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">90,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sava_PercentageOfOccupancy', window );">Percentage of Occupancy</a></td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccrualForTaxesOtherThanIncomeTaxesCurrent', window );">Accrual for Taxes Other than Income Taxes, Current</a></td>
<td class="nump">$ 254,000<span></span>
</td>
<td class="nump">$ 338,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sava_PercentageOfOccupancy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of occupancy.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sava_PercentageOfOccupancy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sava_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccrualForTaxesOtherThanIncomeTaxesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable for real and property taxes. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 720<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483384/720-30-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 8<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccrualForTaxesOtherThanIncomeTaxesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lease payment to be received by lessor for operating lease in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479773/842-30-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LessorOperatingLeasePaymentsToBeReceivedThreeYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lease payment to be received by lessor for operating lease in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479773/842-30-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LessorOperatingLeasePaymentsToBeReceivedThreeYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LessorOperatingLeasePaymentsToBeReceivedTwoYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lease payment to be received by lessor for operating lease in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479773/842-30-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LessorOperatingLeasePaymentsToBeReceivedTwoYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetRentableArea">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Net rentable area for properties owned.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetRentableArea</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:areaItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis=srt_OfficeBuildingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis=srt_OfficeBuildingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=stpr_TX">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=stpr_TX</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46586283987952">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 4 - Real Property and Other Income, Expense - Components of Other Income, Net (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncome', window );">Lease revenue</a></td>
<td class="nump">$ 1,244<span></span>
</td>
<td class="nump">$ 2,283<span></span>
</td>
<td class="nump">$ 2,459<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingExpense', window );">Property operating expenses</a></td>
<td class="num">(832)<span></span>
</td>
<td class="num">(1,376)<span></span>
</td>
<td class="num">(1,462)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other income, net</a></td>
<td class="nump">$ 411<span></span>
</td>
<td class="nump">$ 907<span></span>
</td>
<td class="nump">$ 997<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(7)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46586286209616">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 5 - Property and Equipment (Details Textual) - USD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation</a></td>
<td class="nump">$ 952,000<span></span>
</td>
<td class="nump">$ 1,084,000<span></span>
</td>
<td class="nump">$ 804,000<span></span>
</td>
</tr>
</table>
<div style="display: none;"><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table></div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46586284643392">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Note 5 - Property and Equipment - Components of Property and Equipment (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Gross property and equipment</a></td>
<td class="nump">$ 24,200<span></span>
</td>
<td class="nump">$ 24,138<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Accumulated depreciation</a></td>
<td class="num">(3,236)<span></span>
</td>
<td class="num">(2,284)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">20,964<span></span>
</td>
<td class="nump">21,854<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LandMember', window );">Land [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Gross property and equipment</a></td>
<td class="nump">3,734<span></span>
</td>
<td class="nump">3,734<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingMember', window );">Building [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Gross property and equipment</a></td>
<td class="nump">15,980<span></span>
</td>
<td class="nump">15,980<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingImprovementsMember', window );">Building Improvements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Gross property and equipment</a></td>
<td class="nump">494<span></span>
</td>
<td class="nump">494<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold Improvements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Gross property and equipment</a></td>
<td class="nump">3,062<span></span>
</td>
<td class="nump">3,062<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture and Fixtures [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Gross property and equipment</a></td>
<td class="nump">875<span></span>
</td>
<td class="nump">868<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember', window );">Construction in Progress [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Gross property and equipment</a></td>
<td class="nump">$ 55<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478451/942-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LandMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LandMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46586283737808">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 6 - Intangible Assets (Details Textual) - USD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization of Intangible Assets</a></td>
<td class="nump">$ 180,000<span></span>
</td>
<td class="nump">$ 446,000<span></span>
</td>
<td class="nump">$ 497,000<span></span>
</td>
</tr>
</table>
<div style="display: none;"><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482686/350-30-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table></div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46586284666240">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Note 6 - Intangible Assets - Components of Intangible Assets (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Gross intangible assets</a></td>
<td class="nump">$ 1,387<span></span>
</td>
<td class="nump">$ 1,346<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated amortization</a></td>
<td class="num">(1,350)<span></span>
</td>
<td class="num">(1,170)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Total amortization</a></td>
<td class="nump">37<span></span>
</td>
<td class="nump">176<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_LeasesAcquiredInPlaceMember', window );">Leases, Acquired-in-Place [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Gross intangible assets</a></td>
<td class="nump">1,053<span></span>
</td>
<td class="nump">1,053<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=sava_LeasingCommissionsAndOtherMember', window );">Leasing Commissions and Other [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Gross intangible assets</a></td>
<td class="nump">$ 334<span></span>
</td>
<td class="nump">$ 293<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480265/350-10-S45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480265/350-10-S45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 928<br> -SubTopic 340<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478859/928-340-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 926<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483154/926-20-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_LeasesAcquiredInPlaceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_LeasesAcquiredInPlaceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=sava_LeasingCommissionsAndOtherMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=sava_LeasingCommissionsAndOtherMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46586285156064">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Note 6 - Intangible Assets - Amortization Expense for Finite-lived Intangible Assets (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths', window );">2025</a></td>
<td class="nump">$ 17<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo', window );">2026</a></td>
<td class="nump">14<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree', window );">2027</a></td>
<td class="nump">6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Total amortization</a></td>
<td class="nump">$ 37<span></span>
</td>
<td class="nump">$ 176<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 926<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483154/926-20-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46586285489136">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 7 - Stockholders' Equity and Stock-based Compensation (Details Textual) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Nov. 22, 2022</div></th>
<th class="th"><div>May 05, 2022</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>May 01, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from Issuance of Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 47,329,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common Stock, Par or Stated Value Per Share (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sava_StockOptionsExercisedNetSettledSatisfactionOfExercisePrice', window );">Stock Options Exercised Net Settled Satisfaction Of Exercise Price (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,634<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">418,854<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-Based Payment Arrangement, Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 16,291,000<span></span>
</td>
<td class="nump">$ 4,586,000<span></span>
</td>
<td class="nump">2,066,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveAxis=us-gaap_EmployeeSeveranceMember', window );">Employee Severance [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-Based Payment Arrangement, Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 600,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Share-Based Payment Arrangement, Option [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition (Year)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years 3 months 18 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember', window );">Performance Shares [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 101,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Expirations (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">57,143<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GranteeStatusAxis=us-gaap_ShareBasedPaymentArrangementEmployeeMember', window );">Share-Based Payment Arrangement, Employee [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=sava_The2018EquityIncentivePlanMember', window );">The 2018 Equity Incentive Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period (Year)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common Stock, Par or Stated Value Per Share (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=sava_The2022RegisteredDirectOfferingMember', window );">The 2022 Registered Direct Offering [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Stock Issued During Period, Shares, New Issues (in shares)</a></td>
<td class="nump">1,666,667<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Shares Issued, Price Per Share (in dollars per share)</a></td>
<td class="nump">$ 30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from Issuance of Common Stock</a></td>
<td class="nump">$ 47,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=sava_AtthemarketCommonStockOfferingMember', window );">At-the-market Common Stock Offering [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Stock Issued During Period, Shares, New Issues (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sava_EquityOfferingMaximumAmount', window );">Equity Offering, Maximum Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sava_EquityOfferingPercentageOfCommission', window );">Equity Offering, Percentage of Commission</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sava_EquityOfferingMaximumAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum amount to be issued in the equity offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sava_EquityOfferingMaximumAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sava_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sava_EquityOfferingPercentageOfCommission">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of commission in equity offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sava_EquityOfferingPercentageOfCommission</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sava_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sava_StockOptionsExercisedNetSettledSatisfactionOfExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the number of stock options exercised net settled in satisfaction of the exercise price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sava_StockOptionsExercisedNetSettledSatisfactionOfExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sava_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost not yet recognized for nonvested award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares under non-option equity instrument agreements for which rights to exercise lapsed.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssuedPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or per unit amount of equity securities issued.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssuedPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveAxis=us-gaap_EmployeeSeveranceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveAxis=us-gaap_EmployeeSeveranceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GranteeStatusAxis=us-gaap_ShareBasedPaymentArrangementEmployeeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GranteeStatusAxis=us-gaap_ShareBasedPaymentArrangementEmployeeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=sava_The2018EquityIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=sava_The2018EquityIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=sava_The2022RegisteredDirectOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=sava_The2022RegisteredDirectOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=sava_AtthemarketCommonStockOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=sava_AtthemarketCommonStockOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46586284680176">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 7 - Stockholders' Equity and Stock-based Compensation - Stock Option Activity (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding, options (in shares)</a></td>
<td class="nump">3,039,029<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding, options, weighted average exercise price (in dollars per share)</a></td>
<td class="nump">$ 15.13<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Outstanding as of December 31, 2022, weighted average contractual term (Year)</a></td>
<td class="text">7 years 7 months 9 days<span></span>
</td>
<td class="text">6 years 2 months 15 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Outstanding as of December 31, 2022, aggregate intrinsic value</a></td>
<td class="nump">$ 300<span></span>
</td>
<td class="nump">$ 30,280<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Options granted (in shares)</a></td>
<td class="nump">2,083,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Options granted, weighted average exercise price (in dollars per share)</a></td>
<td class="nump">$ 26.65<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Options exercised (in shares)</a></td>
<td class="num">(240,147)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Options exercised, weighted average exercise price (in dollars per share)</a></td>
<td class="nump">$ 5.25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Options forfeited/canceled (in shares)</a></td>
<td class="num">(418,854)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Options forfeited/canceled, weighted average exercise price (in dollars per share)</a></td>
<td class="nump">$ 24.64<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding, options (in shares)</a></td>
<td class="nump">4,463,028<span></span>
</td>
<td class="nump">3,039,029<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding, options, weighted average exercise price (in dollars per share)</a></td>
<td class="nump">$ 20.15<span></span>
</td>
<td class="nump">$ 15.13<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber', window );">Vested and expected to vest at December 31, 2024 (in shares)</a></td>
<td class="nump">3,965,665<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice', window );">Vested and expected to vest at December 31, 2022, weighted average exercise price (in dollars per share)</a></td>
<td class="nump">$ 19.93<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1', window );">Vested and expected to vest at December 31, 2022, weighted average contractual term (Year)</a></td>
<td class="text">7 years 5 months 8 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue', window );">Vested and expected to vest at December 31, 2022, aggregate intrinsic value</a></td>
<td class="nump">$ 300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Exercisable at December 31, 2024 (in shares)</a></td>
<td class="nump">1,794,501<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Exercisable at December 31, 2022, weighted average exercise price (in dollars per share)</a></td>
<td class="nump">$ 12.86<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Exercisable at December 31, 2022, weighted average contractual term (Year)</a></td>
<td class="text">4 years 11 months 12 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Exercisable at December 31, 2022, aggregate intrinsic value</a></td>
<td class="nump">$ 300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (e)(1)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46586283780080">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 7 - Stockholders' Equity and Stock-based Compensation - Schedule of Stock Options by Exercise Price (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2024 </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Options outstanding (in shares) | shares</a></td>
<td class="nump">4,463,028<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2', window );">Options outstanding, weighted average contractual life (Year)</a></td>
<td class="text">7 years 7 months 6 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1', window );">Options outstanding, weighted average exercise price (in dollars per share)</a></td>
<td class="nump">$ 20.15<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Options exercisable (in shares) | shares</a></td>
<td class="nump">1,794,501<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1', window );">Options exercisable, weighted average exercise price (in dollars per share)</a></td>
<td class="nump">$ 12.86<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=sava_RangeOneMember', window );">Range One [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit', window );">Options, exercise price, lower limit (in dollars per share)</a></td>
<td class="nump">0.95<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Options, exercise price, upper limit (in dollars per share)</a></td>
<td class="nump">$ 4.1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Options outstanding (in shares) | shares</a></td>
<td class="nump">900,303<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2', window );">Options outstanding, weighted average contractual life (Year)</a></td>
<td class="text">3 years 6 months<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1', window );">Options outstanding, weighted average exercise price (in dollars per share)</a></td>
<td class="nump">$ 2.8<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Options exercisable (in shares) | shares</a></td>
<td class="nump">900,303<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1', window );">Options exercisable, weighted average exercise price (in dollars per share)</a></td>
<td class="nump">$ 2.8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=sava_RangeTwoMember', window );">Range Two [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit', window );">Options, exercise price, lower limit (in dollars per share)</a></td>
<td class="nump">5.46<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Options, exercise price, upper limit (in dollars per share)</a></td>
<td class="nump">$ 17.54<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Options outstanding (in shares) | shares</a></td>
<td class="nump">1,049,656<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2', window );">Options outstanding, weighted average contractual life (Year)</a></td>
<td class="text">7 years 1 month 6 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1', window );">Options outstanding, weighted average exercise price (in dollars per share)</a></td>
<td class="nump">$ 16.21<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Options exercisable (in shares) | shares</a></td>
<td class="nump">560,765<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1', window );">Options exercisable, weighted average exercise price (in dollars per share)</a></td>
<td class="nump">$ 15.06<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=sava_RangeThreeMember', window );">Range Three [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit', window );">Options, exercise price, lower limit (in dollars per share)</a></td>
<td class="nump">18.78<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Options, exercise price, upper limit (in dollars per share)</a></td>
<td class="nump">$ 26.57<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Options outstanding (in shares) | shares</a></td>
<td class="nump">539,277<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2', window );">Options outstanding, weighted average contractual life (Year)</a></td>
<td class="text">8 years 8 months 12 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1', window );">Options outstanding, weighted average exercise price (in dollars per share)</a></td>
<td class="nump">$ 21.9<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Options exercisable (in shares) | shares</a></td>
<td class="nump">197,198<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1', window );">Options exercisable, weighted average exercise price (in dollars per share)</a></td>
<td class="nump">$ 21.81<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=sava_RangeFourMember', window );">Range Four [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit', window );">Options, exercise price, lower limit (in dollars per share)</a></td>
<td class="nump">26.91<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Options, exercise price, upper limit (in dollars per share)</a></td>
<td class="nump">$ 26.91<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Options outstanding (in shares) | shares</a></td>
<td class="nump">1,080,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2', window );">Options outstanding, weighted average contractual life (Year)</a></td>
<td class="text">9 years 8 months 12 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1', window );">Options outstanding, weighted average exercise price (in dollars per share)</a></td>
<td class="nump">$ 26.91<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Options exercisable (in shares) | shares</a></td>
<td class="nump">364<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1', window );">Options exercisable, weighted average exercise price (in dollars per share)</a></td>
<td class="nump">$ 26.91<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=sava_RangeFiveMember', window );">Range Five [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit', window );">Options, exercise price, lower limit (in dollars per share)</a></td>
<td class="nump">27.42<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Options, exercise price, upper limit (in dollars per share)</a></td>
<td class="nump">$ 77<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Options outstanding (in shares) | shares</a></td>
<td class="nump">893,792<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2', window );">Options outstanding, weighted average contractual life (Year)</a></td>
<td class="text">9 years 2 months 12 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1', window );">Options outstanding, weighted average exercise price (in dollars per share)</a></td>
<td class="nump">$ 33.02<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Options exercisable (in shares) | shares</a></td>
<td class="nump">135,871<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1', window );">Options exercisable, weighted average exercise price (in dollars per share)</a></td>
<td class="nump">$ 57.4<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The floor of a customized range of exercise prices for purposes of disclosing shares potentially issuable under outstanding stock option awards on all stock option plans and other required information pertaining to awards in the customized range.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares reserved for issuance pertaining to the outstanding exercisable stock options as of the balance sheet date in the customized range of exercise prices for which the market and performance vesting condition has been satisfied.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares reserved for issuance pertaining to the outstanding stock options as of the balance sheet date for all option plans in the customized range of exercise prices.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The ceiling of a customized range of exercise prices for purposes of disclosing shares potentially issuable under outstanding stock option awards on all stock option plans and other required information pertaining to awards in the customized range.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average exercise price as of the balance sheet date for those equity-based payment arrangements exercisable and outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average price as of the balance sheet date at which grantees could acquire the underlying shares with respect to all outstanding stock options which are in the customized range of exercise prices.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term of outstanding stock options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (e)(1)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=sava_RangeOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=sava_RangeOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=sava_RangeTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=sava_RangeTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=sava_RangeThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=sava_RangeThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=sava_RangeFourMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=sava_RangeFourMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=sava_RangeFiveMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=sava_RangeFiveMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46586289133136">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 7 - Stockholders' Equity and Stock-based Compensation - Stock Option Valuation Assumptions (Details) - Share-Based Payment Arrangement, Option [Member] - $ / shares<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected life of option (in years) (Year)</a></td>
<td class="text">7 years<span></span>
</td>
<td class="text">7 years<span></span>
</td>
<td class="text">7 years<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions', window );">Forfeiture rate</a></td>
<td class="nump">4.30%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average fair value of stock options granted (in dollars per share)</a></td>
<td class="nump">$ 25.85<span></span>
</td>
<td class="nump">$ 18.21<span></span>
</td>
<td class="nump">$ 35.16<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Volatility</a></td>
<td class="nump">151.00%<span></span>
</td>
<td class="nump">152.00%<span></span>
</td>
<td class="nump">151.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rates</a></td>
<td class="nump">3.53%<span></span>
</td>
<td class="nump">3.82%<span></span>
</td>
<td class="nump">1.98%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Volatility</a></td>
<td class="nump">170.00%<span></span>
</td>
<td class="nump">155.00%<span></span>
</td>
<td class="nump">154.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rates</a></td>
<td class="nump">4.47%<span></span>
</td>
<td class="nump">4.37%<span></span>
</td>
<td class="nump">3.69%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Restrictions on equity-based instruments during the vesting period, such as the inability to transfer unvested awards, are not taken into account in estimating the fair value of the award. However, restrictions that remain in effect after an award is vested, such as the inability to transfer or hedge vested options or a prohibition on the sale of outstanding vested shares (or other type of equity) for a period of time, affect the estimate of an award's fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46586283774752">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 7 - Stockholders' Equity and Stock-based Compensation - Stock Option and Performance Award Activity (Details) - Performance Shares [Member]<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2024 </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Outstanding, awards (in shares)</a></td>
<td class="nump">7,142<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Granted, awards (in shares)</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Vested, awards (in shares)</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Forfeited/canceled, awards (in shares)</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Outstanding, awards (in shares)</a></td>
<td class="nump">7,142<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46586285081472">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 7 - Stockholders' Equity and Stock-based Compensation - Stock-based Compensation Expense (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">$ 16,291<span></span>
</td>
<td class="nump">$ 4,586<span></span>
</td>
<td class="nump">$ 2,066<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and Development Expense [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">6,492<span></span>
</td>
<td class="nump">2,050<span></span>
</td>
<td class="nump">1,631<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and Administrative Expense [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">$ 9,799<span></span>
</td>
<td class="nump">$ 2,536<span></span>
</td>
<td class="nump">$ 435<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46586288862864">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 9 - Income Taxes (Details Textual) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent</a></td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount', window );">Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount</a></td>
<td class="nump">$ 19,400<span></span>
</td>
<td class="nump">$ 23,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Unrecognized Tax Benefits</a></td>
<td class="nump">9,242<span></span>
</td>
<td class="nump">$ 8,413<span></span>
</td>
<td class="nump">$ 6,496<span></span>
</td>
<td class="nump">$ 5,001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income Tax Expense (Benefit)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued', window );">Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OpenTaxYear', window );">Open Tax Year</a></td>
<td class="text">2020 2021 2022 2023 2024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Domestic Tax Jurisdiction [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Operating Loss Carryforwards</a></td>
<td class="nump">$ 205,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Domestic Tax Jurisdiction [Member] | Research Tax Credit Carryforward [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Tax Credit Carryforward, Amount</a></td>
<td class="nump">23,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Domestic Tax Jurisdiction [Member] | Carryforward Subject to Expiration [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Operating Loss Carryforwards</a></td>
<td class="nump">74,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Domestic Tax Jurisdiction [Member] | Indefinite Life Carryforwards [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Operating Loss Carryforwards</a></td>
<td class="nump">$ 131,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.1.Q1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-10<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482659/740-20-45-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OpenTaxYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tax year that remains open to examination under enacted tax laws, in YYYY format.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OpenTaxYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:gYearListItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 217<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-217<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-15A<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482525/740-10-45-10B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount accrued for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 217<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-217<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAxis=us-gaap_ResearchMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAxis=us-gaap_ResearchMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxPeriodAxis=sava_CarryforwardSubjectToExpirationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxPeriodAxis=sava_CarryforwardSubjectToExpirationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxPeriodAxis=sava_IndefiniteLifeCarryforwardsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxPeriodAxis=sava_IndefiniteLifeCarryforwardsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46586289058768">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 9 - Income Taxes - Schedule of Effective Income Tax Reconciliation (Details)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Tax at federal statutory rate</a></td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes', window );">State tax, net of federal benefit</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost', window );">Share-based compensation</a></td>
<td class="num">(5.70%)<span></span>
</td>
<td class="nump">0.20%<span></span>
</td>
<td class="num">(0.50%)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sava_EffectiveIncomeTaxRateReconciliationTaxCreditResearchAndDevelopmentPercent', window );">Research and development credits</a></td>
<td class="nump">15.40%<span></span>
</td>
<td class="nump">5.10%<span></span>
</td>
<td class="nump">4.90%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sava_EffectiveIncomeTaxRateReconciliationSection162mLimitationPercent', window );">Section 162(m) limitation</a></td>
<td class="num">(0.20%)<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="num">(0.20%)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxContingencies', window );">Uncertain tax positions</a></td>
<td class="num">(6.10%)<span></span>
</td>
<td class="num">(2.00%)<span></span>
</td>
<td class="num">(2.00%)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sava_EffectiveIncomeTaxRateReconciliationTaxAttributeExpirationPercent', window );">Tax attribute expiration</a></td>
<td class="num">(4.10%)<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sava_EffectiveIncomeTaxRateReconciliationChangeInFairValueOfWarrantLiabilities', window );">Change in fair value of warrant liabilities</a></td>
<td class="nump">93.30%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlements', window );">SEC settlement payment</a></td>
<td class="num">(34.50%)<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent', window );">Other</a></td>
<td class="nump">0.30%<span></span>
</td>
<td class="num">(0.30%)<span></span>
</td>
<td class="nump">0.20%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Change in valuation allowance</a></td>
<td class="num">(79.40%)<span></span>
</td>
<td class="num">(24.00%)<span></span>
</td>
<td class="num">(23.40%)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Effective income tax rate</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sava_EffectiveIncomeTaxRateReconciliationChangeInFairValueOfWarrantLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operations, attributable to the change in fair value of warrant liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sava_EffectiveIncomeTaxRateReconciliationChangeInFairValueOfWarrantLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sava_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sava_EffectiveIncomeTaxRateReconciliationSection162mLimitationPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to section 162(m) limitation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sava_EffectiveIncomeTaxRateReconciliationSection162mLimitationPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sava_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sava_EffectiveIncomeTaxRateReconciliationTaxAttributeExpirationPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to tax attribute expiration.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sava_EffectiveIncomeTaxRateReconciliationTaxAttributeExpirationPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sava_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sava_EffectiveIncomeTaxRateReconciliationTaxCreditResearchAndDevelopmentPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research and development tax credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sava_EffectiveIncomeTaxRateReconciliationTaxCreditResearchAndDevelopmentPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sava_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.1.Q1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (a)(6)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to nondeductible expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of reported income tax benefit (expense) from difference to income tax expense (benefit) computed by applying statutory federal (national) income tax rate to pretax income (loss) from continuing operation, attributable to other reconciling items. Excludes state and local income tax expense (benefit), federal tax expense (benefit), statutory income tax expense (benefit) outside of country of domicile, tax credit, nondeductible expense, deduction, income tax settlement, income tax contingency, and cross-border tax law.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to income tax contingencies. Includes, but not limited to, domestic tax contingency, foreign tax contingency, state and local tax contingency, and other contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (a)(8)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationTaxContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to income tax settlements. Including, but not limited to, domestic tax settlement, foreign tax settlement, state and local tax settlement, and other tax settlements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46586285564208">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Note 9 - Income Taxes - Schedule of Deferred Tax Assets and Liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">$ 43,148<span></span>
</td>
<td class="nump">$ 33,322<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost', window );">Share-based compensation</a></td>
<td class="nump">4,814<span></span>
</td>
<td class="nump">2,561<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch', window );">Research and development credit carryforwards</a></td>
<td class="nump">13,789<span></span>
</td>
<td class="nump">12,557<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sava_DeferredTaxAssetsCapitalizedResearchAndDevelopmentExpenses', window );">Capitalized research and development expenses</a></td>
<td class="nump">33,598<span></span>
</td>
<td class="nump">27,538<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOther', window );">Other</a></td>
<td class="nump">1,340<span></span>
</td>
<td class="nump">1,371<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGross', window );">Total deferred tax assets</a></td>
<td class="nump">96,689<span></span>
</td>
<td class="nump">77,349<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Valuation allowance</a></td>
<td class="num">(96,689)<span></span>
</td>
<td class="num">(77,349)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNet', window );">Net deferred tax assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesLeasingArrangements', window );">Operating lease right-of-use assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxLiabilities', window );">Total deferred tax liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsLiabilitiesNet', window );">Net deferred tax asset (liability)</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sava_DeferredTaxAssetsCapitalizedResearchAndDevelopmentExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to capitalized research and development expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sava_DeferredTaxAssetsCapitalizedResearchAndDevelopmentExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sava_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesLeasingArrangements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from leasing arrangements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesLeasingArrangements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46586284134384">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 9 - Income Taxes - Schedule of Unrecognized Tax Benefits (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Beginning balance</a></td>
<td class="nump">$ 8,413<span></span>
</td>
<td class="nump">$ 6,496<span></span>
</td>
<td class="nump">$ 5,001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations', window );">Expired research and development tax credits</a></td>
<td class="num">(665)<span></span>
</td>
<td class="num">(50)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions', window );">Additions based on tax positions related to the current year</a></td>
<td class="nump">1,494<span></span>
</td>
<td class="nump">1,967<span></span>
</td>
<td class="nump">1,495<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Ending balance</a></td>
<td class="nump">$ 9,242<span></span>
</td>
<td class="nump">$ 8,413<span></span>
</td>
<td class="nump">$ 6,496<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 217<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-217<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-15A<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482525/740-10-45-10B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in unrecognized tax benefits resulting from tax positions that have been or will be taken in current period tax return.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 217<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-217<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-15A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in unrecognized tax benefits resulting from lapses of applicable statutes of limitations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-15A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46586283996976">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Note 10 - Commitments (Details Textual) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Feb. 26, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sava_YaleUniversityMember', window );">Yale University [Member] | License Agreement [Member] | Subsequent Event [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitment', window );">Other Commitment</a></td>
<td class="nump">$ 4.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplyCommitmentAxis=sava_SimufilamActiveIngredientMember', window );">Simufilam Active Ingredient [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SignificantSupplyCommitmentRemainingMinimumAmountCommitted', window );">Supply Commitment, Remaining Minimum Amount Committed</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.2<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCommitment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Minimum amount of other commitment not otherwise specified in the taxonomy. Excludes commitments explicitly modeled in the taxonomy, including but not limited to, long-term and short-term purchase commitments, recorded and unrecorded purchase obligations, supply commitments, registration payment arrangements, leases, debt, product warranties, guarantees, environmental remediation obligations, and pensions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCommitment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantSupplyCommitmentRemainingMinimumAmountCommitted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The floor amount as of the balance sheet date that the entity must expend to satisfy the terms of disclosed arrangements (excluding long-term commitments) in which the entity must commit resources to supply goods or services to one or more customers.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantSupplyCommitmentRemainingMinimumAmountCommitted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=sava_YaleUniversityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=sava_YaleUniversityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCommitmentsAxis=sava_LicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCommitmentsAxis=sava_LicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplyCommitmentAxis=sava_SimufilamActiveIngredientMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplyCommitmentAxis=sava_SimufilamActiveIngredientMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46586285341760">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 11 - 2020 Cash Incentive Bonus Plan (Details Textual) - Cash Incentive Bonus Plan [Member]<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Mar. 16, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 16, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Oct. 31, 2020 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sava_CashBonusIncentiveIncrementalAmounts', window );">Cash Bonus Incentive, Incremental Amounts</a></td>
<td class="nump">14<span></span>
</td>
<td class="nump">14<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sava_PerformancePlanMinimumNumberOfDaysValuationMilestoneMustBeAchievedAndMaintained', window );">Performance Plan, Minimum Number of Days Valuation Milestone Must be Achieved and Maintained (Day)</a></td>
<td class="text">20 days<span></span>
</td>
<td class="text">20 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sava_PercentageValuationMilestoneCashBonusAwardSubjectToApprovalAndAdjustment', window );">Percentage Valuation Milestone Cash Bonus Award Subject to Approval and Adjustment</a></td>
<td class="nump">67.00%<span></span>
</td>
<td class="nump">67.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sava_CashIncentiveBonusAward', window );">Cash Incentive Bonus Award</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,500<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax', window );">Share-Based Payment Arrangement, Expense, after Tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sava_PaymentsForCashIncentiveBonus', window );">Payments for Cash Incentive Bonus</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=sava_CashIncentiveBonusPlanMember', window );">Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sava_PerformancePlanValuationMilestoneAmount', window );">Performance Plan, Valuation Milestone Amount</a></td>
<td class="nump">$ 200,000<span></span>
</td>
<td class="nump">$ 200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 74,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sava_CashIncentiveBonusAwardExceedsMaximum', window );">Cash Incentive Bonus Award, Exceeds Maximum</a></td>
<td class="nump">111,400<span></span>
</td>
<td class="nump">111,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=sava_CashIncentiveBonusPlanMember', window );">Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sava_PerformancePlanValuationMilestoneAmount', window );">Performance Plan, Valuation Milestone Amount</a></td>
<td class="nump">5,000,000<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sava_CashIncentiveBonusAwardExceedsMaximum', window );">Cash Incentive Bonus Award, Exceeds Maximum</a></td>
<td class="nump">$ 289,700<span></span>
</td>
<td class="nump">$ 289,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sava_CashBonusIncentiveIncrementalAmounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of incremental amounts for cash bonus incentive.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sava_CashBonusIncentiveIncrementalAmounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sava_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sava_CashIncentiveBonusAward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash incentive bonus award.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sava_CashIncentiveBonusAward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sava_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sava_CashIncentiveBonusAwardExceedsMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash incentive bonus award if the maximum milestone is exceeded.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sava_CashIncentiveBonusAwardExceedsMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sava_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sava_PaymentsForCashIncentiveBonus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of payments for cash incentive bonus.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sava_PaymentsForCashIncentiveBonus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sava_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sava_PercentageValuationMilestoneCashBonusAwardSubjectToApprovalAndAdjustment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>the percentage of valuation milestone cash bonus award subject to approval and adjustment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sava_PercentageValuationMilestoneCashBonusAwardSubjectToApprovalAndAdjustment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sava_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sava_PerformancePlanMinimumNumberOfDaysValuationMilestoneMustBeAchievedAndMaintained">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The minimum number of days valuation milestone must be achieved and maintained in performance plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sava_PerformancePlanMinimumNumberOfDaysValuationMilestoneMustBeAchievedAndMaintained</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sava_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sava_PerformancePlanValuationMilestoneAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of valuation milestone for performance plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sava_PerformancePlanValuationMilestoneAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sava_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax, of expense for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=sava_CashIncentiveBonusPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=sava_CashIncentiveBonusPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46586279736896">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 12 - Contingencies (Details Textual)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">2 Months Ended</th>
<th class="th" colspan="2">20 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 06, 2024</div></th>
<th class="th"><div>Aug. 06, 2024</div></th>
<th class="th"><div>Mar. 18, 2024</div></th>
<th class="th"><div>Jul. 05, 2022</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th">
<div>Feb. 28, 2025 </div>
<div>USD ($)</div>
</th>
<th class="th"><div>Oct. 26, 2021</div></th>
<th class="th"><div>Jun. 20, 2023</div></th>
<th class="th"><div>Jun. 20, 2023</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_LitigationCaseAxis=sava_ViolationsOfFederalSecuritiesLawsMember', window );">Violations of Federal Securities Laws [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyNewClaimsFiledNumber', window );">Loss Contingency, New Claims Filed, Number</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_LitigationCaseAxis=sava_ShareholderDerivativeActionsTexasCourtMember', window );">Shareholder Derivative Actions, Texas Court [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyNewClaimsFiledNumber', window );">Loss Contingency, New Claims Filed, Number</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="nump">4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_LitigationCaseAxis=sava_ShareholderDerivativeActionsTexasStateCourtMember', window );">Shareholder Derivative Actions, Texas State Court Member</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyNewClaimsFiledNumber', window );">Loss Contingency, New Claims Filed, Number</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_LitigationCaseAxis=sava_ShareholderDerivativeActionsDelawareCourtMember', window );">Shareholder Derivative Actions, Delaware Court [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyNewClaimsFiledNumber', window );">Loss Contingency, New Claims Filed, Number</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_LitigationCaseAxis=sava_ShareholderDerivativeActionsMember', window );">Shareholder Derivative Actions [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyNewClaimsFiledNumber', window );">Loss Contingency, New Claims Filed, Number</a></td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_LitigationCaseAxis=sava_ShareholderDerivativeActionsMember', window );">Shareholder Derivative Actions [Member] | Subsequent Event [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LegalFees', window );">Legal Fees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_LitigationCaseAxis=sava_AntislappLawsuitMember', window );">Anti-SLAPP Lawsuit [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sava_NumberOfFormerEmployees', window );">Number of Former Employees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sava_NumberOfFormerEmployees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the number of former employees.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sava_NumberOfFormerEmployees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sava_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LegalFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense provided in the period for legal costs incurred on or before the balance sheet date pertaining to resolved, pending or threatened litigation, including arbitration and mediation proceedings.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(6))<br> -SubTopic 10<br> -Topic 220<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LegalFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyNewClaimsFiledNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The total number of new claims filed pertaining to a loss contingency during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483076/450-20-50-4<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483076/450-20-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyNewClaimsFiledNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=sava_ViolationsOfFederalSecuritiesLawsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=sava_ViolationsOfFederalSecuritiesLawsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=sava_ShareholderDerivativeActionsTexasCourtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=sava_ShareholderDerivativeActionsTexasCourtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=sava_ShareholderDerivativeActionsTexasStateCourtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=sava_ShareholderDerivativeActionsTexasStateCourtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=sava_ShareholderDerivativeActionsDelawareCourtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=sava_ShareholderDerivativeActionsDelawareCourtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=sava_ShareholderDerivativeActionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=sava_ShareholderDerivativeActionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=sava_AntislappLawsuitMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=sava_AntislappLawsuitMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46586285525536">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 13 - Warrant Dividend Distribution (Details Textual) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="3">3 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jan. 03, 2024</div></th>
<th class="th"><div>Dec. 22, 2023</div></th>
<th class="th"><div>May 02, 2024</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>May 07, 2024</div></th>
<th class="th"><div>Jan. 02, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstanding', window );">Warrants and Rights Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 113,363,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromWarrantExercises', window );">Proceeds from Warrant Exercises</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 123,552,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=sava_WarrantsToPurchaseCommonStockMember', window );">Warrants to Purchase Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sava_ClassOfWarrantOrRightIssuedDuringPeriod', window );">Class Of Warrant Or Right Issued During Period (in shares)</a></td>
<td class="nump">16,900,000<span></span>
</td>
<td class="nump">4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)</a></td>
<td class="nump">$ 33<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 22<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight', window );">Class of Warrant or Right, Number of Securities Called by Each Warrant or Right (in shares)</a></td>
<td class="nump">1.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sava_RedemptionPercentageOfWarrants', window );">Redemption Percentage of Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.10%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sava_WarrantRedemptionPrice', window );">Warrant Redemption Price (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstanding', window );">Warrants and Rights Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 65,368,000<span></span>
</td>
<td class="nump">$ 65,368,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sava_ClassOfWarrantOrRightExercisedDuringPeriod', window );">Class of Warrant or Right, Exercised During Period (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,152,000<span></span>
</td>
<td class="nump">674,000<span></span>
</td>
<td class="nump">674,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromWarrantExercises', window );">Proceeds from Warrant Exercises</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 22,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sava_StockIssuedDuringPeriodSharesWarrantExercises', window );">Stock Issued During Period, Shares, Warrant Exercises (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sava_GrossProceedsFromIssuanceOfWarrants', window );">Gross Proceeds From Issuance of Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">126,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfWarrants', window );">Proceeds from Issuance of Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">123,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sava_ProceedsFromWarrantsExercisedThatObligatedToPayCommission', window );">Proceeds From Warrants Exercised That Obligated to Pay Commission</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sava_CommissionPercentageOfGrossProceeds', window );">Commission Percentage of Gross Proceeds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sava_PaymentsOfWarrantExerciseCosts', window );">Payments of Warrant Exercise Costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Payments of Stock Issuance Costs</a></td>
<td class="nump">$ 537,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sava_ClassOfWarrantOrRightExercisedDuringPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the warrants or rights exercised during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sava_ClassOfWarrantOrRightExercisedDuringPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sava_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sava_ClassOfWarrantOrRightIssuedDuringPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of warrants or rights issued during period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sava_ClassOfWarrantOrRightIssuedDuringPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sava_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sava_CommissionPercentageOfGrossProceeds">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the percentage of commission required to be paid from gross proceeds.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sava_CommissionPercentageOfGrossProceeds</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sava_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sava_GrossProceedsFromIssuanceOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross proceeds received from the issuance and sale of warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sava_GrossProceedsFromIssuanceOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sava_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sava_PaymentsOfWarrantExerciseCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the amount of warrant exercise costs during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sava_PaymentsOfWarrantExerciseCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sava_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sava_ProceedsFromWarrantsExercisedThatObligatedToPayCommission">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Dollar amount required to be paid for commission from warrants exercised during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sava_ProceedsFromWarrantsExercisedThatObligatedToPayCommission</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sava_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sava_RedemptionPercentageOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Percent of the cost for redemption of warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sava_RedemptionPercentageOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sava_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sava_StockIssuedDuringPeriodSharesWarrantExercises">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued attributable to warrant exercises.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sava_StockIssuedDuringPeriodSharesWarrantExercises</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sava_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sava_WarrantRedemptionPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Price of warrants if they are redeemed.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sava_WarrantRedemptionPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sava_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which each warrant or right may be converted. For example, but not limited to, each warrant may be converted into two shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for cost incurred directly with the issuance of an equity security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from issuance of rights to purchase common shares at predetermined price (usually issued together with corporate debt).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromWarrantExercises">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from holders exercising their stock warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromWarrantExercises</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of outstanding derivative securities that permit the holder the right to purchase securities (usually equity) from the issuer at a specified price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=sava_WarrantsToPurchaseCommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=sava_WarrantsToPurchaseCommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46586285562336">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 13 - Warrant Dividend Distribution - Changes in Warrants Outstanding and Warrant Liability (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">3 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Balance, shares (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,895,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstanding', window );">Balance, liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 113,363<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">gain from change in fair value of warrant liabilities, liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 108,183<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">gain from change in fair value of warrant liabilities, liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 108,183<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Balance, shares (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstanding', window );">Balance, liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=sava_WarrantsToPurchaseCommonStockMember', window );">Warrants to Purchase Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Balance, shares (in shares)</a></td>
<td class="nump">16,221,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstanding', window );">Balance, liability</a></td>
<td class="nump">$ 65,368<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sava_ClassOfWarrantOrRightExercisedDuringPeriod', window );">Warrants exercised, shares (in shares)</a></td>
<td class="num">(3,152,000)<span></span>
</td>
<td class="num">(674,000)<span></span>
</td>
<td class="num">(674,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sava_ExerciseOfWarrantsResultingInDecreaseInWarrantLiability', window );">Warrants exercised, liability</a></td>
<td class="num">$ (226)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (4,954)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">gain from change in fair value of warrant liabilities, liability</a></td>
<td class="num">(65,142)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(43,041)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">gain from change in fair value of warrant liabilities, liability</a></td>
<td class="num">$ (65,142)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (43,041)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sava_ClassOfWarrantsOrRightsCommonStockWarrantsRedeemed', window );">Redemption of common stock warrants (in shares)</a></td>
<td class="num">(13,069,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Balance, shares (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">16,221,000<span></span>
</td>
<td class="nump">16,221,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstanding', window );">Balance, liability</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 65,368<span></span>
</td>
<td class="nump">$ 65,368<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Balance, shares (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">16,221,000<span></span>
</td>
<td class="nump">16,221,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstanding', window );">Balance, liability</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 65,368<span></span>
</td>
<td class="nump">$ 65,368<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sava_ClassOfWarrantOrRightExercisedDuringPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the warrants or rights exercised during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sava_ClassOfWarrantOrRightExercisedDuringPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sava_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sava_ClassOfWarrantsOrRightsCommonStockWarrantsRedeemed">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the warrants redeemed common stock warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sava_ClassOfWarrantsOrRightsCommonStockWarrantsRedeemed</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sava_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sava_ExerciseOfWarrantsResultingInDecreaseInWarrantLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in warrant liability from exercise of warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sava_ExerciseOfWarrantsResultingInDecreaseInWarrantLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sava_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAdjustmentOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (income) related to adjustment to fair value of warrant liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 13<br> -SubTopic 10<br> -Topic 480<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481766/480-10-25-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAdjustmentOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of outstanding derivative securities that permit the holder the right to purchase securities (usually equity) from the issuer at a specified price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=sava_WarrantsToPurchaseCommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=sava_WarrantsToPurchaseCommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46586284216352">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Note 14 - Subsequent Event (Details Textual) - Workforce Reduction [Member]<br> $ in Millions</strong></div></th>
<th class="th"><div>Jan. 07, 2025</div></th>
<th class="th">
<div>Mar. 31, 2025 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveAxis=sava_WorkforceReductionMember', window );">Forecast [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedCostExpectedCost1', window );">Restructuring and Related Cost, Expected Cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveAxis=sava_WorkforceReductionMember', window );">Subsequent Event [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated', window );">Restructuring and Related Cost, Number of Positions Eliminated</a></td>
<td class="nump">10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent', window );">Restructuring and Related Cost, Number of Positions Eliminated, Period Percent</a></td>
<td class="nump">33.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedCostExpectedCost1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount expected to be recognized in earnings for the specified restructuring cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4.d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4.b.1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedCostExpectedCost1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of positions eliminated during the period as a result of restructuring activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of positions eliminated during the period as a percentage of total positions eliminated during the period in connection with the restructuring plan(s).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveAxis=sava_WorkforceReductionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveAxis=sava_WorkforceReductionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=srt_ScenarioForecastMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=srt_ScenarioForecastMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>84
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M6I56F2$LW/;?^A*L,-P%3>O#_>]DSMQ$0"M3(L.5'!Z&X&OFDKN/1^2=<6S
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M&*P%DG598O'G!BC?+QW?.0S<D6VAS(";)A7>PCVHAVHM=,_MLN2D!"8)9TC
M9NE\\:]7L8FW 3\)[.51&QDGCYP_F<[W?.EX!@@H9,IDP/JR@Q50:A)IC-]M
M3J=;T@B/VX?L7ZUW[>412UAQ^HODJE@Z"P?EL,$U57=\_PU:/U.3+^-4VG^T
M;V*G.CBKI>)E*]8$)6'-%3^W]^%(X$=O"()6$(P5A*T@M$8;,FOK%BN<)H+O
MD3#1.IMIV'MCU=H-8>8IWBNA9XG6J73%F>24Y%A!CFXPQ2P#=&_2272QQ@*8
M*D"1#%-YB3ZC3\A%LM##,G&57MXD<;-VJ9MFJ>"-I6XAFZ#0OT*!%T0#\M5X
M>=B7N]ITYSSHG <V7_1&OK6N%Q!"V]8W.7NZ0A46:(=I#>B",)1S2K&0J +1
M.+X<<MPL,;=+F!=FEWH3S_,3=W=L[%14CS_L^,/S^)OG@G"M"B[(7SUA?#2C
M@_!-_MD1EN\UOQ?\(P)[%J+.0O0A"T3*^C1^](KJ)?=[$3W@:0<\_1"P_CQ*
MA5E.V/84]?0D]7L1/>I91SU[EWK%RU)_,?^CS&>CROQ45 ]^WL'/SX _N\;G
MKTLW&"[R,9$]!XO.P>)\!^-*?/&**5H$7NC/XQ?P X%!$,YB/QYFCSOV^'SV
M,ZH]'FM@('#8@'NTUYESQ@\LMH1)1&&CI=YDKE\?T>S=34?QRFY_CUSIS=0V
M"WW< 6$"]/R&<W7HF!VU.T"E_P!02P,$%     @ B()C6ND5H>W'!   EQ(
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MZR^XX*^/1+U#]%F]\(**&VB2.R<A[$07D!NQ)QNZ=%2%$)0?J+/Z^2<<>;]
M$_0CG:U_D+.SR0N'R0MMWE</RB/AFQRIW$1K>E"E;J]S''WHYA*:R<[CO/6H
M*^=A%:51$"_<PWB*3%62ACI?QJHUX"OQ G]0G4'-!ZBY%>HW6JN4*%LFDJFZ
M4 BI4^0 XG2^HM$08IQXZ03'5.%H'H03'$"%TR2!<:(!)[+B?&92P3 CS2&8
MR!Q B,,PFM  ,F^>SB<Q7)NRQ/-\#\:)!YS8BG-Z7TLF0(C8>.PU2 'I( Q
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M*O-XMPO2G4BV;_<%GIB4K&H/<THRRK5 W=\R)E].] .&O:C5?U!+ P04
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M=\:-.V.?]=D7G2I++B7DL;IE8EN:?+B;#7$<Q3I%AM>CW;$[ .0TQ2AUD!F
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M4U;\,H3$)PX3OZ!G!XOYV2'C%R"=Y4#F+0)_.K=2WJT..]/X(AH-K]08 !Z
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M$4B1))+H%P2.6.1$"20(*!9</V:IFY"XGAMZ[)O0)"1!13PLD20Q -36F&9
MSCZST)DDL9- $7_B3D(PBZ*.66MF3O%Z<+/OI)/(B3TZW@_<+&&1.XF[[5]L
M1.V&X]9,+8R(Y!&.8X)*^?XA#N6V_Q.S^K#8G4/DP-A/W&AT[O'*GV*[?]F"
M6_58YGO [V9N>#TS:7$WR^Q*D@]"H:=;6[_VXRLE%^Q.]GI6Y52PUX ^F5*_
M:;-7MVI'Y!;CG<A%'9EXGA-Z@+]+4W#>=JH=O@)\HX1<F[HQ.=N+)DX2)\"(
M<;@)DSCQG#2);>QXACISTXQX)&Z<LABQ%:0IPR3-^>[$ ])2QY]D=ISYEG:R
M_<5)F6=";&)WF=DPB8:4 &J WS1U09=-0D Q #W-A:'K416.G2PEVABTWB!L
M$##$P03//H2'V7.EX9R+BJ-OO<W1(=F>#KXH%Y2?"+M37BJV-ND)CI6[V<)]
MLCFG\D=M%DKF-HM/N6EF'* YKU9%%Q4+VRNTKCQ<''/;0AC0N^S*,F)H22J$
M1T&Y<$]Z*ZO@^7PWO[<B.VV=H<;B"?Q?5/5I/.OG ]JD7=-M]6V*'7Z3%2?1
M463\V#\B:?W4.\(@L(,X/MJNQ-$1NRGUC[=3A6:CA!"*TARZ"2@*6(>&+'*C
M] C#+&B'(8: 86:&H9M,CI#HVE1IPJC7;1A0J?F[1 4LH!=[+$55L+^$DH/'
ME4WP*U1C$H+.8D>#];U\LFO0W<S5F15 C=TLMH%EZQ**5#*T%9H.^U5E/F_7
M]+W9X66.]@K=;XY<LMYN^"4P/6M:ZC;Z\XPAS'%?W5OTB_B>URLTOK7IA6$_
M,9W"MI2(Z<B"[ )BHYW[K.&'&K6I<*!)2]0E0^T^]0NV&X/?BYPCA(?*LD)"
M+NJ@SP^75X==#]K%<]LN_HWZL]=L/M,X;:O#@?-^I6]!#D4&_*.%B7%B\*YK
M +KAU7[/T2W]2JMAS[C\I4H=.,:L^U\1#OLX-4EE0]WYL-0=T)P*G;/CL(U<
M5:8-EK,:-F>O?,\WQ:%LH=I>*>2#*P73_-1:F%Z8RNS^%P H\!5)3"![XK:W
M$Q=[MQ,&HV#UMWN0%\2B3 \=Y4K#$/JX;5R?R9>#_'@#7;A"XB9K%F(M*KFD
MCW(DA<2))E3[T)[&5+I])PE]]H>HD6DJ0S_\VEH+-D'AFX \#M&UA3&:B0:$
M_TMR4_>=P)1@E,TLL4<F"7VVWHIE8V7WPRZ8Z,.Z^Q@.[&SL&J"DR&>'M#T
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M$C09?+F(P+3SVQI.UV%F5MK1!(9E14\>&N] YZ6F]ND,'Z!_1+-_4$L#!!0
M   ( (B"8UKK[LT7Z04  )P.   9    >&PO=V]R:W-H965T<R]S:&5E=#$W
M+GAM;(U7VV[;.!#]E8&;%@Z@V+KZDB8&<BNV#[V@2;I8+/:!ED8V48G4DG0<
M[]?OD))E.Y&S"Q@4)0\/SQS.#,F+M52_]!+1P'-9"'W96QI3G0^'.EUBR?1
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M6.,/!7LQP/NU0[,>%G+ ]B_*\A]02P,$%     @ B()C6C*RH,"%!   )PH
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M)L=>!/!^X1"K;B,&-G?#Z7]02P,$%     @ B()C6NU.Z##'!   0 L  !D
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MV.:^UBR\V80[TM)XNG&%UY*NN&A9@?97ABX/[8(-])?FV2]02P,$%     @
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M<FMS:&5E=',O<VAE970R,BYX;6Q]E-MNVS ,AE^%\(9==?$A[@%98J#I =N
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MC<Y/ ]!=2W8&J<:WP5*1;2H_K>PKAMHYV/U2V>+H#7? \"YF?P%02P,$%
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M58)<PD.+NC))2HJ]"B< _Q9_Y#*C9 =-)V R!"[J)5MC7-.)LDB/.2@H.,O
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M0X>I,<P(F]2@%6;F$&]@V\EVZ!*(MALJN_TPJ<V;*N_5^XRLF0F,^X<"[W)
MOY#8-+@B58DPR$%2<OP;<#-]MIF]8#9PAP3PX#;!D<TC-PRV965AP[ ]O<L1
M2"G-X0 V+^CL76:;L.8F:4-:=%QDI'Y^/M5,G<%35XU#2F2F3N\Z:6J4ML,P
MW;P,C4GMP]@)F4[Q;7K104W8X^^@8 =O@V[?/O9IL4W<\QS/F^V,,;*(M+MR
M#0CLZV +&O/2#-N/)ELT31>2DG4P,R%P#(W.59<FTS3(!#:AYWL$[X8Y?>KK
MWHELK]I1ZP[:?9\Y[>]S-F.;<?_<Y@WROFHTY,;-E"?R!<7;"^8W(1NM-55
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M\0'-C]5,T<[O4/*R0J%+*4#A8N)=A.?3Q-H[@Y\EKO7.&JR2N91/=G.33[S
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ME6G:**V#V5\(\_J[B4W0_PU,_@-02P,$%     @ B()C6F!,F)O7 @  X@8
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M&I%HU4S4QC"R<E-L(0W-1+?-Z2>$RCK0^Z6DEFX->T'W6YO^ 5!+ P04
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MJ.U+>U^S@A)+<T>Z$8IN7.9U05=<E%J!YF>"+@2=H!WTE^;)/U!+ P04
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MELT/[/Q,'5\FN?9?:+K:,("LUD96'=@JJ)AH1WKL^G "B"87 '$'B#\+&'>
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M WCO1=GOE@/%5Z8#?.8*^DGSN20X(T(#8'W.H0NL!GJ#^K\.T_\ 4$L#!!0
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M]RD<472PQ43Q3=[3+;FB#C$?AM3TH] ;Z'U Q^MQHMO$ZF_$^ ]02P,$%
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MV'5UNXGB>=D8/7"%;58Y7&,G#$(;X/J28W-4372O5??6L]]02P,$%     @
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MUK@O)M[0!@0<<K0*U'QV, ?.K9 )XW>KZ74N+;&_/JA_=;F;7%94PUSR7ZS
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M+4LS\T!9@#E?2_.L6\,ZZ*9H^A=02P,$%     @ B()C6F\C>EO, @  NP@
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M&XDYY2!0E*+G-)+B2DVJYS_G;"E4'#&TI<*CL[*#(O>[/'=R('=,T!>6RKE
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M#C0$KA>H]U/&Y&:@ Y37]>-_ %!+ P04    " "(@F-:7.?A<K<%  #)(0
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M? N>2O-+MI6M8Y'%6BJ>56#T(&-Y^4]?JD#L =S^"8!7 ;PF(#@!\"N _U%
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M_;S\K%#>2+8NSLV?F)0L+2Y7@&/@N8!ZOV!,OMWD ]0?=Z;_ E!+ P04
M" "(@F-:N2HBJ00$  !+#P  &0   'AL+W=O<FMS:&5E=',O<VAE970U,BYX
M;6R=5VV/VC@0_BL6TDE4:LDKL%2 U(4]73_T;K5[O?MLD@FQFL2<;1;VWW?L
MA$ XQZ#R@<3)/$_\S-CCF?F!BQ\R!U#D6!:57 QRI7:?/4\F.914CO@.*GR3
M<5%2A4.Q]>1. $T-J"R\T/<G7DE9-5C.S;-GL9SSO2I8!<^"R'U94O'^" 4_
M+ ;!X/3@A6USI1]XR_F.;N$5U/?=L\"1U[*DK(1*,EX1 =EB\"7XO YB#3 6
M_S XR(M[HJ5L./^A!U_3Q<#7,X("$J4I*%[>8 5%H9EP'O\UI(/VFQIX>7]B
M_]V(1S$;*F'%BW]9JO+%X&% 4LCHOE O_/ '-(+&FB_AA33_Y-#8^@.2[*7B
M90/&&92LJJ_TV#CB A!,>@!A PBO 7$/(&H T;V N $85WNU%..'-55T.1?\
M0(2V1C9]8YQIT"B?53KNKTK@6X8XM?R3*R S\HE\K1)> OF;'D'B\!476+HO
M@/",/&49F/!<&)$72'B5L()1$[_A&A1EA?PP]Q1.2Y-[23.%QWH*8<\4@I!\
MXY7*)7FJ4DB[!![J:46%)U&/H9-Q#<F(1,%'$OIA;)G0ZGYX9(&O[X>'#C51
M&Z+(\,4]?-K;5)$,4A"T(%)1M5=<O!-!%=C<7=,%D>'3&_]MZ8_"8.Z]7?K@
M+JOU+:N.HKA5%#L5O:($((H>/Y(*4QLNL9.X#520,653%5MF<B7IMLG::=(1
M,V[%C-UB<BK@D\X]*<'=@0E9FBUAT^!F&HY'4_\WVPY:U< @[H3!]\,K=3?X
M_='X?_P=S9-6\\3)] (2J$AR0JL4L^P;'A\[/ P4202D3$F;]HE-0C".KV)H
M-?/'U^O2;A;/[+&<MKJF[E@VIU$P"8?E!U*PDJG>8+JIT-EA3S"GMY?I+W!W
M!#^T@A^<3-^K! 0F[DKO1K+CDFFUUOBYB8:34= C]P8PQ'5L!:Y_ =AQPJQU
MPNR.!*L$V^PQ+<%QQT1OT-U,P[C7"[/;07>:=)0%_OEX]YTS6N6TV@+! &>4
M"?)&B[TYTP]4"(H;%L_O#1[BBH$UZ W[U3Z;19%_\;L^64X@EU:W35?L12T3
MN+?OTXI(4*H DXQV]%U?K;K<1,,HMJ3*1EUPASJG35==>%87.B?UE\I!6,6$
M]M,ANHZ+FQ^S2M2S$_N^$/9H.I<V@;NV.2]/O3+K4I(6V(Q03$Q6K6Z^X70V
MBOL"=P,:QKV9Z"8TLGRUZY)S;12XBZ-SM<WJ:EMGYKY2+[BC*KK#9NVVJ95X
M%UU&"6)KNC6)-<^^4G5MWCYM.\(OI@^Z>OZH.T73O9QIZC;S&Q5;5DE20(:4
M_FB*!8VH.[=ZH/C.]#(;KK S,K<Y=KL@M &^SSCV,\U ?Z#MGY<_ 5!+ P04
M    " "(@F-:O(P4%5$#  #D"@  &0   'AL+W=O<FMS:&5E=',O<VAE970U
M,RYX;6R5EFUOVC 0Q[^*%?5%*XWFF4 %2!UH6J4]5*7;7KO)0:PY,;--:??I
M=T[2%(A)NS<0Q_>__.[\<#?9"?E;Y0":/!6\5%,GUWISY;HJS:&@ZE)LH,29
ME9 %U3B4:U=M)-"L$A7<#3QOZ!:4E<YL4KV[E;.)V&K.2KB51&V+@LKGC\#%
M;NKXSLN+.[;.M7GASB8;NH8EZ!^;6XDCM_62L0)*Q41))*RFSK5_-?<#(Z@L
M?C+8J;UG8D)Y$.*W&=QD4\<S1, AU<8%Q;]'F /GQA-R_&F<.NTWC7#_^<7[
MIRIX#.:!*I@+_HME.I\Z(X=DL*);KN_$[C,T <7&7RJXJG[)KK'U'))NE19%
M(T:"@I7U/WUJ$K$G\*,3@J 1!.\5A(T@K *MR:JP%E33V42*'9'&&KV9ARHW
ME1JC8:59QJ66.,M0IV??A 8R)@-R4Z:B ')/GT#A<(G[)=MR(&)%%K "*2$S
MD^1:*="*T#(C7QA]8)QIAHKS!6C*N+I [8_E@IR?79 SPDIRGXNM0FLU<37R
MFJ^Z:</VL68+3K M(+TDH?^!!%X06>3S]\O#0[F+66I3%;2I"BI_T:E4X:'"
MXR.I9N6:<*$42:F4SWB6=E3: ZP]QI5'<Z(>9U'H1Z.)^[@?1]<J#,,@:*T.
M<,,6-^S%7>94PL!L\8S@TN*Y5]2<'!MF[6FXCSGRHR/*KE$0#WT[9-1"1KV0
M=Z" RC2O]E,&CWBM;/"2T"3%_<;TVPF..E!^F(S&1^@6JR".$SM[W++'O>QS
MNF&:<O87$RQ/Q0%/)O%@98\[5&$8CX\W1]<J2.)P9&<?MNS#7O;O.@=I8QI:
M\AEY1T@VH^3$3DA:HJ27Z%Y@+LT%7%\U&J\:6ETU-LJD S >#CNKWK5*DC :
MVSE'+>>HE_,GY5M:5R".-9"6*=@(1YUO#VR(%K,>QG'+.'[SIGIG)L<=@./%
M[K,XH/.]UYKC]>^^UUL4\'XBTM3:@5@-MC@XS=IX[8/M-3FDW:N0_O_N3/Y:
M^:R@_MN@?2:'H*_UR7^[0'67G9R_T#Y?6&&[U:<#VV=2P[I[+8CI_[Y2N6:E
MP@5>H<:[3% LZY:J'FBQJ;J2!Z&QQZD><VQ#01H#G%\)[$R:@6ETVL9V]@]0
M2P,$%     @ B()C6NQ*1Z3E @  [0<  !D   !X;"]W;W)K<VAE971S+W-H
M965T-30N>&ULC57;3N,P$/T5*^(!I(5<F@2*VDJ4L%H>6"$*N\\FF386B9VU
MW0M\_8Z=D&V;M,M+XLLY)W.<\<QH+>2;R@$TV90%5V,GU[JZ=EV5YE!2=2$J
MX+@S%[*D&J=RX:I* LTLJ2S<P/-BMZ2,.Y.177N4DY%8ZH)Q>)1$+<N2RO<I
M%&(]=GSG<^&)+7)M%MS)J*(+F(%^J1XESMQ6)6,E<,4$)Q+F8^?&OTYB@[>
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M6X'QU9B_ EYCK'9,P^>]>I3V"J[["K<8:.7PJH?;E;RD6&0YCA*8IB3/>-L
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M70^%^VEY&%+><+(M-N]7A'.2%I<11B&FLH!XOR:$'V]D!?61U.1_4$L#!!0
M   ( (B"8UH!%@\%;P4  /0Q   9    >&PO=V]R:W-H965T<R]S:&5E=#4W
M+GAM;+6;VV[;.!"&7X7P%HL62&-)/L3I)@:2Z(RF&]3;[L5B+QB;L85*HBM2
M<0OTX9<Z1+92F[:W?VYL2>;_#:G,<,0,=;'BV1>Q8$R2;TF<BLO.0LKENVY7
M3!<LH>*4+UFJ?GG@64*E.LWF7;',&)V5HB3N6H8Q["8T2COCB_+:73:^X+F,
MHY3=943D24*S[]<LYJO+CMEYNO QFB]D<:$[OEC2.9LP^6EYEZFS;D.910E+
M1<13DK&'R\Z5^2XTAX6@;/$Y8BNQ<4R*H=QS_J4X"6:7':/H$8O95!8(JKX>
MV0V+XX*D^O&UAG8:FX5P\_B)[I:#5X.YIX+=\/CO:"87EYU1A\S8 \UC^9&O
M?%8/:%#PICP6Y2=956V'JO$T%Y(GM5CU((G2ZIM^JV_$AL#L[Q!8M< Z5-"K
M!;U#!?U:T#]4,*@%@T,%PUHP?":PK!V"LUIP]MS"8(=@5 M&SP7#'8+S6G!^
MZ!A,X^DO9Y0>5/W)2W^QJ:3CBXRO2%:T5[SBH'2Z4J_<)$J+^)C(3/T:*9T<
M?^"2$=,B;\D-3V64SEDZC9@@KVTF:10+\A?[)G,:OR&O2)22VRB.E5N+BZY4
MQ@M$=UH;\BI#U@Y#)KE5!A:"..F,S;;H?;W>VJ</]N@-#:"K[EISZZRG6W=M
M:8D3MCPEQO"$6(;5W]*A&[W\*I]KY;9>?DNS4V*.=LH=O3S,8V5]4,JM+7)W
MGSP])3UCI]S3RUUV?TJLJO,#\FEBD]>OWFSS"3WFSZE4F.H6FMM<XH!!6-4@
M>EODX?^6M_RIUX1BK^3U=_ ^1SRF1=(0A#\0E\U81F,R8=,\BV01D^_I2I!_
M;EERS[)_M_3W6LLO,NT[L:13=ME1J52P[)%UQK__9@Z-/[9Y+Q)F(V$.$N8B
M81X2YB-A 1(6@F"M*.DW4=+71LE[+L1&KOI^0CZHA[";F$:)(&X4LYFZDA<A
MLBU"M.QC(P0)LY$P!PES*]BPA!6/VX]C-=<^;KH]TIS_L[E^VUR -!>"8"U?
M'C2^/-#Z\F1!,[;@L9KIB<VRZ)$6BP5R52X=Q$GQ[$4+9\\SJ9WWM5:.]6HD
MS$;"'"3,1<(\),Q'P@(D+ 3!6K$R;&)E^(+SOI9];(0@8382YB!A+A+F(6$^
M$A8,?\HW5CO?A#^W6&>DEB^?-;Y\!ICW)Y*JM7DU^U>3_S;/UEHZUK.1,!L)
M<Y P%PGSD# ?"0N0L! $:\7+J(F7T0O._5KVL1&"A-E(F(.$N4B8AX3Y2%@P
MVK>T"4'F6FY_WKC]^2^E"9O%=*6:'+!"T!HZ-@:0,!L)<Y P%PGSD# ?"0N0
ML! $:X6+::QK&<8+Y@D]_-@@@=)L*,V!TEPHS8/2?"@MJ&FZ?($RV(Z C6J>
M^0LI0YLB].2CW1])LZ$T!TISH30/2O.AM !*"U&T=J18ZTBQ7C)76/O^:W"C
MMW]T!.PUZ&QITFLW<:%]\J T'TH+H+0016O[ZKHP;.HKPP?.ZN0'F>3W@GW-
M62J)\UA\:F=\:+T82K.A- =*<Z$T#TKSH;0 2@M1M'84K0O'YI[*,9O3F+B,
M;=N]=*T7'QT,T-HPE.9 :2Z4YM6TP>XG;!]J,(#20A2M[>'K<K*IKR=?J:>9
MMY/W5W=WY5ZA/-HS_T/KQE":#:4Y4)H+I7E0F@^E!5!:B**UHV-=0#;U%>3J
M:;[<6\>S1!TYR3+FWW?E VC)V-Q;9;2A!ATHS872/"C-A]("*"U$T2J/[VYL
M\U;^.R]?*Q!DRO-45MN6FZO-JPM7Y8;]9]>#XI6&<OOX&E.]#W%+LWFDEA0Q
M>U!(X_1,A6Q6O6)0G4B^+#>3WW,I>5(>+AA5"Y.B@?K]@7/Y=%(8:%[T&/\'
M4$L#!!0    ( (B"8UJ":T0SY <  &52   9    >&PO=V]R:W-H965T<R]S
M:&5E=#4X+GAM;+6<67/C-A:%_PI*DTIUJCH6%RVV8[LJ+>Y+VM5.)@]3\T!3
ML,5J+@H!V=W_/B!%4:)(453FS(LM4CC?!9<#@. 5[MZS_"M;4<K)MR1.V?UH
MQ?GZ=CQFX8HF ;O*UC05W[QD>1)PL9F_CMDZI\&R%"7Q6)&DV3@)HG3T<%?N
M>\P?[K(-CZ.4/N:$;9(DR+]_HG'V?C^21[L=7Z+7%2]VC!_NUL$K?:+\C_5C
M+K;&-649)31E49:2G+[<CWZ5;WVE%)0E_AW1=W;PF12'\IQE7XL->WD_DHH:
MT9B&O$ $XM\;7= X+DBB'G]5T%$=LQ >?M[1C?+@Q<$\!XPNLOC/:,E7]Z/K
M$5G2EV 3\R_9NT6K YH6O#"+6?F7O%=EI1$)-XQG2246-4BB=/L_^%:=B .!
M/#DA4"J!,E2@5@+U6# ](9A4@LE0P;023(=6:58)9D,%\THP/Q;,3@BN*\'U
MT @WE>!FJ$"6=E=.&BRI+W;K:JNG)+O++0^^WO+N@LOE%1]O[\7R1M8"'CS<
MY=D[R8OR@E=\*-U0ZL7]&Z6%<9]X+KZ-A(X__)9Q2F25_$S^#/(\2#G1HK=H
M2=.E^,!X'CUO2H-]T"@/HIB1W^DWO@GBGX3BCR>-?/CAI[LQ%Q4I<..P"JIM
M@RHG@LK$SU*^8D1/EW39H=?[]>HYO74FOM(#&(LS6)]&97<:/RF]1"=(KXBD
M?B2*I$PZ*K3HEVLTO"**4LK5KO/9+_>#[T123@;7S]1](^JN2B?EQKG@N9#+
M)^7F_R:W!IRY'KD]7-YUXIWA<J5#[O;+G^BZ]\Q[ R[[_*3:'W++=MXU#0NH
M=4NBEKS)"5[5?C 2B+:C'  P\GG#&1?;4?K:4<%/O<!BR'++UD%([T=B3,)H
M_D9'#S_^2YY)OW0Y# G3D# ="3.0,!,)LY P&PESD# 7"?.0,'\+FY:P8L#^
M]B#+JCI3)4FZ&[]U6'M26WO2:^W'/ LI73+RDF=)/5#0O]$\C!AE7=;N!5YJ
M;21,0\)T),Q PDPDS)JT[RQ%G4Z5PSMKZ]MVR:,2SMD2+K+J'A+F@V -$TYK
M$TZ']:\\(X^;/%R)QU6RR))$C,Z?>!9^)?_Q:?),\_]V^;&7?:D?D3 -"=.1
M, ,),Y$P"PFSD3 '"7.1, \)\T&P1D,PJQN"66]#L(@#)H;6+W5'_#G?CK>)
MS=B&B@?W32X&W.21YE&V)!^BE+!5(.K1]:3^:1MK=MBTSVXDJ=6R+]H%)\T2
M6F^U+W4R$F8@82829B%A-A+F(&$N$N8A83X(UG#RO';R?("3L[V3L\K)'\EO
MFZ(K+[Y[HJ'P,X\H(XL@CH6_G[^3>C"P4[!S/N^MR:4#@'F[T3AJ+C1D/!T)
M,Y P$PFSVJ=U.N]HBFUD4 <)<Y$P#PGS0;"&SZ]KGU__4Y_O'J+)8QZ%]*#,
ML;6761P'.2-KT2J4-N]T^77KX4I5C_KQWJI>.GA'PG0DS$#"3"3,:E^C8NZX
M87!D/ <)<Y$P#PGS0;"&P6]J@]_\GSIR/0A7+=6YOGQ;F>(=Y;[_O9H>^;RW
MQI?Z' G3D3 #"3.1, L)LY$P!PESD3 /"?-!L$:+($O[%^M2;YOPA2YILBY?
MGHLG\9"F/'AM=/!=SNYG7CI,A](T*$V'T@PHS832+"C-AM(<*,V%TKR*)D\.
M7Q5<29+<[.A\5-2FSP\2:.0A\_+DT._E6'[XJ+T_PL6N1](T*$V'T@PHS832
M+"C-AM(<*,V%TKR*=MTT?<OSH)A-SRM[SROH7)=^XL4>1](T*$VO:#UO>(V.
M(K.I.KMN3769@TM:Y\/:T.-TH#3W?/4]:$ ?16M::)\M)O>GBPV8$[OP359_
MP(L=!LTG@]+TBG8X4:S*'=D81D?!V7S2X;)AY2SH8=A0F@.EN5":!Z7Y*%K3
MN?MD,!F>#=9/O-B:T'PP*$V'T@RYG2RE*&K'*R$3&M>"TFPHS8'27"C-@])\
M%*WI\WV^F=R?<+9-*NO**?E(GLIN^&/;_6<[:6@B&I2F5;3&O/KD:MYTF@Z-
M:52TQJOT8VM#4\>@-!M*<Z T%TKSH#0?16M:>Y]!)O>GD)EY)@;?=4=N%!UY
M8?0@#<]/42/3;Q90F@:EZ5": :694)HE=V0!*K.N@88-#>Q :2Z4YD%I/HK6
M=/P^TTSN3S5K#MH'>QV:-0:E:5":#J494)H)I5ER1_*>HLXZO0Y--(/27"C-
M@])\%*WI]7VVF=R?;M;LU^NYZOVTVN^K@)//SW'T&G"Q6?R@)/A>_I8D8L6*
M#)U- 3)99P&E:5":#J49<D>ZER1U/L)#L\R@-!M*<Z T%TKSH#0?16NV!/NT
M-/E,7EIMZ:,<E.8#0*??D:DX"RA-@])T*,VH:,=9"\KTV.W07#,HS8;2'"C-
MA=(\*,U'T9I+D.PSSI3^C#/1B2>TS!Q_:4W,B=Z==8_Q^Z&7&AU*TZ T'4HS
MH#032K,J6F/0T?E+$FA8!TISH30/2O-1M*;3]SEG2G_.V:'3]]/TY1/]:9_+
MK7MBJL[;O_/L#WVQ@Z'I8U": :694)H%I=E0F@.EN5":!Z7Y*-K6YN.#9=H2
MFK^6ZQ4R$F:;E&_76:KWUFLB_EJN#'>T7Y=O3;ECOR7?.ML5#_?X[0*,?I"_
M1BDC,7T1H:2KN6@&\NV:AML-GJW+1>*>,\ZSI/RXHL&2YD4!\?U+EO'=1A&@
M7EGRX6]02P,$%     @ B()C6L@-?F&N!0  >BX  !D   !X;"]W;W)K<VAE
M971S+W-H965T-3DN>&ULO9I=;]LV%(;_"N$50PLTM2C)BI,Y!AKK:\.R!<VZ
M7@R[8"S:%BJ)'DG'Z;\?]6'9LF5:PLYZ$TOR>9]#BJ](^823+>-?Q8I2B5[3
M)!-W@Y64Z]OA4,Q7-"7B UO33'VS8#PE4IWRY5"L.251(4J3H6D8SC E<3:8
M3HIKCWPZ81N9Q!E]Y$ALTI3P;_<T8=N[ 1[L+GR*ERN97QA.)VNRI$]4?EX_
M<G4VK"E1G-),Q"Q#G"[N!A_Q;6@:N:"(^#.F6W%PC/*N/#/V-3_Y.;H;&'F+
M:$+G,D<0]?%"9S1)<I)JQS\5=%#GS(6'QSNZ7W1>=>:9"#ICR9<XDJN[P7B
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M9CETWCN0X)P5PDSD^C/6>GJ6+Y9"ET]8U[&> W&AC4QK,&60\JQZLTWMPQ;
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MPS ,0'_%T)XP!] AB#-E\18$^0%6H@_8$@6*19V_K]JE<9 +&7D]/!+<'FE
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M5NK>7YV=6CMT=T8I)QO9.8'PT/<>,,S#6K<P;-I?0B1]4#$F)9UL9.L$S"/
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MS3>XA(7RFK?UM6'^IU]R+RN__+7:MNT9E%VIKYHWNV_G=M_]??H74$L#!!0
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MZ^4ORZ^=>+]H+S@G^'?G\2]02P,$%     @ B()C6G32QF+> 0  6B,  !,
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M2\WL#5!+ 0(4 Q0    ( (B"8UH'04UB@0   +$    0              "
M 0    !D;V-0<F]P<R]A<' N>&UL4$L! A0#%     @ B()C6CH=W;+N
M*P(  !$              ( !KP   &1O8U!R;W!S+V-O<F4N>&UL4$L! A0#
M%     @ B()C6IE<G",0!@  G"<  !,              ( !S $  'AL+W1H
M96UE+W1H96UE,2YX;6Q02P$"% ,4    " "(@F-:_7-(XK,'   E,@  &
M            @($-"   >&PO=V]R:W-H965T<R]S:&5E=#$N>&UL4$L! A0#
M%     @ B()C6NDH_.9/!0  UQ0  !@              ("!]@\  'AL+W=O
M<FMS:&5E=',O<VAE970R+GAM;%!+ 0(4 Q0    ( (B"8UIO+\76I0(  $P)
M   8              " @7L5  !X;"]W;W)K<VAE971S+W-H965T,RYX;6Q0
M2P$"% ,4    " "(@F-:Z16A[<<$  "7$@  &               @(%6&
M>&PO=V]R:W-H965T<R]S:&5E=#0N>&UL4$L! A0#%     @ B()C6C71#>#@
M"0  <VT  !@              ("!4QT  'AL+W=O<FMS:&5E=',O<VAE970U
M+GAM;%!+ 0(4 Q0    ( (B"8UK&RM>$$P<  #TB   8              "
M@6DG  !X;"]W;W)K<VAE971S+W-H965T-BYX;6Q02P$"% ,4    " "(@F-:
M'!8Q2T4"  "A!@  &               @(&R+@  >&PO=V]R:W-H965T<R]S
M:&5E=#<N>&UL4$L! A0#%     @ B()C6EWX#(Y)"   UB0  !@
M     ("!+3$  'AL+W=O<FMS:&5E=',O<VAE970X+GAM;%!+ 0(4 Q0    (
M (B"8UK12'D3=@,  (\'   8              " @:PY  !X;"]W;W)K<VAE
M971S+W-H965T.2YX;6Q02P$"% ,4    " "(@F-:M"'$NA 2  !9,P  &0
M            @(%8/0  >&PO=V]R:W-H965T<R]S:&5E=#$P+GAM;%!+ 0(4
M Q0    ( (B"8UHTX+)(T (  'P&   9              " @9]/  !X;"]W
M;W)K<VAE971S+W-H965T,3$N>&UL4$L! A0#%     @ B()C6NL.X-$4 P
MO@8  !D              ("!IE(  'AL+W=O<FMS:&5E=',O<VAE970Q,BYX
M;6Q02P$"% ,4    " "(@F-:-PU/ER$#  #V!@  &0              @('Q
M50  >&PO=V]R:W-H965T<R]S:&5E=#$S+GAM;%!+ 0(4 Q0    ( (B"8UHZ
M9T$8(0,  "('   9              " @4E9  !X;"]W;W)K<VAE971S+W-H
M965T,30N>&UL4$L! A0#%     @ B()C6F# B#!C"   &Q4  !D
M     ("!H5P  'AL+W=O<FMS:&5E=',O<VAE970Q-2YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( (B"8UKM3N@PQP0  $ +   9              "
M@1)W  !X;"]W;W)K<VAE971S+W-H965T,C N>&UL4$L! A0#%     @ B()C
M6LMQU:^<!   $@L  !D              ("!$'P  'AL+W=O<FMS:&5E=',O
M<VAE970R,2YX;6Q02P$"% ,4    " "(@F-:+S'MK5L"   C!0  &0
M        @('C@   >&PO=V]R:W-H965T<R]S:&5E=#(R+GAM;%!+ 0(4 Q0
M   ( (B"8UIDBB@]HA,  "D_   9              " @76#  !X;"]W;W)K
M<VAE971S+W-H965T,C,N>&UL4$L! A0#%     @ B()C6D:G2R_O!   ) P
M !D              ("!3I<  'AL+W=O<FMS:&5E=',O<VAE970R-"YX;6Q0
M2P$"% ,4    " "(@F-:QGR-][("  #;!0  &0              @(%TG
M>&PO=V]R:W-H965T<R]S:&5E=#(U+GAM;%!+ 0(4 Q0    ( (B"8UH;TWEI
MD (  )(%   9              " @5V?  !X;"]W;W)K<VAE971S+W-H965T
M,C8N>&UL4$L! A0#%     @ B()C6O=V4M_( @  $@8  !D
M ("!)*(  'AL+W=O<FMS:&5E=',O<VAE970R-RYX;6Q02P$"% ,4    " "(
M@F-:8$R8F]<"  #B!@  &0              @($CI0  >&PO=V]R:W-H965T
M<R]S:&5E=#(X+GAM;%!+ 0(4 Q0    ( (B"8UKB3M<<PP4  $ /   9
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M970S,RYX;6Q02P$"% ,4    " "(@F-:TM2JV20#  #E"P  &0
M    @(&CP0  >&PO=V]R:W-H965T<R]S:&5E=#,T+GAM;%!+ 0(4 Q0    (
M (B"8UH*Z+>Z(@0  .,.   9              " @?[$  !X;"]W;W)K<VAE
M971S+W-H965T,S4N>&UL4$L! A0#%     @ B()C6BQH+N]P!   @1   !D
M             ("!5\D  'AL+W=O<FMS:&5E=',O<VAE970S-BYX;6Q02P$"
M% ,4    " "(@F-:Q*'&^I0"  #Q!@  &0              @('^S0  >&PO
M=V]R:W-H965T<R]S:&5E=#,W+GAM;%!+ 0(4 Q0    ( (B"8UH*+DV.40,
M %(,   9              " @<G0  !X;"]W;W)K<VAE971S+W-H965T,S@N
M>&UL4$L! A0#%     @ B()C6H =0ZF> @  !0<  !D              ("!
M4=0  'AL+W=O<FMS:&5E=',O<VAE970S.2YX;6Q02P$"% ,4    " "(@F-:
M)2,UC"\"  !"!0  &0              @($FUP  >&PO=V]R:W-H965T<R]S
M:&5E=#0P+GAM;%!+ 0(4 Q0    ( (B"8UKEHJDK@@,  &</   9
M      " @8S9  !X;"]W;W)K<VAE971S+W-H965T-#$N>&UL4$L! A0#%
M  @ B()C6HV;BE4P @  404  !D              ("!1=T  'AL+W=O<FMS
M:&5E=',O<VAE970T,BYX;6Q02P$"% ,4    " "(@F-:;R-Z6\P"  "["
M&0              @(&LWP  >&PO=V]R:W-H965T<R]S:&5E=#0S+GAM;%!+
M 0(4 Q0    ( (B"8UKO**6]5P(  &0&   9              " @:_B  !X
M;"]W;W)K<VAE971S+W-H965T-#0N>&UL4$L! A0#%     @ B()C6DE&/\;^
M!P  Z$(  !D              ("!/>4  'AL+W=O<FMS:&5E=',O<VAE970T
M-2YX;6Q02P$"% ,4    " "(@F-:1@_4F-$$  "Z%P  &0
M@(%R[0  >&PO=V]R:W-H965T<R]S:&5E=#0V+GAM;%!+ 0(4 Q0    ( (B"
M8UI<Y^%RMP4  ,DA   9              " @7KR  !X;"]W;W)K<VAE971S
M+W-H965T-#<N>&UL4$L! A0#%     @ B()C6L"84*7B P  (@X  !D
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M=#4R+GAM;%!+ 0(4 Q0    ( (B"8UJ\C!0540,  .0*   9
M  " @;(+ 0!X;"]W;W)K<VAE971S+W-H965T-3,N>&UL4$L! A0#%     @
MB()C6NQ*1Z3E @  [0<  !D              ("!.@\! 'AL+W=O<FMS:&5E
M=',O<VAE970U-"YX;6Q02P$"% ,4    " "(@F-:7_W1XYH"  !(!P  &0
M            @(%6$@$ >&PO=V]R:W-H965T<R]S:&5E=#4U+GAM;%!+ 0(4
M Q0    ( (B"8UJ,1K^9O00  )X:   9              " @2<5 0!X;"]W
M;W)K<VAE971S+W-H965T-38N>&UL4$L! A0#%     @ B()C6@$6#P5O!0
M]#$  !D              ("!&QH! 'AL+W=O<FMS:&5E=',O<VAE970U-RYX
M;6Q02P$"% ,4    " "(@F-:@FM$,^0'  !E4@  &0              @('!
M'P$ >&PO=V]R:W-H965T<R]S:&5E=#4X+GAM;%!+ 0(4 Q0    ( (B"8UK(
M#7YAK@4  'HN   9              " @=PG 0!X;"]W;W)K<VAE971S+W-H
M965T-3DN>&UL4$L! A0#%     @ B()C6J<\W@"Q @  2 @  !D
M     ("!P2T! 'AL+W=O<FMS:&5E=',O<VAE970V,"YX;6Q02P$"% ,4
M" "(@F-:)_W^/U$#  "L%0  #0              @ &I, $ >&PO<W1Y;&5S
M+GAM;%!+ 0(4 Q0    ( (B"8UJ7BKL<P    !,"   +              "
M 24T 0!?<F5L<R\N<F5L<U!+ 0(4 Q0    ( (B"8UI@4VR?W@0  'LH   /
M              "  0XU 0!X;"]W;W)K8F]O:RYX;6Q02P$"% ,4    " "(
M@F-:F!M:GOL!  #+(P  &@              @ $9.@$ >&PO7W)E;',O=V]R
M:V)O;VLN>&UL+G)E;'-02P$"% ,4    " "(@F-:=-+&8MX!  !:(P  $P
M            @ %,/ $ 6T-O;G1E;G1?5'EP97-=+GAM;%!+!08     1 !$
+ ),2  !;/@$    !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>85
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>86
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
.report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

.report table.authRefData a {
	display: block;
	font-weight: bold;
}

.report table.authRefData p {
	margin-top: 0px;
}

.report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

.report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

.report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

.report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
.pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
.report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

.report hr {
	border: 1px solid #acf;
}

/* Top labels */
.report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

.report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

.report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

.report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

.report td.pl div.a {
	width: 200px;
}

.report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
.report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
.report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
.report .re, .report .reu {
	background-color: #def;
}

.report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
.report .ro, .report .rou {
	background-color: white;
}

.report .rou td {
	border-bottom: 1px solid black;
}

.report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
.report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
.report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

.report .nump {
	padding-left: 2em;
}

.report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
.report .text {
	text-align: left;
	white-space: normal;
}

.report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

.report .text .more {
	display: none;
}

.report .text .note {
	font-style: italic;
	font-weight: bold;
}

.report .text .small {
	width: 10em;
}

.report sup {
	font-style: italic;
}

.report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>88
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.25.0.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>185</ContextCount>
  <ElementCount>322</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>true</FootnotesReported>
  <SegmentCount>62</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>8</UnitCount>
  <MyReports>
    <Report instance="sava20241231c_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>000 - Document - Document And Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cassavasciences.com/20241231/role/statement-document-and-entity-information</Role>
      <ShortName>Document And Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="sava20241231c_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>001 - Statement - Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cassavasciences.com/20241231/role/statement-consolidated-balance-sheets</Role>
      <ShortName>Consolidated Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="sava20241231c_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>002 - Statement - Consolidated Balance Sheets (Parentheticals)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cassavasciences.com/20241231/role/statement-consolidated-balance-sheets-parentheticals</Role>
      <ShortName>Consolidated Balance Sheets (Parentheticals)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="sava20241231c_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>003 - Statement - Consolidated Statements of Operations</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cassavasciences.com/20241231/role/statement-consolidated-statements-of-operations-</Role>
      <ShortName>Consolidated Statements of Operations</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="sava20241231c_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>004 - Statement - Consolidated Statements of Stockholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cassavasciences.com/20241231/role/statement-consolidated-statements-of-stockholders-equity</Role>
      <ShortName>Consolidated Statements of Stockholders' Equity</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="sava20241231c_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>005 - Statement - Consolidated Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cassavasciences.com/20241231/role/statement-consolidated-statements-of-cash-flows</Role>
      <ShortName>Consolidated Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="sava20241231c_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>995445 - Disclosure - Insider Trading Arrangements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements</Role>
      <ShortName>Insider Trading Arrangements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="sava20241231c_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>995550 - Disclosure - Cybersecurity Risk Management and Strategy Disclosure</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure</Role>
      <ShortName>Cybersecurity Risk Management and Strategy Disclosure</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="sava20241231c_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>995552 - Disclosure - Note 1 - General, Liquidity and Basis of Presentation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cassavasciences.com/20241231/role/statement-note-1-general-liquidity-and-basis-of-presentation</Role>
      <ShortName>Note 1 - General, Liquidity and Basis of Presentation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="sava20241231c_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>995553 - Disclosure - Note 2 - Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cassavasciences.com/20241231/role/statement-note-2-summary-of-significant-accounting-policies</Role>
      <ShortName>Note 2 - Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="sava20241231c_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>995554 - Disclosure - Note 3 - Prepaid Expenses and Other Current Assets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cassavasciences.com/20241231/role/statement-note-3-prepaid-expenses-and-other-current-assets</Role>
      <ShortName>Note 3 - Prepaid Expenses and Other Current Assets</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="sava20241231c_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>995555 - Disclosure - Note 4 - Real Property and Other Income, Expense</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cassavasciences.com/20241231/role/statement-note-4-real-property-and-other-income-expense</Role>
      <ShortName>Note 4 - Real Property and Other Income, Expense</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="sava20241231c_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>995556 - Disclosure - Note 5 - Property and Equipment</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cassavasciences.com/20241231/role/statement-note-5-property-and-equipment</Role>
      <ShortName>Note 5 - Property and Equipment</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="sava20241231c_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>995557 - Disclosure - Note 6 - Intangible Assets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cassavasciences.com/20241231/role/statement-note-6-intangible-assets</Role>
      <ShortName>Note 6 - Intangible Assets</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="sava20241231c_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>995558 - Disclosure - Note 7 - Stockholders' Equity and Stock-based Compensation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cassavasciences.com/20241231/role/statement-note-7-stockholders-equity-and-stockbased-compensation</Role>
      <ShortName>Note 7 - Stockholders' Equity and Stock-based Compensation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="sava20241231c_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>995559 - Disclosure - Note 8 - Employee 401(k) Benefit Plan</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cassavasciences.com/20241231/role/statement-note-8-employee-401k-benefit-plan</Role>
      <ShortName>Note 8 - Employee 401(k) Benefit Plan</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="sava20241231c_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>995560 - Disclosure - Note 9 - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cassavasciences.com/20241231/role/statement-note-9-income-taxes</Role>
      <ShortName>Note 9 - Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="sava20241231c_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>995561 - Disclosure - Note 10 - Commitments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cassavasciences.com/20241231/role/statement-note-10-commitments</Role>
      <ShortName>Note 10 - Commitments</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="sava20241231c_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>995562 - Disclosure - Note 11 - 2020 Cash Incentive Bonus Plan</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cassavasciences.com/20241231/role/statement-note-11-2020-cash-incentive-bonus-plan</Role>
      <ShortName>Note 11 - 2020 Cash Incentive Bonus Plan</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="sava20241231c_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>995563 - Disclosure - Note 12 - Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cassavasciences.com/20241231/role/statement-note-12-contingencies</Role>
      <ShortName>Note 12 - Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="sava20241231c_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>995564 - Disclosure - Note 13 - Warrant Dividend Distribution</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cassavasciences.com/20241231/role/statement-note-13-warrant-dividend-distribution</Role>
      <ShortName>Note 13 - Warrant Dividend Distribution</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="sava20241231c_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>995565 - Disclosure - Note 14 - Subsequent Event</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cassavasciences.com/20241231/role/statement-note-14-subsequent-event</Role>
      <ShortName>Note 14 - Subsequent Event</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="sava20241231c_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>995567 - Disclosure - Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cassavasciences.com/20241231/role/statement-significant-accounting-policies-policies</Role>
      <ShortName>Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.cassavasciences.com/20241231/role/statement-note-2-summary-of-significant-accounting-policies</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="sava20241231c_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>995568 - Disclosure - Note 2 - Summary of Significant Accounting Policies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cassavasciences.com/20241231/role/statement-note-2-summary-of-significant-accounting-policies-tables</Role>
      <ShortName>Note 2 - Summary of Significant Accounting Policies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.cassavasciences.com/20241231/role/statement-note-2-summary-of-significant-accounting-policies</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="sava20241231c_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>995569 - Disclosure - Note 3 - Prepaid Expenses and Other Current Assets (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cassavasciences.com/20241231/role/statement-note-3-prepaid-expenses-and-other-current-assets-tables</Role>
      <ShortName>Note 3 - Prepaid Expenses and Other Current Assets (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.cassavasciences.com/20241231/role/statement-note-3-prepaid-expenses-and-other-current-assets</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="sava20241231c_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>995570 - Disclosure - Note 4 - Real Property and Other Income, Expense (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cassavasciences.com/20241231/role/statement-note-4-real-property-and-other-income-expense-tables</Role>
      <ShortName>Note 4 - Real Property and Other Income, Expense (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.cassavasciences.com/20241231/role/statement-note-4-real-property-and-other-income-expense</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="sava20241231c_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>995571 - Disclosure - Note 5 - Property and Equipment (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cassavasciences.com/20241231/role/statement-note-5-property-and-equipment-tables</Role>
      <ShortName>Note 5 - Property and Equipment (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.cassavasciences.com/20241231/role/statement-note-5-property-and-equipment</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="sava20241231c_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>995572 - Disclosure - Note 6 - Intangible Assets (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cassavasciences.com/20241231/role/statement-note-6-intangible-assets-tables</Role>
      <ShortName>Note 6 - Intangible Assets (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.cassavasciences.com/20241231/role/statement-note-6-intangible-assets</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="sava20241231c_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>995573 - Disclosure - Note 7 - Stockholders' Equity and Stock-based Compensation (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cassavasciences.com/20241231/role/statement-note-7-stockholders-equity-and-stockbased-compensation-tables</Role>
      <ShortName>Note 7 - Stockholders' Equity and Stock-based Compensation (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.cassavasciences.com/20241231/role/statement-note-7-stockholders-equity-and-stockbased-compensation</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="sava20241231c_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>995574 - Disclosure - Note 9 - Income Taxes (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cassavasciences.com/20241231/role/statement-note-9-income-taxes-tables</Role>
      <ShortName>Note 9 - Income Taxes (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.cassavasciences.com/20241231/role/statement-note-9-income-taxes</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="sava20241231c_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>995575 - Disclosure - Note 13 - Warrant Dividend Distribution (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cassavasciences.com/20241231/role/statement-note-13-warrant-dividend-distribution-tables</Role>
      <ShortName>Note 13 - Warrant Dividend Distribution (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.cassavasciences.com/20241231/role/statement-note-13-warrant-dividend-distribution</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="sava20241231c_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>995576 - Disclosure - Note 1 - General, Liquidity and Basis of Presentation (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cassavasciences.com/20241231/role/statement-note-1-general-liquidity-and-basis-of-presentation-details-textual</Role>
      <ShortName>Note 1 - General, Liquidity and Basis of Presentation (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cassavasciences.com/20241231/role/statement-note-1-general-liquidity-and-basis-of-presentation</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="sava20241231c_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>995577 - Disclosure - Note 2 - Summary of Significant Accounting Policies (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cassavasciences.com/20241231/role/statement-note-2-summary-of-significant-accounting-policies-details-textual</Role>
      <ShortName>Note 2 - Summary of Significant Accounting Policies (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cassavasciences.com/20241231/role/statement-note-2-summary-of-significant-accounting-policies-tables</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="sava20241231c_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>995578 - Disclosure - Note 2 - Summary of Significant Accounting Policies - Quantitative Information of Warrants (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cassavasciences.com/20241231/role/statement-note-2-summary-of-significant-accounting-policies-quantitative-information-of-warrants-details</Role>
      <ShortName>Note 2 - Summary of Significant Accounting Policies - Quantitative Information of Warrants (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>34</Position>
    </Report>
    <Report instance="sava20241231c_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>995579 - Disclosure - Note 2 - Summary of Significant Accounting Policies - Summary Of CODM Segments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cassavasciences.com/20241231/role/statement-note-2-summary-of-significant-accounting-policies-summary-of-codm-segments-details</Role>
      <ShortName>Note 2 - Summary of Significant Accounting Policies - Summary Of CODM Segments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>35</Position>
    </Report>
    <Report instance="sava20241231c_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>995580 - Disclosure - Note 2 - Significant Accounting Policies - Calculation of Net Loss Per Share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cassavasciences.com/20241231/role/statement-note-2-significant-accounting-policies-calculation-of-net-loss-per-share-details</Role>
      <ShortName>Note 2 - Significant Accounting Policies - Calculation of Net Loss Per Share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>36</Position>
    </Report>
    <Report instance="sava20241231c_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>995581 - Disclosure - Note 3 - Prepaid Expenses and Other Current Assets - Prepaid Expenses and Other Current Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cassavasciences.com/20241231/role/statement-note-3-prepaid-expenses-and-other-current-assets-prepaid-expenses-and-other-current-assets-details</Role>
      <ShortName>Note 3 - Prepaid Expenses and Other Current Assets - Prepaid Expenses and Other Current Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>37</Position>
    </Report>
    <Report instance="sava20241231c_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>995582 - Disclosure - Note 4 - Real Property and Other Income, Expense (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cassavasciences.com/20241231/role/statement-note-4-real-property-and-other-income-expense-details-textual</Role>
      <ShortName>Note 4 - Real Property and Other Income, Expense (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cassavasciences.com/20241231/role/statement-note-4-real-property-and-other-income-expense-tables</ParentRole>
      <Position>38</Position>
    </Report>
    <Report instance="sava20241231c_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>995583 - Disclosure - Note 4 - Real Property and Other Income, Expense - Components of Other Income, Net (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cassavasciences.com/20241231/role/statement-note-4-real-property-and-other-income-expense-components-of-other-income-net-details</Role>
      <ShortName>Note 4 - Real Property and Other Income, Expense - Components of Other Income, Net (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="sava20241231c_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>995584 - Disclosure - Note 5 - Property and Equipment (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cassavasciences.com/20241231/role/statement-note-5-property-and-equipment-details-textual</Role>
      <ShortName>Note 5 - Property and Equipment (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cassavasciences.com/20241231/role/statement-note-5-property-and-equipment-tables</ParentRole>
      <Position>40</Position>
    </Report>
    <Report instance="sava20241231c_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>995585 - Disclosure - Note 5 - Property and Equipment - Components of Property and Equipment (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cassavasciences.com/20241231/role/statement-note-5-property-and-equipment-components-of-property-and-equipment-details</Role>
      <ShortName>Note 5 - Property and Equipment - Components of Property and Equipment (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="sava20241231c_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>995586 - Disclosure - Note 6 - Intangible Assets (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cassavasciences.com/20241231/role/statement-note-6-intangible-assets-details-textual</Role>
      <ShortName>Note 6 - Intangible Assets (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cassavasciences.com/20241231/role/statement-note-6-intangible-assets-tables</ParentRole>
      <Position>42</Position>
    </Report>
    <Report instance="sava20241231c_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>995587 - Disclosure - Note 6 - Intangible Assets - Components of Intangible Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cassavasciences.com/20241231/role/statement-note-6-intangible-assets-components-of-intangible-assets-details</Role>
      <ShortName>Note 6 - Intangible Assets - Components of Intangible Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="sava20241231c_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>995588 - Disclosure - Note 6 - Intangible Assets - Amortization Expense for Finite-lived Intangible Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cassavasciences.com/20241231/role/statement-note-6-intangible-assets-amortization-expense-for-finitelived-intangible-assets-details</Role>
      <ShortName>Note 6 - Intangible Assets - Amortization Expense for Finite-lived Intangible Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="sava20241231c_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>995589 - Disclosure - Note 7 - Stockholders' Equity and Stock-based Compensation (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cassavasciences.com/20241231/role/statement-note-7-stockholders-equity-and-stockbased-compensation-details-textual</Role>
      <ShortName>Note 7 - Stockholders' Equity and Stock-based Compensation (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cassavasciences.com/20241231/role/statement-note-7-stockholders-equity-and-stockbased-compensation-tables</ParentRole>
      <Position>45</Position>
    </Report>
    <Report instance="sava20241231c_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>995590 - Disclosure - Note 7 - Stockholders' Equity and Stock-based Compensation - Stock Option Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cassavasciences.com/20241231/role/statement-note-7-stockholders-equity-and-stockbased-compensation-stock-option-activity-details</Role>
      <ShortName>Note 7 - Stockholders' Equity and Stock-based Compensation - Stock Option Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>46</Position>
    </Report>
    <Report instance="sava20241231c_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>995591 - Disclosure - Note 7 - Stockholders' Equity and Stock-based Compensation - Schedule of Stock Options by Exercise Price (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cassavasciences.com/20241231/role/statement-note-7-stockholders-equity-and-stockbased-compensation-schedule-of-stock-options-by-exercise-price-details</Role>
      <ShortName>Note 7 - Stockholders' Equity and Stock-based Compensation - Schedule of Stock Options by Exercise Price (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>47</Position>
    </Report>
    <Report instance="sava20241231c_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>995592 - Disclosure - Note 7 - Stockholders' Equity and Stock-based Compensation - Stock Option Valuation Assumptions (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cassavasciences.com/20241231/role/statement-note-7-stockholders-equity-and-stockbased-compensation-stock-option-valuation-assumptions-details</Role>
      <ShortName>Note 7 - Stockholders' Equity and Stock-based Compensation - Stock Option Valuation Assumptions (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>48</Position>
    </Report>
    <Report instance="sava20241231c_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>995593 - Disclosure - Note 7 - Stockholders' Equity and Stock-based Compensation - Stock Option and Performance Award Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cassavasciences.com/20241231/role/statement-note-7-stockholders-equity-and-stockbased-compensation-stock-option-and-performance-award-activity-details</Role>
      <ShortName>Note 7 - Stockholders' Equity and Stock-based Compensation - Stock Option and Performance Award Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>49</Position>
    </Report>
    <Report instance="sava20241231c_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>995594 - Disclosure - Note 7 - Stockholders' Equity and Stock-based Compensation - Stock-based Compensation Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cassavasciences.com/20241231/role/statement-note-7-stockholders-equity-and-stockbased-compensation-stockbased-compensation-expense-details</Role>
      <ShortName>Note 7 - Stockholders' Equity and Stock-based Compensation - Stock-based Compensation Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>50</Position>
    </Report>
    <Report instance="sava20241231c_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>995595 - Disclosure - Note 9 - Income Taxes (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cassavasciences.com/20241231/role/statement-note-9-income-taxes-details-textual</Role>
      <ShortName>Note 9 - Income Taxes (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cassavasciences.com/20241231/role/statement-note-9-income-taxes-tables</ParentRole>
      <Position>51</Position>
    </Report>
    <Report instance="sava20241231c_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>995596 - Disclosure - Note 9 - Income Taxes - Schedule of Effective Income Tax Reconciliation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cassavasciences.com/20241231/role/statement-note-9-income-taxes-schedule-of-effective-income-tax-reconciliation-details</Role>
      <ShortName>Note 9 - Income Taxes - Schedule of Effective Income Tax Reconciliation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>52</Position>
    </Report>
    <Report instance="sava20241231c_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>995597 - Disclosure - Note 9 - Income Taxes - Schedule of Deferred Tax Assets and Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cassavasciences.com/20241231/role/statement-note-9-income-taxes-schedule-of-deferred-tax-assets-and-liabilities-details</Role>
      <ShortName>Note 9 - Income Taxes - Schedule of Deferred Tax Assets and Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>53</Position>
    </Report>
    <Report instance="sava20241231c_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>995598 - Disclosure - Note 9 - Income Taxes - Schedule of Unrecognized Tax Benefits (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cassavasciences.com/20241231/role/statement-note-9-income-taxes-schedule-of-unrecognized-tax-benefits-details</Role>
      <ShortName>Note 9 - Income Taxes - Schedule of Unrecognized Tax Benefits (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>54</Position>
    </Report>
    <Report instance="sava20241231c_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>995599 - Disclosure - Note 10 - Commitments (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cassavasciences.com/20241231/role/statement-note-10-commitments-details-textual</Role>
      <ShortName>Note 10 - Commitments (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cassavasciences.com/20241231/role/statement-note-10-commitments</ParentRole>
      <Position>55</Position>
    </Report>
    <Report instance="sava20241231c_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>995600 - Disclosure - Note 11 - 2020 Cash Incentive Bonus Plan (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cassavasciences.com/20241231/role/statement-note-11-2020-cash-incentive-bonus-plan-details-textual</Role>
      <ShortName>Note 11 - 2020 Cash Incentive Bonus Plan (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cassavasciences.com/20241231/role/statement-note-11-2020-cash-incentive-bonus-plan</ParentRole>
      <Position>56</Position>
    </Report>
    <Report instance="sava20241231c_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>995601 - Disclosure - Note 12 - Contingencies (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cassavasciences.com/20241231/role/statement-note-12-contingencies-details-textual</Role>
      <ShortName>Note 12 - Contingencies (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cassavasciences.com/20241231/role/statement-note-12-contingencies</ParentRole>
      <Position>57</Position>
    </Report>
    <Report instance="sava20241231c_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>995602 - Disclosure - Note 13 - Warrant Dividend Distribution (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cassavasciences.com/20241231/role/statement-note-13-warrant-dividend-distribution-details-textual</Role>
      <ShortName>Note 13 - Warrant Dividend Distribution (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cassavasciences.com/20241231/role/statement-note-13-warrant-dividend-distribution-tables</ParentRole>
      <Position>58</Position>
    </Report>
    <Report instance="sava20241231c_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>995603 - Disclosure - Note 13 - Warrant Dividend Distribution - Changes in Warrants Outstanding and Warrant Liability (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cassavasciences.com/20241231/role/statement-note-13-warrant-dividend-distribution-changes-in-warrants-outstanding-and-warrant-liability-details</Role>
      <ShortName>Note 13 - Warrant Dividend Distribution - Changes in Warrants Outstanding and Warrant Liability (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>59</Position>
    </Report>
    <Report instance="sava20241231c_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>995604 - Disclosure - Note 14 - Subsequent Event (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cassavasciences.com/20241231/role/statement-note-14-subsequent-event-details-textual</Role>
      <ShortName>Note 14 - Subsequent Event (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cassavasciences.com/20241231/role/statement-note-14-subsequent-event</ParentRole>
      <Position>60</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File>sava-20241231.xsd</File>
    <File>sava-20241231_cal.xml</File>
    <File>sava-20241231_def.xml</File>
    <File>sava-20241231_lab.xml</File>
    <File>sava-20241231_pre.xml</File>
    <File doctype="10-K" isDefinitelyFs="true" isUsgaap="true" original="sava20241231c_10k.htm">sava20241231c_10k.htm</File>
  </InputFiles>
  <SupplementalFiles>
    <File>cab1ac4300e0img001.jpg</File>
    <File>cms.jpg</File>
    <File>slide03.jpg</File>
    <File>slide04.jpg</File>
    <File>slide05.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="651">http://fasb.org/us-gaap/2024</BaseTaxonomy>
    <BaseTaxonomy items="11">http://xbrl.sec.gov/cyd/2024</BaseTaxonomy>
    <BaseTaxonomy items="37">http://xbrl.sec.gov/dei/2024</BaseTaxonomy>
    <BaseTaxonomy items="4">http://xbrl.sec.gov/ecd/2024</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>91
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "sava20241231c_10k.htm": {
   "nsprefix": "sava",
   "nsuri": "http://www.cassavasciences.com/20241231",
   "dts": {
    "schema": {
     "local": [
      "sava-20241231.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-roles-2024.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-types-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-roles-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd",
      "https://xbrl.sec.gov/country/2024/country-2024.xsd",
      "https://xbrl.sec.gov/currency/2024/currency-2024.xsd",
      "https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd",
      "https://xbrl.sec.gov/cyd/2024/cyd-af-2024.xsd",
      "https://xbrl.sec.gov/cyd/2024/cyd-af-sub-2024.xsd",
      "https://xbrl.sec.gov/dei/2024/dei-2024.xsd",
      "https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd",
      "https://xbrl.sec.gov/exch/2024/exch-2024.xsd",
      "https://xbrl.sec.gov/naics/2024/naics-2024.xsd",
      "https://xbrl.sec.gov/sic/2024/sic-2024.xsd",
      "https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd"
     ]
    },
    "calculationLink": {
     "local": [
      "sava-20241231_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "sava-20241231_def.xml"
     ]
    },
    "labelLink": {
     "local": [
      "sava-20241231_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "sava-20241231_pre.xml"
     ]
    },
    "inline": {
     "local": [
      "sava20241231c_10k.htm"
     ]
    }
   },
   "keyStandard": 277,
   "keyCustom": 45,
   "axisStandard": 28,
   "axisCustom": 0,
   "memberStandard": 33,
   "memberCustom": 27,
   "hidden": {
    "total": 72,
    "http://fasb.org/us-gaap/2024": 53,
    "http://xbrl.sec.gov/ecd/2024": 4,
    "http://xbrl.sec.gov/cyd/2024": 5,
    "http://xbrl.sec.gov/dei/2024": 6,
    "http://www.cassavasciences.com/20241231": 4
   },
   "contextCount": 185,
   "entityCount": 1,
   "segmentCount": 62,
   "elementCount": 500,
   "unitCount": 8,
   "baseTaxonomies": {
    "http://fasb.org/us-gaap/2024": 651,
    "http://xbrl.sec.gov/dei/2024": 37,
    "http://xbrl.sec.gov/cyd/2024": 11,
    "http://xbrl.sec.gov/ecd/2024": 4
   },
   "report": {
    "R1": {
     "role": "http://www.cassavasciences.com/20241231/role/statement-document-and-entity-information",
     "longName": "000 - Document - Document And Entity Information",
     "shortName": "Document And Entity Information",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "d_2024-01-01_2024-12-31",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "b",
       "p",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sava20241231c_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "d_2024-01-01_2024-12-31",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "b",
       "p",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sava20241231c_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R2": {
     "role": "http://www.cassavasciences.com/20241231/role/statement-consolidated-balance-sheets",
     "longName": "001 - Statement - Consolidated Balance Sheets",
     "shortName": "Consolidated Balance Sheets",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "2",
     "firstAnchor": {
      "contextRef": "i_2024-12-31",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sava20241231c_10k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "i_2024-12-31",
      "name": "us-gaap:AssetsCurrent",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sava20241231c_10k.htm",
      "unique": true
     }
    },
    "R3": {
     "role": "http://www.cassavasciences.com/20241231/role/statement-consolidated-balance-sheets-parentheticals",
     "longName": "002 - Statement - Consolidated Balance Sheets (Parentheticals)",
     "shortName": "Consolidated Balance Sheets (Parentheticals)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "parenthetical",
     "menuCat": "Statements",
     "order": "3",
     "firstAnchor": null,
     "uniqueAnchor": null
    },
    "R4": {
     "role": "http://www.cassavasciences.com/20241231/role/statement-consolidated-statements-of-operations-",
     "longName": "003 - Statement - Consolidated Statements of Operations",
     "shortName": "Consolidated Statements of Operations",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "4",
     "firstAnchor": {
      "contextRef": "d_2024-01-01_2024-12-31",
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sava20241231c_10k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "d_2024-01-01_2024-12-31",
      "name": "us-gaap:OperatingExpenses",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sava20241231c_10k.htm",
      "unique": true
     }
    },
    "R5": {
     "role": "http://www.cassavasciences.com/20241231/role/statement-consolidated-statements-of-stockholders-equity",
     "longName": "004 - Statement - Consolidated Statements of Stockholders' Equity",
     "shortName": "Consolidated Statements of Stockholders' Equity",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "5",
     "firstAnchor": {
      "contextRef": "i_2021-12-31_StatementEquityComponentsAxis-CommonStockMember",
      "name": "us-gaap:SharesOutstanding",
      "unitRef": "Share",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sava20241231c_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "i_2021-12-31_StatementEquityComponentsAxis-CommonStockMember",
      "name": "us-gaap:SharesOutstanding",
      "unitRef": "Share",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sava20241231c_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R6": {
     "role": "http://www.cassavasciences.com/20241231/role/statement-consolidated-statements-of-cash-flows",
     "longName": "005 - Statement - Consolidated Statements of Cash Flows",
     "shortName": "Consolidated Statements of Cash Flows",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "6",
     "firstAnchor": {
      "contextRef": "d_2024-01-01_2024-12-31",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sava20241231c_10k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "d_2024-01-01_2024-12-31",
      "name": "us-gaap:ShareBasedCompensation",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sava20241231c_10k.htm",
      "unique": true
     }
    },
    "R7": {
     "role": "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
     "longName": "995445 - Disclosure - Insider Trading Arrangements",
     "shortName": "Insider Trading Arrangements",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "7",
     "firstAnchor": null,
     "uniqueAnchor": null
    },
    "R8": {
     "role": "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure",
     "longName": "995550 - Disclosure - Cybersecurity Risk Management and Strategy Disclosure",
     "shortName": "Cybersecurity Risk Management and Strategy Disclosure",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "8",
     "firstAnchor": {
      "contextRef": "d_2024-01-01_2024-12-31",
      "name": "cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sava20241231c_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "d_2024-01-01_2024-12-31",
      "name": "cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sava20241231c_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R9": {
     "role": "http://www.cassavasciences.com/20241231/role/statement-note-1-general-liquidity-and-basis-of-presentation",
     "longName": "995552 - Disclosure - Note 1 - General, Liquidity and Basis of Presentation",
     "shortName": "Note 1 - General, Liquidity and Basis of Presentation",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "9",
     "firstAnchor": {
      "contextRef": "d_2024-01-01_2024-12-31",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sava20241231c_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "d_2024-01-01_2024-12-31",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sava20241231c_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R10": {
     "role": "http://www.cassavasciences.com/20241231/role/statement-note-2-summary-of-significant-accounting-policies",
     "longName": "995553 - Disclosure - Note 2 - Summary of Significant Accounting Policies",
     "shortName": "Note 2 - Summary of Significant Accounting Policies",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "10",
     "firstAnchor": {
      "contextRef": "d_2024-01-01_2024-12-31",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sava20241231c_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "d_2024-01-01_2024-12-31",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sava20241231c_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R11": {
     "role": "http://www.cassavasciences.com/20241231/role/statement-note-3-prepaid-expenses-and-other-current-assets",
     "longName": "995554 - Disclosure - Note 3 - Prepaid Expenses and Other Current Assets",
     "shortName": "Note 3 - Prepaid Expenses and Other Current Assets",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "11",
     "firstAnchor": {
      "contextRef": "d_2024-01-01_2024-12-31",
      "name": "sava:PrepaidExpensesAndOtherCurrentAssetsTextBock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sava20241231c_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "d_2024-01-01_2024-12-31",
      "name": "sava:PrepaidExpensesAndOtherCurrentAssetsTextBock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sava20241231c_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R12": {
     "role": "http://www.cassavasciences.com/20241231/role/statement-note-4-real-property-and-other-income-expense",
     "longName": "995555 - Disclosure - Note 4 - Real Property and Other Income, Expense",
     "shortName": "Note 4 - Real Property and Other Income, Expense",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "12",
     "firstAnchor": {
      "contextRef": "d_2024-01-01_2024-12-31",
      "name": "us-gaap:RealEstateOwnedTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sava20241231c_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "d_2024-01-01_2024-12-31",
      "name": "us-gaap:RealEstateOwnedTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sava20241231c_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R13": {
     "role": "http://www.cassavasciences.com/20241231/role/statement-note-5-property-and-equipment",
     "longName": "995556 - Disclosure - Note 5 - Property and Equipment",
     "shortName": "Note 5 - Property and Equipment",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "13",
     "firstAnchor": {
      "contextRef": "d_2024-01-01_2024-12-31",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sava20241231c_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "d_2024-01-01_2024-12-31",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sava20241231c_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R14": {
     "role": "http://www.cassavasciences.com/20241231/role/statement-note-6-intangible-assets",
     "longName": "995557 - Disclosure - Note 6 - Intangible Assets",
     "shortName": "Note 6 - Intangible Assets",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "14",
     "firstAnchor": {
      "contextRef": "d_2024-01-01_2024-12-31",
      "name": "us-gaap:IntangibleAssetsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sava20241231c_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "d_2024-01-01_2024-12-31",
      "name": "us-gaap:IntangibleAssetsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sava20241231c_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R15": {
     "role": "http://www.cassavasciences.com/20241231/role/statement-note-7-stockholders-equity-and-stockbased-compensation",
     "longName": "995558 - Disclosure - Note 7 - Stockholders' Equity and Stock-based Compensation",
     "shortName": "Note 7 - Stockholders' Equity and Stock-based Compensation",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "15",
     "firstAnchor": {
      "contextRef": "d_2024-01-01_2024-12-31",
      "name": "us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sava20241231c_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "d_2024-01-01_2024-12-31",
      "name": "us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sava20241231c_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R16": {
     "role": "http://www.cassavasciences.com/20241231/role/statement-note-8-employee-401k-benefit-plan",
     "longName": "995559 - Disclosure - Note 8 - Employee 401(k) Benefit Plan",
     "shortName": "Note 8 - Employee 401(k) Benefit Plan",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "16",
     "firstAnchor": {
      "contextRef": "d_2024-01-01_2024-12-31",
      "name": "us-gaap:CompensationAndEmployeeBenefitPlansTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sava20241231c_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "d_2024-01-01_2024-12-31",
      "name": "us-gaap:CompensationAndEmployeeBenefitPlansTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sava20241231c_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R17": {
     "role": "http://www.cassavasciences.com/20241231/role/statement-note-9-income-taxes",
     "longName": "995560 - Disclosure - Note 9 - Income Taxes",
     "shortName": "Note 9 - Income Taxes",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "17",
     "firstAnchor": {
      "contextRef": "d_2024-01-01_2024-12-31",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sava20241231c_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "d_2024-01-01_2024-12-31",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sava20241231c_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R18": {
     "role": "http://www.cassavasciences.com/20241231/role/statement-note-10-commitments",
     "longName": "995561 - Disclosure - Note 10 - Commitments",
     "shortName": "Note 10 - Commitments",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "18",
     "firstAnchor": {
      "contextRef": "d_2024-01-01_2024-12-31",
      "name": "sava:LeasesAndCommitmentsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sava20241231c_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "d_2024-01-01_2024-12-31",
      "name": "sava:LeasesAndCommitmentsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sava20241231c_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R19": {
     "role": "http://www.cassavasciences.com/20241231/role/statement-note-11-2020-cash-incentive-bonus-plan",
     "longName": "995562 - Disclosure - Note 11 - 2020 Cash Incentive Bonus Plan",
     "shortName": "Note 11 - 2020 Cash Incentive Bonus Plan",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "19",
     "firstAnchor": {
      "contextRef": "d_2024-01-01_2024-12-31",
      "name": "sava:CashIncentiveBonusPlanTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sava20241231c_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "d_2024-01-01_2024-12-31",
      "name": "sava:CashIncentiveBonusPlanTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sava20241231c_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R20": {
     "role": "http://www.cassavasciences.com/20241231/role/statement-note-12-contingencies",
     "longName": "995563 - Disclosure - Note 12 - Contingencies",
     "shortName": "Note 12 - Contingencies",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "20",
     "firstAnchor": {
      "contextRef": "d_2024-01-01_2024-12-31",
      "name": "us-gaap:LossContingencyDisclosures",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sava20241231c_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "d_2024-01-01_2024-12-31",
      "name": "us-gaap:LossContingencyDisclosures",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sava20241231c_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R21": {
     "role": "http://www.cassavasciences.com/20241231/role/statement-note-13-warrant-dividend-distribution",
     "longName": "995564 - Disclosure - Note 13 - Warrant Dividend Distribution",
     "shortName": "Note 13 - Warrant Dividend Distribution",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "21",
     "firstAnchor": {
      "contextRef": "d_2024-01-01_2024-12-31",
      "name": "sava:WarrantDividendDistributionTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sava20241231c_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "d_2024-01-01_2024-12-31",
      "name": "sava:WarrantDividendDistributionTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sava20241231c_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R22": {
     "role": "http://www.cassavasciences.com/20241231/role/statement-note-14-subsequent-event",
     "longName": "995565 - Disclosure - Note 14 - Subsequent Event",
     "shortName": "Note 14 - Subsequent Event",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "22",
     "firstAnchor": {
      "contextRef": "d_2024-01-01_2024-12-31",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sava20241231c_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "d_2024-01-01_2024-12-31",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sava20241231c_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R23": {
     "role": "http://www.cassavasciences.com/20241231/role/statement-significant-accounting-policies-policies",
     "longName": "995567 - Disclosure - Significant Accounting Policies (Policies)",
     "shortName": "Significant Accounting Policies (Policies)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "policies",
     "menuCat": "Policies",
     "order": "23",
     "firstAnchor": {
      "contextRef": "d_2024-01-01_2024-12-31",
      "name": "us-gaap:UseOfEstimates",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sava20241231c_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "d_2024-01-01_2024-12-31",
      "name": "us-gaap:UseOfEstimates",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sava20241231c_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R24": {
     "role": "http://www.cassavasciences.com/20241231/role/statement-note-2-summary-of-significant-accounting-policies-tables",
     "longName": "995568 - Disclosure - Note 2 - Summary of Significant Accounting Policies (Tables)",
     "shortName": "Note 2 - Summary of Significant Accounting Policies (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "24",
     "firstAnchor": {
      "contextRef": "d_2024-01-01_2024-12-31",
      "name": "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:FairValueMeasurementPolicyPolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sava20241231c_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "d_2024-01-01_2024-12-31",
      "name": "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:FairValueMeasurementPolicyPolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sava20241231c_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R25": {
     "role": "http://www.cassavasciences.com/20241231/role/statement-note-3-prepaid-expenses-and-other-current-assets-tables",
     "longName": "995569 - Disclosure - Note 3 - Prepaid Expenses and Other Current Assets (Tables)",
     "shortName": "Note 3 - Prepaid Expenses and Other Current Assets (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "25",
     "firstAnchor": {
      "contextRef": "d_2024-01-01_2024-12-31",
      "name": "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "sava:PrepaidExpensesAndOtherCurrentAssetsTextBock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sava20241231c_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "d_2024-01-01_2024-12-31",
      "name": "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "sava:PrepaidExpensesAndOtherCurrentAssetsTextBock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sava20241231c_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R26": {
     "role": "http://www.cassavasciences.com/20241231/role/statement-note-4-real-property-and-other-income-expense-tables",
     "longName": "995570 - Disclosure - Note 4 - Real Property and Other Income, Expense (Tables)",
     "shortName": "Note 4 - Real Property and Other Income, Expense (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "26",
     "firstAnchor": {
      "contextRef": "d_2024-01-01_2024-12-31",
      "name": "us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:RealEstateOwnedTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sava20241231c_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "d_2024-01-01_2024-12-31",
      "name": "us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:RealEstateOwnedTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sava20241231c_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R27": {
     "role": "http://www.cassavasciences.com/20241231/role/statement-note-5-property-and-equipment-tables",
     "longName": "995571 - Disclosure - Note 5 - Property and Equipment (Tables)",
     "shortName": "Note 5 - Property and Equipment (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "27",
     "firstAnchor": {
      "contextRef": "d_2024-01-01_2024-12-31",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sava20241231c_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "d_2024-01-01_2024-12-31",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sava20241231c_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R28": {
     "role": "http://www.cassavasciences.com/20241231/role/statement-note-6-intangible-assets-tables",
     "longName": "995572 - Disclosure - Note 6 - Intangible Assets (Tables)",
     "shortName": "Note 6 - Intangible Assets (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "28",
     "firstAnchor": {
      "contextRef": "d_2024-01-01_2024-12-31",
      "name": "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:IntangibleAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sava20241231c_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "d_2024-01-01_2024-12-31",
      "name": "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:IntangibleAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sava20241231c_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R29": {
     "role": "http://www.cassavasciences.com/20241231/role/statement-note-7-stockholders-equity-and-stockbased-compensation-tables",
     "longName": "995573 - Disclosure - Note 7 - Stockholders' Equity and Stock-based Compensation (Tables)",
     "shortName": "Note 7 - Stockholders' Equity and Stock-based Compensation (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "29",
     "firstAnchor": {
      "contextRef": "d_2024-01-01_2024-12-31",
      "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sava20241231c_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "d_2024-01-01_2024-12-31",
      "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sava20241231c_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R30": {
     "role": "http://www.cassavasciences.com/20241231/role/statement-note-9-income-taxes-tables",
     "longName": "995574 - Disclosure - Note 9 - Income Taxes (Tables)",
     "shortName": "Note 9 - Income Taxes (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "30",
     "firstAnchor": {
      "contextRef": "d_2024-01-01_2024-12-31",
      "name": "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sava20241231c_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "d_2024-01-01_2024-12-31",
      "name": "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sava20241231c_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R31": {
     "role": "http://www.cassavasciences.com/20241231/role/statement-note-13-warrant-dividend-distribution-tables",
     "longName": "995575 - Disclosure - Note 13 - Warrant Dividend Distribution (Tables)",
     "shortName": "Note 13 - Warrant Dividend Distribution (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "31",
     "firstAnchor": {
      "contextRef": "d_2024-01-01_2024-12-31",
      "name": "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "sava:WarrantDividendDistributionTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sava20241231c_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "d_2024-01-01_2024-12-31",
      "name": "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "sava:WarrantDividendDistributionTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sava20241231c_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R32": {
     "role": "http://www.cassavasciences.com/20241231/role/statement-note-1-general-liquidity-and-basis-of-presentation-details-textual",
     "longName": "995576 - Disclosure - Note 1 - General, Liquidity and Basis of Presentation (Details Textual)",
     "shortName": "Note 1 - General, Liquidity and Basis of Presentation (Details Textual)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "32",
     "firstAnchor": {
      "contextRef": "i_2024-12-31",
      "name": "us-gaap:RetainedEarningsAccumulatedDeficit",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sava20241231c_10k.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R33": {
     "role": "http://www.cassavasciences.com/20241231/role/statement-note-2-summary-of-significant-accounting-policies-details-textual",
     "longName": "995577 - Disclosure - Note 2 - Summary of Significant Accounting Policies (Details Textual)",
     "shortName": "Note 2 - Summary of Significant Accounting Policies (Details Textual)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "33",
     "firstAnchor": {
      "contextRef": "d_2024-01-01_2024-12-31",
      "name": "us-gaap:GovernmentAssistanceAmount",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "us-gaap:GovernmentAssistancePolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sava20241231c_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "d_2024-01-01_2024-12-31",
      "name": "us-gaap:GovernmentAssistanceAmount",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "us-gaap:GovernmentAssistancePolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sava20241231c_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R34": {
     "role": "http://www.cassavasciences.com/20241231/role/statement-note-2-summary-of-significant-accounting-policies-quantitative-information-of-warrants-details",
     "longName": "995578 - Disclosure - Note 2 - Summary of Significant Accounting Policies - Quantitative Information of Warrants (Details)",
     "shortName": "Note 2 - Summary of Significant Accounting Policies - Quantitative Information of Warrants (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "34",
     "firstAnchor": {
      "contextRef": "i_2024-12-31_ClassOfWarrantOrRightAxis-WarrantsToPurchaseCommonStockMember_MeasurementInputTypeAxis-MeasurementInputExercisePriceMember",
      "name": "us-gaap:WarrantsAndRightsOutstandingMeasurementInput",
      "unitRef": "Pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock",
       "us-gaap:FairValueMeasurementPolicyPolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sava20241231c_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "i_2024-12-31_ClassOfWarrantOrRightAxis-WarrantsToPurchaseCommonStockMember_MeasurementInputTypeAxis-MeasurementInputExercisePriceMember",
      "name": "us-gaap:WarrantsAndRightsOutstandingMeasurementInput",
      "unitRef": "Pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock",
       "us-gaap:FairValueMeasurementPolicyPolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sava20241231c_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R35": {
     "role": "http://www.cassavasciences.com/20241231/role/statement-note-2-summary-of-significant-accounting-policies-summary-of-codm-segments-details",
     "longName": "995579 - Disclosure - Note 2 - Summary of Significant Accounting Policies - Summary Of CODM Segments (Details)",
     "shortName": "Note 2 - Summary of Significant Accounting Policies - Summary Of CODM Segments (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "35",
     "firstAnchor": {
      "contextRef": "d_2024-01-01_2024-12-31",
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sava20241231c_10k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "d_2024-01-01_2024-12-31_StatementBusinessSegmentsAxis-CodmMonitoringMember",
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
       "us-gaap:SegmentReportingPolicyPolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sava20241231c_10k.htm",
      "unique": true
     }
    },
    "R36": {
     "role": "http://www.cassavasciences.com/20241231/role/statement-note-2-significant-accounting-policies-calculation-of-net-loss-per-share-details",
     "longName": "995580 - Disclosure - Note 2 - Significant Accounting Policies - Calculation of Net Loss Per Share (Details)",
     "shortName": "Note 2 - Significant Accounting Policies - Calculation of Net Loss Per Share (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "36",
     "firstAnchor": {
      "contextRef": "d_2024-01-01_2024-12-31",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sava20241231c_10k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "d_2024-01-01_2024-12-31",
      "name": "us-gaap:DilutiveSecurities",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
       "us-gaap:EarningsPerSharePolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sava20241231c_10k.htm",
      "unique": true
     }
    },
    "R37": {
     "role": "http://www.cassavasciences.com/20241231/role/statement-note-3-prepaid-expenses-and-other-current-assets-prepaid-expenses-and-other-current-assets-details",
     "longName": "995581 - Disclosure - Note 3 - Prepaid Expenses and Other Current Assets - Prepaid Expenses and Other Current Assets (Details)",
     "shortName": "Note 3 - Prepaid Expenses and Other Current Assets - Prepaid Expenses and Other Current Assets (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "37",
     "firstAnchor": {
      "contextRef": "i_2024-12-31",
      "name": "us-gaap:PrepaidInsurance",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock",
       "sava:PrepaidExpensesAndOtherCurrentAssetsTextBock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sava20241231c_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "i_2024-12-31",
      "name": "us-gaap:PrepaidInsurance",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock",
       "sava:PrepaidExpensesAndOtherCurrentAssetsTextBock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sava20241231c_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R38": {
     "role": "http://www.cassavasciences.com/20241231/role/statement-note-4-real-property-and-other-income-expense-details-textual",
     "longName": "995582 - Disclosure - Note 4 - Real Property and Other Income, Expense (Details Textual)",
     "shortName": "Note 4 - Real Property and Other Income, Expense (Details Textual)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "38",
     "firstAnchor": {
      "contextRef": "i_2024-12-31",
      "name": "us-gaap:LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "p",
       "us-gaap:RealEstateOwnedTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sava20241231c_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "i_2024-12-31",
      "name": "us-gaap:LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "p",
       "us-gaap:RealEstateOwnedTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sava20241231c_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R39": {
     "role": "http://www.cassavasciences.com/20241231/role/statement-note-4-real-property-and-other-income-expense-components-of-other-income-net-details",
     "longName": "995583 - Disclosure - Note 4 - Real Property and Other Income, Expense - Components of Other Income, Net (Details)",
     "shortName": "Note 4 - Real Property and Other Income, Expense - Components of Other Income, Net (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "39",
     "firstAnchor": {
      "contextRef": "d_2024-01-01_2024-12-31",
      "name": "us-gaap:OtherNonoperatingIncome",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock",
       "us-gaap:RealEstateOwnedTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sava20241231c_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "d_2024-01-01_2024-12-31",
      "name": "us-gaap:OtherNonoperatingIncome",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock",
       "us-gaap:RealEstateOwnedTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sava20241231c_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R40": {
     "role": "http://www.cassavasciences.com/20241231/role/statement-note-5-property-and-equipment-details-textual",
     "longName": "995584 - Disclosure - Note 5 - Property and Equipment (Details Textual)",
     "shortName": "Note 5 - Property and Equipment (Details Textual)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "40",
     "firstAnchor": {
      "contextRef": "d_2024-01-01_2024-12-31",
      "name": "us-gaap:Depreciation",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sava20241231c_10k.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R41": {
     "role": "http://www.cassavasciences.com/20241231/role/statement-note-5-property-and-equipment-components-of-property-and-equipment-details",
     "longName": "995585 - Disclosure - Note 5 - Property and Equipment - Components of Property and Equipment (Details)",
     "shortName": "Note 5 - Property and Equipment - Components of Property and Equipment (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "41",
     "firstAnchor": {
      "contextRef": "i_2024-12-31",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sava20241231c_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "i_2024-12-31",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sava20241231c_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R42": {
     "role": "http://www.cassavasciences.com/20241231/role/statement-note-6-intangible-assets-details-textual",
     "longName": "995586 - Disclosure - Note 6 - Intangible Assets (Details Textual)",
     "shortName": "Note 6 - Intangible Assets (Details Textual)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "42",
     "firstAnchor": {
      "contextRef": "d_2024-01-01_2024-12-31",
      "name": "us-gaap:AmortizationOfIntangibleAssets",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "us-gaap:IntangibleAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sava20241231c_10k.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R43": {
     "role": "http://www.cassavasciences.com/20241231/role/statement-note-6-intangible-assets-components-of-intangible-assets-details",
     "longName": "995587 - Disclosure - Note 6 - Intangible Assets - Components of Intangible Assets (Details)",
     "shortName": "Note 6 - Intangible Assets - Components of Intangible Assets (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "43",
     "firstAnchor": {
      "contextRef": "i_2024-12-31",
      "name": "us-gaap:FiniteLivedIntangibleAssetsGross",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
       "us-gaap:IntangibleAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sava20241231c_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "i_2024-12-31",
      "name": "us-gaap:FiniteLivedIntangibleAssetsGross",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
       "us-gaap:IntangibleAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sava20241231c_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R44": {
     "role": "http://www.cassavasciences.com/20241231/role/statement-note-6-intangible-assets-amortization-expense-for-finitelived-intangible-assets-details",
     "longName": "995588 - Disclosure - Note 6 - Intangible Assets - Amortization Expense for Finite-lived Intangible Assets (Details)",
     "shortName": "Note 6 - Intangible Assets - Amortization Expense for Finite-lived Intangible Assets (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "44",
     "firstAnchor": {
      "contextRef": "i_2024-12-31",
      "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock",
       "us-gaap:IntangibleAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sava20241231c_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "i_2024-12-31",
      "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock",
       "us-gaap:IntangibleAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sava20241231c_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R45": {
     "role": "http://www.cassavasciences.com/20241231/role/statement-note-7-stockholders-equity-and-stockbased-compensation-details-textual",
     "longName": "995589 - Disclosure - Note 7 - Stockholders' Equity and Stock-based Compensation (Details Textual)",
     "shortName": "Note 7 - Stockholders' Equity and Stock-based Compensation (Details Textual)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "45",
     "firstAnchor": {
      "contextRef": "d_2024-01-01_2024-12-31",
      "name": "us-gaap:ProceedsFromIssuanceOfCommonStock",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sava20241231c_10k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "d_2024-01-01_2024-12-31",
      "name": "sava:StockOptionsExercisedNetSettledSatisfactionOfExercisePrice",
      "unitRef": "Share",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sava20241231c_10k.htm",
      "unique": true
     }
    },
    "R46": {
     "role": "http://www.cassavasciences.com/20241231/role/statement-note-7-stockholders-equity-and-stockbased-compensation-stock-option-activity-details",
     "longName": "995590 - Disclosure - Note 7 - Stockholders' Equity and Stock-based Compensation - Stock Option Activity (Details)",
     "shortName": "Note 7 - Stockholders' Equity and Stock-based Compensation - Stock Option Activity (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "46",
     "firstAnchor": {
      "contextRef": "i_2023-12-31",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "unitRef": "Share",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sava20241231c_10k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "d_2024-01-01_2024-12-31",
      "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sava20241231c_10k.htm",
      "unique": true
     }
    },
    "R47": {
     "role": "http://www.cassavasciences.com/20241231/role/statement-note-7-stockholders-equity-and-stockbased-compensation-schedule-of-stock-options-by-exercise-price-details",
     "longName": "995591 - Disclosure - Note 7 - Stockholders' Equity and Stock-based Compensation - Schedule of Stock Options by Exercise Price (Details)",
     "shortName": "Note 7 - Stockholders' Equity and Stock-based Compensation - Schedule of Stock Options by Exercise Price (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "47",
     "firstAnchor": {
      "contextRef": "i_2024-12-31",
      "name": "us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions",
      "unitRef": "Share",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock",
       "us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sava20241231c_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "i_2024-12-31",
      "name": "us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions",
      "unitRef": "Share",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock",
       "us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sava20241231c_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R48": {
     "role": "http://www.cassavasciences.com/20241231/role/statement-note-7-stockholders-equity-and-stockbased-compensation-stock-option-valuation-assumptions-details",
     "longName": "995592 - Disclosure - Note 7 - Stockholders' Equity and Stock-based Compensation - Stock Option Valuation Assumptions (Details)",
     "shortName": "Note 7 - Stockholders' Equity and Stock-based Compensation - Stock Option Valuation Assumptions (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "48",
     "firstAnchor": {
      "contextRef": "d_2024-01-01_2024-12-31_AwardTypeAxis-EmployeeStockOptionMember",
      "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sava20241231c_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "d_2024-01-01_2024-12-31_AwardTypeAxis-EmployeeStockOptionMember",
      "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sava20241231c_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R49": {
     "role": "http://www.cassavasciences.com/20241231/role/statement-note-7-stockholders-equity-and-stockbased-compensation-stock-option-and-performance-award-activity-details",
     "longName": "995593 - Disclosure - Note 7 - Stockholders' Equity and Stock-based Compensation - Stock Option and Performance Award Activity (Details)",
     "shortName": "Note 7 - Stockholders' Equity and Stock-based Compensation - Stock Option and Performance Award Activity (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "49",
     "firstAnchor": {
      "contextRef": "i_2023-12-31_AwardTypeAxis-PerformanceSharesMember",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "unitRef": "Share",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock",
       "us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sava20241231c_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "i_2023-12-31_AwardTypeAxis-PerformanceSharesMember",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "unitRef": "Share",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock",
       "us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sava20241231c_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R50": {
     "role": "http://www.cassavasciences.com/20241231/role/statement-note-7-stockholders-equity-and-stockbased-compensation-stockbased-compensation-expense-details",
     "longName": "995594 - Disclosure - Note 7 - Stockholders' Equity and Stock-based Compensation - Stock-based Compensation Expense (Details)",
     "shortName": "Note 7 - Stockholders' Equity and Stock-based Compensation - Stock-based Compensation Expense (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "50",
     "firstAnchor": {
      "contextRef": "d_2024-01-01_2024-12-31",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sava20241231c_10k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "d_2024-01-01_2024-12-31_IncomeStatementLocationAxis-ResearchAndDevelopmentExpenseMember",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sava20241231c_10k.htm",
      "unique": true
     }
    },
    "R51": {
     "role": "http://www.cassavasciences.com/20241231/role/statement-note-9-income-taxes-details-textual",
     "longName": "995595 - Disclosure - Note 9 - Income Taxes (Details Textual)",
     "shortName": "Note 9 - Income Taxes (Details Textual)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "51",
     "firstAnchor": {
      "contextRef": "d_2024-01-01_2024-12-31",
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "unitRef": "Pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sava20241231c_10k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "d_2024-01-01_2024-12-31",
      "name": "us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "p",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sava20241231c_10k.htm",
      "unique": true
     }
    },
    "R52": {
     "role": "http://www.cassavasciences.com/20241231/role/statement-note-9-income-taxes-schedule-of-effective-income-tax-reconciliation-details",
     "longName": "995596 - Disclosure - Note 9 - Income Taxes - Schedule of Effective Income Tax Reconciliation (Details)",
     "shortName": "Note 9 - Income Taxes - Schedule of Effective Income Tax Reconciliation (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "52",
     "firstAnchor": {
      "contextRef": "d_2024-01-01_2024-12-31",
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "unitRef": "Pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sava20241231c_10k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "d_2024-01-01_2024-12-31",
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes",
      "unitRef": "Pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sava20241231c_10k.htm",
      "unique": true
     }
    },
    "R53": {
     "role": "http://www.cassavasciences.com/20241231/role/statement-note-9-income-taxes-schedule-of-deferred-tax-assets-and-liabilities-details",
     "longName": "995597 - Disclosure - Note 9 - Income Taxes - Schedule of Deferred Tax Assets and Liabilities (Details)",
     "shortName": "Note 9 - Income Taxes - Schedule of Deferred Tax Assets and Liabilities (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "53",
     "firstAnchor": {
      "contextRef": "i_2024-12-31",
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sava20241231c_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "i_2024-12-31",
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sava20241231c_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R54": {
     "role": "http://www.cassavasciences.com/20241231/role/statement-note-9-income-taxes-schedule-of-unrecognized-tax-benefits-details",
     "longName": "995598 - Disclosure - Note 9 - Income Taxes - Schedule of Unrecognized Tax Benefits (Details)",
     "shortName": "Note 9 - Income Taxes - Schedule of Unrecognized Tax Benefits (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "54",
     "firstAnchor": {
      "contextRef": "i_2023-12-31",
      "name": "us-gaap:UnrecognizedTaxBenefits",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sava20241231c_10k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "d_2024-01-01_2024-12-31",
      "name": "us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sava20241231c_10k.htm",
      "unique": true
     }
    },
    "R55": {
     "role": "http://www.cassavasciences.com/20241231/role/statement-note-10-commitments-details-textual",
     "longName": "995599 - Disclosure - Note 10 - Commitments (Details Textual)",
     "shortName": "Note 10 - Commitments (Details Textual)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "55",
     "firstAnchor": {
      "contextRef": "i_2025-02-26_CounterpartyNameAxis-YaleUniversityMember_OtherCommitmentsAxis-LicenseAgreementMember_SubsequentEventTypeAxis-SubsequentEventMember",
      "name": "us-gaap:OtherCommitment",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "p",
       "sava:LeasesAndCommitmentsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sava20241231c_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "i_2025-02-26_CounterpartyNameAxis-YaleUniversityMember_OtherCommitmentsAxis-LicenseAgreementMember_SubsequentEventTypeAxis-SubsequentEventMember",
      "name": "us-gaap:OtherCommitment",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "p",
       "sava:LeasesAndCommitmentsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sava20241231c_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R56": {
     "role": "http://www.cassavasciences.com/20241231/role/statement-note-11-2020-cash-incentive-bonus-plan-details-textual",
     "longName": "995600 - Disclosure - Note 11 - 2020 Cash Incentive Bonus Plan (Details Textual)",
     "shortName": "Note 11 - 2020 Cash Incentive Bonus Plan (Details Textual)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "56",
     "firstAnchor": {
      "contextRef": "i_2023-03-16_PlanNameAxis-CashIncentiveBonusPlanMember",
      "name": "sava:CashBonusIncentiveIncrementalAmounts",
      "unitRef": "Pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "sava:CashIncentiveBonusPlanTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sava20241231c_10k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "i_2021-12-31_PlanNameAxis-CashIncentiveBonusPlanMember",
      "name": "sava:CashBonusIncentiveIncrementalAmounts",
      "unitRef": "Pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "sava:CashIncentiveBonusPlanTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sava20241231c_10k.htm",
      "unique": true
     }
    },
    "R57": {
     "role": "http://www.cassavasciences.com/20241231/role/statement-note-12-contingencies-details-textual",
     "longName": "995601 - Disclosure - Note 12 - Contingencies (Details Textual)",
     "shortName": "Note 12 - Contingencies (Details Textual)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "57",
     "firstAnchor": {
      "contextRef": "d_2025-02-01_2025-02-28_LitigationCaseAxis-ShareholderDerivativeActionsMember_SubsequentEventTypeAxis-SubsequentEventMember",
      "name": "us-gaap:LegalFees",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-6",
      "ancestors": [
       "p",
       "us-gaap:LossContingencyDisclosures",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sava20241231c_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "d_2025-02-01_2025-02-28_LitigationCaseAxis-ShareholderDerivativeActionsMember_SubsequentEventTypeAxis-SubsequentEventMember",
      "name": "us-gaap:LegalFees",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-6",
      "ancestors": [
       "p",
       "us-gaap:LossContingencyDisclosures",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sava20241231c_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R58": {
     "role": "http://www.cassavasciences.com/20241231/role/statement-note-13-warrant-dividend-distribution-details-textual",
     "longName": "995602 - Disclosure - Note 13 - Warrant Dividend Distribution (Details Textual)",
     "shortName": "Note 13 - Warrant Dividend Distribution (Details Textual)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "58",
     "firstAnchor": {
      "contextRef": "i_2024-01-02",
      "name": "us-gaap:WarrantsAndRightsOutstanding",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
       "sava:WarrantDividendDistributionTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sava20241231c_10k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "i_2023-12-22_ClassOfWarrantOrRightAxis-WarrantsToPurchaseCommonStockMember",
      "name": "us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights",
      "unitRef": "Share",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "sava:WarrantDividendDistributionTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sava20241231c_10k.htm",
      "unique": true
     }
    },
    "R59": {
     "role": "http://www.cassavasciences.com/20241231/role/statement-note-13-warrant-dividend-distribution-changes-in-warrants-outstanding-and-warrant-liability-details",
     "longName": "995603 - Disclosure - Note 13 - Warrant Dividend Distribution - Changes in Warrants Outstanding and Warrant Liability (Details)",
     "shortName": "Note 13 - Warrant Dividend Distribution - Changes in Warrants Outstanding and Warrant Liability (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "59",
     "firstAnchor": {
      "contextRef": "i_2024-01-02",
      "name": "us-gaap:ClassOfWarrantOrRightOutstanding",
      "unitRef": "Share",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
       "sava:WarrantDividendDistributionTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sava20241231c_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "i_2024-01-02",
      "name": "us-gaap:ClassOfWarrantOrRightOutstanding",
      "unitRef": "Share",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
       "sava:WarrantDividendDistributionTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sava20241231c_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R60": {
     "role": "http://www.cassavasciences.com/20241231/role/statement-note-14-subsequent-event-details-textual",
     "longName": "995604 - Disclosure - Note 14 - Subsequent Event (Details Textual)",
     "shortName": "Note 14 - Subsequent Event (Details Textual)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "60",
     "firstAnchor": {
      "contextRef": "i_2025-03-31_RestructuringCostAndReserveAxis-WorkforceReductionMember_StatementScenarioAxis-ScenarioForecastMember",
      "name": "us-gaap:RestructuringAndRelatedCostExpectedCost1",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "p",
       "us-gaap:SubsequentEventsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sava20241231c_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "i_2025-03-31_RestructuringCostAndReserveAxis-WorkforceReductionMember_StatementScenarioAxis-ScenarioForecastMember",
      "name": "us-gaap:RestructuringAndRelatedCostExpectedCost1",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "p",
       "us-gaap:SubsequentEventsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sava20241231c_10k.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "us-gaap_AccountingPoliciesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountingPoliciesAbstract",
     "presentation": [
      "http://www.cassavasciences.com/20241231/role/statement-significant-accounting-policies-policies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountsPayableAndOtherAccruedLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.cassavasciences.com/20241231/role/statement-consolidated-balance-sheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.cassavasciences.com/20241231/role/statement-consolidated-balance-sheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts payable and other accrued expenses",
        "documentation": "Amount of liabilities incurred to vendors for goods and services received, and accrued liabilities classified as other, payable within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccrualForTaxesOtherThanIncomeTaxesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccrualForTaxesOtherThanIncomeTaxesCurrent",
     "crdr": "credit",
     "presentation": [
      "http://www.cassavasciences.com/20241231/role/statement-note-4-real-property-and-other-income-expense-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_AccrualForTaxesOtherThanIncomeTaxesCurrent",
        "terseLabel": "Accrual for Taxes Other than Income Taxes, Current",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable for real and property taxes. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r47",
      "r575",
      "r735"
     ]
    },
    "sava_AccruedDevelopmentExpenseCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.cassavasciences.com/20241231",
     "localname": "AccruedDevelopmentExpenseCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.cassavasciences.com/20241231/role/statement-consolidated-balance-sheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.cassavasciences.com/20241231/role/statement-consolidated-balance-sheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued development expense",
        "documentation": "Amount of accrued development expense, classified as current."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "crdr": "credit",
     "calculation": {
      "http://www.cassavasciences.com/20241231/role/statement-note-5-property-and-equipment-components-of-property-and-equipment-details": {
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.cassavasciences.com/20241231/role/statement-note-5-property-and-equipment-components-of-property-and-equipment-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
        "negatedLabel": "Accumulated depreciation",
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services."
       }
      }
     },
     "auth_ref": [
      "r30",
      "r114",
      "r455"
     ]
    },
    "us-gaap_AdditionalPaidInCapital": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdditionalPaidInCapital",
     "crdr": "credit",
     "calculation": {
      "http://www.cassavasciences.com/20241231/role/statement-consolidated-balance-sheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.cassavasciences.com/20241231/role/statement-consolidated-balance-sheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional paid-in capital",
        "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock."
       }
      }
     },
     "auth_ref": [
      "r57",
      "r605",
      "r790"
     ]
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdditionalPaidInCapitalMember",
     "presentation": [
      "http://www.cassavasciences.com/20241231/role/statement-consolidated-statements-of-stockholders-equity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional Paid-in Capital [Member]",
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders."
       }
      }
     },
     "auth_ref": [
      "r489",
      "r672",
      "r673",
      "r674",
      "r676",
      "r743",
      "r791"
     ]
    },
    "sava_AdjustmentsToAdditionalPaidInCapitalDerecognitionOfWarrantLiabilitiesUponExerciseOfWarrants": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.cassavasciences.com/20241231",
     "localname": "AdjustmentsToAdditionalPaidInCapitalDerecognitionOfWarrantLiabilitiesUponExerciseOfWarrants",
     "crdr": "credit",
     "presentation": [
      "http://www.cassavasciences.com/20241231/role/statement-consolidated-statements-of-stockholders-equity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Derecognition of warrant liabilities upon exercise of warrants",
        "documentation": "Amount of increase in additional paid in capital (APIC) resulting from derecognition of warrant liabilities upon exercise of warrants."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition",
     "crdr": "credit",
     "presentation": [
      "http://www.cassavasciences.com/20241231/role/statement-consolidated-statements-of-stockholders-equity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock-based compensation for stock options",
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for option under share-based payment arrangement."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdjustmentsToAdditionalPaidInCapitalWarrantIssued",
     "crdr": "credit",
     "presentation": [
      "http://www.cassavasciences.com/20241231/role/statement-consolidated-statements-of-stockholders-equity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued",
        "negatedLabel": "Issuance of warrants",
        "documentation": "Amount of increase in additional paid in capital (APIC) resulting from the issuance of warrants. Includes allocation of proceeds of debt securities issued with detachable stock purchase warrants."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r32",
      "r74"
     ]
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://www.cassavasciences.com/20241231/role/statement-consolidated-statements-of-cash-flows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to reconcile net loss to net cash used in operating activities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AllocatedShareBasedCompensationExpense",
     "crdr": "debit",
     "presentation": [
      "http://www.cassavasciences.com/20241231/role/statement-note-7-stockholders-equity-and-stockbased-compensation-details-textual",
      "http://www.cassavasciences.com/20241231/role/statement-note-7-stockholders-equity-and-stockbased-compensation-stockbased-compensation-expense-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total stock-based compensation expense",
        "terseLabel": "Share-Based Payment Arrangement, Expense",
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized."
       }
      }
     },
     "auth_ref": [
      "r307",
      "r313"
     ]
    },
    "us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AllocatedShareBasedCompensationExpenseNetOfTax",
     "crdr": "debit",
     "presentation": [
      "http://www.cassavasciences.com/20241231/role/statement-note-11-2020-cash-incentive-bonus-plan-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax",
        "terseLabel": "Share-Based Payment Arrangement, Expense, after Tax",
        "documentation": "Amount, after tax, of expense for award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": []
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://www.cassavasciences.com/20241231/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AmortizationOfIntangibleAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AmortizationOfIntangibleAssets",
     "crdr": "debit",
     "calculation": {
      "http://www.cassavasciences.com/20241231/role/statement-consolidated-statements-of-cash-flows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.cassavasciences.com/20241231/role/statement-consolidated-statements-of-cash-flows",
      "http://www.cassavasciences.com/20241231/role/statement-note-6-intangible-assets-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amortization of intangible assets",
        "terseLabel": "Amortization of Intangible Assets",
        "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method."
       }
      }
     },
     "auth_ref": [
      "r4",
      "r223",
      "r229",
      "r591"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "presentation": [
      "http://www.cassavasciences.com/20241231/role/statement-note-2-significant-accounting-policies-calculation-of-net-loss-per-share-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
        "terseLabel": "Dilutive common stock options excluded from net loss per share, diluted (in shares)",
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r165"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "presentation": [
      "http://www.cassavasciences.com/20241231/role/statement-note-2-significant-accounting-policies-calculation-of-net-loss-per-share-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Securities [Axis]",
        "documentation": "Information by type of antidilutive security."
       }
      }
     },
     "auth_ref": [
      "r21"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AntidilutiveSecuritiesNameDomain",
     "presentation": [
      "http://www.cassavasciences.com/20241231/role/statement-note-2-significant-accounting-policies-calculation-of-net-loss-per-share-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Securities, Name [Domain]",
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r21"
     ]
    },
    "sava_AntislappLawsuitMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.cassavasciences.com/20241231",
     "localname": "AntislappLawsuitMember",
     "presentation": [
      "http://www.cassavasciences.com/20241231/role/statement-note-12-contingencies",
      "http://www.cassavasciences.com/20241231/role/statement-note-12-contingencies-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Anti-SLAPP Lawsuit [Member]",
        "documentation": "Represents the anti-SLAAP lawsuit"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_Assets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "Assets",
     "crdr": "debit",
     "calculation": {
      "http://www.cassavasciences.com/20241231/role/statement-consolidated-balance-sheets": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.cassavasciences.com/20241231/role/statement-consolidated-balance-sheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_Assets",
        "totalLabel": "Total assets",
        "documentation": "Amount of asset recognized for present right to economic benefit."
       }
      }
     },
     "auth_ref": [
      "r89",
      "r97",
      "r116",
      "r133",
      "r168",
      "r171",
      "r195",
      "r198",
      "r206",
      "r257",
      "r258",
      "r259",
      "r260",
      "r261",
      "r262",
      "r263",
      "r264",
      "r265",
      "r362",
      "r364",
      "r381",
      "r446",
      "r516",
      "r585",
      "r586",
      "r605",
      "r627",
      "r704",
      "r705",
      "r750"
     ]
    },
    "us-gaap_AssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.cassavasciences.com/20241231/role/statement-consolidated-balance-sheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.cassavasciences.com/20241231/role/statement-consolidated-balance-sheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_AssetsCurrent",
        "totalLabel": "Total current assets",
        "documentation": "Amount of asset recognized for present right to economic benefit, classified as current."
       }
      }
     },
     "auth_ref": [
      "r110",
      "r118",
      "r133",
      "r206",
      "r257",
      "r258",
      "r259",
      "r260",
      "r261",
      "r262",
      "r263",
      "r264",
      "r265",
      "r362",
      "r364",
      "r381",
      "r605",
      "r704",
      "r705",
      "r750"
     ]
    },
    "us-gaap_AssetsCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetsCurrentAbstract",
     "presentation": [
      "http://www.cassavasciences.com/20241231/role/statement-consolidated-balance-sheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current assets:"
       }
      }
     },
     "auth_ref": []
    },
    "sava_AtthemarketCommonStockOfferingMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.cassavasciences.com/20241231",
     "localname": "AtthemarketCommonStockOfferingMember",
     "presentation": [
      "http://www.cassavasciences.com/20241231/role/statement-note-7-stockholders-equity-and-stockbased-compensation",
      "http://www.cassavasciences.com/20241231/role/statement-note-7-stockholders-equity-and-stockbased-compensation-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "At-the-market Common Stock Offering [Member]",
        "documentation": "Represents the At-the-Market Common Stock Offering."
       }
      }
     },
     "auth_ref": []
    },
    "dei_AuditorFirmId": {
     "xbrltype": "nonemptySequenceNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AuditorFirmId",
     "presentation": [
      "http://www.cassavasciences.com/20241231/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Firm ID",
        "documentation": "PCAOB issued Audit Firm Identifier"
       }
      }
     },
     "auth_ref": [
      "r631",
      "r632",
      "r644"
     ]
    },
    "dei_AuditorLocation": {
     "xbrltype": "internationalNameItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AuditorLocation",
     "presentation": [
      "http://www.cassavasciences.com/20241231/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Location"
       }
      }
     },
     "auth_ref": [
      "r631",
      "r632",
      "r644"
     ]
    },
    "dei_AuditorName": {
     "xbrltype": "internationalNameItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AuditorName",
     "presentation": [
      "http://www.cassavasciences.com/20241231/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Name"
       }
      }
     },
     "auth_ref": [
      "r631",
      "r632",
      "r644"
     ]
    },
    "us-gaap_AwardTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AwardTypeAxis",
     "presentation": [
      "http://www.cassavasciences.com/20241231/role/statement-note-2-summary-of-significant-accounting-policies",
      "http://www.cassavasciences.com/20241231/role/statement-note-2-summary-of-significant-accounting-policies-details-textual",
      "http://www.cassavasciences.com/20241231/role/statement-note-7-stockholders-equity-and-stockbased-compensation",
      "http://www.cassavasciences.com/20241231/role/statement-note-7-stockholders-equity-and-stockbased-compensation-details-textual",
      "http://www.cassavasciences.com/20241231/role/statement-note-7-stockholders-equity-and-stockbased-compensation-stock-option-and-performance-award-activity-details",
      "http://www.cassavasciences.com/20241231/role/statement-note-7-stockholders-equity-and-stockbased-compensation-stock-option-valuation-assumptions-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Type [Axis]",
        "documentation": "Information by type of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r278",
      "r279",
      "r280",
      "r282",
      "r283",
      "r284",
      "r285",
      "r286",
      "r287",
      "r288",
      "r289",
      "r290",
      "r291",
      "r292",
      "r293",
      "r294",
      "r295",
      "r296",
      "r297",
      "r298",
      "r299",
      "r302",
      "r303",
      "r304",
      "r305",
      "r306"
     ]
    },
    "us-gaap_BuildingImprovementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BuildingImprovementsMember",
     "presentation": [
      "http://www.cassavasciences.com/20241231/role/statement-note-2-summary-of-significant-accounting-policies",
      "http://www.cassavasciences.com/20241231/role/statement-note-2-summary-of-significant-accounting-policies-details-textual",
      "http://www.cassavasciences.com/20241231/role/statement-note-5-property-and-equipment-components-of-property-and-equipment-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Building Improvements [Member]",
        "documentation": "Addition, improvement, or renovation to a facility held for productive use including, but not limited to, office, production, storage and distribution facilities."
       }
      }
     },
     "auth_ref": [
      "r72"
     ]
    },
    "us-gaap_BuildingMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BuildingMember",
     "presentation": [
      "http://www.cassavasciences.com/20241231/role/statement-note-2-summary-of-significant-accounting-policies",
      "http://www.cassavasciences.com/20241231/role/statement-note-2-summary-of-significant-accounting-policies-details-textual",
      "http://www.cassavasciences.com/20241231/role/statement-note-5-property-and-equipment-components-of-property-and-equipment-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Building [Member]",
        "documentation": "Facility held for productive use including, but not limited to, office, production, storage and distribution facilities."
       }
      }
     },
     "auth_ref": [
      "r72"
     ]
    },
    "us-gaap_CapitalExpendituresIncurredButNotYetPaid": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CapitalExpendituresIncurredButNotYetPaid",
     "crdr": "credit",
     "presentation": [
      "http://www.cassavasciences.com/20241231/role/statement-consolidated-statements-of-cash-flows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Purchases of property and equipment included in accounts payable",
        "documentation": "Future cash outflow to pay for purchases of fixed assets that have occurred."
       }
      }
     },
     "auth_ref": [
      "r16",
      "r17",
      "r18"
     ]
    },
    "sava_CarryforwardSubjectToExpirationMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.cassavasciences.com/20241231",
     "localname": "CarryforwardSubjectToExpirationMember",
     "presentation": [
      "http://www.cassavasciences.com/20241231/role/statement-note-9-income-taxes",
      "http://www.cassavasciences.com/20241231/role/statement-note-9-income-taxes-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Carryforward Subject to Expiration [Member]",
        "documentation": "Relating to tax carryforwards subject to expiration."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "crdr": "debit",
     "calculation": {
      "http://www.cassavasciences.com/20241231/role/statement-consolidated-balance-sheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.cassavasciences.com/20241231/role/statement-consolidated-balance-sheets",
      "http://www.cassavasciences.com/20241231/role/statement-note-2-summary-of-significant-accounting-policies-summary-of-codm-segments-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and cash equivalents",
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r112",
      "r573"
     ]
    },
    "us-gaap_CashAndCashEquivalentsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashAndCashEquivalentsPolicyTextBlock",
     "presentation": [
      "http://www.cassavasciences.com/20241231/role/statement-significant-accounting-policies-policies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and Cash Equivalents, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value."
       }
      }
     },
     "auth_ref": [
      "r15"
     ]
    },
    "sava_CashBonusIncentiveIncrementalAmounts": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.cassavasciences.com/20241231",
     "localname": "CashBonusIncentiveIncrementalAmounts",
     "presentation": [
      "http://www.cassavasciences.com/20241231/role/statement-note-11-2020-cash-incentive-bonus-plan-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "sava_CashBonusIncentiveIncrementalAmounts",
        "terseLabel": "Cash Bonus Incentive, Incremental Amounts",
        "documentation": "The number of incremental amounts for cash bonus incentive."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations",
     "crdr": "debit",
     "presentation": [
      "http://www.cassavasciences.com/20241231/role/statement-consolidated-statements-of-cash-flows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations",
        "periodStartLabel": "Cash and cash equivalents at beginning of period",
        "periodEndLabel": "Cash and cash equivalents at end of period",
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r66",
      "r131"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
     "crdr": "debit",
     "calculation": {
      "http://www.cassavasciences.com/20241231/role/statement-consolidated-statements-of-cash-flows": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.cassavasciences.com/20241231/role/statement-consolidated-statements-of-cash-flows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
        "totalLabel": "Net increase (decrease) in cash and cash equivalents",
        "documentation": "Amount of increase (decrease) in cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; excluding effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r1",
      "r66"
     ]
    },
    "sava_CashIncentiveBonusAward": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.cassavasciences.com/20241231",
     "localname": "CashIncentiveBonusAward",
     "crdr": "credit",
     "presentation": [
      "http://www.cassavasciences.com/20241231/role/statement-note-11-2020-cash-incentive-bonus-plan-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "sava_CashIncentiveBonusAward",
        "terseLabel": "Cash Incentive Bonus Award",
        "documentation": "Amount of cash incentive bonus award."
       }
      }
     },
     "auth_ref": []
    },
    "sava_CashIncentiveBonusAwardExceedsMaximum": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.cassavasciences.com/20241231",
     "localname": "CashIncentiveBonusAwardExceedsMaximum",
     "crdr": "credit",
     "presentation": [
      "http://www.cassavasciences.com/20241231/role/statement-note-11-2020-cash-incentive-bonus-plan-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "sava_CashIncentiveBonusAwardExceedsMaximum",
        "terseLabel": "Cash Incentive Bonus Award, Exceeds Maximum",
        "documentation": "Amount of cash incentive bonus award if the maximum milestone is exceeded."
       }
      }
     },
     "auth_ref": []
    },
    "sava_CashIncentiveBonusPlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.cassavasciences.com/20241231",
     "localname": "CashIncentiveBonusPlanMember",
     "presentation": [
      "http://www.cassavasciences.com/20241231/role/statement-note-11-2020-cash-incentive-bonus-plan",
      "http://www.cassavasciences.com/20241231/role/statement-note-11-2020-cash-incentive-bonus-plan-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash Incentive Bonus Plan [Member]",
        "documentation": "Represents the cash incentive bonus plan."
       }
      }
     },
     "auth_ref": []
    },
    "sava_CashIncentiveBonusPlanTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.cassavasciences.com/20241231",
     "localname": "CashIncentiveBonusPlanTextBlock",
     "presentation": [
      "http://www.cassavasciences.com/20241231/role/statement-note-11-2020-cash-incentive-bonus-plan"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash Incentive Bonus Plan [Text Block]",
        "documentation": "The entire disclosure for the cash incentive bonus plan."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CityAreaCode",
     "presentation": [
      "http://www.cassavasciences.com/20241231/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfWarrantOrRightAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfWarrantOrRightAxis",
     "presentation": [
      "http://www.cassavasciences.com/20241231/role/statement-note-13-warrant-dividend-distribution",
      "http://www.cassavasciences.com/20241231/role/statement-note-13-warrant-dividend-distribution-changes-in-warrants-outstanding-and-warrant-liability-details",
      "http://www.cassavasciences.com/20241231/role/statement-note-13-warrant-dividend-distribution-details-textual",
      "http://www.cassavasciences.com/20241231/role/statement-note-2-summary-of-significant-accounting-policies-quantitative-information-of-warrants-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Warrant or Right [Axis]",
        "documentation": "Information by type of warrant or right issued."
       }
      }
     },
     "auth_ref": [
      "r33"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfWarrantOrRightDomain",
     "presentation": [
      "http://www.cassavasciences.com/20241231/role/statement-note-13-warrant-dividend-distribution",
      "http://www.cassavasciences.com/20241231/role/statement-note-13-warrant-dividend-distribution-changes-in-warrants-outstanding-and-warrant-liability-details",
      "http://www.cassavasciences.com/20241231/role/statement-note-13-warrant-dividend-distribution-details-textual",
      "http://www.cassavasciences.com/20241231/role/statement-note-2-summary-of-significant-accounting-policies-quantitative-information-of-warrants-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Warrant or Right [Domain]",
        "documentation": "Name of the class or type of warrant or right outstanding. Warrants and rights represent derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
     "presentation": [
      "http://www.cassavasciences.com/20241231/role/statement-note-13-warrant-dividend-distribution-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
        "terseLabel": "Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)",
        "documentation": "Exercise price per share or per unit of warrants or rights outstanding."
       }
      }
     },
     "auth_ref": [
      "r269"
     ]
    },
    "sava_ClassOfWarrantOrRightExercisedDuringPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.cassavasciences.com/20241231",
     "localname": "ClassOfWarrantOrRightExercisedDuringPeriod",
     "presentation": [
      "http://www.cassavasciences.com/20241231/role/statement-note-13-warrant-dividend-distribution-changes-in-warrants-outstanding-and-warrant-liability-details",
      "http://www.cassavasciences.com/20241231/role/statement-note-13-warrant-dividend-distribution-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "sava_ClassOfWarrantOrRightExercisedDuringPeriod",
        "terseLabel": "Class of Warrant or Right, Exercised During Period (in shares)",
        "negatedTerseLabel": "Warrants exercised, shares (in shares)",
        "documentation": "Represents the warrants or rights exercised during the period."
       }
      }
     },
     "auth_ref": []
    },
    "sava_ClassOfWarrantOrRightFairValueOfCommonStockWarrantsPerWarrant": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://www.cassavasciences.com/20241231",
     "localname": "ClassOfWarrantOrRightFairValueOfCommonStockWarrantsPerWarrant",
     "presentation": [
      "http://www.cassavasciences.com/20241231/role/statement-note-2-summary-of-significant-accounting-policies-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "sava_ClassOfWarrantOrRightFairValueOfCommonStockWarrantsPerWarrant",
        "terseLabel": "Class of Warrant or Right, Fair Value of Common Stock Warrants per Warrant (in dollars per share)",
        "documentation": "Represents the fair value of common stock warrants per warrant."
       }
      }
     },
     "auth_ref": []
    },
    "sava_ClassOfWarrantOrRightIssuedDuringPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.cassavasciences.com/20241231",
     "localname": "ClassOfWarrantOrRightIssuedDuringPeriod",
     "presentation": [
      "http://www.cassavasciences.com/20241231/role/statement-note-13-warrant-dividend-distribution-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "sava_ClassOfWarrantOrRightIssuedDuringPeriod",
        "terseLabel": "Class Of Warrant Or Right Issued During Period (in shares)",
        "documentation": "The number of warrants or rights issued during period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight",
     "presentation": [
      "http://www.cassavasciences.com/20241231/role/statement-note-13-warrant-dividend-distribution-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight",
        "terseLabel": "Class of Warrant or Right, Number of Securities Called by Each Warrant or Right (in shares)",
        "documentation": "Number of securities into which each warrant or right may be converted. For example, but not limited to, each warrant may be converted into two shares."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights",
     "presentation": [
      "http://www.cassavasciences.com/20241231/role/statement-note-13-warrant-dividend-distribution-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights",
        "terseLabel": "Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)",
        "documentation": "Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares."
       }
      }
     },
     "auth_ref": [
      "r269"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfWarrantOrRightOutstanding",
     "presentation": [
      "http://www.cassavasciences.com/20241231/role/statement-note-13-warrant-dividend-distribution-changes-in-warrants-outstanding-and-warrant-liability-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Balance, shares (in shares)",
        "periodStartLabel": "Balance, shares (in shares)",
        "periodEndLabel": "Balance, shares (in shares)",
        "documentation": "Number of warrants or rights outstanding."
       }
      }
     },
     "auth_ref": []
    },
    "sava_ClassOfWarrantOrRightRedemptionPricePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://www.cassavasciences.com/20241231",
     "localname": "ClassOfWarrantOrRightRedemptionPricePerShare",
     "presentation": [
      "http://www.cassavasciences.com/20241231/role/statement-note-2-summary-of-significant-accounting-policies-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "sava_ClassOfWarrantOrRightRedemptionPricePerShare",
        "terseLabel": "Class of Warrant or Right, Redemption Price per Share (in dollars per share)",
        "documentation": "Represents the redemption price per share of warrants or rights."
       }
      }
     },
     "auth_ref": []
    },
    "sava_ClassOfWarrantsOrRightsCommonStockWarrantsRedeemed": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.cassavasciences.com/20241231",
     "localname": "ClassOfWarrantsOrRightsCommonStockWarrantsRedeemed",
     "presentation": [
      "http://www.cassavasciences.com/20241231/role/statement-note-13-warrant-dividend-distribution-changes-in-warrants-outstanding-and-warrant-liability-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "sava_ClassOfWarrantsOrRightsCommonStockWarrantsRedeemed",
        "negatedTerseLabel": "Redemption of common stock warrants (in shares)",
        "documentation": "Represents the warrants redeemed common stock warrants."
       }
      }
     },
     "auth_ref": []
    },
    "sava_CodmMonitoringMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.cassavasciences.com/20241231",
     "localname": "CodmMonitoringMember",
     "presentation": [
      "http://www.cassavasciences.com/20241231/role/statement-note-2-summary-of-significant-accounting-policies-summary-of-codm-segments-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "CODM Monitoring [Member]",
        "documentation": "Relating to CODM monitoring."
       }
      }
     },
     "auth_ref": []
    },
    "sava_CommissionPercentageOfGrossProceeds": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.cassavasciences.com/20241231",
     "localname": "CommissionPercentageOfGrossProceeds",
     "presentation": [
      "http://www.cassavasciences.com/20241231/role/statement-note-13-warrant-dividend-distribution-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "sava_CommissionPercentageOfGrossProceeds",
        "terseLabel": "Commission Percentage of Gross Proceeds",
        "documentation": "Represents the percentage of commission required to be paid from gross proceeds."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommitmentsAndContingencies": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommitmentsAndContingencies",
     "crdr": "credit",
     "presentation": [
      "http://www.cassavasciences.com/20241231/role/statement-consolidated-balance-sheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and contingencies (Notes 10, 11 and 12)",
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur."
       }
      }
     },
     "auth_ref": [
      "r51",
      "r91",
      "r448",
      "r503"
     ]
    },
    "us-gaap_CommitmentsAndContingenciesPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommitmentsAndContingenciesPolicyTextBlock",
     "presentation": [
      "http://www.cassavasciences.com/20241231/role/statement-significant-accounting-policies-policies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for commitments and contingencies, which may include policies for recognizing and measuring loss and gain contingencies."
       }
      }
     },
     "auth_ref": [
      "r31",
      "r557"
     ]
    },
    "us-gaap_CommonStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockMember",
     "presentation": [
      "http://www.cassavasciences.com/20241231/role/statement-consolidated-statements-of-stockholders-equity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock [Member]",
        "documentation": "Stock that is subordinate to all other stock of the issuer."
       }
      }
     },
     "auth_ref": [
      "r617",
      "r618",
      "r619",
      "r621",
      "r622",
      "r623",
      "r624",
      "r672",
      "r673",
      "r676",
      "r743",
      "r789",
      "r791"
     ]
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockParOrStatedValuePerShare",
     "presentation": [
      "http://www.cassavasciences.com/20241231/role/statement-consolidated-balance-sheets-parentheticals",
      "http://www.cassavasciences.com/20241231/role/statement-note-7-stockholders-equity-and-stockbased-compensation-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock, par value (in dollars per share)",
        "terseLabel": "Common Stock, Par or Stated Value Per Share (in dollars per share)",
        "documentation": "Face amount or stated value per share of common stock."
       }
      }
     },
     "auth_ref": [
      "r56"
     ]
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockSharesAuthorized",
     "presentation": [
      "http://www.cassavasciences.com/20241231/role/statement-consolidated-balance-sheets-parentheticals"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock, shares authorized (in shares)",
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r56",
      "r504"
     ]
    },
    "us-gaap_CommonStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockSharesIssued",
     "presentation": [
      "http://www.cassavasciences.com/20241231/role/statement-consolidated-balance-sheets-parentheticals"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock, shares issued (in shares)",
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury."
       }
      }
     },
     "auth_ref": [
      "r56"
     ]
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockSharesOutstanding",
     "presentation": [
      "http://www.cassavasciences.com/20241231/role/statement-consolidated-balance-sheets-parentheticals"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock, shares outstanding (in shares)",
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r56",
      "r504",
      "r522",
      "r791",
      "r792"
     ]
    },
    "us-gaap_CommonStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockValue",
     "crdr": "credit",
     "calculation": {
      "http://www.cassavasciences.com/20241231/role/statement-consolidated-balance-sheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.cassavasciences.com/20241231/role/statement-consolidated-balance-sheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock, $0.001 par value; 120,000,000 shares authorized; 48,203,179 and 42,236,919 shares issued and outstanding at December 31, 2024 and 2023, respectively",
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r56",
      "r450",
      "r605"
     ]
    },
    "us-gaap_CompensationAndEmployeeBenefitPlansTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CompensationAndEmployeeBenefitPlansTextBlock",
     "presentation": [
      "http://www.cassavasciences.com/20241231/role/statement-note-8-employee-401k-benefit-plan"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation and Employee Benefit Plans [Text Block]",
        "documentation": "The entire disclosure for an entity's employee compensation and benefit plans, including, but not limited to, postemployment and postretirement benefit plans, defined benefit pension plans, defined contribution plans, non-qualified and supplemental benefit plans, deferred compensation, share-based compensation, life insurance, severance, health care, unemployment and other benefit plans."
       }
      }
     },
     "auth_ref": [
      "r75",
      "r76",
      "r77",
      "r78"
     ]
    },
    "us-gaap_CompensationRelatedCostsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CompensationRelatedCostsPolicyTextBlock",
     "presentation": [
      "http://www.cassavasciences.com/20241231/role/statement-significant-accounting-policies-policies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Related Costs, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for salaries, bonuses, incentive awards, postretirement and postemployment benefits granted to employees, including equity-based arrangements; discloses methodologies for measurement, and the bases for recognizing related assets and liabilities and recognizing and reporting compensation expense."
       }
      }
     },
     "auth_ref": [
      "r79",
      "r85"
     ]
    },
    "us-gaap_ConstructionInProgressMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConstructionInProgressMember",
     "presentation": [
      "http://www.cassavasciences.com/20241231/role/statement-note-5-property-and-equipment-components-of-property-and-equipment-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Construction in Progress [Member]",
        "documentation": "Structure or a modification to a structure under construction. Includes recently completed structures or modifications to structures that have not been placed into service."
       }
      }
     },
     "auth_ref": []
    },
    "sava_ConsultingAgreementTerm": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.cassavasciences.com/20241231",
     "localname": "ConsultingAgreementTerm",
     "presentation": [
      "http://www.cassavasciences.com/20241231/role/statement-note-2-summary-of-significant-accounting-policies-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "sava_ConsultingAgreementTerm",
        "terseLabel": "Consulting Agreement, Term",
        "documentation": "The consulting agreement term."
       }
      }
     },
     "auth_ref": []
    },
    "sava_ConsultingServicePricePerHour": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.cassavasciences.com/20241231",
     "localname": "ConsultingServicePricePerHour",
     "crdr": "debit",
     "presentation": [
      "http://www.cassavasciences.com/20241231/role/statement-note-2-summary-of-significant-accounting-policies-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "sava_ConsultingServicePricePerHour",
        "terseLabel": "Consulting Service, Price Per Hour",
        "documentation": "The cost per hour for the consulting services."
       }
      }
     },
     "auth_ref": []
    },
    "srt_CounterpartyNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "CounterpartyNameAxis",
     "presentation": [
      "http://www.cassavasciences.com/20241231/role/statement-note-10-commitments",
      "http://www.cassavasciences.com/20241231/role/statement-note-10-commitments-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Axis]"
       }
      }
     },
     "auth_ref": [
      "r135",
      "r136",
      "r266",
      "r268",
      "r399",
      "r405",
      "r445",
      "r576",
      "r578"
     ]
    },
    "dei_CurrentFiscalYearEndDate": {
     "xbrltype": "gMonthDayItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CurrentFiscalYearEndDate",
     "presentation": [
      "http://www.cassavasciences.com/20241231/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Fiscal Year End Date",
        "documentation": "End date of current fiscal year in the format --MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Board Committee or Subcommittee Responsible for Oversight [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r639",
      "r655"
     ]
    },
    "cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskBoardOfDirectorsOversightTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Board of Directors Oversight [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r639",
      "r655"
     ]
    },
    "cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Expertise of Management Responsible [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r641",
      "r657"
     ]
    },
    "cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Positions or Committees Responsible [Flag]"
       }
      }
     },
     "auth_ref": [
      "r641",
      "r657"
     ]
    },
    "cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Positions or Committees Responsible Report to Board [Flag]"
       }
      }
     },
     "auth_ref": [
      "r643",
      "r659"
     ]
    },
    "cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Positions or Committees Responsible [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r641",
      "r657"
     ]
    },
    "cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Processes for Assessing, Identifying, and Managing Threats [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r634",
      "r650"
     ]
    },
    "cyd_CybersecurityRiskManagementProcessesIntegratedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementProcessesIntegratedFlag",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Processes Integrated [Flag]"
       }
      }
     },
     "auth_ref": [
      "r635",
      "r651"
     ]
    },
    "cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementProcessesIntegratedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Processes Integrated [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r635",
      "r651"
     ]
    },
    "cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementStrategyAndGovernanceAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management, Strategy, and Governance [Abstract]"
       }
      }
     },
     "auth_ref": [
      "r633",
      "r649"
     ]
    },
    "cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementStrategyAndGovernanceLineItems",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management, Strategy, and Governance [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r633",
      "r649"
     ]
    },
    "cyd_CybersecurityRiskManagementStrategyAndGovernanceTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementStrategyAndGovernanceTable",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management, Strategy, and Governance [Table]"
       }
      }
     },
     "auth_ref": [
      "r633",
      "r649"
     ]
    },
    "cyd_CybersecurityRiskManagementThirdPartyEngagedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementThirdPartyEngagedFlag",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Third Party Engaged [Flag]"
       }
      }
     },
     "auth_ref": [
      "r636",
      "r652"
     ]
    },
    "cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Flag]"
       }
      }
     },
     "auth_ref": [
      "r638",
      "r654"
     ]
    },
    "cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r638",
      "r654"
     ]
    },
    "cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Process for Informing Board Committee or Subcommittee Responsible for Oversight [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r639",
      "r655"
     ]
    },
    "cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Process for Informing Management or Committees Responsible [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r642",
      "r658"
     ]
    },
    "cyd_CybersecurityRiskRoleOfManagementTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskRoleOfManagementTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Role of Management [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r640",
      "r656"
     ]
    },
    "cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Third Party Oversight and Identification Processes [Flag]"
       }
      }
     },
     "auth_ref": [
      "r637",
      "r653"
     ]
    },
    "us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock",
     "presentation": [
      "http://www.cassavasciences.com/20241231/role/statement-note-3-prepaid-expenses-and-other-current-assets-tables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Table Text Block]",
        "documentation": "Tabular disclosure of the amounts paid in advance for capitalized costs that will be expensed with the passage of time or the occurrence of a triggering event, and will be charged against earnings within one year or the normal operating cycle, if longer; the aggregate carrying amount of current assets, not separately presented elsewhere in the balance sheet; and other deferred costs."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredIncomeTaxLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredIncomeTaxLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://www.cassavasciences.com/20241231/role/statement-note-9-income-taxes-schedule-of-deferred-tax-assets-and-liabilities-details": {
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.cassavasciences.com/20241231/role/statement-note-9-income-taxes-schedule-of-deferred-tax-assets-and-liabilities-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_DeferredIncomeTaxLiabilities",
        "negatedTotalLabel": "Total deferred tax liabilities",
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences."
       }
      }
     },
     "auth_ref": [
      "r52",
      "r53",
      "r90",
      "r339"
     ]
    },
    "sava_DeferredTaxAssetsCapitalizedResearchAndDevelopmentExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.cassavasciences.com/20241231",
     "localname": "DeferredTaxAssetsCapitalizedResearchAndDevelopmentExpenses",
     "crdr": "debit",
     "calculation": {
      "http://www.cassavasciences.com/20241231/role/statement-note-9-income-taxes-schedule-of-deferred-tax-assets-and-liabilities-details": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.cassavasciences.com/20241231/role/statement-note-9-income-taxes-schedule-of-deferred-tax-assets-and-liabilities-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Capitalized research and development expenses",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to capitalized research and development expenses."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxAssetsGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsGross",
     "crdr": "debit",
     "calculation": {
      "http://www.cassavasciences.com/20241231/role/statement-note-9-income-taxes-schedule-of-deferred-tax-assets-and-liabilities-details": {
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.cassavasciences.com/20241231/role/statement-note-9-income-taxes-schedule-of-deferred-tax-assets-and-liabilities-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_DeferredTaxAssetsGross",
        "totalLabel": "Total deferred tax assets",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards."
       }
      }
     },
     "auth_ref": [
      "r340"
     ]
    },
    "us-gaap_DeferredTaxAssetsLiabilitiesNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsLiabilitiesNet",
     "crdr": "debit",
     "calculation": {
      "http://www.cassavasciences.com/20241231/role/statement-note-9-income-taxes-schedule-of-deferred-tax-assets-and-liabilities-details": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.cassavasciences.com/20241231/role/statement-note-9-income-taxes-schedule-of-deferred-tax-assets-and-liabilities-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
        "totalLabel": "Net deferred tax asset (liability)",
        "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting."
       }
      }
     },
     "auth_ref": [
      "r740"
     ]
    },
    "us-gaap_DeferredTaxAssetsNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsNet",
     "crdr": "debit",
     "calculation": {
      "http://www.cassavasciences.com/20241231/role/statement-note-9-income-taxes-schedule-of-deferred-tax-assets-and-liabilities-details": {
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.cassavasciences.com/20241231/role/statement-note-9-income-taxes-schedule-of-deferred-tax-assets-and-liabilities-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_DeferredTaxAssetsNet",
        "totalLabel": "Net deferred tax assets",
        "documentation": "Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards."
       }
      }
     },
     "auth_ref": [
      "r740"
     ]
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsOperatingLossCarryforwards",
     "crdr": "debit",
     "calculation": {
      "http://www.cassavasciences.com/20241231/role/statement-note-9-income-taxes-schedule-of-deferred-tax-assets-and-liabilities-details": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.cassavasciences.com/20241231/role/statement-note-9-income-taxes-schedule-of-deferred-tax-assets-and-liabilities-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net operating loss carryforwards",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards."
       }
      }
     },
     "auth_ref": [
      "r742"
     ]
    },
    "us-gaap_DeferredTaxAssetsOther": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsOther",
     "crdr": "debit",
     "calculation": {
      "http://www.cassavasciences.com/20241231/role/statement-note-9-income-taxes-schedule-of-deferred-tax-assets-and-liabilities-details": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.cassavasciences.com/20241231/role/statement-note-9-income-taxes-schedule-of-deferred-tax-assets-and-liabilities-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_DeferredTaxAssetsOther",
        "terseLabel": "Other",
        "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other."
       }
      }
     },
     "auth_ref": [
      "r742"
     ]
    },
    "us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsTaxCreditCarryforwardsResearch",
     "crdr": "debit",
     "calculation": {
      "http://www.cassavasciences.com/20241231/role/statement-note-9-income-taxes-schedule-of-deferred-tax-assets-and-liabilities-details": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.cassavasciences.com/20241231/role/statement-note-9-income-taxes-schedule-of-deferred-tax-assets-and-liabilities-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and development credit carryforwards",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards."
       }
      }
     },
     "auth_ref": [
      "r742"
     ]
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost",
     "crdr": "debit",
     "calculation": {
      "http://www.cassavasciences.com/20241231/role/statement-note-9-income-taxes-schedule-of-deferred-tax-assets-and-liabilities-details": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.cassavasciences.com/20241231/role/statement-note-9-income-taxes-schedule-of-deferred-tax-assets-and-liabilities-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost",
        "terseLabel": "Share-based compensation",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation."
       }
      }
     },
     "auth_ref": [
      "r742"
     ]
    },
    "us-gaap_DeferredTaxAssetsValuationAllowance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsValuationAllowance",
     "crdr": "credit",
     "calculation": {
      "http://www.cassavasciences.com/20241231/role/statement-note-9-income-taxes-schedule-of-deferred-tax-assets-and-liabilities-details": {
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": -1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.cassavasciences.com/20241231/role/statement-note-9-income-taxes-schedule-of-deferred-tax-assets-and-liabilities-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_DeferredTaxAssetsValuationAllowance",
        "negatedLabel": "Valuation allowance",
        "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized."
       }
      }
     },
     "auth_ref": [
      "r341"
     ]
    },
    "us-gaap_DeferredTaxLiabilitiesLeasingArrangements": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxLiabilitiesLeasingArrangements",
     "crdr": "credit",
     "calculation": {
      "http://www.cassavasciences.com/20241231/role/statement-note-9-income-taxes-schedule-of-deferred-tax-assets-and-liabilities-details": {
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.cassavasciences.com/20241231/role/statement-note-9-income-taxes-schedule-of-deferred-tax-assets-and-liabilities-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_DeferredTaxLiabilitiesLeasingArrangements",
        "negatedLabel": "Operating lease right-of-use assets",
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from leasing arrangements."
       }
      }
     },
     "auth_ref": [
      "r742"
     ]
    },
    "us-gaap_DepositContractsAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DepositContractsAssets",
     "crdr": "debit",
     "calculation": {
      "http://www.cassavasciences.com/20241231/role/statement-note-3-prepaid-expenses-and-other-current-assets-prepaid-expenses-and-other-current-assets-details": {
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.cassavasciences.com/20241231/role/statement-note-3-prepaid-expenses-and-other-current-assets-prepaid-expenses-and-other-current-assets-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contract research organization and other deposits",
        "documentation": "Carrying amount of assets as of the balance sheet date pertaining to amounts paid by the insured (including a ceding company) under insurance or reinsurance contracts for which insurance risk is not transferred."
       }
      }
     },
     "auth_ref": [
      "r209",
      "r210"
     ]
    },
    "us-gaap_Depreciation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "Depreciation",
     "crdr": "debit",
     "calculation": {
      "http://www.cassavasciences.com/20241231/role/statement-consolidated-statements-of-cash-flows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://www.cassavasciences.com/20241231/role/statement-consolidated-statements-of-cash-flows",
      "http://www.cassavasciences.com/20241231/role/statement-note-5-property-and-equipment-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Depreciation",
        "terseLabel": "Depreciation",
        "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation."
       }
      }
     },
     "auth_ref": [
      "r4",
      "r29"
     ]
    },
    "sava_DerecognitionOfWarrantLiabilitiesThroughExercises": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.cassavasciences.com/20241231",
     "localname": "DerecognitionOfWarrantLiabilitiesThroughExercises",
     "crdr": "credit",
     "presentation": [
      "http://www.cassavasciences.com/20241231/role/statement-consolidated-statements-of-cash-flows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Derecognition of warrant liabilities upon exercise of warrants",
        "label": "sava_DerecognitionOfWarrantLiabilitiesThroughExercises",
        "documentation": "Represents the cash flow effect of derecognition of warrant liabilities through exercises."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DerivativesPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DerivativesPolicyTextBlock",
     "presentation": [
      "http://www.cassavasciences.com/20241231/role/statement-significant-accounting-policies-policies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Derivatives, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for its derivative instruments and hedging activities."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r40",
      "r41",
      "r42",
      "r43",
      "r137",
      "r151"
     ]
    },
    "us-gaap_DilutiveSecurities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DilutiveSecurities",
     "crdr": "credit",
     "calculation": {
      "http://www.cassavasciences.com/20241231/role/statement-note-2-significant-accounting-policies-calculation-of-net-loss-per-share-details": {
       "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.cassavasciences.com/20241231/role/statement-note-2-significant-accounting-policies-calculation-of-net-loss-per-share-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_DilutiveSecurities",
        "terseLabel": "Adjustment for change in fair value of warrant liabilities",
        "documentation": "Amount of increase (decrease) to net income used for calculating diluted earnings per share (EPS), resulting from the assumed exercise stock options, restrictive stock units (RSUs), convertible preferred stock of an employee stock ownership plan (ESOP), and other dilutive convertible securities."
       }
      }
     },
     "auth_ref": [
      "r20"
     ]
    },
    "us-gaap_DisclosureTextBlockAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DisclosureTextBlockAbstract",
     "presentation": [
      "http://www.cassavasciences.com/20241231/role/statement-note-1-general-liquidity-and-basis-of-presentation",
      "http://www.cassavasciences.com/20241231/role/statement-note-10-commitments",
      "http://www.cassavasciences.com/20241231/role/statement-note-11-2020-cash-incentive-bonus-plan",
      "http://www.cassavasciences.com/20241231/role/statement-note-12-contingencies",
      "http://www.cassavasciences.com/20241231/role/statement-note-13-warrant-dividend-distribution",
      "http://www.cassavasciences.com/20241231/role/statement-note-14-subsequent-event",
      "http://www.cassavasciences.com/20241231/role/statement-note-2-summary-of-significant-accounting-policies",
      "http://www.cassavasciences.com/20241231/role/statement-note-3-prepaid-expenses-and-other-current-assets",
      "http://www.cassavasciences.com/20241231/role/statement-note-4-real-property-and-other-income-expense",
      "http://www.cassavasciences.com/20241231/role/statement-note-5-property-and-equipment",
      "http://www.cassavasciences.com/20241231/role/statement-note-6-intangible-assets",
      "http://www.cassavasciences.com/20241231/role/statement-note-7-stockholders-equity-and-stockbased-compensation",
      "http://www.cassavasciences.com/20241231/role/statement-note-8-employee-401k-benefit-plan",
      "http://www.cassavasciences.com/20241231/role/statement-note-9-income-taxes"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_DisclosureTextBlockAbstract",
        "terseLabel": "Notes to Financial Statements"
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentAnnualReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentAnnualReport",
     "presentation": [
      "http://www.cassavasciences.com/20241231/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Annual Report",
        "documentation": "Boolean flag that is true only for a form used as an annual report."
       }
      }
     },
     "auth_ref": [
      "r631",
      "r632",
      "r644"
     ]
    },
    "dei_DocumentFinStmtErrorCorrectionFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentFinStmtErrorCorrectionFlag",
     "presentation": [
      "http://www.cassavasciences.com/20241231/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Financial Statement Error Correction [Flag]",
        "documentation": "Indicates whether any of the financial statement period in the filing include a restatement due to error correction."
       }
      }
     },
     "auth_ref": [
      "r631",
      "r632",
      "r644",
      "r646"
     ]
    },
    "dei_DocumentFiscalPeriodFocus": {
     "xbrltype": "fiscalPeriodItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentFiscalPeriodFocus",
     "presentation": [
      "http://www.cassavasciences.com/20241231/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Period Focus",
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalYearFocus": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentFiscalYearFocus",
     "presentation": [
      "http://www.cassavasciences.com/20241231/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Year Focus",
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentInformationLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentInformationLineItems",
     "presentation": [
      "http://www.cassavasciences.com/20241231/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Information [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentInformationTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentInformationTable",
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Information [Table]",
        "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://www.cassavasciences.com/20241231/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentTransitionReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentTransitionReport",
     "presentation": [
      "http://www.cassavasciences.com/20241231/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Transition Report",
        "documentation": "Boolean flag that is true only for a form used as a transition report."
       }
      }
     },
     "auth_ref": [
      "r645"
     ]
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentType",
     "presentation": [
      "http://www.cassavasciences.com/20241231/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DomesticCountryMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DomesticCountryMember",
     "presentation": [
      "http://www.cassavasciences.com/20241231/role/statement-note-9-income-taxes",
      "http://www.cassavasciences.com/20241231/role/statement-note-9-income-taxes-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Domestic Tax Jurisdiction [Member]",
        "documentation": "Designated federal jurisdiction entitled to levy and collect income tax in country of domicile. Includes, but is not limited to, national jurisdiction for non-U.S. jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r322"
     ]
    },
    "us-gaap_EarningsPerShareBasic": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerShareBasic",
     "presentation": [
      "http://www.cassavasciences.com/20241231/role/statement-consolidated-statements-of-operations-",
      "http://www.cassavasciences.com/20241231/role/statement-note-2-significant-accounting-policies-calculation-of-net-loss-per-share-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net loss per share, basic (in dollars per share)",
        "terseLabel": "Net loss per share, basic (in dollars per share)",
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r125",
      "r143",
      "r144",
      "r145",
      "r146",
      "r147",
      "r148",
      "r153",
      "r155",
      "r162",
      "r163",
      "r164",
      "r167",
      "r358",
      "r361",
      "r373",
      "r374",
      "r443",
      "r459",
      "r580"
     ]
    },
    "us-gaap_EarningsPerShareDiluted": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerShareDiluted",
     "presentation": [
      "http://www.cassavasciences.com/20241231/role/statement-consolidated-statements-of-operations-",
      "http://www.cassavasciences.com/20241231/role/statement-note-2-significant-accounting-policies-calculation-of-net-loss-per-share-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net loss per share, diluted (in dollars per share)",
        "terseLabel": "Net loss per share, diluted (in dollars per share)",
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r125",
      "r143",
      "r144",
      "r145",
      "r146",
      "r147",
      "r148",
      "r155",
      "r162",
      "r163",
      "r164",
      "r167",
      "r358",
      "r361",
      "r373",
      "r374",
      "r443",
      "r459",
      "r580"
     ]
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerSharePolicyTextBlock",
     "presentation": [
      "http://www.cassavasciences.com/20241231/role/statement-significant-accounting-policies-policies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements."
       }
      }
     },
     "auth_ref": [
      "r21",
      "r22",
      "r166"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateContinuingOperations": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectiveIncomeTaxRateContinuingOperations",
     "calculation": {
      "http://www.cassavasciences.com/20241231/role/statement-note-9-income-taxes-schedule-of-effective-income-tax-reconciliation-details": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.cassavasciences.com/20241231/role/statement-note-9-income-taxes-schedule-of-effective-income-tax-reconciliation-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
        "totalLabel": "Effective income tax rate",
        "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations."
       }
      }
     },
     "auth_ref": [
      "r322",
      "r599"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
     "calculation": {
      "http://www.cassavasciences.com/20241231/role/statement-note-9-income-taxes-schedule-of-effective-income-tax-reconciliation-details": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://www.cassavasciences.com/20241231/role/statement-note-9-income-taxes-details-textual",
      "http://www.cassavasciences.com/20241231/role/statement-note-9-income-taxes-schedule-of-effective-income-tax-reconciliation-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tax at federal statutory rate",
        "terseLabel": "Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent",
        "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss)."
       }
      }
     },
     "auth_ref": [
      "r134",
      "r322",
      "r349",
      "r599"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance",
     "calculation": {
      "http://www.cassavasciences.com/20241231/role/statement-note-9-income-taxes-schedule-of-effective-income-tax-reconciliation-details": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.cassavasciences.com/20241231/role/statement-note-9-income-taxes-schedule-of-effective-income-tax-reconciliation-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Change in valuation allowance",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets."
       }
      }
     },
     "auth_ref": [
      "r326",
      "r599",
      "r671",
      "r736"
     ]
    },
    "sava_EffectiveIncomeTaxRateReconciliationChangeInFairValueOfWarrantLiabilities": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.cassavasciences.com/20241231",
     "localname": "EffectiveIncomeTaxRateReconciliationChangeInFairValueOfWarrantLiabilities",
     "calculation": {
      "http://www.cassavasciences.com/20241231/role/statement-note-9-income-taxes-schedule-of-effective-income-tax-reconciliation-details": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.cassavasciences.com/20241231/role/statement-note-9-income-taxes-schedule-of-effective-income-tax-reconciliation-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Change in fair value of warrant liabilities",
        "documentation": "Percentage of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operations, attributable to the change in fair value of warrant liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost",
     "calculation": {
      "http://www.cassavasciences.com/20241231/role/statement-note-9-income-taxes-schedule-of-effective-income-tax-reconciliation-details": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.cassavasciences.com/20241231/role/statement-note-9-income-taxes-schedule-of-effective-income-tax-reconciliation-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost",
        "terseLabel": "Share-based compensation",
        "documentation": "Percentage of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to nondeductible expense for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r599",
      "r671",
      "r736",
      "r738"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent",
     "calculation": {
      "http://www.cassavasciences.com/20241231/role/statement-note-9-income-taxes-schedule-of-effective-income-tax-reconciliation-details": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.cassavasciences.com/20241231/role/statement-note-9-income-taxes-schedule-of-effective-income-tax-reconciliation-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other",
        "documentation": "Percentage of reported income tax benefit (expense) from difference to income tax expense (benefit) computed by applying statutory federal (national) income tax rate to pretax income (loss) from continuing operation, attributable to other reconciling items. Excludes state and local income tax expense (benefit), federal tax expense (benefit), statutory income tax expense (benefit) outside of country of domicile, tax credit, nondeductible expense, deduction, income tax settlement, income tax contingency, and cross-border tax law."
       }
      }
     },
     "auth_ref": [
      "r737"
     ]
    },
    "sava_EffectiveIncomeTaxRateReconciliationSection162mLimitationPercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.cassavasciences.com/20241231",
     "localname": "EffectiveIncomeTaxRateReconciliationSection162mLimitationPercent",
     "calculation": {
      "http://www.cassavasciences.com/20241231/role/statement-note-9-income-taxes-schedule-of-effective-income-tax-reconciliation-details": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.cassavasciences.com/20241231/role/statement-note-9-income-taxes-schedule-of-effective-income-tax-reconciliation-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Section 162(m) limitation",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to section 162(m) limitation."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes",
     "calculation": {
      "http://www.cassavasciences.com/20241231/role/statement-note-9-income-taxes-schedule-of-effective-income-tax-reconciliation-details": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://www.cassavasciences.com/20241231/role/statement-note-9-income-taxes-schedule-of-effective-income-tax-reconciliation-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "State tax, net of federal benefit",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit)."
       }
      }
     },
     "auth_ref": [
      "r325",
      "r599",
      "r671",
      "r736"
     ]
    },
    "sava_EffectiveIncomeTaxRateReconciliationTaxAttributeExpirationPercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.cassavasciences.com/20241231",
     "localname": "EffectiveIncomeTaxRateReconciliationTaxAttributeExpirationPercent",
     "calculation": {
      "http://www.cassavasciences.com/20241231/role/statement-note-9-income-taxes-schedule-of-effective-income-tax-reconciliation-details": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://www.cassavasciences.com/20241231/role/statement-note-9-income-taxes-schedule-of-effective-income-tax-reconciliation-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tax attribute expiration",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to tax attribute expiration."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationTaxContingencies": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectiveIncomeTaxRateReconciliationTaxContingencies",
     "calculation": {
      "http://www.cassavasciences.com/20241231/role/statement-note-9-income-taxes-schedule-of-effective-income-tax-reconciliation-details": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.cassavasciences.com/20241231/role/statement-note-9-income-taxes-schedule-of-effective-income-tax-reconciliation-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Uncertain tax positions",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to income tax contingencies. Includes, but not limited to, domestic tax contingency, foreign tax contingency, state and local tax contingency, and other contingencies."
       }
      }
     },
     "auth_ref": [
      "r327",
      "r599",
      "r671",
      "r736"
     ]
    },
    "sava_EffectiveIncomeTaxRateReconciliationTaxCreditResearchAndDevelopmentPercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.cassavasciences.com/20241231",
     "localname": "EffectiveIncomeTaxRateReconciliationTaxCreditResearchAndDevelopmentPercent",
     "calculation": {
      "http://www.cassavasciences.com/20241231/role/statement-note-9-income-taxes-schedule-of-effective-income-tax-reconciliation-details": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.cassavasciences.com/20241231/role/statement-note-9-income-taxes-schedule-of-effective-income-tax-reconciliation-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and development credits",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research and development tax credit."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlements": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectiveIncomeTaxRateReconciliationTaxSettlements",
     "calculation": {
      "http://www.cassavasciences.com/20241231/role/statement-note-9-income-taxes-schedule-of-effective-income-tax-reconciliation-details": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.cassavasciences.com/20241231/role/statement-note-9-income-taxes-schedule-of-effective-income-tax-reconciliation-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlements",
        "negatedLabel": "SEC settlement payment",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to income tax settlements. Including, but not limited to, domestic tax settlement, foreign tax settlement, state and local tax settlement, and other tax settlements."
       }
      }
     },
     "auth_ref": [
      "r671",
      "r736",
      "r737"
     ]
    },
    "us-gaap_EmployeeRelatedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeRelatedLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.cassavasciences.com/20241231/role/statement-consolidated-balance-sheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.cassavasciences.com/20241231/role/statement-consolidated-balance-sheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued compensation and benefits",
        "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r47"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized",
     "crdr": "debit",
     "presentation": [
      "http://www.cassavasciences.com/20241231/role/statement-note-7-stockholders-equity-and-stockbased-compensation-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized",
        "terseLabel": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount",
        "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r308"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "presentation": [
      "http://www.cassavasciences.com/20241231/role/statement-note-7-stockholders-equity-and-stockbased-compensation-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
        "terseLabel": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition (Year)",
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r308"
     ]
    },
    "us-gaap_EmployeeSeveranceMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeSeveranceMember",
     "presentation": [
      "http://www.cassavasciences.com/20241231/role/statement-note-7-stockholders-equity-and-stockbased-compensation",
      "http://www.cassavasciences.com/20241231/role/statement-note-7-stockholders-equity-and-stockbased-compensation-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Employee Severance [Member]",
        "documentation": "Termination of an employee associated with exit from or disposal of business activities or restructurings pursuant to a plan."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EmployeeStockOptionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeStockOptionMember",
     "presentation": [
      "http://www.cassavasciences.com/20241231/role/statement-note-2-significant-accounting-policies-calculation-of-net-loss-per-share-details",
      "http://www.cassavasciences.com/20241231/role/statement-note-2-summary-of-significant-accounting-policies",
      "http://www.cassavasciences.com/20241231/role/statement-note-2-summary-of-significant-accounting-policies-details-textual",
      "http://www.cassavasciences.com/20241231/role/statement-note-7-stockholders-equity-and-stockbased-compensation",
      "http://www.cassavasciences.com/20241231/role/statement-note-7-stockholders-equity-and-stockbased-compensation-details-textual",
      "http://www.cassavasciences.com/20241231/role/statement-note-7-stockholders-equity-and-stockbased-compensation-stock-option-valuation-assumptions-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Option [Member]",
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://www.cassavasciences.com/20241231/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://www.cassavasciences.com/20241231/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://www.cassavasciences.com/20241231/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://www.cassavasciences.com/20241231/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://www.cassavasciences.com/20241231/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r629"
     ]
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCommonStockSharesOutstanding",
     "presentation": [
      "http://www.cassavasciences.com/20241231/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Common Stock, Shares Outstanding",
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCurrentReportingStatus": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCurrentReportingStatus",
     "presentation": [
      "http://www.cassavasciences.com/20241231/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Current Reporting Status",
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityDomain",
     "presentation": [
      "http://www.cassavasciences.com/20241231/role/statement-consolidated-balance-sheets",
      "http://www.cassavasciences.com/20241231/role/statement-consolidated-balance-sheets-parentheticals",
      "http://www.cassavasciences.com/20241231/role/statement-consolidated-statements-of-cash-flows",
      "http://www.cassavasciences.com/20241231/role/statement-consolidated-statements-of-operations-",
      "http://www.cassavasciences.com/20241231/role/statement-document-and-entity-information",
      "http://www.cassavasciences.com/20241231/role/statement-note-1-general-liquidity-and-basis-of-presentation",
      "http://www.cassavasciences.com/20241231/role/statement-note-1-general-liquidity-and-basis-of-presentation-details-textual",
      "http://www.cassavasciences.com/20241231/role/statement-note-10-commitments",
      "http://www.cassavasciences.com/20241231/role/statement-note-10-commitments-details-textual",
      "http://www.cassavasciences.com/20241231/role/statement-note-11-2020-cash-incentive-bonus-plan",
      "http://www.cassavasciences.com/20241231/role/statement-note-11-2020-cash-incentive-bonus-plan-details-textual",
      "http://www.cassavasciences.com/20241231/role/statement-note-12-contingencies",
      "http://www.cassavasciences.com/20241231/role/statement-note-12-contingencies-details-textual",
      "http://www.cassavasciences.com/20241231/role/statement-note-13-warrant-dividend-distribution",
      "http://www.cassavasciences.com/20241231/role/statement-note-13-warrant-dividend-distribution-changes-in-warrants-outstanding-and-warrant-liability-details",
      "http://www.cassavasciences.com/20241231/role/statement-note-13-warrant-dividend-distribution-details-textual",
      "http://www.cassavasciences.com/20241231/role/statement-note-13-warrant-dividend-distribution-tables",
      "http://www.cassavasciences.com/20241231/role/statement-note-14-subsequent-event",
      "http://www.cassavasciences.com/20241231/role/statement-note-14-subsequent-event-details-textual",
      "http://www.cassavasciences.com/20241231/role/statement-note-2-significant-accounting-policies-calculation-of-net-loss-per-share-details",
      "http://www.cassavasciences.com/20241231/role/statement-note-2-summary-of-significant-accounting-policies",
      "http://www.cassavasciences.com/20241231/role/statement-note-2-summary-of-significant-accounting-policies-details-textual",
      "http://www.cassavasciences.com/20241231/role/statement-note-2-summary-of-significant-accounting-policies-quantitative-information-of-warrants-details",
      "http://www.cassavasciences.com/20241231/role/statement-note-2-summary-of-significant-accounting-policies-summary-of-codm-segments-details",
      "http://www.cassavasciences.com/20241231/role/statement-note-2-summary-of-significant-accounting-policies-tables",
      "http://www.cassavasciences.com/20241231/role/statement-note-3-prepaid-expenses-and-other-current-assets",
      "http://www.cassavasciences.com/20241231/role/statement-note-3-prepaid-expenses-and-other-current-assets-prepaid-expenses-and-other-current-assets-details",
      "http://www.cassavasciences.com/20241231/role/statement-note-3-prepaid-expenses-and-other-current-assets-tables",
      "http://www.cassavasciences.com/20241231/role/statement-note-4-real-property-and-other-income-expense",
      "http://www.cassavasciences.com/20241231/role/statement-note-4-real-property-and-other-income-expense-components-of-other-income-net-details",
      "http://www.cassavasciences.com/20241231/role/statement-note-4-real-property-and-other-income-expense-details-textual",
      "http://www.cassavasciences.com/20241231/role/statement-note-4-real-property-and-other-income-expense-tables",
      "http://www.cassavasciences.com/20241231/role/statement-note-5-property-and-equipment",
      "http://www.cassavasciences.com/20241231/role/statement-note-5-property-and-equipment-components-of-property-and-equipment-details",
      "http://www.cassavasciences.com/20241231/role/statement-note-5-property-and-equipment-details-textual",
      "http://www.cassavasciences.com/20241231/role/statement-note-5-property-and-equipment-tables",
      "http://www.cassavasciences.com/20241231/role/statement-note-6-intangible-assets",
      "http://www.cassavasciences.com/20241231/role/statement-note-6-intangible-assets-amortization-expense-for-finitelived-intangible-assets-details",
      "http://www.cassavasciences.com/20241231/role/statement-note-6-intangible-assets-components-of-intangible-assets-details",
      "http://www.cassavasciences.com/20241231/role/statement-note-6-intangible-assets-details-textual",
      "http://www.cassavasciences.com/20241231/role/statement-note-6-intangible-assets-tables",
      "http://www.cassavasciences.com/20241231/role/statement-note-7-stockholders-equity-and-stockbased-compensation",
      "http://www.cassavasciences.com/20241231/role/statement-note-7-stockholders-equity-and-stockbased-compensation-details-textual",
      "http://www.cassavasciences.com/20241231/role/statement-note-7-stockholders-equity-and-stockbased-compensation-schedule-of-stock-options-by-exercise-price-details",
      "http://www.cassavasciences.com/20241231/role/statement-note-7-stockholders-equity-and-stockbased-compensation-stock-option-activity-details",
      "http://www.cassavasciences.com/20241231/role/statement-note-7-stockholders-equity-and-stockbased-compensation-stock-option-and-performance-award-activity-details",
      "http://www.cassavasciences.com/20241231/role/statement-note-7-stockholders-equity-and-stockbased-compensation-stock-option-valuation-assumptions-details",
      "http://www.cassavasciences.com/20241231/role/statement-note-7-stockholders-equity-and-stockbased-compensation-stockbased-compensation-expense-details",
      "http://www.cassavasciences.com/20241231/role/statement-note-7-stockholders-equity-and-stockbased-compensation-tables",
      "http://www.cassavasciences.com/20241231/role/statement-note-8-employee-401k-benefit-plan",
      "http://www.cassavasciences.com/20241231/role/statement-note-9-income-taxes",
      "http://www.cassavasciences.com/20241231/role/statement-note-9-income-taxes-details-textual",
      "http://www.cassavasciences.com/20241231/role/statement-note-9-income-taxes-schedule-of-deferred-tax-assets-and-liabilities-details",
      "http://www.cassavasciences.com/20241231/role/statement-note-9-income-taxes-schedule-of-effective-income-tax-reconciliation-details",
      "http://www.cassavasciences.com/20241231/role/statement-note-9-income-taxes-schedule-of-unrecognized-tax-benefits-details",
      "http://www.cassavasciences.com/20241231/role/statement-note-9-income-taxes-tables",
      "http://www.cassavasciences.com/20241231/role/statement-significant-accounting-policies-policies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity [Domain]",
        "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://www.cassavasciences.com/20241231/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r629"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://www.cassavasciences.com/20241231/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityFilerCategory": {
     "xbrltype": "filerCategoryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityFilerCategory",
     "presentation": [
      "http://www.cassavasciences.com/20241231/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Filer Category",
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": [
      "r629"
     ]
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://www.cassavasciences.com/20241231/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInteractiveDataCurrent": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityInteractiveDataCurrent",
     "presentation": [
      "http://www.cassavasciences.com/20241231/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Interactive Data Current",
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)."
       }
      }
     },
     "auth_ref": [
      "r660"
     ]
    },
    "dei_EntityPublicFloat": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityPublicFloat",
     "crdr": "credit",
     "presentation": [
      "http://www.cassavasciences.com/20241231/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Public Float",
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://www.cassavasciences.com/20241231/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r629"
     ]
    },
    "dei_EntityShellCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityShellCompany",
     "presentation": [
      "http://www.cassavasciences.com/20241231/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Shell Company",
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r629"
     ]
    },
    "dei_EntitySmallBusiness": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntitySmallBusiness",
     "presentation": [
      "http://www.cassavasciences.com/20241231/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Small Business",
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)."
       }
      }
     },
     "auth_ref": [
      "r629"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://www.cassavasciences.com/20241231/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r629"
     ]
    },
    "dei_EntityVoluntaryFilers": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityVoluntaryFilers",
     "presentation": [
      "http://www.cassavasciences.com/20241231/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Voluntary Filers",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityWellKnownSeasonedIssuer",
     "presentation": [
      "http://www.cassavasciences.com/20241231/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Well-known Seasoned Issuer",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A."
       }
      }
     },
     "auth_ref": [
      "r661"
     ]
    },
    "us-gaap_EquityComponentDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EquityComponentDomain",
     "presentation": [
      "http://www.cassavasciences.com/20241231/role/statement-consolidated-statements-of-stockholders-equity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Component [Domain]",
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r107",
      "r122",
      "r123",
      "r124",
      "r138",
      "r139",
      "r140",
      "r142",
      "r147",
      "r149",
      "r151",
      "r169",
      "r207",
      "r208",
      "r236",
      "r270",
      "r347",
      "r348",
      "r355",
      "r356",
      "r357",
      "r359",
      "r360",
      "r361",
      "r366",
      "r367",
      "r368",
      "r369",
      "r370",
      "r371",
      "r372",
      "r382",
      "r383",
      "r384",
      "r385",
      "r386",
      "r387",
      "r392",
      "r393",
      "r396",
      "r458",
      "r476",
      "r477",
      "r478",
      "r489",
      "r542"
     ]
    },
    "sava_EquityOfferingMaximumAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.cassavasciences.com/20241231",
     "localname": "EquityOfferingMaximumAmount",
     "crdr": "credit",
     "presentation": [
      "http://www.cassavasciences.com/20241231/role/statement-note-7-stockholders-equity-and-stockbased-compensation-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "sava_EquityOfferingMaximumAmount",
        "terseLabel": "Equity Offering, Maximum Amount",
        "documentation": "The maximum amount to be issued in the equity offering."
       }
      }
     },
     "auth_ref": []
    },
    "sava_EquityOfferingPercentageOfCommission": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.cassavasciences.com/20241231",
     "localname": "EquityOfferingPercentageOfCommission",
     "presentation": [
      "http://www.cassavasciences.com/20241231/role/statement-note-7-stockholders-equity-and-stockbased-compensation-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "sava_EquityOfferingPercentageOfCommission",
        "terseLabel": "Equity Offering, Percentage of Commission",
        "documentation": "Percentage of commission in equity offering."
       }
      }
     },
     "auth_ref": []
    },
    "sava_ExerciseOfWarrantsResultingInDecreaseInWarrantLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.cassavasciences.com/20241231",
     "localname": "ExerciseOfWarrantsResultingInDecreaseInWarrantLiability",
     "crdr": "debit",
     "presentation": [
      "http://www.cassavasciences.com/20241231/role/statement-note-13-warrant-dividend-distribution-changes-in-warrants-outstanding-and-warrant-liability-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "sava_ExerciseOfWarrantsResultingInDecreaseInWarrantLiability",
        "negatedTerseLabel": "Warrants exercised, liability",
        "documentation": "Amount of decrease in warrant liability from exercise of warrants."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueAdjustmentOfWarrants": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueAdjustmentOfWarrants",
     "crdr": "debit",
     "calculation": {
      "http://www.cassavasciences.com/20241231/role/statement-consolidated-statements-of-operations-": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0,
       "order": 2.0
      },
      "http://www.cassavasciences.com/20241231/role/statement-consolidated-statements-of-cash-flows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://www.cassavasciences.com/20241231/role/statement-consolidated-statements-of-cash-flows",
      "http://www.cassavasciences.com/20241231/role/statement-consolidated-statements-of-operations-",
      "http://www.cassavasciences.com/20241231/role/statement-note-13-warrant-dividend-distribution-changes-in-warrants-outstanding-and-warrant-liability-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Gain from change in fair value of warrant liabilities",
        "negatedLabel": "gain from change in fair value of warrant liabilities, liability",
        "negatedTerseLabel": "gain from change in fair value of warrant liabilities, liability",
        "documentation": "Amount of expense (income) related to adjustment to fair value of warrant liability."
       }
      }
     },
     "auth_ref": [
      "r0",
      "r4"
     ]
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock",
     "presentation": [
      "http://www.cassavasciences.com/20241231/role/statement-note-2-summary-of-significant-accounting-policies-tables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Measurement Inputs and Valuation Techniques [Table Text Block]",
        "documentation": "Tabular disclosure of input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis."
       }
      }
     },
     "auth_ref": [
      "r375",
      "r376",
      "r601"
     ]
    },
    "us-gaap_FairValueMeasurementPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueMeasurementPolicyPolicyTextBlock",
     "presentation": [
      "http://www.cassavasciences.com/20241231/role/statement-significant-accounting-policies-policies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Measurement, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueOfFinancialInstrumentsPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueOfFinancialInstrumentsPolicy",
     "presentation": [
      "http://www.cassavasciences.com/20241231/role/statement-significant-accounting-policies-policies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value of Financial Instruments, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for determining the fair value of financial instruments."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization",
     "crdr": "credit",
     "calculation": {
      "http://www.cassavasciences.com/20241231/role/statement-note-6-intangible-assets-components-of-intangible-assets-details": {
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.cassavasciences.com/20241231/role/statement-note-6-intangible-assets-components-of-intangible-assets-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization",
        "negatedLabel": "Accumulated amortization",
        "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life."
       }
      }
     },
     "auth_ref": [
      "r115",
      "r211",
      "r228",
      "r591"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths",
     "crdr": "debit",
     "calculation": {
      "http://www.cassavasciences.com/20241231/role/statement-note-6-intangible-assets-amortization-expense-for-finitelived-intangible-assets-details": {
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.cassavasciences.com/20241231/role/statement-note-6-intangible-assets-amortization-expense-for-finitelived-intangible-assets-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths",
        "terseLabel": "2025",
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r230",
      "r570",
      "r591"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearThree",
     "crdr": "debit",
     "calculation": {
      "http://www.cassavasciences.com/20241231/role/statement-note-6-intangible-assets-amortization-expense-for-finitelived-intangible-assets-details": {
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.cassavasciences.com/20241231/role/statement-note-6-intangible-assets-amortization-expense-for-finitelived-intangible-assets-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree",
        "terseLabel": "2027",
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r230",
      "r570",
      "r591"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo",
     "crdr": "debit",
     "calculation": {
      "http://www.cassavasciences.com/20241231/role/statement-note-6-intangible-assets-amortization-expense-for-finitelived-intangible-assets-details": {
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.cassavasciences.com/20241231/role/statement-note-6-intangible-assets-amortization-expense-for-finitelived-intangible-assets-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo",
        "terseLabel": "2026",
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r230",
      "r570",
      "r591"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis",
     "presentation": [
      "http://www.cassavasciences.com/20241231/role/statement-note-6-intangible-assets-components-of-intangible-assets-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finite-Lived Intangible Assets by Major Class [Axis]",
        "documentation": "Information by major type or class of finite-lived intangible assets."
       }
      }
     },
     "auth_ref": [
      "r222",
      "r224",
      "r225",
      "r226",
      "r227",
      "r228",
      "r231",
      "r232",
      "r411",
      "r412",
      "r570"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FiniteLivedIntangibleAssetsGross",
     "crdr": "debit",
     "calculation": {
      "http://www.cassavasciences.com/20241231/role/statement-note-6-intangible-assets-components-of-intangible-assets-details": {
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.cassavasciences.com/20241231/role/statement-note-6-intangible-assets-components-of-intangible-assets-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Gross intangible assets",
        "documentation": "Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life."
       }
      }
     },
     "auth_ref": [
      "r211",
      "r228",
      "r412",
      "r591"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain",
     "presentation": [
      "http://www.cassavasciences.com/20241231/role/statement-note-6-intangible-assets-components-of-intangible-assets-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finite-Lived Intangible Assets, Major Class Name [Domain]",
        "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company."
       }
      }
     },
     "auth_ref": [
      "r222",
      "r224",
      "r225",
      "r226",
      "r227",
      "r228",
      "r231",
      "r232",
      "r570"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FiniteLivedIntangibleAssetsNet",
     "crdr": "debit",
     "calculation": {
      "http://www.cassavasciences.com/20241231/role/statement-note-6-intangible-assets-amortization-expense-for-finitelived-intangible-assets-details": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      },
      "http://www.cassavasciences.com/20241231/role/statement-note-6-intangible-assets-components-of-intangible-assets-details": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.cassavasciences.com/20241231/role/statement-note-6-intangible-assets-amortization-expense-for-finitelived-intangible-assets-details",
      "http://www.cassavasciences.com/20241231/role/statement-note-6-intangible-assets-components-of-intangible-assets-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_FiniteLivedIntangibleAssetsNet",
        "totalLabel": "Total amortization",
        "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life."
       }
      }
     },
     "auth_ref": [
      "r411",
      "r696"
     ]
    },
    "sava_FormerPresidentAndChiefExecutiveOfficerMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.cassavasciences.com/20241231",
     "localname": "FormerPresidentAndChiefExecutiveOfficerMember",
     "presentation": [
      "http://www.cassavasciences.com/20241231/role/statement-note-2-summary-of-significant-accounting-policies",
      "http://www.cassavasciences.com/20241231/role/statement-note-2-summary-of-significant-accounting-policies-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Former President and Chief Executive Officer [Member]",
        "documentation": "The former President and Chief Executive Officer."
       }
      }
     },
     "auth_ref": []
    },
    "sava_FormerSeniorOfficerMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.cassavasciences.com/20241231",
     "localname": "FormerSeniorOfficerMember",
     "presentation": [
      "http://www.cassavasciences.com/20241231/role/statement-note-2-summary-of-significant-accounting-policies",
      "http://www.cassavasciences.com/20241231/role/statement-note-2-summary-of-significant-accounting-policies-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Former Senior Officer [Member]",
        "documentation": "Represents the former senior officers."
       }
      }
     },
     "auth_ref": []
    },
    "sava_FormerSeniorVicePresidentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.cassavasciences.com/20241231",
     "localname": "FormerSeniorVicePresidentMember",
     "presentation": [
      "http://www.cassavasciences.com/20241231/role/statement-note-2-summary-of-significant-accounting-policies",
      "http://www.cassavasciences.com/20241231/role/statement-note-2-summary-of-significant-accounting-policies-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Former Senior Vice President [Member]",
        "documentation": "Represents the former vice president."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FurnitureAndFixturesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FurnitureAndFixturesMember",
     "presentation": [
      "http://www.cassavasciences.com/20241231/role/statement-note-5-property-and-equipment-components-of-property-and-equipment-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Furniture and Fixtures [Member]",
        "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GeneralAndAdministrativeExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.cassavasciences.com/20241231/role/statement-consolidated-statements-of-operations-": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.cassavasciences.com/20241231/role/statement-consolidated-statements-of-operations-",
      "http://www.cassavasciences.com/20241231/role/statement-note-2-summary-of-significant-accounting-policies-summary-of-codm-segments-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "General and administrative",
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line."
       }
      }
     },
     "auth_ref": [
      "r63",
      "r526"
     ]
    },
    "us-gaap_GeneralAndAdministrativeExpenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GeneralAndAdministrativeExpenseMember",
     "presentation": [
      "http://www.cassavasciences.com/20241231/role/statement-note-7-stockholders-equity-and-stockbased-compensation-stockbased-compensation-expense-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "General and Administrative Expense [Member]",
        "documentation": "Primary financial statement caption encompassing general and administrative expense."
       }
      }
     },
     "auth_ref": [
      "r63"
     ]
    },
    "us-gaap_GovernmentAssistanceAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GovernmentAssistanceAmount",
     "crdr": "credit",
     "presentation": [
      "http://www.cassavasciences.com/20241231/role/statement-note-2-summary-of-significant-accounting-policies-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_GovernmentAssistanceAmount",
        "terseLabel": "Government Assistance, Income, Increase (Decrease)",
        "documentation": "Amount of increase (decrease) in income from government assistance."
       }
      }
     },
     "auth_ref": [
      "r390"
     ]
    },
    "us-gaap_GovernmentAssistancePolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GovernmentAssistancePolicyTextBlock",
     "presentation": [
      "http://www.cassavasciences.com/20241231/role/statement-significant-accounting-policies-policies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Government Assistance [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for government assistance."
       }
      }
     },
     "auth_ref": [
      "r389",
      "r391"
     ]
    },
    "us-gaap_GovernmentAssistanceStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration": {
     "xbrltype": "enumerationSetItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GovernmentAssistanceStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration",
     "presentation": [
      "http://www.cassavasciences.com/20241231/role/statement-note-2-summary-of-significant-accounting-policies-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_GovernmentAssistanceStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration",
        "terseLabel": "Government Assistance, Income, Increase (Decrease), Statement of Income or Comprehensive Income [Extensible Enumeration]",
        "documentation": "Indicates line item in statement of income or comprehensive income that includes increase (decrease) in income from government assistance."
       }
      }
     },
     "auth_ref": [
      "r390"
     ]
    },
    "us-gaap_GranteeStatusAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GranteeStatusAxis",
     "presentation": [
      "http://www.cassavasciences.com/20241231/role/statement-consolidated-statements-of-stockholders-equity",
      "http://www.cassavasciences.com/20241231/role/statement-note-7-stockholders-equity-and-stockbased-compensation",
      "http://www.cassavasciences.com/20241231/role/statement-note-7-stockholders-equity-and-stockbased-compensation-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Grantee Status [Axis]",
        "documentation": "Information by status of recipient to whom award is granted."
       }
      }
     },
     "auth_ref": [
      "r276",
      "r277",
      "r278",
      "r279",
      "r280",
      "r282",
      "r283",
      "r284",
      "r285",
      "r286",
      "r287",
      "r288",
      "r289",
      "r290",
      "r291",
      "r292",
      "r293",
      "r294",
      "r295",
      "r296",
      "r297",
      "r298",
      "r299",
      "r302",
      "r303",
      "r304",
      "r305",
      "r306"
     ]
    },
    "us-gaap_GranteeStatusDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GranteeStatusDomain",
     "presentation": [
      "http://www.cassavasciences.com/20241231/role/statement-consolidated-statements-of-stockholders-equity",
      "http://www.cassavasciences.com/20241231/role/statement-note-7-stockholders-equity-and-stockbased-compensation",
      "http://www.cassavasciences.com/20241231/role/statement-note-7-stockholders-equity-and-stockbased-compensation-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Grantee Status [Domain]",
        "documentation": "Status of recipient to whom award is granted."
       }
      }
     },
     "auth_ref": [
      "r276",
      "r277",
      "r278",
      "r279",
      "r280",
      "r282",
      "r283",
      "r284",
      "r285",
      "r286",
      "r287",
      "r288",
      "r289",
      "r290",
      "r291",
      "r292",
      "r293",
      "r294",
      "r295",
      "r296",
      "r297",
      "r298",
      "r299",
      "r302",
      "r303",
      "r304",
      "r305",
      "r306"
     ]
    },
    "sava_GrossProceedsFromIssuanceOfWarrants": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.cassavasciences.com/20241231",
     "localname": "GrossProceedsFromIssuanceOfWarrants",
     "crdr": "credit",
     "presentation": [
      "http://www.cassavasciences.com/20241231/role/statement-note-13-warrant-dividend-distribution-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "sava_GrossProceedsFromIssuanceOfWarrants",
        "terseLabel": "Gross Proceeds From Issuance of Warrants",
        "documentation": "Gross proceeds received from the issuance and sale of warrants."
       }
      }
     },
     "auth_ref": []
    },
    "dei_IcfrAuditorAttestationFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "IcfrAuditorAttestationFlag",
     "presentation": [
      "http://www.cassavasciences.com/20241231/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "ICFR Auditor Attestation Flag"
       }
      }
     },
     "auth_ref": [
      "r631",
      "r632",
      "r644"
     ]
    },
    "us-gaap_IncomeStatementAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeStatementAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeStatementLocationAxis",
     "presentation": [
      "http://www.cassavasciences.com/20241231/role/statement-note-7-stockholders-equity-and-stockbased-compensation-stockbased-compensation-expense-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Income Location, Balance [Axis]",
        "documentation": "Information by location in statement of income where disaggregated amount has been reported."
       }
      }
     },
     "auth_ref": [
      "r237",
      "r239",
      "r242",
      "r378",
      "r379",
      "r380",
      "r473",
      "r475",
      "r527",
      "r570",
      "r600",
      "r760"
     ]
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeStatementLocationDomain",
     "presentation": [
      "http://www.cassavasciences.com/20241231/role/statement-note-7-stockholders-equity-and-stockbased-compensation-stockbased-compensation-expense-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Income Location, Balance [Domain]",
        "documentation": "Location in statement of income where disaggregated amount has been reported."
       }
      }
     },
     "auth_ref": [
      "r239",
      "r242",
      "r378",
      "r379",
      "r380",
      "r473",
      "r475",
      "r527",
      "r570",
      "r600",
      "r760"
     ]
    },
    "us-gaap_IncomeTaxAuthorityAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxAuthorityAxis",
     "presentation": [
      "http://www.cassavasciences.com/20241231/role/statement-note-9-income-taxes",
      "http://www.cassavasciences.com/20241231/role/statement-note-9-income-taxes-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Jurisdiction [Axis]",
        "documentation": "Information by income tax jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r130",
      "r322",
      "r323",
      "r332",
      "r344",
      "r599",
      "r741"
     ]
    },
    "us-gaap_IncomeTaxAuthorityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxAuthorityDomain",
     "presentation": [
      "http://www.cassavasciences.com/20241231/role/statement-note-9-income-taxes",
      "http://www.cassavasciences.com/20241231/role/statement-note-9-income-taxes-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Jurisdiction [Domain]",
        "documentation": "Income tax jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r130",
      "r322",
      "r323",
      "r332",
      "r344",
      "r599",
      "r741"
     ]
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxDisclosureTextBlock",
     "presentation": [
      "http://www.cassavasciences.com/20241231/role/statement-note-9-income-taxes"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Text Block]",
        "documentation": "The entire disclosure for income tax."
       }
      }
     },
     "auth_ref": [
      "r134",
      "r317",
      "r322",
      "r328",
      "r329",
      "r330",
      "r336",
      "r343",
      "r350",
      "r352",
      "r353",
      "r354",
      "r488",
      "r599"
     ]
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxExpenseBenefit",
     "crdr": "debit",
     "presentation": [
      "http://www.cassavasciences.com/20241231/role/statement-note-9-income-taxes-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_IncomeTaxExpenseBenefit",
        "terseLabel": "Income Tax Expense (Benefit)",
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations."
       }
      }
     },
     "auth_ref": [
      "r98",
      "r106",
      "r150",
      "r151",
      "r168",
      "r179",
      "r198",
      "r321",
      "r322",
      "r351",
      "r460",
      "r599"
     ]
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxPolicyTextBlock",
     "presentation": [
      "http://www.cassavasciences.com/20241231/role/statement-significant-accounting-policies-policies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements."
       }
      }
     },
     "auth_ref": [
      "r121",
      "r319",
      "r320",
      "r336",
      "r337",
      "r342",
      "r346",
      "r485"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccountsPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInAccountsPayable",
     "crdr": "debit",
     "calculation": {
      "http://www.cassavasciences.com/20241231/role/statement-consolidated-statements-of-cash-flows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.cassavasciences.com/20241231/role/statement-consolidated-statements-of-cash-flows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_IncreaseDecreaseInAccountsPayable",
        "terseLabel": "Accounts payable and other accrued expenses",
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "sava_IncreaseDecreaseInDevelopmentExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.cassavasciences.com/20241231",
     "localname": "IncreaseDecreaseInDevelopmentExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.cassavasciences.com/20241231/role/statement-consolidated-statements-of-cash-flows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://www.cassavasciences.com/20241231/role/statement-consolidated-statements-of-cash-flows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "sava_IncreaseDecreaseInDevelopmentExpense",
        "terseLabel": "Accrued development expense",
        "documentation": "Amount of increase (decrease) in development expense."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInEmployeeRelatedLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://www.cassavasciences.com/20241231/role/statement-consolidated-statements-of-cash-flows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.cassavasciences.com/20241231/role/statement-consolidated-statements-of-cash-flows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities",
        "terseLabel": "Accrued compensation and benefits",
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "presentation": [
      "http://www.cassavasciences.com/20241231/role/statement-consolidated-statements-of-cash-flows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Changes in operating assets and liabilities:"
       }
      }
     },
     "auth_ref": []
    },
    "sava_IncreaseDecreaseInOperatingLeaseRightOfUseAssetsAndLiabilitiesNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.cassavasciences.com/20241231",
     "localname": "IncreaseDecreaseInOperatingLeaseRightOfUseAssetsAndLiabilitiesNet",
     "crdr": "credit",
     "calculation": {
      "http://www.cassavasciences.com/20241231/role/statement-consolidated-statements-of-cash-flows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.cassavasciences.com/20241231/role/statement-consolidated-statements-of-cash-flows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "sava_IncreaseDecreaseInOperatingLeaseRightOfUseAssetsAndLiabilitiesNet",
        "negatedLabel": "Operating lease right-of-use assets and liabilities",
        "documentation": "Amount of increase (decrease) in operating lease right of use assets and liabilities, net."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInOtherOperatingLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInOtherOperatingLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://www.cassavasciences.com/20241231/role/statement-consolidated-statements-of-cash-flows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.cassavasciences.com/20241231/role/statement-consolidated-statements-of-cash-flows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_IncreaseDecreaseInOtherOperatingLiabilities",
        "terseLabel": "Other liabilities",
        "documentation": "Amount of increase (decrease) in operating liabilities classified as other."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "crdr": "credit",
     "calculation": {
      "http://www.cassavasciences.com/20241231/role/statement-consolidated-statements-of-cash-flows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.cassavasciences.com/20241231/role/statement-consolidated-statements-of-cash-flows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
        "negatedLabel": "Prepaid expenses and other current assets",
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "sava_IndefiniteLifeCarryforwardsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.cassavasciences.com/20241231",
     "localname": "IndefiniteLifeCarryforwardsMember",
     "presentation": [
      "http://www.cassavasciences.com/20241231/role/statement-note-9-income-taxes",
      "http://www.cassavasciences.com/20241231/role/statement-note-9-income-taxes-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Indefinite Life Carryforwards [Member]",
        "documentation": "Relating to indefinite life tax carryforwards."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_InsiderTradingArrLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "InsiderTradingArrLineItems",
     "auth_ref": [
      "r647"
     ]
    },
    "sava_InsuranceSettlementsMaximumRecoveryLimit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.cassavasciences.com/20241231",
     "localname": "InsuranceSettlementsMaximumRecoveryLimit",
     "crdr": "credit",
     "presentation": [
      "http://www.cassavasciences.com/20241231/role/statement-note-2-summary-of-significant-accounting-policies-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "sava_InsuranceSettlementsMaximumRecoveryLimit",
        "terseLabel": "Insurance Settlements, Maximum Recovery Limit",
        "documentation": "Represents the maximum amount of monetary recovery for insurance policies."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IntangibleAssetsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IntangibleAssetsDisclosureTextBlock",
     "presentation": [
      "http://www.cassavasciences.com/20241231/role/statement-note-6-intangible-assets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Intangible Assets Disclosure [Text Block]",
        "documentation": "The entire disclosure for all or part of the information related to intangible assets."
       }
      }
     },
     "auth_ref": [
      "r221",
      "r233",
      "r235",
      "r569",
      "r570"
     ]
    },
    "us-gaap_IntangibleAssetsFiniteLivedPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IntangibleAssetsFiniteLivedPolicy",
     "presentation": [
      "http://www.cassavasciences.com/20241231/role/statement-significant-accounting-policies-policies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Intangible Assets, Finite-Lived, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for finite-lived intangible assets. This accounting policy also might address: (1) the amortization method used; (2) the useful lives of such assets; and (3) how the entity assesses and measures impairment of such assets."
       }
      }
     },
     "auth_ref": [
      "r407",
      "r408",
      "r409",
      "r411",
      "r579",
      "r689"
     ]
    },
    "us-gaap_IntangibleAssetsNetExcludingGoodwill": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IntangibleAssetsNetExcludingGoodwill",
     "crdr": "debit",
     "calculation": {
      "http://www.cassavasciences.com/20241231/role/statement-consolidated-balance-sheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.cassavasciences.com/20241231/role/statement-consolidated-balance-sheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Intangible assets, net",
        "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges."
       }
      }
     },
     "auth_ref": [
      "r222",
      "r696",
      "r698"
     ]
    },
    "us-gaap_InterestIncomeExpenseNonoperatingNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InterestIncomeExpenseNonoperatingNet",
     "crdr": "credit",
     "calculation": {
      "http://www.cassavasciences.com/20241231/role/statement-consolidated-statements-of-operations-": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.cassavasciences.com/20241231/role/statement-consolidated-statements-of-operations-"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Interest income",
        "documentation": "Amount of interest income (expense) classified as nonoperating."
       }
      }
     },
     "auth_ref": [
      "r585",
      "r668",
      "r681"
     ]
    },
    "us-gaap_InterestReceivableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InterestReceivableCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.cassavasciences.com/20241231/role/statement-note-3-prepaid-expenses-and-other-current-assets-prepaid-expenses-and-other-current-assets-details": {
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.cassavasciences.com/20241231/role/statement-note-3-prepaid-expenses-and-other-current-assets-prepaid-expenses-and-other-current-assets-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Interest receivable",
        "documentation": "Carrying amount as of the balance sheet date of current interest earned but not received. Also called accrued interest or accrued interest receivable. For classified balance sheets, represents the current amount receivable, that is amounts expected to be collected within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r666"
     ]
    },
    "sava_IssuanceOfWarrantsResultingInRecognitionOfWarrantLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.cassavasciences.com/20241231",
     "localname": "IssuanceOfWarrantsResultingInRecognitionOfWarrantLiabilities",
     "crdr": "credit",
     "presentation": [
      "http://www.cassavasciences.com/20241231/role/statement-consolidated-statements-of-cash-flows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuance of warrants resulting in recognition of warrant liabilities",
        "documentation": "Amount of issuance of warrants resulting in recognition of warrant liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LandMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LandMember",
     "presentation": [
      "http://www.cassavasciences.com/20241231/role/statement-note-5-property-and-equipment-components-of-property-and-equipment-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Land [Member]",
        "documentation": "Part of earth's surface not covered by water."
       }
      }
     },
     "auth_ref": [
      "r708"
     ]
    },
    "us-gaap_LeaseholdImprovementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LeaseholdImprovementsMember",
     "presentation": [
      "http://www.cassavasciences.com/20241231/role/statement-note-5-property-and-equipment-components-of-property-and-equipment-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Leasehold Improvements [Member]",
        "documentation": "Additions or improvements to assets held under a lease arrangement."
       }
      }
     },
     "auth_ref": [
      "r72",
      "r394"
     ]
    },
    "us-gaap_LeasesAcquiredInPlaceMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LeasesAcquiredInPlaceMember",
     "presentation": [
      "http://www.cassavasciences.com/20241231/role/statement-note-6-intangible-assets-components-of-intangible-assets-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Leases, Acquired-in-Place [Member]",
        "documentation": "This element represents the amount of value allocated by a lessor (acquirer) to lease agreements which exist at acquisition of a leased property. Such amount may include the value assigned to tenant relationships and excludes the market adjustment component of the value assigned for above or below-market leases acquired."
       }
      }
     },
     "auth_ref": [
      "r690",
      "r691",
      "r692",
      "r693",
      "r694",
      "r696",
      "r699",
      "r700"
     ]
    },
    "sava_LeasesAndCommitmentsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.cassavasciences.com/20241231",
     "localname": "LeasesAndCommitmentsDisclosureTextBlock",
     "presentation": [
      "http://www.cassavasciences.com/20241231/role/statement-note-10-commitments"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Leases And Commitments Disclosure [Text Block]",
        "documentation": "The entire disclosure regarding leases and commitments."
       }
      }
     },
     "auth_ref": []
    },
    "sava_LeasingCommissionsAndOtherMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.cassavasciences.com/20241231",
     "localname": "LeasingCommissionsAndOtherMember",
     "presentation": [
      "http://www.cassavasciences.com/20241231/role/statement-note-6-intangible-assets-components-of-intangible-assets-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Leasing Commissions and Other [Member]",
        "documentation": "Represents leasing commissions and other."
       }
      }
     },
     "auth_ref": []
    },
    "dei_LegalEntityAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "LegalEntityAxis",
     "presentation": [
      "http://www.cassavasciences.com/20241231/role/statement-consolidated-balance-sheets",
      "http://www.cassavasciences.com/20241231/role/statement-consolidated-balance-sheets-parentheticals",
      "http://www.cassavasciences.com/20241231/role/statement-consolidated-statements-of-cash-flows",
      "http://www.cassavasciences.com/20241231/role/statement-consolidated-statements-of-operations-",
      "http://www.cassavasciences.com/20241231/role/statement-document-and-entity-information",
      "http://www.cassavasciences.com/20241231/role/statement-note-1-general-liquidity-and-basis-of-presentation",
      "http://www.cassavasciences.com/20241231/role/statement-note-1-general-liquidity-and-basis-of-presentation-details-textual",
      "http://www.cassavasciences.com/20241231/role/statement-note-10-commitments",
      "http://www.cassavasciences.com/20241231/role/statement-note-10-commitments-details-textual",
      "http://www.cassavasciences.com/20241231/role/statement-note-11-2020-cash-incentive-bonus-plan",
      "http://www.cassavasciences.com/20241231/role/statement-note-11-2020-cash-incentive-bonus-plan-details-textual",
      "http://www.cassavasciences.com/20241231/role/statement-note-12-contingencies",
      "http://www.cassavasciences.com/20241231/role/statement-note-12-contingencies-details-textual",
      "http://www.cassavasciences.com/20241231/role/statement-note-13-warrant-dividend-distribution",
      "http://www.cassavasciences.com/20241231/role/statement-note-13-warrant-dividend-distribution-changes-in-warrants-outstanding-and-warrant-liability-details",
      "http://www.cassavasciences.com/20241231/role/statement-note-13-warrant-dividend-distribution-details-textual",
      "http://www.cassavasciences.com/20241231/role/statement-note-13-warrant-dividend-distribution-tables",
      "http://www.cassavasciences.com/20241231/role/statement-note-14-subsequent-event",
      "http://www.cassavasciences.com/20241231/role/statement-note-14-subsequent-event-details-textual",
      "http://www.cassavasciences.com/20241231/role/statement-note-2-significant-accounting-policies-calculation-of-net-loss-per-share-details",
      "http://www.cassavasciences.com/20241231/role/statement-note-2-summary-of-significant-accounting-policies",
      "http://www.cassavasciences.com/20241231/role/statement-note-2-summary-of-significant-accounting-policies-details-textual",
      "http://www.cassavasciences.com/20241231/role/statement-note-2-summary-of-significant-accounting-policies-quantitative-information-of-warrants-details",
      "http://www.cassavasciences.com/20241231/role/statement-note-2-summary-of-significant-accounting-policies-summary-of-codm-segments-details",
      "http://www.cassavasciences.com/20241231/role/statement-note-2-summary-of-significant-accounting-policies-tables",
      "http://www.cassavasciences.com/20241231/role/statement-note-3-prepaid-expenses-and-other-current-assets",
      "http://www.cassavasciences.com/20241231/role/statement-note-3-prepaid-expenses-and-other-current-assets-prepaid-expenses-and-other-current-assets-details",
      "http://www.cassavasciences.com/20241231/role/statement-note-3-prepaid-expenses-and-other-current-assets-tables",
      "http://www.cassavasciences.com/20241231/role/statement-note-4-real-property-and-other-income-expense",
      "http://www.cassavasciences.com/20241231/role/statement-note-4-real-property-and-other-income-expense-components-of-other-income-net-details",
      "http://www.cassavasciences.com/20241231/role/statement-note-4-real-property-and-other-income-expense-details-textual",
      "http://www.cassavasciences.com/20241231/role/statement-note-4-real-property-and-other-income-expense-tables",
      "http://www.cassavasciences.com/20241231/role/statement-note-5-property-and-equipment",
      "http://www.cassavasciences.com/20241231/role/statement-note-5-property-and-equipment-components-of-property-and-equipment-details",
      "http://www.cassavasciences.com/20241231/role/statement-note-5-property-and-equipment-details-textual",
      "http://www.cassavasciences.com/20241231/role/statement-note-5-property-and-equipment-tables",
      "http://www.cassavasciences.com/20241231/role/statement-note-6-intangible-assets",
      "http://www.cassavasciences.com/20241231/role/statement-note-6-intangible-assets-amortization-expense-for-finitelived-intangible-assets-details",
      "http://www.cassavasciences.com/20241231/role/statement-note-6-intangible-assets-components-of-intangible-assets-details",
      "http://www.cassavasciences.com/20241231/role/statement-note-6-intangible-assets-details-textual",
      "http://www.cassavasciences.com/20241231/role/statement-note-6-intangible-assets-tables",
      "http://www.cassavasciences.com/20241231/role/statement-note-7-stockholders-equity-and-stockbased-compensation",
      "http://www.cassavasciences.com/20241231/role/statement-note-7-stockholders-equity-and-stockbased-compensation-details-textual",
      "http://www.cassavasciences.com/20241231/role/statement-note-7-stockholders-equity-and-stockbased-compensation-schedule-of-stock-options-by-exercise-price-details",
      "http://www.cassavasciences.com/20241231/role/statement-note-7-stockholders-equity-and-stockbased-compensation-stock-option-activity-details",
      "http://www.cassavasciences.com/20241231/role/statement-note-7-stockholders-equity-and-stockbased-compensation-stock-option-and-performance-award-activity-details",
      "http://www.cassavasciences.com/20241231/role/statement-note-7-stockholders-equity-and-stockbased-compensation-stock-option-valuation-assumptions-details",
      "http://www.cassavasciences.com/20241231/role/statement-note-7-stockholders-equity-and-stockbased-compensation-stockbased-compensation-expense-details",
      "http://www.cassavasciences.com/20241231/role/statement-note-7-stockholders-equity-and-stockbased-compensation-tables",
      "http://www.cassavasciences.com/20241231/role/statement-note-8-employee-401k-benefit-plan",
      "http://www.cassavasciences.com/20241231/role/statement-note-9-income-taxes",
      "http://www.cassavasciences.com/20241231/role/statement-note-9-income-taxes-details-textual",
      "http://www.cassavasciences.com/20241231/role/statement-note-9-income-taxes-schedule-of-deferred-tax-assets-and-liabilities-details",
      "http://www.cassavasciences.com/20241231/role/statement-note-9-income-taxes-schedule-of-effective-income-tax-reconciliation-details",
      "http://www.cassavasciences.com/20241231/role/statement-note-9-income-taxes-schedule-of-unrecognized-tax-benefits-details",
      "http://www.cassavasciences.com/20241231/role/statement-note-9-income-taxes-tables",
      "http://www.cassavasciences.com/20241231/role/statement-significant-accounting-policies-policies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Legal Entity [Axis]",
        "documentation": "The set of legal entities associated with a report."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LegalFees": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LegalFees",
     "crdr": "debit",
     "presentation": [
      "http://www.cassavasciences.com/20241231/role/statement-note-12-contingencies-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_LegalFees",
        "terseLabel": "Legal Fees",
        "documentation": "The amount of expense provided in the period for legal costs incurred on or before the balance sheet date pertaining to resolved, pending or threatened litigation, including arbitration and mediation proceedings."
       }
      }
     },
     "auth_ref": [
      "r665"
     ]
    },
    "us-gaap_LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths",
     "crdr": "debit",
     "presentation": [
      "http://www.cassavasciences.com/20241231/role/statement-note-4-real-property-and-other-income-expense-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths",
        "terseLabel": "Lessor, Operating Lease, Payment to be Received, Year One",
        "documentation": "Amount of lease payment to be received by lessor for operating lease in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r395"
     ]
    },
    "us-gaap_LessorOperatingLeasePaymentsToBeReceivedThreeYears": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LessorOperatingLeasePaymentsToBeReceivedThreeYears",
     "crdr": "debit",
     "presentation": [
      "http://www.cassavasciences.com/20241231/role/statement-note-4-real-property-and-other-income-expense-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_LessorOperatingLeasePaymentsToBeReceivedThreeYears",
        "terseLabel": "Lessor, Operating Lease, Payment to be Received, Year Three",
        "documentation": "Amount of lease payment to be received by lessor for operating lease in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r395"
     ]
    },
    "us-gaap_LessorOperatingLeasePaymentsToBeReceivedTwoYears": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LessorOperatingLeasePaymentsToBeReceivedTwoYears",
     "crdr": "debit",
     "presentation": [
      "http://www.cassavasciences.com/20241231/role/statement-note-4-real-property-and-other-income-expense-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_LessorOperatingLeasePaymentsToBeReceivedTwoYears",
        "terseLabel": "Lessor, Operating Lease, Payment to be Received, Year Two",
        "documentation": "Amount of lease payment to be received by lessor for operating lease in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r395"
     ]
    },
    "us-gaap_Liabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "Liabilities",
     "crdr": "credit",
     "calculation": {
      "http://www.cassavasciences.com/20241231/role/statement-consolidated-balance-sheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.cassavasciences.com/20241231/role/statement-consolidated-balance-sheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_Liabilities",
        "totalLabel": "Total liabilities",
        "documentation": "Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others."
       }
      }
     },
     "auth_ref": [
      "r12",
      "r46",
      "r47",
      "r48",
      "r49",
      "r50",
      "r51",
      "r54",
      "r133",
      "r206",
      "r257",
      "r258",
      "r259",
      "r260",
      "r261",
      "r262",
      "r263",
      "r264",
      "r265",
      "r363",
      "r364",
      "r365",
      "r381",
      "r502",
      "r581",
      "r627",
      "r704",
      "r750",
      "r751"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesAndStockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://www.cassavasciences.com/20241231/role/statement-consolidated-balance-sheets": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.cassavasciences.com/20241231/role/statement-consolidated-balance-sheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_LiabilitiesAndStockholdersEquity",
        "totalLabel": "Total liabilities and stockholders' equity",
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any."
       }
      }
     },
     "auth_ref": [
      "r61",
      "r92",
      "r452",
      "r605",
      "r670",
      "r687",
      "r747"
     ]
    },
    "us-gaap_LiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.cassavasciences.com/20241231/role/statement-consolidated-balance-sheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.cassavasciences.com/20241231/role/statement-consolidated-balance-sheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_LiabilitiesCurrent",
        "totalLabel": "Total current liabilities",
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r48",
      "r111",
      "r133",
      "r206",
      "r257",
      "r258",
      "r259",
      "r260",
      "r261",
      "r262",
      "r263",
      "r264",
      "r265",
      "r363",
      "r364",
      "r365",
      "r381",
      "r605",
      "r704",
      "r750",
      "r751"
     ]
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesCurrentAbstract",
     "presentation": [
      "http://www.cassavasciences.com/20241231/role/statement-consolidated-balance-sheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current liabilities:"
       }
      }
     },
     "auth_ref": []
    },
    "sava_LicenseAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.cassavasciences.com/20241231",
     "localname": "LicenseAgreementMember",
     "presentation": [
      "http://www.cassavasciences.com/20241231/role/statement-note-10-commitments",
      "http://www.cassavasciences.com/20241231/role/statement-note-10-commitments-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "License Agreement [Member]",
        "documentation": "Relating to a license agreement."
       }
      }
     },
     "auth_ref": []
    },
    "srt_LitigationCaseAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "LitigationCaseAxis",
     "presentation": [
      "http://www.cassavasciences.com/20241231/role/statement-note-12-contingencies",
      "http://www.cassavasciences.com/20241231/role/statement-note-12-contingencies-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Litigation Case [Axis]"
       }
      }
     },
     "auth_ref": []
    },
    "srt_LitigationCaseTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "LitigationCaseTypeDomain",
     "presentation": [
      "http://www.cassavasciences.com/20241231/role/statement-note-12-contingencies",
      "http://www.cassavasciences.com/20241231/role/statement-note-12-contingencies-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Litigation Case [Domain]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://www.cassavasciences.com/20241231/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LossContingencyDisclosures": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LossContingencyDisclosures",
     "presentation": [
      "http://www.cassavasciences.com/20241231/role/statement-note-12-contingencies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contingencies Disclosure [Text Block]",
        "documentation": "The entire disclosure for loss and gain contingencies. Describes any existing condition, situation, or set of circumstances involving uncertainty as of the balance sheet date (or prior to issuance of the financial statements) as to a probable or reasonably possible loss incurred by an entity that will ultimately be resolved when one or more future events occur or fail to occur, and typically discloses the amount of loss recorded or a range of possible loss, or an assertion that no reasonable estimate can be made."
       }
      }
     },
     "auth_ref": [
      "r247",
      "r248",
      "r249",
      "r251",
      "r253",
      "r254",
      "r255",
      "r256",
      "r314"
     ]
    },
    "us-gaap_LossContingencyNewClaimsFiledNumber": {
     "xbrltype": "integerItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LossContingencyNewClaimsFiledNumber",
     "presentation": [
      "http://www.cassavasciences.com/20241231/role/statement-note-12-contingencies-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_LossContingencyNewClaimsFiledNumber",
        "terseLabel": "Loss Contingency, New Claims Filed, Number",
        "documentation": "The total number of new claims filed pertaining to a loss contingency during the period."
       }
      }
     },
     "auth_ref": [
      "r702",
      "r703"
     ]
    },
    "srt_MaximumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "MaximumMember",
     "presentation": [
      "http://www.cassavasciences.com/20241231/role/statement-note-11-2020-cash-incentive-bonus-plan",
      "http://www.cassavasciences.com/20241231/role/statement-note-11-2020-cash-incentive-bonus-plan-details-textual",
      "http://www.cassavasciences.com/20241231/role/statement-note-2-summary-of-significant-accounting-policies",
      "http://www.cassavasciences.com/20241231/role/statement-note-2-summary-of-significant-accounting-policies-details-textual",
      "http://www.cassavasciences.com/20241231/role/statement-note-7-stockholders-equity-and-stockbased-compensation-stock-option-valuation-assumptions-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum [Member]"
       }
      }
     },
     "auth_ref": [
      "r250",
      "r252",
      "r253",
      "r254",
      "r273",
      "r314",
      "r377",
      "r406",
      "r472",
      "r474",
      "r481",
      "r494",
      "r495",
      "r546",
      "r548",
      "r550",
      "r551",
      "r553",
      "r567",
      "r568",
      "r588",
      "r592",
      "r594",
      "r601",
      "r602",
      "r603",
      "r604",
      "r614",
      "r706",
      "r752",
      "r753",
      "r754",
      "r755",
      "r756",
      "r757"
     ]
    },
    "us-gaap_MeasurementInputConversionPriceMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MeasurementInputConversionPriceMember",
     "presentation": [
      "http://www.cassavasciences.com/20241231/role/statement-note-2-summary-of-significant-accounting-policies-quantitative-information-of-warrants-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Input, Conversion Price [Member]",
        "documentation": "Measurement input using price per share at which convertible share can be converted into common stock."
       }
      }
     },
     "auth_ref": [
      "r744",
      "r745",
      "r746"
     ]
    },
    "us-gaap_MeasurementInputExercisePriceMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MeasurementInputExercisePriceMember",
     "presentation": [
      "http://www.cassavasciences.com/20241231/role/statement-note-2-summary-of-significant-accounting-policies-quantitative-information-of-warrants-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Input, Exercise Price [Member]",
        "documentation": "Measurement input using agreed upon price for exchange of underlying asset."
       }
      }
     },
     "auth_ref": [
      "r744",
      "r745",
      "r746"
     ]
    },
    "us-gaap_MeasurementInputExpectedDividendRateMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MeasurementInputExpectedDividendRateMember",
     "presentation": [
      "http://www.cassavasciences.com/20241231/role/statement-note-2-summary-of-significant-accounting-policies-quantitative-information-of-warrants-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Input, Expected Dividend Rate [Member]",
        "documentation": "Measurement input using expected dividend rate to be paid to holder of share per year."
       }
      }
     },
     "auth_ref": [
      "r744",
      "r745",
      "r746"
     ]
    },
    "us-gaap_MeasurementInputExpectedTermMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MeasurementInputExpectedTermMember",
     "presentation": [
      "http://www.cassavasciences.com/20241231/role/statement-note-2-summary-of-significant-accounting-policies-quantitative-information-of-warrants-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Input, Expected Term [Member]",
        "documentation": "Measurement input using period financial instrument is expected to be outstanding. Excludes maturity date."
       }
      }
     },
     "auth_ref": [
      "r744",
      "r745",
      "r746"
     ]
    },
    "us-gaap_MeasurementInputPriceVolatilityMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MeasurementInputPriceVolatilityMember",
     "presentation": [
      "http://www.cassavasciences.com/20241231/role/statement-note-2-summary-of-significant-accounting-policies-quantitative-information-of-warrants-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Input, Price Volatility [Member]",
        "documentation": "Measurement input using rate at which price of security will increase (decrease) for given set of returns."
       }
      }
     },
     "auth_ref": [
      "r601",
      "r744",
      "r745",
      "r746"
     ]
    },
    "us-gaap_MeasurementInputRiskFreeInterestRateMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MeasurementInputRiskFreeInterestRateMember",
     "presentation": [
      "http://www.cassavasciences.com/20241231/role/statement-note-2-summary-of-significant-accounting-policies-quantitative-information-of-warrants-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Input, Risk Free Interest Rate [Member]",
        "documentation": "Measurement input using interest rate on instrument with zero risk of financial loss."
       }
      }
     },
     "auth_ref": [
      "r744",
      "r745",
      "r746"
     ]
    },
    "us-gaap_MeasurementInputSharePriceMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MeasurementInputSharePriceMember",
     "presentation": [
      "http://www.cassavasciences.com/20241231/role/statement-note-2-summary-of-significant-accounting-policies-quantitative-information-of-warrants-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Input, Share Price [Member]",
        "documentation": "Measurement input using share price of saleable stock."
       }
      }
     },
     "auth_ref": [
      "r744",
      "r745",
      "r746"
     ]
    },
    "us-gaap_MeasurementInputTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MeasurementInputTypeAxis",
     "presentation": [
      "http://www.cassavasciences.com/20241231/role/statement-note-2-summary-of-significant-accounting-policies-quantitative-information-of-warrants-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Input Type [Axis]",
        "documentation": "Information by type of measurement input used to determine value of asset and liability."
       }
      }
     },
     "auth_ref": [
      "r375",
      "r376",
      "r377",
      "r601"
     ]
    },
    "us-gaap_MeasurementInputTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MeasurementInputTypeDomain",
     "presentation": [
      "http://www.cassavasciences.com/20241231/role/statement-note-2-summary-of-significant-accounting-policies-quantitative-information-of-warrants-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Input Type [Domain]",
        "documentation": "Measurement input used to determine value of asset and liability."
       }
      }
     },
     "auth_ref": [
      "r375",
      "r376",
      "r377",
      "r601"
     ]
    },
    "srt_MinimumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "MinimumMember",
     "presentation": [
      "http://www.cassavasciences.com/20241231/role/statement-note-11-2020-cash-incentive-bonus-plan",
      "http://www.cassavasciences.com/20241231/role/statement-note-11-2020-cash-incentive-bonus-plan-details-textual",
      "http://www.cassavasciences.com/20241231/role/statement-note-2-summary-of-significant-accounting-policies",
      "http://www.cassavasciences.com/20241231/role/statement-note-2-summary-of-significant-accounting-policies-details-textual",
      "http://www.cassavasciences.com/20241231/role/statement-note-7-stockholders-equity-and-stockbased-compensation-stock-option-valuation-assumptions-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum [Member]"
       }
      }
     },
     "auth_ref": [
      "r250",
      "r252",
      "r253",
      "r254",
      "r273",
      "r314",
      "r377",
      "r406",
      "r472",
      "r474",
      "r481",
      "r494",
      "r495",
      "r546",
      "r548",
      "r550",
      "r551",
      "r553",
      "r567",
      "r568",
      "r588",
      "r592",
      "r594",
      "r601",
      "r602",
      "r603",
      "r614",
      "r706",
      "r752",
      "r753",
      "r754",
      "r755",
      "r756",
      "r757"
     ]
    },
    "srt_MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis",
     "presentation": [
      "http://www.cassavasciences.com/20241231/role/statement-note-4-real-property-and-other-income-expense",
      "http://www.cassavasciences.com/20241231/role/statement-note-4-real-property-and-other-income-expense-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Real Estate, Type of Property [Axis]"
       }
      }
     },
     "auth_ref": [
      "r556",
      "r558",
      "r559",
      "r560",
      "r561",
      "r562",
      "r563",
      "r564",
      "r565",
      "r566"
     ]
    },
    "srt_MortgageLoansOnRealEstateNamePropertyTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "MortgageLoansOnRealEstateNamePropertyTypeDomain",
     "presentation": [
      "http://www.cassavasciences.com/20241231/role/statement-note-4-real-property-and-other-income-expense",
      "http://www.cassavasciences.com/20241231/role/statement-note-4-real-property-and-other-income-expense-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Real Estate [Domain]"
       }
      }
     },
     "auth_ref": [
      "r558",
      "r559",
      "r560",
      "r561",
      "r562",
      "r563",
      "r564",
      "r565",
      "r566"
     ]
    },
    "ecd_MtrlTermsOfTrdArrTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "MtrlTermsOfTrdArrTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Material Terms of Trading Arrangement [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r648"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "crdr": "debit",
     "calculation": {
      "http://www.cassavasciences.com/20241231/role/statement-consolidated-statements-of-cash-flows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.cassavasciences.com/20241231/role/statement-consolidated-statements-of-cash-flows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
        "totalLabel": "Net cash provided by financing activities",
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit."
       }
      }
     },
     "auth_ref": [
      "r129"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "presentation": [
      "http://www.cassavasciences.com/20241231/role/statement-consolidated-statements-of-cash-flows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash flows from financing activities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "crdr": "debit",
     "calculation": {
      "http://www.cassavasciences.com/20241231/role/statement-consolidated-statements-of-cash-flows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.cassavasciences.com/20241231/role/statement-consolidated-statements-of-cash-flows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
        "totalLabel": "Net cash used in investing activities",
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets."
       }
      }
     },
     "auth_ref": [
      "r129"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "presentation": [
      "http://www.cassavasciences.com/20241231/role/statement-consolidated-statements-of-cash-flows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash flows from investing activities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "calculation": {
      "http://www.cassavasciences.com/20241231/role/statement-consolidated-statements-of-cash-flows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.cassavasciences.com/20241231/role/statement-consolidated-statements-of-cash-flows",
      "http://www.cassavasciences.com/20241231/role/statement-note-2-summary-of-significant-accounting-policies-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
        "terseLabel": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Net cash used in operating activities",
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities."
       }
      }
     },
     "auth_ref": [
      "r66",
      "r67",
      "r68"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://www.cassavasciences.com/20241231/role/statement-consolidated-statements-of-cash-flows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash flows from operating activities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://www.cassavasciences.com/20241231/role/statement-consolidated-statements-of-operations-": {
       "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted",
       "weight": 1.0,
       "order": 0.0
      },
      "http://www.cassavasciences.com/20241231/role/statement-note-2-significant-accounting-policies-calculation-of-net-loss-per-share-details": {
       "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted",
       "weight": 1.0,
       "order": 0.0
      },
      "http://www.cassavasciences.com/20241231/role/statement-consolidated-statements-of-cash-flows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.cassavasciences.com/20241231/role/statement-consolidated-statements-of-cash-flows",
      "http://www.cassavasciences.com/20241231/role/statement-consolidated-statements-of-operations-",
      "http://www.cassavasciences.com/20241231/role/statement-consolidated-statements-of-stockholders-equity",
      "http://www.cassavasciences.com/20241231/role/statement-note-2-significant-accounting-policies-calculation-of-net-loss-per-share-details",
      "http://www.cassavasciences.com/20241231/role/statement-note-2-summary-of-significant-accounting-policies-summary-of-codm-segments-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net loss",
        "totalLabel": "Net loss",
        "terseLabel": "Net loss",
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent."
       }
      }
     },
     "auth_ref": [
      "r62",
      "r68",
      "r93",
      "r109",
      "r119",
      "r120",
      "r124",
      "r133",
      "r141",
      "r143",
      "r144",
      "r145",
      "r146",
      "r147",
      "r150",
      "r151",
      "r160",
      "r206",
      "r257",
      "r258",
      "r259",
      "r260",
      "r261",
      "r262",
      "r263",
      "r264",
      "r265",
      "r358",
      "r361",
      "r374",
      "r381",
      "r457",
      "r524",
      "r540",
      "r541",
      "r625",
      "r704"
     ]
    },
    "us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetIncomeLossAvailableToCommonStockholdersDiluted",
     "crdr": "credit",
     "calculation": {
      "http://www.cassavasciences.com/20241231/role/statement-consolidated-statements-of-operations-": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      },
      "http://www.cassavasciences.com/20241231/role/statement-note-2-significant-accounting-policies-calculation-of-net-loss-per-share-details": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.cassavasciences.com/20241231/role/statement-consolidated-statements-of-operations-",
      "http://www.cassavasciences.com/20241231/role/statement-note-2-significant-accounting-policies-calculation-of-net-loss-per-share-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted",
        "totalLabel": "Adjusted numerator, diluted",
        "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities, and addition from assumption of issuance of common shares for dilutive potential common shares; of income (loss) available to common shareholders."
       }
      }
     },
     "auth_ref": [
      "r127",
      "r154",
      "r156",
      "r157",
      "r158",
      "r159",
      "r161",
      "r164"
     ]
    },
    "us-gaap_NetRentableArea": {
     "xbrltype": "areaItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetRentableArea",
     "presentation": [
      "http://www.cassavasciences.com/20241231/role/statement-note-4-real-property-and-other-income-expense-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_NetRentableArea",
        "terseLabel": "Net Rentable Area (Square Foot)",
        "documentation": "Net rentable area for properties owned."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "presentation": [
      "http://www.cassavasciences.com/20241231/role/statement-significant-accounting-policies-policies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_NonRule10b51ArrAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonRule10b51ArrAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "ecd_NonRule10b51ArrAdoptedFlag",
        "terseLabel": "Non-Rule 10b5-1 Arrangement Adopted [Flag]"
       }
      }
     },
     "auth_ref": [
      "r648"
     ]
    },
    "ecd_NonRule10b51ArrTrmntdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonRule10b51ArrTrmntdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "ecd_NonRule10b51ArrTrmntdFlag",
        "terseLabel": "Non-Rule 10b5-1 Arrangement Terminated [Flag]"
       }
      }
     },
     "auth_ref": [
      "r648"
     ]
    },
    "us-gaap_NoncashInvestingAndFinancingItemsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NoncashInvestingAndFinancingItemsAbstract",
     "presentation": [
      "http://www.cassavasciences.com/20241231/role/statement-consolidated-statements-of-cash-flows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-cash investing activities"
       }
      }
     },
     "auth_ref": []
    },
    "sava_NoteToFinancialStatementDetailsTextual": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.cassavasciences.com/20241231",
     "localname": "NoteToFinancialStatementDetailsTextual",
     "lang": {
      "en-us": {
       "role": {
        "label": "Note To Financial Statement Details Textual"
       }
      }
     },
     "auth_ref": []
    },
    "sava_NotesToFinancialStatementsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.cassavasciences.com/20241231",
     "localname": "NotesToFinancialStatementsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Notes To Financial Statements [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "sava_NumberOfFormerEmployees": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.cassavasciences.com/20241231",
     "localname": "NumberOfFormerEmployees",
     "presentation": [
      "http://www.cassavasciences.com/20241231/role/statement-note-12-contingencies-details-textual",
      "http://www.cassavasciences.com/20241231/role/statement-note-2-summary-of-significant-accounting-policies-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "sava_NumberOfFormerEmployees",
        "terseLabel": "Number of Former Employees",
        "documentation": "Represents the number of former employees."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NumberOfOperatingSegments": {
     "xbrltype": "integerItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NumberOfOperatingSegments",
     "presentation": [
      "http://www.cassavasciences.com/20241231/role/statement-note-2-summary-of-significant-accounting-policies-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_NumberOfOperatingSegments",
        "terseLabel": "Number of Operating Segments",
        "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues."
       }
      }
     },
     "auth_ref": [
      "r586",
      "r680"
     ]
    },
    "srt_OfficeBuildingMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "OfficeBuildingMember",
     "presentation": [
      "http://www.cassavasciences.com/20241231/role/statement-note-4-real-property-and-other-income-expense",
      "http://www.cassavasciences.com/20241231/role/statement-note-4-real-property-and-other-income-expense-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Office Building [Member]"
       }
      }
     },
     "auth_ref": [
      "r793",
      "r794"
     ]
    },
    "us-gaap_OpenTaxYear": {
     "xbrltype": "gYearListItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OpenTaxYear",
     "presentation": [
      "http://www.cassavasciences.com/20241231/role/statement-note-9-income-taxes-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_OpenTaxYear",
        "terseLabel": "Open Tax Year",
        "documentation": "Tax year that remains open to examination under enacted tax laws, in YYYY format."
       }
      }
     },
     "auth_ref": [
      "r332"
     ]
    },
    "us-gaap_OperatingExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingExpenses",
     "crdr": "debit",
     "calculation": {
      "http://www.cassavasciences.com/20241231/role/statement-consolidated-statements-of-operations-": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.cassavasciences.com/20241231/role/statement-consolidated-statements-of-operations-"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_OperatingExpenses",
        "totalLabel": "Total operating expenses",
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingExpensesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingExpensesAbstract",
     "presentation": [
      "http://www.cassavasciences.com/20241231/role/statement-consolidated-statements-of-operations-"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating expenses:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://www.cassavasciences.com/20241231/role/statement-consolidated-statements-of-operations-": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.cassavasciences.com/20241231/role/statement-consolidated-statements-of-operations-"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_OperatingIncomeLoss",
        "totalLabel": "Operating loss",
        "documentation": "The net result for the period of deducting operating expenses from operating revenues."
       }
      }
     },
     "auth_ref": [
      "r96",
      "r582",
      "r679",
      "r681",
      "r682",
      "r683",
      "r684"
     ]
    },
    "us-gaap_OperatingLossCarryforwards": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLossCarryforwards",
     "crdr": "debit",
     "presentation": [
      "http://www.cassavasciences.com/20241231/role/statement-note-9-income-taxes-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_OperatingLossCarryforwards",
        "terseLabel": "Operating Loss Carryforwards",
        "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws."
       }
      }
     },
     "auth_ref": [
      "r345"
     ]
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
     "presentation": [
      "http://www.cassavasciences.com/20241231/role/statement-note-1-general-liquidity-and-basis-of-presentation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]",
        "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure."
       }
      }
     },
     "auth_ref": [
      "r45",
      "r88",
      "r482",
      "r483"
     ]
    },
    "us-gaap_OtherAssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherAssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.cassavasciences.com/20241231/role/statement-note-3-prepaid-expenses-and-other-current-assets-prepaid-expenses-and-other-current-assets-details": {
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.cassavasciences.com/20241231/role/statement-note-3-prepaid-expenses-and-other-current-assets-prepaid-expenses-and-other-current-assets-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Other",
        "label": "us-gaap_OtherAssetsCurrent",
        "documentation": "Amount of current assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r117",
      "r605"
     ]
    },
    "us-gaap_OtherCommitment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherCommitment",
     "crdr": "credit",
     "presentation": [
      "http://www.cassavasciences.com/20241231/role/statement-note-10-commitments-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_OtherCommitment",
        "terseLabel": "Other Commitment",
        "documentation": "Minimum amount of other commitment not otherwise specified in the taxonomy. Excludes commitments explicitly modeled in the taxonomy, including but not limited to, long-term and short-term purchase commitments, recorded and unrecorded purchase obligations, supply commitments, registration payment arrangements, leases, debt, product warranties, guarantees, environmental remediation obligations, and pensions."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherCommitmentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherCommitmentsAxis",
     "presentation": [
      "http://www.cassavasciences.com/20241231/role/statement-note-10-commitments",
      "http://www.cassavasciences.com/20241231/role/statement-note-10-commitments-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Commitments [Axis]",
        "documentation": "Information by type of other commitment."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherCommitmentsDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherCommitmentsDomain",
     "presentation": [
      "http://www.cassavasciences.com/20241231/role/statement-note-10-commitments",
      "http://www.cassavasciences.com/20241231/role/statement-note-10-commitments-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Commitments [Domain]",
        "documentation": "Other future obligation."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.cassavasciences.com/20241231/role/statement-consolidated-balance-sheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.cassavasciences.com/20241231/role/statement-consolidated-balance-sheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other current liabilities",
        "documentation": "Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r47",
      "r605"
     ]
    },
    "us-gaap_OtherLiabilitiesNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherLiabilitiesNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.cassavasciences.com/20241231/role/statement-consolidated-balance-sheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.cassavasciences.com/20241231/role/statement-consolidated-balance-sheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other non-current liabilities",
        "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r50"
     ]
    },
    "us-gaap_OtherNonoperatingExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherNonoperatingExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.cassavasciences.com/20241231/role/statement-note-4-real-property-and-other-income-expense-components-of-other-income-net-details": {
       "parentTag": "us-gaap_OtherNonoperatingIncomeExpense",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.cassavasciences.com/20241231/role/statement-note-4-real-property-and-other-income-expense-components-of-other-income-net-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_OtherNonoperatingExpense",
        "negatedLabel": "Property operating expenses",
        "documentation": "Amount of expense related to nonoperating activities, classified as other."
       }
      }
     },
     "auth_ref": [
      "r64"
     ]
    },
    "us-gaap_OtherNonoperatingIncome": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherNonoperatingIncome",
     "crdr": "credit",
     "calculation": {
      "http://www.cassavasciences.com/20241231/role/statement-note-4-real-property-and-other-income-expense-components-of-other-income-net-details": {
       "parentTag": "us-gaap_OtherNonoperatingIncomeExpense",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.cassavasciences.com/20241231/role/statement-note-4-real-property-and-other-income-expense-components-of-other-income-net-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lease revenue",
        "documentation": "Amount of income related to nonoperating activities, classified as other."
       }
      }
     },
     "auth_ref": [
      "r126"
     ]
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherNonoperatingIncomeExpense",
     "crdr": "credit",
     "calculation": {
      "http://www.cassavasciences.com/20241231/role/statement-consolidated-statements-of-operations-": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.cassavasciences.com/20241231/role/statement-note-4-real-property-and-other-income-expense-components-of-other-income-net-details": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.cassavasciences.com/20241231/role/statement-consolidated-statements-of-operations-",
      "http://www.cassavasciences.com/20241231/role/statement-note-4-real-property-and-other-income-expense-components-of-other-income-net-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other income, net",
        "totalLabel": "Other income, net",
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other."
       }
      }
     },
     "auth_ref": [
      "r64"
     ]
    },
    "sava_PaymentsForCashIncentiveBonus": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.cassavasciences.com/20241231",
     "localname": "PaymentsForCashIncentiveBonus",
     "crdr": "credit",
     "presentation": [
      "http://www.cassavasciences.com/20241231/role/statement-note-11-2020-cash-incentive-bonus-plan-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "sava_PaymentsForCashIncentiveBonus",
        "terseLabel": "Payments for Cash Incentive Bonus",
        "documentation": "Amount of payments for cash incentive bonus."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PaymentsOfStockIssuanceCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentsOfStockIssuanceCosts",
     "crdr": "credit",
     "presentation": [
      "http://www.cassavasciences.com/20241231/role/statement-note-13-warrant-dividend-distribution-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_PaymentsOfStockIssuanceCosts",
        "terseLabel": "Payments of Stock Issuance Costs",
        "documentation": "The cash outflow for cost incurred directly with the issuance of an equity security."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "sava_PaymentsOfWarrantExerciseCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.cassavasciences.com/20241231",
     "localname": "PaymentsOfWarrantExerciseCosts",
     "crdr": "credit",
     "presentation": [
      "http://www.cassavasciences.com/20241231/role/statement-note-13-warrant-dividend-distribution-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "sava_PaymentsOfWarrantExerciseCosts",
        "terseLabel": "Payments of Warrant Exercise Costs",
        "documentation": "Represents the amount of warrant exercise costs during the period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "crdr": "credit",
     "calculation": {
      "http://www.cassavasciences.com/20241231/role/statement-consolidated-statements-of-cash-flows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.cassavasciences.com/20241231/role/statement-consolidated-statements-of-cash-flows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment",
        "negatedLabel": "Purchases of property and equipment",
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets."
       }
      }
     },
     "auth_ref": [
      "r65"
     ]
    },
    "sava_PercentageOfOccupancy": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.cassavasciences.com/20241231",
     "localname": "PercentageOfOccupancy",
     "presentation": [
      "http://www.cassavasciences.com/20241231/role/statement-note-4-real-property-and-other-income-expense-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "sava_PercentageOfOccupancy",
        "terseLabel": "Percentage of Occupancy",
        "documentation": "Percentage of occupancy."
       }
      }
     },
     "auth_ref": []
    },
    "sava_PercentageValuationMilestoneCashBonusAwardSubjectToApprovalAndAdjustment": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.cassavasciences.com/20241231",
     "localname": "PercentageValuationMilestoneCashBonusAwardSubjectToApprovalAndAdjustment",
     "presentation": [
      "http://www.cassavasciences.com/20241231/role/statement-note-11-2020-cash-incentive-bonus-plan-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "sava_PercentageValuationMilestoneCashBonusAwardSubjectToApprovalAndAdjustment",
        "terseLabel": "Percentage Valuation Milestone Cash Bonus Award Subject to Approval and Adjustment",
        "documentation": "the percentage of valuation milestone cash bonus award subject to approval and adjustment."
       }
      }
     },
     "auth_ref": []
    },
    "sava_PerformancePlanMinimumNumberOfDaysValuationMilestoneMustBeAchievedAndMaintained": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.cassavasciences.com/20241231",
     "localname": "PerformancePlanMinimumNumberOfDaysValuationMilestoneMustBeAchievedAndMaintained",
     "presentation": [
      "http://www.cassavasciences.com/20241231/role/statement-note-11-2020-cash-incentive-bonus-plan-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "sava_PerformancePlanMinimumNumberOfDaysValuationMilestoneMustBeAchievedAndMaintained",
        "terseLabel": "Performance Plan, Minimum Number of Days Valuation Milestone Must be Achieved and Maintained (Day)",
        "documentation": "The minimum number of days valuation milestone must be achieved and maintained in performance plan."
       }
      }
     },
     "auth_ref": []
    },
    "sava_PerformancePlanValuationMilestoneAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.cassavasciences.com/20241231",
     "localname": "PerformancePlanValuationMilestoneAmount",
     "crdr": "credit",
     "presentation": [
      "http://www.cassavasciences.com/20241231/role/statement-note-11-2020-cash-incentive-bonus-plan-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "sava_PerformancePlanValuationMilestoneAmount",
        "terseLabel": "Performance Plan, Valuation Milestone Amount",
        "documentation": "Amount of valuation milestone for performance plan."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PerformanceSharesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PerformanceSharesMember",
     "presentation": [
      "http://www.cassavasciences.com/20241231/role/statement-note-7-stockholders-equity-and-stockbased-compensation",
      "http://www.cassavasciences.com/20241231/role/statement-note-7-stockholders-equity-and-stockbased-compensation-details-textual",
      "http://www.cassavasciences.com/20241231/role/statement-note-7-stockholders-equity-and-stockbased-compensation-stock-option-and-performance-award-activity-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Performance Shares [Member]",
        "documentation": "Share-based payment arrangement awarded for meeting performance target."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PlanNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PlanNameAxis",
     "presentation": [
      "http://www.cassavasciences.com/20241231/role/statement-note-11-2020-cash-incentive-bonus-plan",
      "http://www.cassavasciences.com/20241231/role/statement-note-11-2020-cash-incentive-bonus-plan-details-textual",
      "http://www.cassavasciences.com/20241231/role/statement-note-7-stockholders-equity-and-stockbased-compensation",
      "http://www.cassavasciences.com/20241231/role/statement-note-7-stockholders-equity-and-stockbased-compensation-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Plan Name [Axis]",
        "documentation": "Information by plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r709",
      "r710",
      "r711",
      "r712",
      "r713",
      "r714",
      "r715",
      "r716",
      "r717",
      "r718",
      "r719",
      "r720",
      "r721",
      "r722",
      "r723",
      "r724",
      "r725",
      "r726",
      "r727",
      "r728",
      "r729",
      "r730",
      "r731",
      "r732",
      "r733",
      "r734"
     ]
    },
    "us-gaap_PlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PlanNameDomain",
     "presentation": [
      "http://www.cassavasciences.com/20241231/role/statement-note-11-2020-cash-incentive-bonus-plan",
      "http://www.cassavasciences.com/20241231/role/statement-note-11-2020-cash-incentive-bonus-plan-details-textual",
      "http://www.cassavasciences.com/20241231/role/statement-note-7-stockholders-equity-and-stockbased-compensation",
      "http://www.cassavasciences.com/20241231/role/statement-note-7-stockholders-equity-and-stockbased-compensation-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Plan Name [Domain]",
        "documentation": "Plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r709",
      "r710",
      "r711",
      "r712",
      "r713",
      "r714",
      "r715",
      "r716",
      "r717",
      "r718",
      "r719",
      "r720",
      "r721",
      "r722",
      "r723",
      "r724",
      "r725",
      "r726",
      "r727",
      "r728",
      "r729",
      "r730",
      "r731",
      "r732",
      "r733",
      "r734"
     ]
    },
    "us-gaap_PolicyTextBlockAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PolicyTextBlockAbstract",
     "presentation": [
      "http://www.cassavasciences.com/20241231/role/statement-significant-accounting-policies-policies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_PolicyTextBlockAbstract",
        "terseLabel": "Accounting Policies"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PreferredStockDividendsAndOtherAdjustments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockDividendsAndOtherAdjustments",
     "crdr": "debit",
     "calculation": {
      "http://www.cassavasciences.com/20241231/role/statement-consolidated-statements-of-operations-": {
       "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.cassavasciences.com/20241231/role/statement-consolidated-statements-of-operations-"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_PreferredStockDividendsAndOtherAdjustments",
        "negatedLabel": "Adjustment for change in fair value of warrant liabilities",
        "documentation": "The aggregate value of preferred stock dividends and other adjustments necessary to derive net income apportioned to common stockholders."
       }
      }
     },
     "auth_ref": [
      "r19",
      "r662",
      "r678"
     ]
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockParOrStatedValuePerShare",
     "presentation": [
      "http://www.cassavasciences.com/20241231/role/statement-consolidated-balance-sheets-parentheticals"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred stock, par value (in dollars per share)",
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer."
       }
      }
     },
     "auth_ref": [
      "r55",
      "r267"
     ]
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockSharesAuthorized",
     "presentation": [
      "http://www.cassavasciences.com/20241231/role/statement-consolidated-balance-sheets-parentheticals"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred stock, shares authorized (in shares)",
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r55",
      "r504"
     ]
    },
    "us-gaap_PreferredStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockSharesIssued",
     "presentation": [
      "http://www.cassavasciences.com/20241231/role/statement-consolidated-balance-sheets-parentheticals"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred stock, shares issued (in shares)",
        "documentation": "Number of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt."
       }
      }
     },
     "auth_ref": [
      "r55",
      "r267"
     ]
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockSharesOutstanding",
     "presentation": [
      "http://www.cassavasciences.com/20241231/role/statement-consolidated-balance-sheets-parentheticals"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred stock, shares outstanding (in shares)",
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased."
       }
      }
     },
     "auth_ref": [
      "r55",
      "r504",
      "r522",
      "r791",
      "r792"
     ]
    },
    "us-gaap_PreferredStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockValue",
     "crdr": "credit",
     "calculation": {
      "http://www.cassavasciences.com/20241231/role/statement-consolidated-balance-sheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.cassavasciences.com/20241231/role/statement-consolidated-balance-sheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred stock, $0.001 par value; 10,000,000 shares authorized, none issued and outstanding",
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r55",
      "r449",
      "r605"
     ]
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.cassavasciences.com/20241231/role/statement-consolidated-balance-sheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.cassavasciences.com/20241231/role/statement-note-3-prepaid-expenses-and-other-current-assets-prepaid-expenses-and-other-current-assets-details": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.cassavasciences.com/20241231/role/statement-consolidated-balance-sheets",
      "http://www.cassavasciences.com/20241231/role/statement-note-3-prepaid-expenses-and-other-current-assets-prepaid-expenses-and-other-current-assets-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Prepaid expenses and other current assets",
        "totalLabel": "Total prepaid expenses and other current assets",
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r667"
     ]
    },
    "sava_PrepaidExpensesAndOtherCurrentAssetsTextBock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.cassavasciences.com/20241231",
     "localname": "PrepaidExpensesAndOtherCurrentAssetsTextBock",
     "presentation": [
      "http://www.cassavasciences.com/20241231/role/statement-note-3-prepaid-expenses-and-other-current-assets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Prepaid Expenses and Other Current Assets [Text Bock]",
        "documentation": "The entire disclosure of prepaid expenses and other current assets."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PrepaidInsurance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PrepaidInsurance",
     "crdr": "debit",
     "calculation": {
      "http://www.cassavasciences.com/20241231/role/statement-note-3-prepaid-expenses-and-other-current-assets-prepaid-expenses-and-other-current-assets-details": {
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.cassavasciences.com/20241231/role/statement-note-3-prepaid-expenses-and-other-current-assets-prepaid-expenses-and-other-current-assets-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Prepaid insurance",
        "documentation": "Amount of asset related to consideration paid in advance for insurance that provides economic benefits within a future period of one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r574",
      "r589",
      "r688"
     ]
    },
    "us-gaap_ProceedsFromInsuranceSettlementOperatingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromInsuranceSettlementOperatingActivities",
     "crdr": "debit",
     "presentation": [
      "http://www.cassavasciences.com/20241231/role/statement-note-2-summary-of-significant-accounting-policies-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_ProceedsFromInsuranceSettlementOperatingActivities",
        "terseLabel": "Proceeds from Insurance Settlement, Operating Activities",
        "documentation": "Amount of cash inflow for proceeds from settlement of insurance claim, classified as operating activities. Excludes insurance settlement classified as investing activities."
       }
      }
     },
     "auth_ref": [
      "r128",
      "r571"
     ]
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "crdr": "debit",
     "calculation": {
      "http://www.cassavasciences.com/20241231/role/statement-consolidated-statements-of-cash-flows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.cassavasciences.com/20241231/role/statement-consolidated-statements-of-cash-flows",
      "http://www.cassavasciences.com/20241231/role/statement-note-7-stockholders-equity-and-stockbased-compensation-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from common stock offering, net of issuance costs",
        "terseLabel": "Proceeds from Issuance of Common Stock",
        "documentation": "The cash inflow from the additional capital contribution to the entity."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "us-gaap_ProceedsFromIssuanceOfWarrants": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromIssuanceOfWarrants",
     "crdr": "debit",
     "presentation": [
      "http://www.cassavasciences.com/20241231/role/statement-note-13-warrant-dividend-distribution-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_ProceedsFromIssuanceOfWarrants",
        "terseLabel": "Proceeds from Issuance of Warrants",
        "documentation": "The cash inflow from issuance of rights to purchase common shares at predetermined price (usually issued together with corporate debt)."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "us-gaap_ProceedsFromStockOptionsExercised": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromStockOptionsExercised",
     "crdr": "debit",
     "calculation": {
      "http://www.cassavasciences.com/20241231/role/statement-consolidated-statements-of-cash-flows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.cassavasciences.com/20241231/role/statement-consolidated-statements-of-cash-flows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from issuance of common stock upon exercise of stock options",
        "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r2",
      "r11"
     ]
    },
    "us-gaap_ProceedsFromWarrantExercises": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromWarrantExercises",
     "crdr": "debit",
     "calculation": {
      "http://www.cassavasciences.com/20241231/role/statement-consolidated-statements-of-cash-flows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.cassavasciences.com/20241231/role/statement-consolidated-statements-of-cash-flows",
      "http://www.cassavasciences.com/20241231/role/statement-note-13-warrant-dividend-distribution-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from exercise of common stock warrants, net of exercise costs",
        "terseLabel": "Proceeds from Warrant Exercises",
        "documentation": "The cash inflow associated with the amount received from holders exercising their stock warrants."
       }
      }
     },
     "auth_ref": [
      "r669"
     ]
    },
    "sava_ProceedsFromWarrantsExercisedThatObligatedToPayCommission": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.cassavasciences.com/20241231",
     "localname": "ProceedsFromWarrantsExercisedThatObligatedToPayCommission",
     "crdr": "credit",
     "presentation": [
      "http://www.cassavasciences.com/20241231/role/statement-note-13-warrant-dividend-distribution-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "sava_ProceedsFromWarrantsExercisedThatObligatedToPayCommission",
        "terseLabel": "Proceeds From Warrants Exercised That Obligated to Pay Commission",
        "documentation": "Dollar amount required to be paid for commission from warrants exercised during the period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "presentation": [
      "http://www.cassavasciences.com/20241231/role/statement-note-2-summary-of-significant-accounting-policies",
      "http://www.cassavasciences.com/20241231/role/statement-note-2-summary-of-significant-accounting-policies-details-textual",
      "http://www.cassavasciences.com/20241231/role/statement-note-5-property-and-equipment-components-of-property-and-equipment-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-Lived Tangible Asset [Axis]",
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r394"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentDisclosureTextBlock",
     "presentation": [
      "http://www.cassavasciences.com/20241231/role/statement-note-5-property-and-equipment"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment Disclosure [Text Block]",
        "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections."
       }
      }
     },
     "auth_ref": [
      "r71",
      "r101",
      "r104",
      "r105"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentGross",
     "crdr": "debit",
     "calculation": {
      "http://www.cassavasciences.com/20241231/role/statement-note-5-property-and-equipment-components-of-property-and-equipment-details": {
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.cassavasciences.com/20241231/role/statement-note-5-property-and-equipment-components-of-property-and-equipment-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Gross property and equipment",
        "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures."
       }
      }
     },
     "auth_ref": [
      "r72",
      "r113",
      "r456"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentNet",
     "crdr": "debit",
     "calculation": {
      "http://www.cassavasciences.com/20241231/role/statement-consolidated-balance-sheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.cassavasciences.com/20241231/role/statement-note-5-property-and-equipment-components-of-property-and-equipment-details": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.cassavasciences.com/20241231/role/statement-consolidated-balance-sheets",
      "http://www.cassavasciences.com/20241231/role/statement-note-5-property-and-equipment-components-of-property-and-equipment-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property and equipment, net",
        "totalLabel": "Property and equipment, net",
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r394",
      "r444",
      "r456",
      "r605"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentPolicyTextBlock",
     "presentation": [
      "http://www.cassavasciences.com/20241231/role/statement-significant-accounting-policies-policies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r101",
      "r104",
      "r454"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentTextBlock",
     "presentation": [
      "http://www.cassavasciences.com/20241231/role/statement-note-5-property-and-equipment-tables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Table Text Block]",
        "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "presentation": [
      "http://www.cassavasciences.com/20241231/role/statement-note-2-summary-of-significant-accounting-policies",
      "http://www.cassavasciences.com/20241231/role/statement-note-2-summary-of-significant-accounting-policies-details-textual",
      "http://www.cassavasciences.com/20241231/role/statement-note-5-property-and-equipment-components-of-property-and-equipment-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-Lived Tangible Asset [Domain]",
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software."
       }
      }
     },
     "auth_ref": [
      "r72",
      "r394"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentUsefulLife": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentUsefulLife",
     "presentation": [
      "http://www.cassavasciences.com/20241231/role/statement-note-2-summary-of-significant-accounting-policies-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_PropertyPlantAndEquipmentUsefulLife",
        "terseLabel": "Property, Plant and Equipment, Useful Life (Year)",
        "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment."
       }
      }
     },
     "auth_ref": []
    },
    "srt_RangeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "RangeAxis",
     "presentation": [
      "http://www.cassavasciences.com/20241231/role/statement-note-11-2020-cash-incentive-bonus-plan",
      "http://www.cassavasciences.com/20241231/role/statement-note-11-2020-cash-incentive-bonus-plan-details-textual",
      "http://www.cassavasciences.com/20241231/role/statement-note-2-summary-of-significant-accounting-policies",
      "http://www.cassavasciences.com/20241231/role/statement-note-2-summary-of-significant-accounting-policies-details-textual",
      "http://www.cassavasciences.com/20241231/role/statement-note-7-stockholders-equity-and-stockbased-compensation-stock-option-valuation-assumptions-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]"
       }
      }
     },
     "auth_ref": [
      "r250",
      "r252",
      "r253",
      "r254",
      "r271",
      "r273",
      "r303",
      "r304",
      "r305",
      "r314",
      "r377",
      "r403",
      "r404",
      "r406",
      "r472",
      "r474",
      "r481",
      "r494",
      "r495",
      "r546",
      "r548",
      "r550",
      "r551",
      "r553",
      "r567",
      "r568",
      "r588",
      "r592",
      "r594",
      "r601",
      "r602",
      "r603",
      "r604",
      "r614",
      "r619",
      "r701",
      "r706",
      "r745",
      "r753",
      "r754",
      "r755",
      "r756",
      "r757"
     ]
    },
    "sava_RangeFiveMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.cassavasciences.com/20241231",
     "localname": "RangeFiveMember",
     "presentation": [
      "http://www.cassavasciences.com/20241231/role/statement-note-7-stockholders-equity-and-stockbased-compensation-schedule-of-stock-options-by-exercise-price-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Range Five [Member]",
        "documentation": "Relating to range five."
       }
      }
     },
     "auth_ref": []
    },
    "sava_RangeFourMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.cassavasciences.com/20241231",
     "localname": "RangeFourMember",
     "presentation": [
      "http://www.cassavasciences.com/20241231/role/statement-note-7-stockholders-equity-and-stockbased-compensation-schedule-of-stock-options-by-exercise-price-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Range Four [Member]",
        "documentation": "Relating to range four."
       }
      }
     },
     "auth_ref": []
    },
    "srt_RangeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "RangeMember",
     "presentation": [
      "http://www.cassavasciences.com/20241231/role/statement-note-11-2020-cash-incentive-bonus-plan",
      "http://www.cassavasciences.com/20241231/role/statement-note-11-2020-cash-incentive-bonus-plan-details-textual",
      "http://www.cassavasciences.com/20241231/role/statement-note-2-summary-of-significant-accounting-policies",
      "http://www.cassavasciences.com/20241231/role/statement-note-2-summary-of-significant-accounting-policies-details-textual",
      "http://www.cassavasciences.com/20241231/role/statement-note-7-stockholders-equity-and-stockbased-compensation-stock-option-valuation-assumptions-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Domain]"
       }
      }
     },
     "auth_ref": [
      "r250",
      "r252",
      "r253",
      "r254",
      "r271",
      "r273",
      "r303",
      "r304",
      "r305",
      "r314",
      "r377",
      "r403",
      "r404",
      "r406",
      "r472",
      "r474",
      "r481",
      "r494",
      "r495",
      "r546",
      "r548",
      "r550",
      "r551",
      "r553",
      "r567",
      "r568",
      "r588",
      "r592",
      "r594",
      "r601",
      "r602",
      "r603",
      "r604",
      "r614",
      "r619",
      "r701",
      "r706",
      "r745",
      "r753",
      "r754",
      "r755",
      "r756",
      "r757"
     ]
    },
    "sava_RangeOneMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.cassavasciences.com/20241231",
     "localname": "RangeOneMember",
     "presentation": [
      "http://www.cassavasciences.com/20241231/role/statement-note-7-stockholders-equity-and-stockbased-compensation-schedule-of-stock-options-by-exercise-price-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Range One [Member]",
        "documentation": "Relating to range one."
       }
      }
     },
     "auth_ref": []
    },
    "sava_RangeThreeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.cassavasciences.com/20241231",
     "localname": "RangeThreeMember",
     "presentation": [
      "http://www.cassavasciences.com/20241231/role/statement-note-7-stockholders-equity-and-stockbased-compensation-schedule-of-stock-options-by-exercise-price-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Range Three [Member]",
        "documentation": "Relating to range three."
       }
      }
     },
     "auth_ref": []
    },
    "sava_RangeTwoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.cassavasciences.com/20241231",
     "localname": "RangeTwoMember",
     "presentation": [
      "http://www.cassavasciences.com/20241231/role/statement-note-7-stockholders-equity-and-stockbased-compensation-schedule-of-stock-options-by-exercise-price-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Range Two [Member]",
        "documentation": "Relating to range two."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RealEstateOwnedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RealEstateOwnedTextBlock",
     "presentation": [
      "http://www.cassavasciences.com/20241231/role/statement-note-4-real-property-and-other-income-expense"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Real Estate Owned [Text Block]",
        "documentation": "The entire disclosure for real estate owned (as defined). Generally, the largest component of real estate owned by lenders is assets taken in settlement of troubled loans through surrender or foreclosure. Real estate investments, real estate loans that qualify as investments in real estate, and premises that are no longer used in operations may also be included in real estate owned."
       }
      }
     },
     "auth_ref": [
      "r686"
     ]
    },
    "sava_RedemptionPercentageOfWarrants": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.cassavasciences.com/20241231",
     "localname": "RedemptionPercentageOfWarrants",
     "presentation": [
      "http://www.cassavasciences.com/20241231/role/statement-note-13-warrant-dividend-distribution-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "sava_RedemptionPercentageOfWarrants",
        "terseLabel": "Redemption Percentage of Warrants",
        "documentation": "The Percent of the cost for redemption of warrants."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RelatedPartyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RelatedPartyDomain",
     "presentation": [
      "http://www.cassavasciences.com/20241231/role/statement-note-2-summary-of-significant-accounting-policies",
      "http://www.cassavasciences.com/20241231/role/statement-note-2-summary-of-significant-accounting-policies-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related and Nonrelated Parties [Domain]",
        "documentation": "Related and nonrelated parties. Related party includes, but is not limited to, affiliate, other entity for which investment is accounted for under equity method, trust for benefit of employee, principal owner, management, and member of immediate family, and other party that may be prevented from pursuing separate interests because of control, significant influence, or ownership interest."
       }
      }
     },
     "auth_ref": [
      "r205",
      "r272",
      "r397",
      "r398",
      "r447",
      "r453",
      "r497",
      "r498",
      "r499",
      "r500",
      "r501",
      "r521",
      "r523",
      "r545"
     ]
    },
    "us-gaap_RelatedPartyTransactionAmountsOfTransaction": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RelatedPartyTransactionAmountsOfTransaction",
     "crdr": "debit",
     "presentation": [
      "http://www.cassavasciences.com/20241231/role/statement-note-2-summary-of-significant-accounting-policies-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_RelatedPartyTransactionAmountsOfTransaction",
        "terseLabel": "Related Party Transaction, Amounts of Transaction",
        "documentation": "Amount of transactions with related party during the financial reporting period."
       }
      }
     },
     "auth_ref": [
      "r44",
      "r397"
     ]
    },
    "sava_RelatedPartyTransactionPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.cassavasciences.com/20241231",
     "localname": "RelatedPartyTransactionPolicyTextBlock",
     "presentation": [
      "http://www.cassavasciences.com/20241231/role/statement-significant-accounting-policies-policies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transaction [Policy Text Block]",
        "documentation": "Policy describing the related party transactions."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RelatedPartyTransactionsByRelatedPartyAxis",
     "presentation": [
      "http://www.cassavasciences.com/20241231/role/statement-note-2-summary-of-significant-accounting-policies",
      "http://www.cassavasciences.com/20241231/role/statement-note-2-summary-of-significant-accounting-policies-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related and Nonrelated Parties [Axis]",
        "documentation": "Information by related and nonrelated parties. Related party includes, but is not limited to, affiliate, other entity for which investment is accounted for under equity method, trust for benefit of employee, principal owner, management, and member of immediate family, and other party that may be prevented from pursuing separate interests because of control, significant influence, or ownership interest."
       }
      }
     },
     "auth_ref": [
      "r205",
      "r272",
      "r397",
      "r398",
      "r447",
      "r453",
      "r497",
      "r498",
      "r499",
      "r500",
      "r501",
      "r521",
      "r523",
      "r545",
      "r749"
     ]
    },
    "srt_RepurchaseAgreementCounterpartyNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "RepurchaseAgreementCounterpartyNameDomain",
     "presentation": [
      "http://www.cassavasciences.com/20241231/role/statement-note-10-commitments",
      "http://www.cassavasciences.com/20241231/role/statement-note-10-commitments-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Domain]"
       }
      }
     },
     "auth_ref": [
      "r135",
      "r136",
      "r266",
      "r268",
      "r399",
      "r405",
      "r445",
      "r577",
      "r578"
     ]
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ResearchAndDevelopmentExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.cassavasciences.com/20241231/role/statement-consolidated-statements-of-operations-": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.cassavasciences.com/20241231/role/statement-consolidated-statements-of-operations-",
      "http://www.cassavasciences.com/20241231/role/statement-note-2-summary-of-significant-accounting-policies-summary-of-codm-segments-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and Development Expense",
        "terseLabel": "Research and development",
        "documentation": "Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity."
       }
      }
     },
     "auth_ref": [
      "r316",
      "r570",
      "r585",
      "r758"
     ]
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ResearchAndDevelopmentExpenseMember",
     "presentation": [
      "http://www.cassavasciences.com/20241231/role/statement-note-7-stockholders-equity-and-stockbased-compensation-stockbased-compensation-expense-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and Development Expense [Member]",
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "presentation": [
      "http://www.cassavasciences.com/20241231/role/statement-significant-accounting-policies-policies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and Development Expense, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process."
       }
      }
     },
     "auth_ref": [
      "r315"
     ]
    },
    "us-gaap_ResearchMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ResearchMember",
     "presentation": [
      "http://www.cassavasciences.com/20241231/role/statement-note-9-income-taxes",
      "http://www.cassavasciences.com/20241231/role/statement-note-9-income-taxes-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research Tax Credit Carryforward [Member]",
        "documentation": "Research tax credit carryforwards arising from certain qualifying expenditures incurred to develop new products and processes."
       }
      }
     },
     "auth_ref": [
      "r741"
     ]
    },
    "us-gaap_RestructuringAndRelatedCostExpectedCost1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RestructuringAndRelatedCostExpectedCost1",
     "crdr": "debit",
     "presentation": [
      "http://www.cassavasciences.com/20241231/role/statement-note-14-subsequent-event-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_RestructuringAndRelatedCostExpectedCost1",
        "terseLabel": "Restructuring and Related Cost, Expected Cost",
        "documentation": "Amount expected to be recognized in earnings for the specified restructuring cost."
       }
      }
     },
     "auth_ref": [
      "r240",
      "r243",
      "r244",
      "r246"
     ]
    },
    "us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated": {
     "xbrltype": "integerItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RestructuringAndRelatedCostNumberOfPositionsEliminated",
     "presentation": [
      "http://www.cassavasciences.com/20241231/role/statement-note-14-subsequent-event-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated",
        "terseLabel": "Restructuring and Related Cost, Number of Positions Eliminated",
        "documentation": "The number of positions eliminated during the period as a result of restructuring activities."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent",
     "presentation": [
      "http://www.cassavasciences.com/20241231/role/statement-note-14-subsequent-event-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent",
        "terseLabel": "Restructuring and Related Cost, Number of Positions Eliminated, Period Percent",
        "documentation": "The number of positions eliminated during the period as a percentage of total positions eliminated during the period in connection with the restructuring plan(s)."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RestructuringCostAndReserveAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RestructuringCostAndReserveAxis",
     "presentation": [
      "http://www.cassavasciences.com/20241231/role/statement-note-14-subsequent-event",
      "http://www.cassavasciences.com/20241231/role/statement-note-14-subsequent-event-details-textual",
      "http://www.cassavasciences.com/20241231/role/statement-note-7-stockholders-equity-and-stockbased-compensation",
      "http://www.cassavasciences.com/20241231/role/statement-note-7-stockholders-equity-and-stockbased-compensation-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restructuring Type [Axis]",
        "documentation": "Information by type of restructuring cost."
       }
      }
     },
     "auth_ref": [
      "r240",
      "r241",
      "r244",
      "r245"
     ]
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RetainedEarningsAccumulatedDeficit",
     "crdr": "credit",
     "calculation": {
      "http://www.cassavasciences.com/20241231/role/statement-consolidated-balance-sheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.cassavasciences.com/20241231/role/statement-consolidated-balance-sheets",
      "http://www.cassavasciences.com/20241231/role/statement-note-1-general-liquidity-and-basis-of-presentation-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_RetainedEarningsAccumulatedDeficit",
        "terseLabel": "Retained Earnings (Accumulated Deficit)",
        "documentation": "Amount of accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r58",
      "r74",
      "r451",
      "r479",
      "r480",
      "r487",
      "r505",
      "r605"
     ]
    },
    "us-gaap_RetainedEarningsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RetainedEarningsMember",
     "presentation": [
      "http://www.cassavasciences.com/20241231/role/statement-consolidated-statements-of-stockholders-equity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Retained Earnings [Member]",
        "documentation": "Accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r107",
      "r138",
      "r139",
      "r140",
      "r142",
      "r147",
      "r149",
      "r151",
      "r207",
      "r208",
      "r236",
      "r347",
      "r348",
      "r355",
      "r356",
      "r357",
      "r359",
      "r360",
      "r361",
      "r366",
      "r368",
      "r369",
      "r371",
      "r372",
      "r392",
      "r393",
      "r476",
      "r478",
      "r489",
      "r791"
     ]
    },
    "ecd_Rule10b51ArrAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "Rule10b51ArrAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "ecd_Rule10b51ArrAdoptedFlag",
        "terseLabel": "Rule 10b5-1 Arrangement Adopted [Flag]"
       }
      }
     },
     "auth_ref": [
      "r648"
     ]
    },
    "ecd_Rule10b51ArrTrmntdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "Rule10b51ArrTrmntdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "ecd_Rule10b51ArrTrmntdFlag",
        "terseLabel": "Rule 10b5-1 Arrangement Terminated [Flag]"
       }
      }
     },
     "auth_ref": [
      "r648"
     ]
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SaleOfStockNameOfTransactionDomain",
     "presentation": [
      "http://www.cassavasciences.com/20241231/role/statement-note-7-stockholders-equity-and-stockbased-compensation",
      "http://www.cassavasciences.com/20241231/role/statement-note-7-stockholders-equity-and-stockbased-compensation-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sale of Stock [Domain]",
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement."
       }
      }
     },
     "auth_ref": []
    },
    "srt_ScenarioForecastMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "ScenarioForecastMember",
     "presentation": [
      "http://www.cassavasciences.com/20241231/role/statement-note-14-subsequent-event",
      "http://www.cassavasciences.com/20241231/role/statement-note-14-subsequent-event-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forecast [Member]"
       }
      }
     },
     "auth_ref": [
      "r274",
      "r675"
     ]
    },
    "srt_ScenarioUnspecifiedDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "ScenarioUnspecifiedDomain",
     "presentation": [
      "http://www.cassavasciences.com/20241231/role/statement-note-14-subsequent-event",
      "http://www.cassavasciences.com/20241231/role/statement-note-14-subsequent-event-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Scenario [Domain]"
       }
      }
     },
     "auth_ref": [
      "r152",
      "r274",
      "r663",
      "r675"
     ]
    },
    "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
     "presentation": [
      "http://www.cassavasciences.com/20241231/role/statement-note-9-income-taxes-tables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Deferred Tax Assets and Liabilities [Table Text Block]",
        "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets."
       }
      }
     },
     "auth_ref": [
      "r740"
     ]
    },
    "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
     "presentation": [
      "http://www.cassavasciences.com/20241231/role/statement-note-2-summary-of-significant-accounting-policies-tables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]",
        "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r677"
     ]
    },
    "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
     "presentation": [
      "http://www.cassavasciences.com/20241231/role/statement-note-9-income-taxes-tables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]",
        "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r324",
      "r599",
      "r736"
     ]
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
     "presentation": [
      "http://www.cassavasciences.com/20241231/role/statement-note-7-stockholders-equity-and-stockbased-compensation-tables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]",
        "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement."
       }
      }
     },
     "auth_ref": [
      "r39"
     ]
    },
    "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
     "presentation": [
      "http://www.cassavasciences.com/20241231/role/statement-note-6-intangible-assets-tables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Finite-Lived Intangible Assets [Table Text Block]",
        "documentation": "Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment."
       }
      }
     },
     "auth_ref": [
      "r591",
      "r695"
     ]
    },
    "us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock",
     "presentation": [
      "http://www.cassavasciences.com/20241231/role/statement-note-4-real-property-and-other-income-expense-tables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Other Nonoperating Income (Expense) [Table Text Block]",
        "documentation": "Tabular disclosure of the components of non-operating income or non-operating expense that may include amounts earned from dividends, interest on securities, gains (losses) on securities sold, equity earnings of unconsolidated affiliates, net gain (loss) on sales of business, interest expense and other miscellaneous income or expense items."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfSegmentReportingInformationBySegmentTextBlock",
     "presentation": [
      "http://www.cassavasciences.com/20241231/role/statement-note-2-summary-of-significant-accounting-policies-tables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Segment Reporting Information, by Segment [Table Text Block]",
        "documentation": "Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss."
       }
      }
     },
     "auth_ref": [
      "r26",
      "r27",
      "r28"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfShareBasedCompensationActivityTableTextBlock",
     "presentation": [
      "http://www.cassavasciences.com/20241231/role/statement-note-7-stockholders-equity-and-stockbased-compensation-tables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Activity [Table Text Block]",
        "documentation": "Tabular disclosure of activity for award under share-based payment arrangement. Includes, but is not limited to, outstanding award at beginning and end of year, granted, exercised, forfeited, and weighted-average grant date fair value."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r10",
      "r84"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock",
     "presentation": [
      "http://www.cassavasciences.com/20241231/role/statement-note-7-stockholders-equity-and-stockbased-compensation-tables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Option, Exercise Price Range [Table Text Block]",
        "documentation": "Tabular disclosure of option exercise prices, by grouped ranges, including the upper and lower limits of the price range, the number of shares under option, weighted average exercise price and remaining contractual option terms."
       }
      }
     },
     "auth_ref": [
      "r34"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "presentation": [
      "http://www.cassavasciences.com/20241231/role/statement-note-7-stockholders-equity-and-stockbased-compensation-tables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Option, Activity [Table Text Block]",
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r10",
      "r80"
     ]
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "presentation": [
      "http://www.cassavasciences.com/20241231/role/statement-note-7-stockholders-equity-and-stockbased-compensation-tables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]",
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions."
       }
      }
     },
     "auth_ref": [
      "r87"
     ]
    },
    "us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
     "presentation": [
      "http://www.cassavasciences.com/20241231/role/statement-note-13-warrant-dividend-distribution-tables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]",
        "documentation": "Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable."
       }
      }
     },
     "auth_ref": [
      "r33"
     ]
    },
    "us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock",
     "presentation": [
      "http://www.cassavasciences.com/20241231/role/statement-note-9-income-taxes-tables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Unrecognized Tax Benefits Roll Forward [Table Text Block]",
        "documentation": "Tabular disclosure of the change in unrecognized tax benefits."
       }
      }
     },
     "auth_ref": [
      "r333",
      "r598"
     ]
    },
    "us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock",
     "presentation": [
      "http://www.cassavasciences.com/20241231/role/statement-note-6-intangible-assets-tables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]",
        "documentation": "Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets."
       }
      }
     },
     "auth_ref": [
      "r591",
      "r697"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "Security12bTitle",
     "presentation": [
      "http://www.cassavasciences.com/20241231/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r628"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://www.cassavasciences.com/20241231/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r630"
     ]
    },
    "us-gaap_SegmentDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SegmentDomain",
     "presentation": [
      "http://www.cassavasciences.com/20241231/role/statement-note-2-summary-of-significant-accounting-policies-summary-of-codm-segments-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segments [Domain]",
        "documentation": "Components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity."
       }
      }
     },
     "auth_ref": [
      "r94",
      "r95",
      "r96",
      "r97",
      "r168",
      "r170",
      "r171",
      "r172",
      "r173",
      "r174",
      "r175",
      "r176",
      "r177",
      "r178",
      "r179",
      "r180",
      "r181",
      "r182",
      "r183",
      "r184",
      "r185",
      "r193",
      "r194",
      "r195",
      "r196",
      "r197",
      "r198",
      "r199",
      "r200",
      "r204",
      "r212",
      "r213",
      "r214",
      "r215",
      "r216",
      "r217",
      "r218",
      "r219",
      "r220",
      "r234",
      "r243",
      "r246",
      "r461",
      "r462",
      "r463",
      "r464",
      "r465",
      "r466",
      "r467",
      "r468",
      "r469",
      "r470",
      "r471",
      "r584",
      "r585",
      "r586",
      "r590",
      "r616",
      "r759",
      "r761",
      "r762",
      "r763",
      "r764",
      "r765",
      "r766",
      "r767",
      "r768",
      "r769",
      "r770",
      "r771",
      "r772",
      "r773",
      "r774",
      "r775",
      "r776",
      "r777",
      "r778",
      "r779",
      "r780",
      "r781",
      "r782",
      "r783",
      "r784",
      "r785",
      "r786",
      "r787",
      "r788"
     ]
    },
    "srt_SegmentGeographicalDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "SegmentGeographicalDomain",
     "presentation": [
      "http://www.cassavasciences.com/20241231/role/statement-note-4-real-property-and-other-income-expense",
      "http://www.cassavasciences.com/20241231/role/statement-note-4-real-property-and-other-income-expense-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Domain]"
       }
      }
     },
     "auth_ref": [
      "r202",
      "r203",
      "r413",
      "r414",
      "r415",
      "r416",
      "r417",
      "r418",
      "r419",
      "r420",
      "r421",
      "r422",
      "r423",
      "r424",
      "r425",
      "r426",
      "r427",
      "r428",
      "r429",
      "r430",
      "r431",
      "r432",
      "r433",
      "r434",
      "r435",
      "r436",
      "r437",
      "r438",
      "r439",
      "r440",
      "r441",
      "r442",
      "r491",
      "r492",
      "r493",
      "r547",
      "r549",
      "r552",
      "r554",
      "r556",
      "r558",
      "r559",
      "r560",
      "r561",
      "r562",
      "r563",
      "r564",
      "r565",
      "r566",
      "r572",
      "r593",
      "r606",
      "r607",
      "r608",
      "r609",
      "r610",
      "r611",
      "r612",
      "r613",
      "r615",
      "r619",
      "r707",
      "r759",
      "r761",
      "r762",
      "r764",
      "r765",
      "r766",
      "r767",
      "r768",
      "r769",
      "r770",
      "r771",
      "r772",
      "r773",
      "r774",
      "r775",
      "r776",
      "r777",
      "r778",
      "r779",
      "r780",
      "r781",
      "r782",
      "r783",
      "r784",
      "r785",
      "r786",
      "r787",
      "r788"
     ]
    },
    "us-gaap_SegmentReportingOtherItemAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SegmentReportingOtherItemAmount",
     "crdr": "debit",
     "presentation": [
      "http://www.cassavasciences.com/20241231/role/statement-note-2-summary-of-significant-accounting-policies-summary-of-codm-segments-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other segment items(a)",
        "documentation": "Amount of other expense (income) and loss (gain) calculated as difference between segment revenue and separately disclosed expense category to arrive at segment profit (loss)."
       }
      }
     },
     "auth_ref": [
      "r168",
      "r184",
      "r185",
      "r198",
      "r585"
     ]
    },
    "us-gaap_SegmentReportingPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SegmentReportingPolicyPolicyTextBlock",
     "presentation": [
      "http://www.cassavasciences.com/20241231/role/statement-significant-accounting-policies-policies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Reporting, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for segment reporting."
       }
      }
     },
     "auth_ref": [
      "r186",
      "r187",
      "r188",
      "r189",
      "r190",
      "r191",
      "r192",
      "r201",
      "r202",
      "r583",
      "r584",
      "r587"
     ]
    },
    "us-gaap_SeveranceCosts1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SeveranceCosts1",
     "crdr": "debit",
     "presentation": [
      "http://www.cassavasciences.com/20241231/role/statement-note-2-summary-of-significant-accounting-policies-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_SeveranceCosts1",
        "terseLabel": "Severance Costs",
        "documentation": "Amount of expenses for special or contractual termination benefits provided to current employees involuntarily terminated under a benefit arrangement associated exit or disposal activities pursuant to an authorized plan. Excludes expenses related to one-time termination benefits, a discontinued operation or an asset retirement obligation."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "us-gaap_ShareBasedCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensation",
     "crdr": "debit",
     "calculation": {
      "http://www.cassavasciences.com/20241231/role/statement-consolidated-statements-of-cash-flows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.cassavasciences.com/20241231/role/statement-consolidated-statements-of-cash-flows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_ShareBasedCompensation",
        "terseLabel": "Stock-based compensation",
        "documentation": "Amount of noncash expense for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
     "presentation": [
      "http://www.cassavasciences.com/20241231/role/statement-note-2-summary-of-significant-accounting-policies-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
        "terseLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period (Year)",
        "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition."
       }
      }
     },
     "auth_ref": [
      "r595"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod",
     "presentation": [
      "http://www.cassavasciences.com/20241231/role/statement-note-7-stockholders-equity-and-stockbased-compensation-stock-option-and-performance-award-activity-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod",
        "negatedLabel": "Forfeited/canceled, awards (in shares)",
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r295"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "presentation": [
      "http://www.cassavasciences.com/20241231/role/statement-note-7-stockholders-equity-and-stockbased-compensation-stock-option-and-performance-award-activity-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Granted, awards (in shares)",
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)."
       }
      }
     },
     "auth_ref": [
      "r293"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
     "presentation": [
      "http://www.cassavasciences.com/20241231/role/statement-note-7-stockholders-equity-and-stockbased-compensation-stock-option-and-performance-award-activity-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
        "periodStartLabel": "Outstanding, awards (in shares)",
        "periodEndLabel": "Outstanding, awards (in shares)",
        "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date."
       }
      }
     },
     "auth_ref": [
      "r290",
      "r291"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod",
     "presentation": [
      "http://www.cassavasciences.com/20241231/role/statement-note-7-stockholders-equity-and-stockbased-compensation-stock-option-and-performance-award-activity-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Vested, awards (in shares)",
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r294"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions",
     "presentation": [
      "http://www.cassavasciences.com/20241231/role/statement-note-7-stockholders-equity-and-stockbased-compensation-stock-option-valuation-assumptions-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forfeiture rate",
        "documentation": "Restrictions on equity-based instruments during the vesting period, such as the inability to transfer unvested awards, are not taken into account in estimating the fair value of the award. However, restrictions that remain in effect after an award is vested, such as the inability to transfer or hedge vested options or a prohibition on the sale of outstanding vested shares (or other type of equity) for a period of time, affect the estimate of an award's fair value."
       }
      }
     },
     "auth_ref": [
      "r306"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "presentation": [
      "http://www.cassavasciences.com/20241231/role/statement-note-7-stockholders-equity-and-stockbased-compensation-details-textual",
      "http://www.cassavasciences.com/20241231/role/statement-note-7-stockholders-equity-and-stockbased-compensation-stock-option-valuation-assumptions-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Dividend yield",
        "terseLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate",
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term."
       }
      }
     },
     "auth_ref": [
      "r304"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
     "presentation": [
      "http://www.cassavasciences.com/20241231/role/statement-note-7-stockholders-equity-and-stockbased-compensation-stock-option-valuation-assumptions-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Volatility",
        "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period."
       }
      }
     },
     "auth_ref": [
      "r303"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "presentation": [
      "http://www.cassavasciences.com/20241231/role/statement-note-7-stockholders-equity-and-stockbased-compensation-stock-option-valuation-assumptions-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Risk-free interest rates",
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares."
       }
      }
     },
     "auth_ref": [
      "r305"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations",
     "presentation": [
      "http://www.cassavasciences.com/20241231/role/statement-note-7-stockholders-equity-and-stockbased-compensation-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations",
        "terseLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Expirations (in shares)",
        "documentation": "Number of shares under non-option equity instrument agreements for which rights to exercise lapsed."
       }
      }
     },
     "auth_ref": [
      "r83"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized",
     "presentation": [
      "http://www.cassavasciences.com/20241231/role/statement-note-7-stockholders-equity-and-stockbased-compensation-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized",
        "terseLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized (in shares)",
        "documentation": "Number of shares authorized for issuance under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r597"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "presentation": [
      "http://www.cassavasciences.com/20241231/role/statement-note-7-stockholders-equity-and-stockbased-compensation-stock-option-activity-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exercisable at December 31, 2024 (in shares)",
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan."
       }
      }
     },
     "auth_ref": [
      "r284"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "presentation": [
      "http://www.cassavasciences.com/20241231/role/statement-note-7-stockholders-equity-and-stockbased-compensation-stock-option-activity-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exercisable at December 31, 2022, weighted average exercise price (in dollars per share)",
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r284"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
     "presentation": [
      "http://www.cassavasciences.com/20241231/role/statement-note-7-stockholders-equity-and-stockbased-compensation-details-textual",
      "http://www.cassavasciences.com/20241231/role/statement-note-7-stockholders-equity-and-stockbased-compensation-stock-option-activity-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
        "terseLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period (in shares)",
        "negatedLabel": "Options forfeited/canceled (in shares)",
        "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r288"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "presentation": [
      "http://www.cassavasciences.com/20241231/role/statement-note-7-stockholders-equity-and-stockbased-compensation-stock-option-activity-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Options granted (in shares)",
        "documentation": "Gross number of share options (or share units) granted during the period."
       }
      }
     },
     "auth_ref": [
      "r286"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.cassavasciences.com/20241231/role/statement-note-7-stockholders-equity-and-stockbased-compensation-stock-option-valuation-assumptions-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted average fair value of stock options granted (in dollars per share)",
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology."
       }
      }
     },
     "auth_ref": [
      "r296"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "crdr": "debit",
     "presentation": [
      "http://www.cassavasciences.com/20241231/role/statement-note-7-stockholders-equity-and-stockbased-compensation-stock-option-activity-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Outstanding as of December 31, 2022, aggregate intrinsic value",
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding."
       }
      }
     },
     "auth_ref": [
      "r34"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "presentation": [
      "http://www.cassavasciences.com/20241231/role/statement-note-7-stockholders-equity-and-stockbased-compensation-stock-option-activity-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
        "periodStartLabel": "Outstanding, options (in shares)",
        "periodEndLabel": "Outstanding, options (in shares)",
        "documentation": "Number of options outstanding, including both vested and non-vested options."
       }
      }
     },
     "auth_ref": [
      "r282",
      "r283"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "presentation": [
      "http://www.cassavasciences.com/20241231/role/statement-note-7-stockholders-equity-and-stockbased-compensation-stock-option-activity-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
        "periodStartLabel": "Outstanding, options, weighted average exercise price (in dollars per share)",
        "periodEndLabel": "Outstanding, options, weighted average exercise price (in dollars per share)",
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r282",
      "r283"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue",
     "crdr": "debit",
     "presentation": [
      "http://www.cassavasciences.com/20241231/role/statement-note-7-stockholders-equity-and-stockbased-compensation-stock-option-activity-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Vested and expected to vest at December 31, 2022, aggregate intrinsic value",
        "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r298"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber",
     "presentation": [
      "http://www.cassavasciences.com/20241231/role/statement-note-7-stockholders-equity-and-stockbased-compensation-stock-option-activity-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Vested and expected to vest at December 31, 2024 (in shares)",
        "documentation": "Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r298"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice",
     "presentation": [
      "http://www.cassavasciences.com/20241231/role/statement-note-7-stockholders-equity-and-stockbased-compensation-stock-option-activity-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Vested and expected to vest at December 31, 2022, weighted average exercise price (in dollars per share)",
        "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r298"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "presentation": [
      "http://www.cassavasciences.com/20241231/role/statement-note-2-summary-of-significant-accounting-policies",
      "http://www.cassavasciences.com/20241231/role/statement-note-2-summary-of-significant-accounting-policies-details-textual",
      "http://www.cassavasciences.com/20241231/role/statement-note-7-stockholders-equity-and-stockbased-compensation",
      "http://www.cassavasciences.com/20241231/role/statement-note-7-stockholders-equity-and-stockbased-compensation-details-textual",
      "http://www.cassavasciences.com/20241231/role/statement-note-7-stockholders-equity-and-stockbased-compensation-stock-option-and-performance-award-activity-details",
      "http://www.cassavasciences.com/20241231/role/statement-note-7-stockholders-equity-and-stockbased-compensation-stock-option-valuation-assumptions-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Type [Domain]",
        "documentation": "Award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r278",
      "r279",
      "r280",
      "r282",
      "r283",
      "r284",
      "r285",
      "r286",
      "r287",
      "r288",
      "r289",
      "r290",
      "r291",
      "r292",
      "r293",
      "r294",
      "r295",
      "r296",
      "r297",
      "r298",
      "r299",
      "r302",
      "r303",
      "r304",
      "r305",
      "r306"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://www.cassavasciences.com/20241231/role/statement-note-7-stockholders-equity-and-stockbased-compensation-stock-option-activity-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Options exercised, weighted average exercise price (in dollars per share)",
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares."
       }
      }
     },
     "auth_ref": [
      "r287"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://www.cassavasciences.com/20241231/role/statement-note-7-stockholders-equity-and-stockbased-compensation-stock-option-activity-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Options forfeited/canceled, weighted average exercise price (in dollars per share)",
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated."
       }
      }
     },
     "auth_ref": [
      "r288"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://www.cassavasciences.com/20241231/role/statement-note-7-stockholders-equity-and-stockbased-compensation-stock-option-activity-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Options granted, weighted average exercise price (in dollars per share)",
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options."
       }
      }
     },
     "auth_ref": [
      "r286"
     ]
    },
    "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy",
     "presentation": [
      "http://www.cassavasciences.com/20241231/role/statement-significant-accounting-policies-policies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost."
       }
      }
     },
     "auth_ref": [
      "r275",
      "r281",
      "r300",
      "r301",
      "r302",
      "r303",
      "r306",
      "r309",
      "r310",
      "r311",
      "r312"
     ]
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis",
     "presentation": [
      "http://www.cassavasciences.com/20241231/role/statement-note-7-stockholders-equity-and-stockbased-compensation-schedule-of-stock-options-by-exercise-price-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exercise Price Range [Axis]",
        "documentation": "Information by range of option prices pertaining to options granted."
       }
      }
     },
     "auth_ref": [
      "r37"
     ]
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain",
     "presentation": [
      "http://www.cassavasciences.com/20241231/role/statement-note-7-stockholders-equity-and-stockbased-compensation-schedule-of-stock-options-by-exercise-price-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exercise Price Range [Domain]",
        "documentation": "Supplementary information on outstanding and exercisable share awards as of the balance sheet date which stratifies outstanding options by ranges of exercise prices."
       }
      }
     },
     "auth_ref": [
      "r38"
     ]
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit",
     "presentation": [
      "http://www.cassavasciences.com/20241231/role/statement-note-7-stockholders-equity-and-stockbased-compensation-schedule-of-stock-options-by-exercise-price-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Options, exercise price, lower limit (in dollars per share)",
        "documentation": "The floor of a customized range of exercise prices for purposes of disclosing shares potentially issuable under outstanding stock option awards on all stock option plans and other required information pertaining to awards in the customized range."
       }
      }
     },
     "auth_ref": [
      "r38"
     ]
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions",
     "presentation": [
      "http://www.cassavasciences.com/20241231/role/statement-note-7-stockholders-equity-and-stockbased-compensation-schedule-of-stock-options-by-exercise-price-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Options exercisable (in shares)",
        "label": "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions",
        "documentation": "The number of shares reserved for issuance pertaining to the outstanding exercisable stock options as of the balance sheet date in the customized range of exercise prices for which the market and performance vesting condition has been satisfied."
       }
      }
     },
     "auth_ref": [
      "r36"
     ]
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions",
     "presentation": [
      "http://www.cassavasciences.com/20241231/role/statement-note-7-stockholders-equity-and-stockbased-compensation-schedule-of-stock-options-by-exercise-price-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Options outstanding (in shares)",
        "label": "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions",
        "documentation": "The number of shares reserved for issuance pertaining to the outstanding stock options as of the balance sheet date for all option plans in the customized range of exercise prices."
       }
      }
     },
     "auth_ref": [
      "r81",
      "r82"
     ]
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit",
     "presentation": [
      "http://www.cassavasciences.com/20241231/role/statement-note-7-stockholders-equity-and-stockbased-compensation-schedule-of-stock-options-by-exercise-price-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Options, exercise price, upper limit (in dollars per share)",
        "documentation": "The ceiling of a customized range of exercise prices for purposes of disclosing shares potentially issuable under outstanding stock option awards on all stock option plans and other required information pertaining to awards in the customized range."
       }
      }
     },
     "auth_ref": [
      "r38"
     ]
    },
    "us-gaap_ShareBasedPaymentArrangementEmployeeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedPaymentArrangementEmployeeMember",
     "presentation": [
      "http://www.cassavasciences.com/20241231/role/statement-consolidated-statements-of-stockholders-equity",
      "http://www.cassavasciences.com/20241231/role/statement-note-7-stockholders-equity-and-stockbased-compensation",
      "http://www.cassavasciences.com/20241231/role/statement-note-7-stockholders-equity-and-stockbased-compensation-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Employee [Member]",
        "documentation": "Recipient, of award granted under share-based payment arrangement, over whom grantor exercises or has right to exercise sufficient control to establish employer-employee relationship based on law of pertinent jurisdiction. Includes, but is not limited to, nonemployee director treated as employee when acting as member of board of directors, if elected by grantor's shareholders or appointed to board position to be filled by shareholder election when existing term expires."
       }
      }
     },
     "auth_ref": [
      "r277",
      "r278",
      "r279",
      "r280",
      "r282",
      "r283",
      "r284",
      "r285",
      "r286",
      "r287",
      "r288",
      "r289",
      "r290",
      "r291",
      "r292",
      "r293",
      "r294",
      "r295",
      "r296",
      "r297",
      "r298",
      "r299",
      "r302",
      "r303",
      "r304",
      "r305",
      "r306"
     ]
    },
    "us-gaap_ShareBasedPaymentArrangementNonemployeeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedPaymentArrangementNonemployeeMember",
     "presentation": [
      "http://www.cassavasciences.com/20241231/role/statement-consolidated-statements-of-stockholders-equity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Nonemployee [Member]",
        "documentation": "Recipient, of award granted under share-based payment arrangement, over whom grantor does not exercise nor has right to exercise sufficient control to establish employer-employee relationship based on law of pertinent jurisdiction. Excludes nonemployee director treated as employee when acting as member of board of directors, if elected by grantor's shareholders or appointed to board position to be filled by shareholder election when existing term expires."
       }
      }
     },
     "auth_ref": [
      "r276",
      "r278",
      "r279",
      "r280",
      "r282",
      "r283",
      "r284",
      "r285",
      "r286",
      "r287",
      "r288",
      "r289",
      "r290",
      "r291",
      "r292",
      "r293",
      "r294",
      "r295",
      "r296",
      "r297",
      "r298",
      "r299",
      "r302",
      "r303",
      "r304",
      "r305",
      "r306"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod",
     "presentation": [
      "http://www.cassavasciences.com/20241231/role/statement-note-7-stockholders-equity-and-stockbased-compensation-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod",
        "terseLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period (Year)",
        "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r596"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "presentation": [
      "http://www.cassavasciences.com/20241231/role/statement-note-7-stockholders-equity-and-stockbased-compensation-stock-option-valuation-assumptions-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Expected life of option (in years) (Year)",
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r302"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1",
     "crdr": "debit",
     "presentation": [
      "http://www.cassavasciences.com/20241231/role/statement-note-7-stockholders-equity-and-stockbased-compensation-stock-option-activity-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exercisable at December 31, 2022, aggregate intrinsic value",
        "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable."
       }
      }
     },
     "auth_ref": [
      "r34"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1",
     "presentation": [
      "http://www.cassavasciences.com/20241231/role/statement-note-7-stockholders-equity-and-stockbased-compensation-stock-option-activity-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exercisable at December 31, 2022, weighted average contractual term (Year)",
        "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r34"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "presentation": [
      "http://www.cassavasciences.com/20241231/role/statement-note-7-stockholders-equity-and-stockbased-compensation-stock-option-activity-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Outstanding as of December 31, 2022, weighted average contractual term (Year)",
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r86"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1",
     "presentation": [
      "http://www.cassavasciences.com/20241231/role/statement-note-7-stockholders-equity-and-stockbased-compensation-stock-option-activity-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Vested and expected to vest at December 31, 2022, weighted average contractual term (Year)",
        "documentation": "Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r298"
     ]
    },
    "us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1",
     "presentation": [
      "http://www.cassavasciences.com/20241231/role/statement-note-7-stockholders-equity-and-stockbased-compensation-schedule-of-stock-options-by-exercise-price-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Options exercisable, weighted average exercise price (in dollars per share)",
        "label": "us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1",
        "documentation": "Weighted average exercise price as of the balance sheet date for those equity-based payment arrangements exercisable and outstanding."
       }
      }
     },
     "auth_ref": [
      "r35"
     ]
    },
    "us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1",
     "presentation": [
      "http://www.cassavasciences.com/20241231/role/statement-note-7-stockholders-equity-and-stockbased-compensation-schedule-of-stock-options-by-exercise-price-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Options outstanding, weighted average exercise price (in dollars per share)",
        "label": "us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1",
        "documentation": "The weighted average price as of the balance sheet date at which grantees could acquire the underlying shares with respect to all outstanding stock options which are in the customized range of exercise prices."
       }
      }
     },
     "auth_ref": [
      "r81",
      "r82"
     ]
    },
    "us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2",
     "presentation": [
      "http://www.cassavasciences.com/20241231/role/statement-note-7-stockholders-equity-and-stockbased-compensation-schedule-of-stock-options-by-exercise-price-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Options outstanding, weighted average contractual life (Year)",
        "label": "us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2",
        "documentation": "Weighted average remaining contractual term of outstanding stock options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r86"
     ]
    },
    "sava_ShareholderDerivativeActionsDelawareCourtMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.cassavasciences.com/20241231",
     "localname": "ShareholderDerivativeActionsDelawareCourtMember",
     "presentation": [
      "http://www.cassavasciences.com/20241231/role/statement-note-12-contingencies",
      "http://www.cassavasciences.com/20241231/role/statement-note-12-contingencies-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shareholder Derivative Actions, Delaware Court [Member]",
        "documentation": "Represents shareholder derivative actions in Delaware court."
       }
      }
     },
     "auth_ref": []
    },
    "sava_ShareholderDerivativeActionsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.cassavasciences.com/20241231",
     "localname": "ShareholderDerivativeActionsMember",
     "presentation": [
      "http://www.cassavasciences.com/20241231/role/statement-note-12-contingencies",
      "http://www.cassavasciences.com/20241231/role/statement-note-12-contingencies-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shareholder Derivative Actions [Member]",
        "documentation": "Represents shareholder derivative actions."
       }
      }
     },
     "auth_ref": []
    },
    "sava_ShareholderDerivativeActionsTexasCourtMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.cassavasciences.com/20241231",
     "localname": "ShareholderDerivativeActionsTexasCourtMember",
     "presentation": [
      "http://www.cassavasciences.com/20241231/role/statement-note-12-contingencies",
      "http://www.cassavasciences.com/20241231/role/statement-note-12-contingencies-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shareholder Derivative Actions, Texas Court [Member]",
        "documentation": "Represents shareholder derivative actions in Texas Court"
       }
      }
     },
     "auth_ref": []
    },
    "sava_ShareholderDerivativeActionsTexasStateCourtMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.cassavasciences.com/20241231",
     "localname": "ShareholderDerivativeActionsTexasStateCourtMember",
     "presentation": [
      "http://www.cassavasciences.com/20241231/role/statement-note-12-contingencies",
      "http://www.cassavasciences.com/20241231/role/statement-note-12-contingencies-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shareholder Derivative Actions, Texas State Court Member",
        "documentation": "Represents shareholder derivative actions in Texas State Court."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareholdersEquityAndShareBasedPaymentsTextBlock",
     "presentation": [
      "http://www.cassavasciences.com/20241231/role/statement-note-7-stockholders-equity-and-stockbased-compensation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shareholders' Equity and Share-Based Payments [Text Block]",
        "documentation": "The entire disclosure for shareholders' equity and share-based payment arrangement. Includes, but is not limited to, disclosure of policy and terms of share-based payment arrangement, deferred compensation arrangement, and employee stock purchase plan (ESPP)."
       }
      }
     },
     "auth_ref": [
      "r73",
      "r78"
     ]
    },
    "us-gaap_SharesIssuedPricePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharesIssuedPricePerShare",
     "presentation": [
      "http://www.cassavasciences.com/20241231/role/statement-note-7-stockholders-equity-and-stockbased-compensation-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_SharesIssuedPricePerShare",
        "terseLabel": "Shares Issued, Price Per Share (in dollars per share)",
        "documentation": "Per share or per unit amount of equity securities issued."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharesOutstanding",
     "presentation": [
      "http://www.cassavasciences.com/20241231/role/statement-consolidated-statements-of-stockholders-equity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_SharesOutstanding",
        "periodStartLabel": "Balance (in shares)",
        "periodEndLabel": "Balance (in shares)",
        "documentation": "Number of shares issued which are neither cancelled nor held in the treasury."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SignificantAccountingPoliciesTextBlock",
     "presentation": [
      "http://www.cassavasciences.com/20241231/role/statement-note-2-summary-of-significant-accounting-policies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Significant Accounting Policies [Text Block]",
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity."
       }
      }
     },
     "auth_ref": [
      "r69",
      "r132"
     ]
    },
    "us-gaap_SignificantSupplyCommitmentRemainingMinimumAmountCommitted": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SignificantSupplyCommitmentRemainingMinimumAmountCommitted",
     "crdr": "credit",
     "presentation": [
      "http://www.cassavasciences.com/20241231/role/statement-note-10-commitments-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_SignificantSupplyCommitmentRemainingMinimumAmountCommitted",
        "terseLabel": "Supply Commitment, Remaining Minimum Amount Committed",
        "documentation": "The floor amount as of the balance sheet date that the entity must expend to satisfy the terms of disclosed arrangements (excluding long-term commitments) in which the entity must commit resources to supply goods or services to one or more customers."
       }
      }
     },
     "auth_ref": [
      "r51",
      "r91"
     ]
    },
    "sava_SimufilamActiveIngredientMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.cassavasciences.com/20241231",
     "localname": "SimufilamActiveIngredientMember",
     "presentation": [
      "http://www.cassavasciences.com/20241231/role/statement-note-10-commitments",
      "http://www.cassavasciences.com/20241231/role/statement-note-10-commitments-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Simufilam Active Ingredient [Member]",
        "documentation": "Represents the simufilam active ingredient."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementBusinessSegmentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementBusinessSegmentsAxis",
     "presentation": [
      "http://www.cassavasciences.com/20241231/role/statement-note-2-summary-of-significant-accounting-policies-summary-of-codm-segments-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segments [Axis]",
        "documentation": "Information by business segments."
       }
      }
     },
     "auth_ref": [
      "r94",
      "r95",
      "r96",
      "r97",
      "r108",
      "r168",
      "r170",
      "r171",
      "r172",
      "r173",
      "r174",
      "r175",
      "r176",
      "r177",
      "r178",
      "r179",
      "r180",
      "r181",
      "r182",
      "r183",
      "r184",
      "r185",
      "r193",
      "r194",
      "r195",
      "r196",
      "r197",
      "r198",
      "r199",
      "r200",
      "r204",
      "r212",
      "r213",
      "r214",
      "r215",
      "r216",
      "r217",
      "r218",
      "r219",
      "r220",
      "r234",
      "r238",
      "r243",
      "r246",
      "r461",
      "r462",
      "r463",
      "r464",
      "r465",
      "r466",
      "r467",
      "r468",
      "r469",
      "r470",
      "r471",
      "r584",
      "r585",
      "r586",
      "r590",
      "r616",
      "r759",
      "r761",
      "r762",
      "r763",
      "r764",
      "r765",
      "r766",
      "r767",
      "r768",
      "r769",
      "r770",
      "r771",
      "r772",
      "r773",
      "r774",
      "r775",
      "r776",
      "r777",
      "r778",
      "r779",
      "r780",
      "r781",
      "r782",
      "r783",
      "r784",
      "r785",
      "r786",
      "r787",
      "r788"
     ]
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementEquityComponentsAxis",
     "presentation": [
      "http://www.cassavasciences.com/20241231/role/statement-consolidated-statements-of-stockholders-equity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Components [Axis]",
        "documentation": "Information by component of equity."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r56",
      "r59",
      "r60",
      "r107",
      "r122",
      "r123",
      "r124",
      "r138",
      "r139",
      "r140",
      "r142",
      "r147",
      "r149",
      "r151",
      "r169",
      "r207",
      "r208",
      "r236",
      "r270",
      "r347",
      "r348",
      "r355",
      "r356",
      "r357",
      "r359",
      "r360",
      "r361",
      "r366",
      "r367",
      "r368",
      "r369",
      "r370",
      "r371",
      "r372",
      "r382",
      "r383",
      "r384",
      "r385",
      "r386",
      "r387",
      "r392",
      "r393",
      "r396",
      "r458",
      "r476",
      "r477",
      "r478",
      "r489",
      "r542"
     ]
    },
    "srt_StatementGeographicalAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "StatementGeographicalAxis",
     "presentation": [
      "http://www.cassavasciences.com/20241231/role/statement-note-4-real-property-and-other-income-expense",
      "http://www.cassavasciences.com/20241231/role/statement-note-4-real-property-and-other-income-expense-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Axis]"
       }
      }
     },
     "auth_ref": [
      "r202",
      "r203",
      "r413",
      "r414",
      "r415",
      "r416",
      "r417",
      "r418",
      "r419",
      "r420",
      "r421",
      "r422",
      "r423",
      "r424",
      "r425",
      "r426",
      "r427",
      "r428",
      "r429",
      "r430",
      "r431",
      "r432",
      "r433",
      "r434",
      "r435",
      "r436",
      "r437",
      "r438",
      "r439",
      "r440",
      "r441",
      "r442",
      "r491",
      "r492",
      "r493",
      "r547",
      "r549",
      "r552",
      "r554",
      "r556",
      "r558",
      "r559",
      "r560",
      "r561",
      "r562",
      "r563",
      "r564",
      "r565",
      "r566",
      "r572",
      "r593",
      "r606",
      "r607",
      "r608",
      "r609",
      "r610",
      "r611",
      "r612",
      "r613",
      "r615",
      "r619",
      "r707",
      "r759",
      "r761",
      "r762",
      "r764",
      "r765",
      "r766",
      "r767",
      "r768",
      "r769",
      "r770",
      "r771",
      "r772",
      "r773",
      "r774",
      "r775",
      "r776",
      "r777",
      "r778",
      "r779",
      "r780",
      "r781",
      "r782",
      "r783",
      "r784",
      "r785",
      "r786",
      "r787",
      "r788"
     ]
    },
    "us-gaap_StatementLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementLineItems",
     "presentation": [
      "http://www.cassavasciences.com/20241231/role/statement-consolidated-balance-sheets",
      "http://www.cassavasciences.com/20241231/role/statement-consolidated-balance-sheets-parentheticals",
      "http://www.cassavasciences.com/20241231/role/statement-consolidated-statements-of-cash-flows",
      "http://www.cassavasciences.com/20241231/role/statement-consolidated-statements-of-operations-",
      "http://www.cassavasciences.com/20241231/role/statement-consolidated-statements-of-stockholders-equity",
      "http://www.cassavasciences.com/20241231/role/statement-note-1-general-liquidity-and-basis-of-presentation",
      "http://www.cassavasciences.com/20241231/role/statement-note-1-general-liquidity-and-basis-of-presentation-details-textual",
      "http://www.cassavasciences.com/20241231/role/statement-note-10-commitments",
      "http://www.cassavasciences.com/20241231/role/statement-note-10-commitments-details-textual",
      "http://www.cassavasciences.com/20241231/role/statement-note-11-2020-cash-incentive-bonus-plan",
      "http://www.cassavasciences.com/20241231/role/statement-note-11-2020-cash-incentive-bonus-plan-details-textual",
      "http://www.cassavasciences.com/20241231/role/statement-note-12-contingencies",
      "http://www.cassavasciences.com/20241231/role/statement-note-12-contingencies-details-textual",
      "http://www.cassavasciences.com/20241231/role/statement-note-13-warrant-dividend-distribution",
      "http://www.cassavasciences.com/20241231/role/statement-note-13-warrant-dividend-distribution-changes-in-warrants-outstanding-and-warrant-liability-details",
      "http://www.cassavasciences.com/20241231/role/statement-note-13-warrant-dividend-distribution-details-textual",
      "http://www.cassavasciences.com/20241231/role/statement-note-13-warrant-dividend-distribution-tables",
      "http://www.cassavasciences.com/20241231/role/statement-note-14-subsequent-event",
      "http://www.cassavasciences.com/20241231/role/statement-note-14-subsequent-event-details-textual",
      "http://www.cassavasciences.com/20241231/role/statement-note-2-significant-accounting-policies-calculation-of-net-loss-per-share-details",
      "http://www.cassavasciences.com/20241231/role/statement-note-2-summary-of-significant-accounting-policies",
      "http://www.cassavasciences.com/20241231/role/statement-note-2-summary-of-significant-accounting-policies-details-textual",
      "http://www.cassavasciences.com/20241231/role/statement-note-2-summary-of-significant-accounting-policies-quantitative-information-of-warrants-details",
      "http://www.cassavasciences.com/20241231/role/statement-note-2-summary-of-significant-accounting-policies-summary-of-codm-segments-details",
      "http://www.cassavasciences.com/20241231/role/statement-note-2-summary-of-significant-accounting-policies-tables",
      "http://www.cassavasciences.com/20241231/role/statement-note-3-prepaid-expenses-and-other-current-assets",
      "http://www.cassavasciences.com/20241231/role/statement-note-3-prepaid-expenses-and-other-current-assets-prepaid-expenses-and-other-current-assets-details",
      "http://www.cassavasciences.com/20241231/role/statement-note-3-prepaid-expenses-and-other-current-assets-tables",
      "http://www.cassavasciences.com/20241231/role/statement-note-4-real-property-and-other-income-expense",
      "http://www.cassavasciences.com/20241231/role/statement-note-4-real-property-and-other-income-expense-components-of-other-income-net-details",
      "http://www.cassavasciences.com/20241231/role/statement-note-4-real-property-and-other-income-expense-details-textual",
      "http://www.cassavasciences.com/20241231/role/statement-note-4-real-property-and-other-income-expense-tables",
      "http://www.cassavasciences.com/20241231/role/statement-note-5-property-and-equipment",
      "http://www.cassavasciences.com/20241231/role/statement-note-5-property-and-equipment-components-of-property-and-equipment-details",
      "http://www.cassavasciences.com/20241231/role/statement-note-5-property-and-equipment-details-textual",
      "http://www.cassavasciences.com/20241231/role/statement-note-5-property-and-equipment-tables",
      "http://www.cassavasciences.com/20241231/role/statement-note-6-intangible-assets",
      "http://www.cassavasciences.com/20241231/role/statement-note-6-intangible-assets-amortization-expense-for-finitelived-intangible-assets-details",
      "http://www.cassavasciences.com/20241231/role/statement-note-6-intangible-assets-components-of-intangible-assets-details",
      "http://www.cassavasciences.com/20241231/role/statement-note-6-intangible-assets-details-textual",
      "http://www.cassavasciences.com/20241231/role/statement-note-6-intangible-assets-tables",
      "http://www.cassavasciences.com/20241231/role/statement-note-7-stockholders-equity-and-stockbased-compensation",
      "http://www.cassavasciences.com/20241231/role/statement-note-7-stockholders-equity-and-stockbased-compensation-details-textual",
      "http://www.cassavasciences.com/20241231/role/statement-note-7-stockholders-equity-and-stockbased-compensation-schedule-of-stock-options-by-exercise-price-details",
      "http://www.cassavasciences.com/20241231/role/statement-note-7-stockholders-equity-and-stockbased-compensation-stock-option-activity-details",
      "http://www.cassavasciences.com/20241231/role/statement-note-7-stockholders-equity-and-stockbased-compensation-stock-option-and-performance-award-activity-details",
      "http://www.cassavasciences.com/20241231/role/statement-note-7-stockholders-equity-and-stockbased-compensation-stock-option-valuation-assumptions-details",
      "http://www.cassavasciences.com/20241231/role/statement-note-7-stockholders-equity-and-stockbased-compensation-stockbased-compensation-expense-details",
      "http://www.cassavasciences.com/20241231/role/statement-note-7-stockholders-equity-and-stockbased-compensation-tables",
      "http://www.cassavasciences.com/20241231/role/statement-note-8-employee-401k-benefit-plan",
      "http://www.cassavasciences.com/20241231/role/statement-note-9-income-taxes",
      "http://www.cassavasciences.com/20241231/role/statement-note-9-income-taxes-details-textual",
      "http://www.cassavasciences.com/20241231/role/statement-note-9-income-taxes-schedule-of-deferred-tax-assets-and-liabilities-details",
      "http://www.cassavasciences.com/20241231/role/statement-note-9-income-taxes-schedule-of-effective-income-tax-reconciliation-details",
      "http://www.cassavasciences.com/20241231/role/statement-note-9-income-taxes-schedule-of-unrecognized-tax-benefits-details",
      "http://www.cassavasciences.com/20241231/role/statement-note-9-income-taxes-tables",
      "http://www.cassavasciences.com/20241231/role/statement-significant-accounting-policies-policies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r138",
      "r139",
      "r140",
      "r169",
      "r393",
      "r410",
      "r484",
      "r490",
      "r496",
      "r497",
      "r498",
      "r499",
      "r500",
      "r501",
      "r504",
      "r507",
      "r508",
      "r509",
      "r510",
      "r511",
      "r512",
      "r513",
      "r514",
      "r515",
      "r517",
      "r518",
      "r519",
      "r520",
      "r521",
      "r523",
      "r525",
      "r526",
      "r528",
      "r529",
      "r530",
      "r531",
      "r532",
      "r533",
      "r534",
      "r535",
      "r536",
      "r537",
      "r538",
      "r539",
      "r542",
      "r620"
     ]
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementOfCashFlowsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementOfFinancialPositionAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementOfStockholdersEquityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "srt_StatementScenarioAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "StatementScenarioAxis",
     "presentation": [
      "http://www.cassavasciences.com/20241231/role/statement-note-14-subsequent-event",
      "http://www.cassavasciences.com/20241231/role/statement-note-14-subsequent-event-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Scenario [Axis]"
       }
      }
     },
     "auth_ref": [
      "r152",
      "r274",
      "r663",
      "r664",
      "r675"
     ]
    },
    "us-gaap_StatementTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementTable",
     "presentation": [
      "http://www.cassavasciences.com/20241231/role/statement-consolidated-balance-sheets",
      "http://www.cassavasciences.com/20241231/role/statement-consolidated-balance-sheets-parentheticals",
      "http://www.cassavasciences.com/20241231/role/statement-consolidated-statements-of-cash-flows",
      "http://www.cassavasciences.com/20241231/role/statement-consolidated-statements-of-operations-",
      "http://www.cassavasciences.com/20241231/role/statement-consolidated-statements-of-stockholders-equity",
      "http://www.cassavasciences.com/20241231/role/statement-note-1-general-liquidity-and-basis-of-presentation",
      "http://www.cassavasciences.com/20241231/role/statement-note-1-general-liquidity-and-basis-of-presentation-details-textual",
      "http://www.cassavasciences.com/20241231/role/statement-note-10-commitments",
      "http://www.cassavasciences.com/20241231/role/statement-note-10-commitments-details-textual",
      "http://www.cassavasciences.com/20241231/role/statement-note-11-2020-cash-incentive-bonus-plan",
      "http://www.cassavasciences.com/20241231/role/statement-note-11-2020-cash-incentive-bonus-plan-details-textual",
      "http://www.cassavasciences.com/20241231/role/statement-note-12-contingencies",
      "http://www.cassavasciences.com/20241231/role/statement-note-12-contingencies-details-textual",
      "http://www.cassavasciences.com/20241231/role/statement-note-13-warrant-dividend-distribution",
      "http://www.cassavasciences.com/20241231/role/statement-note-13-warrant-dividend-distribution-changes-in-warrants-outstanding-and-warrant-liability-details",
      "http://www.cassavasciences.com/20241231/role/statement-note-13-warrant-dividend-distribution-details-textual",
      "http://www.cassavasciences.com/20241231/role/statement-note-13-warrant-dividend-distribution-tables",
      "http://www.cassavasciences.com/20241231/role/statement-note-14-subsequent-event",
      "http://www.cassavasciences.com/20241231/role/statement-note-14-subsequent-event-details-textual",
      "http://www.cassavasciences.com/20241231/role/statement-note-2-significant-accounting-policies-calculation-of-net-loss-per-share-details",
      "http://www.cassavasciences.com/20241231/role/statement-note-2-summary-of-significant-accounting-policies",
      "http://www.cassavasciences.com/20241231/role/statement-note-2-summary-of-significant-accounting-policies-details-textual",
      "http://www.cassavasciences.com/20241231/role/statement-note-2-summary-of-significant-accounting-policies-quantitative-information-of-warrants-details",
      "http://www.cassavasciences.com/20241231/role/statement-note-2-summary-of-significant-accounting-policies-summary-of-codm-segments-details",
      "http://www.cassavasciences.com/20241231/role/statement-note-2-summary-of-significant-accounting-policies-tables",
      "http://www.cassavasciences.com/20241231/role/statement-note-3-prepaid-expenses-and-other-current-assets",
      "http://www.cassavasciences.com/20241231/role/statement-note-3-prepaid-expenses-and-other-current-assets-prepaid-expenses-and-other-current-assets-details",
      "http://www.cassavasciences.com/20241231/role/statement-note-3-prepaid-expenses-and-other-current-assets-tables",
      "http://www.cassavasciences.com/20241231/role/statement-note-4-real-property-and-other-income-expense",
      "http://www.cassavasciences.com/20241231/role/statement-note-4-real-property-and-other-income-expense-components-of-other-income-net-details",
      "http://www.cassavasciences.com/20241231/role/statement-note-4-real-property-and-other-income-expense-details-textual",
      "http://www.cassavasciences.com/20241231/role/statement-note-4-real-property-and-other-income-expense-tables",
      "http://www.cassavasciences.com/20241231/role/statement-note-5-property-and-equipment",
      "http://www.cassavasciences.com/20241231/role/statement-note-5-property-and-equipment-components-of-property-and-equipment-details",
      "http://www.cassavasciences.com/20241231/role/statement-note-5-property-and-equipment-details-textual",
      "http://www.cassavasciences.com/20241231/role/statement-note-5-property-and-equipment-tables",
      "http://www.cassavasciences.com/20241231/role/statement-note-6-intangible-assets",
      "http://www.cassavasciences.com/20241231/role/statement-note-6-intangible-assets-amortization-expense-for-finitelived-intangible-assets-details",
      "http://www.cassavasciences.com/20241231/role/statement-note-6-intangible-assets-components-of-intangible-assets-details",
      "http://www.cassavasciences.com/20241231/role/statement-note-6-intangible-assets-details-textual",
      "http://www.cassavasciences.com/20241231/role/statement-note-6-intangible-assets-tables",
      "http://www.cassavasciences.com/20241231/role/statement-note-7-stockholders-equity-and-stockbased-compensation",
      "http://www.cassavasciences.com/20241231/role/statement-note-7-stockholders-equity-and-stockbased-compensation-details-textual",
      "http://www.cassavasciences.com/20241231/role/statement-note-7-stockholders-equity-and-stockbased-compensation-schedule-of-stock-options-by-exercise-price-details",
      "http://www.cassavasciences.com/20241231/role/statement-note-7-stockholders-equity-and-stockbased-compensation-stock-option-activity-details",
      "http://www.cassavasciences.com/20241231/role/statement-note-7-stockholders-equity-and-stockbased-compensation-stock-option-and-performance-award-activity-details",
      "http://www.cassavasciences.com/20241231/role/statement-note-7-stockholders-equity-and-stockbased-compensation-stock-option-valuation-assumptions-details",
      "http://www.cassavasciences.com/20241231/role/statement-note-7-stockholders-equity-and-stockbased-compensation-stockbased-compensation-expense-details",
      "http://www.cassavasciences.com/20241231/role/statement-note-7-stockholders-equity-and-stockbased-compensation-tables",
      "http://www.cassavasciences.com/20241231/role/statement-note-8-employee-401k-benefit-plan",
      "http://www.cassavasciences.com/20241231/role/statement-note-9-income-taxes",
      "http://www.cassavasciences.com/20241231/role/statement-note-9-income-taxes-details-textual",
      "http://www.cassavasciences.com/20241231/role/statement-note-9-income-taxes-schedule-of-deferred-tax-assets-and-liabilities-details",
      "http://www.cassavasciences.com/20241231/role/statement-note-9-income-taxes-schedule-of-effective-income-tax-reconciliation-details",
      "http://www.cassavasciences.com/20241231/role/statement-note-9-income-taxes-schedule-of-unrecognized-tax-benefits-details",
      "http://www.cassavasciences.com/20241231/role/statement-note-9-income-taxes-tables",
      "http://www.cassavasciences.com/20241231/role/statement-significant-accounting-policies-policies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement [Table]",
        "documentation": "Disclosure of information about statement of comprehensive income, income, other comprehensive income, financial position, cash flows, and shareholders' equity."
       }
      }
     },
     "auth_ref": [
      "r138",
      "r139",
      "r140",
      "r169",
      "r205",
      "r393",
      "r410",
      "r484",
      "r490",
      "r496",
      "r497",
      "r498",
      "r499",
      "r500",
      "r501",
      "r504",
      "r507",
      "r508",
      "r509",
      "r510",
      "r511",
      "r512",
      "r513",
      "r514",
      "r515",
      "r517",
      "r518",
      "r519",
      "r520",
      "r521",
      "r523",
      "r525",
      "r526",
      "r528",
      "r529",
      "r530",
      "r531",
      "r532",
      "r533",
      "r534",
      "r535",
      "r536",
      "r537",
      "r538",
      "r539",
      "r542",
      "r620"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "presentation": [
      "http://www.cassavasciences.com/20241231/role/statement-consolidated-statements-of-stockholders-equity",
      "http://www.cassavasciences.com/20241231/role/statement-note-7-stockholders-equity-and-stockbased-compensation-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuance of common stock pursuant to stock offering, net of issuance costs (in shares)",
        "terseLabel": "Stock Issued During Period, Shares, New Issues (in shares)",
        "documentation": "Number of new stock issued during the period."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r55",
      "r56",
      "r74",
      "r486",
      "r542",
      "r555"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationForfeited": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodSharesShareBasedCompensationForfeited",
     "presentation": [
      "http://www.cassavasciences.com/20241231/role/statement-consolidated-statements-of-stockholders-equity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationForfeited",
        "negatedLabel": "Expiration of restricted stock Performance Awards (in shares)",
        "documentation": "Number of shares (or other type of equity) forfeited during the period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "presentation": [
      "http://www.cassavasciences.com/20241231/role/statement-consolidated-statements-of-stockholders-equity",
      "http://www.cassavasciences.com/20241231/role/statement-note-7-stockholders-equity-and-stockbased-compensation-stock-option-activity-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuance of common stock pursuant to exercise of stock options (in shares)",
        "negatedLabel": "Options exercised (in shares)",
        "documentation": "Number of share options (or share units) exercised during the current period."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r55",
      "r56",
      "r74",
      "r287"
     ]
    },
    "sava_StockIssuedDuringPeriodSharesWarrantExercises": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.cassavasciences.com/20241231",
     "localname": "StockIssuedDuringPeriodSharesWarrantExercises",
     "presentation": [
      "http://www.cassavasciences.com/20241231/role/statement-consolidated-statements-of-stockholders-equity",
      "http://www.cassavasciences.com/20241231/role/statement-note-13-warrant-dividend-distribution-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock issued pursuant to warrant exercises, net of exercise costs (in shares)",
        "terseLabel": "Stock Issued During Period, Shares, Warrant Exercises (in shares)",
        "documentation": "Number of shares of stock issued attributable to warrant exercises."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "crdr": "credit",
     "presentation": [
      "http://www.cassavasciences.com/20241231/role/statement-consolidated-statements-of-stockholders-equity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuance of common stock pursuant to stock offering, net of issuance costs",
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r55",
      "r56",
      "r74",
      "r489",
      "r542",
      "r555",
      "r626"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationForfeited": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodValueShareBasedCompensationForfeited",
     "crdr": "debit",
     "presentation": [
      "http://www.cassavasciences.com/20241231/role/statement-consolidated-statements-of-stockholders-equity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationForfeited",
        "negatedLabel": "Expiration of restricted stock Performance Awards",
        "documentation": "Value of forfeited shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP)."
       }
      }
     },
     "auth_ref": [
      "r80"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodValueStockOptionsExercised",
     "crdr": "credit",
     "presentation": [
      "http://www.cassavasciences.com/20241231/role/statement-consolidated-statements-of-stockholders-equity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuance of common stock pursuant to exercise of stock options",
        "documentation": "Value of stock issued as a result of the exercise of stock options."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r56",
      "r59",
      "r60",
      "r74"
     ]
    },
    "sava_StockIssuedDuringPeriodValueWarrantExercises": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.cassavasciences.com/20241231",
     "localname": "StockIssuedDuringPeriodValueWarrantExercises",
     "crdr": "credit",
     "presentation": [
      "http://www.cassavasciences.com/20241231/role/statement-consolidated-statements-of-stockholders-equity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock issued pursuant to warrant exercises, net of exercise costs",
        "documentation": "Value of shares of stock issued attributable to exercises of warrants."
       }
      }
     },
     "auth_ref": []
    },
    "sava_StockOptionsExercisedNetSettledSatisfactionOfExercisePrice": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.cassavasciences.com/20241231",
     "localname": "StockOptionsExercisedNetSettledSatisfactionOfExercisePrice",
     "presentation": [
      "http://www.cassavasciences.com/20241231/role/statement-note-7-stockholders-equity-and-stockbased-compensation-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "sava_StockOptionsExercisedNetSettledSatisfactionOfExercisePrice",
        "terseLabel": "Stock Options Exercised Net Settled Satisfaction Of Exercise Price (in shares)",
        "documentation": "Represents the number of stock options exercised net settled in satisfaction of the exercise price."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://www.cassavasciences.com/20241231/role/statement-consolidated-balance-sheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.cassavasciences.com/20241231/role/statement-consolidated-balance-sheets",
      "http://www.cassavasciences.com/20241231/role/statement-consolidated-statements-of-stockholders-equity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_StockholdersEquity",
        "totalLabel": "Total stockholders' equity",
        "periodStartLabel": "Balance",
        "periodEndLabel": "Balance",
        "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r56",
      "r59",
      "r60",
      "r70",
      "r506",
      "r522",
      "r543",
      "r544",
      "r605",
      "r627",
      "r670",
      "r687",
      "r747",
      "r791"
     ]
    },
    "us-gaap_StockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockholdersEquityAbstract",
     "presentation": [
      "http://www.cassavasciences.com/20241231/role/statement-consolidated-balance-sheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' equity:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubsequentEventMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventMember",
     "presentation": [
      "http://www.cassavasciences.com/20241231/role/statement-note-10-commitments",
      "http://www.cassavasciences.com/20241231/role/statement-note-10-commitments-details-textual",
      "http://www.cassavasciences.com/20241231/role/statement-note-12-contingencies",
      "http://www.cassavasciences.com/20241231/role/statement-note-12-contingencies-details-textual",
      "http://www.cassavasciences.com/20241231/role/statement-note-14-subsequent-event",
      "http://www.cassavasciences.com/20241231/role/statement-note-14-subsequent-event-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event [Member]",
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r388",
      "r401"
     ]
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventTypeAxis",
     "presentation": [
      "http://www.cassavasciences.com/20241231/role/statement-note-10-commitments",
      "http://www.cassavasciences.com/20241231/role/statement-note-10-commitments-details-textual",
      "http://www.cassavasciences.com/20241231/role/statement-note-12-contingencies",
      "http://www.cassavasciences.com/20241231/role/statement-note-12-contingencies-details-textual",
      "http://www.cassavasciences.com/20241231/role/statement-note-14-subsequent-event",
      "http://www.cassavasciences.com/20241231/role/statement-note-14-subsequent-event-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event Type [Axis]",
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r388",
      "r401"
     ]
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventTypeDomain",
     "presentation": [
      "http://www.cassavasciences.com/20241231/role/statement-note-10-commitments",
      "http://www.cassavasciences.com/20241231/role/statement-note-10-commitments-details-textual",
      "http://www.cassavasciences.com/20241231/role/statement-note-12-contingencies",
      "http://www.cassavasciences.com/20241231/role/statement-note-12-contingencies-details-textual",
      "http://www.cassavasciences.com/20241231/role/statement-note-14-subsequent-event",
      "http://www.cassavasciences.com/20241231/role/statement-note-14-subsequent-event-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event Type [Domain]",
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r388",
      "r401"
     ]
    },
    "us-gaap_SubsequentEventsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventsTextBlock",
     "presentation": [
      "http://www.cassavasciences.com/20241231/role/statement-note-14-subsequent-event"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events [Text Block]",
        "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business."
       }
      }
     },
     "auth_ref": [
      "r400",
      "r402"
     ]
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsidiarySaleOfStockAxis",
     "presentation": [
      "http://www.cassavasciences.com/20241231/role/statement-note-7-stockholders-equity-and-stockbased-compensation",
      "http://www.cassavasciences.com/20241231/role/statement-note-7-stockholders-equity-and-stockbased-compensation-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sale of Stock [Axis]",
        "documentation": "Information by type of sale of the entity's stock."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SupplyCommitmentArrangementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SupplyCommitmentArrangementMember",
     "presentation": [
      "http://www.cassavasciences.com/20241231/role/statement-note-10-commitments",
      "http://www.cassavasciences.com/20241231/role/statement-note-10-commitments-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supply Commitment Arrangement [Domain]",
        "documentation": "This item is intended to be populated, by the entity, with Members identifying each supply commitment about which information required or determined to be disclosed is being provided. If only one such commitment exists, this item may be used to capture such information; if multiple commitments exist, this item is the dimensional default, which will aggregate such information, as appropriate."
       }
      }
     },
     "auth_ref": [
      "r51",
      "r91"
     ]
    },
    "us-gaap_SupplyCommitmentAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SupplyCommitmentAxis",
     "presentation": [
      "http://www.cassavasciences.com/20241231/role/statement-note-10-commitments",
      "http://www.cassavasciences.com/20241231/role/statement-note-10-commitments-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supply Commitment [Axis]",
        "documentation": "Information by arrangements in which the entity has committed resources to supply goods or services to a customer."
       }
      }
     },
     "auth_ref": [
      "r51",
      "r91"
     ]
    },
    "stpr_TX": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/stpr/2024",
     "localname": "TX",
     "presentation": [
      "http://www.cassavasciences.com/20241231/role/statement-note-4-real-property-and-other-income-expense",
      "http://www.cassavasciences.com/20241231/role/statement-note-4-real-property-and-other-income-expense-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "TEXAS"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TableTextBlock": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TableTextBlock",
     "presentation": [
      "http://www.cassavasciences.com/20241231/role/statement-note-13-warrant-dividend-distribution-tables",
      "http://www.cassavasciences.com/20241231/role/statement-note-2-summary-of-significant-accounting-policies-tables",
      "http://www.cassavasciences.com/20241231/role/statement-note-3-prepaid-expenses-and-other-current-assets-tables",
      "http://www.cassavasciences.com/20241231/role/statement-note-4-real-property-and-other-income-expense-tables",
      "http://www.cassavasciences.com/20241231/role/statement-note-5-property-and-equipment-tables",
      "http://www.cassavasciences.com/20241231/role/statement-note-6-intangible-assets-tables",
      "http://www.cassavasciences.com/20241231/role/statement-note-7-stockholders-equity-and-stockbased-compensation-tables",
      "http://www.cassavasciences.com/20241231/role/statement-note-9-income-taxes-tables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_TableTextBlock",
        "terseLabel": "Notes Tables"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TaxCreditCarryforwardAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TaxCreditCarryforwardAmount",
     "crdr": "debit",
     "presentation": [
      "http://www.cassavasciences.com/20241231/role/statement-note-9-income-taxes-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_TaxCreditCarryforwardAmount",
        "terseLabel": "Tax Credit Carryforward, Amount",
        "documentation": "The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws."
       }
      }
     },
     "auth_ref": [
      "r345"
     ]
    },
    "us-gaap_TaxCreditCarryforwardAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TaxCreditCarryforwardAxis",
     "presentation": [
      "http://www.cassavasciences.com/20241231/role/statement-note-9-income-taxes",
      "http://www.cassavasciences.com/20241231/role/statement-note-9-income-taxes-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tax Credit Carryforward [Axis]",
        "documentation": "Information by specific tax credit related to an unused tax credit."
       }
      }
     },
     "auth_ref": [
      "r345"
     ]
    },
    "us-gaap_TaxCreditCarryforwardNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TaxCreditCarryforwardNameDomain",
     "presentation": [
      "http://www.cassavasciences.com/20241231/role/statement-note-9-income-taxes",
      "http://www.cassavasciences.com/20241231/role/statement-note-9-income-taxes-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tax Credit Carryforward, Name [Domain]",
        "documentation": "The name of the tax credit carryforward."
       }
      }
     },
     "auth_ref": [
      "r345"
     ]
    },
    "us-gaap_TaxPeriodAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TaxPeriodAxis",
     "presentation": [
      "http://www.cassavasciences.com/20241231/role/statement-note-9-income-taxes",
      "http://www.cassavasciences.com/20241231/role/statement-note-9-income-taxes-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tax Period [Axis]",
        "documentation": "Information by period subject to enacted tax law."
       }
      }
     },
     "auth_ref": [
      "r739"
     ]
    },
    "us-gaap_TaxPeriodDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TaxPeriodDomain",
     "presentation": [
      "http://www.cassavasciences.com/20241231/role/statement-note-9-income-taxes",
      "http://www.cassavasciences.com/20241231/role/statement-note-9-income-taxes-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tax Period [Domain]",
        "documentation": "Identified tax period."
       }
      }
     },
     "auth_ref": [
      "r739"
     ]
    },
    "sava_The2018EquityIncentivePlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.cassavasciences.com/20241231",
     "localname": "The2018EquityIncentivePlanMember",
     "presentation": [
      "http://www.cassavasciences.com/20241231/role/statement-note-7-stockholders-equity-and-stockbased-compensation",
      "http://www.cassavasciences.com/20241231/role/statement-note-7-stockholders-equity-and-stockbased-compensation-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "The 2018 Equity Incentive Plan [Member]",
        "documentation": "Represents the 2018 Equity Incentive Plan."
       }
      }
     },
     "auth_ref": []
    },
    "sava_The2022RegisteredDirectOfferingMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.cassavasciences.com/20241231",
     "localname": "The2022RegisteredDirectOfferingMember",
     "presentation": [
      "http://www.cassavasciences.com/20241231/role/statement-note-7-stockholders-equity-and-stockbased-compensation",
      "http://www.cassavasciences.com/20241231/role/statement-note-7-stockholders-equity-and-stockbased-compensation-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "The 2022 Registered Direct Offering [Member]",
        "documentation": "Represents the 2022 Registered Direct Offering."
       }
      }
     },
     "auth_ref": []
    },
    "srt_TitleOfIndividualAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "TitleOfIndividualAxis",
     "presentation": [
      "http://www.cassavasciences.com/20241231/role/statement-note-2-summary-of-significant-accounting-policies",
      "http://www.cassavasciences.com/20241231/role/statement-note-2-summary-of-significant-accounting-policies-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title and Position [Axis]"
       }
      }
     },
     "auth_ref": [
      "r685",
      "r748"
     ]
    },
    "srt_TitleOfIndividualWithRelationshipToEntityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "TitleOfIndividualWithRelationshipToEntityDomain",
     "presentation": [
      "http://www.cassavasciences.com/20241231/role/statement-note-2-summary-of-significant-accounting-policies",
      "http://www.cassavasciences.com/20241231/role/statement-note-2-summary-of-significant-accounting-policies-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title and Position [Domain]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "TradingSymbol",
     "presentation": [
      "http://www.cassavasciences.com/20241231/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TypeOfRestructuringDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TypeOfRestructuringDomain",
     "presentation": [
      "http://www.cassavasciences.com/20241231/role/statement-note-14-subsequent-event",
      "http://www.cassavasciences.com/20241231/role/statement-note-14-subsequent-event-details-textual",
      "http://www.cassavasciences.com/20241231/role/statement-note-7-stockholders-equity-and-stockbased-compensation",
      "http://www.cassavasciences.com/20241231/role/statement-note-7-stockholders-equity-and-stockbased-compensation-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Type of Restructuring [Domain]",
        "documentation": "Identification of the types of restructuring costs."
       }
      }
     },
     "auth_ref": [
      "r240",
      "r241",
      "r244",
      "r245"
     ]
    },
    "us-gaap_UnrecognizedTaxBenefits": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "UnrecognizedTaxBenefits",
     "crdr": "credit",
     "presentation": [
      "http://www.cassavasciences.com/20241231/role/statement-note-9-income-taxes-details-textual",
      "http://www.cassavasciences.com/20241231/role/statement-note-9-income-taxes-schedule-of-unrecognized-tax-benefits-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_UnrecognizedTaxBenefits",
        "terseLabel": "Unrecognized Tax Benefits",
        "periodStartLabel": "Beginning balance",
        "periodEndLabel": "Ending balance",
        "documentation": "Amount of unrecognized tax benefits."
       }
      }
     },
     "auth_ref": [
      "r318",
      "r333",
      "r598"
     ]
    },
    "us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued",
     "crdr": "credit",
     "presentation": [
      "http://www.cassavasciences.com/20241231/role/statement-note-9-income-taxes-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued",
        "terseLabel": "Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued",
        "documentation": "Amount accrued for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return."
       }
      }
     },
     "auth_ref": [
      "r331",
      "r598"
     ]
    },
    "us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions",
     "crdr": "credit",
     "presentation": [
      "http://www.cassavasciences.com/20241231/role/statement-note-9-income-taxes-schedule-of-unrecognized-tax-benefits-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additions based on tax positions related to the current year",
        "documentation": "Amount of increase in unrecognized tax benefits resulting from tax positions that have been or will be taken in current period tax return."
       }
      }
     },
     "auth_ref": [
      "r334",
      "r598"
     ]
    },
    "us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations",
     "crdr": "debit",
     "presentation": [
      "http://www.cassavasciences.com/20241231/role/statement-note-9-income-taxes-schedule-of-unrecognized-tax-benefits-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations",
        "negatedLabel": "Expired research and development tax credits",
        "documentation": "Amount of decrease in unrecognized tax benefits resulting from lapses of applicable statutes of limitations."
       }
      }
     },
     "auth_ref": [
      "r335"
     ]
    },
    "us-gaap_UseOfEstimates": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "UseOfEstimates",
     "presentation": [
      "http://www.cassavasciences.com/20241231/role/statement-significant-accounting-policies-policies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles."
       }
      }
     },
     "auth_ref": [
      "r23",
      "r24",
      "r25",
      "r99",
      "r100",
      "r102",
      "r103"
     ]
    },
    "us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ValuationAllowanceDeferredTaxAssetChangeInAmount",
     "crdr": "credit",
     "presentation": [
      "http://www.cassavasciences.com/20241231/role/statement-note-9-income-taxes-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount",
        "terseLabel": "Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount",
        "documentation": "Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset."
       }
      }
     },
     "auth_ref": [
      "r338"
     ]
    },
    "sava_ViolationsOfFederalSecuritiesLawsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.cassavasciences.com/20241231",
     "localname": "ViolationsOfFederalSecuritiesLawsMember",
     "presentation": [
      "http://www.cassavasciences.com/20241231/role/statement-note-12-contingencies",
      "http://www.cassavasciences.com/20241231/role/statement-note-12-contingencies-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Violations of Federal Securities Laws [Member]",
        "documentation": "Represents the violations of federal securities laws."
       }
      }
     },
     "auth_ref": []
    },
    "sava_WarrantDividendDistributionTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.cassavasciences.com/20241231",
     "localname": "WarrantDividendDistributionTextBlock",
     "presentation": [
      "http://www.cassavasciences.com/20241231/role/statement-note-13-warrant-dividend-distribution"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrant Dividend Distribution [Text Block]",
        "documentation": "The entire disclosure of warrant dividend distribution."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_WarrantMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WarrantMember",
     "presentation": [
      "http://www.cassavasciences.com/20241231/role/statement-note-2-significant-accounting-policies-calculation-of-net-loss-per-share-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrant [Member]",
        "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount."
       }
      }
     },
     "auth_ref": [
      "r617",
      "r618",
      "r621",
      "r622",
      "r623",
      "r624"
     ]
    },
    "sava_WarrantRedemptionPrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://www.cassavasciences.com/20241231",
     "localname": "WarrantRedemptionPrice",
     "presentation": [
      "http://www.cassavasciences.com/20241231/role/statement-note-13-warrant-dividend-distribution-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "sava_WarrantRedemptionPrice",
        "terseLabel": "Warrant Redemption Price (in dollars per share)",
        "documentation": "Price of warrants if they are redeemed."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_WarrantsAndRightsOutstanding": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WarrantsAndRightsOutstanding",
     "crdr": "credit",
     "presentation": [
      "http://www.cassavasciences.com/20241231/role/statement-note-13-warrant-dividend-distribution-changes-in-warrants-outstanding-and-warrant-liability-details",
      "http://www.cassavasciences.com/20241231/role/statement-note-13-warrant-dividend-distribution-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Balance, liability",
        "terseLabel": "Warrants and Rights Outstanding",
        "periodStartLabel": "Balance, liability",
        "periodEndLabel": "Balance, liability",
        "documentation": "Value of outstanding derivative securities that permit the holder the right to purchase securities (usually equity) from the issuer at a specified price."
       }
      }
     },
     "auth_ref": [
      "r744",
      "r745",
      "r746"
     ]
    },
    "us-gaap_WarrantsAndRightsOutstandingMeasurementInput": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WarrantsAndRightsOutstandingMeasurementInput",
     "presentation": [
      "http://www.cassavasciences.com/20241231/role/statement-note-2-summary-of-significant-accounting-policies-quantitative-information-of-warrants-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrant measurement",
        "documentation": "Value of input used to measure outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur."
       }
      }
     },
     "auth_ref": [
      "r744",
      "r745",
      "r746"
     ]
    },
    "sava_WarrantsToPurchaseCommonStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.cassavasciences.com/20241231",
     "localname": "WarrantsToPurchaseCommonStockMember",
     "presentation": [
      "http://www.cassavasciences.com/20241231/role/statement-note-13-warrant-dividend-distribution",
      "http://www.cassavasciences.com/20241231/role/statement-note-13-warrant-dividend-distribution-changes-in-warrants-outstanding-and-warrant-liability-details",
      "http://www.cassavasciences.com/20241231/role/statement-note-13-warrant-dividend-distribution-details-textual",
      "http://www.cassavasciences.com/20241231/role/statement-note-2-summary-of-significant-accounting-policies-quantitative-information-of-warrants-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrants to Purchase Common Stock [Member]",
        "documentation": "Represents the warrants used to purchase common stock."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WeightedAverageNumberDilutedSharesOutstandingAdjustment",
     "calculation": {
      "http://www.cassavasciences.com/20241231/role/statement-note-2-significant-accounting-policies-calculation-of-net-loss-per-share-details": {
       "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.cassavasciences.com/20241231/role/statement-note-2-significant-accounting-policies-calculation-of-net-loss-per-share-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment",
        "terseLabel": "Dilutive effect of common stock warrants (in shares)",
        "documentation": "The sum of dilutive potential common shares or units used in the calculation of the diluted per-share or per-unit computation."
       }
      }
     },
     "auth_ref": [
      "r677"
     ]
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "calculation": {
      "http://www.cassavasciences.com/20241231/role/statement-note-2-significant-accounting-policies-calculation-of-net-loss-per-share-details": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.cassavasciences.com/20241231/role/statement-consolidated-statements-of-operations-",
      "http://www.cassavasciences.com/20241231/role/statement-note-2-significant-accounting-policies-calculation-of-net-loss-per-share-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shares used in computing net loss per share, diluted (in shares)",
        "totalLabel": "Weighted average dilutive common shares (in shares)",
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period."
       }
      }
     },
     "auth_ref": [
      "r154",
      "r164"
     ]
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "calculation": {
      "http://www.cassavasciences.com/20241231/role/statement-note-2-significant-accounting-policies-calculation-of-net-loss-per-share-details": {
       "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.cassavasciences.com/20241231/role/statement-consolidated-statements-of-operations-",
      "http://www.cassavasciences.com/20241231/role/statement-note-2-significant-accounting-policies-calculation-of-net-loss-per-share-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shares used in computing net loss per share, basic (in shares)",
        "terseLabel": "Weighted average common shares outstanding (in shares)",
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period."
       }
      }
     },
     "auth_ref": [
      "r153",
      "r164"
     ]
    },
    "sava_WorkforceReductionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.cassavasciences.com/20241231",
     "localname": "WorkforceReductionMember",
     "presentation": [
      "http://www.cassavasciences.com/20241231/role/statement-note-14-subsequent-event",
      "http://www.cassavasciences.com/20241231/role/statement-note-14-subsequent-event-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Workforce Reduction [Member]",
        "documentation": "The workforce reduction."
       }
      }
     },
     "auth_ref": []
    },
    "sava_YaleUniversityMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.cassavasciences.com/20241231",
     "localname": "YaleUniversityMember",
     "presentation": [
      "http://www.cassavasciences.com/20241231/role/statement-note-10-commitments",
      "http://www.cassavasciences.com/20241231/role/statement-note-10-commitments-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Yale University [Member]",
        "documentation": "Relating to Yale University."
       }
      }
     },
     "auth_ref": []
    },
    "sava_statement-statement-note-13-warrant-dividend-distribution-changes-in-warrants-outstanding-and-warrant-liability-details": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.cassavasciences.com/20241231",
     "localname": "statement-statement-note-13-warrant-dividend-distribution-changes-in-warrants-outstanding-and-warrant-liability-details",
     "lang": {
      "en-us": {
       "role": {
        "label": "Note 13 - Warrant Dividend Distribution - Changes in Warrants Outstanding and Warrant Liability (Details)"
       }
      }
     },
     "auth_ref": []
    },
    "sava_statement-statement-note-13-warrant-dividend-distribution-tables": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.cassavasciences.com/20241231",
     "localname": "statement-statement-note-13-warrant-dividend-distribution-tables",
     "lang": {
      "en-us": {
       "role": {
        "label": "Note 13 - Warrant Dividend Distribution"
       }
      }
     },
     "auth_ref": []
    },
    "sava_statement-statement-note-2-significant-accounting-policies-calculation-of-net-loss-per-share-details": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.cassavasciences.com/20241231",
     "localname": "statement-statement-note-2-significant-accounting-policies-calculation-of-net-loss-per-share-details",
     "lang": {
      "en-us": {
       "role": {
        "label": "Note 2 - Significant Accounting Policies - Calculation of Net Loss Per Share (Details)"
       }
      }
     },
     "auth_ref": []
    },
    "sava_statement-statement-note-2-summary-of-significant-accounting-policies-quantitative-information-of-warrants-details": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.cassavasciences.com/20241231",
     "localname": "statement-statement-note-2-summary-of-significant-accounting-policies-quantitative-information-of-warrants-details",
     "lang": {
      "en-us": {
       "role": {
        "label": "Note 2 - Summary of Significant Accounting Policies - Quantitative Information of Warrants (Details)"
       }
      }
     },
     "auth_ref": []
    },
    "sava_statement-statement-note-2-summary-of-significant-accounting-policies-summary-of-codm-segments-details": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.cassavasciences.com/20241231",
     "localname": "statement-statement-note-2-summary-of-significant-accounting-policies-summary-of-codm-segments-details",
     "lang": {
      "en-us": {
       "role": {
        "label": "Note 2 - Summary of Significant Accounting Policies - Summary Of CODM Segments (Details)"
       }
      }
     },
     "auth_ref": []
    },
    "sava_statement-statement-note-2-summary-of-significant-accounting-policies-tables": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.cassavasciences.com/20241231",
     "localname": "statement-statement-note-2-summary-of-significant-accounting-policies-tables",
     "lang": {
      "en-us": {
       "role": {
        "label": "Note 2 - Summary of Significant Accounting Policies"
       }
      }
     },
     "auth_ref": []
    },
    "sava_statement-statement-note-3-prepaid-expenses-and-other-current-assets-prepaid-expenses-and-other-current-assets-details": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.cassavasciences.com/20241231",
     "localname": "statement-statement-note-3-prepaid-expenses-and-other-current-assets-prepaid-expenses-and-other-current-assets-details",
     "lang": {
      "en-us": {
       "role": {
        "label": "Note 3 - Prepaid Expenses and Other Current Assets - Prepaid Expenses and Other Current Assets (Details)"
       }
      }
     },
     "auth_ref": []
    },
    "sava_statement-statement-note-3-prepaid-expenses-and-other-current-assets-tables": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.cassavasciences.com/20241231",
     "localname": "statement-statement-note-3-prepaid-expenses-and-other-current-assets-tables",
     "lang": {
      "en-us": {
       "role": {
        "label": "Note 3 - Prepaid Expenses and Other Current Assets"
       }
      }
     },
     "auth_ref": []
    },
    "sava_statement-statement-note-4-real-property-and-other-income-expense-components-of-other-income-net-details": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.cassavasciences.com/20241231",
     "localname": "statement-statement-note-4-real-property-and-other-income-expense-components-of-other-income-net-details",
     "lang": {
      "en-us": {
       "role": {
        "label": "Note 4 - Real Property and Other Income, Expense - Components of Other Income, Net (Details)"
       }
      }
     },
     "auth_ref": []
    },
    "sava_statement-statement-note-4-real-property-and-other-income-expense-tables": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.cassavasciences.com/20241231",
     "localname": "statement-statement-note-4-real-property-and-other-income-expense-tables",
     "lang": {
      "en-us": {
       "role": {
        "label": "Note 4 - Real Property and Other Income, Expense"
       }
      }
     },
     "auth_ref": []
    },
    "sava_statement-statement-note-5-property-and-equipment-components-of-property-and-equipment-details": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.cassavasciences.com/20241231",
     "localname": "statement-statement-note-5-property-and-equipment-components-of-property-and-equipment-details",
     "lang": {
      "en-us": {
       "role": {
        "label": "Note 5 - Property and Equipment - Components of Property and Equipment (Details)"
       }
      }
     },
     "auth_ref": []
    },
    "sava_statement-statement-note-5-property-and-equipment-tables": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.cassavasciences.com/20241231",
     "localname": "statement-statement-note-5-property-and-equipment-tables",
     "lang": {
      "en-us": {
       "role": {
        "label": "Note 5 - Property and Equipment"
       }
      }
     },
     "auth_ref": []
    },
    "sava_statement-statement-note-6-intangible-assets-amortization-expense-for-finitelived-intangible-assets-details": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.cassavasciences.com/20241231",
     "localname": "statement-statement-note-6-intangible-assets-amortization-expense-for-finitelived-intangible-assets-details",
     "lang": {
      "en-us": {
       "role": {
        "label": "Note 6 - Intangible Assets - Amortization Expense for Finite-lived Intangible Assets (Details)"
       }
      }
     },
     "auth_ref": []
    },
    "sava_statement-statement-note-6-intangible-assets-components-of-intangible-assets-details": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.cassavasciences.com/20241231",
     "localname": "statement-statement-note-6-intangible-assets-components-of-intangible-assets-details",
     "lang": {
      "en-us": {
       "role": {
        "label": "Note 6 - Intangible Assets - Components of Intangible Assets (Details)"
       }
      }
     },
     "auth_ref": []
    },
    "sava_statement-statement-note-6-intangible-assets-tables": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.cassavasciences.com/20241231",
     "localname": "statement-statement-note-6-intangible-assets-tables",
     "lang": {
      "en-us": {
       "role": {
        "label": "Note 6 - Intangible Assets"
       }
      }
     },
     "auth_ref": []
    },
    "sava_statement-statement-note-7-stockholders-equity-and-stockbased-compensation-schedule-of-stock-options-by-exercise-price-details": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.cassavasciences.com/20241231",
     "localname": "statement-statement-note-7-stockholders-equity-and-stockbased-compensation-schedule-of-stock-options-by-exercise-price-details",
     "lang": {
      "en-us": {
       "role": {
        "label": "Note 7 - Stockholders' Equity and Stock-based Compensation - Schedule of Stock Options by Exercise Price (Details)"
       }
      }
     },
     "auth_ref": []
    },
    "sava_statement-statement-note-7-stockholders-equity-and-stockbased-compensation-stock-option-activity-details": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.cassavasciences.com/20241231",
     "localname": "statement-statement-note-7-stockholders-equity-and-stockbased-compensation-stock-option-activity-details",
     "lang": {
      "en-us": {
       "role": {
        "label": "Note 7 - Stockholders' Equity and Stock-based Compensation - Stock Option Activity (Details)"
       }
      }
     },
     "auth_ref": []
    },
    "sava_statement-statement-note-7-stockholders-equity-and-stockbased-compensation-stock-option-and-performance-award-activity-details": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.cassavasciences.com/20241231",
     "localname": "statement-statement-note-7-stockholders-equity-and-stockbased-compensation-stock-option-and-performance-award-activity-details",
     "lang": {
      "en-us": {
       "role": {
        "label": "Note 7 - Stockholders' Equity and Stock-based Compensation - Stock Option and Performance Award Activity (Details)"
       }
      }
     },
     "auth_ref": []
    },
    "sava_statement-statement-note-7-stockholders-equity-and-stockbased-compensation-stock-option-valuation-assumptions-details": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.cassavasciences.com/20241231",
     "localname": "statement-statement-note-7-stockholders-equity-and-stockbased-compensation-stock-option-valuation-assumptions-details",
     "lang": {
      "en-us": {
       "role": {
        "label": "Note 7 - Stockholders' Equity and Stock-based Compensation - Stock Option Valuation Assumptions (Details)"
       }
      }
     },
     "auth_ref": []
    },
    "sava_statement-statement-note-7-stockholders-equity-and-stockbased-compensation-stockbased-compensation-expense-details": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.cassavasciences.com/20241231",
     "localname": "statement-statement-note-7-stockholders-equity-and-stockbased-compensation-stockbased-compensation-expense-details",
     "lang": {
      "en-us": {
       "role": {
        "label": "Note 7 - Stockholders' Equity and Stock-based Compensation - Stock-based Compensation Expense (Details)"
       }
      }
     },
     "auth_ref": []
    },
    "sava_statement-statement-note-7-stockholders-equity-and-stockbased-compensation-tables": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.cassavasciences.com/20241231",
     "localname": "statement-statement-note-7-stockholders-equity-and-stockbased-compensation-tables",
     "lang": {
      "en-us": {
       "role": {
        "label": "Note 7 - Stockholders' Equity and Stock-based Compensation"
       }
      }
     },
     "auth_ref": []
    },
    "sava_statement-statement-note-9-income-taxes-schedule-of-deferred-tax-assets-and-liabilities-details": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.cassavasciences.com/20241231",
     "localname": "statement-statement-note-9-income-taxes-schedule-of-deferred-tax-assets-and-liabilities-details",
     "lang": {
      "en-us": {
       "role": {
        "label": "Note 9 - Income Taxes - Schedule of Deferred Tax Assets and Liabilities (Details)"
       }
      }
     },
     "auth_ref": []
    },
    "sava_statement-statement-note-9-income-taxes-schedule-of-effective-income-tax-reconciliation-details": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.cassavasciences.com/20241231",
     "localname": "statement-statement-note-9-income-taxes-schedule-of-effective-income-tax-reconciliation-details",
     "lang": {
      "en-us": {
       "role": {
        "label": "Note 9 - Income Taxes - Schedule of Effective Income Tax Reconciliation (Details)"
       }
      }
     },
     "auth_ref": []
    },
    "sava_statement-statement-note-9-income-taxes-schedule-of-unrecognized-tax-benefits-details": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.cassavasciences.com/20241231",
     "localname": "statement-statement-note-9-income-taxes-schedule-of-unrecognized-tax-benefits-details",
     "lang": {
      "en-us": {
       "role": {
        "label": "Note 9 - Income Taxes - Schedule of Unrecognized Tax Benefits (Details)"
       }
      }
     },
     "auth_ref": []
    },
    "sava_statement-statement-note-9-income-taxes-tables": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.cassavasciences.com/20241231",
     "localname": "statement-statement-note-9-income-taxes-tables",
     "lang": {
      "en-us": {
       "role": {
        "label": "Note 9 - Income Taxes"
       }
      }
     },
     "auth_ref": []
    },
    "sava_statement-statement-significant-accounting-policies-policies": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.cassavasciences.com/20241231",
     "localname": "statement-statement-significant-accounting-policies-policies",
     "lang": {
      "en-us": {
       "role": {
        "label": "Significant Accounting Policies"
       }
      }
     },
     "auth_ref": []
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "13",
   "SubTopic": "10",
   "Topic": "480",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481766/480-10-25-13"
  },
  "r1": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "SubTopic": "230",
   "Topic": "830",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477401/830-230-45-1"
  },
  "r2": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14"
  },
  "r3": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r4": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r5": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "360",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r6": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "825",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-1"
  },
  "r7": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "SubTopic": "10",
   "Topic": "505",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2"
  },
  "r8": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "SubTopic": "10",
   "Topic": "815",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-2"
  },
  "r9": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r10": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r11": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2A",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2A"
  },
  "r12": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22))",
   "SubTopic": "10",
   "Topic": "210",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r13": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15"
  },
  "r14": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-4"
  },
  "r15": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-1"
  },
  "r16": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-3"
  },
  "r17": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-4"
  },
  "r18": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-5"
  },
  "r19": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-11"
  },
  "r20": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r21": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r22": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-2"
  },
  "r23": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-4"
  },
  "r24": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-8"
  },
  "r25": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-9"
  },
  "r26": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r27": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-25"
  },
  "r28": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "30",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r29": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r30": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r31": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "460",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482425/460-10-50-8"
  },
  "r32": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "470",
   "SubTopic": "20",
   "Section": "25",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481284/470-20-25-2"
  },
  "r33": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-1"
  },
  "r34": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r35": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r36": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r37": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r38": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r39": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r40": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-1"
  },
  "r41": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-1A"
  },
  "r42": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4"
  },
  "r43": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-7"
  },
  "r44": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "850",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-3"
  },
  "r45": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/205/tableOfContent"
  },
  "r46": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r47": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r48": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r49": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r50": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(24))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r51": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r52": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(26)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r53": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(26)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r54": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(26))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r55": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r56": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r57": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r58": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r59": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r60": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(31))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r61": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(32))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r62": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r63": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r64": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r65": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13"
  },
  "r66": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24"
  },
  "r67": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25"
  },
  "r68": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r69": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "235",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/235/tableOfContent"
  },
  "r70": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 4.E)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480418/310-10-S99-2"
  },
  "r71": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/360/tableOfContent"
  },
  "r72": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r73": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/505/tableOfContent"
  },
  "r74": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1"
  },
  "r75": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "710",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/710/tableOfContent"
  },
  "r76": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "712",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/712/tableOfContent"
  },
  "r77": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "715",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/715/tableOfContent"
  },
  "r78": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/718/tableOfContent"
  },
  "r79": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r80": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r81": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r82": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r83": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r84": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r85": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r86": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r87": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r88": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "810",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/810/tableOfContent"
  },
  "r89": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r90": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(15)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r91": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r92": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r93": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r94": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r95": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r96": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r97": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r98": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "SubTopic": "20",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482659/740-20-45-2"
  },
  "r99": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1"
  },
  "r100": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1"
  },
  "r101": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-1"
  },
  "r102": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-11"
  },
  "r103": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-12"
  },
  "r104": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-6"
  },
  "r105": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-7"
  },
  "r106": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h))",
   "SubTopic": "10",
   "Topic": "235",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r107": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6"
  },
  "r108": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-1"
  },
  "r109": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-7"
  },
  "r110": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r111": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-5"
  },
  "r112": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r113": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(13))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r114": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r115": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(16))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r116": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r117": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r118": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r119": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A"
  },
  "r120": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B"
  },
  "r121": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-1"
  },
  "r122": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4"
  },
  "r123": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5"
  },
  "r124": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6"
  },
  "r125": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r126": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(7)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r127": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5",
   "Subparagraph": "(SAB Topic 6.B)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-5"
  },
  "r128": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "21B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-21B"
  },
  "r129": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24"
  },
  "r130": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2A"
  },
  "r131": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-8"
  },
  "r132": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-1"
  },
  "r133": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r134": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r135": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(m)(1)(iii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r136": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(m)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r137": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(n))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r138": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23"
  },
  "r139": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24"
  },
  "r140": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5"
  },
  "r141": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r142": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r143": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11"
  },
  "r144": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11"
  },
  "r145": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-3"
  },
  "r146": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-4"
  },
  "r147": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6"
  },
  "r148": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7"
  },
  "r149": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7"
  },
  "r150": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-8"
  },
  "r151": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-9"
  },
  "r152": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5",
   "Subparagraph": "(SAB Topic 11.M.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480530/250-10-S99-5"
  },
  "r153": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-10"
  },
  "r154": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-16"
  },
  "r155": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-2"
  },
  "r156": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "40",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-40"
  },
  "r157": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "40",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-40"
  },
  "r158": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "40",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-40"
  },
  "r159": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "40",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-40"
  },
  "r160": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B"
  },
  "r161": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B"
  },
  "r162": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B"
  },
  "r163": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-7"
  },
  "r164": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r165": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r166": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r167": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-15"
  },
  "r168": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "270",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1"
  },
  "r169": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-1"
  },
  "r170": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-15"
  },
  "r171": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r172": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r173": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r174": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r175": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r176": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r177": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r178": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r179": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r180": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(j)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r181": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "25",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-25"
  },
  "r182": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "25",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-25"
  },
  "r183": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26A"
  },
  "r184": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26B"
  },
  "r185": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26C"
  },
  "r186": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r187": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r188": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r189": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r190": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r191": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r192": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r193": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r194": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r195": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r196": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r197": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31"
  },
  "r198": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(ee)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r199": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r200": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "34",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-34"
  },
  "r201": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "36",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-36"
  },
  "r202": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41"
  },
  "r203": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41"
  },
  "r204": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "42",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-42"
  },
  "r205": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-13"
  },
  "r206": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r207": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4"
  },
  "r208": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-5"
  },
  "r209": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "340",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483081/340-30-45-1"
  },
  "r210": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "340",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483054/340-30-50-1"
  },
  "r211": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480265/350-10-S45-1"
  },
  "r212": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r213": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r214": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r215": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r216": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r217": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r218": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r219": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r220": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r221": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/350-30/tableOfContent"
  },
  "r222": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482686/350-30-45-1"
  },
  "r223": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482686/350-30-45-2"
  },
  "r224": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r225": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r226": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r227": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r228": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r229": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r230": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r231": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r232": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r233": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-3"
  },
  "r234": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-3"
  },
  "r235": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-4"
  },
  "r236": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476166/350-60-65-1"
  },
  "r237": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3"
  },
  "r238": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3"
  },
  "r239": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r240": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1"
  },
  "r241": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1"
  },
  "r242": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1"
  },
  "r243": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1"
  },
  "r244": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.P.4.b.1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-2"
  },
  "r245": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.P.4.b.2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-2"
  },
  "r246": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.P.4.d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-2"
  },
  "r247": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/450-20/tableOfContent"
  },
  "r248": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-1"
  },
  "r249": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-4"
  },
  "r250": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-4"
  },
  "r251": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9"
  },
  "r252": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9"
  },
  "r253": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1"
  },
  "r254": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1"
  },
  "r255": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/450-30/tableOfContent"
  },
  "r256": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483049/450-30-50-1"
  },
  "r257": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r258": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r259": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r260": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r261": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r262": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r263": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r264": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r265": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r266": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r267": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r268": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r269": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3"
  },
  "r270": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1"
  },
  "r271": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r272": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(n)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r273": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5"
  },
  "r274": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5"
  },
  "r275": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/718/tableOfContent"
  },
  "r276": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-1D"
  },
  "r277": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-3"
  },
  "r278": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r279": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r280": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r281": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r282": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r283": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r284": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r285": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r286": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r287": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r288": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r289": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r290": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r291": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r292": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r293": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r294": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r295": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r296": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r297": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r298": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r299": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r300": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r301": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r302": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r303": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r304": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r305": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r306": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r307": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r308": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r309": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.C.Q3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r310": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.1.Q5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r311": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.2.Q6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r312": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.3.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r313": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.F)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r314": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "720",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483359/720-20-50-1"
  },
  "r315": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483044/730-10-05-1"
  },
  "r316": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482916/730-10-50-1"
  },
  "r317": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/740/tableOfContent"
  },
  "r318": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-10B"
  },
  "r319": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-25"
  },
  "r320": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-28"
  },
  "r321": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-10"
  },
  "r322": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12"
  },
  "r323": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12"
  },
  "r324": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r325": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r326": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Subparagraph": "(a)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r327": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Subparagraph": "(a)(8)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r328": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12B"
  },
  "r329": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12C"
  },
  "r330": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-14"
  },
  "r331": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-15"
  },
  "r332": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-15"
  },
  "r333": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-15A"
  },
  "r334": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15A",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-15A"
  },
  "r335": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15A",
   "Subparagraph": "(a)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-15A"
  },
  "r336": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "17",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-17"
  },
  "r337": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-19"
  },
  "r338": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2"
  },
  "r339": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2"
  },
  "r340": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2"
  },
  "r341": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2"
  },
  "r342": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-20"
  },
  "r343": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-21"
  },
  "r344": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-23"
  },
  "r345": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-3"
  },
  "r346": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9"
  },
  "r347": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8"
  },
  "r348": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8"
  },
  "r349": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.1.Q1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1"
  },
  "r350": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.5.Q1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1"
  },
  "r351": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1"
  },
  "r352": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 11.C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-2"
  },
  "r353": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "270",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477891/740-270-50-1"
  },
  "r354": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482603/740-30-50-2"
  },
  "r355": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r356": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r357": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r358": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r359": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r360": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r361": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r362": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25"
  },
  "r363": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25"
  },
  "r364": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3"
  },
  "r365": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3"
  },
  "r366": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r367": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r368": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r369": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r370": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r371": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(i)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r372": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r373": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r374": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r375": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r376": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r377": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r378": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r379": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r380": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3"
  },
  "r381": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28"
  },
  "r382": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-17"
  },
  "r383": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r384": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r385": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r386": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r387": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-1"
  },
  "r388": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-2"
  },
  "r389": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "832",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483507/832-10-50-3"
  },
  "r390": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "832",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483507/832-10-50-3"
  },
  "r391": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "832",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483507/832-10-50-5"
  },
  "r392": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479832/842-10-65-8"
  },
  "r393": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "12A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479165/842-20-35-12A"
  },
  "r394": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-7A"
  },
  "r395": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479773/842-30-50-12"
  },
  "r396": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2"
  },
  "r397": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r398": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r399": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-3"
  },
  "r400": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/855/tableOfContent"
  },
  "r401": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-2"
  },
  "r402": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-2"
  },
  "r403": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r404": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-7"
  },
  "r405": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-9"
  },
  "r406": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "910",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482546/910-10-50-6"
  },
  "r407": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "920",
   "SubTopic": "350",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478609/920-350-50-1"
  },
  "r408": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "920",
   "SubTopic": "350",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478609/920-350-50-1"
  },
  "r409": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "920",
   "SubTopic": "350",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478609/920-350-50-4"
  },
  "r410": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "924",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 11.L)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479941/924-10-S99-1"
  },
  "r411": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "926",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483154/926-20-50-5"
  },
  "r412": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "928",
   "SubTopic": "340",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478859/928-340-50-1"
  },
  "r413": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478934/932-220-50-1"
  },
  "r414": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-18"
  },
  "r415": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-18"
  },
  "r416": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-18"
  },
  "r417": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-19"
  },
  "r418": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r419": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r420": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r421": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r422": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r423": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r424": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r425": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r426": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r427": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r428": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r429": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r430": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r431": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r432": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r433": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r434": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r435": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r436": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-6"
  },
  "r437": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-7"
  },
  "r438": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-8"
  },
  "r439": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-8"
  },
  "r440": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-8"
  },
  "r441": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "280",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478657/932-280-50-1"
  },
  "r442": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478988/932-323-50-1"
  },
  "r443": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(27))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r444": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478451/942-360-50-1"
  },
  "r445": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(1)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r446": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r447": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r448": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r449": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r450": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r451": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r452": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r453": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r454": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r455": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r456": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r457": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r458": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r459": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r460": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r461": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r462": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r463": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r464": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r465": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r466": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column F))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r467": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column G))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r468": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column H))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r469": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column I))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r470": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column J))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r471": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column K))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r472": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r473": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r474": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r475": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-9"
  },
  "r476": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r477": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r478": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r479": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r480": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r481": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.W.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479583/944-40-S99-1"
  },
  "r482": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480424/946-10-50-1"
  },
  "r483": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480424/946-10-50-2"
  },
  "r484": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r485": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(h)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r486": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r487": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-11"
  },
  "r488": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-13"
  },
  "r489": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4"
  },
  "r490": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477796/946-210-45-4"
  },
  "r491": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1"
  },
  "r492": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-2"
  },
  "r493": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r494": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r495": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r496": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r497": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r498": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r499": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r500": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r501": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r502": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r503": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r504": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(16)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r505": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r506": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r507": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r508": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r509": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r510": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r511": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r512": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r513": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r514": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r515": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r516": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r517": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r518": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r519": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r520": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r521": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2"
  },
  "r522": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2"
  },
  "r523": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-3"
  },
  "r524": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-7"
  },
  "r525": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r526": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r527": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(g)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r528": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r529": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r530": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r531": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r532": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r533": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r534": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r535": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r536": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r537": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r538": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r539": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r540": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r541": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(1)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r542": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r543": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r544": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r545": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1"
  },
  "r546": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r547": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column C)(Footnote 5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r548": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r549": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column C)(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r550": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r551": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r552": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r553": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r554": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column F)(Footnote 7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r555": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r556": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "948",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-29(Column A)(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479628/948-310-S99-1"
  },
  "r557": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "954",
   "SubTopic": "450",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477850/954-450-50-1"
  },
  "r558": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r559": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r560": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r561": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r562": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r563": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column F))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r564": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column G))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r565": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column H))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r566": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column I))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r567": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "976",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477332/976-310-50-1"
  },
  "r568": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "978",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479230/978-310-50-1"
  },
  "r569": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "985",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/985-20/tableOfContent"
  },
  "r570": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "985",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481283/985-20-50-2"
  },
  "r571": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "16",
   "Subparagraph": "(c)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-16"
  },
  "r572": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "13H",
   "Subparagraph": "(b)",
   "SubTopic": "40",
   "Topic": "944",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-13H"
  },
  "r573": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r574": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(g)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r575": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "8",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-8"
  },
  "r576": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-16"
  },
  "r577": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-21"
  },
  "r578": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-22"
  },
  "r579": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-4"
  },
  "r580": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "52",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-52"
  },
  "r581": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r582": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31"
  },
  "r583": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r584": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(bb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r585": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "48",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-48"
  },
  "r586": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "49",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-49"
  },
  "r587": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r588": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481933/310-10-55-12A"
  },
  "r589": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "340",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482955/340-10-05-5"
  },
  "r590": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482548/350-20-55-24"
  },
  "r591": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "40",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482640/350-30-55-40"
  },
  "r592": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r593": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r594": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480547/715-80-55-8"
  },
  "r595": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r596": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r597": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r598": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "217",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482663/740-10-55-217"
  },
  "r599": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "231",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482663/740-10-55-231"
  },
  "r600": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "102",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-102"
  },
  "r601": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "103",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-103"
  },
  "r602": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r603": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r604": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r605": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481372/852-10-55-10"
  },
  "r606": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-17"
  },
  "r607": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-21"
  },
  "r608": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-29"
  },
  "r609": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-3"
  },
  "r610": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-2"
  },
  "r611": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-4"
  },
  "r612": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-5"
  },
  "r613": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-6"
  },
  "r614": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-29F"
  },
  "r615": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "9C",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C"
  },
  "r616": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "9C",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C"
  },
  "r617": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1"
  },
  "r618": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r619": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477439/946-210-55-1"
  },
  "r620": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1"
  },
  "r621": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r622": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r623": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r624": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r625": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-10"
  },
  "r626": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-11"
  },
  "r627": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-12"
  },
  "r628": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r629": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r630": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r631": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-K",
   "Number": "249",
   "Section": "310"
  },
  "r632": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Number": "249",
   "Section": "220",
   "Subsection": "f"
  },
  "r633": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K"
  },
  "r634": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "b",
   "Paragraph": "1"
  },
  "r635": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r636": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r637": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r638": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "b",
   "Paragraph": "2"
  },
  "r639": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "c",
   "Paragraph": "1"
  },
  "r640": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "c",
   "Paragraph": "2"
  },
  "r641": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "c",
   "Paragraph": "2",
   "Subparagraph": "i"
  },
  "r642": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "c",
   "Paragraph": "2",
   "Subparagraph": "ii"
  },
  "r643": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "c",
   "Paragraph": "2",
   "Subparagraph": "iii"
  },
  "r644": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Number": "249",
   "Section": "240",
   "Subsection": "f"
  },
  "r645": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r646": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w"
  },
  "r647": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a"
  },
  "r648": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "1"
  },
  "r649": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106"
  },
  "r650": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "b",
   "Paragraph": "1"
  },
  "r651": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r652": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r653": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r654": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "b",
   "Paragraph": "2"
  },
  "r655": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "c",
   "Paragraph": "1"
  },
  "r656": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "c",
   "Paragraph": "2"
  },
  "r657": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "c",
   "Paragraph": "2",
   "Subparagraph": "i"
  },
  "r658": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "c",
   "Paragraph": "2",
   "Subparagraph": "ii"
  },
  "r659": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "c",
   "Paragraph": "2",
   "Subparagraph": "iii"
  },
  "r660": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-T",
   "Number": "232",
   "Section": "405"
  },
  "r661": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "405"
  },
  "r662": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5",
   "Subparagraph": "(SAB Topic 6.B)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-5"
  },
  "r663": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-10"
  },
  "r664": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-3"
  },
  "r665": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(6))",
   "SubTopic": "10",
   "Topic": "220",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r666": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(3)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r667": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r668": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r669": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14"
  },
  "r670": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r671": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r672": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23"
  },
  "r673": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24"
  },
  "r674": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5"
  },
  "r675": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-4"
  },
  "r676": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6"
  },
  "r677": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r678": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r679": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "270",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1"
  },
  "r680": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-18"
  },
  "r681": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r682": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r683": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(ee)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r684": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r685": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-13"
  },
  "r686": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-3"
  },
  "r687": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r688": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "340",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483032/340-10-45-1"
  },
  "r689": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/350-30/tableOfContent"
  },
  "r690": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482686/350-30-45-1"
  },
  "r691": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r692": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r693": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r694": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r695": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r696": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r697": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r698": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r699": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r700": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r701": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "410",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481931/410-30-50-10"
  },
  "r702": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-4"
  },
  "r703": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9"
  },
  "r704": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r705": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r706": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r707": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-5"
  },
  "r708": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r709": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r710": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r711": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r712": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r713": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r714": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r715": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r716": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r717": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r718": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r719": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r720": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r721": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r722": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r723": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r724": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r725": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r726": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r727": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r728": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r729": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r730": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r731": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r732": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r733": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r734": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r735": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "720",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483384/720-30-45-1"
  },
  "r736": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12"
  },
  "r737": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12"
  },
  "r738": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r739": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-15"
  },
  "r740": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2"
  },
  "r741": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-3"
  },
  "r742": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-6"
  },
  "r743": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r744": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r745": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r746": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r747": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28"
  },
  "r748": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-2"
  },
  "r749": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-3"
  },
  "r750": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7"
  },
  "r751": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7"
  },
  "r752": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r753": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r754": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r755": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r756": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r757": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r758": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "912",
   "SubTopic": "730",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479532/912-730-25-1"
  },
  "r759": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479432/944-30-50-2B"
  },
  "r760": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477363/944-310-50-3"
  },
  "r761": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B"
  },
  "r762": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B"
  },
  "r763": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4C"
  },
  "r764": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4D",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4D"
  },
  "r765": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4G",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4G"
  },
  "r766": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r767": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r768": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r769": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r770": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r771": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r772": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r773": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r774": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r775": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r776": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r777": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r778": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r779": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r780": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r781": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r782": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r783": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r784": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B"
  },
  "r785": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B"
  },
  "r786": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B"
  },
  "r787": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2"
  },
  "r788": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2"
  },
  "r789": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4"
  },
  "r790": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r791": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r792": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r793": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "948",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-29(Column A)(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479628/948-310-S99-1"
  },
  "r794": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>92
<FILENAME>0001437749-25-005919-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001437749-25-005919-xbrl.zip
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M)QCC!^52 E4>67+KXDG4N!^3@TXHC%*=?#Y><^RO\<@M^>$D'\VG[Z>'MO+
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M98<3I\*0_3",G_TG> 5K1/W;!UGU6&4F)GC?ZF:*C64VN-#! 7JDZ/NB^RB
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M'8U?Y/&):*)@]B=0DR&6 6B^[?Z\F_&]A#?<!-%"1Y%:2BKQ-?=GP"^5RNR
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MP%^5NF9AAX<'FG\/UOG^>$OB2P^KMRA\"D/IA2X];GZAEI6?!FL\5/OUS;N
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MDVU&@D69]QLO?CS.2 2!4K.W3*'RWH4DW':\XTD--'*]DOSXQWN-J)=FQ\.
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M]]_K <M(N6"%N%I:T]; K^*AA:E'-O9XC_^K)U6',2O'3LYP@\DC,6(92)A
M%FK8IU=4R ) #CJ9-W70]S/(#AYY;S:X^["!Z%$&84K[.7ZYY'_!68L=GVRL
M-/,<P8JWS4(R-V$JO?WK%<G[QL"H_[FPBR[Q,+@C;FTOT$T6>J[C%_(0LZD]
M_,23O 4Q?8[P>G/2%%=J-N'F 9S_\CUMBMI&58ZRAG;HO#3'Y%$Z/]#(^09<
ML5<M(F(.=TH.#<M1E1(;2[SWOK2*:;"KT0;V%P\;NL1FYQY0[GS.5&O@D_CD
M,JP'-RYC$BSNW94I ']M\S2-G3.GYON^ <?)>(R;#V=[G18S[]V$*)Q$AZ5,
M(/Y>=D"<DHN?<GO'-+Q14V2+1PA+-1ETS@^+ER)D1#,7K4"PBO##LLZ&MDX8
M/LF$WST>57620K4->\89;$B_4-%E&'I81B]]EF@6M7&W:HI]^V<Z>_E3H^1%
MR63[R[)>:$#-GS/@41-0&96\\!,1KOJF[9BQKFK*9%&1TG,WQBJ6_;L^:<H<
M4T>%ILGJ1=IM_ 1QYH6ZA=IK+#OERKV\#AE=S75-I>%9]8PW4PG%&1+:;AX,
M]_M<6 )>2$EA-='MT$U'G $]O[L&:E&L(>PR,Z@4GT/<(_RB[(BP5?RL.QL!
M%RR>%G/HG'*1'W+%G7R^Y_E(8()CO9&S(,R'V/(;$N,]$]ALI?C4>(OU[3>^
M@/!]=+6_]@^)[*5":-ERMT.]"=L@1WW&:'SY^H,K]&$5W&@GW6KO9(Y=\M4[
MW=&# #R9;-,Q!VH0LSS+@GJ)NIO<9N>))_*)R==:9*)#M^FS7.:;Z1-_YBWT
M\#A$)@<0K(7>6."%W7\NQ:"1G+O.=):-ROG1=,I5()9USU7H(;S<@[BR?$]5
MN#?8_QMJC>#C0:%-2V\]APO.OK?UXHW'2.#;]G"E$+(=F@ #'#P#F:PI=K-E
M=5QHUD+[_4J?.FM%YII48WCSJ(K6> @ C7MT9DM&SJ^M*R=M +)>&^-^DSX,
M@-H(^=L83O<K/I0_=E,",!B>[/7QIZHU06($7;,7VI/E9_C< SPU.<?<?[KF
MK"PJC=\%IG?6AYK3Q,>!@RM%)4#)CS!JY_<K02L"KS!.PN*%;@Z"%A1P?;4A
M"HM?2\/:;U'Q/I5-2\(M*6>:H46-R:YN=HUIZV3BSG3K<K>!^A'RXI/VV0XS
MAT\&GHV3)(G$Z,B?O$[,SMN@9UR<C>JJ.<]SVM9-H8;A%MD,X2XY&\D?#@DY
MSF":WIV/IK91LJ)NN._++LU<:QM=NMC]2ZO*LCZY1].?)9Q??W#B:0H:S!N.
M]X)=U&$.<UM9<),M+!:G[<L2++WGM[SBW8:;7,=:WUS&\PC*7&[3A536V/N"
MNL]<>=36*?>%\((33:^UKKD;3**:]1T>%7!L"*KWWSM"(YS,)9&)O;/9L *2
M*,A;.@?7-8<[ UD)N=I\%;.FD_0$60,WC@DWG%I?_:,UFY[\>-%IYNDCUCH1
MEQN:;UR(WXF!CO1U@[3S2M:0A.^A6_%85OL:.*3R4?MS^4SJD_5F$X+&=!V[
MTQ]L86K$R*1UN4M$TTN&G2EECOC?%$#GT*)T H-[XU1-^;ZI2\6I_=) [C=O
M97/@'&JEQ'0O11GQY*!?3XG9"XY#HH0LHU6G[2W)4VWY!4AB_3;GDK3+F"KP
MCS'>C0W$'M9B?1[MNL2?C(KXQ@U%/GXXGO@ *$>UFY4X9>P[.J/2/7NDZ DH
M!@V.'KI&Q*8:G@CF%8J4+.>#>9,^6=ICBBK%I1\+'E+K"]L<!]_F]:H7+<\K
MU/\B!D>F/P7AK2;A?X3*_HLLO<\QZ_%!!G'702D^7S7=Q0\GS4KC'U_S](C'
M7#9C#(8U1U?.OU\@0EZ?Z%=5[/@A?:]>2-2:Y?ACP>MN6J;7/I(EOCV#D;(
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MI97J"[@(/#:1SYN9>%O+$KPKB40I$V7'(+C/%'VC%<U_P,F_%?]C"39R/&#
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M8$/4_UII0L+DI]=>VX7BA_^H"9Q-!B_4/FXS\',S3KA8+1V,J30SCCYE]MH
M/!FFO9=HKB7\=I_^\=Y5?I;L/DDZ+I%=G3(NZ3HI-+$4PM+724^B>SHC^TU
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M_K7Y4B'AXM36W>4B+[28#T2,K80<RL&N%]$6R:7KN/W#KPHK%^J>ED3<W1=
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MZ:5$C+BT,U38F"[VR>U!ML2A6=LS=$_4[!LV>  Z^WZ&.E4@3/,MB'<C0WF
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M$D+L 8O7YM3-H!6?TR*M]^D\+UY,6"BE6>Z)V?1C1M$S9%M[9E&?#60I5.>
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M.Z%3A=-Q?P"GOZ>)S&Q0(JTRO[>.Q<.V(;ZW'_/L_W"$O(TH<>F%'J:CU")
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M%%)[&8*=YY V361V$QWZ.&X _)\#3(^W&.I:<SFRB:LD'0? JUE'Y0$C[MT
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MU2!*>N8RN.36^XOA$=J.@>/#* DD_1[!W1]5+/=XW?S0=).*W];%F2X_ER&
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MNF)2[I\@2CW33YE7]97.>49VTYPW&'&JM@[<)BYNA&U'8G1C5@J[LN$KB4A
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M706F-.D)'Z*M^#KH;F_7+3M:#-JW'#O]K "CCGCFB\%C@O<CWQ*UE2-?1VY
M(&\J$X?C&#26O4*!)-@V9NGOXLA<+9X,9$,?>"_P--'#@;62PCWY DIR[=>"
MV=>!FI\.G^(4K1WIS%IEW(,E?.#GO!C1V/GQQ%?'3.?2O"'NE .VN(GM'FV$
M:H1JOCQRMF;=S>?O2,L0$Y5^P\VS>SWH.9RP7N5>[%W\VZ_,;CU_]$#STHT/
MX49]F3<7KM\)T%BQ\RGQP[\-NZ^=^+[BT<'8H=<*<>=869MLN[9TM]=+J#+%
MQOT[Y=H$@_Y-U@*S.SC2CG3>'M: /)$\EH]<BPS*_>]3QT:>FNRL>#YO];ON
M67,+0/&,GX+8EN7QH:^L+.N<HA% )>Z)C,5D04,DC[&P)UT'R$=V^G@)H"H_
MP<];UZ^)N=LBP%J=S+ 8OW"GY[-:&CQ;OD66_G>'M8W0.E\%?>C+^^B##5?%
MGYP+ [N^%V[^L?GY]^\B[3!L81U+@K0C-J^*-P@_LSV$MPY:TG35?_=?42M=
M#OZ[>]-%OQR5$-PG_TLNG0;K5*Z$Q'9%VBL-Z,$B3&.'N&F(X.@-Y-$$LUI#
MH.7)+ID5F2]"_/ZI&#\.P!(]?WG;MG 5L04>@YZ3/EO[=S]W(.R)O+^!6]#R
M.<]*H0UM?F5!'60+C(X.MPFT/]YNTEMK#*!R1T'$BU!:77%<J4M(H?/!"Y7C
MS=<FJ[-,^Z:^FN#9T?D"0Y_G?NT=B*"+/[9VEQAMPV [C/0XC@B.)_4H6G8-
M?)7MGHC8UP+LYWY=/"DOXH/[_*5(6@)Q3^B?>57$_DF>>AG=J_3#+3;_>CL
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MB#VW%M!Z&)<)%\P&<N-A 715Q^YI 4V=,-6)X@3]3!OH;;*PU#8..WMYKT-
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M2(6&7/A@^:A)9SRRVOTC_B')L(MH+)YNC:JN(PMF-:9&#XB=BT/&:'H3B,W
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M:2]:C3*QUOI:8N3(.JUROS[ 0!5(.(S>V6>QHNB.+Q@:&3YJ"#:<TAQEWKR
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M!6$0=GYC1L7^"D,)P\=4Y=5PN3T?_OB(S!/K<4V! (T=!*/(9,06X4^HN$,
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MC9\J&7I?=5W5EF;H&(H?>/N&RV^%[I5:V"(<];K^YS700]"YMRU75)D-&)9
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MR7__5] IT.]%FHA#"?UHR)<7P=!C9^'X+$VH#.?):[M34(<4YEE +_5#B$R
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M7!NY$[F:ZLG\+B-TB#<PNI2 VDS +&0AJ[(;]T(OKV_W C/8-CGZXR69&,[
M?3H,0X3%TIE.>1F*K7YJ2(0\"NVBB4-Y(R91U'BGHZM(@WT24D_F:@VS1=54
M[NW^7-4"UU'?9]8\EW391N1QQKD"6CFJ7K'UHI)27\/56YK7Y7!I-F%1=F$X
M9C)/B,IXF7&"K4V(:U-JJ<I8F6JJUTB%:FJQJ#A:?-!75";(>,=DL?*8?,0<
M6Z]4E3]8?P^/)PC!ON7)VNOS.HB;O Y[7/@SK/@"9WY ^XQ]**K$;;**V_-
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MW?[]@W1?E\GCB8%CRE _BB6@S/Y['%D1$' N (2PN3Q$)4(UX2O5DGB(15Z
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M\=;=0/+2<O6?\J7[JI]8!R$;=F3/?M+=%S8K57A=/ GOM@^#5.%76O 1V\\
MS?Q#.L"'J69M-NC+[\T"L>TVYCOK-58?[' JF 3D3WE $JF/Q>FD9D4@I/FE
M&D9*FJ'?+7DY,0K38]"T'(>/54V_U'442CO(Y2<2_M3@Z29#]]-F=J\'&W1E
MCL?U3><0-*]Y,YCDQ[1PB!2XI-87X'J^H91V=QV]L3&[X;GSF%0-6_G(6<G?
M@&BC)S;.]3 8PXA![TWH!;]BC;)!7^_J^(_936E_7T"I((Y)0E8A;^)#<5-P
MRU@IZ.IG;8)]#'CW- ,M2E[S)1/4KJK59MP82&:#S'58*4-\.:M^V],K4J$5
M,&=LZ@ZD6#QY3_ZO\_0  [3=\X1Z%]B8/],'_3&;-0[Y*N4.H1K0#NCY^L=#
M^ 0Q/EJOKA&\T>VJ"1!N0U6&+7&5)8PTI8$[G"+!+>%"U8609TC8/[_AR,L,
MD'N%A"H%D-!MD )OL!N'*!KA.C>D"B_^G8/9^#KX5]R<H>GIK/RGZA:7:K4E
MM*G?ON,6!EB\/WE$.+W=^W*5T,D46D=S>Z6?2:.[0P:R\.V1D,N>LU<E:DX:
MXJ.0_C\1[:_6&Y.:+6/:K#K(;@0KH0DOV2.].<YNOE8[*9,QG73BTUH+KNEX
M(B0_<[A[L.WN=M""OFY.SK)%YH4_;TGJE>E55?!?W6NAU)?GXTR!\Q?U^3"Z
MC[AJP;0B0]5S3/N3E,/8_%>EVU=U7*\N;^[9X5AC226N$H#BQA-#O846$&Z(
M)8)T\M"V7']>IZ-M61DM?0:7=O3C8T,?FLZ)2PAJ+SKT<:2J5Y*1D8YJV0.9
M<?,?JU<JP[4FB8O^6%J,$/%Q;_#7)VUW=ZPK_46N3.R/&_O5NV37U]16OV.#
M+$3,_ ,.AW>]":)-')/4B#"_]6M.#*MR+TDC:?B1U#N=GX8^9H+6W9 /7.!4
M5\'?C6[3?,_ 7PD):_HB%%XSEF ^59$>U]6L0VO^,%UJ;4F/ESQ!+VN@M__S
M7T%O1Q#7]6R)P:V?6RD2<AVE;GGVA&+G1U]YH:;ES3:W29M*2R>O6?_(;(G^
MJ^7Y 9Y9FJ2<3+?FHE";\#H;%*/(_#Q3*#,CI. 0IQ]Q5A-$E:ZGP+_7.;]0
M/U7P?3]W#U/XG2JRH[$G/4^)KPQUHG($D3?*U]'+5:T2P'.X)T"KG0UZ5<AA
M^KO, GW?DI[IP*FFQPR3KX O6?5IN'%K)H3\%/#GK9Q4MA?KU.4:N]!7&E2,
M%7( 8%:8N]@;YALW^(8Y\*_*JCG-\ &22Q^Y7N#([B[L&%<71("A,8T76AQ8
M0"F6T]SK_9Y-EYZ^2VS40\>5BEG1>6NB<XE2OX.%:IJK*P9]SPT*C,W.)?+Y
MB5#K+*[J/^\XIQWXIO:FM-=A9S\'6;0VBUISZU/<D?G#)R[Z"(Q8G&&#Q)[F
MF/80!5X?BII%OBG04#UBV!M^@0WZ*:G)<DT IV*/&!Y:W O)9(,.C^H26\5N
MSW-V^1JEM\0&"8G9 \$^LGVK6]"3SBY>H1!^F<&@J@C+L-*JQC1G5SGWV(A7
MOC#H42>X?X4G0YQ6 CO!\)QJ<B*S0:VJ(HB!Z5),-!OD!3L *+:.V;5-6'</
M ")6PW@OV&GXK4E(S'"X#97U[!/#&@@-_+PH*4H?#)?%Q)2>*_?5VW>#?FUR
M:MTK9GYD<!@U"-1I<B#LZGY(25&)R4SQX;;DB^*[(AW8*.S)9L7)Q31<W";5
M?]_3J#_8Y6"[$PV;J.]%VW<U%">JG&\<;KP<6 :(N?S6T&,>LJFMB7;*%+E;
MBS71"DA?H"K/9SVP&\QGKC&.L$%_4Q+LAIH:\I 5-"QT4,,?D/G)$J>MQ509
M#V[!1MTH*ICI-1[[T1YTB5C/ %U86;J]VC;D(#DBT]Z@0Q1Y:D1VM+8>\=?K
MV02I=Y&0ETF(B#M ^13^-9J/=1S!L=#@9X9\K!\L*9IQYZL\P)@,/KK$.D<_
M-\B0+@:,6QSYHGV#V"#J/V]LK#V=_MT(*VPN_&A,%K,,*#&"?UI.2^$@4(5*
M;1ZD#2=_0FA=[=._..TBU=[.DJ -8SUR'CEJ)GT>L!BH[#4\=K^JNNKU:9^#
M,C6)VFTM(V,5>A]<K9VP_G^!3HRP01ZCQX_8\A]YL/:E8]_#N,;IH=4=MXN"
M5ZN>I]K(K<,W+U)2;V$GV"#0[G+KI"P;],*.TDW5H',YT-82I6DUB;),S";^
MI*L#@J]S+'<X7X/4'FEL5'^TBW"S;E" U)Z6]>D(+MY?KL8,>L0D0!>1M6P:
MR^T.C6')(QSAJGS(:T P&?(4>ZK1@TZP8=9= <<.@T]?47TQEO_JRH3=-'6G
MBR-1@>2K]!8@.]=K?71T85("\!#"/UW5/[77-W2E<B"W6E=AP3(O!UO"!HVI
MZ)Q\<LWZ^:FIBL:X-XU*5@^NM)>VNKW*4A-X7?B9&7,<<201(5;C]^>8ZH5K
M-@F6U^*-ZYV%=TW@1XFCR;N0(754T^(.[O?H;Z3'?;(=46: 6A47W*</+4,\
MW-D/;4^;>UHCFABG=)$#4#;(U]Z+-)XF_GF).XC$[P7S^QUL[Y([H*'8$1N"
M\2$]O!QCI3ESZLDQJ>O'QAP>WU*+EL[BED#@:P+?M9\ZOMKA4<V[(G2RXZ_0
MVHOGWZ#\M;^><S\B=O<!.-#]S7<)[HX/YR(VXF,-"]9"A4O/!GU=G,&7=:&=
M?!=VS(.:Z1O4P"7"R,P'I ;=B_Y&KGLM5G^^.NCF GKL,'JK>.493 35^20L
MBQ?(V5VF+Y,3^2 (Z.=BOA;*>)DB]<!O=%8$D5*W^J'KON3(:Z_UUWN3IKM?
M&\76C)SZ.(5NYS$2M$L*?P;+A-%LHS# A7GJETB()]]K-FC/C;#.M;YGMU"*
M"D:W.EY"3Z6CJXGZF-$>\E_23.;!N_B[W;1O<TT^T:1Q![-P^3D$M]:HDH<(
M6IK06Y=E]_Y)?FA4A[+6\-NDW;HKJ2$KR/0I 1+M.7 Z26T*>LC]+^SNVTW4
MM4.X_OJI[J%Z[%IX6FC[Q+F:I\C#(:?0TP=I:CJ'6"\-I/%X_ZX&\,KU,(Z$
M2(S:(ZX.E9_:'E)^B(-WYI6EF\/JO?(:MJLPG;(O<"H.<HI75OK#ESFL_9L2
M"K;]YV.FMH3N(3Q]C5;6L\^/G\>R=.59'?Z[\YQ@L81E?BKP&97_:@W2P#K0
MM6I8R@9AT"_%,,5H"FG:)75;&DV ,((LF:](&P0V2$(P\H$!7A!LW1'Z'V?D
M_V(&PW))4BQ?(5F/L,H&/0UH^%?D6Y0E$K #V'G\.S#Z@19C@Q/+"&R/\>_D
M&J1+S.^@6[0G_A4X.V#+GQ'!4/SZ[[B0<C%6&!M$^8PI,:XA1RTA$C?V\5/B
M?O\*;%F[5\,R8 F-_G?8$8Z7TF>#Z'W&P]+C]&M;^L9A3!+MI-:_(LO_B71B
M@R39H.,K^']'7KG%!F6A@87L?[+T<2]+NI&U!G")_2NVH-]_)BL$]M^A_RM?
M6Z^V&7<CK?!A3,+F?^TA[[*F;I:]V[F]",S&KAW\WSL?[H.:9_)I@]QHRRPC
MC=@7P>$^-;"?,5NFP\0T(L:806?40#CL!RAUP;9S:&"90D D1UX_$3U]B;C1
MNK@&2]92$CC+/9YB!ZKP;95G C+NJ_X9A^/5['ONIV[-LWCL?+<A8[@6_HP+
MJ$-> M.Q'(S?05[5.I!!2410XM,8O8 9&7*2<X=KAPD"]=PX?<5IO#C@Z4*7
M+6UZH?N3**J263@^X9KC:-!1[K!4.B-]6TG%57[-5$8Y\'AY,$$W]?+'J36D
MK&!I6:'ILD4QM+V0ZJ%@^4F&#5J0RL:GUGEN#.& P"UIBFH'[D6S,O.UANJ)
MQ2R]/J0U!<W-T +LLGL,LTN0QV'"5<Q8X-;<N&E<6SU7JS(/Y;2#UT6YV"!N
M?S_]L$"WZ:AIJNY\YUY)-4JFG!<@1WE_:3GS[9S?V+%?-J&7-8=T0!67A5H?
MREW FT&\2&-VK3 !UBDGP*P-78GM@)P!8NW7H!W:C&O[.HZ(0R[ 8B X<2LR
MHK4<>0/(A=,/.=!YV:!H0W%$A#7&A);Z8NOVEH3HL)D\9J2ENC]G '_E=Z%U
M](]-JP[WIYKS:W7=9PZ%7E5+C)I__';6XNUN<L+<9F@"F0(/J2(E>=;%OG6*
M43275QR='#..<"7U0^#HJ1BPJ(;_,[0D2@MH, :DZ3C*;.]\*USB!* W91=S
M!2:(:&[36WME*)I2U="KUR$I11MZX2BH?+ ].%1BL^:B4H'P4/;)Y;T-NC7K
M>"1=CC(7M>^#(HBNK9CM7T>(W?QM>!KQ60PBZIUV%.M?A-1[SM$ARPC?9MU%
M*[B6))C6N-/_C:AKWOVRT84LMKS/37U&J]=.LF6PV* H7TOP=AFPE_ <,IUU
M*FGD+RZ&$N;XDP*;@?B+(0^NGN=ZQ\VI)A1;8Y1;E;H2N \5LZ>\7&6=!/;,
ML!?D'T3$O;YR,1M>_,Q7W.3*K+3+^K?HNT79O?;60KNAKVWD2RZ$GOUMG?[=
M\TS#=T-/4_\/BF/;R.J:>SN^^*8I[V"/]^[]\5BY[6;N\=W4FNQ@D?5=C2%E
M"$':Z%OYUZDRI95[)P[$.W8<V+U^\=O9;T:'3UT%D1L:0"967$9GV2#(R\>Z
MYP]V?5/[+OPNK%6<#<KN_'[^ZF1X\^]3U2'Q#QIZ1!:NL4Y!/K)!!HJ,5UUF
M.PF!&[(ZBSTY_CT>A*&%37R$#_JK?4BIJ>VL579,%6OH8Y633QJ^"&^VO1<&
M5G4UD8[Z3>'*#0DQ>?=]L;7+/MPMEERY*'CD+.$JZO[?%KI\=P[%4E<<+"Z9
M[#?G;&_B5)P@M\+_'K9<7LT%,A.>GCNPR<JJ6LHZ/,X&<=N]N"%0CA$"[F<^
M2PE9(2J)O=NXI7YK>.S@5P$]<F,[5/[V=YT6EO#>7N FN2%!:LE,+]TI/>11
M?F7M\[FQFVJKB7.3CU:5\RWEY24G$=EON>^GB)W1F;%3 ?-#>6+;B(5AUQ,O
MO'3HNJBC?;U$5E'N+-PCMW3I7=Y([.G.^VKO'VF<M6LCYN00':[EO"W9=<Y,
M&:X.UXC _HY"7@4RR?[CXQ1(F[F_#;'1C*8PWSIY+J8CBV^XQ&@M*LA%'7(H
MKL"/NJJB[*<<E##V^HBD7GJ8RNKM9]F/%;LV"<^QQ[>HJMLAAH9TK3@5I&P
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M'/)&1S>+,"#T[(7PK,Q<;Y;D0'>B)\VO--<5GNRM[LV1K .MZ-PE:Z<;D?
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M5W0"M\+CTEOQE.L:#XIJ;Y78&3C(R>.\4]6-/!CGNVLSE,6= ]]/!VQ=NE>
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MS$F/2C?Y+@V!)_7,6=,TK_[P(-+L(L./ R0-=.7=Q7TSI-#R#N8I YF#<N2
M3^4MGL[K214.Q([!I@JV)8_0=\71?VY+1G:BW?6<&-B-!0BTM47[#&6KS+-C
M-'O@@U._I%-$/=YNOCFZ1ZI%IC]^RQ9)'(?*,N%_&!S /[=!M\H9*J!:P&=1
MT@PS.J$3S>G;IS;7Q)"788<<%K-.<]IB;)#>LM@T.5,,YGM]U3=\;WL,KED]
M(#G2[B]X\D*2W,CU!O 0>JR[-1!Y@YEI>!F0T'A4:8)TH6UT9$E$.334I%M6
M#7@.K4AVB=55+H<E.9"?S?-=>D9Y,WC82"X ?#M%#N>\R0+36?C<,&A7!B8:
M=6G>GV&:!]X5/M1]MEMB/Q3W@7S"_ Z!-[[P=4Q58/N]?!NMGE[H&[F'N1*^
M8A&XYIBFI#X'E.*1K;!?EW-?YUIEE&3FG^W,6SOK,[1%;<+,8BW8H*C09L-Q
MIW$C#KQX:>^@%R8G>=M;LW3.,]Z[Q2%42_S:#W,EO_DF#E+,KN8,1K+TKZNC
M((R+@=0IO,@4A<F\4U,CLS>'+WG4#<H0.O[>#_77/?%GB4W?%JF+%\1^8[(C
M.+(C:VOW$$VN?8Q8:*=85@1-LGJK-I(O3 WU1@VD^#>&>$EOFZ)O\PDL= DN
M>MZC' ^UA*JVULED/,#)Q<QY#P[O&8!O[%IQ2.GY4610U!HR%' >Z=)$&'>9
M+(2K%%=&3 43*'@.BQR6!J:YSP+S-,*A6AHVKOTQ8KF@?),E%4G/0%N.^&_C
MUSZ95;)!"(P/&P1CU<P[F+6HGGR8Q/K540QG;;U>AVULH4V0-9A^<*=@2L6/
M<"?D45Y4D#"G9^XF1+&.!=*+^'9+L;PC4406/U0X$) P3L03\B/W88 4MNO5
M]=<H=89.9&TK]#CB(__NDH,TEP1F!KYG/89N1$,VUEC&%Z.WW'8YS#- *^&P
M'PRI 1-V@+GB'3LX'$ LVV=.5,%N$X2DJR-,T'^B^7I8&;M!3'[&G!.Z5<SP
MTCB5EQXSO=AMS08=RW_=!67QQK@E/HT(-3A2PQ#@(<\V<P-U4];/^I"7R5<-
M:/G6,I'<6_-"3&Y?PQ<L:0:''_V<#QT@2HX<_8HVQIZ8K;9[165MQ:XO4WWK
M5U)=\\KW3!!EE0Y46;C_TS:GFZ6<(Z6/FT$=_N<J@Q=0BFT@B"!#H$-\"A'8
M\329HZ3/&]9VZ5 D%,,'6-SWZ9JC,1_HJJURX@+Z6F6K<EEK!<(SDH')X\]@
M#4[0G43T>::W=.M\,@E+E\12DOLKT,:J)U1RUHMV;-F@]R4WJ!RNA9D5L\P7
MT73U9F5(Z'YX2H,2GFL6O1N0'1%:,PVD_'-URN\ YE @'=Q:)G(6/*([M;.&
M7F>#7.?J>6# A9T.[:LD.D\K<$9.]$)Y-UA>%M<U.1[*C[T/^\J+5;NT']C@
M/1OESBBYJ@ZZ^LMXU=UFZ9:Z,46HAB&$[5"#UXQ-UNU+(N\,L$!>X$I]4D5(
M!7V/0 YM2X#>*:=_H"L IOWW:715)<-S+HX3RP+CN\O^^8=KJE.I4MMWT_FR
M7^[I(\*4'^^Z>*ZLS&1=/I7<_,YDR'1GH6E-F7^>C'K#DLMIJHZP& @94&T+
M:0B_.V#FTOP]: #W#ZC#@>T)33R&(?<T$+O2=)]OQK\\@Q9".ZDV;B"$7Q&C
MO%+#B@,^65R,YU7((RNU6BWT9P3''>A9U 2L8O6]WR8FAB1L>(QQDU[VA@([
M"6AU3 JE4Z OD&*J,;/#C7>RA.I9OX<TCN$^F8<,6*._>+%.OSNFX1O.2-#M
M%N%MJF]8&T_?UNNO8GJVA<=0C6A@*%TD1JPC !XN^8DNU[;M6/9&ZX7[*2!Q
MP/)KJF6TF=F$I)54_=<W BN&0N=#<*:27(]ME+UFA9+,_$L>1 [6N:P4/<H<
MWG/ZN5$$T,F\06\W?@@0TTA6;<9.N6R08?*$TQ#$>G[9?P33]=B7$*^O^^<
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M!R_M$2FH G;K-R0)0*T0RJ]^@E':&KDGFR!E;!AJ-Y#!6TVMM$"EU$KL"K&
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MS%?2'1R5/0T,BM-!_S_7YO#_ 5!+ P04    " "(@F-:K])'V*,>  !YL
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MBT[\'%.A,':I8P*B8 ,&")],"-AX\IWG$XRQ.8ZWM# PXAZJATBE(,'&M.Z
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M@U2+?I4Y>B\2AY]XN4!)4+"$.>%!S@TO\%LRR8%3<#[FV#2Y_=H30>>:%'L
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M-6E7Q9I^O$F]I2L]^M+'6W0 )'#5M&ZBN#!$15O;B5 $E]U:<Z[9S,V;3C>
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M=#E_S0>L.*;+^@"<_S\#_P-02P,$%     @ B()C6G>2XCFB!P  *C    T
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MS[LV(.>3-BT&UW.M&F#XA,V(6J+K@[H-(7M-4I/PK'>R&NA_$4[X)X(:D:'
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MN[7;1PJ9>$-"9@8J=;@[_.2!=GB\<]G;*JLP=X6EEWS3+[ZP[[BC/YJ2$C0
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M]Y+<I\Z\[?FN0JMN1SJ\@=\3&?F,0@%&C7K#Q^/CWJFXUE*-+983IU'W>7_
M'P^J#SCU/7^H=HM(F';%C7&RVL:REX5C1W?.4F-38]IEP>]PYF^\K-2V6$4C
M=-^G>A)G$;!0N3.?A7)GD49PV0<?\<(^YW81MO7_HMR'IX[.+PY:H?L-#FV+
MU8[-! (38REO)OG#5-97 D+)SA]A'-W7X "TZ_'KO>/K1UB.-V6^X?8/_PD=
MV29(?]-+<1W$(J(:T_C!<K%3P>U7;');8I"77;N9AS1:(7D7?MV=(^T+E\'
M&4L?-(7-_MZ3WUM'#J"+WU0;7<K_)EBD^H:-\Z^/_NOR\Y?IU>7[M]/?KM]>
M_@,_7!O=O7K_[LOUUK55-K5F/;R88,GQZOVG?W[L9H,G\/NZ(_\ %8^Q6P]4
MGCX<_#]02P,$%     @ B()C6N+O[?9$%0  Z7\   T   !E>%\W-S$X,C8N
M:'1M[3UK4QNYLI]/?H4N>]D#5;8!DR</5Q%#LM1F"05L;9TZ=>N49D:V%<:C
MB:2Q\?GUM[LEC6>,#22;A"0VE8"MF9%:4JO?W7,PL,.T<S 0/.D\^<>!E385
M'7'SGQ<O=EZVG[?@ZL&6:WSR#[C^/\TF>RLRH;D5"8LF[&I09(G0QVHHV+G2
MEJ>LR7:VVJ^VVMOM9VRGO;?[<F^GS8[^8,UFYV H+&?Q@&LC[.%:87O-EVN^
M->-#<;C64WK(;3,15L16JFR-Q2JS(H.[K4A%/E"9.,S46N?)P98#^B!2R809
M.TGI\<PVC?ROV&,[V[G=9]30XT.93O;8KQ\+9?>OY% 8=B;&[$(->>8:]UG.
MDT1F_3VV+3.VW=J1V3Z+"VV4WF.\L&H?Q\S#0$.N^S*#F_,;1@-9<6.;/)5]
M:-2R/PAC?Q8PL"9X;VU6X;E_SCSRSP:CE@8S0LO>K6&AKZAS<C.0D;1LYU5K
MYV KZAQLX5WP)^\\>>BL4M'[CB;U:Q:9?+\^CT2.0N]5P&- 'Z%Q?#GL,YX"
M+J4P49&JOFI]R/MKS.AXM@WZA.YJJU.%^!; ^U,(:5WHZXAKR3.[ER%6I_M^
M>?'R= +YPC%FAJB.T%XP0F7:?M:U,0$33L\N3X]/+MC5Q='QZ=E;=O[^W6GW
M7PXG%H/RA:=K>90*%BD-I.-P;1L.N4A3?P#+[R;G<?CN01K+Q X0 [;7/6Y*
MH#XP(F(L'E"@44#$=+A_)+25,4\#)EB5TUUX4S+3Z>YS@I,NSCD0BP_# W#_
M'FQV.[/38N4V(!!;-ED :B!'CP:J8P$I.R]TKHR8!S;\U;@?\!<W^WL]2(M&
MJ"S@A\)8V9M4!ZVBGL>;-R*A)3$"F(:T$@9,^=BP7"M'>NU L+S0P/R,8 I0
ME,,14+WJ \!/<P$<)S-L/%",:\'X&'_#;< 584-@@$QE>1&E,F8R<]P2V"3C
MD2HL ]ZJACG/)@W&H0\X1/@71TZDB5-EBGIGC8?U!N>&*>A%.[C@4\:LYHF
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MSJK<C+'P;9L,Z"3CB<I1T; #:5@X'5=^<<\5D*T)VT#4\(^[IK*+"#8:M\<
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M2M.\K86XI=R(0110A1$#E2;4(H=#D2"$S"%!=8U -@6@@-8B_  I+B'U BL
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M,=>B5Z15S^- C6E4'YL]Q-$8SHA:*QVUOG$RT:/M_&OR1$_#[ZM.YTI0_N(
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MO7?T&%1F0S+X-+83.O7!B-[$@@FF!%>#%1GAMJ3PQ9"R%NC>!Q7!0 :PC10
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M^=ZMB8/:CQ7V0?9UY 99%7*NE3O]T]SINX_G3M]=N=-7[O25._WOOEBGT$C
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M[7UG=QM'EO9G^U?4RUV/R7- BD')(L6S%$7)W+%I'I(.\VE/H;L E-7HQG0
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MH1[4U8CI,M NK (#DG./6OM""MH6<8Z&9_QC3\:HU/'AE^1>%645(1GT]:T
MC$] K 369F %/E\[?_WBGVMV6M<ZK4<XT/8/]I6;F1K4YKWF$\*FZ2/$LZ-W
MO;JZ<"_K0#%%,$#KMZ/!9EE<SW^8**"C\]=GO__J4=V^*CUDV\9T'8*[9!K+
ML=DVTZX=[AB\-_[C^X-1:4<Y/WI]LOGBXN3HGYM'KZY.+IX)F5W+&9B._:($
MAPA/*E?1!NP+ S"*W<G;?5 R&<8)_FN;_@]^)Y,WPQ)X*=V,OYK;])]?=F\Z
MGMP[;_G5;\>_Z/Q-"_!>L _=='W7,$,7%0=+^8P$;O(> O>R+I(WX"Z39F6Q
M^QN[?S'XV04(#,&U15&WSBX\/17(G-?X=82<BH+'02DW:4IP#RKT3)08&<NC
MML;&.A (FA4;Z"*6!EL"1Q2$+<_8FAIFYAX#-A\(]"#0!QF@90,6 8%6I"9T
M#@(VR]B]6-]]](-0$N:/$GZ#O=T\"=Q@OPPVSL!/!F^X(CR$?0M:OATW0$L2
M6)$QN9*L(*3!_:9+AD<+-*.?R2J5_W8 _:\,.71,K3V^KJH&QH=MKAI\*G9I
MW)B[VSM/Q6_C7(,#*T[ < +U>)JC9,*3)HW#YM:<982>.R(7;(\A6*-Y!A5,
M$/7L"+?? 0FDS)("/%7<APZ3E5<]88#H5=O ZD5^-/JU1'T]' -<#E$5&?O4
MI<(W@%)->3X$6_A75V@A,F!1SR9,6(J6O<D*/;2N/S=%^2F%3/H^5EWH&-Y@
MUK4@!/+]*6ZC%#Q*[R$$#@-HX/;#?W,656CUPQOYM-^HF86XIJH-S/0,\HBD
M2;A(T=0BTV/@.:2##8%453(-T^"@-.24? ^T$<L"9K6)DHIXG!](U4"598NB
MW*\;F"*]#^@S>#F\3;U-$$>*UMI#TI8$3\!<1TIF]0A(/$D\Q,:K!-G6E(1Y
MP*2 0\8&8:E@+6#=FIWC.9NO+4O#9I,<3% H&VDQI,R(+(NWM(OIS7X2-NI?
MCR_]=P.2V$($%OPRF*>T<0 \-12]"#@AOH9X:%6SK"#QVGKQBC,]9ZKWB3JA
M4X[31!#/105@JSO"2)>)!LV(!E.+@Q&! UHL&\7$5K<A#'P O!(P/7MTTM5$
M)1K>;[TS&&0J$T,,)2,%)/R+P8"5KJ%]HA_Y1L6/('9@44#8FM2X7%)0T JI
MR^N":SF$(R$<WF(DQGM3Z19H/B ZF?9:$"K\#>&2UJBRZE!CUT7Y9AY/!!8J
MKE<TZVEV\!XT>_(6Q:D%">;PLE+I<1^L'A4&%."\)7TG$6%&*68!^YX@+PP5
M"0<!B()+.549B&(>"1'GAL0@J(F&A+HE4Z-Y_%!&9]T(/SOR YKOJY',!ATZ
M"=D*N(;>XI#MM@EG9ND7SFJJ 'D](ZE.AOP*LUI&C\/WH,<+E14LO#KM&XZ^
MFYA*#Z5&KE##(^"(]HZ)K2\*4/0L,2XPX#%G$+R;$F@8XZ<^,P?S>+;$)9@R
M61K,J>39.A4?/2_ UY+69T$<%9VH-EG.B7<3B[*O)EU?5:"_B6YA'#=ZQWRF
M108J@./*UBA0<:H.T+T?KQ[!(BO]5JP_WA"$),.L!S4'><WPO<YPH1<,X0I0
M-)"1F:,1%FBD[M78N%NT+.3A^?/+I$\]PHCD)C'?@I5]_3&FO7>),5TIUN G
M;M=<<*ECQX.]C?U>,!!<#A[3K/'SE76E8[3#6K? &0V*=([HUQ@";O+,AGF!
M4'3FB3;M$MC@S@ %RLE(/&1&"J>R)5XVI4T4P*7&S 5F!,9N.:!.,">N9DSV
M#X5*<X5QD81R"RIX?"C+M-N[]CL3NCI]\'+0<")/AVB:T.]Q86*S-FSD A\]
M#.GF0^:G*BDFBCDE-G=(9.75P.00A:9^@L]5M:/^+HE&&1Z]$&H@A8J,5UE?
M(]C6]62#,D#F=_<>6>IK@+!W[Q'"WEU!V%\&A/W1U<+#=U4+ 7K0H1T^M3K]
M E(/7BJ)6>21R=JE2MN"FA6HM]6P<F(L*6<=]>/$:-047V^-Q\ "/,T9T:$D
M@UCAF6Q3.8NL*S<GAL02#5NF",3JF#:8:1B&,%EHA&6A!]]7C#PP3)%&47^*
M[>>HV9V%F/I\+N<#.M>O/XO=O005,6>TTE8M3#6J1R!]AKR7J4F\Z'@8]VU+
MG!5HZ0[9GP2UYC6>29ICKPXGCJ9KG47I:/.O!=%8NL0F RY6%GK+]$#%V"$;
MN3&NNG(8/U .KL-RF?M.PV0Z..HFM]#U3<XA QOXF"XH^@^.43T#UVB;TF<K
M^U+P0B@S$W/!JR:K[;ESOBD6?I3"@-$:CEJ78\N;X$O%&7@3Y/O:%,ME\GH^
M,.,E0\OP9G2/G37\$4Y6*^ 8F&\]VK"^TOQBX6T>_UN\)W\7?;,O2Z6,RZH*
MA4#DSK%A3[_GY-$ Z3/LUU<)5@@:UDO#A!0/U3L0WV>_9T4^W,0="A\+.(]1
MF\6AC75KLX^+$C=8YB*'Y_#0?]K>X(,>% @WDE\1ZTDOU#=ZQO@W<8,H1D$Y
M5"&69*CEC48 P[L/\X$2-$2FBI<2!=)N*\[F#Y5LXXHA72.T>#=Q1L$>4H
MWGX]T@F^E#A)^G#2#?[ -R:^WB=EX ^#V,S$A<+$;>E4'Q+#ZP(DT07AK$A(
MH:7V8A:A+L>RJ=2\!+R5">)D#$I"U6TN3-T\RQOFN2XK3MI'?E/ .\ >,$$=
M)V_KO!.KZHH"!%-W*^T<I5,N!> 5<D:'R8)+,(9$R.)D5-PO7T>ZB_>Y8JAY
MN04Y=PC=F)V%%J7 B."X&1LW'[/XUO>,P#/;;M/R;1:[S<P(3O^3HVP?E+T?
M[RUB;WT'ITJ\PEA&4TZ*RL;%0ZW=BUAX$!1T(E';LLRQDGGU#$A\0S"KH*W
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MX"&NVMZGB_5;.K'D.NX]X0[RV;S:.UCP8$%YR,"JN?6^;&#&Z>3C !=K=KI
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MZN [9&5W_87Z,2:2PI/_ 5!+ P04    " "(@F-:F_$!+:9,  !RF@8 %0
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M.Q8!HR?$'KZ\V,,7Y:/2P@[AU73;#!%\6<&7%7Q9XW1L!$TZ:-)8->GV9]%
MVO4/D9R4.%M0^2DBV9GDML5N#2/XUJD;20GJ=%"GCUJ=OMS)_Z04?[@6;=$S
M*,]!>0[*<U">@_(<E&>7RK/U$320SOQC)%2QBR5+Y7R*TG6[\>*6OS^H6A!1
MLE<PPE*C;CV^;WV[(Z%!&S]F;5QS_<$DSY=D%?,_2+YW5^1T/B=<"U.V[>>
MS/LE^?#-^Y_.2Y&^E,LA4PG0RJS7DPCMXXJ\#Q]NR8**G' R.Z.<)'GS-%IU
M]*HXCZ,0^OA-Q%W!)O)(>"RE%%:>N[[U,)2/LK3X1SE]N2(FS@MAD'%MN^&H
M-5:S-;0<#\6#EL^](7S.^$JMKNK.9*-4-[3V2_FFLIFI+GY-DT%H-%>&'[X
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M@P)XS I@C?#+7_Y]FDJ!F\XW9N#&"MS=T#>=G[+5:H.6WIJ*-X1O_CR@U-V
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M,&Y**C9U7W=I]@!NC/T&XV9C9.K" S9=$%S=HJ'>W#@D081K4RJ" VA>QU$
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M+[>5/T)2]8KVJW@MI/X]6:]3FB@IK%Q7\J<7P]1RDER\*3CA@Q,^..&#$_Z
M)=#Y,U+'>N^[Z4C][7T<Q0,9DQ\B4:Q6,7]6]I&@DJ>Y_'CJRL8D847I"HW6
M3'Y0JFRIEZ8)FZVBS2[2UKKLY=V^S<T>F0CVYS';GQK,\*F4BT],"BKCNCL,
M&MMY5>XW%XX?7#,^R4]CSI\E::4[7:.N6_7URM5'N:?S.%7%PV8KN6^HZY.5
MBW 3.=7P ^SEE9-KDE=^S2M]H97:-EZIK(_ FF<;U,>OBZ7:SXWU4&K;X*9R
MV++Q%26W9*VR';-%&:11JMEDI<Y7,_U-O89QP)T40JJ70FR(-%5V O4);L^
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MDH1]&-;*-XEN@8*_I$6H!QWV!,PDQ,WE^1."+CYT([+X^6Q[6KK==4*.6\\
M1;//#]WVTA9VV8HM;&C204+>"*%P8!%PXOU"");K, 'V7A-TT'D7 M#L/D&'
MK'?PV9UQC:T>=!O//I!5;!6B6WA^H;H)MNK0AL ]E"5L^E9'1!:4;2P*65<8
M*91?+)I:1_@IE%TLRI9?,+1_(']Y6>^/==CU\D[>\O<'I49%R9X>5?T>L?*@
MC>(DIX^J1[N+CGMZN\>D@/[9"(7<FXL-C;>0NT.4UZNKFU["'B?/;X,BZC:C
MUZJR\OE<%R DF./WC'6V?B-TL93VY.21\'A!MOO[#:?:>RX]OWU4,[NQSPNI
M-5UFE4[1TRP:WC2J&2O=TSL63%=K]_BF4<W8GB?X,LNE\BIH8JI!V_O[QCI[
MO9X4VO>,=;8&."DLWSZJF?V5",5.5E:\2^2?]TS]M,?R9+'@4C7+B9=5WIF>
M(YO]7C<'V]<?V=P.L)6X(0K7=Q P1?M%0>QCWGLA8ESS7*.*#S'3+<D8UUR_
M5N*'F&9["OS/\$/S1OG0;)V_/N??FR:TUQ>.=?X.9..6*->?/&E4#355-Z>(
MTWO"5QXFUI:24<VX_@S7\?FAIQGO0,FH9MQ:F?(M^NX)#)FIQYZ9.GSV8KC'
MQ$_*2;C'Q/H;!8RW!XQW?][FL6+$A_ ?CQ1X/KCN.E80NI_HV%@1ZGW'7,>*
M7!_*BW1<D'?72']TF/<!O>=CQ<[WC8L9*])^V/C 6,'\PT1JQY8#@#'*.K:\
M NR^R[$E+B #MD"G[]@T^ ;$,W1:1J? ]P%BADX6.NU]Z$@D=.)0ZO\>8N/C
M2;M*EF16I&1WW<@F>TA$#\\1V:R<:*V6CK]DK/8TC2!%JRMS(7&K.;HRWL0M
MS>TNMVI_NJ"/]66U34V<O9P5O.GE;YJX>ODT:V+\30M7K[Z739I>7M/&V>L_
MLZ:7'[9 @!^LW(B3(E\R3O\BLU_DAL7WO(KJ3G)Q\OQ*,RN9,=4K[^]-8YFQ
MMUP8[YWH\4UAQJ!O&O2F#Z?\7+'/A%=_T=7+Y8]]3J'FE>.=P\IBG\[W[(B-
M9>%C.IO?/OZ9W7,C#3"S^K>/=V9_6:]]KWO-*Q%@<ELR]';%F9Q4=BA<OR2-
M]QN\79LFAD_(@F;*$782R^$\?1-')![Q-W*303 8=0&U[A^U'E#<SNI;]VF#
M-\:"'!JNHT/(>W.">)8Z0%RG1UE@  \BJM2#\:_#D5P[X4WJ--Y;?/D!WB9$
MYTO'EP;@:TIT<15\ ']O,Z()<_G=1T+F6\A\^U(RW_IPX.,[Y/Q/D-'3B>_(
M\S]!4,\ZOL.P R!M8/_4F'/C4+IBCRJIKN?@XU@3ZM#$9KIC3]\X;\NI(F2V
M^OI<H0\%E82=9\5*TE(-*_(#6*B%,U@-+EZ\P>HUKQEJ!>?LQ$-KI&4;MW=U
M7<M.RB8/HMR:-?[OAM9>'?:W1! I;<M)-CLCCR1E:T622NO(A,Y_#^KCP)T_
MCU/1RW;0] %8*UZ;%^WF=_4?M<W(7_X_4$L#!!0    ( (B"8UKCMF3Z^&@
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MYE=VV:69/2C;H"\-&G[#!+J4G^:D87(&#;'U+]GZT8CFIAX<5H--;#&4IH>
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MO(;X(\7=H<QC42L8<<2KT15A<XY>1W+13+*(/"_'ZT-2UY2V\]J6-*7"7=R
MODJ*FCW,=4K/F5JV@'EM\TY@6\8QV5*+2Q%G0;=EGO!W2_37Q18GRHWJH=,
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MG!=]N>.]NT+?6[GG#.)]N_W=\M-I,*L&QL] 9^E3FN \*=MN9:U[*\URTIX
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M;M(9)/&LT7$&S+$WGS?6J%5'L"C6.#6),HD<,<5Y7E%_]B+-L'@;., /LB$
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M$Q7Z>+ML7";_V)85+SE]1Y9)DC)B1]EUE":7^6FT2:LHJUL'B<9"DNM(\#S
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M&(T.CP/_EJ."YK4^*TI@L[?,N%M_P6K84=^7/>"[I^.B-$%,9M$#)\6F1CN
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M;IW@9G6 *R.;76_=+,JT\VW:UCE(FCH'K.C:P((#M(?0DB("IK-U'='68?O
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MJ\I!2Z[S";CJHGQJ]W46.]@L\-I #U,B3XO8!$)!;RSV"5=V&EW!)P*RHSY
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MTFR]&Q+Q9)NIQA.R.MG2?P0\H^ESWW!Y !TB!W",QLMG<2.M[A5!)C-VB72
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MXTEB3G6?91VJ8AM7VX+59<F3&]%8\92459-8U#81/,_2=9I'\JQ6L\G@92(
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M[)R?,3S^X.=\&1NXDMG1O3T4WCYY/]"?Z"^;7]'_87%%^IO_#5!+ P04
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M;N>+:P:^FP 4=5] 44\1B1SI"PC"_;2M&=47E[<<&$W3K2^@@)8,1.WU:/G
M#V*9=<C_\*'^G-RC#P\)3FY!;2^HS=>90_O=U[Q.U0H7E?U"TZ'=W-F^0UM&
M1W!H&W5HWZ X1_DDX^EGVQ>@=HJTZ=H'L3A!68XF"XJJV2/V9,M;>N:^%I#X
M":_*.4[CU23A4>77V8(+!E+8@%UZ(.[WF&U^&7L&S=FD%E,D:]?=@*ZX[;W2
M.1%EYTKQ(B@+HVIFG,9[M"Z9"!<?3/:W]#3N<ZWZCC<D8?P<. JJF!9+1 ]V
M>(F72];4*<U2GY>\<7"5>^ JY[EZZ*^2)\P\B<X_4%N75"N*2BI:NZ9<7B5*
MU=XR]>MU^K+?$0[RK10S!]C/+3>R*21N&D( 0@C 6SA"","A*='?$ "ECD,Z
MJ1-CAP<D_A(]@=,73*1'"FE]=OH#CUQH(]HRDC?( (JRJ*057WQZJD6D;[KS
M!AGA+('9Y<:. ^ADAIE13R<B0&VF&ONT@$HD8%>)_\$ 6F847^9'>_'C-*MI
M]!<Q,MK*$"%BI#%BI+U#W%WDR#MN+/PZ8AV7O*  JFJ/18\D8[ROTUCW^C?P
M> [B2_1("R$GAFLHY,M=K;LS_@[D%Y)!VALC2QH! ^SB6;A)JS"%C_$S4U!7
MS6]9]+MYJG FIZKI=_,A'=ST)8@U.?K-#C5"A!I^'6^(Q?@Y<!0D$N[-ZH_.
M$ 0R0G4A.)6#4SDXE75-U\?"#%%(%6/G6GH:GMI5':$ZO+PZ/%SQ]04.N3]/
MH/N,G7GI3BC10,?NL9/S+;8'C)UOFWZ&\?OC@I\!>"X,SK_P/DH((Y$M<*8-
M:1=;%G5WX#V04A*<!4:=!1,V:)[&Z_5-_#DOL21W4=[2,QN\*.5S7Y7] E'\
M%/,=8E+=9Y=?H#3^S'X^)R65I8"V&\(P\>WHM4HBVW_CO .XHOXVR*XF95?:
M18/TP,"OF*35QIY/YU>(4<#6$4I*B@NV'_/U+B9;LZMQ=\H->_"B(NB<!\HW
M>WG$C2S3)TS=@C0=KQME_!PX<@3=D)SM85MAZ65/H,B)H>X0G"\A S=DX XY
M W=<&G=PU05777#5Z1IJ)1(IT9$&QXY%R-SKYL-1:38^.',4:Z6U5CIVQP<0
MF_9&DK&[1?H"2&Z)&7N>3@\H*0V98T_DZ0&CTXPS"'F ]O( !WHW,'#M0/Q-
M8S^Q0ZA""%4X0D*SB#;4PNLN4.&;B,D"-&9_S_ 3GJ%LQCXPAO!CR9^M&[@
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MTS,,=I;'@MDPF V#V3"8#8/94*L$6R\"IR]SJ ?D>E9MP,AZ5.>N?T$?C.+
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M<G/U;,;EO@X!+2&@1>3.E$@I1$="&#L6H0Y&MT@'E;3K0\B#8JVTUE3&'AX
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MT<]47+$0UFD8?!S?Q0+IXLSJ+R")SY%&D;%%S^ ;"+Z!+KZ!?F7EX ,X'1^
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M-Z*IG2VX$D_'E1BJX W:Q#W$Y!30^6Q@<@R_\!U8[C)HTQZJX4A/*'*FQ?_
M#MF]Q31"?Y5X<[)6WS_RZ[JJ\W1[7Y?P^^WAVTZ?-TZ'?<W>$DM!QW>CXQM_
MO2!MW](DLY6YDE8/VAC6C^X*E*NA>IV'5#5-&@FMU=<J5_6)MC\.^5/Y<2[.
MM +T& ('TC0I4)_AU(B3SBV-GL%X$XPW78PWY@^J8,8Y'3,.Y" AK?9L7Q!2
M6WG A[$OAB_-2:-]./H2 ZN)4PL!U9<9%0*F@S59-PBHA9;JS#HHN61JMGD1
MU053<77=:R7-I?O+FON_ [3%0P=U&VAK^H.1SZB1[^CFXO-XC8LXY9>F2,6
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M@0KB;H^65; M#O_ *L'NP06Q!P&[YV%REXQ"ABHY*@XL@2S^SB-8AZMPU[1
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M>GBPUZGN=WA'.'L[G6VGLW%\%?6$8J'H4@VDC$0_M$7#5%ZI1(AUM1A=J+"
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MBV33&&S&,V=6#3;-^6'37!ALI E>Z>0J6P>D$[DQXR?PJ>4#6EGC-M4K ]#
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M8#UB?N"+S\R"9'L0L3I@HO!]C<6_KP[_GWGGH B&(\#[G$*MT02$T9_WP,J
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MZ$C_0*J>%P9V! TA&V--6-I"7:M)GF,3]*RD5L(1$@O6;=,_DU>>C$".2/(
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MX>RE_%*3)H%:D:,V@+ RA, @&)@4J1J-6P?+@_ASA=*&)P>-"70)")"^$WE
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M).&5?M(Z!HJ54,@_J7&0L?L,&JY\=B[:*L8M-?<JZ*#9)?N5LL&('5'$IV"
MC(8S6:=COR;&:CI3AJIG=,8W 77F)!@P2N'B46?0W!-AYK,F%^RG*?,%Y\T7
MW"OS!<M\P3)?\'GY@K^E!2X/) U(&) Z:7-C,$@3A-+F 8'LC73BGY5H>0?[
M6*E*A9W%.!JW0M$=T%$DK["+4''3<O>$^]SEE!PT;2DVX)') 3/Y&$]<![WT
M'WS _;%WFL8_^MVHSJ8%LB1':3%9$\MXT,:B#%. 0&^NL).>] $.>O/:S9F
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MSINHWK\K+ *TI0\7I^!><7Q<OC,J_3#-R-8WZ$8Y3K+3VAC/L?+B^#!9T,/
M_W3!A"=;)V\/MWD;5@O:BN>5"O8!@XIRHQC025X#!&IWLG:UM,^3%V&ST-,2
M- /-6VP"W8:']IEI0'V0)L>B4)Z)0M'ZL)VC0*&\S6KLIF+G)U ZI<G#_9U?
MC?F@6^ZY$@AI@WL%UL*D=4TD:5._H8/W6'MKGH3,.R>62TN.8&7>>;6>>4>-
M-DL%Q?/2&%* XUN?F,>//GUBWM-:8V*:+SXSM[]Q-I#?T/Y;#_E]L('\;B"_
M&\COU4GQ&M'D[K ET[0:+?@D9>Y"'+LP!<&29LYQ+)=Z-(^3!5AEH) _&$M
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M3O)SSLQI6Y*+6O^] 4GKR@=_-FO,=57]?&YVL#..3\P(?LGTGRU=0XZ.B:M
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M%O!=RX(<QK(J=]1Z)*<V@^[M;4VO%L5QJ!VE\8*_D;Y.WT:6-EE/K6A([K1
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M3N+<=1L(>K@H3Q<Z5]O;6>K?UYG+@QZ2B.[HC&IYHV!3M@Y/7C7>]%%%Q3L
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MV3HZ?O5FF_79_@_/SZHR_X#.$W,MW-4_2"S1*=E8PP+ *I9P*&"T)YI*T7T
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M:5KX@IZLEV?[/* ;??@@7>V,.3D;D,VO.EM/-5/P['"HBC)$I%^%#K7GV[Q
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M=_Y)5]NRVE57QXB\>X/H#1A5I(*].\2MNY&;7:C.69!2H,_I@R1[F-%F;WP
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MLDKER2P\APX5R8J3B]WD&]>27I6#4<U7LQE\:*OK)TYQ^6D%U!K-S]T2O9=
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M=[EXEF!NC6,X& KD7@@@O% 4$,5-J'#PI$1(F.KY3J.1QULP&'=GO3L5TS4
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MO!VG?8''\(LUORHKZ(=1<?#=UR/N!NR=2Q2GHHV@BWC>0=&O\)@@:FPL#-+
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M3U1K/U"F_>F@%5*44)U0;R7=1>D5>OU+VE."Q%M.9'#*$M!KLN<6P=BV"4Z
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MS[BRV,+CIDH.-1;&9NTP=-%DY""KB1+:5+=WQ3^).,??RU_T$ME:B6:&SOA
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MC7/QL/?5]P9T:/10#'S1;"^TY^HHQ!O1FD9B \A3E0Y(VIR)4:Z208>OPQW
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MK(P\P[],*BD%ZRKO+ED54!>3.ACGPX+"G\T$??3]BV<?VT2-^5)MDIT34?E
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M,B4QS%>:EW@F". 7U7I]\;5W1]_0KSC^$5S;MFC:G5OZ( I0)[(8TBZDV*.
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MKXCE:NOX<6FVX;SJ&JX':ONFAT!,Z+KHUI*D9Y^3V87B"70,\7C9<+((OPG
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MC-?Y>V)]Q9?[^"EA'?H;PP+(OH1.F^;\4NAY_J+<"TN,^(CZFS=_' C&D>X
M^9EC.3?T\@F[T=0PSI^LS'5XR\S/G5:L4DN3TUNY9Y)^(;V;/\=SW+/IEE4-
M9"E+,A=U3DV[R='0O2,SKPV@71]*[E-7V$%+S@RMIN4#2U3=\I<J5X?0WQ"D
M<+<2)#1)YZ5?>I:-'4,F=>6J6$_V[L7\B\^>SJI;]A/87+XE]7R;F.2VX4\7
MV25SV23*K)L7#!]!M5I=WB]E6T:>;\$YG"':ONI[I8E+EGAB>&2]>8F'J7V8
M\X4>LMK>BG:C<#T()E52+!'WTXV%P808]7  O6=\=W#_YKTD:R- XG);E==U
MTQ$G%&^N+I,-*[B)EZM*N5*849?,+%DU8"SYP59,Q-'8?7/2 -0]E1YBLF"*
MU3?Q,B^^*Y;Z:"_AT91^A!7DA-5NURPYS&?70-[S39OM #ZBH3;?SC%[9PW?
M&<>:KHXX\52KIWU/V=WKZST?$=M "6C@/*.[3>0:W-DMWV.W+D'R#J F6Q&;
M27KN:+*?IZQ_-"G10"J_EY'28D]\,Y Z3E@]I\?AIZ$LD?FKZ8SK8&V!<(O&
MB74KU>^1K> > /:P&?JE;8%!>?K1QT\+@0QDCT$ !D&[=@!!F9I<JF% (TDK
M!.O0WQ$OS'I/N'L2,#9CZ)J&K& X\I 9&.PWK>KU\!'$]\;[)ATBX4/@,L9.
MJ&"%"H$0BWPZ!K0IJ%:S:)_()'@-9UH,OH;\9RF]/J<B9A7#O!>5T"CR$#$3
M A[YE:EG/3L>"83\64/-#=NP8;:)0@&'2B>/_L^ NBN\K1Z[\+:\'A3+O-M+
M59<WSBZ>7^&N:5]CI%246:NS?D6F=>HPU]/]%(_8#CHY-$5,0< L",32)RLO
M!GQBZE8[II03]*>6OK!^YQZ0SVMZO,GB2P<VT_L:\8%H5?-%Q3F9G.EJ>4LF
MW%>RA,KJW7+Y!9(#YKRBVGI+=?&.\..]=,9<T>LF]\LG.N2 \@[*G*+D_$BK
MTV:5:9[_0"7S36!=*QF;JMZ1KVDP=RAYJ7!D>K-T#]ZZ_.WX!W%&#]$J"Y\/
M! "YQX8&A^& 7#4G>5E!Z9*5B>]'QJ4-3/*3??1 4';8 *GGDOI @BAI1R->
MOTT^;RD\'JR%&5?<AOC8T5-0F,>Y=&C#O>?X@L;5CER;::H.HCY+_8* 8'+-
M5Y2.,J7Q--Z>N,./]H/DKG_R2L"EKK=0U_OMI:YWJ>M=ZGIGJU<^K^@2%V?(
MP&=2*R83S"B2Z.S%&V]99EQ,**8D6N[-33P&0C2@.&OA0*%GG>CFPH1CHE$-
M]SG2_$O,-"&%WG&^&RS&)(X'+PM^<* C-!&<EB[G<O(G79D"G?-+(3$(N)7
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MD]6?67'Y #YD=\YC;&<K$I3/;N#?V$Z:Z7Y90&#9ZVF@C-('GANCV66^CA,
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MM 1TG8H(7FT-O;YZ$PU42\=68NAW=TJ]0%ERPF([4(,)X1J][J'\>T:2)6G
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MIIR&5F30E#PG1CW,.T<F<KQR(!!#51X"WR1UO6SYC*FF>J&NBZ];)&Y%44H
M:QI5:&>(TVP74'K /<+YE;M<:,6?Z=HBH"B1)L_5.0:W1RG1/'%SWZ+VOE1<
M9S*F+UWGKM:[-V".I,1Z7$N\:;EV7=$1JK'4MAVNM6(B$K'XE=&63$Y),R:E
M[.V<("M3BU@6$7%7S+C=P%?VY,(&-9- TH3RN2G5874=:QO*'%'&5,H.:8+@
MF^P\6 8\LM3*/9DU2A8#E[2OL%#$Z^C$[6@!+W96(+=4T:ZG%2)Z[E3-UX(#
M7@(GO[%[VIM /)3[0/*.4ND$3;3&) P=#U?J+>Z%J$[U(*DI9SNPNW,(H1?C
M$JCYM-Q2\,299$GR\)?S7M0210*\O*2PS;S*0POU(K&J[(3W$4F_JG,:B.O0
MWW&15&W@^,7,+U<5&ZD92U(\&+7L.K PN6(".&=.<$KF"1IERCT%,0UX0T@Y
M/C;<NP#8)K .. \$H+VEQ) 0#DWW<Q+!>P)8^?1P-TC"&4,2MJ+'BFK44.MK
MZW+)UHIHOZ3: 9)5='#M*?55UTQ47)F$? ,-*C8T8Q])!-&J>K<?$0;NRG>2
M%7IG5D9X>:7B;NB<3=5NA@,?$7Q4WA*YIP">6J^KI!M.D7B#T6:1*>CW @Y$
M.9]FDZ>',XZ\0>1KB)*863J_NR[ A:YQ6VJZ->[4F>I">(UY!KOO[E2LE*F8
M@YDZ7#=$+!EF!%@!%R8<+WXU'@!^5@HV^8%+)B5=.:F'[/MN<Y-O!7I$8RJE
M:#O]8YIHS1UOKGVY0A=>NU,3[ <)KE['8DMW^/*^>DW[)9%!R]A:4!"M/3B7
MY:*\/^OH+_(T[BJ4 Q/'3'X8N8/%/[)RA>A%A150S57/YQ?=_TVCBME.OJ7(
MXM+@LKKZ6-N#0.AI)O9Y4U\362>OJ-W 91A%5?_YQ3,#1;@L (#8SN&/&SJ.
MN)ZK)I*IXH+NR"F'_J;A^I;/5B %X2[8W<1C?=O<963(\7!MAZ,AK_DXU5NK
M&YG:;N)[9DV>$KU6RNQ^[Y>='S.N<KP.)ZQMT11V^1%ECRXTP:)2FDPOP>DL
MF!1MX4 V)K'F9FP3P/'-GW<)RZPWFIL0W"(^%*75Z#Y"9&T%I3CA(CG:*-$^
M3;>-F]; [ O,<[\_Y?M<V:/GDVD/I7S]R4#,5Y\^YEV95^2??F(PQ#))G2KB
MX4TV&,,C3)J5O;N0KT<!A)A;!F MO4_@^XI7Y/>J6V;K87L=N!ZGEH.[FXK[
M-D]B6<>CX=P3DLN38I;C:1?=LA D 1EJ6E>$'A[H3;.D!TO/0C->4&AH%#%S
MP6KA&,&T5VV3F%I0MV_N4M%8*8U93\D-6R8-W?#13L,,2/OVW^E4Y['&>*;+
MS&Q0W49\2,\&W+:++IOGWLWSR=,IFM&-NBY2V5#YH39[GJE1=%STM)Z2%4S[
M(NZ[3M!4=)^'\!X5!&AP8 IL@&8O0;PX<;I$('9"D2;S4U"O(#GOT?H3>A;V
M@+=)7R%]L ZGIMZJT 5U-UY6T(-7T(]L/%(&0'%K=,8/M9(R;E7$&\8Q]1;G
M[G)<$-<M<C?M(S%)>?$'4055ZD2R5%OVW$VH]=F<N^@)W:+5K\=T R(B8:BW
M[?9<*M'K9\.@NP@@;CC<V WM'MK*EA#+,2"0Y[&_>9&'EU1H2C7$D4N*AP8U
M2>=T,O(,@_@__>+Y35:']CH[=%X[G?>[E&SFLC0_I!!C2CS%3.U17\Y+TTWS
MO=R6PE:*M4V$#(WW!2=OTMI2F)%GZ;$N%?DC$6,[98<P,K2/RV)=$#P+")[?
M7! \%P3/KP+!\]-:E-S5^-1E9%[)^<",9Q3!P,Q:M)/5'5CAB$IWFK%_8!7M
MXN$ER#N-]G]%'QJI9HSHRWH;+T4>!]08ZJMU)73('%ENF\UP2-2Y96N,_-&E
MHLLQ@)B\/SG?<6C&HYN$$TDX#)&T>C%TTAGDV@ MYNSYB(%$\6BZDY/W9 5=
M-2+MCFX.+GDM+^.>4\MFH1=>7LJL;\MVR\I@AR-%+/J6V0H#\9J,0Y!^P=6Z
M;<HMY(6I>8/?.[U7BH2&L3":?BBZ+W% MJS+5T<'I"&V!'IUO'_T&BFC//<F
M\'6RMI6&G*0-L/6F3BD4Q19E 3+.SM?,-4L Y'J(=2%A+W4,D@6,$XZJEGX-
M\E]X""J+4A]F*&\K+M)J-9Z6@-T&A>^ &IWKF1;G'U(XF^!J6OU-BYFD#V&J
M9[/YSY)VF3;;Q:N%[ZB=.CZL7]+YBMY!_F&;B"N$^QDTIW$(APID":<W3L,C
M^MGF0!'&E* ,)^FJ?7Q$*0@K#F'T?A37C L)^'(J?'#U></P@99+"N-=T@D*
MD)2GYA$)CQ,U\DAL8@Y63.V<M+ D(N$PA,^E8/JT)OUI26-;E.Y[$GO)5R>1
MAN68UWK<5<(79&)1JP^J#_W2ES8.!W+($'?9@OIC_'+\MKY@QS*G6P.FJEXS
M%LR^7!.QTC6WX]=46@SU(LB%\IL:7BN!-&X7[]=#I7"#%=FRMFDN8K=P41PF
M&9***EI6Z*]ZZHJ(5_R@NOW0%P7)*+;;J]<A',=6G</;^B2E2QE&U. Y9\ G
MPE9X-]\/>_"@_?FK0)-G$#)#]S3U"&M#H[YNY, 2M [#N!S::^?@1XHOFUG$
MA-%A3NW@-'@)^*'-I&,I333T].ARC3\2CD#Q'P.ZG?2FS=S]"K9'VL\J#V_W
MHD*'E=N)O@.YO3*KN],RS=,L6%A6SBO$<RJK=E)U'Y7N>(<'TNZ[X-SF<6Z>
MX9\,4V[+XT\FM!L_+'Y6G-$$%U6@W/,77WS)*Q%;?3>"OX74\^=7;9S3"70*
MV:C1+XN9WZ#HE4L#)&@;X.\SF5FGW&8PJNS-,!+1Y,>U6'4W03#G=#K=5$=Q
M)#5KFMYY%NNW8.]4QW;M@5=V1Y'';27';5 VW)AOR!1\6W!^S&!6)#)A_ A.
MQND]1M?U/8-NSEK /)*9XMM3VV1%H!%WY!$BT04@%TW)BZ;D8V*RY[*>R"^M
MVU!207%LHN"\&A)-F"$<1?U%@^*7-<^*>Q20:=W4T<2'NX2N/3?9\$LDA41G
M1M7!,=F?6,<QAA#1QK+T.*J+E\7QZ!='[G#GL[UKLHH?0B1\N#!_V!)?\1;E
M+A!+&&J&I&Y2;IK;ZCKZM9IX4G ^$\U$RW*1//E%K!%.I;B**_MO(>'Y;YO]
M< ASD$ 4PQM;+Y;IO>B2O(4<^X(_NMBJ<9+,\7]]\566\.($!B0Z%WI(J(&E
MJ[8AH24H.M]%%S?>L=#\FOQ;W7IXPL7X[D)-3,_EGX&CV 3\ME"&F&0Z3>%8
M7&/=Q(),E9P0?6[(,;N4\J%?_'VP_F-N\W7]Q@S\IJ)'!]H6/@SI<;=M*8>A
M%K&P,ZKOJ1>WD/1^#.80_,\K:\\F 'Q#"ABA$S?.IJT.E6A_=6 +D3\A9O,Q
M_[G&6L'!^-Z4,\UO$_6IGUR9YM?3HO+LP5&TD!21GI^T; D<>WY2,K4_1;4T
M9[(/KZS#JUSMXR*BPS7Q..4V@O55,8=!FVO&=L&8JEDJ<0U.'BVFCQX##M[/
MK4;TB*TS5@4CVKG0I;:Q%@!Q:\Q-5H1(_?:+N0:?[5NHPK:"=T*HII5WS:DW
MM9EG+0AJ@]3X1MSI+>\ #0L*!;;6#+AV!SYR7*A.RH)QES*Z*^Z1+K=;<!5W
M LA*33?:!J446<R:)/^4<H!K6C*HV*&A,X@IR>2KA&IM;YE PAJ(:/%NR.O0
M^NG<:S-F5D\A7R#01N!WO;(>RPHG!CE"E"9:25VSFI]WJ7F))N-IZI*;MGST
MPVZR%L\K/FWB&IQVX_M4:RZ;YV=8;[:8$CU3[2*O@&&G09&$<YO-=[_C6*Z9
MX1@\)KS#75/\<*3W[6_\PXV2P@N9VIGC918)J\+9;;.K>BGZ"!PRQTYF/3V<
MZR;<-KJ1L;&9@"7,O#6RK.KM,U@R"=>NRZ[ZN?>.)3P_OJ DWP E^=L+2O*"
MDOQ5H"1_8H.2JM0&VZ?Z:_1RHJ7WE)G G8U9)F^C]6_$WTCTE@< +YC64QM*
M530A[\BQ #?NK)2)FQ!!)"@=NT4NI&>J)HKJ6ZC0,K'VI?P[RY,+9J.DH 64
M #4>DG91FBHW?>L3^_9OOS2>K+[(+L?-P.I?"2X)RX"13;74&2720%ER\WHO
M:HK_CDZ<Z_CFXO/K(AMJ:<:D)EXO04_'_6W50);C X$($5.?K"27/MJ-NH[N
M[Z3F+C1<S3!4@D&27# \QG8(A;&,: _F@) UTWQH!*[J;P8851ZDVF8H!/6D
M(EZ*^ JL-'(DTN+-26,*RF+S1.,)UH.(1?'+WH1RW]]LRG9A=%05K$8X_DUO
MX7T)H"I^!#H*WQ8G"]N4$_!GQB ;K)2O\4,CXBE NK+01GRPUB$%Z((&:1L3
MP4'<HFI,>)X=._?&%4,W*X&7N2;!N).$ 'EA5/I0"VF#=H9CC NWB8K5ZVKS
MFEP!'!3[W=4VWEIC/.EPHX>_)=^6UNY&TB#=PFTUVR9YN9MJ3<R^Y"!0;$)X
M]FPD_7A@^=(FP\T _>K<<\R.X9,5:/><64#$I'OWMMG?\BR;C:>UQ6R4<1]N
M!Z:CXKBXP@&=B_#HAF)H-K$,(>]C?W8+89V++SGVZ!'11<&R)4QX8,IPV!B5
M@@NG@)1F2IA!1< ]([KC""3J$0GO/*M7CF5*\;<_R2SCB^ "X#IR'HA;$NE+
MP>DE&D'PBE0=JP' 'W5US\2Z(EF(?F*_\VX\HZCVO$C:VT<C4@ZB0!"O3E37
M(JHC3-"ZR,%G)V;VY#/UC%6L0%^JK;![%GD@2?B:;373(6Z%WBK^:@\5'"ZX
MTFC2#1G=/J&KF'+MR1;:V"^,2;_KP^%@G!>EI:]&R?P^;;54''Q 2]S[Y$$\
M,P@0^"@FZ@4YZK 4T@$:3S=WO#%8WH4/NT77HX Z/4&;:F3[-LR2F,-J=<[9
MB,?7(+3SUEH4I!-8'C8G-:.%-B<;T$# -<B!1#N1XAKHSM!AKW<<;_$LQ4:%
MF2)50+BD$7^NP/H.T^NJ-LP&7&B-)P9EUTW+IK> 2:WB0/*_PG?14G:F(6>:
M4SU+\KFAOJ*V^)"=<FKN4U?,%Y05*84P@O]!?>X9P%G/YHG33;?JD%%G^-DZ
M;)BIR99$&4>I/3;BZ/3AND5QW: 8KF"7?HGD5X<CQ=/\-[NY$"%MW"*GI-,Q
M36:4:G!D7]76Q>5$V#9]$!RIPPC1EQ>')H4KP6LK'XO!Z\<X[8?7H+1@\J#:
MT_M'I411ZK=-^QJ-1ZNO@V99\VRW#:>YQ"JUL+FA)07&DO>LA^_-6E-(0#B&
M'-17_GM("/^6+;ZI!Q-MFPR^*F32FN>?[VR&HO?Q\4<^>'3?HX7_R2?_FU4M
MYR;UKLS]:ZP6[*R;(0Z =;P;<S++HX5>2NPZZ=<-O,&Q_-1"<TA3LR;5V ND
MC/:B=NZ3U5]"N=T0(7MZP<ZKAJ35B?BSZ3KVC_G(XK5*_M$^D$2;LO1&RTO2
MPO,)\=QHG*H0+=)0VXA1.$YR34(M*!:?5#U8R,HQEMAWTK-+R$%XF&U2^SQ$
M6[X/7!APZ?:,*92E04*".F >3E(I  2"J8EHE(F HR6I4?S+\7G1[6-([PH.
M]N1^6.$5@+OUAE@WXPE?;8*RCQE-*J#>(V0 'V&)^V UHO?OYU=E,1:S815*
M7J'"]>V(O4WI9EN>KOI&E/-T96:/D'%C*(U-TV<<A-KFBOMSJ?6ZK*7Y@8X7
MH6.:&I3E+NGS"?9SMN<1--8D1GF-->P(C0L71/,:FVCD@NXECF?V^U5H6TI?
M IG AS$<TDL&<2F#."90@@!D7,L+CJ+LI,^_DS[[9YL>31&F:-X\;!;A%8J.
MJ^ S%:WKL@-42(POHQ<,''O3@R&>W55, [H;VII:(P9E)\R>;X7(=C,<1,I<
MBH!*(+2U#2@>.EM*Z@,D5(&T#]./W7"(0\H)R5KQH=+W+ <!-C2/80Q6H]/'
M\DKRUW;8BRF@5[3!A!;TM^1P[ZMP*\- [ND#QK%A:P]F^(7/%-3ZS:H+JYOF
M#J)F5_&SJ)ANG=&B=R1*.V%KC69X[]5V"\Y8K*,O/X *-A=!!/.A:I[:N\DS
MK;H3A>Y8<8?07\)PKYB,=<W<9"Y/UED6G1/0Y=XEP/\^;*\M';J-RXQBR*M#
M^1JN#M,2[LIX])TT&12_1,T3KX6HJ!0J)HKR2LGNQ=CM&#=4#-F1*&K4,8--
MC0=JEC"PQ29W8_)A$4413'Y*%YHU1D\I^P5Q8:Y/D#7C")A6S%W#C<44W8;F
MR-N;:!7KO"! L6J+-9HM,SKVO42I>SE^GME1]BQOLE"1[D7J7;@@&,6!D8#%
M098C>2R@1>:$&1]&87M12'LDR('?79 #%^3 !3EPSO7^\WP:70JA*NSDBY 2
MDG']V6E;@+UBAD@&+HGF2,518WG/>(^+=S[GG0N8U3GH.O;,@\TU8)XD<3!5
MU.SO\4_=MMK8"9?0@>SI%0H3I)1MS\<MG<EG"WN<VMG'4+?;BWANJF-2+6P?
M_]UMRF.0_O#TM+)TN S4U :-9 H>%!RM:M4&$%V*A*Z*43":>S,@X7#NTF"5
M<JQ!25R%<DYS-)Q?NC21$ Z,=P(>$0S-<^5;F2EI,G2(%KOLA"J%95_V%7-S
M.H<><PL?A$@GWV1?V@A$?VG@.AK=I&S[.K2BK3;6H[C[,7?QN'>='"(4, ^H
M\!*9-278!;RQS9+]R_7 &-XH7;U,;7\Z4B9O;[U F&<(6T4/5:"IOGZ3,HKH
M" DUMQ=8GI_Y. &HR,L!/Z#[1$KY#TK\_TI.DSDSED)C:L\JG-I//1Q"2\9J
MBG99P$B89A*7MF=L(34[B1W+#5?&M"O!JMX7I.LLU/ 7%-=6+TVH\ZMH##0Q
M2G>BZ&*H[5?/&*GP\:>?_@YZX>6!\ZX?4$+YZ4=__,O+KYX]P\\?__%#-G!4
MQ4:<16M]3/&46!YF7R^AYA#/(8K!<ROTQR4,W%",33J7$'/(!J]6CEQF/^"M
MFD!#^!TLVYY71*-1NSEUAN4QK ZC,\I=?&M^DT9OG$TKMZTM/L^3E4G_P:9X
M,^/8V>I0,91@)1,"X=7 /-_]26:&BBKI(RFAW'7-AB1I]&,L?KT_^2,9,TP9
M_=J:"="'*(^L=5HUMV#KT[,8B1M(<N=Y.+FF5+H3D52T?@>*?9T$K-L4#F0Q
M'LC9+:&0+U3:]8B%3>7U.+K.6^PS^OISZI5IVKHJR0VG%VA77\DE:?=\\/SY
M5\\^5+O;-\UK9<>*9N/I1T\_BD<#\DGN0ANY4+?Z8!MV>K9HMH2RP.[#T3AC
M\7<?)GIL 0!XW%_@WS+GY.N5KA/(1=0B!V%92&3Z3D?.<LT-!+(:6+LB,48%
M@J95,B8YC%!(X!?'(9IE/LMN?!%;F,>AQ7G-!#KXC+1I=8&Q.9(2P2A9;6ON
M0><>+R>TDB4+M$T^*G$?Q!,R+%T8"X8SH)O5L2)B:RZ1S8P2*V>,+L_N)JT/
M::/MC+PG4T&NYV=+LYA<0Z+?S"ZAY$;U4-A29XJ2OH#T.7YS>Q[ Y<ZLRP>N
MI\#8R8=-E9P>*S2:=5D*"RTNH]%+LK2NKD>1__QLI;W XX8\HKU/F=ZF.?:0
M#:1U7.XMT5NU"Q8ASQJ.3():@J^Q(\4@?/5U,@B4P#N$K*C&=N&38M1FS!ZV
ML*71)/EWBKYA6>?O).,CQD !ZIWU;HFMZ @M*@B?I54.7"*94F@*L L#WOW3
MBCQ99495&#"FPHY/K@VSKVW/CE_20/":^W\5^5C>A+Z@5?I5<OEYY%Y$4QJ/
M#/C0%%<9S: 6_S]&\?\36<GQX[I+.C?9>%AZ$QD:XZZGI&]+1V!A2S<QU],"
M/-H9.+^ ;8V:*>,N^G(M0I2'0ID8W#+3J3BS,]\+]]KJI'>U*&=IQZR!LJ+7
ML?U'G.E>Q=\9OMM#;XL'+7<US EGX"97Z67 960OF9G\.5["_GPL_<9;%D&D
MBAH)U\>C>0/I<S1'QO_=T=DCK)UDNI[1/:+=>!6]).!G4&5E!UI<@1BDDS'I
MSLQMW, D$<FQ4-6E:8X_WQ!N))ZG?*<8R]3-+>^_K\KV=;'ZZU^?TWWQ -:.
MOZ_TF-"S/1[Y%#@T=S4?S\^C^UG>EJMOB&E2\>SI?:UGME219*1<AF-T<@A!
M28/#@;T9/8;1<$2AI'E4EZUZ*S4S<%K])0DDN6LT<4J;7TSRF#WL"\P?M9@T
M^25AVF@ZN<FUGR'OE/FPVX^F4)$\V#Z\)'V;+Q/[C1[T>>KHM8EJ;!-[RB';
MI0K$'FU7A!FB*L:!#AQ!/^(I0[&PI3._-Q DAV"S)6 R8-JZ<BIB>R:(=>X6
ME?;P+6H$*C=M<Q7B #2'Z.2-U6"-G<7L%)?8/-BRGB'%!9HK')0C<L]2M#(1
MQ.P7M&BW;V(T&53F5R0^J1Y*-0R=!NX))@W3(9PWF9>R=$*']ZL7T64'2<<G
M[#;\!B:/ZIU'PC2@<>*[BMKFHYUX^MO_[82/>8U;"I818=L@>$()RG5>O8RK
MS;>8MK0YA6KX"R)"EF6+#W:T'<GR&&Z1'A76P1.=4E$8#EHO8+UZO-GB/?PE
M?LO_$,&DF^@*Q4>.SFI);EUKH;/)8Y-[G3FD1/)/UJMF%1_"4@/K?L>D&RM8
M*'K3H;8QS=8X2:&5MPV+%;;&T,OY52:M"-_!&;J5[&>G1C(> YS(%L:[[*.X
M*SE>W-YSJ\B>=LXZZ76+42+4(ZE3&S]G.PLV][LX DKU:D8IVJO*(+Y$!#41
MMQZI'PCE@1UOM.5[U?7LPJ&Z:H<8$L:UV324>HN34M)*S Y:XP'TKD_9TQ>A
M.M[!85),9=P-!'>*PUS*H22IWLQVK@?@$^T()>6L?7P&4$NU=;EMH 96[;>[
MJN4?Z71"N84P^P"OHD<JFJ ^!ORW"A.$F$$O35K3QQ2J%2#BR1/OHE$].6)E
M+@0Y8Y>FM14(*#Z3*'C$H+/ 1,O\TI)12$1=Z9"30V'&'NN=C">7UYX_GVRA
MECD^TW_=8E<4)J0 ,AF('Z+G]4:X_)\\?KA -Q:@&[^_0#<NT(T+=.,^U+1#
M@!Z. PX9KB +!2(7=Q67YR,>2+12%CJ((BL9;;@GE$T>HNU4GSZ!!^/Q?EK3
MZ=]S!S1<C)3EL2(!<S4K8E'$)QIR.0Z5)-%)+(A+4^#=+%)7&?L-XAB:$"0+
M$_"[6?%?"[ @JE#S[^7.Y729$<GH\CYS[]2@#)[7T_S3NE*P%L^.I/M,6;9)
M@M"A#GP;\"6W,I-; 8R8$O(0P62%JI&,.N(0J1U(U9@0+"E5RZLBN6IH]MZ?
M7$61.BQI'<Q5.A^ A)&,Y8A)@Q8O'FIPD7YA>3A='K;<\GIF$!"ZY$:JFO$Y
M0ZO4I F"@4SHT,=M\3W<M/J*%&W2IB\[@+S%EQ6^@[B0A^W5&C'7_!5I&.,#
M*%/!_(<">C9+<J&8G\#IG>N;79DZK!^S-!^+XL[9/#@BM'$9)'/C9ADFGL3P
MM3O2J,P7J\U*':(S*Z2IYRRI@).:M!J52"VQ(S[_^DO?DZ_]JXWD8CV?BD0_
MM\.>L"CB8[-+SV5!N_]MU0Y=T#Q.QHDBLF8<H<(F7_4W5(MP0"S&5J';F>;4
M6VZX^D2/*KW&NY;;RXA@I#G>$/GCQADQ-)5UR32WTB',WW8%Y&U%D0$99*,:
MD%A&;YR3Q"B (8XKM8_MF^MKP2L)DTG9'JB_&QPT5<N\#P=RZMK@=WE;UEUS
MH-^F[\;]RYP/.P4_2<F&0>O;@,U+,\L*<O&RU080NKNPADQ4X9\/@( ]$2/%
MY1=884M(;*3=/92U"B';B9D=F(5C4%H^-4U7*L'+.;N%!6HGFQ@(?VZ9L'(Z
M%,M9G@M_FBW5 G5+3*P:5OW<OI/%,7<0WWL.9P&:;^6;H JTWS*C^SBQ@;+M
M0Q6J;:$0O,)MU E+R'C$$OGG2$[:6 45)XCC)Y>PYKT0),_8]9UFH&Y#RR&X
M$I,CT0D:G+]6K\,=>D/%$]. U3.NFMET;:8X!^-IU(*T2;CP%ZSK>:[E&2*1
M)=K'!09,]B(X6<!_F]7]H7IB-+&G[T,NT.[FD$>5F030Y2=(%^2L&ZDW3TRT
MDE%TS1NK>[]J!$/8<U4@-6#9XFT7]ZC?:;(R"V8X@CWO&SY;\&9-[IO'+63[
M,OP8[F;:N[B=PP=ATE)#+EPH,<.42;<"$*V@']'WY4)(*]8X+4;MPLOUOI:7
M*#\L;';<FY0F9%IIL>29NJE!P,9&!>"]T"9L2W22 +'V)"(. LRG5RY?QEW1
MNI]U[0FAE?#2T&5=O*2XV\QX%RL?05FP1*>,7-/%3;/TJ0NMSWHBS;>HFVN&
M!9U[S/-D1VZRX4@7/@WL(QIEY( XW"^DEO)8Q$.E&U<FB[1\ ?>\YA41OHM^
M2LMJRHIF?_:2:<^%9CVK(XH1C48VSK7TPL>%'3?;M5%1E\>*Y(@-V9[8U-A<
MB<L3;W.D$P4V&!7%^Y9EYHW,N3C2/&MQ<+R%+GGRB_5TC,M.&>5HV^W+.[07
M]_&+UI GORWW!%_K;\RJ.DU$V0W4NE<'\NRB4\[T!'ST?NVD948W&>\$+NFH
M2,BX[9(E\="3KBQ71IX51RC%:_%]J_$!)/ER'%Y"O),'!QX"Y9,;HM <KYD@
MMDS!3!,(T@D4[%=DBWHL<TKKM\'E8I 8\J&!%JI$8="_1@(N <#;LIP<&?I6
MX]6X;G<[+>02U-=!4=*RTF)6^H:6Q?SM1.]:SB^O[3=W>XZ&O<=.]Q$0K1N+
MW!WHI@P_HV-4K?/(^USPH%<?/,"#_K!0<H\TJ3/8;;',GD]KZ++*SL+).R$W
MFJ>VFN=3>NN2RFPKQ..D/7I' K&">.FDVP80VO-SR9.H844G34U$&"C 3N9G
M4UYS*,3L>3W!14$Y>$2^R3(;RW<UURB+'+E:'^TR+82>-3<5%'VAV)@^Q^Q*
MD&!.B99'Z\$PYN<FQQJBC/#1;W0+0,<,?C_;"K$U8?2?QDK4&THJ:7_LY&TD
MTLM2'["X]5@/0#"G1"3$203%P;K<RES60A"M%DM4;3RPFPTX2/X>FB,AP;^G
MI $;06KG W\?\GC()%?:F*8-L-'5""/)CTI?:&Z^-XINL8KZB/C)-<_IV1]7
MR.9U?,3HB3-5EXF-6&\)A*%P-(7Q3%:<O]1N%D$CNS!K60YJ*5LCZ4L+Q9[M
M:9JOT=5"+2\<(TD^FU,H$R'><78C3V0  /WUEYUVC)T+\TRBFG+3"/ <,9RI
MFX_P@[;&>:KD(TWVU5QG>^8D7"((M)Q&!I.9]@X^,GK "PYA 8?PAPL.X8)#
MN. 0[O-Z7663RT[1(M]6+9/=&B)9E+@\AV+*/II@V\67G)3&-Y2Z%2Y-/4$7
MD_U>E>-.JEY<D1@?L^*9%&.PN?1'%]K1%#\*O+5T[(/,K)@(\RFI@73T:S?B
M0+4-Z;Q'5.-*"H56GN,C5%11K[H.GXF!YGX RWMT*&.@1)^XB3<QKGTR.4W'
M0IC:)F0Z7@5I!%C',74BQH&AP_DFWF%32M[@CL"$7>["9$1L=R'C7F"0:!(+
ME<%8&H4*S2')<Y 6,Y6WO U"&Q7J3+5.&JW@']MW,[YD2VL(Q'*L"#=AL,AV
M(N[.V ?46B"*/*</H3T,B\.#] U_W;%8T#:>F2FA8E8:^;!UJFLC_G;7[$[Y
MQTU;K3E/E5:C-O"[QRZH+(Z<C/#AE5Y&G-166R'P9+<OW=ZXO( _1A+V5HIF
M/.6U4I;KX%L4@8Z;?64 =E2.F+!Z)<(9,'2HC"K3N>^X80Z.31#Z1.MX>=>X
MU)_W!/E,3P^?WH35B7Z/2=U*J0RD#9*%<S 1#0U$B)9U&#Q=K#C_R-,.880?
MR?WRF4*N=O\0@/F"WYI/>(P%>#/0S)N5LPL) 46Q642#6[GPO2B;(FU1KP 3
M;W[SCZ%\#>(=9/1!-LS\\GW8AT0.BB68A(ONRC[_M +^;Z)=(-N+*YR.-XT$
M?/C6N78"X9M>A6,T6O%4XE \O@?^X=]3X>_H=:*:PS:XGH F<[ZR*F,F#@DZ
MBC@ ^Y.TRU4 &U FFC+/X^8+!T:8 @.DRH^N:F56N-\;R0KYYZ0TXUN?K$M$
M>D/(_CNFH.YFZ)G/TLEBURM22B#5,'0H)J.M@I4PO^LY8[-H-48IFK>V&-_.
MC>=8"-0IUY=*Y-IU"V,UX>Z6U%A"5=ROM)U*ZSP6U%W#525/9Z1)+=N%K.CL
M9J9,*[-I)_T:*3<WNU)_(?7BG\N*.GYQO_A(S2MK@"+(G?7BB.CV:=)H_&3U
M@K$H %().;S2%(.4(TV$[DMKD2S\3I:2OVSSI/*M^&Z U#B5S9E.3;^-D4@@
M@B5G*7K'YY9V.M-9[9O<9<Y:B\208R%C#EIR')7K*RM0*:%>MK_%J:2O2PY0
MP8[O:F6^8S?L&\8XDL!N260C/7-5(U;)D6XQ?$"W-6!LI[KD\VOGFFM')RF;
M,X )7'=R2K@6LBJT<!F7NW1A2KNX[T);!Y.@4L#)Q1T;-?%VBECEV<Q9%\&)
M L H4 >&\A@<!8@36,%IFN/5QC*-KC*]6!NGUL_1TO*F8]TRTERME?_J/I2O
MD240=\9]C>7<F@RK*6R!DE'*'1NE_BNF;^1@)T<<X<(AP#I)P/T[=L7I:4I(
M%S_H#"D/T5NITF&K%1W8&BI"D?025:'TS;-6$5*-TLZ Z^AQ4EW":DZ,27!A
M;Z.EMCE< ?K[07?HT%]^D$4@-&F^Z+'=)9 T+Z88W]=AKV\4)T=HN-R$ 2C1
MCC[QIG/%!:"*68B8F[+T$H ^IKBI_AZ#Q02\<#73)!:I8"-?G$Q:+49W,UW'
MVR8>+]HL#:.CKAYS9D03&%=4O$?#D#[DE^0FNDT$\_20VJ?4]##Z! XV@(Q/
ME;A45)8'6<)W%G1H!U.<I.GW^.:DN<??2Q!\JXD:?ZFAE]ZO U*@>M'Y.I#S
M8H0IF UK!T_=U=8A!/^?ODIL GM5T($_Q 5$:G\8:>;D;*HY4)44=+@N7:P.
M39S*LM>.!"?)(S<#:@UB%#D(V$D]:KDYD_])>*_,EU(9H$L69-Y_=Q$9PRX,
MVRGSH6 ,VH!3+=LC[;BX3P=MHS(]6Y5=&H[-!!8A"\)60_!K8;H0N#[? MG;
M 2Q)OAU_YP#QP'U:+/<N7J>AI)YWNFCB !U?]94#U"'MRUCI3I$-'%FRJ00$
M$')4-&H<]% VB(T4[1XO36:ID]%CZ*N5V]NJ:RR;A//"#2; %J0Z*K;5,!>6
M5YKK%V'NFH?V7$P8AA]?%'S!!"Q@ CZ]8 (NF( +)N"A,D<-#K$-4]-@")..
M-7JH#F"1[+U##9%'#03@F91[@B%R.R08Y43ZG!U>Y"CLW*!R*O4S<5;KND7C
M+>IQ1$.W8N0CZ75)AT#)UUPW=8SOXJH5O0.FTJ& V9XW>>U\BS/7IN@GOVK*
M0^7)%)=(/1@IDR'JX[8A*F9%O7'WK0D^*K.:YDFD?0U/L YY/P0\DD&IIR&U
MM!\V(F/<$..#-"]H?448:_,:,(::1X2/?-7[=>B^T8$L0S;['27K1?DT;G4"
MWJ5/FD(D==>F[CSU"&Q>+,Z\#>XO?*\T(H4\86NQ&5,$:],#C>U0JS,L/I7F
M]['<XM:P+A!S9<#"&QWG(SL,Q$?.W2@EE F1:$DL=4O]6]P=#PP]/'&:C_>K
M#"R=,*K!N;&"BLN#5_=,E'B\63QUR0\N24"&^CIZ[EMV9.&Z@C.9>M"NV-9*
M,>D*'6EYHQ'G./;[+#?+-)C:/1S_/^[\P/@(P9/\=_0'7A-ZIKU&:2C)GG99
MV;&,!C5:? ZU4TPM04CWNB(4"7OP^CNPIT5[VE-N+#MDTB/>H >(Z@3>2_>.
M^_15^3C(17WQ !W;WVH]B/V>&#\U^93J0QR!L=#V6 U_RNQ+SEAX_C03+?$]
MN&.![!3P>-5@3$C>=B:-@;ZW?AXYKP1Z7L!9=1ON'SI0[_4PZMIN"'L:K1S]
M@DO_[ )TLP%F.5D!:6P9EJ5,\R:SG(>6,V.; /\26!+CA?3Q!68+7^0^X#[%
MO-F/LX8*>$O![IB\)*V@FDCQ._)HD(^GD15AH+;?-?NJT=K<Y!E&'0<9*&O:
MWC9&7.)Q]PS'R@<F,=!3H1]2S4!ED%)XSQI'!RIFISX"5-1U\%.Q+FD;*:NB
MR&LDFZRR&G$XQ](;^VIGJAMV37\^3Y-AN0:U<SLF)^U<]1X6C$_;3'CCW"GT
M<PL\_KS'\,N<Y<9*OCE^M,FS*Y)16;$82\GL.]5L^\<@G1DP&W,?\/U*Q3C3
ME9IGYCE#$J9AAF#TX@C,. )PZ.?FJ8[C%L<=.WYA%9"'NRF!67)I-P?K8FI1
MI05)*"'E1(L'5-<K[]32363;9RY_)O.>8D!-PFM<)%UNM!1S3?8"N,MC#[IU
MJ[,8$E?.\O0@L.$6MK!<LM ,0RU9;UP>*,1RXABJ](ZNJ6T2GL:Z=A(CH]RQ
MM>AMV^%:V.JJ!HS6K<'LX;FQ5*_BR8#KCBM@JUA93[5!0)_RNFZ(X"ENU8[Y
MJ'@M\JF[0G-=:VS<LMV,HT/(I/RP=-.:5OYW3* 9ANU2\0%9N14(W'D9N9AJ
M<L,Q4;"=X:-;N_ND4X,'>VFUY6Z463938YKK:#,*>\&CTK<9@9_C&A(7(M4%
MQ!R^U>-0#B&+O7%]'TW/T"S>TSUN?JEKYDY$2=C"M,)'>_=;F\V"5,:IHEWX
M>35&NS,/-"J"&,!S'DG@N&VX#I<O#O+^XG8@BNC:%NY9:,+;=+V_9[7/K,M'
M@QHT0;*U)+>/2U9<T";,+"$4()Q==8=B :;JYOLZNN6CJPCYG1,QF$E^/89C
M_9/?/2[BF06NF=&49".>#W.:EH5Y\]@=QW<E2%).?\8K[G7;PP'0C3BF84.@
M=[UOUH8/X9AV77;5#Z+[=AVYC,*)5]>&[%R3;]NXZ!BDA;($';G8-@C,5UE$
M1:P"IQ?UM6C:=OJ"%#F^#I0*3"R)S-P.0@=I(!E4'JRBH]^ZM'$(:'E449IZ
MBTPU5=]SC*2)$T?N-!N^V[+C*2QKP^: !"81]0A?8PZ?L8QPBNV(IK4P9.JN
M;+WTAQK\&!#VJ^^;.DP[;.(K[IOZVBM#Y<M,Z'YF;,,$Z>([H1@B6IC,C$^D
M"(/7R6H GB#&7\0)RW)"GBIUROMV&(<@[5SS=Q*KJ9LLCUFO7G9M&?;"G??U
M$%=!N9)C^[]?$Z=-*" UD-AXA+^2?J14@F*U-5++-S ?N'&M9D-'(@ELOT,7
M_ZU.8BIHK]LF+@A3=N&5)ZLB]2]@D^)5I+%+2^L*.L_W+.N53B.YG"NPYWXL
M74"]*FIFC&:V[PF>DCHU)OFMB8<XS5 X.6$TC %7?5=",6,_=,H72P[<%GUH
M1W.2TIQ@(J+;D^ZA 'E*<^Y/LER.#?O6V>(7TD "6EX[F63T!,*P<MO#HI%^
MEYB!^0/O@AF8QPS\_J,+9N""&?A58 ;> 6^BCT$<1R>)3A\HJ8%2"EG;ZJ9I
MMEQ@$'X6,K*Y:Q-]!<2 \ZF!6>90SB=J_654LB\]45QJ=<IO*NS<B9TZT<N*
M.^>;)^?)VQ@]';=01:0^UU0Q44 Z?_0:D-ZJ$RCGG#*<8R7>MIP6EQ:8A4'R
MG'""6//Y#_:AE4= 5/%R6E^K)PAZVC#'#^W;^%$6W.S:^O1QQ6P/( O]<C;I
M344V6H17PM1^JTX=VO],"$#;#XTB<1XE/_*=UE4SPJ3N*FL+@JOB6FS+>I48
MX5W-+F.?1\V&#M35*904/O 2B:N"N$^SC_94)39%\OC?7;]8&9-<P80H7PJ6
MEO"R]6D9-^-G3I*_$M]EN@+_%?_"XX<.QWEUBA&51NE5$JP$.F<<++!;Z%V(
MOV[+KF\'8<Z8H[\O1N_?]^%PY"M?P[VU 1G!*KBKX>S[%T*I?]7LKI36V,+$
M%J])'*O*AA\?@CL,C5CT&5IN-S'0(<,9]LU=853?D[&0#!-U+%@RWNA*LDYO
MUQL>Q]TUA1?WA,A8+]05,UT0^W+].(I\/[/=>;ID=[Z9'A$Z4V@L;\-MN4_G
M1<*#M*"V9X+C\TH12KUW$!V,;.<(+4:F8-J6JB^^,D)X*2??Q!47<"!Q)5F.
M7UT7DA4&GXBPES;70Y#?7PG/"#Z,^-UE@$993Y$888);C,\XU>6P@]9.12U6
M0EB[#C?E?D<?'KA4QNFM;)\N9>OOLUBY(W$_D;AG9IYOH+?@>\%;\#E![X#X
M5OM1"U&6*WF9@SYY0&6A6=D(74S.9G+O@#R*C+IK3VY<Y\#(M]+7V9]2VC(C
ML]H1IV%;,3'T?6"\]\]-6307!"^CW4(+/8ZU3#$\$&XP5?'QG]>DZ^S?L\>R
M?95Y *\2N>>8@14U3LLG61(T52F*5$&,0WYB=2JCLLGVDR&9C*()E->IL=UE
MT0Y-#5Y74<;(KG-$D]B&45A2H)Y]"8N%>&2VX1\#FKBSJZE>$DK$!&53=2#>
M_$ZW)\_@,KC&[.5AAC!@AJ#;P]=@&)*36"R8'P--4\F<%]&)FE6KO,!7+Y!X
MND&EQ#" :%D>WO?PD$_)%E>:VV].78QR"*7L %0LKS17$,@-D1\+YDP8ET\@
M:N-*F:)MDZX[6?ERHXO5>K#5>CG>A\D9Y7."<@V2_6T\HU&E=%\*7T6+7@Y2
MWH8=P2LT;L=&8*];P92S-B?S>*0+FYN Z3?,[Z91Q:+D N*;Q)7\[]'2W9:;
MC/6M8"IHOQR3;5X.Z"=_S,SR2G2T=*< %)]8?&C5<K#"(TATQ_1E"5+9#&T4
M5J).W"$1,3/7D#) "UU.,(E?I:0;B\)H_8]=LR>K+YHV-$ M, ;&:0ETA&80
MOX)C6UB:8G)FS >5Q7T.VH)P8.[EPKUI0V]$^[A!L1J+ZB3@*14EKFXHP++L
ME=-\>%],PIND5F;MQS_]Y]]8CP54-;MQT$R^X6ED,D!ND@7GB?D4O%8V(:(L
ML34Z:JMF:K/_2(-(Z"C6%,BH?M ]NCW*E,-0_E'BL+@ON><:>G3+-.TY:\!A
MPY3^RM? D!.Y+XXP3V(F@>I2I]I.Y5.=W,XEG?DR9[14'&M&_)5D*K.[S]()
MHE9X8MZA7(5G,LB&M68*AZS8=Y<)LCPL)9WW;9$?0J^4A'Z89K)1.J1WCD>Z
MU/X6:G\?7VI_E]K?KZ+V]].@"[_&$?EU G7^V4SK\XQE\7EYK,AK_)I!/0Q\
M?0? OW??)XE(%J@G"JP]9HGXIN1 (D5#JDDRW1\Q!FZ"5!@(6*VC2B<GPM61
MKH9/XS+ REW[7(??(X!C/M(N"YNQF5EJ S5_P<=8G"_O6)9V$3(Q__+T-T\^
MX=>-;[6GN=4IHB+;BEOW7H1-0$GNDX^+U=./XG>H*A._/OF#=%1LD2Z)_LQA
M$+<CD%>"[/:__.:CWS[Y.+OGXR,Q>0133@'Q:),FW]$8OU</)-'=S2KVH$RA
MFGW<E0+0)%CW$^DU"BOZ[:[<R_40Y<:'D7)LM9/.=?;GN:/%,NM,H^T6,"M*
M(7(NM'VDT  :*<[1=S-8)8>T>#P?B3>YN4'>?T^E3WJ=G#\!+_6/(=Z5P9GZ
M(UT9:S_^COY?0*LBB<6;C)A69;LA9HC16LJQS4K:99TKX.0C>@L"(C;MZ#WC
M=Q#J4P?CNU^0CVACI!4Z/6,2&X)%CW$B^>$?</90Y2&=9]P9))?!.A6V$1\R
MED2^%UV]1S(^H^?@_B=V^O_//WWT3RORGH]4):NO[=_=L=SHO^>BKBS?\5&,
M#MB+_E._;K8G=DG_U%OL01)_:/H7_[!OCN9V_ZG?CN^0/W:_O>^3;FP775++
MX/YXWOB__O.GO_O]ISRP9Q^S'/KFW3UFUM^:'PC2$7ARQ\'X=>)/[7_^K\N$
M/J()%;:)K*=:]4#TH)BI+TFN_]B&K,1C_W#NP641//I%P-D%Z\AEA(A"'9#Z
MMVE.)14G_JMM1-KG,%TQET7PZ!<!T!"64B=I$R/=$)=&@JDD"L&_:';R_Y>9
M_V7.?/127V=DRT0\?JM"9&CJA\N;445?=OLO>LY9CJ6P]O="*_"%80&H1%8+
MU_JPI%QLE$"7.7_T<VXTS#=5FU,PSY!P7^;ST<^GTFDX3XU%'9@_PN'QN>7F
M2)O50'\4QFV7DWHC:2F*!X@EM XY9PM#7;3M*1-GO*R@1[^"?-6_/CFQ\:18
M+IA)UL%PU"8YVN0RUX]^K@\A]$*?X^J3O.V))@*9Y'7@XHU(L0A2Y8_TL<L,
M/_89'H$X]P9%+!1>91%[3L9@V* 2_9G<X$)M_U94H%,FZ^G,Z<>X77)A?<2?
M-)$;?Z2$\>/*8;]3/8YC6QE&RE!IZ-^1[)O\"=4ZKGC.\-J.H>,YVPQ8NF^:
M_3;^36)Z90C'U:3?9\/X!>YSJ4]:J2J\J7<TT DJ2,URC";#LR=A1H&0,6%/
MN3^):A47'0'>G<+,)[3BX+4AT,T[AY"]&QP%4YY0>KUEC'V5=<D:G %?PK84
M'(H5;WU=7C^^XL^C732>"\ CAZTRQB9PHM2"&>M;=Z+#E'.1-CT>!J!Q7GEH
MIKE +9;K[DN3*JI9&2W<N>F<G[_[)LXV(%L2:ZUA:56*$H9:95N/<>>1(;F[
M"9SK'8 &45P $_[3;4 (XS3K: %8=V(']D9NY1^_#[T[@0=%IX#PZJX ND^Z
MZ%6K.#C6*1()Q[!-[,\#]7,*T@"=C[?A3+$<CNX-ZA^]*2H8&]_A@"[,:(J8
M E'TEH$11O,.$QB1JF_GU_W]@&>\Z%ORA96RU<0\SCRM,YGBWE'+SH,%@)ZL
MOI(N QYR#*EL=5XXJ_(V#@4S7YY;G&^V,,%O=* (4Q#GVR8.%4VDJ@['*XLX
M*_X>!S-^ )/VSH^&"[IX 5W\]((NOJ"++^CBASAZ=6/66"!G6H AOG=T6&QN
MP*5O?V:TW8ZTX+@[=%W2*<SM9MF5+L[8LC.6!KZ3VA>%7TU&F4QPQ">K5Z9C
M;U.@SHD %I=U]4P?R4,M*?8C$IGHAP!0 9%7GN1L8OD$CF_%9%!$4QTJIJ'>
M-W50T:!Q\W>FG%+(LW,0-ZGVT1M3/4BKNR;9F0J ,V_%(A?NC=R8\=&\>D6M
MFY#)S=@KXU24MWJ6[^)$L[ +BW1,:7V,W1.\H)D4J(S8A*1\ C!%(GMN>$V]
M$FU;-5@<.$ U;^8_?F;"E0NR[OU*WFD3/6=84DWF(1"K9:MSR<L_^HD_:Y0?
M ,&8,<KT:V..SDREK+)P0>K],A>+TT&+QVF\?EG5IMD%RF3Z1W:(*_/ &;Q.
MP2CS/=#F,<"/%ZFZ&U7#4H@(ZU?HZ1X7TVV%NPF5R4QO=L[BPEF/LEZENK4P
MN2PRB6O-.EG 3"7%.QO"=7X!)?V"5S>K7^Q.['I2JJSC'S=4L52']-^3/A-G
MF>XNL_U+G.TZ7#<$.Z9)W%$HD/1)D0RL3[EV2K':1[M0\Y*P2F;9MF5];;*T
MT6C8R0<>>:2O+HOAL2^&&-BTHE+($P^)-4H2FURC>L#L#7G'Y;+;'_\$.R_"
ML*;X.7QW+%%O*!SD%"1'#U*<7"%YGM4=J+D.?$X9/5%A(I?$/72!M/PB5HU
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M?5\+K]>7L<-,3H23%]%HIV0JD8) FC=D*US0(6N'R?S/MJIKR?E'.5P8WE4
MVSE.4ZH:)CH"/C!,\0'8C^54 ^KKVG(NQ@,EA/B3I)E$W_&!IFM_5]26>7F:
M2G584K64^'5KUMX0+AO3BT?9L)SB#AX*6(^+:&TL0*H\U@B[-1 ?6(O&![LF
MFEL2J[A)ALL>IZ">$0E=S?D.]7$3X8BQT.VG8%V;VX?5M]"5TX(QVL Z:XB/
M92A90(CMUMCANL7:E#KH-&SP#B=IRI1-[*?SRV2P-&$\-U^;X9E0FY#MTUQM
MD=Z2(KW=MDBO+=)KB_0V+QM;XS\:NYPQG3=V$A?OY,*YF8-1ATY(M4?BJ262
M.7%]QU2:M31>GE/PAJ9G5!#R'QVN%!-8>#Z<J".'<$,&%7%9=L5>*(4E&RP2
M+('7S-A*GU#&(\)3L7*V-GFOB\[KTCYEF$CP0Z8FSK'HY3*/\T+*&W$$Q=JF
M&1RXX2R+<Y7I@Z].@ZC=XRL\5V5JT(ROE>P[#1619-I#E>-4+&7[:6! \BLL
MB8DV<1K;&M@2 4UZ52!"4YJCC2%^U+6Z![;O!'^P<7Q.I<&M(!M>LVG4;2KC
MVRWWI*FL-*&D LI:J 9%Q;NF'IPKL,F(P)+Z^;'E0F/%.ZU\QKL(H[@L4)XH
M0#71.52.]N;*;</C)@[T?Y&3%$84&K(NCO6 )8=T.&0I<\5JG9AK3MN1DBXH
MS$%%>GAHZ-8/"MOIP9M-JPM?MY*D,?:^C#,EV5MZGAX=@LDE%%\@S2 !99P+
MD-Q"QPM<5APDL$=91]7BF;82307/X+:47[3KA;./PW'['RL H+3-<3L$]%4X
M\K!&(<Q),39) %O5E@O%C7; 8 KT?,8X/G!!Q9+'&F"=V*ZFLRGX7JN#Q3!*
M0N13HERY<RLE/LT$5A1\.RR\)4TFRR3M^C:5BH^5_E(=5\\Q?C)UPSM:L_I>
M8Y49TZ5D1&=/PU>Y/86,UR>'EY/?Q[/BP?MU[C?B_+<X':!VP!P)P^M9;2[9
M;(>\GL\#A\]7B* 66M0JR=$%I[Z)C0LA *H]6"EQ@2+YW(9\M]^3UC^G]LME
M41-,PW" $0]MG8FB;D1O AL/_L@J5MKFG#V=PL:,$EK]0JMF4M>@"ST.\0BF
M&N@&(D TF35:_1F8;),@1T39280:-=#JGH*^_#.8:2-8>E2_DKDBJPV96'4&
M*(239HQ)\MRW+8C<I.C"^SEQ3&1]P:!NX':MCH(HJW5/UB>+@]T-P3NP13%<
MQ'PF6!T(VF(L5+9!P_.<C2)O/%Z[NV0RKWACI47#YG*#?ZOWE1087F-;K:02
M>AIN4C-3 J[.N;%E8#)Q0YVRN7"!YL)WR8X@[<E8B6*ZJ@,W1"Q'P@+*0[75
M7YP@4_'J6'F47A>5(3>KV/O.I6)#DNWHLSW'3@78;(5VWBP?[LB%;V!29OA^
M#B:*[7VJ=DYO=JH\(K[B-;Q=]5J8)51^@5X8O7P5'TP\;"GP1M.^:3'63S]Y
M_HFGJV@NC=]7B0F UN4V:UO"09?1L<,^ZL*-26ZHO@I,X0('/(-C@UP:,>,]
MZ4NC@+'%G(^(>'MI2[Z0XXVI&-""(&CS<Q;-%#6V:]O2H!K5L4<$P4AFV<"/
M5. /%J7>.DUD/M'>-+U@J_UF)O^-XP:%O[Q(:FFP=J6DNB= &^7>-,J]UT:Y
MVRAW&^5>99U\7F(P5!0=.![@WZ "%3KI@5+&X[E,L0LH5O5JEFB!4 ..,GMQ
M,U.D6W?AL&LX\#63U/A";-G04?C8RI2VA4_T]I9?:BO>4O@\P'HY/CZ'L(S<
MD[;J]H9+1\J( @\1QHA'JM,_Y%L34R<^E?Z^N]_I'HG+?*DX$]#KBRM-/;3*
MX"6Q4UQUE$^2I"3J-H9(3;RW6*_9Z^[\O>-=I%-3.BNV@(UOV8CZVHG#J@I#
M$B1ASC5=Y;<MH$8P=@]JTKK3\KNT]?;/" ].&H8I9Z%KA]*,^NRD+4<\"6G:
M3*N1Y;87YU&LLA3I"V>W]L0:JRLKL;'F LUU=#&<+T.%*6&+5DJV7DITQ3JS
M6HOI9E+J#0T$=<;WA4Q2N^A;O^B.+G"11T0=^ L*PN>L; -P16/9A6,8T4%"
M<16,1B5)BCU( DH]2,N"#IP%$6K.13;<MI6U1R!K1FPHSS6NPI$8.H'?DPA=
M@8O"'#<<F".(^JPU.1[#6E?6E4^465E0&QZV'B:V;]?%P,4R+60>"&U/KU.I
M@D"SJL#>*:YS:,5@Z\6 ^0>&61E)JPY6UV!)2\E)Z2]JWE+0/++U-"3*IEO-
MH0EQS,2&PJ)&,+,U=4>M-_%H)<5-^6%GDK &4<4I)[,KI).+5IZ1AU;7;_^*
M!PS40=:]T\:$75G< Z_[UW)I8*OPSK.@5&OGJ;@<ZZ';U=_^U7<\.JFBU_GY
M6J^!K9H2A="N[M:O;@7LN)+E&,R],O>%,3*/0I552@F=^O7-EOGVQKQRP6]U
M"3>3,:])@N]"E-9)T2T^\V("&Y@G $N3*'7@="X0(C7G>@.J74*1P Q2K89)
M$F:ZADVNQ-3@(,VR],HF!BW$Y%QGD=,1N(I>BFW&.?=*P;-P7/H^K(KRC?M@
M7MY$%=WBI&Z=X-[>(Q^%EGW\[TLY8FGB3]Q2Y:JMQ4!$F 8R8.L&M1Z\<D'V
MX-J-/()Q!1GW<[0G]M:?V(UV-\7NJ6,R"44^!B[8BZF;Y ZN9.YK[B(LLC":
MNEW^K5_^Q38C":[7VLLPNCZ(4I/0)VEH\RF/8HVE&<F#'9VDTVB(UE8(C\GF
M+I&'(P,M".:C6%=''[N<KID:!UD82ZG.%+Y=M"2LUQ['64*894GAS56@J_QU
M13_M%U"4LK-\[T.0A\%_;*>U])=1F8S+7V,-*&IH6*=CS>4\*]C2RS]9@NZP
MTH;';@O>Z#*-RZDRE846<XGZ@MD7H@K-,M%A>4F_92D6.V(,IF#, VLA,!&D
M@<!B^$KJT),Z2/M^5V0SFK85,V"NML3/5HZUX_U*5)BF3R,T2LL46V*@'S='
M6N:V#7V3DLOZ'J&^/8E*-KU=QWN;QG%Z)7_F5I41MY!+92NV_,D$U9\>:+IL
M@R;G]O4[FYA*\*5#W=G1Y-\Z"S:@'O+"$"^+Y46/@&FK8KK.4LR/$NN2'6C%
MFZ9QFE90%\(JE-8B8E>DVC"DI"IJ#+[.0'7;IT -7C1>M*J8>YCJ7IPPPJ,%
M&2L"[GHWDQ<4]$:(*L*U1 ("9H@D-3;&4^FP;*C'/VOF4)8.0FIQRB<VL4;F
M_(QR*EQ"4X40P;9 7GTN\Z0>549+Y'98:9HB!-V%X A+$:^J!@AY9'7V]X(4
M0E"4 56;UUK\G*44OC&*AV'PRB?H!$Z169P;O9BT\ZO]G49)&J'0TL K;UG:
MS3;Q;.^I@,295C>^!8%:N%U[HEO,([#=@EV_,K>]XXYT8().AF&!_O"O96(1
M(!3!4YA&/5VW19GBS(T5+HJ@HT.K<M@X<.?5O"%!_-'@\7Q>?"Y6.Q)6L]E4
M//?T%0TWHJ_GRB4X[GWGY5&)(B>M=QGET:#AJ- !2OQCF6D-N023QWE7!Y&G
MBG!H,:DWV-"ZU5@8OO74(+L*+"*Y"X3Z'8,I&4:!=1X02JB<:7PE[62D;@P)
M\?^:&B1KR#/;0N3>MD@N:9'<;ULDVQ;)MD5R)9:/Z#\$N_#>LH?R0%;0 \_$
MV6B1!L+P,3!_?42(OZ"2$L:M0Z-#DL--R':S-(\L%'HS0  ?FHB'6 ,F4V%K
MCC:"9@>2CX7O8_:3#1LA\YM13)^3]6R38B0$S)L( 8^Q[I9A%,"6PV)KHNJ*
MLJD&J'!1'06CG=<.75DQ-/&/#$[G!24B](AM4)<+CPQ+-R\EXVP$F/ )\OOZ
M S<#NOEX!%..;C=%]<VA%B&O0R8: Z5TI8(O*.02!PH50[P,36;MRB!R%LX-
M-+J<F,/N&]*0,2A"+3E$"K[X.+;$\ JP1TMM#R/-<H +A(AO:#O"V@V_$',C
M6GRX1KRY%B#_%J(=%/X2)X<QKIQP0S4"P^9M!3.&C&28Y1&^,5$@+*0DM8@2
MDJ6#L64Q,LT8'0 G@[E9!8$R >\6T++BIF8E%O&,48H2W1R-(9HPR$+=XHR4
MXZ!LI^+&VC@-%?<21>/U=@]'GXA"Y:NH>2%9<%'&TF&)#Y%(=Z%R(PU&"[#4
M!II$QP#!A$@-%6.\U+P*6)+2$TZOW/%>,S.JW)<5H/-JA$\I7)2-FYGJ$IV]
M;,'8!>]0;RGR]1"TK3K"("00&Q#=-&<BH8OS_T:F=/19J](O%"R@S,::L",.
MAK7I(N[37$//.F]"O9GA%$Q&@I[$\YANJL]3%U[?9<9PU*;YO-T]%6! 9Y8C
M+'G/9[ X))F4#%C%HFL0E:]Q!IY?:Y,158,F_D6\X7'"I[3FWD7*@U2H@PW\
M'D?+M2I 0%&-<@>J?9EZ9J<?FSA,<2<,+T]C*MIV];"ABI!\R5=YFUF9X3Y@
M)BL0O"RDT1!2HB.(</3 ?6:DL\R1P'#7LM&P5ZQST?%.L!O9\BUM:)02P]:-
M3"%K_V+0.B\T]IUY7N(D(*YA9_!Q3 8"6BM\Y,E=ZSC3U[2C'SP&<[^^R@DL
MV XB!--DTR;(W7*HX23(D.%#'SQL0KQ6,<-EPC_"88*VD[0MQ00"/\5N5V:G
MA*\.^/@PF@&+WR6Q)AN#R3E:1V7!45FV0CIOAS5*9+:31!?<3(!E"7@(,I0+
M+$$*JD04$9U]3=\:S&$]EZPPHRE/["X;,01I)B@8M.RD^F"G3V<%%4PM(',S
M75?*'(6PH>G$MF(!)G@RQC T$Q=^G9-@*)T3DT<[^5@M-P^_3-LB+G]7\P8A
MT2@5B]NYQ=MI\7:VL+0GX& SAPT&*5A?7IX*Q5@"Y@TEM3@+Q^#0=#D7RH?@
M-7&!A)@"O]+WD2/-?/(<OXDI]7[W)7U,/_=>OJ!:C9C)IU0 S@M6ORRO\5M6
M/M3*Z_<EKPK)&!)KZ)=31'! B_HR9<>#S7 2+;G(R&DK7JUXK1XF>:PA$F^0
MAP@>#WF"22I6GDB48VMY6.F:5,&#P?T)XE;:6FG;H"7="7#@KWR$HB./C@,[
MV.PM8#0""VM<V=-@1ZOKJ%MQ:\5MG;@1RHU7SO#G7M?O=ND_IRN2>9F(4EKP
MUY>+(]Q'JLF$$DX8E".K)2FV1D$^0LY!!O#H,HK56%<L.S100>Z,E<MXF)M-
MM>7F-RDWM_5;!#QO0A!.[,*4Z>J:+A +-U3AANHOQ-+J=W>U6)E+=;'"J1,6
M>1=<41F9J6EW;P "-(D&4;%L8%P]1M$+L?:P',[DW8;I=*#-0P[?)G/#8:9E
M5Z25#G@IL[;D-U2$#Y_I,FQ#:6.;@9U[(&WNE(*C2QY2)E3[C7$B(D_7]&"2
M=)H:(A],< 58L4UYKH**])R):2,O;N:0BOIU[ 7$.);:RR(=4XUA)7*]23#-
M"74UA5']>I0LS:X?'7MB=4CGRV*B8J_H1(_9-R,5DBX((Z;0PS7*"L.B5 79
M@S^>8$?1$%OG Z899)8-4#LY^GNP2\JIIYE.,4D8ERXV**5X,?%"66))%WFF
M9T&Z'^#-"0_<9FB=9H)W^!YP;>]X=[<*$4^4@ MA5QU4EQ8"GB>7J"D=D!8(
M'#JZ?X,2I9R)?1\#34<:S!92&S_6AT&!$L% +Z:QX#W3N=H. K7^-4#GZP/9
M%&B^T4Q:W"HUSIOO0%Y/6,6AN#[D>=$L VW-\Y*:YX.VYKFM>7X2-<_WK-&)
M>K+J;XB*)KO/>(FA]"]AT>1PDDI[".MC)X6'WP?G-<)2T8H-3V55"D,7$T76
M?*X4P?,,,E'2H+>GY(MXS&7+-5/PU$1:4+D")G#J1.H'@QT(.4<T6.RZQ/@C
M>6-,'BEL-O#PRVB<9M*12@>&YF?E6DC*XR9P[Z&J^?S+G[PRU<W')-:(17F%
M?]XM!'.IJ+G%,J>>'KP!63-T[EWBM#$O\E#W<_*4_1N.LAQ)X$R@ /]L>#DK
M7)WFH'9>0#-2RYM395O 4L$33_@RBX_:ON-R&S88>UI&7G86Y(4ZSL@4KNP8
MVT)K3=^&O5(S?9FVCUB[P]RQD&]@$O,*&\/8=^HCJ6RYI!X\[M KYC.VWU"\
MRPB[$-^6N-4S[.3C2N;%C:31AU;H$R/43G,]S8M;-9(OEHVD)N1+>&/8B3U$
MDU*!NTGJ@X'**55!I$),(XA3M\""J&6?O1:<V?I;.P-F7*4H$?QK.ITP@F'>
M/N9&1WW3*\7E;?JVRR6%/&3#3;Q&Q6PR#@[\B/HP3.1$L>Z->/7N3B]AP($J
MKER/$!$6KM,5_M0*W$YM. 1G(36LNW6'V=$))<($_ EJ'7O]#1X"$JV!PL^R
M.2SW%=9/;X-CNV5!L!/:O UTUM30 ?MJ/,9BVL*ZL>LFF9Q,#.!_)6PN,"M^
MZ'?W._O\QO!B,6\UDOF!&D=4]0[V"-H $08I^\<=\(K18M*!R]VCOK8ZSG35
MZ2?%-M)I&BKV5H\..!+-*L%W(VM54;+'#:4RIE@&JVV6M:\GZ!72O"6BAPH(
MB==B#L^,1KEFTF8NH2+X*NH&L2DT")D80304B373?9VJ8%!=IOE:2C9)<=IZ
M!2G*Q)=T&:HK7>$C[B8G0W*_^R.I*CHZLY2Q+2EFO8,Q:PED<^TQZ3!G> 1@
M8M4AM=R$Y5 MVY ;32A99\%7S7M>W;%-P[ MX)+1L92WLR#'?T?4Z8Y.RBIX
M5X+NUL1@;OR-#VM,96FH&)N_<F_"(KW(N@MW5=DPXH +O ?8F1SK=8Z/-<"S
M56B22@&U;>1H+J1N;C>$^\F]*#-!( JF8XO;6*B9S$,^G+G3%&/FVA4P$;H1
MX21(T3L\S]VO! (SI$+&\#L[P_Y0 O43Q^Z2HY]3S#E?,"AJP BC4M+T=LUT
M!R)6WY8%=0&1I-KOB9P9\W:Q:\T:K!; )HPD8HBJJE[Q2Q8@M?.0/95I'ZI6
MI=\>I4T948J94=%T@+O?M1:#&6@O N;(RQF3<]86^ZI9:E:0HELT:A=/)*'B
M"#YM<(51R?%^72HG2VAKC:#4I:3-(IIQ6-IYBBB >DU+TQ*KPPBZJZ;"<M^P
M>)*&EE8Y.<:(X5[Z56=*J('%R\U1J;!8P?W 5,.C00>,U,*79D%$H0S;Q4J%
M^U&:N8=FA5I>TQ)KY)C5HV\^LK@V P5?T;/(WM/G+MY/BQ4V#BX,&J>2Q/-*
M77-S?/.VL(=F 6=X'H@N9)0Q(NW%=<J0U7?5M"].<L?[)X@)WB>(<W)3::_!
M 6Q*7EP;HJ+^^>UF$MIJMM\-M; AE:Z:Y'LU>UPZZY?/)LD@![S12A#T(8.1
M R9^IR>W=%8N"64@5BQ<JXK+A*HCZW6Z#2,C/CQ8 .)8DW,T$/.Q+"9I1C8X
M)[-P[/UN[\@[GR81G%?@,F!J!6WECW&0L)!5C#ORU)N$JBY0M+B('SWC\Y/W
M(-])(SJ0S>,OZ-)J5_!5@H-GN"'J:W=T+,_J[:O8^["/EE"Q.P0IH%O^789C
M+EBA(^^+\O7<H@J=SHS!8;9]IA"ABK81]F=:%*MU[9F\"A@_4@Z05VN\-#8"
MKY].TN842>2%X#C<K;2Z?E[LON4(X_I120(A1[>)NF2_+)<XCF9:- AN4D65
M1E$ F[H YP?+"77GL$9 U=1@OA,Z8%4Q0:Q)1,,<9B4G#,I<PI*,5EJ%L6 :
MVK&2/+UTS#F/ZW@7J)>6O8CT@55HA>S@##*=J3+?&038H1]8GYMC$>AZDS.(
MG[-+;%'5$SCCT H@M%<+X>H3_H;48T;9L)QR?BGWOB2@VAA*G_OS$P\E,\5(
MNWCL=H=K*VF@XDA=*HG7.@W=MCBA\A0:KAA=NMK"I'/@Y2=P&E]B\1:W'[FO
MU*AIZ#'Q7*KTICZ;;>072\,K=G(2^H$V>ZXB*1VKJ!4,:A<8T8DX+C&$*35V
M/;V:19F18/5F>JQ2-.1KW#W?5%6RX*]'9NV I3!2;$=H-%8Z_2SJJ@-\2H)+
MLY)RA$./QUH(Z[;FE8Z3L6AJV(8K.1P;$G]+P%+EB;:4KN.]3S/JL34</3J?
MI[$=R<%R\"9T@%YG/G&)X'0FR6@HI)&HDYD.641X34$]Z'@G"Z$?$ M!^_7M
M31IG]SHAG462"]IZ7--3M1L<D,5JJ9D&:[RVS#S\X=16 &U6 7385@"U%4 W
MKP#"'_!#WFX;5 ?=40 U\*+PK\\B.$-Z@V=P[A;X7/VK+ 5<">]X!G_T>K\B
M#,5 M,3B_[,;\GO"J5DNM1SA7$VG/%??%^;AAW0+@&L?2)R&57$:-HK3Z2;B
M=#H?X#E-A^=\6T1HU0:.OL)-DP\E%1=S \+7XA.^?/@OC!CM='OP/_ZQU]_9
M[3WSDF *KS"<AS]7WA8!0]\;.^PC8S.I_&V:G5#&""S&,\$<@Q]/DI NAA\_
M3S ^F7^&!_^*2O<9+<RP?[3?.SC<?096^C"8X2D #I0^FYO+EU9HRULK93+_
M[?18E*)7!)7ZO@I*=H%P9&HL,C#;NF%7161[1M98*';& 0&^(U4'<?S38D-=
M84 @QJ9\FGUT3C$JG"!.%#EC1($AJ.*FM0Q[J<%U+8)LKIL(1XR+!X\Q35^U
M+Q>*GE-RC13XO@7%H,PU#LJ8H?_&F\,VVS%_*-"JI[-;#_$7T#'.$J!!,$'*
M&VJLC++PEY_4]-4.$4%6GD;1!ZE$<S_H/)*UW49!["\;[-VK2ZQC&:/J".OZ
ML-??/=K?/SS:I>02.8@S_:TZ!%ZA!#'4E91\GL-!!D('CGG@FU 67)(%.2C7
M(0;B?=D(TUE)/KY*+J,L3035#ILCA^Y;4(5(((YG!J^4,Y)?]:)<E*&.3G$8
M1#I/V'</J9YZZ+KXB#>(FSB[C(:<#)^F"8+#ZOJ1JS3[4AL^@V+9XCN5A+,T
MTHA\IGBQ\1UJY -7/,(IA@)VV'FGI *JAZ%H ^'6D>(8VMDS!2.38*6+Z\EQ
MKC@=XU7PS<D\-ZJ!F)+H-PW75UE0JC3W-3B;[TW9"5?.1#%"<?-;2;FIOTP@
M3,R08X\E1N6"&"N^P2'2Y097RL34G)>M/C%34]POC ]&\35=(4NIO>D,\X5_
MRNIC,4%6Z%Q+$$ZX'=L4'^B;SE(D>.#N,W?SW<NIVJ@=CA^?WOI#:6!H+\W&
M01+]:=!1T7;ADA[N1.78T$3%LPH":&( 8U&@48.X\6DDV1S#7;6P!]KB<V)<
M(H]N'IE"296++LL8TP$VV/T']XEK,D=!_ 2)@<T0J2O]P%_R69#H%=@!X=F)
MONY,HA#&_+/1G'O/7D58T(1O!%_\Y2?\TBL4?^Z4AN>[V\/EB&0%)C4Y9O_5
MQ!_5GVXJB!QMPPC.\#*?JI.=@WHB%[V*.DR)"EH7Y^^A&NH^$IY?$ <G#NJ.
M"K_*$X<Y9+M;X[F&Y=M@MG8/CXWAP=.$IH=,@)2 +84 K<[++,/@H0NPNR5;
M]K8/<PW>?2)X_>?9)YVTF+^+OJAX_CFM7_6)\%>Q$G#9>;^OJW$-5$ JZ803
MJBWU/E&NB@XLH3\RF1/*:B5SKG^LK@HFX$*;^[(I/#Z'E<2@74AR>2U*EN"F
M-"D9+)O%UV/IK7VA2H=@; &_N2#1KQ+ON-#F-?6_U0IWRR1]&^9JJ0=PH0R$
MGTLZXNV0OLQ!OCE1"L*%IN6O+@C^N1$< ?X37"U3M%%QE8@YC%%A\,9B:EA4
M_5K31G7#$)S'(",PP92+J,$<QH2?W*=B6AG3EVTL&UFKB?&*9JPM69X'"R81
M(,_YR( ]GF,*# /KS9&BO?N.%#5KA*7=;LBM0U0$://>5UAH*W3$@_K8G])8
MG8^LI[WLF#W@8A<M;7@JG3D;^K,U!K&"W<#AZR(0S7S'GI2X:@8;G_U6"@DM
M]9ZE.2+7=0A1;KPC@R0/-PVE/),L +"^X.AGEWN#D1M:/\N\B*G>)*HR7U1A
M\C%M7RXU[=)Q%DQ]<.Y4-E[Z?C[XO<EX!_NE%ZP0] ,L(KDUM-E/2/6>7_K\
M412KUC?\%E-E$]?I^-;WI42\WJ89"RL(#RE\S+]%1:'4>791#H;ZMT^6?P*^
MLO0HD/$>=WDWC\HX;H(-)K%2LM?JKI9V,C66RJFFD:KL\=QUB'W'XV4R#$YM
M>)2YG\$3U$Z,%5DZ1O;9 ,YI]A(*F^">MB(_*A,.B'$;<DS["3F3';RZRFM1
MR]'5!#0>=;Q=455T;KZ%L&>F7MC,K"Y^"T.L.A73B(+/XOBS-RL%,E2J@X8_
M;4@]5'XAFD@[_(J.K$$"5H=-W<6Y.Z0HU_T07#/'#$V.AM(,'28$JI<''9,F
M0A"'M%1J?):,1#X%PQ*<FP26#%EAV=VI4J#40B<2UV@R-S7SE0X;UK[D\BF,
MO"'6W0PE-"-JL($^FJ76U@U9S=D4@:6K15M;<8ITL%G6(*>_4.,T>OFH5BR2
MXN)TZ7YS(IV-XV4;J4$[4T1A,Y-XJ9I=4PZS2KMN2=ZY7TD[]QNRSC;A#-_L
M;Y* _L@I*1"#MIBYH2<'RU"Q8Y' ' Q-%RBY$[P#;$TX4 +<=!XI&*[Z8\6"
MB0A&"^4:1T944-Y$!>%_2N)C@*WW/J MQ+ J)L@_"H9B*((II*AKQC?9PSJ?
M%6<*OJCYHI6965?8?-MV7Z*2PI80B@GJBT9X+ D15A#O2'DI/U*WUM2F8PHC
M)(SJ:@O&,6.VXK% 4<L<WQH;P%71X27&"1X.RQF"_5>_V]__41\ 9N!+>E3:
MPL)'4UAXU!86MH6%CPU:;/O*&7<K=L#N.CM@=Q,[X!V!^'RT(#Z/RQRX.P^]
M5Q<2XS8O29P&4A3!PZ82",UXB?\ZC1S4-Q,EEUQ.&KG5\K8Q=@%=B0LN$+:J
MPE!)W4_,72H96.R*B)C&TB1/=4+P%)[TITJ\CZH0%/2\') S17; V]<GB]4-
MW(,+QV]T*4A)"R\G+9<$$T#7V6'PQ<X I>'2VBG2(C+%W@WTK01:E!^"5@?&
MF+#T:K&@2\R2LJ I-2T4[JQ%UDD%^P(\98; [GB?*'H5FW1DP= JB_..H&]U
M[D%-MIM@'P2B;TN12HC],3E77.2J*#B)S&!//CA4Y/2RM5AQ4PWUJ#7LI ^D
MXYT4[/"S%"6IZQ8*(-TTH!XF\4G!"Y<\FYF9S.!P%,Z$Z?YRTSY"G5>8$^8%
ME?R@;L+E;BC=&USP-&G4+O1T>>[L0BK+\,GM8]2=+.1DF/B[#*)8@&UL01H_
MX*0Y-V-CCFA=+RY69,I40A/]K.0_<<W>8BU.K[OS=WX47/<AA3'V^J;O6=J3
M0ES,<(-&)?3;8;%#7V>H3G5_'M6D2-+I7GMR[^/\6G%8[54.J[VF4NF]30ZH
M]T@0?!&,%'@"KTT+Y",[INYC'!\00\) U3V-_N^/)Y\^>V=GVUX<_S#FX'YE
MA^TW[;#]S@8;C GM47_;(I._Y-3@ KKR#:$E^":[?N$@TK[7FAX.K3-D;LF\
MCP(808<J?]>!!M^63H=[7#"97B?3UJJM1>0 %S0E]]!\5]3]_2'(P^ _OM/*
MG<^G@S3VGEV<_..D\^P[$J3?-+E#*SUU_,FW:I"5Z"'TNQ0;W/<%KYF@86L1
MQ@,>NT-HKK'+J%H4L2B:(&P8Y, 4S"GL=$:K,BDI*EEEXR,[M :G!'^QU\IS
M*JAI.E]8N8].*@U4HD8,4\R!7/"!$-@(@=8$< 8OFRANU08MKD#K8%X5TV*#
M+/VBG\/>!=$%*O5=P<->:,S$#VFR\\FNOWL^M9O+M2B_KU;/U;:+3B^SH=-*
MRN.0E*?$=O4ZP@H%4.$?L==EWHI@'4C1!)8L/46FB.I*T.-4D"4,4L@(RCZY
M/1B[D\814V"NT9J"1,?KJB7 28BAN *K'DRI#/4C(;,>F@5PQ(1ZO9BZ:5 :
M*%V3S.QW>WWO.2+@=3N'^P[F7QT]CN)M^) ?=O=J$'<O:*SN+;M\RWZGV]WH
MED?[G</J+=TN@0 ;V:(91O%F3%-'/%%!/O'T&UKPQA0L$260B#3G]QN(:%.P
M2U*PQVT*MDW!/K84[%V%%2F&Y7WDIEPJGOY;%LPFCXBS\![2GHT93@1XGR()
M3.;45FJ>@ #;D4=$KP*V\J<RQI3*8,=P+[P1P%PB"*3VQ(SQXUU@.\M_J&J)
M'[E&AX(PTU.HZ9KS94%$MR74?;U8[T$EUGO0%.L]V"#6^W\_*2I/"__?FDCL
MC<HE*[O[&=&/=@_:LWG=V7S4;<_F]FQ^2KAKAQ5M==BDK0XWRDSI"HE&1N.<
M\L$EE:W2<7*2!/$\CS@D;++TI[HUF*[Y9)N);4]HFTRNCX. MV$FP^H,!S+#
M.&$>7"-N<4,?ML8<::"2R2<:U35302C$Y?_6/2S41[ 9.BR-:"C6!QHB8$LH
MI_Y#Q;FZHCS ^DH0X5)RWE>XXJBR!5&/=^(T_<((^F8$C.#.E5S2YX$=>KK(
MB NY&1\^=[\G\R:X*2DAJD:7>#%'+EP"%ZH3E]^Y R?3Y30"]4]9B5$CR.VY
M84XRR*]B<R4*>RY 3*B_(Z2>DTO%N0F^DAZ&-5T$2>^0&3!4!"+&2 >VPVDE
ME5 9(]1@S(.9*W .P@CY"Q0A/<LB^93&T&,BCB8R WU-6,KK8<&^4?*DQ$8C
MJLDHS"<]_ 0[JRT0^.JE=YMLMRIX>3>*&IOB$!/%:U6>.XY3,#^"R\"[&!)(
M.>RVLV38P41>8 #:P$9 7)1!E#J@+]K]X3U9[Q'A+JMIQ$HERC50D[A !28)
MR8)D<KSL$F&5& T I9^,.4>)G,1_@A4W=<A-X2(52,GAYXO3'=W[H691K&;Y
MG >0I-A5F/.[X3",!H%7PKX1PN2AF_9>TJ9DQVR:7KH?!+;MC.##HD1OS$%&
M<59$SP)-PNC=!([ JO";7A%N"F^V%9[>MJ MG%/U8\#$Q,%,E; H7IB58RP)
M#>G4])$=MAQ%,39>7P4YOQZ[SP9@4%FH?]W'BHTW*0H'R:9N-UPJ>*:&\B,1
MQ>S:>R,5'"$!25^I,$-.5,+,I<DXK: ?,M@AC<.,G/;34IFG_#Y1Z1(BV5JF
MN/MMZ-ZFV THJ0%64D8): (ZZJ76U>HQVJX)# B,'F9<@KE/5)FEH._H"E)=
MQ!>A]8E@WL,:(WT%&AI2O;MLR?Q&'>4+%:(I3UBG+5BI6;Q 4JO8.4V\0F@%
ME4GTGU*QQJ.>VI^,G('951 <G_,^HRC+<=YV&,9>6F"EN1OW 4GJNE'Q:]0+
MZ!U@,D6H"G2*Y(S8,(L9\,%BFP7,RAQ1Y3.BB$9C4MK/Q>XY.1,SYP72PE7Y
M10Q9" &OH;4.>H'KPFF!L' =:2<T"0B^*,*]19>&K!U[_/"4F&OB4XN>JI()
M1DO%]B42"G@AU-J8Y'*81 *^HX%G",)+^T4J3X$)S0L!-A2OS7V9SG>4VUV7
MS*3>@^(J1;-CAOS.P9#4/<X=0^NQ3G<6X.?[?06C@G8/:N^STVSD<6,H1ZK^
M^JS[S,.0SPPW33(VO^>S8*A_;PH55C1==_950C^_%(,TG',<Y9?"!,R(O@U-
M.%GP(IV96-$O15A_0G781;CNRN9.]"5'_>V%D/[W_SH^.#SFB5TYS* LTH<;
M9MIDK8CJ<0T61!\$[>78+61^N_C+E'[PIFFLAB4QLI/AH T5LH &BMUTM#YT
M.Y;8-IN9-$MMZ9?X26VRX:?LU?_'T3DC>O CBG@K[=^UM%<:\$!.PR@8)VF^
M6O@OP E]_54DG\VLJV#NN(ULH\/1*ZA/R\686N@D8^?E 7;M4_=<G*9B*5]'
MC+<Z0G O?MD27$+CJ["-)1J+G&-94_H8/1GO^=MW'TY>5)UF(AZO^LS?["N3
M?1P()S1"W@<#A*%(L_POWJP<Q%$^044K'AJ9&"$X^PF;U"&']*C,.>8B63*8
M,; .X_>(=3[Y0J$Z7AWR$TC&Y[G&(_(]^U?%_'TF-$R?1,D(YJ72]H?=IRN<
MAZNFSD3K+,)U63G#%9C.XQ3):B,NS1*P'E @>_LO#SWP ]("O0&P5!4(TW"2
M8E*)NE=GB(WV7*Y,3DXGGUYHS"!F>L,)PUG%L\:,$,ZG*1Y/4X4Y[BBGN1(R
MK%4N;,?[:%8#-O7.@O,\8E1NC)I?"2,=*'?P&S(&[+!KDM2D",1 DX[5$2OY
M/$,]E*OH3\)#%Q] EN$\<8KJ#W11/?@RE.JD,!>QNKV+AM3O>C+.E. .X=?I
M(?\,A+78(:RN. D,(#]%GEK8= PU+5!U]2A X_G=&.UZ6!=\N\( &W:N@Q=/
MS<)7)$&*B4\OF3R:> A3)'2/=#B=^WMUMH$LKDJXAC@YDXB;Q9@U\4V)8"X^
M149!L46![YWE6: 8UOX47, PH :+54/1D<2I*B9I2.YSJ?F-KS4.>NA_@;>9
M+#Q3R WYV;J=TJ&;9&9 YQP7#VPA9K5B$NC)OG<ZB1*8!WYY=I/-]-QP7!P[
M61S=YN.IKP<=#$GJ\"!2C0X23R=S+TOG<#R0;8*_$@RXIZE', .4*">I1]3D
M(U,FRL&_4.7#+!J@]I/UQA$TO"?A$C2\!>71^'(AM# /=+@:78\"T>TPL4A'
MF@0H2JGZKVJ<U0Z"--+@06:/MTNEKS$YKAR.FX0IHV'<E>'KE_8%/DW!@# F
M%#%'<4(XWKF7!<G80"* *C[&5^IW][J6PE.60&8"@4"3W(J'/@9,OSW)*W%+
M\@ ZWFF:"44$/0D6"%'=8"ZHK=["?A/4 'Z= 8Y'=DUR_5+RI>\E%GL];$U*
MP9WJ4_XSA[Q="Z%:YT!%#C;,_ORU$^Q^L3Z!]V0F^3H![\85L6PXPG"!QNM5
MBGLK3*?$_SZ+P1H<I#M"KH*&^T).0W(4>.B@A5[1^57S"]X]W"G2G2EH!P*
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MEC@:''A"QQ$C,A/2KJ83]JVIR#35H('A<1C22J=*<_JM?V\:V! -(#BJ\97
M9Q-F8F,,$*>9>16$ X:[)^10H9$35<"ZBTF:NV_N^+>!YN46Y&-]J#L Q!2X
M0XK3(&]X[B0"JRVCK8!OGT4*%POOA7*3PLP+:6=]IJ\<TE0R#-&<2X4 %02(
M;9AAE W+*6(2#G&"71L(EN-J$L%8D7Z&/J$7)_,'EAI?_-]E.):7&Z0E+^LP
MR#*:59Q*Y:PJ#=I96!$(,&$XO!6$Z"^#*QMD)K)5HSD]80?:Y?H-(Y"HS$2B
M*NO K\E7D.7DS%%*DL+4$VT(J1I"JKB6SLZ';3749F>H\F$6#9A)^P-L(/'0
MG/CUNFTXF\%>(-K=.%=7L-!"B@DR=I(DN-"?2$7@-GB+,MCK[OS=$+A6&($Y
MNK(X4O2IRAQ]$K@\1<J:RS2^9(L>=B9*"4;8<9/:0,!7(J,F;@ATEMFI<.?$
M$7N\RLC;@%E<86D"!@YG*W^J0$&$J+XJNM'>1>_7DET]C.;,M5_3]%;"A.L.
M*0)E9DEPG2U<Y</U1>/#[>*Y7YU&Y4R;65R>-EQPO&"*_LI0'\VH"&B+H?H(
M=9^KJ% ]?KOT9KMI3;@XQ'O>ART!:LODL7*8[XBMPP:P.3X#]M&0 A*XN4_9
MC,! C 0S*%Y%:H9THSZFF>.##T%S6X?TP>$$J=Z9K\DHEHP!E9S):D"1EK1]
MB$[;U04<9M?VE\HI[0=;S1"X.IL2;(HT+S-%)!6L _1%,4:6Z5S%4=#P\=2L
M,YC0F\/>C6!/,'7#@':)#IA*;!)&5C%"YD8;AFQVZ-<%!96AW1 86V%N(B[F
M*S2XCG?1H)1Q/&*8TOQ34(]CF1S/,58R#Y6?0(?*1+$IE9AIX9O5A@QOQZ$^
MYQS(E&=CMS8,5ETI_(VGCX"+FY:>YV(* FG3QL16I*U>G&I0G/P29+-'R0["
M&_.,@Q6&*R&/P:,C5W''^U4- V'-*A-)_Y -5DW%Y$KG:'Q>!^0\P7?3+\34
M&&0+LN6-MB&/);@,HIA7GL]C#$5S0L7EE+-?&"@TVW/[Q:H<Z.BCRNMR:<3"
M&3S)MT1^K['3)*/.6PM/7[B-.:4QAZITDBI*)FQ$5N>OLJI-S\ES3CE96<''
M#93AL8_GCH5*F-I.J@B6DR8),_MHYL)@T-;R>GT]KE/7SGIK]O6%M;-P\^B$
MF#O_E+UW]=EV,@NUAW1[2*\<IJEY.94B%KCX(\9#HI#W]XEH,O*R.9U#H0,*
M(:3F@%X:<-?%,4(#9*Z+$GB7HC3&M1@)X,!DX0YF*N;>):BD-.,#'36T$PT
MK6H#+4/TOV,^63Z)5IL%<WMIM5IB728MH#H?-$="X33";W.42,^*T>^H'^S!
MJH,<3J0B)R(F+.YP;'M24B&<L\%PSH<IW;L2HI%4'1WH836F<X7'51#/_Q3V
M)4HSC>2\U%DS&U^!JR@M1UZ[FZS%T%!!P9C+-&*N-2E@D<.25H[R7?0:CL7
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MZ@+Q!.+=7%9B&$Q):]M@@NJ>T %@=,M1E9,)PY0EFN%4EPSGQG4/O9Y_<'
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MI(/L]6>KKY-H$%%?! RQ2%T?G:'=4FP$#I%93@IP/E( ACF\[6AI(3!9+&Q
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M$SUO97UC67=%C.O:<BXO<&283X5)$"XOO^?ZFO[10F'.,K19(7["('%>$!N
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M=H.GWE759?3JM<KAX)NYQSQ;E 8]88N7NA:9$,L&SV0,>Y41FA.@&*,I]@2
M!336&0H*A3.0Z-ATG&F7*X^FY2B*@RD7D@>7P>NO%(4(::X&C$.*)2+86R]V
MV0:&#3GO*P?6-"[PO"QP0X@Q1H4MSL&PJ 5 .][KS9 S_5H\D2QC]O88L-@;
M1I=13/U&5#T_4PG8=G/!B#!8F-086Q34X5\=-3AP#1%,AH>B@$PR3JF]^KJ3
MT;!(%HF05ZKZ=N)%BD&-G\31%_C;)$TIKTJQ(MO%G)8%-?)(F O,Q@'^W?<F
MNF<%S+PHMZ[G'-,U>41=S?H)^MG4C$XMX@'U?RQ$TIQV:'L_[60[GC\Y'12
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MCQ-K]MMM;:[:U#[,KQN^57</7FCW:!.5823DJ+%^89-SZ@Z)O<Q_Q\:RTG;
MSO%*F_A&AP38PV02WO+Q<,>2></)%XOLL+LB<W(?:_CLU:D4>C*5ZL^W/N/M
M7;Z7N]R^?MQBG=A MJ(WU#+LV\:MI5VS'Z]K""Q;P1O?<-$#>?;JAV5W[]<
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MVMM7(/-@D-FKYZ $Y8+,]ME%OR[7F_ML3"=*^<>K/9%[:=VTJZ[,E%8J)['
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MN*QG_8MV>"#J$""JO) [%PM<WT_8F=^[CNTH!B[M"YYKU@"9KMQJ%E"HI)(
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M$Z>90HV:U,M.S%WLE'9GGXI:TG9LZG7E9KLB#9O6=)$]LF3%TZ::/.[^3Y0
MQ)U_QJ[)3=$UN0K>PD%,/[A]W=KGUC6Y(?=:';G3$1<[!3_G/P\#U=WZ7E"]
MU[ZSXD9>8#D6RXW,6*Y"/^5.HR'7VY6\[A'@+K_84+>9&=T5::[<;X$B4AGF
M?6QF>;6AG8CLUGID%]5IN=F3.ZU*\EYQU2XZ+8OQQ?AB?#&^&%^,?^#CBUL
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M7HDM^E^F'D4T>!3;D^OVG)39M[XSUH-KC:<*EE,P)]+<0J//6=#+>_*WJ]&
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M)J=STY=>7C)/2PY!84S@<*Q/?%'1G)MYH;,^$4+C069SQ5B@]\8P'9C",1%
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M,2]^_/]^ZG::O4$5Z V!M%&Q]X+%*33\8'$.%0^&&TCT7!J"=J>AS.3&A>2
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M+9DG9_!]IL/27 I#NE-L5?D;.-2+DGH?VI%!_P\C.CRO5*C5'J9:*!:=)ZT
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MBP[VYEE [-U6O0'J)0'DS^&WCN62LS4[O[?'YI0N?0OW, AVHL"3\/^I#9;
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M9 H:'BH^[.O\2[R>-YHKRLL+*.E,T0I9+]*[)W?D;#2.>)W*I 6W??MI:39
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MG::SP3$C?6KJ:B4(LR77=XC/%^*@,-C%=>O:RO4C8"=L@ZA$N'$M.'?7(M&
M$2$5,I!G0MWG5.3IGP5\?@,$A&7V2Z/.?F^U4KH0"97#7%QGK6U$0K4PU]UG
M1ZY*6 C9LAD=<\X"L/QW+%9N.?*>]V0_PC+@1U3"1():XP7*NAVE_8MLQW(Y
M# T,-GP!O&QG0V3: ?HD])_&ZN/M,WTXEQ,H,&^^RD^7R,AVO4D/8_/6>.#(
M+(V5=;)+SX,DD++G%P2Z;P+=->Z@: *=:#^(6OLOL<QEVJ05Z9N?*DJ@)V67
MKB])P)HBQ:<S5-PZK7X042LAB*%H8=DYNVBVY69,VME)FYL' **$\(02-"X
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M. &;.L5IM?BJ2Y+CB-Q()/ZDTBG;$C^<\V5PS$-#I7T02N0 K;T6M,M2.EG
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M<#Q4R7+G,"0L$O;S7 HY$# NT1P!:2@\,'$.0RNA0E0!4!)Q$G>9DSM.'MQ
MP8T!"JBV&/.LO'#EC#V CYA:,S5DFJ#GKN#E9T^9??$ZNS(5EY$G>AL4%@J[
MQFZ@ 6N,&^"W@=3/I:&O(;.S8:_@3(8&R# =C/2Y:3D(AQM8>7)$-@5"[3<Y
M8B]JB?+:,)G UDW I07G_B]@.+7?#/,-Q 11;-, 4%#CP:+%V%4RT?"MT8).
M HA%,+EV9$[VB)LF=MC,!*!'PV0YMX-_^41#-TSB>\5?:0[&T0(IXF9QPE%<
M!R2!HXTY^223K+>73[6$]3$-!>;4B<VH%WB/IL/TE-+A+<D "91Z(,HG--S
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M@<A'3IV?I1?D ,CRU&!S@)SSU$#TE4U-RT&[#:U_]%6'IEW!J71PZJO$W@\
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MFM*!YI%Z;U2 *1U@MD\SNU7Y6B>B\KWSW.DF89;J M',Z0)Q&#1V:""]=RN
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MFEQL,Z!7 )-WGI3ZOW^';O!38N_\P\4G. O<&1]QKCXA_$]\)KW8W[7C4M>
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MP-H?VB&R'GHS;/,;"XP9HA\^%D0;^]]_7+2:YS_A"Z=3(#,?L;UNO.,O,L+
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MRW7I?"\I<JN60#2:M48C/5,"$9D(YHRG\&:E'$IJ2Z4!2.I?0@UPM;WZ7C(
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MKH[M#N;L58,YBTU\7C3FN9KP7,V.W26*5A.>CQ&DNY[P7)(\##D.^+RQY7'
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M-P,\G5L3] >^R ^!==+>:OBG7)"XJBIB!](:,B\PD<3,0*(T)RQ\R+899_#
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MLT4<]@"L""Q)=L8UKVBKXNWR!NYX(_I<,#3/:7<OS5=%^K,L\107>UE;O$S
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MIQ[QQSO78T/33Y-/1B TAWINOL\(V?#?S36'Z33JZ49#^JBJ'-0%59Z0]0P
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MFOX,X&.A)Q@#0F"'F /;\B=2XYJ:L ;\'_T] M@AG+.717K,6CJY[ 2Q!H@
MZ2";914^UJ)T"KXF7X36?(('!Y(S#8%L@*I,L$,"/#5P9>)L@G:"@)%;_ YO
MQB5KX(OW8#K6?TT^J5$PQWN/F:,G<YZDN*LO=U]J2*4?Y#&$1G&&'SQX1$=@
MATT9^MN,EZU&LQW]_:HBAI@ +8X+R+HDAP76X\,Z8JZRYSY:(V3LIN\Z%/4
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MFC1_N*5;GHG6'\&UH_G"O2XDZ_^P["EWLA07]:?""6XM!KACO/?,1_C7FCS
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M(DF^B-N>(L,*GQ%:E>BDJ3Y6CI0,#94G>?8RWZY1B++.N&-X:$19&PM,M"M
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M^KXJ]:4V9TI]\3(R5 M.9 GR0T;9+>< ),-^B+ $?>F3)-ZS/M+Y+VR+W@%
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MA0M**]VT^@^G4>&HI86T<E<@2_%'35P4Z5.%4_Q39>2-S?/_!U!+ P04
M" "(@F-:(OO@@W=B  #X;0  "P   '-L:61E,#,N:G!G[+MU5)S-LB\\!)=
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ME<ZP#!PFD+ I.=:ISO] ^P>R_QHPW_]/R/X)['_C6@"@0$.]3AXT.D 8</M
MF_4-Z;]"#%U?F86BA:C-$<MU=!?W366IU:H-2/A7;?AN^RS\UI=6SU4/T>\L
M#E4;SCJFEOIOYS<^VT=\;0O$*TLO?DR98[])^GV;Q- I@+5I[?AK]6WI->QX
MVWQVI].0HS/5+.&)E]>/,6A2H]MRR7.:'\[%>-8XXA/D#;Z6X!K![>O!SC?0
M$ZY@CRP5*CP-"_/BU%2LG4\;"^F!A1O"1Q7,6K='0B()"-WI*Q_"<;#JU]NQ
M+-4'W.U+S>/>:8!^F>#4<>_;XW4,X!+NXN7LC3!4%N:YJ*C' L\=;H_.#M7Q
M"='O7,R_6]*V*#L4@<Q<(J8$BZ>IT3AS?%<4HOE(F#_;($FN;;9^WA\D>4='
M4\F$M08!_)YR4]^0\#&VW'@KL:F5MNF2Z^BRR+0=>EGKX&[ LQ@SRJ=>=V!P
M7)/<,S58NN[?#=L$W[GXL%'D-&UMVB"ASC2AQPKJRU_\)B!><I<L>JX0S^1I
M5W(&-U8_$M%W5;;;ZS$6G'7NZL=T=9_1&BZ&(3I@9QCRH)!-U;'7VJ=;F]VE
M.<^F*LLE&!VRY92.HV-!+#33PLV9HICK7^+H7K059X(<%?%1ZJDXK?ZNFN:)
MC!M_N3>NU/4Y:\&[M(2-9*4=ES*JSV- ,7GQH5%[[^J!H:>62+X;)QVKA82X
M-C<OV:683B5D<SCDHT@?10,%C+HX3O>M7N!#6;.[(:966JK#;+0F(BI*\S?%
M%%-XWJ>WRIE4EI;V=-D3>T5)VG/J?+(YM^,YW$K=Y8R24@C=1J'ITF>G;YX$
MIYY,34M6]2SP4W!8+=@_X?EZT4)'VHF,T<S^I,M+CJD-V)HI\=S&VDQ[?[X]
MYO]$LT'K/) [;31^ZI_;C'V_LR2I2OE8N'6%-;$'?F>[?8Y5%K;QEGEVU/)W
MDHPF$_.L,Y6$-!<?%]W@]YGNO,0]3/5XL]7WSJOH.HA.J?#R:<.C!A<@9;$F
M)%1N3$'ZE^S">="3286O)8 &'S1H^[8K+(3;V*OR(BTPK285C\9$R.E&$"GD
M(OZNN&Q@_?$48\%-AT0D.)$TM<R>C'33D5KHQ&TS5Z_M+JJPTW'=TU(0@V$H
MS&%H3"/..UD/X!/-6N-,>8/Y_+UG- *8U; *YS;XJ#?C[$V@/H71I3R%)_8#
ML\V Q6K-[^YK[;R:PX\?U73\_IB*2BQ9(;2 _P<$'33C]:% ]TEKXNDCF?_5
M$ B1-*$Y])3__.+V\5?38;+=@G?W._)"MWD5J%=;U<R*'&U61*4H!LC.4-O2
M89B]&,=%GHLI%V<$UNN)+>I7'J"5#MJ0S[F?*)ML<JV-<P\B@7D]9DS7>(CA
MLQ\!S#@PW +G(QZU6/GUL1! 6<X%Q9" \#K:^[TTF&D.EZD:R\5"3O@$H)O,
M)P'9\(\D3EOV:;'P_FV$%HIN(;<*S155XR6F5=$S1U;,^(IT]KY] BBF5UB'
M*HK'V^4)#A3='.W^"VUI7Z;RS^H#;+/"/W/EVS,F;T4(CI.T1ERNM,8=C(U-
M[E2%J->M(@93!JUG]W<PG-#/8+$7TS57%N2XK3Z1M@G-@JN=!,$*5?' J9.>
MCC94K0W]G,URWDY!L+9ZB44=C=*DS5'<!L@DC3K,Q#^DQ2@<%WU)=9 V59W!
M_4T(,%S'S7(C=C28)L#&9.+42N>SGFV#P>21X/TNSVGHXVQ<[1J3S2]A>-D,
M[[0';RAI#E<V=X///J/>[&E"L0<<JI[N+J);P"0=-\>>!]N(<H%/68O[U6%*
MDSRF.._9?K@"C$+1$MX(X_=4W>F5DP1.FE</6*-66A<32<S4GX3+ 3K[/J^]
MQ![5*!0/6#]K\*)OYW>M<,VV>*ZOOK/D\G"NP2:86:]+J?PH<M]X&.V!FE#R
M5EXT4/5NI4DG;-K1W/4#=C$8Q;I13;*3A(L_&OA\K;NIR0<,<)*%LPRN:65;
MF07Y)>IR;M^/Z7V^*0IS:3M$[)@MQQVO00M^P8Y0J)ED='*T=7:EZHAV=V6+
M$W0C=8*N]13$2J'GH2[U_+GI. C_R[+Q*\D!G_5L)F;2]O/OMC@'M#@C>/_K
M/IH49\X/W[W0P<;E(N[NZR2HYL$V.24WD_T7B2P?&48!-YP'*JI\E^;YT]I!
MY[;OO 3/:8)LMH!GNX%6-FGZ7>K5J1.QCBE')]Z'^:UG7[,_='L2Z2I13:Y-
M$H^ZST, ;L.J/OS>E[K^XJ@M:3[]$:DV)C.OL>)1%FQ>M*>NA2(>ZFJ_9.*.
MV2"D$5%M=+O'KC,2X<\)*C5</RG'5$P6Y)9#=M"\J8J+^(;3KG5H= =>IW/^
M<(PH(*P_)WX;S^ILJ^WTS) #@/K& JM]F->Z*MPM331*T=6&-WUU&JQ+/7MB
M&*IQ@(A;;QR)S?]Q%&AQO)=5\3,E==Y<@S8K).IU.7^$_3>$MSI_"[["3'ZY
MTY(_.AQ[0)*' +R8S!6U(0#5_-W;]DNNF\N+Q_A[O/;YN?0KS/17/N'J<N$]
M.N'GL]I<<9+_8$*S%?[0"(Z2(&!(6(J?IHHTQ*6G!Y/KW=^!^U6N%*\MOH(]
M(0 VPD57(V*Q]LLS"" RNS_^Y2O)!98@IK=6>OH*!#"L/>SW'[]ANF-  &-=
M+Z+Y61'%RI>/J_>!['2<J0,&XD\9[Z?,-F*.U(6OT.-?[K$\0O9E<XV,]GL@
M@*ZJB-]EX#V*#\\7M(]88\\PQA! F[AN5CH[3G7$U3SP?XW!+#:U*T%LC_UV
MI**Z0+MC>&/_DLQP_T?AT(MHQ*O)]^!^U1 ZG8A8K*=@\.XV!$ &C/KP]-2^
M1=^#J1-(_T_>@F5SUZE1HQ^:#3YV<#UAD@^76M/*2F:\BH'//PK!XYW.$,#7
MF"?:EY[I]CW])@B@7>H%JU%<O2;^*M(A&^T11PD"R/0]?'FFN5/\ZP &AQ#!
MG/8<OUA<4['I<PB XNUO"*!.Z@5S[(A)^26 O_WQ*GT==*5T$_T236>F#_YB
MD7[%N@P!K.9  $C"%;7R#[@G$,#I)-C?=@+X1]G)?X%'>X?9B[MD6*5G8W'/
MCA<9Q50XH4!X'7.N?<]Y&GQ&_.&LK"ED4%')U>2L1^6[NVK;]@N0 @) R&N%
M #Z594, W\[!_B1G(9:K5WP'PG=H.'?J.N(?3$GVJ]H:U8<@ *B(>\*()_*D
MVV?4IH@7Z)X73/ ONG+P^&$!!+ FH+>NXXSIR0,!R ;.T=^#UUA?02=# -]=
M-5X]5'3[\M3WAY^_!#P^\QI$7PU?,>S3EC+W7#>UZ=VA@/MW((!UHEGA/8M7
M:]I?![]:$GY(<L6I^PHX 0+XU21-VXQ6.G,! 708O@"Y7^T^J7RU6_7T^3[B
MB5[#B4B-S?4N^N+SU;!4W[Y,Z5TFA[7TE)PL&P2@T-04MB5YC(6(E## GPAN
M8:!0N4O-VJM'7[3@NG6YI9Y>&D*^]UR#YE$CN#<,?[-;4*R04B?68G7C\JI+
M_9X _'LAXAG^I/UTX=4]?_FN-MEBGFNAI;T0.LKQJ!%B$WUA]NT^ $B_A=8]
MFWS8).:XT/&0&SWDDED:.9J9!Y^IF)[@3<<SP*^AIY4>O]3>7_P<]NJY\:^O
MT9/_&CU_Z:C&;+S%LS&MXZL-2H-336*W2\YFM(-&.8_^N#M;VN=JS5C=0]0M
M3]7XQE@=IE>R_^U^G\#D-%CS'U*'7GJGP7O"?\)PZHG^E_E<2 AJ,?\[7BJ<
M)/%SZH#9@&/G5(%%1(%LED99GS.YI5V\#AHLK-N0&D%A*?R4IM1LD&3X&9M<
M>OL"(AEO%S$?DAS3OH$NN;RG]]#3#Q+]9@@@(V7U]M?$#7+[ ^+(GRRC5G6N
M]L,K[HLS@489\P0QOZ:)>/R.0H?UJ*,O3R&S%S 75/J0>]S:TQ,JH7F<E8H2
M!!@CC8KH>Q-?[>U_O+U]2ZY7H?,*7<[V<=WL$7;U&>8U%-JPL^71]T8XN$X+
MYWN<:7'K/;]C&!5868]IO[,(3]Y,1[7P\%CI*];J0E[B;/+.,A(=S<<%I#T#
M*^$BC![AZ[_J.7R0S=,=()Z>V0W=/871*O_;XM1B:#8_H:D/V:"CKJ>G#M/&
MCJ"@L#N.ZA^155IK^EGY7D;F%6RH\)&.S$L <OF?I0J\8<Y]C3;8N><'^;/2
M0;I_!'KL=5*:GL-KG/_[/) "SNLZY!1X76[B/$S,Y#X4T0]2.A+(5=^T<B^H
M((#T^"=_>7%@1> _TN? 2#UX_!\95.\U@[*!_V<"_8(F_+HN$AI_*XIC59*)
M8RI _:?D^.XN7J7%,J#J['(,1GD $+DBD1S"JF3G3A@2_VBI]VKGZZ:P]HN^
MW?3#?I;[Q(2B]NG-;#L$(-H( 71^5P%;6T( 5PSI3[CBP&KPE,AP>$C(+KBN
M%@)XP!I[02'/_JL,P>27)%0C)Q5U_N?:\M<Y+ .??<$B6=2" )Z1=B$ .'3%
MH]6K<4>*K*S&U>-2\(N_(P3@AU#PLC ' >RI"]^QA$280 !Y?HE$6%BC$,!?
M5/_5)$_N9P["_KV",M>_ZA;^BTWS[?L9.T!Q<<?VO^K^BTW$KY$J"\_&1\^0
M^E?E?['IQO;!C#?JO^N-8@_J:N:BN0EMC=J4&T>$G-#!*J-8% 2*\%!:.W-M
MS!C.O:P07]\0V@PTYKO8YW2:X)KZIF2YR$700-OLA4Q0=4M8"3ZE[4D:0_HT
M]?@ULF4%)Q/U_/8$:BJA=#T&HX.[O\_2Q%;9RK/E7.VRRUS7S9N+8RHGYG>4
M#(T12G+LXP"I&[BLQKE9AGLFIB/F<GP&YP87/Y,WK/JLC3XTVP)(^_X2635/
MGU.<!<I.+B5>)I)>IC0FMXS: TX(--<3Q-:MG_+0@D:GHB5)\?,+1PP+]#2'
MGNNS/J&0F-ACU;:<Y<@2^B>JBIDZI)QIG'DZZC8+A]3T&TW^Y(@NR_=#B2I3
M55F# W^4H7^6%;CSI? 4>#>_+$_4,@1SV5TT1)!"B#6Z ;<>#0>_9EY4ZO32
MMNYPGR;WX0J7(Q4HU]PZ><(XS^R57.S)NW*_ %QIO =H$YK&I&;G6NSIDH^G
M=W#7::4UD,YR!FU'7RC:4BMIXI LOZ#7&"ZT<BO,4%1$KZ"CU.-PPP1E!+T=
M\8EVD 2@*7E&:(4(NO0=#3!-9_4D?<*)=1&S;G$F3"$IH%1R9JY[ J^AQ2W+
MXTYFC#,I#2\=++CLE1^;QD(U)1J%8]D_F=\&V^  H)8FZ*;(0VRK+?$9C]GT
M1+:UNX3Z#=-D#P:"7L[V).!G6UL.DCQ6GH/+2_TG]A%C7:_&/N_F<Z9:;_R0
M>=3,GSHN.^EVU3-&)M1@7OQD9$,*V_G8!WV)]W6^U0H"*(]T8-X-75@R/_5T
M-J7.S =:Z,DO>YW)[KRLO[</W-JEDMRUX3U4H]2A!SF:/C?G4G*=K_SP_.EK
MSSDDAPO%?7('[<K#E((:>_Q@DHU:;!!O!Z]J8D2_B5)2HNIS"X.NLG/^ML11
M"L5>5F!(>#Z*7.%SM/62JH/]17C.&M+7^57;PQ,<FL3MM]3?)K5EGVOS\7*F
M&6V4/L$L?K<C9RCS:LLIUO>\#!EICI"-D9&1Y+3&E(&YU15[M,%J:4QW8Q3(
M*@WW1R!=\_K56B?HT@^JJ2]QNHB^9XS_3K8<>N88@+M+FE3Q4)9*M* EY6U5
MCQ86Q5&$5ST%+; 37V>9?WV+%C/<<Y;7;%XB..U2SQ7/8!-9F(3IY(ZZA'$P
M"-@B!,@3QT[.VLTY#5"8,YV6FJH8J;..?F?>_"8U]NJX6I$O&]X,"E4XE3IB
M=7FL-(F4(0T$(1?L4?VG&E)<)U'FR9BJ\+-7!=W\UPR<EQVL)LX$G3PPCOUC
M6$RY3^K12]T^<2!SKT+T7@0>&)),F'<65H.-%B&T.7]+G2K*FE-&C3)&TTQ)
MIH^5P2+494+'@2;<+LN3C4S8OS9?T!%0X[&BY1:WWC)J\M]RCZ1KWV:@!E][
M\_%WFMW>##G("623+J=_]IAFLXQ3L*3YG*828HC/AZ,O,-(=BO956&N+R4CE
M;"[&WC&KY O7TB<.9I-+X2"6Y88VQZG"?1"^)75B<6]2ZN!]M/DXO3S/_ X;
M]O)<]MLNBE* Q< &,K+E8S*H<:..Q:I+AE3A,<#M0;6OK3[LFWN42K?)BH:A
M?I^P') S++?'U'W#VN!<":^^QZ:0&=H8*:;SBG-$FYPI/!, $">*R\3X8"S"
M]PV^(L/4U;I(0U?N;%&WDZ/P-IH7BCS1M!BTM,]BP<92'Z"/<(F+@F$'YVW)
MK5I35X-/ >HBI&;HSQ8-@9LA]6T7Y5?#]D/6ZLG1/1BMYU(B#9\^_J4E%5-/
MD<DTY;[GMLF!L)]S#L,Z5B"^U<@%8G,0\EY)_SP3)J.8+(]T:#(E)JGTZR,"
MY1H*<:ME3$.TR$UQ, 4BUGBRE7_?6)VJ(+\^M,[;Z^O<WL(O: N9%PJU7=P)
M+-)GV<+*Z;^:<J6H:UZB.I$NHF.7T^+NZQ\T%K,BE>;H5C 5-?%OFI^# 9%:
MM5/$G^T;4.'+T"P*>@;F$6MBYV/6"UU^ZZ(]!+]6&WNSA3@]20P65>:&2M]7
M):1;!)YR4%)2]/4=9ZN>N.V.\Y=:HA)2RT\TLVGX$7]N?<7J%\OKTHL_4CB<
M! T(3B_TU"Z)=3(:@[^AQ0;S(-='\\V95LLVIRS= +/-=:DG.7MCG5HED.M^
M$'2;1J4%IJT\TW.?FP03Y:C+%WVLD+&S-HR,"?A)B+D_Q]ES1[^W>LBM5;J<
MVQ.["2IMP3:9V A9F$<;; Z"2J81<"HA.$59M= EFZNIAOF1#[I_\$_Q1YUM
MB%6WF1J/_/35R1-W95@PN_((^R&W=&9[)K?ED*HGFWY)HG'8*/0;&*F"BB:#
MNH48I..R*U\_?<I49B@K8?GC1X%78D). S+V=FCQ+I*=/"#-8OLX/P2D5HW#
MOEP[V6G!Q R#4:E& N;7($\_M1T%2H/5=;H6V'\?78-T)'AU1YU3R6(S(_.^
MJNOBR3<44ROQ^0K5;B8)II5:ELL[NF-MFE^LZN;6V%$P@(:7@H/66&Q$8SHV
M:MI(F$;B,IUM;FY+T2)S3\JP->J%3D*C,9 WB\EZ/A?D%ND7$4V_L(Q;U_I/
MTLPR44SC^F,?00!<\B)[:'66HG-*OM?YK^NXMSZRAQ;IJSH1D+S%53O\ NV]
M;A@W<%IK8^?8V!+T@_:$\82 XC;-5N,.9K,2BV?*UID$LP2GTH+D2XQFLSG+
M)'W",(7ML/#W*)^%XM\2BX$UII7W87O>?*J>(Q*K\E5)%Q?&O@M8RY3E$\!6
MM]2ZQ%+F,),O$2K<]4FR1^I"AOU2^F"G?!JDCX1.A=<3CAO(UN(Q\M/#4MD@
M2DM&-NK].)%FY"6?)$'?MO5C#D&U#SAFCN0"'C_%C:+(154#=L$-V12%I1&L
M#6N74R'GS:U"%TPNDADUS9:2SMZ"F3#\M.+R";Z.'8+RNYIDG/7I"JG6SI)&
MC16M4AL7.Z0R,W W-)X>6  73$^8FR_'>*>ZAAXD@\4K%BX+WBGU\?'HG=9(
M)]&:J%CB;JTWP>ZP=476V3.NG_*TM$$&YG(V5= 5NW&]#OQ&YSKU836_:\OA
M==QOQAP=88NE8 PI[W-94[,+KVX+;^@X"SPEG.K;Z"9J=FI!RW(KT"[0'XDJ
M6PCU'U&!-)@WY]3128-[QP4=G-B$H+C[)E/BQ#Z>0UW#\H65\@7U(QQU>*5Q
MLLIZ5E$]H\X U?;&:<(4ITR.9U$F5:?\F@;+[+)/!=X%$I]UI7NA^!],?5EG
MBW_W=A[C'6ZH"4()2PM,]<&GQ6ZW<58T3K=\<CDD.NS!#J3XM%5=E-@5W>Y:
M[*G&.9)7;@Y[  J3/[K%]PZ=2V]QN*A[/2I:,WZ]U\UP5"J@KD<S\]3\&=Y(
MHC5V-F4SZR7I;:L, 8CU:<O[4@5SKF( +>*C-$OB7L2XC6^S[DU#>?N)^Y*.
M6B@7:X7121Z\Y9_?$XFM#^$\NS!CM$1-O];=@S:8BN( _8,%E*;16FO&6S2L
MV!K4=Z)W+E$ORFFLWQ))SB@TD]3"RO>J*\,99%KKS$TQ(^P&77HOK$P(Y.1F
MM3<;."<L'GK" PUO1D25,?EGV# K!VY(TBM@IKG32*NK6CS5P@\T*8)-8OI]
M<A"^1R*2@JO ]!/2:K4U5+F.R?)08U1AP^\/,"A*2USJ2I'7OL =#[.N*,G!
MZ]-[IJ,><-]&Z8R9&UH7!(9! #4E.T[.T#;;QGVG?&P7]G[C:L=]035[;[#<
M;;A%F84GLLRYNCUX.]:(OS9P#+3(YXEMP<=IS"AN)=$F3G+:QS)VV$>*/#BJ
MCK!J4>)HR643/:?EPO:W-M2SD85[2>!S0Y-BZ2+0YT=ZSGJO!)<M:\MX<O\V
M3=N9M&2'9D6T"1?1)LK_RGIIQ][W65VJT()K02Z5\WDQMM[?E565$0S@I4S[
M522[P8 ;EA%FPZQU &W_KMX_):%7R(;/>_U^NE FBT!RJ\1IJ%G'4G8R^]M2
MGVE![71\M,3!HU=TSE;9U  T6;@$S]KL]FA\&:BS&&PB@,SY?/93TFAAHFL[
MJU*[D.!%.=07SO%8:U9K);U GI"K^CZ"$F[]JY+0QT5YW>_$K+/E ^2?W@]1
MP(1A5K/R %#S4O).BS!"Z/9F?;NDZFM!QG4:\69AQFR&:;E!>#2%0GF-BSKD
M-PR!;A3*KE\*Y>UQ$V*E-A(POEH12QRY=NIZS-;H4E<UI'39PAX=%87V\IN0
M?0H;2I=#M30<_FSJL?8XO:*X6G"4.*QMGG3T\)TOI_*W+#WC!%4R+R*A#0[\
MU]7$JI0S'@-X.?=';_Q+N>;*"</ XZ^ZV=;.5$-B!PJ4%ODP99/9-E#+'3P]
M'C0+^A<MJWS"'WA6&PR%M7S?*DWN[( \W;WFR7YVT8JDAF)RH:V)*Q5,_I:C
MW<HZLWYR>1 3.58_<IF=D(3B82(<(NLC8D$5' ':KK]50RRQ$9[0+,&@DAP.
M?&\5K3RP>'%.2E&&\&39\/B96#UY%[@- 7BZ]>U^ECET_Y VHG>[CS]4$UXD
M!?!;,E(\IB0,VI3WJX6/4'&8S0(=TFVHPAP';_UL&[>_E0 *CO&4'N,O*)9:
MXHR&1@U.?$SV(7BJ):T7##9@7[6V450ZX*K%#Q$1QU3!_+.P_DDSXN)((5C
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M<T7@U0+ANQ#AOVE4J17&"&-7GLB()EPX8-PS->D,]K4%A-_OMCHV@;O7P7E
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M]>82],D>^;YRN&CB"(\*A,MSM9.OKL:(Y4-O]U&05I72+Y;]^ZP O^"YN96
M0%SRT4GI+Q,JLF5E2T)"@$O%6OIL9LM9;R%GZ4R+"_T'9!W^5?<BH?%H"IB(
MLM,-1;^.^4@/]8Q@]&"HZ<A7>6BY<&(H4,X#/- <]%4B_>$8M^))O<B'DM:3
M,.W1O?RJ0:'N!8X4^DX=VC&KUJXU8UP"#.[! 8_Y=CN9@0HU#9ZQ(>NXBU+;
MLF-+7M!^=^C*=+R8T>))='EB:@NC&0_O@8DD0Y?E8[?NCZO2/N%9&34MO@_O
MF9I/%(["(D74E'T1!!'(\S/>A-#^YU1D@6^=5VQA74[!)KJLPJO](E$Z(<N5
M.L[IC;>[0JQQ=/68;!;P.[.M,0P^ ^,= VCTMNSKZ LR?+OO <%VS/'M!_^J
M6!\X41$89E1QK9?%"@@@S2/P!7GG=2.Q;"UN3M'*?AV2/7I;DG[<C':_6P!>
M:[-]H8[X:R>>UH)?(T*IX9U4GHQ^M80&2^NW!M)0.R#]UU3+."&TF34=\@7D
M8Z%=^2D*.'[+FAC+82EJ">0YF*>,,X;\OZLT^WO7(L;RBX7R>4 @=_ 5;%7(
MSNOH6&.I(!XEJ+>ACOW4U38M;V%[V]\N+#&Z('ZY4?,166Z1F"CQJT?JK6^O
M.Q+>3<N$ 'SOV^^2A/_6>Q^M]M'AW1-OY'X\]BV.RR\P/4_I]H]187L_XUO6
M#AY"9M9IE?SU)=<H$+! RFKBN4CF1\$Z6VI'W@S2:$\P(6&,COK-<N#3Y;3P
MF=[K&>P]\&\]U3&6RE$]-V6M5M_^5.EN/5 '4\^9%(8QX*D$3W+)/K38R#3M
MNG:#"=%+!#L&YA2S0G.YY#)G/XK/GS04E<WQJEAXT87D<DP! NCT6GV2)?E;
M3_:WA>*T +LM^3ZK.8-UOHBABXVT.#'[3X:H\'O>W<G&17"@JS$-:$1BNJ:.
M>B8OF+#_A$C'R*'[A%<!8<TPUX7DW\CFI"-E<?Z <L@WC3Y4<(#]UA5V< 3%
MKH_27I_Z%][/8#:/70&G?46M.Z#J9'Y-XV2YT]Y.R*09E:9!9#9'6&/05IK@
M&,]NJ1/XWZ@@G*S]MK-QIG.3;$Y5%E.X6.+JX?%[A2!!AA!E>[/S\)(;/CQV
M7J.'*"#=VAB=FM\MCHIIVA^WZ-]YA,:UP<+2?>7*?>4ZYKG^"P0@<(WVA#/R
M6O9-_+T[?1&A_!K+^6X?3Z:]1/_C7_=<0PC ^C=X3/ 3! !["3[G+%Z+NS29
M8\:FBZ:SQ<IF%YN(>T.)UP7P\%-4U$)I<MT!:HICJN--_SD . J1GETUK=2:
MW=%AJE5];U#B%N':6^""+A-1?FJ>E?-;'[%:!LD7ML2Q(S!_/S6EUV]>LL7M
M%T ?JY<^^E#+;\T_^+XZD8H2B"FIL^03XP^(\9DM),$T__ZKDK/[E-&:5M(Z
MQP6IM+8>P);##4/LJ%4H'S?P;K*UWTGVW3[^# 00@SKTWM86$Z9-BJ'=Q7.7
MD5?047.%NJJQ8<;6(-A5\":,J;2 Z=OK)M0H\$8$_N6--\.7)]D\^+ OYB>?
M(Y']'SF;AQZK)&&.X0G]^G3IYV>LA*O451ZE"2APHTR(D-+2[G?SM=2C7<U<
MU"J[#H3>S2I=;+QED6BRU!C8*K!#41*(XHB">IY%Z';!H\BC]_1&4ZUN#GC@
M1]2E2K("F>#.?_I5@$N?6L3]@13#?<R!(1>,:1[5^SE@FQ*#4O<32)**\7[Q
MPI"'1^!J;>986*EN>MV=*;'=98<7?3R; C6C<(M8Y,DB56I1A5DCA2KP^S4M
M(_>2^=Y%]CP>^4K."*9]0;3 +NX2N]\WEQES#L^(X^)DX$3+7&-EHZ6D*S5C
MUR#7A1P._,Z]@WJM!]9LN:$Q9:&C765"%L9 I%V1')SWP!IJ/J&2IL5-_#&;
MQ"20D12/(HTK;)KX>P!@;>WR6'YAR!,YRLH^VLUAF]E6:8>5*.=LD+F\K*7]
M9RRNVQ+1W1+4PA**G1MFDDT\V-W6N.3 0_W&IS7$G)F)K9TRHD+BMP,<%[6@
MA/>(!Y11!VS\SG[,;#+E #X_8:7XDBK<3M^XH_*QQCUZA[:;O +7+1MH_SQW
M^E:]9)A2IY>.S/@C2"!LT>UF1#WFU\/PPG>K&TH#*6S@6^+>X PC/,IXP^A&
M74S#;Y;C3-<,H$9=?G>!*<*P][%*HGR;I&E]2=4[P.JOUXN':72/FG^V=I";
MVI-6<UE*I/R.^0:;M(UX$$UB*"$ @0:ZU/8.).<M1+N1+HE]:]]!D7;ID5[#
MY<X+[V@:-P1P+Q4$:E=.;DF6Z<IS#OJ'\R3^CJ/\@(2F33)8LJ!+M21DT<=A
M2&F=1!W63@W8^)E/70N+F;A;O<_M(90,YJG%/E\HT@8)SL7O"OZ2U#1$";P-
MZ8@=>KO*[944IP>W(F/-+V44HRUE:^;5:]\\<KD@52&U&7"X9*\;V(AL/1@S
MAU= ,\W$E!/ :RKNOM2'L4OU^TTWFA?TZ]1D.%",,7-H?CDGFHDQR]HWKF_A
MLB\FU5!=$"QA^ZB8<K7E@N6"]G95<]4]7LMLF@P4%^=,K/<@988.O1X$4\RP
MZR+T(F'9(J4X@[!6=8+4]38B5]S1V]H4+54@TQ"U8&2:S@ PRH<2-4(\"X(G
MYR&PA5M=?WN<HCS,S"@5E<**WO=2*2*PAHIV6[F2 P%\MU6J:PH'>?-P3"P-
M;)6D*2^6Z)F9ZB(NXR$Y('F^X<':4U&ZF405^^)F+S-2HE/^Y+FT6OUI3S0K
M\\N1IE:]65:US5%.R6M"(?N_/4S]WR7<I-36:?SCN%);JUMS0@S0$(I5YC2K
M&FIS$/S/3KS38\T)","R9P/!V3(,7T*].NX#_<QXPB6M\=O&;XP?MT)#7YS;
M"RPBS0O;UIF1K!FU:(D_9CA3%O \60JXM4L87<),W8M01&T_<B13J.,I]=G@
M4*1YN):^CZVC6GA,P/Z*-3NIF<0PS[&_54EF_"V;?'A*BOH7 J7_"B_NJ9;B
M?GWINGAEC%0=5]:\@3=K#MD%PB@U"K 0'G U -?$ %KT[.*ICW&O_]GU <;:
M#HHBO:"@K-:2@":6F1F;'=- DPUM,.<8[Y;F&U^*LF.,)SP]D, QZV"2'"9"
M-5D^_ 9Q$OG'3V[TS:_/X03\=@H D #^7@O[%WM#[ SC<+>LAB;V3T3=OE*J
MT@7\R32\^I);:_IJ_G&EYE^G*.7V*7G8Q#FL"3($$=4 :P^/JB-=X4!!WD-I
M96M-WY"E3=N:Q\3K4@.>#LMTH<F79;RZX&@!8_;%6&'1KMG\&8,9YV#2V"L'
M1J;=L*VZV*G11@4".U)6G8Q8TO<#\ M-I0-AB_%$X>;8JN:Z++A8O5)*4&.9
MIT#^(\+\GP<W3,;FWM;>)C'RSFA/,L=B0VW#> G^"G(>6(^)CPW[(=-M9WDY
ML_7RE@99!QO>GX;M#O VHT!#,+N9_&['Q[H!+MAX"QH.@A;(0X^6R,"FQI^4
MM*J:%7*(I*AI6ZJ>YDZB6T HQW59E2&[N#ARILEE?KZFC%BCBR!MOS31IJVK
MXDHW"\O6KP3!3C\#I2YS[$V9AX$)HC:TB'J)S2A78UHG?F_8$$@?\+EI#[KR
M/&YRCXT(@]:.G_A+1G+,+1VH DX(DE4C2X*T>+)$D=\XH V/'*K7'M,H:1I9
M:I1QDG!+-U:A3I(W1 W&,MU*K"#T$ZK+6H(M/:(%6S)G>;6P>2AVE7UY;PN-
M$\E"I A3R./TLVF@?SN8>TKI?;DH)GQW5E90=W1S1HGOM]*,G-KET&T= AWI
M&':W>=XC2_UMLBSAYH4 N]SJ+IF:7#,4-3F (!*W?&3ZN@]KL5- G04HP$P9
M(HX:GA\ 'VDA_77VU15IFFZVJ@'(;D:O):<L!JB_?L4@G9HR6#5KU'&:I8-
M[FBWE&5/'5_(CYPSJ9MF/'I47 )FP$4.DY DL6H9K'5E07M3PHM.U"3@,@&D
ML''^B-<J29@4'<) _NO?%>S_I$TGS_+W!P\J^-]F:N[4O+LEK#3KOG4[7_+N
MJ[>-;40\H.ZOWC';OO!J\;FXV%Y2I/?OTY;9'KW00@ 9)ZFOE>QK@;SYTSN]
MA^2*:*K]3'OUR2%<7GCLR2_Y_V?\?\=H!;K+B!2N=SH!'Q"^7BF[,U1HG+Y"
M8"['YVKX0,\OT:QR'!5/:K3I?YVS;NP9)GW2VXJIJ*"@*(X)-7*7^.&##9,3
M!%"A/98K9-1BAF2B31+'B$U"=]#7@'NJD907X0UV+VDR7_AI\D K7C<P0Z&F
MVG>J_A4!'@^7%VMU0DLB.[R[8:EOG+',:E&5F_7H\G3%;%1D*5?!=#'2$N/F
MUXZUI;KDG/=X8TV[+Y=^FY/]&B;,U3;HG&*VF8^%/<512C;?;GNRCZ2TK+Q$
MC&OO&"MKA%@LF=@%P"4WLH@ 4P;]?FG31\,E[?UL>*)3A(U!,PC.=WX["C>3
MO7]1A!"EM\-(WS&<88JV2%5+[>-:XH[C/!&;Y(FSS)?G9,IHK*D=EE_([A]M
M5=Y6&,(8V@N<O$G\DGDX88[]$)=J)GZE5O?#IJH?2O\+:S\JN+F!6]!E+I^-
M(90O@,A.PMS\T=3:OS]"*.)74VQ<1=2O: %%&<3Z1H5T2BG\0J7N$SRRJ@S]
MD\,YG)RSJ_,GMA^2$7)JS2Q=NZ!B^D1<MGC8ZM!(--ZRT9!X-;FN+2#L<U0A
MZ "H4#N9*P.T] \9(,+*7,6GM;)9@&;#^"A@*CBB7GG6EFUKN+.T_TM*34:8
MBVEPA(,.J3B#<I.@UTX2WMJ#"?.Y&(=<H,$-I'&QM9C?HG;AG0-:S/]Y;#-&
M9VP5]\M8^FDHNJ&7P6+L4]-4+>7TK@]ZC'*:YX^LPQ@; U*,5X"HPH3JMB*
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MBL:&27(7\+O6Z=%U1$N#%M,T=>&N![43OUSM^3MJ"$"ZJ7+TOLRK68]["(V
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M36@LR"]&E[^53+8%[6&<'#.1HW0T5RX26MZFML("+<W6DS:.BI<:.J%/LB
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M_YB2\2ZT9T+;BE>,V\C(S8KMJ<UZVR.J3;JW5*[ AY<P*[*8"M+9X%5?9Q1
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M=C/[UMEE";@1GH[[7L##V"I=,62]'7\]@!Z ^^+ABQ>"W<\,4X-VA]-[O*-
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M3LV\JIE;,^_M4ZOJ5.U]UC[?7NO[]MKG/,T]K0)P%6459 %(2$@ D^<+\+0
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MO/WZ7EL29CK_!%CENH_TC6BN:/5/SI6Q]JWX\@3(LGT"K)S*P2\E;]$J'IX
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M5G*UK4+>B@CXXN:W2S?5JC4M03":,G*5O59!8+CSTT^AL3Y,?%!A/TI6)+/
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MWGA*79^_^P28AZB2U*V/NO&\F%N@"*;<Q$NDQ$A0^20<NS)AY/8H.'L!G>:
MIE()&97',I;8P,H/J0F*A<0V\871T8K].\'KG@>N;)Z'M0OZ=>.2T(._W]-_
M@,9+ F<:^_MH]"K,WSCG3NU4L%>=RM988X=>;[&%0TX.>VY<$S^7:VK&.VVC
MAHJEN8Z^8_657,=N,[>:KGT0%GMXH6PVU>\N!)<X2+X<]=B=2K&+:$(7$><)
M6Z7H\PJ]P[GEJ+B5"[&823UV9/WV/LKO6-+82Q6ARD\)]-^I:]_UHX[7\J/X
M&ZLIKS:VM+U_K#0O[[-S@<$VF(7XOO%J(\B_AD^- Q;[4/;JW (>6[&L135W
M&N' .\ _O8(HUT#H,X69_9 3W<WY2S?ZOIGYSS4@A8J,[46*M:Z,QR.T=/^1
MXI0IQ"+@[.AL<DA&OTR%)*8J73 H[I.[:;/[N+K-XYMI+MGO8EYET^.&'CE[
M',O [AC3099+ _,7)7.B1NO;^M1=,AXM?J*2)Y6]!3[O(:J^&KO^\W[^+SA2
M/]Y)[D/\%7?%I->](UG$K$O"DW#G/KR.3+-\5*TE6M2GXDW&)=BI37_%&..<
M.\%<P8-P7K<(N7-6:#T%P$A4([GP$6-;1S]C2"C:YTW\N74E<5JLQ5?"RWJV
M6KB^& 4#99(S_><LM!GH%NYI^Q:F/^\H&=-NZU'WR3AET)]B5X#7,:F0I>NJ
MXQZWEI4*XBY_RQ;^P'K=DDC_2"3CH[H.O#>%[+"8%NCWWWH9+9-9N)\]^I87
M:@<?1L/ROX -[.2/;"K>3K8HK[/M'[_$%%X+AIVMWXV% 1E^];\U3ZMB:##2
ML*9H_59R2]/=JJW='&5\T.]?4[[18$,NM,5E_S>8;9O;\(? RIH8@<:.@K_Q
MK"EKZ,4>VS![BV'YGHAJ$+^A[/(@\R58D3!,5-=2O5#SS'BKRTGH2VQ4(W]V
M#N+L^O.I;V+"V]US^')9A\+7[A\?S7;$>I$L^_=KL6CT5")B;B96)@Q(NNUK
MI6*77OM_KD4C#NM3F?+3+2\?N%&1>SY.;5 -E(,,I\7D5^!F^[I-U:WC?!3>
MG8GE1(R-M$F<(CSWS8Z3:4!G^B,F-NH>&<_>FF*/H!;EU=V113>XX6$GLCV2
MR5G5CQK/D()Q#TQ$2E<;[/(7(HAOJ'CO12>''9NDN,430#J*)]?E-36/!?V&
M^Z?8_FPU^T+AC'\"@#-M9S4CII2W.$+_3$KX3]P!.CM[3AGLDOA9.WGJN?+R
MFE^>AF$J.\_52&P0H9H4ZG\QRK:BD[LN>%LN_^%(R]XL/45A=H/'>B,=Y'>8
MPXQ$[FH9B4;<Y1%MC&_U +NESB8KBN+"+X"(LR' 4K@#G<IS5Z$5^]W0F(K7
MS/E00^DSGSK(.0[T:IWEN UUWRB5*LI^E$+I@TA?0@P17!_;?37+RS*,#V5^
M&""_V<?M).I;HIO6>EQKMI,]_C1.BB]%NU$ASN(\U."4FQ"]MAQ(5=P=</&I
M_NV!86H][TVSV[:G\%V+&:3ZA/.G*56$@YR0$D5?ZS>^@P4+AP\6&?*;)Z <
M?%D5Y"))/5=!==^N!-*4ZR"^=CPEL/CZ&-5,W4=!@9I:GBQQ*4O:U5M-P1.T
M;W#^NM\QJH1:LY*@*)UR*LOSQJ&D405A8?ZI20M\64\J(,L &R.Q'!=.UP/&
M@EI]:Y#=1%EYRM'+H*$;Q_[YQ??;I%_/#4933U8^!_8DDDP6I(/-S=VNY>MF
M"236I=?,_1-I%08ZQ,(N5J5WI&_59UAK#&4&H[P53XRB<_:";[L->YW^<CS.
MO G@V>:H$SLDN]4\M)>:\I&&&.CL$>^=CJ92_3(]/5B2 4[BHZNCPR IRLL;
MU7/Y M&FSKD"L>+5"B:GGAR8V!@;I*7,?E0>7E2"GZO/RO/U$3\(E/B'!K@2
M16BMZ(.H YJ:F+_$S0?%HL^M"M"8>G0MW!@IR&WRF)-*M&AQ?E]-)^C25G6&
M= FFF9^I%:3_/<L9=6-<=ROWQM@1Y))\]T],B":BB'X]O,909D.-'=V70!UW
M/92IJ !OG5O(1#D2'I,OOKW0)9+'0F^U6=@1($[9A+=P5QLJV26.!-]\M%'X
M3)*UK^>B-L:FMV9ALF>$.^EJ:'@I&I1N9P$%"6-]J6:/?4>'A=31NQ&M:.O!
M*Z/ ,5^V+!.H(F*6%X=?9N>80->X4>9"J#;&N69A9D----4B-)E*QF7L58SD
M[$Z?C>NBB24/4 .O<9#/\Q/=O1UV)<OP3LK<MK(F%6+*ZI,2T5HB=![R#HH=
M4#K9Z#J?ZP.^7?J=6_DX9GP1/!;;(K'X($6CPC+N(S&1-?78:34-J</O8I43
MW^^GXZ8L6,S\Y8W=4%X>YC?YG%"4ARL!?$H319XGBGUJ#4K).HJ#0ZP HI@H
MC0@WB-SJ$JNH*(45:$!K]-)^P[,\0XX7:[6&FS[*RZ4\(,S@[(A83A2X6D8^
M="<X$&7ZD.[,,=-FR83#Z&X][=,7%J : L?<A5W9)JGY9GA:!WO8&3)$YM&W
M45*N;N>[\GW93G*HYN9H8<F'VXJX7BA)9D(6H+58Y[SWD0.C"NR^(SHS%VQ@
MT[+-1.\AS[(![B&0P\2[_@YT=!1?&>"$4O+R-2:=I/+XQ2&3C/+;T7GU'K7X
M0?M4AZ]'HU[;3,*7I6#1M>T0OBD'.FB*S78]R)AU?>VO_)I=59;Y6<5D4PKS
M=MP>L1R'Y<F=5%5M>WT46[+$PE<P?1PH*19&<[-5VIV@ML.Z[B$GK_^=.UC6
MM. )8)D ?(6V,AYM[ =MEI'PE,@>C-);^$-.58K[,> 0ABE<FLMC4(.'U>[I
MY*^J",4)=+&QA/J_E;L32'/IUHZ),1$:C%T\A=7OY&88/B]\0<+)?A=<9BS3
M_O5PY)5V3?<U%^V9?K%I-/(XAF5(ESWV;C5)?=1!56W<,!EG^E7G@X;%"?I7
ME_*F,/&\NQ#6 ^<)#R[9'W_4A6O04EQJ'YZ+E\]>T16MRLYKJ2PM%$S!YHN)
M5L/P-^8-Q8=P;._8CK*F?W1(E_(J::UP>O<VN/ G8QE:"M]-,N7O="&.#LK-
MB#/Q8DPN@(V(:WYD6=Z7/J+(J:6%[]R#\G^*[M]Y$$VKJ688=O9O17^[%_/A
M%!._>G-%V_S!^KK=V\W]<M1S1($IX,*S+*<^F3&1K_UQPN0L?DMY[PFP3+TD
M1#0^H?0OS$<EJY$$V@V>?P/D+;RU:V(6)!/:F&@3A/8G"YI.HL)=J=/:+7#3
M12PRYE=OR'31T.3WN*>IH8TRE,^9)LO8OJ;,U1V\=)SHDK'B$.8-3&$A?-?%
M^9=V]9HPQ?Z'BR^=>L!M+WJ8#GM0A/DPPT?I>G/THC&_?ST.+2?63^OT0'\?
MMJ <S-<8?2>PKA1NK12LK>6VN!KCJ>X5K>B:]-U%6>0,>*AUQ)]@H6;'N7EF
M?B[QV']>:\T$=:G]<A5W1%GX)[H#_E'/*A)2ZO20*9]@58OV(6;P)9EXW[!M
M6_(J%8'\]-<*,"J\-?HW1VRY81R#SY&FN@-)VJSJ/Q H"[?YQU!V,VAGLF8X
M(=-OF^M#>PC@2RVBA&EI8'%5K_#/"/\LVS*;V:JE3U<G9<VBAA)V=%]BJM,>
M3ZPS0(4Y0>I*5I2%(]-\HE2*^\H-#;(K$.5M_0-PMC[02,XQ<+*&X80D9&NV
M';H,-Q8:Y=1[(QJJ9SKY@=HM\;K'I5;]7X(9N-:*#68$&YT=;H!:%6^.:(;H
M@SZA1CHY3DB--?*WRA"F@I<"M#"8<V(ZPYBS7OR[82UY;6A Q\NW)\!TS=-Q
M8ATH95##UE&YK]=$ @D<%[?*>4T)3?HK8HK6P0*+A8A-9&UFB"\[E6IF5E/S
MY&4[05FSY+V&2/IH//7*ZF_Y5-7Z ?;,!"LY<Y&=-I*P@?Z&RL89NS?;)5(=
M?^[=S-H"C'%V]O;V"Q;0]',]($-D!+&!3'=]L%2<$#Y]MZ#LR4.U+)[?8;T2
M'YANA_U;5V!-;=7-_EI5T=6^8Y13]L%E&T-C^$.>'.EU17E&0Z__H-3B9N.5
M?!/NA^N'-:_V@R]P\&Q@Y_#YEMFKL_PZ2+XQ+\/<?+/+J:#PG]&CWE:SA2ZX
M>%KB,;A@X2-L/-5#41:M?V! ^D#5-ESUI/Q[WM* *\0&)E"/_X)<WD33#$<M
MAD7D%%A"F#7&@K#.>@7F4U:X$$>:5C0^K'!;WW^S\+K&3M Z:\2=6BS2,G'@
MZR$_$^Q%([2QIHEX_^6&A'G50CUD\(,U%9L*#I*'"FQ/M%!,'"(GID*O0 S
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M"(&7W4]0HBI(F0NM1F4DHS5)OE NU-'WB.@P2?)C(QGDQR1. .< L.CZ@NB
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M78:6XF\6U@M.BF/'V7WI2#(!0O7,);HP5T+ E_>T2T%JS?'/@S3+N ZY[I\
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MS<?)]:>2^! --LM_U8;,K@]\^\KO!;A=[JQ:@H& \0?:CNKW*=/F83;FG]Y
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MU30@?-].ZN&.AXNM3=2;JV YX!^,DN].G:+/(O(N6;KN[(/3]'6PSBS7+-?
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MF[*Z$/W/\4J2_VMKP?]TX_@[]Q]02P,$%     @ B()C6C*SP_V,I0  "+$
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MKT:?A#Q?-UEXY!.@Z\HSX9GI&/,;\MZ)$S"C;U*WN&F.W<F7XZL*#L_<8A5
M:JW'TZJ*S."5V^5F@SV<6>MHIM_\WPTZ[TU"N[JD&*Y+UT>()'75TM^2'0\'
MJE)S6*KA(PO:_?*^NASKY%*;5UAR+M8?^[S1OO0E]SY6&FL#RNB)P%:ZMGLH
M7=NK,%$.VK0*&5P1Z;Q)1W$1O]C3QC(L4U%9*<FHFI(D_R4E,7,11[C_G+ZT
M&02VR0P-=[Y'3A@H[E(YP>):CQ3@/AV$Q>VM;=@+3@<=-M^22[C*Q>;.<>3
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M],P$Z3 E>-'N:A4E8*MH):7TI44;H]>FJ,(^0^R5G^FWD13U6%UJ,M$23D1
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MG\4&#XA\[/D<Y9'%0&YB&::!3$IIH;,7WQHR]>H[2*;W"0!;W6(Z].Y-V7A
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M"Q6-WC/@#WKFFB*86;\$/,<MCY*0MIW+9)53PZ0DYJC._O(P.WH'QZ%%W3M
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M:A<8FZQ(3+B5-_Q]H!+3#@8JY,']?E&'+0U#HU=B%F__.*#Y"H. EN'LIOL
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M:=@Y64TL:CPJ?,.[-@\J'Z^65+*J3UB-)@YC^MQB2S_=K<.H-=*$"X9Z3M-
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M\S4S'?0KJMS,!CJJN( SF9,>:QE>;_'J!N\B>J>;K/$2'59D98R+-G%K(+W
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M'Q+K2L*L>%.*\PAIBC.-C#>F;"Y[-7)",\(:Q4E4D0EL+<1I;?02VO4_*PO
M+POU;<HA9^%/*!(U=L+'!5AG'I3QQ&B'?8X^1IQ+L62BVER))&RAY".>3KEK
M3+G.5?<^:J2WD3MMRX^6FB>HIKR.7@UG=G(^8A8Y8?SL+)]--RR>LO<$2I&(
M/).T35&K'%\:1?&$KW57V-(BK0#^MU]EQF9D'T-I(D.9*ZJOA P0<^VB&HBB
MA$"Q0_+^.I1[= 0>]2EPM.\'I#)[DR=9 N2$="H8&N*,DF-TK(9SKN\T$L&
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MK-]G/=C"9)7GB;3(J()J:<T6L2OY=OW%@XB7]OSF(JLMS8#U".N5@-++KT+
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MEF(Z/;,VN\!F$\+SDFKI^#U\9>_[^":9^^[1A?-3VI%UX30Y4[^+*YQ#EP2
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MD#H'_H/U!)J."$HJRSB/^(P+%617:D&'?OQF _H(%0S+FC<VVJ$.^$'7JT@
MB="*Z+X#_*@Y<+YPEL]EV#TA=/-ZEUDPO:T']_1S3#C?>B.,=,QFN9?1'I9M
MM1+Y5,M_'V:L@HT<MJ]]Q^I3$;&VWT7KNFUX*SBVSW=-/:$E_\OI=W5KO#["
M\5NF1=17E@F&2.''(-UQUQ@+&/,CEQ0K?2..^.Q::YL?]&+PLS.R)Y_ XW<
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MG>[=3?\'4$L! A0#%     @ B()C6N/>*(0H9P  NVX  !8
M ( !     &-A8C%A8S0S,#!E,&EM9S P,2YJ<&=02P$"% ,4    " "(@F-:
MU;,93+49 0#3(@$ !P              @ %<9P  8VUS+FIP9U!+ 0(4 Q0
M   ( (B"8UJOTD?8HQX  'FP   -              "  3:! 0!E>%\W-38Y
M-#4N:'1M4$L! A0#%     @ B()C6H+9UF+  @  D0T   T
M ( !!* ! &5X7S<U-CDT-BYH=&U02P$"% ,4    " "(@F-:H\!QF]\#   /
M&@  #0              @ 'OH@$ 97A?-S4V.30W+FAT;5!+ 0(4 Q0    (
M (B"8UKK];+DQ <  #HP   -              "  ?FF 0!E>%\W-38Y-#@N
M:'1M4$L! A0#%     @ B()C6G>2XCFB!P  *C    T              ( !
MZ*X! &5X7S<U-CDT.2YH=&U02P$"% ,4    " "(@F-:LRY)(;@$   E$P
M#0              @ &UM@$ 97A?-S4V.34P+FAT;5!+ 0(4 Q0    ( (B"
M8UI@/DP_^!,  #]8   -              "  9B[ 0!E>%\W-38Y-3$N:'1M
M4$L! A0#%     @ B()C6N+O[?9$%0  Z7\   T              ( !N\\!
M &5X7S<W,3@R-BYH=&U02P$"% ,4    " "(@F-:".WE[= L  !Z\@  #0
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M '-A=F$M,C R-#$R,S%?;&%B+GAM;%!+ 0(4 Q0    ( (B"8UJ9(]D4H5
M -\A!P 5              "  4CI @!S879A+3(P,C0Q,C,Q7W!R92YX;6Q0
M2P$"% ,4    " "(@F-:M;C$9_U, P#PC1T %0              @ $<.@,
M<V%V83(P,C0Q,C,Q8U\Q,&LN:'1M4$L! A0#%     @ B()C6B+[X(-W8@
M^&T   L              ( !3(<& '-L:61E,#,N:G!G4$L! A0#%     @
MB()C6H*^\)8S8@  BV8   L              ( ![.D& '-L:61E,#0N:G!G
M4$L! A0#%     @ B()C6C*SP_V,I0  "+$   L              ( !2$P'
B '-L:61E,#4N:G!G4$L%!@     4 !0 Q00  /WQ!P    $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>93
<FILENAME>sava20241231c_10k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:cyd="http://xbrl.sec.gov/cyd/2024"
  xmlns:dei="http://xbrl.sec.gov/dei/2024"
  xmlns:ecd="http://xbrl.sec.gov/ecd/2024"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:sava="http://www.cassavasciences.com/20241231"
  xmlns:srt="http://fasb.org/srt/2024"
  xmlns:stpr="http://xbrl.sec.gov/stpr/2024"
  xmlns:thunderdome="http://www.RDGFilings.com"
  xmlns:us-gaap="http://fasb.org/us-gaap/2024"
  xmlns:utr="http://www.xbrl.org/2009/utr"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="sava-20241231.xsd" xlink:type="simple"/>
    <context id="d_2024-01-01_2024-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="i_2024-06-28">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
        </entity>
        <period>
            <instant>2024-06-28</instant>
        </period>
    </context>
    <context id="i_2025-02-27">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
        </entity>
        <period>
            <instant>2025-02-27</instant>
        </period>
    </context>
    <context id="i_2024-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="i_2023-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="d_2023-01-01_2023-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="d_2022-01-01_2022-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i_2021-12-31_StatementEquityComponentsAxis-CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i_2021-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i_2021-12-31_StatementEquityComponentsAxis-RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i_2021-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="d_2022-01-01_2022-12-31_GranteeStatusAxis-ShareBasedPaymentArrangementEmployeeMember_StatementEquityComponentsAxis-CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="d_2022-01-01_2022-12-31_GranteeStatusAxis-ShareBasedPaymentArrangementEmployeeMember_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="d_2022-01-01_2022-12-31_GranteeStatusAxis-ShareBasedPaymentArrangementEmployeeMember_StatementEquityComponentsAxis-RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="d_2022-01-01_2022-12-31_GranteeStatusAxis-ShareBasedPaymentArrangementEmployeeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="d_2022-01-01_2022-12-31_GranteeStatusAxis-ShareBasedPaymentArrangementNonemployeeMember_StatementEquityComponentsAxis-CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementNonemployeeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="d_2022-01-01_2022-12-31_GranteeStatusAxis-ShareBasedPaymentArrangementNonemployeeMember_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementNonemployeeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="d_2022-01-01_2022-12-31_GranteeStatusAxis-ShareBasedPaymentArrangementNonemployeeMember_StatementEquityComponentsAxis-RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementNonemployeeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="d_2022-01-01_2022-12-31_GranteeStatusAxis-ShareBasedPaymentArrangementNonemployeeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementNonemployeeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="d_2022-01-01_2022-12-31_StatementEquityComponentsAxis-CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="d_2022-01-01_2022-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="d_2022-01-01_2022-12-31_StatementEquityComponentsAxis-RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i_2022-12-31_StatementEquityComponentsAxis-CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i_2022-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i_2022-12-31_StatementEquityComponentsAxis-RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i_2022-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="d_2023-01-01_2023-12-31_GranteeStatusAxis-ShareBasedPaymentArrangementEmployeeMember_StatementEquityComponentsAxis-CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="d_2023-01-01_2023-12-31_GranteeStatusAxis-ShareBasedPaymentArrangementEmployeeMember_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="d_2023-01-01_2023-12-31_GranteeStatusAxis-ShareBasedPaymentArrangementEmployeeMember_StatementEquityComponentsAxis-RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="d_2023-01-01_2023-12-31_GranteeStatusAxis-ShareBasedPaymentArrangementEmployeeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="d_2023-01-01_2023-12-31_GranteeStatusAxis-ShareBasedPaymentArrangementNonemployeeMember_StatementEquityComponentsAxis-CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementNonemployeeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="d_2023-01-01_2023-12-31_GranteeStatusAxis-ShareBasedPaymentArrangementNonemployeeMember_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementNonemployeeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="d_2023-01-01_2023-12-31_GranteeStatusAxis-ShareBasedPaymentArrangementNonemployeeMember_StatementEquityComponentsAxis-RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementNonemployeeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="d_2023-01-01_2023-12-31_GranteeStatusAxis-ShareBasedPaymentArrangementNonemployeeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementNonemployeeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="d_2023-01-01_2023-12-31_StatementEquityComponentsAxis-CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="d_2023-01-01_2023-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="d_2023-01-01_2023-12-31_StatementEquityComponentsAxis-RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="i_2023-12-31_StatementEquityComponentsAxis-CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="i_2023-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="i_2023-12-31_StatementEquityComponentsAxis-RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="d_2024-01-01_2024-12-31_GranteeStatusAxis-ShareBasedPaymentArrangementEmployeeMember_StatementEquityComponentsAxis-CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="d_2024-01-01_2024-12-31_GranteeStatusAxis-ShareBasedPaymentArrangementEmployeeMember_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="d_2024-01-01_2024-12-31_GranteeStatusAxis-ShareBasedPaymentArrangementEmployeeMember_StatementEquityComponentsAxis-RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="d_2024-01-01_2024-12-31_GranteeStatusAxis-ShareBasedPaymentArrangementEmployeeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="d_2024-01-01_2024-12-31_GranteeStatusAxis-ShareBasedPaymentArrangementNonemployeeMember_StatementEquityComponentsAxis-CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementNonemployeeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="d_2024-01-01_2024-12-31_GranteeStatusAxis-ShareBasedPaymentArrangementNonemployeeMember_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementNonemployeeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="d_2024-01-01_2024-12-31_GranteeStatusAxis-ShareBasedPaymentArrangementNonemployeeMember_StatementEquityComponentsAxis-RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementNonemployeeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="d_2024-01-01_2024-12-31_GranteeStatusAxis-ShareBasedPaymentArrangementNonemployeeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementNonemployeeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="d_2024-01-01_2024-12-31_StatementEquityComponentsAxis-CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="d_2024-01-01_2024-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="d_2024-01-01_2024-12-31_StatementEquityComponentsAxis-RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="i_2024-12-31_StatementEquityComponentsAxis-CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="i_2024-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="i_2024-12-31_StatementEquityComponentsAxis-RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="i_2024-01-03">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
        </entity>
        <period>
            <instant>2024-01-03</instant>
        </period>
    </context>
    <context id="i_2024-12-31_ClassOfWarrantOrRightAxis-WarrantsToPurchaseCommonStockMember_MeasurementInputTypeAxis-MeasurementInputExercisePriceMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sava:WarrantsToPurchaseCommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExercisePriceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="i_2024-12-31_ClassOfWarrantOrRightAxis-WarrantsToPurchaseCommonStockMember_MeasurementInputTypeAxis-MeasurementInputConversionPriceMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sava:WarrantsToPurchaseCommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputConversionPriceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="i_2024-12-31_ClassOfWarrantOrRightAxis-WarrantsToPurchaseCommonStockMember_MeasurementInputTypeAxis-MeasurementInputSharePriceMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sava:WarrantsToPurchaseCommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputSharePriceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="i_2024-12-31_ClassOfWarrantOrRightAxis-WarrantsToPurchaseCommonStockMember_MeasurementInputTypeAxis-MeasurementInputPriceVolatilityMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sava:WarrantsToPurchaseCommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="i_2024-12-31_ClassOfWarrantOrRightAxis-WarrantsToPurchaseCommonStockMember_MeasurementInputTypeAxis-MeasurementInputRiskFreeInterestRateMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sava:WarrantsToPurchaseCommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="i_2024-12-31_ClassOfWarrantOrRightAxis-WarrantsToPurchaseCommonStockMember_MeasurementInputTypeAxis-MeasurementInputExpectedTermMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sava:WarrantsToPurchaseCommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="i_2024-12-31_ClassOfWarrantOrRightAxis-WarrantsToPurchaseCommonStockMember_MeasurementInputTypeAxis-MeasurementInputExpectedDividendRateMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sava:WarrantsToPurchaseCommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="i_2024-05-07">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
        </entity>
        <period>
            <instant>2024-05-07</instant>
        </period>
    </context>
    <context id="d_2024-01-01_2024-12-31_StatementBusinessSegmentsAxis-CodmMonitoringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">sava:CodmMonitoringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="d_2023-01-01_2023-12-31_StatementBusinessSegmentsAxis-CodmMonitoringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">sava:CodmMonitoringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="d_2022-01-01_2022-12-31_StatementBusinessSegmentsAxis-CodmMonitoringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">sava:CodmMonitoringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i_2024-12-31_StatementBusinessSegmentsAxis-CodmMonitoringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">sava:CodmMonitoringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="i_2023-12-31_StatementBusinessSegmentsAxis-CodmMonitoringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">sava:CodmMonitoringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="d_2024-01-01_2024-12-31_AwardTypeAxis-EmployeeStockOptionMember_RangeAxis-MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="d_2024-01-01_2024-12-31_AwardTypeAxis-EmployeeStockOptionMember_RangeAxis-MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="d_2024-01-01_2024-12-31_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-EmployeeStockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="d_2023-01-01_2023-12-31_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-EmployeeStockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="d_2022-01-01_2022-12-31_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-EmployeeStockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="d_2024-01-01_2024-12-31_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="d_2023-01-01_2023-12-31_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="d_2022-01-01_2022-12-31_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i_2024-12-31_PropertyPlantAndEquipmentByTypeAxis-BuildingMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="i_2024-12-31_PropertyPlantAndEquipmentByTypeAxis-BuildingImprovementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="d_2024-07-15_2024-07-15_TitleOfIndividualAxis-FormerPresidentAndChiefExecutiveOfficerMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">sava:FormerPresidentAndChiefExecutiveOfficerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-15</startDate>
            <endDate>2024-07-15</endDate>
        </period>
    </context>
    <context id="d_2024-07-16_2024-07-16_TitleOfIndividualAxis-FormerSeniorVicePresidentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">sava:FormerSeniorVicePresidentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-16</startDate>
            <endDate>2024-07-16</endDate>
        </period>
    </context>
    <context id="d_2024-01-01_2024-12-31_TitleOfIndividualAxis-FormerSeniorOfficerMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">sava:FormerSeniorOfficerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="d_2024-01-01_2024-09-30_TitleOfIndividualAxis-FormerSeniorOfficerMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">sava:FormerSeniorOfficerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="i_2024-07-16_RelatedPartyTransactionsByRelatedPartyAxis-FormerSeniorVicePresidentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">sava:FormerSeniorVicePresidentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-07-16</instant>
        </period>
    </context>
    <context id="d_2024-01-01_2024-12-31_RelatedPartyTransactionsByRelatedPartyAxis-FormerSeniorVicePresidentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">sava:FormerSeniorVicePresidentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="i_2021-08-04_MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis-OfficeBuildingMember_StatementGeographicalAxis-TX">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis">srt:OfficeBuildingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:TX</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-08-04</instant>
        </period>
    </context>
    <context id="i_2024-12-31_MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis-OfficeBuildingMember_StatementGeographicalAxis-TX">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis">srt:OfficeBuildingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:TX</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="i_2023-12-31_MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis-OfficeBuildingMember_StatementGeographicalAxis-TX">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis">srt:OfficeBuildingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:TX</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="i_2024-12-31_PropertyPlantAndEquipmentByTypeAxis-LandMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LandMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="i_2023-12-31_PropertyPlantAndEquipmentByTypeAxis-LandMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LandMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="i_2023-12-31_PropertyPlantAndEquipmentByTypeAxis-BuildingMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="i_2023-12-31_PropertyPlantAndEquipmentByTypeAxis-BuildingImprovementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="i_2024-12-31_PropertyPlantAndEquipmentByTypeAxis-LeaseholdImprovementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="i_2023-12-31_PropertyPlantAndEquipmentByTypeAxis-LeaseholdImprovementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="i_2024-12-31_PropertyPlantAndEquipmentByTypeAxis-FurnitureAndFixturesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="i_2023-12-31_PropertyPlantAndEquipmentByTypeAxis-FurnitureAndFixturesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="i_2024-12-31_PropertyPlantAndEquipmentByTypeAxis-ConstructionInProgressMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="i_2023-12-31_PropertyPlantAndEquipmentByTypeAxis-ConstructionInProgressMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="i_2024-12-31_FiniteLivedIntangibleAssetsByMajorClassAxis-LeasesAcquiredInPlaceMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LeasesAcquiredInPlaceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="i_2023-12-31_FiniteLivedIntangibleAssetsByMajorClassAxis-LeasesAcquiredInPlaceMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LeasesAcquiredInPlaceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="i_2024-12-31_FiniteLivedIntangibleAssetsByMajorClassAxis-LeasingCommissionsAndOtherMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">sava:LeasingCommissionsAndOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="i_2023-12-31_FiniteLivedIntangibleAssetsByMajorClassAxis-LeasingCommissionsAndOtherMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">sava:LeasingCommissionsAndOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="d_2022-11-22_2022-11-22_SubsidiarySaleOfStockAxis-The2022RegisteredDirectOfferingMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sava:The2022RegisteredDirectOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-11-22</startDate>
            <endDate>2022-11-22</endDate>
        </period>
    </context>
    <context id="i_2022-11-22_SubsidiarySaleOfStockAxis-The2022RegisteredDirectOfferingMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sava:The2022RegisteredDirectOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-11-22</instant>
        </period>
    </context>
    <context id="i_2023-05-01_SubsidiarySaleOfStockAxis-AtthemarketCommonStockOfferingMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sava:AtthemarketCommonStockOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-05-01</instant>
        </period>
    </context>
    <context id="d_2024-01-01_2024-12-31_SubsidiarySaleOfStockAxis-AtthemarketCommonStockOfferingMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sava:AtthemarketCommonStockOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="d_2022-05-05_2022-05-05_PlanNameAxis-The2018EquityIncentivePlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sava:The2018EquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-05-05</startDate>
            <endDate>2022-05-05</endDate>
        </period>
    </context>
    <context id="i_2022-05-05_PlanNameAxis-The2018EquityIncentivePlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sava:The2018EquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-05-05</instant>
        </period>
    </context>
    <context id="d_2024-01-01_2024-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-RangeOneMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">sava:RangeOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="i_2024-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-RangeOneMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">sava:RangeOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="d_2024-01-01_2024-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-RangeTwoMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">sava:RangeTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="i_2024-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-RangeTwoMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">sava:RangeTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="d_2024-01-01_2024-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-RangeThreeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">sava:RangeThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="i_2024-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-RangeThreeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">sava:RangeThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="d_2024-01-01_2024-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-RangeFourMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">sava:RangeFourMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="i_2024-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-RangeFourMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">sava:RangeFourMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="d_2024-01-01_2024-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-RangeFiveMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">sava:RangeFiveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="i_2024-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-RangeFiveMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">sava:RangeFiveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="d_2023-01-01_2023-12-31_AwardTypeAxis-EmployeeStockOptionMember_RangeAxis-MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="d_2023-01-01_2023-12-31_AwardTypeAxis-EmployeeStockOptionMember_RangeAxis-MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="d_2022-01-01_2022-12-31_AwardTypeAxis-EmployeeStockOptionMember_RangeAxis-MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="d_2022-01-01_2022-12-31_AwardTypeAxis-EmployeeStockOptionMember_RangeAxis-MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="d_2024-01-01_2024-12-31_AwardTypeAxis-EmployeeStockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="d_2023-01-01_2023-12-31_AwardTypeAxis-EmployeeStockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="d_2022-01-01_2022-12-31_AwardTypeAxis-EmployeeStockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i_2024-12-31_AwardTypeAxis-EmployeeStockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="i_2023-12-31_AwardTypeAxis-PerformanceSharesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="d_2024-01-01_2024-12-31_AwardTypeAxis-PerformanceSharesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="i_2024-12-31_AwardTypeAxis-PerformanceSharesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="d_2022-01-01_2022-12-31_AwardTypeAxis-PerformanceSharesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i_2022-12-31_AwardTypeAxis-PerformanceSharesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="d_2024-01-01_2024-12-31_IncomeStatementLocationAxis-ResearchAndDevelopmentExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="d_2023-01-01_2023-12-31_IncomeStatementLocationAxis-ResearchAndDevelopmentExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="d_2022-01-01_2022-12-31_IncomeStatementLocationAxis-ResearchAndDevelopmentExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="d_2024-01-01_2024-12-31_IncomeStatementLocationAxis-GeneralAndAdministrativeExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="d_2023-01-01_2023-12-31_IncomeStatementLocationAxis-GeneralAndAdministrativeExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="d_2022-01-01_2022-12-31_IncomeStatementLocationAxis-GeneralAndAdministrativeExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="d_2024-01-01_2024-12-31_RestructuringCostAndReserveAxis-EmployeeSeveranceMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="d_2023-01-01_2023-12-31_RestructuringCostAndReserveAxis-EmployeeSeveranceMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="d_2023-01-01_2023-12-31_SubsidiarySaleOfStockAxis-AtthemarketCommonStockOfferingMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sava:AtthemarketCommonStockOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="d_2022-01-01_2022-12-31_RestructuringCostAndReserveAxis-EmployeeSeveranceMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i_2024-12-31_IncomeTaxAuthorityAxis-DomesticCountryMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="i_2024-12-31_IncomeTaxAuthorityAxis-DomesticCountryMember_TaxPeriodAxis-CarryforwardSubjectToExpirationMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">sava:CarryforwardSubjectToExpirationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="i_2024-12-31_IncomeTaxAuthorityAxis-DomesticCountryMember_TaxPeriodAxis-IndefiniteLifeCarryforwardsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">sava:IndefiniteLifeCarryforwardsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="i_2024-12-31_IncomeTaxAuthorityAxis-DomesticCountryMember_TaxCreditCarryforwardAxis-ResearchMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="i_2024-12-31_SupplyCommitmentAxis-SimufilamActiveIngredientMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SupplyCommitmentAxis">sava:SimufilamActiveIngredientMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="i_2025-02-26_CounterpartyNameAxis-YaleUniversityMember_OtherCommitmentsAxis-LicenseAgreementMember_SubsequentEventTypeAxis-SubsequentEventMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sava:YaleUniversityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">sava:LicenseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-02-26</instant>
        </period>
    </context>
    <context id="i_2023-03-16_PlanNameAxis-CashIncentiveBonusPlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sava:CashIncentiveBonusPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-16</instant>
        </period>
    </context>
    <context id="i_2023-03-16_PlanNameAxis-CashIncentiveBonusPlanMember_RangeAxis-MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sava:CashIncentiveBonusPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-16</instant>
        </period>
    </context>
    <context id="i_2023-03-16_PlanNameAxis-CashIncentiveBonusPlanMember_RangeAxis-MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sava:CashIncentiveBonusPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-16</instant>
        </period>
    </context>
    <context id="d_2023-03-16_2023-03-16_PlanNameAxis-CashIncentiveBonusPlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sava:CashIncentiveBonusPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-03-16</startDate>
            <endDate>2023-03-16</endDate>
        </period>
    </context>
    <context id="d_2023-01-01_2023-03-16_PlanNameAxis-CashIncentiveBonusPlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sava:CashIncentiveBonusPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-16</endDate>
        </period>
    </context>
    <context id="i_2020-10-31_PlanNameAxis-CashIncentiveBonusPlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sava:CashIncentiveBonusPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-10-31</instant>
        </period>
    </context>
    <context id="i_2021-12-31_PlanNameAxis-CashIncentiveBonusPlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sava:CashIncentiveBonusPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i_2021-12-31_PlanNameAxis-CashIncentiveBonusPlanMember_RangeAxis-MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sava:CashIncentiveBonusPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="d_2021-01-01_2021-12-31_PlanNameAxis-CashIncentiveBonusPlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sava:CashIncentiveBonusPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="d_2024-01-01_2024-12-31_PlanNameAxis-CashIncentiveBonusPlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sava:CashIncentiveBonusPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="d_2021-08-28_2021-10-26_LitigationCaseAxis-ViolationsOfFederalSecuritiesLawsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">sava:ViolationsOfFederalSecuritiesLawsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-08-28</startDate>
            <endDate>2021-10-26</endDate>
        </period>
    </context>
    <context id="d_2022-06-30_2022-06-30_LitigationCaseAxis-ViolationsOfFederalSecuritiesLawsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">sava:ViolationsOfFederalSecuritiesLawsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-06-30</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="d_2021-11-04_2023-06-20_LitigationCaseAxis-ShareholderDerivativeActionsTexasCourtMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">sava:ShareholderDerivativeActionsTexasCourtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-11-04</startDate>
            <endDate>2023-06-20</endDate>
        </period>
    </context>
    <context id="d_2021-11-01_2023-06-20_LitigationCaseAxis-ShareholderDerivativeActionsTexasCourtMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">sava:ShareholderDerivativeActionsTexasCourtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-11-01</startDate>
            <endDate>2023-06-20</endDate>
        </period>
    </context>
    <context id="d_2021-11-01_2023-06-20_LitigationCaseAxis-ShareholderDerivativeActionsTexasStateCourtMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">sava:ShareholderDerivativeActionsTexasStateCourtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-11-01</startDate>
            <endDate>2023-06-20</endDate>
        </period>
    </context>
    <context id="d_2021-11-01_2023-06-20_LitigationCaseAxis-ShareholderDerivativeActionsDelawareCourtMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">sava:ShareholderDerivativeActionsDelawareCourtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-11-01</startDate>
            <endDate>2023-06-20</endDate>
        </period>
    </context>
    <context id="d_2022-07-05_2022-07-05_LitigationCaseAxis-ShareholderDerivativeActionsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">sava:ShareholderDerivativeActionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-05</startDate>
            <endDate>2022-07-05</endDate>
        </period>
    </context>
    <context id="d_2024-03-18_2024-03-18_LitigationCaseAxis-ShareholderDerivativeActionsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">sava:ShareholderDerivativeActionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-03-18</startDate>
            <endDate>2024-03-18</endDate>
        </period>
    </context>
    <context id="d_2024-09-06_2024-09-06_LitigationCaseAxis-ShareholderDerivativeActionsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">sava:ShareholderDerivativeActionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-09-06</startDate>
            <endDate>2024-09-06</endDate>
        </period>
    </context>
    <context id="d_2025-02-01_2025-02-28_LitigationCaseAxis-ShareholderDerivativeActionsMember_SubsequentEventTypeAxis-SubsequentEventMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">sava:ShareholderDerivativeActionsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-02-01</startDate>
            <endDate>2025-02-28</endDate>
        </period>
    </context>
    <context id="d_2024-08-06_2024-08-06_LitigationCaseAxis-AntislappLawsuitMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">sava:AntislappLawsuitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-08-06</startDate>
            <endDate>2024-08-06</endDate>
        </period>
    </context>
    <context id="d_2023-12-22_2023-12-22_ClassOfWarrantOrRightAxis-WarrantsToPurchaseCommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sava:WarrantsToPurchaseCommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-12-22</startDate>
            <endDate>2023-12-22</endDate>
        </period>
    </context>
    <context id="i_2023-12-22_ClassOfWarrantOrRightAxis-WarrantsToPurchaseCommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sava:WarrantsToPurchaseCommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-22</instant>
        </period>
    </context>
    <context id="d_2024-01-03_2024-01-03_ClassOfWarrantOrRightAxis-WarrantsToPurchaseCommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sava:WarrantsToPurchaseCommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-03</startDate>
            <endDate>2024-01-03</endDate>
        </period>
    </context>
    <context id="i_2024-01-03_ClassOfWarrantOrRightAxis-WarrantsToPurchaseCommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sava:WarrantsToPurchaseCommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-01-03</instant>
        </period>
    </context>
    <context id="i_2024-05-07_ClassOfWarrantOrRightAxis-WarrantsToPurchaseCommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sava:WarrantsToPurchaseCommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-05-07</instant>
        </period>
    </context>
    <context id="i_2024-12-31_ClassOfWarrantOrRightAxis-WarrantsToPurchaseCommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sava:WarrantsToPurchaseCommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="d_2024-01-04_2024-03-31_ClassOfWarrantOrRightAxis-WarrantsToPurchaseCommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sava:WarrantsToPurchaseCommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-04</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="d_2024-04-01_2024-05-02_ClassOfWarrantOrRightAxis-WarrantsToPurchaseCommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sava:WarrantsToPurchaseCommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-05-02</endDate>
        </period>
    </context>
    <context id="d_2024-01-01_2024-12-31_ClassOfWarrantOrRightAxis-WarrantsToPurchaseCommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sava:WarrantsToPurchaseCommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="i_2024-01-02">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
        </entity>
        <period>
            <instant>2024-01-02</instant>
        </period>
    </context>
    <context id="d_2024-01-03_2024-03-31_ClassOfWarrantOrRightAxis-WarrantsToPurchaseCommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sava:WarrantsToPurchaseCommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-03</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="i_2024-03-31_ClassOfWarrantOrRightAxis-WarrantsToPurchaseCommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sava:WarrantsToPurchaseCommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="d_2024-04-01_2024-06-30_ClassOfWarrantOrRightAxis-WarrantsToPurchaseCommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sava:WarrantsToPurchaseCommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="i_2024-06-30_ClassOfWarrantOrRightAxis-WarrantsToPurchaseCommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sava:WarrantsToPurchaseCommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="i_2024-09-30_ClassOfWarrantOrRightAxis-WarrantsToPurchaseCommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sava:WarrantsToPurchaseCommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="d_2025-01-07_2025-01-07_RestructuringCostAndReserveAxis-WorkforceReductionMember_SubsequentEventTypeAxis-SubsequentEventMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">sava:WorkforceReductionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-07</startDate>
            <endDate>2025-01-07</endDate>
        </period>
    </context>
    <context id="i_2025-03-31_RestructuringCostAndReserveAxis-WorkforceReductionMember_StatementScenarioAxis-ScenarioForecastMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">sava:WorkforceReductionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="d_2024-10-01_2024-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
        </entity>
        <period>
            <startDate>2024-10-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <unit id="USD">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="Share">
        <measure>shares</measure>
    </unit>
    <unit id="NonApplicable">
        <measure>thunderdome:item</measure>
    </unit>
    <unit id="USDPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="Pure">
        <measure>pure</measure>
    </unit>
    <unit id="Year">
        <measure>utr:Y</measure>
    </unit>
    <unit id="SquareFoot">
        <measure>utr:sqft</measure>
    </unit>
    <unit id="Day">
        <measure>utr:D</measure>
    </unit>
    <dei:EntityCentralIndexKey
      contextRef="d_2024-01-01_2024-12-31"
      id="thunderdome-EntityCentralIndexKey">0001069530</dei:EntityCentralIndexKey>
    <dei:EntityRegistrantName
      contextRef="d_2024-01-01_2024-12-31"
      id="thunderdome-EntityRegistrantName">CASSAVA SCIENCES INC</dei:EntityRegistrantName>
    <dei:AmendmentFlag contextRef="d_2024-01-01_2024-12-31" id="ixv-13141">false</dei:AmendmentFlag>
    <dei:CurrentFiscalYearEndDate contextRef="d_2024-01-01_2024-12-31" id="ixv-13142">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentFiscalPeriodFocus contextRef="d_2024-01-01_2024-12-31" id="ixv-13143">FY</dei:DocumentFiscalPeriodFocus>
    <dei:DocumentFiscalYearFocus contextRef="d_2024-01-01_2024-12-31" id="ixv-13144">2024</dei:DocumentFiscalYearFocus>
    <cyd:CybersecurityRiskManagementProcessesIntegratedFlag contextRef="d_2024-01-01_2024-12-31" id="c123855784">true</cyd:CybersecurityRiskManagementProcessesIntegratedFlag>
    <cyd:CybersecurityRiskManagementThirdPartyEngagedFlag contextRef="d_2024-01-01_2024-12-31" id="c123855379">true</cyd:CybersecurityRiskManagementThirdPartyEngagedFlag>
    <cyd:CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag contextRef="d_2024-01-01_2024-12-31" id="c123855380">false</cyd:CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag>
    <cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag contextRef="d_2024-01-01_2024-12-31" id="c123855788">true</cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag>
    <cyd:CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock contextRef="d_2024-01-01_2024-12-31" id="c123855789">Our full Board of Directors oversees the risk management process for the Company, which includes identifying, assessing and managing enterprise-level risks. The Board administers this oversight function directly through the Board of Directors as a whole, as well as through its standing committees that address risks inherent in their respective areas of oversight. The risk oversight responsibility of the Board of Directors and its committees is supported by the management reporting processes, which are designed to provide visibility to the Board of Directors and to the personnel who are responsible for risk assessment and information about the identification, assessment and management of critical risks, and management&#x2019;s risk mitigation strategies.  Our cybersecurity risk program directly integrates and is intended to align with the Board of Directors&#x2019; overall risk management process.</cyd:CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock>
    <us-gaap:CommitmentsAndContingencies
      contextRef="i_2024-12-31"
      id="c123862498"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="i_2023-12-31"
      id="c123862499"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="i_2024-12-31"
      decimals="INF"
      id="c123855767"
      unitRef="USDPerShare">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="i_2023-12-31"
      decimals="INF"
      id="c123855768"
      unitRef="USDPerShare">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="i_2024-12-31"
      decimals="INF"
      id="c123855769"
      unitRef="Share">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="i_2023-12-31"
      decimals="INF"
      id="c123855770"
      unitRef="Share">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued
      contextRef="i_2024-12-31"
      decimals="-3"
      id="c123855771"
      unitRef="Share">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="i_2024-12-31"
      decimals="-3"
      id="c123855773"
      unitRef="Share">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesIssued
      contextRef="i_2023-12-31"
      decimals="-3"
      id="c123855772"
      unitRef="Share">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="i_2023-12-31"
      decimals="-3"
      id="c123855774"
      unitRef="Share">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i_2024-12-31"
      decimals="INF"
      id="c123855775"
      unitRef="USDPerShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i_2023-12-31"
      decimals="INF"
      id="c123855776"
      unitRef="USDPerShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="i_2024-12-31"
      decimals="INF"
      id="c123855777"
      unitRef="Share">120000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="i_2023-12-31"
      decimals="INF"
      id="c123855778"
      unitRef="Share">120000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="i_2024-12-31"
      decimals="INF"
      id="c123855779"
      unitRef="Share">48203179</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i_2024-12-31"
      decimals="INF"
      id="c123855781"
      unitRef="Share">48203179</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="i_2023-12-31"
      decimals="INF"
      id="c123855780"
      unitRef="Share">42236919</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i_2023-12-31"
      decimals="INF"
      id="c123855782"
      unitRef="Share">42236919</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:GovernmentAssistanceAmount
      contextRef="d_2023-01-01_2023-12-31"
      decimals="-3"
      id="c123855794"
      unitRef="USD">0</us-gaap:GovernmentAssistanceAmount>
    <us-gaap:GovernmentAssistanceStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration contextRef="d_2024-01-01_2024-12-31" id="c123855795">http://fasb.org/us-gaap/2024#ResearchAndDevelopmentExpense</us-gaap:GovernmentAssistanceStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="i_2024-12-31_ClassOfWarrantOrRightAxis-WarrantsToPurchaseCommonStockMember_MeasurementInputTypeAxis-MeasurementInputExpectedDividendRateMember"
      decimals="-3"
      id="c123854924"
      unitRef="Pure">0</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="d_2024-01-01_2024-12-31_AwardTypeAxis-EmployeeStockOptionMember_RangeAxis-MinimumMember"
      id="c123855418">P1Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="d_2024-01-01_2024-12-31_AwardTypeAxis-EmployeeStockOptionMember_RangeAxis-MaximumMember"
      id="c123855419">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <sava:NumberOfFormerEmployees
      contextRef="d_2024-01-01_2024-09-30_TitleOfIndividualAxis-FormerSeniorOfficerMember"
      decimals="INF"
      id="c123855449"
      unitRef="Pure">2</sava:NumberOfFormerEmployees>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="d_2024-01-01_2024-12-31_SubsidiarySaleOfStockAxis-AtthemarketCommonStockOfferingMember"
      decimals="-3"
      id="c123855525"
      unitRef="Share">0</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
      contextRef="d_2022-05-05_2022-05-05_PlanNameAxis-The2018EquityIncentivePlanMember"
      id="c123855537">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="d_2024-01-01_2024-12-31_AwardTypeAxis-EmployeeStockOptionMember"
      decimals="-3"
      id="c123855198"
      unitRef="Pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="d_2023-01-01_2023-12-31_AwardTypeAxis-EmployeeStockOptionMember"
      decimals="-3"
      id="c123855199"
      unitRef="Pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="d_2022-01-01_2022-12-31_AwardTypeAxis-EmployeeStockOptionMember"
      decimals="-3"
      id="c123855200"
      unitRef="Pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions
      contextRef="d_2024-01-01_2024-12-31_AwardTypeAxis-EmployeeStockOptionMember"
      decimals="3"
      id="c123855201"
      unitRef="Pure">0.043</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions
      contextRef="d_2023-01-01_2023-12-31_AwardTypeAxis-EmployeeStockOptionMember"
      decimals="-3"
      id="c123855202"
      unitRef="Pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions
      contextRef="d_2022-01-01_2022-12-31_AwardTypeAxis-EmployeeStockOptionMember"
      decimals="-3"
      id="c123855203"
      unitRef="Pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="d_2023-01-01_2023-12-31_SubsidiarySaleOfStockAxis-AtthemarketCommonStockOfferingMember"
      decimals="-3"
      id="c123855800"
      unitRef="Share">0</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="d_2022-01-01_2022-12-31_RestructuringCostAndReserveAxis-EmployeeSeveranceMember"
      decimals="-3"
      id="c123855801"
      unitRef="USD">0</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="d_2023-01-01_2023-12-31"
      decimals="2"
      id="c123855808"
      unitRef="Pure">0.21</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="d_2024-01-01_2024-12-31"
      decimals="-3"
      id="c123855598"
      unitRef="USD">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:OpenTaxYear contextRef="d_2024-01-01_2024-12-31" id="c123855602">2020 2021 2022 2023 2024</us-gaap:OpenTaxYear>
    <us-gaap:LossContingencyNewClaimsFiledNumber
      contextRef="d_2021-08-28_2021-10-26_LitigationCaseAxis-ViolationsOfFederalSecuritiesLawsMember"
      decimals="INF"
      id="c123855699"
      unitRef="Pure">4</us-gaap:LossContingencyNewClaimsFiledNumber>
    <us-gaap:LossContingencyNewClaimsFiledNumber
      contextRef="d_2021-08-28_2021-10-26_LitigationCaseAxis-ViolationsOfFederalSecuritiesLawsMember"
      decimals="INF"
      id="c123855700"
      unitRef="Pure">4</us-gaap:LossContingencyNewClaimsFiledNumber>
    <us-gaap:LossContingencyNewClaimsFiledNumber
      contextRef="d_2022-06-30_2022-06-30_LitigationCaseAxis-ViolationsOfFederalSecuritiesLawsMember"
      decimals="INF"
      id="c123855701"
      unitRef="Pure">1</us-gaap:LossContingencyNewClaimsFiledNumber>
    <us-gaap:LossContingencyNewClaimsFiledNumber
      contextRef="d_2021-11-04_2023-06-20_LitigationCaseAxis-ShareholderDerivativeActionsTexasCourtMember"
      decimals="INF"
      id="c123855705"
      unitRef="Pure">4</us-gaap:LossContingencyNewClaimsFiledNumber>
    <us-gaap:LossContingencyNewClaimsFiledNumber
      contextRef="d_2021-11-01_2023-06-20_LitigationCaseAxis-ShareholderDerivativeActionsTexasCourtMember"
      decimals="INF"
      id="c123855706"
      unitRef="Pure">2</us-gaap:LossContingencyNewClaimsFiledNumber>
    <us-gaap:LossContingencyNewClaimsFiledNumber
      contextRef="d_2021-11-01_2023-06-20_LitigationCaseAxis-ShareholderDerivativeActionsTexasStateCourtMember"
      decimals="INF"
      id="c123855707"
      unitRef="Pure">1</us-gaap:LossContingencyNewClaimsFiledNumber>
    <us-gaap:LossContingencyNewClaimsFiledNumber
      contextRef="d_2021-11-01_2023-06-20_LitigationCaseAxis-ShareholderDerivativeActionsDelawareCourtMember"
      decimals="INF"
      id="c123855708"
      unitRef="Pure">1</us-gaap:LossContingencyNewClaimsFiledNumber>
    <us-gaap:LossContingencyNewClaimsFiledNumber
      contextRef="d_2022-07-05_2022-07-05_LitigationCaseAxis-ShareholderDerivativeActionsMember"
      decimals="INF"
      id="c123855709"
      unitRef="Pure">3</us-gaap:LossContingencyNewClaimsFiledNumber>
    <us-gaap:LossContingencyNewClaimsFiledNumber
      contextRef="d_2024-03-18_2024-03-18_LitigationCaseAxis-ShareholderDerivativeActionsMember"
      decimals="INF"
      id="c123855711"
      unitRef="Pure">2</us-gaap:LossContingencyNewClaimsFiledNumber>
    <us-gaap:LossContingencyNewClaimsFiledNumber
      contextRef="d_2024-09-06_2024-09-06_LitigationCaseAxis-ShareholderDerivativeActionsMember"
      decimals="INF"
      id="c123855713"
      unitRef="Pure">2</us-gaap:LossContingencyNewClaimsFiledNumber>
    <sava:ClassOfWarrantOrRightIssuedDuringPeriod
      contextRef="d_2023-12-22_2023-12-22_ClassOfWarrantOrRightAxis-WarrantsToPurchaseCommonStockMember"
      decimals="INF"
      id="c123855719"
      unitRef="Share">4</sava:ClassOfWarrantOrRightIssuedDuringPeriod>
    <sava:ClassOfWarrantOrRightIssuedDuringPeriod
      contextRef="d_2024-01-03_2024-01-03_ClassOfWarrantOrRightAxis-WarrantsToPurchaseCommonStockMember"
      decimals="-5"
      id="c123855721"
      unitRef="Share">16900000</sava:ClassOfWarrantOrRightIssuedDuringPeriod>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight
      contextRef="i_2024-01-03_ClassOfWarrantOrRightAxis-WarrantsToPurchaseCommonStockMember"
      decimals="INF"
      id="c123855724"
      unitRef="Share">1.5</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight>
    <sava:RedemptionPercentageOfWarrants
      contextRef="i_2024-05-07_ClassOfWarrantOrRightAxis-WarrantsToPurchaseCommonStockMember"
      decimals="3"
      id="c123855726"
      unitRef="Pure">0.001</sava:RedemptionPercentageOfWarrants>
    <us-gaap:WarrantsAndRightsOutstanding
      contextRef="i_2024-12-31_ClassOfWarrantOrRightAxis-WarrantsToPurchaseCommonStockMember"
      decimals="-3"
      id="c123855728"
      unitRef="USD">0</us-gaap:WarrantsAndRightsOutstanding>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="i_2024-06-30_ClassOfWarrantOrRightAxis-WarrantsToPurchaseCommonStockMember"
      decimals="-3"
      id="c123855372"
      unitRef="Share">0</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="i_2024-09-30_ClassOfWarrantOrRightAxis-WarrantsToPurchaseCommonStockMember"
      decimals="-3"
      id="c123855374"
      unitRef="Share">0</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:WarrantsAndRightsOutstanding
      contextRef="i_2024-09-30_ClassOfWarrantOrRightAxis-WarrantsToPurchaseCommonStockMember"
      decimals="-3"
      id="c123855375"
      unitRef="USD">0</us-gaap:WarrantsAndRightsOutstanding>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="i_2024-12-31_ClassOfWarrantOrRightAxis-WarrantsToPurchaseCommonStockMember"
      decimals="-3"
      id="c123855376"
      unitRef="Share">0</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:WarrantsAndRightsOutstanding
      contextRef="i_2024-12-31_ClassOfWarrantOrRightAxis-WarrantsToPurchaseCommonStockMember"
      decimals="-3"
      id="c123855377"
      unitRef="USD">0</us-gaap:WarrantsAndRightsOutstanding>
    <ecd:Rule10b51ArrAdoptedFlag contextRef="d_2024-10-01_2024-12-31" id="c123855759">false</ecd:Rule10b51ArrAdoptedFlag>
    <ecd:NonRule10b51ArrAdoptedFlag contextRef="d_2024-10-01_2024-12-31" id="c123855822">false</ecd:NonRule10b51ArrAdoptedFlag>
    <ecd:Rule10b51ArrTrmntdFlag contextRef="d_2024-10-01_2024-12-31" id="c123855823">false</ecd:Rule10b51ArrTrmntdFlag>
    <ecd:NonRule10b51ArrTrmntdFlag contextRef="d_2024-10-01_2024-12-31" id="c123855824">false</ecd:NonRule10b51ArrTrmntdFlag>
    <dei:DocumentType contextRef="d_2024-01-01_2024-12-31" id="ixv-14653">10-K</dei:DocumentType>
    <dei:DocumentAnnualReport contextRef="d_2024-01-01_2024-12-31" id="ixv-14654">true</dei:DocumentAnnualReport>
    <dei:DocumentPeriodEndDate contextRef="d_2024-01-01_2024-12-31" id="ixv-14655">2024-12-31</dei:DocumentPeriodEndDate>
    <dei:DocumentTransitionReport contextRef="d_2024-01-01_2024-12-31" id="ixv-14656">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber contextRef="d_2024-01-01_2024-12-31" id="ixv-14657">000-29959</dei:EntityFileNumber>
    <dei:EntityIncorporationStateCountryCode contextRef="d_2024-01-01_2024-12-31" id="ixv-14658">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber contextRef="d_2024-01-01_2024-12-31" id="ixv-14659">91-1911336</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="d_2024-01-01_2024-12-31" id="ixv-14660">6801 N. Capital of Texas Highway, Building 1; Suite 300</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown contextRef="d_2024-01-01_2024-12-31" id="ixv-14661">Austin</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="d_2024-01-01_2024-12-31" id="ixv-14662">TX</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="d_2024-01-01_2024-12-31" id="ixv-14663">78731</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="d_2024-01-01_2024-12-31" id="ixv-14664">512</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="d_2024-01-01_2024-12-31" id="ixv-14665">501-2444</dei:LocalPhoneNumber>
    <dei:Security12bTitle contextRef="d_2024-01-01_2024-12-31" id="ixv-14666">Common Stock, $0.001 par value</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="d_2024-01-01_2024-12-31" id="ixv-14667">SAVA</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="d_2024-01-01_2024-12-31" id="ixv-14668">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityWellKnownSeasonedIssuer contextRef="d_2024-01-01_2024-12-31" id="ixv-14669">No</dei:EntityWellKnownSeasonedIssuer>
    <dei:EntityVoluntaryFilers contextRef="d_2024-01-01_2024-12-31" id="ixv-14670">No</dei:EntityVoluntaryFilers>
    <dei:EntityCurrentReportingStatus contextRef="d_2024-01-01_2024-12-31" id="ixv-14671">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent contextRef="d_2024-01-01_2024-12-31" id="ixv-14672">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory contextRef="d_2024-01-01_2024-12-31" id="ixv-14673">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness contextRef="d_2024-01-01_2024-12-31" id="ixv-14674">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany contextRef="d_2024-01-01_2024-12-31" id="ixv-14675">false</dei:EntityEmergingGrowthCompany>
    <dei:IcfrAuditorAttestationFlag contextRef="d_2024-01-01_2024-12-31" id="ixv-14676">false</dei:IcfrAuditorAttestationFlag>
    <dei:DocumentFinStmtErrorCorrectionFlag contextRef="d_2024-01-01_2024-12-31" id="ixv-14677">false</dei:DocumentFinStmtErrorCorrectionFlag>
    <dei:EntityShellCompany contextRef="d_2024-01-01_2024-12-31" id="ixv-14678">false</dei:EntityShellCompany>
    <dei:EntityPublicFloat
      contextRef="i_2024-06-28"
      decimals="0"
      id="ixv-14679"
      unitRef="USD">558000000</dei:EntityPublicFloat>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="i_2025-02-27"
      decimals="INF"
      id="ixv-14680"
      unitRef="Share">48307896</dei:EntityCommonStockSharesOutstanding>
    <cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock contextRef="d_2024-01-01_2024-12-31" id="c2851673">
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -1pt;"&gt;&lt;i&gt;Risk Management and Strategy&lt;/i&gt;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -1pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -1pt; text-indent: 18pt;"&gt;In the normal course of business, we collect and store sensitive information, including proprietary and confidential business information, intellectual property, information regarding clinical and non-clinical trials, sensitive &lt;em style="font: inherit;"&gt;third&lt;/em&gt;-party information and employee information.&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -1pt; text-indent: 18pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -2pt; text-indent: 18pt;"&gt;We have processes designed to protect our information systems, data, assets, infrastructure, and computing environments from cybersecurity threats and risks. Our cybersecurity strategy includes the use of managed detection and response services to monitor our network infrastructure and associated endpoints for possible cybersecurity threats. In addition, we use multi-factor authentication, perform periodical penetration testing and other logical, physical and technical controls designed to deter, prevent, mitigate and respond to cybersecurity threats. Further, our information systems include continuous alert plans, and we provide periodical cybersecurity reminders to our employees to emphasizes the importance of adherence to our security policies.&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -2pt; text-indent: 18pt;"&gt;We conduct organizational risk assessment, which help management in identifying data assets and recognizing and assessing potential threats, and investigating potential vulnerabilities. We are in the process of reviewing and &lt;span style="-sec-ix-hidden:c123855784"&gt;implementing&lt;/span&gt; incremental information technology strategies to mitigate cybersecurity risks and their possible impacts. Risk assessments enable management to make risk management decisions and assign resources to mitigate risk. We also periodically engage &lt;span style="-sec-ix-hidden:c123855379"&gt;third&lt;/span&gt; parties to assess the effectiveness of our cybersecurity practices.&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;"&gt;&#160;&lt;/p&gt;
   As of the date of this Annual Report, we do not believe that any past cybersecurity incidents that have been detected have materially affected, or are reasonably likely to materially affect, our business strategy, results of operations, or financial condition.&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -2pt; text-indent: 18pt;"&gt;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -1pt; text-indent: 18pt;"&gt;See &#x201c;Risk Factors - Risks Related to Our Business and Operations&#x201d; for additional information about the risks to our business associated with cybersecurity or a breach or compromise to our information security systems.&lt;/p&gt;
  </cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock>
    <cyd:CybersecurityRiskManagementProcessesIntegratedTextBlock contextRef="d_2024-01-01_2024-12-31" id="c123855783">We have processes designed to protect our information systems, data, assets, infrastructure, and computing environments from cybersecurity threats and risks. Our cybersecurity strategy includes the use of managed detection and response services to monitor our network infrastructure and associated endpoints for possible cybersecurity threats. In addition, we use multi-factor authentication, perform periodical penetration testing and other logical, physical and technical controls designed to deter, prevent, mitigate and respond to cybersecurity threats. Further, our information systems include continuous alert plans, and we provide periodical cybersecurity reminders to our employees to emphasizes the importance of adherence to our security policies.</cyd:CybersecurityRiskManagementProcessesIntegratedTextBlock>
    <cyd:CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock contextRef="d_2024-01-01_2024-12-31" id="c123855785">As of the date of this Annual Report, we do not believe that any past cybersecurity incidents that have been detected have materially affected, or are reasonably likely to materially affect, our business strategy, results of operations, or financial condition.</cyd:CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock>
    <cyd:CybersecurityRiskBoardOfDirectorsOversightTextBlock contextRef="d_2024-01-01_2024-12-31" id="c2851674">
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -20pt; text-indent: 18pt;"&gt;&lt;i&gt;Governance&lt;/i&gt;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -2pt; text-indent: 18pt;"&gt;Our Director of Information Technology has responsibilities which include preventing and monitoring cybersecurity threats and utilizes the assistance of external vendors in this effort. Our Director of Information Technology regularly reports to senior management regarding the status of our cybersecurity program, emerging cybersecurity threats, long-term cybersecurity investments and strategies, and oversight of our cybersecurity profile.&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -2pt; text-indent: 18pt;"&gt;&lt;span style="-sec-ix-hidden:c123855789"&gt;Our full Board of Directors oversees the risk management process for the Company, which includes identifying, assessing and managing enterprise-level risks. The Board administers this oversight function directly through the Board of Directors as a whole, as well as through its standing committees that address risks inherent in their respective areas of oversight. The risk oversight responsibility of the Board of Directors and its committees is supported by the management reporting processes, which are designed to provide visibility to the Board of Directors and to the personnel who are responsible for risk assessment and information about the identification, assessment and management of critical risks, and management&#x2019;s risk mitigation strategies. Our cybersecurity risk program directly integrates and is intended to align with the Board of Directors&#x2019; overall risk management process.&lt;/span&gt;&lt;/p&gt;
  </cyd:CybersecurityRiskBoardOfDirectorsOversightTextBlock>
    <cyd:CybersecurityRiskRoleOfManagementTextBlock contextRef="d_2024-01-01_2024-12-31" id="c123855786">Our Director of Information Technology has responsibilities which include preventing and monitoring cybersecurity threats and utilizes the assistance of external vendors in this effort. Our Director of Information Technology regularly reports to senior management regarding the status of our cybersecurity program, emerging cybersecurity threats, long-term cybersecurity investments and strategies, and oversight of our cybersecurity profile.</cyd:CybersecurityRiskRoleOfManagementTextBlock>
    <cyd:CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock contextRef="d_2024-01-01_2024-12-31" id="c123855790">Our full Board of Directors oversees the risk management process for the Company, which includes identifying, assessing and managing enterprise-level risks. The Board administers this oversight function directly through the Board of Directors as a whole, as well as through its standing committees that address risks inherent in their respective areas of oversight. The risk oversight responsibility of the Board of Directors and its committees is supported by the management reporting processes, which are designed to provide visibility to the Board of Directors and to the personnel who are responsible for risk assessment and information about the identification, assessment and management of critical risks, and management&#x2019;s risk mitigation strategies. Our cybersecurity risk program directly integrates and is intended to align with the Board of Directors&#x2019; overall risk management process.</cyd:CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock>
    <dei:AuditorFirmId contextRef="d_2024-01-01_2024-12-31" id="ixv-14685">42</dei:AuditorFirmId>
    <dei:AuditorName contextRef="d_2024-01-01_2024-12-31" id="ixv-14686">Ernst &amp; Young LLP</dei:AuditorName>
    <dei:AuditorLocation contextRef="d_2024-01-01_2024-12-31" id="ixv-14687">Austin, Texas</dei:AuditorLocation>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i_2024-12-31"
      decimals="-3"
      id="c123854612"
      unitRef="USD">128574000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i_2023-12-31"
      decimals="-3"
      id="c123854613"
      unitRef="USD">121136000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="i_2024-12-31"
      decimals="-3"
      id="c123854614"
      unitRef="USD">7958000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="i_2023-12-31"
      decimals="-3"
      id="c123854615"
      unitRef="USD">8497000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="i_2024-12-31"
      decimals="-3"
      id="c123854616"
      unitRef="USD">136532000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="i_2023-12-31"
      decimals="-3"
      id="c123854617"
      unitRef="USD">129633000</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i_2024-12-31"
      decimals="-3"
      id="c123854618"
      unitRef="USD">20964000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i_2023-12-31"
      decimals="-3"
      id="c123854619"
      unitRef="USD">21854000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="i_2024-12-31"
      decimals="-3"
      id="c123854620"
      unitRef="USD">37000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="i_2023-12-31"
      decimals="-3"
      id="c123854621"
      unitRef="USD">176000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:Assets
      contextRef="i_2024-12-31"
      decimals="-3"
      id="c123854622"
      unitRef="USD">157533000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="i_2023-12-31"
      decimals="-3"
      id="c123854623"
      unitRef="USD">151663000</us-gaap:Assets>
    <us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent
      contextRef="i_2024-12-31"
      decimals="-3"
      id="c123854626"
      unitRef="USD">7654000</us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent>
    <us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent
      contextRef="i_2023-12-31"
      decimals="-3"
      id="c123854627"
      unitRef="USD">10573000</us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent>
    <sava:AccruedDevelopmentExpenseCurrent
      contextRef="i_2024-12-31"
      decimals="-4"
      id="c123854628"
      unitRef="USD">2440000</sava:AccruedDevelopmentExpenseCurrent>
    <sava:AccruedDevelopmentExpenseCurrent
      contextRef="i_2023-12-31"
      decimals="-3"
      id="c123854629"
      unitRef="USD">3037000</sava:AccruedDevelopmentExpenseCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="i_2024-12-31"
      decimals="-3"
      id="c123854630"
      unitRef="USD">1357000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="i_2023-12-31"
      decimals="-5"
      id="c123854631"
      unitRef="USD">200000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="i_2024-12-31"
      decimals="-3"
      id="c123854632"
      unitRef="USD">299000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="i_2023-12-31"
      decimals="-3"
      id="c123854633"
      unitRef="USD">385000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="i_2024-12-31"
      decimals="-4"
      id="c123854634"
      unitRef="USD">11750000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="i_2023-12-31"
      decimals="-3"
      id="c123854635"
      unitRef="USD">14195000</us-gaap:LiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="i_2024-12-31"
      decimals="-3"
      id="c123854636"
      unitRef="USD">79000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="i_2023-12-31"
      decimals="-3"
      id="c123854637"
      unitRef="USD">0</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:Liabilities
      contextRef="i_2024-12-31"
      decimals="-3"
      id="c123854638"
      unitRef="USD">11829000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="i_2023-12-31"
      decimals="-3"
      id="c123854639"
      unitRef="USD">14195000</us-gaap:Liabilities>
    <us-gaap:PreferredStockValue
      contextRef="i_2024-12-31"
      decimals="-3"
      id="c123854640"
      unitRef="USD">0</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockValue
      contextRef="i_2023-12-31"
      decimals="-3"
      id="c123854641"
      unitRef="USD">0</us-gaap:PreferredStockValue>
    <us-gaap:CommonStockValue
      contextRef="i_2024-12-31"
      decimals="-3"
      id="c123854642"
      unitRef="USD">48000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="i_2023-12-31"
      decimals="-3"
      id="c123854643"
      unitRef="USD">42000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital
      contextRef="i_2024-12-31"
      decimals="-3"
      id="c123854644"
      unitRef="USD">550767000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital
      contextRef="i_2023-12-31"
      decimals="-3"
      id="c123854645"
      unitRef="USD">518195000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i_2024-12-31"
      decimals="-3"
      id="c123854646"
      unitRef="USD">-405111000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i_2023-12-31"
      decimals="-3"
      id="c123854647"
      unitRef="USD">-380769000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="i_2024-12-31"
      decimals="-3"
      id="c123854648"
      unitRef="USD">145704000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i_2023-12-31"
      decimals="-3"
      id="c123854649"
      unitRef="USD">137468000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="i_2024-12-31"
      decimals="-3"
      id="c123854650"
      unitRef="USD">157533000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="i_2023-12-31"
      decimals="-3"
      id="c123854651"
      unitRef="USD">151663000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="d_2024-01-01_2024-12-31"
      decimals="-3"
      id="c123854662"
      unitRef="USD">69637000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="d_2023-01-01_2023-12-31"
      decimals="-3"
      id="c123854663"
      unitRef="USD">89423000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="d_2022-01-01_2022-12-31"
      decimals="-3"
      id="c123854664"
      unitRef="USD">68032000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="d_2024-01-01_2024-12-31"
      decimals="-3"
      id="c123854665"
      unitRef="USD">71809000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="d_2023-01-01_2023-12-31"
      decimals="-3"
      id="c123854666"
      unitRef="USD">16534000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="d_2022-01-01_2022-12-31"
      decimals="-3"
      id="c123854667"
      unitRef="USD">11988000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:OperatingExpenses
      contextRef="d_2024-01-01_2024-12-31"
      decimals="-3"
      id="c123854668"
      unitRef="USD">141446000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="d_2023-01-01_2023-12-31"
      decimals="-3"
      id="c123854669"
      unitRef="USD">105957000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="d_2022-01-01_2022-12-31"
      decimals="-4"
      id="c123854670"
      unitRef="USD">80020000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="d_2024-01-01_2024-12-31"
      decimals="-3"
      id="c123854671"
      unitRef="USD">-141446000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="d_2023-01-01_2023-12-31"
      decimals="-3"
      id="c123854672"
      unitRef="USD">-105957000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="d_2022-01-01_2022-12-31"
      decimals="-4"
      id="c123854673"
      unitRef="USD">-80020000</us-gaap:OperatingIncomeLoss>
    <us-gaap:InterestIncomeExpenseNonoperatingNet
      contextRef="d_2024-01-01_2024-12-31"
      decimals="-4"
      id="c123854674"
      unitRef="USD">8510000</us-gaap:InterestIncomeExpenseNonoperatingNet>
    <us-gaap:InterestIncomeExpenseNonoperatingNet
      contextRef="d_2023-01-01_2023-12-31"
      decimals="-3"
      id="c123854675"
      unitRef="USD">7833000</us-gaap:InterestIncomeExpenseNonoperatingNet>
    <us-gaap:InterestIncomeExpenseNonoperatingNet
      contextRef="d_2022-01-01_2022-12-31"
      decimals="-3"
      id="c123854676"
      unitRef="USD">2777000</us-gaap:InterestIncomeExpenseNonoperatingNet>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="d_2024-01-01_2024-12-31"
      decimals="-3"
      id="c123854677"
      unitRef="USD">411000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="d_2023-01-01_2023-12-31"
      decimals="-3"
      id="c123854678"
      unitRef="USD">907000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="d_2022-01-01_2022-12-31"
      decimals="-3"
      id="c123854679"
      unitRef="USD">997000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="d_2024-01-01_2024-12-31"
      decimals="-3"
      id="c123854680"
      unitRef="USD">-108183000</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="d_2023-01-01_2023-12-31"
      decimals="-3"
      id="c123854681"
      unitRef="USD">-0</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="d_2022-01-01_2022-12-31"
      decimals="-3"
      id="c123854682"
      unitRef="USD">-0</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:NetIncomeLoss
      contextRef="d_2024-01-01_2024-12-31"
      decimals="-3"
      id="c123854683"
      unitRef="USD">-24342000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="d_2023-01-01_2023-12-31"
      decimals="-3"
      id="c123854684"
      unitRef="USD">-97217000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="d_2022-01-01_2022-12-31"
      decimals="-3"
      id="c123854685"
      unitRef="USD">-76246000</us-gaap:NetIncomeLoss>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="d_2024-01-01_2024-12-31"
      decimals="-3"
      id="c123854686"
      unitRef="Share">46329000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="d_2023-01-01_2023-12-31"
      decimals="-3"
      id="c123854687"
      unitRef="Share">41932000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="d_2022-01-01_2022-12-31"
      decimals="-3"
      id="c123854688"
      unitRef="Share">40202000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="d_2024-01-01_2024-12-31"
      decimals="INF"
      id="c123854689"
      unitRef="USDPerShare">-0.53</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="d_2023-01-01_2023-12-31"
      decimals="INF"
      id="c123854690"
      unitRef="USDPerShare">-2.32</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="d_2022-01-01_2022-12-31"
      decimals="INF"
      id="c123854691"
      unitRef="USDPerShare">-1.9</us-gaap:EarningsPerShareBasic>
    <us-gaap:NetIncomeLoss
      contextRef="d_2024-01-01_2024-12-31"
      decimals="-3"
      id="c123854692"
      unitRef="USD">-24342000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="d_2023-01-01_2023-12-31"
      decimals="-3"
      id="c123854693"
      unitRef="USD">-97217000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="d_2022-01-01_2022-12-31"
      decimals="-3"
      id="c123854694"
      unitRef="USD">-76246000</us-gaap:NetIncomeLoss>
    <us-gaap:PreferredStockDividendsAndOtherAdjustments
      contextRef="d_2024-01-01_2024-12-31"
      decimals="-3"
      id="c123854695"
      unitRef="USD">43793000</us-gaap:PreferredStockDividendsAndOtherAdjustments>
    <us-gaap:PreferredStockDividendsAndOtherAdjustments
      contextRef="d_2023-01-01_2023-12-31"
      decimals="-3"
      id="c123854696"
      unitRef="USD">-0</us-gaap:PreferredStockDividendsAndOtherAdjustments>
    <us-gaap:PreferredStockDividendsAndOtherAdjustments
      contextRef="d_2022-01-01_2022-12-31"
      decimals="-3"
      id="c123854697"
      unitRef="USD">-0</us-gaap:PreferredStockDividendsAndOtherAdjustments>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted
      contextRef="d_2024-01-01_2024-12-31"
      decimals="-3"
      id="c123854698"
      unitRef="USD">-68135000</us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted
      contextRef="d_2023-01-01_2023-12-31"
      decimals="-3"
      id="c123854699"
      unitRef="USD">-97217000</us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted
      contextRef="d_2022-01-01_2022-12-31"
      decimals="-3"
      id="c123854700"
      unitRef="USD">-76246000</us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="d_2024-01-01_2024-12-31"
      decimals="-3"
      id="c123854701"
      unitRef="Share">46604000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="d_2023-01-01_2023-12-31"
      decimals="-3"
      id="c123854702"
      unitRef="Share">41932000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="d_2022-01-01_2022-12-31"
      decimals="-3"
      id="c123854703"
      unitRef="Share">40202000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:EarningsPerShareDiluted
      contextRef="d_2024-01-01_2024-12-31"
      decimals="INF"
      id="c123854704"
      unitRef="USDPerShare">-1.46</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="d_2023-01-01_2023-12-31"
      decimals="INF"
      id="c123854705"
      unitRef="USDPerShare">-2.32</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="d_2022-01-01_2022-12-31"
      decimals="INF"
      id="c123854706"
      unitRef="USDPerShare">-1.9</us-gaap:EarningsPerShareDiluted>
    <us-gaap:SharesOutstanding
      contextRef="i_2021-12-31_StatementEquityComponentsAxis-CommonStockMember"
      decimals="INF"
      id="c123854724"
      unitRef="Share">40016792</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i_2021-12-31_StatementEquityComponentsAxis-CommonStockMember"
      decimals="-4"
      id="c123854725"
      unitRef="USD">40000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i_2021-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"
      decimals="-3"
      id="c123854726"
      unitRef="USD">461181000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i_2021-12-31_StatementEquityComponentsAxis-RetainedEarningsMember"
      decimals="-3"
      id="c123854727"
      unitRef="USD">-207306000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i_2021-12-31"
      decimals="-3"
      id="c123854728"
      unitRef="USD">253915000</us-gaap:StockholdersEquity>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="d_2022-01-01_2022-12-31_GranteeStatusAxis-ShareBasedPaymentArrangementEmployeeMember_StatementEquityComponentsAxis-CommonStockMember"
      decimals="-3"
      id="c123854730"
      unitRef="USD">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="d_2022-01-01_2022-12-31_GranteeStatusAxis-ShareBasedPaymentArrangementEmployeeMember_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"
      decimals="-3"
      id="c123854731"
      unitRef="USD">1972000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="d_2022-01-01_2022-12-31_GranteeStatusAxis-ShareBasedPaymentArrangementEmployeeMember_StatementEquityComponentsAxis-RetainedEarningsMember"
      decimals="-3"
      id="c123854732"
      unitRef="USD">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="d_2022-01-01_2022-12-31_GranteeStatusAxis-ShareBasedPaymentArrangementEmployeeMember"
      decimals="-3"
      id="c123854733"
      unitRef="USD">1972000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="d_2022-01-01_2022-12-31_GranteeStatusAxis-ShareBasedPaymentArrangementNonemployeeMember_StatementEquityComponentsAxis-CommonStockMember"
      decimals="-3"
      id="c123854735"
      unitRef="USD">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="d_2022-01-01_2022-12-31_GranteeStatusAxis-ShareBasedPaymentArrangementNonemployeeMember_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"
      decimals="-3"
      id="c123854736"
      unitRef="USD">94000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="d_2022-01-01_2022-12-31_GranteeStatusAxis-ShareBasedPaymentArrangementNonemployeeMember_StatementEquityComponentsAxis-RetainedEarningsMember"
      decimals="-3"
      id="c123854737"
      unitRef="USD">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="d_2022-01-01_2022-12-31_GranteeStatusAxis-ShareBasedPaymentArrangementNonemployeeMember"
      decimals="-3"
      id="c123854738"
      unitRef="USD">94000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensationForfeited
      contextRef="d_2022-01-01_2022-12-31_StatementEquityComponentsAxis-CommonStockMember"
      decimals="INF"
      id="c123854739"
      unitRef="Share">57143</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensationForfeited>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationForfeited
      contextRef="d_2022-01-01_2022-12-31_StatementEquityComponentsAxis-CommonStockMember"
      decimals="-3"
      id="c123854740"
      unitRef="USD">-0</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationForfeited>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationForfeited
      contextRef="d_2022-01-01_2022-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"
      decimals="-3"
      id="c123854741"
      unitRef="USD">-0</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationForfeited>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationForfeited
      contextRef="d_2022-01-01_2022-12-31_StatementEquityComponentsAxis-RetainedEarningsMember"
      decimals="-3"
      id="c123854742"
      unitRef="USD">-0</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationForfeited>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationForfeited
      contextRef="d_2022-01-01_2022-12-31"
      decimals="-3"
      id="c123854743"
      unitRef="USD">-0</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationForfeited>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="d_2022-01-01_2022-12-31_StatementEquityComponentsAxis-CommonStockMember"
      decimals="INF"
      id="c123854744"
      unitRef="Share">109241</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="d_2022-01-01_2022-12-31_StatementEquityComponentsAxis-CommonStockMember"
      decimals="-3"
      id="c123854745"
      unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="d_2022-01-01_2022-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"
      decimals="-3"
      id="c123854746"
      unitRef="USD">475000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="d_2022-01-01_2022-12-31_StatementEquityComponentsAxis-RetainedEarningsMember"
      decimals="-3"
      id="c123854747"
      unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="d_2022-01-01_2022-12-31"
      decimals="-3"
      id="c123854748"
      unitRef="USD">475000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="d_2022-01-01_2022-12-31_StatementEquityComponentsAxis-CommonStockMember"
      decimals="INF"
      id="c123854749"
      unitRef="Share">1666667</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="d_2022-01-01_2022-12-31_StatementEquityComponentsAxis-CommonStockMember"
      decimals="-3"
      id="c123854750"
      unitRef="USD">2000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="d_2022-01-01_2022-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"
      decimals="-3"
      id="c123854751"
      unitRef="USD">47327000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="d_2022-01-01_2022-12-31_StatementEquityComponentsAxis-RetainedEarningsMember"
      decimals="-3"
      id="c123854752"
      unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="d_2022-01-01_2022-12-31"
      decimals="-3"
      id="c123854753"
      unitRef="USD">47329000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:NetIncomeLoss
      contextRef="d_2022-01-01_2022-12-31_StatementEquityComponentsAxis-CommonStockMember"
      decimals="-3"
      id="c123854755"
      unitRef="USD">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="d_2022-01-01_2022-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"
      decimals="-3"
      id="c123854756"
      unitRef="USD">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="d_2022-01-01_2022-12-31_StatementEquityComponentsAxis-RetainedEarningsMember"
      decimals="-3"
      id="c123854757"
      unitRef="USD">-76246000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="d_2022-01-01_2022-12-31"
      decimals="-3"
      id="c123854758"
      unitRef="USD">-76246000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="i_2022-12-31_StatementEquityComponentsAxis-CommonStockMember"
      decimals="INF"
      id="c123854759"
      unitRef="Share">41735557</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i_2022-12-31_StatementEquityComponentsAxis-CommonStockMember"
      decimals="-3"
      id="c123854760"
      unitRef="USD">42000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i_2022-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"
      decimals="-3"
      id="c123854761"
      unitRef="USD">511049000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i_2022-12-31_StatementEquityComponentsAxis-RetainedEarningsMember"
      decimals="-3"
      id="c123854762"
      unitRef="USD">-283552000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i_2022-12-31"
      decimals="-3"
      id="c123854763"
      unitRef="USD">227539000</us-gaap:StockholdersEquity>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="d_2023-01-01_2023-12-31_GranteeStatusAxis-ShareBasedPaymentArrangementEmployeeMember_StatementEquityComponentsAxis-CommonStockMember"
      decimals="-3"
      id="c123854765"
      unitRef="USD">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="d_2023-01-01_2023-12-31_GranteeStatusAxis-ShareBasedPaymentArrangementEmployeeMember_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"
      decimals="-3"
      id="c123854766"
      unitRef="USD">4493000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="d_2023-01-01_2023-12-31_GranteeStatusAxis-ShareBasedPaymentArrangementEmployeeMember_StatementEquityComponentsAxis-RetainedEarningsMember"
      decimals="-3"
      id="c123854767"
      unitRef="USD">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="d_2023-01-01_2023-12-31_GranteeStatusAxis-ShareBasedPaymentArrangementEmployeeMember"
      decimals="-3"
      id="c123854768"
      unitRef="USD">4493000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="d_2023-01-01_2023-12-31_GranteeStatusAxis-ShareBasedPaymentArrangementNonemployeeMember_StatementEquityComponentsAxis-CommonStockMember"
      decimals="-3"
      id="c123854770"
      unitRef="USD">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="d_2023-01-01_2023-12-31_GranteeStatusAxis-ShareBasedPaymentArrangementNonemployeeMember_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"
      decimals="-3"
      id="c123854771"
      unitRef="USD">93000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="d_2023-01-01_2023-12-31_GranteeStatusAxis-ShareBasedPaymentArrangementNonemployeeMember_StatementEquityComponentsAxis-RetainedEarningsMember"
      decimals="-3"
      id="c123854772"
      unitRef="USD">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="d_2023-01-01_2023-12-31_GranteeStatusAxis-ShareBasedPaymentArrangementNonemployeeMember"
      decimals="-3"
      id="c123854773"
      unitRef="USD">93000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="d_2023-01-01_2023-12-31_StatementEquityComponentsAxis-CommonStockMember"
      decimals="INF"
      id="c123854774"
      unitRef="Share">501362</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="d_2023-01-01_2023-12-31_StatementEquityComponentsAxis-CommonStockMember"
      decimals="-3"
      id="c123854775"
      unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="d_2023-01-01_2023-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"
      decimals="-4"
      id="c123854776"
      unitRef="USD">2560000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="d_2023-01-01_2023-12-31_StatementEquityComponentsAxis-RetainedEarningsMember"
      decimals="-3"
      id="c123854777"
      unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="d_2023-01-01_2023-12-31"
      decimals="-4"
      id="c123854778"
      unitRef="USD">2560000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:NetIncomeLoss
      contextRef="d_2023-01-01_2023-12-31_StatementEquityComponentsAxis-CommonStockMember"
      decimals="-3"
      id="c123854780"
      unitRef="USD">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="d_2023-01-01_2023-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"
      decimals="-3"
      id="c123854781"
      unitRef="USD">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="d_2023-01-01_2023-12-31_StatementEquityComponentsAxis-RetainedEarningsMember"
      decimals="-3"
      id="c123854782"
      unitRef="USD">-97217000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="d_2023-01-01_2023-12-31"
      decimals="-3"
      id="c123854783"
      unitRef="USD">-97217000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="i_2023-12-31_StatementEquityComponentsAxis-CommonStockMember"
      decimals="INF"
      id="c123854784"
      unitRef="Share">42236919</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i_2023-12-31_StatementEquityComponentsAxis-CommonStockMember"
      decimals="-3"
      id="c123854785"
      unitRef="USD">42000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i_2023-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"
      decimals="-3"
      id="c123854786"
      unitRef="USD">518195000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i_2023-12-31_StatementEquityComponentsAxis-RetainedEarningsMember"
      decimals="-3"
      id="c123854787"
      unitRef="USD">-380769000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i_2023-12-31"
      decimals="-3"
      id="c123854788"
      unitRef="USD">137468000</us-gaap:StockholdersEquity>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="d_2024-01-01_2024-12-31_GranteeStatusAxis-ShareBasedPaymentArrangementEmployeeMember_StatementEquityComponentsAxis-CommonStockMember"
      decimals="-3"
      id="c123854790"
      unitRef="USD">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="d_2024-01-01_2024-12-31_GranteeStatusAxis-ShareBasedPaymentArrangementEmployeeMember_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"
      decimals="-3"
      id="c123854791"
      unitRef="USD">15054000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="d_2024-01-01_2024-12-31_GranteeStatusAxis-ShareBasedPaymentArrangementEmployeeMember_StatementEquityComponentsAxis-RetainedEarningsMember"
      decimals="-3"
      id="c123854792"
      unitRef="USD">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="d_2024-01-01_2024-12-31_GranteeStatusAxis-ShareBasedPaymentArrangementEmployeeMember"
      decimals="-3"
      id="c123854793"
      unitRef="USD">15054000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="d_2024-01-01_2024-12-31_GranteeStatusAxis-ShareBasedPaymentArrangementNonemployeeMember_StatementEquityComponentsAxis-CommonStockMember"
      decimals="-3"
      id="c123854795"
      unitRef="USD">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="d_2024-01-01_2024-12-31_GranteeStatusAxis-ShareBasedPaymentArrangementNonemployeeMember_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"
      decimals="-3"
      id="c123854796"
      unitRef="USD">1237000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="d_2024-01-01_2024-12-31_GranteeStatusAxis-ShareBasedPaymentArrangementNonemployeeMember_StatementEquityComponentsAxis-RetainedEarningsMember"
      decimals="-3"
      id="c123854797"
      unitRef="USD">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="d_2024-01-01_2024-12-31_GranteeStatusAxis-ShareBasedPaymentArrangementNonemployeeMember"
      decimals="-3"
      id="c123854798"
      unitRef="USD">1237000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued
      contextRef="d_2024-01-01_2024-12-31_StatementEquityComponentsAxis-CommonStockMember"
      decimals="-3"
      id="c123854800"
      unitRef="USD">-0</us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued
      contextRef="d_2024-01-01_2024-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"
      decimals="-3"
      id="c123854801"
      unitRef="USD">113363000</us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued
      contextRef="d_2024-01-01_2024-12-31_StatementEquityComponentsAxis-RetainedEarningsMember"
      decimals="-3"
      id="c123854802"
      unitRef="USD">-0</us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued
      contextRef="d_2024-01-01_2024-12-31"
      decimals="-3"
      id="c123854803"
      unitRef="USD">113363000</us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued>
    <sava:StockIssuedDuringPeriodSharesWarrantExercises
      contextRef="d_2024-01-01_2024-12-31_StatementEquityComponentsAxis-CommonStockMember"
      decimals="INF"
      id="c123854804"
      unitRef="Share">5739247</sava:StockIssuedDuringPeriodSharesWarrantExercises>
    <sava:StockIssuedDuringPeriodValueWarrantExercises
      contextRef="d_2024-01-01_2024-12-31_StatementEquityComponentsAxis-CommonStockMember"
      decimals="-3"
      id="c123854805"
      unitRef="USD">6000</sava:StockIssuedDuringPeriodValueWarrantExercises>
    <sava:StockIssuedDuringPeriodValueWarrantExercises
      contextRef="d_2024-01-01_2024-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"
      decimals="-3"
      id="c123854806"
      unitRef="USD">123546000</sava:StockIssuedDuringPeriodValueWarrantExercises>
    <sava:StockIssuedDuringPeriodValueWarrantExercises
      contextRef="d_2024-01-01_2024-12-31_StatementEquityComponentsAxis-RetainedEarningsMember"
      decimals="-3"
      id="c123854807"
      unitRef="USD">0</sava:StockIssuedDuringPeriodValueWarrantExercises>
    <sava:StockIssuedDuringPeriodValueWarrantExercises
      contextRef="d_2024-01-01_2024-12-31"
      decimals="-3"
      id="c123854808"
      unitRef="USD">123552000</sava:StockIssuedDuringPeriodValueWarrantExercises>
    <sava:AdjustmentsToAdditionalPaidInCapitalDerecognitionOfWarrantLiabilitiesUponExerciseOfWarrants
      contextRef="d_2024-01-01_2024-12-31_StatementEquityComponentsAxis-CommonStockMember"
      decimals="-3"
      id="c123854810"
      unitRef="USD">0</sava:AdjustmentsToAdditionalPaidInCapitalDerecognitionOfWarrantLiabilitiesUponExerciseOfWarrants>
    <sava:AdjustmentsToAdditionalPaidInCapitalDerecognitionOfWarrantLiabilitiesUponExerciseOfWarrants
      contextRef="d_2024-01-01_2024-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"
      decimals="-4"
      id="c123854811"
      unitRef="USD">5180000</sava:AdjustmentsToAdditionalPaidInCapitalDerecognitionOfWarrantLiabilitiesUponExerciseOfWarrants>
    <sava:AdjustmentsToAdditionalPaidInCapitalDerecognitionOfWarrantLiabilitiesUponExerciseOfWarrants
      contextRef="d_2024-01-01_2024-12-31_StatementEquityComponentsAxis-RetainedEarningsMember"
      decimals="-3"
      id="c123854812"
      unitRef="USD">0</sava:AdjustmentsToAdditionalPaidInCapitalDerecognitionOfWarrantLiabilitiesUponExerciseOfWarrants>
    <sava:AdjustmentsToAdditionalPaidInCapitalDerecognitionOfWarrantLiabilitiesUponExerciseOfWarrants
      contextRef="d_2024-01-01_2024-12-31"
      decimals="-4"
      id="c123854813"
      unitRef="USD">5180000</sava:AdjustmentsToAdditionalPaidInCapitalDerecognitionOfWarrantLiabilitiesUponExerciseOfWarrants>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="d_2024-01-01_2024-12-31_StatementEquityComponentsAxis-CommonStockMember"
      decimals="INF"
      id="c123854814"
      unitRef="Share">227013</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="d_2024-01-01_2024-12-31_StatementEquityComponentsAxis-CommonStockMember"
      decimals="-3"
      id="c123854815"
      unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="d_2024-01-01_2024-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"
      decimals="-3"
      id="c123854816"
      unitRef="USD">918000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="d_2024-01-01_2024-12-31_StatementEquityComponentsAxis-RetainedEarningsMember"
      decimals="-3"
      id="c123854817"
      unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="d_2024-01-01_2024-12-31"
      decimals="-3"
      id="c123854818"
      unitRef="USD">918000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:NetIncomeLoss
      contextRef="d_2024-01-01_2024-12-31_StatementEquityComponentsAxis-CommonStockMember"
      decimals="-3"
      id="c123854820"
      unitRef="USD">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="d_2024-01-01_2024-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"
      decimals="-3"
      id="c123854821"
      unitRef="USD">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="d_2024-01-01_2024-12-31_StatementEquityComponentsAxis-RetainedEarningsMember"
      decimals="-3"
      id="c123854822"
      unitRef="USD">-24342000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="d_2024-01-01_2024-12-31"
      decimals="-3"
      id="c123854823"
      unitRef="USD">-24342000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="i_2024-12-31_StatementEquityComponentsAxis-CommonStockMember"
      decimals="INF"
      id="c123854824"
      unitRef="Share">48203179</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i_2024-12-31_StatementEquityComponentsAxis-CommonStockMember"
      decimals="-3"
      id="c123854825"
      unitRef="USD">48000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i_2024-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"
      decimals="-3"
      id="c123854826"
      unitRef="USD">550767000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i_2024-12-31_StatementEquityComponentsAxis-RetainedEarningsMember"
      decimals="-3"
      id="c123854827"
      unitRef="USD">-405111000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i_2024-12-31"
      decimals="-3"
      id="c123854828"
      unitRef="USD">145704000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="d_2024-01-01_2024-12-31"
      decimals="-3"
      id="c123854838"
      unitRef="USD">-24342000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="d_2023-01-01_2023-12-31"
      decimals="-3"
      id="c123854839"
      unitRef="USD">-97217000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="d_2022-01-01_2022-12-31"
      decimals="-3"
      id="c123854840"
      unitRef="USD">-76246000</us-gaap:NetIncomeLoss>
    <us-gaap:ShareBasedCompensation
      contextRef="d_2024-01-01_2024-12-31"
      decimals="-3"
      id="c123854841"
      unitRef="USD">16291000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="d_2023-01-01_2023-12-31"
      decimals="-3"
      id="c123854842"
      unitRef="USD">4586000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="d_2022-01-01_2022-12-31"
      decimals="-3"
      id="c123854843"
      unitRef="USD">2066000</us-gaap:ShareBasedCompensation>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="d_2024-01-01_2024-12-31"
      decimals="-3"
      id="c123854844"
      unitRef="USD">-108183000</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="d_2023-01-01_2023-12-31"
      decimals="-3"
      id="c123854845"
      unitRef="USD">0</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="d_2022-01-01_2022-12-31"
      decimals="-3"
      id="c123854846"
      unitRef="USD">0</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:Depreciation
      contextRef="d_2024-01-01_2024-12-31"
      decimals="-3"
      id="c123854847"
      unitRef="USD">952000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="d_2023-01-01_2023-12-31"
      decimals="-3"
      id="c123854848"
      unitRef="USD">1084000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="d_2022-01-01_2022-12-31"
      decimals="-3"
      id="c123854849"
      unitRef="USD">804000</us-gaap:Depreciation>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="d_2024-01-01_2024-12-31"
      decimals="-4"
      id="c123854850"
      unitRef="USD">180000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="d_2023-01-01_2023-12-31"
      decimals="-3"
      id="c123854851"
      unitRef="USD">446000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="d_2022-01-01_2022-12-31"
      decimals="-3"
      id="c123854852"
      unitRef="USD">497000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="d_2024-01-01_2024-12-31"
      decimals="-3"
      id="c123854853"
      unitRef="USD">-539000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="d_2023-01-01_2023-12-31"
      decimals="-3"
      id="c123854854"
      unitRef="USD">-1714000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="d_2022-01-01_2022-12-31"
      decimals="-3"
      id="c123854855"
      unitRef="USD">-1189000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <sava:IncreaseDecreaseInOperatingLeaseRightOfUseAssetsAndLiabilitiesNet
      contextRef="d_2024-01-01_2024-12-31"
      decimals="-3"
      id="c123854856"
      unitRef="USD">-0</sava:IncreaseDecreaseInOperatingLeaseRightOfUseAssetsAndLiabilitiesNet>
    <sava:IncreaseDecreaseInOperatingLeaseRightOfUseAssetsAndLiabilitiesNet
      contextRef="d_2023-01-01_2023-12-31"
      decimals="-3"
      id="c123854857"
      unitRef="USD">17000</sava:IncreaseDecreaseInOperatingLeaseRightOfUseAssetsAndLiabilitiesNet>
    <sava:IncreaseDecreaseInOperatingLeaseRightOfUseAssetsAndLiabilitiesNet
      contextRef="d_2022-01-01_2022-12-31"
      decimals="-3"
      id="c123854858"
      unitRef="USD">9000</sava:IncreaseDecreaseInOperatingLeaseRightOfUseAssetsAndLiabilitiesNet>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="d_2024-01-01_2024-12-31"
      decimals="-3"
      id="c123854859"
      unitRef="USD">-2919000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="d_2023-01-01_2023-12-31"
      decimals="-3"
      id="c123854860"
      unitRef="USD">6896000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="d_2022-01-01_2022-12-31"
      decimals="-3"
      id="c123854861"
      unitRef="USD">-3449000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <sava:IncreaseDecreaseInDevelopmentExpense
      contextRef="d_2024-01-01_2024-12-31"
      decimals="-3"
      id="c123854862"
      unitRef="USD">-597000</sava:IncreaseDecreaseInDevelopmentExpense>
    <sava:IncreaseDecreaseInDevelopmentExpense
      contextRef="d_2023-01-01_2023-12-31"
      decimals="-3"
      id="c123854863"
      unitRef="USD">757000</sava:IncreaseDecreaseInDevelopmentExpense>
    <sava:IncreaseDecreaseInDevelopmentExpense
      contextRef="d_2022-01-01_2022-12-31"
      decimals="-3"
      id="c123854864"
      unitRef="USD">-523000</sava:IncreaseDecreaseInDevelopmentExpense>
    <us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities
      contextRef="d_2024-01-01_2024-12-31"
      decimals="-3"
      id="c123854865"
      unitRef="USD">1157000</us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities>
    <us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities
      contextRef="d_2023-01-01_2023-12-31"
      decimals="-4"
      id="c123854866"
      unitRef="USD">30000</us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities>
    <us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities
      contextRef="d_2022-01-01_2022-12-31"
      decimals="-3"
      id="c123854867"
      unitRef="USD">-1707000</us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities>
    <us-gaap:IncreaseDecreaseInOtherOperatingLiabilities
      contextRef="d_2024-01-01_2024-12-31"
      decimals="-3"
      id="c123854868"
      unitRef="USD">-7000</us-gaap:IncreaseDecreaseInOtherOperatingLiabilities>
    <us-gaap:IncreaseDecreaseInOtherOperatingLiabilities
      contextRef="d_2023-01-01_2023-12-31"
      decimals="-3"
      id="c123854869"
      unitRef="USD">-304000</us-gaap:IncreaseDecreaseInOtherOperatingLiabilities>
    <us-gaap:IncreaseDecreaseInOtherOperatingLiabilities
      contextRef="d_2022-01-01_2022-12-31"
      decimals="-3"
      id="c123854870"
      unitRef="USD">-136000</us-gaap:IncreaseDecreaseInOtherOperatingLiabilities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="d_2024-01-01_2024-12-31"
      decimals="-3"
      id="c123854871"
      unitRef="USD">-116929000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="d_2023-01-01_2023-12-31"
      decimals="-3"
      id="c123854872"
      unitRef="USD">-82025000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="d_2022-01-01_2022-12-31"
      decimals="-3"
      id="c123854873"
      unitRef="USD">-77514000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="d_2024-01-01_2024-12-31"
      decimals="-3"
      id="c123854874"
      unitRef="USD">103000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="d_2023-01-01_2023-12-31"
      decimals="-3"
      id="c123854875"
      unitRef="USD">414000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="d_2022-01-01_2022-12-31"
      decimals="-3"
      id="c123854876"
      unitRef="USD">2712000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="d_2024-01-01_2024-12-31"
      decimals="-3"
      id="c123854877"
      unitRef="USD">-103000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="d_2023-01-01_2023-12-31"
      decimals="-3"
      id="c123854878"
      unitRef="USD">-414000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="d_2022-01-01_2022-12-31"
      decimals="-3"
      id="c123854879"
      unitRef="USD">-2712000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="d_2024-01-01_2024-12-31"
      decimals="-3"
      id="c123854880"
      unitRef="USD">918000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="d_2023-01-01_2023-12-31"
      decimals="-4"
      id="c123854881"
      unitRef="USD">2560000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="d_2022-01-01_2022-12-31"
      decimals="-3"
      id="c123854882"
      unitRef="USD">475000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromWarrantExercises
      contextRef="d_2024-01-01_2024-12-31"
      decimals="-3"
      id="c123854883"
      unitRef="USD">123552000</us-gaap:ProceedsFromWarrantExercises>
    <us-gaap:ProceedsFromWarrantExercises
      contextRef="d_2023-01-01_2023-12-31"
      decimals="-3"
      id="c123854884"
      unitRef="USD">0</us-gaap:ProceedsFromWarrantExercises>
    <us-gaap:ProceedsFromWarrantExercises
      contextRef="d_2022-01-01_2022-12-31"
      decimals="-3"
      id="c123854885"
      unitRef="USD">0</us-gaap:ProceedsFromWarrantExercises>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="d_2024-01-01_2024-12-31"
      decimals="-3"
      id="c123854886"
      unitRef="USD">0</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="d_2023-01-01_2023-12-31"
      decimals="-3"
      id="c123854887"
      unitRef="USD">0</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="d_2022-01-01_2022-12-31"
      decimals="-3"
      id="c123854888"
      unitRef="USD">47329000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="d_2024-01-01_2024-12-31"
      decimals="-4"
      id="c123854889"
      unitRef="USD">124470000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="d_2023-01-01_2023-12-31"
      decimals="-4"
      id="c123854890"
      unitRef="USD">2560000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="d_2022-01-01_2022-12-31"
      decimals="-3"
      id="c123854891"
      unitRef="USD">47804000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
      contextRef="d_2024-01-01_2024-12-31"
      decimals="-3"
      id="c123854892"
      unitRef="USD">7438000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
      contextRef="d_2023-01-01_2023-12-31"
      decimals="-3"
      id="c123854893"
      unitRef="USD">-79879000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
      contextRef="d_2022-01-01_2022-12-31"
      decimals="-3"
      id="c123854894"
      unitRef="USD">-32422000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="i_2023-12-31"
      decimals="-3"
      id="c123854895"
      unitRef="USD">121136000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="i_2022-12-31"
      decimals="-3"
      id="c123854896"
      unitRef="USD">201015000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="i_2021-12-31"
      decimals="-3"
      id="c123854897"
      unitRef="USD">233437000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="i_2024-12-31"
      decimals="-3"
      id="c123854898"
      unitRef="USD">128574000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="i_2023-12-31"
      decimals="-3"
      id="c123854899"
      unitRef="USD">121136000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="i_2022-12-31"
      decimals="-3"
      id="c123854900"
      unitRef="USD">201015000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="d_2024-01-01_2024-12-31"
      decimals="-3"
      id="c123854901"
      unitRef="USD">0</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="d_2023-01-01_2023-12-31"
      decimals="-3"
      id="c123854902"
      unitRef="USD">0</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="d_2022-01-01_2022-12-31"
      decimals="-4"
      id="c123854903"
      unitRef="USD">340000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <sava:IssuanceOfWarrantsResultingInRecognitionOfWarrantLiabilities
      contextRef="d_2024-01-01_2024-12-31"
      decimals="-3"
      id="c123854904"
      unitRef="USD">113363000</sava:IssuanceOfWarrantsResultingInRecognitionOfWarrantLiabilities>
    <sava:IssuanceOfWarrantsResultingInRecognitionOfWarrantLiabilities
      contextRef="d_2023-01-01_2023-12-31"
      decimals="-3"
      id="c123854905"
      unitRef="USD">0</sava:IssuanceOfWarrantsResultingInRecognitionOfWarrantLiabilities>
    <sava:IssuanceOfWarrantsResultingInRecognitionOfWarrantLiabilities
      contextRef="d_2022-01-01_2022-12-31"
      decimals="-3"
      id="c123854906"
      unitRef="USD">0</sava:IssuanceOfWarrantsResultingInRecognitionOfWarrantLiabilities>
    <sava:DerecognitionOfWarrantLiabilitiesThroughExercises
      contextRef="d_2024-01-01_2024-12-31"
      decimals="-4"
      id="c123854907"
      unitRef="USD">-5180000</sava:DerecognitionOfWarrantLiabilitiesThroughExercises>
    <sava:DerecognitionOfWarrantLiabilitiesThroughExercises
      contextRef="d_2023-01-01_2023-12-31"
      decimals="-3"
      id="c123854908"
      unitRef="USD">0</sava:DerecognitionOfWarrantLiabilitiesThroughExercises>
    <sava:DerecognitionOfWarrantLiabilitiesThroughExercises
      contextRef="d_2022-01-01_2022-12-31"
      decimals="-3"
      id="c123854909"
      unitRef="USD">0</sava:DerecognitionOfWarrantLiabilitiesThroughExercises>
    <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock contextRef="d_2024-01-01_2024-12-31" id="c2851675">
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;1.&lt;/em&gt;&lt;/b&gt; &lt;b&gt;General, Liquidity and Basis of Presentation&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"&gt;Cassava Sciences, Inc. and its wholly-owned subsidiary (collectively referred to as the &#x201c;Company&#x201d;) discovers and develops proprietary pharmaceutical product candidates that &lt;em style="font: inherit;"&gt; may &lt;/em&gt;offer significant improvements to patients and healthcare professionals. The Company generally focuses its product discovery and development efforts on disorders of the nervous system.&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;b&gt;&lt;i&gt;Basis of Consolidation&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&#xfeff;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"&gt;The consolidated financial statements include the accounts of the Company and its wholly-owned subsidiary. All intercompany transactions have been eliminated in consolidation.&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;&lt;b&gt;&lt;i&gt;Liquidity &lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"&gt;The Company has incurred significant net losses and negative cash flows since inception, and as a result has an accumulated deficit of $405.1&#160;million at &lt;em style="font: inherit;"&gt; December 31, 2024. &lt;/em&gt;The Company expects its cash requirements to be significant in the future. The amount and timing of the Company&#x2019;s future cash requirements will depend on regulatory and market acceptance of its product candidates and the resources it devotes to researching and developing, formulating, manufacturing, commercializing and supporting its products. The Company &lt;em style="font: inherit;"&gt; may &lt;/em&gt;seek additional funding through public or private financing in the future, if such funding is available and on terms acceptable to the Company. There are &lt;em style="font: inherit;"&gt;no&lt;/em&gt; assurances that additional financing will be available on favorable terms, or at all. However, management believes that the current working capital position will be sufficient to meet the Company&#x2019;s working capital needs for at least the next &lt;em style="font: inherit;"&gt;12&lt;/em&gt; months.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;
  </us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i_2024-12-31"
      decimals="-5"
      id="c123855382"
      unitRef="USD">-405100000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:SignificantAccountingPoliciesTextBlock contextRef="d_2024-01-01_2024-12-31" id="c2851676">
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;2.&lt;/em&gt; Summary of Significant Accounting Policies&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;&lt;b&gt;&lt;i&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;&lt;b&gt;&lt;i&gt;Use of Estimates&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"&gt;The Company makes estimates and assumptions in preparing its consolidated financial statements in conformity with accounting principles generally accepted in the United States. These estimates and assumptions affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amount of revenue earned and expenses incurred during the reporting period. The Company evaluates&#160;its estimates on an ongoing basis, including those estimates related to legal liabilities, common stock warrant liabilities, stock based compensation, clinical trials and manufacturing agreements. Actual results could differ from these estimates and assumptions.&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;&lt;b&gt;&lt;i&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;&lt;b&gt;&lt;i&gt;Proceeds from Grants&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"&gt;During &lt;em style="font: inherit;"&gt;2024&lt;/em&gt; and &lt;em style="font: inherit;"&gt;2023,&lt;/em&gt; there were no reimbursements received pursuant to National Institutes of Health (&#x201c;NIH&#x201d;) research grants. In &lt;em style="font: inherit;"&gt;2022,&lt;/em&gt; the Company received $0.9 million of reimbursement&#160;from the NIH&#160;and National Institute on Drug Abuse. The Company records the proceeds from these grants as reductions to its &lt;span style="-sec-ix-hidden:c123855795"&gt;research and development expenses&lt;/span&gt;.&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;/p&gt;&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&#160;&lt;/p&gt;


   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;&lt;b&gt;&lt;i&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;&lt;b&gt;&lt;i&gt;Cash and Cash Equivalents and Concentration of Credit Risk&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"&gt;The Company invests in cash and cash equivalents. The Company considers highly-liquid financial instruments with original maturities of &lt;em style="font: inherit;"&gt;three&lt;/em&gt; months or less to be cash equivalents. Highly liquid investments that are considered cash equivalents include money market accounts and funds, certificates of deposit and U.S. Treasury securities. The Company maintains&#160;its cash and cash equivalents at &lt;em style="font: inherit;"&gt;one&lt;/em&gt; financial institution.&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;&lt;b&gt;&lt;i&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;&lt;b&gt;&lt;i&gt;Fair Value Measurements &lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 18pt;"&gt;The Company recognizes financial instruments in accordance with the authoritative guidance on fair value measurements and disclosures for financial assets and liabilities. This guidance defines fair value, establishes a framework for measuring fair value in accordance with GAAP, and expands disclosures about fair value measurements. The guidance also establishes a &lt;em style="font: inherit;"&gt;three&lt;/em&gt;-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value. These tiers include:&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 36pt;text-indent:-18pt;"&gt;&#160;&lt;/p&gt;
   &lt;table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr style="vertical-align: top;"&gt;&lt;td style="width: 18pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 18pt;"&gt; &lt;p style="margin: 0pt; text-align: justify; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#x25cf;&lt;/p&gt; &lt;/td&gt;&lt;td style="width: auto;"&gt; &lt;p style="margin: 0pt; text-align: justify; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;Level &lt;em style="font: inherit;"&gt;1&lt;/em&gt; includes quoted prices in active markets.&lt;/p&gt; &lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;
   &lt;table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr style="vertical-align: top;"&gt;&lt;td style="width: 18pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 18pt;"&gt; &lt;p style="margin: 0pt; text-align: justify; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#x25cf;&lt;/p&gt; &lt;/td&gt;&lt;td style="width: auto;"&gt; &lt;p style="margin: 0pt; text-align: justify; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;Level &lt;em style="font: inherit;"&gt;2&lt;/em&gt; includes significant observable inputs, such as quoted prices for identical or similar securities, or other inputs that are observable and can be corroborated by observable market data for similar securities. The Company uses market pricing and other observable market inputs obtained from &lt;em style="font: inherit;"&gt;third&lt;/em&gt;-party providers. It uses the bid price to establish fair value where a bid price is available. The Company does &lt;em style="font: inherit;"&gt;not&lt;/em&gt; have any financial instruments where the fair value is based on Level &lt;em style="font: inherit;"&gt;2&lt;/em&gt; inputs.&lt;/p&gt; &lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;
   &lt;table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr style="vertical-align: top;"&gt;&lt;td style="width: 18pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 18pt;"&gt; &lt;p style="margin: 0pt; text-align: justify; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#x25cf;&lt;/p&gt; &lt;/td&gt;&lt;td style="width: auto;"&gt; &lt;p style="margin: 0pt; text-align: justify; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;Level &lt;em style="font: inherit;"&gt;3&lt;/em&gt; includes unobservable inputs that are supported by little or &lt;em style="font: inherit;"&gt;no&lt;/em&gt; market activity. The Company does &lt;em style="font: inherit;"&gt;not&lt;/em&gt; have any financial instruments where the fair value is based on Level &lt;em style="font: inherit;"&gt;3&lt;/em&gt; inputs.&lt;/p&gt; &lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"&gt;If a financial instrument uses inputs that fall in different levels of the hierarchy, the instrument will be categorized based upon the lowest level of input that is significant to the fair value calculation. The fair value of cash and cash equivalents was based on Level &lt;em style="font: inherit;"&gt;1&lt;/em&gt; inputs at &lt;em style="font: inherit;"&gt; December 31, 2024&#160;&lt;/em&gt;and &lt;em style="font: inherit;"&gt;2023.&lt;/em&gt;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify; text-indent: 18pt;"&gt;The fair value of common stock warrants of $6.71 per warrant was determined at distribution on &lt;em style="font: inherit;"&gt; January 3, 2024 &lt;/em&gt;using a Monte Carlo valuation model since the warrants were&#160;&lt;em style="font: inherit;"&gt;not&lt;/em&gt; traded on the open market on &lt;em style="font: inherit;"&gt; January 3, 2024. &lt;/em&gt;Warrant trading on Nasdaq began on &lt;em style="font: inherit;"&gt; January 4, 2024. &lt;/em&gt;Quantitative information regarding Level &lt;em style="font: inherit;"&gt;3&lt;/em&gt; fair value measurements for common stock warrants is&#160;as follows:&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;&#160;&lt;/p&gt;

    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 85%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Exercise price per warrant&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;33.00&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Conversion rate - common shares per warrant&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;1.50&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Closing price of common stock&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;23.72&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Volatility&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;75&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;%&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Risk-free interest rate&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;5.40&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;%&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Expected life of option (in years)&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;0.3&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Dividend yield&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: right; margin: 0pt;"&gt;&lt;span style="-sec-ix-hidden:c123854924"&gt;zero&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;

   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -1pt; text-indent: 18pt;"&gt;The common stock warrants stopped&#160;trading on Nasdaq after &lt;em style="font: inherit;"&gt; May 2, 2024 &lt;/em&gt;and subsequently had little or &lt;em style="font: inherit;"&gt;no&lt;/em&gt; market activity. As of &lt;em style="font: inherit;"&gt; May 7, 2024,&#160;&lt;/em&gt;the warrants were presumed to have &lt;em style="font: inherit;"&gt;no&lt;/em&gt; value since they&#160;were redeemed for a nominal payment of $0.001 per warrant.&lt;/p&gt;
   &lt;p style="margin: 0pt 0pt 0pt -9pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/p&gt;&lt;p style="margin: 0pt 0pt 0pt -9pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;&lt;b&gt;&lt;i&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;&lt;b&gt;&lt;i&gt;Segment Information&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"&gt;The Company reports segment information based on how it internally evaluates the operating performance of its business units, or segments. The Company&#x2019;s operations are confined to one business segment: the development of novel drugs and diagnostics.&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-indent: 18pt; text-align: justify;"&gt;The Company&#x2019;s reportable segment&#160;reflects the manner in which its chief operating decision maker ("CODM") allocates resources and assesses performance. The Company's CODM is the President and Chief Executive Officer. The primary measure used by the Company's CODM for purposes of allocating resources is based on net loss that also is reported on the income statement as consolidated net loss. The measure of segment assets is reported on the balance sheet as cash and cash equivalents.&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-indent: 18pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify; text-indent: 18pt;"&gt;The Company has &lt;em style="font: inherit;"&gt;not&lt;/em&gt; generated any product revenue in the current period and expects to continue to incur significant expenses and operating losses for the foreseeable future as we advance our product candidates through stages of development and clinical trials.&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify; text-indent: 18pt;"&gt;As such, the CODM uses cash forecast models in deciding how to invest in&#160;the development of novel drugs and diagnostics. Such cash forecast models are reviewed to assess the entity-wide operating results and performance. Net loss is used to monitor budget versus actual results. Monitoring budgeted versus actual results, net cash used in operating activities for the period and cash on hand are used in assessing performance of the segment.&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-indent: 18pt;"&gt;&#160;&lt;/p&gt;


   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-indent: 18pt;"&gt;The following table summarizes expenses by category regularly reviewed by the CODM&#160;(in thousands):&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td colspan="10" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;&lt;em style="font: inherit;"&gt;&lt;em style="font: inherit;"&gt;Years Ended December 31,&lt;/em&gt;&lt;/em&gt;&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;2024&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;2023&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;2022&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 55%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Operating expenses&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;"&gt;Research and development&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;69,637&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;89,423&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;68,032&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;"&gt;General and administrative&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;71,809&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;16,534&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;11,988&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Other segment items(a)&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;(117,104&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;(8,740&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;(3,774&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Net loss&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;24,342&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;97,217&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;76,246&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;

   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;(a) Other segment items include interest income, other income, net and gain from change in fair value of warrant liabilities.&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 18pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 18pt;"&gt;The following table summarizes assets regularly reviewed by the CODM&#160;(in thousands):&lt;/p&gt;

    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr class="finHeading" style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="6" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;December 31,&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr class="finHeading" style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;2024&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;2023&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 70%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Cash and cash equivalents&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;128,574&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;121,136&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;

   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-indent: 18pt;"&gt;For the year ended &lt;em style="font: inherit;"&gt; December 31, 2024, &lt;/em&gt;and &lt;em style="font: inherit;"&gt;2023,&lt;/em&gt; the net cash used in operating activities was $116.9&#160;million and $82.0&#160;million, respectively.&#160;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;&lt;b&gt;&lt;i&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;&lt;b&gt;&lt;i&gt;Stock-based Compensation&lt;/i&gt;&lt;/b&gt;&lt;b&gt; &lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"&gt;The Company recognizes non-cash expense for the fair value of all stock options and other share-based awards. The Company uses the Black-Scholes option valuation model (&#x201c;Black-Scholes&#x201d;) to calculate the fair value of stock options, using the single-option award approach and straight-line attribution method. This model requires the input of subjective assumptions including expected stock price volatility, expected life and estimated forfeitures of each award. These assumptions consist of estimates of future market conditions, which are inherently uncertain, and therefore, are subject to management&#x2019;s judgment. For all options granted, it recognizes the resulting fair value as expense on a straight-line basis over the vesting period of each respective stock option, generally &lt;span style="-sec-ix-hidden:c123855418"&gt;one&lt;/span&gt;&#160;to&#160;&lt;span style="-sec-ix-hidden:c123855419"&gt;four&lt;/span&gt; years.&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"&gt;The Company has granted share-based awards that vest upon achievement of certain performance criteria (&#x201c;Performance Awards&#x201d;). The Company multiplies the number of Performance Awards by the fair value of its common stock on the date of grant to calculate the fair value of each award. It estimates an implicit service period for achieving performance criteria for each award. The Company recognizes the resulting fair value as expense over the implicit service period when it concludes that achieving the performance criteria is probable. It periodically reviews and updates as appropriate its estimates of implicit service periods and conclusions on achieving the performance criteria. Performance Awards vest and common stock is issued upon achievement of the performance criteria.&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&#160;&lt;/p&gt;


   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;&lt;b&gt;&lt;i&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;&lt;b&gt;&lt;i&gt;Net Loss per Share&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-indent: 18pt; text-align: justify;"&gt;Basic net loss&#160;per common share is computed by dividing the net loss&#160;available to common stockholders by the weighted-average number of common shares outstanding during the period. Diluted net loss&#160;per common share is computed by dividing the net loss&#160;available to common stockholders by the weighted-average number of common shares outstanding and potentially dilutive securities outstanding during the period using the treasury stock method. Potentially dilutive securities are excluded from the computations of diluted earnings per share if their effect would be anti-dilutive. A net loss&#160;causes all potentially dilutive securities to be anti-dilutive. Potentially dilutive securities consist of outstanding common stock options&#160;and Performance Awards.&#160;There is &lt;em style="font: inherit;"&gt;no&lt;/em&gt; difference between the Company&#x2019;s net loss and comprehensive loss. The numerators and denominators in the calculation of basic and diluted net loss per share were as follows (in thousands, except net loss per share data):&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"&gt;&#160;&lt;/p&gt;

    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="10" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;&lt;em style="font: inherit;"&gt;&lt;em style="font: inherit;"&gt;Years ended December 31,&lt;/em&gt;&lt;/em&gt;&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;2024&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;2023&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;2022&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 55%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Numerator, basic:&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;"&gt;Net loss&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;(24,342&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;(97,217&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;(76,246&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Denominator, basic:&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;"&gt;Weighted average common shares outstanding&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;46,329&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;41,932&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;40,202&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Net loss per share, basic&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;(0.53&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;(2.32&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;(1.90&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Numerator, diluted:&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;"&gt;Net loss&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;(24,342&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;(97,217&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;(76,246&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;"&gt;Adjustment for change in fair value of warrant liabilities&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;(43,793&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Adjusted numerator, diluted&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;(68,135&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;(97,217&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;(76,246&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Denominator, diluted:&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;"&gt;Weighted average common shares outstanding&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;46,329&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;41,932&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;40,202&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;"&gt;Dilutive effect of common stock warrants&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;275&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;"&gt;Weighted average dilutive common shares&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;46,604&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;41,932&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;40,202&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Net loss per share, diluted&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;(1.46&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;(2.32&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;(1.90&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Dilutive common stock options excluded from net loss per share, diluted&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;3,154&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;2,123&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;2,055&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Dilutive Performance Awards excluded from loss per share, diluted&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;7&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;7&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;7&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;

   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"&gt;&#160;&lt;/p&gt;&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"&gt;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&lt;b&gt;&lt;i&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&lt;b&gt;&lt;i&gt;Warrant Liabilities&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 18pt;"&gt;The Company accounts for warrants as either equity-classified or liability-classified instruments based on an assessment of the warrant&#x2019;s specific terms and in accordance with the Financial Accounting Standards Board (&#x201c;FASB&#x201d;) Accounting Standards Codification (&#x201c;ASC&#x201c;) &lt;em style="font: inherit;"&gt;480,&lt;/em&gt; &#x201c;Distinguishing Liabilities from Equity&#x201d;, and ASC &lt;em style="font: inherit;"&gt;815,&lt;/em&gt; &#x201c;Derivatives and Hedging&#x201d;. The assessment considers whether the warrants are freestanding financial instruments pursuant to ASC &lt;em style="font: inherit;"&gt;480,&lt;/em&gt; meet the definition of a liability pursuant to ASC &lt;em style="font: inherit;"&gt;480,&lt;/em&gt; and whether the warrants meet all of the requirements for equity classification under ASC &lt;em style="font: inherit;"&gt;815,&lt;/em&gt; including whether the warrants are indexed to the Company&#x2019;s own shares, among other conditions for equity classification. This assessment, which requires the use of professional judgment, is conducted at the time of warrant issuance and as of each subsequent quarterly period end date while the warrants are outstanding.&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 18pt;"&gt;For issued or modified warrants that meet all of the criteria for equity classification, the warrants are required to be recorded as a component of additional paid-in capital at the time of issuance. For issued or modified warrants that do &lt;em style="font: inherit;"&gt;not&lt;/em&gt; meet all the criteria for equity classification, the warrants are required to be recorded at their initial fair value of the date of issuance, and each balance sheet date thereafter. Changes in the estimated fair value of liability classified warrants are recognized as a non-cash gain or loss on the statements of operations. Costs associated with issuing the warrants classified as derivative liabilities are charged to operations when the warrants are issued.&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;&lt;/p&gt;


   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;&lt;b&gt;&lt;i&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;&lt;b&gt;&lt;i&gt;Fair Value of Financial Instruments&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"&gt;Financial instruments include accounts payable, accrued expenses, accrued development expense and other liabilities. The estimated fair value of certain financial instruments &lt;em style="font: inherit;"&gt; may &lt;/em&gt;be determined using available market information or other appropriate valuation methodologies. However, considerable judgment is required in interpreting market data to develop estimates of fair value; therefore, the estimates are &lt;em style="font: inherit;"&gt;not&lt;/em&gt; necessarily indicative of the amounts that could be realized or would be paid in a current market exchange. The effect of using different market assumptions and/or estimation methodologies &lt;em style="font: inherit;"&gt; may &lt;/em&gt;be material to the estimated fair value amounts. The carrying amounts of accounts payable,&#160;accrued expenses, accrued development expense&#160;and other liabilities&#160;are at cost, which approximates fair value due to the short maturity of those instruments.&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;&lt;b&gt;&lt;i&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;&lt;b&gt;&lt;i&gt;Research Contracts, Prepaids and Accruals&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"&gt;The Company has entered into various research and development contracts with research institutions and other &lt;em style="font: inherit;"&gt;third&lt;/em&gt;-party vendors. These agreements are generally cancelable. Related payments are recorded as research and development expenses as incurred. The Company records prepaids and accruals for estimated ongoing research costs. When evaluating the adequacy of&#160;prepaid expenses and accrued liabilities, the Company analyzes progress of the studies including the phase or completion of events, invoices received and contracted costs. Significant judgments and estimates are made in determining the prepaid and accrued balances at the end of any reporting period. Actual results could differ from the Company&#x2019;s estimates. The Company&#x2019;s historical prepaid and accrual estimates have &lt;em style="font: inherit;"&gt;not&lt;/em&gt; been materially different from actual costs.&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;&lt;b&gt;&lt;i&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;&lt;b&gt;&lt;i&gt;Incentive Bonus Plan&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"&gt;In &lt;em style="font: inherit;"&gt;2020,&lt;/em&gt; the Company established the &lt;em style="font: inherit;"&gt;2020&lt;/em&gt; Cash Incentive Bonus Plan (the &#x201c;CIB Plan&#x201d;) to incentivize CIB Plan participants. Awards under the CIB Plan are accounted for as liability awards under ASC&#160;&lt;em style="font: inherit;"&gt;718&lt;/em&gt; &#x201c;&lt;i&gt;Stock-based Compensation&lt;/i&gt;&#x201d;.&#160;The fair value of each&#160;potential CIB Plan&#160;award&#160;will be&#160;determined&#160;once&#160;a&#160;grant date occurs and&#160;will be&#160;remeasured each reporting period.&#160;Compensation expense associated with the CIB Plan&#160;will be&#160;recognized over the expected achievement period for each&#160;CIB Plan award, when&#160;a Performance Condition&#160;(as defined below) is considered probable of being met. See Note &lt;em style="font: inherit;"&gt;11&lt;/em&gt; for further discussion of the CIB Plan.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;/p&gt;
   &lt;p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left"&gt;&lt;b&gt;&lt;i&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left"&gt;&lt;b&gt;&lt;i&gt;Property and Equipment&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"&gt;Property and equipment are&#160;recorded at cost, net of accumulated depreciation. Depreciation is recorded using the straight-line method over the estimated useful lives of the assets. Owned buildings and related improvements have estimated useful lives of 39 years and approximately 10 years, respectively. Tenant improvements&#160;related to leased space are amortized using the straight-line method over the useful lives of the improvements or the remaining term of the corresponding leases, whichever is shorter.&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"&gt;Property and equipment are reviewed for impairment when events or changes in circumstances indicate the carrying amount of an asset &lt;em style="font: inherit;"&gt; may &lt;/em&gt;&lt;em style="font: inherit;"&gt;not&lt;/em&gt; be recoverable. If property and equipment are considered to be impaired, an impairment loss is recognized.&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;&lt;b&gt;&lt;i&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;&lt;b&gt;&lt;i&gt;Intangible Assets&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"&gt;Acquired intangible assets are recorded at fair value at the date of acquisition and primarily consist of lease-in-place agreements and leasing commissions. Intangible assets are amortized over the estimated life of the lease-in-place agreements.&#160;Intangible assets also include&#160;leasing commissions, which are amortized over the life of the lease agreement.&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"&gt;Intangible assets are reviewed for impairment on an annual basis, and when there is reason to believe that their values have been diminished or impaired. If intangible assets are considered to be impaired, an impairment loss is recognized.&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"&gt;&#160;&lt;/p&gt;&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"&gt;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;"&gt;&lt;b&gt;&lt;i&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;"&gt;&lt;b&gt;&lt;i&gt;Insurance Recoveries&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 18pt;"&gt;We record proceeds from our&#160;insurance policies&#160;when the loss event has&#160;occurred, and proceeds are estimable and probable of being recovered. Insurance recoveries&#160;and proceeds received are recorded as a reduction to general and administrative expense.&#160;There was approximately $9.9&#160;million&#160;and $0.1 million of insurance recoveries recorded during the year ended &lt;em style="font: inherit;"&gt; December 31, 2024 &lt;/em&gt;and &lt;em style="font: inherit;"&gt;2023,&lt;/em&gt; respectively. The applicable policy year had&#160;a $10.0 million recovery limit which has been reached at &lt;em style="font: inherit;"&gt; December 31, 2024.&lt;/em&gt;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;"&gt;&#160;&lt;/p&gt;&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;"&gt;&lt;/p&gt;


   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;"&gt;&lt;b&gt;&lt;i&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;"&gt;&lt;b&gt;&lt;i&gt;Related Party Transactions&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-indent: 18pt; text-align: justify;"&gt;On &lt;em style="font: inherit;"&gt; July 15, 2024, &lt;/em&gt;our former&#160;President and Chief Executive Officer&#160;resigned from the Company, effective as of &lt;em style="font: inherit;"&gt; September 13, 2024 (&lt;/em&gt;the &#x201c;Effective Date&#x201d;). Pursuant to the terms of his employment agreement, our former&#160;President and Chief Executive Officer is&#160;receiving&#160;severance compensation equal to $1.23 million over &lt;em style="font: inherit;"&gt;twelve&lt;/em&gt; months following the Effective Date. Severance compensation was included in general and administrative expense.&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-indent: 18pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-indent: 18pt; text-align: justify;"&gt;On &lt;em style="font: inherit;"&gt; July 16, 2024, &lt;/em&gt;our former Senior Vice President (SVP), Neuroscience agreed to step down from her employment with the Company, effective immediately. Our former SVP, Neuroscience is the spouse of our former&#160;President and Chief Executive Officer. Pursuant to a separation agreement, our former SVP, Neuroscience is&#160;receiving&#160;severance compensation equal to $0.5 million in quarterly installments over &lt;em style="font: inherit;"&gt;twelve&lt;/em&gt; months.&#160;Severance compensation was included in research and development&#160;expense.&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-indent: 18pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -2pt; text-indent: 18pt; text-align: justify;"&gt;Included in accrued compensation and benefits at &lt;em style="font: inherit;"&gt; December 31, 2024 &lt;/em&gt;is approximately $1.2&#160;million of accrued severance costs for the &lt;span style="-sec-ix-hidden:c123855449"&gt;two&lt;/span&gt; former senior officers.&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -2pt; text-indent: 18pt; text-align: justify;"&gt;On &lt;em style="font: inherit;"&gt; July 16, 2024, &lt;/em&gt;the Company entered into a one-year consulting agreement&#160;with the Company&#x2019;s former SVP, Neuroscience.&#160;Pursuant to the terms of the consulting agreement, the&#160;consultant is providing services&#160;for purposes of providing information and support for scientific research and/or obtaining governmental approval for the Company&#x2019;s products.&#160;The Company will pay&#160;$500&#160;per hour&#160;for such&#160;consulting services. The Company incurred fees totaling $43,000 under the consulting agreement during the year ended &lt;em style="font: inherit;"&gt; December 31, 2024.&lt;/em&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;&lt;b&gt;&lt;i&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;&lt;b&gt;&lt;i&gt;Income Taxes&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"&gt;The Company accounts for income taxes under the asset and liability method.&#160;Deferred tax assets and liabilities are recognized for the estimated future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. &#160;Deferred tax balances are adjusted to reflect tax rates based on currently enacted tax laws, which will be in effect in the years in which the temporary differences are expected to reverse.&#160;The Company has accumulated significant deferred tax assets that reflect the tax effects of net operating loss and tax credit carryovers and temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. Realization of certain deferred tax assets is dependent upon future earnings. The Company is uncertain about the timing and amount of any future earnings. Accordingly, the Company offsets these deferred tax assets with a valuation allowance.&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"&gt;The Company accounts for uncertain tax positions in accordance with ASC &lt;em style="font: inherit;"&gt;740,&lt;/em&gt; &#x201c;Income Taxes&#x201d;, which clarifies the accounting for uncertainty in tax positions. These provisions require recognition of the impact of a tax position in the Company&#x2019;s financial statements only if that position is more likely than &lt;em style="font: inherit;"&gt;not&lt;/em&gt; of being sustained upon examination by taxing authorities, based on the technical merits of the position. Any interest and penalties related to uncertain tax positions will be reflected as a component of income tax expense.&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"&gt;&#160;&lt;/p&gt;&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"&gt;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;"&gt;&lt;b&gt;&lt;i&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;"&gt;&lt;b&gt;&lt;i&gt;Recent Accounting Pronouncements&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
   &lt;p style="text-align: justify; margin: 0pt 0pt 0pt -9pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify; text-indent: 18pt;"&gt;In &lt;em style="font: inherit;"&gt; November 2023, &lt;/em&gt;the FASB&#160;issued Accounting Standards Update ("ASU") &lt;em style="font: inherit;"&gt;2023&lt;/em&gt;-&lt;em style="font: inherit;"&gt;07,&lt;/em&gt; Segment Reporting (Topic &lt;em style="font: inherit;"&gt;280&lt;/em&gt;): Improvements to Reportable Segment Disclosures. This ASU includes amendments that expand the existing reportable segment disclosure requirements and requires disclosure of (i) significant expense categories and amounts by reportable segment as well as the segment&#x2019;s profit or loss measure(s) that are regularly provided to the chief operating decision maker (the &#x201c;CODM&#x201d;) to allocate resources and assess performance; (ii) how the CODM uses each reported segment profit or loss measure to allocate resources and assess performance; (iii) the nature of other segment balances contributing to reported segment profit or loss that are &lt;em style="font: inherit;"&gt;not&lt;/em&gt; captured within segment revenues or expenses; and (iv) the title and position of the individual or name of the group or committee identified as the CODM. This guidance requires retrospective application to all prior periods presented in the financial statements and is effective for fiscal years beginning after &lt;em style="font: inherit;"&gt; December 15, 2023 &lt;/em&gt;and interim periods within fiscal years beginning after &lt;em style="font: inherit;"&gt; December 15, 2024.&#160;&lt;/em&gt;The Company adopted this guidance and has included enhanced disclosures relating to its reportable segments. See &lt;i&gt;Business Segments&lt;/i&gt;, included in this Note &lt;em style="font: inherit;"&gt;2&lt;/em&gt; to the Consolidated Financial Statements, for the Company's updated disclosure.&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify; text-indent: 18pt;"&gt;&#160;&lt;/p&gt;


   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt;"&gt;&lt;i&gt;&lt;b&gt;Accounting Guidance Issued But &lt;em style="font: inherit;"&gt;Not&lt;/em&gt; Adopted as of &lt;em style="font: inherit;"&gt; December 31, 2024&lt;/em&gt;&lt;/b&gt;&lt;/i&gt;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-indent: 18pt; text-align: justify;"&gt;In &lt;em style="font: inherit;"&gt; November 2024, &lt;/em&gt;the FASB issued ASU &lt;em style="font: inherit;"&gt;2024&lt;/em&gt;-&lt;em style="font: inherit;"&gt;03,&lt;/em&gt; Income Statement&#x2014;Reporting Comprehensive Income&#x2014;Expense Disaggregation Disclosures (Subtopic &lt;em style="font: inherit;"&gt;220&lt;/em&gt;-&lt;em style="font: inherit;"&gt;40&lt;/em&gt;): Disaggregation of Income Statement Expenses. This ASU includes amendments that require entities to bifurcate specified expense line items on the income statement into underlying components, including employee compensation, depreciation, and intangible asset amortization, as applicable. Qualitative descriptions of the remaining components are required. These enhanced disclosures are required for both interim and annual periods. In &lt;em style="font: inherit;"&gt; January 2025, &lt;/em&gt;the FASB subsequently issued ASU &lt;em style="font: inherit;"&gt;2025&lt;/em&gt;-&lt;em style="font: inherit;"&gt;01,&lt;/em&gt; Income Statement&#x2014;Reporting Comprehensive Income&#x2014;Expense Disaggregation Disclosures (Subtopic &lt;em style="font: inherit;"&gt;220&lt;/em&gt;-&lt;em style="font: inherit;"&gt;40&lt;/em&gt;): Clarifying the Effective Date, to provide clarification on the ASU's effective date. The new standard is effective for fiscal years beginning after &lt;em style="font: inherit;"&gt; December 15, 2026 &lt;/em&gt;on a prospective basis with the option to apply it retrospectively, and for interim periods&#160;within fiscal years beginning after &lt;em style="font: inherit;"&gt; December 15, 2027. &lt;/em&gt;Early adoption is permitted. The adoption of this guidance will result in the Company being required to include enhanced disclosures around income statement expenses.&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-indent: 18pt; text-align: justify;"&gt;In &lt;em style="font: inherit;"&gt; December 2023, &lt;/em&gt;the FASB issued ASU &lt;em style="font: inherit;"&gt;2023&lt;/em&gt;-&lt;em style="font: inherit;"&gt;09,&lt;/em&gt; Income Taxes (Topic &lt;em style="font: inherit;"&gt;740&lt;/em&gt;): Improvements to Income Tax Disclosures. The ASU requires that an entity disclose specific categories in the effective tax rate reconciliation as well as reconciling items that meet a quantitative threshold. Further, the ASU requires additional disclosures on income tax expense and taxes paid, net of refunds received, by jurisdiction. The new standard is effective for annual periods beginning after &lt;em style="font: inherit;"&gt; December 15, 2024 &lt;/em&gt;on a prospective basis with the option to apply it retrospectively. Early adoption is permitted. The adoption of this guidance will result in the company being required to include enhanced income tax related disclosures.&lt;/p&gt;
   &lt;p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left"&gt;&#160;&lt;/p&gt;&lt;p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left"&gt;&lt;/p&gt;
  </us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:UseOfEstimates contextRef="d_2024-01-01_2024-12-31" id="c123862978">&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;&lt;b&gt;&lt;i&gt;Use of Estimates&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"&gt;The Company makes estimates and assumptions in preparing its consolidated financial statements in conformity with accounting principles generally accepted in the United States. These estimates and assumptions affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amount of revenue earned and expenses incurred during the reporting period. The Company evaluates&#160;its estimates on an ongoing basis, including those estimates related to legal liabilities, common stock warrant liabilities, stock based compensation, clinical trials and manufacturing agreements. Actual results could differ from these estimates and assumptions.&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;&#160;&lt;/p&gt;</us-gaap:UseOfEstimates>
    <us-gaap:GovernmentAssistancePolicyTextBlock contextRef="d_2024-01-01_2024-12-31" id="c123862979">&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;&lt;b&gt;&lt;i&gt;Proceeds from Grants&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"&gt;During &lt;em style="font: inherit;"&gt;2024&lt;/em&gt; and &lt;em style="font: inherit;"&gt;2023,&lt;/em&gt; there were no reimbursements received pursuant to National Institutes of Health (&#x201c;NIH&#x201d;) research grants. In &lt;em style="font: inherit;"&gt;2022,&lt;/em&gt; the Company received $0.9 million of reimbursement&#160;from the NIH&#160;and National Institute on Drug Abuse. The Company records the proceeds from these grants as reductions to its &lt;span style="-sec-ix-hidden:c123855795"&gt;research and development expenses&lt;/span&gt;.&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;/p&gt;</us-gaap:GovernmentAssistancePolicyTextBlock>
    <us-gaap:GovernmentAssistanceAmount
      contextRef="d_2024-01-01_2024-12-31"
      decimals="-3"
      id="c123855388"
      unitRef="USD">0</us-gaap:GovernmentAssistanceAmount>
    <us-gaap:GovernmentAssistanceAmount
      contextRef="d_2022-01-01_2022-12-31"
      decimals="-5"
      id="c123855390"
      unitRef="USD">900000</us-gaap:GovernmentAssistanceAmount>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock contextRef="d_2024-01-01_2024-12-31" id="c123862980">&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;&lt;b&gt;&lt;i&gt;Cash and Cash Equivalents and Concentration of Credit Risk&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"&gt;The Company invests in cash and cash equivalents. The Company considers highly-liquid financial instruments with original maturities of &lt;em style="font: inherit;"&gt;three&lt;/em&gt; months or less to be cash equivalents. Highly liquid investments that are considered cash equivalents include money market accounts and funds, certificates of deposit and U.S. Treasury securities. The Company maintains&#160;its cash and cash equivalents at &lt;em style="font: inherit;"&gt;one&lt;/em&gt; financial institution.&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;&#160;&lt;/p&gt;</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <us-gaap:FairValueMeasurementPolicyPolicyTextBlock contextRef="d_2024-01-01_2024-12-31" id="c123862981">&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;&lt;b&gt;&lt;i&gt;Fair Value Measurements &lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 18pt;"&gt;The Company recognizes financial instruments in accordance with the authoritative guidance on fair value measurements and disclosures for financial assets and liabilities. This guidance defines fair value, establishes a framework for measuring fair value in accordance with GAAP, and expands disclosures about fair value measurements. The guidance also establishes a &lt;em style="font: inherit;"&gt;three&lt;/em&gt;-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value. These tiers include:&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 36pt;text-indent:-18pt;"&gt;&#160;&lt;/p&gt;
   &lt;table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr style="vertical-align: top;"&gt;&lt;td style="width: 18pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 18pt;"&gt; &lt;p style="margin: 0pt; text-align: justify; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#x25cf;&lt;/p&gt; &lt;/td&gt;&lt;td style="width: auto;"&gt; &lt;p style="margin: 0pt; text-align: justify; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;Level &lt;em style="font: inherit;"&gt;1&lt;/em&gt; includes quoted prices in active markets.&lt;/p&gt; &lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;
   &lt;table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr style="vertical-align: top;"&gt;&lt;td style="width: 18pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 18pt;"&gt; &lt;p style="margin: 0pt; text-align: justify; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#x25cf;&lt;/p&gt; &lt;/td&gt;&lt;td style="width: auto;"&gt; &lt;p style="margin: 0pt; text-align: justify; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;Level &lt;em style="font: inherit;"&gt;2&lt;/em&gt; includes significant observable inputs, such as quoted prices for identical or similar securities, or other inputs that are observable and can be corroborated by observable market data for similar securities. The Company uses market pricing and other observable market inputs obtained from &lt;em style="font: inherit;"&gt;third&lt;/em&gt;-party providers. It uses the bid price to establish fair value where a bid price is available. The Company does &lt;em style="font: inherit;"&gt;not&lt;/em&gt; have any financial instruments where the fair value is based on Level &lt;em style="font: inherit;"&gt;2&lt;/em&gt; inputs.&lt;/p&gt; &lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;
   &lt;table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr style="vertical-align: top;"&gt;&lt;td style="width: 18pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 18pt;"&gt; &lt;p style="margin: 0pt; text-align: justify; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#x25cf;&lt;/p&gt; &lt;/td&gt;&lt;td style="width: auto;"&gt; &lt;p style="margin: 0pt; text-align: justify; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;Level &lt;em style="font: inherit;"&gt;3&lt;/em&gt; includes unobservable inputs that are supported by little or &lt;em style="font: inherit;"&gt;no&lt;/em&gt; market activity. The Company does &lt;em style="font: inherit;"&gt;not&lt;/em&gt; have any financial instruments where the fair value is based on Level &lt;em style="font: inherit;"&gt;3&lt;/em&gt; inputs.&lt;/p&gt; &lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"&gt;If a financial instrument uses inputs that fall in different levels of the hierarchy, the instrument will be categorized based upon the lowest level of input that is significant to the fair value calculation. The fair value of cash and cash equivalents was based on Level &lt;em style="font: inherit;"&gt;1&lt;/em&gt; inputs at &lt;em style="font: inherit;"&gt; December 31, 2024&#160;&lt;/em&gt;and &lt;em style="font: inherit;"&gt;2023.&lt;/em&gt;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify; text-indent: 18pt;"&gt;The fair value of common stock warrants of $6.71 per warrant was determined at distribution on &lt;em style="font: inherit;"&gt; January 3, 2024 &lt;/em&gt;using a Monte Carlo valuation model since the warrants were&#160;&lt;em style="font: inherit;"&gt;not&lt;/em&gt; traded on the open market on &lt;em style="font: inherit;"&gt; January 3, 2024. &lt;/em&gt;Warrant trading on Nasdaq began on &lt;em style="font: inherit;"&gt; January 4, 2024. &lt;/em&gt;Quantitative information regarding Level &lt;em style="font: inherit;"&gt;3&lt;/em&gt; fair value measurements for common stock warrants is&#160;as follows:&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;&#160;&lt;/p&gt;

    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 85%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Exercise price per warrant&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;33.00&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Conversion rate - common shares per warrant&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;1.50&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Closing price of common stock&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;23.72&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Volatility&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;75&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;%&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Risk-free interest rate&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;5.40&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;%&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Expected life of option (in years)&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;0.3&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Dividend yield&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: right; margin: 0pt;"&gt;&lt;span style="-sec-ix-hidden:c123854924"&gt;zero&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;

   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -1pt; text-indent: 18pt;"&gt;The common stock warrants stopped&#160;trading on Nasdaq after &lt;em style="font: inherit;"&gt; May 2, 2024 &lt;/em&gt;and subsequently had little or &lt;em style="font: inherit;"&gt;no&lt;/em&gt; market activity. As of &lt;em style="font: inherit;"&gt; May 7, 2024,&#160;&lt;/em&gt;the warrants were presumed to have &lt;em style="font: inherit;"&gt;no&lt;/em&gt; value since they&#160;were redeemed for a nominal payment of $0.001 per warrant.&lt;/p&gt;
   &lt;p style="margin: 0pt 0pt 0pt -9pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/p&gt;</us-gaap:FairValueMeasurementPolicyPolicyTextBlock>
    <sava:ClassOfWarrantOrRightFairValueOfCommonStockWarrantsPerWarrant
      contextRef="i_2024-01-03"
      decimals="INF"
      id="c123855406"
      unitRef="USDPerShare">6.71</sava:ClassOfWarrantOrRightFairValueOfCommonStockWarrantsPerWarrant>
    <us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock contextRef="d_2024-01-01_2024-12-31" id="c2851677">
    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 85%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Exercise price per warrant&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;33.00&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Conversion rate - common shares per warrant&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;1.50&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Closing price of common stock&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;23.72&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Volatility&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;75&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;%&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Risk-free interest rate&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;5.40&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;%&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Expected life of option (in years)&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;0.3&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Dividend yield&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: right; margin: 0pt;"&gt;&lt;span style="-sec-ix-hidden:c123854924"&gt;zero&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;
   </us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="i_2024-12-31_ClassOfWarrantOrRightAxis-WarrantsToPurchaseCommonStockMember_MeasurementInputTypeAxis-MeasurementInputExercisePriceMember"
      decimals="INF"
      id="c123854918"
      unitRef="Pure">33</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="i_2024-12-31_ClassOfWarrantOrRightAxis-WarrantsToPurchaseCommonStockMember_MeasurementInputTypeAxis-MeasurementInputConversionPriceMember"
      decimals="INF"
      id="c123854919"
      unitRef="Pure">1.5</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="i_2024-12-31_ClassOfWarrantOrRightAxis-WarrantsToPurchaseCommonStockMember_MeasurementInputTypeAxis-MeasurementInputSharePriceMember"
      decimals="INF"
      id="c123854920"
      unitRef="Pure">23.72</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="i_2024-12-31_ClassOfWarrantOrRightAxis-WarrantsToPurchaseCommonStockMember_MeasurementInputTypeAxis-MeasurementInputPriceVolatilityMember"
      decimals="2"
      id="c123854921"
      unitRef="Pure">0.75</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="i_2024-12-31_ClassOfWarrantOrRightAxis-WarrantsToPurchaseCommonStockMember_MeasurementInputTypeAxis-MeasurementInputRiskFreeInterestRateMember"
      decimals="3"
      id="c123854922"
      unitRef="Pure">0.054</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="i_2024-12-31_ClassOfWarrantOrRightAxis-WarrantsToPurchaseCommonStockMember_MeasurementInputTypeAxis-MeasurementInputExpectedTermMember"
      decimals="INF"
      id="c123854923"
      unitRef="Pure">0.3</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <sava:ClassOfWarrantOrRightRedemptionPricePerShare
      contextRef="i_2024-05-07"
      decimals="INF"
      id="c123855411"
      unitRef="USDPerShare">0.001</sava:ClassOfWarrantOrRightRedemptionPricePerShare>
    <us-gaap:SegmentReportingPolicyPolicyTextBlock contextRef="d_2024-01-01_2024-12-31" id="c123862982">&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;&lt;b&gt;&lt;i&gt;Segment Information&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"&gt;The Company reports segment information based on how it internally evaluates the operating performance of its business units, or segments. The Company&#x2019;s operations are confined to one business segment: the development of novel drugs and diagnostics.&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-indent: 18pt; text-align: justify;"&gt;The Company&#x2019;s reportable segment&#160;reflects the manner in which its chief operating decision maker ("CODM") allocates resources and assesses performance. The Company's CODM is the President and Chief Executive Officer. The primary measure used by the Company's CODM for purposes of allocating resources is based on net loss that also is reported on the income statement as consolidated net loss. The measure of segment assets is reported on the balance sheet as cash and cash equivalents.&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-indent: 18pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify; text-indent: 18pt;"&gt;The Company has &lt;em style="font: inherit;"&gt;not&lt;/em&gt; generated any product revenue in the current period and expects to continue to incur significant expenses and operating losses for the foreseeable future as we advance our product candidates through stages of development and clinical trials.&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify; text-indent: 18pt;"&gt;As such, the CODM uses cash forecast models in deciding how to invest in&#160;the development of novel drugs and diagnostics. Such cash forecast models are reviewed to assess the entity-wide operating results and performance. Net loss is used to monitor budget versus actual results. Monitoring budgeted versus actual results, net cash used in operating activities for the period and cash on hand are used in assessing performance of the segment.&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-indent: 18pt;"&gt;&#160;&lt;/p&gt;


   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-indent: 18pt;"&gt;The following table summarizes expenses by category regularly reviewed by the CODM&#160;(in thousands):&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td colspan="10" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;&lt;em style="font: inherit;"&gt;&lt;em style="font: inherit;"&gt;Years Ended December 31,&lt;/em&gt;&lt;/em&gt;&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;2024&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;2023&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;2022&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 55%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Operating expenses&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;"&gt;Research and development&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;69,637&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;89,423&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;68,032&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;"&gt;General and administrative&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;71,809&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;16,534&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;11,988&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Other segment items(a)&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;(117,104&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;(8,740&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;(3,774&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Net loss&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;24,342&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;97,217&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;76,246&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;

   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;(a) Other segment items include interest income, other income, net and gain from change in fair value of warrant liabilities.&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 18pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 18pt;"&gt;The following table summarizes assets regularly reviewed by the CODM&#160;(in thousands):&lt;/p&gt;

    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr class="finHeading" style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="6" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;December 31,&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr class="finHeading" style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;2024&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;2023&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 70%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Cash and cash equivalents&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;128,574&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;121,136&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;

   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-indent: 18pt;"&gt;For the year ended &lt;em style="font: inherit;"&gt; December 31, 2024, &lt;/em&gt;and &lt;em style="font: inherit;"&gt;2023,&lt;/em&gt; the net cash used in operating activities was $116.9&#160;million and $82.0&#160;million, respectively.&#160;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;</us-gaap:SegmentReportingPolicyPolicyTextBlock>
    <us-gaap:NumberOfOperatingSegments
      contextRef="d_2024-01-01_2024-12-31"
      decimals="INF"
      id="c123855412"
      unitRef="Pure">1</us-gaap:NumberOfOperatingSegments>
    <us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock
      contextRef="d_2024-01-01_2024-12-31"
      id="A9262710-C620-44C9-9C88-087499052833">
    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td colspan="10" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;&lt;em style="font: inherit;"&gt;&lt;em style="font: inherit;"&gt;Years Ended December 31,&lt;/em&gt;&lt;/em&gt;&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;2024&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;2023&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;2022&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 55%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Operating expenses&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;"&gt;Research and development&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;69,637&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;89,423&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;68,032&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;"&gt;General and administrative&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;71,809&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;16,534&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;11,988&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Other segment items(a)&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;(117,104&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;(8,740&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;(3,774&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Net loss&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;24,342&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;97,217&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;76,246&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;

    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr class="finHeading" style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="6" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;December 31,&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr class="finHeading" style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;2024&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;2023&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 70%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Cash and cash equivalents&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;128,574&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;121,136&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;
   </us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="d_2024-01-01_2024-12-31_StatementBusinessSegmentsAxis-CodmMonitoringMember"
      decimals="-3"
      id="c123854931"
      unitRef="USD">69637000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="d_2023-01-01_2023-12-31_StatementBusinessSegmentsAxis-CodmMonitoringMember"
      decimals="-3"
      id="c123854932"
      unitRef="USD">89423000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="d_2022-01-01_2022-12-31_StatementBusinessSegmentsAxis-CodmMonitoringMember"
      decimals="-3"
      id="c123854933"
      unitRef="USD">68032000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="d_2024-01-01_2024-12-31_StatementBusinessSegmentsAxis-CodmMonitoringMember"
      decimals="-3"
      id="c123854934"
      unitRef="USD">71809000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="d_2023-01-01_2023-12-31_StatementBusinessSegmentsAxis-CodmMonitoringMember"
      decimals="-3"
      id="c123854935"
      unitRef="USD">16534000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="d_2022-01-01_2022-12-31_StatementBusinessSegmentsAxis-CodmMonitoringMember"
      decimals="-3"
      id="c123854936"
      unitRef="USD">11988000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:SegmentReportingOtherItemAmount
      contextRef="d_2024-01-01_2024-12-31_StatementBusinessSegmentsAxis-CodmMonitoringMember"
      decimals="-3"
      id="c123854937"
      unitRef="USD">-117104000</us-gaap:SegmentReportingOtherItemAmount>
    <us-gaap:SegmentReportingOtherItemAmount
      contextRef="d_2023-01-01_2023-12-31_StatementBusinessSegmentsAxis-CodmMonitoringMember"
      decimals="-4"
      id="c123854938"
      unitRef="USD">-8740000</us-gaap:SegmentReportingOtherItemAmount>
    <us-gaap:SegmentReportingOtherItemAmount
      contextRef="d_2022-01-01_2022-12-31_StatementBusinessSegmentsAxis-CodmMonitoringMember"
      decimals="-3"
      id="c123854939"
      unitRef="USD">-3774000</us-gaap:SegmentReportingOtherItemAmount>
    <us-gaap:NetIncomeLoss
      contextRef="d_2024-01-01_2024-12-31_StatementBusinessSegmentsAxis-CodmMonitoringMember"
      decimals="-3"
      id="c123854940"
      unitRef="USD">24342000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="d_2023-01-01_2023-12-31_StatementBusinessSegmentsAxis-CodmMonitoringMember"
      decimals="-3"
      id="c123854941"
      unitRef="USD">97217000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="d_2022-01-01_2022-12-31_StatementBusinessSegmentsAxis-CodmMonitoringMember"
      decimals="-3"
      id="c123854942"
      unitRef="USD">76246000</us-gaap:NetIncomeLoss>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i_2024-12-31_StatementBusinessSegmentsAxis-CodmMonitoringMember"
      decimals="-3"
      id="c123854944"
      unitRef="USD">128574000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i_2023-12-31_StatementBusinessSegmentsAxis-CodmMonitoringMember"
      decimals="-3"
      id="c123854945"
      unitRef="USD">121136000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="d_2024-01-01_2024-12-31"
      decimals="-5"
      id="c123855416"
      unitRef="USD">-116900000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="d_2023-01-01_2023-12-31"
      decimals="-6"
      id="c123855417"
      unitRef="USD">-82000000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:CompensationRelatedCostsPolicyTextBlock contextRef="d_2024-01-01_2024-12-31" id="c123862983">&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;&lt;b&gt;&lt;i&gt;Stock-based Compensation&lt;/i&gt;&lt;/b&gt;&lt;b&gt; &lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"&gt;The Company recognizes non-cash expense for the fair value of all stock options and other share-based awards. The Company uses the Black-Scholes option valuation model (&#x201c;Black-Scholes&#x201d;) to calculate the fair value of stock options, using the single-option award approach and straight-line attribution method. This model requires the input of subjective assumptions including expected stock price volatility, expected life and estimated forfeitures of each award. These assumptions consist of estimates of future market conditions, which are inherently uncertain, and therefore, are subject to management&#x2019;s judgment. For all options granted, it recognizes the resulting fair value as expense on a straight-line basis over the vesting period of each respective stock option, generally &lt;span style="-sec-ix-hidden:c123855418"&gt;one&lt;/span&gt;&#160;to&#160;&lt;span style="-sec-ix-hidden:c123855419"&gt;four&lt;/span&gt; years.&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"&gt;The Company has granted share-based awards that vest upon achievement of certain performance criteria (&#x201c;Performance Awards&#x201d;). The Company multiplies the number of Performance Awards by the fair value of its common stock on the date of grant to calculate the fair value of each award. It estimates an implicit service period for achieving performance criteria for each award. The Company recognizes the resulting fair value as expense over the implicit service period when it concludes that achieving the performance criteria is probable. It periodically reviews and updates as appropriate its estimates of implicit service periods and conclusions on achieving the performance criteria. Performance Awards vest and common stock is issued upon achievement of the performance criteria.&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&#160;&lt;/p&gt;
   </us-gaap:CompensationRelatedCostsPolicyTextBlock>
    <us-gaap:EarningsPerSharePolicyTextBlock contextRef="d_2024-01-01_2024-12-31" id="c123862984">&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;&lt;b&gt;&lt;i&gt;Net Loss per Share&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-indent: 18pt; text-align: justify;"&gt;Basic net loss&#160;per common share is computed by dividing the net loss&#160;available to common stockholders by the weighted-average number of common shares outstanding during the period. Diluted net loss&#160;per common share is computed by dividing the net loss&#160;available to common stockholders by the weighted-average number of common shares outstanding and potentially dilutive securities outstanding during the period using the treasury stock method. Potentially dilutive securities are excluded from the computations of diluted earnings per share if their effect would be anti-dilutive. A net loss&#160;causes all potentially dilutive securities to be anti-dilutive. Potentially dilutive securities consist of outstanding common stock options&#160;and Performance Awards.&#160;There is &lt;em style="font: inherit;"&gt;no&lt;/em&gt; difference between the Company&#x2019;s net loss and comprehensive loss. The numerators and denominators in the calculation of basic and diluted net loss per share were as follows (in thousands, except net loss per share data):&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"&gt;&#160;&lt;/p&gt;

    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="10" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;&lt;em style="font: inherit;"&gt;&lt;em style="font: inherit;"&gt;Years ended December 31,&lt;/em&gt;&lt;/em&gt;&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;2024&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;2023&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;2022&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 55%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Numerator, basic:&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;"&gt;Net loss&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;(24,342&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;(97,217&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;(76,246&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Denominator, basic:&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;"&gt;Weighted average common shares outstanding&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;46,329&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;41,932&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;40,202&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Net loss per share, basic&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;(0.53&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;(2.32&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;(1.90&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Numerator, diluted:&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;"&gt;Net loss&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;(24,342&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;(97,217&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;(76,246&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;"&gt;Adjustment for change in fair value of warrant liabilities&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;(43,793&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Adjusted numerator, diluted&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;(68,135&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;(97,217&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;(76,246&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Denominator, diluted:&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;"&gt;Weighted average common shares outstanding&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;46,329&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;41,932&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;40,202&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;"&gt;Dilutive effect of common stock warrants&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;275&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;"&gt;Weighted average dilutive common shares&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;46,604&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;41,932&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;40,202&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Net loss per share, diluted&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;(1.46&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;(2.32&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;(1.90&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Dilutive common stock options excluded from net loss per share, diluted&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;3,154&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;2,123&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;2,055&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Dilutive Performance Awards excluded from loss per share, diluted&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;7&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;7&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;7&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;

   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"&gt;&#160;&lt;/p&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock contextRef="d_2024-01-01_2024-12-31" id="c2851680">
    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="10" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;&lt;em style="font: inherit;"&gt;&lt;em style="font: inherit;"&gt;Years ended December 31,&lt;/em&gt;&lt;/em&gt;&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;2024&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;2023&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;2022&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 55%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Numerator, basic:&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;"&gt;Net loss&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;(24,342&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;(97,217&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;(76,246&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Denominator, basic:&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;"&gt;Weighted average common shares outstanding&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;46,329&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;41,932&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;40,202&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Net loss per share, basic&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;(0.53&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;(2.32&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;(1.90&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Numerator, diluted:&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;"&gt;Net loss&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;(24,342&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;(97,217&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;(76,246&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;"&gt;Adjustment for change in fair value of warrant liabilities&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;(43,793&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Adjusted numerator, diluted&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;(68,135&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;(97,217&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;(76,246&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Denominator, diluted:&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;"&gt;Weighted average common shares outstanding&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;46,329&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;41,932&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;40,202&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;"&gt;Dilutive effect of common stock warrants&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;275&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;"&gt;Weighted average dilutive common shares&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;46,604&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;41,932&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;40,202&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Net loss per share, diluted&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;(1.46&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;(2.32&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;(1.90&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Dilutive common stock options excluded from net loss per share, diluted&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;3,154&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;2,123&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;2,055&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Dilutive Performance Awards excluded from loss per share, diluted&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;7&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;7&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;7&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;
   </us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
    <us-gaap:NetIncomeLoss
      contextRef="d_2024-01-01_2024-12-31"
      decimals="-3"
      id="c123854952"
      unitRef="USD">-24342000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="d_2023-01-01_2023-12-31"
      decimals="-3"
      id="c123854953"
      unitRef="USD">-97217000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="d_2022-01-01_2022-12-31"
      decimals="-3"
      id="c123854954"
      unitRef="USD">-76246000</us-gaap:NetIncomeLoss>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="d_2024-01-01_2024-12-31"
      decimals="-3"
      id="c123854955"
      unitRef="Share">46329000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="d_2023-01-01_2023-12-31"
      decimals="-3"
      id="c123854956"
      unitRef="Share">41932000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="d_2022-01-01_2022-12-31"
      decimals="-3"
      id="c123854957"
      unitRef="Share">40202000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="d_2024-01-01_2024-12-31"
      decimals="INF"
      id="c123854958"
      unitRef="USDPerShare">-0.53</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="d_2023-01-01_2023-12-31"
      decimals="INF"
      id="c123854959"
      unitRef="USDPerShare">-2.32</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="d_2022-01-01_2022-12-31"
      decimals="INF"
      id="c123854960"
      unitRef="USDPerShare">-1.9</us-gaap:EarningsPerShareBasic>
    <us-gaap:NetIncomeLoss
      contextRef="d_2024-01-01_2024-12-31"
      decimals="-3"
      id="c123854961"
      unitRef="USD">-24342000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="d_2023-01-01_2023-12-31"
      decimals="-3"
      id="c123854962"
      unitRef="USD">-97217000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="d_2022-01-01_2022-12-31"
      decimals="-3"
      id="c123854963"
      unitRef="USD">-76246000</us-gaap:NetIncomeLoss>
    <us-gaap:DilutiveSecurities
      contextRef="d_2024-01-01_2024-12-31"
      decimals="-3"
      id="c123854964"
      unitRef="USD">-43793000</us-gaap:DilutiveSecurities>
    <us-gaap:DilutiveSecurities
      contextRef="d_2023-01-01_2023-12-31"
      decimals="-3"
      id="c123854965"
      unitRef="USD">0</us-gaap:DilutiveSecurities>
    <us-gaap:DilutiveSecurities
      contextRef="d_2022-01-01_2022-12-31"
      decimals="-3"
      id="c123854966"
      unitRef="USD">0</us-gaap:DilutiveSecurities>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted
      contextRef="d_2024-01-01_2024-12-31"
      decimals="-3"
      id="c123854967"
      unitRef="USD">-68135000</us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted
      contextRef="d_2023-01-01_2023-12-31"
      decimals="-3"
      id="c123854968"
      unitRef="USD">-97217000</us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted
      contextRef="d_2022-01-01_2022-12-31"
      decimals="-3"
      id="c123854969"
      unitRef="USD">-76246000</us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="d_2024-01-01_2024-12-31"
      decimals="-3"
      id="c123854970"
      unitRef="Share">46329000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="d_2023-01-01_2023-12-31"
      decimals="-3"
      id="c123854971"
      unitRef="Share">41932000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="d_2022-01-01_2022-12-31"
      decimals="-3"
      id="c123854972"
      unitRef="Share">40202000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment
      contextRef="d_2024-01-01_2024-12-31"
      decimals="-3"
      id="c123854973"
      unitRef="Share">275000</us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment>
    <us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment
      contextRef="d_2023-01-01_2023-12-31"
      decimals="-3"
      id="c123854974"
      unitRef="Share">0</us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment>
    <us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment
      contextRef="d_2022-01-01_2022-12-31"
      decimals="-3"
      id="c123854975"
      unitRef="Share">0</us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="d_2024-01-01_2024-12-31"
      decimals="-3"
      id="c123854976"
      unitRef="Share">46604000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="d_2023-01-01_2023-12-31"
      decimals="-3"
      id="c123854977"
      unitRef="Share">41932000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="d_2022-01-01_2022-12-31"
      decimals="-3"
      id="c123854978"
      unitRef="Share">40202000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:EarningsPerShareDiluted
      contextRef="d_2024-01-01_2024-12-31"
      decimals="INF"
      id="c123854979"
      unitRef="USDPerShare">-1.46</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="d_2023-01-01_2023-12-31"
      decimals="INF"
      id="c123854980"
      unitRef="USDPerShare">-2.32</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="d_2022-01-01_2022-12-31"
      decimals="INF"
      id="c123854981"
      unitRef="USDPerShare">-1.9</us-gaap:EarningsPerShareDiluted>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="d_2024-01-01_2024-12-31_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-EmployeeStockOptionMember"
      decimals="-3"
      id="c123854982"
      unitRef="Share">3154000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="d_2023-01-01_2023-12-31_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-EmployeeStockOptionMember"
      decimals="-3"
      id="c123854983"
      unitRef="Share">2123000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="d_2022-01-01_2022-12-31_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-EmployeeStockOptionMember"
      decimals="-3"
      id="c123854984"
      unitRef="Share">2055000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="d_2024-01-01_2024-12-31_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-WarrantMember"
      decimals="-3"
      id="c123854985"
      unitRef="Share">7000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="d_2023-01-01_2023-12-31_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-WarrantMember"
      decimals="-3"
      id="c123854986"
      unitRef="Share">7000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="d_2022-01-01_2022-12-31_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-WarrantMember"
      decimals="-3"
      id="c123854987"
      unitRef="Share">7000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:DerivativesPolicyTextBlock contextRef="d_2024-01-01_2024-12-31" id="c123863015">&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&lt;b&gt;&lt;i&gt;Warrant Liabilities&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 18pt;"&gt;The Company accounts for warrants as either equity-classified or liability-classified instruments based on an assessment of the warrant&#x2019;s specific terms and in accordance with the Financial Accounting Standards Board (&#x201c;FASB&#x201d;) Accounting Standards Codification (&#x201c;ASC&#x201c;) &lt;em style="font: inherit;"&gt;480,&lt;/em&gt; &#x201c;Distinguishing Liabilities from Equity&#x201d;, and ASC &lt;em style="font: inherit;"&gt;815,&lt;/em&gt; &#x201c;Derivatives and Hedging&#x201d;. The assessment considers whether the warrants are freestanding financial instruments pursuant to ASC &lt;em style="font: inherit;"&gt;480,&lt;/em&gt; meet the definition of a liability pursuant to ASC &lt;em style="font: inherit;"&gt;480,&lt;/em&gt; and whether the warrants meet all of the requirements for equity classification under ASC &lt;em style="font: inherit;"&gt;815,&lt;/em&gt; including whether the warrants are indexed to the Company&#x2019;s own shares, among other conditions for equity classification. This assessment, which requires the use of professional judgment, is conducted at the time of warrant issuance and as of each subsequent quarterly period end date while the warrants are outstanding.&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 18pt;"&gt;For issued or modified warrants that meet all of the criteria for equity classification, the warrants are required to be recorded as a component of additional paid-in capital at the time of issuance. For issued or modified warrants that do &lt;em style="font: inherit;"&gt;not&lt;/em&gt; meet all the criteria for equity classification, the warrants are required to be recorded at their initial fair value of the date of issuance, and each balance sheet date thereafter. Changes in the estimated fair value of liability classified warrants are recognized as a non-cash gain or loss on the statements of operations. Costs associated with issuing the warrants classified as derivative liabilities are charged to operations when the warrants are issued.&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;&#160;&lt;/p&gt;</us-gaap:DerivativesPolicyTextBlock>
    <us-gaap:FairValueOfFinancialInstrumentsPolicy contextRef="d_2024-01-01_2024-12-31" id="c123863016">&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;&lt;b&gt;&lt;i&gt;Fair Value of Financial Instruments&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"&gt;Financial instruments include accounts payable, accrued expenses, accrued development expense and other liabilities. The estimated fair value of certain financial instruments &lt;em style="font: inherit;"&gt; may &lt;/em&gt;be determined using available market information or other appropriate valuation methodologies. However, considerable judgment is required in interpreting market data to develop estimates of fair value; therefore, the estimates are &lt;em style="font: inherit;"&gt;not&lt;/em&gt; necessarily indicative of the amounts that could be realized or would be paid in a current market exchange. The effect of using different market assumptions and/or estimation methodologies &lt;em style="font: inherit;"&gt; may &lt;/em&gt;be material to the estimated fair value amounts. The carrying amounts of accounts payable,&#160;accrued expenses, accrued development expense&#160;and other liabilities&#160;are at cost, which approximates fair value due to the short maturity of those instruments.&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;&#160;&lt;/p&gt;</us-gaap:FairValueOfFinancialInstrumentsPolicy>
    <us-gaap:ResearchAndDevelopmentExpensePolicy contextRef="d_2024-01-01_2024-12-31" id="c123863017">&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;&lt;b&gt;&lt;i&gt;Research Contracts, Prepaids and Accruals&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"&gt;The Company has entered into various research and development contracts with research institutions and other &lt;em style="font: inherit;"&gt;third&lt;/em&gt;-party vendors. These agreements are generally cancelable. Related payments are recorded as research and development expenses as incurred. The Company records prepaids and accruals for estimated ongoing research costs. When evaluating the adequacy of&#160;prepaid expenses and accrued liabilities, the Company analyzes progress of the studies including the phase or completion of events, invoices received and contracted costs. Significant judgments and estimates are made in determining the prepaid and accrued balances at the end of any reporting period. Actual results could differ from the Company&#x2019;s estimates. The Company&#x2019;s historical prepaid and accrual estimates have &lt;em style="font: inherit;"&gt;not&lt;/em&gt; been materially different from actual costs.&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;&#160;&lt;/p&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy contextRef="d_2024-01-01_2024-12-31" id="c123863018">&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;&lt;b&gt;&lt;i&gt;Incentive Bonus Plan&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"&gt;In &lt;em style="font: inherit;"&gt;2020,&lt;/em&gt; the Company established the &lt;em style="font: inherit;"&gt;2020&lt;/em&gt; Cash Incentive Bonus Plan (the &#x201c;CIB Plan&#x201d;) to incentivize CIB Plan participants. Awards under the CIB Plan are accounted for as liability awards under ASC&#160;&lt;em style="font: inherit;"&gt;718&lt;/em&gt; &#x201c;&lt;i&gt;Stock-based Compensation&lt;/i&gt;&#x201d;.&#160;The fair value of each&#160;potential CIB Plan&#160;award&#160;will be&#160;determined&#160;once&#160;a&#160;grant date occurs and&#160;will be&#160;remeasured each reporting period.&#160;Compensation expense associated with the CIB Plan&#160;will be&#160;recognized over the expected achievement period for each&#160;CIB Plan award, when&#160;a Performance Condition&#160;(as defined below) is considered probable of being met. See Note &lt;em style="font: inherit;"&gt;11&lt;/em&gt; for further discussion of the CIB Plan.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
    <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock contextRef="d_2024-01-01_2024-12-31" id="c123863019">&lt;p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left"&gt;&lt;b&gt;&lt;i&gt;Property and Equipment&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"&gt;Property and equipment are&#160;recorded at cost, net of accumulated depreciation. Depreciation is recorded using the straight-line method over the estimated useful lives of the assets. Owned buildings and related improvements have estimated useful lives of 39 years and approximately 10 years, respectively. Tenant improvements&#160;related to leased space are amortized using the straight-line method over the useful lives of the improvements or the remaining term of the corresponding leases, whichever is shorter.&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"&gt;Property and equipment are reviewed for impairment when events or changes in circumstances indicate the carrying amount of an asset &lt;em style="font: inherit;"&gt; may &lt;/em&gt;&lt;em style="font: inherit;"&gt;not&lt;/em&gt; be recoverable. If property and equipment are considered to be impaired, an impairment loss is recognized.&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;&#160;&lt;/p&gt;</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="i_2024-12-31_PropertyPlantAndEquipmentByTypeAxis-BuildingMember"
      id="c123855436">P39Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="i_2024-12-31_PropertyPlantAndEquipmentByTypeAxis-BuildingImprovementsMember"
      id="c123855437">P10Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:IntangibleAssetsFiniteLivedPolicy contextRef="d_2024-01-01_2024-12-31" id="c123863020">&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;&lt;b&gt;&lt;i&gt;Intangible Assets&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"&gt;Acquired intangible assets are recorded at fair value at the date of acquisition and primarily consist of lease-in-place agreements and leasing commissions. Intangible assets are amortized over the estimated life of the lease-in-place agreements.&#160;Intangible assets also include&#160;leasing commissions, which are amortized over the life of the lease agreement.&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"&gt;Intangible assets are reviewed for impairment on an annual basis, and when there is reason to believe that their values have been diminished or impaired. If intangible assets are considered to be impaired, an impairment loss is recognized.&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"&gt;&#160;&lt;/p&gt;</us-gaap:IntangibleAssetsFiniteLivedPolicy>
    <us-gaap:CommitmentsAndContingenciesPolicyTextBlock contextRef="d_2024-01-01_2024-12-31" id="c123863021">&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;"&gt;&lt;b&gt;&lt;i&gt;Insurance Recoveries&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 18pt;"&gt;We record proceeds from our&#160;insurance policies&#160;when the loss event has&#160;occurred, and proceeds are estimable and probable of being recovered. Insurance recoveries&#160;and proceeds received are recorded as a reduction to general and administrative expense.&#160;There was approximately $9.9&#160;million&#160;and $0.1 million of insurance recoveries recorded during the year ended &lt;em style="font: inherit;"&gt; December 31, 2024 &lt;/em&gt;and &lt;em style="font: inherit;"&gt;2023,&lt;/em&gt; respectively. The applicable policy year had&#160;a $10.0 million recovery limit which has been reached at &lt;em style="font: inherit;"&gt; December 31, 2024.&lt;/em&gt;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;"&gt;&#160;&lt;/p&gt;</us-gaap:CommitmentsAndContingenciesPolicyTextBlock>
    <us-gaap:ProceedsFromInsuranceSettlementOperatingActivities
      contextRef="d_2024-01-01_2024-12-31"
      decimals="-5"
      id="c123855439"
      unitRef="USD">9900000</us-gaap:ProceedsFromInsuranceSettlementOperatingActivities>
    <us-gaap:ProceedsFromInsuranceSettlementOperatingActivities
      contextRef="d_2023-01-01_2023-12-31"
      decimals="-5"
      id="c123855440"
      unitRef="USD">100000</us-gaap:ProceedsFromInsuranceSettlementOperatingActivities>
    <sava:InsuranceSettlementsMaximumRecoveryLimit
      contextRef="d_2024-01-01_2024-12-31"
      decimals="-7"
      id="c123855442"
      unitRef="USD">10000000</sava:InsuranceSettlementsMaximumRecoveryLimit>
    <sava:RelatedPartyTransactionPolicyTextBlock contextRef="d_2024-01-01_2024-12-31" id="c123863022">&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;"&gt;&lt;b&gt;&lt;i&gt;Related Party Transactions&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-indent: 18pt; text-align: justify;"&gt;On &lt;em style="font: inherit;"&gt; July 15, 2024, &lt;/em&gt;our former&#160;President and Chief Executive Officer&#160;resigned from the Company, effective as of &lt;em style="font: inherit;"&gt; September 13, 2024 (&lt;/em&gt;the &#x201c;Effective Date&#x201d;). Pursuant to the terms of his employment agreement, our former&#160;President and Chief Executive Officer is&#160;receiving&#160;severance compensation equal to $1.23 million over &lt;em style="font: inherit;"&gt;twelve&lt;/em&gt; months following the Effective Date. Severance compensation was included in general and administrative expense.&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-indent: 18pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-indent: 18pt; text-align: justify;"&gt;On &lt;em style="font: inherit;"&gt; July 16, 2024, &lt;/em&gt;our former Senior Vice President (SVP), Neuroscience agreed to step down from her employment with the Company, effective immediately. Our former SVP, Neuroscience is the spouse of our former&#160;President and Chief Executive Officer. Pursuant to a separation agreement, our former SVP, Neuroscience is&#160;receiving&#160;severance compensation equal to $0.5 million in quarterly installments over &lt;em style="font: inherit;"&gt;twelve&lt;/em&gt; months.&#160;Severance compensation was included in research and development&#160;expense.&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-indent: 18pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -2pt; text-indent: 18pt; text-align: justify;"&gt;Included in accrued compensation and benefits at &lt;em style="font: inherit;"&gt; December 31, 2024 &lt;/em&gt;is approximately $1.2&#160;million of accrued severance costs for the &lt;span style="-sec-ix-hidden:c123855449"&gt;two&lt;/span&gt; former senior officers.&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -2pt; text-indent: 18pt; text-align: justify;"&gt;On &lt;em style="font: inherit;"&gt; July 16, 2024, &lt;/em&gt;the Company entered into a one-year consulting agreement&#160;with the Company&#x2019;s former SVP, Neuroscience.&#160;Pursuant to the terms of the consulting agreement, the&#160;consultant is providing services&#160;for purposes of providing information and support for scientific research and/or obtaining governmental approval for the Company&#x2019;s products.&#160;The Company will pay&#160;$500&#160;per hour&#160;for such&#160;consulting services. The Company incurred fees totaling $43,000 under the consulting agreement during the year ended &lt;em style="font: inherit;"&gt; December 31, 2024.&lt;/em&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;</sava:RelatedPartyTransactionPolicyTextBlock>
    <us-gaap:SeveranceCosts1
      contextRef="d_2024-07-15_2024-07-15_TitleOfIndividualAxis-FormerPresidentAndChiefExecutiveOfficerMember"
      decimals="-4"
      id="c123855444"
      unitRef="USD">1230000</us-gaap:SeveranceCosts1>
    <us-gaap:SeveranceCosts1
      contextRef="d_2024-07-16_2024-07-16_TitleOfIndividualAxis-FormerSeniorVicePresidentMember"
      decimals="-5"
      id="c123855446"
      unitRef="USD">500000</us-gaap:SeveranceCosts1>
    <us-gaap:SeveranceCosts1
      contextRef="d_2024-01-01_2024-12-31_TitleOfIndividualAxis-FormerSeniorOfficerMember"
      decimals="-5"
      id="c123855448"
      unitRef="USD">1200000</us-gaap:SeveranceCosts1>
    <sava:ConsultingAgreementTerm
      contextRef="i_2024-07-16_RelatedPartyTransactionsByRelatedPartyAxis-FormerSeniorVicePresidentMember"
      decimals="INF"
      id="c123855450"
      unitRef="Pure">1</sava:ConsultingAgreementTerm>
    <sava:ConsultingServicePricePerHour
      contextRef="i_2024-07-16_RelatedPartyTransactionsByRelatedPartyAxis-FormerSeniorVicePresidentMember"
      decimals="INF"
      id="c123855451"
      unitRef="USD">500</sava:ConsultingServicePricePerHour>
    <us-gaap:RelatedPartyTransactionAmountsOfTransaction
      contextRef="d_2024-01-01_2024-12-31_RelatedPartyTransactionsByRelatedPartyAxis-FormerSeniorVicePresidentMember"
      decimals="INF"
      id="c123855452"
      unitRef="USD">43000</us-gaap:RelatedPartyTransactionAmountsOfTransaction>
    <us-gaap:IncomeTaxPolicyTextBlock contextRef="d_2024-01-01_2024-12-31" id="c123863023">&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;&lt;b&gt;&lt;i&gt;Income Taxes&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"&gt;The Company accounts for income taxes under the asset and liability method.&#160;Deferred tax assets and liabilities are recognized for the estimated future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. &#160;Deferred tax balances are adjusted to reflect tax rates based on currently enacted tax laws, which will be in effect in the years in which the temporary differences are expected to reverse.&#160;The Company has accumulated significant deferred tax assets that reflect the tax effects of net operating loss and tax credit carryovers and temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. Realization of certain deferred tax assets is dependent upon future earnings. The Company is uncertain about the timing and amount of any future earnings. Accordingly, the Company offsets these deferred tax assets with a valuation allowance.&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"&gt;The Company accounts for uncertain tax positions in accordance with ASC &lt;em style="font: inherit;"&gt;740,&lt;/em&gt; &#x201c;Income Taxes&#x201d;, which clarifies the accounting for uncertainty in tax positions. These provisions require recognition of the impact of a tax position in the Company&#x2019;s financial statements only if that position is more likely than &lt;em style="font: inherit;"&gt;not&lt;/em&gt; of being sustained upon examination by taxing authorities, based on the technical merits of the position. Any interest and penalties related to uncertain tax positions will be reflected as a component of income tax expense.&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"&gt;&#160;&lt;/p&gt;</us-gaap:IncomeTaxPolicyTextBlock>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="d_2024-01-01_2024-12-31" id="c123863024">&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;"&gt;&lt;b&gt;&lt;i&gt;Recent Accounting Pronouncements&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
   &lt;p style="text-align: justify; margin: 0pt 0pt 0pt -9pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify; text-indent: 18pt;"&gt;In &lt;em style="font: inherit;"&gt; November 2023, &lt;/em&gt;the FASB&#160;issued Accounting Standards Update ("ASU") &lt;em style="font: inherit;"&gt;2023&lt;/em&gt;-&lt;em style="font: inherit;"&gt;07,&lt;/em&gt; Segment Reporting (Topic &lt;em style="font: inherit;"&gt;280&lt;/em&gt;): Improvements to Reportable Segment Disclosures. This ASU includes amendments that expand the existing reportable segment disclosure requirements and requires disclosure of (i) significant expense categories and amounts by reportable segment as well as the segment&#x2019;s profit or loss measure(s) that are regularly provided to the chief operating decision maker (the &#x201c;CODM&#x201d;) to allocate resources and assess performance; (ii) how the CODM uses each reported segment profit or loss measure to allocate resources and assess performance; (iii) the nature of other segment balances contributing to reported segment profit or loss that are &lt;em style="font: inherit;"&gt;not&lt;/em&gt; captured within segment revenues or expenses; and (iv) the title and position of the individual or name of the group or committee identified as the CODM. This guidance requires retrospective application to all prior periods presented in the financial statements and is effective for fiscal years beginning after &lt;em style="font: inherit;"&gt; December 15, 2023 &lt;/em&gt;and interim periods within fiscal years beginning after &lt;em style="font: inherit;"&gt; December 15, 2024.&#160;&lt;/em&gt;The Company adopted this guidance and has included enhanced disclosures relating to its reportable segments. See &lt;i&gt;Business Segments&lt;/i&gt;, included in this Note &lt;em style="font: inherit;"&gt;2&lt;/em&gt; to the Consolidated Financial Statements, for the Company's updated disclosure.&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify; text-indent: 18pt;"&gt;&#160;&lt;/p&gt;


   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt;"&gt;&lt;i&gt;&lt;b&gt;Accounting Guidance Issued But &lt;em style="font: inherit;"&gt;Not&lt;/em&gt; Adopted as of &lt;em style="font: inherit;"&gt; December 31, 2024&lt;/em&gt;&lt;/b&gt;&lt;/i&gt;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-indent: 18pt; text-align: justify;"&gt;In &lt;em style="font: inherit;"&gt; November 2024, &lt;/em&gt;the FASB issued ASU &lt;em style="font: inherit;"&gt;2024&lt;/em&gt;-&lt;em style="font: inherit;"&gt;03,&lt;/em&gt; Income Statement&#x2014;Reporting Comprehensive Income&#x2014;Expense Disaggregation Disclosures (Subtopic &lt;em style="font: inherit;"&gt;220&lt;/em&gt;-&lt;em style="font: inherit;"&gt;40&lt;/em&gt;): Disaggregation of Income Statement Expenses. This ASU includes amendments that require entities to bifurcate specified expense line items on the income statement into underlying components, including employee compensation, depreciation, and intangible asset amortization, as applicable. Qualitative descriptions of the remaining components are required. These enhanced disclosures are required for both interim and annual periods. In &lt;em style="font: inherit;"&gt; January 2025, &lt;/em&gt;the FASB subsequently issued ASU &lt;em style="font: inherit;"&gt;2025&lt;/em&gt;-&lt;em style="font: inherit;"&gt;01,&lt;/em&gt; Income Statement&#x2014;Reporting Comprehensive Income&#x2014;Expense Disaggregation Disclosures (Subtopic &lt;em style="font: inherit;"&gt;220&lt;/em&gt;-&lt;em style="font: inherit;"&gt;40&lt;/em&gt;): Clarifying the Effective Date, to provide clarification on the ASU's effective date. The new standard is effective for fiscal years beginning after &lt;em style="font: inherit;"&gt; December 15, 2026 &lt;/em&gt;on a prospective basis with the option to apply it retrospectively, and for interim periods&#160;within fiscal years beginning after &lt;em style="font: inherit;"&gt; December 15, 2027. &lt;/em&gt;Early adoption is permitted. The adoption of this guidance will result in the Company being required to include enhanced disclosures around income statement expenses.&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-indent: 18pt; text-align: justify;"&gt;In &lt;em style="font: inherit;"&gt; December 2023, &lt;/em&gt;the FASB issued ASU &lt;em style="font: inherit;"&gt;2023&lt;/em&gt;-&lt;em style="font: inherit;"&gt;09,&lt;/em&gt; Income Taxes (Topic &lt;em style="font: inherit;"&gt;740&lt;/em&gt;): Improvements to Income Tax Disclosures. The ASU requires that an entity disclose specific categories in the effective tax rate reconciliation as well as reconciling items that meet a quantitative threshold. Further, the ASU requires additional disclosures on income tax expense and taxes paid, net of refunds received, by jurisdiction. The new standard is effective for annual periods beginning after &lt;em style="font: inherit;"&gt; December 15, 2024 &lt;/em&gt;on a prospective basis with the option to apply it retrospectively. Early adoption is permitted. The adoption of this guidance will result in the company being required to include enhanced income tax related disclosures.&lt;/p&gt;
   &lt;p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left"&gt;&#160;&lt;/p&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <sava:PrepaidExpensesAndOtherCurrentAssetsTextBock contextRef="d_2024-01-01_2024-12-31" id="c2851681">
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;3.&lt;/em&gt; Prepaid Expenses and Other Current Assets&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"&gt;Prepaid and other current assets at&#160;&lt;em style="font: inherit;"&gt; December 31, 2024&#160;&lt;/em&gt;and &lt;em style="font: inherit;"&gt;2023&lt;/em&gt;&#160;consisted of the following (in thousands):&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"&gt;&#160;&lt;/p&gt;

    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;"&gt;&#160;&lt;/td&gt;&lt;td colspan="6" rowspan="1" style="text-align: center; font-family: Times New Roman; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;&lt;em style="font: inherit;"&gt;December 31,&lt;/em&gt;&lt;/em&gt;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;2024&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;2023&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 70%;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;"&gt;Prepaid insurance&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;800&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;759&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;"&gt;Contract research organization and other deposits&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;6,173&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;6,489&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;"&gt;Interest receivable&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;947&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;962&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;"&gt;Other&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;38&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;287&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt; text-indent: -9pt;"&gt;Total prepaid expenses and other current assets&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;7,958&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;8,497&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;

   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"&gt;Contract research organization and other deposits represent cash payments made to vendors in excess of expenses incurred.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;
  </sava:PrepaidExpensesAndOtherCurrentAssetsTextBock>
    <us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock contextRef="d_2024-01-01_2024-12-31" id="c2851682">
    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;"&gt;&#160;&lt;/td&gt;&lt;td colspan="6" rowspan="1" style="text-align: center; font-family: Times New Roman; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;&lt;em style="font: inherit;"&gt;December 31,&lt;/em&gt;&lt;/em&gt;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;2024&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;2023&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 70%;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;"&gt;Prepaid insurance&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;800&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;759&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;"&gt;Contract research organization and other deposits&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;6,173&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;6,489&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;"&gt;Interest receivable&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;947&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;962&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;"&gt;Other&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;38&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;287&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt; text-indent: -9pt;"&gt;Total prepaid expenses and other current assets&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;7,958&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;8,497&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;
   </us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock>
    <us-gaap:PrepaidInsurance
      contextRef="i_2024-12-31"
      decimals="-5"
      id="c123854996"
      unitRef="USD">800000</us-gaap:PrepaidInsurance>
    <us-gaap:PrepaidInsurance
      contextRef="i_2023-12-31"
      decimals="-3"
      id="c123854997"
      unitRef="USD">759000</us-gaap:PrepaidInsurance>
    <us-gaap:DepositContractsAssets
      contextRef="i_2024-12-31"
      decimals="-3"
      id="c123854998"
      unitRef="USD">6173000</us-gaap:DepositContractsAssets>
    <us-gaap:DepositContractsAssets
      contextRef="i_2023-12-31"
      decimals="-3"
      id="c123854999"
      unitRef="USD">6489000</us-gaap:DepositContractsAssets>
    <us-gaap:InterestReceivableCurrent
      contextRef="i_2024-12-31"
      decimals="-3"
      id="c123855000"
      unitRef="USD">947000</us-gaap:InterestReceivableCurrent>
    <us-gaap:InterestReceivableCurrent
      contextRef="i_2023-12-31"
      decimals="-3"
      id="c123855001"
      unitRef="USD">962000</us-gaap:InterestReceivableCurrent>
    <us-gaap:OtherAssetsCurrent
      contextRef="i_2024-12-31"
      decimals="-3"
      id="c123855002"
      unitRef="USD">38000</us-gaap:OtherAssetsCurrent>
    <us-gaap:OtherAssetsCurrent
      contextRef="i_2023-12-31"
      decimals="-3"
      id="c123855003"
      unitRef="USD">287000</us-gaap:OtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="i_2024-12-31"
      decimals="-3"
      id="c123855004"
      unitRef="USD">7958000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="i_2023-12-31"
      decimals="-3"
      id="c123855005"
      unitRef="USD">8497000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:RealEstateOwnedTextBlock contextRef="d_2024-01-01_2024-12-31" id="c2851683">
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;4.&lt;/em&gt; Real Property and Other Income, Expense&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"&gt;The Company owns a &lt;em style="font: inherit;"&gt;two&lt;/em&gt;-building office complex in Austin, Texas, a portion of which serves as its corporate headquarters. Maintenance, physical facilities, leasing, property management and other key responsibilities related to property ownership are&#160;outsourced to professional real-estate managers. The office complex measures approximately 90,000 rentable square feet.&#160;At &lt;em style="font: inherit;"&gt; December 31, 2024, &lt;/em&gt;the Company&#160;occupied approximately 25% of the property with the remainder&#160;either leased or available for lease to &lt;em style="font: inherit;"&gt;third&lt;/em&gt; parties. Gross rental income under existing &lt;em style="font: inherit;"&gt;third&lt;/em&gt;-party leases at &lt;em style="font: inherit;"&gt; December 31, 2024 &lt;/em&gt;is expected to total&#160;$0.3 million in &lt;em style="font: inherit;"&gt;2025,&lt;/em&gt; $0.4&#160;million in &lt;em style="font: inherit;"&gt;2026&lt;/em&gt; and $0.2&#160;million in &lt;em style="font: inherit;"&gt;2027.&lt;/em&gt;&lt;/p&gt;
   &lt;p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left"&gt;&#160;&lt;/p&gt;


   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"&gt;The Company records the net income from building operations and leases as other income, net, as leasing is &lt;em style="font: inherit;"&gt;not&lt;/em&gt; core to the Company&#x2019;s operations. Building depreciation and amortization for space &lt;em style="font: inherit;"&gt;not&lt;/em&gt; occupied by the Company is included in general and administrative expense. Building depreciation and amortization for space occupied by the Company is allocated between general and administrative expense and research and development expense. Components of other income, net, for the periods presented were as follows (in thousands):&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&#160;&lt;/p&gt;

    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="10" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;&lt;em style="font: inherit;"&gt;&lt;em style="font: inherit;"&gt;Years ended December 31,&lt;/em&gt;&lt;/em&gt;&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;2024&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;2023&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;2022&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 55%;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;"&gt;Lease revenue&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;1,244&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;2,283&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;2,459&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;"&gt;Property operating expenses&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;(832&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;(1,376&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"&gt;(1,462&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt; text-indent: -9pt;"&gt;Other income, net&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;411&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;907&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;997&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;

   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 18pt;"&gt;The Company had accrued property taxes related to the building totaling $254,000 and $338,000 at&#160;&lt;em style="font: inherit;"&gt; December 31, 2024&#160;&lt;/em&gt;and&#160;&lt;em style="font: inherit;"&gt;2023,&lt;/em&gt; respectively, included in other current liabilities.&lt;/p&gt;
   &lt;p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left"&gt;&#160;&lt;/p&gt;
  </us-gaap:RealEstateOwnedTextBlock>
    <us-gaap:NetRentableArea
      contextRef="i_2021-08-04_MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis-OfficeBuildingMember_StatementGeographicalAxis-TX"
      decimals="INF"
      id="c123855477"
      unitRef="SquareFoot">90000</us-gaap:NetRentableArea>
    <sava:PercentageOfOccupancy
      contextRef="i_2024-12-31_MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis-OfficeBuildingMember_StatementGeographicalAxis-TX"
      decimals="2"
      id="c123855478"
      unitRef="Pure">0.25</sava:PercentageOfOccupancy>
    <us-gaap:LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths
      contextRef="i_2024-12-31"
      decimals="-5"
      id="c123855481"
      unitRef="USD">300000</us-gaap:LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths>
    <us-gaap:LessorOperatingLeasePaymentsToBeReceivedTwoYears
      contextRef="i_2024-12-31"
      decimals="-5"
      id="c123855483"
      unitRef="USD">400000</us-gaap:LessorOperatingLeasePaymentsToBeReceivedTwoYears>
    <us-gaap:LessorOperatingLeasePaymentsToBeReceivedThreeYears
      contextRef="i_2024-12-31"
      decimals="-5"
      id="c123855485"
      unitRef="USD">200000</us-gaap:LessorOperatingLeasePaymentsToBeReceivedThreeYears>
    <us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock contextRef="d_2024-01-01_2024-12-31" id="c2851684">
    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="10" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;&lt;em style="font: inherit;"&gt;&lt;em style="font: inherit;"&gt;Years ended December 31,&lt;/em&gt;&lt;/em&gt;&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;2024&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;2023&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;2022&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 55%;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;"&gt;Lease revenue&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;1,244&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;2,283&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;2,459&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;"&gt;Property operating expenses&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;(832&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;(1,376&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"&gt;(1,462&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt; text-indent: -9pt;"&gt;Other income, net&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;411&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;907&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;997&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;
   </us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock>
    <us-gaap:OtherNonoperatingIncome
      contextRef="d_2024-01-01_2024-12-31"
      decimals="-3"
      id="c123855012"
      unitRef="USD">1244000</us-gaap:OtherNonoperatingIncome>
    <us-gaap:OtherNonoperatingIncome
      contextRef="d_2023-01-01_2023-12-31"
      decimals="-3"
      id="c123855013"
      unitRef="USD">2283000</us-gaap:OtherNonoperatingIncome>
    <us-gaap:OtherNonoperatingIncome
      contextRef="d_2022-01-01_2022-12-31"
      decimals="-3"
      id="c123855014"
      unitRef="USD">2459000</us-gaap:OtherNonoperatingIncome>
    <us-gaap:OtherNonoperatingExpense
      contextRef="d_2024-01-01_2024-12-31"
      decimals="-3"
      id="c123855015"
      unitRef="USD">832000</us-gaap:OtherNonoperatingExpense>
    <us-gaap:OtherNonoperatingExpense
      contextRef="d_2023-01-01_2023-12-31"
      decimals="-3"
      id="c123855016"
      unitRef="USD">1376000</us-gaap:OtherNonoperatingExpense>
    <us-gaap:OtherNonoperatingExpense
      contextRef="d_2022-01-01_2022-12-31"
      decimals="-3"
      id="c123855017"
      unitRef="USD">1462000</us-gaap:OtherNonoperatingExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="d_2024-01-01_2024-12-31"
      decimals="-3"
      id="c123855018"
      unitRef="USD">411000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="d_2023-01-01_2023-12-31"
      decimals="-3"
      id="c123855019"
      unitRef="USD">907000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="d_2022-01-01_2022-12-31"
      decimals="-3"
      id="c123855020"
      unitRef="USD">997000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:AccrualForTaxesOtherThanIncomeTaxesCurrent
      contextRef="i_2024-12-31_MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis-OfficeBuildingMember_StatementGeographicalAxis-TX"
      decimals="INF"
      id="c123855490"
      unitRef="USD">254000</us-gaap:AccrualForTaxesOtherThanIncomeTaxesCurrent>
    <us-gaap:AccrualForTaxesOtherThanIncomeTaxesCurrent
      contextRef="i_2023-12-31_MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis-OfficeBuildingMember_StatementGeographicalAxis-TX"
      decimals="INF"
      id="c123855491"
      unitRef="USD">338000</us-gaap:AccrualForTaxesOtherThanIncomeTaxesCurrent>
    <us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock contextRef="d_2024-01-01_2024-12-31" id="c2851685">
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;5.&lt;/em&gt; Property and Equipment&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"&gt;The components of property and equipment, net, as of&#160;&lt;em style="font: inherit;"&gt; December 31, 2024&#160;&lt;/em&gt;and &lt;em style="font: inherit;"&gt;2023&lt;/em&gt;&#160;were as follows (in thousands):&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"&gt;&#160;&lt;/p&gt;

    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="6" rowspan="1" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: center;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;&lt;em style="font: inherit;"&gt;December 31,&lt;/em&gt;&lt;/em&gt;&lt;/b&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;2024&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;2023&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 70%;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;"&gt;Land&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;3,734&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;3,734&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;"&gt;Buildings&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;15,980&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;15,980&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;"&gt;Site improvements&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;494&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;494&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;"&gt;Tenant improvements&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;3,062&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;3,062&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;"&gt;Furniture and equipment&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;875&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;868&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px;"&gt; &lt;p style="margin: 0pt; font-size: 10pt; font-family: Times New Roman;"&gt;Construction in progress&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"&gt;55&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt; text-indent: -9pt;"&gt;Gross property and equipment&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;24,200&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;24,138&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;"&gt;Accumulated depreciation&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;(3,236&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;(2,284&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt; text-indent: -9pt;"&gt;Property and equipment, net&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;20,964&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;21,854&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;

   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"&gt;Depreciation expense for property and equipment was&#160;$952,000, $1,084,000&#160;and&#160;$804,000&#160;for the years ended &lt;em style="font: inherit;"&gt; December 31, 2024, &lt;/em&gt;&lt;em style="font: inherit;"&gt;2023&lt;/em&gt;&#160;and &lt;em style="font: inherit;"&gt;2022,&lt;/em&gt; respectively.&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&#160;&lt;/p&gt;
  </us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
    <us-gaap:PropertyPlantAndEquipmentTextBlock contextRef="d_2024-01-01_2024-12-31" id="c2851686">
    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="6" rowspan="1" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: center;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;&lt;em style="font: inherit;"&gt;December 31,&lt;/em&gt;&lt;/em&gt;&lt;/b&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;2024&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;2023&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 70%;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;"&gt;Land&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;3,734&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;3,734&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;"&gt;Buildings&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;15,980&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;15,980&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;"&gt;Site improvements&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;494&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;494&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;"&gt;Tenant improvements&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;3,062&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;3,062&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;"&gt;Furniture and equipment&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;875&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;868&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px;"&gt; &lt;p style="margin: 0pt; font-size: 10pt; font-family: Times New Roman;"&gt;Construction in progress&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"&gt;55&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt; text-indent: -9pt;"&gt;Gross property and equipment&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;24,200&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;24,138&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;"&gt;Accumulated depreciation&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;(3,236&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;(2,284&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt; text-indent: -9pt;"&gt;Property and equipment, net&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;20,964&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;21,854&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;
   </us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i_2024-12-31_PropertyPlantAndEquipmentByTypeAxis-LandMember"
      decimals="-3"
      id="c123855025"
      unitRef="USD">3734000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i_2023-12-31_PropertyPlantAndEquipmentByTypeAxis-LandMember"
      decimals="-3"
      id="c123855026"
      unitRef="USD">3734000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i_2024-12-31_PropertyPlantAndEquipmentByTypeAxis-BuildingMember"
      decimals="-4"
      id="c123855027"
      unitRef="USD">15980000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i_2023-12-31_PropertyPlantAndEquipmentByTypeAxis-BuildingMember"
      decimals="-4"
      id="c123855028"
      unitRef="USD">15980000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i_2024-12-31_PropertyPlantAndEquipmentByTypeAxis-BuildingImprovementsMember"
      decimals="-3"
      id="c123855029"
      unitRef="USD">494000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i_2023-12-31_PropertyPlantAndEquipmentByTypeAxis-BuildingImprovementsMember"
      decimals="-3"
      id="c123855030"
      unitRef="USD">494000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i_2024-12-31_PropertyPlantAndEquipmentByTypeAxis-LeaseholdImprovementsMember"
      decimals="-3"
      id="c123855031"
      unitRef="USD">3062000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i_2023-12-31_PropertyPlantAndEquipmentByTypeAxis-LeaseholdImprovementsMember"
      decimals="-3"
      id="c123855032"
      unitRef="USD">3062000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i_2024-12-31_PropertyPlantAndEquipmentByTypeAxis-FurnitureAndFixturesMember"
      decimals="-3"
      id="c123855033"
      unitRef="USD">875000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i_2023-12-31_PropertyPlantAndEquipmentByTypeAxis-FurnitureAndFixturesMember"
      decimals="-3"
      id="c123855034"
      unitRef="USD">868000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i_2024-12-31_PropertyPlantAndEquipmentByTypeAxis-ConstructionInProgressMember"
      decimals="-3"
      id="c123855035"
      unitRef="USD">55000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i_2023-12-31_PropertyPlantAndEquipmentByTypeAxis-ConstructionInProgressMember"
      decimals="-3"
      id="c123855036"
      unitRef="USD">0</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i_2024-12-31"
      decimals="-5"
      id="c123855037"
      unitRef="USD">24200000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i_2023-12-31"
      decimals="-3"
      id="c123855038"
      unitRef="USD">24138000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="i_2024-12-31"
      decimals="-3"
      id="c123855039"
      unitRef="USD">3236000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="i_2023-12-31"
      decimals="-3"
      id="c123855040"
      unitRef="USD">2284000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i_2024-12-31"
      decimals="-3"
      id="c123855041"
      unitRef="USD">20964000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i_2023-12-31"
      decimals="-3"
      id="c123855042"
      unitRef="USD">21854000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:Depreciation
      contextRef="d_2024-01-01_2024-12-31"
      decimals="INF"
      id="c123855495"
      unitRef="USD">952000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="d_2023-01-01_2023-12-31"
      decimals="INF"
      id="c123855496"
      unitRef="USD">1084000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="d_2022-01-01_2022-12-31"
      decimals="INF"
      id="c123855497"
      unitRef="USD">804000</us-gaap:Depreciation>
    <us-gaap:IntangibleAssetsDisclosureTextBlock contextRef="d_2024-01-01_2024-12-31" id="c2851687">
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;6.&lt;/em&gt; Intangible Assets&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"&gt;The components of intangible assets, net, as of&#160;&lt;em style="font: inherit;"&gt; December 31, 2024&#160;&lt;/em&gt;and &lt;em style="font: inherit;"&gt;2023&lt;/em&gt;&#160;were as follows (in thousands):&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"&gt;&#160;&lt;/p&gt;

    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;"&gt;&#160;&lt;/td&gt;&lt;td colspan="6" rowspan="1" style="font-family: Times New Roman; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; text-align: center; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;&lt;em style="font: inherit;"&gt;December 31,&lt;/em&gt;&lt;/em&gt;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;2024&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;2023&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 70%;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;"&gt;Lease-in-place agreements&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;1,053&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;1,053&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;"&gt;Leasing commissions and other&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;334&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;293&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt; text-indent: -9pt;"&gt;Gross intangible assets&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;1,387&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;1,346&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;"&gt;Accumulated amortization&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;(1,350&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;(1,170&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt; text-indent: -9pt;"&gt;Intangible assets, net&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;37&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;176&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;

   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"&gt;Amortization expense for intangible assets was $180,000, $446,000 and $497,000 for the years ended &lt;em style="font: inherit;"&gt; December 31, 2024, &lt;/em&gt;&lt;em style="font: inherit;"&gt;2023&lt;/em&gt;&#160;and &lt;em style="font: inherit;"&gt;2022,&lt;/em&gt; respectively.&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"&gt;&#160;&lt;/p&gt;


   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"&gt;Amortization expense for finite-lived intangible assets is expected to be as follows (in thousands):&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"&gt;&#160;&lt;/p&gt;

    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 85%;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;"&gt;&lt;b&gt;&lt;span style="text-decoration: underline; "&gt;For the year ending December 31,&lt;/span&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;"&gt;2025&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;17&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;"&gt;2026&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;14&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px;"&gt; &lt;p style="margin: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;2027&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"&gt;6&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;"&gt;Total amortization&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;37&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;

   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
  </us-gaap:IntangibleAssetsDisclosureTextBlock>
    <us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock contextRef="d_2024-01-01_2024-12-31" id="c2851688">
    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;"&gt;&#160;&lt;/td&gt;&lt;td colspan="6" rowspan="1" style="font-family: Times New Roman; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; text-align: center; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;&lt;em style="font: inherit;"&gt;December 31,&lt;/em&gt;&lt;/em&gt;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;2024&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;2023&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 70%;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;"&gt;Lease-in-place agreements&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;1,053&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;1,053&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;"&gt;Leasing commissions and other&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;334&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;293&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt; text-indent: -9pt;"&gt;Gross intangible assets&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;1,387&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;1,346&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;"&gt;Accumulated amortization&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;(1,350&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;(1,170&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt; text-indent: -9pt;"&gt;Intangible assets, net&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;37&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;176&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;
   </us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i_2024-12-31_FiniteLivedIntangibleAssetsByMajorClassAxis-LeasesAcquiredInPlaceMember"
      decimals="-3"
      id="c123855047"
      unitRef="USD">1053000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i_2023-12-31_FiniteLivedIntangibleAssetsByMajorClassAxis-LeasesAcquiredInPlaceMember"
      decimals="-3"
      id="c123855048"
      unitRef="USD">1053000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i_2024-12-31_FiniteLivedIntangibleAssetsByMajorClassAxis-LeasingCommissionsAndOtherMember"
      decimals="-3"
      id="c123855049"
      unitRef="USD">334000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i_2023-12-31_FiniteLivedIntangibleAssetsByMajorClassAxis-LeasingCommissionsAndOtherMember"
      decimals="-3"
      id="c123855050"
      unitRef="USD">293000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i_2024-12-31"
      decimals="-3"
      id="c123855051"
      unitRef="USD">1387000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i_2023-12-31"
      decimals="-3"
      id="c123855052"
      unitRef="USD">1346000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i_2024-12-31"
      decimals="-4"
      id="c123855053"
      unitRef="USD">1350000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i_2023-12-31"
      decimals="-4"
      id="c123855054"
      unitRef="USD">1170000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i_2024-12-31"
      decimals="-3"
      id="c123855055"
      unitRef="USD">37000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i_2023-12-31"
      decimals="-3"
      id="c123855056"
      unitRef="USD">176000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="d_2024-01-01_2024-12-31"
      decimals="INF"
      id="c123855502"
      unitRef="USD">180000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="d_2023-01-01_2023-12-31"
      decimals="INF"
      id="c123855503"
      unitRef="USD">446000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="d_2022-01-01_2022-12-31"
      decimals="INF"
      id="c123855504"
      unitRef="USD">497000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock contextRef="d_2024-01-01_2024-12-31" id="c2851689">
    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 85%;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;"&gt;&lt;b&gt;&lt;span style="text-decoration: underline; "&gt;For the year ending December 31,&lt;/span&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;"&gt;2025&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;17&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;"&gt;2026&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;14&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px;"&gt; &lt;p style="margin: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;2027&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"&gt;6&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;"&gt;Total amortization&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;37&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;
   </us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths
      contextRef="i_2024-12-31"
      decimals="-3"
      id="c123855057"
      unitRef="USD">17000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo
      contextRef="i_2024-12-31"
      decimals="-3"
      id="c123855058"
      unitRef="USD">14000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree
      contextRef="i_2024-12-31"
      decimals="-3"
      id="c123855059"
      unitRef="USD">6000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i_2024-12-31"
      decimals="-3"
      id="c123855060"
      unitRef="USD">37000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock contextRef="d_2024-01-01_2024-12-31" id="c2851690">
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;7.&lt;/em&gt; Stockholders' Equity and Stock-Based Compensation&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;&lt;b&gt;&lt;i&gt;Preferred Stock&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"&gt;The Company&#x2019;s Board of Directors (the &#x201c;Board&#x201d;) has the authority to issue preferred stock in &lt;em style="font: inherit;"&gt;one&lt;/em&gt; or more series and to fix the rights, preferences, privileges, restrictions and the number of shares constituting any series or the designation of the series.&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;&lt;b&gt;&lt;i&gt;&lt;em style="font: inherit;"&gt;2022&lt;/em&gt; Registered Direct Offering&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"&gt;On &lt;em style="font: inherit;"&gt; November&#160;&lt;/em&gt;&lt;em style="font: inherit;"&gt;22,&lt;/em&gt; &lt;em style="font: inherit;"&gt;2022,&lt;/em&gt; the Company completed a common stock offering pursuant to which certain investors purchased 1,666,667 shares of common stock at a price of $30.00 per share. Net proceeds of the offering were approximately $47.3&#160;million after deducting offering expenses.&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -1pt;"&gt;&lt;b&gt;&lt;i&gt;Common Stock Warrant Distribution&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -1pt; text-indent: 18pt;"&gt;See Notes &lt;em style="font: inherit;"&gt;2&lt;/em&gt; and &lt;em style="font: inherit;"&gt;13&lt;/em&gt;&#160;regarding the distribution of common stock warrants on &lt;em style="font: inherit;"&gt; January 3, 2024.&lt;/em&gt;&lt;/p&gt;
   &lt;p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;&lt;b&gt;&lt;i&gt;At the Market (ATM) Common Stock Issuance &lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"&gt;On &lt;em style="font: inherit;"&gt; May 1, 2023, &lt;/em&gt;the Company entered into an&#160;at-the-market offering program (&#x201c;ATM&#x201d;) to sell, from time to time, shares of Company common stock having an aggregate offering price of up to $200 million in common stock pursuant to a shelf registration statement that was filed with the U.S. Securities and Exchange Commission (the &#x201c;SEC&#x201d;) on &lt;em style="font: inherit;"&gt; May 1, 2023 &lt;/em&gt;and became effective immediately upon filing. The Company is obligated to pay a commission of up to 3% of the gross proceeds from the sale of shares of common stock under&#160;the ATM. As of the filing of this Annual Report on Form &lt;em style="font: inherit;"&gt;10&lt;/em&gt;-K, the Company is &lt;em style="font: inherit;"&gt;no&lt;/em&gt; longer a Well-Known Seasoned Issuer, as defined by the SEC. Thus, the Company&#160;is &lt;em style="font: inherit;"&gt;not&lt;/em&gt; eligible to sell securities under the ATM under its existing &#x201c;automatic&#x201d; shelf registration statement on Form S-&lt;em style="font: inherit;"&gt;3&lt;/em&gt; unless and until it files a new Form S-&lt;em style="font: inherit;"&gt;3&lt;/em&gt; that is declared effective by the SEC.&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"&gt;There were&#160;&lt;span style="-sec-ix-hidden:c123855525"&gt;no&lt;/span&gt;&#160;common stock sales under the ATM during the year&#160;ended &lt;em style="font: inherit;"&gt; December 31, 2024 &lt;/em&gt;and &lt;em style="font: inherit;"&gt;2023.&lt;/em&gt;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;&lt;b&gt;&lt;i&gt;&lt;em style="font: inherit;"&gt;2008&lt;/em&gt; Equity Incentive Plan &lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"&gt;Under the Company&#x2019;s &lt;em style="font: inherit;"&gt;2008&lt;/em&gt; Equity Incentive Plan, or &lt;em style="font: inherit;"&gt;2008&lt;/em&gt; Equity Plan, its employees, directors and consultants received share-based awards, including grants of stock options and performance awards. The &lt;em style="font: inherit;"&gt;2008&lt;/em&gt; Equity Plan expired in &lt;em style="font: inherit;"&gt; December 2017. &lt;/em&gt;Share-based awards generally expire &lt;em style="font: inherit;"&gt;ten&lt;/em&gt; years from the date of grant.&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;&lt;b&gt;&lt;i&gt;&lt;em style="font: inherit;"&gt;2018&lt;/em&gt; Equity Incentive Plan &lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"&gt;The Company&#x2019;s Board or a designated Committee of the Board is responsible for administration of the Company&#x2019;s &lt;em style="font: inherit;"&gt;2018&lt;/em&gt; Omnibus Incentive Plan (the &lt;em style="font: inherit;"&gt;2018&lt;/em&gt; Plan) and determines the terms and conditions of each option granted, consistent with the terms of the &lt;em style="font: inherit;"&gt;2018&lt;/em&gt; Plan. The Company&#x2019;s employees, directors, and consultants are eligible to receive awards under the &lt;em style="font: inherit;"&gt;2018&lt;/em&gt; Plan, including grants of stock options and performance awards. Share-based awards generally expire &lt;span style="-sec-ix-hidden:c123855537"&gt;ten&lt;/span&gt; years from the date of grant. The &lt;em style="font: inherit;"&gt;2018&lt;/em&gt; Plan, as amended in &lt;em style="font: inherit;"&gt; May&#160;&lt;/em&gt;&lt;em style="font: inherit;"&gt;2022,&lt;/em&gt; provides for issuance of up to 5,000,000 shares of common stock, par value $0.001 per share, subject to adjustment as provided in the &lt;em style="font: inherit;"&gt;2018&lt;/em&gt; Plan.&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"&gt;When stock options or performance awards are exercised net of the exercise price and taxes, the number of shares of stock issued is reduced by the number of shares equal to the amount of taxes owed by the award recipient and that number of shares are cancelled. The Company &lt;em style="font: inherit;"&gt; may &lt;/em&gt;then use its cash to pay tax authorities the amount of statutory taxes owed by and on behalf of the award recipient.&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&#160;&lt;/p&gt;


   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;&lt;b&gt;&lt;i&gt;Stock Options&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"&gt;The following summarizes information about stock option activity during &lt;em style="font: inherit;"&gt;2024:&lt;/em&gt;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"&gt;&#160;&lt;/p&gt;

    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-family: Times New Roman; font-size: 10pt;"&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Weighted Average&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Weighted Average&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-family: Times New Roman; font-size: 10pt;"&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Number of&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Weighted Average&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Remaining Contractual&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Aggregate Intrinsic Value&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Options&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Exercise Price&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Term in Years&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;in Millions&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 40%;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;"&gt;Outstanding as of December 31, 2023&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;3,039,029&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;15.13&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;6.21&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;30.28&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt; &lt;p style="margin: 0pt 0pt 0pt 9pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;Options granted&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; text-align: right; padding: 0; margin: 0"&gt;2,083,000&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;26.65&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt; &lt;p style="margin: 0pt 0pt 0pt 9pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;Options exercised&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; text-align: right; padding: 0; margin: 0"&gt;(240,147&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding: 0; margin: 0"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;5.25&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt; &lt;p style="margin: 0pt 0pt 0pt 9pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;Options forfeited/canceled&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; text-align: right; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"&gt;(418,854&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;24.64&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;"&gt;Outstanding as of December 31, 2024&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;4,463,028&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;20.15&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;7.61&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;0.30&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;"&gt;Vested and expected to vest at December 31, 2024&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 3px double rgb(0, 0, 0);"&gt;3,965,665&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;19.93&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;7.44&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;0.30&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;"&gt;Exercisable at December 31, 2024&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 3px double rgb(0, 0, 0);"&gt;1,794,501&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;12.86&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;4.95&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;0.30&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;

   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"&gt;Of the stock options exercised during the year ended &lt;em style="font: inherit;"&gt; December 31, 2024, &lt;/em&gt;6,634&#160;stock options were net settled in satisfaction of the exercise price, with &lt;em style="font: inherit;"&gt;no&lt;/em&gt; cash proceeds received. In addition, an employee surrendered 6,500 shares of common stock in conjunction with&#160;a net exercise of a stock option. The common shares&#160;surrendered were&#160;retired by the Company.&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"&gt;The following summarizes information about stock options at &lt;em style="font: inherit;"&gt; December 31, 2024&#160;&lt;/em&gt;by a range of exercise prices:&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"&gt;&#160;&lt;/p&gt;

    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="text-align: center; font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="text-align: center; font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="10" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;&lt;em style="font: inherit;"&gt;&lt;em style="font: inherit;"&gt;Options outstanding&lt;/em&gt;&lt;/em&gt;&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;&lt;em style="font: inherit;"&gt;Options exercisable&lt;/em&gt;&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="text-align: center; font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="text-align: center; font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="text-align: center; font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Weighted&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="text-align: center; font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="text-align: center; font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="text-align: center; font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="text-align: center; font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="text-align: center; font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="text-align: center; font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;average&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Weighted&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="text-align: center; font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Weighted&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="text-align: center; font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="text-align: center; font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Number of&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;remaining&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;average&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Number of&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;average&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td colspan="6" style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;&lt;em style="font: inherit;"&gt;Range of exercise prices&lt;/em&gt;&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;outstanding&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;contractual&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;exercise&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;vested&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;exercise&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td colspan="2" style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;From&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;To&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;options&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;life (in years)&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;price&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;options&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;price&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;$&lt;/td&gt;&lt;td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;0.95&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;4.10&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;900,303&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;3.5&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;2.80&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;900,303&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;2.80&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;$&lt;/td&gt;&lt;td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;5.46&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;17.54&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;1,049,656&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;7.1&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;16.21&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;560,765&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;15.06&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;$&lt;/td&gt;&lt;td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;18.78&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;$&lt;/td&gt;&lt;td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;26.57&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;539,277&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;8.7&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;$&lt;/td&gt;&lt;td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;21.90&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;197,198&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;$&lt;/td&gt;&lt;td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;21.81&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px;"&gt;$&lt;/td&gt;&lt;td style="width: 7%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px;"&gt;26.91&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px;"&gt;$&lt;/td&gt;&lt;td style="width: 7%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px;"&gt;26.91&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 7%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px;"&gt;1,080,000&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 7%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px;"&gt;9.7&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px;"&gt;$&lt;/td&gt;&lt;td style="width: 7%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px;"&gt;26.91&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 7%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px;"&gt;364&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px;"&gt;$&lt;/td&gt;&lt;td style="width: 7%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px;"&gt;26.91&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;$&lt;/td&gt;&lt;td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;27.42&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;77.00&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid black;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 7%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid black;"&gt;893,792&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;9.2&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;33.02&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid black;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 7%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid black;"&gt;135,871&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;57.40&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; font-family: Times New Roman; font-size: 10pt;"&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; font-family: Times New Roman; font-size: 10pt;"&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;4,463,028&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;7.6&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;20.15&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;1,794,501&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;12.86&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;

   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"&gt;The Company uses Black-Scholes to estimate the fair value of options granted. Black-Scholes considers a number of factors, including the market price of the Company&#x2019;s common stock. Factors utilized in Black-Scholes to value each stock option granted, and the weighted average fair value of options granted during the years ended&#160;&lt;em style="font: inherit;"&gt; December 31, 2024, &lt;/em&gt;&lt;em style="font: inherit;"&gt;2023&lt;/em&gt;&#160;and &lt;em style="font: inherit;"&gt;2022&lt;/em&gt;&#160;were as follows:&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"&gt;&#160;&lt;/p&gt;

    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;2024&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;2023&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;2022&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 55%;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;"&gt;Volatility&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;151% to 170%&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;152% to 155%&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;151% to 154%&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;"&gt;Risk-free interest rates&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;3.53% to 4.47%&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;3.82% to 4.37%&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;1.98% to 3.69%&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;"&gt;Expected life of option (in years)&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;7&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;7&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;7&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;"&gt;Dividend yield&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: right;"&gt;&lt;span style="-sec-ix-hidden:c123855198"&gt;zero&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: right;"&gt;&lt;span style="-sec-ix-hidden:c123855199"&gt;zero&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: right;"&gt;&lt;span style="-sec-ix-hidden:c123855200"&gt;zero&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;"&gt;Forfeiture rate&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: right;"&gt;&lt;span style="-sec-ix-hidden:c123855201"&gt;4.3&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;%&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: right;"&gt;&lt;span style="-sec-ix-hidden:c123855202"&gt;zero&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: right;"&gt;&lt;span style="-sec-ix-hidden:c123855203"&gt;zero&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;"&gt;Weighted average fair value of stock options granted&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;25.85&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;18.21&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;35.16&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;

   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"&gt;Volatility is based on reviews of the historical volatility of the Company&#x2019;s common stock. Risk-free interest rates are based on yields of U.S. treasury notes in effect at the date of grant. Expected life of option is based on actual historical option exercises. Dividend yield is zero because the Company does &lt;em style="font: inherit;"&gt;not&lt;/em&gt; anticipate paying cash dividends in the foreseeable future.&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"&gt;As of &lt;em style="font: inherit;"&gt; December 31, 2024, &lt;/em&gt;the Company expects to recognize compensation expense of $50.6&#160;million related to non-vested options held by equity plan participants over the weighted average remaining recognition period of 2.3&#160;years.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;


   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;&lt;i&gt;Performance Awards&lt;/i&gt;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"&gt;The following summarizes information about performance award activity during &lt;em style="font: inherit;"&gt;2024:&lt;/em&gt;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"&gt;&#160;&lt;/p&gt;

    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Number of Performance Awards&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 85%;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;"&gt;Outstanding as of December 31, 2023&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;7,142&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt; text-indent: -9pt;"&gt;Granted&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt; text-indent: -9pt;"&gt;Vested&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt; text-indent: -9pt;"&gt;Forfeited/canceled&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;"&gt;Outstanding as of December 31, 2024&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;7,142&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;

   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"&gt;During the year ended &lt;em style="font: inherit;"&gt; December 31, 2022, &lt;/em&gt;a total of 57,143 shares of restricted stock awards expired as performance criteria related to these Performance Awards were &lt;em style="font: inherit;"&gt;not&lt;/em&gt; attained. These shares of restricted stock were returned to the &lt;em style="font: inherit;"&gt;2008&lt;/em&gt; Equity Incentive Plan, which expired in &lt;em style="font: inherit;"&gt; December 2017, &lt;/em&gt;and thus were retired.&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"&gt;If and when outstanding Performance Awards vest, the Company would recognize $101,000 in stock-based compensation expense. These performance awards expire in &lt;em style="font: inherit;"&gt;2026.&lt;/em&gt;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;&lt;b&gt;&lt;i&gt;Stock-Based Compensation Expense&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"&gt;The following summarizes information about stock-based compensation expense, in thousands:&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"&gt;&#160;&lt;/p&gt;

    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="10" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;&lt;em style="font: inherit;"&gt;&lt;em style="font: inherit;"&gt;Years ended December 31,&lt;/em&gt;&lt;/em&gt;&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;2024&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;2023&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;2022&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 55%;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;"&gt;Research and development&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;6,492&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;2,050&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;1,631&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;"&gt;General and administrative&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;9,799&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;2,536&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;435&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;"&gt;Total stock-based compensation expense&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;16,291&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;4,586&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;2,066&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;

   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-indent: 18pt; text-align: justify;"&gt;On &lt;em style="font: inherit;"&gt; September 13, 2024, &lt;/em&gt;the Company&#160;entered into a Consulting Agreement&#160;with our former President and Chief Executive Officer for a period of &lt;em style="font: inherit;"&gt;one&lt;/em&gt; year, which was&#160;subsequently terminated on &lt;em style="font: inherit;"&gt; January 23, 2025. &lt;/em&gt;The services to be provided under the Consulting Agreement were &lt;em style="font: inherit;"&gt;not&lt;/em&gt; deemed substantive for continuous service requirements of stock option vesting, resulting in&#160;a stock option modification under ASC &lt;em style="font: inherit;"&gt;718.&lt;/em&gt; The Company's stock-based compensation expense for the year ended &lt;em style="font: inherit;"&gt; December 31, 2024 &lt;/em&gt;included approximately $0.6&#160;million from the stock option modification accounting. See further discussion in Note &lt;em style="font: inherit;"&gt;2&lt;/em&gt; under "Related Party Transactions". There were no such costs during the years ended &lt;em style="font: inherit;"&gt; December 31, 2023 &lt;/em&gt;and &lt;em style="font: inherit;"&gt;2022.&lt;/em&gt;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&#160;&lt;/p&gt;
  </us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="d_2022-11-22_2022-11-22_SubsidiarySaleOfStockAxis-The2022RegisteredDirectOfferingMember"
      decimals="INF"
      id="c123855513"
      unitRef="Share">1666667</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="i_2022-11-22_SubsidiarySaleOfStockAxis-The2022RegisteredDirectOfferingMember"
      decimals="INF"
      id="c123855514"
      unitRef="USDPerShare">30</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="d_2022-11-22_2022-11-22_SubsidiarySaleOfStockAxis-The2022RegisteredDirectOfferingMember"
      decimals="-5"
      id="c123855515"
      unitRef="USD">47300000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <sava:EquityOfferingMaximumAmount
      contextRef="i_2023-05-01_SubsidiarySaleOfStockAxis-AtthemarketCommonStockOfferingMember"
      decimals="-8"
      id="c123855518"
      unitRef="USD">200000000</sava:EquityOfferingMaximumAmount>
    <sava:EquityOfferingPercentageOfCommission
      contextRef="i_2023-05-01_SubsidiarySaleOfStockAxis-AtthemarketCommonStockOfferingMember"
      decimals="2"
      id="c123855519"
      unitRef="Pure">0.03</sava:EquityOfferingPercentageOfCommission>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="i_2022-05-05_PlanNameAxis-The2018EquityIncentivePlanMember"
      decimals="INF"
      id="c123855540"
      unitRef="Share">5000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i_2022-05-05_PlanNameAxis-The2018EquityIncentivePlanMember"
      decimals="INF"
      id="c123855541"
      unitRef="USDPerShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock contextRef="d_2024-01-01_2024-12-31" id="c2851691">
    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-family: Times New Roman; font-size: 10pt;"&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Weighted Average&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Weighted Average&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-family: Times New Roman; font-size: 10pt;"&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Number of&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Weighted Average&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Remaining Contractual&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Aggregate Intrinsic Value&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Options&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Exercise Price&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Term in Years&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;in Millions&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 40%;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;"&gt;Outstanding as of December 31, 2023&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;3,039,029&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;15.13&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;6.21&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;30.28&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt; &lt;p style="margin: 0pt 0pt 0pt 9pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;Options granted&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; text-align: right; padding: 0; margin: 0"&gt;2,083,000&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;26.65&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt; &lt;p style="margin: 0pt 0pt 0pt 9pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;Options exercised&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; text-align: right; padding: 0; margin: 0"&gt;(240,147&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding: 0; margin: 0"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;5.25&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt; &lt;p style="margin: 0pt 0pt 0pt 9pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;Options forfeited/canceled&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; text-align: right; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"&gt;(418,854&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;24.64&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;"&gt;Outstanding as of December 31, 2024&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;4,463,028&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;20.15&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;7.61&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;0.30&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;"&gt;Vested and expected to vest at December 31, 2024&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 3px double rgb(0, 0, 0);"&gt;3,965,665&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;19.93&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;7.44&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;0.30&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;"&gt;Exercisable at December 31, 2024&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 3px double rgb(0, 0, 0);"&gt;1,794,501&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;12.86&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;4.95&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;0.30&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;
   </us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="i_2023-12-31"
      decimals="INF"
      id="c123855074"
      unitRef="Share">3039029</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="i_2023-12-31"
      decimals="INF"
      id="c123855075"
      unitRef="USDPerShare">15.13</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="d_2023-01-01_2023-12-31" id="c123855076">P6Y2M15D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="i_2023-12-31"
      decimals="-4"
      id="c123855077"
      unitRef="USD">30280000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="d_2024-01-01_2024-12-31"
      decimals="INF"
      id="c123855078"
      unitRef="Share">2083000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="d_2024-01-01_2024-12-31"
      decimals="INF"
      id="c123855079"
      unitRef="USDPerShare">26.65</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="d_2024-01-01_2024-12-31"
      decimals="INF"
      id="c123855082"
      unitRef="Share">240147</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="d_2024-01-01_2024-12-31"
      decimals="INF"
      id="c123855083"
      unitRef="USDPerShare">5.25</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="d_2024-01-01_2024-12-31"
      decimals="INF"
      id="c123855086"
      unitRef="Share">418854</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="d_2024-01-01_2024-12-31"
      decimals="INF"
      id="c123855087"
      unitRef="USDPerShare">24.64</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="i_2024-12-31"
      decimals="INF"
      id="c123855090"
      unitRef="Share">4463028</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="i_2024-12-31"
      decimals="INF"
      id="c123855091"
      unitRef="USDPerShare">20.15</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="d_2024-01-01_2024-12-31" id="c123855092">P7Y7M9D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="i_2024-12-31"
      decimals="-5"
      id="c123855093"
      unitRef="USD">300000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
      contextRef="i_2024-12-31"
      decimals="INF"
      id="c123855094"
      unitRef="Share">3965665</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
      contextRef="i_2024-12-31"
      decimals="INF"
      id="c123855095"
      unitRef="USDPerShare">19.93</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1 contextRef="d_2024-01-01_2024-12-31" id="c123855096">P7Y5M8D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
      contextRef="i_2024-12-31"
      decimals="-5"
      id="c123855097"
      unitRef="USD">300000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="i_2024-12-31"
      decimals="INF"
      id="c123855098"
      unitRef="Share">1794501</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="i_2024-12-31"
      decimals="INF"
      id="c123855099"
      unitRef="USDPerShare">12.86</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1 contextRef="d_2024-01-01_2024-12-31" id="c123855100">P4Y11M12D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
      contextRef="i_2024-12-31"
      decimals="-5"
      id="c123855101"
      unitRef="USD">300000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <sava:StockOptionsExercisedNetSettledSatisfactionOfExercisePrice
      contextRef="d_2024-01-01_2024-12-31"
      decimals="INF"
      id="c123855545"
      unitRef="Share">6634</sava:StockOptionsExercisedNetSettledSatisfactionOfExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="d_2024-01-01_2024-12-31_GranteeStatusAxis-ShareBasedPaymentArrangementEmployeeMember"
      decimals="INF"
      id="c123855547"
      unitRef="Share">6500</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock contextRef="d_2024-01-01_2024-12-31" id="c2851692">
    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="text-align: center; font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="text-align: center; font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="10" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;&lt;em style="font: inherit;"&gt;&lt;em style="font: inherit;"&gt;Options outstanding&lt;/em&gt;&lt;/em&gt;&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;&lt;em style="font: inherit;"&gt;Options exercisable&lt;/em&gt;&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="text-align: center; font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="text-align: center; font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="text-align: center; font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Weighted&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="text-align: center; font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="text-align: center; font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="text-align: center; font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="text-align: center; font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="text-align: center; font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="text-align: center; font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;average&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Weighted&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="text-align: center; font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Weighted&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="text-align: center; font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="text-align: center; font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Number of&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;remaining&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;average&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Number of&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;average&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td colspan="6" style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;&lt;em style="font: inherit;"&gt;Range of exercise prices&lt;/em&gt;&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;outstanding&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;contractual&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;exercise&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;vested&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;exercise&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td colspan="2" style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;From&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;To&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;options&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;life (in years)&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;price&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;options&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;price&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;$&lt;/td&gt;&lt;td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;0.95&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;4.10&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;900,303&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;3.5&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;2.80&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;900,303&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;2.80&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;$&lt;/td&gt;&lt;td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;5.46&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;17.54&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;1,049,656&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;7.1&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;16.21&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;560,765&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;15.06&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;$&lt;/td&gt;&lt;td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;18.78&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;$&lt;/td&gt;&lt;td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;26.57&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;539,277&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;8.7&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;$&lt;/td&gt;&lt;td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;21.90&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;197,198&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;$&lt;/td&gt;&lt;td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;21.81&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px;"&gt;$&lt;/td&gt;&lt;td style="width: 7%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px;"&gt;26.91&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px;"&gt;$&lt;/td&gt;&lt;td style="width: 7%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px;"&gt;26.91&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 7%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px;"&gt;1,080,000&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 7%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px;"&gt;9.7&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px;"&gt;$&lt;/td&gt;&lt;td style="width: 7%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px;"&gt;26.91&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 7%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px;"&gt;364&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px;"&gt;$&lt;/td&gt;&lt;td style="width: 7%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px;"&gt;26.91&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;$&lt;/td&gt;&lt;td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;27.42&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;77.00&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid black;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 7%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid black;"&gt;893,792&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;9.2&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;33.02&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid black;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 7%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid black;"&gt;135,871&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;57.40&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; font-family: Times New Roman; font-size: 10pt;"&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; font-family: Times New Roman; font-size: 10pt;"&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;4,463,028&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;7.6&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;20.15&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;1,794,501&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;12.86&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;
   </us-gaap:ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit
      contextRef="d_2024-01-01_2024-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-RangeOneMember"
      decimals="INF"
      id="c123855144"
      unitRef="USDPerShare">0.95</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit
      contextRef="d_2024-01-01_2024-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-RangeOneMember"
      decimals="INF"
      id="c123855145"
      unitRef="USDPerShare">4.1</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
      contextRef="i_2024-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-RangeOneMember"
      decimals="INF"
      id="c123855146"
      unitRef="Share">900303</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2
      contextRef="d_2024-01-01_2024-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-RangeOneMember"
      id="c123855147">P3Y6M</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1
      contextRef="i_2024-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-RangeOneMember"
      decimals="INF"
      id="c123855148"
      unitRef="USDPerShare">2.8</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
      contextRef="i_2024-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-RangeOneMember"
      decimals="INF"
      id="c123855149"
      unitRef="Share">900303</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1
      contextRef="i_2024-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-RangeOneMember"
      decimals="INF"
      id="c123855150"
      unitRef="USDPerShare">2.8</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit
      contextRef="d_2024-01-01_2024-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-RangeTwoMember"
      decimals="INF"
      id="c123855151"
      unitRef="USDPerShare">5.46</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit
      contextRef="d_2024-01-01_2024-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-RangeTwoMember"
      decimals="INF"
      id="c123855152"
      unitRef="USDPerShare">17.54</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
      contextRef="i_2024-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-RangeTwoMember"
      decimals="INF"
      id="c123855153"
      unitRef="Share">1049656</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2
      contextRef="d_2024-01-01_2024-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-RangeTwoMember"
      id="c123855154">P7Y1M6D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1
      contextRef="i_2024-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-RangeTwoMember"
      decimals="INF"
      id="c123855155"
      unitRef="USDPerShare">16.21</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
      contextRef="i_2024-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-RangeTwoMember"
      decimals="INF"
      id="c123855156"
      unitRef="Share">560765</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1
      contextRef="i_2024-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-RangeTwoMember"
      decimals="INF"
      id="c123855157"
      unitRef="USDPerShare">15.06</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit
      contextRef="d_2024-01-01_2024-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-RangeThreeMember"
      decimals="INF"
      id="c123855158"
      unitRef="USDPerShare">18.78</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit
      contextRef="d_2024-01-01_2024-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-RangeThreeMember"
      decimals="INF"
      id="c123855159"
      unitRef="USDPerShare">26.57</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
      contextRef="i_2024-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-RangeThreeMember"
      decimals="INF"
      id="c123855160"
      unitRef="Share">539277</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2
      contextRef="d_2024-01-01_2024-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-RangeThreeMember"
      id="c123855161">P8Y8M12D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1
      contextRef="i_2024-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-RangeThreeMember"
      decimals="INF"
      id="c123855162"
      unitRef="USDPerShare">21.9</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
      contextRef="i_2024-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-RangeThreeMember"
      decimals="INF"
      id="c123855163"
      unitRef="Share">197198</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1
      contextRef="i_2024-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-RangeThreeMember"
      decimals="INF"
      id="c123855164"
      unitRef="USDPerShare">21.81</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit
      contextRef="d_2024-01-01_2024-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-RangeFourMember"
      decimals="INF"
      id="c123855165"
      unitRef="USDPerShare">26.91</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit
      contextRef="d_2024-01-01_2024-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-RangeFourMember"
      decimals="INF"
      id="c123855166"
      unitRef="USDPerShare">26.91</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
      contextRef="i_2024-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-RangeFourMember"
      decimals="INF"
      id="c123855167"
      unitRef="Share">1080000</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2
      contextRef="d_2024-01-01_2024-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-RangeFourMember"
      id="c123855168">P9Y8M12D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1
      contextRef="i_2024-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-RangeFourMember"
      decimals="INF"
      id="c123855169"
      unitRef="USDPerShare">26.91</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
      contextRef="i_2024-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-RangeFourMember"
      decimals="INF"
      id="c123855170"
      unitRef="Share">364</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1
      contextRef="i_2024-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-RangeFourMember"
      decimals="INF"
      id="c123855171"
      unitRef="USDPerShare">26.91</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit
      contextRef="d_2024-01-01_2024-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-RangeFiveMember"
      decimals="INF"
      id="c123855172"
      unitRef="USDPerShare">27.42</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit
      contextRef="d_2024-01-01_2024-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-RangeFiveMember"
      decimals="INF"
      id="c123855173"
      unitRef="USDPerShare">77</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
      contextRef="i_2024-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-RangeFiveMember"
      decimals="INF"
      id="c123855174"
      unitRef="Share">893792</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2
      contextRef="d_2024-01-01_2024-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-RangeFiveMember"
      id="c123855175">P9Y2M12D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1
      contextRef="i_2024-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-RangeFiveMember"
      decimals="INF"
      id="c123855176"
      unitRef="USDPerShare">33.02</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
      contextRef="i_2024-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-RangeFiveMember"
      decimals="INF"
      id="c123855177"
      unitRef="Share">135871</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1
      contextRef="i_2024-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-RangeFiveMember"
      decimals="INF"
      id="c123855178"
      unitRef="USDPerShare">57.4</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
      contextRef="i_2024-12-31"
      decimals="INF"
      id="c123855181"
      unitRef="Share">4463028</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2 contextRef="d_2024-01-01_2024-12-31" id="c123855182">P7Y7M6D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1
      contextRef="i_2024-12-31"
      decimals="INF"
      id="c123855183"
      unitRef="USDPerShare">20.15</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
      contextRef="i_2024-12-31"
      decimals="INF"
      id="c123855184"
      unitRef="Share">1794501</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1
      contextRef="i_2024-12-31"
      decimals="INF"
      id="c123855185"
      unitRef="USDPerShare">12.86</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock contextRef="d_2024-01-01_2024-12-31" id="c2851693">
    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;2024&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;2023&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;2022&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 55%;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;"&gt;Volatility&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;151% to 170%&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;152% to 155%&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;151% to 154%&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;"&gt;Risk-free interest rates&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;3.53% to 4.47%&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;3.82% to 4.37%&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;1.98% to 3.69%&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;"&gt;Expected life of option (in years)&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;7&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;7&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;7&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;"&gt;Dividend yield&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: right;"&gt;&lt;span style="-sec-ix-hidden:c123855198"&gt;zero&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: right;"&gt;&lt;span style="-sec-ix-hidden:c123855199"&gt;zero&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: right;"&gt;&lt;span style="-sec-ix-hidden:c123855200"&gt;zero&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;"&gt;Forfeiture rate&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: right;"&gt;&lt;span style="-sec-ix-hidden:c123855201"&gt;4.3&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;%&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: right;"&gt;&lt;span style="-sec-ix-hidden:c123855202"&gt;zero&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: right;"&gt;&lt;span style="-sec-ix-hidden:c123855203"&gt;zero&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;"&gt;Weighted average fair value of stock options granted&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;25.85&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;18.21&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;35.16&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;
   </us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="d_2024-01-01_2024-12-31_AwardTypeAxis-EmployeeStockOptionMember_RangeAxis-MinimumMember"
      decimals="2"
      id="c123855209"
      unitRef="Pure">1.51</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="d_2024-01-01_2024-12-31_AwardTypeAxis-EmployeeStockOptionMember_RangeAxis-MaximumMember"
      decimals="1"
      id="c123855210"
      unitRef="Pure">1.70</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="d_2023-01-01_2023-12-31_AwardTypeAxis-EmployeeStockOptionMember_RangeAxis-MinimumMember"
      decimals="2"
      id="c123855223"
      unitRef="Pure">1.52</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="d_2023-01-01_2023-12-31_AwardTypeAxis-EmployeeStockOptionMember_RangeAxis-MaximumMember"
      decimals="2"
      id="c123855224"
      unitRef="Pure">1.55</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="d_2022-01-01_2022-12-31_AwardTypeAxis-EmployeeStockOptionMember_RangeAxis-MinimumMember"
      decimals="2"
      id="c123855237"
      unitRef="Pure">1.51</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="d_2022-01-01_2022-12-31_AwardTypeAxis-EmployeeStockOptionMember_RangeAxis-MaximumMember"
      decimals="2"
      id="c123855238"
      unitRef="Pure">1.54</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="d_2024-01-01_2024-12-31_AwardTypeAxis-EmployeeStockOptionMember_RangeAxis-MinimumMember"
      decimals="4"
      id="c123855211"
      unitRef="Pure">0.0353</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="d_2024-01-01_2024-12-31_AwardTypeAxis-EmployeeStockOptionMember_RangeAxis-MaximumMember"
      decimals="4"
      id="c123855212"
      unitRef="Pure">0.0447</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="d_2023-01-01_2023-12-31_AwardTypeAxis-EmployeeStockOptionMember_RangeAxis-MinimumMember"
      decimals="4"
      id="c123855225"
      unitRef="Pure">0.0382</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="d_2023-01-01_2023-12-31_AwardTypeAxis-EmployeeStockOptionMember_RangeAxis-MaximumMember"
      decimals="4"
      id="c123855226"
      unitRef="Pure">0.0437</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="d_2022-01-01_2022-12-31_AwardTypeAxis-EmployeeStockOptionMember_RangeAxis-MinimumMember"
      decimals="4"
      id="c123855239"
      unitRef="Pure">0.0198</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="d_2022-01-01_2022-12-31_AwardTypeAxis-EmployeeStockOptionMember_RangeAxis-MaximumMember"
      decimals="4"
      id="c123855240"
      unitRef="Pure">0.0369</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="d_2024-01-01_2024-12-31_AwardTypeAxis-EmployeeStockOptionMember"
      id="c123855195">P7Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="d_2023-01-01_2023-12-31_AwardTypeAxis-EmployeeStockOptionMember"
      id="c123855196">P7Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="d_2022-01-01_2022-12-31_AwardTypeAxis-EmployeeStockOptionMember"
      id="c123855197">P7Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="d_2024-01-01_2024-12-31_AwardTypeAxis-EmployeeStockOptionMember"
      decimals="INF"
      id="c123855204"
      unitRef="USDPerShare">25.85</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="d_2023-01-01_2023-12-31_AwardTypeAxis-EmployeeStockOptionMember"
      decimals="INF"
      id="c123855205"
      unitRef="USDPerShare">18.21</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="d_2022-01-01_2022-12-31_AwardTypeAxis-EmployeeStockOptionMember"
      decimals="INF"
      id="c123855206"
      unitRef="USDPerShare">35.16</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="d_2024-01-01_2024-12-31_AwardTypeAxis-EmployeeStockOptionMember"
      decimals="-3"
      id="c123855550"
      unitRef="Pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="i_2024-12-31_AwardTypeAxis-EmployeeStockOptionMember"
      decimals="-5"
      id="c123855552"
      unitRef="USD">50600000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="d_2024-01-01_2024-12-31_AwardTypeAxis-EmployeeStockOptionMember"
      id="c123855553">P2Y3M18D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock contextRef="d_2024-01-01_2024-12-31" id="c2851694">
    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Number of Performance Awards&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 85%;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;"&gt;Outstanding as of December 31, 2023&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;7,142&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt; text-indent: -9pt;"&gt;Granted&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt; text-indent: -9pt;"&gt;Vested&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt; text-indent: -9pt;"&gt;Forfeited/canceled&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;"&gt;Outstanding as of December 31, 2024&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;7,142&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;
   </us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="i_2023-12-31_AwardTypeAxis-PerformanceSharesMember"
      decimals="INF"
      id="c123855250"
      unitRef="Share">7142</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="d_2024-01-01_2024-12-31_AwardTypeAxis-PerformanceSharesMember"
      decimals="INF"
      id="c123855251"
      unitRef="Share">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="d_2024-01-01_2024-12-31_AwardTypeAxis-PerformanceSharesMember"
      decimals="INF"
      id="c123855252"
      unitRef="Share">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="d_2024-01-01_2024-12-31_AwardTypeAxis-PerformanceSharesMember"
      decimals="INF"
      id="c123855253"
      unitRef="Share">-0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="i_2024-12-31_AwardTypeAxis-PerformanceSharesMember"
      decimals="INF"
      id="c123855254"
      unitRef="Share">7142</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations
      contextRef="d_2022-01-01_2022-12-31_AwardTypeAxis-PerformanceSharesMember"
      decimals="INF"
      id="c123855556"
      unitRef="Share">57143</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="i_2022-12-31_AwardTypeAxis-PerformanceSharesMember"
      decimals="INF"
      id="c123855559"
      unitRef="USD">101000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock contextRef="d_2024-01-01_2024-12-31" id="c2851695">
    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="10" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;&lt;em style="font: inherit;"&gt;&lt;em style="font: inherit;"&gt;Years ended December 31,&lt;/em&gt;&lt;/em&gt;&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;2024&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;2023&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;2022&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 55%;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;"&gt;Research and development&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;6,492&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;2,050&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;1,631&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;"&gt;General and administrative&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;9,799&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;2,536&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;435&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;"&gt;Total stock-based compensation expense&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;16,291&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;4,586&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;2,066&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;
   </us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="d_2024-01-01_2024-12-31_IncomeStatementLocationAxis-ResearchAndDevelopmentExpenseMember"
      decimals="-3"
      id="c123855261"
      unitRef="USD">6492000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="d_2023-01-01_2023-12-31_IncomeStatementLocationAxis-ResearchAndDevelopmentExpenseMember"
      decimals="-4"
      id="c123855262"
      unitRef="USD">2050000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="d_2022-01-01_2022-12-31_IncomeStatementLocationAxis-ResearchAndDevelopmentExpenseMember"
      decimals="-3"
      id="c123855263"
      unitRef="USD">1631000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="d_2024-01-01_2024-12-31_IncomeStatementLocationAxis-GeneralAndAdministrativeExpenseMember"
      decimals="-3"
      id="c123855264"
      unitRef="USD">9799000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="d_2023-01-01_2023-12-31_IncomeStatementLocationAxis-GeneralAndAdministrativeExpenseMember"
      decimals="-3"
      id="c123855265"
      unitRef="USD">2536000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="d_2022-01-01_2022-12-31_IncomeStatementLocationAxis-GeneralAndAdministrativeExpenseMember"
      decimals="-3"
      id="c123855266"
      unitRef="USD">435000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="d_2024-01-01_2024-12-31"
      decimals="-3"
      id="c123855267"
      unitRef="USD">16291000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="d_2023-01-01_2023-12-31"
      decimals="-3"
      id="c123855268"
      unitRef="USD">4586000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="d_2022-01-01_2022-12-31"
      decimals="-3"
      id="c123855269"
      unitRef="USD">2066000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="d_2024-01-01_2024-12-31_RestructuringCostAndReserveAxis-EmployeeSeveranceMember"
      decimals="-5"
      id="c123855564"
      unitRef="USD">600000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="d_2023-01-01_2023-12-31_RestructuringCostAndReserveAxis-EmployeeSeveranceMember"
      decimals="-3"
      id="c123855566"
      unitRef="USD">0</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:CompensationAndEmployeeBenefitPlansTextBlock contextRef="d_2024-01-01_2024-12-31" id="c2851696">
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;8.&lt;/em&gt; Employee &lt;em style="font: inherit;"&gt;401&lt;/em&gt;(k) Benefit Plan&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"&gt;The Company has a defined-contribution savings plan under Section &lt;em style="font: inherit;"&gt;401&lt;/em&gt;(k) of the Internal Revenue Code. The plan covers substantially all employees. Employees are eligible to participate in the plan the &lt;em style="font: inherit;"&gt;first&lt;/em&gt; day of the month after hire and &lt;em style="font: inherit;"&gt; may &lt;/em&gt;contribute up to the current statutory limits under Internal Revenue Service regulations. The &lt;em style="font: inherit;"&gt;401&lt;/em&gt;(k) plan permits the Company to make additional matching contributions on behalf of all employees. Through &lt;em style="font: inherit;"&gt; December 31, 2024, &lt;/em&gt;the Company has &lt;em style="font: inherit;"&gt;not&lt;/em&gt; made any matching contributions to the &lt;em style="font: inherit;"&gt;401&lt;/em&gt;(k) plan.&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"&gt;&#160;&lt;/p&gt;


  </us-gaap:CompensationAndEmployeeBenefitPlansTextBlock>
    <us-gaap:IncomeTaxDisclosureTextBlock contextRef="d_2024-01-01_2024-12-31" id="c2851697">
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;9.&lt;/em&gt; Income Taxes&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"&gt;The Company did &lt;em style="font: inherit;"&gt;not&lt;/em&gt; provide for income taxes during the periods presented because it had book and federal taxable losses in those years and the tax benefit that would have resulted from the pre-tax losses was fully offset by a change in the valuation allowance.&lt;/p&gt;
   &lt;p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"&gt;The reconciliation of the statutory federal income tax rate to the Company&#x2019;s effective tax rate for periods presented was as follows:&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"&gt;&#160;&lt;/p&gt;

    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="10" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;&lt;em style="font: inherit;"&gt;&lt;em style="font: inherit;"&gt;Year ended December 31,&lt;/em&gt;&lt;/em&gt;&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;2024&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;2023&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;2022&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 55%;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;"&gt;Tax at federal statutory rate&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;21&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;%&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;21&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;%&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;21&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;%&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;"&gt;State tax, net of federal benefit&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;"&gt;Share-based compensation&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;(5.7&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;0.2&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;(0.5&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;"&gt;Research and development credits&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;15.4&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;5.1&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;4.9&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;"&gt;Section 162(m) limitation&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;(0.2&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;(0.2&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt; &lt;p style="margin: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;Uncertain tax positions&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;(6.1&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;(2.0&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;(2.0&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt; &lt;p style="margin: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;Tax attribute expiration&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;(4.1&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt; &lt;p style="margin: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;Change in fair value of warrant liabilities&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;93.3&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt; &lt;p style="margin: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;SEC settlement payment&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;(34.5&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;"&gt;Other&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;0.3&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;(0.3&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;0.2&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;"&gt;Change in valuation allowance&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;(79.4&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;(24.0&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;(23.4&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;"&gt;Effective income tax rate&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"&gt;%&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"&gt;%&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"&gt;%&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;

   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;&lt;i&gt;Deferred tax assets and valuation allowance&lt;/i&gt;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"&gt;Deferred tax assets reflect the tax effects of net operating loss and tax credit carryforwards and temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. The Company&#x2019;s deferred taxes assets at&#160;&lt;em style="font: inherit;"&gt; December 31, 2024&#160;&lt;/em&gt;and &lt;em style="font: inherit;"&gt;2023&lt;/em&gt;&#160;were valued at the corporate tax rate of 21%. The Company offsets its deferred tax assets by a valuation allowance because it is uncertain about the timing and amount of any future profits. Significant components of its deferred tax assets are as follows (in thousands):&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"&gt;&#160;&lt;/p&gt;

    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;&lt;em style="font: inherit;"&gt;December 31,&lt;/em&gt;&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;2024&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;2023&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 70%;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Deferred tax assets:&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;"&gt;Net operating loss carryforwards&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;43,148&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;33,322&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;"&gt;Share-based compensation&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;4,814&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;2,561&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;"&gt;Research and development credit carryforwards&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;13,789&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;12,557&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;"&gt;Capitalized research and development expenses&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;33,598&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;27,538&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;"&gt;Other&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;1,340&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;1,371&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Total deferred tax assets&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;96,689&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;77,349&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;"&gt;Valuation allowance&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;(96,689&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;(77,349&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Net deferred tax assets&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Deferred tax liabilities:&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;"&gt;Operating lease right-of-use assets&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Total deferred tax liabilities&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Net deferred tax asset (liability)&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;

   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"&gt;The valuation allowance increased by $19.4&#160;million and $23.3&#160;million in&#160;&lt;em style="font: inherit;"&gt;2024&lt;/em&gt;&#160;and &lt;em style="font: inherit;"&gt;2023,&lt;/em&gt; respectively, due primarily to continuing operations.&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"&gt;The Company&#x2019;s net operating loss carryforwards of $205.5&#160;million are federal, of which $74.1&#160;million expires between &lt;em style="font: inherit;"&gt;2029&lt;/em&gt; and &lt;em style="font: inherit;"&gt;2037&lt;/em&gt; and $131.4&#160;million carries forward indefinitely. As of &lt;em style="font: inherit;"&gt; December 31, 2024, &lt;/em&gt;the Company had federal research and development tax credits of approximately $23.0&#160;million, which expire in the years &lt;em style="font: inherit;"&gt;2025&lt;/em&gt;&#160;through &lt;em style="font: inherit;"&gt;2044.&lt;/em&gt;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&#160;&lt;/p&gt;


   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;&lt;i&gt;Unrecognized tax benefits&lt;/i&gt;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"&gt;As of &lt;em style="font: inherit;"&gt; December 31, 2024, &lt;/em&gt;&lt;em style="font: inherit;"&gt;2023&lt;/em&gt;&#160;and &lt;em style="font: inherit;"&gt;2022,&lt;/em&gt; the Company has unrecognized tax benefits related to tax credits of $9.2&#160;million, $8.4&#160;million and $6.5&#160;million, respectively. &lt;span style="-sec-ix-hidden:c123855598"&gt;None&lt;/span&gt; of the unrecognized tax benefits as of &lt;em style="font: inherit;"&gt; December 31, 2024, &lt;/em&gt;if recognized, would impact the effective tax rate due to the valuation allowance and no interest or penalties have been recognized. A reconciliation of the beginning and ending balance of unrecognized tax benefits is as follows (in thousands):&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"&gt;&#160;&lt;/p&gt;

    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="10" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;&lt;em style="font: inherit;"&gt;&lt;em style="font: inherit;"&gt;Year ended December 31,&lt;/em&gt;&lt;/em&gt;&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;2024&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;2023&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;2022&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 55%;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Beginning balance&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;8,413&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;6,496&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;5,001&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt; &lt;p style="margin: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;Expired research and development tax credits&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;(665&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;(50&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Additions based on tax positions related to the current year&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;1,494&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;1,967&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;1,495&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Ending balance&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;9,242&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;8,413&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;6,496&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;

   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 18pt;"&gt;As of &lt;em style="font: inherit;"&gt; December 31, 2024, &lt;/em&gt;there were &lt;em style="font: inherit;"&gt;no&lt;/em&gt; unrecognized tax benefits that we expect would change significantly over the next &lt;em style="font: inherit;"&gt;12&lt;/em&gt; months.&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 18pt;"&gt;The Company files U.S. and Texas income tax returns. In the United States, the statute of limitations with respect to the federal income tax returns for tax years after &lt;span style="-sec-ix-hidden:c123855602"&gt;2020&lt;/span&gt;&#160;are open to audit; however, since the Company has net operating losses, the taxing authority has the ability to review tax returns prior to the &lt;em style="font: inherit;"&gt;2021&lt;/em&gt;&#160;tax year and make adjustments to these net operating loss carryforwards.&#160;We are &lt;em style="font: inherit;"&gt;not&lt;/em&gt; under audit in any taxing jurisdiction at this time.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;
  </us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock contextRef="d_2024-01-01_2024-12-31" id="c2851698">
    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="10" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;&lt;em style="font: inherit;"&gt;&lt;em style="font: inherit;"&gt;Year ended December 31,&lt;/em&gt;&lt;/em&gt;&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;2024&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;2023&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;2022&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 55%;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;"&gt;Tax at federal statutory rate&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;21&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;%&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;21&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;%&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;21&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;%&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;"&gt;State tax, net of federal benefit&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;"&gt;Share-based compensation&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;(5.7&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;0.2&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;(0.5&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;"&gt;Research and development credits&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;15.4&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;5.1&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;4.9&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;"&gt;Section 162(m) limitation&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;(0.2&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;(0.2&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt; &lt;p style="margin: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;Uncertain tax positions&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;(6.1&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;(2.0&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;(2.0&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt; &lt;p style="margin: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;Tax attribute expiration&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;(4.1&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt; &lt;p style="margin: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;Change in fair value of warrant liabilities&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;93.3&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt; &lt;p style="margin: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;SEC settlement payment&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;(34.5&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;"&gt;Other&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;0.3&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;(0.3&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;0.2&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;"&gt;Change in valuation allowance&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;(79.4&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;(24.0&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;(23.4&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;"&gt;Effective income tax rate&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"&gt;%&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"&gt;%&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"&gt;%&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;
   </us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="d_2024-01-01_2024-12-31"
      decimals="2"
      id="c123855276"
      unitRef="Pure">0.21</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="d_2023-01-01_2023-12-31"
      decimals="2"
      id="c123855277"
      unitRef="Pure">0.21</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="d_2022-01-01_2022-12-31"
      decimals="2"
      id="c123855278"
      unitRef="Pure">0.21</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="d_2024-01-01_2024-12-31"
      decimals="0"
      id="c123855279"
      unitRef="Pure">0</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="d_2023-01-01_2023-12-31"
      decimals="0"
      id="c123855280"
      unitRef="Pure">0</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="d_2022-01-01_2022-12-31"
      decimals="0"
      id="c123855281"
      unitRef="Pure">0</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost
      contextRef="d_2024-01-01_2024-12-31"
      decimals="3"
      id="c123855282"
      unitRef="Pure">-0.057</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost
      contextRef="d_2023-01-01_2023-12-31"
      decimals="3"
      id="c123855283"
      unitRef="Pure">0.002</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost
      contextRef="d_2022-01-01_2022-12-31"
      decimals="3"
      id="c123855284"
      unitRef="Pure">-0.005</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost>
    <sava:EffectiveIncomeTaxRateReconciliationTaxCreditResearchAndDevelopmentPercent
      contextRef="d_2024-01-01_2024-12-31"
      decimals="3"
      id="c123855285"
      unitRef="Pure">0.154</sava:EffectiveIncomeTaxRateReconciliationTaxCreditResearchAndDevelopmentPercent>
    <sava:EffectiveIncomeTaxRateReconciliationTaxCreditResearchAndDevelopmentPercent
      contextRef="d_2023-01-01_2023-12-31"
      decimals="3"
      id="c123855286"
      unitRef="Pure">0.051</sava:EffectiveIncomeTaxRateReconciliationTaxCreditResearchAndDevelopmentPercent>
    <sava:EffectiveIncomeTaxRateReconciliationTaxCreditResearchAndDevelopmentPercent
      contextRef="d_2022-01-01_2022-12-31"
      decimals="3"
      id="c123855287"
      unitRef="Pure">0.049</sava:EffectiveIncomeTaxRateReconciliationTaxCreditResearchAndDevelopmentPercent>
    <sava:EffectiveIncomeTaxRateReconciliationSection162mLimitationPercent
      contextRef="d_2024-01-01_2024-12-31"
      decimals="3"
      id="c123855288"
      unitRef="Pure">-0.002</sava:EffectiveIncomeTaxRateReconciliationSection162mLimitationPercent>
    <sava:EffectiveIncomeTaxRateReconciliationSection162mLimitationPercent
      contextRef="d_2023-01-01_2023-12-31"
      decimals="0"
      id="c123855289"
      unitRef="Pure">0</sava:EffectiveIncomeTaxRateReconciliationSection162mLimitationPercent>
    <sava:EffectiveIncomeTaxRateReconciliationSection162mLimitationPercent
      contextRef="d_2022-01-01_2022-12-31"
      decimals="3"
      id="c123855290"
      unitRef="Pure">-0.002</sava:EffectiveIncomeTaxRateReconciliationSection162mLimitationPercent>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxContingencies
      contextRef="d_2024-01-01_2024-12-31"
      decimals="3"
      id="c123855291"
      unitRef="Pure">-0.061</us-gaap:EffectiveIncomeTaxRateReconciliationTaxContingencies>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxContingencies
      contextRef="d_2023-01-01_2023-12-31"
      decimals="2"
      id="c123855292"
      unitRef="Pure">-0.02</us-gaap:EffectiveIncomeTaxRateReconciliationTaxContingencies>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxContingencies
      contextRef="d_2022-01-01_2022-12-31"
      decimals="2"
      id="c123855293"
      unitRef="Pure">-0.02</us-gaap:EffectiveIncomeTaxRateReconciliationTaxContingencies>
    <sava:EffectiveIncomeTaxRateReconciliationTaxAttributeExpirationPercent
      contextRef="d_2024-01-01_2024-12-31"
      decimals="3"
      id="c123855294"
      unitRef="Pure">-0.041</sava:EffectiveIncomeTaxRateReconciliationTaxAttributeExpirationPercent>
    <sava:EffectiveIncomeTaxRateReconciliationTaxAttributeExpirationPercent
      contextRef="d_2023-01-01_2023-12-31"
      decimals="0"
      id="c123855295"
      unitRef="Pure">0</sava:EffectiveIncomeTaxRateReconciliationTaxAttributeExpirationPercent>
    <sava:EffectiveIncomeTaxRateReconciliationTaxAttributeExpirationPercent
      contextRef="d_2022-01-01_2022-12-31"
      decimals="0"
      id="c123855296"
      unitRef="Pure">0</sava:EffectiveIncomeTaxRateReconciliationTaxAttributeExpirationPercent>
    <sava:EffectiveIncomeTaxRateReconciliationChangeInFairValueOfWarrantLiabilities
      contextRef="d_2024-01-01_2024-12-31"
      decimals="3"
      id="c123855297"
      unitRef="Pure">0.933</sava:EffectiveIncomeTaxRateReconciliationChangeInFairValueOfWarrantLiabilities>
    <sava:EffectiveIncomeTaxRateReconciliationChangeInFairValueOfWarrantLiabilities
      contextRef="d_2023-01-01_2023-12-31"
      decimals="0"
      id="c123855298"
      unitRef="Pure">0</sava:EffectiveIncomeTaxRateReconciliationChangeInFairValueOfWarrantLiabilities>
    <sava:EffectiveIncomeTaxRateReconciliationChangeInFairValueOfWarrantLiabilities
      contextRef="d_2022-01-01_2022-12-31"
      decimals="0"
      id="c123855299"
      unitRef="Pure">0</sava:EffectiveIncomeTaxRateReconciliationChangeInFairValueOfWarrantLiabilities>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxSettlements
      contextRef="d_2024-01-01_2024-12-31"
      decimals="3"
      id="c123855300"
      unitRef="Pure">0.345</us-gaap:EffectiveIncomeTaxRateReconciliationTaxSettlements>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxSettlements
      contextRef="d_2023-01-01_2023-12-31"
      decimals="0"
      id="c123855301"
      unitRef="Pure">-0</us-gaap:EffectiveIncomeTaxRateReconciliationTaxSettlements>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxSettlements
      contextRef="d_2022-01-01_2022-12-31"
      decimals="0"
      id="c123855302"
      unitRef="Pure">-0</us-gaap:EffectiveIncomeTaxRateReconciliationTaxSettlements>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent
      contextRef="d_2024-01-01_2024-12-31"
      decimals="3"
      id="c123855303"
      unitRef="Pure">0.003</us-gaap:EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent
      contextRef="d_2023-01-01_2023-12-31"
      decimals="3"
      id="c123855304"
      unitRef="Pure">-0.003</us-gaap:EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent
      contextRef="d_2022-01-01_2022-12-31"
      decimals="3"
      id="c123855305"
      unitRef="Pure">0.002</us-gaap:EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="d_2024-01-01_2024-12-31"
      decimals="3"
      id="c123855306"
      unitRef="Pure">-0.794</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="d_2023-01-01_2023-12-31"
      decimals="2"
      id="c123855307"
      unitRef="Pure">-0.24</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="d_2022-01-01_2022-12-31"
      decimals="3"
      id="c123855308"
      unitRef="Pure">-0.234</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="d_2024-01-01_2024-12-31"
      decimals="0"
      id="c123855309"
      unitRef="Pure">0</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="d_2023-01-01_2023-12-31"
      decimals="0"
      id="c123855310"
      unitRef="Pure">0</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="d_2022-01-01_2022-12-31"
      decimals="0"
      id="c123855311"
      unitRef="Pure">0</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="d_2024-01-01_2024-12-31"
      decimals="2"
      id="c123855579"
      unitRef="Pure">0.21</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock contextRef="d_2024-01-01_2024-12-31" id="c2851699">
    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;&lt;em style="font: inherit;"&gt;December 31,&lt;/em&gt;&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;2024&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;2023&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 70%;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Deferred tax assets:&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;"&gt;Net operating loss carryforwards&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;43,148&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;33,322&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;"&gt;Share-based compensation&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;4,814&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;2,561&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;"&gt;Research and development credit carryforwards&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;13,789&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;12,557&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;"&gt;Capitalized research and development expenses&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;33,598&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;27,538&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;"&gt;Other&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;1,340&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;1,371&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Total deferred tax assets&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;96,689&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;77,349&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;"&gt;Valuation allowance&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;(96,689&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;(77,349&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Net deferred tax assets&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Deferred tax liabilities:&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;"&gt;Operating lease right-of-use assets&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Total deferred tax liabilities&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Net deferred tax asset (liability)&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;
   </us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="i_2024-12-31"
      decimals="-3"
      id="c123855316"
      unitRef="USD">43148000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="i_2023-12-31"
      decimals="-3"
      id="c123855317"
      unitRef="USD">33322000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
      contextRef="i_2024-12-31"
      decimals="-3"
      id="c123855318"
      unitRef="USD">4814000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
      contextRef="i_2023-12-31"
      decimals="-3"
      id="c123855319"
      unitRef="USD">2561000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch
      contextRef="i_2024-12-31"
      decimals="-3"
      id="c123855320"
      unitRef="USD">13789000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch
      contextRef="i_2023-12-31"
      decimals="-3"
      id="c123855321"
      unitRef="USD">12557000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
    <sava:DeferredTaxAssetsCapitalizedResearchAndDevelopmentExpenses
      contextRef="i_2024-12-31"
      decimals="-3"
      id="c123855322"
      unitRef="USD">33598000</sava:DeferredTaxAssetsCapitalizedResearchAndDevelopmentExpenses>
    <sava:DeferredTaxAssetsCapitalizedResearchAndDevelopmentExpenses
      contextRef="i_2023-12-31"
      decimals="-3"
      id="c123855323"
      unitRef="USD">27538000</sava:DeferredTaxAssetsCapitalizedResearchAndDevelopmentExpenses>
    <us-gaap:DeferredTaxAssetsOther
      contextRef="i_2024-12-31"
      decimals="-4"
      id="c123855324"
      unitRef="USD">1340000</us-gaap:DeferredTaxAssetsOther>
    <us-gaap:DeferredTaxAssetsOther
      contextRef="i_2023-12-31"
      decimals="-3"
      id="c123855325"
      unitRef="USD">1371000</us-gaap:DeferredTaxAssetsOther>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="i_2024-12-31"
      decimals="-3"
      id="c123855326"
      unitRef="USD">96689000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="i_2023-12-31"
      decimals="-3"
      id="c123855327"
      unitRef="USD">77349000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="i_2024-12-31"
      decimals="-3"
      id="c123855328"
      unitRef="USD">96689000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="i_2023-12-31"
      decimals="-3"
      id="c123855329"
      unitRef="USD">77349000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="i_2024-12-31"
      decimals="-3"
      id="c123855330"
      unitRef="USD">0</us-gaap:DeferredTaxAssetsNet>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="i_2023-12-31"
      decimals="-3"
      id="c123855331"
      unitRef="USD">0</us-gaap:DeferredTaxAssetsNet>
    <us-gaap:DeferredTaxLiabilitiesLeasingArrangements
      contextRef="i_2024-12-31"
      decimals="-3"
      id="c123855332"
      unitRef="USD">-0</us-gaap:DeferredTaxLiabilitiesLeasingArrangements>
    <us-gaap:DeferredTaxLiabilitiesLeasingArrangements
      contextRef="i_2023-12-31"
      decimals="-3"
      id="c123855333"
      unitRef="USD">-0</us-gaap:DeferredTaxLiabilitiesLeasingArrangements>
    <us-gaap:DeferredIncomeTaxLiabilities
      contextRef="i_2024-12-31"
      decimals="-3"
      id="c123855334"
      unitRef="USD">-0</us-gaap:DeferredIncomeTaxLiabilities>
    <us-gaap:DeferredIncomeTaxLiabilities
      contextRef="i_2023-12-31"
      decimals="-3"
      id="c123855335"
      unitRef="USD">-0</us-gaap:DeferredIncomeTaxLiabilities>
    <us-gaap:DeferredTaxAssetsLiabilitiesNet
      contextRef="i_2024-12-31"
      decimals="-3"
      id="c123855336"
      unitRef="USD">0</us-gaap:DeferredTaxAssetsLiabilitiesNet>
    <us-gaap:DeferredTaxAssetsLiabilitiesNet
      contextRef="i_2023-12-31"
      decimals="-3"
      id="c123855337"
      unitRef="USD">0</us-gaap:DeferredTaxAssetsLiabilitiesNet>
    <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount
      contextRef="d_2024-01-01_2024-12-31"
      decimals="-5"
      id="c123855580"
      unitRef="USD">19400000</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
    <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount
      contextRef="d_2023-01-01_2023-12-31"
      decimals="-5"
      id="c123855581"
      unitRef="USD">23300000</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
    <us-gaap:OperatingLossCarryforwards
      contextRef="i_2024-12-31_IncomeTaxAuthorityAxis-DomesticCountryMember"
      decimals="-5"
      id="c123855584"
      unitRef="USD">205500000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="i_2024-12-31_IncomeTaxAuthorityAxis-DomesticCountryMember_TaxPeriodAxis-CarryforwardSubjectToExpirationMember"
      decimals="-5"
      id="c123855585"
      unitRef="USD">74100000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="i_2024-12-31_IncomeTaxAuthorityAxis-DomesticCountryMember_TaxPeriodAxis-IndefiniteLifeCarryforwardsMember"
      decimals="-5"
      id="c123855588"
      unitRef="USD">131400000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:TaxCreditCarryforwardAmount
      contextRef="i_2024-12-31_IncomeTaxAuthorityAxis-DomesticCountryMember_TaxCreditCarryforwardAxis-ResearchMember"
      decimals="-6"
      id="c123855589"
      unitRef="USD">23000000</us-gaap:TaxCreditCarryforwardAmount>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="i_2024-12-31"
      decimals="-5"
      id="c123855595"
      unitRef="USD">9200000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="i_2023-12-31"
      decimals="-5"
      id="c123855596"
      unitRef="USD">8400000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="i_2022-12-31"
      decimals="-5"
      id="c123855597"
      unitRef="USD">6500000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
      contextRef="i_2024-12-31"
      decimals="-3"
      id="c123855599"
      unitRef="USD">0</us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued>
    <us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock contextRef="d_2024-01-01_2024-12-31" id="c2851700">
    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="10" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;&lt;em style="font: inherit;"&gt;&lt;em style="font: inherit;"&gt;Year ended December 31,&lt;/em&gt;&lt;/em&gt;&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;2024&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;2023&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;2022&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 55%;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Beginning balance&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;8,413&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;6,496&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;5,001&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt; &lt;p style="margin: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;Expired research and development tax credits&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;(665&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;(50&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Additions based on tax positions related to the current year&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;1,494&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;1,967&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;1,495&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Ending balance&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;9,242&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;8,413&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;6,496&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;
   </us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="i_2023-12-31"
      decimals="-3"
      id="c123855346"
      unitRef="USD">8413000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="i_2022-12-31"
      decimals="-3"
      id="c123855347"
      unitRef="USD">6496000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="i_2021-12-31"
      decimals="-3"
      id="c123855348"
      unitRef="USD">5001000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations
      contextRef="d_2024-01-01_2024-12-31"
      decimals="-3"
      id="c123855349"
      unitRef="USD">665000</us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations>
    <us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations
      contextRef="d_2023-01-01_2023-12-31"
      decimals="-4"
      id="c123855350"
      unitRef="USD">50000</us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations>
    <us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations
      contextRef="d_2022-01-01_2022-12-31"
      decimals="-3"
      id="c123855351"
      unitRef="USD">-0</us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
      contextRef="d_2024-01-01_2024-12-31"
      decimals="-3"
      id="c123855352"
      unitRef="USD">1494000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
      contextRef="d_2023-01-01_2023-12-31"
      decimals="-3"
      id="c123855353"
      unitRef="USD">1967000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
      contextRef="d_2022-01-01_2022-12-31"
      decimals="-3"
      id="c123855354"
      unitRef="USD">1495000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="i_2024-12-31"
      decimals="-3"
      id="c123855355"
      unitRef="USD">9242000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="i_2023-12-31"
      decimals="-3"
      id="c123855356"
      unitRef="USD">8413000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="i_2022-12-31"
      decimals="-3"
      id="c123855357"
      unitRef="USD">6496000</us-gaap:UnrecognizedTaxBenefits>
    <sava:LeasesAndCommitmentsDisclosureTextBlock contextRef="d_2024-01-01_2024-12-31" id="c2851701">
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;10.&lt;/em&gt; Commitments&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;&lt;i&gt;Other Commitments&lt;/i&gt;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"&gt;The Company conducts its product research and development programs through a combination of internal and collaborative programs that include, among others, arrangements with universities, contract research organizations and clinical research sites. It has contractual arrangements with these organizations that are generally cancelable. The Company&#x2019;s obligations under these contracts are largely based on services performed.&#160;The Company also had non-cancellable commitments for the manufacture of simufilam's active pharmaceutical ingredient totaling approximately $1.2&#160;million recorded in prepaid expenses and other current assets&#160;at &lt;em style="font: inherit;"&gt; December 31, 2024. &lt;/em&gt;The Company is dependent on contract development and manufacturing organizations for the manufacture of all our materials for clinical studies.&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify; text-indent: 18pt;"&gt;On &lt;em style="font: inherit;"&gt; February 26, 2025, &lt;/em&gt;the Company&#160;entered into a License Agreement (the &#x201c;License Agreement&#x201d;) with Yale University (&#x201c;Yale&#x201d;) pursuant to which the Company was granted exclusive worldwide rights, with rights to sublicense, to Yale&#x2019;s interest in certain patent and other intellectual property rights that could be useful or necessary to the development and commercialization of simufilam for the treatment of Tuberous Sclerosis Complex (TSC)-related epilepsy and other potential indications. Pursuant to the License Agreement, the Company has agreed to use reasonable commercial efforts to implement a plan that it has designed for such development and commercialization. In exchange for the rights acquired pursuant to the License Agreement, the Company agreed to pay Yale (i) a nominal upfront license fee, (ii) payments upon the achievement of specified clinical, regulatory and commercial milestones, totaling up to $4.5 million and (iii) upon transfer to a &lt;em style="font: inherit;"&gt;third&lt;/em&gt; party in connection with a regulatory priority review voucher, if issued, a low-to-mid double digit percentage of any consideration received for such transfer. The Company also agreed to pay Yale tiered royalties, ranging from a low- to mid- single digit percentage, on aggregate net sales of licensed products, subject to tiered minimum annual royalty payments ranging from the low- to mid- hundreds of thousands of dollars.&lt;/p&gt;
   &lt;p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify; text-indent: 9pt;"&gt;Unless earlier terminated, the License Agreement will continue on a country-by-country basis until the later of (i) the date on which the last valid claim of the license patents expires or otherwise lapses, (ii) the end of any government or regulatory exclusivity period, and (iii) &lt;em style="font: inherit;"&gt;10&lt;/em&gt; years following the date of &lt;em style="font: inherit;"&gt;first&lt;/em&gt; sale of licensed product in such country.&lt;/p&gt;
   &lt;p style="text-align: justify; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; margin: 0pt;"&gt;&#160;&lt;/p&gt;


  </sava:LeasesAndCommitmentsDisclosureTextBlock>
    <us-gaap:SignificantSupplyCommitmentRemainingMinimumAmountCommitted
      contextRef="i_2024-12-31_SupplyCommitmentAxis-SimufilamActiveIngredientMember"
      decimals="-5"
      id="c123855606"
      unitRef="USD">1200000</us-gaap:SignificantSupplyCommitmentRemainingMinimumAmountCommitted>
    <us-gaap:OtherCommitment
      contextRef="i_2025-02-26_CounterpartyNameAxis-YaleUniversityMember_OtherCommitmentsAxis-LicenseAgreementMember_SubsequentEventTypeAxis-SubsequentEventMember"
      decimals="-5"
      id="c123855607"
      unitRef="USD">4500000</us-gaap:OtherCommitment>
    <sava:CashIncentiveBonusPlanTextBlock contextRef="d_2024-01-01_2024-12-31" id="c2851702">
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;&lt;b&gt;Note &lt;em style="font: inherit;"&gt;11.&lt;/em&gt;&lt;/b&gt;&#160;&lt;b&gt; &lt;em style="font: inherit;"&gt;2020&lt;/em&gt; Cash Incentive Bonus Plan&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"&gt;In &lt;em style="font: inherit;"&gt; August 2020, &lt;/em&gt;the Board approved the CIB Plan. The CIB Plan was established to promote the long-term success of the Company by creating an &#x201c;at-risk&#x201d; cash bonus program that rewards&#160;CIB Plan&#160;participants with additional cash compensation in lockstep with significant increases in the Company&#x2019;s market capitalization. The CIB Plan is considered &#x201c;at-risk&#x201d; because CIB Plan participants&#160;will&#160;&lt;em style="font: inherit;"&gt;not&lt;/em&gt; receive a cash bonus&#160;unless&#160;the Company&#x2019;s market capitalization increases&#160;significantly and&#160;certain&#160;other&#160;conditions specified in the CIB Plan&#160;are met.&#160;Specifically, CIB Plan participants&#160;will&#160;&lt;em style="font: inherit;"&gt;not&lt;/em&gt;&#160;be paid&#160;any cash bonuses unless (&lt;em style="font: inherit;"&gt;1&lt;/em&gt;) the Company completes a&#160;merger or acquisition transaction that constitutes a sale of ownership of the Company or its assets (a Merger Transaction) or (&lt;em style="font: inherit;"&gt;2&lt;/em&gt;) the Compensation Committee of the Board&#160;(the Compensation Committee) determines the Company has sufficient cash on hand, as defined in the CIB Plan. Because&#160;of the inherent discretion and uncertainty regarding&#160;these&#160;requirements, the Company has concluded that&#160;a&#160;CIB Plan&#160;grant date has &lt;em style="font: inherit;"&gt;not&lt;/em&gt; occurred&#160;as of &lt;em style="font: inherit;"&gt; December 31, 2024.&#160;&lt;/em&gt;&lt;/p&gt;
   &lt;p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"&gt;CIB Plan participants will be paid all earned cash bonuses allocated under the CIB&#160;Plan in the event of a Merger Transaction.&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-indent: 18pt; text-align: justify;"&gt;As of &lt;em style="font: inherit;"&gt; December 31, 2022, &lt;/em&gt;the Company&#x2019;s independent directors were participants in the CIB Plan. However, effective &lt;em style="font: inherit;"&gt; March 16, 2023, &lt;/em&gt;the Board&#160;amended the CIB Plan to remove all independent directors as participants in the CIB Plan and the independent directors consented to such removal. The independent directors&#x2019; share of potential benefits under the CIB Plan were completely forfeited to the Company and will &lt;em style="font: inherit;"&gt;not&lt;/em&gt; be allocated to any other participant under the CIB Plan. The Company&#x2019;s independent directors have &lt;em style="font: inherit;"&gt;not&lt;/em&gt; received, and as a result of such amendment will never receive, any payments under the CIB Plan.&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"&gt;The Company&#x2019;s market capitalization for purposes of the CIB Plan&#160;is&#160;determined based on either (&lt;em style="font: inherit;"&gt;1&lt;/em&gt;) the closing price&#160;of &lt;em style="font: inherit;"&gt;one&lt;/em&gt; share of the Company's common stock on the Nasdaq Capital&#160;Market&#160;multiplied by the total issued and outstanding shares and options to purchase shares of the Company, or (&lt;em style="font: inherit;"&gt;2&lt;/em&gt;) the aggregate consideration payable to security holders of the Company in a&#160;Merger Transaction. This constitutes a market condition under applicable accounting guidance.&#160; &#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"&gt;The CIB Plan&#160;triggers a potential cash bonus each time&#160;the&#160;Company&#x2019;s market capitalization increases significantly, up to a maximum&#160;&lt;em style="font: inherit;"&gt;$5&lt;/em&gt;&#160;billion in market capitalization. The CIB Plan specifies 14&#160;incremental&#160;amounts&#160;between&#160;$200&#160;million and&#160;$5&#160;billion&#160;(each increment,&#160;a &#x201c;Valuation Milestone&#x201d;). Each&#160;Valuation Milestone&#160;triggers&#160;a potential cash bonus award in a pre-set amount defined in the CIB Plan. Each&#160;Valuation&#160;Milestone&#160;must be achieved and maintained for &lt;em style="font: inherit;"&gt;no&lt;/em&gt; less than 20 consecutive trading days for&#160;CIB Plan&#160;participants to be eligible for a potential cash bonus award.&#160;Approximately 67% of each&#160;cash bonus award&#160;associated with a Valuation Milestone&#160;is subject to&#160;adjustment and&#160;approval&#160;by the Compensation Committee.&#160;Any amounts&#160;&lt;em style="font: inherit;"&gt;not&lt;/em&gt; awarded by the Compensation Committee&#160;are&#160;&lt;em style="font: inherit;"&gt;no&lt;/em&gt; longer available for distribution.&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"&gt;If the Company were to exceed a $5&#160;billion market capitalization&#160;for &lt;em style="font: inherit;"&gt;no&lt;/em&gt; less than 20 consecutive trading days, all&#160;Valuation&#160;Milestones would be deemed achieved, in which case cash bonus awards would&#160;range from&#160;a minimum of&#160;$111.4&#160;million&#160;up to&#160;a hypothetical maximum of&#160;$289.7&#160;million.&#160;Payment of cash bonuses is deferred until such time as&#160;(&lt;em style="font: inherit;"&gt;1&lt;/em&gt;)&#160;the Company completes a Merger Transaction, or&#160;(&lt;em style="font: inherit;"&gt;2&lt;/em&gt;)&#160;the&#160;Compensation Committee determines the&#160;Company has sufficient cash&#160;on hand&#160;to render payment&#160;(each, a &#x201c;Performance Condition&#x201d;),&#160;neither&#160;of which &lt;em style="font: inherit;"&gt; may &lt;/em&gt;ever occur. Accordingly, there can be &lt;em style="font: inherit;"&gt;no&lt;/em&gt; assurance that&#160;CIB Plan&#160;participants will&#160;ever&#160;be&#160;paid a cash bonus that is awarded under the CIB Plan, even if the Company&#x2019;s market capitalization increases&#160;significantly.&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"&gt;The CIB Plan is accounted for as a liability award.&#160;The fair value of each&#160;Valuation&#160;Milestone&#160;award&#160;will be&#160;determined&#160;once&#160;a&#160;grant date occurs and&#160;will be&#160;remeasured each reporting period.&#160;Compensation expense associated with the CIB Plan&#160;will be&#160;recognized over the expected achievement period for each&#160;of the 14&#160;Valuation&#160;Milestones, when&#160;a Performance Condition&#160;is considered probable of being met. &#160;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 18pt;"&gt;In &lt;em style="font: inherit;"&gt; October 2020, &lt;/em&gt;the Company&#160;achieved&#160;the &lt;em style="font: inherit;"&gt;first&lt;/em&gt;&#160;Valuation&#160;Milestone.&#160;Subsequently in &lt;em style="font: inherit;"&gt;2020,&lt;/em&gt; the Compensation Committee&#160;approved&#160;a potential cash bonus&#160;award&#160;of&#160;$6.5&#160;million&#160;in total&#160;for&#160;all CIB Plan participants (after taking into account the &lt;em style="font: inherit;"&gt; March 2023 &lt;/em&gt;CIB Plan amendment), subject to future satisfaction of a Performance Condition.&#160;There is &lt;em style="font: inherit;"&gt;no&lt;/em&gt; continuing service requirement for CIB Plan participants once&#160;the Compensation Committee approves a cash&#160;bonus award.&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"&gt;During the year ended &lt;em style="font: inherit;"&gt; December 31, 2021, &lt;/em&gt;the Company achieved 11 additional Valuation Milestones.&#160;On &lt;em style="font: inherit;"&gt; February 13, 2025,&#160;&lt;/em&gt;the Compensation Committee concluded that &lt;em style="font: inherit;"&gt;no&lt;/em&gt; discretionary&#160;cash bonus amounts would be awarded for the 11 milestones achieved in &lt;em style="font: inherit;"&gt;2021&lt;/em&gt; nor for the &lt;em style="font: inherit;"&gt;2&lt;/em&gt; remaining CIB Plan milestones, which have &lt;em style="font: inherit;"&gt;not&lt;/em&gt; been achieved. Therefore,&#160;&lt;em style="font: inherit;"&gt;no&lt;/em&gt;&#160;compensation expense has been recorded&#160;and&#160;&lt;em style="font: inherit;"&gt;no&lt;/em&gt;&#160;payments have been made&#160;since &lt;em style="font: inherit;"&gt;no&lt;/em&gt;&#160;grant date has occurred and &lt;em style="font: inherit;"&gt;no&lt;/em&gt;&#160;Performance Conditions are considered probable of being met.&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"&gt;&#160;&lt;/p&gt;


   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"&gt;The achievement the 11&#160;milestones&#160;in&#160;&lt;em style="font: inherit;"&gt;2021&lt;/em&gt; triggered a&#160;non-discretionary potential Company obligation&#160;to a CIB Plan participant&#160;of $74.9&#160;million&#160;(after taking into account the &lt;em style="font: inherit;"&gt; March 2023 &lt;/em&gt;CIB Plan amendment) and contingent upon future satisfaction of a Performance Condition. However,&#160;no&#160;compensation expense has been recorded&#160;and&#160;&lt;em style="font: inherit;"&gt;no&lt;/em&gt;&#160;payments have been made&#160;since &lt;em style="font: inherit;"&gt;no&lt;/em&gt;&#160;grant date has occurred and &lt;em style="font: inherit;"&gt;no&lt;/em&gt;&#160;Performance Conditions are considered probable of being met.&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"&gt;&lt;em style="font: inherit;"&gt;No&lt;/em&gt; Valuation Milestones were achieved during the years&#160;ended &lt;em style="font: inherit;"&gt; December 31, 2024, &lt;/em&gt;&lt;em style="font: inherit;"&gt;2023&lt;/em&gt;&#160;and &lt;em style="font: inherit;"&gt;2022.&lt;/em&gt;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"&gt;As discussed in Note &lt;em style="font: inherit;"&gt;12,&lt;/em&gt; on &lt;em style="font: inherit;"&gt; January 24, 2025, &lt;/em&gt;the Delaware Court of Chancery entered a Final Order and Judgment approving the Stipulation and dismissing an action related to the CIB&#160;Plan with prejudice. The Final Order and Judgment requires&#160;the Company to further amend&#160;the CIB Plan, as provided in the Stipulation.&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"&gt;No actual cash payments were authorized or made to participants under the CIB Plan through &lt;em style="font: inherit;"&gt; December 31, 2024&#160;&lt;/em&gt;and the date of filing of this Annual Report on Form &lt;em style="font: inherit;"&gt;10&lt;/em&gt;-K.&lt;/p&gt;
   &lt;p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left"&gt;&#160;&lt;/p&gt;
  </sava:CashIncentiveBonusPlanTextBlock>
    <sava:CashBonusIncentiveIncrementalAmounts
      contextRef="i_2023-03-16_PlanNameAxis-CashIncentiveBonusPlanMember"
      decimals="INF"
      id="c123855625"
      unitRef="Pure">14</sava:CashBonusIncentiveIncrementalAmounts>
    <sava:PerformancePlanValuationMilestoneAmount
      contextRef="i_2023-03-16_PlanNameAxis-CashIncentiveBonusPlanMember_RangeAxis-MinimumMember"
      decimals="-8"
      id="c123855626"
      unitRef="USD">200000000</sava:PerformancePlanValuationMilestoneAmount>
    <sava:PerformancePlanValuationMilestoneAmount
      contextRef="i_2023-03-16_PlanNameAxis-CashIncentiveBonusPlanMember_RangeAxis-MaximumMember"
      decimals="-9"
      id="c123855627"
      unitRef="USD">5000000000</sava:PerformancePlanValuationMilestoneAmount>
    <sava:PerformancePlanMinimumNumberOfDaysValuationMilestoneMustBeAchievedAndMaintained
      contextRef="d_2023-03-16_2023-03-16_PlanNameAxis-CashIncentiveBonusPlanMember"
      id="c123855629">P20D</sava:PerformancePlanMinimumNumberOfDaysValuationMilestoneMustBeAchievedAndMaintained>
    <sava:PercentageValuationMilestoneCashBonusAwardSubjectToApprovalAndAdjustment
      contextRef="i_2023-03-16_PlanNameAxis-CashIncentiveBonusPlanMember"
      decimals="2"
      id="c123855630"
      unitRef="Pure">0.67</sava:PercentageValuationMilestoneCashBonusAwardSubjectToApprovalAndAdjustment>
    <sava:PerformancePlanValuationMilestoneAmount
      contextRef="i_2023-03-16_PlanNameAxis-CashIncentiveBonusPlanMember_RangeAxis-MaximumMember"
      decimals="-9"
      id="c123855633"
      unitRef="USD">5000000000</sava:PerformancePlanValuationMilestoneAmount>
    <sava:PerformancePlanMinimumNumberOfDaysValuationMilestoneMustBeAchievedAndMaintained
      contextRef="d_2023-01-01_2023-03-16_PlanNameAxis-CashIncentiveBonusPlanMember"
      id="c123855635">P20D</sava:PerformancePlanMinimumNumberOfDaysValuationMilestoneMustBeAchievedAndMaintained>
    <sava:CashIncentiveBonusAwardExceedsMaximum
      contextRef="i_2023-03-16_PlanNameAxis-CashIncentiveBonusPlanMember_RangeAxis-MinimumMember"
      decimals="-5"
      id="c123855636"
      unitRef="USD">111400000</sava:CashIncentiveBonusAwardExceedsMaximum>
    <sava:CashIncentiveBonusAwardExceedsMaximum
      contextRef="i_2023-03-16_PlanNameAxis-CashIncentiveBonusPlanMember_RangeAxis-MaximumMember"
      decimals="-5"
      id="c123855637"
      unitRef="USD">289700000</sava:CashIncentiveBonusAwardExceedsMaximum>
    <sava:CashBonusIncentiveIncrementalAmounts
      contextRef="i_2023-03-16_PlanNameAxis-CashIncentiveBonusPlanMember"
      decimals="INF"
      id="c123855641"
      unitRef="Pure">14</sava:CashBonusIncentiveIncrementalAmounts>
    <sava:CashIncentiveBonusAward
      contextRef="i_2020-10-31_PlanNameAxis-CashIncentiveBonusPlanMember"
      decimals="-5"
      id="c123855644"
      unitRef="USD">6500000</sava:CashIncentiveBonusAward>
    <sava:CashBonusIncentiveIncrementalAmounts
      contextRef="i_2021-12-31_PlanNameAxis-CashIncentiveBonusPlanMember"
      decimals="INF"
      id="c123855646"
      unitRef="Pure">11</sava:CashBonusIncentiveIncrementalAmounts>
    <sava:CashBonusIncentiveIncrementalAmounts
      contextRef="i_2021-12-31_PlanNameAxis-CashIncentiveBonusPlanMember"
      decimals="INF"
      id="c123855648"
      unitRef="Pure">11</sava:CashBonusIncentiveIncrementalAmounts>
    <sava:CashBonusIncentiveIncrementalAmounts
      contextRef="i_2021-12-31_PlanNameAxis-CashIncentiveBonusPlanMember"
      decimals="INF"
      id="c123855657"
      unitRef="Pure">11</sava:CashBonusIncentiveIncrementalAmounts>
    <sava:PerformancePlanValuationMilestoneAmount
      contextRef="i_2021-12-31_PlanNameAxis-CashIncentiveBonusPlanMember_RangeAxis-MinimumMember"
      decimals="-5"
      id="c123855659"
      unitRef="USD">74900000</sava:PerformancePlanValuationMilestoneAmount>
    <us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax
      contextRef="d_2021-01-01_2021-12-31_PlanNameAxis-CashIncentiveBonusPlanMember"
      decimals="-3"
      id="c123855660"
      unitRef="USD">0</us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax>
    <sava:PaymentsForCashIncentiveBonus
      contextRef="d_2024-01-01_2024-12-31_PlanNameAxis-CashIncentiveBonusPlanMember"
      decimals="-3"
      id="c123855668"
      unitRef="USD">0</sava:PaymentsForCashIncentiveBonus>
    <us-gaap:LossContingencyDisclosures contextRef="d_2024-01-01_2024-12-31" id="c2851703">
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;12.&lt;/em&gt; Contingencies&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 18pt;"&gt;The Company is, and from time to time, the Company &lt;em style="font: inherit;"&gt; may &lt;/em&gt;become, involved in litigation or other legal proceedings and claims, including U.S. government inquiries, investigations and Citizen Petitions submitted to FDA. In addition, the Company has received, and from time to time &lt;em style="font: inherit;"&gt; may &lt;/em&gt;receive, inquiries from government authorities relating to matters arising from the ordinary course of business.&#160;The outcome of these proceedings is inherently uncertain. Regardless of outcome, legal proceedings can have an adverse impact on the Company because of defense and settlement costs, diversion of management resources, and other factors. At this time, &lt;em style="font: inherit;"&gt;no&lt;/em&gt; assessment can be made as to their likely outcome or whether the outcome will be material to the Company other than as disclosed below. The Company believes that its total provisions for legal matters are adequate based upon currently available information.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 5pt;"&gt;&lt;i&gt;Update on Government Investigations&lt;/i&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 5pt;text-indent:25pt;"&gt;Beginning in &lt;em style="font: inherit;"&gt; August 2021, &lt;/em&gt;the Company has received subpoenas, a Civil Investigative Demand (&#x201c;CID&#x201d;) and other requests for documents and information from the Department of Justice (&#x201c;DOJ&#x201d;) and document requests from the SEC, each seeking corporate information and documents concerning the research and development of simufilam and/or SavaDx. The Company has been providing documents and information in response to these subpoenas, the CID and requests for information.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 4pt;text-indent:25pt;"&gt;On &lt;em style="font: inherit;"&gt; September 26, 2024, &lt;/em&gt;the Company announced that it had reached a settlement with the SEC&#160;resolving the SEC investigation of the Company&#x2019;s disclosures regarding its Phase &lt;em style="font: inherit;"&gt;2b&lt;/em&gt; clinical trial of simufilam for the treatment of Alzheimer&#x2019;s disease (the &#x201c;Phase &lt;em style="font: inherit;"&gt;2b&lt;/em&gt; Study&#x201d;) and related matters. The SEC also agreed to a settlement with &lt;em style="font: inherit;"&gt;two&lt;/em&gt; former senior employees of the Company. Pursuant to these settlements, the U.S. District Court for the Western District of Texas entered final consent judgment on &lt;em style="font: inherit;"&gt; October 18, 2024, &lt;/em&gt;on a complaint filed by the SEC against the Company and its &lt;em style="font: inherit;"&gt;two&lt;/em&gt; former senior employees. The Company has neither admitted nor denied the allegations of the complaint. The SEC&#x2019;s complaint alleged that certain disclosures by the Company regarding the Phase &lt;em style="font: inherit;"&gt;2b&lt;/em&gt; Study violated certain federal securities laws and SEC rules, including negligence-based disclosure violations of Sections &lt;em style="font: inherit;"&gt;17&lt;/em&gt;(a)(&lt;em style="font: inherit;"&gt;2&lt;/em&gt;) and &lt;em style="font: inherit;"&gt;17&lt;/em&gt;(a)(&lt;em style="font: inherit;"&gt;3&lt;/em&gt;) of the Securities Act of &lt;em style="font: inherit;"&gt;1933,&lt;/em&gt; as amended (the &#x201c;Securities Act&#x201d;), as well as recordkeeping and reporting requirements under the Securities Exchange Act of &lt;em style="font: inherit;"&gt;1934,&lt;/em&gt; as amended (the &#x201c;Exchange Act&#x201d;). The complaint alleges that the Company&#x2019;s SEC reports and other public statements regarding the Phase &lt;em style="font: inherit;"&gt;2b&lt;/em&gt; Study negligently contained materially misleading statements and omissions. The SEC&#x2019;s allegations with respect to the Company&#x2019;s &lt;em style="font: inherit;"&gt;two&lt;/em&gt; former employees relate to these employees&#x2019; roles in such disclosures. Under its settlement, the Company consented to a permanent injunction against future violations of Section &lt;em style="font: inherit;"&gt;17&lt;/em&gt;(a) of the Securities Act, Section &lt;em style="font: inherit;"&gt;13&lt;/em&gt;(a)(&lt;em style="font: inherit;"&gt;1&lt;/em&gt;) of the Exchange Act and Rules &lt;em style="font: inherit;"&gt;12b&lt;/em&gt;-&lt;em style="font: inherit;"&gt;20,&lt;/em&gt; &lt;em style="font: inherit;"&gt;13a&lt;/em&gt;-&lt;em style="font: inherit;"&gt;1,&lt;/em&gt; &lt;em style="font: inherit;"&gt;13a&lt;/em&gt;-&lt;em style="font: inherit;"&gt;11&lt;/em&gt; and &lt;em style="font: inherit;"&gt;13a&lt;/em&gt;-&lt;em style="font: inherit;"&gt;13&lt;/em&gt; under the Exchange Act. In addition, the Company&#160;paid a civil monetary penalty of &lt;em style="font: inherit;"&gt;$40&lt;/em&gt; million in &lt;em style="font: inherit;"&gt; November 2024.&lt;/em&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 5pt;text-indent:25pt;"&gt;The Company continues to cooperate with the DOJ related to requests for documents and information, including those related to conduct alleged in the indictment of Dr. Hoau-Yan Wang announced by DOJ on &lt;em style="font: inherit;"&gt; June 28, 2024. &lt;/em&gt;The Company cannot predict the outcome or impact of&#160;ongoing matters, including whether a government authority &lt;em style="font: inherit;"&gt; may &lt;/em&gt;pursue an enforcement action against the Company or others. The Company does &lt;em style="font: inherit;"&gt;not&lt;/em&gt; at this time anticipate, however, that DOJ will bring criminal charges against or seek a criminal resolution with the Company.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;


   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 5pt;"&gt;&lt;i&gt;Securities Class Actions and Shareholder Derivative Actions&lt;/i&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 5pt;text-indent:18pt;"&gt;Between &lt;em style="font: inherit;"&gt; August 27, 2021 &lt;/em&gt;and &lt;em style="font: inherit;"&gt; October 26, 2021, &lt;/em&gt;&lt;span style="-sec-ix-hidden:c123855699"&gt;four&lt;/span&gt; putative class action lawsuits were filed alleging violations of the federal securities laws by the Company and certain named officers. The complaints rely on allegations contained in Citizen Petitions submitted to FDA and allege that various statements made by the defendants regarding simufilam were rendered materially false and misleading. The Citizen Petitions were all subsequently denied by FDA. These actions were filed in the U.S. District Court for the Western District of Texas. The complaints seek unspecified compensatory damages and other relief on behalf of a purported class of purchasers.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 8pt; text-align: justify; text-indent: 18pt;"&gt;On &lt;em style="font: inherit;"&gt; June 30, 2022, &lt;/em&gt;a federal judge consolidated the &lt;span style="-sec-ix-hidden:c123855700"&gt;four&lt;/span&gt; class action lawsuits into &lt;span style="-sec-ix-hidden:c123855701"&gt;one&lt;/span&gt; case and appointed a lead plaintiff and a lead counsel. Lead plaintiff filed a consolidated amended complaint on &lt;em style="font: inherit;"&gt; August 18, 2022 &lt;/em&gt;on behalf of a putative class of purchasers of the Company&#x2019;s securities between &lt;em style="font: inherit;"&gt; September 14, 2020 &lt;/em&gt;and &lt;em style="font: inherit;"&gt; July 26, 2022. &lt;/em&gt;On &lt;em style="font: inherit;"&gt; May 11, 2023, &lt;/em&gt;the court dismissed with prejudice plaintiffs&#x2019; claims against&#160;defendant Nadav Friedmann, PhD, MD,&#160;our former Chief Medical Officer and a Company director, who&#160;is now deceased, but otherwise denied defendants&#x2019; motion to&#160;dismiss. Defendants filed an answer to the consolidated amended complaint on &lt;em style="font: inherit;"&gt; July 3, 2023. &lt;/em&gt;On &lt;em style="font: inherit;"&gt; February 22, 2024, &lt;/em&gt;plaintiffs filed a motion to supplement their complaint to extend the putative class period through &lt;em style="font: inherit;"&gt; October 12, 2023.&#160; &lt;/em&gt;The court granted that Motion on &lt;em style="font: inherit;"&gt; June 12, 2024, &lt;/em&gt;and plaintiffs filed a supplemental complaint on &lt;em style="font: inherit;"&gt; June 13, 2024.&#160;&lt;/em&gt;On &lt;em style="font: inherit;"&gt; November 13, 2024, &lt;/em&gt;Plaintiffs filed a &lt;em style="font: inherit;"&gt;second&lt;/em&gt; motion to supplement their complaint. On &lt;em style="font: inherit;"&gt; March 13, 2024, &lt;/em&gt;plaintiffs filed a Motion for Class Certification. On &lt;em style="font: inherit;"&gt; February 25, 2025, &lt;/em&gt;the Court denied Plaintiff&#x2019;s Motion for Class Certification without prejudice, explaining that rulings on pending motions, including specifically Plaintiffs&#x2019; &lt;em style="font: inherit;"&gt;second&lt;/em&gt; motion to supplement their complaint, could affect disposition of class certification.&#160;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 5pt;text-indent:18pt;"&gt;On &lt;em style="font: inherit;"&gt; November 4, 2021, &lt;/em&gt;a related shareholder derivative action was filed, purportedly on behalf of the Company, in the U.S. District Court for the Western District of Texas, asserting claims under the U.S. securities laws and state fiduciary duty laws against certain named officers and the members of the Company&#x2019;s Board. This complaint relies on the allegations made in Citizen Petitions that were submitted to (and subsequently denied by) FDA. The complaint alleges, among other things, that the individual defendants exposed the Company to unspecified damages and securities law liability by causing it to make materially false and misleading statements, in violation of the U.S. securities laws and in breach of their fiduciary duties to the Company. The derivative case seeks, among other things, to recover unspecified compensatory damages on behalf of the Company arising out of the individual defendants&#x2019; alleged wrongful conduct. Although the plaintiff in this derivative case does &lt;em style="font: inherit;"&gt;not&lt;/em&gt; seek relief against the Company, the Company has certain indemnification obligations to the individual defendants. Between &lt;em style="font: inherit;"&gt; November 4, 2021 &lt;/em&gt;and &lt;em style="font: inherit;"&gt; June 20, 2023, &lt;/em&gt;&lt;span style="-sec-ix-hidden:c123855705"&gt;four&lt;/span&gt; additional shareholder derivative actions were filed alleging substantially similar claims, &lt;span style="-sec-ix-hidden:c123855706"&gt;two&lt;/span&gt; in the U.S. District Court for the Western District of Texas, &lt;span style="-sec-ix-hidden:c123855707"&gt;one&lt;/span&gt; in Texas state court (Travis County District Court) and &lt;span style="-sec-ix-hidden:c123855708"&gt;one&lt;/span&gt; in the Delaware Court of Chancery. On &lt;em style="font: inherit;"&gt; July 5, 2022, &lt;/em&gt;the &lt;span style="-sec-ix-hidden:c123855709"&gt;three&lt;/span&gt; actions in the Western District of Texas were consolidated into a single action. All of the foregoing actions are currently stayed pending further developments in the consolidated securities action described above.&#160;On &lt;em style="font: inherit;"&gt; November 9, 2023, &lt;/em&gt;another shareholder derivative action alleging substantially similar claims was filed in the U.S. District Court for the Western District of Texas.&#160;The parties to that case expect that it will be consolidated into the existing consolidated federal court shareholder derivative action.&lt;/p&gt;
   &lt;p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 5pt;text-indent:18pt;"&gt;On &lt;em style="font: inherit;"&gt; February 2, 2024, &lt;/em&gt;a putative class action lawsuit was filed, purportedly on behalf of the Company,&#160;alleging violations of the federal securities law by the Company and certain named officers. The complaint relies on an &lt;em style="font: inherit;"&gt; October 12, 2023 &lt;/em&gt;article that describes a purported leaked report of alleged scientific misconduct by a&#160;scientific collaborator of the Company at City University of New York. The complaint alleges that various statements made by the defendants regarding simufilam were rendered materially false and misleading by this article. The action was filed in the U.S. District Court for the Northern District of Illinois. The complaint seeks unspecified compensatory damages and other relief on behalf of a purported class of purchasers of the Company&#x2019;s securities between &lt;em style="font: inherit;"&gt; August 18, 2022 &lt;/em&gt;and &lt;em style="font: inherit;"&gt; October 12, 2023. &lt;/em&gt;On &lt;em style="font: inherit;"&gt; May 28, 2024, &lt;/em&gt;the Northern District of Illinois transferred this action to the Western District of Texas.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;


   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 5pt;text-indent:18pt;"&gt;Beginning on &lt;em style="font: inherit;"&gt; March 18, 2024, &lt;/em&gt;&lt;span style="-sec-ix-hidden:c123855711"&gt;two&lt;/span&gt; related shareholder derivative actions were filed, purportedly on behalf of the Company, in the U.S. District Court for the Northern District of Illinois, asserting claims under the U.S. securities laws and state fiduciary duty laws against certain named officers and the members of the Company&#x2019;s Board. The complaints rely on an &lt;em style="font: inherit;"&gt; October 12, 2023 &lt;/em&gt;article that describes a purported leaked report of alleged scientific misconduct by a&#160;scientific collaborator of the Company at City University of New York. The complaints allege, among other things, that the individual defendants exposed the Company to unspecified damages and securities law liability by causing it to make materially false and misleading statements, in violation of the U.S. securities laws and in breach of their fiduciary duties to the Company. The derivative cases seek, among other things, to recover unspecified compensatory damages on behalf of the Company arising out of the individual defendant&#x2019;s alleged wrongful conduct. Although the plaintiffs in these derivative cases do &lt;em style="font: inherit;"&gt;not&lt;/em&gt; seek relief against the Company, the Company has certain indemnification obligations to the individual defendants.&#160;On &lt;em style="font: inherit;"&gt; September 6, 2024, &lt;/em&gt;these &lt;span style="-sec-ix-hidden:c123855713"&gt;two&lt;/span&gt; cases were consolidated and stayed pending further developments in the shareholder class action initially filed in the Northern District of Illinois on &lt;em style="font: inherit;"&gt; February 2, 2024.&lt;/em&gt;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 5pt;text-indent:18pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 5pt;text-indent:18pt;"&gt;The Company disputes the allegations and intends to defend against these lawsuits vigorously. The Company is unable to estimate the possible loss or range of loss, if any, associated with these lawsuits.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 5pt;text-indent:18pt;"&gt;On &lt;em style="font: inherit;"&gt; December 13, 2024, &lt;/em&gt;a putative class action lawsuit was filed, purportedly on behalf of the Company,&#160;alleging violations of the federal securities law by the Company and certain named officers. The complaint alleges that various statements made by the defendants regarding simufilam were revealed to be materially false and misleading by the release of top-line results for the Company&#x2019;s RETHINK-ALZ Phase &lt;em style="font: inherit;"&gt;3&lt;/em&gt; clinical trial on &lt;em style="font: inherit;"&gt; November 25, 2024. &lt;/em&gt;The action was filed in the U.S. District Court for the Western District of Texas. The complaint seeks unspecified compensatory damages and other relief on behalf of a purported class of purchasers of the Company&#x2019;s securities between &lt;em style="font: inherit;"&gt; February 7, 2024, &lt;/em&gt;and &lt;em style="font: inherit;"&gt; November 24, 2024.&#160;&lt;/em&gt;The Company believes that the likelihood of an unfavorable outcome is &lt;em style="font: inherit;"&gt;not&lt;/em&gt; probable, however, it is reasonably possible that the Company &lt;em style="font: inherit;"&gt; may &lt;/em&gt;incur a loss. The Company is unable to reasonably estimate the amount or range of potential loss at this time.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 5pt;text-indent:18pt;"&gt;On &lt;em style="font: inherit;"&gt; August 19, 2022, &lt;/em&gt;a shareholder derivative action was filed, purportedly on behalf of the Company, in the Delaware Court of Chancery, asserting claims under state fiduciary duty laws against certain named officers and members of the Company&#x2019;s Board. The complaint alleges, among other things, that the individual defendants breached their fiduciary duties by approving the CIB Plan in &lt;em style="font: inherit;"&gt; August 2020. &lt;/em&gt;The complaints sought unspecified compensatory damages and other relief. On &lt;em style="font: inherit;"&gt; January 6, 2023, &lt;/em&gt;the plaintiffs filed an amended complaint. Defendants filed a partial answer to the amended complaint on &lt;em style="font: inherit;"&gt; March 10, 2023, &lt;/em&gt;and moved to partially dismiss the amended complaint on &lt;em style="font: inherit;"&gt; March 14, 2023.&lt;/em&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 5pt;text-indent:18pt;"&gt;On &lt;em style="font: inherit;"&gt; May 28, 2024, &lt;/em&gt;the parties entered into a Stipulation and Agreement of Settlement, Compromise, and Release (the &#x201c;Stipulation&#x201d;) to resolve the action. The Stipulation and exhibits thereto, including the proposed Notice of Pendency of Settlement of Class and Derivative Action (the &#x201c;Notice&#x201d;) and [Proposed] Scheduling Order with Respect to Notice and Settlement Hearing (the &#x201c;Scheduling Order&#x201d;), were filed in the Delaware Court of Chancery on &lt;em style="font: inherit;"&gt; May 28, 2024.&#160;&lt;/em&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 5pt;text-indent:18pt;"&gt;On &lt;em style="font: inherit;"&gt; June 26, 2024, &lt;/em&gt;the Delaware Court of Chancery entered the Scheduling Order, which included approval of the Notice.&#160; The Delaware Court of Chancery held a settlement hearing on &lt;em style="font: inherit;"&gt; September 9, 2024. &lt;/em&gt;On &lt;em style="font: inherit;"&gt; January 24, 2025, &lt;/em&gt;the Delaware Court of Chancery entered a Final Order and Judgment approving the Stipulation and dismissing the action with prejudice. Pursuant to the Final Order, the Company paid $1 million in attorneys&#x2019; fees and expenses in &lt;em style="font: inherit;"&gt; February 2025, &lt;/em&gt;which was recorded in accounts payable and other accrued expenses at &lt;em style="font: inherit;"&gt; December 31, 2024.&lt;/em&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 7pt;"&gt;&lt;i&gt;Anti-SLAPP Lawsuit&lt;/i&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 7pt; text-indent: 18pt; text-align: justify;"&gt;On &lt;em style="font: inherit;"&gt; August 6, 2024, &lt;/em&gt;a lawsuit was filed in the District Court for the Southern District of New York which, as amended and as joined by intervenor plaintiffs, asserts claims, including a claim under the New York Anti-SLAPP Law, against the Company and against two former officers to whom the Company has certain indemnification obligations.&#160;The amended complaint and the complaint in intervention seeks costs and damages relating to a defamation action filed by the Company against the plaintiffs and subsequently dismissed voluntarily and without prejudice by the Company.&#160;The Company intends to&#160;defend the lawsuit vigorously.&#160;The Company is unable to estimate the possible loss or range of loss, if any, associated with this lawsuit.&lt;/p&gt;
   &lt;p style="text-align: justify; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; margin: 0pt;"&gt;&#160;&lt;/p&gt;
  </us-gaap:LossContingencyDisclosures>
    <us-gaap:LegalFees
      contextRef="d_2025-02-01_2025-02-28_LitigationCaseAxis-ShareholderDerivativeActionsMember_SubsequentEventTypeAxis-SubsequentEventMember"
      decimals="-6"
      id="c123855716"
      unitRef="USD">1000000</us-gaap:LegalFees>
    <sava:NumberOfFormerEmployees
      contextRef="d_2024-08-06_2024-08-06_LitigationCaseAxis-AntislappLawsuitMember"
      decimals="INF"
      id="c123855717"
      unitRef="Pure">2</sava:NumberOfFormerEmployees>
    <sava:WarrantDividendDistributionTextBlock contextRef="d_2024-01-01_2024-12-31" id="c2851704">
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;13.&lt;/em&gt; Warrant Dividend Distribution&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -2pt; text-indent: 18pt;"&gt;On &lt;em style="font: inherit;"&gt; January 3, 2024, &lt;/em&gt;the Company&#160;made a distribution&#160;to the holders of record of the Company&#x2019;s&#160;common stock&#160;in the form of warrants to purchase shares of common stock. Each holder of record of the Company's common stock as of the close of business on &lt;em style="font: inherit;"&gt; December 22, 2023 &lt;/em&gt;received &lt;span style="-sec-ix-hidden:c123855719"&gt;four&lt;/span&gt; warrants for every 10&#160;shares of common stock (rounded down&#160;for any fractional warrant) resulting in the issuance of approximately &lt;span style="-sec-ix-hidden:c123855721"&gt;16.9&lt;/span&gt; million&#160;warrants.&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;"&gt;&#160;&lt;/p&gt;


   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-indent: 18pt;"&gt;Each warrant entitled&#160;the holder to purchase, at the holder&#x2019;s sole expense and exclusive election, at an exercise price of $33.00 per warrant, &lt;span style="-sec-ix-hidden:c123855724"&gt;one&lt;/span&gt; and &lt;em style="font: inherit;"&gt;one&lt;/em&gt;-half shares of common stock (rounded down&#160;for any fractional shares). Payment for shares of common stock upon exercise of warrants was required to&#160;be in cash.&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -2pt; text-indent: 18pt;"&gt;On &lt;em style="font: inherit;"&gt; April 15, 2024, &lt;/em&gt;the Company announced&#160;that all outstanding warrants would&#160;be redeemed on &lt;em style="font: inherit;"&gt; May 7, 2024&#160;(&lt;/em&gt;the &#x201c;Redemption Date&#x201d;). The redemption price was equal to &lt;span style="-sec-ix-hidden:c123855726"&gt;1/10&lt;/span&gt; of $0.01 per warrant. The warrants were exercisable at any time starting on &lt;em style="font: inherit;"&gt; January 3, 2024&#160;&lt;/em&gt;until the business day prior to the Redemption Date. There are &lt;span style="-sec-ix-hidden:c123855728"&gt;no&lt;/span&gt; remaining warrants currently outstanding.&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -2pt; text-indent: 18pt;"&gt;The warrants were subject to the terms and conditions of the Warrant Agreement (including Form of Warrant), dated &lt;em style="font: inherit;"&gt; January 3, 2024, &lt;/em&gt;between Cassava Sciences, Inc., Computershare Inc., and Computershare Trust Company, N.A. as filed in a Current Report on&#160;Form &lt;em style="font: inherit;"&gt;8&lt;/em&gt;-K with the SEC on &lt;em style="font: inherit;"&gt; January 3, 2024. &lt;/em&gt;The warrants were&#160;listed and traded separately from the Company's common stock on the Nasdaq Capital Market under the ticker &#x201c;SAVAW&#x201d;.&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -4pt; text-indent: 9pt;"&gt;From &lt;em style="font: inherit;"&gt; January 3, 2024 &lt;/em&gt;to &lt;em style="font: inherit;"&gt; March 31, 2024, &lt;/em&gt;a total of approximately 674,000&#160;warrants were exercised resulting in net proceeds to the Company of approximately $22.3&#160;million. The Company issued approximately 1.0 million&#160;shares of common stock&#160;from the exercise of warrants through &lt;em style="font: inherit;"&gt; March 31, 2024.&lt;/em&gt;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -4pt; text-indent: 9pt;"&gt;Subsequent to &lt;em style="font: inherit;"&gt; March 31, 2024 &lt;/em&gt;and through the Redemption Date, a total of approximately &lt;em style="font: inherit;"&gt;3.15&lt;/em&gt; million&#160;warrants were exercised resulting in gross proceeds to the Company of approximately &lt;em style="font: inherit;"&gt;$104.0&lt;/em&gt;&#160;million. The Company issued approximately 4.7 million shares of common stock&#160;from the exercise of warrants from &lt;em style="font: inherit;"&gt; March 31, 2024 &lt;/em&gt;through the Redemption Date.&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;"&gt;Gross proceeds for the year ended &lt;em style="font: inherit;"&gt; December 31,&#160;&lt;/em&gt;&lt;em style="font: inherit;"&gt;2024&lt;/em&gt; from the warrant distribution totaled approximately $126.3&#160;million from the issuance of approximately 5.7 million common shares at $22.00 per share. Total net proceeds of the warrant distribution were approximately $123.6&#160;million&#160;after deducting&#160;exercise&#160;expenses and commissions.&lt;/p&gt;
   &lt;p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -4pt; text-indent: 9pt;"&gt;After the &lt;em style="font: inherit;"&gt;first&lt;/em&gt; $20 million of gross proceeds, the Company was&#160;obligated to pay a commission of&#160;2.5% of the gross proceeds from the sale of shares of common stock from&#160;warrant exercises&#160;to the Company's financial advisor for the warrant distribution. Total cost&#160;of warrant exercises through the Redemption Date were approximately $2.7&#160;million.&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -4pt; text-indent: 9pt;"&gt;Costs of the warrant distribution totaling&#160;approximately $537,000 were recorded&#160;as general and administrative expenses in the statements of operations upon distribution of the warrants on &lt;em style="font: inherit;"&gt; January 3, 2024.&lt;/em&gt;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -4pt; text-indent: 9pt; text-align: justify;"&gt;The outstanding warrants were&#160;classified as liabilities in accordance with ASC &lt;em style="font: inherit;"&gt;480&lt;/em&gt; and ASC &lt;em style="font: inherit;"&gt;815,&lt;/em&gt; which requires&#160;the warrants to be measured at initial fair value&#160;on &lt;em style="font: inherit;"&gt; January 3, 2024&#160;&lt;/em&gt;and at each reporting period thereafter, with the changes in fair value recognized as a non-cash gain or loss&#160;in our consolidated statements of operations. As of &lt;em style="font: inherit;"&gt; December 31, 2024, &lt;/em&gt;there were no warrants outstanding.&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-indent: 18pt; text-align: justify;"&gt;During the period from common stock warrant distribution on &lt;em style="font: inherit;"&gt; January 3, 2024 &lt;/em&gt;to the Redemption Date, changes in the Company's common stock warrants liability and&#160;warrants outstanding were as follows (in thousands):&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt;"&gt;&#160;&lt;/p&gt;

    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr class="finHeading" style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;Number of Common Stock Warrants&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;Common Stock Warrant Liability&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 70%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Distribution of common stock warrants on January 3, 2024&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;16,895&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;113,363&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;"&gt;Warrants exercised&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;(674&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;(4,954&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;"&gt;Gain from change in fair value of warrant liabilities&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"&gt;&lt;em style="font: inherit;"&gt;&#x2014;&lt;/em&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;(43,041&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Balance at March 31, 2024&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;16,221&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;65,368&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;"&gt;Warrants exercised&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;(3,152&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;(226&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;"&gt;Gain from change in fair value of warrant liabilities&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;&lt;em style="font: inherit;"&gt;&#x2014;&lt;/em&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;(65,142&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;"&gt;Redemption of common stock warrants&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;(13,069&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"&gt;&lt;em style="font: inherit;"&gt;&#x2014;&lt;/em&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Balance as of June 30, 2024&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;"&gt;&lt;span style="-sec-ix-hidden:c123855372"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Balance as of September 30, 2024&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;"&gt;&lt;span style="-sec-ix-hidden:c123855374"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&lt;span style="-sec-ix-hidden:c123855375"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Balance as of December 31, 2024&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;"&gt;&lt;span style="-sec-ix-hidden:c123855376"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&lt;span style="-sec-ix-hidden:c123855377"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;

   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -10pt; text-indent: 18pt;"&gt;See Note &lt;em style="font: inherit;"&gt;2&lt;/em&gt; for additional information regarding common stock warrants and associated warrant liability.&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -10pt; text-indent: 18pt;"&gt;&#160;&lt;/p&gt;


  </sava:WarrantDividendDistributionTextBlock>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="i_2023-12-22_ClassOfWarrantOrRightAxis-WarrantsToPurchaseCommonStockMember"
      decimals="INF"
      id="c123855720"
      unitRef="Share">10</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="i_2024-01-03_ClassOfWarrantOrRightAxis-WarrantsToPurchaseCommonStockMember"
      decimals="INF"
      id="c123855723"
      unitRef="USDPerShare">33</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <sava:WarrantRedemptionPrice
      contextRef="i_2024-05-07_ClassOfWarrantOrRightAxis-WarrantsToPurchaseCommonStockMember"
      decimals="INF"
      id="c123855727"
      unitRef="USDPerShare">0.01</sava:WarrantRedemptionPrice>
    <sava:ClassOfWarrantOrRightExercisedDuringPeriod
      contextRef="d_2024-01-04_2024-03-31_ClassOfWarrantOrRightAxis-WarrantsToPurchaseCommonStockMember"
      decimals="INF"
      id="c123855730"
      unitRef="Share">674000</sava:ClassOfWarrantOrRightExercisedDuringPeriod>
    <us-gaap:ProceedsFromWarrantExercises
      contextRef="d_2024-01-04_2024-03-31_ClassOfWarrantOrRightAxis-WarrantsToPurchaseCommonStockMember"
      decimals="-5"
      id="c123855731"
      unitRef="USD">22300000</us-gaap:ProceedsFromWarrantExercises>
    <sava:StockIssuedDuringPeriodSharesWarrantExercises
      contextRef="d_2024-01-04_2024-03-31_ClassOfWarrantOrRightAxis-WarrantsToPurchaseCommonStockMember"
      decimals="INF"
      id="c123855732"
      unitRef="Share">1</sava:StockIssuedDuringPeriodSharesWarrantExercises>
    <sava:StockIssuedDuringPeriodSharesWarrantExercises
      contextRef="d_2024-04-01_2024-05-02_ClassOfWarrantOrRightAxis-WarrantsToPurchaseCommonStockMember"
      decimals="INF"
      id="c123855735"
      unitRef="Share">4.7</sava:StockIssuedDuringPeriodSharesWarrantExercises>
    <sava:GrossProceedsFromIssuanceOfWarrants
      contextRef="d_2024-01-01_2024-12-31_ClassOfWarrantOrRightAxis-WarrantsToPurchaseCommonStockMember"
      decimals="-5"
      id="c123855737"
      unitRef="USD">126300000</sava:GrossProceedsFromIssuanceOfWarrants>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="i_2024-12-31_ClassOfWarrantOrRightAxis-WarrantsToPurchaseCommonStockMember"
      decimals="-5"
      id="c123855738"
      unitRef="Share">5700000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="i_2024-12-31_ClassOfWarrantOrRightAxis-WarrantsToPurchaseCommonStockMember"
      decimals="INF"
      id="c123855739"
      unitRef="USDPerShare">22</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ProceedsFromIssuanceOfWarrants
      contextRef="d_2024-01-01_2024-12-31_ClassOfWarrantOrRightAxis-WarrantsToPurchaseCommonStockMember"
      decimals="-5"
      id="c123855740"
      unitRef="USD">123600000</us-gaap:ProceedsFromIssuanceOfWarrants>
    <sava:ProceedsFromWarrantsExercisedThatObligatedToPayCommission
      contextRef="d_2024-01-04_2024-03-31_ClassOfWarrantOrRightAxis-WarrantsToPurchaseCommonStockMember"
      decimals="-7"
      id="c123855742"
      unitRef="USD">20000000</sava:ProceedsFromWarrantsExercisedThatObligatedToPayCommission>
    <sava:CommissionPercentageOfGrossProceeds
      contextRef="d_2024-01-04_2024-03-31_ClassOfWarrantOrRightAxis-WarrantsToPurchaseCommonStockMember"
      decimals="3"
      id="c123855743"
      unitRef="Pure">0.025</sava:CommissionPercentageOfGrossProceeds>
    <sava:PaymentsOfWarrantExerciseCosts
      contextRef="d_2024-01-01_2024-12-31_ClassOfWarrantOrRightAxis-WarrantsToPurchaseCommonStockMember"
      decimals="-5"
      id="c123855744"
      unitRef="USD">2700000</sava:PaymentsOfWarrantExerciseCosts>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="d_2024-01-03_2024-01-03_ClassOfWarrantOrRightAxis-WarrantsToPurchaseCommonStockMember"
      decimals="INF"
      id="c123855745"
      unitRef="USD">537000</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:WarrantsAndRightsOutstanding
      contextRef="i_2024-12-31_ClassOfWarrantOrRightAxis-WarrantsToPurchaseCommonStockMember"
      decimals="-3"
      id="c123855748"
      unitRef="USD">0</us-gaap:WarrantsAndRightsOutstanding>
    <us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock contextRef="d_2024-01-01_2024-12-31" id="c2851705">
    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr class="finHeading" style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;Number of Common Stock Warrants&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;Common Stock Warrant Liability&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 70%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Distribution of common stock warrants on January 3, 2024&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;16,895&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;113,363&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;"&gt;Warrants exercised&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;(674&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;(4,954&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;"&gt;Gain from change in fair value of warrant liabilities&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"&gt;&lt;em style="font: inherit;"&gt;&#x2014;&lt;/em&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;(43,041&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Balance at March 31, 2024&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;16,221&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;65,368&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;"&gt;Warrants exercised&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;(3,152&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;(226&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;"&gt;Gain from change in fair value of warrant liabilities&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;&lt;em style="font: inherit;"&gt;&#x2014;&lt;/em&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;(65,142&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;"&gt;Redemption of common stock warrants&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;(13,069&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"&gt;&lt;em style="font: inherit;"&gt;&#x2014;&lt;/em&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Balance as of June 30, 2024&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;"&gt;&lt;span style="-sec-ix-hidden:c123855372"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Balance as of September 30, 2024&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;"&gt;&lt;span style="-sec-ix-hidden:c123855374"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&lt;span style="-sec-ix-hidden:c123855375"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Balance as of December 31, 2024&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;"&gt;&lt;span style="-sec-ix-hidden:c123855376"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&lt;span style="-sec-ix-hidden:c123855377"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;
   </us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="i_2024-01-02"
      decimals="-3"
      id="c123855358"
      unitRef="Share">16895000</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:WarrantsAndRightsOutstanding
      contextRef="i_2024-01-02"
      decimals="-3"
      id="c123855359"
      unitRef="USD">113363000</us-gaap:WarrantsAndRightsOutstanding>
    <sava:ClassOfWarrantOrRightExercisedDuringPeriod
      contextRef="d_2024-01-03_2024-03-31_ClassOfWarrantOrRightAxis-WarrantsToPurchaseCommonStockMember"
      decimals="-3"
      id="c123855360"
      unitRef="Share">674000</sava:ClassOfWarrantOrRightExercisedDuringPeriod>
    <sava:ExerciseOfWarrantsResultingInDecreaseInWarrantLiability
      contextRef="d_2024-01-03_2024-03-31_ClassOfWarrantOrRightAxis-WarrantsToPurchaseCommonStockMember"
      decimals="-3"
      id="c123855361"
      unitRef="USD">4954000</sava:ExerciseOfWarrantsResultingInDecreaseInWarrantLiability>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="d_2024-01-03_2024-03-31_ClassOfWarrantOrRightAxis-WarrantsToPurchaseCommonStockMember"
      decimals="-3"
      id="c123855363"
      unitRef="USD">43041000</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="i_2024-03-31_ClassOfWarrantOrRightAxis-WarrantsToPurchaseCommonStockMember"
      decimals="-3"
      id="c123855364"
      unitRef="Share">16221000</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:WarrantsAndRightsOutstanding
      contextRef="i_2024-03-31_ClassOfWarrantOrRightAxis-WarrantsToPurchaseCommonStockMember"
      decimals="-3"
      id="c123855365"
      unitRef="USD">65368000</us-gaap:WarrantsAndRightsOutstanding>
    <sava:ClassOfWarrantOrRightExercisedDuringPeriod
      contextRef="d_2024-04-01_2024-06-30_ClassOfWarrantOrRightAxis-WarrantsToPurchaseCommonStockMember"
      decimals="-3"
      id="c123855366"
      unitRef="Share">3152000</sava:ClassOfWarrantOrRightExercisedDuringPeriod>
    <sava:ExerciseOfWarrantsResultingInDecreaseInWarrantLiability
      contextRef="d_2024-04-01_2024-06-30_ClassOfWarrantOrRightAxis-WarrantsToPurchaseCommonStockMember"
      decimals="-3"
      id="c123855367"
      unitRef="USD">226000</sava:ExerciseOfWarrantsResultingInDecreaseInWarrantLiability>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="d_2024-04-01_2024-06-30_ClassOfWarrantOrRightAxis-WarrantsToPurchaseCommonStockMember"
      decimals="-3"
      id="c123855369"
      unitRef="USD">65142000</us-gaap:FairValueAdjustmentOfWarrants>
    <sava:ClassOfWarrantsOrRightsCommonStockWarrantsRedeemed
      contextRef="d_2024-04-01_2024-06-30_ClassOfWarrantOrRightAxis-WarrantsToPurchaseCommonStockMember"
      decimals="-3"
      id="c123855370"
      unitRef="Share">13069000</sava:ClassOfWarrantsOrRightsCommonStockWarrantsRedeemed>
    <us-gaap:WarrantsAndRightsOutstanding
      contextRef="i_2024-06-30_ClassOfWarrantOrRightAxis-WarrantsToPurchaseCommonStockMember"
      decimals="-3"
      id="c123855373"
      unitRef="USD">0</us-gaap:WarrantsAndRightsOutstanding>
    <us-gaap:SubsequentEventsTextBlock contextRef="d_2024-01-01_2024-12-31" id="c2851706">
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -19pt; text-indent: 18pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;14.&lt;/em&gt; Subsequent Event&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -19pt; text-indent: 18pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-indent: 18pt;"&gt;On &lt;em style="font: inherit;"&gt; January 7, 2025, &lt;/em&gt;the Company announced a reduction&#160;its workforce by 10 employees, a reduction of 33% (the &#x201c;Workforce Reduction&#x201d;). The Company communicated the Workforce Reduction to affected employees on &lt;em style="font: inherit;"&gt; January 7, 2025.&lt;/em&gt;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-indent: 18pt;"&gt;The Company estimates that it will incur approximately $0.4 million of &lt;em style="font: inherit;"&gt;one&lt;/em&gt;-time costs in connection with the Workforce Reduction, primarily related to severance payments. The Company expects the Workforce Reduction to be completed, and the majority of the associated costs and cash payments to be incurred, during the &lt;em style="font: inherit;"&gt;first&lt;/em&gt; quarter of &lt;em style="font: inherit;"&gt;2025.&lt;/em&gt;&#160;&lt;/p&gt;
  </us-gaap:SubsequentEventsTextBlock>
    <us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminated
      contextRef="d_2025-01-07_2025-01-07_RestructuringCostAndReserveAxis-WorkforceReductionMember_SubsequentEventTypeAxis-SubsequentEventMember"
      decimals="INF"
      id="c123855752"
      unitRef="Pure">10</us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminated>
    <us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent
      contextRef="d_2025-01-07_2025-01-07_RestructuringCostAndReserveAxis-WorkforceReductionMember_SubsequentEventTypeAxis-SubsequentEventMember"
      decimals="2"
      id="c123855753"
      unitRef="Pure">0.33</us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent>
    <us-gaap:RestructuringAndRelatedCostExpectedCost1
      contextRef="i_2025-03-31_RestructuringCostAndReserveAxis-WorkforceReductionMember_StatementScenarioAxis-ScenarioForecastMember"
      decimals="-5"
      id="c123855754"
      unitRef="USD">400000</us-gaap:RestructuringAndRelatedCostExpectedCost1>
    <link:footnoteLink
      xlink:role="http://www.xbrl.org/2003/role/link"
      xlink:type="extended">
        <link:loc
          xlink:href="#c123854937"
          xlink:label="c123854937"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#c123854938"
          xlink:label="c123854938"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#c123854939"
          xlink:label="c123854939"
          xlink:type="locator"/>
        <link:footnote id="f6b7c5421-b40f-4704-986f-7fafec64f3cf" xlink:label="f6b7c5421-b40f-4704-986f-7fafec64f3cf" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-us">Other segment items include interest income, other income, net and gain from change in fair value of warrant liabilities.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="c123854937"
          xlink:to="f6b7c5421-b40f-4704-986f-7fafec64f3cf"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="c123854938"
          xlink:to="f6b7c5421-b40f-4704-986f-7fafec64f3cf"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="c123854939"
          xlink:to="f6b7c5421-b40f-4704-986f-7fafec64f3cf"
          xlink:type="arc"/>
    </link:footnoteLink>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
